<SEC-DOCUMENT>0001628280-17-011891.txt : 20171128
<SEC-HEADER>0001628280-17-011891.hdr.sgml : 20171128
<ACCEPTANCE-DATETIME>20171128173244
ACCESSION NUMBER:		0001628280-17-011891
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		92
FILED AS OF DATE:		20171128
DATE AS OF CHANGE:		20171128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-221791
		FILM NUMBER:		171226276

	BUSINESS ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>exicures-1november2017.htm
<DESCRIPTION>S-1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC63F0D02D0D10A620B6A28AA85A94253"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As filed with the Securities and Exchange Commission on November 28, 2017</font></div><div style="line-height:120%;padding-bottom:0px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Registration Number 333-          </font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">WASHINGTON, D.C. 20549 </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">FORM S-1&#160;</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">REGISTRATION STATEMENT&#160;</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">UNDER&#160;</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">THE SECURITIES ACT OF 1933&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exicure, Inc. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Delaware</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or other jurisdiction of incorporation or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2834</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Primary Standard Industrial</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Classification Code Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">81-5333008</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">8045 Lamon Avenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Suite 410</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Skokie, IL 60077</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(847) 673-1700</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Corporation Service Company</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">251 Little Falls Drive</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Wilmington, DE 19808</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(866) 403-5272</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Copies to:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sam Zucker</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Sidley Austin LLP</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1001 Page Mill Road</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Building 1</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Palo Alto, California 94304</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(650) 565-7000</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Approximate date of commencement of proposed sale to the public:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">From time to time after this registration statement is declared effective.</font></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. </font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  (Check one): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:14%;"></td><td style="width:27%;"></td><td style="width:21%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large Accelerated filer </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated Filer </font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Do not check if a </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">smaller reporting company)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller reporting company </font><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:52%;"></td><td style="width:12%;"></td><td style="width:12%;"></td><td style="width:12%;"></td><td style="width:12%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">CALCULATION OF REGISTRATION FEE </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title of Each Class of</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities To be Registered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">to be</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Registered(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Proposed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering Price</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Per Unit(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Proposed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering&#160;Price(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Registration&#160;Fee</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common Stock, par value $0.0001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39,714,143</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$3.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$119,142,429</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$14,833.24</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Represents shares offered by the selling stockholders. Includes an indeterminable number of additional shares of common stock, pursuant to Rule 416 under the Securities Act of 1933, as amended, that may be issued to prevent dilution from stock splits, stock dividends or similar transactions that could affect the shares to be offered by the selling stockholders. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(a) under the Securities Act of 1933, as amended, based upon the original sale price of the shares of common stock registered hereunder. On September 26, 2017, October 27, 2017 and November 2, 2017, Exicure, Inc. sold shares of common stock at a price per share of $3.00 in closings of a private placement offering. The price per share and aggregate offering price in the table above are based on the price per share in the private placement of $3.00 per share of the registrant&#8217;s common stock. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </font></div><div><br></div><hr style="page-break-after:always"><div><a name="sE306585057784A8A232628AA85DA7330"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ee2724;font-weight:bold;">The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities pursuant to this prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;">SUBJECT TO COMPLETION, DATED NOVEMBER 28, 2017</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRELIMINARY PROSPECTUS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="image49.jpg" alt="image49.jpg" style="height:61px;width:254px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">39,714,143</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Shares of Common Stock</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus relates to the offering and resale by the selling stockholders identified herein of up to 39,714,143 shares of common stock of Exicure, Inc., par value $0.0001 per share, which includes (i) 26,666,627 shares of common stock privately issued to the selling stockholders on September 26, 2017 in exchange for shares of Exicure Operating Company, a Delaware corporation, which became our wholly owned subsidiary on September 26, 2017, (ii) 2,080,000 shares of common stock held by the pre-Merger stockholders of Max-1 Acquisition Corporation, (iii) an aggregate of 10,504,196 shares of common stock issued through closings of the private placement offering on September 26, 2017, October 27, 2017, and November 2, 2017, and (iv) an aggregate of 463,320 shares of common stock issued to placement agents, or issuable to such placement agents upon exercise of common stock warrants, in each case, issued in connection with the private placement offering. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We will not receive any proceeds from the sale of these shares by the selling stockholders.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders may sell the shares </font><font style="font-family:inherit;font-size:10pt;color:#000000;">of our common stock offered by this prospectus from time to time through the means described in this prospectus under the caption</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;&#8220;Plan of Distribution.&#8221; For a list of the selling stockholders, see the section entitled &#8220;Selling Stockholders&#8221; on page 156. We have borne and will continue to bear the costs relating to the registration of these shares. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There is not currently, and there has never been, any established public trading market for any of our securities. Our securities are not currently eligible for trading on any national securities exchange, including the NASDAQ Stock Market, or any over-the-counter markets, including the OTC Markets&#8212;OTCQB tier, or the OTCQB. We cannot assure you that our securities will become eligible for trading on any exchange or market. In connection with this offering, we have arranged for a registered broker-dealer to apply to have our common stock quoted on the OTCQB or another over-the-counter system. Until such time as our common stock is quoted on the OTCQB or another public trading market otherwise develops, the selling stockholders identified herein may only sell their shares of our common stock pursuant to this prospectus at a fixed price of $3.00 per share, for a total offering amount of $119,142,429. At and after such time, the selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws, and, as such, are eligible for reduced public company reporting requirements. See &#8220;Prospectus Summary</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Emerging Growth Company.&#8221; </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:21.367521367521366%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing in our common stock involves a high degree of risk. Before making an investment decision, please read &#8220;Risk Factors&#8221; on page </font><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s1A439ABFF26778CE189B28AA879E6D96"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11</font></a><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;of this prospectus.</font></div><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:21.367521367521366%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sCC986E4F3B4CFBB9B0AB28AA7A323348"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:92%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sa29610c8f60e4cd893296525d0e348a4"><font style="font-family:inherit;font-size:10pt;">ABOUT THIS PROSPECTUS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sa29610c8f60e4cd893296525d0e348a4">ii</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0EEEEDAFC7D83B73046128AA87D0AC41"><font style="font-family:inherit;font-size:10pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0EEEEDAFC7D83B73046128AA87D0AC41">iii</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD03DE01B3B742CEEED3C28AA862E60E4"><font style="font-family:inherit;font-size:10pt;">PROSPECTUS SUMMARY</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD03DE01B3B742CEEED3C28AA862E60E4">1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sa0ebce7ffb33442189305dca7ecaca5d"><font style="font-family:inherit;font-size:10pt;">THE OFFERING</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sa0ebce7ffb33442189305dca7ecaca5d">8</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8c8e128e5424426d81072ef20dc28900"><font style="font-family:inherit;font-size:10pt;">SUMMARY FINANCIAL DATA</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8c8e128e5424426d81072ef20dc28900">9</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A439ABFF26778CE189B28AA879E6D96"><font style="font-family:inherit;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A439ABFF26778CE189B28AA879E6D96">11</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A6C79E1D5CAFFAA99BA28AA87F00B75"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF THE MERGER, THE PRIVATE PLACEMENT, AND RELATED TRANSACTIONS </font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A6C79E1D5CAFFAA99BA28AA87F00B75">50</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76D2451D398D1357FDCE28AA8B12383F"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF OUR BUSINESS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76D2451D398D1357FDCE28AA8B12383F">52</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BF8BBE906CA4FFA9F4D28AA88EBA73D"><font style="font-family:inherit;font-size:10pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1BF8BBE906CA4FFA9F4D28AA88EBA73D">96</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C20F89CE6A72C17DF0128AA8CD2C7E4"><font style="font-family:inherit;font-size:10pt;">DIRECTORS AND EXECUTIVE OFFICERS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C20F89CE6A72C17DF0128AA8CD2C7E4">123</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0AC8CDA7B1F926F384F28AA8D05A123"><font style="font-family:inherit;font-size:10pt;">EXECUTIVE AND DIRECTOR COMPENSATION</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0AC8CDA7B1F926F384F28AA8D05A123">132</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2E12F58B19020FD6456C28AA8D2887D3"><font style="font-family:inherit;font-size:10pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2E12F58B19020FD6456C28AA8D2887D3">147</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE2CA0EBAB221B5A3B2BA28AA8D59BC75"><font style="font-family:inherit;font-size:10pt;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE2CA0EBAB221B5A3B2BA28AA8D59BC75">150</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s679CB80D6DC608278C8B28AA8D7B0259"><font style="font-family:inherit;font-size:10pt;">DIVIDEND POLICY</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s679CB80D6DC608278C8B28AA8D7B0259">151</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB093D432588905E3C30A28AA8DAC0674"><font style="font-family:inherit;font-size:10pt;">DETERMINATION OF OFFERING PRICE</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB093D432588905E3C30A28AA8DAC0674">152</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0C2908423008FFCE7D6428AA8DCDBF2D"><font style="font-family:inherit;font-size:10pt;">MARKET INFORMATION FOR OUR COMMON STOCK</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0C2908423008FFCE7D6428AA8DCDBF2D">153</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1AABF9BC4CAFCA6D0D828AA8DFFB1C0"><font style="font-family:inherit;font-size:10pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1AABF9BC4CAFCA6D0D828AA8DFFB1C0">154</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s761DE476982C7CD0AEAC28AA8E20AB25"><font style="font-family:inherit;font-size:10pt;">SELLING STOCKHOLDERS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s761DE476982C7CD0AEAC28AA8E20AB25">156</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0AA541428736649A281928AA8E53C384"><font style="font-family:inherit;font-size:10pt;">PLAN OF DISTRIBUTION</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0AA541428736649A281928AA8E53C384">162</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s676D1BFE361D52F9A8BB28AA8E74F453"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF CAPITAL STOCK</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s676D1BFE361D52F9A8BB28AA8E74F453">164</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s914560fc691a43ed8e254995498242fe"><font style="font-family:inherit;font-size:10pt;">SHARES ELIGIBLE FOR FUTURE SALE</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s914560fc691a43ed8e254995498242fe">169</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2d5b2720a4eb4fbda60bfbee739581f3"><font style="font-family:inherit;font-size:10pt;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2d5b2720a4eb4fbda60bfbee739581f3">172</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1ad6d38be2f640debd2af95693de17b2"><font style="font-family:inherit;font-size:10pt;">EXPERTS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1ad6d38be2f640debd2af95693de17b2">172</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s762cf1d83fa74e90a98fd120e05f2102"><font style="font-family:inherit;font-size:10pt;">WHERE YOU CAN FIND MORE INFORMATION</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s762cf1d83fa74e90a98fd120e05f2102">172</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="sa29610c8f60e4cd893296525d0e348a4"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">You should rely only on the information contained in this prospectus or contained in any prospectus supplement or free writing prospectus filed with the Securities and Exchange Commission, or the SEC. Neither we nor the selling stockholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the SEC. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. You should assume that the information appearing in this prospectus, the applicable prospectus supplement and any related free writing prospectus is accurate only as of the respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For investors outside the United States: Neither we nor the selling stockholders have done anything that would permit this offering or possession or distribution of this prospectus, any prospectus supplement or free writing prospectus filed with the SEC, in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus, any prospectus supplement or free writing prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus, any prospectus supplement or free writing prospectus outside the United States. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ii</font></div></div><hr style="page-break-after:always"><div><a name="s0EEEEDAFC7D83B73046128AA87D0AC41"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus, including the sections entitled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Description of Our Business,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. All statements other than statements of historical fact contained in this prospectus, in any applicable prospectus supplement and in any related free writing prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and Investigational New Drug application, or IND, Investigational Medicinal Product Dossier, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our dependence on current and future collaborators for developing, obtaining regulatory approval for and commercializing therapeutic candidates in the collaboration; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our or a current or future collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the rate and degree of market acceptance of any approved therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the commercialization of any approved therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to establish and maintain collaborations and retain commercial rights for our therapeutic candidates in the collaborations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our estimates of our expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to the use of proceeds from our private placement offering, and our needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to obtain additional funds for our operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our reliance on third parties to conduct our preclinical studies and clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to attract and retain qualified key management and technical personnel; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iii</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our expectations regarding the time during which we will be an emerging growth company under the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Jumpstart Our Business Startups Act of 2012, or the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">JOBS Act; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our financial performance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the impact of government regulation and developments relating to our competitors or our industry; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus, in any applicable prospectus supplement and in any related free writing prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any forward-looking statement in this prospectus, in any applicable prospectus supplement and in any related free writing prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus and the documents that we reference therein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus, any applicable prospectus supplement and any related free writing prospectus also contain or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iv</font></div></div><hr style="page-break-after:always"><div><a name="sD03DE01B3B742CEEED3C28AA862E60E4"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS SUMMARY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">This summary highlights certain information about us, this offering and selected information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the securities covered by this prospectus. For a more complete understanding of Exicure and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus, any related prospectus supplement and any related free writing prospectus, including the information set forth in the section titled &#8220;Risk Factors&#8221; in this prospectus, any related prospectus supplement and any related free writing prospectus in their entirety before making an investment decision.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">All references to &#8220;Exicure OpCo&#8221; herein refer to Exicure, Inc. (formerly AuraSense Therapeutics, LLC), a privately held Delaware corporation, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">which changed its name to &#8220;Exicure Operating Company&#8221;. Unless otherwise stated or the context otherwise indicates, references to &#8220;Exicure,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or similar terms refer to Exicure, Inc. and our wholly-owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of the Company.</font></div><div><a name="s70F6E1F041805969984928AA8650854B"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in a Phase 1 clinical trial of our lead therapeutic candidate, AST-005, and in preclinical studies of two other therapeutic candidates, XCUR17 and AST-008, both of which we are advancing to the clinic.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting </font><font style="font-family:inherit;font-size:10pt;color:#000000;">tumor necrosis factor, or TNF, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">for the treatment of mild to moderate psoriasis that is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of tumor necrosis factor messenger RNA, or TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle. While we did not observe an antipsoriatic effect in our Phase 1 clinical trial, we believe this is due to the short duration of the treatment. The results of a clinical trial with etanercept, a systemic TNF inhibitor, indicate that at least four weeks of therapy is required before antipsoriatic efficacy can be observed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue Pharma L.P., or Purdue, referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to&#160;AST-005,&#160;an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets.&#160; Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a&#160;non-refundable&#160;development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5&#160;million upon successful completion of certain research, regulatory and commercial sales milestones. We cannot assure you that these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our second therapeutic candidate, XCUR17, is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway, in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the keratinocytes of the skin. We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect this clinical trial to be completed in mid-2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our third therapeutic candidate,&#160;AST-008,&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors. We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in colon cancer, breast cancer, lymphoma and melanoma mouse models. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008&#160;applied in combination with certain checkpoint inhibitors exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. Importantly, in an&#160;anti-PD-1&#160;antibody-resistant breast cancer mouse model, administration of&#160;AST-008&#160;with certain&#160;anti-PD-1,&#160;or programmed death 1, antibodies restored the anti-tumor activity of these antibodies. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of&#160;AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models. We filed a CTA for a Phase 1 clinical trial of&#160;AST-008&#160;in the United Kingdom in the second quarter of 2017. In the third quarter of 2017, we received an authorization from the Medicines and Healthcare products Regulatory Agency, or MHRA, the competent health authority of the United Kingdom, to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. We expect this trial to be completed in mid-2018. We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Given the extensive potential therapeutic applications for our SNA platform, we believe it is important to enter into selective partnerships to broaden the indications we can pursue and accelerate the development of new programs. To that end, on December&#160;2, 2016, we entered into the Purdue Collaboration. We believe this collaboration exemplifies our strategy of establishing alliances with leaders with a proven track record in the development and global commercialization of treatments for patients with chronic conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that we have a strong intellectual property, or IP, position in the field of SNA therapeutics. As of September 30, 2017, our patent portfolio consists of over 45 issued patents and allowed patent applications and over 125 pending patent applications. We have licensed IP from Northwestern University and have also independently filed patents to protect our IP. Our license from Northwestern University is for exclusive worldwide rights to the use of SNA technology for therapeutic applications. Any patents arising from&#160;AST-005,&#160;XCUR17 or AST-008 applications would expire by 2035, 2037, and 2034 or 2035, respectively.</font></div><div><a name="s627E4AD96F90C39AFBD828AA86822E6F"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to build a leading nucleic acid therapeutics company based on our proprietary SNA technology. The key elements of our strategy are:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Support Purdue in its clinical development of&#160;AST-005;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Advance therapeutics incorporating our SNA technology for the treatment of skin diseases;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Advance&#160;AST-008&#160;through clinical development for immuno-oncology applications;&#160;</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Use our proprietary SNA technology to develop additional therapeutic candidates;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Enter into additional partnerships to accelerate development and commercialization of our SNA therapeutic candidates; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Build, enhance and protect our proprietary SNA intellectual property.&#160;</font></div></td></tr></table><div><a name="sA0BCCF7C059A0AE3049128AA86A4830E"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Therapeutic Development Pipeline</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our research and development programs include the development of three SNA therapeutic candidates to address unmet medical needs in the treatment of mild to moderate psoriasis and solid tumors as well as early stage research activities in neurology, ophthalmology, respiratory and gastrointestinal applications, and the development of SNAs that target IL-4RA. These early stage research activities are described in more detail in the sections entitled &#8220;&#8212;Early development programs&#8221; and &#8220;&#8212;SNA targeting IL-4RA for atopic dermatitis.&#8221; The table below sets forth the stage of development of our three SNA therapeutic candidates as of October 2, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="a20171128revisedpipeline.jpg" alt="a20171128revisedpipeline.jpg" style="height:177px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">TNF = Tumor Necrosis Factor; IL-17RA = Interleukin 17 Receptor Alpha; TLR9 = Toll-like Receptor 9</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(1) AST-005 is the subject of the Purdue Collaboration described below in &#8220;Description of Our Business&#8212;Our Research and Development Programs&#8212;Purdue Collaboration.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Regulatory documents are prepared and submitted to the appropriate health authority to enable clinical trials in any given jurisdiction. In the United States, this document is called an IND application, while in other jurisdictions, this document is often called an investigational medicinal product dossier, or IMPD, which is submitted as part of a CTA. The content and scope of an IND and a CTA are similar.</font></div><div><a name="sA229B2FB2367ABAFDEED28AA86D5D99C"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our ability to implement our current business strategy is subject to numerous risks, as more fully described in the section titled &#8220;Risk Factors.&#8221; These risks include, among others, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability;</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are dependent on Purdue for the successful development of therapeutic candidates in our collaboration arrangement with Purdue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Because we rely on third party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may not successfully engage in strategic transactions, including any collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expense, and present significant distractions to our management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our internal computer systems, or those of our contract research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs;</font></div></td></tr></table></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently license patent rights from Northwestern University and may in the future license patent rights from third party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </font></div></td></tr></table><div><a name="sfce1e2f8140d40729c8cac6fc5abf43e"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reverse Merger </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;26, 2017, pursuant to an Agreement and Plan of Merger and Reorganization among Max-1 Acquisition Corporation, or Max-1, Max-1 Acquisition Sub, Inc., and Exicure OpCo, or the Merger Agreement, Max-1 Acquisition Sub, Inc. merged with and into Exicure OpCo, with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of our Company. This transaction is referred to herein as the Merger. The Merger was effective as of September&#160;26, 2017 upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware, or the Effective Time. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the Merger, we acquired the business of Exicure OpCo, a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. See</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8220;Description of Our Business&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">below</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;At the Effective Time, each outstanding share of Exicure OpCo&#8217;s common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into 0.49649 shares of our common stock, and each outstanding share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into 0.7666652 shares of our common stock. As a result, an aggregate of 26,666,627 shares of our common stock were issued to the holders of Exicure OpCo&#8217;s capital stock after adjustments due to rounding for fractional shares. In addition, pursuant to the Merger Agreement options to purchase 7,414,115 shares of Exicure OpCo&#8217;s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase 3,680,997&#160;shares of our common stock. See</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8220;Description of Capital Stock&#8212;Options&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">below for more information. The issuance of shares of our common stock, or options to purchase our common stock, to holders of Exicure OpCo&#8217;s capital stock and options, as applicable, are collectively referred to as the Share Conversion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger was treated as a recapitalization and reverse acquisition for our Company for financial reporting purposes. Exicure OpCo is considered the acquirer for accounting purposes, and our historical financial statements before the Merger will be replaced with the historical financial statements of Exicure OpCo before the Merger in our filings with the SEC. The Merger was intended to be treated as a tax-free reorganization under Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The issuance of shares of our common stock, and options to purchase our common stock, to holders of Exicure OpCo&#8217;s capital stock and options in connection with the Merger was not registered under the Securities Act of 1933, as amended, or the Securities Act, in reliance upon the exemption from registration provided by Section&#160;4(a)(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering, and Rule 506(b) of Regulation D promulgated by the SEC. These securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement, and are subject to further contractual restrictions on transfer as described below. This prospectus relates to the sale or other disposition from time to time of up to 39,714,143 shares of our common stock issued in connection with the Merger and the Private Placement, or held by the pre-Merger stockholders of Max-1.</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sb620aad7086f4006bb24747c388dda00"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Private Placement Offering </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, October 27, 2017 and November 2, 2017, we sold an aggregate of 10,504,196 shares of our common stock pursuant to closings of a private placement offering, or the Private Placement, for up to 13,333,333 shares of our common stock at a purchase price of $3.00 per share, or the Sale Price. The Company </font><font style="font-family:inherit;font-size:10pt;color:#000000;">and Katalyst Securities LLC, a U.S. registered broker-dealer, together with its sub-agents, the Placement Agents, may agree to extend the period for additional closings up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">November 30, 2017. To the extent the Private Placement is extended, the Company may also sell an additional 3,333,333 shares of common stock at the Sale Price to cover over-subscriptions in the event the Private Placement is oversubscribed. The Company granted to the investors in the Private Placement registration rights requiring the Company to register those shares of common stock for public resale. The then existing stockholders of Exicure who agreed to become parties to the registration rights agreement also became entitled to such registration rights. The aggregate gross proceeds from the closings of the Private Placement were $31.5 million (before deducting placement agent fees and expenses of such closings, which are estimated at $4.0 million).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The closings of the Private Placement were exempt from registration under Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Private Placement was sold to &#8220;accredited investors,&#8221; as defined in Regulation D, and was conducted on a &#8220;reasonable best efforts&#8221; basis. </font></div><div><a name="sb4475afc5ee54578b3241593afddcba2"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Emerging Growth Company</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including </font><font style="font-family:inherit;font-size:10pt;color:#000000;">if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30, if we have total annual gross revenue of approximately $1.1&#160;billion or more during any fiscal year, or if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise generally applicable to public companies. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reduced disclosure about our executive compensation arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">no requirement that we hold non-binding advisory votes on executive compensation or golden parachute arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have taken advantage of some of these reduced disclosure and other requirements, and thus the information we provide stockholders may be different than you might get from other public companies in which you hold shares.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, Section 107 of the JOBS Act provides that an emerging growth company can use the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. This permits an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sBA8AF9744A83FA68371E28AA86F7074C"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Corporate Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We were originally incorporated in the State of Delaware on February 6, 2017 under the name &#8220;Max-1 Acquisition Corporation.&#8221; Prior to the Merger, Max-1 was a &#8220;shell&#8221; company registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act, with no specific business plan or purpose until it began operating the business of Exicure OpCo through the Merger transaction on September 26, 2017. Exicure OpCo was originally formed as a limited liability company under the name AuraSense Therapeutics, LLC in the State of Delaware in June 2011 and was a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. AuraSense Therapeutics, LLC was subsequently converted into AuraSense Therapeutics, Inc., a Delaware corporation, on July&#160;9, 2015, and changed its name on the same date to Exicure, Inc. Immediately after giving effect to the Merger and the initial closing of the Private Placement, the business of Exicure OpCo became our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our corporate headquarters are located at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077, and our telephone number is (847) 673-1700. We maintain a website at www.exicuretx.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or our other filings with the SEC, and should not be relied upon. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All trademarks, service marks and trade names appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sa0ebce7ffb33442189305dca7ecaca5d"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE OFFERING</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:30%;"></td><td style="width:70%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock offered by selling stockholders</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,714,143 shares (including 413,320 shares of common stock issuable upon the exercise of warrants to purchase common stock held by certain selling stockholders)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,300,823 shares</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of proceeds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will not receive any proceeds from the sale of the shares of common stock offered by the selling stockholders.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The selling stockholders may only sell their shares of our common stock pursuant to this prospectus at a fixed price of $3.00 per share until such time as our common stock is quoted on the OTCQB, or another public trading market for our common stock otherwise develops. At and after such time, the selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk factors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read the &#8220;Risk Factors&#8221; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market for our shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is not now and never has been any market for our securities and an active market may never develop. In connection with this offering, we have arranged for a broker-dealer to apply to have our common stock quoted on the OTCQB or another over-the-counter system. In the future, we intend to seek to have our common stock quoted on a national securities exchange. However, we may not be successful in having our shares quoted on an over-the-counter market or listed on a national securities exchange.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The number of shares of common stock outstanding is based on an aggregate of 39,300,823 shares outstanding as of November 15, 2017, and excludes: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">413,320&#160;shares of common stock issuable upon the exercise of the warrants issued to the Placement Agents in connection with the Private Placement, or the Placement Agent Warrants; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">options to purchase an aggregate of 3,680,997&#160;shares of our common stock that were subject to options originally granted under the Exicure, Inc. 2015 Equity Incentive Plan, or the 2015 Plan, to former Exicure OpCo option holders and assumed by us in connection with the Merger; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">431,750 shares of our common stock reserved under the Exicure, Inc. 2017 Employee Stock Purchase Plan, referred to as the ESPP; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">5,842,525 shares of our common stock, less the number of shares subject to issued and outstanding awards under the 2015 Plan that were assumed in the Merger, reserved for issuance under the Exicure, Inc. 2017 Equity Incentive Plan, or the 2017 Plan, as future incentive awards to executive officers, employees, consultants and directors. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless otherwise indicated in this prospectus, all share and per share figures assume no exercise of outstanding options or warrants after November 15, 2017, and reflect (i) the conversion of all shares of Exicure OpCo common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock then outstanding for an aggregate of 26,666,627 shares of our common stock upon the Effective Time of the Merger on September 26, 2017; and (ii) the filing and effectiveness of our amended and restated certificate of incorporation which occurred on November 15, 2017; provided, however, the share and per share numbers in the audited financial statements of Exicure for the year ended December 31, 2015 and 2016 included in this prospectus are not adjusted to give effect to the Merger. </font></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s8c8e128e5424426d81072ef20dc28900"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY FINANCIAL DATA</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The following tables set forth summary financial data for us as of September 30, 2017 and for the nine months ended September 30, 2017 and 2016, and as of and for the years ended December 31, 2016 and 2015 and should be read together with the our consolidated financial statements and the related notes and the sections of this prospectus entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; appearing elsewhere in this prospectus. The summary financial data in this section is not intended to replace our financial statements and related notes. The summary consolidated financial data as of September&#160;30, 2017 and for the nine months ended September&#160;30, 2017 and 2016 are derived from our unaudited consolidated financial statements included elsewhere in this prospectus. In our opinion, these unaudited consolidated financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such consolidated financial data. The summary financial data as of December 31, 2016 and 2015 and for the years ended December 31, 2016 and 2015 are derived from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of our future results, and our operating results for the nine-month period ended September&#160;30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2017 or any other interim periods or any future year or period.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017 &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Data</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,689</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-redeemable preferred stock</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-2</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-1</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,541</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,604</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">All share and per share figures in the following table are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:4px;text-indent:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months Ended</font></div><div style="text-align:center;padding-left:4px;text-indent:1px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands except share and per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Statement of Operations Data</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,659</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,461</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,719</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,162</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(516</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(149.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,870</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s1A439ABFF26778CE189B28AA879E6D96"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this prospectus, you should carefully consider the risk factors discussed below when considering an investment in our common stock and any risk factors that may be set forth in the applicable prospectus supplement, any related free writing prospectus, as well as the other information contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the market price of our common stock could decline and you could lose some or all of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary SNA technology. We have a limited operating history. Since our inception in June 2011, we have devoted our resources to the development of SNA technology. We have had significant operating losses since our inception. As of September&#160;30, 2017 and as of December&#160;31, 2016, we have generated an accumulated deficit of $50.4&#160;million and $41.4&#160;million, respectively. For the the nine months ended September&#160;30, 2017 and for the years ended December&#160;31, 2016 and 2015, our net loss was $8.9&#160;million, $16.9&#160;million, and $13.2&#160;million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We plan to develop a pipeline of therapeutic candidates using our proprietary SNAs as therapeutic agents. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNAs and the identification and optimization of SNAs is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on SNAs is both preliminary and limited. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">discover that the SNAs do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNAs. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNAs may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock will decline. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Further, the U.S. Food and Drug Administration, or the FDA, has limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize therapeutics using SNAs, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board, or IRB, approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. In our completed Phase 1 trial, AST-005 did not show an antipsoriatic effect. Although we believe this result was due to the short length of this clinical trial, there is no guarantee that AST-005 will show an antipsoriatic effect in future clinical trials of longer duration. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">delays in submitting INDs or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, or European Union national competent authorities, regarding the scope or design of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">delays in enrolling research subjects in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">high drop-out rates of research subjects; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">greater than anticipated clinical trial costs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">poor effectiveness of our therapeutic candidates during clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">failure of our third party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">varying interpretations of data by the FDA and similar foreign regulatory agencies. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of larger, later-stage controlled clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale. As of September&#160;30, 2017 and December&#160;31, 2016, we had $22.9&#160;million and $19.6&#160;million in cash and cash equivalents, respectively. Based on our current operating plan, we believe that our available cash and cash equivalents as of September 30, 2017, when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately $11.2 million for the sale of common stock in the Private Placement, but excluding any potential proceeds from options exercises, is sufficient to fund our current operating plans into 2019. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to establish and maintain successful licenses, collaborations and alliances; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to satisfy the requirements of clinical trial protocols, including patient enrollment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to obtain regulatory approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to obtain additional capital to support and expand our operations; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to market our products to achieve acceptance and use by the medical community in general. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">realize revenue from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants, and proceeds from our loan agreement with Hercules Technology Growth Capital, or Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">variations in the level of expense related to our therapeutic candidates or future development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">additions and departures of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">regulatory developments affecting our therapeutic candidates or those of our competitors; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">changes in general market and economic conditions. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on Purdue for the successful development of therapeutic candidates in our collaboration arrangement with Purdue. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue. As part of the agreement, Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005, an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5 million upon successful completion of certain research, regulatory and commercial sales milestones. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The success of our collaboration programs with Purdue depends largely upon the efforts of Purdue. Purdue has sole discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, it applies to the development and, if approval is obtained, commercialization and marketing of the therapeutic candidates covered by the collaboration. Purdue may not be effective in obtaining approvals for the therapeutic candidates developed under the collaboration arrangement or marketing or arranging for necessary supply, manufacturing or distribution relationships for any approved products. Purdue may change its strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Purdue has a variety of marketed products, and its own corporate objectives may not be consistent with our best interests. If Purdue fails to develop, obtain regulatory approval for or ultimately commercialize any therapeutic candidate under our collaboration or if Purdue terminates our collaboration, our business, financial condition, results of operations and prospects could be materially and adversely affected. In addition, any dispute or litigation proceedings we may have with Purdue in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We rely on third party clinical investigators, contract research organizations, or CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable Good Laboratory Practices, or GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and Good Clinical Practices, or GCPs, including requirements for conducting, recording and reporting the results of preclinical studies and clinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we rely on third party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We rely on third party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a single source supplier on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as current Good Manufacturing Practices, or cGMPs. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to continue to rely on third party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">loss of the cooperation of a future collaborator; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">requirements to cease distribution or to recall batches of our therapeutic candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not successfully engage in strategic transactions, including any collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expense, and present significant distractions to our management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or in-licensing of therapeutic candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved therapeutic candidate do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired therapeutics, therapeutic candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and may have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our therapeutic candidates and have a negative impact on the competitiveness of any therapeutic candidate that reaches market. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded pharmaceutical, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Dynavax Technologies Corp., Idera Pharmaceuticals, Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our lead therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie Inc.&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab and pembrolizumab. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third party payors to accept and use, or to provide favorable reimbursement for, any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the timing of our receipt of any marketing and commercialization approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms of any approvals and the countries in which approvals are obtained; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the safety and efficacy of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">relative convenience and ease of administration of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the willingness of patients to accept any new methods of administration; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the success of our physician education programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the availability of adequate government and third party payor reimbursement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the pricing of our products, particularly as compared to alternative treatments; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless certain exceptions apply. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, David S. Snyder, our Chief Financial Officer, and Ekambar Kandimalla, Ph.D., our Chief Scientific Officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have limited experience in therapeutic development and limited experience with clinical trials of therapeutic candidates. As our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment, registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Price controls imposed in foreign markets may adversely affect our future profitability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our therapeutics or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including debarment or disqualification of those employees from participation in FDA-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive, and financial penalties may also apply. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Skokie, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Skokie facilities comply with the relevant guidelines of Skokie, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our information technology systems could face serious disruptions that could adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our current operations are located in our facilities situated in Skokie, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017 and as of December&#160;31, 2016, we had $22.9&#160;million and $19.6&#160;million in cash and cash equivalents, respectively. We historically have invested excess cash in certificates of deposit or money market mutual funds which invest exclusively in U.S. government or U.S. government agency securities. These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S. sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues. We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounting methods and policies for biotechnology companies, including policies governing revenue recognition, research and development and related expenses, and accounting for stock-based compensation, are subject to review, interpretation and guidance from our auditors and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise change or revise our historical financial statements, including those contained in this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business may be affected by litigation and government investigations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, defense of litigation claims can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of September 30, 2017, our patent portfolio consists of over 45 issued patents and allowed patent applications and over 125 pending patent applications. We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011, involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A third party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will develop additional proprietary technologies that are patentable. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The patents of others will not have an adverse effect on our business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently license patent rights from Northwestern University and may in the future license patent rights from third party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. See &#8220;Description of Our Business&#8212;Our Intellectual Property&#8212;Northwestern University License Agreements.&#8221; We may also license additional third party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutics. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">inter alia</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We or our licensors, or any current or future strategic partners, may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We or our licensors, or any current or future strategic partners, may be subject to third party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">It is also possible that we have failed to identify relevant third party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to pr</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">otect the con</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">fidentiality of our trade secrets, our business and competitive position would be harmed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the terms of the Northwestern University license agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may independently develop similar or superior technology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University license agreements. The Northwestern University license agreements indicate that the rights licensed to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or the Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to the Company&#8217;s knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. In addition, because there may be therapeutic candidates approved for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the therapeutic candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third party payors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Although we do not currently have any products on the market, once we begin commercializing our therapeutic candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;padding-top:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#000000;">presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">adverse regulatory inspection findings; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">warning or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, marketing our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">suspension of review or refusal to approve pending applications or supplements to approved applications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">exclusion from participation in government-funded healthcare programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">exclusion from eligibility for the award of government contracts for our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">FDA debarment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">suspension or withdrawal of therapeutic approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">seizures or administrative detention of therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">injunctions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">civil and criminal penalties and fines. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any therapeutics we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the product is typically furnished incident to a physician&#8217;s services; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use); and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the product has been approved by the FDA. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under current law, as a condition of receiving Medicare Part B reimbursement (the Medicare program that generally covers physician-administered, outpatient drugs) for a manufacturer&#8217;s eligible drugs or biologicals, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program, the Veterans Health Administration program, and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Reimbursement rates under Medicare Part B would depend in part on whether the newly approved therapeutic would be eligible for a unique billing code. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that the efforts of governments and third party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Among the provisions of the ACA addressing coverage and reimbursement of pharmaceutical products, of importance to our potential therapeutic candidates are the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Separately, pursuant to the health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, in recent years, the U.S. Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures. For example, as a result of the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015, an annual 2% reduction to Medicare payments took effect on April&#160;1, 2013 and has been extended through 2025. These across-the-board spending cuts could adversely affect our future revenues, earnings, and cash flows. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing coverage, reimbursement, and marketing of products regulated by CMS or other government agencies. In addition to new legislation, CMS coverage and reimbursement policies are often revised or interpreted in ways that may significantly affect our business and our products. In particular, we expect that the new administration and the U.S. Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive departments </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#8217;s Administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The healthcare industry is heavily regulated in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">the</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a healthcare company, our operations, clinical trial activities and interactions with healthcare providers may be subject to extensive regulation in the U.S., particularly if the company receives FDA approval for any of its therapeutics in the future. For example, if we receive FDA approval for a therapeutic for which reimbursement is available under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g., the False Claims Act), prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g., the federal Anti-Kickback Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals, or Open Payments. We are not able to predict how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices and activities under one or more of these laws. If our past or present operations are found to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Similarly, HIPAA prohibits, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">obtain</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or the BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place, beginning in January 2013, although the American Taxpayer Relief Act of 2012 delayed the BCA&#8217;s automatic cuts until March&#160;1, 2013. While the Medicare program&#8217;s eligibility and scope of benefits are generally exempt from these cuts, Medicare payments to providers and Part D health plans are not exempt. The BCA did, however, provide that the Medicare cuts to providers and Part D health plans would not exceed two percent. President Obama issued the sequestration order on March&#160;1, 2013, and cuts went into effect on April&#160;1, 2013. Additionally, the Bipartisan Budget Act of 2015 extended sequestration for Medicare through fiscal year 2025. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The U.S. federal budget remains in flux, which could, among other things, cut Medicare payments to providers. The Medicare program is frequently mentioned as a target for spending cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. In addition, we cannot predict any impact President Trump&#8217;s administration and the U.S. Congress may have on the federal budget. If federal spending is reduced, anticipated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we could be sued and held liable for harm caused to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the therapeutic may become less competitive; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant developments stemming from the United Kingdom&#8217;s recent referendum on membership in the European Union could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June&#160;23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union. This referendum has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and this uncertainty may last for years. Any business we conduct, now and in the future, in the United Kingdom, the European Union, and worldwide could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom&#8217;s referendum. The referendum, and the likely withdrawal of the United Kingdom from the European Union it triggers, has caused and, along with events potentially occurring in the future as a consequence of the United Kingdom&#8217;s withdrawal, including the possible breakup of the United Kingdom, may continue to cause significant volatility in global financial markets, including in global currency and debt markets. This volatility could cause a slowdown in economic activity in the United Kingdom, Europe, or globally, which could adversely affect our operating results and growth prospects. In addition, our business could be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">negatively affected by new trade agreements between the United Kingdom and other countries, including the U.S., and by the possible imposition of trade or other regulatory barriers in the United Kingdom. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">It is currently unclear how regulations affecting clinical trials, the approval of our future therapeutic candidates, and the sale of these therapeutic candidates will be affected by this referendum either in the United Kingdom or elsewhere in Europe. These possible negative impacts, and others resulting from the United Kingdom&#8217;s actual or threatened withdrawal from the European Union, may adversely affect our operating results and growth prospects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock and the Offering </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data in this prospectus. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.1&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If a market for our common stock develops, its market price could fluctuate substantially due to a variety of factors, including the other risks described in this section of the prospectus titled &#8220;Risk Factors&#8221; and the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the success of competitive therapeutics or technologies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our therapeutics; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the recruitment or departure of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">announcement and expectation of additional financing efforts; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">speculation in the press or investment community; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">trading volume of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the concentrated ownership of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">changes in accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">natural disasters and other calamities; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">general economic, industry and market conditions. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The future issuance of equity or of debt securities that are convertible into equity may dilute your investment and reduce your equity interest. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. To the extent that additional capital is raised through the issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities. For example, we have agreed, at our expense, to prepare this registration statement, and to cause us to file this registration statement with the SEC registering the resale of up to a maximum of 46,269,418 shares of our common stock issued in connection with the Merger and the Private Placement or held by pre-Merger stockholders of Max-1. Once effective, this registration statement will permit the resale of these shares at any time for up to five years following the effective date of this registration statement. The resale of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Furthermore, we expect that, because there will be a large number of shares registered pursuant to this registration statement, selling stockholders will continue to offer shares covered by this registration statement for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to this registration statement may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our&#160;debt obligations expose us to risks that could adversely affect our business, operating results and&#160;financial condition and may result in further dilution to our stockholders. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have entered into a loan and security agreement with Hercules pursuant to which we may borrow in an aggregate principal amount of up to $10.0&#160;million from Hercules at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;color:#000000;">) minus 3.50%. We were required to make interest only payments on the amounts borrowed until June 2017. Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019. Any remaining obligations under the loan agreement and other loan documents (other than the warrant) are due and payable on the maturity date. On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement. To the extent we desire to prepay the indebtedness prior to maturity, we will be obligated to pay a prepayment penalty to Hercules ranging from 1% to 3% of the amounts being prepaid, depending on when such prepayment occurs. The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets. Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing. Hercules has not yet exercised this right to participate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our ability to make payments on this indebtedness depends on our ability to generate cash in the future. We expect to experience negative cash flow for the foreseeable future as we fund our operations and capital expenditures. There can be no assurance that we will be in a position to repay this indebtedness when due or obtain extensions of the maturity date. We anticipate that we will need to secure additional funding in order for us to be able to satisfy our obligations when due. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If that additional funding involves the sale of equity securities or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">convertible securities, it would result in the issuance of additional shares of our capital stock, which would result in dilution to our stockholders. The indebtedness is secured by substantially all of our assets other than intellectual property, on which we have given Hercules a negative pledge. In addition, under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without the prior consent of Hercules. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This level of debt could have important consequences to you as an investor in our securities. For example, it could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">limit our flexibility in planning for the development, clinical testing, approval and marketing of our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">place us at a competitive disadvantage compared to any of our competitors that are less leveraged than we are; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">increase our vulnerability to both general and industry-specific adverse economic conditions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">limit our ability to obtain additional funds. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The employment agreements with our executive officers may require us to pay severance benefits to officers in connection with termination of employment or upon a change of control of us, which could harm our financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each of David A. Giljohann, our Chief Executive Officer, Ekambar Kandimalla, our Chief Scientific Officer, and David S. Snyder, our Chief Financial Officer, is entitled to receive cash severance equal to twelve months, six months, and six months, respectively, of his base salary if his employment is terminated by us without cause (as such term is defined in his employment offer letter). In addition, our 2015 Plan, which was assumed by us in the Merger, generally provides for accelerated vesting of equity awards upon the involuntary termination of an employee within the twelve month period following a change in control (as defined under the plan) and accelerated vesting of equity awards upon a change of control (as defined under the plan) for each of our executive officers. This vesting acceleration is intended to provide each of our executive officers with the full benefit of their equity awards and reward them for a successful outcome for our stockholders. The accelerated vesting of equity awards could result in dilution to our existing stockholders and harm the market price of our common stock. The payment of these severance benefits could harm our financial condition. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There is currently no market for our common stock and we cannot assure you that any market will ever develop. You may therefore be unable to re-sell shares of our common stock at times and prices that you believe are appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is not listed on a national securities exchange or any other exchange, or quoted on an over-the-counter market. Therefore, there is no trading market, active or otherwise, for our common stock and our common stock may never be included for trading on any stock exchange, automated quotation system or any over-the-counter market. Accordingly, our common stock is highly illiquid and you will likely experience difficulty in re-selling such shares at times and prices that you may desire and without depressing the market price for the shares or at all. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our common stock may not be eligible for listing or quotation on any securities exchange. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not currently meet the initial quantitative listing standards of any national securities exchange or over-the-counter trading system. We</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">cannot assure you that we will be able to meet the initial listing standards of any national securities exchange, or, if we do meet such initial listing</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">standards, that we will be able to maintain any such listing. Further, the national securities exchanges are adopting so-called &#8220;seasoning&#8221; rules that</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">will require that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">we meet certain requirements, including prescribed periods of time trading over-the-counter and minimum filings of periodic reports</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">with the SEC, before we are eligible to apply for listing on such national securities exchanges. We have contacted an authorized market maker for</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">an over-the-counter quotation system for sponsorship of our common stock, but we cannot guarantee that such sponsorship will be approved and</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">our common stock listed and quoted for sale. Even if our common stock is quoted for sale on an over-the-counter quotation system, buyers may</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">be insufficient in numbers to allow for a robust market and it may prove impossible to sell your shares. In addition, an investor may find it difficult</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">to obtain accurate quotations as to the market value of our common stock. In addition, if we fail to meet the criteria set forth in SEC regulations,</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">accredited investors. Consequently, such regulations may deter broker-dealers from recommending or selling our common stock, which may further</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">affect its liquidity. This would also make it more difficult for us to raise additional capital. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The designation of our common stock as a &#8220;penny stock&#8221; would limit the liquidity of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock may be deemed a &#8220;penny stock&#8221; (as that term is defined under Rule 3a51-1 of the Exchange Act) in any market that may develop in the future. Generally, a &#8220;penny stock&#8221; is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share. Prices often are not available to buyers and sellers and the market may be very limited. Penny stocks in start-up companies are among the riskiest equity investments. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">document prepared by the SEC. The document provides information about penny stocks and the nature and level of risks involved in investing in</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">the penny stock market. A broker must also provide purchasers with bid and offer quotations and information regarding broker and salesperson</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">compensation and make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">agreement to the purchase. Many brokers choose not to participate in penny stock transactions. Because of the penny stock rules, there may be</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">less trading activity in penny stocks in any market that develops for our common stock in the future and stockholders are likely to have difficulty</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">selling their shares. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The shares of common stock issued in connection with the Merger and the Private Placement are &#8220;restricted securities&#8221; and, as such, may not be sold except in limited circumstances. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">None of the shares of common stock issued in connection with the Merger and the Private Placement have been registered under the Securities Act or registered or qualified under any state securities laws. The shares of common stock issued in connection with the Merger and the Private Placement were sold and/or issued and will be sold and/or issued pursuant to exemptions contained in and under those laws. Accordingly, such shares of common stock are &#8220;restricted securities&#8221; as defined in Rule 144 under the Securities Act and must, therefore, be held indefinitely unless registered under applicable federal and state securities laws, or an exemption is available from the registration requirements of those laws. The certificates representing the shares of common stock issued in connection with the Merger and the Private Placement reflect their restricted status. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed to register the shares of common stock issued in connection with the Merger and the Private Placement and shares of common stock held by the pre-Merger stockholders of Max-1. We cannot assure you, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">however, that the SEC will declare this registration statement effective, thereby enabling the shares of common stock issued in connection with the Merger or the Private Placement or held by our pre-Merger stockholders to be freely tradable. In addition, Rule 144 under the Securities Act, which permits the resale, subject to various terms and conditions, of limited amounts of restricted securities after they have been held for six months will not immediately apply to our common stock because we were at one time designated as a &#8220;shell company&#8221; under SEC regulations. Pursuant to Rule 144(i), securities issued by a current or former shell company that otherwise meet the holding period and other requirements of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after the date on which the issuer filed current &#8220;Form 10 information&#8221; (as defined in Rule 144(i)) with the SEC reflecting that it ceased being a shell company, and provided that at the time of a proposed sale pursuant to Rule 144, the issuer has satisfied certain reporting requirements under the Exchange Act. We believe this requirement to file Form 10 information has been satisfied by the filing of our Current Report on Form 8-K with the SEC on October 2, 2017 , as amended by our Current Report on Form 8-K/A filed with the SEC on November 7, 2017, or the Form 8-K. Because, as a former shell company, the reporting requirements of Rule 144(i) will apply regardless of holding period, the restrictive legends on certificates for the shares of common stock issued in connection with the Merger and the Private Placement cannot be removed except in connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to timely register the shares of common stock issued to stockholders in the Merger or the Private Placement, then the ability to re-sell shares of such common stock will be delayed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed, at our expense, to prepare this registration statement, and to cause our Company to file this registration statement with the SEC registering the resale of up to a maximum of 46,269,418 shares of our common stock issued in connection with the Merger and the Private Placement or held by our pre-Merger stockholders. To the extent this registration statement is not declared effective by the SEC, or there are delays resulting from the SEC review process and comments raised by the SEC during that process, the shares of common stock proposed to be covered by this registration statement will not be eligible for resale until this registration statement is effective or an exemption from registration, such as Rule 144, becomes available. If this registration statement is not filed within 60 days of the final closing of the Private Placement, then we may be subject to certain liquidated damages pursuant to the registration rights agreement we entered into with the holders of up to a maximum of 46,269,418 shares of our common stock issued in connection with the Merger and the Private Placement or held by our pre-Merger stockholders. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because our management will have broad discretion over the use of the net proceeds from the Private Placement, you may not agree with how we use them and the proceeds may not be invested successfully. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to use the net proceeds to us from the Private Placement to fund research and development, preclinical studies and clinical trial expenses and potential in-licensing of intellectual property and technology or other acquisition activities, and other general corporate purposes, including funding the costs of operating as a public company, and therefore, our management will have broad discretion as to the use of the Private Placement proceeds. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for our Company. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, and because we will not be listed on a national securities exchange, security analysts of brokerage firms may not provide coverage of our Company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development. The failure to receive research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because the Merger was a reverse merger, the registration statement we file with respect to the shares of common stock received by investors in connection with the Merger and the Private Placement and held by the pre-Merger stockholders of Max-1 may be subject to heightened scrutiny by the SEC. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain SEC rules are more restrictive when applied to reverse merger companies, such as the ability of stockholders to re-sell their shares of common stock pursuant to Rule 144, and the SEC may subject the registration statement we file with respect to the shares of common stock received by investors in connection with the Merger and the Private Placement and held by the pre-Merger stockholders of Max-1 to heightened scrutiny. In addition, securities analysts of major brokerage firms may not provide coverage of our capital stock or business. Because we became a public reporting operating company through a reverse merger, there is no incentive to brokerage firms to recommend the purchase of our common stock. We cannot assure you that brokerage firms will want to provide analyst coverage of our capital stock or business in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Based on the beneficial ownership of our common stock as of November 15, 2017, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;47.9 percent of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our corporate documents and the DGCL contain provisions that may enable our board of directors to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">stagger the terms of our board of directors and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">authorize our board of directors to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of any national securities exchange or other exchange and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a public company, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on any national securities exchange or other exchange or quoted on an over-the-counter market. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may incur significant costs from class action litigation due to our expected stock volatility. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of current or future collaborators or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. This risk is especially relevant to us because pharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. The Merger, our prior equity offerings and other changes in our stock ownership may have resulted in ownership changes. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><a name="s5A6C79E1D5CAFFAA99BA28AA87F00B75"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE MERGER, THE PRIVATE PLACEMENT, AND RELATED TRANSACTIONS </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Merger </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;26, 2017, Max-1, Max-1 Acquisition Sub, Inc., and Exicure OpCo entered into the Merger Agreement. Pursuant to the terms of the Merger Agreement, on September&#160;26, 2017, Max-1 Acquisition Sub, Inc. merged with and into Exicure OpCo, which was the surviving corporation and thus became our wholly-owned subsidiary. At the Effective Time of the Merger, each outstanding share of Exicure OpCo&#8217;s common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into 0.49649 shares of our common stock, and each outstanding share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into 0.7666652 shares of our common stock. As a result, an aggregate of 26,666,627 shares of our common stock were issued to the holders of Exicure OpCo&#8217;s capital stock after adjustments due to rounding for fractional shares. In addition, pursuant to the Merger Agreement options to purchase 7,414,115 shares of Exicure OpCo&#8217;s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase 3,680,997&#160;shares of our common stock. See</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8220;Description of Capital Stock&#8212;Options&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">below for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the consummation of the Merger, Exicure OpCo changed its name to &#8220;Exicure Operating Company&#8221; and we adopted Exicure OpCo&#8217;s former company name, &#8220;Exicure, Inc.&#8221;, as our company name. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the Merger, we acquired the business of Exicure OpCo, a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. See</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8220;Description of Our Business&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">below</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger Agreement contained customary representations and warranties and pre- and post-closing covenants of each party and customary closing conditions. As a condition to the Merger, we entered into an indemnity agreement with our former officers and directors, or the Pre-Merger Indemnity Agreement, pursuant to which we agreed to indemnify such former officers and directors for actions taken by them in their official capacities relating to the consideration, approval and consummation of the Merger and certain related transactions. The form of the Pre-Merger Indemnity Agreement is filed as an exhibit to this prospectus. All descriptions of the Pre-Merger Indemnity Agreement herein are qualified in their entirety by reference to the text thereof filed as an exhibit hereto, which is incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger was treated as a recapitalization and reverse acquisition for our Company for financial reporting purposes. Exicure OpCo is considered the acquirer for accounting purposes, and our historical financial statements before the Merger will be replaced with the historical financial statements of Exicure OpCo before the Merger in filings with the SEC. The Merger was intended to be treated as a tax-free reorganization under Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The issuance of shares of our common stock, and options to purchase our common stock, to holders of Exicure OpCo&#8217;s capital stock and options in connection with the Merger was not registered under the Securities Act, in reliance upon the exemption from registration provided by Section&#160;4(a)(2) of the Securities Act, which exempts transactions by an issuer not involving any public offering, and Rule 506(b) of Regulation D promulgated by the SEC. These securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement, and are subject to further contractual restrictions on transfer as described below. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Private Placement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the Effective Time of the Merger, we sold an aggregate of 10,504,196 shares of our common stock pursuant to closings of a Private Placement for up to 13,333,333 shares of our common stock on September 26, 2017, October 27, 2017 and November 2, 2017, respectively, at the Sale Price of $3.00 per share. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We and the Placement Agents may agree to extend the period for additional closings up to November 30, 2017. To the extent the period for additional closings is extended and the Private Placement is over-subscribed, the Company</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;may also sell </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">an additional 3,333,333 shares of common stock at the Sale Price to cover over-subscriptions in the event the Private Placement is oversubscribed. We granted to the investors in the Private Placement registration rights requiring us to register those shares of common stock for public resale. The then existing stockholders of Exicure who agreed to become parties to the registration rights agreement also became entitled to such registration rights. As of November 15, 2017, the aggregate gross proceeds from the Private Placement were $31.5 million (before deducting placement agent fees and expenses of such closings, which are estimated at approximately $4.0 million).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to certain customary exceptions, investors in the Private Placement have anti-dilution protection with respect to the shares of common stock sold in the Private Placement such that if within eighteen (18)&#160;months after the initial closing of the Private Placement we issue certain additional shares of common stock or common stock equivalents for a consideration per share less than the Sale Price, or the Lower Price, each such investor will be entitled to receive from us additional shares of common stock in an amount such that, when added to the number of shares of common stock initially purchased by such investor in the Private Placement and still held of record and beneficially owned by such investor at the time of the dilutive issuance, or the Held Shares, will equal the number of shares of common stock that such investor&#8217;s aggregate purchase price for the Held Shares would have purchased at the Lower Price. Either (i)&#160;holders of a majority of the then Held Shares or (ii)&#160;a representative of the holders of the then Held Shares, which representative shall be appointed by the three investors who then hold the largest number of Held Shares, may waive the anti-dilution rights of all Private Placement investors with respect to a particular issuance by us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This price-based anti-dilution protection will automatically terminate upon our receipt of gross proceeds of $40.0&#160;million or more in one or more related closings in a bona fide transaction in which we issue shares of common stock or certain common stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed to indemnify and hold harmless Katalyst Securities LLC, its affiliates, officers, directors, employees, agents and controlling persons, each an Indemnified Person, to the fullest extent permitted by law, against certain liabilities that may be incurred in connection with the Private Placement, including certain liabilities under the Securities Act, and, where such indemnification is not available, to contribute to the payments an Indemnified Person may be required to make in respect of such liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each investor in any subsequent closing of the Private Placement, or a Subsequent Closing, was required, or will be required, to represent that, at the time of the applicable closing, it (i)&#160;had a substantive, pre-existing relationship with us, or had direct contact with the Company or the Placement Agents or other enumerated parties outside of the Private Placement, (ii)&#160;was not identified or contacted through the marketing of the Private Placement, and (iii)&#160;did not independently contact us as a result of general solicitation by means of our Current Report on Form 8-K filed with the SEC on October 2, 2017, as amended, any press release or any other public disclosure disclosing the material terms of the Private Placement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The closings of the Private Placement were exempt from registration under Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Private Placement was sold to &#8220;accredited investors,&#8221; as defined in Regulation D, and was conducted on a &#8220;reasonable best efforts&#8221; basis. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The form of the Merger Agreement, the forms of Subscription Agreement entered into in connection with the closings of the Private Placement, the Purchaser Rights Letter and the forms of the Placement Agent Warrants described herein are each filed as an exhibit to this prospectus. All descriptions of the Merger Agreement, Subscription Agreements, the Purchaser Rights Letter and Placement Agent Warrants herein are qualified in their entirety by reference to the text thereof filed as exhibits hereto, which are incorporated herein by reference.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><a name="s76D2451D398D1357FDCE28AA8B12383F"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF OUR BUSINESS </font></div><div><a name="sAB978B8BAA848173EA8D28AA8B322264"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary SNA technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in a Phase 1 clinical trial of our lead therapeutic candidate, AST-005, and in preclinical studies of two other therapeutic candidates, XCUR17 and AST-008, both of which we are advancing to the clinic.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting TNF for the treatment of mild to moderate psoriasis that is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle. While we did not observe an antipsoriatic effect in our Phase 1 clinical trial, we believe this is due to the short duration of the treatment. The results of a clinical trial with etanercept, a systemic TNF inhibitor, indicate that at least four weeks of therapy is required before antipsoriatic efficacy can be observed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue, referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to&#160;AST-005,&#160;an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets.&#160; Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a&#160;non-refundable&#160;development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5&#160;million upon successful completion of certain research, regulatory and commercial sales milestones. We cannot assure you that these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our second therapeutic candidate, XCUR17, is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway, in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the keratinocytes of the skin.  We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect this clinical trial to be completed in mid-2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our third therapeutic candidate,&#160;AST-008,&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors.  We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">colon cancer, breast cancer, lymphoma and melanoma mouse models. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008&#160;applied in combination with certain checkpoint inhibitors exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. Importantly, in an&#160;anti-PD-1&#160;antibody-resistant breast cancer mouse model, administration of&#160;AST-008&#160;with certain&#160;anti-PD-1,&#160;or programmed death 1, antibodies restored the anti-tumor activity of these antibodies. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of&#160;AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models. We filed a CTA for a Phase 1 clinical trial of&#160;AST-008&#160;in the United Kingdom in the second quarter of 2017. In the third quarter of 2017, we received an authorization from the MHRA, the competent health authority of the United Kingdom, to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. We expect this trial to be completed in mid-2018.  We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors.</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Given the extensive potential therapeutic applications for our SNA platform, we believe it is important to enter into selective partnerships to broaden the indications we can pursue and accelerate the development of new programs. To that end, on December&#160;2, 2016, we entered into the Purdue Collaboration. We believe this collaboration exemplifies our strategy of establishing alliances with leaders with a proven track record in the development and global commercialization of treatments for patients with chronic conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that we have a strong intellectual property, or IP, position in the field of SNA therapeutics. As of September 30, 2017, our patent portfolio consists of over 45 issued patents and allowed patent applications and over 125 pending patent applications. We have licensed IP from Northwestern University and have also independently filed patents to protect our IP. Our license from Northwestern University is for exclusive worldwide rights to the use of SNA technology for therapeutic applications. Any patents arising from&#160;AST-005,&#160;XCUR17 or AST-008 applications would expire by 2035, 2037, and 2034 or 2035, respectively.</font></div><div><a name="s53693CE3A3DA9B2D5CC728AA8B647FE4"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to build a leading nucleic acid therapeutics company based on our proprietary SNA technology. The key elements of our strategy are: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Support Purdue in its clinical development of AST-005.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In October 2016, we completed a Phase 1 clinical trial for the treatment of mild to moderate psoriasis that suggested that AST-005, delivered topically, is potentially capable of gene regulation in the skin. We believe these results preliminarily demonstrate the potential therapeutic application of SNA as a platform for local gene regulation. AST-005 is the subject of the Purdue Collaboration. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Advance therapeutics incorporating our SNA technology for the treatment of skin diseases.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect this clinical trial to be completed in mid-2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Advance AST-008 through clinical development for immuno-oncology applications. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We have conducted preclinical studies of AST-008 in immuno-oncology applications including bladder, breast and colorectal cancer, lymphoma and melanoma. We believe AST-008 is applicable in two cancer treatment strategies: as a monotherapy or in combination with checkpoint inhibitors. We began our Phase 1 clinical trial for&#160;AST-008&#160;in the United Kingdom in the fourth quarter of 2017. We expect this trial to be completed in mid-2018.  We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;padding-top:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe AST-008 may be an attractive partnership candidate and we may explore that possibility after our Phase 1 clinical trial results are available. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Use our proprietary SNA technology to develop additional therapeutic candidates.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;One of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. We expect that our gene regulatory SNAs may have potential therapeutic applications in organs beyond the liver, such as the brain, eye, gastrointestinal tract, lung and skin. We believe the most promising therapeutic targets for SNAs are antibody targets with confirmed therapeutic benefit. We envision taking advantage of these properties by inhibiting these targets with local application of SNAs. We believe that this approach combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapy. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Enter into additional partnerships to accelerate development and commercialization of our SNA therapeutic candidates.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Our proprietary SNA technology allows for the potential therapeutic application of nucleic acids in multiple tissues and organs, providing the opportunity to partner with pharmaceutical companies that have development or commercial expertise in a particular therapeutic area of interest where it would be uneconomical or impractical for us to develop SNA therapeutics independently. In addition, in the immuno-oncology field, in preclinical studies we have demonstrated the ability of our immuno-oncology SNAs to work in combination with certain checkpoint inhibitors, creating further potential  opportunities to partner our SNAs with companies developing or marketing checkpoint inhibitors. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Build, enhance and protect our proprietary SNA intellectual property. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe the three-dimensional structure of our SNAs provides novel technological and commercial opportunities. We have licensed IP from Northwestern University and have also filed patents independently to protect our IP. Our license from Northwestern University is for exclusive worldwide rights to the use of SNA technology for therapeutic applications. We will continue to protect our IP and innovations arising from our research and development efforts, and prudently in-license technologies where appropriate for protection of our therapeutic pipeline and the broader SNA technology.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Any patents arising from AST-005, XCUR17 or AST-008 applications would expire by 2035, 2037, and 2034 or 2035, respectively. </font></div></td></tr></table><div><a name="sC88592E2DE55D312666C28AA8B857D57"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Introduction to Nucleic Acid Therapeutics </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview of nucleic acids as a therapeutic modality </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Historically, therapeutic development has been focused on small molecules and biologics, or protein-based therapeutics, including antibodies. Development of small molecule therapeutics often involves screening thousands of compounds, sometimes without a known protein structure or active site to which the small molecule can bind and affect its disease-related function. Protein-based therapeutics are also subject to limitations. For example, the choice of targets that antibodies can address is typically limited to extracellular protein targets. However, the majority of protein targets are located inside the cell, making them undruggable by antibodies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Nucleic acid therapeutics represent a treatment approach differing in many important ways from small molecules and biologics. Nucleic acid therapeutics are based on the well-established scientific understanding that DNA in the nucleus of cells is converted into an intermediate molecule, called messenger RNA, or mRNA, that serves as the template for making proteins. Therapeutic gene regulation is the use of nucleic acid therapeutics to modulate the production of target proteins by changing the amount of mRNA that is converted to protein, thereby providing an approach to treating diseases at their genetic origin. Our SNAs are a type of nucleic acid therapeutic. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe the development timeline for nucleic acid therapeutic candidates will be shorter than that of small molecules and antibodies. Nucleic acid therapeutics can be directed against most mRNA, including the mRNA of proteins that cannot be targeted by small molecules or antibodies. Due to the detailed knowledge of mRNA sequences in humans, nucleic acid therapeutics can be engineered to be specific to a region of an mRNA sequence while interacting minimally with all other mRNA sequences. Moreover, due to the well-defined length and composition of mRNA sequences, a relatively small set of rationally designed therapeutic candidates, usually </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">hundreds, can be synthesized and tested for activity against an mRNA target. This is in contrast to the small molecule drug development process that requires a much larger number of candidates to be screened. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Challenges in developing nucleic acid therapeutics </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Significant progress has been made in the development of nucleic acid therapeutics. As of the fourth quarter of 2017, four nucleic acid therapeutics were being marketed and many were in various stages of clinical development. However, we believe there are ongoing technical challenges in the nucleic acid therapeutics field. Nucleic acids are molecules that, when administered without proper formulation, encounter a number of barriers to their bioavailability, biodistribution, and desired biological activity. These challenges have often been met by chemically modifying the oligonucleotide and by encapsulating or complexing it with a lipid or polymer carrier. Despite these advances in the delivery of oligonucleotides, the biodistribution of these molecules remains a challenge since oligonucleotides typically accumulate in the liver after subcutaneous or intravenous administration, thereby limiting their primary application to diseases of the liver. In contrast, the results of our Phase 1 clinical trial of AST-005 demonstrated the potential therapeutic application of our gene regulatory SNAs to modulate target mRNA expression after topical application to psoriatic lesions. Further, in an array of experiments, we have demonstrated that SNAs, administered locally without encapsulation or complexation, enter cells and organs. We believe the local administration of our gene regulatory SNAs will potentially enable safe and efficacious therapeutic applications to organs beyond the liver. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview of immuno-oncology as a therapeutic modality </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In healthy individuals, the immune system fights off pathogens, such as bacteria and viruses. The immune system should also recognize cancer cells as foreign and eliminate them. However, cancers present a challenge because they have developed strategies to resist detection and clearance by the immune system. Immuno-oncology approaches help the patient&#8217;s immune system identify a cancer as foreign and stimulate a tumor-clearing immune response. One of the greatest benefits of the immuno-oncology approach is the continuous, durable anti-tumor response that can be achieved long after discontinuation of treatment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Current immuno-oncology therapeutic approaches generally fall into three broad categories. First, there are approaches that stimulate the immune system to detect and eliminate tumors. Examples include cytokines and toll-like receptor, or TLR, agonists. Second, some therapeutics make a cancer more readily visible to the immune system. These therapeutics include checkpoint inhibitors, such as those that target CTLA4, or cytotoxic T-lymphocyte-associated protein 4, PD-1, and PD-L1, or programmed death-ligand 1. Third, there are adoptive cell transfer therapies, including dendritic cell vaccines and chimeric antigen receptor T-cells, or CAR-Ts, that direct the immune system to target a specific type of cancer. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The knowledge of the TLR activation pathway is central to the understanding of how the immune system is stimulated to target cancer. TLRs are membrane- and endosome-bound receptors found on a number of cell types, including specialized immune cells. TLRs recognize specific molecular patterns ordinarily presented by pathogens. When cells recognize pathogens, they produce and release protein signals called cytokines that mobilize the immune system to fight invading pathogens. In addition, they activate antigen presenting cell and helper T-cells, which then coordinate the longer-term pathogen specific adaptive immune response, and as a result, confer long-term immunity to the host.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Checkpoint proteins, such as CTLA4 and PD-1, are expressed on the surface of T-cells and inhibit the function of activated T-cells. Cancers are difficult to treat because they have developed mechanisms to take advantage of these checkpoint proteins thereby evading detection and clearance by the immune system. Inhibiting these checkpoint proteins, especially PD-1 and PD-L1, has proven to be a highly effective anti-cancer therapy in some patients. Nevertheless, checkpoint inhibitors targeting the PD-1 pathway have limited clinical efficacy as monotherapy, with response rates of 20% or less in many common types of cancers, including breast and colon cancers. Emerging evidence suggests that checkpoint inhibitors are effective primarily in patients whose tumors already have pre-existent CD8 T-cell infiltrate, i.e. immune system is already capable of recognizing the tumors. We </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">believe the challenge in the field is to increase the efficacy of checkpoint inhibitors in a broader cancer patient population by converting tumors that are non-T-cell inflamed to T-cell inflamed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Preclinical data suggest our immuno-oncology SNAs delivered in combination with certain checkpoint inhibitors generate a greater anti-tumor activity than such checkpoint inhibitors alone. In mouse tumor models, administration of AST-008 with anti-PD-1 antibodies suppresses regulatory T-cells, or Tregs, and myeloid-derived suppressor cells, or MDSCs, and increases the levels of CD8 effector T-cells. We believe these important results suggest that the combination of immuno-oncology SNAs and checkpoint inhibitors could potentially treat a larger proportion of cancer patients than checkpoint inhibitors alone. </font></div><div><a name="s47288C9C0E601B5BF8D628AA8BB75DD3"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Proprietary Technology: Spherical Nucleic Acids </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our therapeutic discovery and development efforts rely on our proprietary SNA technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid molecules that are radially arranged in three dimensions. We refer to these synthetic nucleic acid molecules in our SNAs as oligonucleotides and the radial orientation of the oligonucleotides without lipid or polymer encapsulation as our &#8220;inside out&#8221; or &#8220;3-D&#8221; approach. Our SNAs, unlike many other nucleic acid therapeutics, do not require lipid or polymer encapsulation or complexation in order to be delivered. Encapsulation is the process of confining the nucleic acids inside the cavities of larger structures, typically liposomes, whereas complexation is the process of creating an assembly of nucleic acids bound together with other molecules, typically lipids or polymers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This arrangement of oligonucleotides allows our proprietary SNAs to enter cells through class A scavenger receptors. Class&#160;A scavenger receptors are commonly found on the surface of cells throughout the body, which we believe provides a ubiquitous mechanism of cellular entry for the local administration of our SNA therapeutic candidates. This mechanism of cellular entry is different from many other nucleic acid therapeutics that typically bind to receptors found only in the liver. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The broad cellular and tissue penetration properties of SNAs enable two distinct therapeutic approaches. Gene regulatory SNAs can be designed to modulate the production of target proteins for a potential therapeutic benefit without triggering an unintended immune response. Immuno-oncology SNAs can be designed to potentially elicit an anti-tumor immune response. Accordingly, we are developing both gene regulatory SNAs for diseases beyond the liver and immuno-oncology SNAs for solid and hematological cancers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Examples of our proprietary SNA constructs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;"><img src="twosnasa04.jpg" alt="twosnasa04.jpg" style="height:261px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">All of our SNAs contain oligonucleotides that are densely packed and radially oriented. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe the key advantages of our proprietary SNAs include: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">SNAs cross certain biological barriers to deliver nucleic acid therapeutics. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Local delivery of nucleic acid therapeutics through biological barriers, such as the skin, has been a significant technical challenge. In our successful Phase 1 clinical trial of AST-005, we showed that SNAs can be delivered without the use of needles, and that our SNAs are capable of reducing the expression of the target TNF gene in lesional patient skin after topical application. Further, in preclinical studies, we have demonstrated delivery and activity of our SNAs in the eye, lung, and gastrointestinal tract. Considered together, we believe that these results indicate that the SNA platform has therapeutic potential for gene regulation in the skin. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Gene regulatory SNAs are potentially well tolerated.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Phase 1 clinical trial of AST-005 resulted in no drug associated adverse events when AST-005 was applied topically to the skin of patients with mild to moderate psoriasis. There are three key elements to our safety strategy. First, by administering gene regulatory SNAs locally, we expect to avoid systemic exposure thereby decreasing safety risk. Second, because SNAs enter cells and tissues without lipid or polymer encapsulation or complexation, we expect to avoid the toxicity risks associated with these delivery systems. Finally, due to the nuclease resistance attributable to the architecture of the SNA, we use fewer chemical modifications than are customary in nucleic acid therapeutic development. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">SNAs can be administered locally into a number of different cell and tissue types. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">SNAs enter cells through class A scavenger receptors, which are present on the surface of many cell types. We believe that by accessing this mechanism, our SNAs could have therapeutic applications in organs beyond the liver, such as the brain, eye, gastrointestinal tract, lung, and skin. In preclinical studies, more than 50 cell lines and primary cells have been shown to internalize SNAs. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Immuno-oncology SNAs may produce a powerful immune response against tumors.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In preclinical studies, SNAs localized to endosomes and stimulated the immune system via TLRs. We have also observed in preclinical studies that SNAs can generate a cancer-specific adaptive immune response. In addition, in preclinical studies in a variety of cancer models, SNAs, in combination with certain checkpoint inhibitors, exhibited a greater anti-tumor response and increased survival than did such checkpoint inhibitors alone. Moreover, when administered as a monotherapy, AST-008 exhibited anti-tumor activity in mouse cancer models. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">SNAs have shown greater resistance to nuclease degradation.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Nucleases are proteins that degrade oligonucleotides. In preclinical studies, SNAs have been shown to have an increased nuclease resistance compared to linear oligonucleotides. We believe this is a result of our 3-D approach, and as a consequence, we believe that smaller amounts of SNAs may be required to achieve therapeutic efficacy compared to linear oligonucleotides. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">SNAs can be manufactured at commercial scale. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Based on our manufacturing work to date, we believe</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">SNAs can be made in a low cost, high-throughput, scalable, and reproducible manner using cGMPs. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We plan to develop SNA-based therapeutics utilizing two distinct approaches. First, we will use SNA constructs containing oligonucleotides for gene regulation applications in target organs. Our first development programs have been focused on the skin because of a combination of unmet medical need and low barriers to achieving therapeutic and mechanistic proof of concepts. As we progress, we will explore the use of SNAs in other local applications, such as the brain, lung, eye and gastrointestinal tract. Second, we will seek to design SNAs for immuno-oncology applications. We believe the properties of our proprietary SNAs will allow us to develop therapeutic candidates in both fields. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="sD33098AA3304413E160128AA8BD78D25"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gene regulatory SNAs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Introduction to gene regulation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Gene regulation is the process of modulating target protein levels within cells. This could be a powerful approach for developing targeted therapies for diseases with known genetic origins. This approach may be for therapeutic targets that are identified as &#8220;undruggable&#8221; with small molecules or antibodies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Gene regulation can be achieved with a number of approaches, three of which, siRNA-, miRNA-, and antisense-based therapeutics, have been the focus of commercial development. Small interfering RNAs, or siRNAs, are double-stranded RNA-like oligonucleotides that harness RNA interference, or RNAi, a potent and natural biological mechanism. When delivered into cells, siRNAs can lead to target mRNA degradation and a decrease in protein expression. miRNAs are naturally occurring small RNA molecules that modulate protein expression. Antisense therapeutics are short single-stranded oligonucleotides that bind to target mRNA and thus prevent its translation into protein. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Gene regulatory SNA advantages for therapeutic applications </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe our gene regulatory SNAs provide the attractive features of nucleic acid therapeutics while potentially overcoming their limitations. In preclinical studies we demonstrated that gene regulatory SNAs can enter cells to a much greater extent than linear oligonucleotides and we believe do so with minimal toxicity. Our gene regulatory SNAs are designed to enter cells through class A scavenger receptors. These class A receptors are commonly found on the surface of cells throughout the body thereby providing a mechanism of cellular entry that can be accessed through the local administration of SNA therapeutics. This mechanism of cellular entry is different from many nucleic acid therapeutics which typically bind to receptors found only in the liver. We believe our gene regulatory SNAs are not limited to diseases of the liver. We have shown that certain gene regulatory SNAs cross the stratum corneum and deliver nucleic acid therapeutics to the epidermal and dermal layers of the skin ex vivo. We believe the ability of our gene regulatory SNAs to penetrate through biological barriers will open up new opportunities for the use of nucleic acid therapeutics in local applications. We believe that our gene regulatory SNAs may also have therapeutic applications in organs such as the brain, eye, gastrointestinal tract, liver, lung, and skin. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Immuno-oncology SNAs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe our immuno-oncology SNAs are potent and specific activators of TLRs. It has been demonstrated that oligonucleotides containing specific nucleotide sequences bind to TLRs and induce a robust immune response. The challenge in the immuno-oncology field has been to expose these oligonucleotides to the cells of the immune system in such a way as to optimally bind the TLRs and launch the activation pathway. Based on the results of our preclinical studies, we believe our immuno-oncology SNAs enter cells of the immune system, bind to a variety of TLRs, and generate a robust immune response. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SNAs localize to endosomes of immune cells, engage multiple TLRs, and activate the immune system.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="snatlrgraphica06.jpg" alt="snatlrgraphica06.jpg" style="height:296px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note: Image not to scale</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immuno-oncology SNA advantages for therapeutic applications </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that SNAs are well suited for immuno-oncology applications because of four key properties: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Results of our preclinical studies indicate that SNAs are capable of being internalized into and concentrated in the endosomes of the cells where TLRs are located. Our immuno-oncology SNAs bind to and signal through TLRs to induce innate and adaptive immune responses. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">SNAs present their TLR agonists in a 3-D presentation, which we believe allows SNAs to engage TLRs more efficiently. We have designed and demonstrated SNAs which activate multiple classes of TLRs in cultured mouse macrophages and human B cells, as well as in a lymphoma mouse model. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">SNAs can potentially induce a broad immune response. We believe that such a broad immune response could include the production of cytokines that induce a potent adaptive immune response, which in turn, may confer long-term immunity. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In preclinical studies, immuno-oncology SNAs enhance the activity of certain checkpoint inhibitors. For example, SNAs administered in combination with anti-PD-1 antibodies have restored the anti-tumor activity of those antibodies in anti-PD-1 antibody resistant breast and colorectal cancer, and in lymphoma and melanoma mouse models. Moreover, no palpable tumors grew in the mouse breast cancer model after a second injection of tumor cells, which we believe indicates the occurrence of an adaptive immune response against that tumor. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that these properties collectively make our proprietary SNAs an attractive therapeutic approach for immuno-oncology applications. </font></div><div><a name="s26DEF0043B5D7110D69B28AA8C0ACC3E"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Research and Development Programs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our research and development programs include the development of three SNA therapeutic candidates to address unmet medical needs in the treatment of mild to moderate psoriasis and solid tumors as well as early stage </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">research activities in neurology, ophthalmology, respiratory and gastrointestinal applications, and the development of SNAs that target IL-4RA. These early stage research activities are described in more detail in the sections entitled &#8220;&#8212;Early development programs&#8221; and &#8220;&#8212;SNA targeting IL-4RA for atopic dermatitis.&#8221; The table below sets forth the stage of development of our three SNA therapeutic candidates as of October 2, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="a20171128revisedpipeline.jpg" alt="a20171128revisedpipeline.jpg" style="height:177px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">TNF = Tumor Necrosis Factor; IL-17RA = Interleukin 17 Receptor Alpha; TLR9 = Toll-like Receptor 9</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(1) AST-005 is the subject of the Purdue Collaboration described below in &#8220;Description of Our Business&#8212;Our Research and Development Programs&#8212;Purdue Collaboration.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Regulatory documents are prepared and submitted to the appropriate health authority to enable clinical trials in any given jurisdiction. In the United States, this document is called an IND application, while in other jurisdictions, this document is often called an IMPD, which is submitted as part of a CTA. The content and scope of an IND and a CTA are similar.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AST-005</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">topically applied SNAs for psoriasis </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is a therapeutic candidate for the treatment of mild to moderate psoriasis, which is often defined as psoriasis that affects less than 10% body surface area and is generally not treated with systemic antibody therapy. AST-005 is an SNA containing TNF antisense oligonucleotides and is intended to be applied in a gel to psoriatic lesions. The clinical success of systemically delivered anti-TNF antibodies has validated TNF as a clinically relevant therapeutic target for psoriasis. We believe that the local inhibition of TNF with AST-005 may result in targeted therapeutic activity in patients with mild to moderate psoriasis, where, given their systemic risks, treatment with anti-TNF antibodies falls outside of the current American Academy of Dermatology guidelines. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In our Phase 1 clinical trial, AST-005 resulted in no drug associated adverse events, and AST-005 reduced the production of TNF mRNA in psoriatic skin after topical application. We believe these results demonstrate the potential therapeutic application of AST-005 in the tissue of interest, and that SNAs are potentially capable of regulating gene expression in human skin. On December&#160;2, 2016, we entered into the Purdue Collaboration for further development of AST-005 in mild to moderate psoriasis and in other indications. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Psoriasis market and current treatments </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">According to a 2016 Global Report on Psoriasis issued by the World Health Organization, the prevalence of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis a serious global problem with at least 100&#160;million individuals affected worldwide. According to LeadDiscovery, in 2009, over 4.5&#160;million prescriptions </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">were written for patients with psoriasis in the U.S., with approximately 3.9&#160;million of these prescriptions written for topical therapies.</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Patients suffering from severe psoriasis can benefit from antibody therapeutics, such as etanercept or adalimumab. These antibodies target TNF, a cytokine that plays a central role in the inflammation underlying psoriasis. When injected, the antibodies bind to TNF, diminishing TNF&#8217;s ability to act as an inflammatory signal. Patients with limited disease, or mild to moderate psoriasis, can be treated with topical or oral anti-inflammatory therapeutic agents. These patients are generally not treated with systemic anti-TNF antibodies due to adverse health risks. According to the American Academy of Dermatology, patients with limited skin disease should not automatically be treated with systemic treatments if they do not improve, because treatment with systemic therapy may carry more risk than the disease itself. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accordingly, topically applied agents, such as corticosteroids, are widely used to treat mild to moderate psoriasis. Unlike antibodies that target a specific pathway to treat psoriasis, topical therapies generally have a non-specific mechanism of action, which may cause skin thinning, skin irritation, and other side effects. Moreover, many of these therapies become less effective at treating the disease over time as patients become refractory to treatment. Findings from National Psoriasis Foundation surveys conducted between 2003 and 2011 indicate that 52.3% of patients with psoriasis were dissatisfied with their treatment.</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe there is an unmet medical need in mild to moderate psoriasis for a locally administered therapeutic that combines the specificity of antibodies with the convenience of topical corticosteroids without the side effects of either class of therapeutics. To date, the skin has proven to be a barrier to the penetration of many potential therapies. Some approaches for delivering oligonucleotides directly into the skin require injections, which may be uncomfortable and painful. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our approach </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is intended to be administered locally as a topically applied gel to psoriatic lesions. We developed AST-005 to enter into cells of the epidermis and dermis and modulate the expression of TNF. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Clinical success of systemically delivered anti-TNF antibodies has validated TNF as a clinically relevant target for psoriasis. TNF is an important trigger and mediator of inflammatory responses. Excessive TNF production in the skin causes keratinocyte and T-cell proliferation as well as immune cell infiltration, which results in the formation of psoriatic lesions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical development of AST-005 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We gathered experimental evidence of the biological activity of AST-005 in both healthy and psoriatic human skin samples prior to undertaking a Phase 1 clinical trial. As a consequence, we believe we had a deeper understanding of how AST-005 would perform during clinical trials than would be ordinarily possible with traditional therapeutic development. Data from our preclinical studies demonstrated that AST-005 penetrates into, and modulates the production of TNF in, both healthy and psoriatic human skin after topical application. We believe we had preliminarily demonstrated the intended therapeutic mechanism of action of AST-005 in the tissue of interest in advance of a Phase 1 clinical trial. We intend to use this model when developing other gene regulatory SNA compounds. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We also examined AST-005 in a mouse model of psoriasis known as the imiquimod model. AST-005 was applied topically in an ointment. Histological and biomarker results showed that AST-005 prevents the development of psoriatic phenotype in mouse models of the disease. A biomarker is a substance whose measurement is indicative of a disease state. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Finally, we performed studies which demonstrate that our SNAs cause minimal off-target changes in gene expression in human skin cells and in mouse tissue. Such experiments demonstrated that SNA treatment leads to fewer genetic misregulations as compared to linear oligonucleotides against the same target delivered with a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">commercially available lipid encapsulation-based oligonucleotide delivery system. A misregulated gene is expressed at an inappropriately high or low level. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 1 clinical development for AST-005 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We conducted a Phase 1 clinical trial to assess the safety, antipsoriatic efficacy and pharmacodynamic effect of AST-005 in 15 mild to moderate psoriasis patients in Germany. The primary endpoint of the clinical trial was the change in psoriatic infiltrate thickness compared to the start of the study, which is a method of measuring antipsoriatic effects. Secondary endpoints included evaluation of antipsoriatic efficacy by a clinical score, safety and tolerability assessments, and target mRNA reduction. The clinical trial design allowed for intrapatient comparisons of AST-005 to a placebo and a currently approved therapeutic. A mask containing five holes, or test fields, was placed on the patients&#8217; psoriatic lesions, enabling the application of different agents within one lesion. The test fields were treated with one of three strengths of a gel containing AST-005, a matched control gel without AST-005 and an approved therapeutic administered 10 times over a 12-day treatment period. Safety assessments included a complete physical examination with special focus on the skin, vital signs, and laboratory assessments. At the end of the clinical trial, full biopsy punches were taken of the AST-005 gel and vehicle gel treated areas for measurement of TNF mRNA expression. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Phase 1 clinical trial design utilized a mask that allowed for the evaluation of multiple strengths of AST-005, a placebo, and a currently approved therapeutic within one psoriatic lesion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;"><img src="psoriasisskinmask.jpg" alt="psoriasisskinmask.jpg" style="height:316px;width:300px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;color:#000000;">We believe our clinical trial design is consistent with other topical studies that have been accepted b</font><font style="font-family:inherit;font-size:10pt;color:#000000;">y the FDA, and the European Medicines Agency, or the EMA. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The results of the clinical trial showed no adverse events related to treatment with AST-005. In addition, AST-005 application reduced the expression of TNF mRNA in a dose dependent manner in the psoriatic skin of the patients. The TNF mRNA reduction elicited by the highest strength of AST-005 gel was statistically significant when compared to the effects of the vehicle. These results demonstrate that topically applied SNAs are potentially capable of reducing gene expression in the skin of psoriasis patients, and we believe that these results demonstrate the potential therapeutic application of our gene regulatory SNA platform. While the results of the clinical trial did not show antipsoriatic efficacy, we believe antipsoriatic efficacy was not to be expected based on the length of treatment in this clinical trial. The results of a clinical trial with etanercept, a systemic TNF inhibitor, indicate that four weeks of therapy is required before antipsoriatic efficacy can be observed. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A gel containing AST-005 reduced the target TNF mRNA expression in the lesional psoriatic skin of patients in a dose dependent manner after topical application in a Phase 1 clinical trial. The knockdown achieved by the high strength of gel was statistically significant compared to the vehicle treated skin. * p &lt; 0.05 </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ast5phase1results.jpg" alt="ast5phase1results.jpg" style="height:320px;width:405px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into the Purdue Collaboration for further development of AST-005 in mild to moderate psoriasis and in other indications. Together with Purdue, we will pursue continued development of AST-005 in psoriasis and potentially in other indications. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">XCUR17</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">a topically applied anti-IL-17RA SNA </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">XCUR17, our second therapeutic candidate, targets the mRNA that encodes IL-17RA, a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the IL-17 pathway, in which IL-17RA is a key driver of psoriasis. IL-17 binding to IL-17RA on keratinocytes stimulates and perpetuates the inflammation cascade of psoriasis. IL-17RA-mediated inflammation can be inhibited by disrupting the protein&#8217;s function. Brodalumab, an anti-IL-17RA monoclonal antibody, was approved by the FDA as an effective treatment for chronic moderate to severe plaque psoriasis. Our strategy is to reduce the levels of IL-17RA in the skin by topically applying XCUR17. In preclinical studies, XCUR17 showed inhibition of IL-17RA expression in the keratinocytes of the skin. We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017.  We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect this clinical trial to be completed in mid-2018. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Our ap</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">proa</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">ch</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The clinical success of a systemically delivered anti-IL-17RA antibody has validated that target as a clinically relevant target for psoriasis. The IL-17 pathway is important for initiating and sustaining inflammatory responses. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">IL-17RA stimulation in the skin causes keratinocyte and T-cell proliferation as well as immune cell infiltration, which results in the formation of psoriatic lesions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are developing XCUR17, an SNA containing IL-17RA antisense oligonucleotides. XCUR17 is intended to be applied locally as a topically applied gel to psoriatic lesions. We expect XCUR17 to enter into cells of the epidermis, especially keratinocytes, and modulate the production of IL-17RA. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical development of XCUR17 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Similar to the AST-005 preclinical development, we have gathered experimental evidence of the biological activity of XCUR17 in healthy human skin samples prior to undertaking a Phase 1 clinical trial. As a consequence, we believe we have a deeper understanding of how XCUR17 will perform during clinical trials than would be ordinarily possible with traditional therapeutic development. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">XCUR17 exhibits cellular uptake and skin penetration properties. Specifically, XCUR17 enters into keratinocytes </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">in&#160;vitro</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and enters into healthy human skin </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">ex vivo</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;after topical application. In addition, it also down-regulates the expression of IL-17RA mRNA and protein in keratinocytes </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Further, XCUR17 gel down-regulates IL-17RA mRNA in healthy human skin </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">ex vivo</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Topical application of XCUR17 in a prototype gel to healthy human skin ex vivo results in a dose-dependent decrease in IL-17RA mRNA expression. * p &lt; 0.05; *** p&lt; 0.001 vs the controls </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="xcur17preclinicalresults.jpg" alt="xcur17preclinicalresults.jpg" style="height:325px;width:398px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Planned Phase 1 clinical development for XCUR17 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We filed a CTA to conduct a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect this clinical trial to be completed in mid-2018. The primary endpoints of the clinical trial will be safety and tolerability, and the secondary endpoints will include the measurement of IL-17RA mRNA and protein levels from lesional skin biopsies, lesional skin histology and other assessments of mRNA targets in the psoriasis network. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The clinical trial design allows for intrapatient comparisons of XCUR17 to a placebo and a currently approved therapeutic. A mask containing 5 holes will be placed on the patient&#8217;s skin, enabling the application of three different </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">strengths of a gel containing XCUR17 as well as a placebo and a currently approved therapeutic within one psoriatic lesion. The drug will be applied daily for 26 days in up to 25 patients. Over the course of the clinical trial, the safety and tolerability of XCUR17 will be monitored. In addition, the severity of psoriasis in the treated areas will be assessed. At the end of the clinical trial, biopsy samples from XCUR17- and vehicle-treated areas will be taken and interrogated for IL-17RA and downstream mRNA modulation to demonstrate that XCUR17 engages the target of interest and has an effect on inflammation in the skin. We believe our clinical trial design is consistent with the clinical trial design for other topically applied therapeutic candidates that have been accepted by the FDA and EMA. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional gene regulation programs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that additional gene regulation programs are enabled by the successful results of our Phase 1 clinical trial with AST-005 and the results from preclinical testing of XCUR17. We are also evaluating the use of AST-005 in other indications where anti-TNF therapeutics have been successful and where we believe we have a strategic advantage. In addition, we believe that the initial clinical results of our Phase 1 clinical trial of AST-005 may have important implications for the application of our proprietary SNA technology across a broad range of organs and diseases. First, there were no adverse events related to treatment with AST-005 in the Phase 1 clinical trial and we also observed initial pharmacodynamic activity in the Phase 1 clinical trial. We believe that there are other skin diseases for which we can design therapeutically relevant SNAs. Other targets of interest include IL-17RA, which we are addressing with XCUR17, and interleukin 4 receptor alpha, or IL-4RA, and other targets at various levels of preclinical development. We also believe that the initial clinical trial results of AST-005 suggest that our SNAs will have potential therapeutic applications in other organs and diseases for which local administration would be appropriate such as the brain, eye, gastrointestinal tract, liver, and lung. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AST-008</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">an SNA for immuno-oncology </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our third therapeutic candidate, AST-008, an SNA consisting of a TLR9 agonist, is being developed for the treatment of cancer. We believe AST-008 may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. We have observed that administration of AST-008 as a monotherapy can have anti-tumor activity in colon cancer, breast cancer, lymphoma and melanoma mouse models. We have also observed that, in preclinical studies in a variety of tumor models, AST-008 applied in combination with certain checkpoint inhibitors exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. Importantly, in an anti-PD-1 antibody-resistant breast cancer mouse model, administration of AST-008 with certain anti-PD-1, or programmed death 1, antibodies restored the anti-tumor activity of these antibodies. We have also demonstrated that AST-008 is active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of AST-008 also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of AST-008 in combination with certain checkpoint inhibitors confers adaptive immunity in breast and colon cancer mouse models. We began subject dosing in our clinical trial for AST-008 in the fourth quarter of 2017. We expect this trial to be completed in mid-2018.  We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our approach </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our preclinical data with AST-008 illustrate many of the important attributes of our proprietary SNA technology. Our immuno-oncology SNAs bind to class A scavenger receptors and are localized on the endosomes of immune cells. These same endosomes contain TLRs and are responsible for inducing an innate immune response. SNAs present their TLR agonists externally, in a 3-D configuration, which allows SNAs to bind to TLRs efficiently. We have designed and prepared SNAs which activate multiple classes of TLRs. Our preclinical data show that SNAs induce a broad immune response. We believe that such broad immune response includes the production of cytokines that induce a potent adaptive immune response, which in turn, may confer long-term immunity. In preclinical studies, local administration of AST-008 elicits systemic pro-inflammatory cytokine response. In mouse tumor </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">models, administration of AST-008 with anti-PD-1 antibodies suppresses regulatory T-cells, or Tregs, and myeloid-derived suppressor cells, or MDSCs, and increases the levels of CD8 effector T-cells. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AST-008 in combination with checkpoint inhibitors </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have demonstrated that the combination of AST-008 with certain anti-PD-1 antibodies enhances therapeutic activity in a number of animal models, including breast and colorectal cancers, as well as lymphoma and melanoma. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Breast cancer mouse model.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;We have demonstrated that administration of AST-008 with a selected anti-PD-1 antibody shows a durable anti-tumor response in an anti-PD-1 antibody insensitive mouse breast cancer model. This study was carried out with four groups, each consisting of eight mice per group. The four groups were vehicle treatment, antibody treatment alone, linear oligonucleotide plus antibody treatment, and AST-008 plus antibody treatment. Both the AST-008 and the linear oligonucleotide comparator treatments consisted of subcutaneous administration on days 3, 6, 9, 12, and 15 after tumor implantation at a dose of 0.8 mg/kg per injection. In the three groups where mice received anti-PD-1 antibody therapy, drug administration was performed intraperitoneally on days 3, 8 and 13 at a dose of 10 mg/kg per injection. The mice were monitored for mortality and their tumor volumes were periodically measured. The mice treated with the combination of AST-008 and the anti-PD-1 antibody had average tumor volume reductions of greater than 90% compared to anti-PD-1 antibody treatment alone. In addition, treatment with AST-008 resulted in an 88% average decrease in tumor volume compared to mice treated with linear oligonucleotides at the same dose. At the conclusion of the initial phase of the experiment, seven out of eight mice in the group treated with the combination of AST-008 and the anti-PD-1 antibody had no palpable tumors. In contrast, no mice treated with linear oligonucleotides and the anti-PD-1 antibody survived. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the next phase of this study, we re-challenged the seven surviving mice from the combination group that was treated with AST-008 and anti-PD-1 with the same breast cancer tumor type. A new group of six mice that had never received any therapy, referred to here as na&#239;ve mice, was also inoculated with the same breast cancer tumor type for comparison. The tumor growth and survival were monitored in both groups of mice without further treatment with the AST-008 and anti-PD-1 antibody combination. No palpable tumors were observed in the surviving mice from the combination group through day 105 of the study, whereas na&#239;ve mice showed tumor growth. Finally, on day 105 of the study, the mice from the combination group that had survived two rounds of tumor implantation were injected with different tumor types. The mouse colon cancer tumors grew in the animals that had survived two challenges with breast cancer cells. Taken together, we believe these data demonstrate an adaptive immune response and a systemic anti-cancer vaccination against the treated tumor type. We believe these data also demonstrate that AST-008 has the potential to synergize with checkpoint inhibitors for immuno-oncology applications. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Importantly, AST-008 in combination with selected anti-PD-1 antibodies shows significantly greater activity compared to the linear oligonucleotides of the same sequence and concentration. We believe this demonstrates the potential advantage of our proprietary SNA design compared to linear oligonucleotides for effecting a tumor clearing response. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">AST-008 in combination with a certain anti-PD-1 antibody in breast cancer mouse model resistant to anti-PD-1 treatment. Surviving mice from the experiment treated with anti-PD-1 and AST-008 survived when re-injected with the same EMT6 breast cancer cells, but did not survive when injected with unrelated CT-26 or 4T1 cancer cells. * p &lt; 0.0001 versus vehicle treated group. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ast008breastcancer.jpg" alt="ast008breastcancer.jpg" style="height:307px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Melanoma mouse model. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We have demonstrated the synergy of AST-008 with a selected anti-PD-1 antibody in a mouse melanoma model where the antibody is not effective on its own. This is representative of most advanced melanoma patients who receive anti-PD-1 antibodies because the majority of patients do not respond to the therapy. This study was executed with 10 mice per group, and there were four treatment groups. The animals were treated with vehicle, an anti-PD-1 antibody alone, AST-008 alone, or a combination of the antibody and AST-008. AST-008 was administered subcutaneously on days 3, 6, 9, 12, and 15 after tumor implantation at a dose of 0.8 mg/kg/injection. The anti-PD-1 antibody was injected intraperitoneally on days 5, 10 and 15 at a dose of 10 mg/kg/injection. AST-008 treatment resulted in a large decrease in tumor volume and an increase in survival versus the mice treated with vehicle or antibody alone. Importantly, mice treated with both AST-008 and the anti-PD-1 antibody had no measurable tumor volume, in contrast to animals treated with the anti-PD-1 antibody alone, where no meaningful tumor volume change or survival was observed compared to the vehicle treated group. Moreover, median survival for the anti-PD-1 treatment group was 36 days whereas median survival for the combination group was greater than 67 days, at least an 86% increase. These results suggest that AST-008 treatment may be able to potentiate anti-PD-1 antibody therapy when the antibody is ineffective on its own. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The combination of AST-008 with an anti-PD-1 antibody shows improved tumor volume reduction and increased median survival in a mouse model of melanoma compared to anti-PD-1 antibody alone. * p &lt; 0.0001 vs vehicle treated group. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ast008melanoma.jpg" alt="ast008melanoma.jpg" style="height:212px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Lymphoma mouse model.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In a third demonstration of how AST-008 treatment can synergize with checkpoint inhibitor antibodies, we combined our SNA with an anti-PD-1 antibody in a lymphoma mouse model. This study used 10 mice per group, and the study had four groups. At the start of the study, A20 mouse lymphoma tumor cells were implanted in mice on day 0. Mice received vehicle, AST-008 alone, the anti-PD-1 antibody alone, or a combination of AST-008 and the antibody. AST-008 was injected directly into the tumor at a dose of 2.4 mg/kg, while the antibody was dosed intraperitoneally at 5 mg/kg. Therapy began on day 8 of the study when average tumor volume was 100mm</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">3</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">Both agents were dosed once a week for a total of four doses. Over the course of the study, the mice were monitored for mortality and tumor volume was measured twice a week until study termination. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-008 monotherapy greatly decreased the t</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;color:#000000;">umor volume gr</font><font style="font-family:inherit;font-size:10pt;color:#000000;">owth rate and increased the proportion of animals surviving to the end of the study to 80%, compared to both the vehicle and anti-PD-1 antibody groups, where survival was only 20%. Importantly, in the AST-008 and a-PD-1 antibody combination group, the tumor completely regressed in nine out of 10 animals, and 90% of the mice in the group survived to the end of the study. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Tumor growth and survival curves for combinations of AST-008 and an anti-PD-1 antibody in a lymphoma mouse model </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ast008lymphoma.jpg" alt="ast008lymphoma.jpg" style="height:788px;width:624px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AST-008 as a monotherapy for cancer. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe AST-008 potentially can be used as a monotherapy to treat cancer. We have examined AST-008 in a colon cancer mouse model, as well as in a melanoma model. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Mouse colon cancer model.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Mice were</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">implanted with colon cancer tumors. Once the tumor volume reached approximately 100 mm</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">3</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">, the mice were treated with vehicle or varying doses of the mouse analogue of AST-008, referred to as mu-AST-008. The mu-AST-008 was administered by intratumoral injection every three days, starting on the ninth day after tumor implantation, for a total of five doses. The dose levels were 0.8, 3.2, or 6.4 mg/kg/injection. The mice were monitored for mortality, and tumor volume measurements were obtained twice weekly until day 40 of the experiment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The mice treated with mu-AST-008 had a dose dependent increase in survival and decrease of tumor burden compared to mice receiving the vehicle. A complete clearance of the tumors was observed in animals receiving the 6.4 mg/kg/injection dose of mu-AST-008. In addition, no mice in the group receiving the high dose of mu-AST-008 had died at day 40 of the study, while all of the vehicle-treated animals died by day 33. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Intratumoral treatment with the mouse analogue of AST-008, referred to as mu-AST-008, reduces tumor volume and increases survival in a colon cancer mouse model in a dose dependent manner. * = p &lt; 0.0001 versus vehicle on day 23.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ast008coloncancer.jpg" alt="ast008coloncancer.jpg" style="height:202px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe the results of this study demonstrate that AST-008 has potential as a monotherapy for cancer. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical development plan for AST-008 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We began&#160;subject dosing in the Phase 1 clinical trial for AST-008 in the fourth quarter of 2017.  The Phase 1 clinical trial is the first-in-human clinical trial of AST-008 and will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of AST-008 by subcutaneous administration in healthy volunteers. The clinical trial is planned to be a randomized, single ascending dose, or SAD, and randomized, double-blind multiple ascending dose, or MAD, trial. Subjects will be recruited in five or more SAD cohorts. After the fourth SAD cohort, the first of three or more MAD cohorts will begin recruiting. We plan to dose a total at least 44 healthy subjects during this Phase 1 clinical trial. We expect this trial to be completed in mid-2018. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SNA targeting IL-4RA for atopic dermatitis </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis. The signaling of the cytokines IL-4 and IL-13 is believed to play a role in the pathogenesis of atopic dermatitis. Both of those cytokines require binding to the IL-4RA protein to produce inflammatory signaling. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Atopic dermatitis is a chronic rash characterized by inflammation and itching. The lifetime prevalence of atopic dermatitis is&#160;10-20%&#160;in&#160;children&#160;and 1-3% in adults. Its prevalence has increased two- to threefold during the past three decades in industrialized countries. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Current Treatments </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Current mild to moderate atopic dermatitis treatments aim to reduce inflammation and itchiness. Combinations of antihistamines, topical corticosteroids and topical immunomodulators are the current standard of care. Corticosteroid therapy use requires caution, however, because prolonged use can cause skin atrophy and tachyphylaxis. The FDA has warned of lymphoma and other cancers associated with prolonged use of topical immunomodulators. Antihistamines do not treat the disease, but are only useful to dull the urge to scratch to relieve itching. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Recently, a clinical trial of dupilumab, a fully human monoclonal antibody that is directed against the shared alpha subunit of the IL-4 receptor and that blocks signaling from both IL-4 and IL-13, showed efficacy in moderate to severe atopic dermatitis. Dupilumab is now marketed in the United States for the treatment of moderate to severe atopic dermatitis. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our Approach </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that an anti-IL-4RA SNA applied topically to the skin will reduce the levels of IL-4RA mRNA, and in turn IL-4RA protein, in the skin thereby preventing the inflammatory signaling through both IL-4 and IL-13. Late stage clinical trials with dupilumab have confirmed that inhibiting the function of IL-4RA leads to successful treatment of atopic dermatitis. We believe our approach of modulating IL-4RA specifically and locally will result in an improved safety profile versus topical antihistamines, corticosteroids and immunomodulators, as well as systemically administered antibodies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early development programs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to our named pipeline programs, a variety of early stage research efforts are ongoing in areas we believe will best leverage the properties of the SNA. Potential applications of the SNA include those in neurology, ophthalmology, respiratory, and the gastrointestinal tract. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Neurology </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Despite delivery challenges, nucleic-acid based therapy has been successfully developed to treat a central nervous system, or CNS, disorder. Nusinersen, by Ionis Pharmaceuticals and Biogen Inc., was approved in late 2016 for the treatment of spinal muscular atrophy, or SMA by the FDA. SMA is a genetic disorder characterized by progressive muscle wasting and loss of muscle function due to motor neuron dysfunction. SMA is characterized by reduced amount of survival of motor neuron 1, or SMN1, protein. The severity of the disease depends on the amount of a related protein, SMN2, where lesser quantities of SMN2 are correlated to more severe disease. SMN2 is similar to SMN1, but in patients with SMA, has a mutation that leads to production of truncated protein, which is normally rapidly degraded. Nusinersen is designed to mitigate the effects of this mutation by directing the production of a more stable variant of SMN2, increasing the level of SMN2 protein, and thus improving motor function. In clinical trials, SMA patients treated with nusinersen achieved and sustained meaningful improvement in motor function and survival compared to untreated patients. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To evaluate the superiority of the SNA over linear oligonucleotides in directing the production of a more stable variant of the SMN2 protein, we compared the effects of nusinersen in linear format with nusinersen in SNA format in cells derived from SMA patients. The data showed that treatment with SNA format of nusinersen results in greater levels of the more stable variant of SMN2 mRNA compared with linear format. SNA format of nusinersen resulted in up to 45-fold increase in the more stable SMN2 mRNA variant versus controls, while a much smaller 2.5-fold increase was observed using nusinersen in the linear format. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Nusinersen in the SNA format significantly increases the levels of stable variant of SMN2</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">compared to the linear format as measured by changes in mRNA levels in cells derived</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">from SMA patients.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="smafibroblastdata.jpg" alt="smafibroblastdata.jpg" style="height:398px;width:302px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe these results suggest that nucleic acid therapeutics based on SNA may have superior pharmacodynamic properties compared to those in the linear format, some of which are already approved by the FDA. The results also suggest that our SNA technology may have applications in a broad range of genetic disorders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ophthalmology </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ophthalmic therapies, such as antibodies, peptides or aptamers, are typically injected into the eye to reach their target tissues and achieve therapeutic effects. We believe that the penetration properties of the SNA may result in the delivery of therapeutically relevant concentrations of oligonucleotides to certain tissues in the eye after topical administration in the form of eyedrops. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To assess penetration into the eye, Dutch belted rabbits were given either eyedrops containing no SNAs, referred to as vehicle, or an SNA in a formulation targeting an ocular gene of interest. The eyedrops were administered to the animals 18 times over the course of five days. On the fifth day, the rabbit eyes were analyzed for SNA content. The results indicate that SNAs were detected in tissues at the surface of the eye, where the application occurred, but also in the retina and vitreous humor, indicating that the SNA had penetrated into the eye.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The distribution of SNAs in rabbit eyes when administered as topical drops demonstrates that SNAs penetrate the eye</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="ophthalmologyrabbiteyesdata.jpg" alt="ophthalmologyrabbiteyesdata.jpg" style="height:430px;width:512px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe these results are a promising step in demonstrating that SNAs may be used to treat ophthalmic diseases with eyedrops, an alternative to injections requiring medical personnel. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Respiratory </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Altering the immunological state of the lung has promising therapeutic implications for the treatment of allergic diseases, such as asthma. In a preliminary assessment, we demonstrated an alteration of the immunological state both locally in the lung and systemically in mice after the inhalation of SNAs. An intranasal dose of PBS or nebulized formulation of AST-008 was administered to mice at 7.5 mg/kg to assess the pharmacodynamic effects of SNA delivery to the lungs. Four mice per group were used. At 4, 10, 16, or 24 hours following administration, serum was collected from the animals and bronchoalveolar lavage, or BAL, was performed to produce fluid from the lung surface. Finally, lung tissue was also collected from the animals. The fluids and tissue were subjected to cytokine concentration analysis. The results show that nebulized SNAs can produce a cytokine response in the lung tissue and BAL fluid, as well as systemically, as measured in the mouse serum. We believe these results have implications for the potential treatment of allergic diseases of the lung. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Nebulized SNAs can induce an immune response in lung tissue, BAL, and serum.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><img src="respiratoryactivitydata.jpg" alt="respiratoryactivitydata.jpg" style="height:187px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gastrointestinal </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A variety of gastrointestinal disorders, including ulcerative colitis and Crohn&#8217;s disease, collectively referred to as irritable bowel disease, or IBD, are inadequately treated with existing therapies such as immunosuppressive steroids and anti-TNF antibodies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that orally applied SNAs may provide the opportunity to treat diseases such as IBD by taking advantage of the local tissue penetration of the SNA technology. Accordingly, the effect of oral SNA treatment was assessed in an induced IBD mouse model. After the induction of colitis, the mice were treated with anti-TNF SNAs on day 1, 2, 3 and 4, for a total four doses, at 100 or 200 &#181;g/dose/mouse by oral gavage. Control mice were treated with vehicle only. The mice were monitored for mortality and scored clinically for seven days. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Clinical scores for the mice during the course of the study were assigned by considering the body weight, stool consistency, bleeding and any abnormalities observed in fur coat and abdomen. Gross pathology scores were assigned on the last day of study from the colons removed from the animals after euthanization. Gross pathology scores ranging from 0 to 5, indicating no abnormalities and multiple ulcers, respectively, were assigned based on the severity of the inflammation and ulceration in the colon. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The results showed improvement in clinical score and gross pathology for animals treated with 200 &#181;g/dose of anti-TNF SNAs compared to those treated with vehicle only. Overall, the results suggest that oral administration of SNA had a positive effect on disease symptoms as reflected by lower clinical and pathology scores. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Oral administration of anti-TNF SNAs improve clinical scoring, left panel, and pathology results, right panel, in a mouse model of IBD. * p &lt;0.05 vs vehicle</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><img src="ibddata.jpg" alt="ibddata.jpg" style="height:266px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Novel TLR9 agonists </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are developing novel TLR9 agonist SNAs that produce cytokine profiles distinct from AST-008 in an effort to broaden our armamentarium of options for treatment of cancer, respiratory and autoimmune diseases. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purdue Collaboration </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the Purdue Collaboration we entered into with Purdue on December&#160;2, 2016, Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005, an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5&#160;million upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to $16.5 million. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to $410.0 million. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to $350.0 million.&#160;There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Purdue is entitled to terminate the Purdue Collaboration by providing the Company with advance written notice. The agreement also provides termination provisions for material breaches of contract provisions that are customary for agreements of this type. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">By working with Purdue, we believe we will be able to discover and develop the next generation of nucleic acid therapies that have the potential to substantially advance the field of targeted therapies. We believe this collaboration </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">exemplifies our strategy of establishing alliances with leaders with a proven track record in the development and global commercialization of treatments for patients with chronic conditions. </font></div><div><a name="se3de987ba40048bf9046e711fe5b415c"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Intellectual Property </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Proprietary Protection </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our therapeutic candidates, manufacturing and process discoveries and other know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing on our proprietary rights. We have been building and continue to build our intellectual property portfolio relating to our AST-005, XCUR17 and AST-008 therapeutic candidates and our SNA technology platform. Our policy is to seek to protect our proprietary position by, among other methods, filing and licensing U.S. and certain foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also intend to rely on trade secrets, know-how, and technological innovation to develop and maintain our proprietary position. We cannot be sure that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications filed or licensed by us in the future, nor can we be sure that any of our existing owned or licensed patents or any patents that may be granted or licensed to us in the future will be commercially useful in protecting our technology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Rights </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our patent portfolio includes pending patent applications and issued patents in the United States and in foreign countries. As of September 30, 2017, our patent portfolio consists of over 45 issued patents and allowed patent applications and over 125 pending patent applications. Our general practice is to seek patent protection in major markets worldwide, including the U.S., Canada, China, Japan, Australia, certain members of the European Union, among others. All of the issued patents and allowed patent applications are licensed from Northwestern University. Among the pending patent applications, we license 44 from NU, we exclusively own 73, and we jointly own 8 with Northwestern University. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our license from Northwestern University is for royalty bearing worldwide exclusive rights to the use of SNAs for therapeutic applications. Pursuant to the license, we are allowed to manufacture, use, offer for sale, sell and import products covered by the licensed patent rights. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our AST-005 patent portfolio includes one pending U.S. patent application and corresponding applications in 28 foreign jurisdictions. The pending applications are composition of matter and method of use type applications and include claims to an oligonucleotide that is 18 nucleotides in length, and methods of use for treating dermal and other disorders. Any patents that may issue from these applications would expire by 2035. The expiration dates do not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our AST-008 patent portfolio includes 24 pending U.S. nonprovisional and foreign patent applications. Foreign jurisdictions where we are seeking patent protection for our AST-008 patent portfolio include Canada, China, Japan, Australia, the European Union, India, South Korea and Mexico. Each of these applications is a composition of matter and method of use type application. The claims of these applications are directed to certain nanoscale constructs, liposomal particles, and multivalent nanostructures, and their methods of use for treating cancer and other disorders. Any patents that may issue from these applications would expire by 2034 or 2035. The expiration dates do not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our XCUR17 patent portfolio includes one pending international patent application filed under the Patent Cooperation Treaty, or PCT. The pending PCT application is a composition of matter and method of use type </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">application and includes claims to one or more oligonucleotides that are 18 nucleotides in length, and methods of use for treating dermal and other disorders. We have the option of pursuing patent protection for this pending PCT application in the U.S. and elsewhere. Any patents that may issue from this application would expire by 2037. The expiration date does not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon receiving FDA approval for AST-005, XCUR17 or AST-008, we intend to list applicable patents in the FDA&#8217;s Orange Book. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Patent life determination depends on the date of filing of the application and other factors as promulgated under the patent laws. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Secret and Other Protection </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to patented intellectual property, we also rely on trade secrets and proprietary know-how to protect our technology, especially when we do not believe that patent protection is appropriate or can be obtained. It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships. These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be the property of our Company. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Intellectual Property Rights </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We seek trademark protection in the United States when appropriate. We have filed for trademark protection for the following marks: LIFE HAPPENS IN 3D, LIFE IN 3D, and EXICURE. We currently have one registered trademark, EXICURE. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, we may find it necessary or prudent to obtain licenses from third party intellectual property holders. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Northwestern University License Agreements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In September 2009, Northwestern University and AuraSense LLC, or ASLLC, one of our significant stockholders, entered into a license agreement under which Northwestern University granted ASLLC an exclusive, worldwide license under certain Northwestern University patents and patent applications to exploit products and processes in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as or accompanying therapeutics or theradiagonostics and in or for intracellular diagnostic applications and intracellular research. On December&#160;12, 2011, ASLLC assigned to us all of its worldwide rights and interests under the Northwestern University-ASLLC license in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;). In accordance with the terms and conditions of this assignment, we assumed all liabilities and obligations of ASLLC to Northwestern University as set forth Northwestern University its license agreement in the assigned field and in August 2015 we entered into a restated license agreement with Northwestern University. In February 2016, we obtained exclusive license as to Northwestern University&#8217;s rights in certain SNA technology we jointly own with Northwestern University. Our license to Northwestern University&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with Northwestern University to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">in wound healing in diabetes. Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015. For purposes of the assigned field, therapeutic uses means the use of products and processes that are covered by the patents and patent applications licensed from Northwestern University for the purpose of providing a therapy or course of medical treatment to address a medical condition or disease. The Northwestern University license agreements provide to us the exclusive, worldwide right to make, have made, use, modify, sell, offer for sale and import any product or process that is covered by any claim in the licensed Northwestern University patents and patent applications. We have the right to sublicense these rights to third parties. The Northwestern University license agreements require us to use commercially reasonable efforts, consistent with demand in the marketplace, regulatory procedures and industry conditions and development timelines, to research, develop, market and manufacture the licensed products. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our rights under the Northwestern University license agreements are subject to a variety of material limitations. First, the license specifically excludes use of the licensed patent rights to perform qualitative or quantitative </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">in vitro </font><font style="font-family:inherit;font-size:10pt;color:#000000;">analysis, testing, or measurement as well as detection of a variety of combinations of biodiagnostics field subsets and targets. Second, the license specifically prohibits us from using the licensed patent rights with regard to diagnostics, including without limitation, theradiagnostics. Third, though the license is otherwise exclusive in the assigned field, Northwestern University retains the right to use the licensed patent rights for research, teaching, and other educational purposes, including the right to distribute and publish materials related to the licensed patent rights. Fourth, the license is subject to the rights of the U.S. government under any and all applicable laws including substantially manufacturing all licensed products in the U.S. unless such requirement is waived by the U.S. government. Fifth, other than in certain circumstances, the Northwestern University license agreements are non-transferable without the consent of Northwestern University. Under the terms of the Northwestern University license agreements, depending on the circumstances, either we or Northwestern University can sue to enforce the patent rights against third party infringers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to secure the assignment of the Northwestern University-ASLLC license in the field, we assumed the obligation to pay Northwestern University an annual license fee, which may be credited against any royalties based on sales of licensed products that are due to Northwestern University in the same year, and to reimburse Northwestern University for expenses associated with the prosecution and maintenance of the licensed patent rights. In addition, we assumed the obligation to pay Northwestern University royalties at a low single-digit percentage of any net revenue generated by our sale or transfer of any licensed product. In the event we grant a sublicense under the licensed patent rights, we also assumed the obligation to pay Northwestern University, on a quarterly basis, the greater of a mid-teen percentage of all sublicensee royalties or a low single-digit percent of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product. As of September 30, 2017, we have paid to Northwestern University an aggregate of $3.2&#160;million in consideration of each of the obligations described above. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may terminate our license agreements with Northwestern University at any time by providing 90 days written notice to Northwestern University. Northwestern University may terminate the agreements or, alternatively, convert our exclusive rights to non-exclusive rights if we fail to comply with certain prescribed timelines for research, development, marketing and manufacturing milestones for the licensed products. Northwestern University may also terminate the agreements if we sue, or do not terminate all agreements with a sublicensee who sues Northwestern University, in a matter not arising from the agreements themselves. Either party may terminate the agreements in the event of a material breach by the other that remains uncured for a period of 30 days after the non-breaching party provides notice to the breaching party. The agreements will automatically terminate if we reach specified thresholds of financial distress. In the event of termination, all rights immediately revert to Northwestern University. The agreements will automatically expire upon the expiration of the last to expire patent rights. In the event of expiration, the license automatically becomes a non-exclusive, irrevocable, fully-paid license to use or sublicense the use of know-how to make and sell products in each country where the license had previously been in effect. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our technology licenses and assignments </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage with a focus on jurisdictions that represent significant global pharmaceutical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">markets. Generally, patents have a term of twenty years from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened. We are pursuing worldwide patent protection for at least novel molecules, compositions of matter, pharmaceutical formulations, methods of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our research and development efforts. We continuously assess whether it is strategically more favorable to maintain confidentiality for the &#8220;know-how&#8221; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we strategically tailor our claims in accordance with the existing patent landscape around a particular technology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued patents can be subject to oppositions, interferences and other third party challenges that can result in the revocation of the patent or limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant. Competitors may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short period of time following commercialization. We cannot predict with any certainty if any third party U.S. or foreign patent rights, or other proprietary rights, will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against any such claims, substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad, and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we deem it necessary to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material adverse effect on our business, results of operations and financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships. These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be the property of the company. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other territories worldwide.</font></div><div><a name="s0A04DD03E7BAD986CBBF28AA8C2B6A2A"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing and Supply </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our therapeutic candidates. We currently contract with only one therapeutic substance and three drug product manufacturers for the supply of SNAs and we expect to continue to do so to meet the preclinical and any clinical requirements of our therapeutic candidates. We do not have a long-term agreement with these third parties. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreements for the supply of such therapeutic materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, it would materially harm our business. We typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our contract manufacturing organizations manufacture our therapeutic candidates subject to cGMP conditions. cGMPs are regulatory requirements for the production of therapeutics that will be used in humans.</font></div><div><a name="sE38BEDAF8692255E118028AA8C626667"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that our scientific knowledge and expertise in SNA-based therapies provide us with competitive advantages over the various companies and other entities that are attempting to develop oligonucleotide based-therapeutics. However, we face competition at the technology and therapeutic indication levels from both large and small biotechnology companies, academic institutions, government agencies and public and private research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will be based in part upon our ability to identify, develop and manage a portfolio of therapeutics that are safer and more effective than competing products in the treatment of our targeted patients. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than any therapeutics we may develop. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Competition in oligonucleotide-based therapeutics </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. We believe that while our SNA technology, its associated intellectual property and our scientific and technical know-how gives us a competitive advantage in this space, competition from many sources remains. Our competition includes larger and better funded pharmaceutical, biotechnological and oligonucleotide therapeutic firms. Moreover, we not only compete with other firms, but also with current and future therapeutics. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Dynavax Technologies Corp., Idera Pharmaceuticals, Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for the finite funding available from biotechnology and pharmaceutical companies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If our lead therapeutic candidates are approved for the indications for which we undertake clinical trials, they will compete with therapies that are either in development or currently marketed, such as the following: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Competition in psoriasis </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There are currently a number of therapeutics on the market for the treatment of psoriasis. Over the counter medications such as salicylic acid and zinc pyrithione are used for treating mild to moderate psoriatic lesions. Prescription medications such as corticosteroids, calcipotriene, retinoids are available and can be applied topically. Oral therapeutics like cyclosporine and methotrexate are also used. Finally, injectable antibody-based therapies are used to decrease TNF-driven inflammation and thus reduce the symptoms of the disorder in the case of severe psoriasis. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Competition in immuno-oncology </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There are a number of competitive products to SNAs for immuno-oncology on the market and in development. Ipilimumab and nivolumab from Bristol-Myers Squibb Company, atezolizumab from the Roche Group, as well as pembrolizumab from Merck&#160;&amp; Co., Inc., are now marketed for the treatment of advanced melanoma or other cancers, and these and other therapeutic products are in development for other immuno-oncology applications. In addition, adoptive cell therapies such as CAR-T cells are showing great promise for the treatment of B-cell malignancies in clinical trials.</font></div><div><a name="s68CE5CECA094611A3B7528AA8C806411"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation and Product Approval </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Governmental authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing, sales, and export and import of products such as those we are developing. Our therapeutic candidates must be approved by the FDA through the NDA process before they may be legally marketed in the U.S. and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. government regulation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">NDA approval processes</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938, or the FDCA, and implementing regulations. If we fail to comply with applicable FDA or other requirements at any time during the product development or approval process, or after approval, we may become subject to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">refusal to approve pending applications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">license suspension or revocation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">withdrawal of an approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">imposition of a clinical hold; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">warning or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">seizures or administrative detention of product; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">product recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">total or partial suspension of production or distribution; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">injunctions, fines, disgorgement, or civil or criminal penalties. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The process required by the FDA before a therapeutic candidate may be marketed in the U.S. generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLPs, and other applicable regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCPs, to establish the safety and efficacy of the therapeutic candidate for its intended use; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">submission to the FDA of an NDA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the therapeutic candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the therapeutic candidate&#8217;s identity, strength, quality and purity; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">FDA review and approval of the NDA. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain any approvals for our therapeutic candidates will be granted on a timely basis, if at all. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Once a therapeutic candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. Currently, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected adverse reactions in a timely manner, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigation brochure or any findings from other studies or animal or </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;testing that suggest a significant risk in humans exposed to the therapeutic. An IRB at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the trial until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trials results to public registries. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Phase 1-The therapeutic candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the therapeutic candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Phase 2-Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Phase 3-Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Human clinical trials are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the therapeutic candidate has been associated with unexpected serious harm to patients. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A drug being studied in clinical trials may be made available to individual patients, in certain circumstances. Pursuant to the 21st Century Cures Act, or Cures Act, which was signed into law in December 2016, the manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational drug. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the development of a new therapeutic candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the new therapeutic. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Concurrent with clinical trials, sponsors usually complete additional animal safety studies and also develop additional information about the chemistry and physical characteristics of the therapeutic candidate and finalize a process for manufacturing commercial quantities of the therapeutic candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and the manufacturer must develop methods for testing the quality, purity and potency of the therapeutic candidate. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the therapeutic candidate does not undergo unacceptable deterioration over its proposed&#160;shelf-life. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for products and an annual establishment fee on facilities used to manufacture prescription drug products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">its first human therapeutic application for review. Within 60 days following submission of the application, the FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. NDAs receive either standard or priority review. A therapeutic representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations carefully when making decisions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditures of time, money and effort in the areas of training, record keeping, production and quality control. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the product approval process, the FDA also will determine whether a REMS plan is necessary to assure the safe use of the product. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS plan. The FDA will not approve an NDA without a REMS plan, if required. The FDA has authority to require a REMS plan under the Food and Drug Administration Amendments Act of 2007, or FDAAA, when necessary to ensure that the benefits of a therapeutic outweigh the risks. In determining whether a REMS plan is necessary, the FDA must consider the size of the population likely to use the therapeutic, the seriousness of the disease or condition to be treated, the expected benefit of the therapeutic, the duration of treatment, the seriousness of known or potential adverse events, and whether the therapeutic is a new molecular entity. A REMS plan may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate health care providers of the risks, limitations on who may prescribe or dispense the therapeutic, or other measures that the FDA deems necessary to assure the safe use of the therapeutic. In addition, the REMS plan must include a timetable to assess the strategy at 18 months, three years, and seven years after the strategy&#8217;s approval. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The FDA may also require a REMS plan for a therapeutic that is already on the market if it determines, based on new safety information, that a REMS plan is necessary to ensure that the product&#8217;s benefits outweigh its risks. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the NDA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the NDA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the NDA is resubmitted, FDA may again decide that the resubmitted NDA does not satisfy the criteria for approval. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">may require post-marketing clinical trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, designed to further assess a product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Companion Diagnostics</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The FDA has issued a final guidance document addressing the agency&#8217;s policy in relation to in vitro companion diagnostic tests. The guidance explains that for some therapeutics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. However, the FDA may decide that it is appropriate to approve such a product without an approved or cleared in vitro companion diagnostic device when the therapeutic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared in vitro companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared in vitro companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. Because the FDA&#8217;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expedited review and approval.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough therapy, which are intended to expedite or simplify the process for reviewing therapeutic candidates, or provide for the approval of a therapeutic candidate on the basis of a surrogate endpoint. Even if a therapeutic candidate qualifies for one or more of these programs, the FDA may later decide that the therapeutic candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will be lengthened. Generally, therapeutic candidates that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of therapeutic candidates to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Priority review is designed to give a therapeutic candidate that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness, an initial review within eight months as compared to a standard review time of twelve months. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated therapeutic candidate and expedite review of the application for a therapeutic candidate designated for priority review. Accelerated approval, which is described in Subpart H of 21 CFR Part 314, provides for an earlier approval for a new therapeutic candidate that is intended to treat a serious or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a therapeutic candidate receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the product may be subject to accelerated withdrawal procedures. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law in July 2012, the U.S. Congress encouraged the FDA to utilize innovative and flexible approaches to the assessment of therapeutic candidates under accelerated approval. The law required the FDA to issue related guidance and also promulgate confirming regulatory changes. In May 2014, the FDA published a final Guidance for Industry titled &#8220;Expedited Programs for Serious Conditions&#8212;Drugs and Biologics,&#8221; which provides guidance on FDA programs that are intended to facilitate and expedite development and review of new therapeutic candidates as well as </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">threshold criteria generally applicable to concluding that a therapeutic candidate is a candidate for these expedited development and review programs. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new program for Breakthrough Therapy Designation, established by FDASIA to subject a new category of drugs to accelerated approval. A sponsor may seek FDA designation of a therapeutic candidate as a &#8220;breakthrough therapy&#8221; if the therapeutic is intended, alone or in combination with one or more other therapeutics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapeutic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment to, an IND, but ideally no later than the end of the Phase 2 meeting. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Similar to FDASIA, the Cures Act, which was signed into law in December 2016, includes numerous provisions intended to accelerate the development of new products regulated by the FDA. As an example, the Cures Act provides that the FDA may allow the sponsor of an NDA for a genetically targeted drug or variant protein targeted drug to rely upon data and information previously developed by the same sponsor (or another sponsor that has provided the sponsor with a contractual right of reference to such data and information) and submitted by the sponsor in support of one or more previously approved applications submitted to the FDA for a drug that incorporates or utilizes the same or similar genetically targeted technology or the same variant protein targeted drug. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Patent term restoration and marketing exclusivity.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A therapeutic candidate is a new chemical entity if the FDA has not previously approved any other new therapeutic candidate containing the same active moiety, which is the molecule or ion responsible for the action of the therapeutic candidate substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such therapeutic candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing therapeutic candidate. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for therapeutic candidates containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Orphan drug designation.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic for that particular disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The FDA may revoke orphan drug designation, and if it does, it will publicize the drug is no longer designated as an orphan drug. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If a therapeutic candidate with orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Pediatric exclusivity and pediatric use.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the therapeutic candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved indications where it determines that information relating to the use of a therapeutic candidate in a pediatric population, or part of the pediatric population, may not produce health benefits in that population. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most therapeutic candidates and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the therapeutic candidate is safe and effective. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. The FDA also must post the PREA noncompliance letter and sponsor&#8217;s response. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As part of the FDASIA, the U.S. Congress made a few revisions to BPCA and PREA, which were slated to expire on September&#160;30, 2012, and made both laws permanent. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Post-approval requirements.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the therapeutic candidate reaches the market. Later discovery of previously unknown problems with a therapeutic candidate may result in restrictions on the therapeutic candidate or even complete withdrawal of the therapeutic candidate from the market. After approval, some types of changes to the approved therapeutic candidate, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved therapeutic </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">candidates that have been commercialized, and the FDA under some circumstances has the power to prevent or limit further marketing of a therapeutic candidate based on the results of these post-marketing programs. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any therapeutic candidates manufactured or distributed by us or our collaborators pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">record-keeping requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reporting of adverse experiences associated with the therapeutic candidate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">providing the FDA with updated safety and efficacy information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">therapeutic sampling and distribution requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Therapeutic manufacturers, their subcontractors, and other entities involved in the manufacture and distribution of approved therapeutic candidates are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with ongoing regulatory requirements, including cGMPs, which impose extensive procedural, substantive and record-keeping requirements upon us and any third-party manufacturers that we may decide to use if our therapeutic candidates are approved. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations would also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon us and the third-party manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizures of products, injunctive actions or other civil penalties. We cannot be certain we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials or require us to recall a product from distribution. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">New Legislation and Regulations</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulation outside of the U.S. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The currently applicable Clinical Trials Directive 2001/20/EC and Commission Directive 2005/28/EC on GCP setting out the system for the approval of clinical trials in the European Union, or EU, have been implemented through national legislation in the EU Member States. Under this system, an applicant must obtain approval from the national competent authorities in all EU Member States in which the clinical trials are to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site once approved by the competent ethics committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In 2014, a new Clinical Trials Regulation 536/2014, replacing the current Clinical Trials Directive, was adopted. The new Regulation will become directly applicable in all EU Member States (without national implementation) once the EU Portal and Database are fully functional. The Regulation was expected to apply by October 2018. However, due to technical difficulties with the development of the IT systems, it is currently expected that the&#160;new&#160;Regulation&#160;will come into application during 2019. The new Regulation seeks to simplify and streamline the approval of clinical trials in the EU. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State, who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the EU, a company may submit a marketing authorization application either: (i)&#160;at the national level with the national competent authorities in one EU Member State, or the national procedure; (ii)&#160;via mutual recognition of a national authorization in other EU Member States, or the mutual recognition procedure; (iii)&#160;at the national level in several EU Member States, or the decentralized procedure; or (iv)&#160;at centralized level with the European Medicines Agency, or EMA, referred to as the centralized procedure. The national procedure allows sponsor to choose the EU Member State in which he wishes to first submit an application. The mutual recognition procedure allows a marketing authorization granted in one EU Member State via the national procedure to be recognized in other EU Member States. The decentralized procedure allows a medicine that has not yet been authorized in the EU to be authorized in several EU Member States. The centralized procedure, whereby a medicine receives marketing authorization in all EU Member States, is compulsory for certain medicines and is optional for other types of medicines if the applicant can show eligibility. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten (10)&#160;years of market exclusivity for the approved indication unless certain exceptions apply. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Reform </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2010, Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional policy reforms. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes, and fraud and abuse, impacting existing government healthcare programs and resulting in the development of new programs, including Medicare payment for performance initiatives, and improvements to the physician quality reporting system and feedback program. Other aspects of the ACA include, but are not limited to: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Increases in pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs, and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospital. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Requirements on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Requirements on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Establishment of the Independent Payment Advisory Board, which, since 2014, has had authority to recommend certain changes to the Medicare program to reduce expenditures by the program when spending exceeds a certain growth rate and such changes could result in reduced payments for prescription drugs. Under certain circumstances, these recommendations will become law unless Congress enacts legislation achieving the same or greater Medicare cost savings. However, as of early 2017, the President has yet to nominate anyone to serve on the board. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Establishment of the Patient-Centered Outcomes Research Institute to identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Establishment the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the sale, marketing, coverage, and reimbursement of products regulated by CMS or other government agencies. In addition to new legislation, CMS regulations and policies are often revised or interpreted by the agency in ways significantly affecting our business and our products. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In particular, we expect that the new administration and the U.S. Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated it is his administration&#8217;s policy to seek the prompt repeal of the ACA and directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#8217;s administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or the impact of potential legislation on us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Furthermore, political, economic, and regulatory influences frequently subject the healthcare industry in the U.S. to fundamental change. For example, initiatives to reduce the federal budget and debt and to reform healthcare coverage are increasing cost-containment efforts. We anticipate federal agencies, Congress, state legislatures, and the private sector will continue to review and assess alternative healthcare benefits, controls on healthcare spending, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for or the amounts federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures, and limit or eliminate our spending on development projects and affect our ultimate profitability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-Party Payor Coverage and Reimbursement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S., sales of any products for which we may receive regulatory marketing approval will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Medicaid Drug Rebate Program, which is part of the federal Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for receiving federal reimbursement for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order for a pharmaceutical product to (i)&#160;receive federal reimbursement under Medicaid and Medicare Part B (the part of the federal Medicare program covering outpatient items and services for the aged and disabled) or (ii)&#160;be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program, which is a federal program that requires manufacturers to provide discounts to certain statutorily defined safety-net providers. The required 340B discount on a given product is calculated based on certain Medicaid Drug Rebate Program metrics the manufacturer is required to report to CMS. The failure to report or the misreporting of such pricing metrics could result in significant civil monetary penalties and fines, including up to $178,156 (adjusted for inflation) for each item of false or omitted information and $17,816 (adjusted for inflation) per day per labeler code for each day the submission of such pricing information is late beyond the due date. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities, which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which may not include all FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded product on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Furthermore, a payor&#8217;s decision to provide coverage for a product does not imply an adequate reimbursement rate will be available. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of therapeutics have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Our drug candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be&#160;cost-effective compared to other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Further, the American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality, or AHRQ, and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to the U.S.&#160;Congress. In addition, the ACA requires, among other things, that AHRQ broadly disseminate findings from federally funded comparative clinical effectiveness research. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our therapeutic candidates if any such therapeutic, or the condition that it is intended to treat, is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2025 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which among other things, also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare drugs and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Finally, in some foreign countries, the proposed pricing for a therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, in the EU, pricing and reimbursement of pharmaceutical products are regulated at a national level under the individual EU Member States&#8217; social security systems. Some foreign countries provide options to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A country may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Even if approved for reimbursement, historically, therapeutic candidates launched in some foreign countries such as some countries in the EU do not follow price structures of the U.S.&#160;and prices generally tend to be significantly lower. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Regulations </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing strategies. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conducts our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, and physician sunshine laws and regulations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. Violations of the federal Anti-Kickback Statute can result in significant civil monetary and criminal penalties, including $21,916 (adjusted annually for inflation) per kickback plus three times the amount of remuneration and a five year prison term per violation. Further, violation of the federal Anti-Kickback Statute can also form the basis for False Claims Act liability (discussed below). The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the&#160;Anti-Kickback Statute to reach large settlements with healthcare companies based on allegedly inappropriate consulting, discounting and other financial arrangements with physicians and others in a position to refer patients to receive items or services reimbursable by a federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only government programs. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in very significant monetary penalties, including $10,957-$21,916 (adjusted annually for inflation) for each false claim and treble the amount of the government&#8217;s damages. The federal government continues to use the False Claims Act, and the accompanying threat of significant liability, in its investigations and prosecutions of pharmaceutical and biotechnology companies throughout the U.S. Such investigations and prosecutions frequently involve, for example, the alleged promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with the False Claims Act and other applicable fraud and abuse laws. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The U.S.&#160;federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and its implementing regulations, including the final omnibus rule published on January&#160;25, 2013, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Penalties include up to $55,010 per violation (with a maximum fine of $1,650,300 per violation category per year) (adjusted for inflation) and ten years in prison. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may also be subject to federal transparency laws, including the federal Physician Payment Sunshine Act, which was part of the ACA and requires manufacturers of certain drugs and biologics, among others, to track and disclose payments and other transfers of value they make to U.S. physicians and teaching hospitals, as well as physician ownership and investment interests in the manufacturer. This information is subsequently made publicly available in a searchable format on a CMS website. Failure to disclose required information may result in civil monetary penalties of up to an aggregate of $163,117 per year (or up to an aggregate of $1,087,450 per year for &#8220;knowing failures&#8221;) (adjusted for inflation), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or other healthcare providers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Finally, as noted above, analogous state laws and regulations, such as, state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Similarly, many states also have laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Environment </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our third party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties for failure to comply with these laws and regulations. </font></div><div><a name="s62B83AD58DE6A3DA780328AA8CB1BA39"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales and Marketing </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our current focus is on the development of our existing portfolio, the initiation and completion of clinical trials and, if and where appropriate, the registration of our therapeutic candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization approval for any of our therapeutic candidates, we intend to market the product through strategic alliances and distribution agreements with third parties. The ultimate implementation of our strategy for realizing the financial value of our therapeutic candidates is dependent on the results of clinical trials for our therapeutic candidates, the availability of funds and the ability to negotiate acceptable commercial terms with third parties. </font></div><div><a name="s535a5f1f1da6401280568d85d7f0df1b"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Advisors </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We seek advice from our advisory board, which consists of a number of leading executive officers, scientists and physicians, on strategic direction, scientific and medical matters. Our advisory board meets periodically to assess </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our research and development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the design and implementation of our clinical programs; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our patent and publication strategies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">new technologies relevant to our research and development programs; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">specific scientific and technical issues relevant to our business. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The current members of our advisory board are as follows. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Position and Institutional Affiliation</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Freddy Boey, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deputy President and Provost, Nanyang Technological University</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Booth</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Business Officer, Probiodrug AG</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Hodges, MBBS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer, Amplyx Pharmaceuticals</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig Mundie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Mundie&#160;&amp; Associates</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amy S. Paller, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Walter J. Hamlin Professor and Chair Department of Dermatology, Northwestern University Feinberg School of Medicine</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Steven T. Rosen, M.D., F.A.C.P.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provost/Chief Scientific Officer, City of Hope</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Robert P. Schleimer, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief, Division of Medicine-Allergy-Immunology, Northwestern University</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oliver von Stein, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founder&#160;&amp; CEO, iModia Biotech GmbH</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Tyree</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founder&#160;&amp; CEO, Tyree Capital Partners</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John J. Renger, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Head of Clinical R&amp;D/Translational Medicine, Purdue Pharma, L.P.</font></div></td></tr></table></div></div><div><a name="s6635a1f0d8ce4385bd455a30f91b2fac"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017, we have 23 full time employees, nine of whom have Ph.D. degrees. Of these full time employees, 16 are engaged in research and development activities and seven are engaged in finance, legal, human resources, business development and general management. We have no collective bargaining agreement with our employees and we have not experienced any work stoppages. We consider our relations with our employees to be good. </font></div><div><a name="s7b37e7a452ed4c1d964751392067c389"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our corporate headquarters are located in Skokie, Illinois, where we lease approximately 12,000 square feet of office and laboratory space. The lease term for our office and laboratory space in Skokie, Illinois commenced in March 2012 for a lease term of three years. In March 2014, we amended the lease agreement to extend the term for an additional six years, which expires in 2021. In May 2016, we amended the lease agreement to include additional space to be used primarily for administrative functions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that our existing facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists as we grow. When our lease expires, we may exercise our renewal options or look for additional or alternate space for our operations. We believe that suitable additional or alternative space will be available in the future on commercially reasonable terms. </font></div><div><a name="s29ae8e487e30474d85e09345fc1b5746"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><a name="s1BF8BBE906CA4FFA9F4D28AA88EBA73D"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading &#8220;Special Note Regarding Forward-Looking Statements&#8221; elsewhere in this prospectus. You should review the disclosure under the heading &#8220;Risk Factors&#8221; in this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </font></div><div><a name="sd455dbfbd879475d98b97f4d8dec72fd"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in a Phase 1 clinical trial of our lead therapeutic candidate, AST-005, and in preclinical studies of two other therapeutic candidates, XCUR17 and AST-008, both of which we are advancing to the clinic.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting </font><font style="font-family:inherit;font-size:10pt;color:#000000;">tumor necrosis factor, or TNF, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">for the treatment of mild to moderate psoriasis that is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of tumor necrosis factor messenger RNA, or TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle. While we did not observe an antipsoriatic effect in our Phase 1 clinical trial, we believe this is due to the short duration of the treatment. The results of a clinical trial with etanercept, a systemic TNF inhibitor, indicate that at least four weeks of therapy is required before antipsoriatic efficacy can be observed.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to&#160;AST-005,&#160;an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets.&#160; Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a&#160;non-refundable&#160;development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5&#160;million upon successful completion of certain research, regulatory and commercial sales milestones. We cannot assure you that these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, we are eligible to receive royalties ranging from the low single digits to a maximum of 10% on future net sales of such commercialized therapeutic candidates. We are conducting, on behalf of Purdue, a Phase 1b clinical trial in psoriasis patients in Germany to evaluate the effect of higher concentrations of&#160;AST-005&#160;gel on TNF mRNA and downstream mRNA expression. Patient dosing is complete and no serious adverse events have been reported. We expect to have the topline results of the clinical trial in early 2018.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our second therapeutic candidate, XCUR17, is an SNA targeted to IL-17RA for the treatment of mild to moderate psoriasis. We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. We expect the first patient in our Phase 1 clinical trial to be dosed in early 2018. We expect </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">this clinical trial to be completed in mid-2018.  Our third therapeutic candidate, AST-008, is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications. AST-008 has exhibited anti-tumor activity as both a monotherapy and in combination with certain checkpoint inhibitors across a range of preclinical models of solid and hematological cancers. In the third quarter of 2017, we received an authorization from the MHRA to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. We expect this trial to be completed in mid-2018. We ultimately plan to clinically advance&#160;AST-008&#160;in combination with checkpoint inhibitors.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and all of our </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in revenue through September&#160;30, 2017 has been earned through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. In addition to our revenue, through September 30, 2017, we have funded our operations through private placements of preferred stock with gross proceeds totaling $42.8&#160;million, sales of common stock in an initial closing of the Private Placement with gross proceeds totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and debt financing totaling $6.0&#160;million. As of September&#160;30, 2017, our cash and cash equivalents were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since our inception, we have incurred significant operating losses. Our net loss was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2016 and 2015, respectively. As of September&#160;30, 2017, our accumulated deficit was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to continue to incur significant and increasing losses in the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">conduct further preclinical studies and clinical trials of AST-008 and XCUR17;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">increase research and development for the discovery and development of additional therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">advance other therapeutic candidates into preclinical and clinical development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">increase our research and development to enhance our technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">procure clinical trial materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">operate as a public company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have not generated any commercial product revenue nor do we expect to generate substantial revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates. Successful therapeutic development and regulatory approval are subject to significant uncertainty and we expect will take at least five years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="s164956F5AC65E6593D5728AA8921097A"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The audited financial statements of Exicure, Inc. for the fiscal years ended December&#160;31, 2016 and 2015, and the unaudited interim consolidated financial statements for the nine months ended September 30, 2017 and 2016, contained herein, include a summary of our significant accounting policies and should be read in conjunction with the discussion below. </font></div><div><a name="s9068f759dd6b4ed5a2569986b0f3433d"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the Merger Agreement, Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of&#160;Max-1,&#160;merged with and into Exicure OpCo., with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of&#160;Max-1. The Merger was effective as of September 26, 2017, or the Effective Time, upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of&#160;Max-1 Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into 0.49649 shares of&#160;Max-1 common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into 0.7666652 shares of&#160;Max-1 common stock. As a result, an aggregate of 26,666,627 shares of&#160;Max-1&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the 2,080,000 shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement options to purchase 7,414,115 shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase 3,680,997&#160;shares of&#160;Max-1&#160;common stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware,&#160;Max-1 changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger&#8221;, whereby Exicure OpCo is considered the accounting acquirer in the Merger. Exicure OpCo was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i)&#160;legacy Exicure OpCo shareholders own approximately 94% of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii)&#160;legacy Exicure OpCo directors will hold all six board seats of the combined company, and (iii)&#160;legacy Exicure OpCo management will hold all key positions in management of the combined company. The transaction is accounted for as an asset acquisition rather than a business combination because as of the acquisition date,&#160;Max-1 did not meet the definition of a business as defined by U.S. Generally Accepted Accounting Principles, or GAAP.  Consequently, the assets, liabilities and operations that are reflected in Exicure&#8217;s historical financial statements prior to the Merger will be those of&#160;Exicure OpCo, and the consolidated financial statements after completion of the Merger will include the assets, liabilities and results of operations of Exicure OpCo up to the day prior to the closing of the Merger and the assets, liabilities and results of operations of the combined company from and after the closing date of the Merger.  The assets and liabilities of Max-1 included in the accompanying consolidated financial statements are recorded at the historical cost basis of&#160;Max-1.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Private Placement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the Effective Time of the Merger, we held several closings of the Private Placement on September 26, 2017, October 27, 2017 and November 2, 2017 in which we sold to accredited investors approximately $31.5&#160;million worth of shares of common stock (before deducting placement agent fees and expenses which are </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">estimated at approximately $4.0 million), or 10,504,196&#160;shares, at a price of $3.00 per share. Also, we granted the investors in the Private Placement registration rights requiring us to register those shares of common stock for public resale. The then existing stockholders of Exicure OpCo who agreed to become parties to the registration rights agreement also became entitled to such registration rights. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company and the Placement Agents may agree to extend the period for additional closings up to November 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each investor in any Subsequent Closing of the Private Placement was required to represent that, at the time of the applicable closing, it (i)&#160;had a substantive, pre-existing relationship with us, or had direct contact with the Company or the Placement Agents or other enumerated parties outside of the Private Placement, (ii)&#160;was not identified or contacted through the marketing of the Private Placement, and (iii)&#160;did not independently contact us as a result of general solicitation by means of our Form 8-K, any press release or any other public disclosure disclosing the material terms of the Private Placement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We view our operations and manage our business as one segment, which is the discovery, research and development of treatments based on our SNA technology.</font></div><div><a name="sB59BF06B698BFFE16BBB28AA899298F5"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">While our significant accounting policies are described in the notes to our financial statements appearing in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We recognize revenue when the following criteria have been met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;delivery has occurred or services have been rendered and risk of loss has passed; (3)&#160;the fee is fixed or determinable; and (4)&#160;collectability is reasonably assured. When payments are received in advance of recognizing revenue, we include the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have generated all of our revenue to date through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. We have not generated any commercial product revenue. Historically, our research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence, or VSOE, of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for our research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, we recognize revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, Exicure entered into a research collaboration, option and license agreement with Purdue and referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million. In addition, we are eligible to receive up to $776.5&#160;million upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$410.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$350.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June&#160;2, 2017. We did not complete such qualified equity financing before June&#160;2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In accordance with ASC 605-25, we identified the following deliverables at the inception of the Purdue Collaboration agreement: (1)&#160;exclusive rights to the TNF-&#945; target, (2)&#160;the obligation to participate in a joint research committee, (3)&#160;the provision of research and development activities based on a prescribed full-time employee rate per year, (4)&#160;a non-voting board of director observer role, (5)&#160;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, (6)&#160;the option for an exclusive development and commercialization license to AST-005 or a TNF-&#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8)&#160;the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets. We determined that deliverables (2), (4), (5), and (6)&#160;do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6)&#160;were combined with deliverables (1)&#160;and (3) as a single unit of accounting. We concluded that, at the inception of the agreement, deliverables (7)&#160;and (8) are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront $10.0&#160;million is allocated to deliverables (7)&#160;and (8).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The upfront payment of $10.0&#160;million was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6)&#160;above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">14.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the nine months ended September 30, 2017, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which included </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of research and development activities that will be reimbursed by Purdue and is presented on a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">gross basis in the accompanying statement of operations.  During the year ended December&#160;31, 2016, we recognized collaboration revenue of $0.7&#160;million.  As of September 30, 2017 and December 31, 2016, deferred revenue relating to the Purdue Collaboration was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, is classified as current portion of deferred revenue in the accompanying balance sheet.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. We recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, we have not recognized any contingent payments in connection with the Purdue Collaboration as revenue.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our grant contracts have typically been cost or cost-plus fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. We consider fixed fees under cost and cost-plus fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. We analyze costs for contracts and reimbursable grants to ensure that reporting of revenues on a gross basis instead of on a net basis is appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have entered into certain grant contracts containing milestone payments. We recognize revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, we have no further performance obligations relating to the event and collectability is reasonably assured. If these criteria are not met, we recognize milestone payments ratably over the remaining period of our performance obligations under the grant contract. For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1)&#160;relate solely to past performance; (2)&#160;be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3)&#160;be commensurate with either our efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017 and December 31, 2016, and for the nine months ended September 30, 2017 and 2016, the Company was not participating in any grant research activities involving milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We measure the cost of common stock option awards at fair value and record the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. We measure fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, we remeasure fair value at each financial statement reporting date and recognize compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger, Exicure OpCo&#8217;s outstanding common stock options were assumed and converted into Exicure common stock options.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Black-Scholes option-pricing model requires the input of highly subjective assumptions, including: (1)&#160;the estimated grant date fair value of Exicure's or Exicure OpCo&#8217;s (as the case may be) common stock; (2)&#160;the option exercise price; (3)&#160;the expected term of the option in years; (4)&#160;the annualized volatility of the stock; (5)&#160;the risk-free interest rate; and (6)&#160;the annual rate of quarterly dividends on the stock. We make those estimates as follows:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair value of Exicure OpCo's common stock.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Exicure OpCo&#8217;s common stock has not yet been publicly traded, therefore we estimate the fair value of the common stock underlying our stock options. The grant date fair value of Exicure OpCo&#8217;s common stock has been determined by its board of directors exercising their judgment in the consideration of a variety of factors. Please see &#8220;&#8212;Exicure OpCo common stock valuation&#8221; below for a detailed discussion of the assumptions used in estimating the grant date fair value of the common stock underlying Exicure OpCo&#8217;s stock options. For financial reporting purposes and principally to aid Exicure OpCo in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure OpCo has periodically estimated the per share fair value of its common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, or the Practice Aid. Exicure OpCo performed these valuations as of the following dates: March&#160;31, 2012; July&#160;31, 2013; June&#160;30, 2014; December&#160;31, 2014; March&#160;31, 2015; June&#160;30, 2015; September&#160;30, 2015; December&#160;31, 2015; March&#160;31, 2016; June&#160;30, 2016; October&#160;31, 2016; December&#160;15, 2016; March&#160;31, 2017; and June&#160;30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair value of Exicure&#8217;s common stock.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Exicure&#8217;s common stock has not yet been publicly traded, therefore we estimate the fair value of the common stock underlying our stock options. At September 30, 2017, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be $3.00, which is the per share price paid by outside investors in the Private Placement on September 26, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Option exercise price.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;For all common stock options granted prior to August&#160;31, 2013, the grant date exercise price was equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share based on the purchase price per share of Exicure OpCo&#8217;s Series B-1 preferred stock sold in December 2011. For all common stock options granted between August&#160;31, 2013 and October&#160;2, 2014, the grant date exercise price was equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.62</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share based on the purchase price per share of Exicure OpCo&#8217;s Series B-2 preferred stock sold in June 2013. On October&#160;3, 2014, Exicure OpCo&#8217;s board of directors determined that the fair value of Exicure OpCo&#8217;s common stock was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share and further determined that for all periods prior to October&#160;3, 2014, the fair value of Exicure OpCo&#8217;s common stock was less than or equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. Also on October&#160;3, 2014, Exicure OpCo&#8217;s board of directors took action by way of unanimous written consent to modify the exercise price on all outstanding stock options to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to reflect the board&#8217;s determination of fair value of Exicure OpCo&#8217;s common stock for all periods prior to such date. No other terms of the repriced stock options were modified and these repriced stock options continued to vest according to their original vesting schedules and retained their original expiration dates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After the October&#160;3, 2014 modification, Exicure OpCo granted additional common stock options as follows.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Grant&#160;Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common&#160;Stock&#160;at</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/3/2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/17/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/28/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5/14/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5/21/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5/22/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,612</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/24/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,045,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5/11/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8/10/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/4/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">No additional common stock options were granted since January&#160;4, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Expected term.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In determining the expected term of the options, Exicure and Exicure OpCo elected to use the &#8220;simplified&#8221; method in accordance with SEC SAB No.&#160;107, Share-Based Payments. The use of the &#8220;simplified&#8221; method under SAB No.&#160;107 was extended beyond December&#160;31, 2007, in accordance with SAB No.&#160;110, Share-Based Payment, issued on December&#160;21, 2007, until such time when there is sufficient information to make more refined estimates on the estimated life of options. SAB No.&#160;110 expressed the views of the staff regarding the use of the &#8220;simplified&#8221; method, as discussed in SAB No.&#160;107, in developing an estimate of the expected term of &#8220;plain vanilla&#8221; share options in accordance with ASC 718, Share-Based Payment. SAB No.&#160;110 allows companies that do not have historically sufficient experience to provide a reasonable estimate to continue use of the &#8220;simplified&#8221; method for estimating the expected term of &#8220;plain vanilla&#8221; share options grants after December&#160;31, 2007. The Company will continue to use the &#8220;simplified&#8221; method until we have enough historical experience to provide a reasonable estimate of expected term in accordance with SAB No.&#160;110.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Volatility.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Because Exicure&#8217;s and Exicure OpCo&#8217;s common stock has not been freely traded in any market or public exchange, we do not have information on the trading volatility of Exicure&#8217;s and Exicure OpCo&#8217;s common stock. Consequently, we have derived our assumption for volatility by examining the historical volatilities of several unrelated public companies within our industry. When selecting the industry peer group of companies to be used in the volatility calculation, we also consider the stage of development, size and financial leverage of each potential comparable company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Risk-free rate.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Dividend yield. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Neither Exicure or Exicure OpCo have declared or paid cash dividends and we do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are also required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exicure OpCo common stock valuation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo has historically granted common stock options at exercise prices not less than the fair value of its common stock. As there has been no public market for Exicure OpCo&#8217;s common stock to date, the estimated fair value of its common stock has been determined by its board of directors.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On each occasion when Exicure OpCo&#8217;s board determined the fair value of its common stock, they considered each of the factors listed below as well as certain qualitative factors particular to each grant:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the prices of Exicure OpCo&#8217;s preferred stock sold to or exchanged between outside investors in arm&#8217;s length transactions, and the rights, preferences and privileges of Exicure OpCo&#8217;s preferred stock as compared to those of Exicure OpCo&#8217;s common stock, including the liquidation preferences of Exicure OpCo&#8217;s preferred stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo&#8217;s results of operations, financial position and the status of research and development efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo&#8217;s limited capital resources and the risks inherent in raising additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the composition of, and changes to, Exicure OpCo&#8217;s management team and board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the lack of liquidity of Exicure OpCo&#8217;s common stock as a private company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo&#8217;s stage of development and business strategy and the material risks related to Exicure OpCo&#8217;s business and industry;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the achievement of enterprise milestones, including entering into collaboration and license agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the valuation of publicly traded companies considered to be similar in industry and/or business model to Exicure OpCo as well as recently completed mergers and acquisitions of companies similar in industry and/or business model to Exicure OpCo;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any external market conditions affecting the global synthetic biology market, the global market for cancer therapeutics, and the global market for nanoparticles in biotechnology and pharmaceuticals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the likelihood of achieving a liquidity event for the holders of Exicure OpCo&#8217;s common stock and stock options, such as an initial public offering or a sale of Exicure OpCo, given prevailing market conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the state of the initial public offering market for similarly situated privately held biotechnology companies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any recent contemporaneous valuations prepared by Exicure OpCo&#8217;s board of directors and management in accordance with methodologies outlined in the Practice Aid.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have periodically determined, for financial reporting purposes, the estimated per share fair value of Exicure OpCo&#8217;s common stock at various dates using contemporaneous and retrospective valuations. These valuations have been performed in accordance with the guidance outlined in the Practice Aid.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Common stock valuation methodologies.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;These contemporaneous and retrospective valuations discussed below were prepared in accordance with the guidelines in the Practice Aid, which prescribes several valuation approaches for setting the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its common units. We generally used the income and market approaches. When applying the market approach, we used the guideline company and precedent transaction methodologies based on inputs from comparable public companies&#8217; equity valuations and comparable acquisition transactions to estimate Exicure OpCo&#8217;s enterprise value. In applying the income approach, we applied the discounted cash flow method based on Exicure OpCo&#8217;s projections.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to determine the fair market value of Exicure OpCo&#8217;s common stock, Exicure OpCo&#8217;s board of directors first valued the enterprise and then allocated that value through the capital structure.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Methods used to determine the enterprise value of Exicure OpCo.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Exicure OpCo&#8217;s board considered three basic approaches to determining value as outlined in the Practice Aid: 1) Market Approach, 2) Income Approach, and 3) Asset-Based or Cost Approach.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Market Approach.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Market Approach relies on an analysis of publicly traded companies similar in industry and/or business model to Exicure OpCo. This methodology uses these guideline companies to develop relevant market multiples and ratios, using metrics such as revenue, earnings before interest and taxes, or EBIT, earnings before interest, taxes, depreciation and amortization, or EBITDA, net income and/or tangible book value. These multiples and values are then applied to Exicure OpCo&#8217;s corresponding financial metrics. Since no two companies are perfectly comparable, premiums or discounts may be applied to the subject company&#8217;s metrics if its position in its industry is significantly different from the position of the guideline companies, or if its intangible attributes are significantly different.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Application of the Market Approach will also consider the actual prices paid in merger and acquisition transactions for companies similar to Exicure OpCo. Exit multiples of total purchase price paid to revenue, EBIT, EBITDA, net income and/or tangible book value may be developed for each comparable transaction, if the data is available. These multiples are then applied to Exicure OpCo&#8217;s corresponding latest 12-month and projected financial metrics.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">New to the Practice Aid is the &#8220;Back-solve Method.&#8221; The Back-solve Method, a form of the Market Approach to valuation, derives the implied equity value for one type of equity security (e.g., common stock) from a contemporaneous transaction involving another type of equity security (e.g., preferred stock). The Back-solve Method relies on the Black-Scholes Option pricing model to determine the value of the common stock. Inputs into the Black-Scholes model were determined by an analysis of publicly traded companies similar in industry and/or business model to Exicure OpCo.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the periods under consideration, Exicure OpCo raised preferred stock financing in arm&#8217;s length market transactions on six occasions: December 2011, June 2013, June 2014, February 2015, October 2015, and January 2016. All of Exicure OpCo&#8217;s preferred stock financings included independent, third-party investors and therefore we believe are reliable indications of the fair value for the class of preferred stock acquired at the time. We also believe they form a reasonable basis for estimating the fair value of Exicure OpCo&#8217;s common stock. In the board&#8217;s judgment, the proximity between these financings and the date for which a fair market value determination of Exicure OpCo&#8217;s common stock was required, indicate that the Back-solve Method is the most appropriate method for determining fair market value of Exicure OpCo&#8217;s common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Income Approach.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Exicure OpCo&#8217;s board determined that the Income Approach cannot be appropriately applied to Exicure OpCo. Exicure OpCo is at a very early stage in its development and is not currently generating material positive cash flow nor do we anticipate generating material positive cash flows within the economic time horizon typically considered in a discounted cash flow analysis. As discussed elsewhere in this prospectus, Exicure OpCo is an early stage biotechnology company and Exicure OpCo&#8217;s primary activities to date have been research and development of potential new therapeutics based upon its technology. We believe that any valuation of Exicure OpCo&#8217;s common stock&#8217;s fair value must recognize that Exicure OpCo is subject to a risky and lengthy period of time until commercial product revenue, if any, is earned. Exicure OpCo&#8217;s future business model is also uncertain and could include a variety of technology and product licensing opportunities in addition to commercial product revenue from product sales. As a consequence, Exicure OpCo&#8217;s board has determined that the projection of typical inputs into the Income Approach such as market size, market share, product revenue and the future expense and capital expenditures to support that forecast revenue, cannot be reasonably generated by Exicure OpCo at this time.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Cost Approach.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Cost Approach involves identifying Exicure OpCo&#8217;s significant tangible assets, estimating the individual current market values of each and then totaling them to derive the value of the business as a whole. The board determined that, based on Exicure OpCo&#8217;s industry and stage of development, Exicure OpCo&#8217;s tangible assets are not a reasonable estimation of Exicure OpCo&#8217;s enterprise value.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Methods used to allocate Exicure OpCo&#8217;s enterprise value to each class of securities.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across Exicure OpCo&#8217;s classes and series of capital stock to determine the fair value of Exicure OpCo&#8217;s common stock at each valuation date. The methods we considered consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Current Value Method.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Under the Current Value Method, once the fair value of the enterprise is established, the value is allocated to the various series of preferred and common stock based on their respective seniority, liquidation preferences or conversion values, whichever is greatest. We believe that application of the Current Value Method is generally only appropriate when a liquidity event in the form of an acquisition or dissolution of the company is imminent and expectations about the future value of the company are virtually irrelevant. Alternatively, the Current Value Method can be used when the company is so early in its development that no significant economic value has yet been created above the value of the capital invested in the business. We believe neither circumstance fits Exicure OpCo and so we did not use this method in allocating fair value to each of Exicure OpCo&#8217;s classes of stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Option Pricing Method.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Prior to March&#160;31, 2015, the principal method by which we allocated value to each class of preferred stock and to the common stock was the Option Pricing Method. Subsequent to March&#160;31, 2015 the Option Pricing Method was used in combination with the Probability Weighted Expected Return method (see below) using a Hybrid Method (see below). Under the Option Pricing Method, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. Because of the various liquidation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">preferences granted to Exicure OpCo&#8217;s different classes of preferred stock, we utilized a lattice-based option-pricing model. We utilized a twenty-five step binomial lattice in order to estimate a wide range of possible future values for Exicure OpCo&#8217;s total enterprise value. The binomial lattice is based on the following parameters:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">dividend yield</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">risk-free rate</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">volatility</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">time to maturity</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">initial firm value</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The resultant values at the end nodes of the lattice tree were then allocated based on the respective preferences of each class of preferred stock with the residual flowing to the common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Probability-weighted Expected Return Method.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Under the Probability-weighted Expected Return Method, or PWERM, the value of Exicure OpCo&#8217;s common stock is estimated based upon an analysis of values for Exicure OpCo assuming possible future events:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Initial public offering, or IPO</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Strategic merger or sale</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dissolution/No value to common</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Private company</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The per share value of the common stock using PWERM is based upon the probability-weighted present value of expected future equity values, under each of the possible future event scenarios, as well as the rights and preferences of each stock class.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Hybrid Method.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;As outlined in the Practice Aid, in certain circumstances, it may be appropriate to use a hybrid of certain allocation methodologies. In Exicure OpCo&#8217;s circumstances, the per share values calculated under the Option Pricing Method and PWERM are weighted appropriately to arrive at a final fair market value per share value of Exicure OpCo&#8217;s common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since March&#160;31, 2015, Exicure OpCo&#8217;s board has utilized the PWERM analysis to determine the fair value of Exicure OpCo&#8217;s common stock in combination with the Option Pricing Method (see above) using a Hybrid Method. As discussed below, on those occasions the board utilized the Hybrid Method where they considered both the results from the Option Pricing Method and the results of PWERM analysis where particular consideration was given to the value of Exicure OpCo in the event of an IPO of Exicure OpCo&#8217;s stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">October&#160;3, 2014.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On October&#160;3, 2014, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock was less than or equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per common share for all periods from the formation of Exicure OpCo until October&#160;3, 2014. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As part of its determination the board considered four separate retrospective analyses of Exicure OpCo&#8217;s common stock. Those analyses, each prepared by an independent third party appraiser in accordance with the Practice Aid, indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.36</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of March&#160;31, 2012, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.42</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of July&#160;31, 2013, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.70</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of June&#160;30, 2014.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October&#160;3, 2014, the board determined the fair value of Exicure OpCo&#8217;s common stock as of October&#160;3, 2014 to be </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock Exicure OpCo&#8217;s board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo and the Option Pricing Method for determining the fair value of Exicure OpCo&#8217;s common stock. An important input into the application of the Back-solve Method was the June 2014 sale of Exicure OpCo&#8217;s Series C preferred stock for net proceeds of $13.5&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">April&#160;28, 2015 and May&#160;22, 2015.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On April&#160;28, 2015 and May&#160;22, 2015, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such dates was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.03</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board, for the first time, considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method using the Hybrid Method.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the February 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $4.6&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.03</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of March&#160;31, 2015. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo&#160;had occurred since March&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">November&#160;24, 2015.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On November&#160;24, 2015, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such date was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.97</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method using the Hybrid Method.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the October 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $15.0&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.97</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of September&#160;30, 2015. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo&#160;had occurred since September&#160;30, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the board&#8217;s judgment the increase in fair value from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.64</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at October&#160;3, 2014 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.70</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at December&#160;31, 2014 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.03</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at April&#160;28, 2015 and May&#160;22, 2015 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.97</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at November&#160;24, 2015 reasonably reflected both the scientific and clinical progress of Exicure OpCo&#8217;s research programs and prospective therapeutic candidates as well as the possibility of an IPO.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">May&#160;11, 2016.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On May&#160;11, 2016, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such date was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.91</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method in the Hybrid Method. The board&#8217;s analysis reflected that, based on then-existing market conditions, the IPO prospects for Exicure OpCo had diminished since the previous time the board determined fair value on November&#160;24, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the October 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $15.0&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and the January 2016 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $0.4&#160;million also at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Back-solve analysis also took into consideration changes in the market value of benchmark equity indices and the value created from cash spent on research and development, or R&amp;D, activities. As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.91</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of March&#160;31, 2016. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo&#160;had occurred since March&#160;31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the board&#8217;s judgment the decrease in fair value from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.97</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at November&#160;24, 2015 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.91</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at May&#160;11, 2016 reasonably reflected the diminished IPO prospects, based on then-existing market conditions, for Exicure OpCo while also reflecting the scientific and clinical progress of Exicure OpCo&#8217;s research programs and prospective therapeutic candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">August&#160;10, 2016.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On August&#160;10, 2016, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such date was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.11</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above in the section captioned &#8220;Exicure OpCo common stock valuation.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method in the Hybrid Method. The board&#8217;s analysis reflected that the IPO prospects for Exicure OpCo were generally consistent with those assumed in May 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the October 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $15.0&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and the January 2016 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $0.4&#160;million also at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Back-solve analysis also took into consideration changes in the market value of benchmark equity indices and the value created from cash spent on R&amp;D activities. As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.11</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of June&#160;30, 2016. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo had occurred since June&#160;30, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the board&#8217;s judgment the increase in fair value from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.91</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at May&#160;11, 2016 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.11</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at August&#160;10, 2016 reasonably reflected the scientific and clinical progress of Exicure OpCo&#8217;s research programs and prospective therapeutic candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">November&#160;9, 2016.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On November&#160;9, 2016, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such date was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.42</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method in the Hybrid Method. The board&#8217;s analysis reflected that, based on then-existing market conditions, the IPO prospects for Exicure OpCo had improved as compared to the assumption at August 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the October 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $15.0&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and the January 2016 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $0.4&#160;million also at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Back-solve analysis also took into consideration changes in the market value of benchmark equity indices and the value created from cash spent on R&amp;D activities. As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.42</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of October&#160;31, 2016. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo&#160;had occurred since October&#160;31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the board&#8217;s judgment the increase in fair value from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.11</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at August&#160;10, 2016 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.42</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at November&#160;9, 2016 reasonably reflects both the scientific and clinical progress of Exicure OpCo&#8217;s research programs and prospective therapeutic candidates, as well as the completion of the Phase 1 trial for AST-005 and an understanding of the progress in negotiating the then pending Purdue Collaboration.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">January&#160;4, 2017.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;On January&#160;4, 2017, Exicure OpCo&#8217;s board determined that the fair value of Exicure OpCo&#8217;s common stock as of such date was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4.21</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. In its deliberation the board considered all of the qualitative and quantitative factors detailed above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In determining the fair value of Exicure OpCo&#8217;s common stock, the board relied principally on the Back-solve Method for determining the enterprise value of Exicure OpCo. When determining the fair value of Exicure OpCo&#8217;s common stock, the board considered both the probability of an IPO of Exicure OpCo&#8217;s common stock in a PWERM analysis and the results provided by the Option Pricing Method. The fair value determined using the PWERM analysis was aggregated with the fair value determined by the Option Pricing Method in the Hybrid Method. The board&#8217;s analysis reflected that, based on then-existing market conditions, the IPO prospects for Exicure OpCo had improved as compared to the assumption at November 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An important input into the application of the Back-solve Method was the October 2015 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $15.0&#160;million at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and the January 2016 sale of Exicure OpCo&#8217;s Series C preferred stock for aggregate proceeds of $0.4&#160;million also at a per share price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Back-solve analysis also took into consideration changes in the market value of benchmark equity indices and the value created from cash spent on R&amp;D activities. As part of its determination the board considered a contemporaneous valuation of Exicure OpCo&#8217;s common stock prepared by an independent third party appraiser in accordance with the Practice Aid, which indicated a per share value for Exicure OpCo&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4.21</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of December&#160;15, 2016. The board concluded in its deliberations that this valuation remained an important input into its deliberations since in its judgment no material change in the value of Exicure OpCo&#160;had occurred since December&#160;15, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the board&#8217;s judgment the increase in fair value from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.42</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at November&#160;9, 2016 to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4.21</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at January&#160;4, 2017 reasonably reflects both the scientific and clinical progress of Exicure OpCo&#8217;s research programs and prospective </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">therapeutic candidates, the execution of the Purdue Collaboration agreement on December&#160;2, 2016, receipt of the upfront payment from Purdue, and the improved IPO prospects for Exicure OpCo.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Results of valuation models may vary.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;There are significant judgments and estimates inherent in the determination of these valuations. These judgments and estimates include assumptions regarding Exicure OpCo&#8217;s future performance, including the successful enrollment and completion of Exicure OpCo&#8217;s clinical studies as well as the determination of the appropriate valuation methods. If we had made different assumptions, our equity-based compensation expense could have been different. The foregoing valuation methodologies are not the only methodologies available and they will not be used after the Private Placement is complete. We cannot make assurances as to any particular valuation for Exicure OpCo&#8217;s common stock. Accordingly, investors are cautioned not to place undue reliance on the foregoing valuation methodologies as an indicator of future stock prices.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common stock warrant liability</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of expected volatility at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of fair value of the common stock at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$34,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&#8217;s financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div><a name="s432A10F3E0387FBC716028AA89C51A03"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of Statements of Operations</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have earned all of our revenue through September&#160;30, 2017 through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. We do not intend for government grants to be a principal commercial or strategic focus, but will evaluate opportunities when consistent with our strategic priorities. We have not generated any commercial product revenue and do not expect to generate any product revenue for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the future, we may generate revenue from partnership activities including a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Purdue Collaboration or any future collaborations and licenses. We expect that any such revenue we generate will fluctuate in future periods as a result of the timing of achievement, if at all, of preclinical, clinical, regulatory and commercialization milestones, the timing and amount of any payments to us relating to such milestones and the extent to which any of our therapeutic candidates are approved and successfully commercialized by us or potential development partners. If we, or any potential development partner fails to develop therapeutic candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially and adversely affected.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense consists of costs associated with our research activities, including discovery and development of our SNAs, and their therapeutic applications. Our research and development expenses include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">direct research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, and consultants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">laboratory materials and supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">costs of maintaining our intellectual property portfolio, including license fees, sublicense fees, patent maintenance and other similar fees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">employee-related expenses, including salaries, bonuses, benefits and equity-based compensation expense; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expense research and development costs as they are incurred. A significant portion of our research and development costs are not tracked by project as they benefit multiple projects or our technology.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect our research and development expenses to increase for the foreseeable future as we advance our therapeutic candidates through preclinical studies and clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. We or future development partners may never succeed in obtaining marketing approval for any of our therapeutic candidates. The probability of success for each therapeutic candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All of our research and development programs are at an early stage and successful development of future therapeutic candidates from these programs is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future therapeutic candidate and are difficult to predict. We anticipate we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to our ability to maintain or enter into development partnership with respect to each therapeutic candidate, the scientific and clinical success of each therapeutic candidate as well as ongoing assessments as to the commercial potential of therapeutic candidates. We will need to raise additional capital and may seek collaborations in the future in order to advance our various therapeutic candidates. Additional private or public financings may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">General and administrative expense consists primarily of salaries and related benefits, including equity-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include travel expenses, professional fees for auditing, tax and legal services and allocated facility-related costs not otherwise included in research and development expenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company. These increases will likely include legal, accounting and filing fees, directors&#8217; and officers&#8217; liability insurance premiums and fees associated with investor relations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (loss), net</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our preferred and common stock warrant liabilities, and gains and losses on foreign currency transactions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></div><hr style="page-break-after:always"><div><a name="s231E2713FA0B58940B5328AA8A1D1AE5"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the Nine Months Ended September&#160;30, 2017 and 2016</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the results of our operations for the nine months ended September&#160;30, 2017 and 2016 (in thousands, except percentages):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We recognized revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2017. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million in December 2016 which was deferred and is recognized as collaboration revenue over the period in which the revenue is earned. We recognized </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of collaboration revenue during the nine months ended September&#160;30, 2017, which included $1.4&#160;million of research and development activities that is reimbursable by Purdue and is presented on a gross basis in the accompanying consolidated statement of operations. The grant income revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;recognized in the nine months ended September&#160;30, 2016 related to our performance as a primary contractor or as a subcontractor on government grants that concluded in early 2016. We did not have any active grants as of September&#160;30, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not intend for government grants to be a principal commercial or strategic focus, but will evaluate opportunities when consistent with our strategic priorities. We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Purdue Collaboration or any future collaboration and licenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine&#160;Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical development programs expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,326</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Platform and discovery-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,702</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, depreciation, and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">648</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">599</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2017 and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2016, an increase of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;">35%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Included in clinical development expense for the nine months ended September 30, 2017 was approximately $1.4 million of expense that is reimbursed by Purdue (included in revenue) related to the Phase 1b trial of AST-005. The increase in research and development expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was primarily due to a net increase in costs related to our clinical development programs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  This net increase was mostly due to higher costs for preparation for the Phase 1 clinical trials of both AST-008 and XCUR17.  Higher employee-related expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, mostly the result of an increase in headcount and salary increases, essentially offset lower platform and discovery-related expense of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which reflected lower costs related to contract research organizations and higher costs to maintain our intellectual property portfolio. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect our research and development expenses to increase in 2018 as we continue spending on our clinical development programs, further develop our SNA technology platform and broaden our pipeline of SNA-based candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expense</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine&#160;Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">General and administrative expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2017 and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2016, an increase of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;">76%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. This increase is primarily due to higher costs for legal and accounting services of approximately $1.1&#160;million, which were incurred in support of a potential public offering that was abandoned during the second quarter of 2017. Higher equity-based compensation expense of $0.6&#160;million, mostly related to stock options granted in January 2017, and expense of $0.2 million related to the termination of a contract with a placement agent that did not participate in the Private Placement also contributed to the increase in general and administrative expense in the nine months ended September&#160;30, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company. These increases will likely include legal, accounting and filing fees, directors&#8217; and officers&#8217; liability insurance premiums and fees associated with investor relations.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other income (loss), net</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our preferred and common stock warrant liabilities, and gains and losses on foreign currency transactions. Other income, net of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September 30, 2017 included a gain of $0.2 million in connection with the fair value adjustment of the liability for the preferred stock warrants that terminated in connection with the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2016 and 2015 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes the results of our operations for the years ended December&#160;31, 2016 and 2015 (in thousands, except percentages): </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,869</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,488</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,488</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to stockholders of the Company</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of the Company</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/m</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We recognized revenue of $1.0&#160;million for the year ended December&#160;31, 2016 and $2.4&#160;million for the year ended December&#160;31, 2015. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million in December 2016 which was deferred and is recognized as collaboration revenue over the period in which the revenue is earned. We recognized $0.7&#160;million of collaboration revenue during the year ended December&#160;31, 2016. The grant income revenue recognized in both the years ended December&#160;31, 2016 and 2015 related to our performance as a primary contractor or as a subcontractor on government grants. The decrease in grant income revenue of $2.0&#160;million is principally due to the conclusion of a grant in early 2016. We did not have any active grants as of December&#160;31, 2016. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We do not intend for government grants to be a principal commercial or strategic focus, but will evaluate opportunities when consistent with our strategic priorities. We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Purdue Collaboration or any future collaboration and licenses.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Research and development expense </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical development programs expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Platform and discovery-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,314</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,152</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, depreciation, and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,659</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense was $13.7&#160;million for the year ended December&#160;31, 2016 and $10.1&#160;million for the year ended December&#160;31, 2015, an increase of $3.5&#160;million, or 35%. This increase was primarily due to a Northwestern University License Agreements fee and a net increase in costs related to our three therapeutic development programs of $1.0&#160;million in 2016. The net increase of $1.0&#160;million in 2016 related to our three therapeutic development programs and was mostly due to higher costs for the preparation of XCUR17 and AST-008 for Phase 1 clinical trials, partially offset by lower costs associated with AST-005 for which we completed the Phase 1 trial during 2016. Also contributing to the increase in research and development costs in 2016 were higher materials and supplies expense of $0.6&#160;million for internal research and development activities associated with the development and discovery of new therapeutic candidates and higher compensation and related expense of $0.4&#160;million, mostly associated with the hiring of our Chief Scientific Officer in October 2015 as well as the addition of new employees during 2016 and the impact of general and promotional salary increases during 2016. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect our research and development expenses to increase in 2018 as we continue spending on our clinical development programs, further develop our SNA technology platform and broaden our pipeline of SNA-based candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and administrative expense </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">General and administrative expense was $3.5&#160;million for the year ended December&#160;31, 2016 and $5.4&#160;million for the year ended December&#160;31, 2015, a decrease of $1.9&#160;million, or 35%. This decrease is primarily due to lower costs for accounting, legal and other professional services fees of $2.1&#160;million, which were incurred generally in support of a potential public offering or other financing, partially offset by higher equity-based compensation expense of $0.2&#160;million for the year ended December&#160;31, 2016. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other income (loss), net </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our warrant liability, and gains and losses on foreign currency transactions. Other income (loss), net was not significant to our results of operations in both of the years ended December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net loss attributable to members of AuraSense Therapeutics, LLC and net loss attributable to stockholders of the Company </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net loss attributable to members of AuraSense Therapeutics, LLC of $7.5&#160;million in the year ended December&#160;31, 2015 represents the net loss incurred prior to the corporate conversion (as discussed in Note 1 of the accompanying financial statements). Net loss incurred after the corporate conversion is included in net loss attributable to stockholders of the Company. </font></div><div><a name="sA9EFF74E8E263AAF99E328AA8A45F20E"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To date we have primarily funded our operations through private placements of equity securities, the Purdue Collaboration, a debt financing, and grants from governmental agencies. Through September&#160;30, 2017, we have received approximately $84.1 million in aggregate gross proceeds from these transactions, including $42.8 million in aggregate gross proceeds from private placement offerings of preferred stock, $20.3 million gross proceeds from the initial closing of the Private Placement on September 26, 2017, an upfront payment of $10.0&#160;million in connection with the Purdue Collaboration, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in debt financing, and an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;from grants awarded by governmental agencies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 27, 2017 and November 2, 2017, we sold a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of the Company&#8217;s common stock, par value $0.0001 per share in subsequent closings of the Private Placement, resulting in approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since our inception, we have not generated any product revenue and have incurred recurring net losses.  Our Company is not profitable, and we cannot provide any assurance that we will ever be profitable. As of September&#160;30, 2017, we have an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. We believe that our cash and cash equivalents as of September 30, 2017 of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the sale of common stock in the Private Placement, but excluding any potential proceeds from option exercises, is sufficient to fund the Company into 2019. See &#8220;&#8212;Funding Requirements&#8221; below for additional information on our future capital needs.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table shows a summary of our cash flows for the nine months ended September&#160;30, 2017 and 2016 and the years ended December 31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine&#160;Months&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(726</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(315</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(394</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,313</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,399</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September&#160;30, 2017 and 2016, respectively. The increase in cash used in operating activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was primarily due to the cash impact of higher research and development expenses in the nine months ended September&#160;30, 2017, the payment of $1.5&#160;million in connection with the Northwestern University License Agreements, the payment for legal and accounting services of approximately $1.1&#160;million, which were incurred in support of a potential public offering that was abandoned during the second quarter of 2017, as well as the prepayment of directors and officers liability insurance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in operating activities was $5.1&#160;million and $12.2&#160;million for the years ended December&#160;31, 2016 and 2015, respectively. The decrease in cash used in operating activities of $7.2&#160;million was primarily due to the receipt of the $10.0&#160;million upfront payment in connection with the Purdue Collaboration in December 2016, partially offset by the cash impact of a higher net loss in the year ended December&#160;31, 2016. The higher net loss in the year ended December&#160;31, 2016 was primarily due to an increase in research and development efforts partially offset by lower general and administrative expenses. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash used in investing activities was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September 30, 2017 and 2016, respectively, and $0.4&#160;million and $12,000 for the years ended December&#160;31, 2016 and 2015, respectively. Cash used in investing activities for each of the above-mentioned periods was primarily due to the purchase of scientific equipment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing activities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash provided by financing activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18.5 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;during the nine months ended September 30, 2017 is primarily due to the sale of common stock in the Private Placement on September 26, 2017.  Gross proceeds from the Private Placement of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, less financing costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, were partially offset by the repayment of debt of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net cash provided by financing activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;during the nine months ended </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">September 30, 2016 is mostly due to net proceeds of $5.9&#160;million from our February 2016 secured debt financing with Hercules and $0.4&#160;million from our January 2016 Series C preferred stock offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Net cash provided by financing activities was $6.3&#160;million and $19.6&#160;million for the years ended December&#160;31, 2016 and 2015. Net cash provided by financing activities during the year ended December&#160;31, 2016 relates to net proceeds of $5.9&#160;million from our February 2016 secured debt financing and $0.4&#160;million from our January 2016 Series C preferred stock offering. Net cash provided by financing activities during the year ended December&#160;31, 2015 relates to the sale of preferred units/stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hercules Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February&#160;17, 2016, we entered into a loan and security agreement with Hercules. The loan agreement provided for funding in an aggregate principal amount of up to $10.0&#160;million in two separate tranches. The first tranche was funded on February&#160;17, 2016 in the amount of $6.0&#160;million. A second tranche of $4.0&#160;million was available provided that we met certain milestones on or before December&#160;31, 2016. We did not meet these milestones and, therefore, we did not draw the second tranche, the availability of which expired on December&#160;31, 2016. The principal balance of the term loan under the Hercules loan facility bears interest at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in The Wall Street Journal) minus 3.50%. We were required to make interest-only payments through June 2017. Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019. Any remaining obligations under the loan agreement and other loan documents (other than the warrant described below) are due and payable on the maturity date. On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement. In addition, if we prepaid the term loan on or prior to February&#160;1, 2017, we would be required to pay a prepayment charge equal to 3% of the amount being prepaid, if we prepay the term loan after February&#160;1, 2017 but on or prior to February&#160;1, 2018, we must pay a prepayment charge equal to 2% of the amount being prepaid, and if we prepay the term loan after February&#160;1, 2018, we must pay a prepayment charge of 1% of the amount being prepaid. The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The term loan under the Hercules loan facility is secured by substantially all of our assets, other than intellectual property, which is the subject of a negative pledge. Under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without Hercules&#8217; prior consent.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing. Hercules has not yet exercised this right to participate.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with our financing with Hercules, we issued Hercules a warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">80,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of our Series&#160;C preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share, plus an additional number of shares in the event that the second tranche of funding had been drawn before it expired on December&#160;31, 2016. The warrant terminated at the closing of the Merger.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect that our primary uses of capital will continue to be third-party clinical research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. We believe that our existing cash and cash equivalents as of September&#160;30, 2017, when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the sale of common stock in the Private Placement, but excluding any potential proceeds from option exercises, is sufficient to meet our anticipated cash requirements into 2019. However, we may require additional capital for the further development of our existing therapeutic candidates and may also need to raise additional funds sooner to pursue other development activities related to additional therapeutic candidates. We believe that we will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements to fund our current operating plans into 2019, which we believe will allow us to execute on the strategy and pipeline development as described in this prospectus. To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We cannot assure you that such additional financing, if available, can be obtained on terms acceptable to us. If we are unable to obtain such additional financing, we would need to reevaluate our future operating plans.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements are difficult to forecast and will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the number and characteristics of therapeutic candidates that we pursue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the progress, costs and results of our preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the outcome, timing and cost of regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">delays that may be caused by changing regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the cost and timing of hiring new employees to support our continued growth;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in this prospectus for additional risks associated with our substantial capital requirements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Until such time, if ever, we generate product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="s388ab91a4f2844428a92e5e39965bc7d"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a summary of our significant contractual obligations as of December&#160;31, 2016 (in thousands).</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments&#160;Due&#160;by&#160;Period </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;than&#160;1</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1-3&#160;Years </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3-5&#160;Years </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">After&#160;5&#160;Years </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease obligations (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">688</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest payments on long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,497</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,943</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Includes principal only. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Future minimum lease payments under our non-cancelable operating lease for our current office and lab space in Skokie, Illinois that expires in February 2021. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We enter into agreements in the normal course of business with contract research organizations&#160;and vendors for clinical trials, preclinical studies, and other services and products for operating purposes which are cancelable at any time by us, generally upon 30 days prior written notice. We also have obligations to make future payments to Northwestern University that become due and payable on the achievement of certain commercial milestones. These payments are not included in this table of contractual obligations.</font></div><div><a name="s93781600BC4922F5D67828AA8A6AEDE2"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-balance Sheet Arrangements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></div><div><a name="s5E9F3E99634C70E7791728AA8A8B1252"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosure About Market Risk </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Some of the securities that we invest in may have market risk related to changes in interest rates. As of September&#160;30, 2017 and as of December&#160;31, 2016 and 2015, we had cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22.9 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and $18.7 million, respectively, consisting of interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100&#160;basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, money market funds, government and non-government debt securities and corporate obligations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></div><hr style="page-break-after:always"><div><a name="sC182CB84BEA4BA10BBA628AA8ABCE7ED"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">JOBS Act </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2012, the JOBS Act was enacted by the federal government. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act.</font></div><div><a name="s4114aa6ea6244c0a87c79326409622b0"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Effective at the Effective Time of the Merger, Raich Ende Malter&#160;&amp; Co. LLP, was dismissed as the independent registered public accounting firm that audits the financial statements of our Company. Effective as of the Effective Time, our board of directors engaged KPMG LLP, as the independent registered public accounting firm to audit the Company&#8217;s financial statements for the fiscal year ending December&#160;31, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Raich Ende Malter&#160;&amp; Co. LLP&#8217;s audit report on our financial statements for the period from February&#160;6, 2017 (Max-1&#8217;s inception) through February&#160;28, 2017 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles except that the report dated March&#160;21, 2017 contained statements indicating there is substantial doubt about the Company&#8217;s ability to continue as a going-concern. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the period from February&#160;6, 2017 through February&#160;28, 2017 and the subsequent interim period through the date of Raich Ende Malter&#160;&amp; Co. LLP&#8217;s dismissal, there were no disagreements with Raich Ende Malter&#160;&amp; Co. LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Raich Ende Malter&#160;&amp; Co. LLP would have caused it to make reference to the subject matter thereof in connection with its report. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the period from February&#160;6, 2017 through February&#160;28, 2017 and the subsequent interim period through the date of Raich Ende Malter&#160;&amp; Co. LLP&#8217;s dismissal, neither the Company nor anyone acting on its behalf consulted KPMG LLP regarding the application of accounting principles to a specified transaction, either completed or proposed or the type of audit opinion that might be rendered on the Company&#8217;s financial statements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have provided Raich Ende Malter&#160;&amp; Co. LLP with a copy of the disclosures it is making in this registration statement prior to the filing hereof and have requested that Raich Ende Malter&#160;&amp; Co. LLP furnish to us a letter addressed to the SEC stating whether it agrees with the statements made herein. Raich Ende Malter&#160;&amp; Co. LLP has furnished such letter, which letter is filed as Exhibit 16.1 hereto, as required by Item 304(a)(3) of Regulation S-K. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></div><hr style="page-break-after:always"><div><a name="s4C20F89CE6A72C17DF0128AA8CD2C7E4"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIRECTORS AND EXECUTIVE OFFICERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth the names and certain information regarding each of our directors and executive officers as of September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:60%;"></td><td style="width:1%;"></td><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Age</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer, Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David S. Snyder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ekambar Kandimalla, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Scientific Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chad A. Mirkin, Ph.D. (4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. Shad Thaxton, M.D., Ph.D. (1)(3)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David R. Walt,Ph.D. (2)(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay R. Venkatesan, M.D. (1)(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen S. Kim (1)(2)(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the audit committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the compensation committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Member of the nominating and corporate governance committee. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chairman of the board of directors. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Officers </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">David A. Giljohann, Ph.D., Chief Executive Officer, director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dr.&#160;Giljohann is our Chief Executive Officer and director. Dr. Giljohann has served as Exicure OpCo&#8217;s chief executive fficer since November 2013 and has been on Exicure OpCo&#8217;s board of directors since March 2014. From July 2012 to October 2013, Dr.&#160;Giljohann was Exicure OpCo&#8217;s Chief Operating Officer. From 2011 until June 2012, Dr.&#160;Giljohann served as Exicure OpCo&#8217;s principal scientist. Dr.&#160;Giljohann was Exicure OpCo&#8217;s founding scientist in 2011. Prior to that, Dr.&#160;Giljohann was the founding scientist of AuraSense, LLC, Exicure OpCo&#8217;s largest stockholder, in 2009. Dr.&#160;Giljohann completed his Ph.D. in the laboratory of Dr.&#160;Chad&#160;A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare&#8482; and SNA constructs. Dr.&#160;Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist&#8217;s &#8220;Top 40 Under 40 Power List&#8221; in 2014. Dr.&#160;Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr.&#160;Giljohann obtained his Ph.D. in 2009 from Northwestern University. We believe that Dr.&#160;Giljohann&#8217;s experience in biotechnology research and development provides him with the qualifications and skills to serve as a member of our board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">David S. Snyder, Chief Financial Officer </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Mr.&#160;Snyder is our Chief Financial Officer. Mr. Snyder joined Exicure OpCo&#8217;s executive leadership team as chief financial officer in July 2014. Prior to joining Exicure OpCo, Mr.&#160;Snyder was executive vice president and chief financial officer of Cellular Dynamics International, Inc. where he was responsible for all financial functions, human resources, and general administration. At Cellular Dynamics, Mr.&#160;Snyder helped lead the successful IPO of that company in July of 2013. Mr.&#160;Snyder previously served as senior vice president of finance, site vice president and chief financial officer of Roche NimbleGen from 2007 to 2008. From 2006 to 2007, he served as vice president and chief financial officer of NimbleGen Systems, Inc. At NimbleGen, Mr.&#160;Snyder helped prepare the company for an IPO and then helped manage the sale of NimbleGen to Roche. Prior to NimbleGen, Mr.&#160;Snyder was the chief financial officer of a variety of public and private companies within software, real estate, and diversified manufacturing industries. He has served as a director of Invenra, Inc. since 2012. He has also served on the Board of Trustees of Ottawa University from 2012 through 2014. Mr.&#160;Snyder received a B.A., summa cum laude, from </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ottawa University and an MBA with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ekambar Kandimalla, Chief Scientific Officer </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dr.&#160;Kandimalla is our Chief Scientific Officer. Dr. Kandimalla joined Exicure OpCo as its chief scientific officer in October 2015, bringing over 20 years of discovery research and preclinical drug development experience. Dr.&#160;Kandimalla has led discovery of oligonucleotide therapeutics targeting mRNA, miRNA and toll-like receptors for the treatment of broad disease indications, including cancers, asthma-allergies, autoimmune, cardiovascular and metabolic diseases. Dr.&#160;Kandimalla has extensive experience in oligonucleotide chemistry, in vitro and in vivo pharmacology, target identification and validation to late stage discovery. From June 2014 to October 2015, Dr.&#160;Kandimalla served as chief scientific officer of ChemGenes Corporation, where he was responsible for external collaborations for product development and overall R&amp;D strategy as well as day to day lab operations Dr.&#160;Kandimalla was at Idera Pharmaceuticals Inc., formerly Hybridon, Inc., from June 1992 to June 2014 in various roles of increasing responsibility, including serving as vice president of discovery, where he was responsible for generating new product pipeline, supporting early drug development, and establishing and maintaining external scientific collaborations. Prior to joining Hybridon, Dr.&#160;Kandimalla carried out postdoctoral research at Molecular Biophysics Unit of Indian Institute of Science, and Department of Chemistry of the University of Alberta. Dr.&#160;Kandimalla is an author on over 150 publications, including reviews and book chapters, and a co-inventor on approximately 300 issued or pending patents worldwide. Dr.&#160;Kandimalla received a Ph.D. in Chemistry, M.Sc. in Biochemistry and B.Sc. in Chemistry, all from Andhra University, India. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Directors </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chad A. Mirkin, Ph.D., director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dr.&#160;Mirkin is our non-employee director and has served as a member of Exicure OpCo&#8217;s board of directors since 2011. Dr.&#160;Mirkin is Director of the International Institute for Nanotechnology at Northwestern University, as well as the George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science and Engineering, and Professor of Medicine. Dr.&#160;Mirkin is a Fellow of the American Association for the Advancement of Science and the National Academy of Engineering. Dr.&#160;Mirkin served on the President&#8217;s Council of Advisors on Science and Technology, or PCAST, during the Obama administration from April 2009 to January 2017. Dr.&#160;Mirkin is one of the founders of and has served as President of AuraSense, LLC, Exicure OpCo&#8217;s largest stockholder, since December 2009. Dr.&#160;Mirkin has also served as a director of Nanosphere, Inc. from 2000 until May 2013, and NanoInk, Inc., from 2002 to 2010. Dr.&#160;Mirkin holds a B.S. degree from Dickinson College and a Ph.D. degree in chemistry from the Pennsylvania State University. We believe that Dr.&#160;Mirkin&#8217;s significant scientific knowledge and expertise in the application of nanotechnology to the development of nucleic acid products provide him with the requisite experience, qualifications, attributes and skills necessary to serve as a member of our board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">C. Shad Thaxton, M.D., Ph.D., director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dr.&#160;Thaxton is our non-employee director and has served on Exicure OpCo&#8217;s board of directors since 2011. Dr.&#160;Thaxton is an Assistant Professor in the Department of Urology at Northwestern University, Feinberg School of Medicine. Dr.&#160;Thaxton is one of the founders of and has served as Vice President of AuraSense, LLC, our largest stockholder, since December 2009. Dr.&#160;Thaxton has been recognized for his accomplishments with 13 awards, including most recently, Bioscience Technology&#8217;s 2009 Researcher of the Year and the MIT Technology Review&#8217;s TR35 Award, as one of the world&#8217;s top innovators under the age of 35. Dr.&#160;Thaxton holds a B.A. degree in Environmental Biology from the University of Colorado, Boulder and received his M.D. and Ph.D. degrees from the Feinberg School of Medicine and Interdepartmental Biological Sciences programs, respectively, at Northwestern University. We believe that Dr.&#160;Thaxton&#8217;s significant scientific knowledge and expertise in nanomedicine provide him with the requisite experience, qualifications, attributes and skills necessary to serve as a member of our board of directors. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">David R. Walt, Ph.D., director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dr.&#160;Walt is our non-employee director and has served on Exicure OpCo&#8217;s board of directors since 2013. Dr.&#160;Walt is the founder of Illumina, Inc. (NASDAQ: ILMN) and has been its director and chairman of the scientific advisory board since June 1998. Since July 2017, Dr.&#160;Walt is a professor in the Department of Pathology at Brigham and Women&#8217;s Hospital and a Core Faculty member at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr.&#160;Walt is also a member of the faculty at Harvard Medical School in the Department of Pathology and has been a Howard Hughes Medical Institute Professor since 2006. Prior to July 2017, Dr.&#160;Walt was a University Professor at Tufts University since 2014, the Robinson Professor of Chemistry at Tufts University since 1995. Dr.&#160;Walt also serves as a board member for Quanterix, Inc., a privately-held company focused on single molecule analysis for clinical diagnostics. Dr.&#160;Walt holds a B.S. degree in Chemistry from the University of Michigan and received his Ph.D. degree in Chemical Biology from the State University of New York at Stony Brook. We believe that Dr.&#160;Walt&#8217;s scientific and business experience, including his diversified background as a director of public and private biotechnology companies, provide him with the qualifications and skills to serve as a member of our board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jay R. Venkatesan, M.D., director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Jay R. Venkatesan, M.D. is our non-employee director and has served on Exicure OpCo&#8217;s board since March 2014. Since June 2016, Dr.&#160;Venkatesan has served as President of Alpine Immune Sciences, Inc., a development-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies, where he previously served as Chief Executive Officer from November 2015 to June 2016. Dr.&#160;Venkatesan has served as a member of Alpine&#8217;s board of directors since November 2015. Prior to joining Alpine, Dr.&#160;Venkatesan was the Executive Vice President and General Manager of Oncothyreon, Inc. (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon&#8217;s acquisition of Alpine Biosciences, where he served as co-founder and Chief Executive Officer. Previously, Dr.&#160;Venkatesan was the Founder, Portfolio Manager, and Managing Director of Ayer Capital Management, a global healthcare equity fund from January 2008 to December 2013. Prior to that, he was a Director at Brookside Capital Partners from 2002 to 2007. Earlier in his career, Dr.&#160;Venkatesan was involved in healthcare investing at Partricof&#160;&amp; Co. Ventures from 1995 to 1996 and consulting at McKinsey&#160;&amp; Company from 1993 to 1995. In addition, Dr.&#160;Venkatesan currently serves on the board of directors of Ioyance Biotherapeutics (NASDAQ: IOVA) (formerly Lion Biotechnologies), Transplant Genomics, and CellBioTherapy. Dr.&#160;Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from Williams College. We believe that Dr.&#160;Venkatesan&#8217;s experience as the founder of multiple biotechnology companies and his experience in venture capital provide him with the qualifications and skills to serve as a member of our board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Helen S. Kim, director </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ms.&#160;Kim is our non-employee director and has served on Exicure OpCo&#8217;s board since July 2014. Ms.&#160;Kim has performed numerous leadership roles with public and private companies managing research and therapeutic development from preclinical to commercialization. Ms.&#160;Kim has over 25 years of experience in leadership roles in biotechnology. Since 2014, Ms.&#160;Kim has served as the executive vice president of business development at Kite Pharma, Inc. (NASDAQ: KITE). Ms.&#160;Kim served as chief business officer of NGM Biopharmaceuticals Inc., from August 2009 to January 2012. Ms.&#160;Kim was on the board of director ImmunoCellular Therapeutics, Ltd., from August 2011 to September 2014. Currently, she serves as a director of Sunesis Pharmaceuticals since July 2009, and Forsight VISION 4 since September 2012. Prior to NGM, she was the chief executive officer and president of Kosan Biosciences Incorporated prior to the sale of the company to Bristol-Myers Squibb in 2008. Ms.&#160;Kim&#8217;s additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms.&#160;Kim also recently served as chief program officer for the Gordon and Betty Moore Foundation. Ms.&#160;Kim received a B.S. in Chemical Engineering from Northwestern University and an MBA from the University of Chicago. We believe Ms.&#160;Kim&#8217;s experience as an entrepreneur in the life sciences industry and her management experience provide her with the qualifications and skills to serve as a member of our board of directors. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Composition </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors currently consists of six members. Our amended and restated certificate of incorporation, which became effective on November 15, 2017, provides that the number of directors may be changed only by resolution of the board of directors. All directors will hold office until their successors have been elected and qualified or appointed or the earlier of their death, resignation or removal. Executive officers are appointed and serve at the discretion of the board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have a staggered board, and our directors are divided into three classes, designated as Class&#160;I, consisting of two&#160;directors, Class&#160;II, consisting of&#160;two&#160;directors, and Class&#160;III, consisting of&#160;two&#160;directors, with no more than one class eligible for reelection at any annual stockholder meeting. The&#160;two&#160;Class&#160;I directors will initially be elected for a term expiring on the date of our 2018 annual stockholder meeting and thereafter will be elected to serve terms of three years. The&#160;two&#160;Class II directors will initially be elected for a term expiring on the date of our 2019 annual stockholder meeting and thereafter will be elected to serve terms of three years. The&#160;two&#160;Class III directors will initially be elected for a term expiring on the date of our 2020 annual stockholder meeting and thereafter will be elected to serve terms of three years. The division of our board of directors into three classes with staggered three year terms may delay or prevent a change of our management or a change in control. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth the names and classes of our directors: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Class&#160;I&#160;directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Class&#160;II&#160;directors&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Class&#160;III&#160;directors&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David&#160;R.&#160;Walt,&#160;Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen&#160;S.&#160;Kim</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chad&#160;A.&#160;Mirkin,&#160;Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David&#160;A.&#160;Giljohann,&#160;Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C.&#160;Shad&#160;Thaxton,&#160;M.D.,&#160;Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay&#160;R.&#160;Venkatesan,&#160;Ph.D.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Independence </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our securities are not listed on a national securities exchange or on any inter-dealer quotation system which has a requirement that a majority of directors be independent. We evaluate independence by the standards for director independence set forth in the NASDAQ Marketplace Rules and the rules and regulations of the SEC. Under such rules, our board of directors has determined that all members of the board of directors, except David A. Giljohann, Ph.D., Chad A. Mirkin, Ph.D. and C. Shad Thaxton, M.D., Ph.D., are independent directors. Dr.&#160;Giljohann is not an independent director under these rules because of his role as our Chief Executive Officer. Drs. Mirkin and Thaxton are not independent directors under these rules because of their role as managers and unitholders of AuraSense, LLC, which is our largest stockholder. In addition, Dr.&#160;Mirkin currently has a consulting agreement with Exicure OpCo that is expected to be assumed by us. In making such independence determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common stock. We expect to transition the composition and functioning of our board of directors and each of our committees to comply with all applicable requirements of the NASDAQ Stock Market and the rules and regulations of the SEC within applicable transition periods. There are no family relationships among any of our directors or executive officers. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Committees </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors has established the committees described below and may establish others from time to time. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to post the charters for each of our committees on our website at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.exicuretx.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;prior to the effective date of this registration statement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Audit committee </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our audit committee will initially be comprised of&#160;C. Shad Thaxton, M.D., Ph.D., Jay R. Venkatesan, M.D., and Helen S. Kim. Jay Venkatesan, M.D.&#160;will serve as the chairperson of the committee. We expect that our board of directors will determine that each member of the audit committee is &#8220;independent&#8221; for audit committee purposes as that term is defined in the applicable rules of the SEC and The NASDAQ Stock Market. We also expect that our board of directors will designate Jay Venkatesan, M.D. as an &#8220;audit committee financial expert,&#8221; as defined under the applicable rules of the SEC. The audit committee&#8217;s responsibilities will include: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">appointing, approving the compensation of and assessing the independence of our independent registered public accounting firm; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing annually a report by the independent registered public accounting firm regarding the independent registered public accounting firm&#8217;s internal quality control procedures and various issues relating thereto; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting with both management and the independent registered public accounting firm; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">establishing policies and procedures for the receipt and retention of accounting related complaints and concerns, including a confidential, anonymous mechanism for the submission of concerns by employees; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">periodically reviewing legal compliance matters, including any securities trading policies, periodically reviewing significant accounting and other financial risks or exposures to our Company and reviewing and, if appropriate, approving all transactions between our Company and any related party (as described in Item&#160;404 of Regulation S-K promulgated under the Exchange Act); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">establishing policies for the hiring of employees and former employees of the independent registered public accounting firm; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">preparing the audit committee report required by SEC rules to be included in our annual proxy statement. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The audit committee will have the power to investigate any matter brought to its attention within the scope of its duties and will have the authority to retain counsel and advisors to fulfill its responsibilities and duties. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation committee </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our compensation committee will initially be comprised of David R. Walt, Ph.D., Jay R. Venkatesan, M.D., and Helen S. Kim. David R. Walt, Ph.D. will serve as the chairperson of the committee. We expect that our board of directors will determine that each member of the compensation committee is an independent director for compensation committee purposes as that term is defined in the applicable rules of the NASDAQ Stock Market, is a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3(d)(3) promulgated under the Exchange Act and is an &#8220;outside director&#8221; within the meaning of Section&#160;162(m) of the Internal Revenue Code, as amended. The compensation committee&#8217;s responsibilities will include, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">evaluating the performance of our chief executive officer in light of such corporate goals and objectives and approving the compensation of our chief executive officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing and approving the compensation of our other executive officers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing our compensation, welfare, benefit and pension plans and similar plans; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reviewing and making recommendations to the board of directors with respect to director compensation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">preparing for inclusion in our proxy statement the report, if any, of the compensation committee required by the SEC. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The compensation committee will have the power to investigate any matter brought to its attention within the scope of its duties and will have the authority to retain counsel and advisors to fulfill its responsibilities and duties. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nominating and corporate governance committee </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our nominating and corporate governance committee will initially be comprised of&#160;C. Shad Thaxton, M.D., Ph.D., David R. Walt, Ph.D., and Helen S. Kim. Helen Kim will serve as the chairperson of the committee. We expect that our board of directors will determine that each of the committee members is an independent director for nominating and corporate governance committee purposes as that term is defined in the applicable rules of The NASDAQ Stock Market. The nominating and corporate governance committee&#8217;s responsibilities will include, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">developing and recommending to the board of directors criteria for membership on the board of directors and committees; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">identifying individuals qualified to become members of the board of directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">recommending to the board of directors the persons to be nominated for election as directors and to each committee of the board of directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">annually reviewing our corporate governance guidelines; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">monitoring and evaluating the performance of the board of directors and leading the board in an annual self-assessment of its practices and effectiveness. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The nominating and corporate governance committee will have the power to investigate any matter brought to its attention within the scope of its duties and will have the authority to retain counsel and advisors to fulfill its responsibilities and duties. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Assessment and Compensation Practices </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property as more fully discussed in the section entitled &#8220;Risk Factors&#8221; appearing elsewhere in this prospectus. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our management assessed and discussed with our compensation committee our compensation policies and practices for our employees as they relate to our risk management and, based upon this assessment, we believe that any risks arising from such policies and practices are not reasonably likely to have a material adverse effect on us in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our employees&#8217; base salaries are fixed in amount and thus we do not believe that they encourage excessive risk taking. While performance-based cash bonuses focus on achievement of short-term or annual goals, which may encourage the taking of short-term or annual risks at the expense of long-term results, we believe that our compensation policies help mitigate this risk and our performance-based cash bonuses are limited, representing a small portion of the total compensation opportunities available to most employees. We also believe that our performance-based cash bonuses appropriately balance risk and the desire to focus our employees on specific short-term goals important to our success and do not encourage unnecessary or excessive risk taking. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A significant proportion of the compensation provided to our employees is in the form of long-term equity-based incentives that we believe are important to help further align our employees&#8217; interests with those of our stockholders. We do not believe that these equity-based incentives encourage unnecessary or excessive risk taking because their ultimate value is tied to our stock price. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Board Diversity </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, will take into account many factors, including the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">diversity of personal and professional background, perspective and experience; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">personal and professional integrity, ethics and values; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">experience in corporate management, operations or finance, such as serving as an officer or former officer of a publicly held company, and a general understanding of marketing, finance and other elements relevant to the success of a publicly-traded company in today&#8217;s business environment; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">experience relevant to our industry and with relevant social policy concerns; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">experience as a board member or executive officer of another publicly held company; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">relevant academic expertise or other proficiency in an area of our operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">practical and mature business judgment, including ability to make independent analytical inquiries; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">promotion of a diversity of business or career experience relevant to our success; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any other relevant qualifications, attributes or skills. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Currently, our board of directors evaluates each individual in the context of the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Code of Business Conduct and Ethics </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to post our code of business conduct and ethics on our website at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.exicuretx.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;prior to the effective date of this registration statement. We expect that any amendments to the code, or any waivers of its requirements, will be disclosed on our website.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitation of Liability and Indemnification </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that to the fullest extent permitted by the DGCL, a director shall not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Our amended and restated bylaws provide that we shall indemnify and hold harmless our directors and officers to the fullest extent permitted by applicable law, except that we will not be required to indemnify or hold harmless any director or officer in connection with any proceeding initiated by such person unless the proceeding was authorized by our board of directors. Under our amended and restated bylaws, such rights shall not be exclusive of any other rights acquired by directors and officers, including by agreement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws provide that we will pay expenses to any director or officer prior to the final disposition of the proceeding, provided, however, that such advancements shall be made only upon receipt of an undertaking by such director or officer to repay all amounts advanced if it should be ultimately determined that such director or officer is not entitled to indemnification under the amended and restated bylaws or otherwise. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to the indemnification obligations required by our amended and restated certificate of incorporation and amended and restated bylaws, we have entered into indemnification agreements with each of our directors and officers. These agreements provide for the indemnification of our directors and executive officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought or threatened to be brought against them by reason of the fact that they are or were our agents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a condition to the Merger, we also entered into a Pre-Merger Indemnity Agreement with our former officers and directors, pursuant to which we agreed to indemnify such former officers and directors for actions taken by them in their official capacities relating to the consideration, approval and consummation of the Merger and certain related transactions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to obtain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, we have been informed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The above provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. The provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these amended and restated certificate of incorporation provisions, amended and restated bylaw provisions, indemnification agreements and the insurance are necessary to attract and retain qualified persons as directors and officers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceedings that might result in a claim for such indemnification. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></div><hr style="page-break-after:always"><div><a name="sD0AC8CDA7B1F926F384F28AA8D05A123"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXECUTIVE AND DIRECTOR COMPENSATION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This section is historical and has not been adjusted to give effect to the Merger or the share conversion ratio pursuant to the Merger Agreement. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Merger Executive Officers and Directors</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, our board of directors approved the issuance of an aggregate of 756,960 shares of our common stock to Ian Jacobs, Mark Tompkins, Montrose Capital Partners Limited, and a designee of a service provider for each party&#8217;s services to the Company in connection with the negotiation of the Merger Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Other than the stock issuance above and entry into Pre-Merger Indemnity Agreements described in &#8220;Certain Relationships and Related Party Transactions&#8212;Indemnification Agreements and Directors&#8217; and Officers&#8217; Liability Insurance,&#8221; our directors and officers prior to the Merger did not receive any cash or other compensation since the Company was incorporated on February 6, 2017. In addition, no retirement, pension, profit sharing, stock option or insurance programs or other similar programs were adopted by the Company for the benefit of its employees prior to the Merger, other than the approval of the 2017 Plan, the ESPP and the assumption and conversion of options to purchase 7,414,115 shares of Exicure OpCo&#8217;s common stock issued and outstanding immediately prior to the closing of the Merger pursuant to Exicure OpCo&#8217;s 2015 Plan into options to purchase 3,680,997 shares of our common stock, as described above in the &#8220;Description of the Merger, the Private Placement, and Related Transactions&#8221; section.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the Merger on September 26, 2017, Exicure OpCo became our wholly owned subsidiary. The following summarizes the compensation earned by Exicure OpCo&#8217;s executive officers and directors for 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director Compensation Table</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31, 2016 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table presents information regarding the compensation of Exicure OpCo&#8217;s non-employee directors for 2016. The compensation paid to David A. Giljohann, Exicure OpCo&#8217;s Chief Executive Officer, is presented below under &#8220;Executive Compensation&#8221; and the related explanatory notes. </font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fees</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Earned or</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid In</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Awards</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1)</sup></font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">All Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Compensation</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(2)</sup></font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($) &#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chad A. Mirkin, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. Shad Thaxton, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David R. Walt, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay R. Venkatesan, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen S. Kim</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">There were no option awards granted to our non-employee directors during 2016. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts reported in this column represent consulting fees received by Dr.&#160;Mirkin for providing consulting services to Exicure OpCo during 2016. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Director Compensation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo provides an annual cash retainer of $25,000 to its non-employee directors, paid quarterly in advance and prorated for their service during the applicable year. In 2014, Exicure OpCo&#8217;s non-employee directors also received an option grant to purchase 100,000 shares of common stock, with the exception of Dr.&#160;Walt, who received the grant in 2013. In April 2015, Exicure OpCo&#8217;s non-employee directors received an option grant to purchase 50,000 shares of common stock. The common stock options are contingent on the directors&#8217; continued provision of non-employee services and are subject to forfeiture if continued service terminates for any reason. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the terms of the 2015 Plan, which was adopted by Exicure OpCo&#8217;s board of directors on October&#160;6, 2015 and approved by Exicure OpCo&#8217;s stockholders on October&#160;13, 2015, these and any other initial stock option grants to each director vest 25% on the first 12-month anniversary of the grant date and vest 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent stock option grants vest 1/48th monthly until fully vested at the end of 48 months. At December&#160;31, 2016, each of Exicure OpCo&#8217;s non-employee directors held 150,000 common stock options. Other than these options, none of Exicure OpCo&#8217;s non-employee directors held any other equity awards on that date. In January 2017, Exicure OpCo granted 50,000 options to each of its non-employee directors that vest 1/12th monthly until fully vested at the end of 12 months. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January&#160;18, 2017, Exicure OpCo&#8217;s board approved revised annual cash compensation guidelines for its non-employee directors. Pursuant to the cash compensation guidelines, Exicure OpCo will provide an annual cash retainer of $35,000 to each non-employee director and an additional $30,000 to the Chairperson of the board.&#160;Exicure OpCo will also provide annual cash retainers in the following amounts: $7,500 for each member of the Audit Committee and an additional $7,500 for the Chairperson of the Audit Committee; $5,000 for each member of the Compensation Committee and an additional $5,000 for the Chairperson of the Compensation Committee; $5,000 for each member of the Nominating and Governance Committee and an additional $3,000 for the Chairperson of the Nominating and Governance Committee. All cash compensation will be paid quarterly in advance and prorated for service during an applicable year.&#160;These guidelines, which may be subject to amendment, are expected to remain in place and continue to be used by the Company. On January&#160;18, 2017, the Exicure OpCo board also approved equity award guidelines to non-employee board members. The guidelines, which may be amended by the board at any time, provide that each new board member will be granted a stock option for the number of shares of common stock equal to approximately 0.10% of the total capital stock, options, and warrants of Exicure OpCo outstanding immediately following the completion of the Private Placement, on an as converted to common stock basis.&#160;This option award will vest 1/36th monthly over three years.&#160;Proximate to each annual meeting of Exicure OpCo&#8217;s stockholders, the Exicure OpCo board agreed to grant to each continuing board member a stock option for the number of shares of common stock equal to approximately 0.05% of the total capital stock, options, and warrants of Exicure OpCo outstanding immediately following the completion of an initial public offering, on an as converted to common stock basis. This option will vest 1/12th monthly until fully vested at the end of 12 months. The first annual award for a new board member will be prorated for a partial year of service for any time period between the member&#8217;s joining date and the date of the annual stockholder meeting. These guidelines, which may be subject to amendment, were approved as part of Exicure OpCo&#8217;s transition to becoming a public company and are expected to remain in place and continue to be used by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo has entered into an amended and restated board service agreement with each of its non-employee directors regarding the director compensation described above and covering reimbursement of expenses incurred by such directors in attending meetings of its board of directors and committees thereof, and in carrying out such director&#8217;s duties as a director or as a member of any committee of its board of directors. These agreements, which may be amended from time to time, will remain in place and are expected to be assumed by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consulting Arrangement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo entered into a consulting agreement with Dr.&#160;Mirkin, dated as of October&#160;1, 2011, pursuant to which Dr.&#160;Mirkin provides services to Exicure OpCo and earns consulting fees of $100,000 per year, subject to adjustments. Services provided by Dr.&#160;Mirkin under this agreement consist of, but are not limited to, providing Exicure OpCo with scientific advice and counseling with regards to technological developments and initiatives related to SNA nano-structures. This consulting agreement expires on October&#160;1, 2021. The Company expects to enter into an agreement with Dr.&#160;Mirkin to assume Exicure OpCo&#8217;s obligations under this consulting agreement. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Compensation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo&#8217;s executive compensation program is based on a pay-for-performance philosophy. Exicure OpCo designed its executive compensation program to align executive compensation with its business objectives and the interests of its stockholders and to enable it to attract, retain and reward executives who contribute to its success. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This section provides a discussion of the compensation paid or awarded to Exicure OpCo&#8217;s Chief Executive Officer and its two other most highly compensated executive officers as of December&#160;31, 2016. Exicure OpCo refers to these individuals as its &#8220;named executive officers.&#8221; For 2016, Exicure OpCo&#8217;s named executive officers were: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">David A. Giljohann, Chief Executive Officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">David S. Snyder, Chief Financial Officer; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Ekambar Kandimalla, Chief Scientific Officer. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To date, compensation for Exicure OpCo&#8217;s named executive officers was comprised primarily of the following three main components. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Base Salary</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Base salaries are determined on a case-by-case basis for each executive. The base salary levels are designed to reflect each executive officer&#8217;s experience, expertise and performance, as well as market compensation levels for similar positions. In addition, in evaluating 2016 base salary levels, the Exicure OpCo board of directors considered an assessment of the competitive market performed by an independent compensation consultant. On December&#160;16, 2016, Exicure OpCo&#8217;s compensation committee approved an increase of Dr.&#160;Giljohann&#8217;s base salary to $350,000 per year, effective January&#160;1, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Annual Cash Incentive Bonuses</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Annual cash incentive bonuses provide incentive award opportunities for the achievement of performance goals established by our board of directors.&#160;The payment of awards under Exicure OpCo 2016 annual cash incentive bonus program and 2017 annual cash incentive bonus program is subject to the attainment of specific performance goals relating to research and development and financing. Each executive&#8217;s target bonus amount is expressed as a percentage of the executive&#8217;s base salary and is intended to be commensurate with the executive&#8217;s position and responsibilities. The actual 2016 bonus awards were approved on January&#160;17, 2017 by Exicure OpCo&#8217;s compensation committee for two of the named executive officers, namely, 20% of base salary for Mr.&#160;Snyder, and 32% of base salary for Dr.&#160;Giljohann. The 2017 target bonuses for the named executive officers are 25% of base salary for Mr.&#160;Snyder and Dr.&#160;Kandimalla and 40% of base salary for Dr.&#160;Giljohann. Pursuant to their employment agreements, upon the closing date of Exicure OpCo&#8217;s initial public offering, Mr.&#160;Snyder&#8217;s minimum target annual bonus shall be equal to at least 45% of base salary for each year during the employment period in which he participates in the annual incentive program and Dr.&#160;Giljohann&#8217;s minimum target annual bonus shall be equal to at least 50% of base salary for each year during the employment period in which he participates in the annual incentive program. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock Option Awards</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. We believe equity awards in the form of options to purchase shares of our common stock provides an incentive for our executives to focus on driving growth in our stock price and long-term value creation and help it to attract and retain key talent. In addition, we believe that the granting of stock options further aligns the interests of our executive officers with those of our stockholders as the options only have value if our stock price increases after the date of grant. In January 2017, Exicure OpCo&#8217;s board granted options to Dr.&#160;Giljohann and Mr.&#160;Snyder that would vest in 48 equal monthly installments, in each case, based on the executive&#8217;s continued service with Exicure OpCo during the vesting period. There were no options granted to Exicure OpCo&#8217;s named officers during 2016. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our named executive officers are also eligible to participate in our 401(k) plan, 2017 Plan and ESPP and health and welfare benefit plans generally available to other employees. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our compensation committee reviews our executive compensation program on an annual basis or more frequently as it deems appropriate. During 2016, Exicure OpCo retained an independent compensation consultant to assist in evaluating the 2016 executive compensation program, including an assessment of the competitive market for similar positions at comparable companies. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary Compensation Table</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December&#160;31, 2016 and 2015 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table provides a summary of compensation paid to Exicure OpCo&#8217;s principal executive officer and its two other most highly compensated executive officers, referred to as the named executive officers, for the years ended December&#160;31, 2016 and 2015. </font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Name and</font></div><div style="font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Principal</font></div><div style="font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Base</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Salary</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Bonus</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Awards</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($) &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Awards</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(1) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Non-Equity</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Incentive Plan</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(2) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">All Other</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(3) </sup></font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">($) </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">David A. Giljohann, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) (5) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">257,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">82,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">339,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">249,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,223,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">124,399</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,597,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">David S. Snyder</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">314,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">62,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">377,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">305,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,943</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">410,793</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Ekambar Kandimalla, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">267,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">270,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chief Scientific Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">385,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">452,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Pursuant to applicable SEC executive compensation disclosure rules, the amounts reported in this column reflect the grant date fair value of the Exicure OpCo option awards granted to Exicure OpCo named executive officers during 2015 and do not reflect the actual amounts earned. These values have been determined in accordance with FASB ASC Topic 718. For a discussion of the assumptions and methodologies used to calculate these amounts, please see the discussion of option awards contained in Note&#160;6, Equity-Based Compensation, to Exicure OpCo&#8217;s financial statements for the years ended December&#160;31, 2016 and 2015 included elsewhere in this prospectus. There were no options granted to our named executive officers during 2016. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Pursuant to the terms of the named executive officer&#8217;s employment agreement or offer letter, each named executive officer is eligible to receive an annual bonus award, subject to the achievement of annual performance milestones as determined by Exicure OpCo&#8217;s board of directors in its sole discretion. These amounts represent the earned amounts in connection with the achievement of 2016 annual performance milestones (paid in 2017) and the achievement of 2015 annual performance milestones (paid in 2016). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The amount for Dr.&#160;Kandimalla relates to the reimbursement of relocation expenses pursuant to Dr.&#160;Kandimalla&#8217;s employment agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr.&#160;Giljohann also serves as a member of Exicure OpCo&#8217;s board of directors but does not receive any additional compensation for his service as a director. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">On December&#160;16, 2016, the compensation committee of Exicure OpCo&#8217;s board of directors approved an increase to Dr.&#160;Giljohann&#8217;s base salary to $350,000 per year effective January&#160;1, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr.&#160;Kandimalla commenced employment with Exicure OpCo in October 2015. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment and Change in Control Arrangements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo generally executes an offer of employment or employment agreement before an executive joins the company. This offer describes the basic terms of the executive&#8217;s employment, including his or her start date, starting salary, bonus target and any equity awards. In addition, in the case of each of Dr.&#160;Giljohann, Dr.&#160;Kandimalla and Mr.&#160;Snyder, his offer letter or employee agreement, as applicable, also provides that if his employment is terminated by Exicure OpCo without cause (as such term is defined in the agreement), he will be entitled to receive cash severance equal to twelve months, six months, and six months, respectively, of his base salary. Exicure OpCo&#8217;s named executive officers are not eligible to receive any severance or enhanced benefits upon a change in control of the Company other than the accelerated vesting of stock option awards upon a change in control. The Company expects to enter into agreements with its executive officers to assume Exicure OpCo&#8217;s obligations under these employment agreements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Defined Contribution Plan </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo sponsors a defined contribution plan intended to qualify under Section&#160;401 of the Internal Revenue Code, as amended from time to time, or the Code, or a 401(k) plan.&#160;Employees who are at least 21 years of age are generally eligible to participate and may enter the plan on the first day of any month. Participants may make pre-tax contributions or Roth 401(k) contributions up to the maximum limit established by the Code.&#160;These contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participant&#8217;s directions. Participants are immediately and fully vested in their contributions. Currently, Exicure OpCo does not make matching contributions or discretionary contributions to the 401(k) plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at December&#160;31, 2016 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table presents information regarding the outstanding options held by each of Exicure OpCo&#8217;s named executive officers as of December&#160;31, 2016. None of the named executive officers held any outstanding restricted unit or other equity awards as of that date. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercisable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">securities</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unexercised</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unexercisable(#)</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">($)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160; (1) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Option</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">expiration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">date</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/20/2012</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/20/2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/31/2012</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/31/2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/29/2014</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,771</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1/29/2024</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/28/2015</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">379,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/28/2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/24/2015</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386,836</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,041,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/24/2025</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David S. Snyder</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/3/2014</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">455,274</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/3/2024</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/28/2015</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4/28/2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ekambar Kandimalla, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Scientific Officer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;padding-bottom:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/24/2015</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/24/2025</font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the October 2014 repricing of Exicure OpCo&#8217;s outstanding option awards, the option exercise price for all outstanding options was adjusted to $0.32 per share. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25% of the shares subject to these options vest on the one-year anniversary of the vesting commencement date, and 1/48th of the shares subject to these options vest each month thereafter on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of such month), subject to the executive continuing to be employed by Exicure OpCo through the applicable vesting date. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These options vest in 48 equal monthly installments, subject to the executive continuing to be employed by Exicure OpCo through the applicable vesting date. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Incentive Plans </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December&#160;31, 2016, Exicure OpCo&#8217;s employees, directors and consultants held outstanding options for the purchase of up to 6,222,448 common shares. As of December&#160;31, 2016, 2,956,455 of those options were vested and the balance was not vested. The weighted-average exercise price of those vested and unvested options was $0.51 and $0.72 per share, respectively, and each of those options had a maximum term of ten years from the applicable date of grant. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following summary provides more detailed information concerning Exicure OpCo&#8217;s equity compensation plan. This summary is qualified in its entirety by the full text of the compensation plan and related form of award agreement, each of which has been filed as an exhibit to this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo adopted and its board of directors approved an Equity Incentive Plan in September 2011, which was subsequently amended and restated, and approved by its board of directors in June 2014. Under this Equity Incentive Plan, Exicure OpCo granted options to purchase shares of our common stock. All of the options that were granted under this Equity Incentive Plan were amended and restated at the time of the corporate conversion so that they are now granted under Exicure OpCo&#8217;s 2015 Plan as described below. There are currently no options granted under this Equity Incentive Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2015 Equity Incentive Plan </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2015 Plan was approved by Exicure OpCo&#8217;s board of directors on October&#160;6, 2015 and Exicure OpCo&#8217;s stockholders on October&#160;13, 2015, and was assumed by us upon the Merger. Upon the closing of the Merger, we converted each option to purchase Exicure OpCo common stock that remained outstanding under the 2015 Plan, whether vested or unvested, into an option to purchase such number of shares of our common stock equal to the number of shares of Exicure OpCo common stock subject to the option immediately prior to the Merger multiplied by the applicable Merger conversion ratio (which was equal to 0.49649), with any fraction rounded down to the nearest whole number. The exercise price per share of each such assumed option is equal to the exercise price of the Exicure OpCo option prior to the assumption divided by the applicable Merger conversion ratio (which was equal to 0.49649) (rounded up to the nearest whole cent). Otherwise, each assumed option continues to have, and will be subject to, the same terms and conditions as applied to the Exicure OpCo option immediately prior to the Merger, including, without limitation, the same vesting schedule. The terms of the 2015 Plan continue to govern the options covering an aggregate of 3,680,997 shares of our common stock subject to awards assumed by us except that all references in the 2015 Plan to Exicure OpCo will now be deemed to refer to us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The 2015 Plan was intended to align the interests of Exicure OpCo&#8217;s stockholders and the recipients of awards under the 2015 Plan, and to advance its interests by attracting and retaining directors, officers, employees and other service providers and motivating them to act in its long-term best interests. The material terms of the 2015 Plan are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Plan term</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2015 Plan term began upon the date of approval by Exicure OpCo&#8217;s board of directors, subject to approval by its stockholders within 12 months after such board approval, and terminates on the tenth anniversary of its effective date, unless terminated earlier by the board. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Eligible participants</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. All officers, directors, employees, consultants, agents and independent contractors, and persons expected to become officers, directors, employees, consultants, agents and independent contractors of the company or any of our subsidiaries are eligible to receive awards under the 2015 Plan. The compensation committee of our board determines the participants under the 2015 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Shares authorized</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Prior to the Merger, 9,806,006 shares of common stock were available for awards granted under the 2015 Plan, subject to adjustment for stock splits and other similar changes in capitalization. The number of available shares could be reduced by the aggregate number of shares that became subject to outstanding awards granted under the 2015 Plan. As of the first day of each calendar year beginning on or after January&#160;1, 2017, the number of shares available for all awards under the 2015 Plan, other than incentive stock options, will automatically increase by 4% of the number of shares that are issued and outstanding as of that date, unless the compensation committee approves an increase of a lesser percentage. To the extent that shares subject to an outstanding award granted under the 2015 Plan are not issued or delivered by reason of the expiration, termination, cancellation or forfeiture of such award or by reason of the settlement of an award in cash, then those shares would again be available under the 2015 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Award types</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Awards include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units and performance units. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Administration</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The compensation committee will interpret and administer the 2015 Plan. The compensation committee&#8217;s interpretation, construction and administration of the 2015 Plan and all of its determinations thereunder will be conclusive and binding on all persons. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The compensation committee shall have the authority to determine the participants in the 2015 Plan, the form, amount and timing of any awards, the performance goals, if any, and all other terms and conditions pertaining to any award. The compensation committee may take any action such that (i)&#160;any outstanding options and stock appreciation rights become exercisable in part or in full, (ii)&#160;all or any portion of a restriction period on any restricted stock or restricted stock units will lapse, (iii)&#160;all or a portion of any performance period applicable to any performance-based award will lapse and (iv)&#160;any performance measures applicable to any outstanding award will be deemed satisfied at the target level or any other level. Subject to the terms of the 2015 Plan relating to grants to our executive officers and directors, the compensation committee may delegate some or all of its powers and authority to the Chief Executive Officer and President or other executive officer as the compensation committee deems appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock options and stock appreciation rights</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2015 Plan provides for the grant of stock options and stock appreciation rights. Stock options may be either tax-qualified incentive stock options or non-qualified stock options. The compensation committee will determine the terms and conditions to the exercisability of each option and stock appreciation right. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The period for the exercise of a non-qualified stock option or stock appreciation right will be determined by the compensation committee provided that no option may be exercised later than ten years after its date of grant. The exercise price of a non-qualified stock option and the base price of a stock appreciation right will not be less than 100% of the fair market value of a share of our common stock on the date of grant, provided that the base price of a stock appreciation right granted in tandem with an option will be the exercise price of the related option. A stock appreciation right entitles the holder to receive upon exercise, subject to tax withholding in respect of an employee, shares of our common stock, which may be restricted stock, with a value equal to the difference between the fair market value of our common stock on the exercise date and the base price of the stock appreciation right. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each incentive stock option will be exercisable for not more than ten years after its date of grant, unless the optionee owns greater than ten percent of the voting power of all shares of our capital stock, or a &#8220;ten percent holder&#8221;, in which case the option will be exercisable for not more than five years after its date of grant. The exercise price of an incentive stock option will not be less than the fair market value of a share of our common stock on its date of grant, unless the optionee is a ten percent holder, in which case the option exercise price will be the price required by the Code, currently 110% of fair market value. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon exercise, the option exercise price may be paid in cash, by the delivery of previously owned shares of our common stock, share withholding or through a cashless exercise arrangement, as permitted by the applicable award agreement. All of the terms relating to the exercise, cancellation or other disposition of an option or stock appreciation right upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The compensation committee, without stockholder approval, may amend or replace any previously granted option or stock appreciation right in a repricing transaction under the rules of any stock exchange on which our stock is then traded. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with our adoption of the 2015 Plan, we amended and restated each of our then outstanding option agreements using our new form of option agreement. The exercise price and the grant date of each of those outstanding options remained unchanged. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock awards</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2015 Plan provides for the grant of stock awards. The compensation committee may grant a stock award as a bonus stock award, a restricted stock award or a restricted stock unit award and, in the case of a restricted stock award or restricted stock unit award, the compensation committee may determine that such award will be subject to the attainment of performance measures over an established performance period. All of the terms </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">relating to the satisfaction of performance measures and the termination of a restriction period, or the forfeiture and cancellation of a stock award upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The agreement awarding restricted stock units will specify whether such award may be settled in shares of our common stock, cash or a combination thereof and whether the holder will be entitled to receive dividend equivalents, on a current or deferred basis, with respect to such award. Prior to settlement of a restricted stock unit in shares of our common stock, the holder of a restricted stock unit will have no rights as our stockholder. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless otherwise set forth in a restricted stock award agreement, the holder of shares of restricted stock will have rights as our stockholder, including the right to vote and receive dividends with respect to the shares of restricted stock, except that distributions other than regular cash dividends and regular cash dividends with respect to shares of restricted stock subject to performance-based vesting conditions will be held by us and will be subject to the same restrictions as the restricted stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance unit awards</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2015 Plan also provides for the grant of performance unit awards. Each performance unit is a right, contingent upon the attainment of performance measures within a specified performance period, to receive a specified cash amount, shares of our common stock or a combination thereof which may be restricted stock, having a fair market value equal to such cash amount. Prior to the settlement of a performance unit award in shares of our common stock, the holder of such award will have no rights as our stockholder with respect to such shares. Performance units will be non-transferable and subject to forfeiture if the specified performance measures are not attained during the specified performance period. All of the terms relating to the satisfaction of performance measures and the termination of a performance period, or the forfeiture and cancellation of a performance unit award upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance goals. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2015 Plan, the vesting or payment of performance-based awards will be subject to the satisfaction of certain performance goals. The performance goals applicable to a particular award will be determined by the compensation committee at the time of grant. The performance goals may be one or more of the following corporate-wide or subsidiary, division, operating unit or individual measures, stated in either absolute terms or relative terms, such as rates of growth or improvement: the attainment by a share of our common stock of a specified fair market value for a specified period of time, earnings per share, return to stockholders (including dividends), return on assets, return on equity, our earnings before or after taxes and/or interest, revenues, expenses, market share, cash flow or cost reduction goals, interest expense after taxes, return on investment, return on investment capital, return on operating costs, economic value created, operating margin, gross margin, achievement of annual operating profit plans, net income before or after taxes, pretax earnings before interest, depreciation and/or amortization, pretax operating earnings after interest expense and before incentives, and/or extraordinary or special items, operating earnings, net cash provided by operations, and strategic business criteria, consisting of one or more objectives based on meeting specified market penetration, geographic business expansion goals, cost targets, days sales outstanding goals, customer satisfaction, reductions in errors and omissions, reductions in lost business, management of employment practices and employee benefits, supervision of litigation and information technology, quality and quality audit scores, productivity, efficiency, and goals relating to acquisitions or divestitures, or any combination of the foregoing. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Amendment or termination of the 2015 Plan.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The board may amend or terminate the 2015 Plan as it deems advisable, subject to any requirement of stockholder approval required by law, rule or regulation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Change of control.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In the event of a change of control, the board may, in its discretion, (1)&#160;provide that (A)&#160;some or all outstanding options and stock appreciation rights will immediately become exercisable in full or in part, (B)&#160;the restriction period applicable to some or all outstanding stock awards will lapse in full or in part, (C)&#160;the performance period applicable to some or all outstanding awards will lapse in full or in part, and (D)&#160;the performance measures applicable to some or all outstanding awards will be deemed to be satisfied at the target or any other level, (2)&#160;require that shares of stock of the corporation resulting from such change of control, or a parent corporation thereof, be substituted for some or all of our shares subject to an outstanding award, and/or (3)&#160;require </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">outstanding awards, in whole or in part, to be surrendered by the holder, and to be immediately canceled, and to provide for the holder to receive (A)&#160;a cash payment in an amount equal to (i)&#160;in the case of an option or stock appreciation right, the number of our shares then subject to the portion of such option or stock appreciation right surrendered, whether vested or unvested, multiplied by the excess, if any, of the fair market value of a share of our common stock as of the date of the change of control, over the purchase price or base price per share of our common stock subject to such option or stock appreciation right, (ii)&#160;in the case of a stock award, the number of shares of our common stock then subject to the portion of such award surrendered, whether vested or unvested, multiplied by the fair market value of a share of our common stock as of the date of the change of control, and (iii)&#160;in the case of a performance unit award, the value of the performance units then subject to the portion of such award surrendered; (B)&#160;shares of capital stock of the corporation resulting from such change of control, or a parent corporation thereof, having a fair market value not less than the amount determined under clause (A)&#160;above; or (C)&#160;a combination of the payment of cash pursuant to clause (A)&#160;above and the issuance of shares pursuant to clause (B)&#160;above. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2015 Plan, a change of control will occur upon: (i)&#160;a person&#8217;s or entity&#8217;s acquisition, other than from us, of beneficial ownership of 50% or more of either our then outstanding shares or the combined voting power of our then outstanding voting securities, but excluding certain acquisitions by the company, its subsidiaries or employee benefit plans, or by a corporation in which our stockholders hold a majority interest; (ii)&#160;a reorganization, merger or consolidation of the company if our stockholders do not thereafter beneficially own more than 50% of the outstanding shares or combined voting power of the resulting company or (iii)&#160;a complete liquidation or dissolution of the company or of the sale or other disposition of all or substantially all of our assets; but excluding, in any case, the initial public offering or any bona fide primary or secondary public offering following the occurrence of the initial public offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">New plan benefits.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The benefits that might be received by officers, employees and non-employee directors cannot be determined at this time. All officers, employees and non-employee directors were eligible for consideration to participate in the 2015 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Equity Incentive Plan </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, the board of directors adopted and the Company&#8217;s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan, referred to as the 2017 Plan. The 2017 Plan is intended to align the interests of our stockholders and the recipients of awards under the 2017 Plan, and to advance our interests by attracting and retaining directors, officers, employees and other service providers and motivating them to act in our long-term best interests. The material terms of the 2017 Plan are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Plan term</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2017 Plan became effective on November 15, 2017, and terminates on the tenth anniversary of its effective date, unless terminated earlier by our board of directors. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Eligible participants</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. All officers, directors, employees, consultants, agents and independent contractors, and persons expected to become officers, directors, employees, consultants, agents and independent contractors of our Company or any of our subsidiaries are eligible to receive awards under the 2017 Plan. The compensation committee of our board will determine the participants under the 2017 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Shares authorized</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. 2,158,708 shares of common stock will be available for awards granted under the 2017 Plan, plus up to 3,683,817 shares subject to options originally granted under the 2015 Plan and assumed in connection with the merger of Exicure OpCo with Max-1 Acquisition Sub, Inc., subject to adjustment for stock splits and other similar changes in capitalization. The number of available shares will be reduced by the aggregate number of shares that become subject to outstanding awards granted under the 2017 Plan. As of the first day of each calendar year beginning on or after January&#160;1, 2020, the number of shares available for all awards under the 2017 Plan, other than incentive stock options, will automatically increase by a number equal to the least of (i) 4,600,000 shares, (ii)&#160;five percent (5%) of the number of shares that are issued and outstanding as of that date, or (iii)&#160;a lesser number of shares as determined by the compensation committee. To the extent that shares subject to an outstanding award granted under the 2017 Plan are not issued or delivered by reason of the expiration, termination, cancellation or forfeiture of such award or by reason of the settlement of an award in cash, then those shares will again be available under the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">2017 Plan. In addition, any shares covered by an award that have been surrendered in connection with the payment of the award exercise or purchase price or in satisfaction of tax withholding obligations incident to the grant, exercise, vesting or settlement of an award will be deemed not to have been issued for purposes of determining the maximum number of shares which may be issued pursuant to all awards under the 2017 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Award types</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Awards include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Administration</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The compensation committee will interpret and administer the 2017 Plan. The compensation committee&#8217;s interpretation, construction and administration of the 2017 Plan and all of its determinations thereunder will be conclusive and binding on all persons. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The compensation committee shall have the authority to determine the participants in the 2017 Plan, the form, amount and timing of any awards, the performance goals, if any, and all other terms and conditions pertaining to any award. The compensation committee may take any action such that (i)&#160;any outstanding options and stock appreciation rights become exercisable in part or in full, (ii)&#160;all or any portion of a restriction period on any restricted stock or restricted stock units will lapse, (iii)&#160;all or a portion of any performance period applicable to any performance-based award will lapse and (iv)&#160;any performance measures applicable to any outstanding award will be deemed satisfied at the target level or any other level. Subject to the terms of the 2017 Plan relating to grants to our executive officers and directors, the compensation committee may delegate some or all of its powers and authority to the Chief Executive Officer and President or other executive officer as the compensation committee deems appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock options and stock appreciation rights</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2017 Plan provides for the grant of stock options and stock appreciation rights. Stock options may be either tax-qualified incentive stock options or non-qualified stock options. The compensation committee will determine the terms and conditions to the exercisability of each option and stock appreciation right. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The period for the exercise of a non-qualified stock option or stock appreciation right will be determined by the compensation committee provided that no option may be exercised later than ten years after its date of grant. The exercise price of a non-qualified stock option and the base price of a stock appreciation right will not be less than 100% of the fair market value of a share of our common stock on the date of grant, provided that the base price of a stock appreciation right granted in tandem with an option will be the exercise price of the related option. A stock appreciation right entitles the holder to receive upon exercise, subject to tax withholding in respect of an employee, shares of our common stock, which may be restricted stock, with a value equal to the difference between the fair market value of our common stock on the exercise date and the base price of the stock appreciation right. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each incentive stock option will be exercisable for not more than 10 years after its date of grant, unless the optionee owns greater than 10% of the voting power of all shares of our capital stock, or a &#8220;ten percent holder&#8221;, in which case the option will be exercisable for not more than five years after its date of grant. The exercise price of an incentive stock option will not be less than the fair market value of a share of our common stock on its date of grant, unless the optionee is a ten percent holder, in which case the option exercise price will be the price required by the Code, currently 110% of fair market value. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Upon exercise, the option exercise price may be paid in cash, by the delivery of previously owned shares of our common stock, share withholding or through a cashless exercise arrangement, as permitted by the applicable award agreement. All of the terms relating to the exercise, cancellation or other disposition of an option or stock appreciation right upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The compensation committee, without stockholder approval, may (i)&#160;reduce the exercise price of any previously granted option or the base appreciation amount of any previously granted stock appreciation right, or (ii)&#160;cancel any previously granted option or stock appreciation right at a time when its exercise price or base appreciation amount </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(as applicable) exceeds the fair market value of the underlying shares, in exchange for another option, stock appreciation right or other award or for cash. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stock awards</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2017 Plan provides for the grant of stock awards. The compensation committee may grant a stock award as a bonus stock award, a restricted stock award or a restricted stock unit award and, in the case of a restricted stock award or restricted stock unit award, the compensation committee may determine that such award will be subject to the attainment of performance measures over an established performance period. All of the terms relating to the satisfaction of performance measures and the termination of a restriction period, or the forfeiture and cancellation of a stock award upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The agreement awarding restricted stock units will specify whether such award may be settled in shares of our common stock, cash or a combination thereof and whether the holder will be entitled to receive dividend equivalents, on a current or deferred basis, with respect to such award. Prior to settlement of a restricted stock unit in shares of our common stock, the holder of a restricted stock unit will have no rights as our stockholder. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless otherwise set forth in a restricted stock award agreement, the holder of shares of restricted stock will have rights as our stockholder, including the right to vote and receive dividends with respect to the shares of restricted stock, except that distributions other than regular cash dividends and regular cash dividends with respect to shares of restricted stock subject to performance-based vesting conditions will be held by us and will be subject to the same restrictions as the restricted stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance unit awards</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The 2017 Plan provides for the grant of performance unit awards. Each performance unit is a right, contingent upon the attainment of performance measures within a specified performance period, to receive a specified cash amount, shares of our common stock or a combination thereof which may be restricted stock, having a fair market value equal to such cash amount. Prior to the settlement of a performance unit award in shares of our common stock, the holder of such award will have no rights as our stockholder with respect to such shares. Performance units will be non-transferable and subject to forfeiture if the specified performance measures are not attained during the specified performance period. All of the terms relating to the satisfaction of performance measures and the termination of a performance period, or the forfeiture and cancellation of a performance unit award upon a termination of employment, whether by reason of disability, retirement, death or any other reason, will be determined by the compensation committee. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Cash-based awards.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The 2017 Plan also provides for the grant of cash-based awards. Each cash-based award is an award denominated in cash that may be settled in cash and/or shares, which may be subject to restrictions, as established by the compensation committee. Prior</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">to the end of the date that the exemption for the 2017 Plan under Section&#160;162(m) of the Code expires, the maximum aggregate amount of cash that may be issued to &#8220;covered employees&#8221; within the meaning of Section&#160;162(m) of the Code pursuant to cash-based awards is $20,000,000. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Performance goals. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2017 Plan, the vesting or payment of performance-based awards will be subject to the satisfaction of certain performance goals. The performance goals applicable to a particular award will be determined by the compensation committee at the time of grant. The performance goals may be one or more of the following corporate-wide or subsidiary, division, operating unit or individual measures, stated in either absolute terms or relative terms, such as rates of growth or improvement: the attainment by a share of our common stock of a specified fair market value for a specified period of time, earnings per share, return to stockholders (including dividends), return on assets, return on equity, our earnings before or after taxes and/or interest, revenues, expenses, market share, cash flow or cost reduction goals, interest expense after taxes, return on investment, return on investment capital, return on operating costs, economic value created, operating margin, gross margin, achievement of annual operating profit plans, net income before or after taxes, pretax earnings before interest, depreciation and/or amortization, pretax operating earnings after interest expense and before incentives, and/or extraordinary or special items, operating earnings, net cash provided by operations, and strategic business criteria, consisting of one or more objectives based on meeting specified market penetration, geographic business expansion goals, cost targets, days sales outstanding goals, customer satisfaction, reductions in errors and omissions, reductions in lost business, management of employment practices and employee benefits, supervision of litigation and information technology, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">quality and quality audit scores, productivity, efficiency, and goals relating to acquisitions or divestitures, or any combination of the foregoing. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Individual Limits. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the date that the exemption for the 2017 Plan under Section&#160;162(m) of the Code expires, (i)&#160;the maximum number of shares with respect to which stock options and stock appreciation rights, or a combination thereof, may be granted during any fiscal year of the Company to any person is 1,666,667 shares, (ii)&#160;the maximum number of shares with respect to which awards subject to performance measures or performance units denominated in common stock that may be granted during any fiscal year of the Company to any person is 1,666,667 shares, (iii)&#160;the maximum amount that may be earned by any person with respect to performance units denominated in cash granted during any fiscal year of the Company to any person is $5,000,000, and (iv)&#160;the maximum amount that may be paid to any person with respect to cash-based awards that are intended to be performance-based compensation during each 12-month period that constitutes or is part of each applicable performance period is $5,000,000, provided that the foregoing limitation in (iv)&#160;shall be prorated for any performance period consisting of fewer than 12 months. In connection with a participant&#8217;s commencement of employment with the Company, the per person limits set forth above will be multiplied by two. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">With respect to non-employee directors, the maximum grant date fair value of shares that may be granted to an individual non-employee director during any fiscal year of the Company is $1,000,000. In connection with a non-employee director&#8217;s commencement of service with the Company, the per person limit set forth in the previous sentence will be $2,000,000. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Amendment or termination of the 2017 Plan.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The board may amend or terminate the 2017 Plan as it deems advisable, subject to any requirement of stockholder approval required by law, rule or regulation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Change of control.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In the event of a change of control, our board of directors may, in its discretion, (1)&#160;provide that (A)&#160;some or all outstanding options and stock appreciation rights will immediately become exercisable in full or in part, (B)&#160;the restriction period applicable to some or all outstanding stock awards will lapse in full or in part, (C)&#160;the performance period applicable to some or all outstanding awards will lapse in full or in part, and (D)&#160;the performance measures applicable to some or all outstanding awards will be deemed to be satisfied at the target or any other level, (2)&#160;provide that some or all outstanding awards will terminate without consideration as of the date of the change of control, (3)&#160;require that shares of stock of the corporation resulting from such change of control, or a parent corporation thereof, be substituted for some or all of our shares subject to an outstanding award, and/or (4)&#160;require outstanding awards, in whole or in part, to be surrendered by the holder, and to be immediately canceled, and to provide for the holder to receive (A)&#160;a cash payment in an amount equal to (i)&#160;in the case of an option or stock appreciation right, the number of our shares then subject to the portion of such option or stock appreciation right surrendered, whether vested or unvested, multiplied by the excess, if any, of the fair market value of a share of our common stock as of the date of the change of control, over the purchase price or base price per share of our common stock subject to such option or stock appreciation right, (ii)&#160;in the case of a stock award, the number of shares of our common stock then subject to the portion of such award surrendered, whether vested or unvested, multiplied by the fair market value of a share of our common stock as of the date of the change of control, and (iii)&#160;in the case of a performance unit award, the value of the performance units then subject to the portion of such award surrendered; (B)&#160;shares of capital stock of the corporation resulting from such change of control, or a parent corporation thereof, having a fair market value not less than the amount determined under clause (A)&#160;above; or (C)&#160;a combination of the payment of cash pursuant to clause (A)&#160;above and the issuance of shares pursuant to clause (B)&#160;above. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the 2017 Plan, a change of control will occur upon: (i)&#160;a person&#8217;s or entity&#8217;s acquisition, other than from us, of beneficial ownership of 50% or more of either our then outstanding shares or the combined voting power of our then outstanding voting securities, but excluding certain acquisitions by the company, its subsidiaries or employee benefit plans, or by a corporation in which our stockholders hold a majority interest; (ii)&#160;a reorganization, merger or consolidation of the company if our stockholders do not thereafter beneficially own more than 50% of the outstanding shares or combined voting power of the resulting company, (iii)&#160;certain changes to the incumbent directors of our Company, or (iv)&#160;a complete liquidation or dissolution of the company or of the sale or other disposition of all or substantially all of our assets; but excluding, in any case, the initial public offering or any bona fide primary or secondary public offering following the occurrence of the initial public offering. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">New plan benefits.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The benefits that might be received by officers, employees and non-employee directors cannot be determined at this time. All officers, employees and non-employee directors are eligible for consideration to participate in the 2017 Plan. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Employee Stock Purchase Plan </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, the board of directors adopted and the Company&#8217;s stockholders approved the Exicure, Inc. 2017 Employee Stock Purchase Plan, referred to as the ESPP. The ESPP is intended to enable eligible employees of the Company and designated affiliates to purchase shares of our common stock at a discount following its effectiveness. In this description, we sometimes refer to an eligible employee&#8217;s right to purchase shares of our common stock under the ESPP as an &#8220;option.&#8221; Purchases will be accomplished through participation in discrete offer periods. The ESPP is intended to qualify as an employee stock purchase plan under Section&#160;423 of the Code. The material terms of the ESPP are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Plan term. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The ESPP term became effective on November 15, 2017, and terminates on the tenth anniversary of its effective date, unless terminated earlier by the board or a committee designated by the board, referred to as the administrator. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Shares authorized. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We initially reserved 431,750 shares of our common stock for issuance under the ESPP. In addition, the ESPP provides for an annual increase to the number of shares of our common stock available for issuance thereunder on the first business day of each calendar year beginning with the calendar year following the calendar year in which the ESPP becomes effective, equal to the least of (i)&#160;300,000 shares, (ii)&#160;three-tenths of a percent (0.3%) of the number of shares of our common stock outstanding as of the last day of the immediately preceding calendar year, or (iii)&#160;a lesser number of shares determined by the administrator. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Offerings</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The ESPP is implemented by offerings of rights to all eligible employees from time to time. The maximum length for an offer period is 27 months. Unless otherwise determined by the administrator, it is anticipated that the offer periods will be for successive six-month periods. The commencement date of the first offer period has not been set. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Eligible participants</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Any employee of the Company and designated affiliates are eligible to participate in the ESPP if such employee (i)&#160;customarily works more than 20 hours per week for more than five months per calendar year, (ii)&#160;has been employed for such continuous period as the administrator may require (up to a maximum of two years), and (iii)&#160;is not a citizen or resident of a non-U.S. jurisdiction. Unless determined otherwise by the administrator, employees who have not been employed continuously for the one-month period preceding the first day of an offer period will not be eligible to participate in the ESPP for the corresponding offer period. The administrator has the authority to permit such categories of employees to participate in the ESPP in its discretion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">No employee is eligible to participate in the ESPP if, immediately after the grant of purchase rights, such employee would own capital stock possessing 5% or more of the total combined voting power or value of all classes of the capital stock of the Company or of any parent or subsidiary of the Company. In addition, no employee may purchase more than $25,000 worth of common stock (determined at the fair market value of the shares at the time such rights are granted) under all employee stock purchase plans of the Company and its parent and subsidiary corporations in any calendar year. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Participation in the ESPP</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. When an offer period commences, employees who meet the eligibility requirements and wish to participate in the ESPP will be required to enroll in a timely manner. Under the ESPP, eligible employees generally will be able to acquire shares of our common stock by accumulating funds through payroll deductions. Eligible employees will be able to select a rate of payroll deduction between 1% and 15% of their eligible compensation. An employee&#8217;s payroll deduction authorization (as modified by any change of status notice) will remain in effect for successive offer periods unless terminated. An employee&#8217;s participation automatically ends upon termination of employment for any reason. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Purchase Price</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The purchase price for shares of our common stock purchased under the ESPP may be as low as 85% of the lower of the fair market value of our common stock on the first trading day of the applicable offer period or the last trading day of the applicable offer period. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Payment of Purchase Price; Payroll Deductions.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The purchase price of the shares is accumulated by payroll deductions over the offer period. A participant may increase or decrease his or her payroll deduction during an offer period, but the administrator is authorized to limit the number of payroll deduction rate changes during any offer period. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Purchase of Stock. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with offerings made under the ESPP, the administrator has determined that in no event shall a participant be permitted to purchase more than 1,000 shares of common stock during each offer period. However, the administrator may increase or decrease, in its absolute discretion, the maximum number of shares of common stock that a participant may purchase in future offer periods. If the administrator determines that the aggregate number of shares to be purchased upon exercise of rights granted in the offering would exceed the number of shares of common stock available, the compensation committee shall make a pro rata allocation of available shares pursuant to a &#8220;bottom up&#8221; allocation method in which all option exercises for one share will be satisfied first, followed by all exercises for two shares, and so on, until all available shares have been exhausted. Any amount remaining in a participant&#8217;s payroll account following such allocation will be returned to the participant. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Withdrawal. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">A participant may, by giving notice to the Company: (i)&#160;withdraw all but not less than all the payroll deductions credited to the participant&#8217;s account and not yet used to exercise the participant&#8217;s option under the ESPP, in which case all of the participant&#8217;s payroll deductions credited to the participant&#8217;s account will be paid to the participant as soon as administratively practicable after receipt of the notice of withdrawal, the participant&#8217;s option for the offer period will be terminated automatically and no further payroll deductions for the purchase of shares will be made during the offer period; or (ii)&#160;terminate future payroll deductions, but allow accumulated payroll deductions to be used to exercise the participant&#8217;s option under the plan, in which case all of the participant&#8217;s payroll deductions credited to the participant&#8217;s account will be applied to the exercise of the participant&#8217;s option on the next exercise date, after which such participant&#8217;s option for the offer period will be terminated automatically and all remaining accumulated payroll deduction amounts will be returned to the participant. If a participant withdraws from an offer period, payroll deductions will not resume at the beginning of the succeeding offer period, unless the participant re-enrolls in the ESPP. Further procedures for withdrawal may be specified by the administrator on a uniform and nondiscriminatory basis. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Restrictions on Transfer.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Rights granted under the ESPP are not transferable except by will or the applicable laws of descent and distribution. Any attempt at transferring rights granted under the ESPP will be without effect, except the administrator may treat such act as an election to withdraw funds from an offering period in its discretion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Adjustment Provisions.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Upon certain transactions by the Company, such as a stock split, reverse stock split, stock dividend, combination, reclassification, merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation or any similar transaction or other increase or decrease in the number of issued shares of Company common stock effected without receipt of consideration by the Company, the administrator will equitably adjust the number of shares that may be issued under the ESPP, the purchase price, or the maximum number of shares that may be purchased in any offer period, as well as any other terms the administrator determines requires adjustment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Effect of Certain Corporate Transactions.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;In the event of a corporate transaction, each option will be assumed by the successor corporation or a parent or subsidiary of the successor corporation, unless the administrator determines to shorten the offer period then in progress, in which case the options will either be exercised automatically or the Company will pay the option holder an amount equal to the excess, if any, of (x)&#160;the fair market value of the shares subject to the options over (y)&#160;the purchase price due had the options been exercised automatically. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the ESPP, a corporate transaction will occur upon: (i)&#160;a merger or consolidation of the Company in which the Company is not the surviving entity; (ii)&#160;a disposition of all or substantially all of the Company&#8217;s assets; (iii)&#160;the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">complete liquidation or dissolution of the Company; or (iv)&#160;any reverse merger in which the Company is the surviving entity but (A)&#160;the shares of Company common stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, or (B)&#160;in which securities possessing more than 50% of the total combined voting power of the Company&#8217;s outstanding securities are transferred to person(s) different from those who held such securities immediately prior to such merger; or (v)&#160;an acquisition by any person(s), other than the Company or a Company-sponsored employee benefit plan, of beneficial ownership of more than 50% of the total combined voting power of the Company&#8217;s outstanding securities. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Duration, Amendment and Termination.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The ESPP will terminate on the tenth anniversary of its effective date, unless it is terminated earlier by the administrator. The administrator may at any time and for any reason terminate or amend the ESPP. Except in connection with certain corporate transactions or changes in capitalization, no such termination can adversely affect options previously granted, provided that the ESPP may be terminated by the administrator under certain circumstances if the administrator determines that the termination of the ESPP or one or more offer periods is in our best interests or in the best interests of our stockholders. Except as described in the previous sentence, or in connection with certain corporate transactions or changes in capitalization, no amendment may make any change in any option theretofore granted which adversely affects the rights of any participant without the consent of affected participants. To the extent necessary to comply with Section&#160;423 of the Code (or any successor rule or provision or any other applicable law), we will obtain stockholder approval of any amendment in such a manner and to such a degree as required. In addition, the administrator is entitled to, without stockholder approval and regardless of whether any participant rights have been adversely affected, establish limitations or procedures that the administrator determines advisable and which are consistent with the ESPP, including limiting the frequency and/or number of changes in the amount withheld during offer periods, determining the length and frequency of future offer periods, and establishing or changing share purchase limits.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></div><hr style="page-break-after:always"><div><a name="s2E12F58B19020FD6456C28AA8D2887D3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Below we describe transactions and series of related transactions to which we were a party, or may be a party, and which we have entered into since January&#160;1, 2015, in which: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the amounts involved exceeds or will exceed the lesser of $120,000 or 1% of the average of Exicure OpCo&#8217;s total assets as of the end of the last two completed fiscal years; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any of our directors, executive officers or holders of more than five percent of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales and Issuances of Units and Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following descriptions are historical and have not been adjusted to give effect to the Merger or the share conversion ratio pursuant to the Merger Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuances of Membership Units </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2014 and February 2015, prior to our corporate conversion, Exicure OpCo issued and sold an aggregate of 5.9&#160;million Class&#160;C units and 2.0&#160;million Class&#160;C units, respectively, at a purchase price of $2.30 per unit, for an aggregate purchase price of approximately $13.6&#160;million and $4.6&#160;million, respectively. Following Exicure OpCo&#8217;s corporate conversion, in October 2015 and January 2016, it issued and sold and aggregate of 6.5&#160;million and 0.2&#160;million shares of Series C preferred stock at a purchase price of $2.30 per share for an aggregate purchase price of approximately $15.0&#160;million and $0.4&#160;million, respectively. The following table sets forth the number of Class&#160;C units and Series C preferred stock, as applicable, issued to Exicure OpCo&#8217;s directors, executive officers and holders of more than five percent of its capital stock, or an affiliate or immediate family member thereof. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Class&#160;C</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series&#160;C</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Purchase Price</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gates Ventures, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,391,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,999,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David R. Walt, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497,392</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,144,002</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay R. Venkatesan, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:bold;">Issuances of Preferred Stock </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In July 2015, in connection with Exicure OpCo&#8217;s corporate conversion, it issued 22,924,209 shares of Series A preferred stock, 4,937,813 shares of Series B-1 preferred stock, 2,827,844 shares of Series B-2 preferred stock, and 7,921,662 shares of Series C preferred stock upon conversion of 22,924,210 Class&#160;A units, 4,937,818 Class&#160;B-I units, 2,827,848 Class&#160;B-II units and 7,921,669 Class&#160;C units. Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure OpCo, resulting in 17 fewer aggregate shares of outstanding preferred stock of Exicure OpCo as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. In addition, all options to purchase Exicure OpCo common units converted into options to purchase an equivalent number of shares of Exicure OpCo&#8217;s common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015 and January 2016, Exicure OpCo sold 6,542,783 shares and 195,651 shares, respectively, of its Series C preferred stock at a price of $2.30 per share. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For information regarding the number of shares of stock issued to, or options held by, Exicure OpCo&#8217;s directors, executive officers and holders of more than five percent of our capital stock, or an affiliate or immediate family </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">member thereof, see the sections titled, &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Executive and Director Compensation.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock Issued in the Private Placement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain of our existing investors, including investors affiliated with certain of our directors, and Dr.&#160;Giljohann, our Chief Executive Officer, have purchased an aggregate of 4,213,153&#160;shares of our common stock in the Private Placement, for an aggregate purchase price of $12.6&#160;million. Such purchases were made on the same terms as the shares that were sold to other investors in the Private Placement and not pursuant to any pre-existing contractual rights or obligations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each investor in any Subsequent Closing of the Private Placement was required to represent that, at the time of the applicable closing, it (i)&#160;had a substantive, pre-existing relationship with us, or had direct contact with the Company or the Placement Agents or other enumerated parties outside of the Private Placement, (ii)&#160;was not identified or contacted through the marketing of the Private Placement, and (iii)&#160;did not independently contact us as a result of general solicitation by means of the Form 8-K, any press release or any other public disclosure disclosing the material terms of the Private Placement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investors&#8217; Rights Agreement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo entered into an investors&#8217; rights agreement that provides holders of its preferred stock, including holders of five percent or more of its capital stock and entities affiliated with certain of its directors, with registration rights and rights of first refusal in favor of the holders of its preferred stock with respect to certain issuances of its capital stock and securities convertible into or exercisable or exchangeable for its capital stock. This investors&#8217; rights agreement terminated upon the closing of the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholder Agreement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo entered into a stockholder agreement that provides certain holders of its capital stock, including certain holders of five percent or more of its capital stock and entities affiliated with certain of its directors, rights of co-sale with respect to any proposed sale of a majority of its capital stock. This agreement terminated upon the closing of the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Director and Executive Officer Compensation </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">See the section titled &#8220;Executive and Director Compensation&#8221; for information regarding compensation of Exicure OpCo&#8217;s directors and named executive officers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employment Agreements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo executed an offer of employment with each of its executives. This offer describes the basic terms of the executive&#8217;s employment, including his or her start date, starting salary, bonus target and any equity awards. See &#8220;Executive and Director Compensation&#8212;Employment and Change in Control Arrangements&#8221; for more information. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-employee Director Agreements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with their service on Exicure OpCo&#8217;s board of directors, Exicure OpCo entered into agreements with David R. Walt, Ph.D., Chad A. Mirkin, Ph.D., C. Shad Thaxton, M.D., Ph.D., Jay R. Venkatesan, M.D., and Helen S. Kim, Exicure OpCo&#8217;s non-employee directors. Each of these agreements was amended and restated in August 2015 following Exicure OpCo&#8217;s corporate conversion. Exicure OpCo also entered into a consulting agreement with Dr.&#160;Mirkin in October 2011. See &#8220;Executive and Director Compensation&#8212;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Director Compensation Table</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Year Ended December 31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Consulting Arrangement&#8221; and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8220;Executive and Director Compensation&#8212;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Director Compensation Table</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Year Ended December 31, 2016</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Director Compensation&#8221; </font><font style="font-family:inherit;font-size:10pt;color:#000000;">for more information regarding these agreements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification Agreements and Directors&#8217; and Officers&#8217; Liability Insurance </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure OpCo has entered into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require Exicure OpCo or will require it to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of Exicure OpCo, arising out of the person&#8217;s services as a director or executive officer. As a condition to the Merger, we also entered into a Pre-Merger Indemnity Agreement with our former officers and directors, pursuant to which we agreed to indemnify such former officers and directors for actions taken by them in their official capacities relating to the consideration, approval and consummation of the Merger and certain related transactions. The form of the Pre-Merger Indemnity Agreement is filed as an exhibit to this prospectus. All descriptions of the Pre-Merger Indemnity Agreement herein are qualified in their entirety by reference to the text thereof filed as an exhibit hereto, which is incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Policies and Procedures for Related Party Transactions </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors has adopted a written related person transaction policy to set forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item&#160;404 of Regulation S-K promulgated under the Exchange Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds or will exceed the lesser of $120,000 or 1% of the average of Exicure OpCo&#8217;s total assets as of the end of the last two completed fiscal years and a related person had, has or will have a direct or indirect material interest, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. As provided by our audit committee charter, our audit committee will be responsible for reviewing and approving in advance the related party transactions covered by our related transaction policies and procedures.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></div><hr style="page-break-after:always"><div><a name="sE2CA0EBAB221B5A3B2BA28AA8D59BC75"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are filing this registration statement of which this prospectus forms a part to permit holders of the shares of our common stock described in the section entitled &#8220;Selling Stockholders&#8221; to resell such shares. We will not receive any proceeds from the resale of any shares offered by this prospectus by the selling stockholders.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></div><hr style="page-break-after:always"><div><a name="s679CB80D6DC608278C8B28AA8D7B0259"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIVIDEND POLICY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently intend to retain future earnings, if any, for use in the operation of our business and to fund future growth. We have never declared or paid cash dividends on our common stock and we do not intend to pay any cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors in light of conditions then-existing, including factors such as our results of operations, financial condition and requirements, business conditions and covenants under any applicable contractual arrangements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></div><hr style="page-break-after:always"><div><a name="sB093D432588905E3C30A28AA8DAC0674"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DETERMINATION OF OFFERING PRICE </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders may only sell their shares of our common stock pursuant to this prospectus at a fixed price of $3.00 per share until such time as our common stock is quoted on the OTCQB or another public trading market for our common stock otherwise develops. At and after such time, the selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices. The fixed price of $3.00 at which the selling stockholders may sell their shares pursuant to this prospectus was determined based upon the purchase price per share of our Common Stock in closings of the Private Placement completed on September 26, 2017, October 27, 2017 and November 2, 2017, respectively. The exercise price at which any holder of a warrant may purchase shares was determined based upon the purchase price per share of our Common Stock in closings of the Private Placement. We have included a fixed price at which selling stockholders may sell their shares pursuant to this prospectus prior to the time there is a public market for our stock in order to comply with the rules of the SEC that require that, if there is no market for the shares being registered, this registration statement must include a price at which the shares may be sold. Except to the extent that we are involved in an underwritten secondary offering of common stock, if any, by the selling stockholders, all shares being offered pursuant to this prospectus will be sold by the selling stockholders without our involvement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></div><hr style="page-break-after:always"><div><a name="s0C2908423008FFCE7D6428AA8DCDBF2D"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARKET INFORMATION FOR OUR COMMON STOCK</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is not listed on a national securities exchange, an over-the-counter market or any other exchange. Therefore, there is no trading market, active or otherwise, for our common stock and our common stock may never be included for trading on any stock exchange, automated quotation system or any over-the-counter market. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 15, 2017, we have 39,300,823 shares of common stock outstanding held by 204 stockholders of record.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></div><hr style="page-break-after:always"><div><a name="sF1AABF9BC4CAFCA6D0D828AA8DFFB1C0"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth certain information relating to the beneficial ownership of our common stock as of November 15, 2017, by: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">each person, or group of affiliated persons, known by us to beneficially own more than five percent of the outstanding shares of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">each of our directors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">each of our named executive officers; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">all directors and executive officers as a group. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or dispositive power as well as any shares that the individual has the right to acquire within 60 days of November 15, 2017 through the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and dispositive power with respect to all shares of common stock held by that person. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The percentage of shares beneficially owned is computed on the basis of 39,300,823&#160;shares of our common stock outstanding as of November 15, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Shares of common stock that a person has the right to acquire within 60 days of November 15, 2017, are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise noted below, the address of the persons listed on the table is c/o Exicure, Inc., 8045 Lamon Avenue, Suite 410, Skokie, IL 60077.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beneficial&#160;Owner</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Greater&#160;than&#160;5%&#160;Stockholders</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common&#160;Stock</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beneficially&#160;Owned&#160;(#)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(1)</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common&#160;Stock</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beneficially&#160;Owned&#160;(%)&#160;(1)</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AuraSense, LLC</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,267,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gates Ventures, LLC</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,333,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors and Named Executive Officers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chad A. Mirkin, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,387,048</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. Shad Thaxton, M.D., Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,357,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David R. Walt, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">859,768</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay R. Venkatesan, M.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(7) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen S. Kim</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David A. Giljohann, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(9) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,049,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David S. Snyder</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(10) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ekambar Kandimalla, Ph.D.</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(11) </sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All directors and executive officers as a group (8 persons)</font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(12) </sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,405,818</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicates beneficial ownership of less than one percent of the outstanding shares of common stock. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Includes an aggregate of 10,504,196&#160;shares of common stock issued upon the consummation of all closings of the Private Placement. We and the Placement Agents may agree to extend the period for additional closings up to November 30, 2017.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Excludes (a) 22,567 shares of common stock held by Chad Mirkin, (b) 6,669 shares of common stock held by Chad A. Mirkin Living Trust, (c) 89,988&#160;shares of common stock issuable to Chad Mirkin upon exercise of options exercisable within 60 days of November 15, 2017, and (d) 89,988&#160;shares of common stock issuable to C. Shad Thaxton upon exercise of options exercisable within 60 days of November 15, 2017, in each case over which AuraSense, LLC has no voting power or dispositive power. Drs. Mirkin and Thaxton serve as managers of AuraSense, LLC and share voting and dispositive power over the shares of the Company held by AuraSense, LLC. The address of the principal place of business of AuraSense, LLC is 8045 Lamon Avenue, Suite 410, Skokie, IL 60077. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The address of the principal place of business of Gates Ventures, LLC is 2365 Carillon Point, Kirkland, WA 98033. William H. Gates III has sole voting and dispositive power over the shares of the Company as the sole member of Gates Ventures, LLC.&#160;The address of the principal place of business of William H. Gates III is One Microsoft Way, Redmond, WA 98052. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 22,567 shares of common stock held by Chad Mirkin, (b) 6,669 shares of common stock held by Chad A. Mirkin Living Trust, (c) 89,988 shares of common stock issuable to Chad Mirkin upon exercise of options exercisable within 60 days of November 15, 2017, and (d) 11,267,824 shares held by AuraSense, LLC. Dr.&#160;Mirkin is the Trustee of the Chad A. Mirkin Living Trust, and has voting or dispositive power over such entity. Dr.&#160;Mirkin is a member of the Board of Managers of AuraSense, LLC and shares voting and dispositive power with respect to all shares of common stock held by AuraSense, LLC. Excludes shares held by Dr.&#160;Mirkin&#8217;s brother, who does not live in the same household as Dr.&#160;Mirkin. Dr.&#160;Mirkin disclaims beneficial ownership of shares held by his brother. The address of Dr.&#160;Mirkin is c/o AuraSense, LLC, 8045 Lamon Avenue, Suite 410, Skokie, IL 60077. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 89,988 shares of common stock issuable to Dr.&#160;Thaxton upon exercise of options exercisable within 60 days of November 15, 2017, and (b) 11,267,824 shares held by AuraSense, LLC. Dr.&#160;Thaxton is a member of the Board of Managers of AuraSense, LLC and shares voting and dispositive power with respect to all shares of common stock held by AuraSense, LLC. The address of Dr.&#160;Thaxton is c/o AuraSense, LLC, 8045 Lamon Avenue, Suite 410, Skokie, IL 60077. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 767,711 shares held by David R. Walt and (b) 92,057&#160;shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. Excludes shares held by Dr.&#160;Walt&#8217;s children, who do not live in the same household as Dr.&#160;Walt. Dr.&#160;Walt disclaims beneficial ownership of shares held by his children. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 190,957 shares held by the Venkatesan-Louizides Trust, (b) 156,858 shares held by Ayer Special Situations Fund I, LP, (c) 52,234 shares held by Jay R. Venkatesan and (d) 39,822&#160;shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. Dr.&#160;Venkatesan is the Trustee of the Venkatesan-Louizides Trust and the Managing Director of the Ayer Special Situations Fund I, and has voting or dispositive power over such entities. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 82,747&#160;shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 16,666 shares of common stock held by Dr.&#160;Giljohann, and (b) 1,032,490 shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. Dr.&#160;Giljohann is a member of AuraSense, LLC but does not have voting or investment power over any of the shares held directly by AuraSense, LLC. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 344,536 shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 152,704 shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of (a) 12,481,486&#160;shares of common stock held by our directors, including 11,267,824 shares held by AuraSense, LLC, a company in which Drs. Mirkin and Thaxton serve as managers and share voting and dispositive power, and (b) 1,830,007&#160;shares issuable pursuant to stock options exercisable within 60 days of November 15, 2017 held by our directors and three executive officers. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></div><hr style="page-break-after:always"><div><a name="s761DE476982C7CD0AEAC28AA8E20AB25"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SELLING STOCKHOLDERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus covers the resale by the selling stockholders identified below of 39,714,143 shares of our common stock. The selling stockholders were pre-Merger stockholders of our predecessor, Max-1, or acquired our securities in connection with the Merger and the Private Placement and, with respect to 413,320 shares underlying warrants to purchase shares of our Common Stock, in connection with their services as Placement Agents for the Private Placement. The registration of the common stock of the selling stockholders through this prospectus constitutes a secondary offering and is not an offering by or on behalf of the Company. We will not receive any proceeds from the resale of the common stock by the selling stockholders. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as disclosed in the footnotes below, none of the selling stockholders has been an officer or director of ours or any of our predecessors or affiliates within the past three years. Except as disclosed in the footnotes below, no selling stockholder had a material relationship with the company or any of its affiliates within the last three years. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table and the accompanying footnotes are based in part on information supplied to us by the selling stockholders. The table and footnotes assume that the selling stockholders will sell all of the shares listed. However, because the selling stockholders may sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholders or that will be held by the selling stockholders after completion of any sales. We do not know how long the selling stockholders will hold the shares before selling them. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The inclusion of any shares in this table does not constitute an admission of beneficial ownership by the persons named below. </font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned Before the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Being </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned After the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(%) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of Selling Stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aurasense, LLC </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,267,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,267,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gates Ventures, LLC </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,333,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,333,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AbbVie Inc. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,939,113</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,939,113</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mark Tompkins </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,825,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,825,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">346 Long LLC </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Luye Pharma Group Ltd </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Northwestern University </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,564,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,564,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AB/TF Partners LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,333,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,333,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gakasa Holdings LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">David R Walt </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">767,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">767,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patrick G Ryan and Shirley W Ryan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Craig J Mundie</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Eager Info Investments Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">666,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">666,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">GBR Investments LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corbett M W Ryan Living Trust dated July 13 2001</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">233,381</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">IL Dept of Commerce &amp; Economic Opportunity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Innovation Endeavors, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Rhoderic Peter Mirkin and Daryl J Mirkin</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(8)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mark Ratner Trust Agreement U/A/D 9/10/1983</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,268</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,268</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned Before the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Being </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned After the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(%) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Venkatesan-Louizides Trust </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AVGF - PAV1 Exicure 2017, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Paul Tompkins</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Rathmann Family Foundation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">David Lies</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ernest W Moody Revocable Trust dtd Jan 14 2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The 2000 Welch Charitable Remainder Unitrust Agreement II</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Delta Eight Investments Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,964</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ayer Special Situations Fund I LP </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(10)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael Silverman </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(11)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Roberta B McIntire and Chris Scott McIntire</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allred Trust Dated January 26 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stephen Renaud </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(12)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Peter K Janssen </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(13)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Slagle Creek Partners LP</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Montrose Capital Partners Limited </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(14)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ian Jacobs </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(15)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gibralt Capital Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acequia Capital IV LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">James R Gibbs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Richard B Silverman and Barbara K Silverman</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Justin Keener d/b/a JMJ Financial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lincoln Park Capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Richard B Silverman Trust dated August 14 2005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Margaret Simon Wise GST Trust</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Matthew Simon GST Trust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Philip Silverman GST Trust</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Seth Benison </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(16)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">RP Capital LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sergei Gryaznov</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,473</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Clayton A Struve</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Craig Whited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael Chabot and Victoria Chabot</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015 Irrevocable Trust FBO Devin M Chabot</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015 Irrevocable Trust FBO Elizabeth Chabot</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015 Irrevocable Trust FBO Matthew R Chabot</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lefkofsky Family Foundation </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lynx Financial (HK) Limited </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(17)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Robert Kamerschen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned Before the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Being </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned After the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(%) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jay Venkatesan </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(18)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">FirstFire Global Opportunities Fund LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dyke Rogers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Joseph Schump</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patrick Patel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Katalyst Securities LLC</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(19)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patrick Wood-Prince Revocable Trust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pitt Investments LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Mariann Pancoe Trust 11/22/1997</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,514</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,514</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Brio Capital Master Fund Ltd</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Iroquois Capital Investment Group LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Richard Wickel </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alfred G Wirth</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Primary Capital LLC</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(20)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gordon Beck</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stanley Rose</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">George E Conniff and Diane M Conniff 2002 Family Trust Agreement dtd March 28 2002</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Irwin Blitt Rev Trust dtd 01 28 79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael J Mathieu</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael L &amp; Sharon D Willis JTWROS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">C James Prieur &amp; Karen Prieur JTWROS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gerard Tarde and Mary Elizabeth Tarde</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Samuel K Skinner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,333</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Carolyn K Phillips</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mary Elizabeth Phillips Ainsley Trust (dated August 29 2001)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lee Harrison Corbin</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Henry Bienen and Leigh Bienen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Anthony Joseph Schaeffer Revocable Trust U/A dtd 8/20/2002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Kathleen J Schaeffer Revocable Trust U/A dtd 8/20/2002</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adolfo &amp; Donna H Carmona JTWROS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Henry Bienen </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">MSK Venture Partners LLC </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(21)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alexandra Koppel Guardian for Regina R.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cresswell Advisors Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">James Prete</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">John C Blazier &amp; Fleur Christensen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thomas Zahavi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">William T Moody</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned Before the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Being </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned After the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(%) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael A Terry &amp; Lynne M Terry</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,824</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">William W Bradley Rev Trust</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mark D Booth Revocable Trust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chad A Mirkin </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(22)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Hartwell Davis Jr</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Christopher Cozzolino </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(23)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Brian Davies </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(24)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Andrew Brenner</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Anthony Azzara</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Daniel E Gruesser &amp; Susan P Gruesser JTWROS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Schein Ventures LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charles Smith Living Trust</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Pitt Family Irrevocable Trust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alice Phillips Topping 2000 Trust (dtd 03/02/2000)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Currie Family Trust</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Peter W Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stephanie Walt </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Edwin H Morgens</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">John R Raphael Revocable Trust dtd 07/06/07 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trust UA2 Will Hallie Hicklin FBO Lauren Morgens</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">KP Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,866</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,866</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">B Adrian Kesala</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Applied Food Sciences Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Arnova LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Binker of Fifth Avenue LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chitayat-Mahboubian Family Trust dtd 08 10 2009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ernest J &amp; Michele M Mattei JTWROS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Iroquois Master Fund Ltd</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lee J Seidler Revocable Trust dtd 4/12/1990</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael Bigger Custodian for Andreas Bigger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Michael Bigger Custodian for Mathias Bigger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Osprey I LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Susan and Dennis Wellington</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Mihir Parikh and Keerti Gurushanthaiah Trust dtd 11 22 2005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Timothy M Swager</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Veronica Marano and Thomas M Volckening JTWROS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Anthony J Schaeffer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Brian K Langham</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Daniel Schrag</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned Before the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Being </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Owned After the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Offering</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(#) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(%) </font><font style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">David A Giljohann </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(25)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kathleen J Schaeffer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lane Gensburg</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">M&amp;T Bank as Trustee FBO Jeffrey Benison IRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Robert L Bahr Revocable Trust 1985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Timothy M Swager and Anne Swager</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vipul B Patel</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Teresa D Dereniak</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alexander Pancoe  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Morgan Janssen </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(26)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Alexander Pancoe Irrevocable Trust</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stourbridge Investments LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kevin Rutherford</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patrick Wood-Prince</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Eleanor D Pancoe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Janice Nakovich</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,915</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,915</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vinayak P Dravid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">EFD Capital Inc. </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(27)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Chad A Mirkin Living Trust </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(28)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jesse Janssen </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(29)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Benjamin &amp; Jerold Brokerage I, LLC </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(30)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Kola Agbaje </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(31)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Paul Ehrenstein </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(32)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Opes Equities, Inc. </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(33)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Roman Livson </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(34)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stockholders holding in the aggregate less than 1% of outstanding shares </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(35)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Less than 1%</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Applicable percentage ownership is based on 39,300,823 shares of our common stock outstanding as of November 15, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Assumes the sale of all shares offered in this prospectus.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aurasense LLC is our largest stockholder. Dr. Chad A. Mirkin and Dr. C. Shad Thaxton, both of which are our current directors, serve as managers of AuraSense, LLC and share voting and dispositive power over the shares of the Company held by AuraSense, LLC.  Excludes (a) 22,567 shares of common stock held by Chad Mirkin and (b) 6,669 shares of common stock held by Chad A. Mirkin Living Trust, in each case over which AuraSense, LLC has no voting power or dispositive power. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">William H. Gates III has sole voting and dispositive power over the shares of the Company as the sole member of Gates Ventures, LLC. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 1,825,667 shares of common stock held by Mark Tompkins, a former director of Max-1, our predecessor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The Company has entered into license agreements with Northwestern University. See &#8220;Description of Our Business&#8212;Our Intellectual Property&#8212;Northwestern University License Agreements.&#8221;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. David R. Walt is our director. Excludes shares held by Dr. Walt&#8217;s children, who do not live in the same household as Dr. Walt. Dr. Walt disclaims beneficial ownership of shares held by his children.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Rhoderic Mirkin is the brother of Dr. Chad A. Mirkin, our director. Dr. Mirkin&#8217;s brother does not live in the same household as Dr. Mirkin. Dr. Mirkin disclaims beneficial ownership of shares held by his brother. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Jay Venkatesan is our director. Dr. Venkatesan is the Trustee of the Venkatesan-Louizides Trust and has voting or dispositive power over such entity.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Jay Venkatesan is our director. Dr. Venkatesan is the Managing Director of the Ayer Special Situations Fund I and has voting or dispositive power over such entity.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 6,000 of these shares to Michael Silverman. Includes 66,437 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 3,000 of these shares to Stephen Renaud. Includes 41,993 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 7,000 of these shares to Peter K. Janssen. Includes 44,000 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(14)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Mark Tompkins is a former director of Max-1, our predecessor, and is a principal of Montrose Capital Partners Limited. Mr. Tompkins has sole voting and investment control over the shares of common stock owned by Montrose Capital Partners Limited. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(15)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Ian Jacobs is a former director and officer of Max-1, our predecessor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(16) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 30,000 of these shares to Seth Benison. Includes 51,776 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(17)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 58,333 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(18)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Jay Venkatesan is our director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(19)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Katalyst Securities LLC served as our placement agent in connection with the Private Placement. Consists of 46,666 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(20)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Primary Capital LLC served as a sub-agent to our placement agent, Katalyst Securities LLC, in connection with the Private Placement. Consists of 37,334 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(21)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">MSK Venture Partners LLC was a service provider in connection with the Merger.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(22) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Chad A. Mirkin is our director. Excludes shares held by Dr. Mirkin&#8217;s brother, who does not live in the same household as Dr. Mirkin. Dr. Mirkin disclaims beneficial ownership of shares held by his brother. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(23)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 3,000 of these shares to Christopher Cozzolino. Includes 8,657 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(24)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 21,000 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(25)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Giljohann is our Chief Executive Officer and director.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(26)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 15,912 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(27)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 11,301 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(28)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Dr. Chad A. Mirkin is our director and is the Trustee of the Chad A. Mirkin Living Trust, and has voting or dispositive power over such entity. Excludes shares held by Dr. Mirkin&#8217;s brother, who does not live in the same household as Dr. Mirkin. Dr. Mirkin disclaims beneficial ownership of shares held by his brother. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(29)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 3,097 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(30)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benjamin &amp; Jerold Brokerage I, LLC served as a sub-agent to our placement agent, Katalyst Securities LLC, in connection with the Private Placement. Consists of 2,217 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(31)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 2,217 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(32)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 1,400 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(33)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">In connection with the Private Placement, Katalyst Securities LLC was entitled to receive 50,000 shares of our common stock. Katalyst Securities LLC has assigned its right to 1,000 of these shares to Opes Equities, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(34)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of 980 shares of common stock underlying Placement Agent Warrants.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(35)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Consists of selling stockholders not otherwise listed in this table who within the group indicated collectively own less than 1% of our common stock.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161</font></div></div><hr style="page-break-after:always"><div><a name="s0AA541428736649A281928AA8E53C384"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">an exchange distribution in accordance with the rules of the applicable exchange; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">privately negotiated transactions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">short sales; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">a combination of any such methods of sale; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any other method permitted pursuant to applicable law. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The selling stockholders and any underwriters, broker-dealers or agents that are involved in selling the common stock or interests therein may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder in the Private Placement has informed us that it does not have any agreement or understanding, directly or indirectly, with any person to distribute the common stock. If a selling stockholder is deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, it will be subject to the prospectus delivery requirements of the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to this registration statement that includes this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed with the selling stockholders to keep this registration statement of which this prospectus constitutes a part effective for five years from the date it is declared effective by the SEC or until the date on which all of the shares required to be registered by us have been transferred other than to certain enumerated permitted assignees under the Registration Rights Agreement.  See the section of this prospectus captioned &#8220;Shares Eligible for Future Sale&#8212;Registration Rights.&#8221; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163</font></div></div><hr style="page-break-after:always"><div><a name="s676D1BFE361D52F9A8BB28AA8E74F453"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have authorized capital stock consisting of 200,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of November 15, 2017, we had 39,300,823&#160;shares of common stock issued and outstanding, and no shares of preferred stock issued and outstanding. Unless stated otherwise, the following discussion summarizes the terms and provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which has been publicly filed with the SEC. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The holders of shares of our common stock are entitled to one vote per share on all matters to be voted upon by our stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of our common stock are entitled to receive ratably any dividends that may be declared from time to time by our board of directors out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, the holders of shares of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. The outstanding shares of our common stock are fully paid and&#160;non-assessable,&#160;and any shares of our common stock to be issued upon an offering pursuant to this prospectus will be fully paid and nonassessable upon issuance. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as our board of directors deems relevant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following description of our preferred stock and the description of the terms of any particular series of our preferred stock that we choose to issue hereunder are not complete. These descriptions are qualified in their entirety by reference to our amended and restated certificate of incorporation and the certificate of designation, if and when adopted by our board of directors, relating to that series. The rights, preferences, privileges and restrictions of the preferred stock of each series will be fixed by the certificate of designation relating to that series. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently have no shares of preferred stock outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the holders of our common stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors may specify the following characteristics of any preferred stock: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the maximum number of shares; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the designation of the shares; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the annual dividend rate, if any, whether the dividend rate is fixed or variable, the date or dates on which dividends will accrue, the dividend payment dates, and whether dividends will be cumulative; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the price and the terms and conditions for redemption, if any, including redemption at our option or at the option of the holders, including the time period for redemption, and any accumulated dividends or premiums; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any sinking fund or similar provision, and, if so, the terms and provisions relating to the purpose and operation of the fund; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms and conditions, if any, for conversion or exchange of shares of any other class or classes of our capital stock or any series of any other class or classes, or of any other series of the same class, or any other securities or assets, including the price or the rate of conversion or exchange and the method, if any, of adjustment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the voting rights; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or restrictions. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any preferred stock issued will be fully paid and nonassessable upon issuance. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 15, 2017, the Placement Agent Warrants consist of 32 warrants and entitle their holders to purchase an aggregate of 413,320&#160;shares of common stock, with a term of three years and an exercise price of $3.00 per share. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Placement Agent Warrants contain customary provisions for adjustment in the event of stock splits, subdivision or combination or mergers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The summary descriptions of the warrants described above are qualified in their entirety by reference to the form of such warrants filed as an exhibit to this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Options to purchase shares of Exicure OpCo common stock that were originally granted under the 2015 Plan to certain of Exicure OpCo&#8217;s employees, officers and directors were converted into options to purchase 3,680,997&#160;shares of our common stock with a weighted average exercise price of $1.79 per share when they were assumed by us in connection with the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Convertible Securities </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 15, 2017, other than the securities described above, we do not have any outstanding convertible securities. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lock-up Agreements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the initial closing of the Private Placement, holders of approximately 27.7&#160;million shares&#160;of our common stock have agreed, subject to certain exceptions, not to dispose of or hedge any shares of common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the lock-up agreement continuing through the date nine months after the date of the Merger and the initial closing of the Private Placement, except with our prior written consent. Shares of our common stock issued pursuant to certain payments to the Placement Agents in connection with the Private Placement will also be subject </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to a lock-up agreement for a period of 18 months.  See </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#8220;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Shares Eligible for Future Sale&#8212;Lock-Up Agreements&#8221; below for more information. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registration Rights </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the Private Placement, we entered into a Registration Rights Agreement with our investors. See </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#8220;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Shares Eligible for Future Sale&#8212;Registration Rights&#8221; below for more information. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Provisions of Our Charter Documents </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately&#160;one-third&#160;of the board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of our outstanding voting stock from obtaining control of our board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation provides that directors may be removed with cause by the affirmative vote of the holders of a majority of the voting power of all of our outstanding stock or without cause by the affirmative vote of the holders of at least 66 and 2/3% of the voting power of all of our outstanding stock. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that certain amendments of our certificate of incorporation and amendments by our stockholders of our amended and restated bylaws require the approval of at least 66 and 2/3% of the voting power of all of our outstanding stock. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could delay changes in management. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation also provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. This forum selection provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder at the time of giving notice and at the time of the meeting, who is entitled to vote at the meeting and who has complied with the notice requirements of our amended and restated bylaws in all respects. The amended and restated bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of our stockholders. However, our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws provide that a special meeting of our stockholders may be called only by our Secretary and at the direction of our board of directors by resolution adopted by a majority of our board of directors. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of our board of directors, the president or the chief executive officer believed the matter should be considered or until the next annual meeting</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#160;provided</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace our board of directors also could be delayed until the next annual meeting. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws do not allow our stockholders to act by written consent without a meeting. Without the availability of stockholder action by written consent, a holder controlling a majority of our capital stock would not be able to amend our amended and restated bylaws or remove directors without holding a stockholders&#8217; meeting. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Delaware Law </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are subject to the provisions of Section&#160;203 of the DGCL, or Section&#160;203. Under Section&#160;203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">prior to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">at or subsequent to such time, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 and 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under Section&#160;203, a &#8220;business combination&#8221; includes: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In general, Section&#160;203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in management. It is possible that these provisions may make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following such time, if any, as our capital stock is listed on a national securities exchange or is held of record by more than 2,000 stockholders, we will be subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, as amended. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitations of Liability and Indemnification Matters </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For a discussion of liability and indemnification, please see the section titled &#8220;Directors and Executive Officers&#8212;Limitation of Liability and Indemnification.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There is currently no transfer agent for our common stock. In connection with applying to have our common stock quoted on OTC Markets, we intend to appoint American Stock Transfer&#160;&amp; Trust Company, LLC, or AST, as transfer agent and registrar for our common stock. AST&#8217;s address is 6201 15</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th </sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">Avenue, Brooklyn, New York 11219 and its telephone number is 718-921-8200.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168</font></div></div><hr style="page-break-after:always"><div><a name="s914560fc691a43ed8e254995498242fe"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHARES ELIGIBLE FOR FUTURE SALE</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prior to the Merger, there has been a limited public market for our common stock. As described below, only a limited number of shares of our common stock will be available for sale in the public market for a period of several months after consummation of the Merger due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing price of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 15, 2017, we had 39,300,823&#160;shares of common stock outstanding, of which our directors and executive officers beneficially own an aggregate of 12,481,486&#160;shares. Of those outstanding shares, no shares of our common stock are freely tradable, without restriction, as of the date of this prospectus. No shares issued in connection with the Merger or the Private Placement can be publicly sold under Rule 144 promulgated under the Securities Act until 12 months after the date of filing of our Form 8-K.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of Restricted Shares </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Of the approximately 39,300,823&#160;shares of common stock outstanding upon completion of the closings of the Private Placement, all of such shares will be &#8220;restricted securities&#8221; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, which rules are summarized below. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lock-up Agreements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the initial closing of the Private Placement, holders of approximately 27.7&#160;million shares&#160;of our common stock have agreed, subject to certain exceptions, not to dispose of or hedge any shares of common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the lock-up agreement continuing through the date nine months after the date of the Merger and the initial closing of the Private Placement, except with our prior written consent. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Shares of our common stock issued pursuant to certain payments to the Placement Agents in connection with the Private Placement will also be subject to a lock-up agreement for a period of 18 months.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the lock-up periods set forth in the agreements described above, and assuming that no parties are released from these agreements and that there is no extension of the lock-up period, certain of the shares of common stock that are restricted securities or are held by our affiliates as of the date of the Merger will be eligible for sale in the public market in compliance with Rule 144 under the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rule 144 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to Rule 144 promulgated under the Securities Act, sales of the securities of a former shell company, such as us, under that rule are not permitted (i)&#160;until at least 12 months have elapsed from the date on which our Form 8-K was filed with the SEC and (ii)&#160;unless at the time of a proposed sale, we are subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act and have filed all reports and other materials required to be filed by Section&#160;13 or 15(d) of the Exchange Act, as applicable, during the preceding 12 months, other than Current Reports on Form 8-K. We intend to register such shares for sale under the Securities Act, but are currently a &#8220;voluntary filer&#8221; and are not subject to the reporting requirements of Section&#160;13 or Section&#160;15(d) of the Exchange Act. As a result, unless we register such shares for sale under the Securities Act, most of our stockholders will be forced to hold their shares of our common stock for at least that 12-month period before they are eligible to sell those shares, and even after that 12-month period, sales may not be made under Rule 144 unless we and the selling stockholders are in compliance with other requirements of Rule 144. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In general, Rule 144 provides that (i)&#160;any of our non-affiliates that has held restricted common stock for at least 12 months is thereafter entitled to sell its restricted stock freely and without restriction, provided that we remain compliant and current with our SEC reporting obligations, and (ii)&#160;any of our affiliates, which includes our directors, executive officers and other persons in control of us, that has held restricted common stock for at least 12 months is thereafter entitled to sell its restricted stock subject to the following restrictions: (a)&#160;we are compliant and current with our SEC reporting obligations, (b)&#160;certain manner of sale provisions are satisfied, (c)&#160;a Form 144 is filed with the SEC, and (d)&#160;certain volume limitations are satisfied, which limit the sale of shares within any three-month period to a number of shares that does not exceed 1% of the total number of outstanding shares or, if our common stock is then listed or quoted for trading on a national securities exchange, then the greater of 1% of the total number of outstanding shares and the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of the Form 144 with respect to the sale. A person who has ceased to be an affiliate at least three months immediately preceding the sale and who has owned such shares of common stock for at least one year is entitled to sell the shares under Rule 144 without regard to any of the limitations described above. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation S </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Regulation S under the Securities Act provides that shares owned by any person may be sold without registration in the U.S., provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the U.S. (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our shares of common stock may be sold in some other manner outside the U.S. without requiring registration in the U.S. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rule 701 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock from us in connection with a written compensatory stock or option plan or other written agreement, in compliance with Rule 701 under the Securities Act, before the effective date of the Merger (to the extent such common stock is not subject to a lock-up agreement) is entitled to rely on Rule 701 to resell such shares beginning 90 days after we become subject to the public company reporting requirements of the Exchange Act in reliance on Rule 144, but without compliance with the holding period requirements contained in Rule 144. Accordingly, subject to any applicable lock-up agreements, beginning 90 days after we become subject to the public company reporting requirements of the Exchange Act, under Rule 701 persons who are not our &#8220;affiliates,&#8221; as defined in Rule 144, may resell those shares without complying with the minimum holding period or public information requirements of Rule 144, and persons who are our &#8220;affiliates&#8221; may resell those shares without compliance with Rule 144&#8217;s minimum holding period requirements (subject to the terms of the lock-up agreement referred to above, if applicable). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registration Rights </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the Private Placement, we entered into a Registration Rights Agreement, pursuant to which we have agreed that promptly, but no later than 60 calendar days from the final closing of the Private Placement, we will file a Registration Statement with the SEC covering (a)&#160;the shares of common stock issued in the Private Placement, (b)&#160;the shares of common stock issuable upon exercise of the Placement Agent Warrants, (c)&#160;the shares of common stock issued upon the conversion of all of the equity securities of Exicure OpCo outstanding prior to the Merger and (d) 2,080,000 shares of common stock held by our pre-Merger stockholders, or collectively, the Registrable Shares. We will use our commercially reasonable efforts to ensure that such Registration Statement is declared effective within 150 calendar days after the final closing of the Private Placement. Subject to customary limitations, if we are late in filing the Registration Statement, if the Registration Statement is not declared effective within 150 days after the final closing of the Private Placement, if we fail to maintain the effectiveness of the Registration Statement, or the holders of Registrable Shares cannot use the Registration Statement to resell the Registrable Shares, for a period of more than 15 consecutive trading days (except for suspension of the use of the Registration Statement in connection with the filing of a post-effective amendment in connection with filing our Annual Report on Form 10-K for the time reasonably required to respond to any comments from the SEC on the post-effective amendment or during a permitted blackout period as described in the Registration Rights Agreement) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">or following the listing or inclusion for quotation on the OTC Markets Group, the NASDAQ Stock Market, the New York Stock Exchange or the NYSE American, trading of our common stock is suspended or halted for more than three consecutive trading days or if the Registrable Shares are not listed or quoted on such markets, collectively, the Registration Events, we will make payments to each holder of Registrable Shares as monetary penalties at a rate equal to 12% per annum of the total value of Registrable Shares held or purchased by such holder and affected during the period, based on the monetary values assigned in the Registration Rights Agreement, subject to a 5% cap with respect to such holder&#8217;s Registrable Shares that are affected by all Registration Events in the aggregate. No monetary penalties will accrue with respect to any Registrable Shares removed from the Registration Statement in response to a comment from the staff of the SEC limiting the number of shares of common stock which may be included in the Registration Statement, or Cutback Comment, or after the Registrable Shares may be resold without volume or other limitations under Rule 144 or another exemption from registration under the Securities Act. Any cutback resulting from a Cutback Comment shall be allocated first to the shares of common stock issuable upon the exercise of the Placement Agent Warrants and second to the other Registrable Shares taken together, in each case, pro rata based on the total number of such shares held by or issuable to each holder in such group. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We must use commercially reasonable efforts to keep the Registration Statement effective for five years from the date it is declared effective by the SEC or until the date on which all Registrable Securities have been transferred other than to certain enumerated permitted assignees under the Registration Rights Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will pay all expenses in connection with any registration obligation provided in the Registration Rights Agreement, including, without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws, and the fees and disbursements of our counsel and of our independent accountants and reasonable fees and disbursements of counsel to the investors, not to exceed $35,000. Each investor will be responsible for its own sales commissions, if any, transfer taxes and the expenses of any attorney or other advisor such investor decides to employ. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All descriptions of the Registration Rights Agreement herein are qualified in their entirety by reference to the text thereof filed as Exhibit 4.2 hereto, which is incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Plans </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to file with the SEC a registration statement under the Securities Act covering the shares of common stock that we may issue (i)&#160;upon exercise of outstanding options under the assumed 2015 Plan, and (ii)&#160;that are outstanding or reserved for issuance under the 2017 Plan and the ESPP. Such registration statement is expected to be filed and become effective as soon as practicable after the registration of our shares of common stock with the SEC pursuant to this registration statement on Form S-1. Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up agreements described above, if applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></div><hr style="page-break-after:always"><div><a name="s2d5b2720a4eb4fbda60bfbee739581f3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The validity of the shares of our common stock being offered by this prospectus will be passed upon for us by Sidley Austin LLP, Palo Alto, California.</font></div><div><a name="s1ad6d38be2f640debd2af95693de17b2"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The financial statements of Exicure OpCo as of December 31, 2016 and 2015, and for each of the years in the two-year period ended December 31, 2016, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</font></div><div><a name="s762cf1d83fa74e90a98fd120e05f2102"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have filed with the SEC this registration statement on Form S-1 under the Securities Act with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes a part of this registration statement, does not contain all of the information in this registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, you should refer to this registration statement and the exhibits filed as part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to this registration statement. Each of these statements is qualified in all respects by this reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are subject to the informational requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including this registration statement, over the Internet at the SEC&#8217;s website at http://www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at: 8045 Lamon Avenue, Suite 410, Skokie, IL 60077, (847) 673-1700. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></div><hr style="page-break-after:always"><div><a name="s8F883581D9584E1A539728AA8EA53F96"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:91%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">PAGE</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Audited Financial Statements - December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C2D119D4C42793E5EBF28AA8EFAC3CC"><font style="font-family:inherit;font-size:10pt;">Independent Auditors&#8217; Report</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C2D119D4C42793E5EBF28AA8EFAC3CC">F-2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC76E384B969E9B8CD2AA28AA7448113B"><font style="font-family:inherit;font-size:10pt;">Balance Sheets as of December&#160;31, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC76E384B969E9B8CD2AA28AA7448113B">F-3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE2BB45DD4C9926420BA28AA74294BCD"><font style="font-family:inherit;font-size:10pt;">Statements of Operations for the years ended December&#160;31, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE2BB45DD4C9926420BA28AA74294BCD">F-4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC14D9ABCC8691AB485BF28AA74196EFC"><font style="font-family:inherit;font-size:10pt;">Statement of Changes in Members&#8217; Equity and Stockholders&#8217; Equity for the years ended December&#160;31, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC14D9ABCC8691AB485BF28AA74196EFC">F-5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEFF4613D462DF1CB754A28AA8F9F8F1F"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows for the years ended December&#160;31, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEFF4613D462DF1CB754A28AA8F9F8F1F">F-7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2a4015fe9ee54ea693244ca8442d0780"><font style="font-family:inherit;font-size:10pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2a4015fe9ee54ea693244ca8442d0780">F-8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Interim Consolidated Financial Statements - September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEA8045729F47CADB2FD328AA9209DA2E"><font style="font-family:inherit;font-size:10pt;">Balance Sheets as of September 30, 2017 and December 31, 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEA8045729F47CADB2FD328AA9209DA2E">F-27</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8B42E0717343E278B0BA28AA923A3378"><font style="font-family:inherit;font-size:10pt;">Statements of Operations for the nine months ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8B42E0717343E278B0BA28AA923A3378">F-28</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s912A929CD6028F6A5C7428AA7463E380"><font style="font-family:inherit;font-size:10pt;">Statement of Changes in Stockholders&#8217; Equity for the nine months ended September 30, 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s912A929CD6028F6A5C7428AA7463E380">F-29</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0F8FE878DFC9EF3B4DC728AA928EB9E0"><font style="font-family:inherit;font-size:10pt;">Statements of Cash Flows for the nine months ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0F8FE878DFC9EF3B4DC728AA928EB9E0">F-30</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#se6ccc944233e4f3bab2b3e3a8c3e6467"><font style="font-family:inherit;font-size:10pt;">Notes to Unaudited Interim Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#se6ccc944233e4f3bab2b3e3a8c3e6467">F-31</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s4C2D119D4C42793E5EBF28AA8EFAC3CC"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Independent Auditors&#8217; Report </font></div><div style="line-height:120%;padding-bottom:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure, Inc.: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have audited the accompanying balance sheets of Exicure, Inc. (formerly AuraSense Therapeutics, LLC) as of December&#160;31, 2016 and 2015, and the related statements of operations, changes in members&#8217; equity and stockholders&#8217; equity, and cash flows for the years then ended. These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We conducted our audits in accordance with the auditing standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Exicure, Inc. as of December&#160;31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended in conformity with U.S.&#160;generally accepted accounting principles. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in note 1 to the financial statements, the Company has suffered recurring losses from operations and will be required to raise additional capital or alternative means of financial support to fund operations. These factors raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(signed) KPMG LLP </font></div><div style="line-height:120%;padding-bottom:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chicago, Illinois </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">March&#160;17, 2017, except for Note 12, as to which the date is October 2, 2017 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="sC76E384B969E9B8CD2AA28AA7448113B"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC) </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BALANCE SHEETS </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, and per share data) </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled revenue receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,041</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deposit on leased facility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Northwestern University License Agreements fee</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,034</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-redeemable preferred stock</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C: $0.00001 par value per share; 21,000,000 shares authorized; 14,660,096 issued and outstanding, December 31, 2016; liquidation value of $50,577 at December 31, 2016; 14,464,445 shares issued and outstanding, December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-II: $0.00001 par value per share; 2,827,844 shares authorized, issued and outstanding, December 31, 2016 and 2015 </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-I: $0.00001 par value per share; 4,937,813 shares authorized, issued and outstanding, December 31, 2016 and 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A: $0.00001 par value per share; 22,924,209 shares authorized, issued and outstanding, December 31, 2016 and 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.00001 par value per share; 62,000,000 shares authorized; 265,158 issued and outstanding December 31, 2016; 166,875 issued and outstanding, December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,448</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,230</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="sDE2BB45DD4C9926420BA28AA74294BCD"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Grant income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,488</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="sC14D9ABCC8691AB485BF28AA74196EFC"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC) </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT OF CHANGES IN MEMBERS&#8217; EQUITY AND STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except units and shares)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="47"></td></tr><tr><td style="width:11%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Non-Redeemable Preferred Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Class C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Class B (Series B-II)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Class B (Series B-I)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Class A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional Paid-in- Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total Members&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5,911,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">13,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,827,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">4,937,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">22,924,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(11,349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">11,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of membership units, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,010,219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to members of AuraSense Therapeutics, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of Limited Liability Company to Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,921,669</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,827,848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,937,818</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(22,924,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(135</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(153,750</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(246</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,837</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of preferred stock, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC) </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENT OF CHANGES IN MEMBERS&#8217; EQUITY AND STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except units and shares)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="47"></td></tr><tr><td style="width:9%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Non-Redeemable Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series B-II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series B-I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional Paid-in- Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at<br>December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of Limited Liability Company to Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,921,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,827,844</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,937,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,924,209</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,530</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of preferred stock, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,542,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,979</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,663</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">14,464,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">33,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,827,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">4,937,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">22,924,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">166,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(5,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">18,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">98,283</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of preferred stock, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">195,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(16,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">14,660,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">33,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,827,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">4,937,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">22,924,209</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">265,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(17,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(22,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,448</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="sEFF4613D462DF1CB754A28AA8F9F8F1F"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of long-term debt issuance costs and fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled revenue receivable and accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Northwestern University License Agreements fee</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(394</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(394</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from long-term borrowing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from preferred unit/stock offerings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of common unit/stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of long-term debt fees and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of preferred unit/stock financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,399</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents - beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs-preferred stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs-accrued and payable loan fees and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash investing activities (capital expenditure) included in other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><a name="s2a4015fe9ee54ea693244ca8442d0780"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div><div><a name="sA0051CD7F814F94176FE28AA8FC1A782"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure, Inc. (formerly AuraSense Therapeutics, LLC) (the Company) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid, or SNA, technology. The Company believes the design of the Company&#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. No preferred stock was provided in consideration for fractional membership units. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date. On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement. Pursuant to this agreement AuraSense, LLC received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class A Units of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$143</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, scientific equipment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$309</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$317</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for accrued legal expenses related to patent protection. The net book value of Parent&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company. Under the terms of the License Agreement and the Partial Assignment of License, Northwestern University received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">229,242</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;units. Also on December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B (Series B-1) units with net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B (Series B-2) units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,911,450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,010,219</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,542,783</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In January 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">195,651</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These transactions are described in more detail below in Note 5, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements as of, and for the years ended, December 31, 2016 and 2015, have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Going concern</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2016, the Company has generated an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$41,441</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, existing working capital at December 31, 2016 is not sufficient to sustain operations beyond September 30, 2017. As discussed in Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, on September 26, 2017 the Company completed the Merger with Max-1 Acquisition Corporation and the Private Placement for the sale of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,302</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of Exicure shares of Common Stock, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares, at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share (see Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). The combined company is expected to have approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$17,394</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in additional capital after the Private Placement. Management believes cash as of December 31, 2016, when combined with the cash raised in connection with the Private Placement, is sufficient to fund the Company through September 30, 2018. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, the Company completed the Merger with Max-1 Acquisition Corporation (see Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). Pursuant to the terms of the Merger, each outstanding share of Exicure capital stock (other than shares of Series C Preferred Stock of Exicure) was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Acquisition Corporation&#8217;s Common Stock and each outstanding share of Series C Preferred Stock of Exicure was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Acquisition Corporation&#8217;s Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><a name="sE185201FA195375EF8BA28AA8FF3CF51"></a></div><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts receivable and unbilled revenue receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments. Management believes that the Company&#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of credit risk and other risks and uncertainties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,731</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at two institutions, respectively. These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation-Going Concern</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three to seven&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets. Depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$180</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$133</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;impairment losses were recorded from inception in December 2011 through December 31, 2016.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred stock warrant liability</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of preferred stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The preferred stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. The Company classifies the liability as noncurrent as settlement is not expected within the next 12&#160;months. There were no preferred stock warrants outstanding as of December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purdue Collaboration </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma L.P., or Purdue, and referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In addition, the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Company is eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$770,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;upon successful completion of certain research, regulatory and commercial sales milestones. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of the Company&#8217;s control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive single to low double digit royalties on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&#160;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverable (2)&#8212;obligation to participate in a joint research committee, deliverable (4)&#8212;a non-voting board of director observer role, deliverable (5)&#8212;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, and deliverable (6)&#8212;the option to obtain an exclusive development and commercialization license for AST-005 or a new TNF-&#945; development candidate other than AST-005 do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverable (1)&#8212;the exclusive rights to the TNF-&#945; target and deliverable (3)&#8212;the provision of research and development activities, as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverable (7)&#8212;the option to select and develop three additional collaboration targets and deliverable (8)&#8212;the option to obtain an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;is allocated to these deliverables. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of 14.5 months. During the year ended December 31, 2016, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$690</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As of December 31, 2016, deferred revenue relating to the Purdue Collaboration was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$9,310</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8,276</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;is classified as current portion of deferred revenue in the accompanying balance sheet.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has entered into certain grant contracts containing milestone payments. The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract. For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2016 and 2015, and for the years then ended, the Company was not participating in any grant research activities involving milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments and geographic information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All material long-lived assets of the Company are located in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred rent</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes. Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company established a full valuation allowance against its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The Company adopted this guidance in the first quarter of 2016 and adoption did not have a material impact on the accompanying financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160;Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160;The guidance will be effective for the Company in the first quarter of 2017 and early adoption is permitted.&#160;The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div><div><a name="sDCEB612671408CAF223A28AA90161509"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Property and Equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Components of property and equipment were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Construction in process at December 31, 2015 represents the purchase of scientific equipment in December 2015 that was placed in service during the second quarter of 2016.</font></div><div><a name="s1CE1BF34D956F37F63E428AA7A4FD2A3"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Debt</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2016, the Company closed a </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;loan facility with Hercules Technology Growth Capital (HTGC) at a floating interest rate equal to the greater of either (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;or (ii) the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;plus the United States prime rate minus </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3.50%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, with an initial advance against this loan facility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Total proceeds net of fees and issuance costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,839</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160;Fees and issuance costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$161</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, as well as fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$231</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of September 1, 2019 using the effective interest method.&#160;Interest amounts are payable monthly beginning on March 1, 2016 through the maturity date of September 1, 2019.&#160;Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date. In 2016, the Company met certain terms in the loan agreement so that principal amounts are payable monthly beginning on July 1, 2017. The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&#160;Additionally, HTGC shall have the right to participate in a future financing of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;under the same terms and conditions and pricing afforded to other participants in that future financing.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the February 2016 HTGC loan, HTGC also has the right to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">104,348</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Series C preferred stock at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and recorded as a reduction in the carrying amount of long-term debt on the Company&#8217;s balance sheet. This discount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;will be amortized to interest expense through the loan maturity date of September 1, 2019 using the effective interest method.&#160;The Company will estimate the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and will record any changes in fair value to other income (expense), net on the Company&#8217;s statement of operations.&#160;At December 31, 2016 the carrying value of long-term debt is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,667</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and the fair value of the preferred stock warrant liability is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$201</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. See Note 9, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information on the fair value of the preferred stock warrant liability.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2016, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$478</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;during the year ended December 31, 2016.</font></div><div><a name="sDDF1EF56A6BB4E70B98728AA9069FC53"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As discussed in Note 1, the Company converted from a limited liability company into a C corporation on July 9, 2015. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure, Inc., resulting in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">17</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;less aggregate shares of outstanding preferred stock of Exicure, Inc. as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc. The Company completed a reverse-merger with Max-1 Acquisition Corporation on September 26, 2017; see Notes 1 and 12 for additional information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class A Units/Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement. In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class A units.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.10</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per unit or an aggregate value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,217</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&#8217;s net book value. The net book value of AuraSense, LLC&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class A units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,209</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. Series A preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class A units/Series A preferred stock are senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class B Units/Series B Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Class B units/Series B preferred stock are divided into two tranches and have been issued in two series: Class B-I/Series B-1 and Class B-II/Series B-2.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-I/Series B-1</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B-I units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.10</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,432</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;including a receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:inherit;font-size:10pt;color:#000000;">454,545</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$61</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-II/Series B-2</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On June 27, 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B-II units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,676</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and proceeds net of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$35</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in financing costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class B-I units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class B-II units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,813</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,844</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. Series B-1 and Series B-2 preferred stock, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class B units/Series B preferred stock are senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class C Units/Series C Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 13, 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,911,450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,596</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$117</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 6, 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,010,219</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per unit. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,921,669</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class C units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,921,662</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. Series C preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,542,783</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15,048</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$69</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">195,651</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class C units/Series C preferred stock are senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders are entitled to receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;times the aggregate cash contribution of all holders of Class C preferred units/stock.  </font></div><div><a name="s2DEAE21ECAE3795737CD28AA7742E3AA"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the 2014 Plan). In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure, Inc. common stock. On </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">October 6, 2015, the Board of Directors adopted the Exicure, Inc. 2015 Equity Incentive Plan (the 2015 Plan), subject to approval by the Company&#8217;s stockholders. Such stockholders approval was received on October 13, 2015. The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate number of shares of common stock available for awards granted under the 2015 Plan is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9,806,006</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As of the first day of each calendar year beginning on or after January 1, 2017, the number of shares available for all awards under the 2015 Plan, other than incentive stock options, will automatically increase by </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the number of shares that are issued and outstanding as of that date, unless the compensation committee approves an increase of a lesser percentage. The aggregate number of common stock options available for grant under the 2015 Plan was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,318,400</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The common stock options are contingent on the participants&#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial stock option grant to an employee, director or consultant vests </font><font style="font-family:inherit;font-size:10pt;color:#000000;">25%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months. Subsequent stock option grants vest 1/48th monthly until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months. The term of common stock option grants is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">ten</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;years unless terminated earlier as described above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at December 31, 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,630</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.6 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions. In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:58%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 2.24%; weighted avg. 1.58%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59% to 2.08%; weighted avg. 1.73%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.2% to 83.6%; weighted avg. 79.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.9% to 85.4%; weighted avg. 82.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2016 and 2015 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br>weighted avg. $0.69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br>weighted avg. $0.69</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of its common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the years ended December 31, 2016 and 2015 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.90</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.53</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 3, 2014, the Board took action by way of unanimous written consent to modify the strike price on all outstanding common unit options to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.32</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;(the Modification). The Board determined that for all periods wherein common unit option had been granted, the fair value of the Company&#8217;s common units was equal to or less than </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.32</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per common unit. No other terms of the repriced common unit options were modified and these repriced common unit options continued to vest according to their original vesting schedules and retained their original expiration dates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All outstanding common unit options were revalued as of October 3, 2014 (the Modification Date) based on valuation assumptions reflecting current facts and circumstances then existing. The Modification affected grants to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">twenty</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;participants comprising all current employees and board members and to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">seven</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;non-employee advisors. For all common unit options, the Company calculated the incremental fair value attributable to the Modification by calculating the fair value of all outstanding awards immediately before and immediately after the Modification under the valuation assumptions existing as of the Modification Date. For all vested options, the incremental fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;calculated thereby was recognized as expense immediately. For all unvested options, the incremental fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$90</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as calculated thereby will be recognized as expense over the remaining service period of each awardee.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:37%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,954,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,941,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(166,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200,625</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382,321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,956,455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,025,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the years ended December 31, 2016 and 2015 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$63</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$36</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div><div><a name="s85B849EC52A781E6761528AA7459171C"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pretax loss before income taxes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16,941</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,151</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2016 and 2015, respectively, which consists entirely of losses in the U.S. and resulted in no provision for income tax expense during the years then ended.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax expense at statutory rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss prior to C corporation conversion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity classification change</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s effective income tax rate for the years ended December 31, 2016 and 2015 is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of the Company&#8217;s net deferred tax assets are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Net Operating Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Fixed Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Accrued Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Equity-Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Deferred Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Taxes, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has recorded a full valuation allowance against its deferred tax assets at December 31, 2016 and 2015.  This determination is based on significant negative evidence, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Cumulative losses:</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The Company has been in a significant cumulative loss position since its inception in 2011. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Projected realization of net operating loss carry forward amounts:</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;&#32;Projections of future pre-tax book loss and taxable losses based on the Company&#8217;s recent actual performance and current industry data indicate it is more likely than not that the benefits will not be recognized.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2016, the Company had a federal net operating loss carryforward of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,727</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which will begin to expire in 2035.  The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,727</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of state net operating loss carryforwards which will begin to expire in 2027. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December&#160;31, 2016 and 2015, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;unrecognized tax benefits. The Company&#8217;s estimate of the potential outcome of any uncertain tax position is subject to management&#8217;s assessment of relevant risks, facts and circumstances existing at that time. The Company evaluates uncertain tax positions to determine if it is more-likely-than-not that they would be sustained upon examination. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to taxation in the U.S. and various state jurisdictions. The Company remains subject to examination by U.S. federal and state tax authorities for the years 2013 through 2016. There are no pending examinations in any jurisdiction.  </font></div><div><a name="s6423C689B1F1BFAE438828AA90EDBE48"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s5DE27D198883E47BC76528AA910F397B"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs&#8212;unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs&#8212;other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs&#8212;unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the preferred stock warrant liability was determined using the Black-Scholes option-pricing model. The fair value of the preferred stock warrant is based significantly on the fair value of the Series C preferred stock, which is developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.26%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">62.99%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;expected dividends.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the preferred stock warrant liability at December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:79%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of expected volatility at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$12</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of fair value of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Series C preferred stock at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$26</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the year ended December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the reverse merger (see Note 12), the warrants were terminated under the terms of the warrant agreement immediately prior to the completion of the reverse merger and the preferred stock warrant liability will be reduced to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">zero</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div><a name="s0A116A09FB9C15005BE728AA9141DB48"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;through February 2021, and includes a renewal option and an early termination option at the end of February 2018. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016. Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$52</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of December 31, 2016 and 2015, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense allocated to AuraSense, LLC (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Note 11, Related-Party Transactions, for more information.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of December 31, 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (NU) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product. In August 2015, the Company entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology the Company jointly owns with NU (the &#8220;February 2016 license agreement&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). The Company&#8217;s rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;). As of December 31, 2016, the Company has paid to NU an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,534</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in consideration of each of the obligations described above. At December 31, 2016, the accrued Northwestern License Agreements fee was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which was paid in January 2017.</font></div><div><a name="sCF10E21C2F38D1C5E40428AA782DE174"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC. When scientists employed by the Company perform work on research grants awarded to AuraSense, LLC, the hours worked are accumulated on timesheets and the associated salary cost is billed to AuraSense, LLC on a quarterly basis. The Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC. Through December 31, 2015, these shared expenses were allocated between the Company and AuraSense, LLC on a percentage basis under the terms of an agreement between the companies. The value of these shared expenses was also included in the quarterly billing between the Company and AuraSense, LLC. Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">arrangement. Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC. The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$57</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at December 31, 2016 and 2015, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following presents amounts billed to AuraSense, LLC and recognized in the accompanying statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shared costs with AuraSense, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of the Company paid by AuraSense, LLC, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$100</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in each of the years ended December 31, 2016 and 2015 in connection with these consulting services and these amounts are recognized as an expense in the accompanying statement of operations.</font></div><div><a name="s84C207A3800CDF5F6CB828AA919458DD"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Subsequent Events</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the Merger Agreement, Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation (&#8220;Max-1&#8221;), merged with and into Exicure, with Exicure remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 Acquisition Corporation (the &#8220;Merger&#8221;). The Merger was effective as of September 26, 2017 (the &#8220;Effective Time&#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of Max-1 Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure&#8217;s common and preferred stock (other than shares of Exicure&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Common Stock, and each share of Exicure&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Common Stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Common Stock were issued to the holders of Exicure&#8217;s capital stock. In addition, pursuant to the Merger Agreement options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,419,740</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure&#8217;s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 Common Stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, Max-1 Corporation changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger&#8221;, whereby Exicure is considered the accounting acquirer in the Merger. Exicure was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i) legacy Exicure shareholders own approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">94%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii) legacy Exicure directors will hold all </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;board seats of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(formerly AuraSense Therapeutics, LLC)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the combined company, and (iii) legacy Exicure management will hold all key positions in management of the combined company. The transaction will be accounted for as an asset acquisition rather than a business combination because as of the acquisition date, Max-1 does not meet the definition of a business as defined by U.S. GAAP. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Private placement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the Effective Time of the Merger, Max-1 (now renamed Exicure, Inc.) sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Offering Price&#8221;). The Company may hold one or more subsequent closings at any time prior to October 31, 2017, unless otherwise extended, to sell the remaining shares in the private placement offering. The Company may also sell an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock at the Offering Price to cover over-subscriptions in the event the private placement offering is oversubscribed. The private placement offering is referred to herein as the Offering. The Company granted to the investors in the Offering registration rights requiring the Company to register those shares of common stock for public resale. The then existing stockholders of Exicure who agreed to become parties to the registration rights agreement also became entitled to such registration rights. The initial closing of the Offering was on September 26, 2017. The aggregate gross proceeds from the initial closing of the Offering were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,302</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;(before deducting placement agent fees and expenses of the initial closing of the Offering, which are estimated at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,900</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the initial closing of the Offering, the Company issued warrants to the placement agents to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">163,174</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of common stock. The warrants expire on March 27, 2021 and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div><hr style="page-break-after:always"><div><a name="sEA8045729F47CADB2FD328AA9209DA2E"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled revenue receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from related party (Note 12)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net (Note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:100px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt (Note 5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">509</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities (Note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of deferred revenue (Note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,276</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net (Note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,670</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrant liability (Note 10)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability (Note 10)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion (Note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity (Note 6):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-redeemable preferred stock</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C: $0.00001 par value per share; no shares authorized, issued, and outstanding, September 30, 2017; 16,100,000 shares authorized; 11,239,359 shares issued and outstanding, December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-2: $0.00001 par value per share; no shares authorized, issued, and outstanding, September 30, 2017; 1,403,984 shares authorized, issued and outstanding, December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B-1: $0.00001 par value per share; no shares authorized, issued, and outstanding, September 30, 2017; 2,451,560 shares authorized, issued and outstanding, December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A: $0.00001 par value per share; no shares authorized, issued, and outstanding, September 30, 2017; 11,381,640 shares authorized, issued and outstanding, December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 35,513,987 issued and outstanding, September 30, 2017; 30,782,380 shares authorized, 131,644 issued and outstanding, December 31, 2016 </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,219</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,682</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,448</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Unaudited Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-27</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s8B42E0717343E278B0BA28AA923A3378"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,624</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,502</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,413</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,279</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,329</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,806</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Unaudited Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-28</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s912A929CD6028F6A5C7428AA7463E380"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except shares)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="47"></td></tr><tr><td style="width:13%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Non-Redeemable Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series B-2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series B-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional Paid-in- Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at<br>December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">11,239,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">33,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,403,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,451,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">11,381,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">131,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(17,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(22,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58,440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Share conversion in connection with the Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,239,359</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(33,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,403,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,451,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,381,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(135</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28,556,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">42,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,767,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">35,513,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">43,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(31,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">11,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Unaudited Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-29</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s0F8FE878DFC9EF3B4DC728AA928EB9E0"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of long-term debt issuance costs and fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled revenue receivable and accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,361</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(359</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(726</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from common stock offering</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from preferred stock offering</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from long-term borrowing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of common stock options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of long-term debt fees and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of common stock financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of preferred stock financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents - beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issuance costs (accounts payable and accrued expenses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs (accounts payable)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Accompanying Notes to Unaudited Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-30</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="se6ccc944233e4f3bab2b3e3a8c3e6467"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div><div><a name="s53572EC3B4F54FB1B58628AA76937763"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure, Inc. (&#8220;Parent&#8221;) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. We believe the design of the Company&#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Throughout these unaudited consolidated financial statements, the terms &#8220;the Company&#8221; and &#8220;Exicure&#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the merger agreement,&#160;Max-1&#160;Acquisition Sub, Inc., a wholly-owned subsidiary of&#160;Max-1&#160;Acquisition Corporation&#160;(&#8220;Max-1&#8221;),&#160;merged with and into Exicure, Inc. (formerly AuraSense Therapeutics, LLC), a privately-held Delaware corporation referred to herein as Exicure OpCo., with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of&#160;Max-1&#160;Acquisition Corporation (the &#8220;Merger&#8221;). The Merger was effective as of September 26, 2017 (the &#8220;Effective Time&#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of&#160;Max-1&#160;Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of&#160;Max-1&#160;common stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware,&#160;Max-1 changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger,&#8221; whereby Exicure OpCo is considered the accounting acquirer in the Merger. Exicure OpCo was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i)&#160;legacy Exicure OpCo shareholders own approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">94%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii)&#160;legacy Exicure OpCo directors will hold all six board seats of the combined company, and (iii)&#160;legacy Exicure OpCo management will hold all positions in management of the combined company. The transaction is accounted for as an asset acquisition rather than a business combination because as of the acquisition date,&#160;Max-1&#160;does not meet the definition of a business as defined by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).  Consequently, the assets, liabilities and operations that are reflected in Exicure&#8217;s historical financial statements prior to the Merger will be those of&#160;Exicure OpCo, and the consolidated financial statements after completion of the Merger will include the assets, liabilities and results of operations of Exicure OpCo up to the day prior to the closing of the Merger and the assets, liabilities and results of operations of the combined company from and after the closing date of the Merger.  The assets and liabilities of Max-1 included in the accompanying consolidated financial statements are recorded at the historical cost basis of&#160;Max-1.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In these unaudited consolidated financial statements, unless otherwise indicated, all share and per share figures are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capitalization Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date.  On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement.  Pursuant to this agreement AuraSense, LLC received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class A Units of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$143</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, scientific equipment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$309</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$317</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for accrued legal expenses related to patent protection. The net book value of Parent&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License Agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company.  Under the terms of the License Agreement and the Partial Assignment of License Agreement, Northwestern University received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">113,816</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;units. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Unaudited Consolidated Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively. No preferred stock was provided in consideration for fractional membership units.  Each outstanding option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;common unit of AuraSense Therapeutics, LLC was converted into an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;share of common stock of Exicure OpCo. In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,837</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was reclassified to Additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Refer to Note 6, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">for more information on capital stock transactions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been presented in conformity with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017, the Company has generated an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50,378</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">current operating plans, it believes that existing working capital at September 30, 2017 when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11,211</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the sale of common stock (see Note 13, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">), but excluding any potential proceeds from option exercises, is sufficient to fund its current operating plans into 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unaudited interim financial information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying interim consolidated balance sheet as of September 30, 2017, the interim consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, the interim consolidated statement of changes in stockholders&#8217; equity for the nine months ended September 30, 2017, and the interim consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016, are unaudited. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of September 30, 2017, the results of its operations for the three and nine months ended September 30, 2017 and 2016, and the results of its cash flows for the nine months ended September 30, 2017 and 2016. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2017 and 2016 are unaudited. The results for the three and nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, or any other interim periods, or any future year or period.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates. </font></div><div><a name="s2D80B69FBC3F5FC5EBD728AA92E1E3BE"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts receivable and unbilled revenue receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&#8220;Purdue&#8221;) and, in 2016, grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.  Management </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">believes that the Company&#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of credit risk and other risks and uncertainties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22,936</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Liquidity Risk</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">seven</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;impairment losses were recorded from inception in December 2011 through September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common stock warrant liability</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet.  Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has entered into certain grant contracts containing milestone payments.  The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured.  If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract.  For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, the Company was not participating in any grant research activities involving milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments and geographic information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred rent</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease and is presented in &#8220;Other noncurrent assets&#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company established a full valuation allowance against its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div><a name="s305B856C201CF6C9D19128AA93022307"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue and referred to herein as the &#8220;Purdue Collaboration.&#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In addition, the Company is eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$776,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;on future net sales of such commercialized therapeutic </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&#160;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverables (2), (4), (5), and (6) do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverables (1) and (3) as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverables (7) and (8) are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;is allocated to deliverables (7) and (8). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">14.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;months.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the three months ended September 30, 2017, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,497</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which included </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$428</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the nine months ended September 30, 2017, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which included </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,417</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  As of September 30, 2017 and December 31, 2016, deferred revenue relating to the Purdue Collaboration was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,103</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$9,310</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,103</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8,276</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, is classified as current portion of deferred revenue in the accompanying balance sheet.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-38</font></div></div><hr style="page-break-after:always"><div><a name="s3C8E7BB330D68FD0948228AA933540EF"></a></div><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Supplemental Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,835</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$70</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$46</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the three months ended September 30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$159</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$132</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for the nine months ended September 30, 2017 and 2016, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Northwestern University License Agreements fee (Note 11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sF346A6B812D395769BBF28AA79574DCE"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Debt</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2016, the Company closed a </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;loan facility, with an initial advance against this loan facility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, with Hercules Technology Growth Capital (&#8220;Hercules&#8221;). The loan bears a floating interest rate equal to the greater of either (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;or (ii) the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;plus the United States prime rate minus </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3.50%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. &#160; Total proceeds net of fees and issuance costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,839</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Fees and issuance costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$161</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, as well as fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$231</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on our balance sheet and will be amortized to interest expense through the maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;using the effective interest method.&#160; Interest amounts were payable monthly beginning on March 1, 2016 through the maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date.  In 2016, the Company met certain terms in the loan agreement so that principal amounts became payable monthly beginning on July 1, 2017.  The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&#160; Additionally, HTGC shall have the right to participate in a future financing of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;under the same terms and conditions and pricing afforded to other participants in that future financing.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the February 2016 HTGC loan, HTGC also had the right to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">80,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Series C preferred stock at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and recorded as a reduction in the carrying amount of long-term debt on our balance sheet.  This discount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;will be amortized to interest expense through the loan maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;using the effective interest </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">method.&#160; The Company estimated the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and recorded any changes in fair value to other income (expense), net on our statement of operations. See Note 10, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information on the fair value of the preferred stock warrant liability.  The warrant agreement to purchase shares of preferred stock was terminated on September 26, 2017 in connection with the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At September 30, 2017 and December 31, 2016, the carrying value of long-term debt is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,221</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,667</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At September 30, 2017, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$158</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$153</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;during the three months ended September 30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$470</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$327</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;during the nine months ended September 30, 2017 and 2016, respectively.</font></div><div><a name="s3E98972596E1779FCE0D28AA75048C58"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, in connection with the Merger, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of&#160;Max-1&#160;common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">200,000,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;authorized and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">35,513,987</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The holders of shares of the Company&#8217;s common stock are entitled to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&#160;non-assessable.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September, 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of preferred stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;authorized and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Private Placement Offering</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, following the Effective Time of the Merger,&#160;the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering (the &#8220;Offering&#8221;) for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Offering Price&#8221;).  The aggregate net proceeds from the initial closing of the Offering (after deducting placement agent fees and expenses of the initial offering of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,037</font><font style="font-family:inherit;font-size:10pt;color:#000000;">) were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$17,235</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Warrants to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">163,174</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock were issued to the placement agents.  The warrants expire on March 27, 2021 and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share.  The warrants to purchase common stock are classified as a liability and presented as a dividend that offsets the gross proceeds of the Offering within the accompanying consolidated statement of equity.  The common stock warrant liability will be remeasured each period at fair value.  See Note 10, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for more information on the common stock warrant liability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As discussed in Note 13, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">the Company held subsequent closings on October 27, 2017 and November 2, 2017 (the &#8220;Subsequent Closings&#8221;) and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock in the private placement offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to certain customary exceptions, investors in the Offering have anti-dilution protection with respect to the shares of common stock sold in the Offering such that if within eighteen (18)&#160;months after the initial closing of the Offering the Company issues certain additional shares of common stock or common stock equivalents for a consideration per share less than the Offering Price (the &#8220;Lower Price&#8221;), each such investor will be entitled to receive from the Company additional shares of common stock in an amount such that, when added to the number of shares of common stock initially purchased by such investor in the Offering and still held of record and beneficially owned by such investor at the time of the dilutive issuance (the &#8220;Held Shares&#8221;), will equal the number of shares of common stock that such investor&#8217;s aggregate purchase price for the Held Shares would have purchased at the Lower Price. Either (i)&#160;holders of a majority of the then Held Shares or (ii)&#160;a representative of the holders of the then Held Shares, which representative shall be appointed by the three investors who then hold the largest number of Held Shares, may waive the anti-dilution rights of all Offering investors with respect to a particular issuance by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This price-based anti-dilution protection will automatically terminate upon our receipt of gross proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$40,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;or more in one or more related closings in a bona fide transaction in which we issue shares of common stock or certain common stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Offering was exempt from registration under Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Offering was sold to &#8220;accredited investors,&#8221; as defined in Regulation D, and was conducted on a &#8220;reasonable best efforts&#8221; basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Registration Rights</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the Offering, the Company entered into a Registration Rights Agreement, pursuant to which the Company has agreed that promptly, but no later than 60 calendar days from the final closing of the Offering, the Company will file a registration statement with the SEC, or the Registration Statement.  Each </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Investor in the Subsequent Closing also entered into the same registration rights agreement signed by investors in the initial closing of the Offering, which requires that the Company file a &#8220;resale&#8221; registration statement with the SEC covering the shares of common stock and warrants issued in the Offering, certain other shares of common stock issued in connection with the Company&#8217;s recently closed reverse merger, and shares held by the Company&#8217;s&#160;pre-merger stockholders, within 60 calendar days from the final closing of the Offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Capitalization Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All share and per share figures herein are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, Exicure OpCo converted from a limited liability company into a C corporation.  In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively.  Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure OpCo, resulting in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">46</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;less aggregate shares of outstanding preferred stock of Exicure OpCo as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;share of common stock of Exicure OpCo.   </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class A Units/Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement.  In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class A units.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per unit or an aggregate value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,217</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&#8217;s net book value. The net book value of AuraSense, LLC&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class A units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,640</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure OpCo Series A preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class A units/Series A preferred stock were senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class B Units/Series B Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Class B units/Series B preferred stock were divided into two tranches and have been issued in two series: Class B-1/Series B-1 and Class B-2/Series B-2.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-1/Series B-1</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,571</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B-1 units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,432</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;including a receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:inherit;font-size:10pt;color:#000000;">225,677</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$61</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-2/Series B-2</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On June 27, 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,995</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class B-2 units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.62</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,676</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and proceeds net of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$35</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in financing costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,571</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class B-1 units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,995</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class B-2 units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,560</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,984</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure OpCo Series B-1 and Series B-2 preferred stock, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class B units/Series B preferred stock were senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class C Units/Series C Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 13, 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,532,112</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,596</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$117</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 6, 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,541,168</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;of its Class C units at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per unit.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,073,280</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Class C units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,073,226</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure OpCo Series C preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,016,134</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15,048</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$69</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">149,999</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class C units/Series C preferred stock were senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Exicure OpCo Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders were entitled to receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;times the aggregate cash contribution of all holders of Class C preferred units/stock. </font></div><div><a name="sE2DA750B6353CFDE760128AA93B7576F"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, the Board adopted and Exicure&#8217;s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which is expected to become effective on or about November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,842,525</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock, which includes </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,158,708</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,683,817</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) and were assumed in the Merger. Awards that may be awarded under the 2017 Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards.  The 2017 Plan also provides that the number of shares reserved for issuance thereunder will be increased annually on the first day of each year beginning in 2020 by the least of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,600,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares, five percent (</font><font style="font-family:inherit;font-size:10pt;color:#000000;">5%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">)&#160;of the shares of Exicure common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares as determined by the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Company&#8217;s compensation committee. No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan.  The aggregate number of common stock options available for grant under the 2017 Plan was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,158,708</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 6, 2015, the Exicure OpCo board of directors adopted the 2015 Plan, subject to approval by the Company&#8217;s stockholders.  Such stockholders approval was received on October 13, 2015.  The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.  Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the &#8220;2014 Plan&#8221;).  In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure OpCo common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The common stock options are contingent on the participants&#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason.  The initial stock option grant to an employee, director or consultant vests </font><font style="font-family:inherit;font-size:10pt;color:#000000;">25%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48 months</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Subsequent stock option grants vest 1/48th monthly until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48 months</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  The term of common stock option grants is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">ten</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;years unless terminated earlier as described above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at September 30, 2017 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,352</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.5 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:61%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 6.9 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 1.41%; weighted avg. 1.26%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.9% to 82.4%; weighted avg. 80.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2017 and 2016 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of Exicure OpCo&#8217;s common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid). At September 30, 2017, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is the per share price paid by outside investors in the Offering on September 26, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.92</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.53</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:39%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657,843</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$202</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-45</font></div></div><hr style="page-break-after:always"><div><a name="sE2AE76485563CB898DC428AA93DBF2EF"></a></div><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company incurred a pretax loss in each of the three and nine months ended September 30, 2017 and 2016, which consists entirely of loss in the U.S. and resulted in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;provision for income tax expense during the periods then ended. The effective tax rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in each of the three and nine months ended September 30, 2017 and 2016 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div><div><a name="s22DCB580FA856665A9A728AA7B483435"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:75%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sB4AE801B26CD74CD41BE28AA9431B3A1"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s preferred stock warrant liability and common stock warrant liability are classified within Level 3 of the fair value hierarchy.  The fair value of the preferred stock warrant liability and common stock warrant liability was determined using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the preferred stock warrant was based significantly on the fair value of the Series C preferred stock, which was developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.26%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">62.99%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;expected dividends.  In connection with the Merger, the warrants to purchase preferred stock were terminated and therefore the related liability was reduced to zero.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the common stock warrant is based significantly on the fair value of the Company&#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.44%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">78.71%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;expected dividends.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:79%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of expected volatility at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;change in the estimate of fair value of the common stock at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$34</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the nine months ended September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s117056D981B07920C65B28AA94500E71"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$52</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;as of September 30, 2017 and December 31, 2016, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of September 30, 2017 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, we obtained exclusive license as to NU&#8217;s rights in certain SNA technology we jointly own with NU (the &#8220;February 2016 license agreement&#8221;). Our license to NU&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of September 30, 2017, the Company has paid to NU an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,247</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in consideration of each of the obligations described above. </font></div><div><a name="sF33AA5BD22445E5AE3C328AA9482F596"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except unit, share, per unit, and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$3</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;at September 30, 2017 and December 31, 2016, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company or (of the Company paid by AuraSense, LLC), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$75</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in each of the nine months ended September 30, 2016 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.</font></div><div><a name="s0c5a6b5f3b554cb786ac8e2e70fbe34d"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Subsequent Events</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Private placement - subsequent closings</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 27, 2017 and November 2, 2017, Exicure entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with several accredited investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to issue and sell a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of the Company&#8217;s common stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Shares&#8221;) resulting in approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11,211</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company. These shares were issued in Subsequent Closings of the Offering for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock (the &#8220;Maximum Amount&#8221;) at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Sale Price&#8221;). The Company and Katalyst Securities LLC, a U.S. registered broker-dealer (together with its sub-agents, the &#8220;Placement Agents&#8221;) may agree to extend the period for additional closings up to November 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 14, 2017, the Company has sold a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of common stock for a total of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$31,513</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in connection with all closings of the Offering (before deducting placement agent fees and expenses which are estimated at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). Placement Agents have received an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,968</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;in cash placement fees and will receive warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">413,320</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock (the &#8220;Warrants&#8221;) in connection with all closings of the Offering as of November 14, 2017. The Warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;per share and have been issued on the same terms in all prior closings of the Offering. The Placement Agents will also receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">50,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock in connection with all closings of the Offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-50</font></div></div><hr style="page-break-after:always"><div><a name="sF2938A9BDE984EC3243A28AA94A3C0AB"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="image49.jpg" alt="image49.jpg" style="height:85px;width:357px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s0F054F85AFCA9FEFDE0828AA94D620F2"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INFORMATION NOT REQUIRED IN THE PROSPECTUS </font></div><div><a name="s2B7C5B3BDA02E215840228AA94F7BB54"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13. Other Expenses of Issuance and Distribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth the estimated fees and expenses payable by us in connection with the offering of the securities being registered.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEC registration fee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$14,833.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting fees and expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees and expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Printing and miscellaneous expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">To be provided in an amendment.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="sD4EFDD2945F642F68B9F28AA9529875A"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14. Indemnification of Directors and Officers.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys&#8217; fees) actually and reasonably incurred. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that to the fullest extent permitted by the DGCL, a director shall not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Our amended and restated bylaws provide that we shall indemnify and hold harmless our directors and officers to the fullest extent permitted by applicable law, except that we will not be required to indemnify or hold harmless any director or officer in connection with any proceeding initiated by such person unless the proceeding was authorized by our board of directors. Under our amended and restated bylaws, such rights shall not be exclusive of any other rights acquired by directors and officers, including by agreement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws provide that we will pay expenses to any director or officer prior to the final disposition of the proceeding, provided, however, that such advancements shall be made only upon receipt of an </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-1</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">undertaking by such director or officer to repay all amounts advanced if it should be ultimately determined that such director or officer is not entitled to indemnification under the amended and restated bylaws of or otherwise. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to the indemnification obligations required by our amended and restated certificate of incorporation and amended and restated bylaws, we have entered into indemnification agreements with each of our directors and officers. These agreements provide for the indemnification of our directors and executive officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought or threatened to be brought against them by reason of the fact that they are or were our agents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As a condition to the Merger, we also entered into a Pre-Merger Indemnity Agreement with our former officers and directors, pursuant to which we agreed to indemnify such former officers and directors for actions taken by them in their official capacities relating to the consideration, approval and consummation of the Merger and certain related transactions. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We expect to obtain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The above provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. The provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these amended and restated certificate of incorporation provisions, amended and restated bylaw provisions, indemnification agreements and the insurance are necessary to attract and retain qualified persons as directors and officers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceedings that might result in a claim for such indemnification. </font></div><div><a name="s6749A4DBBA299E5E9F0728AA954BCED1"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15. Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Set forth below is information regarding shares of common stock, warrants and stock options issued or granted by us within the past three years that were not registered under the Securities Act: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;26, 2017, October 27, 2017, and November 2, 2017, in connection with the closings of the Private Placement, we issued an aggregate of 10,504,196&#160;shares of common stock at a price of $3.00 per share to accredited investors for aggregate gross proceeds of approximately $31.5&#160;million. On September&#160;26, 2017, October 27, 2017, and November 2, 2017, in connection with the closings of the Private Placement, we issued warrants to purchase an aggregate of 163,174, 132,884, and 117,262 shares, respectively, of common stock to the Placement Agents for the Private Placement, at an exercise price of $3.00 per share. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">We and the Placement Agents may agree to extend the period for additional closings up to November 30, 2017. To the extent the period for additional closings is extended, the Company may also </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;padding-top:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#000000;">sell an additional 3,333,333 shares of common stock at the Sale Price to cover over-subscriptions in the event the Private Placement is oversubscribed.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;26, 2017, pursuant to the terms of the Merger Agreement, all of the shares of capital stock of Exicure OpCo, including restricted common stock issued by Exicure OpCo to its pre-Merger stockholders (which outstanding amounts were first converted into shares of Exicure OpCo common stock immediately prior to the Effective Time of the Merger), were converted into an aggregate of 26,666,627 shares of our common stock after adjustments due to rounding for fractional shares. In addition, we assumed all outstanding options to purchase Exicure OpCo common stock that remained outstanding under the 2015 Plan, whether vested or unvested, and converted them into options to purchase an aggregate of 3,680,997&#160;shares of our common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, the board of directors of Max-1 Acquisition Corporation approved the issuance of an aggregate of 756,960 shares of Max-1 Acquisition Corporation common stock to Ian Jacobs, Mark Tompkins, Montrose Capital Partners Limited, and a designee of a service provider for each party&#8217;s services to the Company in connection with the negotiation of the Merger Agreement. In addition, in connection with the consummation of the Merger, Max-1 Acquisition Corporation sold 73,040 shares of common stock of Max-1 Acquisition Corporation to a pre-existing stockholder pursuant to a common stock purchase agreement for a purchase price per share of $0.025 for aggregate proceeds of $1,826.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The transactions described in paragraphs A, B and C were exempt from registration under Section 4(a)(2) of the Securities Act (or Rule 506 of Regulation D) as not involving any public offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales of Unregistered Securities of Exicure OpCo </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following list sets forth information as to all securities Exicure OpCo sold from January&#160;1, 2014 through immediately prior to the consummation of the Merger, which were not registered under the Securities Act. The following description is historical and has not been adjusted to give effect to the Merger or the share conversion ratio pursuant to the Merger Agreement. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015 and January 2016, Exicure OpCo issued an aggregate of 6,738,434 shares of Series C preferred stock at a price per share of $2.30 for aggregate gross consideration of approximately $15.0&#160;million to 21 accredited investors. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure OpCo granted stock options and stock awards to employees, directors and consultants under the 2015 Plan covering an aggregate of 8,395,552 shares of common stock, at a weighted-average exercise price of $0.82 per share. Of these, options covering an aggregate of 592,946 shares were canceled without being exercised. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure OpCo sold an aggregate of 382,866 shares of common stock to employees, directors and consultants for cash consideration in the aggregate amount of $129,592.91 upon the exercise of stock options and stock awards. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The transaction described in paragraph 1 above was exempt from registration under Section 4(a)(2) of the Securities Act (or Rule 506 of Regulation D) as not involving any public offering. We also deemed the grants of stock options and stock awards described in paragraphs 2 and 3 above to be exempt from registration under the Securities Act in reliance on Rule 701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about us.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">None of the securities described in this Item 15 were sold through an underwriter and, accordingly, there were no underwriting discounts or commissions involved. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-3</font></div></div><hr style="page-break-after:always"><div><a name="s220D28ACE1596D96D8B928AA957B25B7"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16. Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The exhibit index attached hereto is incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Financial Statement Schedules </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All schedules have been omitted because the information required to be set forth in the schedules is either not applicable or is included in our financial statements or notes to those financial statements. </font></div><div><a name="sFCCD38F48845B9AF213A28AA959CE742"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 17. Undertakings.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The undersigned registrant hereby undertakes:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to include any prospectus required by Section 10(a)(3) of the Securities Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">bona fide</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;offering thereof.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">That, for the purpose of determining liability under the Securities Act to any purchaser:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each prospectus filed pursuant to Rule 424(b) as part of the registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Provided</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">however</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;padding-top:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#000000;">prior to such date of first use.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-5</font></div></div><hr style="page-break-after:always"><div><a name="s6514CD48D1E899B74F6928AA95F2A9DA"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.58119658119658%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">EXHIBIT</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">EXHIBIT&#160;DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1(2)&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex21.htm"><font style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger and Reorganization, dated September 26, 2017, by and among Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Exicure OpCo, a Delaware corporation.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex31.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Merger relating to the merger of Max-1 Acquisition Sub., Inc. with and into Exicure OpCo, filed with the Secretary of State of the State of Delaware on September 26, 2017.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex32.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex33.htm"><font style="font-family:inherit;font-size:10pt;">Form of Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex34.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws, as currently in effect.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Shares of Common Stock issued to Placement Agent.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex42.htm"><font style="font-family:inherit;font-size:10pt;">Form of Registration Rights Agreement by and among the Company and the persons named therein.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicures-1xexhibit51.htm"><font style="font-family:inherit;font-size:10pt;">Opinion of Sidley Austin LLP.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex101.htm"><font style="font-family:inherit;font-size:10pt;">2015 Equity Incentive Plan and forms of awards thereunder, assumed in the Merger.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex102.htm"><font style="font-family:inherit;font-size:10pt;">2017 Equity Incentive Plan and forms of award agreements thereunder.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex103.htm"><font style="font-family:inherit;font-size:10pt;">2017 Employee Stock Purchase Plan.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex104.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex105.htm"><font style="font-family:inherit;font-size:10pt;">Form of Subscription Agreement by and between the Company and each investor in the initial closing of the Private Placement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex106.htm"><font style="font-family:inherit;font-size:10pt;">Form of Amended and Restated Board Member Service Agreement by and between Exicure OpCo and each of its non-executive directors.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex107.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement dated as of February&#160;2, 2016 by and between Exicure OpCo and David A. Giljohann, Ph.D.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex108.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Employment Agreement dated as of February&#160;2, 2016 by and between Exicure OpCo and David&#160;S. Snyder.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex109.htm"><font style="font-family:inherit;font-size:10pt;">Employment Offer Letter dated as of September&#160;16, 2015 by and between Exicure OpCo and Ekambar Kandimalla, Ph.D.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1010.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment to Offer Letter dated as of January&#160;8, 2016 by and between Exicure OpCo and Ekambar Kandimalla, Ph.D.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1011.htm"><font style="font-family:inherit;font-size:10pt;">Consulting Agreement dated as of October&#160;1, 2011 by and between AuraSense Therapeutics, LLC and Chad A. Mirkin, Ph.D.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1012.htm"><font style="font-family:inherit;font-size:10pt;">Lease Agreement dated as of February&#160;13, 2012 by and between AuraSense Therapeutics, LLC and FC Skokie SPE, LLC.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1013.htm"><font style="font-family:inherit;font-size:10pt;">Letter dated as of March&#160;12, 2012 regarding the Lease Agreement by and between AuraSense Therapeutics, LLC and FC Skokie SPE, LLC.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1014.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment to Lease dated as of March&#160;31, 2014 by and between AuraSense Therapeutics, LLC and FC Skokie PQ, LLC, as successor in interest to FC Skokie SPE, LLC.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.58119658119658%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1015.htm"><font style="font-family:inherit;font-size:10pt;">Second Amendment to Lease dated as of May&#160;26, 2016 by and between Exicure OpCo and FC Skokie PQ, LLC, as successor in interest to FC Skokie SPE, LLC.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1016.htm"><font style="font-family:inherit;font-size:10pt;">Loan and Security Agreement dated as of February&#160;17, 2016 by and between Exicure OpCo and Hercules.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1017.htm"><font style="font-family:inherit;font-size:10pt;">Amendment No.&#160;1 to Loan and Security Agreement dated as of October&#160;10, 2016 by and between Exicure OpCo and Hercules.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18(2)+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1018.htm"><font style="font-family:inherit;font-size:10pt;">Form of Pre-Merger Indemnity Agreement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000121390017006605/f8k061517ex10i_max1acq.htm"><font style="font-family:inherit;font-size:10pt;">Form of Common Stock Purchase Agreement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20(2)*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1020x11717.htm"><font style="font-family:inherit;font-size:10pt;">Restated License Agreement between Exicure OpCo and Northwestern University dated as of August 15, 2015.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21(2)*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1021x11717.htm"><font style="font-family:inherit;font-size:10pt;">License Agreement between Exicure OpCo and Northwestern University dated as of February 10, 2016 and effective as of May 27, 2014.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22(2)*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1022x11717.htm"><font style="font-family:inherit;font-size:10pt;">License Agreement between Exicure OpCo and Northwestern University dated as of June 17, 2016.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23(2)*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1023x11717.htm"><font style="font-family:inherit;font-size:10pt;">Amendment One to the Amended Restated License Agreement between Exicure OpCo and Northwestern University dated as of September 27, 2016.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24(2)*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1024x11717.htm"><font style="font-family:inherit;font-size:10pt;">Research Collaboration, Option and License Agreement between Exicure OpCo and Purdue Pharma L.P. dated as of December 2, 2016.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1025x11717.htm"><font style="font-family:inherit;font-size:10pt;">Side Agreement to Northwestern Agreements by and among Exicure OpCo, Northwestern University and Purdue Pharma L.P. dated as of October 11, 2016.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517331329/d487646dex101.htm"><font style="font-family:inherit;font-size:10pt;">Form of Subscription Agreement by and between the Company and each investor in connection with the subsequent closings of the Private Placement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517331329/d487646dex102.htm"><font style="font-family:inherit;font-size:10pt;">Form of Purchaser Rights Letter to be delivered by the Company to each investor in the initial closing of the Private Placement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.1(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicures-1xexhibit161.htm"><font style="font-family:inherit;font-size:10pt;">Letter from Raich Ende Malter&#160;&amp; Co. LLP as to the change in certifying accountant, dated as of November 28, 2017. </font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicures-1xexhibit211.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of Exicure, Inc.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicures-1xexhibit231.htm"><font style="font-family:inherit;font-size:10pt;">Consent of KPMG LLP, independent registered public accounting firm.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.2(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exicures-1xexhibit51.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Sidley Austin LLP (included in Exhibit 5.1). </font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.1(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s83CD3699ED3EFF30829728AA95CF41F3"><font style="font-family:inherit;font-size:10pt;">Power of Attorney (included on the signature page hereto).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;  Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(b)(2) of Regulation&#160;S-K.&#160;We hereby undertake to furnish supplementally a copy of any of the omitted schedules and exhibits to the SEC on a confidential basis upon request.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+  Indicates&#160;a&#160;management&#160;contract&#160;or&#160;compensatory&#160;plan.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*  </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment, and omitted portions have been filed separately with the SEC</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Incorporated by reference to the indicated exhibit in Max-1 Acquisition Corporation&#8217;s Current Report on Form 8-K filed on June 19, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on October 2, 2017, as amended by our Current Report on Form 8-K/A filed on November 7, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) Incorporated by reference to the indicated exhibit in our Current Report on Form 8-K filed on November 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4) Filed herewith. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-8</font></div></div><hr style="page-break-after:always"><div><a name="s83CD3699ED3EFF30829728AA95CF41F3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">SIGNAT</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">URES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Skokie, State of Illinois, on November 28, 2017.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.58119658119658%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:59%;"></td><td style="width:5%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/David A. Giljohann</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">principal executive officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">principal financial officer and principal accounting officer</font><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We, the undersigned directors and officers of Exicure, Inc. (the Company), hereby severally constitute and appoint David A. Giljohann and David S. Snyder, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-1 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney. This Power of Attorney does not revoke any power of attorney previously granted by the undersigned, or any of them.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated on the date indicated:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TITLE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DATE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/David A. Giljohann</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">principal executive officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/David S. Snyder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">principal financial officer and principal accounting officer</font><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David S. Snyder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Chad A. Mirkin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director and Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chad A. Mirkin, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/C. Shad Thaxton</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">C. Shad Thaxton, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/David R. Walt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David R. Walt, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Jay R. Venkatesan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay R. Venkatesan, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Helen S. Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Helen S. Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">II-10</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exicures-1xexhibit51.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s330E7390D84166E5794DCBC6A31C4C55"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:29%;"></td><td style="width:38%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-top:16px;"><img src="exhibit51exicures1226_image1.gif" alt="exhibit51exicures1226_image1.gif" style="height:30px;width:120px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;"><br></font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">SIDLEY AUSTIN LLP</font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">1001 PAGE MILL ROAD</font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">BUILDING 1</font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">PALO ALTO, CA 94304</font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">+1 650 565 7000</font></div><div style="padding-bottom:4px;font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">+1 650 565 7100</font></div><div style="font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;"><br></font></div><div style="font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;"><br></font></div><div style="font-size:6.5pt;"><font style="font-family:Arial;font-size:6.5pt;">AMERICA  </font><font style="font-family:inherit;font-size:6.5pt;">&#8226;</font><font style="font-family:Arial;font-size:6.5pt;">&#160;&#160;ASIA PACIFIC  </font><font style="font-family:inherit;font-size:6.5pt;">&#8226;</font><font style="font-family:Arial;font-size:6.5pt;">&#160;&#160;EUROPE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 5.1</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">November 28, 2017</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exicure, Inc. </font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8045 Lamon Ave, Suite 410</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Skokie IL 60077</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;">Re:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Registration Statement on Form S-1</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ladies and Gentlemen:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We refer to the Registration Statement on Form S-1 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Registration Statement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) being filed on the date hereof by Exicure, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with the Securities and Exchange Commission (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SEC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Securities Act</font><font style="font-family:inherit;font-size:12pt;">&#8221;).&#160;The Registration Statement relates to the registration under the Securities Act of 39,714,413 shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and consists of (i) 26,666,627 shares of Common Stock that were privately issued to certain selling stockholders described in the Registration Statement on September 26, 2017 in exchange for shares of Exicure Operating Company, a Delaware corporation, which became the Company&#8217;s wholly owned subsidiary following a merger transaction (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Merger</font><font style="font-family:inherit;font-size:12pt;">&#8221;), (ii) 2,080,000 shares of Common Stock that are held by the pre-Merger stockholders of Max-1 Acquisition Corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Max-1</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Company&#8217;s predecessor, (iii) an aggregate of 10,504,196 shares of Common Stock that were issued through closings of a private placement offering on September 26, 2017, October 27, 2017, and November 2, 2017, (iv) 50,000 shares of Common Stock were issued to placement agents in connection with the private placement offering (clauses (i) through (iv) shall collectively be referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Offering Shares</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and (v) 413,320 shares of Common Stock issuable to placement agents upon exercise of Common Stock warrants (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warrants</font><font style="font-family:inherit;font-size:12pt;">&#8221;) issued in connection with the private placement offering (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warrant Shares,</font><font style="font-family:inherit;font-size:12pt;">&#8221; and, together with the Offering Shares, the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Registrable Shares</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The Registerable Shares may be offered and sold by the selling stockholders referenced in the prospectus, as amended or supplemented from time to time, which is a part of the Registration Statement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We have examined and relied upon copies of the Registration Statement, the Company&#8217;s certificate of incorporation, as amended, as in effect on the date hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Certificate of Incorporation</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Company&#8217;s amended and restated bylaws, as in effect on the date hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Bylaws</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the form of the Warrants and the resolutions adopted by the board of directors of the Company and Max-1 relating to the Registration Statement and the issuance of the Warrants and the Registrable Shares by the Company (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Resolutions</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this </font></div><div><br></div><div><div style="line-height:120%;font-size:5.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:5.5pt;"><font style="font-family:Arial;font-size:5.5pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sidley Austin (CA) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:24px;"><img src="exhibit51exicures1226_image1.gif" alt="exhibit51exicures1226_image1.gif" style="height:30px;width:121px;"></div><div style="padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exicure, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">November 28, 2017</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page 2</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">opinion letter.  We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination.  As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Based on and subject to the foregoing and the other limitations, qualifications and assumptions set forth herein, we are of the opinion that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Offering Shares are validly issued, fully paid and non-assessable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:72px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Warrant Shares will be validly issued, fully paid and non-assessable when (i) the Registration Statement, as finally amended (including any necessary post-effective amendments) has become effective under the Securities Act and (ii) certificates representing the Warrant Shares shall have been duly executed, countersigned and registered and duly delivered and paid for upon exercise of the applicable Warrants in accordance with their terms or, if the Warrant Shares being issued are to be issued in uncertificated form, the Company&#8217;s books shall reflect the issuance of such Warrant Shares to the purchasers thereof against payment of the exercise price of the applicable Warrants.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For purposes of this opinion letter, we have assumed that, at the time of the issuance, sale and delivery of each Warrant Share, the Certificate of Incorporation, the Bylaws, the Resolutions and each applicable Warrant will not have been modified or amended and will be in full force and effect, that the consideration paid for each Warrant Share will not be less than the par value thereof and that there will be a sufficient number of shares of Common Stock authorized and then available for issuance under the Certificate of Incorporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This opinion letter is limited to the General Corporation Law of the State of Delaware.  We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement and to the reference to our Firm included in or made a part of the Registration Statement.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:24px;"><img src="exhibit51exicures1226_image1.gif" alt="exhibit51exicures1226_image1.gif" style="height:30px;width:121px;"></div><div style="padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exicure, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">November 28, 2017</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Page 3</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Very truly yours,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Sidley Austin LLP</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>3
<FILENAME>exicures-1xexhibit161.htm
<DESCRIPTION>EXHIBIT 16.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBF6F5663A42B27983564CBD543170238"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 16.1 </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 28, 2017 </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 F Street NE </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549 </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ladies and Gentlemen: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have read the section under the heading &#8220;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure&#8221; included in the Registration Statement on Form S-1 of Exicure, Inc. to be filed on or about November 28, 2017 and agree with the statements contained therein as they relate to our firm. We have no basis to agree or disagree with other statements of the registrant contained therein. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Respectfully submitted, </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Raich Ende Malter </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Melville, New York</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exicures-1xexhibit211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2A561336C59DFB35FFABCBDDE651FD5F"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 21.1 </font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Subsidiaries of Exicure, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Jurisdiction of Organization:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure Operating Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exicures-1xexhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8A6D33759A3114134636CBDB5FAB10CF"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors <br>Exicure, Inc.:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the use of our report dated March 17, 2017, except as to Note 12, as to which the date is October 2, 2017, with respect to the balance sheets of Exicure, Inc. as of December 31, 2016 and 2015, and the related statements of operations, changes in members&#8217; equity and stockholders&#8217; equity, and cash flows for the two-year period ended December 31, 2016, included herein, and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:50.99206349206349%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160; </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chicago, Illinois <br>November 28, 2017</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>xcur-20171031.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:de49c79e48964e53906a0ae4c77f2ed8,x:1a9d8380844345b7b2e791b434cc56ba-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xcur="http://www.exicuretx.com/20171031" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="xcur-20171031.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassBIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassBIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassBIIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredClassBIIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-07-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-11</xbrli:startDate>
			<xbrli:endDate>2016-01-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-06-27</xbrli:startDate>
			<xbrli:endDate>2013-06-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_dei_LegalEntityAxis_xcur_NorthwesternUniversityMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">xcur:NorthwesternUniversityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-06</xbrli:startDate>
			<xbrli:endDate>2015-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_dei_LegalEntityAxis_xcur_NorthwesternUniversityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">xcur:NorthwesternUniversityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-06</xbrli:startDate>
			<xbrli:endDate>2015-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-11</xbrli:startDate>
			<xbrli:endDate>2016-01-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:SeriesCPreferredStockConvertedintoMax1CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-06-13</xbrli:startDate>
			<xbrli:endDate>2014-06-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-06-27</xbrli:startDate>
			<xbrli:endDate>2013-06-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-06-13</xbrli:startDate>
			<xbrli:endDate>2014-06-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-02</xbrli:startDate>
			<xbrli:endDate>2016-12-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec01-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec02-02_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-02</xbrli:startDate>
			<xbrli:endDate>2016-12-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_xcur_FeeTypeAxis_xcur_FeesatMaturityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="xcur:FeeTypeAxis">xcur:FeesatMaturityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb1716_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-17</xbrli:startDate>
			<xbrli:endDate>2016-02-17</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_xcur_FeeTypeAxis_xcur_FeesatIssuanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="xcur:FeeTypeAxis">xcur:FeesatIssuanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb1716_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-17</xbrli:startDate>
			<xbrli:endDate>2016-02-17</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_PreferredUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct03">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct03-03">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-03</xbrli:startDate>
			<xbrli:endDate>2014-10-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_SubsequentEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xcur:SubsequentEmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xcur:InitialEmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xcur:InitialEmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct13_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_SubsequentEmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xcur:SubsequentEmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xcur:InitialEmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-06</xbrli:startDate>
			<xbrli:endDate>2015-10-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb1716_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-17</xbrli:startDate>
			<xbrli:endDate>2016-02-17</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_SharedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:SharedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_SharedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:SharedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept26_us-gaap_CounterpartyNameAxis_xcur_PreMergerShareholdersMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:PreMergerShareholdersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:SubsidiaryOfCommonParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:SeriesCPreferredStockConvertedintoMax1CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct27-Nov2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-27</xbrli:startDate>
			<xbrli:endDate>2017-11-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2011-12-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Dec0111Sep3017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec02-02_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-02</xbrli:startDate>
			<xbrli:endDate>2016-12-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_PreferredUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:PreferredUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">xcur:ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB2PreferredMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-06-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassAUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:SeriesB1PreferredMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB1UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-09</xbrli:startDate>
			<xbrli:endDate>2015-07-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassB2UnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xcur:ClassCUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-22</xbrli:startDate>
			<xbrli:endDate>2017-09-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Sept22_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureOpCo2015EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_RangeAxis_us-gaap_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-09-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Dec12-Sep30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-12-12</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:QuarterlyFeeForIndirectCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:DirectLaborOnResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">xcur:AuraSenseLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Sep26-Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-26</xbrli:startDate>
			<xbrli:endDate>2017-11-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov14-14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-14</xbrli:startDate>
			<xbrli:endDate>2017-11-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="individual">
		<xbrli:measure>xcur:individual</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="target">
		<xbrli:measure>xcur:target</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="vote_per_share">
		<xbrli:measure>xcur:vote_per_share</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q3YTD" id="Fact-6560CED085D08F568133E4387554EEE4">false</dei:AmendmentFlag>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q3YTD" id="Fact-A682790008E0AE754434E4384664414E">2017-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q3YTD" id="Fact-5B0A37B4510C5D5401ECE4383940505C">S-1</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q3YTD" id="Fact-A3F4716E69430493864CE4380EF343B4">0001698530</dei:EntityCentralIndexKey>
	<dei:EntityFilerCategory contextRef="FD2017Q3YTD" id="Fact-26D7C287CAA04DFB1937E438297EF5D0">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q3YTD" id="Fact-85C4CAFF4BC78A64D015E437FE7ACE22">EXICURE, INC.</dei:EntityRegistrantName>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9372AA673E82AB2F5391C1B1206A841F" unitRef="usd">635000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-ED761D4EE8CBA9A8729AC1B1206AEEE0" unitRef="usd">509000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-94E472E23C7B6157F4DC3EACC4F4F2BB" unitRef="usd">2379000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-71F0E61D4371526BFB4EC1AF367D1F98" unitRef="usd">71000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0804FE4CE6EB3D72FE23C1AF368C3650" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-90530F8CA62D3CC10C0F3ED0C091965A" unitRef="usd">2160000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-B75E9C928EE6E7F8CC243ED0C09965C0" unitRef="usd">2496000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2056F6F7A50107C87B77C50B599EA207" unitRef="usd">78000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-60AAF800DE2D76006FCCC50B591AFABE" unitRef="usd">123000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-C6CBA8356793B2783E84506EA63D477D" unitRef="usd">1004000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="I2011Q4Dec12_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-23569B2028CBA27F0638C5689DB9F473" unitRef="usd">317000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2012Q1" decimals="-3" id="Fact-DDA76C7B80DC4D3B22F5C5CD14B973B1" unitRef="usd">52000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-27C23E801FCB2583ABE1C5CD6366A64E" unitRef="usd">48000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5DE86E1B844FC7E0DE35C5CD542067C0" unitRef="usd">50000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccruedRentCurrentAndNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-620C505C134DAAA1DB387928950EECDA" unitRef="usd">48000</us-gaap:AccruedRentCurrentAndNoncurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-2FA7FD110DEEA61BDCA6C58A7977BD77" unitRef="usd">437000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-35BF41F13593FC673903C58A77DE4113" unitRef="usd">617000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q3" decimals="-3" id="Fact-D90A608A1501FB54D8BE511FB5D5AADF" unitRef="usd">776000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q4" decimals="-3" id="Fact-B980F16CFC64AAF10581C1B289B22F9F" unitRef="usd">-18293000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-F4ADF2E467E0821C38CCC1B289A206E3" unitRef="usd">-17578000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q3" decimals="-3" id="Fact-C3D58F65DAA8B2795E123EBDDB944723" unitRef="usd">43219000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="I2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-7C0FAEB84315CC74F649DFB7935ED3D9" unitRef="usd">17394000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q3Jan01-Jul08" decimals="-3" id="Fact-22D8A60C00A35C65EEFDC53BF04D4FA7" unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-01F5D56C417FA3EB44B5C53BF04A206B" unitRef="usd">138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q4Jul09-Dec31" decimals="-3" id="Fact-0151401E05BF528D1540DEDEB3A17CE8" unitRef="usd">233000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1AAB88D9519AA96F70E9DEDEB0646945" unitRef="usd">233000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B76C641A84AC49E4586ADEDEF248D2D4" unitRef="usd">682000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6DE3C3FEA757DB079E70DEDEEF04C9AC" unitRef="usd">682000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3A328DA14C66AD74F946472BEE6FAB76" unitRef="usd">1104000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-98005196F94475AB0766472BEE719CD3" unitRef="usd">1104000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-33D81290DEAD4F9D3B6BDF658B69072C" unitRef="usd">370000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-108E642983813D326183DF658B6FB15E" unitRef="usd">302000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-0074DF0ADF822D60AA1DDF658B6CFCAF" unitRef="usd">68000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-991A3D780ED94CD36C385652026DB1B9" unitRef="usd">167000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-89AF3E5E68A6634E1F40565201A588E0" unitRef="usd">127000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-076FD4071B1B121C3F06565200CBE5EE" unitRef="usd">40000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4D33E8BCE130622F7CF5565222A95A18" unitRef="usd">507000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-1250D8B63D48D0FC73FC565221FA5548" unitRef="usd">388000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DB9269B5C963C20973FD5652210621E4" unitRef="usd">119000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1C705DC1005BC9D2CD06DF65A88AACEA" unitRef="usd">682000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-B98E3356B512ADD8BA1DDF65A87BBE33" unitRef="usd">522000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-0B2BE1BD427AE4F0CAB3DF65A870559F" unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-8B8F3865A37801B0B30C5651EFF0436A" unitRef="usd">362000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-4C751FBE8462E01885C05651EFF2C253" unitRef="usd">319000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-CABD4AFA208F7D045AB05651EFEE4FBB" unitRef="usd">43000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8881194A69962CDAFAB9565212B787E1" unitRef="usd">1104000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-5BB5DCB158428233D56B565211F16CE9" unitRef="usd">975000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-6D8DDCF30A0232497BEA565211130F0E" unitRef="usd">129000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4ACD1B09F5238ED03FD8DEF413A4898B" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-59CCB5FFB7F072706403494B0CFC129E" unitRef="usd">137000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-624D0090B6F7919E0AD9DEF4139B2296" unitRef="usd">193000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2C9905C2F530E5010D0E494B0CEC5C0E" unitRef="usd">150000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="0" id="Fact-7BBA91E160EB5008154AC5B45C42A2B9" unitRef="shares">6528052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-E0DC27547590BD41E1D1637748CF9EBB" unitRef="shares">3038772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-2811D78A3CDC895FB8116385D14C0334" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="0" id="Fact-3B6B861F95395EBB2DD0C59AC701E663" unitRef="shares">6222448</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-B28ED6FE3520B5B99A02637748C5A1CA" unitRef="shares">3678359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-C272BCD70E8DC1FC0F06637748CF040C" unitRef="shares">163174</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-4137227BF25585323D71C1B0089C67C7" unitRef="usd">19621000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-2538A751033879D64C35C1B008A1A2DD" unitRef="usd">20576000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q3" decimals="-3" id="Fact-7446EB4B0BD99276E13D3EA572B41EB1" unitRef="usd">25371000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C3006DE6EF71D28C8214C1AFB3F35EF0" unitRef="usd">19204000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-10996379C957B7ACAE29C1AFB3ECB7EC" unitRef="usd">20041000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-89C81104E58595D040DE3EA443EA25D3" unitRef="usd">24280000</us-gaap:AssetsCurrent>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D5FEF185716CD10A7E51DF0944E73366" unitRef="usd">107000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-92BACCB65F07FDD8170FDF0944E3CC3E" unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-A44FF87F57890E42FBD1DEF6F0E62D82" unitRef="usd">11332000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-97022B92CD1E08B372BEC1AC7E8779F3" unitRef="usd">18731000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-3" id="Fact-153670F04E1196BC1D6B495FD2E7BA23" unitRef="usd">14068000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-393B873BE1AD2D8CBF7EC1AC7E8759D0" unitRef="usd">19623000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-3" id="Fact-F0C3AFE791F9290C958B3EA22B5877DA" unitRef="usd">22936000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EE6C013C86278416E3B7DEF6DBB6B3DE" unitRef="usd">7399000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-3" id="Fact-8B055BAEED8037965CE249719AEB5961" unitRef="usd">-4663000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-76C0A79FBA1DE49F224FDEF6DBBE1324" unitRef="usd">892000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B3B454BE108D3DE156D149719AEB9FC3" unitRef="usd">3313000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="2" id="Fact-BFD3130434F030876A255645F0098D37" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-1C107C0E31667B6F7E41DF992352BFF5" unitRef="usdPerShare">2.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-B0E4AAB97FDE4BDC0B69C632BDB85129" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-F4BDAE834CD47BF147275627C4A7E748" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q4Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-388807BA27EA2B1400E7A701BA4F3683" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-27FE1BE5A9127ECAF34CC6329D76766F" unitRef="shares">163174</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-E7BCE9BE19EC588B78EE562739E0423A" unitRef="shares">163174</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q4Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="0" id="Fact-4FB43563D2878897BBADA6F2F68810C8" unitRef="shares">413320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-C90B673496326D85EF5356454969D355" unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-81BAFCF94619051EFB66DF98FEAB4514" unitRef="shares">104348</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-B605FA73C1DBD7901555C51125E1A63F" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-BB6C9458C6B3B7ED3C66C51124E5D449" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-19EBB36BD4648FAD8328C50F8967F274" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-266F903D892E8135BFE1C51127D0650C" unitRef="shares">62000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-112C51E7E423B46DD1C2C50F8CD62EB6" unitRef="shares">30782380</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-419E0F349440446A1935C51126D68E98" unitRef="shares">62000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-6D0A5C6A2F5879E99444C50F8BDE7DAA" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-C6D3EC7A7FC353797880C5112A70E3E9" unitRef="shares">166875</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-5F13CEDBDBDB0E3FAD9CC50F8ECA2767" unitRef="shares">131644</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-D87C30D278A86BA2439FC51128D48D7C" unitRef="shares">265158</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q3" decimals="INF" id="Fact-A77DFDCC7937ED38908FC50F8DD3DECC" unitRef="shares">35513987</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-C1BDCB11AC7F0BA2F478C5112C5FF9A8" unitRef="shares">166875</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-AB6E1D63A11B61DCFB45C50F90BD042F" unitRef="shares">131644</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-06210157D69EFEFE1C4FC5112B6C6297" unitRef="shares">265158</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-32AF1F1C5C7B6A46AC2EC50F8FC33A1E" unitRef="shares">35513987</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q3Sept26_us-gaap_CounterpartyNameAxis_xcur_PreMergerShareholdersMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember" decimals="INF" id="Fact-D00980852CFA892868769DB91015DF14" unitRef="shares">2080000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q3Sept26_us-gaap_CounterpartyNameAxis_xcur_PreMergerShareholdersMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember" decimals="0" id="Fact-A3E352E5552EAE2F0EBCB59D0926B3CF" unitRef="shares">2080000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-82E979CB726D3F8C23D3C1B278076F00" unitRef="usd">0</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-8BCF91A8D7D180886E2DC1B2780179B3" unitRef="usd">0</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q3" decimals="-3" id="Fact-F195BD4B7EB4AF08963A3EBF6DFE678B" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="INF" id="Fact-1D090CB7BDADDDBF5E447523382B09FD" unitRef="shares">11381611</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-AFBB9A75FA958F5151C36DB5CFA16B22" unitRef="shares">22924210</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="0" id="Fact-D9E77479A046F8D6A86C0096A2A53193" unitRef="shares">2451571</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="0" id="Fact-60BFF7B0DE542816AF0AFFB31BCBFAC8" unitRef="shares">4937818</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="INF" id="Fact-76D0FB75FE1EDB950CB603DEF14A5137" unitRef="shares">1403995</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="0" id="Fact-C34B65BCF444AAF5A07AFFB36AC264C5" unitRef="shares">2827848</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="INF" id="Fact-0296ABD81DDE7C4517635922F7202D82" unitRef="shares">6073280</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-695DD71A4E4DAFCD70FCDF96671CF3AD" unitRef="shares">7921669</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-DFCA49DF168A5539EA6758F3F342C9D8" unitRef="shares">11381640</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-BE28BCDA954B8D841F09DF9142BB2609" unitRef="shares">22924209</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-199DE2646C65ADBA1B1A59232C1F19CC" unitRef="shares">6073226</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-D9B1469E0AE3938D2E6ADF9680A8CF2D" unitRef="shares">7921662</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredMember" decimals="INF" id="Fact-714F81D2B9FD5D695F9D591F39319A2F" unitRef="shares">2451560</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-9991EC49227A8FAF1EC6DF93ED1DCD9F" unitRef="shares">4937813</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredMember" decimals="INF" id="Fact-DBCCB0E74DB7DDFC6DF9591F497AFDA0" unitRef="shares">1403984</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-3CD325094C681920A4FFDF9406959751" unitRef="shares">2827844</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-741864A34B9F98A2089B58EBB590542C" unitRef="shares">26666627</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-624DA2D57543AE1C5778C5E25D442E0C" unitRef="shares">26666627</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q1Feb1716_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="4" id="Fact-E834F515D5190FE9CE88C58EE93C9AD6" unitRef="number">0.0995</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2016Q4" decimals="-3" id="Fact-697F2CC2E3405E6F19C3C5903FC2A011" unitRef="usd">6000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q3" decimals="-3" id="Fact-14DD17C2EB51CCA6430453A7FEBB0DE0" unitRef="usd">5404000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-05E630912E570821B7A9C58EC6DCA415" unitRef="number">0.0995</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q4" decimals="-3" id="Fact-6756B2ADF5BF5E682F38C5904068A3A8" unitRef="usd">298000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q3" decimals="-3" id="Fact-82BD4A94B8AB8936AB7F53AB631C602C" unitRef="usd">164000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-E0CCD35E7623292395AFFED45F896452" unitRef="usd">134000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2015Q4YTD" decimals="-3" id="Fact-730D8D4338B6F9DA0E48DF08D934625A" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4B26D79A6A028F468BA8503E83D87649" unitRef="usd">231000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E33E035359069A091469DF08D92D1C83" unitRef="usd">231000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F203B11F89B65B6CF381503E83DC15F3" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2016Q4" decimals="-3" id="Fact-FCCDB3BC87FABCF14F77C590410A6B35" unitRef="usd">35000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q3" decimals="-3" id="Fact-7C4AC83AFFA8A0D4289A53B1D56B5316" unitRef="usd">19000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_xcur_FeeTypeAxis_xcur_FeesatIssuanceMember" decimals="-3" id="Fact-465A256490A02AAB7DB4C58F44E78AE3" unitRef="usd">161000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_xcur_FeeTypeAxis_xcur_FeesatMaturityMember" decimals="-3" id="Fact-5818AF989D56C56D3303C58F5F75DF41" unitRef="usd">231000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4" decimals="-3" id="Fact-7688BC452EF32A6AA1325B2E55D67660" unitRef="usd">9310000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q3" decimals="-3" id="Fact-9FB67425B446C5405F156D891F29EFE8" unitRef="usd">3103000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-21369B3D239E00CF3EF5C1B18D787E0D" unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3F630B2B2C1D422EFDCEC1B18D88C358" unitRef="usd">8276000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-AE7007EA741239EC5D7B3EAFE4D77036" unitRef="usd">3103000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B8EA515EEAC90BF274B5C1B1F8E48725" unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1395DDF94FE80DABBC45C1B1F8F5209A" unitRef="usd">1034000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-320C4EDC0D9304D568893EB63F4317C4" unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2015Q4" decimals="-3" id="Fact-F784CE95FB607F795793DF52B2A1B971" unitRef="usd">330000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2016Q4" decimals="-3" id="Fact-F88E7341B5EB71F9F88DDF52B29BBE68" unitRef="usd">306000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-3" id="Fact-68B152AE3DAAE0B2A8F0DF5520EEBC37" unitRef="usd">4000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-BA4285586AAB9D5CB0C0DF5520F217CB" unitRef="usd">2000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-43C8A74692A77A3F0F28DF51AD7D8F93" unitRef="usd">1749000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-8C9D78F86EECF6F1EF97DF51AD80D1B4" unitRef="usd">8107000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-AAF82DFDC25699BB26A8DF52636063BD" unitRef="usd">62000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-60341B60409B014CBE4BDF5263528578" unitRef="usd">57000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-3" id="Fact-555F11B2DED2C7BBB98FDF546767717F" unitRef="usd">187000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-3" id="Fact-90B8C45774B1D0C532E1DF5467649D70" unitRef="usd">436000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-4F93595B985B37C96E67DF5414FE64CA" unitRef="usd">195000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-A9AC51DED4010B1D3B6CDF5414FBCF70" unitRef="usd">184000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-A0AB18B7D142E236F94EDF54B30DD173" unitRef="usd">2519000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-1F9A1B55B49D4FB04C6EDF54B2FD4AB9" unitRef="usd">9088000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-E83254AD02B2C839EA84DF56DBDC6E36" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-AD44704A4F4238577449DF56DBDA6676" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="FI2015Q4" decimals="-3" id="Fact-F45E1F8A7C900F8521E7DF568F5751F8" unitRef="usd">4000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
	<us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="FI2016Q4" decimals="-3" id="Fact-293051587784A5DE7B55DF568F5C5952" unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B22265FA07E883E5A6E2DEF3E372AF40" unitRef="usd">133000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-B737E4813AC42C7A0729512130C380F6" unitRef="usd">46000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B187B2818F431F494B1949484591B8EE" unitRef="usd">132000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E9689914CF58EFB1972DDEF3E3697139" unitRef="usd">180000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-1145F928BA4D89413EC7512130C493F0" unitRef="usd">70000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DepreciationAmortizationAndAccretionNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2D18C49467F5F7A4858E494845A18231" unitRef="usd">159000</us-gaap:DepreciationAmortizationAndAccretionNet>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9A7D16BFA64F2EE2B5FCC1AF8797AED8" unitRef="usd">57000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-02C7E4B6E9075185B2B0C5DB54DAA40B" unitRef="usd">57000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9D353D7CBBD77AF0F1CCC1AF8789F15E" unitRef="usd">15000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-91FBFF02F69ECCCEFA2BC5DB354D5566" unitRef="usd">15000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-647EE5AE11E3430B15559D66685A2E0C" unitRef="usd">13000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-D8811B45B9A1B909EF6F3EA5D06345ED" unitRef="usd">13000</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-EE2DCAF8DD66AE7AF09BC52FDDC288BF" unitRef="usdPerShare">-121.63</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-850D5FE2A58F5D9E7FAC4742945609E1" unitRef="usdPerShare">-36.09</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3YTD" decimals="2" id="Fact-3D54AA27470FBF772A4D47429450653D" unitRef="usdPerShare">-103.15</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-D43B4020AB07F308D8D7C52FDDCD7B90" unitRef="usdPerShare">-74.16</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-7F9A9DDC4E37BE043E824742945379E3" unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-A0E7222E424573405CE947429458ECE7" unitRef="usdPerShare">-48.73</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="3" id="Fact-C9A3846962F9C6B3E780DF32D39000FD" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="2" id="Fact-0F37146DACBE2F2CF1E5C6917C2D9DCA" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q3QTD" decimals="2" id="Fact-53FBAF9D4EC9A0C04B04512FFA92D393" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q3YTD" decimals="2" id="Fact-49E6E07DFDC105F9E753512FFC7B4337" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="3" id="Fact-82E7DA79EABF6763741CDF32D3882BB5" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="2" id="Fact-59C45ACA015508015FECC69059696A2A" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3QTD" decimals="2" id="Fact-613D554FDCD383344AE351287A17FFB2" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3YTD" decimals="2" id="Fact-5D761551EB48BC9324E1512FFBB27E57" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-B3836BCE7F82AE90960EDF2FE457CE77" unitRef="number">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-2561DBF2D3ED63C4135BDF2FE45B2367" unitRef="number">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="3" id="Fact-DF1C54D88ECC18A0BEA0DF33A38450A0" unitRef="number">-0.190</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="3" id="Fact-8F7F7166EA59B812E16ADF33A3879183" unitRef="number">-0.388</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="3" id="Fact-47B2C5389025C847190FDF33ED2C199C" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="3" id="Fact-5EA9DE4D4EF5FC5564B4DF33ED1D572B" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="3" id="Fact-BEA8D516C563CC26BC76DF3248D79A3C" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="3" id="Fact-76BECCB9A3A251014044DF3248DA537C" unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9CE1BB1BA832A1DDF1EEC50B78CF77D3" unitRef="usd">499000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-459CC3D1E3D7D75DC328C50B77F14F71" unitRef="usd">423000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-7A74154DA0DBE1CC0724506D68585C37" unitRef="usd">513000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q4" decimals="-3" id="Fact-F521D6BF5F2D08F774CDC594826F22EA" unitRef="usd">1630000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q3" decimals="-3" id="Fact-9DA9B3EDB24B282F2230563D442A1946" unitRef="usd">2352000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2014Q4Oct03" decimals="-3" id="Fact-E65FB4B84FC55E951E18DF89EB92C12D" unitRef="usd">90000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q4YTD" id="Fact-B4EC7DDC6F3669D46D5CC594AD7B6258">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q3YTD" id="Fact-F1FA1B9B6C40C8FC0637563DFD1AAED1">P2Y6M0D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-21772924CF73DB22586EDEF42E8195AE" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-5BB316FF04A275E42BBC494C794E29DC" unitRef="usd">67000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5D0B5F5FB598CE48487BDEF42E7C9DE9" unitRef="usd">67000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5C50316C8E1E464733F4494C794EA974" unitRef="usd">-201000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2016Q1Feb1716_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-1BE9D347132995FD4C11C5C658B13B40" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A732CB9EC651CA4F1D6C5AF03A4C9BE9" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-36F36CC160A42E117D2CC5C79D5F6B3B" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BF5FF1CA97C453A2A5CB5AECDBACDB31" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q1Feb1716_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" id="Fact-A2EDD7EC8E0AAF3EBD11C5C603B67EC3">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" id="Fact-CE789D884054FD4E557F5AEFCF6BC240">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" id="Fact-2D8579F7ABE8774777EDC5C7950BB18D">P4Y7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" id="Fact-3A755F49972635FA3E195AEBF847D8AA">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2016Q1Feb1716_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="4" id="Fact-B3E9F637B82CACB79A8AC5C63D28AAAA" unitRef="number">0.6299</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-D4D5D78A0AAF691FA39C5AF01A5EE5F2" unitRef="number">0.7871</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="4" id="Fact-54BDF1678866097F03A3C5C79A5FD24B" unitRef="number">0.7620</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-FF405A7D2AF7B880C5D25AEC8B854A67" unitRef="number">0.7878</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q1Feb1716_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="4" id="Fact-16E99231F10AD40BB32FC5C61F9C5F32" unitRef="number">0.0126</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-00F9FD3247EE8AC03C515AEFF67A7A12" unitRef="number">0.0144</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="4" id="Fact-1A3327A054102718E68BC5C797F04C73" unitRef="number">0.0182</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-2CEEC5644ED11D02352F5AEC47F4AD61" unitRef="number">0.0146</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-D2071B86FFA074AB78E9C5C91E66F6CB" unitRef="usd">67000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-80102A096729087539D55FCDCFC74EF1" unitRef="usd">-201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-8F5F0B789387D051EF9E5FCDCFC4428C" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C462943C61FD73AA36265FCDCFC2C38D" unitRef="usd">-201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2016Q4YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-F1CDD55DB0FA29C311B4C5C91C35441F" unitRef="usd">134000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-915E2FBAFCA1DEFBC10F5FCE7DA70C18" unitRef="usd">211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6066B58B0229D83FA2D95FCE7DA9858F" unitRef="usd">211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2017Q3YTD_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B1CE5E6A700EDFCA31E05FCE7DAC5E84" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2015Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-F70D4BDF35A10FB4B443C5C919FBB02A" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-10114634E66A5A3862FFC5C920972306" unitRef="usd">201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-AB866ADADAD2B2341CA65FCCC2A2EB05" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B0D8318BE0C6C7957256C6663DA9C2D9" unitRef="usd">201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember" decimals="-3" id="Fact-368D2FB3847AC5A199525FCCFAAE3738" unitRef="usd">211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7A516677ABB41F861E835FCCFAFD4C5B" unitRef="usd">211000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q3_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-8CF85BA13D789C33E8635FCCFB64FF3D" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="I2017Q3Sept26_us-gaap_FairValueByLiabilityClassAxis_xcur_WarrantLiabilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-CC0635B26C1738101481E016075CBF12" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A04B3F3240F6B933F645C52E18188D51" unitRef="usd">5408000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-16946E86312B990F949F4930B8AEBC8C" unitRef="usd">849000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1993CDB0FD60C648D9004930B8AE2B32" unitRef="usd">2736000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5854E417A1AB119298D9C52E18153C9B" unitRef="usd">3539000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9B3A5BA3A4EBDF6C95FA4930B89E0B14" unitRef="usd">1270000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-CEDF0FE620C1399524C74930B8AE6208" unitRef="usd">4806000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4C7AF8A92DABC163367ADF32ED8BB502" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD" decimals="-3" id="Fact-66B80BD8AC94DAE1C455512F8D1C539E" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-3" id="Fact-40906BF4793434E01F9C512F8F0611D6" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3EFC91FEC49818181FDADF32ED92533E" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-3" id="Fact-E02F4DA7F1CC9D1629A7512EA29370F4" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-3" id="Fact-CF3458396981855A1472512F8E5E5F58" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ED8228E97F6560E63F2EDF33786B21A5" unitRef="usd">2500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9DDC677871E1AC13FE24DF33786F6B23" unitRef="usd">6570000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-42FB25B535AFBD95BE0DDF2F77941A22" unitRef="usd">-4471000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DEE524E1E7EC217EE29FDF2F7791C9EC" unitRef="usd">-5760000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5082F2002095D3959B43DF3411E655C2" unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0136048AFD93DEF82D54DF3411F44D5F" unitRef="usd">7000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-60936DD3C16A7B1B7CF2DF3232893B59" unitRef="usd">-244000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-160B4D4B3F8CEFB8CDB4DF323286AC8B" unitRef="usd">-860000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E6E73868FC903CA43318DEF498153FF2" unitRef="usd">-18000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1A21285DAFBBF1ADC10C495217F433B6" unitRef="usd">-359000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FFBBC11CD83DB6305A0BDEF498110A42" unitRef="usd">-126000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-87FBA906B11592A74EDC495218037420" unitRef="usd">1361000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-6037A3FAE79381C058E94953B97CA215" unitRef="usd">2000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9A6B050E840BC81981774953B98BD399" unitRef="usd">-948000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2995606AE8244970D751DEF4CDA5AFC1" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7958D96466F238D76418495479AAA780" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EC430AC77F395B6732E9DEF4CDA82ACC" unitRef="usd">9310000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-753DAFA7BDEBED617CC5495479A2653C" unitRef="usd">-6207000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-35B6F4267205DA1F513FDEF466329F7C" unitRef="usd">-38000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7BF841BD5435ED4DB42149505E8F9934" unitRef="usd">-49000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-9AD0604172350E95CC26DEF46628C829" unitRef="usd">-42000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B9B0DB3D7F82387D9EAD49505E8FAD5D" unitRef="usd">-2000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7893A02DF5B6260DE882DF070A0F4760" unitRef="usd">268000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7EC93FF009856AE12A04DF0709F6A347" unitRef="usd">-76000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EDB0EA5580325C7162DBDF075514A91C" unitRef="usd">-63000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F02F7D481DEE4A913AF0DF075518580B" unitRef="usd">79000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FBDE20A2A48DD1BA253ADEF4E3F93EF4" unitRef="usd">4000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1970286060FCAC90E9044954F1F5C733" unitRef="usd">1000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CC2B750AC836DF0746E3DEF4E3EFE96E" unitRef="usd">2000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9232B0CF9F596F9F51764954F1EDE5BA" unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4AB473B05270762FE4DADEF47EAE988F" unitRef="usd">128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q3YTD" decimals="-3" id="Fact-831B52829CE3A63E09944950D492F0CD" unitRef="usd">151000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-84A203ACA45AB325F2BCDEF47EA38CC3" unitRef="usd">244000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7246910DDF0A543B6F3C4950D4A24859" unitRef="usd">727000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2015Q4YTD" decimals="-3" id="Fact-39253A2EA5C27B462729DEF44D647F7D" unitRef="usd">-316000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9A7045C81D1B6B33F5BC494E852DA899" unitRef="usd">-237000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4A3A391B359A49F542C5DEF44D67431D" unitRef="usd">-237000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7CF48055311395EECFEF494E852DD2DE" unitRef="usd">201000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4D4A75275350D3F5E176C52E5B34CE3B" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-EFA0ED1F7D9D988BD1EF4931B98A2942" unitRef="usd">208000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9E16C6390408873FD2024931B98A665D" unitRef="usd">516000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-499DE72E1508FF5D6CD8C52E5B2CECD5" unitRef="usd">724000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-69B4402F7BDCBE0159CC4931B97A301D" unitRef="usd">201000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D46736171E656E3158DE4931B99EAB5B" unitRef="usd">616000</us-gaap:InterestExpense>
	<us-gaap:InterestPaid contextRef="FD2016Q3QTD" decimals="-3" id="Fact-A11F5D3B9CBEE4E1B22A53B8E116BA1D" unitRef="usd">153000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A0214BA3F6410F071DE053B8E1190369" unitRef="usd">327000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A0137B0E9CEC09030DC4C5909DCCB5E9" unitRef="usd">478000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q3QTD" decimals="-3" id="Fact-FAFAE60D96F2712133E453B8E11E9C1F" unitRef="usd">158000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D44C82EE8D4C4486C4BA53B8E114E724" unitRef="usd">470000</us-gaap:InterestPaid>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="FD2014Q4QTD" id="Fact-8E2D8CBA7C24E89D62F5C5CCE88B90CC">P6Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-7631065CF7BBB6077B33C1B219BE3451" unitRef="usd">1391000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-C3B9229620A913F1EE9BC1B219B926E3" unitRef="usd">18128000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q3" decimals="-3" id="Fact-887B5FA6ADBF5A6F35D83EB6D7485FFB" unitRef="usd">13689000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-D860A8CB8AF56BD20112C1B2C18F5C67" unitRef="usd">19621000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-E99C74B14F42CACE7624C1B2C1912470" unitRef="usd">20576000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-58E1A6E2890ECA1887FA3EBEF838C3F6" unitRef="usd">25371000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-1DD50B5D86A8009C6183C1B168F7F654" unitRef="usd">1343000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-96DAECEF85C295820B16C1B168F79747" unitRef="usd">12158000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-A4D299E97254C69711F03EB02AEEF7F7" unitRef="usd">10529000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCredit contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="-3" id="Fact-14AEE7690F5C5A3188FA5665863CF3A6" unitRef="usd">6000000</us-gaap:LineOfCredit>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="INF" id="Fact-D5D28521B92F6E711D1CC58E81FCDADC" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-3" id="Fact-6849D0150E36B33039FF53B9CAC4E724" unitRef="usd">5667000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q3" decimals="-3" id="Fact-97021666BD2534E7B6D353AB8567DF82" unitRef="usd">5221000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-CE91FD95168F0F56ECBDC1B057BF20B1" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-063AF66ACC2913E7D379C1B057B60637" unitRef="usd">1213000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-61DEAE40894BF15C06ED3EAC5A9861DB" unitRef="usd">2551000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2016Q4" decimals="-3" id="Fact-56DAC14A3344A48AA571C5903F1D18BB" unitRef="usd">2164000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2017Q3" decimals="-3" id="Fact-D33B89B9B2B350EF848553A0FD5FD2A3" unitRef="usd">2172000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2016Q4" decimals="-3" id="Fact-330C63BA339141050F64C5903E712B41" unitRef="usd">2623000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2017Q3" decimals="-3" id="Fact-BCAE6810B33D29642CF953A07B5C8DBB" unitRef="usd">2620000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2016Q4" decimals="-3" id="Fact-8501D5F33B274F51A847C5903DCFBCC6" unitRef="usd">1213000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2017Q3" decimals="-3" id="Fact-39961AC2034E428491C953A006990FBA" unitRef="usd">612000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F2621E10FDB5845CE153C1B1B76D20DB" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-1856F8B4207DF34BCBB1C1B1B773C45D" unitRef="usd">4454000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-0C9517C6494AED62B27B3EB3C2248B8D" unitRef="usd">2670000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3FFC6208CEF6E913FDE5DEF6A36C1F51" unitRef="usd">19613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CD28052428B1EE65D7A64970FB3F3A0D" unitRef="usd">6329000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5B929D516EA6905E6520DEF6A37BED25" unitRef="usd">6336000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-32ABD9D1BE8E34A2BDF54970FB3F4C97" unitRef="usd">18486000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D09192B31366C305CFF2DEF5B84CC8EA" unitRef="usd">-12000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-58F01DF2BF808A47173F495DFB918B50" unitRef="usd">-315000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3491C8E7CD25F60F4301DEF5B83D683C" unitRef="usd">-394000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F5253490811E220362CF495DFB9150B3" unitRef="usd">-726000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A11B289AFABEFF8105A8DEF590D73A78" unitRef="usd">-12202000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FC81BA74174E990BED364955840A5B70" unitRef="usd">-10677000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DE3F11ECE4DF8222552CDEF590DEBAF7" unitRef="usd">-5050000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FD220348776DF3639DD94955840A7AB5" unitRef="usd">-14447000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="D2015Q3Jan01-Jul08" decimals="-3" id="Fact-66E9604309D29A575A39E0B217EF85FF" unitRef="usd">-7488000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-596693236A37619E21EBC53CD487221A" unitRef="usd">-7488000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2015Q4Jul09-Dec31" decimals="-3" id="Fact-9EBC41CC70BED18A84ACE0B218C282C5" unitRef="usd">-5663000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-97C7681F40FF3D7CD33BDEDFFFEDB6F5" unitRef="usd">-5663000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-734E288587EA847EEFA0C5347BC5DB14" unitRef="usd">-13151000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-7C8438FF01B9B0906BB34933F7325AF0" unitRef="usd">-3526000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E8FC386DD4B3B22240A45E40CC34293D" unitRef="usd">-11299000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B19B2BAC2E530A6A0C70E06363BFA313" unitRef="usd">-16941000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-F6CF4BFEFC48A3AB8FF1DEE035071587" unitRef="usd">-16941000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-19B5FEB8F67E8473F1E54933F7321A78" unitRef="usd">-2313000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D3B3833795F9FEAF682A5E40CC3F0726" unitRef="usd">-8937000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E1B9031E15B6727C63705B1614B40012" unitRef="usd">-8937000</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-228B98F10FC630FEC074C52E7D322384" unitRef="usd">-7000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-672F49309B3F244E42C64933559148B7" unitRef="usd">-264000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2191E8444DFDF5E307034933552472D0" unitRef="usd">-580000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6BDD44C2D26FB6703E2EC52E7D345A1E" unitRef="usd">-779000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-4BF3FAB9D79B0AECAE06493355914BC8" unitRef="usd">-38000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D1CF47CE3EBD7BBE68C349335591A9EA" unitRef="usd">-476000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A7BC23986FF652862191C52E2AD89CB2" unitRef="usd">15532000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-C5D9870AB6C6082F6AC4493118D39B86" unitRef="usd">3262000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3YTD" decimals="-3" id="Fact-F3092A98226AC14C86F1493118E28F03" unitRef="usd">11065000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3D4AA9F43751D942131BC52E2ADF7372" unitRef="usd">17198000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-0EBE739294BC8852D0E7493118C37B12" unitRef="usd">4772000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3YTD" decimals="-3" id="Fact-497D5B1C286C1357EEAF493118D36D71" unitRef="usd">16085000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-112D252820CD907DE42EC52E44A55BFE" unitRef="usd">-13144000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-6E53AB07A6B60C9A3AA24931706FCC5E" unitRef="usd">-3262000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-5E3E7D0A36C8A12C88684931706F90B4" unitRef="usd">-10719000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-02B754F10C1B2938A235C52E449EA822" unitRef="usd">-16162000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-D09CC34CBB3C63BA6C3B4931706F2AB3" unitRef="usd">-2275000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A83D73118ED8B61955F94931706FD6E5" unitRef="usd">-8461000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2016Q4" decimals="-3" id="Fact-ECCF421EDA7881DAD4B3C5D1D3DC8E98" unitRef="usd">1435000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q3" decimals="-3" id="Fact-219E445CA8751630B3FA5B047D27CF82" unitRef="usd">1184000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2016Q4" decimals="-3" id="Fact-CD54823B4B7A73460F70C5D1D1E6800B" unitRef="usd">59000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q3" decimals="-3" id="Fact-B0FD3CA665CE395320F25B03DC0D43DA" unitRef="usd">59000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2016Q4" decimals="-3" id="Fact-F7EB0BDCFB54F2CC7D50C5D1D0E9035A" unitRef="usd">353000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q3" decimals="-3" id="Fact-D787B8C3B436692C04105B02DDA48C18" unitRef="usd">353000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2016Q4" decimals="-3" id="Fact-E49BC69699A2C49C54F8C5D1CFEC4CB6" unitRef="usd">347000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q3" decimals="-3" id="Fact-3B09917631B67712FB835B0263C6D6E0" unitRef="usd">347000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2016Q4" decimals="-3" id="Fact-13C5BDA928EFA2D0D48DC5D1CEF944C2" unitRef="usd">341000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q3" decimals="-3" id="Fact-552317B3574DD441736C5B0233F39AD4" unitRef="usd">341000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2016Q4" decimals="-3" id="Fact-4525B985E0E77B4F3A92C5D1D2DCADE6" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q3" decimals="-3" id="Fact-3736170665556E4D929F5B042DBBAA78" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2016Q4" decimals="-3" id="Fact-5C8DE13A9D7897E825E3C5D1CDFFDC88" unitRef="usd">335000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2017Q3" decimals="-3" id="Fact-A322C5F4269D84F0E98D5B01F8033B96" unitRef="usd">84000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0535479845D6C906FE8EC5CF733D90B3" unitRef="usd">250000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2016Q3QTD" decimals="-3" id="Fact-ACDFEFAC07777A4C60CE6018C74A8126" unitRef="usd">83000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2016Q3YTD" decimals="-3" id="Fact-8C1620B40A2F09C433B36018C74FD549" unitRef="usd">191000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BA127AC6FBA6E368CC88C5CF1D2D5756" unitRef="usd">266000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2017Q3QTD" decimals="-3" id="Fact-CEC7564AF293D08B8AA96018C7540D9E" unitRef="usd">77000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseContingentRentals contextRef="FD2017Q3YTD" decimals="-3" id="Fact-99F02B0B993E1BB5960F6018C74C84CF" unitRef="usd">232000</us-gaap:OperatingLeasesRentExpenseContingentRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7DD27EF691D403565B2AC5CF722D3BB4" unitRef="usd">253000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F497F7900402BCEEC87860186F064F43" unitRef="usd">83000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2016Q3YTD" decimals="-3" id="Fact-655E69249C92A6CD67E060186EB971BD" unitRef="usd">216000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A5A0FB31A07314781F25C5CF1C35E6E2" unitRef="usd">299000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2E9D64FA6FCF908DAF2F60186EA217FE" unitRef="usd">83000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A8DDBBF4D438659E310B60186ED7F456" unitRef="usd">249000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F941264F1530095B2E1AC5D0DD9C2590" unitRef="usd">486000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D7BF12707CCE1DB4BDA0601927D85326" unitRef="usd">166000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1E916F5415A374289F9B601927DFBD1E" unitRef="usd">407000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-257AFCAEEF4BF6E0EEF4C5D05ACF6404" unitRef="usd">565000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-4B82516C490EFB71D7DC601927C835BA" unitRef="usd">160000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-50D95737B2A05825E684601927DBD90A" unitRef="usd">481000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-436AD5F3697C29ACF62DDF4D9202DFF6" unitRef="usd">20727000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-9EDC23564CA6A92ED70FDF4D91F18C4E" unitRef="usd">20727000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-E4613BF28A611FF2E203C50B92CEE6B6" unitRef="usd">131000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6A696A3FA8D89454E7BEC50B921DC107" unitRef="usd">114000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-9E3D1042FC72E38C9697506CE905AA0A" unitRef="usd">979000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6A37F9ED42AE91A0DEB63EA54574841E" unitRef="usd">32000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-5E7F41054512F3B0B9BC3EA545746A78" unitRef="usd">32000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B3BBE3C78BD6AD7E7DB3C1B209578A7D" unitRef="usd">48000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D598A09D82216C13BA2BC1B2095A3602" unitRef="usd">281000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-BD6DCB6E6C5709DFB34C3EB5CD209D2D" unitRef="usd">279000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-558D58A43CEDE53201B4C52E6A6247A5" unitRef="usd">-7000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-4959A283B497CD1FE1864932C81E54B0" unitRef="usd">-56000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-93EDB71A0357E6B075E84932C81EDF21" unitRef="usd">-64000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-003EB4D387C204C1E426C52E6A6A155D" unitRef="usd">-55000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-EE9ED8D7D7FDE943E2154932C82E6476" unitRef="usd">163000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6ADC018EAB6EC7A6CDE24932C82ED74F" unitRef="usd">140000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E24DB58F9CDEE61EEAFFDEF64574CFF7" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-0EF42CD0C65F47CA63A6496676BF817A" unitRef="usd">141000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3914A02BFC1D26D403F4DEF6457BEC99" unitRef="usd">141000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-26106ADBC2046D3F9DAA496676CE3A17" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="-3" id="Fact-F319DE381ACFE03A4882DF92EDB1BE30" unitRef="usd">61000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="-3" id="Fact-0BBAD8631D2FED0DEADDDF93A9E10779" unitRef="usd">35000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-094E1A35ECDB6468B5B7DF95B5677AA1" unitRef="usd">117000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-943435745F7BA6EEBC82DF9638867F81" unitRef="usd">43000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-9103229674AA6C01E7BCDF96FA397DCF" unitRef="usd">69000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-4F3680657EBCF8150247DF9781C9A944" unitRef="usd">6000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-E720350AA6402FB51E16C64D454C0670" unitRef="usd">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-23FEB2222B1FF1C5B0AD56223D86314A" unitRef="usd">3037000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q4Sep26-Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-7142A108411980A2F0C2A6F13100553F" unitRef="usd">3966000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-89157925EE71A737EA5FDEF5A3BB22D6" unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B7035631D50043BCC5EE495DABCA2DB4" unitRef="usd">315000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5AD92FB9635906DBD66EDEF5A3B5E9AA" unitRef="usd">394000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4A46579F035154A839AE495DABBA7923" unitRef="usd">726000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-BE76074502B5976D7413C51A082330DF" unitRef="usd">50577000</us-gaap:PreferredStockLiquidationPreferenceValue>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-203FC73572832BAF449FC511159EEBF3" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-23B3D751137D4792F80DC510E346AD37" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-605FFD4F9F7F791E0275C51104FE0E53" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-6053B0947B15D3694193C510F3D5D5B7" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-D83FD57D6DCC49803A81C51113775AE6" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-D4B1D2115417AF371D63C510E12C765A" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-B3AFE562A8D064E146A9C511032CCFF1" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-655DCBB5D181197D8B91C510F23B3EC0" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-74A90747718453ECAB24561204547B6E" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-10F4C6C741BC33DD4CE9C50F769F6C28" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-6BD26B7A77A2832BCBA5C50F41477CEC" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-3637D419FFB3E1704851C50F66563715" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-FC4506460B5F80A4D873C50F53EC695F" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-A7FDDCF687B1E03CCF05C51119D68D15" unitRef="shares">22924209</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-A52BF9C12681AC025A9CC510E70EB218" unitRef="shares">21000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-CB4F49F0347CF1C966E2C51108E241A2" unitRef="shares">4937813</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-C7E2D460A10249D534BAC510F7D0B526" unitRef="shares">2827844</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-DF8E4D45FAE768AAA0BEC50F7CACE7C8" unitRef="shares">11381640</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-09122B85C2E10F2ECDB3C51117E3C8A9" unitRef="shares">22924209</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-B1CE6F9FCDADFDC0858EC50F47CC5BEF" unitRef="shares">16100000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-0EEBA9E5691F2CCACDA0C510E535A142" unitRef="shares">21000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-E7B2780E6114F85DBDF2C50F6BED8FC9" unitRef="shares">2451560</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-F327E1C3080F57137B88C511069F22C7" unitRef="shares">4937813</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-12CCDEFD71B0DC89B51DC50F59DCABB6" unitRef="shares">1403984</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-1AB79B7329CCEBD507DFC510F5CF91FF" unitRef="shares">2827844</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-C61380693A11DB6E9AB7561145DA7533" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-8F87E89C68D820F4D4FCC50F7A663494" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-0371E2E9A705027867C1C50F45D87A44" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-E653B1D2F3BE142AE75DC50F6A1BA0A8" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-D1922FBBF7ED44D65517C50F5820E48E" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-47641F37BD3E70E663A0C5111E23E1CA" unitRef="shares">22924209</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-AC05238072DD5CF5BF65C510EAF021F8" unitRef="shares">14464445</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-AF8B0673A2AE342176E4C5110C38C7AC" unitRef="shares">4937813</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-B7C5CAF80D912AD75476C510FB63F987" unitRef="shares">2827844</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-F177F8F571D9C1D48FD9C50F80E84FA1" unitRef="shares">11381640</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-1A33A64735BC364B4D98C5111BD2ABF2" unitRef="shares">22924209</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-E707588B12A6F2C5F421C50F4BA5624C" unitRef="shares">11239359</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-80C8A013139A484FE290C510E9013B3C" unitRef="shares">14660096</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-E4477927D5D95CA712A6C50F6FA5F9D7" unitRef="shares">2451560</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-11942FA49C471FB49C4AC5110AA5B687" unitRef="shares">4937813</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-B49ABB0F6A8135FFE57CC50F5E16F7C0" unitRef="shares">1403984</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-7D8CDF3F35965182A24EC510F95E4CB8" unitRef="shares">2827844</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3" decimals="INF" id="Fact-3B05CA31B519416BB3FF5613CA3E6EFD" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-D339F361D278FFD36235C50F7E819A80" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-8A4B736BCFBAD81A30C3C50F498F984A" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-5071C7153010CE1390EDC50F6DB167D7" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-94DBE4CF3DD17AE7DEB6C50F5BEEE520" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-B680195CF0C31FB93216C51121B4B448" unitRef="shares">22924209</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-EBF1F9E67C6603A1EF3AC510EEAA958B" unitRef="shares">14464445</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-6EBFA5CCDAF952D0A374C5110F5E4340" unitRef="shares">4937813</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-382875B6FADFF6B5ABE1C510FF235B2B" unitRef="shares">2827844</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-2143091B46A2276EA7E5C50F859FFC68" unitRef="shares">11381640</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-10D56605201FA0750D3EC5112000CC2E" unitRef="shares">22924209</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-E5E2C4D772F8970C1B3DC50F4FB467EA" unitRef="shares">11239359</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-0D165358F0B2C4F6042FC510ECB284BA" unitRef="shares">14660096</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-F434E2EE1C46C99FBF62C50F7338E007" unitRef="shares">2451560</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-0C95B69FCE5A611FDAF2C5110DC5C2D2" unitRef="shares">4937813</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-29040000B30C3FB4C5EEC50F62527F5D" unitRef="shares">1403984</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-CC65344F9F360C9FFCBCC510FD5241F5" unitRef="shares">2827844</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-B2BBCDEA2BE5792CF29956130D944A35" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-0DCAE6C12178C6068845C50F8331B599" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-96A46ED8581011262002C50F4DABDF11" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="INF" id="Fact-76451573190551DD3CA2C50F71433106" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="INF" id="Fact-69617E902CB83B3E9157C50F6028B29F" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-2328E46740CDDA7B7E62C1B25DE63ADB" unitRef="usd">135000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-67D6AB4DEF8E94E24423C1B25E746CA3" unitRef="usd">33039000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="-3" id="Fact-D9EF6A42FF629AB1BCB3C1B25DD71886" unitRef="usd">5371000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="-3" id="Fact-AF54EE0094F578A8CDC2C1B25E05E17F" unitRef="usd">3641000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-2FAC805552EF2F8EBF8BC1B25E44EE2E" unitRef="usd">135000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-1CA63FBAC9AD43F644CAC1B25E25D33A" unitRef="usd">33483000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="-3" id="Fact-A8440EEA5E9A5CDB1052C1B25DCE3E83" unitRef="usd">5371000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="-3" id="Fact-E2CAB3BD1BE9944938B7C1B25EB2B1B6" unitRef="usd">3641000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-A8B5501EF21D9449BB7C3EC46FF8F6B4" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-3500A7F4161BD586A2E63EC46FF8E148" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember" decimals="-3" id="Fact-0C2E307CB391B844E06E3EC47007C7AA" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember" decimals="-3" id="Fact-656E8D93BE91119BBB133EC46FF88AA8" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-BFAA195D2541589970E4C1AF9E83BF65" unitRef="usd">179000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8FFCD03E0694B9D4DB82C1AF9E717E27" unitRef="usd">403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-39DB3F65FB57F882A7063EA4053433FD" unitRef="usd">1130000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="D2016Q1Feb1716_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember" decimals="-3" id="Fact-3AB8DFF9E5218138B203C58F27B573EC" unitRef="usd">5839000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-23FB4F31F1E3988386A14962E795B763" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BD5CC155C794726801AA4962E7955459" unitRef="usd">20302000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6A4BC0A7997835A1E989DEF5F56739C3" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q3YTD" decimals="-3" id="Fact-49BDC0E5959950CEE155496444DA95E4" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-59283BD5BC3918340066DEF5F56E87C2" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-95811351BD3ECFD9E6FF496444DBEF37" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="-3" id="Fact-E061A1E8BB187C81E25EC56BF07CC5BA" unitRef="usd">5371000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="-3" id="Fact-C77DC93FB11CEAF39ECFC56C56A48532" unitRef="usd">3641000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-E18D5F6469BC5AAE8B57C56F95B57F6F" unitRef="usd">13479000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-F5E67A4EE8848C367A36C56FC20BE88C" unitRef="usd">4581000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-6FA801E305821193854CC56FF01D55F8" unitRef="usd">14979000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-BEDA0D50CC88FB2C116DC5703EC99A1C" unitRef="usd">444000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-199A1D37246CC7A534D6DEF9398CE76F" unitRef="usd">19672000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4BCF618664B38F02C65E4963B214685F" unitRef="usd">450000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DC1A2A5046117879C690DEF93975BAF2" unitRef="usd">450000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1116DAE37A010159F02E4963B2143039" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AD991DC6B7E93DF540A0DEF61E7C85E4" unitRef="usd">53000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CDB0DEB144B91C67E7F64964C8179B08" unitRef="usd">26000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-529555888326569A7821DEF61E8DC66D" unitRef="usd">33000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q3YTD" decimals="-3" id="Fact-31BB39E47EF048CF03534964C8193EC5" unitRef="usd">43000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-E4C589746896F825EE3BC58A76D804D2" unitRef="usd">822000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-5D397B830F37CBDD9627C58A7382A97A" unitRef="usd">107000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-A6A522093042DDF4211AC58A65619FC6" unitRef="usd">627000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-C3CD6B93E70344187904C58A6BE4E44E" unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-62EE82B5D61A349C5B03C58A68A26076" unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember" decimals="-3" id="Fact-BA3FFFFD74398064310FC58A6FAFE7EB" unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-FE792C8EDECF4F48BDF3C58A753B8C21" unitRef="usd">1120000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-6CD2EC351449F6A1B9FBC58A7171BB25" unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-52246D570E3918E751C4C58A63A0210E" unitRef="usd">993000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-402F6A14183B6AD6B6F4C58A6A1A10B1" unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-E5F9AB9FE3841949396FC58A66D94EB3" unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember" decimals="-3" id="Fact-F2CF5BF55E2099107544C58A6D64563A" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3" decimals="-3" id="Fact-83D1BDE8A4460B2E01CC511F3E3C98E1" unitRef="usd">1835000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-618A9E873565A823143A511F3E417272" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-02357F4560444A016CEC511F3E3AE3AE" unitRef="usd">1586000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-E146AC11278B8B871F78511F3E46AB59" unitRef="usd">31000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-051D8B9CE225944FBE75511F3E32C4A9" unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xcur_ComputersandSoftwareMember" decimals="-3" id="Fact-8D2328F7F435BC186C67511F3E36486A" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2011Q4Dec12_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-1E7258039B404BCC4DC0C568506C7EA8" unitRef="usd">309000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-588E46867AEB90836FC5C1AFCB635378" unitRef="usd">385000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-26E509D425CC5F789DB1C1AFCB633C86" unitRef="usd">503000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q3" decimals="-3" id="Fact-C8DAF05E2F7D87C82D563EA4EE8FAE9D" unitRef="usd">1059000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-98BFDF65F2E56CE9D8C15A2E40607292">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-5B4C7B1EA781659CA5125A2E40542EDC">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2015Q4YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-3" id="Fact-447C6C1F2E896E77A647C5DF66172CAD" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q4YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-3" id="Fact-C486612965ECB8D509E6C5DC59B69EE7" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2017Q3YTD_us-gaap_RelatedPartyTransactionAxis_xcur_ConsultingServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" decimals="-3" id="Fact-086E45096BFEB984DCF760087B227362" unitRef="usd">75000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9AAC8D88989E9A6C35FF4965065687C3" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C49AE16F1BAF5460486B496506468197" unitRef="usd">595000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5BCB3B42B6341B16EE956D86745CAAFE" unitRef="usd">428000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4F998DD7C5CB276B7F2E6D87CA9BE076" unitRef="usd">1417000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-40976D67AA604D19553CC52E04744EC1" unitRef="usd">10124000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D0DCC233885B80144BF349304FCB9B43" unitRef="usd">2413000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4FC789E45D0EBE06553049304FDAD9DD" unitRef="usd">8329000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-ECCD0D4C0A6059D006E6C52E046F5C98" unitRef="usd">13659000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-A1A27EB6FF543CAEF38B49304FDB2DF1" unitRef="usd">3502000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-509BA9E1BB77D085A4C849304FDD6C5F" unitRef="usd">11279000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-6671BA3758E3C2866473C1B29B32CCF9" unitRef="usd">-5663000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-AF32654345F70317B566C1B29B3685EC" unitRef="usd">-22604000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q3" decimals="-3" id="Fact-891F352AC8594342C6983EBE28D41A27" unitRef="usd">-31541000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6316DCA3A15B3F9D7E5BC52D72BFCC84" unitRef="usd">2388000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3QTD" decimals="-3" id="Fact-A34883C4ECB14BBC1D99492EE430B2D2" unitRef="usd">0</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1070CF5DDB11B2467570492EE41170A3" unitRef="usd">346000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7A887702DD989CC84D35C52D72C3A8EE" unitRef="usd">346000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3QTD" decimals="-3" id="Fact-8D5AECD559CF8DE8AAB1492EE42145F3" unitRef="usd">0</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5F66635EB5D401347085492EE4211ADA" unitRef="usd">0</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-F4C62C5B242052BFA3F7C5E114D4263E" unitRef="usd">45000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-4F5F739621226F1A9ADDC5E0F58B92CB" unitRef="usd">-59000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-24F7E3F9F5021ACF6B6CC5E0289757E8" unitRef="usd">34000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-593B8665203DD1D184BAC5E0C0391424" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_SharedCostsMember" decimals="-3" id="Fact-78C9E65FCB6C05210D68DF1460B7680A" unitRef="usd">70000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-81F373F3B4BD52BCD7605FF92F218B72" unitRef="usd">8000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-2CCCFA4051D11DAB4C4B5FF929977149" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-F5DCD4EA19A894650A025FF9288F59AA" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-1F9EE8861C085E7B35985FF92AA3CE23" unitRef="usd">8000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-B0B34A2FB38DB4E180FE5FF92A6C0F10" unitRef="usd">21000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-DC01C9D3C0BB93B6360F5FF92ABD7AF8" unitRef="usd">-4000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-797E6D42B368D6F319625FF92EB5FBF5" unitRef="usd">2000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-3C013258F0242FDEAE3E5FF92A7BC5C9" unitRef="usd">23000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-EBCA58817D3B6E1EBEB5C5E111ED89CD" unitRef="usd">29000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-D126EE8CCE27719F2FABC5E0F270FFAA" unitRef="usd">-4000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-7DEA5E64803F8100CB1AC5E02300E3DA" unitRef="usd">3000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-05CDE93721D957DE1C12C5E0BC5652D2" unitRef="usd">30000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_SharedCostsMember" decimals="-3" id="Fact-FDE5F7B6BB49E6679E12DF145E1E6DE1" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-D698F9BAB22FE7708C0C5FF928FFB549" unitRef="usd">4000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-21494C9FD30B7C9210DA5FF92EEF520A" unitRef="usd">1000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-3D42195A44F80F02FC715FF92A8DAD50" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-70407FFA087E1ED8ECC35FF92841EBB3" unitRef="usd">3000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-A498D7E4E602C5A646515FF92C749EF6" unitRef="usd">13000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectCostsMember" decimals="-3" id="Fact-CF0916DCE94EF6EFBDD45FF927E34E85" unitRef="usd">4000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_DirectLaborOnResearchMember" decimals="-3" id="Fact-86C3AA9D8D40AE90CBB55FF9281223F5" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember_us-gaap_RelatedPartyTransactionAxis_xcur_QuarterlyFeeForIndirectCostsMember" decimals="-3" id="Fact-78169A5C75E44D4FBA7A5FF927F66B12" unitRef="usd">9000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6A96DAA97128CBA9729AC52DEB0ABB74" unitRef="usd">2388000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-616353A9DC00AA59E709492E04338645" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E35C581AC3B84E2367C2492E042BEF11" unitRef="usd">346000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D20240BC5A568AB84F09C52DEB11298C" unitRef="usd">1036000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5C98FBAFDEC5EC0C9A0C492E042F1E7A" unitRef="usd">2497000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D44FE051E4BAA292B45D492E041F38F2" unitRef="usd">7624000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="-3" id="Fact-8209757B908ACCE2409FDF929AD126B3" unitRef="usd">5432000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="-3" id="Fact-E6E3732DD5AC44A7783CDF938E7A5D11" unitRef="usd">3676000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-720A6DA4023244244AEFDF9470808522" unitRef="usd">13596000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="-3" id="Fact-EDF527C57CB0C7ECCEDADF961E4BF562" unitRef="usd">4624000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-A9A48B2721269514D3A2DF96DEC45D86" unitRef="usd">15048000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-EAE46FDD18715C2F98D5DF97642F201B" unitRef="usd">450000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-A04B43D9D25921EEF4DDDFB54A86A68D" unitRef="usd">20302000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-0A28D81DE5F8ED8A7E6D5623D1299635" unitRef="usd">17235000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q4Oct27-Nov2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-728D7A41C33B8625AACCA67FB4403AC7" unitRef="usd">11211000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q4Sep26-Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-BC5D9F8F2F587C98F1EBA6F013A54674" unitRef="usd">31513000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="INF" id="Fact-B535C4F83DEA44930F9E592161753551" unitRef="shares">4532112</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-9EB69377A329BD02A08BDF9434CDF64E" unitRef="shares">5911450</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="INF" id="Fact-05C5B5CEC3FD28BF4FA15921E08BC212" unitRef="shares">1541168</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-9B8997D6A98D754A8B49DF95E6F6562A" unitRef="shares">2010219</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-8E425EA54C52AA7D0B12592354282F53" unitRef="shares">5016134</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q3Oct1toOct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-6A127ADE51015EE50B1FDF96A5F43D5B" unitRef="shares">6542783</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-A9E19A5DA078E9C2A3B05923B6391185" unitRef="shares">149999</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-0505EEE96385A0FD2CB0DF97317AB9D7" unitRef="shares">195651</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-C92312B7FA057D221CF3DFB4B5DAEAA9" unitRef="shares">6767360</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-E79BD1B99087D649116E561582CA089D" unitRef="shares">6767360</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Oct27-Nov2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="0" id="Fact-08897BA6702F56D6B94BA2F520F1C4B4" unitRef="shares">3736836</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Sep26-Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="0" id="Fact-7BF6C2351A090128DD10A6EFCEF24348" unitRef="shares">10504196</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="2" id="Fact-6C3DF69B2EC5FBD7EEE058F65CF06F14" unitRef="usdPerShare">2.22</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-4FF268649D289D349018DF927E52F966" unitRef="usdPerShare">1.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="2" id="Fact-AC628FB0C4D72D3E7EC4591A4D7AF70B" unitRef="usdPerShare">2.62</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-12FF2FAB130C609F5551DF937446351B" unitRef="usdPerShare">1.30</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="2" id="Fact-7CC3D9F64C815A854076592177B0957A" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2014Q2Jun13_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-B47B75BBC9E2A79FA83ADF9450A01206" unitRef="usdPerShare">2.30</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember" decimals="2" id="Fact-D4D7A9207752402697AA5921F0308355" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Feb6_us-gaap_StatementClassOfStockAxis_xcur_ClassCUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-F5EA6DEDC6BC28FD7666DF96038460BF" unitRef="usdPerShare">2.30</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="2" id="Fact-5317D05B6BD181A8C1705923625C232F" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-50ECC6F14520409CF4A9DF96BF3CDDFA" unitRef="usdPerShare">2.30</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="2" id="Fact-69237A89CC444850B4D65923C6D3D165" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2016Q1Jan11_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-5200F732989AC2816EC1DF974889DB31" unitRef="usdPerShare">2.30</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-4A753F07BD57D302BA7EC62E23D0FCE5" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="2" id="Fact-35A6660612A7C2C23BC9DFB505C75B89" unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q4Oct26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="4" id="Fact-773AE62073EF30F5A577A6BED998E88C" unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SecurityDeposit contextRef="FI2015Q4" decimals="-3" id="Fact-C392D3C6808C78E54A17C1AFE4761701" unitRef="usd">32000</us-gaap:SecurityDeposit>
	<us-gaap:SecurityDeposit contextRef="FI2016Q4" decimals="-3" id="Fact-6B13F5DD466F5265AEFBC1AFE473D1EF" unitRef="usd">32000</us-gaap:SecurityDeposit>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ADEE0BE17F71D7C348FFDEF3FCE34E7B" unitRef="usd">370000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FF7C951B61E0138ED2334949CD86D492" unitRef="usd">507000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-78D45225F2398647299EDEF3FCD114D0" unitRef="usd">682000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-58E17234C45EB553A78C4949CD777225" unitRef="usd">1104000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" id="Fact-E4D6ABF1252FC3CD264CC593BEAC666C">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_SubsequentEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" id="Fact-017B59DA309B51317B9FC593D909B2BE">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-01A59B18479481A72DB6C5A836B04246" unitRef="usdPerShare">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-2483FB7D6CA9CF2415DFC5A834B31B8D" unitRef="usdPerShare">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-DB0820FE94B53CD717B3C5A838A6E091" unitRef="usdPerShare">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-8A253493B5F834EDC99C56733982E598" unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-5ABEE00632AD6B3AAE695673397E349F" unitRef="usdPerShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-FB1CAAE1A4ED269A4F8756733987B78A" unitRef="usdPerShare">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-10D17FBA6DA2B453CF41C5A74F703C60" unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-D16528B292236DAA1475C5A74D2520CC" unitRef="usdPerShare">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-B38A8B4F70B1D38D5E3CC5A751AF501A" unitRef="usdPerShare">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="FI2017Q3" decimals="2" id="Fact-77EECB92FCDAF021880B56720EC747C2" unitRef="usdPerShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-665ED03B0FBC88112EECC5AB1D19078D" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q3YTD" decimals="2" id="Fact-31A2B2E9CDAFBBED2DB4565FE0A0B78C" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="2" id="Fact-B481BB2C7D63AFA8D5B8C5AB19005080" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q3YTD" decimals="2" id="Fact-FD8497E48193EE2A8EC7565FBFECB5C4" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-DBF4C7705BBB82A389B9C5AB0DE59068" unitRef="number">0.854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-68756F5CCC2879CA1173C5AB0BFB5FA3" unitRef="number">0.789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="3" id="Fact-06A0E6091A8AA3136798C5AB0FC450E9" unitRef="number">0.822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-87E5091C03FD92405DB7565F035E401F" unitRef="number">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-6E97475D23AA511FBF3F565F04086C04" unitRef="number">0.799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="3" id="Fact-D375A8EF26EADCE63321565F03A64F58" unitRef="number">0.809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-168945E4DF7EFC6C3ECBC5AB07BAB671" unitRef="number">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-3D93473EFFF873BFDEB7C5AB0582FF5D" unitRef="number">0.792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="3" id="Fact-765D4B1F375D8FD0EE55C5AB0A0FCEFD" unitRef="number">0.799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-CAAA6C25A29261EF8B4F565ED307BA15" unitRef="number">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-62A342BDA8F8DEC83DCC565ED3198E77" unitRef="number">0.808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="3" id="Fact-DF034FAC200E0DA2AE3D565ED315E138" unitRef="number">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-C853421950789620A01FC5AB014B1285" unitRef="number">0.0208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-EBDC6F8C5F8106478FD5C5AAFF2AC9FB" unitRef="number">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="4" id="Fact-043BE0BAFBA306B126DBC5AB02F41295" unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-D59AB018B3144DC84EC9565E326D3599" unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-3472371666D0C6C9B53B565E3263B4C5" unitRef="number">0.0101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="4" id="Fact-5962A248D3A03CAFEA0F565E325C77BC" unitRef="number">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-502EC7B8D02433C773E8C5AAFA1CD22C" unitRef="number">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-5F992C7288D9963C728BC5AAF823B907" unitRef="number">0.0101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="4" id="Fact-6712118740D56187EB32C5AAFC4BF88D" unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="4" id="Fact-F12213A313C683B88C35565DF7F71BCC" unitRef="number">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="4" id="Fact-DE8A024CB901F57633DC565DF7EA8276" unitRef="number">0.0197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="4" id="Fact-E8BAB0229A9CD4412E3C565DF8154100" unitRef="number">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2015Q4Oct13_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" decimals="INF" id="Fact-11B47452C3A0B2C74F6FDF787037DDDA" unitRef="shares">9806006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="INF" id="Fact-D869ADE10A41F3B095A055F5ABC047C4" unitRef="shares">5842525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q4_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" decimals="INF" id="Fact-9CCD8E058E7DF4A6628DDF73A0E35CA4" unitRef="shares">3318400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2017Q3Sept22_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" decimals="INF" id="Fact-B433BFCBA4469622E89755F7D980949D" unitRef="shares">3683817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="INF" id="Fact-E89EBFA2CFFBED97E42F55F7CF290E09" unitRef="shares">2158708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-AFDAAAE028BC2753FF72C59ACA15E28B" unitRef="shares">2956455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q3" decimals="INF" id="Fact-F674E8C4F045F012F6CF56ED793CB0C2" unitRef="shares">2131730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-3AF7D2756110FA6E4B71C59ACAF3EAE1" unitRef="usdPerShare">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q3" decimals="2" id="Fact-F0C04C8634B0B7D8869156EE3D478A87" unitRef="usdPerShare">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-45F59D9D5FC340DE14D3C595A6E66607" unitRef="usd">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C297029DA6F853FCC07A5646EF1F01E3" unitRef="usd">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DB68A97E9E31AC44ED9FC595A787D2FB" unitRef="usd">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5BDDFD879BF09C6854A75646EEE14F1A" unitRef="usd">202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-70F53D765E10C922D443C59A9888F819" unitRef="shares">200625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-A86695AE7C3028DFC63EC59AC427332F" unitRef="shares">382321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q3YTD" decimals="INF" id="Fact-63753EFC1A3512848AFE56E631F2F67D" unitRef="shares">10396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-4F56A2EB9D014A22A92EC59A8E19F120" unitRef="shares">3941134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-B09C7BDF1B5010DDDD3EC59AA3B37A7B" unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q3YTD" decimals="INF" id="Fact-E623F7FB732BB6C17FF256E58F1074CB" unitRef="shares">657843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-15BD42BA62F759B9F4DBC59531E54B2D" unitRef="usdPerShare">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q3YTD" decimals="2" id="Fact-8623893AC3B4717568CD5643A220C36E" unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-76C621B0826B3EE2DA3CC59532CDCF53" unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD" decimals="2" id="Fact-B9807B28A97B74350093564373D5E8AA" unitRef="usdPerShare">2.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-570EC094D0F7097300CFC59A8854AF54" unitRef="shares">2954418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-5FB1038752E7693097E7C59A9DBF8267" unitRef="shares">6528052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-BCFD7FD3A9855F68676B56E50231B626" unitRef="shares">3089352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-83E9B1E9AF39AC146CFADF603DF2C3BF" unitRef="shares">6222448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q3" decimals="INF" id="Fact-DCE1C1F45F0B117903A6473DE0258BE3" unitRef="shares">3678359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-FF401D2B82AAD9C1F687C59A89DDB525" unitRef="usdPerShare">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-31AE3E7A1EE9C8F2DFFBC59A9F5F9E36" unitRef="usdPerShare">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-00A56977C5D54A952C5556E915D1644A" unitRef="usdPerShare">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-8CECE758E901231D186AC59AC7B56070" unitRef="usdPerShare">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q3" decimals="2" id="Fact-614803C746ACB23F008456E915BF13B2" unitRef="usdPerShare">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-3" id="Fact-7E49554273BAA0945E69C59AD106B428" unitRef="usd">8888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2017Q3" decimals="-3" id="Fact-7BA071140DF9280D485356F0FF827F91" unitRef="usd">5195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2015Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-3" id="Fact-16D3DB53C790B262D168C59AA2A18ED8" unitRef="usd">2310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2016Q4" decimals="-3" id="Fact-E4A1457C75443D0B7DE456F011684D8D" unitRef="usd">9143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-3" id="Fact-9B89D51A3F97DAD1096DC59AC97AAB29" unitRef="usd">9143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q3" decimals="-3" id="Fact-66F288CAEE2F4B0123F456F08E8F3D20" unitRef="usd">5257000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-8299A8AD7F2937934310C59ACD0457F2" unitRef="shares">6025583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q3" decimals="INF" id="Fact-7BB37B3A70D6CB674DE556EE9929491E" unitRef="shares">3595855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-6510AE4964533B30CC4BC59ACF5F935C" unitRef="usdPerShare">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2017Q3" decimals="2" id="Fact-7CD6E759A958F0B1911E56EF2343CAF7" unitRef="usdPerShare">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="D2014Q4Oct03-03" decimals="-3" id="Fact-D6677DA3984435A5F962DF8240343833" unitRef="usd">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected contextRef="D2014Q4Oct03-03" decimals="INF" id="Fact-8C0042FFE32551328894DF86FC04C0C7" unitRef="individual">20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-4E83D78ED8E0741AAC02C59A94F4205A" unitRef="usdPerShare">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-FE1C02D710647FDD7763C59AC22165F0" unitRef="usdPerShare">0.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD" decimals="2" id="Fact-8433083DDC5C8B3D058356E9C9D8D27A" unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-D1CEB533F5704E799773C59A9A29D65A" unitRef="usdPerShare">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-3D29D8DF0FB8D8B9BC17C59AC50FB247" unitRef="usdPerShare">0.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD" decimals="2" id="Fact-7E63B6EA3C5B1E13594B56EA3D676E1D" unitRef="usdPerShare">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-753B4158402E8A30EE92C59A8FB96495" unitRef="usdPerShare">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-7C1FE2A56113B0137241C59ABCFA2719" unitRef="usdPerShare">1.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD" decimals="2" id="Fact-C063A36CD79B9001390D56E981E90F63" unitRef="usdPerShare">4.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-F0BA6C4F27ECF043DA3DC5A82FCA38D7" unitRef="usdPerShare">0.98</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-138A8C25933BF99039C2C5A82DE3CB82" unitRef="usdPerShare">0.51</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-7250A996D91A15A51E47C5A831E65640" unitRef="usdPerShare">0.69</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-37D9EAC2602813832C2F56731C29D239" unitRef="usdPerShare">2.12</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-D62619D7E3FFF94B9E5756731C375667" unitRef="usdPerShare">1.91</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q3_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-CBAD91EDBFC0CBFA78AA56731C315AA5" unitRef="usdPerShare">1.98</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-F4F6FC978A1FDA6FB450C5A74877893E" unitRef="usdPerShare">1.20</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-71F5A375C98196B9BA40C5A745DFE085" unitRef="usdPerShare">0.95</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2016Q4_us-gaap_RangeAxis_us-gaap_WeightedAverageMember" decimals="2" id="Fact-BDA74317891E550ECE14C5A74AC8FBD7" unitRef="usdPerShare">1.14</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="FI2017Q3" decimals="2" id="Fact-4CE80F65BBEC8F833A62567255DE8FA1" unitRef="usdPerShare">4.21</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="2" id="Fact-46204E7C10F254DC67B1C5939E92EE67" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_InitialEmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="4" id="Fact-736A33AC43A56CD98F5F56326A1928AC" unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_xcur_SubsequentEmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="4" id="Fact-7EF4390448C78AA37E60C5A0C009B38C" unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2015Q4Oct6_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" id="Fact-A2CABE4B9BDB2B00E1BEDF723E7B6096">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-AC5C1E00E48771EF46CDC5AAF577CA70">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-44D6847C47445B36550BC5AAF3952E73">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-0223340285E4CEF9C9D7565D82A81D3B">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-8C30EA0B22BC15F55AFA565D82B11863">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-F17615144FCD803B35DFC5AAF035B165">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-B5D2BA8BD39E457FA591C5AAEDACC55C">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-B0043A0B9719D95E6ADB565D82AC610E">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-445F46D13A6270241130565D82A46579">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2016Q4_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="-3" id="Fact-99580752A19E648FE76EC59ACC7970A3" unitRef="usd">4683000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q3" decimals="-3" id="Fact-16B9F8023AC5AAC3D2A156F158C25FDC" unitRef="usd">3704000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" id="Fact-20D2033202C87C5F83C9C59ACBB687CF">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q3YTD" id="Fact-7DB1C2D8952592106FC556F1E5C5D6C6">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" id="Fact-CEEA2E68DFA737C346BBC59AA1007184">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-A1E92D0B2704805AAE6056F255AF4E1E">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" id="Fact-269F18F170E582119B67C59AC893A9D0">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q3YTD" id="Fact-98433993E5023976DA1D56F255B23BD2">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" id="Fact-D7F8F77C7F4EB1B1DAF8C59AD020B3B0">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q3YTD" id="Fact-A19CD6AA6728A9E5724D56F2941051B8">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-50B5D000C59109E6089DC5393ACBBB7E" unitRef="shares">22924210</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-15F41AB18F60C456BFE5C5392D5FA180" unitRef="shares">2827848</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-243160A549F6EB5D9E22C53934482FE3" unitRef="shares">4937818</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-FE23072C00BFFDFBDAD6C539263DFE9F" unitRef="shares">5911450</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="INF" id="Fact-7917C79EB40508508F3DC539414E9714" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-CCD99B7311AF82B1394EDED1DCC02931" unitRef="shares">22924209</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-1095DDC5F0663647B5A9DED1CD5D6B0B" unitRef="shares">14464445</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-88A147CF571A62CC2DC3DED1D732BEA5" unitRef="shares">4937813</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-27F44C0F5FDCB562D242DED1D2A30C02" unitRef="shares">2827844</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-56062B87B06A30488604DED1E2808B3B" unitRef="shares">166875</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-22098D8905C5C3C7329B5E84ADA9FBFB" unitRef="shares">11381640</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-6E0DB0DC27DB7133F217DED256A85DDF" unitRef="shares">22924209</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-A57F255420E395F681DB5E84AD95CFBF" unitRef="shares">11239359</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-6F8C010CFB5D572F4A8BDED24780D611" unitRef="shares">14660096</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-92BF41938C7409741E815E84AD953294" unitRef="shares">2451560</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-FAF7118509178DAAC43DDED2519572E7" unitRef="shares">4937813</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-FD1E2D5E2C5197BD43575E84AD9F6593" unitRef="shares">1403984</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-6802AA5A5FEE0420CCF8DED24D1823C5" unitRef="shares">2827844</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A65DD46289A4AAE7C45F5E84ADA97672" unitRef="shares">131644</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-FC3D220226F359946B98DED25C31E1D7" unitRef="shares">265158</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-E714AD9AB1DC6286D52F5E84AD77DB36" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-80520151C4A12A1E3E705E84AD9F4765" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-8CB1AAB4382A3F5FCCBC5E84AD6DCC0B" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-0BBD4C0186EE328C54195E84AD9570FB" unitRef="shares">0</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D40C99C1C0A126B04EB35E84AD9FFFDE" unitRef="shares">35513987</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="0" id="Fact-39A1805A8797BD98095B58EBCC20C5A0" unitRef="shares">11381611</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-B5C362DC4A86F23D598AFE59707C76D4" unitRef="shares">22924210</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="INF" id="Fact-DE594A28D959E26E0FE258F5BE404B48" unitRef="shares">2451571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-F239F089635854FDF7FFDF925A5C7D22" unitRef="shares">4937818</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember" decimals="0" id="Fact-169F3E055CAED97D68D903F0247C1FD0" unitRef="shares">1403995</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2013Q2Jun27_us-gaap_StatementClassOfStockAxis_xcur_ClassB2UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-5C2C6F204C1EBECEC0BADF9345091CAE" unitRef="shares">2827848</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-A9E3EB0442B280B66281DEE271AF4747" unitRef="shares">6542783</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q4Nov14-14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="0" id="Fact-13DE72C76783725E4F47A794DDD003AC" unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-7D81C833F052E7AF7088DEE2E74173B7" unitRef="shares">195651</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-14195FF95D25AC65E685472F65BB6BC1" unitRef="shares">6767360</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="INF" id="Fact-8A0A6E5DC1C3C4C2A3A3C53B88119797" unitRef="shares">153750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A8BCD13B05B904559021DEDF58560C6E" unitRef="shares">13125</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-E53171EA8D54BA990613C59A9353F5E2" unitRef="shares">166875</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9E6B8D5DFB4D71CF4BF7DEDF8833786E" unitRef="shares">98283</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-ACF1B0494820155CA1C7C59AC13DE6BB" unitRef="shares">98283</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q3YTD" decimals="INF" id="Fact-3253ABD98D383D6467E356E5E496D149" unitRef="shares">58440</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D484D1C96A71BA1915EE472AD4A0C522" unitRef="shares">58440</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2015Q4Jul09-Dec31" decimals="-3" id="Fact-2E302D76FC4305DA3110DEE3C95D9B82" unitRef="usd">14979000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FC0D401B853B2A0A5D44DEE3454B2173" unitRef="usd">14979000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DDCB1A0A030506C43E6EDEE3EDACA80A" unitRef="usd">444000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-634388ECD0FEA6B2FF6FDEE353B1D3A5" unitRef="usd">444000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9C9BC0B969BE36A8AEB6472D57E4614B" unitRef="usd">17055000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FA2EBB81D528D47BD854472D57E69B1F" unitRef="usd">17054000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2BE82064BDC51396F510472D57E8C308" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D2015Q3Jan01-Jul08" decimals="-3" id="Fact-E82A89D3A5D4EA789AC2C53BAD14CEEB" unitRef="usd">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FDF6A6B4CA13642734D7C53BACEC1D9F" unitRef="usd">-12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="-3" id="Fact-90077019121B125C9D8FC53BACFAB9DE" unitRef="usd">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D2015Q4Jul09-Dec31" decimals="-3" id="Fact-69E282C1A84C7BD4D2D5DEDF5EBA8F73" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-15021D00DD2A4E81C83EDEDF5B7B411E" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA235874BC4B40977564DEDF8EB548FF" unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-20F7642FD84C001F54E4DEDF8B78B299" unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5E75578F4A595990179B472A44801A93" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1AD972E06E7EB80594E2472A4480F559" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-CEC0061751232A198EAEC5394B9BB379" unitRef="usd">11397000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-035E324C263E9BC515A2C5393E0CE19A" unitRef="usd">135000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-BD810C24539B13FFC48CC53930ED30FE" unitRef="usd">3641000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C47104E6ACD568022454C5393811B57F" unitRef="usd">5371000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-445A41963429E669622FC5392A16E715" unitRef="usd">13479000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-927778260BC3149B4310C5394666B1F8" unitRef="usd">120000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="-3" id="Fact-6BCD40695D741136FC5DC53943C9CED7" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-333CA8FFB0B13C1F297CC53949036FC4" unitRef="usd">-11349000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-CB86C5A6F2FAB8F88234C1B2AF7F58FF" unitRef="usd">18230000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-25B4DFDEAB05CF5B0F8BDED1DF93A02C" unitRef="usd">135000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-E57AC2B5A44ED9B3BB66DED1CFE6DF09" unitRef="usd">33039000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9B9BFF25487799FE0F41DED1DA03C532" unitRef="usd">5371000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-1DE984AD0D929FB75FB3DED1D4EC81F8" unitRef="usd">3641000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-44B69D337D8431BF088FDED1E666E95A" unitRef="usd">-18293000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7DD52821745C19145F16DED1E4695A54" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-16054CB21A8F06371744DED1E8C57CA9" unitRef="usd">-5663000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-4A75A03B98477DD8DE83C1B2AF80201B" unitRef="usd">2448000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-A1BEA1FF7C3E2376F7A3DED2596AC26F" unitRef="usd">135000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-CE51A39C3A4449916E74DED24A494797" unitRef="usd">33483000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-966E57D32DD7924C6B20DED253DADB00" unitRef="usd">5371000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-E80FFAC12265AE542C84DED24F6CA9DE" unitRef="usd">3641000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9E0B8080FD94B939A731DED2608CD650" unitRef="usd">-17578000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-04623CDF4876F59C9660DED25E4060EE" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-227397BF51A04AA20084DED2628181BC" unitRef="usd">-22604000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-DD053D27BAA16E50E6B93EBE89684709" unitRef="usd">11682000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-AE0B55099A36AC52BEDD5E84AD777BF0" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9FC92261C5372558691D5E84AD9F4160" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-326E8E7319F0776952705E84AD9FB464" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-6A120A380214F1447B4E5E84AD8BC1B4" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B552E382B17D7E2819C65E84AD8BDF5F" unitRef="usd">43219000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6BCB94B1FF237863C1025E84ADA9A940" unitRef="usd">4000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-980B5DDB7D563F43CBFD5E84AD8B1A8E" unitRef="usd">-31541000</us-gaap:StockholdersEquity>
	<us-gaap:TangibleAssetImpairmentCharges contextRef="D2016Q4Dec01-Dec31" decimals="-3" id="Fact-214773A1F7F3F0C61450DF9F40FE0694" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
	<us-gaap:TangibleAssetImpairmentCharges contextRef="D2017Q3Dec0111Sep3017" decimals="-3" id="Fact-1D4C0C5C33F046FE00945A3073365D1E" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
	<us-gaap:UnbilledContractsReceivable contextRef="I2011Q4Dec12_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-21530B2828B3CCC0DAF7C56833D06861" unitRef="usd">143000</us-gaap:UnbilledContractsReceivable>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-29E506B21E55F83FFD1BC1ACE22F03E8" unitRef="usd">166000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C6EB24E3FA095BAAEC04C1ACE22703C5" unitRef="usd">0</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-E5D3233F7C03FFA7DD9A3EA657AC8227" unitRef="usd">201000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-3" id="Fact-864CFA8C1C2E67A5E5E6FDFFDFB8D922" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-A73C8918E9977A5328B0FDFFAF8DAFEF" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-5E74143103E2A875CCDCC52FEFC5E7BD" unitRef="shares">108123</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3QTD" decimals="0" id="Fact-0ADCDE2CF3832E77E6F147438A03F5C5" unitRef="shares">97691</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3YTD" decimals="0" id="Fact-DD21C760B6B051BEF0F947438A03F7F3" unitRef="shares">109539</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-E4E76638ED29F7F7A6B6C52FEFC6FBFD" unitRef="shares">228447</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="0" id="Fact-C805FD2AD969AF5886E347438A13986D" unitRef="shares">1725906</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3YTD" decimals="0" id="Fact-66C3159BC391273C598047438A13B023" unitRef="shares">183395</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<xcur:AccountsReceivableSaleOfStock contextRef="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="-3" id="Fact-497D46398609F2759483DF92B3DAECBF" unitRef="usd">500000</xcur:AccountsReceivableSaleOfStock>
	<xcur:AccruedLicenseAgreementFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-BFE9EE0FE39BBFA02CC6C1B41E928C5B" unitRef="usd">0</xcur:AccruedLicenseAgreementFeesCurrent>
	<xcur:AccruedLicenseAgreementFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-015FD6173710EDFF8952C1B41DB31EB3" unitRef="usd">1500000</xcur:AccruedLicenseAgreementFeesCurrent>
	<xcur:AccruedLicenseAgreementFeesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-F9AE58DBCA91EB73C474511B7D030F61" unitRef="usd">0</xcur:AccruedLicenseAgreementFeesCurrent>
	<xcur:AdjustmentToAdditionalPaidInCapitalConversionOfCapital contextRef="D2015Q3Jul09-09_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-B5ECE1BCC509809D7E3CB66BCE336C53" unitRef="usd">18837000</xcur:AdjustmentToAdditionalPaidInCapitalConversionOfCapital>
	<xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="0" id="Fact-08D2588F8BF77429E3D0B748336F65C3" unitRef="target">3</xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets>
	<xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-E9FC49DB40C0DBBC9636C57835469BB0" unitRef="target">3</xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets>
	<xcur:CollaborationAgreementRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8785EAD3994BE86B91F5C52DD1A4E639" unitRef="usd">0</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-3616E434E1D31F111807493D0C0A3B89" unitRef="usd">0</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-09D143B0EEC933DAB142493D0C0A46DE" unitRef="usd">0</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C36DD8BEBADCE896B775C52DD1A1D067" unitRef="usd">690000</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2017Q3QTD" decimals="-3" id="Fact-E9925F0B4E3848FDEA11493D0C0A28CF" unitRef="usd">2497000</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C09EDCD8067DB7B988D6493D0C0AFA01" unitRef="usd">7624000</xcur:CollaborationAgreementRevenue>
	<xcur:CollaborationAgreementUpfrontPayment contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-B3556392B6F2C366146CC57752FB7894" unitRef="usd">10000000</xcur:CollaborationAgreementUpfrontPayment>
	<xcur:CollaborativeArrangementEquityReceivedNumberofShares contextRef="I2011Q4Dec12_dei_LegalEntityAxis_xcur_NorthwesternUniversityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="0" id="Fact-E6A50BF7EACF680628637A27C7F79CF2" unitRef="shares">229242</xcur:CollaborativeArrangementEquityReceivedNumberofShares>
	<xcur:CollaborativeArrangementEquityReceivedNumberofShares contextRef="I2011Q4Dec12_dei_LegalEntityAxis_xcur_NorthwesternUniversityMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="0" id="Fact-384F96514DE0336D2395A3A9825DB58E" unitRef="shares">113816</xcur:CollaborativeArrangementEquityReceivedNumberofShares>
	<xcur:CollaborativeArrangementEquityReceivedPercent contextRef="I2011Q4Dec12_dei_LegalEntityAxis_xcur_NorthwesternUniversityMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="3" id="Fact-81326B3471DAA1CB0E5DC568E511CBE5" unitRef="number">0.010</xcur:CollaborativeArrangementEquityReceivedPercent>
	<xcur:CommonStockVotingRightsforEachShare contextRef="FI2017Q3" decimals="0" id="Fact-714400B759ED38D833A1A6E436A9D824" unitRef="vote_per_share">1</xcur:CommonStockVotingRightsforEachShare>
	<xcur:CommonStockWarrantLiability contextRef="FI2016Q4" decimals="-3" id="Fact-8ADFAB7DF229189DD7EA3ECE49931EE2" unitRef="usd">0</xcur:CommonStockWarrantLiability>
	<xcur:CommonStockWarrantLiability contextRef="FI2017Q3" decimals="-3" id="Fact-0969F9EB01B7255A8C5B3ECE4991321B" unitRef="usd">211000</xcur:CommonStockWarrantLiability>
	<xcur:ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction contextRef="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" decimals="2" id="Fact-FE071CB63A051D73CF557907C2AC5BE3" unitRef="number">0.94</xcur:ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction>
	<xcur:ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction contextRef="D2017Q3Sept26_us-gaap_StatementClassOfStockAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-C2AE98907B7F1188614AC62C7DBA6ED4" unitRef="number">0.94</xcur:ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" decimals="INF" id="Fact-7FE76C139397B77CE4FE9C207F0699D1" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" decimals="INF" id="Fact-247A88EF6443FB0572DF9C20804B789D" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" decimals="INF" id="Fact-5DC9B5647D120C2260599C20814251A3" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" decimals="INF" id="Fact-FE66FC87550270E469FE9C2082C30386" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" decimals="INF" id="Fact-A10A77F4ACAC3052640E7A19556B7B62" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7E95E37A72E97EE603967A19F37C8E6C" unitRef="number">1</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" decimals="INF" id="Fact-B493E31D282A78955F496D8D9B96A119" unitRef="number">0.49649</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-7267DB0A5666A7172A09C587A3FF7C96" unitRef="number">0.49649</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" decimals="INF" id="Fact-83190007E6C82501443C5E3A5F257ED0" unitRef="number">0.49649</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-3DD8E7864C6917278056C5E200012F6F" unitRef="number">0.49649</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" decimals="INF" id="Fact-EDC6DEDE6A00FBE0881A6D8DB0363BCC" unitRef="number">0.7666652</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockConversionRatio contextRef="D2017Q3Sept26_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-D1A1D1CBB3D35284CDD1C587C7F56E54" unitRef="number">0.7666652</xcur:ConversionofStockConversionRatio>
	<xcur:ConversionofStockNumberofSharesEffectivelyNotConverted contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_PreferredUnitsMember" decimals="INF" id="Fact-E0A1B800CDC550B9F7447A1242799AEF" unitRef="shares">46</xcur:ConversionofStockNumberofSharesEffectivelyNotConverted>
	<xcur:ConversionofStockNumberofSharesEffectivelyNotConverted contextRef="D2015Q3Jul09-09_us-gaap_StatementClassOfStockAxis_xcur_PreferredUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="0" id="Fact-6DC25D2015FF865F5A27C5FFE10BF3B3" unitRef="shares">17</xcur:ConversionofStockNumberofSharesEffectivelyNotConverted>
	<xcur:DebtInstrumentBasisSpreadonVariableRateDecrease contextRef="D2016Q1Feb1716_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="4" id="Fact-C7970E45C3402068F5A9C58F09778FAB" unitRef="number">0.0350</xcur:DebtInstrumentBasisSpreadonVariableRateDecrease>
	<xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C4D9CEDC4399DDDECBC1DF41DFF2E5D4" unitRef="usd">-671000</xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-990249208B4A2D72DE65DF41DFD41C8F" unitRef="usd">0</xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent contextRef="FD2015Q4YTD" decimals="3" id="Fact-B2824673BC747AD29555DF42A13FDD4E" unitRef="number">0.051</xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent>
	<xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent contextRef="FD2016Q4YTD" decimals="3" id="Fact-2E8A6C8E0E524E278865DF42A13AFE20" unitRef="number">0.000</xcur:EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent>
	<xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-46C2D4FED896AB05E168DF40148E1F02" unitRef="usd">2546000</xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7FD63146C0E5CB74F5D2DF40147A140E" unitRef="usd">0</xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent contextRef="FD2015Q4YTD" decimals="3" id="Fact-E34A1AEB2C5892A076CFDF40FBD2542C" unitRef="number">-0.194</xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent>
	<xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent contextRef="FD2016Q4YTD" decimals="3" id="Fact-4CDD15718D1CA744DD06DF40FBB94A55" unitRef="number">0.000</xcur:EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent>
	<xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3CBD7A11DF754BF7CC2ADF3DFFA1339A" unitRef="usd">340000</xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E52DBA7CDD67165A8BEBDF3DFF9BEAF5" unitRef="usd">43000</xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount>
	<xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="FD2015Q4YTD" decimals="3" id="Fact-3ABDAF1068CD4EA6B76BDF3F1F66DDA5" unitRef="number">-0.026</xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
	<xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent contextRef="FD2016Q4YTD" decimals="3" id="Fact-D0FEB6010A993172D199DF3F1F4B79FE" unitRef="number">-0.003</xcur:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
	<xcur:EstimatedFairValueofCommonStockPerShare contextRef="FI2017Q3" decimals="2" id="Fact-B4E0D5DE4B72108329CDBC1CE9D56F0E" unitRef="usdPerShare">3.00</xcur:EstimatedFairValueofCommonStockPerShare>
	<xcur:EstimatedFairValueofCommonStockPerShare contextRef="I2014Q4Oct03" decimals="2" id="Fact-63D7D80E5CA53550B5ADDF70DCD78E69" unitRef="usdPerShare">0.32</xcur:EstimatedFairValueofCommonStockPerShare>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C43427737B6F94FC7123C5C82C4BC484" unitRef="usd">12000</xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2EEC6212CBDF141B0AE65FDDD08585A1" unitRef="usd">18000</xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6EC2946F1FC9AC247F7AC5C84958C522" unitRef="usd">26000</xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock>
	<xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BECB6FE5CB6C036CE0985FDAFFDD2B13" unitRef="usd">34000</xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock>
	<xcur:IncreaseDecreaseAccruedProfessionalFees contextRef="FD2015Q4YTD" decimals="-3" id="Fact-516307D1FFC98128973EDF066F3B54FD" unitRef="usd">29000</xcur:IncreaseDecreaseAccruedProfessionalFees>
	<xcur:IncreaseDecreaseAccruedProfessionalFees contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EDFC0E319B9F2AFC072FDF066F27BEEB" unitRef="usd">45000</xcur:IncreaseDecreaseAccruedProfessionalFees>
	<xcur:IncreaseDecreaseInAccruedLicenseAgreementFees contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F2C611DBAF3388C3C739DF03239B5C52" unitRef="usd">0</xcur:IncreaseDecreaseInAccruedLicenseAgreementFees>
	<xcur:IncreaseDecreaseInAccruedLicenseAgreementFees contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D6D2A71D0ED70A1C5698DF0323A34B62" unitRef="usd">1500000</xcur:IncreaseDecreaseInAccruedLicenseAgreementFees>
	<xcur:IssuanceOfCommonStockWarrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9E8F538B376ECB3C1E5950406801CB56" unitRef="usd">0</xcur:IssuanceOfCommonStockWarrants>
	<xcur:IssuanceOfCommonStockWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-053C09895E03DA646C70504067FF635E" unitRef="usd">211000</xcur:IssuanceOfCommonStockWarrants>
	<xcur:IssuanceofPreferredStockWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A6DBB699E3C57B45A0F0DF083DC8E3D7" unitRef="usd">0</xcur:IssuanceofPreferredStockWarrants>
	<xcur:IssuanceofPreferredStockWarrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7C54A6004D6356EEEB9A5040E4744C44" unitRef="usd">134000</xcur:IssuanceofPreferredStockWarrants>
	<xcur:IssuanceofPreferredStockWarrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5B38C85E9A8D4E47903EDF083DC3BF36" unitRef="usd">134000</xcur:IssuanceofPreferredStockWarrants>
	<xcur:IssuanceofPreferredStockWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AC31A24417EAC56A68B45040E46EA726" unitRef="usd">0</xcur:IssuanceofPreferredStockWarrants>
	<xcur:LineOfCreditFacilityRightToParticipateInFutureFinancingAmount contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-3" id="Fact-22E871157975EE827B41C58F7A3D69FA" unitRef="usd">1000000</xcur:LineOfCreditFacilityRightToParticipateInFutureFinancingAmount>
	<xcur:MembersCapitalContributions contextRef="D2011Q4Dec11_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember" decimals="-3" id="Fact-A213A4CA0EBFEE44F9B4C568BA7D9755" unitRef="usd">135000</xcur:MembersCapitalContributions>
	<xcur:MembersCapitalContributionsFairValue contextRef="D2011Q4Dec11_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_SubsidiaryOfCommonParentMember_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="-3" id="Fact-6172A0A03B5F5E52DE39C6000EE4D0D2" unitRef="usd">25217000</xcur:MembersCapitalContributionsFairValue>
	<xcur:MembersCapitalSharePriceFairValue contextRef="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember" decimals="2" id="Fact-76118B93F3500EB76FDF58EF3EFD0C59" unitRef="usdPerShare">2.22</xcur:MembersCapitalSharePriceFairValue>
	<xcur:MembersCapitalSharePriceFairValue contextRef="I2011Q4Dec12_us-gaap_StatementClassOfStockAxis_xcur_ClassAUnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="2" id="Fact-B0EA96E359DDC8D61911C60069C65B03" unitRef="usdPerShare">1.10</xcur:MembersCapitalSharePriceFairValue>
	<xcur:MembershipUnitsIssuedDuringPeriodSharesNewIssues contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-93F533DB084ACF948F9EDEEAAF6B331C" unitRef="shares">2010219</xcur:MembershipUnitsIssuedDuringPeriodSharesNewIssues>
	<xcur:MembershipUnitsIssuedDuringPeriodValueNewIssues contextRef="D2015Q3Jan01-Jul08" decimals="-3" id="Fact-AD576CC7BCA8F7967012DEEAC1FE1A52" unitRef="usd">4581000</xcur:MembershipUnitsIssuedDuringPeriodValueNewIssues>
	<xcur:MembershipUnitsIssuedDuringPeriodValueNewIssues contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C021EAA9E9A6BC20648CDEEAB225153F" unitRef="usd">4581000</xcur:MembershipUnitsIssuedDuringPeriodValueNewIssues>
	<xcur:OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3EBDAFB10C9219F32989DF1885BACF06" unitRef="usd">17000</xcur:OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty>
	<xcur:OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty contextRef="FD2016Q4YTD" decimals="-3" id="Fact-311E48AD8E6EC09A8A33DF1885B8B419" unitRef="usd">0</xcur:OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty>
	<xcur:PaymentsOfCommonStockFinancingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-EEC0F44FA93F1D589A34496E96ABD7C2" unitRef="usd">0</xcur:PaymentsOfCommonStockFinancingCosts>
	<xcur:PaymentsOfCommonStockFinancingCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A968F25B94D151B28036496E969B1C85" unitRef="usd">1264000</xcur:PaymentsOfCommonStockFinancingCosts>
	<xcur:PaymentsOfPreferredStockFinancingCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-46D4CA9909A30EFEA647DEF68C3B0D32" unitRef="usd">112000</xcur:PaymentsOfPreferredStockFinancingCosts>
	<xcur:PaymentsOfPreferredStockFinancingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C993AA77C467C46C9336497003407DE6" unitRef="usd">6000</xcur:PaymentsOfPreferredStockFinancingCosts>
	<xcur:PaymentsOfPreferredStockFinancingCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2EE1B26DBD23BED94218DEF68C2BD14C" unitRef="usd">6000</xcur:PaymentsOfPreferredStockFinancingCosts>
	<xcur:PaymentsOfPreferredStockFinancingCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0B19A1E1B7E36A797BF44970034000FE" unitRef="usd">0</xcur:PaymentsOfPreferredStockFinancingCosts>
	<xcur:PaymentsToPrivatePlacementAgentsForPrivatePlacement contextRef="D2017Q4Sep26-Nov14_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="-3" id="Fact-13286FE6AFD54FB9CE1EA79118C8C30F" unitRef="usd">1968000</xcur:PaymentsToPrivatePlacementAgentsForPrivatePlacement>
	<xcur:PaymentsforLicenseAgreements contextRef="D2017Q3Dec12-Sep30" decimals="-3" id="Fact-9670B74EC79F3D652B2B7942987F15DB" unitRef="usd">3247000</xcur:PaymentsforLicenseAgreements>
	<xcur:PaymentsforLicenseAgreements contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F6419B797BE5D2EB1655C5D26BCF0643" unitRef="usd">1534000</xcur:PaymentsforLicenseAgreements>
	<xcur:PreferredStockLiquidationPreferencePercentOfAggregateCashContributions contextRef="FD2016Q4YTD" decimals="INF" id="Fact-B6C3F7A9CF4C33671312C5FF5236DF8C" unitRef="number">1.5</xcur:PreferredStockLiquidationPreferencePercentOfAggregateCashContributions>
	<xcur:PreferredStockLiquidationPreferencePercentOfAggregateCashContributions contextRef="FD2017Q3YTD" decimals="INF" id="Fact-1A7C467AE35790494DFCA2951A8C7171" unitRef="number">1.5</xcur:PreferredStockLiquidationPreferencePercentOfAggregateCashContributions>
	<xcur:PreferredStockWarrantLiability contextRef="FI2015Q4" decimals="-3" id="Fact-F5D95564A7899F343C7FC1B1D02D5D7C" unitRef="usd">0</xcur:PreferredStockWarrantLiability>
	<xcur:PreferredStockWarrantLiability contextRef="FI2016Q4" decimals="-3" id="Fact-A11BFF3881832722D6A3C1B1D0296BAC" unitRef="usd">201000</xcur:PreferredStockWarrantLiability>
	<xcur:PreferredStockWarrantLiability contextRef="FI2017Q3" decimals="-3" id="Fact-279880AE937D235A5C5B3ECDBBDD0E44" unitRef="usd">0</xcur:PreferredStockWarrantLiability>
	<xcur:PreferredStockWarrantLiability contextRef="I2016Q1Feb17_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_LineOfCreditFacilityAxis_xcur_HerculesTechnologyGrowthCapitalMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LoansPayableMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-AEDA36A9AB6011F0CB81C58FB42FF8D7" unitRef="usd">134000</xcur:PreferredStockWarrantLiability>
	<xcur:PriceBasedAnitDilutionProtectionGrossProceedsThreshold contextRef="D2017Q3Sept26" decimals="-3" id="Fact-A9AC70A95B2CB9B911F55E384191262D" unitRef="usd">40000000</xcur:PriceBasedAnitDilutionProtectionGrossProceedsThreshold>
	<xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty contextRef="D2016Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-589E57096855EB315F5EC5DB158B426A" unitRef="usd">8000</xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty>
	<xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty contextRef="D2017Q1Jan1_us-gaap_CounterpartyNameAxis_xcur_AuraSenseLLCMember" decimals="-3" id="Fact-41E9B375FA829C4CB8676000FF36A59E" unitRef="usd">3000</xcur:RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty>
	<xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate contextRef="FI2016Q4" decimals="-3" id="Fact-366F15C613BD17D77DC7DFB9E0B8E8BF" unitRef="usd">-41441000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
	<xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate contextRef="FI2017Q3" decimals="-3" id="Fact-7C1F38C229B39F08023B6DA5152F0614" unitRef="usd">-50378000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-F91EE7A24E2E421B3D629DC847CD5808" unitRef="usd">350000000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-22056B4F072F50A3ABC19DC720C88BF1" unitRef="usd">410000000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-5DB30A408A02FA3D06699DC43F0D5BA7" unitRef="usd">16500000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent contextRef="D2016Q4Dec02-02_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="2" id="Fact-2CDD5602215F95A122559DD19A21C674" unitRef="number">0.10</xcur:RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-625F12035D66C03472FFC58106C1B689">P14M15D</xcur:RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-1F1DE06F5FAB1C3C4D22C57808DB704D" unitRef="usd">770000000</xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue>
	<xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue contextRef="D2016Q4Dec02-02_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-65BBA8E3EC625BD6B8D75B3D39E8850F" unitRef="usd">776500000</xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue>
	<xcur:SaleOfStockNumberOfSharesRelatedToAccountReceivable contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember" decimals="INF" id="Fact-EA061A5241FC252BA12B5919665D84D9" unitRef="shares">225677</xcur:SaleOfStockNumberOfSharesRelatedToAccountReceivable>
	<xcur:SaleOfStockNumberOfSharesRelatedToAccountReceivable contextRef="D2011Q4Dec11_us-gaap_StatementClassOfStockAxis_xcur_ClassB1UnitsMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioPreviouslyReportedMember" decimals="INF" id="Fact-FCD25D3C84C3C50B6ABDDF92CC5666DE" unitRef="shares">454545</xcur:SaleOfStockNumberOfSharesRelatedToAccountReceivable>
	<xcur:SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions contextRef="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-76C2B3215EBCE23BD52FDFB3DBD4AA66" unitRef="shares">3333333</xcur:SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions>
	<xcur:SaleofStockNumberofSharesAvailableForOffering contextRef="D2017Q3Sept26_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-90EA08F53FE6FE3D3202C62E025A0F21" unitRef="shares">13333333</xcur:SaleofStockNumberofSharesAvailableForOffering>
	<xcur:SaleofStockNumberofSharesAvailableForOffering contextRef="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="0" id="Fact-A4172625738EBE1E86B0A6D970EF322E" unitRef="shares">13333333</xcur:SaleofStockNumberofSharesAvailableForOffering>
	<xcur:SaleofStockNumberofSharesAvailableForOffering contextRef="D2017Q3Sept26_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-D55BEAE4A3D684F821DE5629648CB41E" unitRef="shares">13333333</xcur:SaleofStockNumberofSharesAvailableForOffering>
	<xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-F42430A61C084C49D7EC472717722B9B" unitRef="shares">-11381640</xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-8A7DD814BF88F4F221B5472717754157" unitRef="shares">-11239359</xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-40930187C001A7BF205F472717748072" unitRef="shares">-2451560</xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-1E36353900B401D016224727176C11C5" unitRef="shares">-1403984</xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-24B44F8200000AF8AD0E472717774C93" unitRef="shares">28556543</xcur:ShareConversionDuringPeriodSharesInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-1A76B3A67079819325C5DECE787630D4" unitRef="shares">-22924210</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-2291F4BC048FFB7420D8DECE786CB1AA" unitRef="shares">-2827848</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-F8B154F8C6FFD137FF69DECE787B8B4A" unitRef="shares">-4937818</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-F910667B03BCFDE67000DECE788166F0" unitRef="shares">-7921669</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="INF" id="Fact-1A32C01CA5F6B5CD49E8DECE78890064" unitRef="shares">-153750</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-4FD216F8C4965085CEBADED0F28FBD58" unitRef="shares">22924209</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-624B739C025F499685E9DED0E5E3731C" unitRef="shares">7921662</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-2F845E4DB2D1EEB6CA9BDED0EDE06267" unitRef="shares">4937813</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-42C3F9D6A2D2B7B080BFDED0E95DFB7C" unitRef="shares">2827844</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8E948B427539231C9335DED0F71AA45B" unitRef="shares">153750</xcur:ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD" decimals="-3" id="Fact-74234E5612A0B45B9778472680E136CE" unitRef="usd">-31000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9C97F730F77BFD7AF011472680E391B1" unitRef="usd">-135000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-F3B111550E1F006FE784472680D79EB8" unitRef="usd">-33483000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-0947AC931E7042D9F4C8472680DECFDC" unitRef="usd">-5371000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B6D2F97F4EF584239787472680D90B96" unitRef="usd">-3641000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9C7BC170866A837CD0F3472680DC5BCE" unitRef="usd">42596000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueInConnectionWithMerger contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D8FCB3EFEF330960C4BC472680DF561C" unitRef="usd">3000</xcur:ShareConversionDuringPeriodValueInConnectionWithMerger>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08" decimals="-3" id="Fact-2F10C0091964D8BA5B12DECF994DEAE0" unitRef="usd">-8677000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-BB8377B6E4B22C58C5ABDECF984052E7" unitRef="usd">-135000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-EE7680D382C840E31FF3DECF98E79FE6" unitRef="usd">-3641000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassBIMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-65F428E6425F77441C7FDECF981EB984" unitRef="usd">-5371000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementClassOfStockAxis_xcur_PreferredClassCMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-3CC6C679AF93D35024CADECF989E8B91" unitRef="usd">-18060000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-18660E3CF1F1AEFFE3EFDECF98661BE7" unitRef="usd">-246000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember" decimals="-3" id="Fact-E5651C4A5F86595DDE2FDECF982CE20F" unitRef="usd">-61000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q3Jan01-Jul08_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-7C7F542939A1211C14FADECF998B6595" unitRef="usd">18837000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31" decimals="-3" id="Fact-7B52BA926F2808168FAFDED0FD834FFA" unitRef="usd">8677000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-AA078AF4DB4CA01A72C5DED0F55CE01D" unitRef="usd">135000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-7997774A1EB87A507D79DED0E77A0767" unitRef="usd">18060000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB1PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-BF22D8605335C8344671DED0F02FA7F5" unitRef="usd">5371000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementClassOfStockAxis_xcur_SeriesB2PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-31145A74F9EF2C981047DED0EBA18E1E" unitRef="usd">3641000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation contextRef="D2015Q4Jul09-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-239BA8E41410DE295F49DED0FA09C47C" unitRef="usd">-18530000</xcur:ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-13D57B66810B3A914BF6C5AB173DF167" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2016Q3YTD" decimals="2" id="Fact-CDF8BC12D086CFA1319B565F9401611A" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2016Q4YTD" decimals="2" id="Fact-BADD9080AB859914C4EAC5AB1303A159" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2017Q3YTD" decimals="2" id="Fact-F083572D3F5D17272208565F93FCD541" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding contextRef="I2015Q4Oct13_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" decimals="2" id="Fact-CBA1D8F40D8AB5EA6EB4DF756610636D" unitRef="number">0.04</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding contextRef="I2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="2" id="Fact-1F15C8FF0A5822AD740D56026B39D359" unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares contextRef="D2017Q3Sept22_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="INF" id="Fact-C9A04374CE487E47C3F955FE04C178A3" unitRef="shares">4600000</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod contextRef="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember" decimals="INF" id="Fact-C778296B80CD3844ACF96D8D75B1EC10" unitRef="shares">3680997</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod contextRef="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureInc.2017EquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-22F508B4754B85BEA1A0C62D44413E04" unitRef="shares">3680997</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio contextRef="D2015Q3Jul09-09_us-gaap_ConversionOfStockByUniqueDescriptionAxis_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" decimals="INF" id="Fact-CEB216012FD2881EB7917A19F4890D92" unitRef="number">1</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod contextRef="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember" decimals="INF" id="Fact-9828A71C08F255A7E54E6D8D45F53EED" unitRef="shares">7414115</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod contextRef="D2017Q3Sept26_us-gaap_PlanNameAxis_xcur_ExicureOpCo2015EquityIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-B071B45916ABD2F94EFFC5E29F21F36D" unitRef="shares">7419740</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice contextRef="I2014Q4Oct03" decimals="2" id="Fact-4D12D7F27A63BC343D0FDF8618670E74" unitRef="usdPerShare">0.32</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice>
	<xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected contextRef="D2014Q4Oct03-03" decimals="INF" id="Fact-6F5DF4CF9A59AA1DD7B5DF87B445C1CC" unitRef="individual">7</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected>
	<xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B418C8E0F0D75714C198503EF50ACF36" unitRef="usd">0</xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F438BBF0698AE5293766503EF507C97C" unitRef="usd">1773000</xcur:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-20508E27DFAC2DC551C0DFE8BA32C4F5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been presented in conformity with GAAP.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-D89F2E218424CA487C5FDF9B9B3C44AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying financial statements as of, and for the years ended, December 31, 2016 and 2015, have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2017Q3YTD" id="Fact-61A0B49319A51EB79BAA6E35DEEC6505">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description of Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Exicure, Inc. (&amp;#8220;Parent&amp;#8221;) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&amp;#8217;s proprietary Spherical Nucleic Acid (&amp;#8220;SNA&amp;#8221;) technology. We believe the design of the Company&amp;#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&amp;#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Throughout these unaudited consolidated financial statements, the terms &amp;#8220;the Company&amp;#8221; and &amp;#8220;Exicure&amp;#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;The Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September 26, 2017, pursuant to the merger agreement,&amp;#160;Max-1&amp;#160;Acquisition Sub, Inc., a wholly-owned subsidiary of&amp;#160;Max-1&amp;#160;Acquisition Corporation&amp;#160;(&amp;#8220;Max-1&amp;#8221;),&amp;#160;merged with and into Exicure, Inc. (formerly AuraSense Therapeutics, LLC), a privately-held Delaware corporation referred to herein as Exicure OpCo., with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of&amp;#160;Max-1&amp;#160;Acquisition Corporation (the &amp;#8220;Merger&amp;#8221;). The Merger was effective as of September 26, 2017 (the &amp;#8220;Effective Time&amp;#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At the Effective Time, the legal existence of&amp;#160;Max-1&amp;#160;Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&amp;#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock, and each share of Exicure OpCo&amp;#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock. As a result, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;26,666,627&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock were issued to the holders of Exicure OpCo&amp;#8217;s capital stock, which is incremental to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,080,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;7,414,115&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,680,997&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of&amp;#160;Max-1&amp;#160;common stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware,&amp;#160;Max-1 changed its name to Exicure, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Merger is considered a &amp;#8220;reverse merger,&amp;#8221; whereby Exicure OpCo is considered the accounting acquirer in the Merger. Exicure OpCo was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i)&amp;#160;legacy Exicure OpCo shareholders own approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;94%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii)&amp;#160;legacy Exicure OpCo directors will hold all six board seats of the combined company, and (iii)&amp;#160;legacy Exicure OpCo management will hold all positions in management of the combined company. The transaction is accounted for as an asset acquisition rather than a business combination because as of the acquisition date,&amp;#160;Max-1&amp;#160;does not meet the definition of a business as defined by accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;).  Consequently, the assets, liabilities and operations that are reflected in Exicure&amp;#8217;s historical financial statements prior to the Merger will be those of&amp;#160;Exicure OpCo, and the consolidated financial statements after completion of the Merger will include the assets, liabilities and results of operations of Exicure OpCo up to the day prior to the closing of the Merger and the assets, liabilities and results of operations of the combined company from and after the closing date of the Merger.  The assets and liabilities of Max-1 included in the accompanying consolidated financial statements are recorded at the historical cost basis of&amp;#160;Max-1.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In these unaudited consolidated financial statements, unless otherwise indicated, all share and per share figures are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&amp;#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;the Company&amp;#8217;s common stock, and each share of Exicure OpCo&amp;#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;the Company&amp;#8217;s&amp;#160;common stock.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Capitalization Prior to the Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date.  On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement.  Pursuant to this agreement AuraSense, LLC received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;11,381,611&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class A Units of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$143&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, scientific equipment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$309&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and a liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$317&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for accrued legal expenses related to patent protection. The net book value of Parent&amp;#8217;s contribution at inception was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$135&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License Agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company.  Under the terms of the License Agreement and the Partial Assignment of License Agreement, Northwestern University received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;113,816&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; units. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Unaudited Consolidated Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively. No preferred stock was provided in consideration for fractional membership units.  Each outstanding option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; common unit of AuraSense Therapeutics, LLC was converted into an option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; share of common stock of Exicure OpCo. In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$18,837&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; was reclassified to Additional paid in capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Refer to Note 6, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Stockholders&amp;#8217; Equity, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;for more information on capital stock transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been presented in conformity with GAAP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Liquidity risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of September 30, 2017, the Company has generated an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$50,378&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&amp;#8217;s current operating plans, it believes that existing working capital at September 30, 2017 when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$11,211&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the sale of common stock (see Note 13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;), but excluding any potential proceeds from option exercises, is sufficient to fund its current operating plans into 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Unaudited interim financial information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying interim consolidated balance sheet as of September 30, 2017, the interim consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, the interim consolidated statement of changes in stockholders&amp;#8217; equity for the nine months ended September 30, 2017, and the interim consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016, are unaudited. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&amp;#8217;s financial position as of September 30, 2017, the results of its operations for the three and nine months ended September 30, 2017 and 2016, and the results of its cash flows for the nine months ended September 30, 2017 and 2016. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2017 and 2016 are unaudited. The results for the three and nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, or any other interim periods, or any future year or period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&amp;#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2016Q4YTD" id="Fact-C5C7AB38D1EAA878733CC5FD83D62B4E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description of Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Exicure, Inc. (formerly AuraSense Therapeutics, LLC) (the Company) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&amp;#8217;s proprietary Spherical Nucleic Acid, or SNA, technology. The Company believes the design of the Company&amp;#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&amp;#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. No preferred stock was provided in consideration for fractional membership units. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date. On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement. Pursuant to this agreement AuraSense, LLC received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;22,924,210&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class A Units of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$143&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, scientific equipment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$309&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and a liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$317&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for accrued legal expenses related to patent protection. The net book value of Parent&amp;#8217;s contribution at inception was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$135&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company. Under the terms of the License Agreement and the Partial Assignment of License, Northwestern University received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;229,242&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; units. Also on December 12, 2011, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,937,818&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B (Series B-1) units with net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,371&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In June 2013, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,827,848&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B (Series B-2) units for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,641&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In June 2014, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5,911,450&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,479&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In February 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,010,219&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$4,581&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In October 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,542,783&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$14,979&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In January 2016, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;195,651&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$444&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;These transactions are described in more detail below in Note 5, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying financial statements as of, and for the years ended, December 31, 2016 and 2015, have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Going concern&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of December 31, 2016, the Company has generated an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$41,441&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&amp;#8217;s current operating plans, existing working capital at December 31, 2016 is not sufficient to sustain operations beyond September 30, 2017. As discussed in Note 12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, on September 26, 2017 the Company completed the Merger with Max-1 Acquisition Corporation and the Private Placement for the sale of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$20,302&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of Exicure shares of Common Stock, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,767,360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares, at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share (see Note 12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;). The combined company is expected to have approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$17,394&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in additional capital after the Private Placement. Management believes cash as of December 31, 2016, when combined with the cash raised in connection with the Private Placement, is sufficient to fund the Company through September 30, 2018. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reverse merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September 26, 2017, the Company completed the Merger with Max-1 Acquisition Corporation (see Note 12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;). Pursuant to the terms of the Merger, each outstanding share of Exicure capital stock (other than shares of Series C Preferred Stock of Exicure) was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Acquisition Corporation&amp;#8217;s Common Stock and each outstanding share of Series C Preferred Stock of Exicure was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Acquisition Corporation&amp;#8217;s Common Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&amp;#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-B43522B966E56F5F4FAE6E3EC472A5E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-7A2EEF374F2C17CFD1FDDF9D76B5AF63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-C32F8A8A03A527759BD16E4A5368D052">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Purdue Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue and referred to herein as the &amp;#8220;Purdue Collaboration.&amp;#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&amp;#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. In addition, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$776,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$16,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$410,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$350,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&amp;#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&amp;#160;Purdue&amp;#8217;s right to participate in a future&amp;#160;qualified equity&amp;#160;financing of the&amp;#160;Company&amp;#160;if such financing occurs prior to&amp;#160;June 2, 2017&amp;#160;or the pricing of&amp;#160;the&amp;#160;initial public offering&amp;#160;of shares&amp;#160;of the Company&amp;#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&amp;#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverables (2), (4), (5), and (6) do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverables (1) and (3) as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverables (7) and (8) are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; is allocated to deliverables (7) and (8). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;14.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;During the three months ended September 30, 2017, the Company recognized collaboration revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2,497&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$428&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the nine months ended September 30, 2017, the Company recognized collaboration revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$7,624&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,417&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  As of September 30, 2017 and December 31, 2016, deferred revenue relating to the Purdue Collaboration was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,103&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$9,310&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,103&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$8,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively, is classified as current portion of deferred revenue in the accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-F472AA06B510F286218B6E8C1E048ACB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$52&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; as of September 30, 2017 and December 31, 2016, respectively, calculated on the basis of the extended lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;232&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of September 30, 2017 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Northwestern University license agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&amp;#8217;s 2009 license agreement with Northwestern University (&amp;#8220;NU&amp;#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &amp;#8220;assigned field&amp;#8221;); (2)&amp;#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&amp;#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&amp;#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&amp;#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &amp;#8220;restated license agreement&amp;#8221;). In February 2016, we obtained exclusive license as to NU&amp;#8217;s rights in certain SNA technology we jointly own with NU (the &amp;#8220;February 2016 license agreement&amp;#8221;). Our license to NU&amp;#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &amp;#8220;June 2016 license agreement&amp;#8221;). Our rights and obligations in these 2016 agreements&amp;#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &amp;#8220;the Northwestern University License Agreements&amp;#8221;).  As of September 30, 2017, the Company has paid to NU an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,247&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in consideration of each of the obligations described above.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-1040D38E6AA70B03CB68C60357DAA085">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; through February 2021, and includes a renewal option and an early termination option at the end of February 2018. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016. Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$52&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; as of December 31, 2016 and 2015, respectively, calculated on the basis of the extended lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Year Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense allocated to AuraSense, LLC (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;See Note 11, Related-Party Transactions, for more information.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of December 31, 2016 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Northwestern University license agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&amp;#8217;s 2009 license agreement with Northwestern University (NU) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &amp;#8220;assigned field&amp;#8221;); (2)&amp;#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&amp;#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&amp;#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&amp;#8217;s sale or transfer of any licensed product. In August 2015, the Company entered into a restated license agreement with NU (the &amp;#8220;restated license agreement&amp;#8221;). In February 2016, the Company obtained exclusive license as to NU&amp;#8217;s rights in certain SNA technology the Company jointly owns with NU (the &amp;#8220;February 2016 license agreement&amp;#8221;). The Company&amp;#8217;s license to NU&amp;#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &amp;#8220;June 2016 license agreement&amp;#8221;). The Company&amp;#8217;s rights and obligations in these 2016 agreements&amp;#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &amp;#8220;the Northwestern University License Agreements&amp;#8221;). As of December 31, 2016, the Company has paid to NU an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,534&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in consideration of each of the obligations described above. At December 31, 2016, the accrued Northwestern License Agreements fee was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which was paid in January 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q3YTD" id="Fact-F16B797CB2D5FAAF67BF6E403FF18C7D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$22,936&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$19,623&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&amp;#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Description of Business and Basis of Presentation&amp;#8212;Liquidity Risk&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2016Q4YTD" id="Fact-24AA500604FB97116890DF9E485C8432">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$19,623&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$18,731&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; at two institutions, respectively. These deposits exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&amp;#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Description of Business and Basis of Presentation-Going Concern&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-FC678F30182796230BA4DFE8DB64E087">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The accompanying consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-968287F9256DDCD09E216E524ED168B3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On February 17, 2016, the Company closed a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; loan facility, with an initial advance against this loan facility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, with Hercules Technology Growth Capital (&amp;#8220;Hercules&amp;#8221;). The loan bears a floating interest rate equal to the greater of either (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;9.95%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; or (ii) the sum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;9.95%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; plus the United States prime rate minus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &amp;#160; Total proceeds net of fees and issuance costs were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,839&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&amp;#160; Fees and issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$161&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, as well as fees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$231&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on our balance sheet and will be amortized to interest expense through the maturity date of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;September&amp;#160;1, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; using the effective interest method.&amp;#160; Interest amounts were payable monthly beginning on March 1, 2016 through the maturity date of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;September&amp;#160;1, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&amp;#160; Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date.  In 2016, the Company met certain terms in the loan agreement so that principal amounts became payable monthly beginning on July 1, 2017.  The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&amp;#160; Additionally, HTGC shall have the right to participate in a future financing of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; under the same terms and conditions and pricing afforded to other participants in that future financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In connection with the February 2016 HTGC loan, HTGC also had the right to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;80,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Series C preferred stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$134&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and recorded as a reduction in the carrying amount of long-term debt on our balance sheet.  This discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$134&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; will be amortized to interest expense through the loan maturity date of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;September&amp;#160;1, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; using the effective interest method.&amp;#160; The Company estimated the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and recorded any changes in fair value to other income (expense), net on our statement of operations. See Note 10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information on the fair value of the preferred stock warrant liability.  The warrant agreement to purchase shares of preferred stock was terminated on September 26, 2017 in connection with the Merger. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At September 30, 2017 and December 31, 2016, the carrying value of long-term debt is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,221&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,667&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At September 30, 2017, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company paid interest on debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$158&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$153&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; during the three months ended September 30, 2017 and 2016, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$470&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$327&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; during the nine months ended September 30, 2017 and 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-F1C932E707328D67C6D1C5FE0A811B8A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On February 17, 2016, the Company closed a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; loan facility with Hercules Technology Growth Capital (HTGC) at a floating interest rate equal to the greater of either (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;9.95%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; or (ii) the sum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;9.95%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; plus the United States prime rate minus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, with an initial advance against this loan facility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&amp;#160; Total proceeds net of fees and issuance costs were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,839&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&amp;#160;Fees and issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$161&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, as well as fees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$231&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on the Company&amp;#8217;s balance sheet and will be amortized to interest expense through the maturity date of September 1, 2019 using the effective interest method.&amp;#160;Interest amounts are payable monthly beginning on March 1, 2016 through the maturity date of September 1, 2019.&amp;#160;Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date. In 2016, the Company met certain terms in the loan agreement so that principal amounts are payable monthly beginning on July 1, 2017. The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&amp;#160;Additionally, HTGC shall have the right to participate in a future financing of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; under the same terms and conditions and pricing afforded to other participants in that future financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In connection with the February 2016 HTGC loan, HTGC also has the right to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;104,348&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Series C preferred stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$134&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and recorded as a reduction in the carrying amount of long-term debt on the Company&amp;#8217;s balance sheet. This discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$134&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; will be amortized to interest expense through the loan maturity date of September 1, 2019 using the effective interest method.&amp;#160;The Company will estimate the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and will record any changes in fair value to other income (expense), net on the Company&amp;#8217;s statement of operations.&amp;#160;At December 31, 2016 the carrying value of long-term debt is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,667&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and the fair value of the preferred stock warrant liability is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$201&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. See Note 9, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information on the fair value of the preferred stock warrant liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At December 31, 2016, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company paid interest on debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$478&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; during the year ended December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DeferredChargesPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-A809742B1215BEBFF2AF6E42B414C5E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&amp;#8217;s operating lease and is presented in &amp;#8220;Other noncurrent assets&amp;#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
	<us-gaap:DeferredChargesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-AEDB281DA204488E7698DFA41BD34C4F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&amp;#8217;s operating lease. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q3YTD" id="Fact-2E9BAA0CBEB47553D04B6E74F08B52E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September&amp;#160;22, 2017, the Board adopted and Exicure&amp;#8217;s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the &amp;#8220;2017 Plan&amp;#8221;), which is expected to become effective on or about November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5,842,525&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure common stock, which includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,158,708&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,683,817&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;) and were assumed in the Merger. Awards that may be awarded under the 2017 Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards.  The 2017 Plan also provides that the number of shares reserved for issuance thereunder will be increased annually on the first day of each year beginning in 2020 by the least of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,600,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares, five percent (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;)&amp;#160;of the shares of Exicure common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares as determined by the Company&amp;#8217;s compensation committee. No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan.  The aggregate number of common stock options available for grant under the 2017 Plan was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,158,708&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; as of September 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On October 6, 2015, the Exicure OpCo board of directors adopted the 2015 Plan, subject to approval by the Company&amp;#8217;s stockholders.  Such stockholders approval was received on October 13, 2015.  The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.  Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the &amp;#8220;2014 Plan&amp;#8221;).  In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure OpCo common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The common stock options are contingent on the participants&amp;#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason.  The initial stock option grant to an employee, director or consultant vests &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;48 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Subsequent stock option grants vest 1/48th monthly until fully vested at the end of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;48 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  The term of common stock option grants is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; years unless terminated earlier as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Unamortized equity-based compensation expense at September 30, 2017 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2,352&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which is expected to be amortized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2.5 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.3 to 6.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0 to 6.9 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.97% to 2.17%; weighted avg. 2.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.01% to 1.41%; weighted avg. 1.26%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.8% to 83.1%; weighted avg. 81.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79.9% to 82.4%; weighted avg. 80.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The expected term is based upon the &amp;#8220;simplified method&amp;#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &amp;#8220;simplified method&amp;#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2017 and 2016 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.91 to $2,12; weighted avg. $1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.91 to $2,12; weighted avg. $1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&amp;#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of Exicure OpCo&amp;#8217;s common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid). At September 30, 2017, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which is the per share price paid by outside investors in the Offering on September 26, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2017 and 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.92&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1.53&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per common stock option, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,089,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,678,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,131,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,704&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Expected to Vest - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,595,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2017 and 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$202&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q4YTD" id="Fact-C2C9ADB48EA9F38CF777C600FE7576E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the 2014 Plan). In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure, Inc. common stock. On October 6, 2015, the Board of Directors adopted the Exicure, Inc. 2015 Equity Incentive Plan (the 2015 Plan), subject to approval by the Company&amp;#8217;s stockholders. Such stockholders approval was received on October 13, 2015. The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The aggregate number of shares of common stock available for awards granted under the 2015 Plan is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;9,806,006&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. As of the first day of each calendar year beginning on or after January 1, 2017, the number of shares available for all awards under the 2015 Plan, other than incentive stock options, will automatically increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the number of shares that are issued and outstanding as of that date, unless the compensation committee approves an increase of a lesser percentage. The aggregate number of common stock options available for grant under the 2015 Plan was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,318,400&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The common stock options are contingent on the participants&amp;#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial stock option grant to an employee, director or consultant vests &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; months. Subsequent stock option grants vest 1/48th monthly until fully vested at the end of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;48&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; months. The term of common stock option grants is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; years unless terminated earlier as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Unamortized equity-based compensation expense at December 31, 2016 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,630&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which is expected to be amortized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2.6 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions. In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0 to 7.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.2 to 7.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.01% to 2.24%; weighted avg. 1.58%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59% to 2.08%; weighted avg. 1.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79.2% to 83.6%; weighted avg. 79.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.9% to 85.4%; weighted avg. 82.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The expected term is based upon the &amp;#8220;simplified method&amp;#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &amp;#8220;simplified method&amp;#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2016 and 2015 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95 to $1.20; weighted avg. $1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95 to $1.20; weighted avg. $1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.51 to $0.98;&lt;br clear="none"/&gt;weighted avg. $0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.51 to $0.98;&lt;br clear="none"/&gt;weighted avg. $0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&amp;#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of its common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The weighted-average grant date fair value of common stock options granted in the years ended December 31, 2016 and 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.53&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per common stock option, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On October 3, 2014, the Board took action by way of unanimous written consent to modify the strike price on all outstanding common unit options to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; (the Modification). The Board determined that for all periods wherein common unit option had been granted, the fair value of the Company&amp;#8217;s common units was equal to or less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per common unit. No other terms of the repriced common unit options were modified and these repriced common unit options continued to vest according to their original vesting schedules and retained their original expiration dates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;All outstanding common unit options were revalued as of October 3, 2014 (the Modification Date) based on valuation assumptions reflecting current facts and circumstances then existing. The Modification affected grants to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;twenty&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; participants comprising all current employees and board members and to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; non-employee advisors. For all common unit options, the Company calculated the incremental fair value attributable to the Modification by calculating the fair value of all outstanding awards immediately before and immediately after the Modification under the valuation assumptions existing as of the Modification Date. For all vested options, the incremental fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$16&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; calculated thereby was recognized as expense immediately. For all unvested options, the incremental fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; as calculated thereby will be recognized as expense over the remaining service period of each awardee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,954,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,941,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(166,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(200,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,528,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(98,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(382,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,222,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,956,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Expected to Vest - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,025,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value of common stock options exercised during the years ended December 31, 2016 and 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$63&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$36&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-FDD6BDAACA49502F0DB06E7E0AC93544">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-E98E927A86D24769B0C2DFA5F9437571">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-96E859619708B87DE0DF6E7BC9982C4F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,725,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,539&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(103.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&amp;#8217;s net loss per share during the periods ending on the dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,678,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,038,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q4YTD" id="Fact-6AE56A9D1C8FB19B15A7C601AC3F01EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2016 and 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(121.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,222,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,528,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-3FC343D591938EA8A8A06E88E5007CC7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the common stock warrant liability at September 30, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-FADDB09CFAC4299A2CE3C602ABE302B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the preferred stock warrant liability at December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q3YTD" id="Fact-08463E3D48E0498B551C6E87D54F606A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company uses the market approach and Level 1 inputs to value its cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&amp;#160;2 of the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s preferred stock warrant liability and common stock warrant liability are classified within Level 3 of the fair value hierarchy.  The fair value of the preferred stock warrant liability and common stock warrant liability was determined using the Black-Scholes option-pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the preferred stock warrant was based significantly on the fair value of the Series C preferred stock, which was developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5.0 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, expected volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;62.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; expected dividends.  In connection with the Merger, the warrants to purchase preferred stock were terminated and therefore the related liability was reduced to zero.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the common stock warrant is based significantly on the fair value of the Company&amp;#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following assumptions: expected term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2.0 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.44%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, expected volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;78.71%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; expected dividends.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the common stock warrant liability at September 30, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; change in the estimate of expected volatility at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$18&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; change in the estimate of fair value of the common stock at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$34&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Preferred Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-D8BFF927591076BFD07DC60262B4B20D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs&amp;#8212;unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs&amp;#8212;other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs&amp;#8212;unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company uses the market approach and Level 1 inputs to value its cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&amp;#160;2 of the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the preferred stock warrant liability was determined using the Black-Scholes option-pricing model. The fair value of the preferred stock warrant is based significantly on the fair value of the Series C preferred stock, which is developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5.0 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, expected volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;62.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; expected dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following assumptions were used to estimate the fair value of the preferred stock warrant liability at December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; change in the estimate of expected volatility at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$12&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; change in the estimate of fair value of the Series C preferred stock at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$26&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the year ended December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance of preferred stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In connection with the reverse merger (see Note 12), the warrants were terminated under the terms of the warrant agreement immediately prior to the completion of the reverse merger and the preferred stock warrant liability will be reduced to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q3YTD" id="Fact-29D014E2E922EE130B046E8859DC061D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Preferred Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q4YTD" id="Fact-E9DD73694FD3491EFD9DC602E3EFE81B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a reconciliation of the Company&amp;#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the year ended December 31, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Issuance of preferred stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss included in other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q3YTD" id="Fact-6C25FBFEF8AC744A0C856E3F8B25AB70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2016Q4YTD" id="Fact-4AD16485F5316EA91935DF9E06F8054D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-358304C1E5C3C7C1C8506E79253892D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company incurred a pretax loss in each of the three and nine months ended September 30, 2017 and 2016, which consists entirely of loss in the U.S. and resulted in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; provision for income tax expense during the periods then ended. The effective tax rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in each of the three and nine months ended September 30, 2017 and 2016 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-46AB945D02C35CCE3CE1C60160C07727">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Pretax loss before income taxes was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$16,941&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,151&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2016 and 2015, respectively, which consists entirely of losses in the U.S. and resulted in no provision for income tax expense during the years then ended.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss prior to C corporation conversion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Entity classification change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(671&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s effective income tax rate for the years ended December 31, 2016 and 2015 is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The significant components of the Company&amp;#8217;s net deferred tax assets are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Net Operating Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Tax Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Deferred Rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Taxes, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has recorded a full valuation allowance against its deferred tax assets at December 31, 2016 and 2015.  This determination is based on significant negative evidence, including: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Cumulative losses:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; The Company has been in a significant cumulative loss position since its inception in 2011. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Projected realization of net operating loss carry forward amounts:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;  Projections of future pre-tax book loss and taxable losses based on the Company&amp;#8217;s recent actual performance and current industry data indicate it is more likely than not that the benefits will not be recognized.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At December 31, 2016, the Company had a federal net operating loss carryforward of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$20,727&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, which will begin to expire in 2035.  The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$20,727&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of state net operating loss carryforwards which will begin to expire in 2027. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At December&amp;#160;31, 2016 and 2015, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; unrecognized tax benefits. The Company&amp;#8217;s estimate of the potential outcome of any uncertain tax position is subject to management&amp;#8217;s assessment of relevant risks, facts and circumstances existing at that time. The Company evaluates uncertain tax positions to determine if it is more-likely-than-not that they would be sustained upon examination. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is subject to taxation in the U.S. and various state jurisdictions. The Company remains subject to examination by U.S. federal and state tax authorities for the years 2013 through 2016. There are no pending examinations in any jurisdiction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-3EE6484FF9C0C492FF7A6E437F830207">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company established a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-334FBD1C17E3D367A284DFA4D1938154">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes. Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company established a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-F2E7409FCF9F28B2B5E36E441476B963">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&amp;#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&amp;#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-C56A4DCFD644A634D509DFA51800D7E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017. The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The Company adopted this guidance in the first quarter of 2016 and adoption did not have a material impact on the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160;ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&amp;#160;Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&amp;#160;The guidance will be effective for the Company in the first quarter of 2017 and early adoption is permitted.&amp;#160;The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-066953C3C705059819576E4094E6114F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; impairment losses were recorded from inception in December 2011 through September 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-635CA0BB988A89C05B5DDF9E99E16DE0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three to seven&amp;#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets. Depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$180&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$133&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2016 and 2015, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; impairment losses were recorded from inception in December 2011 through December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q3YTD" id="Fact-F9BB294A004D8564CC6A6E4EA6EA0C1D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2016Q4YTD" id="Fact-AB1EC72A18B6E5621C21C5FA4404EBF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Components of property and equipment were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-BDAA3F3AE18D38E59F996E3F204280A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&amp;#8220;Purdue&amp;#8221;) and, in 2016, grant proceeds for services under government grant agreements. The Company&amp;#8217;s management believes these receivables are fully collectible.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-2291B51231C1B44C29D2DF9DB2289282">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Accounts receivable and unbilled revenue receivable consist of grant proceeds for services under government grant agreements. The Company&amp;#8217;s management believes these receivables are fully collectible.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-4BFDDDB0C7B012836A566E8F8BC399BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related-Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&amp;#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The amounts due from AuraSense, LLC in connection with the above mentioned activities were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; at September 30, 2017 and December 31, 2016, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct labor on research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs of AuraSense LLC paid by the Company or (of the Company paid by AuraSense, LLC), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$75&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in each of the nine months ended September 30, 2016 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-00D37C5C6BC39CC5DF34C604DC6B1AF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related-Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC. When scientists employed by the Company perform work on research grants awarded to AuraSense, LLC, the hours worked are accumulated on timesheets and the associated salary cost is billed to AuraSense, LLC on a quarterly basis. The Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&amp;#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC. Through December 31, 2015, these shared expenses were allocated between the Company and AuraSense, LLC on a percentage basis under the terms of an agreement between the companies. The value of these shared expenses was also included in the quarterly billing between the Company and AuraSense, LLC. Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement. Under the amended shared services agreement, the Company bills AuraSense, LLC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC. The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The amounts due from AuraSense, LLC in connection with the above mentioned activities were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$57&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; at December 31, 2016 and 2015, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following presents amounts billed to AuraSense, LLC and recognized in the accompanying statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct labor on research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shared costs with AuraSense, LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs of the Company paid by AuraSense, LLC, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$100&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in each of the years ended December 31, 2016 and 2015 in connection with these consulting services and these amounts are recognized as an expense in the accompanying statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q3YTD" id="Fact-11C3D4E2D4A825C67AB86E430597C95C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2016Q4YTD" id="Fact-54483BC3C9D00B8EEF3CDFA462B399F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-B5B6D7B9E5F74C5C239B6E41915DC78D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet.  Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&amp;#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &amp;#8220;standalone value&amp;#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The arrangement&amp;#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Payments or reimbursements for the Company&amp;#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has entered into certain grant contracts containing milestone payments.  The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured.  If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract.  For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&amp;#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-783266200C7FAC229107DFA33F429584">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&amp;#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &amp;#8220;standalone value&amp;#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The arrangement&amp;#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Payments or reimbursements for the Company&amp;#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-67B2A728A5BE047B2F416E5041593B57">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued Northwestern University License Agreements fee (Note 11)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll-related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-AD8951805163CA3A833D6E7CF93FECD5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&amp;#8217;s net loss per share during the periods ending on the dates presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,678,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,038,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;163,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2017Q3YTD" id="Fact-0B3E0274D8429EA9B9BA6E75B09F99D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2016Q4YTD" id="Fact-4494DDD2907AB1E9AEB5DF63B4DF5B70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;370&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-01198F86D07E492886B7C68EA1037A2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The significant components of the Company&amp;#8217;s net deferred tax assets are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Net Operating Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;306&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Equity-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,519&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Tax Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Deferred Rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred Taxes, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q3YTD" id="Fact-BF5268FF257737CADAAA6E7C5C2E4201">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,725,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;109,539&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(48.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(103.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q4YTD" id="Fact-14397CA4AB27CAC10516C6020E2ED8C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,941&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average basic and diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per share - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(121.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,222,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,528,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q4YTD" id="Fact-13C4F45B339E104EF1B5C68DE854F6FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State income tax expense at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss prior to C corporation conversion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Entity classification change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(671&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-254C4032B1E3F5F3A2246E8CAB3D2859">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of September 30, 2017 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2016Q4YTD" id="Fact-3A58684F6E113F25DC67C603F741ACD7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Future minimum lease payments as of December 31, 2016 are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2017Q3YTD" id="Fact-47D7DCD374C8BDA324736E52D7DBB63C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At September 30, 2017, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,670&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2016Q4YTD" id="Fact-4C2B914BA92D36327A6EC5FE3D30B3B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At December 31, 2016, the principal maturities of the long-term debt were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal balance outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;less: unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Noncurrent portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,454&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-C029CF8301F9C32801826E8EE8F4F9D6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct labor on research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs of AuraSense LLC paid by the Company or (of the Company paid by AuraSense, LLC), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
	<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-20D6D2C6624139BFCFC8C60517E9DE31">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The following presents amounts billed to AuraSense, LLC and recognized in the accompanying statement of operations in connection with the above mentioned activities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct labor on research activities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shared costs with AuraSense, LLC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quarterly fee for indirect costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Direct costs of the Company paid by AuraSense, LLC, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
	<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="FD2017Q3YTD" id="Fact-68962233B06651FE190DE466993CB9F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;232&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
	<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="FD2016Q4YTD" id="Fact-F9305C6B9335F442AD4AC603BB2D5355">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Rent expense consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Year Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Straight-line rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense allocated to AuraSense, LLC (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total rent expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;565&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;See Note 11, Related-Party Transactions, for more information.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q3YTD" id="Fact-F396FC2AD30CF17615276E7751AF1484">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,089,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,678,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,131,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,704&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Expected to Vest - September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,595,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2016Q4YTD" id="Fact-3813826C9CA23EC8D775DF634166AAA0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,954,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,941,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(166,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(200,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,528,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(98,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(382,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,222,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,956,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and Expected to Vest - December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,025,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-5B8BF7CB86F5FF6764586E76C7B0FF74">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2017 and 2016 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.91 to $2,12; weighted avg. $1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.91 to $2,12; weighted avg. $1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.3 to 6.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0 to 6.9 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.97% to 2.17%; weighted avg. 2.07%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.01% to 1.41%; weighted avg. 1.26%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.8% to 83.1%; weighted avg. 81.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79.9% to 82.4%; weighted avg. 80.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q4YTD" id="Fact-F27259B1DD99C51D131BDF63793E1181">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2016 and 2015 are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Options Granted During Period Ended:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value of Underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price of Common Stock Option&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95 to $1.20; weighted avg. $1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.95 to $1.20; weighted avg. $1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.51 to $0.98;&lt;br clear="none"/&gt;weighted avg. $0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.51 to $0.98;&lt;br clear="none"/&gt;weighted avg. $0.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Years Ended &lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0 to 7.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.2 to 7.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.01% to 2.24%; weighted avg. 1.58%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.59% to 2.08%; weighted avg. 1.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;79.2% to 83.6%; weighted avg. 79.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78.9% to 85.4%; weighted avg. 82.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-8AA70183AB4D4E1F2F5E6E4268C93BD0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has determined it has one operating segment. Disaggregating the Company&amp;#8217;s operations is impracticable because the Company&amp;#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-869F9DDA2741DC5F5FCCDFA3EE3B778F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has determined it has one operating segment. Disaggregating the Company&amp;#8217;s operations is impracticable because the Company&amp;#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All material long-lived assets of the Company are located in the United States.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q3YTD" id="Fact-32314F563EA1E8CEFE326E4204E6B3F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q4YTD" id="Fact-1E337BE7116ECA789CFFDFA3BD8AC773">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q3YTD" id="Fact-37379A5B07110629FBCF6E3DD0A192CB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts receivable and unbilled revenue receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&amp;#8220;Purdue&amp;#8221;) and, in 2016, grant proceeds for services under government grant agreements. The Company&amp;#8217;s management believes these receivables are fully collectible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.  Management believes that the Company&amp;#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of credit risk and other risks and uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$22,936&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$19,623&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&amp;#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Description of Business and Basis of Presentation&amp;#8212;Liquidity Risk&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; impairment losses were recorded from inception in December 2011 through September 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&amp;#8217;s own stock are classified as a liability on the Company&amp;#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet.  Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&amp;#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &amp;#8220;standalone value&amp;#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The arrangement&amp;#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Payments or reimbursements for the Company&amp;#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has entered into certain grant contracts containing milestone payments.  The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured.  If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract.  For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&amp;#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, the Company was not participating in any grant research activities involving milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segments and geographic information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has determined it has one operating segment. Disaggregating the Company&amp;#8217;s operations is impracticable because the Company&amp;#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&amp;#8217;s operating lease and is presented in &amp;#8220;Other noncurrent assets&amp;#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company established a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&amp;#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&amp;#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q4YTD" id="Fact-856ECAC49B672DB157A7C5FCEFA81D45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company considers all highly liquid investments with original maturities of three&amp;#160;months or less to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts receivable and unbilled revenue receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Accounts receivable and unbilled revenue receivable consist of grant proceeds for services under government grant agreements. The Company&amp;#8217;s management believes these receivables are fully collectible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments. Management believes that the Company&amp;#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of credit risk and other risks and uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$19,623&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$18,731&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; at two institutions, respectively. These deposits exceed federally insured limits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&amp;#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Description of Business and Basis of Presentation-Going Concern&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, for more information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three to seven&amp;#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets. Depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$180&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$133&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the years ended December 31, 2016 and 2015, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; impairment losses were recorded from inception in December 2011 through December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred stock warrant liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of preferred stock that are not indexed to the Company&amp;#8217;s own stock are classified as a liability on the Company&amp;#8217;s balance sheet. The preferred stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. The Company classifies the liability as noncurrent as settlement is not expected within the next 12&amp;#160;months. There were no preferred stock warrants outstanding as of December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&amp;#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &amp;#8220;standalone value&amp;#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The arrangement&amp;#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Payments or reimbursements for the Company&amp;#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Purdue Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma L.P., or Purdue, and referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&amp;#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. In addition, the Company is eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$770,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; upon successful completion of certain research, regulatory and commercial sales milestones. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of the Company&amp;#8217;s control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive single to low double digit royalties on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&amp;#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&amp;#160;Purdue&amp;#8217;s right to participate in a future&amp;#160;qualified equity&amp;#160;financing of the&amp;#160;Company&amp;#160;if such financing occurs prior to&amp;#160;June 2, 2017&amp;#160;or the pricing of&amp;#160;the&amp;#160;initial public offering&amp;#160;of shares&amp;#160;of the Company&amp;#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&amp;#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverable (2)&amp;#8212;obligation to participate in a joint research committee, deliverable (4)&amp;#8212;a non-voting board of director observer role, deliverable (5)&amp;#8212;Purdue&amp;#8217;s right to participate in a future&amp;#160;qualified equity&amp;#160;financing of the&amp;#160;Company&amp;#160;if such financing occurs prior to&amp;#160;June 2, 2017&amp;#160;or the pricing of&amp;#160;the&amp;#160;initial public offering&amp;#160;of shares&amp;#160;of the Company&amp;#8217;s common stock, and deliverable (6)&amp;#8212;the option to obtain an exclusive development and commercialization license for AST-005 or a new TNF-&amp;#945; development candidate other than AST-005 do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverable (1)&amp;#8212;the exclusive rights to the TNF-&amp;#945; target and deliverable (3)&amp;#8212;the provision of research and development activities, as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverable (7)&amp;#8212;the option to select and develop three additional collaboration targets and deliverable (8)&amp;#8212;the option to obtain an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; is allocated to these deliverables. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of 14.5 months. During the year ended December 31, 2016, the Company recognized collaboration revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$690&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. As of December 31, 2016, deferred revenue relating to the Purdue Collaboration was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$9,310&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$8,276&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; is classified as current portion of deferred revenue in the accompanying balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has entered into certain grant contracts containing milestone payments. The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract. For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&amp;#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of December 31, 2016 and 2015, and for the years then ended, the Company was not participating in any grant research activities involving milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segments and geographic information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has determined it has one operating segment. Disaggregating the Company&amp;#8217;s operations is impracticable because the Company&amp;#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All material long-lived assets of the Company are located in the United States. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&amp;#8217;s operating lease. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and development expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes. Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company established a full valuation allowance against its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017. The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The Company adopted this guidance in the first quarter of 2016 and adoption did not have a material impact on the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160;ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&amp;#160;Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&amp;#160;The guidance will be effective for the Company in the first quarter of 2017 and early adoption is permitted.&amp;#160;The Company is currently evaluating the impact of this guidance on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-BEC9161D51FD493EE29D6E6CAA346877">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September 26, 2017, in connection with the Merger, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&amp;#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock, and each share of Exicure OpCo&amp;#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock. As a result, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;26,666,627&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;Max-1&amp;#160;common stock were issued to the holders of Exicure OpCo&amp;#8217;s capital stock, which is incremental to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,080,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;7,414,115&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,680,997&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of&amp;#160;Max-1&amp;#160;common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of September 30, 2017, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;200,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of common stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; authorized and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;35,513,987&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The holders of shares of the Company&amp;#8217;s common stock are entitled to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&amp;#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&amp;#8217;s board of directors (the &amp;#8220;Board&amp;#8221;) out of funds legally available for that purpose. In the event of the Company&amp;#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&amp;#160;non-assessable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of September, 30, 2017, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of preferred stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; authorized and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Private Placement Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September 26, 2017, following the Effective Time of the Merger,&amp;#160;the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,767,360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering (the &amp;#8220;Offering&amp;#8221;) for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;13,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. common stock at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share (the &amp;#8220;Offering Price&amp;#8221;).  The aggregate net proceeds from the initial closing of the Offering (after deducting placement agent fees and expenses of the initial offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,037&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;) were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$17,235&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;163,174&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of common stock were issued to the placement agents.  The warrants expire on March 27, 2021 and have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share.  The warrants to purchase common stock are classified as a liability and presented as a dividend that offsets the gross proceeds of the Offering within the accompanying consolidated statement of equity.  The common stock warrant liability will be remeasured each period at fair value.  See Note 10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for more information on the common stock warrant liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As discussed in Note 13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Subsequent Events, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;the Company held subsequent closings on October 27, 2017 and November 2, 2017 (the &amp;#8220;Subsequent Closings&amp;#8221;) and sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,736,836&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. common stock in the private placement offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Subject to certain customary exceptions, investors in the Offering have anti-dilution protection with respect to the shares of common stock sold in the Offering such that if within eighteen (18)&amp;#160;months after the initial closing of the Offering the Company issues certain additional shares of common stock or common stock equivalents for a consideration per share less than the Offering Price (the &amp;#8220;Lower Price&amp;#8221;), each such investor will be entitled to receive from the Company additional shares of common stock in an amount such that, when added to the number of shares of common stock initially purchased by such investor in the Offering and still held of record and beneficially owned by such investor at the time of the dilutive issuance (the &amp;#8220;Held Shares&amp;#8221;), will equal the number of shares of common stock that such investor&amp;#8217;s aggregate purchase price for the Held Shares would have purchased at the Lower Price. Either (i)&amp;#160;holders of a majority of the then Held Shares or (ii)&amp;#160;a representative of the holders of the then Held Shares, which representative shall be appointed by the three investors who then hold the largest number of Held Shares, may waive the anti-dilution rights of all Offering investors with respect to a particular issuance by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;This price-based anti-dilution protection will automatically terminate upon our receipt of gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; or more in one or more related closings in a bona fide transaction in which we issue shares of common stock or certain common stock equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Offering was exempt from registration under Section&amp;#160;4(a)(2) of the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Offering was sold to &amp;#8220;accredited investors,&amp;#8221; as defined in Regulation D, and was conducted on a &amp;#8220;reasonable best efforts&amp;#8221; basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Registration Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In connection with the Merger and the Offering, the Company entered into a Registration Rights Agreement, pursuant to which the Company has agreed that promptly, but no later than 60 calendar days from the final closing of the Offering, the Company will file a registration statement with the SEC, or the Registration Statement.  Each Investor in the Subsequent Closing also entered into the same registration rights agreement signed by investors in the initial closing of the Offering, which requires that the Company file a &amp;#8220;resale&amp;#8221; registration statement with the SEC covering the shares of common stock and warrants issued in the Offering, certain other shares of common stock issued in connection with the Company&amp;#8217;s recently closed reverse merger, and shares held by the Company&amp;#8217;s&amp;#160;pre-merger stockholders, within 60 calendar days from the final closing of the Offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Capitalization Prior to the Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;All share and per share figures herein are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&amp;#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;the Company&amp;#8217;s common stock, and each share of Exicure OpCo&amp;#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of&amp;#160;the Company&amp;#8217;s&amp;#160;common stock.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On July 9, 2015, Exicure OpCo converted from a limited liability company into a C corporation.  In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively.  Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure OpCo, resulting in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;46&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; less aggregate shares of outstanding preferred stock of Exicure OpCo as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; share of common stock of Exicure OpCo.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class A Units/Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement.  In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;11,381,611&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class A units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per unit or an aggregate value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$25,217&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&amp;#8217;s net book value. The net book value of AuraSense, LLC&amp;#8217;s contribution at inception was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$135&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;11,381,611&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class A units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;11,381,640&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure OpCo Series A preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class A units/Series A preferred stock were senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class B Units/Series B Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Class B units/Series B preferred stock were divided into two tranches and have been issued in two series: Class B-1/Series B-1 and Class B-2/Series B-2.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Class B-1/Series B-1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. On December 12, 2011, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,451,571&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B-1 units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.22&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,432&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; including a receivable of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;225,677&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$61&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,371&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Class B-2/Series B-2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. On June 27, 2013, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1,403,995&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B-2 units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.62&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,676&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and proceeds net of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in financing costs were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,641&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,451,571&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class B-1 units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1,403,995&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class B-2 units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,451,560&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1,403,984&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure OpCo Series B-1 and Series B-2 preferred stock, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class B units/Series B preferred stock were senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class C Units/Series C Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On June 13, 2014, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,532,112&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,596&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$117&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,479&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On February 6, 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1,541,168&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per unit.  Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$4,624&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$43&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$4,581&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,073,280&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class C units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,073,226&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure OpCo Series C preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In October 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5,016,134&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share.  Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$15,048&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$69&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$14,979&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On January 11, 2016, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;149,999&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share.  Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$450&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.  Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$6&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$444&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class C units/Series C preferred stock were senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Exicure OpCo Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders were entitled to receive &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; times the aggregate cash contribution of all holders of Class C preferred units/stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q4YTD" id="Fact-763E11AF5821DEDE1D1BC5FECACAE849">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As discussed in Note 1, the Company converted from a limited liability company into a C corporation on July 9, 2015. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure, Inc., resulting in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; less aggregate shares of outstanding preferred stock of Exicure, Inc. as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc. The Company completed a reverse-merger with Max-1 Acquisition Corporation on September 26, 2017; see Notes 1 and 12 for additional information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class A Units/Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement. In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;22,924,210&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class A units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per unit or an aggregate value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$25,217&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&amp;#8217;s net book value. The net book value of AuraSense, LLC&amp;#8217;s contribution at inception was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$135&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;22,924,210&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class A units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;22,924,209&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. Series A preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class A units/Series A preferred stock are senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class B Units/Series B Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Class B units/Series B preferred stock are divided into two tranches and have been issued in two series: Class B-I/Series B-1 and Class B-II/Series B-2.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Class B-I/Series B-1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. On December 12, 2011, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,937,818&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B-I units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,432&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; including a receivable of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;454,545&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$61&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$5,371&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Class B-II/Series B-2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. On June 27, 2013, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,827,848&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class B-II units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,676&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and proceeds net of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in financing costs were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,641&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,937,818&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class B-I units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,827,848&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class B-II units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;4,937,813&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,827,844&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. Series B-1 and Series B-2 preferred stock, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class B units/Series B preferred stock are senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Class C Units/Series C Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On June 13, 2014, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;5,911,450&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units at a price per unit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,596&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$117&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$13,479&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On February 6, 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;2,010,219&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of its Class C units at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per unit. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$4,624&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$43&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$4,581&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As further discussed above, in connection with the corporate conversion, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;7,921,669&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; Class C units were converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;7,921,662&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. Series C preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In October 2015, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,542,783&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$15,048&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$69&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$14,979&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On January 11, 2016, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;195,651&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of its Series C preferred stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share. Total gross proceeds raised thereby were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$450&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. Net proceeds after associated costs and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$6&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$444&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;"&gt;Liquidation preference&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;. The Class C units/Series C preferred stock are senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders are entitled to receive &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;1.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; times the aggregate cash contribution of all holders of Class C preferred units/stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q3YTD" id="Fact-19B899326D9EE143DC386E9047DD9609">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Private placement - subsequent closings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On October 27, 2017 and November 2, 2017, Exicure entered into subscription agreements (the &amp;#8220;Subscription Agreements&amp;#8221;) with several accredited investors (the &amp;#8220;Investors&amp;#8221;) pursuant to which the Company agreed to issue and sell a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,736,836&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of the Company&amp;#8217;s common stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share (the &amp;#8220;Shares&amp;#8221;) resulting in approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$11,211&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in gross proceeds to the Company. These shares were issued in Subsequent Closings of the Offering for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;13,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of common stock (the &amp;#8220;Maximum Amount&amp;#8221;) at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share (the &amp;#8220;Sale Price&amp;#8221;). The Company and Katalyst Securities LLC, a U.S. registered broker-dealer (together with its sub-agents, the &amp;#8220;Placement Agents&amp;#8221;) may agree to extend the period for additional closings up to November 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;As of November 14, 2017, the Company has sold a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;10,504,196&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of common stock for a total of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$31,513&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in connection with all closings of the Offering (before deducting placement agent fees and expenses which are estimated at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3,966&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;). Placement Agents have received an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$1,968&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; in cash placement fees and will receive warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;413,320&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure common stock (the &amp;#8220;Warrants&amp;#8221;) in connection with all closings of the Offering as of November 14, 2017. The Warrants have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share and have been issued on the same terms in all prior closings of the Offering. The Placement Agents will also receive &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure common stock in connection with all closings of the Offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2016Q4YTD" id="Fact-1366E2CF7E138CBCEAA2C6057A92338B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Reverse merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;On September 26, 2017, pursuant to the Merger Agreement, Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation (&amp;#8220;Max-1&amp;#8221;), merged with and into Exicure, with Exicure remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 Acquisition Corporation (the &amp;#8220;Merger&amp;#8221;). The Merger was effective as of September 26, 2017 (the &amp;#8220;Effective Time&amp;#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;At the Effective Time, the legal existence of Max-1 Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure&amp;#8217;s common and preferred stock (other than shares of Exicure&amp;#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.49649&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Common Stock, and each share of Exicure&amp;#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;0.7666652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Common Stock. As a result, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;26,666,627&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Common Stock were issued to the holders of Exicure&amp;#8217;s capital stock. In addition, pursuant to the Merger Agreement options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;7,419,740&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure&amp;#8217;s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,680,997&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Max-1 Common Stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, Max-1 Corporation changed its name to Exicure, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Merger is considered a &amp;#8220;reverse merger&amp;#8221;, whereby Exicure is considered the accounting acquirer in the Merger. Exicure was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i) legacy Exicure shareholders own approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;94%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii) legacy Exicure directors will hold all &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; board seats of the combined company, and (iii) legacy Exicure management will hold all key positions in management of the combined company. The transaction will be accounted for as an asset acquisition rather than a business combination because as of the acquisition date, Max-1 does not meet the definition of a business as defined by U.S. GAAP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Private placement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Following the Effective Time of the Merger, Max-1 (now renamed Exicure, Inc.) sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;6,767,360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;13,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of Exicure, Inc. common stock at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share (the &amp;#8220;Offering Price&amp;#8221;). The Company may hold one or more subsequent closings at any time prior to October 31, 2017, unless otherwise extended, to sell the remaining shares in the private placement offering. The Company may also sell an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;3,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; shares of common stock at the Offering Price to cover over-subscriptions in the event the private placement offering is oversubscribed. The private placement offering is referred to herein as the Offering. The Company granted to the investors in the Offering registration rights requiring the Company to register those shares of common stock for public resale. The then existing stockholders of Exicure who agreed to become parties to the registration rights agreement also became entitled to such registration rights. The initial closing of the Offering was on September 26, 2017. The aggregate gross proceeds from the initial closing of the Offering were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$20,302&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; (before deducting placement agent fees and expenses of the initial closing of the Offering, which are estimated at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$2,900&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;In connection with the initial closing of the Offering, the Company issued warrants to the placement agents to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;163,174&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of common stock. The warrants expire on March 27, 2021 and have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; per share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2017Q3YTD" id="Fact-D7545E45A3D5DB67C4EA6E4F37034A40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Supplemental Balance Sheet Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,059&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$46&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the three months ended September 30, 2017 and 2016, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$159&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;$132&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt; for the nine months ended September 30, 2017 and 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued Northwestern University License Agreements fee (Note 11)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll-related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2016Q4YTD" id="Fact-B2765388B3F3E64AE914C5F97F5C9A62">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Components of property and equipment were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Scientific equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,120&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Construction in process at December 31, 2015 represents the purchase of scientific equipment in December 2015 that was placed in service during the second quarter of 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2016Q4YTD" id="Fact-44D7642E31CDAD4884D9DF9C4F27107C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&amp;#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<xcur:WarrantsorRightsPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-52AD346D874D71AA3D316E40F159A91E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&amp;#8217;s own stock are classified as a liability on the Company&amp;#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</xcur:WarrantsorRightsPolicyPolicyTextBlock>
	<xcur:WarrantsorRightsPolicyPolicyTextBlock contextRef="FD2016Q4YTD" id="Fact-8659395168261FB3FE0EDFA278833400">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of preferred stock that are not indexed to the Company&amp;#8217;s own stock are classified as a liability on the Company&amp;#8217;s balance sheet. The preferred stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. The Company classifies the liability as noncurrent as settlement is not expected within the next 12&amp;#160;months. There were no preferred stock warrants outstanding as of December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</xcur:WarrantsorRightsPolicyPolicyTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>xcur-20171031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exicuretx.com/20171031" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xcur="http://www.exicuretx.com/20171031" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20171031_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20171031_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20171031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20171031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheets" roleURI="http://www.exicuretx.com/role/BalanceSheets">
        <link:definition>1001000 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.exicuretx.com/role/BalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2411402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails">
        <link:definition>2411404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesScheduleOfRentExpenseDetails" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails">
        <link:definition>2411403 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2311301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exicuretx.com/role/Debt">
        <link:definition>2105100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails">
        <link:definition>2405402 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesOfLongTermDebtDetails" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails">
        <link:definition>2405403 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exicuretx.com/role/DebtTables">
        <link:definition>2305301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentationDetails" roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails">
        <link:definition>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.exicuretx.com/role/EquityBasedCompensation">
        <link:definition>2107100 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails">
        <link:definition>2407404 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails">
        <link:definition>2407405 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationNarrativeDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails">
        <link:definition>2407402 - Disclosure - Equity-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleOfCompensationExpenseDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails">
        <link:definition>2407403 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails">
        <link:definition>2407406 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exicuretx.com/role/FairValueMeasurements">
        <link:definition>2110100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2410402 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2410404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails">
        <link:definition>2410403 - Disclosure - Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables">
        <link:definition>2310301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exicuretx.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2408404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2408403 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxesTables" roleURI="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables">
        <link:definition>2308301 - Disclosure - Income Taxes Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2408402 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.exicuretx.com/role/LossPerCommonShare">
        <link:definition>2109100 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2409403 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationOfEarningsPerShareDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails">
        <link:definition>2409402 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables">
        <link:definition>2309301 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PurdueCollaboration" roleURI="http://www.exicuretx.com/role/PurdueCollaboration">
        <link:definition>2103100 - Disclosure - Purdue Collaboration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PurdueCollaborationDetails" roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails">
        <link:definition>2403401 - Disclosure - Purdue Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions">
        <link:definition>2112100 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2412402 - Disclosure - Related-Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails">
        <link:definition>2412403 - Disclosure - Related-Party Transactions - Schedule of Revenue from Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables">
        <link:definition>2312301 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails">
        <link:definition>2402402 - Disclosure - Significant Accounting Policies - Concentrations of Credit Risk and Other Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>2402403 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPurdueCollaborationDetails" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails">
        <link:definition>2402404 - Disclosure - Significant Accounting Policies - Purdue Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementOfChangesInStockholdersEquity" roleURI="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity">
        <link:definition>1003000 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfCashFlows" roleURI="http://www.exicuretx.com/role/StatementsOfCashFlows">
        <link:definition>1004000 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperations" roleURI="http://www.exicuretx.com/role/StatementsOfOperations">
        <link:definition>1002000 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exicuretx.com/role/StockholdersEquity">
        <link:definition>2106100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCapitalizationPriorToMergerDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails">
        <link:definition>2406403 - Disclosure - Stockholders' Equity - Capitalization Prior to the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCurrentCapitalizationDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails">
        <link:definition>2406401 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPrivatePlacementPostMergerDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails">
        <link:definition>2406402 - Disclosure - Stockholders' Equity - Private Placement Post-Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exicuretx.com/role/SubsequentEvents">
        <link:definition>2113100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails">
        <link:definition>2413401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2104100 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails">
        <link:definition>2404403 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails">
        <link:definition>2404402 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2304301 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="xcur_AccountsReceivableSaleOfStock" name="AccountsReceivableSaleOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="xcur_AccruedLicenseAgreementFeesCurrent" name="AccruedLicenseAgreementFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" name="AdjustmentToAdditionalPaidInCapitalConversionOfCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_AuraSenseLLCMember" name="AuraSenseLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ClassAUnitsMember" name="ClassAUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ClassB1UnitsMember" name="ClassB1UnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ClassB2UnitsMember" name="ClassB2UnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ClassCUnitsMember" name="ClassCUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" name="CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementRevenue" name="CollaborationAgreementRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborationAgreementUpfrontPayment" name="CollaborationAgreementUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_CollaborativeArrangementEquityReceivedNumberofShares" name="CollaborativeArrangementEquityReceivedNumberofShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_CollaborativeArrangementEquityReceivedPercent" name="CollaborativeArrangementEquityReceivedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="xcur_CommitmentsandContingenciesAbstract" name="CommitmentsandContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_CommonStockVotingRightsforEachShare" name="CommonStockVotingRightsforEachShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_CommonStockWarrantLiability" name="CommonStockWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" name="CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ComputersandSoftwareMember" name="ComputersandSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConsultingServicesMember" name="ConsultingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" name="ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" name="ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" name="ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" name="ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" name="ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" name="ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" name="ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ConversionofStockConversionRatio" name="ConversionofStockConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ConversionofStockNumberofSharesEffectivelyNotConverted" name="ConversionofStockNumberofSharesEffectivelyNotConverted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_DebtInstrumentBasisSpreadonVariableRateDecrease" name="DebtInstrumentBasisSpreadonVariableRateDecrease" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_DirectCostsMember" name="DirectCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_DirectLaborOnResearchMember" name="DirectLaborOnResearchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount" name="EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent" name="EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount" name="EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent" name="EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_EstimatedFairValueofCommonStockPerShare" name="EstimatedFairValueofCommonStockPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="xcur_ExicureInc.2017EquityIncentivePlanMember" name="ExicureInc.2017EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ExicureOpCo2015EquityIncentivePlanMember" name="ExicureOpCo2015EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" name="ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" name="FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" name="FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_FeeTypeAxis" name="FeeTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_FeeTypeDomain" name="FeeTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_FeesatIssuanceMember" name="FeesatIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_FeesatMaturityMember" name="FeesatMaturityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_HerculesTechnologyGrowthCapitalMember" name="HerculesTechnologyGrowthCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_IncreaseDecreaseAccruedProfessionalFees" name="IncreaseDecreaseAccruedProfessionalFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_IncreaseDecreaseInAccruedLicenseAgreementFees" name="IncreaseDecreaseInAccruedLicenseAgreementFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_InitialEmployeeStockOptionMember" name="InitialEmployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_IssuanceOfCommonStockWarrants" name="IssuanceOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_IssuanceofPreferredStockWarrants" name="IssuanceofPreferredStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount" name="LineOfCreditFacilityRightToParticipateInFutureFinancingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="xcur_MembersCapitalContributions" name="MembersCapitalContributions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_MembersCapitalContributionsFairValue" name="MembersCapitalContributionsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_MembersCapitalSharePriceFairValue" name="MembersCapitalSharePriceFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues" name="MembershipUnitsIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues" name="MembershipUnitsIssuedDuringPeriodValueNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_NorthwesternUniversityMember" name="NorthwesternUniversityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty" name="OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_PaymentsOfCommonStockFinancingCosts" name="PaymentsOfCommonStockFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_PaymentsOfPreferredStockFinancingCosts" name="PaymentsOfPreferredStockFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement" name="PaymentsToPrivatePlacementAgentsForPrivatePlacement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_PaymentsforLicenseAgreements" name="PaymentsforLicenseAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_PreMergerShareholdersMember" name="PreMergerShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_PreferredClassBIIMember" name="PreferredClassBIIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_PreferredClassBIMember" name="PreferredClassBIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_PreferredClassCMember" name="PreferredClassCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions" name="PreferredStockLiquidationPreferencePercentOfAggregateCashContributions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_PreferredStockWarrantLiability" name="PreferredStockWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="xcur_PreferredUnitsMember" name="PreferredUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold" name="PriceBasedAnitDilutionProtectionGrossProceedsThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_QuarterlyFeeForIndirectCostsMember" name="QuarterlyFeeForIndirectCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" name="RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" name="RetainedEarningsAccumulatedDeficitInceptiontoDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" name="RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting" name="RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" name="RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable" name="SaleOfStockNumberOfSharesRelatedToAccountReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions" name="SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SaleofStockNumberofSharesAvailableForOffering" name="SaleofStockNumberofSharesAvailableForOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SeriesB1PreferredMember" name="SeriesB1PreferredMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SeriesB1PreferredStockMember" name="SeriesB1PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SeriesB2PreferredMember" name="SeriesB2PreferredMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SeriesB2PreferredStockMember" name="SeriesB2PreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" name="SeriesCPreferredStockConvertedintoMax1CommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger" name="ShareConversionDuringPeriodSharesInConnectionWithMerger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation" name="ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_ShareConversionDuringPeriodValueInConnectionWithMerger" name="ShareConversionDuringPeriodValueInConnectionWithMerger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation" name="ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SharedCostsMember" name="SharedCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" name="StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SubsequentEmployeeStockOptionMember" name="SubsequentEmployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_SupplementalBalanceSheetInformationAbstract" name="SupplementalBalanceSheetInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="xcur_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="xcur_WarrantsorRightsPolicyPolicyTextBlock" name="WarrantsorRightsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>xcur-20171031_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheets" xlink:href="xcur-20171031.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:href="xcur-20171031.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20171031.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20171031.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20171031.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20171031.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20171031.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20171031.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20171031.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20171031.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20171031.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20171031.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20171031.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:href="xcur-20171031.xsd#IncomeTaxesIncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20171031.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20171031.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20171031.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20171031.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="xcur-20171031.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:href="xcur-20171031.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfOperations" xlink:href="xcur-20171031.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20171031.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20171031.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:href="xcur-20171031.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_LongTermDebtCurrent_f61bf97e-c3a5-ba72-7591-eba8e7bb6a44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_D3B3DEE68FF40458E7AFA694242CDFAD" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_D3B3DEE68FF40458E7AFA694242CDFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_6375706FC844E697DDBF3ECDAFA9EB35" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_xcur_PreferredStockWarrantLiability_6375706FC844E697DDBF3ECDAFA9EB35" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_22C277AFD9872E2A0F6D3ECE3FF2BC72" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_xcur_CommonStockWarrantLiability_22C277AFD9872E2A0F6D3ECE3FF2BC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_0af4cf4f-dd4e-4a27-50f3-b3447f0d9b89" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_0af4cf4f-dd4e-4a27-50f3-b3447f0d9b89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_01d226b5-d89e-45e6-1279-541e7b5bf1df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_01d226b5-d89e-45e6-1279-541e7b5bf1df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_ce8ab880-26a6-6928-af17-3886b0ee741d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_SecurityDeposit_ce8ab880-26a6-6928-af17-3886b0ee741d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_5fcb8627-b558-5566-1abf-864642e66a13" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_5fcb8627-b558-5566-1abf-864642e66a13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_f9f96586-cf02-591c-086f-9aaf67596c0b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_f9f96586-cf02-591c-086f-9aaf67596c0b" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty" xlink:label="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_28EA7FF87423CD386B63DF187BF22018" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_28EA7FF87423CD386B63DF187BF22018" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1d12118-f49a-bc63-5339-100c22e4468d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1d12118-f49a-bc63-5339-100c22e4468d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_21d3fdc5-0c57-3147-2d98-67c225186166" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_21d3fdc5-0c57-3147-2d98-67c225186166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_72c898ba-c3c2-b4c9-2447-6291f802b723" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_72c898ba-c3c2-b4c9-2447-6291f802b723" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_F393EEA771033A512EF3DF3DF535DD2E" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_F393EEA771033A512EF3DF3DF535DD2E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_4E9A843BBC67F7F4D7EEDF400B6B44A6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_4E9A843BBC67F7F4D7EEDF400B6B44A6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_5961A011AE0DE8747B88DF41D52C8B66" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_5961A011AE0DE8747B88DF41D52C8B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3D9029CC9E83D6F550E9DF3F15855F20" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3D9029CC9E83D6F550E9DF3F15855F20" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_50A62C3FEE36C34D0A19DF40F320546B" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_50A62C3FEE36C34D0A19DF40F320546B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_383EA21AB231069ED786DF4298B142C8" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_383EA21AB231069ED786DF4298B142C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9b039144-dc24-2381-1de5-20fa04e9b091" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9b039144-dc24-2381-1de5-20fa04e9b091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_6cd34f19-57d8-aa6f-5d3a-fb8e0fc91b31" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_6cd34f19-57d8-aa6f-5d3a-fb8e0fc91b31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_566fd81d-ab31-e2a8-2025-7a0dce40b34d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_566fd81d-ab31-e2a8-2025-7a0dce40b34d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseInAccruedLicenseAgreementFees" xlink:label="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_62405C57340E48C71C5CDF0317A492C2" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_62405C57340E48C71C5CDF0317A492C2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseAccruedProfessionalFees" xlink:label="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_2B25904C36E5325BD8EFDF0665BEB0A6" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_2B25904C36E5325BD8EFDF0665BEB0A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c9abab12-acb3-3ee7-961a-1c1811712114" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c9abab12-acb3-3ee7-961a-1c1811712114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4d3877b9-c422-1a38-6e8b-b087f89bd0b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4d3877b9-c422-1a38-6e8b-b087f89bd0b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e5f1c7a4-b42a-8461-2001-b1f20e51b257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfCommonStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_4C63B44F2FAE6155685875075902EF8A" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_4C63B44F2FAE6155685875075902EF8A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfPreferredStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfPreferredStockFinancingCosts_6AF3FAC383B4EF5C58DB496FF6A9614F" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_xcur_PaymentsOfPreferredStockFinancingCosts_6AF3FAC383B4EF5C58DB496FF6A9614F" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_3F55313F06E9F18342DB7A654AA9DC54" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_xcur_CollaborationAgreementRevenue_3F55313F06E9F18342DB7A654AA9DC54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_D3B3DEE68FF40458E7AFA694242CDFAD" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_D3B3DEE68FF40458E7AFA694242CDFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>xcur-20171031_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheets" xlink:href="xcur-20171031.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:href="xcur-20171031.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20171031.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20171031.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20171031.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20171031.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20171031.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20171031.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20171031.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20171031.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20171031.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20171031.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20171031.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:href="xcur-20171031.xsd#IncomeTaxesIncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20171031.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20171031.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20171031.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20171031.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="xcur-20171031.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:href="xcur-20171031.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfOperations" xlink:href="xcur-20171031.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20171031.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20171031.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:href="xcur-20171031.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:to="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:to="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:to="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:to="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6AF803B57564D8487E55FEBFAECE6B9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6AF803B57564D8487E55FEBFAECE6B9C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_97AB91DB2EBE473E6C5BFEBFAECE8AFF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_xcur_SeriesB2PreferredStockMember_97AB91DB2EBE473E6C5BFEBFAECE8AFF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_A1871658E7A8052945B9FEBFAECEDF3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_xcur_SeriesB1PreferredStockMember_A1871658E7A8052945B9FEBFAECEDF3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_FEA1AF07B8BD4DDCD386FEBFAECED1CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_FEA1AF07B8BD4DDCD386FEBFAECED1CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:to="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4FA403CCDE4E2C03F195FEBFAECE4944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4FA403CCDE4E2C03F195FEBFAECE4944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3F134F0F1E18B821E49CFEBFAECF5E99" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3F134F0F1E18B821E49CFEBFAECF5E99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AAA9D989682B243D117CFEBFAED0FFCD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AAA9D989682B243D117CFEBFAED0FFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E5EFACFD9D93957E739DFEBFAED0CB98" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E5EFACFD9D93957E739DFEBFAED0CB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9B6B336C3936DE8A04A3FEBFAED1BDD9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9B6B336C3936DE8A04A3FEBFAED1BDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:to="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_8F61EC5265C0F8991196FEE92EDDF28A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_8F61EC5265C0F8991196FEE92EDDF28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:to="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:to="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_E2F324A0C3A2C0D2FBEFFEE92EDDBC3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_E2F324A0C3A2C0D2FBEFFEE92EDDBC3F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_2BE8056BB5CF93C5FCFCFEE92EDD79F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_xcur_SeriesB2PreferredStockMember_2BE8056BB5CF93C5FCFCFEE92EDD79F0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_CF1F4C063B7C7768F283FEE92EDDFA4A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_xcur_SeriesB1PreferredStockMember_CF1F4C063B7C7768F283FEE92EDDFA4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_123B4BA00F7075AC94F0FEE92EDDD2E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_123B4BA00F7075AC94F0FEE92EDDD2E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41A1CFBCCC7926231C85FEE92EDD4209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41A1CFBCCC7926231C85FEE92EDD4209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2269189F9E7837C587A5FEE92EDEFA17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2269189F9E7837C587A5FEE92EDEFA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_78F860489B845327FA0AFEE92EDE1E4D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesIssued_78F860489B845327FA0AFEE92EDE1E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7973C62CBF7D62A6B6B0FEE92EDE5DD0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7973C62CBF7D62A6B6B0FEE92EDE5DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F72BD9D342B30D778D6AFEE92EDEFFBE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F72BD9D342B30D778D6AFEE92EDEFFBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E12ECFEA279763507266FEE92EDE6E26" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E12ECFEA279763507266FEE92EDE6E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_02EF820F01588F3B1270FEE92EDE8B93" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesIssued_02EF820F01588F3B1270FEE92EDE8B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B968E9DEBEDD93D5E302FEE92EDE76B5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B968E9DEBEDD93D5E302FEE92EDE76B5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_D92C3A709F54F469979CFEBF3428182E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_D92C3A709F54F469979CFEBF3428182E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_7A50D45B825BC44B75EFFEBF3429035A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:to="loc_xcur_WarrantLiabilityMember_7A50D45B825BC44B75EFFEBF3429035A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeAxis" xlink:label="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeDomain" xlink:label="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:to="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA_default" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeDomain" xlink:label="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:to="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatIssuanceMember" xlink:label="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:to="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatMaturityMember" xlink:label="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:to="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:to="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:to="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D02EF0B7075379227476FEBF34298FFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:to="loc_us-gaap_MinimumMember_D02EF0B7075379227476FEBF34298FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_648E86212B5D942964F0FEBF3429BEA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:to="loc_us-gaap_MaximumMember_648E86212B5D942964F0FEBF3429BEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:to="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:to="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_65CFCDF8905F006DD43DFEBF342AC97F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_65CFCDF8905F006DD43DFEBF342AC97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_7EB6F0AD67A6AD15CB99FEBF342A94AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:to="loc_us-gaap_PreferredStockMember_7EB6F0AD67A6AD15CB99FEBF342A94AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:to="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:to="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:to="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:to="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:to="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:to="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:to="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DebtInstrumentBasisSpreadonVariableRateDecrease" xlink:label="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount" xlink:label="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A31EE1FD6B0556A1A935FEBF342B2CCE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A31EE1FD6B0556A1A935FEBF342B2CCE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FB5469707BEB98AB9554FEBF342CDF3F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FB5469707BEB98AB9554FEBF342CDF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_40DAC5F0F7045C62FED2F930ADBC83C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_40DAC5F0F7045C62FED2F930ADBC83C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_29BC7406E62D5027FAE2F930ADBCC12B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:to="loc_us-gaap_PrivatePlacementMember_29BC7406E62D5027FAE2F930ADBCC12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B0FBC52D4F5E0726A86EF930ADBC05A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:to="loc_us-gaap_SubsequentEventMember_B0FBC52D4F5E0726A86EF930ADBC05A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreMergerShareholdersMember" xlink:label="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:to="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:to="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:to="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_NorthwesternUniversityMember" xlink:label="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:to="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_14A4C9F8778E07E4610FF930ADBD48F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_14A4C9F8778E07E4610FF930ADBD48F8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_B9015130E6346F7F0005F930ADBD5BA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_B9015130E6346F7F0005F930ADBD5BA2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E7CAC9606283FE242E56F930ADBD57B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E7CAC9606283FE242E56F930ADBD57B2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_98D0AB19008732F5B186F930ADBD083A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_98D0AB19008732F5B186F930ADBD083A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_D81AEE23E2C19D917AEEF930ADBDD358" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_D81AEE23E2C19D917AEEF930ADBDD358" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_D52CF6C33FFE4314C1A5F930ADBD57D9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_D52CF6C33FFE4314C1A5F930ADBD57D9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_D539077F8F7B81F308F4F930ADBD8D90" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_D539077F8F7B81F308F4F930ADBD8D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:to="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:to="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_312D2404866C0985DFCEF930ADBD8CE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_312D2404866C0985DFCEF930ADBD8CE4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_A49877BFAB5188BD2241F930ADBDBD10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_A49877BFAB5188BD2241F930ADBDBD10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:to="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:to="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:to="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:to="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_02732C9D51E8D8AEB5BEF930ADBECF7B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_02732C9D51E8D8AEB5BEF930ADBECF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:to="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:to="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_6A6A969D48A3615DAA1DF930ADBE8F54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_6A6A969D48A3615DAA1DF930ADBE8F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ED923B7E73CC9FA71A39F930ADBEACBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_us-gaap_CommonStockMember_ED923B7E73CC9FA71A39F930ADBEACBD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB1UnitsMember" xlink:label="loc_xcur_ClassB1UnitsMember_F31BCD75F6AD3FAF971FF930ADBE2A76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassB1UnitsMember_F31BCD75F6AD3FAF971FF930ADBE2A76" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB2UnitsMember" xlink:label="loc_xcur_ClassB2UnitsMember_A1AF0DCFFD20B0351BE1F930ADBE29D7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassB2UnitsMember_A1AF0DCFFD20B0351BE1F930ADBE29D7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassCUnitsMember" xlink:label="loc_xcur_ClassCUnitsMember_61221C10007EF0B2D259F930ADBEE4F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassCUnitsMember_61221C10007EF0B2D259F930ADBEE4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1353C4B6FE69DD5B2090F930ADBEFDAB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1353C4B6FE69DD5B2090F930ADBEFDAB" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_703A13EB3C78AB78BCA2F930ADBEC177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_ConversionofStockConversionRatio_703A13EB3C78AB78BCA2F930ADBEC177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_F8C06E6D0D503A368287F930ADBE0350" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_F8C06E6D0D503A368287F930ADBE0350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_1F0A928FD3342D19DE29F930ADBFB9ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_1F0A928FD3342D19DE29F930ADBFB9ED" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_BF6D4B38BDC1B90F30CAF930ADBFA573" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_BF6D4B38BDC1B90F30CAF930ADBFA573" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" xlink:label="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_1516020404FB27322EC1F930ADBF598B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_1516020404FB27322EC1F930ADBF598B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25B3FBC0E83AC841AC0AF930ADBF774E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25B3FBC0E83AC841AC0AF930ADBF774E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributions" xlink:label="loc_xcur_MembersCapitalContributions_D3627CFDDFA020688810F930ADBF5483" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_MembersCapitalContributions_D3627CFDDFA020688810F930ADBF5483" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedPercent" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedNumberofShares" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_359203391936775922E1F930ADBF3CB5" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_359203391936775922E1F930ADBF3CB5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_E52B9089545DCA9D6DB1F930ADBF220D" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_E52B9089545DCA9D6DB1F930ADBF220D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DB19600C72FC34273FEAF930ADBFDAA5" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DB19600C72FC34273FEAF930ADBFDAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_C8A7D8EA6105996E2418F930ADBFE80B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_C8A7D8EA6105996E2418F930ADBFE80B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_083F1B7CFA90A9A8BD09F930ADBF9D82" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_083F1B7CFA90A9A8BD09F930ADBF9D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:to="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:to="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:to="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:to="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:to="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:to="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_BC586F60D2F079247D58C54A931558AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_MinimumMember_BC586F60D2F079247D58C54A931558AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_64D23A6E839A4E74DD0FC54A9315E122" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_MaximumMember_64D23A6E839A4E74DD0FC54A9315E122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_A434A4F7CDE3DF1B0583C54A93152CD2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_WeightedAverageMember_A434A4F7CDE3DF1B0583C54A93152CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:to="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:to="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:to="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_720AEE360387812CFCC3FB33D54260A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:to="loc_us-gaap_MinimumMember_720AEE360387812CFCC3FB33D54260A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:to="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:to="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_F96D4B5015B742CE1C1BFB33D5428E69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_F96D4B5015B742CE1C1BFB33D5428E69" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_4A648BFD4CFA8E822BF9FB33D54292C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_4A648BFD4CFA8E822BF9FB33D54292C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_InitialEmployeeStockOptionMember" xlink:label="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SubsequentEmployeeStockOptionMember" xlink:label="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:to="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:to="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EstimatedFairValueofCommonStockPerShare" xlink:label="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:to="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_7D491A172009CCBBF97EFEBFAE1FD318" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_7D491A172009CCBBF97EFEBFAE1FD318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:to="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:to="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:to="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:to="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:to="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:to="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:to="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_6BAD62A69C969DB188BBE06FB70048AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:to="loc_us-gaap_PreferredStockMember_6BAD62A69C969DB188BBE06FB70048AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AAEF8B43A718CB50D7F0E06FB70039C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:to="loc_us-gaap_CommonStockMember_AAEF8B43A718CB50D7F0E06FB70039C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_D6096C1328DF135F2066E06FB700431A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:to="loc_xcur_WarrantLiabilityMember_D6096C1328DF135F2066E06FB700431A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_99E1DAA9487B66E3E62DE06FB714F45E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:to="loc_xcur_WarrantLiabilityMember_99E1DAA9487B66E3E62DE06FB714F45E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:to="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:to="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_000985E0D6635A2E133BE09E3E871048" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:to="loc_us-gaap_CommonStockMember_000985E0D6635A2E133BE09E3E871048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:to="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_A2420C91E3E4482070C7E06FB71929F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_A2420C91E3E4482070C7E06FB71929F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_960CE116C606B7B19ECBE06FB7196E4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_960CE116C606B7B19ECBE06FB7196E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_605D36C7F1A21999F602E06FB7199BAA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_605D36C7F1A21999F602E06FB7199BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_8F788B81CEFBD6444964E06FB719940E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_8F788B81CEFBD6444964E06FB719940E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:to="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13B559E8F33758468644FDFB2D22B48C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_NetIncomeLoss_13B559E8F33758468644FDFB2D22B48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:to="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6F75F761A82BC4E4EFC7C54A97C4ED86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6F75F761A82BC4E4EFC7C54A97C4ED86" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:to="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:to="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4A7CA344A6FEA9D8BAAEF930AD9F05AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:to="loc_us-gaap_MaximumMember_4A7CA344A6FEA9D8BAAEF930AD9F05AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:to="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:to="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:to="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:to="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:to="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:to="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_15D2BC6338B6E2F8A78CFB33D4E8500B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:to="loc_xcur_AuraSenseLLCMember_15D2BC6338B6E2F8A78CFB33D4E8500B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectLaborOnResearchMember" xlink:label="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharedCostsMember" xlink:label="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:to="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:to="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:to="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:to="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FB19593F5391A9F2F266F930ADA925C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:to="loc_us-gaap_MinimumMember_FB19593F5391A9F2F266F930ADA925C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_67663FDA6E30D7CA84A5F930ADA99F0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:to="loc_us-gaap_MaximumMember_67663FDA6E30D7CA84A5F930ADA99F0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:to="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_5EB7A2734B440F5A58E8FDFB2DD796A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_5EB7A2734B440F5A58E8FDFB2DD796A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9F9D5CEE4E5D02BA1BFFFDFB2DD76F55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9F9D5CEE4E5D02BA1BFFFDFB2DD76F55" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_03FB90E6A4D745E45F7BFDFB2DD86F9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_03FB90E6A4D745E45F7BFDFB2DD86F9A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_AC81A7A3A5B11A604E7FFDFB2DD88899" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_AC81A7A3A5B11A604E7FFDFB2DD88899" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_BD3320ECB835952729BCFDFB2DD82424" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_BD3320ECB835952729BCFDFB2DD82424" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_11FE0F3D3C9675B29E64FDFB2DD82A79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementRevenue_11FE0F3D3C9675B29E64FDFB2DD82A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FC0B6A3F14F5857B5E68FDFB2DD8FB92" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_us-gaap_DeferredRevenue_FC0B6A3F14F5857B5E68FDFB2DD8FB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C22CC9E967C9C5F005ADFDFB2DD83063" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_us-gaap_DeferredRevenueCurrent_C22CC9E967C9C5F005ADFDFB2DD83063" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:to="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_07679EA0F9003BB96A1DFEBFAEB2834E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_07679EA0F9003BB96A1DFEBFAEB2834E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:to="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:to="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_45F6C7A491566A8157F9FEBFAEB25198" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_CommonStockMember_45F6C7A491566A8157F9FEBFAEB25198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:to="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:to="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassCMember" xlink:label="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIIMember" xlink:label="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIMember" xlink:label="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_D4F2108FFEE0104BC9CDFEBFAEB3CB55" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_D4F2108FFEE0104BC9CDFEBFAEB3CB55" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2A77BA2DCF597F49D91DFEBFAEB40E90" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2A77BA2DCF597F49D91DFEBFAEB40E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:to="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:to="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:to="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:to="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredUnitsMember" xlink:label="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB1UnitsMember" xlink:label="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB2UnitsMember" xlink:label="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassCUnitsMember" xlink:label="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredMember" xlink:label="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredMember" xlink:label="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockNumberofSharesEffectivelyNotConverted" xlink:label="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalSharePriceFairValue" xlink:label="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributionsFairValue" xlink:label="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributions" xlink:label="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccountsReceivableSaleOfStock" xlink:label="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable" xlink:label="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions" xlink:label="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:to="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:to="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_0D6DD2BEE2F6BC8A2D43FEBFAE55D2D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:to="loc_us-gaap_InvestorMember_0D6DD2BEE2F6BC8A2D43FEBFAE55D2D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreMergerShareholdersMember" xlink:label="loc_xcur_PreMergerShareholdersMember_21B278046534343BFB31FEBFAE55D946" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:to="loc_xcur_PreMergerShareholdersMember_21B278046534343BFB31FEBFAE55D946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_63CE61405E54ACCAD0D1FEBFAE56DEB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:to="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_63CE61405E54ACCAD0D1FEBFAE56DEB7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_04B4C3B06F06D46DF596FEBFAE56A20D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_04B4C3B06F06D46DF596FEBFAE56A20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:to="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:to="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_E5755C3AA01DD9D6E7D4FEBFAE56B48B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_E5755C3AA01DD9D6E7D4FEBFAE56B48B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_9B32B4F865A05C013F7EFEBFAE56EB0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_9B32B4F865A05C013F7EFEBFAE56EB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:to="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:to="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_91B9F7BAF97FB66690F8FEBFAE56B507" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:to="loc_us-gaap_CommonStockMember_91B9F7BAF97FB66690F8FEBFAE56B507" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_C3988DA3D58EF51E7C14FEBFAE562C25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_ConversionofStockConversionRatio_C3988DA3D58EF51E7C14FEBFAE562C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_FA5A2B7F5CF122EEAEE1FEBFAE566410" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_FA5A2B7F5CF122EEAEE1FEBFAE566410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_243BBA602FEA1EC972DFFEBFAE56D9AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_243BBA602FEA1EC972DFFEBFAE56D9AC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_C96854326ABE2FEB854BFEBFAE57E660" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_C96854326ABE2FEB854BFEBFAE57E660" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_35C5988688D24B4D72B9FEBFAE57694D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_35C5988688D24B4D72B9FEBFAE57694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockVotingRightsforEachShare" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D5178A3463E3753719C8FEBFAE4E6A03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:to="loc_us-gaap_SubsequentEventMember_D5178A3463E3753719C8FEBFAE4E6A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_183B27B1AB317AA16950FEBFAE4E766F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:to="loc_us-gaap_PrivatePlacementMember_183B27B1AB317AA16950FEBFAE4E766F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E98BB19D27D4C5ABD907FEBFAE4E9732" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E98BB19D27D4C5ABD907FEBFAE4E9732" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofSharesAvailableForOffering" xlink:label="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_BA92E053E381AEB3FF15FEBFAE4EBD29" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_BA92E053E381AEB3FF15FEBFAE4EBD29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_064C6AB8A8583D2000FEFEBFAE4EA575" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_064C6AB8A8583D2000FEFEBFAE4EA575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_FA537A93F14ADD116B6EFEBFAE4F165F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_FA537A93F14ADD116B6EFEBFAE4F165F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_AFD6B80BF47EA4AB8CF3FEBFAE4FECF5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_AFD6B80BF47EA4AB8CF3FEBFAE4FECF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_A6A997799E315EA8067AFEBFAE4F5DA6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_A6A997799E315EA8067AFEBFAE4F5DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821FC5753C08A4BF90D7FEBFAE4F2CBC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821FC5753C08A4BF90D7FEBFAE4F2CBC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold" xlink:label="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:to="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:to="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:to="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:to="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FB606C75EF923B04CD2BFB33D4DE8246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:to="loc_us-gaap_CommonStockMember_FB606C75EF923B04CD2BFB33D4DE8246" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_F994A1433657312C6E75FB33D4DE4C57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_F994A1433657312C6E75FB33D4DE4C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_56AD874F68BC8107BC4FFB33D4DE5126" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_56AD874F68BC8107BC4FFB33D4DE5126" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:to="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5A83E2E5AD0491AC2BBEFB33D4DEC396" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:to="loc_us-gaap_SubsequentEventMember_5A83E2E5AD0491AC2BBEFB33D4DEC396" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_71DD789DE5359505A647FB33D4DEFF33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_ConversionofStockConversionRatio_71DD789DE5359505A647FB33D4DEFF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_068F4BD9C1AFE3AFBFDBFB33D4DEEC0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_068F4BD9C1AFE3AFBFDBFB33D4DEEC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2164B01867E76033AD10FB33D4DE6B70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2164B01867E76033AD10FB33D4DE6B70" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions" xlink:label="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FA7FDC2E80BB9A43D63BFB33D4DE4F15" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FA7FDC2E80BB9A43D63BFB33D4DE4F15" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofSharesAvailableForOffering" xlink:label="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_92F0E6C3BD1483279237FB33D4DE56C4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_92F0E6C3BD1483279237FB33D4DE56C4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement" xlink:label="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A0A3524CF151CD8D529AFB33D4DEA81B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A0A3524CF151CD8D529AFB33D4DEA81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_1B0B6AF8A8F1CB2DEB22FB33D4DE3F9C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_1B0B6AF8A8F1CB2DEB22FB33D4DE3F9C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" xlink:label="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_977954028EFAE98E3BFEC51AA9A8DF50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_EquipmentMember_977954028EFAE98E3BFEC51AA9A8DF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_B4E7C5395765AA46901AC51AA9A906B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_B4E7C5395765AA46901AC51AA9A906B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5A98BD514C688D6DAD2FC51AA9A9B1E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5A98BD514C688D6DAD2FC51AA9A9B1E1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>xcur-20171031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF_label_en-US" xlink:label="lab_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:label id="lab_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF_documentation_en-US" xlink:label="lab_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommitmentsandContingenciesAbstract" xlink:label="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:to="lab_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended lease term</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent liability</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:to="lab_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:type="arc" />
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548_terseLabel_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate consideration paid to NU for agreement obligations</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548_label_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548_documentation_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsforLicenseAgreements" xlink:label="loc_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:to="lab_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:type="arc" />
    <link:label id="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9_terseLabel_en-US" xlink:label="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Northwestern University License Agreements fee (Note 11)</link:label>
    <link:label id="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9_label_en-US" xlink:label="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued License Agreement Fees, Current</link:label>
    <link:label id="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9_documentation_en-US" xlink:label="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued License Agreement Fees, Current</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:to="lab_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:to="lab_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:to="lab_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="arc" />
    <link:label id="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD_terseLabel_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD_label_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD_documentation_en-US" xlink:label="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:to="lab_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:to="lab_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:to="lab_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:to="lab_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="arc" />
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of 10% change in expected volatility rate</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="arc" />
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of 10% change in the estimate of fair value of the common stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:to="lab_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purdue Collaboration</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from Related Party</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:to="lab_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:to="lab_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported</link:label>
    <link:label id="lab_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE_label_en-US" xlink:label="lab_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:to="lab_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="arc" />
    <link:label id="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379_terseLabel_en-US" xlink:label="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exicure OpCo Common and Preferred, Excluding Series C Preferred</link:label>
    <link:label id="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379_label_en-US" xlink:label="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exicure OpCo Common And Preferred, Excluding Series C Preferred [Member]</link:label>
    <link:label id="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379_documentation_en-US" xlink:label="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exicure OpCo Common And Preferred, Excluding Series C Preferred [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:to="lab_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7_verboseLabel_en-US" xlink:label="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock Converted into Common Stock</link:label>
    <link:label id="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7_label_en-US" xlink:label="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock Converted into Max-1 Common Stock [Member]</link:label>
    <link:label id="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7_documentation_en-US" xlink:label="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock Converted into Max-1 Common Stock [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:to="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Common Unit of AuraSense Therapeutics, LLC Into One Share of Common Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5_label_en-US" xlink:label="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Common Unit Of AuraSense Therapeutics, LLC Into One Share Of Common Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5_documentation_en-US" xlink:label="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Common Unit Of AuraSense Therapeutics, LLC Into One Share Of Common Stock Of Exicure OpCo [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:to="lab_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Class A Unit of AuraSense Therapeutics, LLC Into One Share of Series A Preferred Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F_label_en-US" xlink:label="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Class A Unit Of AuraSense Therapeutics, LLC Into One Share Of Series A Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F_documentation_en-US" xlink:label="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Class A Unit Of AuraSense Therapeutics, LLC Into One Share Of Series A Preferred Stock Of Exicure OpCo</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:to="lab_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Class B-1 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-1 Preferred Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8_label_en-US" xlink:label="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Class B-1 Unit Of AuraSense Therapeutics, LLC Into One Share Of Series B-1 Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8_documentation_en-US" xlink:label="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Class B-1 Unit Of AuraSense Therapeutics, LLC Into One Share Of Series B-1 Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:to="lab_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Class B-2 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-2 Preferred Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5_label_en-US" xlink:label="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Class B-2 Unit Of AuraSense Therapeutics, LLC Into One Share Of Series B-2 Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5_documentation_en-US" xlink:label="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Class B-2 Unit Of AuraSense Therapeutics, LLC Into One Share Of Series B-2 Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:to="lab_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Class C Unit of AuraSense Therapeutics, LLC Into One Share of Series C Preferred Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756_label_en-US" xlink:label="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Class C Unit Of AuraSense Therapeutics, LLC Into One Share Of Series C Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756_documentation_en-US" xlink:label="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Class C Unit Of AuraSense Therapeutics, LLC Into One Share Of Series C Preferred Stock Of Exicure OpCo [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:to="lab_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Options to Purchase Common Units of AuraSense Therapeutics, LLC Into Options to Purchase Common Stock of Exicure OpCo</link:label>
    <link:label id="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B_label_en-US" xlink:label="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Options To Purchase Common Units Of AuraSense Therapeutics, LLC Into Options To Purchase Common Stock Of Exicure OpCo [Member]</link:label>
    <link:label id="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B_documentation_en-US" xlink:label="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Options To Purchase Common Units Of AuraSense Therapeutics, LLC Into Options To Purchase Common Stock Of Exicure OpCo [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:to="lab_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:to="lab_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary of Common Parent</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary of Common Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:to="lab_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD_terseLabel_en-US" xlink:label="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Units</link:label>
    <link:label id="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD_label_en-US" xlink:label="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Units [Member]</link:label>
    <link:label id="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD_documentation_en-US" xlink:label="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Units [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredUnitsMember" xlink:label="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="lab_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="arc" />
    <link:label id="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1_verboseLabel_en-US" xlink:label="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A Preferred Units</link:label>
    <link:label id="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1_label_en-US" xlink:label="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A Units [Member]</link:label>
    <link:label id="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1_documentation_en-US" xlink:label="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class A Units [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:to="lab_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="arc" />
    <link:label id="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C_terseLabel_en-US" xlink:label="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B-1 Preferred Units</link:label>
    <link:label id="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C_label_en-US" xlink:label="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B-1 Units [Member]</link:label>
    <link:label id="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C_documentation_en-US" xlink:label="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B-1 Units [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB1UnitsMember" xlink:label="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:to="lab_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="arc" />
    <link:label id="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E_terseLabel_en-US" xlink:label="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B-2 Preferred Units</link:label>
    <link:label id="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E_label_en-US" xlink:label="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B-2 Units [Member]</link:label>
    <link:label id="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E_documentation_en-US" xlink:label="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B-2 Units [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB2UnitsMember" xlink:label="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:to="lab_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="arc" />
    <link:label id="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5_terseLabel_en-US" xlink:label="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class C Preferred Units</link:label>
    <link:label id="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5_label_en-US" xlink:label="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class C Units [Member]</link:label>
    <link:label id="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5_documentation_en-US" xlink:label="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class C Units [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassCUnitsMember" xlink:label="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:to="lab_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767_terseLabel_en-US" xlink:label="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Preferred Stock</link:label>
    <link:label id="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767_label_en-US" xlink:label="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Preferred [Member]</link:label>
    <link:label id="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767_documentation_en-US" xlink:label="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Preferred [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredMember" xlink:label="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:to="lab_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE_terseLabel_en-US" xlink:label="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2 Preferred Stock</link:label>
    <link:label id="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE_label_en-US" xlink:label="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Preferred [Member]</link:label>
    <link:label id="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE_documentation_en-US" xlink:label="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Preferred [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredMember" xlink:label="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:to="lab_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="lab_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073_terseLabel_en-US" xlink:label="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073_label_en-US" xlink:label="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Conversion Ratio</link:label>
    <link:label id="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073_documentation_en-US" xlink:label="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Conversion Ratio</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:to="lab_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397_terseLabel_en-US" xlink:label="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares not converted (in shares)</link:label>
    <link:label id="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397_label_en-US" xlink:label="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Number of Shares Effectively Not Converted</link:label>
    <link:label id="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397_documentation_en-US" xlink:label="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Number of Shares Effectively Not Converted</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockNumberofSharesEffectivelyNotConverted" xlink:label="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:to="lab_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option conversion ratio</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Converted, Conversion Ratio</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Converted, Conversion Ratio</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="arc" />
    <link:label id="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA_terseLabel_en-US" xlink:label="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA_label_en-US" xlink:label="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Members' Capital, Share Price, Fair Value</link:label>
    <link:label id="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA_documentation_en-US" xlink:label="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Members' Capital, Share Price, Fair Value</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalSharePriceFairValue" xlink:label="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:to="lab_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="arc" />
    <link:label id="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B_terseLabel_en-US" xlink:label="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B_label_en-US" xlink:label="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Members' Capital, Contributions, Fair Value</link:label>
    <link:label id="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B_documentation_en-US" xlink:label="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Members' Capital, Contributions, Fair Value</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributionsFairValue" xlink:label="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:to="lab_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="arc" />
    <link:label id="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712_terseLabel_en-US" xlink:label="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution at net book value</link:label>
    <link:label id="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712_label_en-US" xlink:label="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Members' Capital, Contributions</link:label>
    <link:label id="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712_documentation_en-US" xlink:label="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Members' Capital, Contributions</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributions" xlink:label="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:to="lab_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share in sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received from sale of stock, gross</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="arc" />
    <link:label id="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9_terseLabel_en-US" xlink:label="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable as result of sale of stock</link:label>
    <link:label id="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9_label_en-US" xlink:label="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Sale Of Stock</link:label>
    <link:label id="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9_documentation_en-US" xlink:label="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Sale Of Stock</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccountsReceivableSaleOfStock" xlink:label="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:to="lab_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="arc" />
    <link:label id="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381_terseLabel_en-US" xlink:label="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares related to sale of stock accounts receivable (in shares)</link:label>
    <link:label id="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381_label_en-US" xlink:label="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Related To Account Receivable</link:label>
    <link:label id="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381_documentation_en-US" xlink:label="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Related To Account Receivable</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable" xlink:label="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:to="lab_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from preferred stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D_terseLabel_en-US" xlink:label="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation preference, percent of aggregate cash contributions</link:label>
    <link:label id="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D_label_en-US" xlink:label="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Liquidation Preference, Percent Of Aggregate Cash Contributions</link:label>
    <link:label id="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D_documentation_en-US" xlink:label="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Liquidation Preference, Percent Of Aggregate Cash Contributions</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions" xlink:label="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:to="lab_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight-line rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Contingent Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:type="arc" />
    <link:label id="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F_negatedTerseLabel_en-US" xlink:label="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Rent expense allocated to AuraSense, LLC</link:label>
    <link:label id="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F_label_en-US" xlink:label="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals, Allocation to Related Party</link:label>
    <link:label id="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F_documentation_en-US" xlink:label="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals, Allocation to Related Party</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty" xlink:label="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:to="lab_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Principal balance outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:to="lab_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:to="lab_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:type="arc" />
    <link:label id="lab_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E_label_en-US" xlink:label="lab_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E_documentation_en-US" xlink:label="lab_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DocumentAndEntityInformationAbstract" xlink:label="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="lab_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5_label_en-US" xlink:label="lab_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:to="lab_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:to="lab_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47_label_en-US" xlink:label="lab_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:to="lab_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F_terseLabel_en-US" xlink:label="lab_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F_label_en-US" xlink:label="lab_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:to="lab_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:to="lab_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004_label_en-US" xlink:label="lab_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:to="lab_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:to="lab_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="lab_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:to="lab_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:to="lab_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="arc" />
    <link:label id="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D_terseLabel_en-US" xlink:label="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exicure OpCo 2015 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D_label_en-US" xlink:label="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exicure OpCo 2015 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D_documentation_en-US" xlink:label="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exicure OpCo 2015 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:to="lab_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="arc" />
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B_terseLabel_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B_label_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B_documentation_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:to="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC_terseLabel_en-US" xlink:label="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock Converted into Max-1 Common Stock</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:to="lab_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:to="lab_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="lab_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:type="arc" />
    <link:label id="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467_terseLabel_en-US" xlink:label="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares available for over-subscriptions</link:label>
    <link:label id="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467_label_en-US" xlink:label="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Additional Shares Available For Over-Subscriptions</link:label>
    <link:label id="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467_documentation_en-US" xlink:label="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Additional Shares Available For Over-Subscriptions</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions" xlink:label="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:to="lab_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="arc" />
    <link:label id="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F_terseLabel_en-US" xlink:label="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for sale of stock (in shares)</link:label>
    <link:label id="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F_label_en-US" xlink:label="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Available For Offering</link:label>
    <link:label id="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F_documentation_en-US" xlink:label="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Available For Offering</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofSharesAvailableForOffering" xlink:label="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:to="lab_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="arc" />
    <link:label id="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06_terseLabel_en-US" xlink:label="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to private placement agents</link:label>
    <link:label id="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06_label_en-US" xlink:label="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Private Placement Agents For Private Placement</link:label>
    <link:label id="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06_documentation_en-US" xlink:label="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Private Placement Agents For Private Placement</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement" xlink:label="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:to="lab_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options converted (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Converted in Period</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Converted in Period</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion grants in the period (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion Grants in Period</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion Grants in Period</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="arc" />
    <link:label id="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE_terseLabel_en-US" xlink:label="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent ownership after transaction</link:label>
    <link:label id="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE_label_en-US" xlink:label="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Percentage Of Ownership By Legacy Shareholders After Transaction</link:label>
    <link:label id="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE_documentation_en-US" xlink:label="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Percentage Of Ownership By Legacy Shareholders After Transaction</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" xlink:label="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:to="lab_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E_label_en-US" xlink:label="lab_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:to="lab_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3_label_en-US" xlink:label="lab_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="lab_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD_label_en-US" xlink:label="lab_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:to="lab_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF_label_en-US" xlink:label="lab_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:to="lab_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:to="lab_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5_terseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Amount</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Amount</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD_terseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss prior to C corporation conversion</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Amount</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Amount</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41_terseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity classification change</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Entity Classification Change, Amount</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Entity Classification Change, Amount</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4_negatedTerseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293_negatedTerseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss prior to C corporation conversion</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Percent</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Percent</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:type="arc" />
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC_negatedTerseLabel_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Entity classification change</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC_label_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Entity Classification Change, Percent</link:label>
    <link:label id="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC_documentation_en-US" xlink:label="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Entity Classification Change, Percent</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:to="lab_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, beginning period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding, ending period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, beginning period (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, exercised (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, forfeitures (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, ending period (dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-Average Exercise Price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Weighted-Average Exercise Price (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and Expected to Vest, Aggregate Intrinsic Value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:to="lab_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purdue Collaboration</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:to="lab_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional collaboration targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:to="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment received for research agreement</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35_label_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:to="lab_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate research milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate regulatory milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate commercial milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial sales royalty, percent</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="arc" />
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period for unit of accounting</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Performance Period for Unit of Accounting</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Performance Period for Unit of Accounting</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC_label_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Revenue</link:label>
    <link:label id="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Revenue</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:to="lab_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursable research and development activities</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:to="lab_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:to="lab_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="lab_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:to="lab_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="arc" />
    <link:label id="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F_terseLabel_en-US" xlink:label="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Merger Shareholders</link:label>
    <link:label id="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F_label_en-US" xlink:label="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Merger Shareholders [Member]</link:label>
    <link:label id="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F_documentation_en-US" xlink:label="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Merger Shareholders [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreMergerShareholdersMember" xlink:label="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:to="lab_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF_label_en-US" xlink:label="lab_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:to="lab_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A_label_en-US" xlink:label="lab_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:to="lab_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="arc" />
    <link:label id="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28_terseLabel_en-US" xlink:label="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Northwestern University</link:label>
    <link:label id="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28_label_en-US" xlink:label="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Northwestern University [Member]</link:label>
    <link:label id="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28_documentation_en-US" xlink:label="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Northwestern University [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_NorthwesternUniversityMember" xlink:label="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:to="lab_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="arc" />
    <link:label id="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494_terseLabel_en-US" xlink:label="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock</link:label>
    <link:label id="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494_label_en-US" xlink:label="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock [Member]</link:label>
    <link:label id="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494_documentation_en-US" xlink:label="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:to="lab_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:to="lab_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2_label_en-US" xlink:label="lab_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:to="lab_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="arc" />
    <link:label id="lab_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A_terseLabel_en-US" xlink:label="lab_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A Units</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:to="lab_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="lab_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:to="lab_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926_terseLabel_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of units received</link:label>
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926_label_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Received, Percent</link:label>
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926_documentation_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Received, Percent</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedPercent" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:to="lab_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="arc" />
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091_terseLabel_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of units received (in shares)</link:label>
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091_label_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Received, Number of Shares</link:label>
    <link:label id="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091_documentation_en-US" xlink:label="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Received, Number of Shares</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedNumberofShares" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:to="lab_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="arc" />
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415_terseLabel_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification to additional paid in capital</link:label>
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415_label_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Conversion Of Capital</link:label>
    <link:label id="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415_documentation_en-US" xlink:label="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Conversion Of Capital</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:to="lab_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="arc" />
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31_terseLabel_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit generated, since inception</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31_label_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31_documentation_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:to="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:to="lab_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6_label_en-US" xlink:label="lab_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="lab_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="lab_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Redeemable Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:to="lab_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689_terseLabel_en-US" xlink:label="lab_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Units</link:label>
    <link:label id="lab_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689_label_en-US" xlink:label="lab_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Member Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:to="lab_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:to="lab_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077_terseLabel_en-US" xlink:label="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class C</link:label>
    <link:label id="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077_label_en-US" xlink:label="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class C [Member]</link:label>
    <link:label id="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077_documentation_en-US" xlink:label="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Class C [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassCMember" xlink:label="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:to="lab_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC_terseLabel_en-US" xlink:label="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B (Series B-II)</link:label>
    <link:label id="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC_label_en-US" xlink:label="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class B-II [Member]</link:label>
    <link:label id="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC_documentation_en-US" xlink:label="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Class B-II [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIIMember" xlink:label="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:to="lab_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD_terseLabel_en-US" xlink:label="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B (Series B-I)</link:label>
    <link:label id="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD_label_en-US" xlink:label="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class B-I [Member]</link:label>
    <link:label id="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD_documentation_en-US" xlink:label="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Class B-I [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIMember" xlink:label="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:to="lab_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863_label_en-US" xlink:label="lab_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:to="lab_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF_terseLabel_en-US" xlink:label="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2</link:label>
    <link:label id="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF_label_en-US" xlink:label="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Preferred Stock [Member]</link:label>
    <link:label id="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF_documentation_en-US" xlink:label="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:to="lab_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="arc" />
    <link:label id="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444_terseLabel_en-US" xlink:label="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1</link:label>
    <link:label id="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444_label_en-US" xlink:label="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444_documentation_en-US" xlink:label="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:to="lab_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:to="lab_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:to="lab_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:to="lab_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="arc" />
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3_terseLabel_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of membership units, net (in shares)</link:label>
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3_label_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Membership Units Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3_documentation_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Membership Units Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:to="lab_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="arc" />
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2_terseLabel_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of membership units, net</link:label>
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2_label_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Membership Units Issued During Period, Value, New Issues</link:label>
    <link:label id="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2_documentation_en-US" xlink:label="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Membership Units Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:to="lab_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="arc" />
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D_terseLabel_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share conversion in connection with the Merger (in shares)</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D_label_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Shares, In Connection With Merger</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D_documentation_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Shares, In Connection With Merger</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:to="lab_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="arc" />
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3_terseLabel_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share conversion in connection with the Merger</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3_label_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Value, In Connection With Merger</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3_documentation_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Value, In Connection With Merger</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:to="lab_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="arc" />
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959_terseLabel_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Limited Liability Company to Corporation (in shares)</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959_label_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Shares, Limited Liability Company to Corporation</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959_documentation_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Shares, Limited Liability Company to Corporation</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:to="lab_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="arc" />
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E_terseLabel_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Limited Liability Company to Corporation</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E_label_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Value, Limited Liability Company to Corporation</link:label>
    <link:label id="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E_documentation_en-US" xlink:label="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Conversion During Period, Value, Limited Liability Company to Corporation</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:to="lab_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:to="lab_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:to="lab_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:to="lab_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:type="arc" />
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF_label_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF_documentation_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:to="lab_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:to="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:to="lab_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:to="lab_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482_label_en-US" xlink:label="lab_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:to="lab_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="arc" />
    <link:label id="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944_terseLabel_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AuraSense</link:label>
    <link:label id="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944_label_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AuraSense, LLC [Member]</link:label>
    <link:label id="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944_documentation_en-US" xlink:label="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AuraSense, LLC [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:to="lab_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214_label_en-US" xlink:label="lab_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:to="lab_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="arc" />
    <link:label id="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1_terseLabel_en-US" xlink:label="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1_label_en-US" xlink:label="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1_documentation_en-US" xlink:label="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:to="lab_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:type="arc" />
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C_terseLabel_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly revenue from related party for indirect costs</link:label>
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C_label_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Quarterly Revenue From Transactions With Related Party</link:label>
    <link:label id="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C_documentation_en-US" xlink:label="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Quarterly Revenue From Transactions With Related Party</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:to="lab_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="arc" />
    <link:label id="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04_terseLabel_en-US" xlink:label="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct labor on research activities</link:label>
    <link:label id="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04_label_en-US" xlink:label="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Labor On Research [Member]</link:label>
    <link:label id="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04_documentation_en-US" xlink:label="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Labor On Research [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectLaborOnResearchMember" xlink:label="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:to="lab_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="arc" />
    <link:label id="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5_terseLabel_en-US" xlink:label="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shared costs with AuraSense, LLC</link:label>
    <link:label id="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5_label_en-US" xlink:label="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shared Costs [Member]</link:label>
    <link:label id="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5_documentation_en-US" xlink:label="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shared Costs [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharedCostsMember" xlink:label="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:to="lab_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="arc" />
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151_terseLabel_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly fee for indirect costs</link:label>
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151_label_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Fee For Indirect Costs [Member]</link:label>
    <link:label id="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151_documentation_en-US" xlink:label="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Quarterly Fee For Indirect Costs [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:to="lab_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="arc" />
    <link:label id="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28_terseLabel_en-US" xlink:label="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct costs of the Company paid by AuraSense, LLC, net</link:label>
    <link:label id="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28_label_en-US" xlink:label="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Costs [Member]</link:label>
    <link:label id="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28_documentation_en-US" xlink:label="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Costs [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:to="lab_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:to="lab_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:to="lab_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:to="lab_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="arc" />
    <link:label id="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862_terseLabel_en-US" xlink:label="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Employee Stock Option</link:label>
    <link:label id="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862_label_en-US" xlink:label="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Employee Stock Option [Member]</link:label>
    <link:label id="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862_documentation_en-US" xlink:label="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_InitialEmployeeStockOptionMember" xlink:label="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:to="lab_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="arc" />
    <link:label id="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848_terseLabel_en-US" xlink:label="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Employee Stock Option</link:label>
    <link:label id="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848_label_en-US" xlink:label="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Employee Stock Option [Member]</link:label>
    <link:label id="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848_documentation_en-US" xlink:label="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsequent Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SubsequentEmployeeStockOptionMember" xlink:label="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:to="lab_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2_label_en-US" xlink:label="lab_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:to="lab_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B_label_en-US" xlink:label="lab_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:to="lab_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First 12-month anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized as a percentage of common stock outstanding (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights as a percentage, by month</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="arc" />
    <link:label id="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3_terseLabel_en-US" xlink:label="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of common stock, per share (in dollars per share)</link:label>
    <link:label id="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3_label_en-US" xlink:label="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value of Common Stock, Per Share</link:label>
    <link:label id="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3_documentation_en-US" xlink:label="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Fair Value of Common Stock, Per Share</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EstimatedFairValueofCommonStockPerShare" xlink:label="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:to="lab_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of current employees and board members affected from modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Employees Affected</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of non-employees affected from modification</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Non-Employees Affected</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Non-Employees Affected</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="arc" />
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Modified strike price (in dollars per share)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Modified Strike Price</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Modified Strike Price</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental fair value of compensation cost from modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Underlying Common Stock (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D_label_en-US" xlink:label="lab_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:to="lab_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price of Common Stock Option (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss included in other income (expense), net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="lab_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="arc" />
    <link:label id="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641_terseLabel_en-US" xlink:label="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fee Type [Axis]</link:label>
    <link:label id="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641_label_en-US" xlink:label="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fee Type [Axis]</link:label>
    <link:label id="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641_documentation_en-US" xlink:label="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fee Type [Axis]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeAxis" xlink:label="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:to="lab_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="arc" />
    <link:label id="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA_terseLabel_en-US" xlink:label="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fee Type [Domain]</link:label>
    <link:label id="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA_label_en-US" xlink:label="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fee Type [Domain]</link:label>
    <link:label id="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA_documentation_en-US" xlink:label="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Fee Type [Axis]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeDomain" xlink:label="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:to="lab_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="arc" />
    <link:label id="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0_terseLabel_en-US" xlink:label="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees at Issuance</link:label>
    <link:label id="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0_label_en-US" xlink:label="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fees at Issuance [Member]</link:label>
    <link:label id="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0_documentation_en-US" xlink:label="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fees at Issuance [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatIssuanceMember" xlink:label="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:to="lab_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="arc" />
    <link:label id="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB_terseLabel_en-US" xlink:label="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees at Maturity</link:label>
    <link:label id="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB_label_en-US" xlink:label="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fees at Maturity [Member]</link:label>
    <link:label id="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB_documentation_en-US" xlink:label="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fees at Maturity [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatMaturityMember" xlink:label="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:to="lab_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="arc" />
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D_terseLabel_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D_label_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D_documentation_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:to="lab_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:to="lab_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:to="lab_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:to="lab_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:to="lab_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:to="lab_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:to="lab_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:to="lab_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial draw amount</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048_label_en-US" xlink:label="lab_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:to="lab_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floating interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="arc" />
    <link:label id="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of prime rate (as a percent)</link:label>
    <link:label id="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5_label_en-US" xlink:label="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate, Decrease</link:label>
    <link:label id="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate, Decrease</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DebtInstrumentBasisSpreadonVariableRateDecrease" xlink:label="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:to="lab_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="arc" />
    <link:label id="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA_terseLabel_en-US" xlink:label="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to participate in future financing, amount</link:label>
    <link:label id="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA_label_en-US" xlink:label="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Right To Participate In Future Financing, Amount</link:label>
    <link:label id="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA_documentation_en-US" xlink:label="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Right To Participate In Future Financing, Amount</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount" xlink:label="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:to="lab_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable on debt instrument</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392_verboseLabel_en-US" xlink:label="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock warrant liability</link:label>
    <link:label id="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392_label_en-US" xlink:label="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392_documentation_en-US" xlink:label="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:to="lab_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:to="lab_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF_label_en-US" xlink:label="lab_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:to="lab_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:to="lab_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable and unbilled revenue receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of credit risk and other risks and uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:type="arc" />
    <link:label id="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C_terseLabel_en-US" xlink:label="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrant liability</link:label>
    <link:label id="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C_label_en-US" xlink:label="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants or Rights Policy [Policy Text Block]</link:label>
    <link:label id="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C_documentation_en-US" xlink:label="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants or Rights Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantsorRightsPolicyPolicyTextBlock" xlink:label="loc_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:to="lab_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments and geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:type="arc" />
    <link:label id="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681_terseLabel_en-US" xlink:label="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price-based anti-dilution protection gross proceeds threshold</link:label>
    <link:label id="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681_label_en-US" xlink:label="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Price-Based Anit-Dilution Protection, Gross Proceeds Threshold</link:label>
    <link:label id="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681_documentation_en-US" xlink:label="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price-Based Anit-Dilution Protection, Gross Proceeds Threshold</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold" xlink:label="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:to="lab_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_97DB9FD54AA8AF25BCE8C0DF29C05FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_406D53301CC622FAA255C0DF29C0500E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2827124A3E79CCD042F9C0DF29C0123C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_41139150F366B72EFC3AC0DF29C0BA19" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:to="lab_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="arc" />
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166_terseLabel_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, voting rights for each share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166_label_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166_documentation_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockVotingRightsforEachShare" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:to="lab_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:to="lab_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="arc" />
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation Expense Classification in Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions Used to Determine Fair Value of Common Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="arc" />
    <link:label id="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD_terseLabel_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD_label_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD_documentation_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:to="lab_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:to="lab_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Operating Losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:to="lab_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:to="lab_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of long-term debt issuance costs and fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue receivable and accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Unbilled Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:to="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:type="arc" />
    <link:label id="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE_terseLabel_en-US" xlink:label="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Northwestern University License Agreements fee</link:label>
    <link:label id="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE_label_en-US" xlink:label="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued License Agreement Fees</link:label>
    <link:label id="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE_documentation_en-US" xlink:label="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued License Agreement Fees</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseInAccruedLicenseAgreementFees" xlink:label="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:to="lab_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:type="arc" />
    <link:label id="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC_terseLabel_en-US" xlink:label="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC_label_en-US" xlink:label="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Professional Fees</link:label>
    <link:label id="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC_documentation_en-US" xlink:label="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Professional Fees</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseAccruedProfessionalFees" xlink:label="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:to="lab_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term borrowing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of long-term debt fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:type="arc" />
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E_negatedTerseLabel_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of common stock financing costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E_label_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E_documentation_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfCommonStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:to="lab_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:type="arc" />
    <link:label id="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834_negatedTerseLabel_en-US" xlink:label="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of preferred stock financing costs</link:label>
    <link:label id="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834_label_en-US" xlink:label="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Preferred Stock Financing Costs</link:label>
    <link:label id="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834_documentation_en-US" xlink:label="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Preferred Stock Financing Costs</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfPreferredStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:to="lab_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents - beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:type="arc" />
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7_terseLabel_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issuance costs (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7_label_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7_documentation_en-US" xlink:label="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:to="lab_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:type="arc" />
    <link:label id="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C_terseLabel_en-US" xlink:label="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock warrants</link:label>
    <link:label id="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C_label_en-US" xlink:label="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock Warrants</link:label>
    <link:label id="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C_documentation_en-US" xlink:label="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock Warrants</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IssuanceOfCommonStockWarrants" xlink:label="loc_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:to="lab_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:type="arc" />
    <link:label id="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B_terseLabel_en-US" xlink:label="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock warrants</link:label>
    <link:label id="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B_label_en-US" xlink:label="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Preferred Stock Warrants</link:label>
    <link:label id="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B_documentation_en-US" xlink:label="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Preferred Stock Warrants</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IssuanceofPreferredStockWarrants" xlink:label="loc_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:to="lab_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs (accounts payable)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing activities (capital expenditure) included in other accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:to="lab_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:to="lab_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation value</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="lab_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="lab_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable from related party (Note 12)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:to="lab_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net (Note 4)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposit on leased facility</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:to="lab_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7_label_en-US" xlink:label="lab_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:to="lab_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt (Note 5)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:to="lab_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:to="lab_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="arc" />
    <link:label id="lab_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228_verboseLabel_en-US" xlink:label="lab_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Northwestern University License Agreements fee</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:to="lab_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities (Note 4)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue (Note 3)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:to="lab_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:to="lab_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net (Note 4)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="arc" />
    <link:label id="lab_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060_terseLabel_en-US" xlink:label="lab_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock warrant liability (Note 10)</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:to="lab_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="arc" />
    <link:label id="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability (Note 10)</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:to="lab_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion (Note 3)</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299_label_en-US" xlink:label="lab_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:to="lab_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (Note 6):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="lab_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:to="lab_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 35,513,987 issued and outstanding, September 30, 2017; 30,782,380 shares authorized, 131,644 issued and outstanding, December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:to="lab_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:to="lab_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="lab_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:to="lab_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant income</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:to="lab_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE_label_en-US" xlink:label="lab_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:to="lab_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:to="lab_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:to="lab_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:to="lab_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E_label_en-US" xlink:label="lab_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:to="lab_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:to="lab_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions used to Estimate Fair Value of Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>xcur-20171031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheets" xlink:href="xcur-20171031.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:href="xcur-20171031.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:href="xcur-20171031.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:href="xcur-20171031.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:href="xcur-20171031.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:href="xcur-20171031.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:href="xcur-20171031.xsd#DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:href="xcur-20171031.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="xcur-20171031.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:href="xcur-20171031.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:href="xcur-20171031.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:href="xcur-20171031.xsd#EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:href="xcur-20171031.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:href="xcur-20171031.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:href="xcur-20171031.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:href="xcur-20171031.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:href="xcur-20171031.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:href="xcur-20171031.xsd#IncomeTaxesIncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:href="xcur-20171031.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:href="xcur-20171031.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:href="xcur-20171031.xsd#LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:href="xcur-20171031.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaboration" xlink:href="xcur-20171031.xsd#PurdueCollaboration" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#PurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:href="xcur-20171031.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:href="xcur-20171031.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:href="xcur-20171031.xsd#SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="xcur-20171031.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:href="xcur-20171031.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StatementsOfOperations" xlink:href="xcur-20171031.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:href="xcur-20171031.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:href="xcur-20171031.xsd#StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:href="xcur-20171031.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:href="xcur-20171031.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:href="xcur-20171031.xsd#SupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9C405F236F853AC53E43FEBFAECD3403" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9C405F236F853AC53E43FEBFAECD3403" xlink:to="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:to="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_652B06B2C398BDD1BE67FEBFAECE5A60" xlink:to="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6AF803B57564D8487E55FEBFAECE6B9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6AF803B57564D8487E55FEBFAECE6B9C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_97AB91DB2EBE473E6C5BFEBFAECE8AFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_xcur_SeriesB2PreferredStockMember_97AB91DB2EBE473E6C5BFEBFAECE8AFF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_A1871658E7A8052945B9FEBFAECEDF3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_xcur_SeriesB1PreferredStockMember_A1871658E7A8052945B9FEBFAECEDF3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_FEA1AF07B8BD4DDCD386FEBFAECED1CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_660852977735F44E389DFEBFAECE5B37" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_FEA1AF07B8BD4DDCD386FEBFAECED1CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F7831E460D019D05549FFEBFAECD3F93" xlink:to="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:to="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4FA403CCDE4E2C03F195FEBFAECE4944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4FA403CCDE4E2C03F195FEBFAECE4944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_16BC7655F45F7E12BDE7FEBFAECEE9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_48F48DD5A15FBE5A730CFEBFAECFCEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_887573B053EE63DED326FEBFAECF8046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_419114CBEB2B5A873482FEBFAECFE181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_091AF7C3CA052C701DCEFEBFAECECA6E" xlink:to="loc_us-gaap_AssetsCurrent_C1824EB08ED6980C8ACBFEBFAECF8E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_290A1570E06ECFF45AC6FEBFAECFC3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5515F4817BC524762558FEBFAECF0DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_SecurityDeposit_85DA8E2F1AA8E8281965FEBFAECF610C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0D933853D1CB31F6E585FEBFAECEDD2F" xlink:to="loc_us-gaap_Assets_6032B8F53862527889B5FEBFAECFB9E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19AE8C3C31DC762E7783FEBFAECE12C1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_LongTermDebtCurrent_887A8F39D1F1C9943D1FFEBFAECF2FCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccountsPayableCurrent_8AB0386999BCC87AC1A0FEBFAECF7F2E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_3B13EA1232AA6B1A8B46FEBFAECFF228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3F134F0F1E18B821E49CFEBFAECF5E99" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3F134F0F1E18B821E49CFEBFAECF5E99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AAA9D989682B243D117CFEBFAED0FFCD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_AAA9D989682B243D117CFEBFAED0FFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_E06C2DFD2612854D9326FEBFAED06DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F9CE0B1800A4CFD730A4FEBFAED09A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E5EFACFD9D93957E739DFEBFAED0CB98" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E5EFACFD9D93957E739DFEBFAED0CB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83E034BEB289E4CE4DD9FEBFAECF1522" xlink:to="loc_us-gaap_LiabilitiesCurrent_DE5C584D15AF5221CEC3FEBFAED0E7BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_16BB9C4791308B38BE13FEBFAED02729" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_xcur_PreferredStockWarrantLiability_7B991C0B2EF493CC1D4BFEBFAED01060" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockWarrantLiability" xlink:label="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_xcur_CommonStockWarrantLiability_9716DF6668202BE410F4FEBFAED0338D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_9D0D4CF107369F66CE0EFEBFAED0294F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_AC6CBB7C8B0840D647DAFEBFAED09A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_Liabilities_D13A2E65C3EDA683E0E0FEBFAED05299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_PreferredStockValue_0719AEB4B872888AA520FEBFAED1112F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_CommonStockValue_A127DA7ACBF4C461EF01FEBFAED1FA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9B6B336C3936DE8A04A3FEBFAED1BDD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9B6B336C3936DE8A04A3FEBFAED1BDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FBC898BF42F961449823FEBFAED1D51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2F1072FB6B66C21B1BB5FEBFAED17E00" xlink:to="loc_us-gaap_StockholdersEquity_E3FBDAE325E792D4ECEDFEBFAED1C45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FBBFDEDB2189DB5EBC8BFEBFAECF9493" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_112DEEFF041B8F2AAB1CFEBFAED1F3B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31E5E2327BF016E9C30AFEE92EDCA3D8" xlink:to="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:to="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_0DF26F754A401E9E6E8DFEE92EDCC83E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_8F61EC5265C0F8991196FEE92EDDF28A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_18819B1721CE63DF430AFEE92EDC3FD8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_8F61EC5265C0F8991196FEE92EDDF28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_076DAB374B07372508EEFEE92EDDF33E" xlink:to="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_E2F324A0C3A2C0D2FBEFFEE92EDDBC3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_E2F324A0C3A2C0D2FBEFFEE92EDDBC3F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_2BE8056BB5CF93C5FCFCFEE92EDD79F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_xcur_SeriesB2PreferredStockMember_2BE8056BB5CF93C5FCFCFEE92EDD79F0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_CF1F4C063B7C7768F283FEE92EDDFA4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_xcur_SeriesB1PreferredStockMember_CF1F4C063B7C7768F283FEE92EDDFA4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_123B4BA00F7075AC94F0FEE92EDDD2E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45A2807D837722138EF6FEE92EDD9CB1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_123B4BA00F7075AC94F0FEE92EDDD2E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E5321B6C436FE3ACB2CFFEE92EDC19DE" xlink:to="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41A1CFBCCC7926231C85FEE92EDD4209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41A1CFBCCC7926231C85FEE92EDD4209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2269189F9E7837C587A5FEE92EDEFA17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2269189F9E7837C587A5FEE92EDEFA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_78F860489B845327FA0AFEE92EDE1E4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesIssued_78F860489B845327FA0AFEE92EDE1E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7973C62CBF7D62A6B6B0FEE92EDE5DD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7973C62CBF7D62A6B6B0FEE92EDE5DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_1AF328BC3EEA4E8A48DDFEE92EDE306F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F72BD9D342B30D778D6AFEE92EDEFFBE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F72BD9D342B30D778D6AFEE92EDEFFBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E12ECFEA279763507266FEE92EDE6E26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E12ECFEA279763507266FEE92EDE6E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_02EF820F01588F3B1270FEE92EDE8B93" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesIssued_02EF820F01588F3B1270FEE92EDE8B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B968E9DEBEDD93D5E302FEE92EDE76B5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E147FC558B25C2E155CBFEE92EDDC1CF" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B968E9DEBEDD93D5E302FEE92EDE76B5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A1F0015BF08DB8B9B1DAC51AA8EDF9D8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9EF5662507D246606A5EC51AA8ED7F1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommitmentsandContingenciesAbstract" xlink:label="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_234071DA5F904691396ADEF103A33650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:to="loc_us-gaap_AccruedRentCurrentAndNoncurrent_9D9B376D3394152CCF64DEF103A39A89" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsforLicenseAgreements" xlink:label="loc_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:to="loc_xcur_PaymentsforLicenseAgreements_462CC9B1DCF4B8A82DC0DEF103A52548" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CommitmentsandContingenciesAbstract_0F3A0D670CFA1544847ADEF103A207BF" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_C5B4042937CC52D08D6BDF1AD83253F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_F350F0BD3060B129E891DEF103862164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_E7060B98E7262BD8F934DEF1038774EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_41EB6CAA862589483C8FDEF10387ED93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_81D0988B613F808FDE4FDEF10387064E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C3434BEEC7823765C17ADEF10387E0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E39A86917F44DA321AABDEF10387FCFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDD1B8564C3192D69CADDEF10386D370" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_909A20A5B69BA8C8194FDEF103871C3E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A4B68D89D976457B982CDEF103929697" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A4B68D89D976457B982CDEF103929697" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_C4F0B141D880E3A33903DEF10392BAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseContingentRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A4B68D89D976457B982CDEF103929697" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseContingentRentals_CEAA1D608CC60CC9A0D1DEF10392559B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty" xlink:label="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A4B68D89D976457B982CDEF103929697" xlink:to="loc_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty_85ADE9A2F52A374C338FDF1887B3207F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A4B68D89D976457B982CDEF103929697" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_D08B30EFA840BF2CC647DEF10393AEAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D086024DD0A6102CC0B7E44423D65BFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D086024DD0A6102CC0B7E44423D65BFB" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_3AA24FCE767BE715588CE44423D64F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D086024DD0A6102CC0B7E44423D65BFB" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9B94F92F60A78304D68AE44423D643E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_897FA9E50D12D0C13320C51AA9A1F75E" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8F7F2C23DAD07068F81AC51AA9A174ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7D0BFF0CED35D43657A4FEBF3427C94B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7D0BFF0CED35D43657A4FEBF3427C94B" xlink:to="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_325D25DA8F4717394F7DFEBF3428112E" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_D92C3A709F54F469979CFEBF3428182E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_26357F3F370698E8F22DFEBF3428D8D8" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_D92C3A709F54F469979CFEBF3428182E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_BF01BC74FD4967715385FEBF3429E68F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_7A50D45B825BC44B75EFFEBF3429035A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_A5CC360772D724831E4BFEBF3429442C" xlink:to="loc_xcur_WarrantLiabilityMember_7A50D45B825BC44B75EFFEBF3429035A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeAxis" xlink:label="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeeTypeDomain" xlink:label="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_FeeTypeAxis_5CB86BBA32ED6A1054A6FEBF3429E641" xlink:to="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatIssuanceMember" xlink:label="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:to="loc_xcur_FeesatIssuanceMember_7A58BDAF93E1C1110F0EFEBF3429F0D0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FeesatMaturityMember" xlink:label="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_FeeTypeDomain_032F9A0A396B1C95305BFEBF3429FDCA" xlink:to="loc_xcur_FeesatMaturityMember_341C8A99D32CD4CE8249FEBF34297FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_EB6FE15F713B123EB44EFEBF3429290B" xlink:to="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D02EF0B7075379227476FEBF34298FFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:to="loc_us-gaap_MinimumMember_D02EF0B7075379227476FEBF34298FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_648E86212B5D942964F0FEBF3429BEA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F9C7AC575ED00493EEDAFEBF342968B4" xlink:to="loc_us-gaap_MaximumMember_648E86212B5D942964F0FEBF3429BEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6CEE15A986379A4B0FA4FEBF3429032E" xlink:to="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_65CFCDF8905F006DD43DFEBF342AC97F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_65CFCDF8905F006DD43DFEBF342AC97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_7EB6F0AD67A6AD15CB99FEBF342A94AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_13251EB675AA07E2579AFEBF3429A86C" xlink:to="loc_us-gaap_PreferredStockMember_7EB6F0AD67A6AD15CB99FEBF342A94AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_118CDDB2A76E0E2F526FFEBF342A73DC" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_HerculesTechnologyGrowthCapitalMember" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_F7EC65E4AC757B001E92FEBF342A3A36" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_CB11A03A9E01935EB4C6FEBF342A1E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_A843403E49C6099AAB5AFEBF342A296F" xlink:to="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_F378F60D70E5CA2208D8FEBF342A580A" xlink:to="loc_us-gaap_SecuredDebtMember_F3FAE1745E8B932B1106FEBF342A393C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83982040F3303E120486FEBF342AA85A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00DAAAB6C92CDFC225CFFEBF342A8A61" xlink:to="loc_us-gaap_LoansPayableMember_20BB9843A9C7F9ABFAC6FEBF342A4768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_78785C9D25A3EE5113C7FEBF342A1E3F" xlink:to="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_BB841FCC364E6A03728CFEBF342A97CC" xlink:to="loc_us-gaap_PrimeRateMember_11DBFFF9DBB36D1374BAFEBF342BEEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A9CED65CC9B85C543B64FEBF3428BD31" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_AEE29F2D9813B999E910FEBF342B0A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LineOfCredit_AE30FF28E6BC436F7E2CFEBF342B3048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CD595509A0B01AE1917DFEBF342B7C41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3F0425A2986D916F9973FEBF342BA150" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DebtInstrumentBasisSpreadonVariableRateDecrease" xlink:label="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease_7B55FF30C9D0A3456521FEBF342BE1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3DF64F13547B47D5621FEBF342B6AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_47A1B3C680B90F91FFAFFEBF342B23EA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount" xlink:label="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount_55F9AA28302496D58CC9FEBF342B22FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8C26413F9369A7162ECBFEBF342BBDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A31EE1FD6B0556A1A935FEBF342B2CCE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_A31EE1FD6B0556A1A935FEBF342B2CCE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockWarrantLiability" xlink:label="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_xcur_PreferredStockWarrantLiability_E7025E3C3B9E467B20C2FEBF342CB392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F4565FD12BB5F7CCB909FEBF342CAE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_LongTermDebt_1DB358A6E39249B47DECFEBF342CB8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FB5469707BEB98AB9554FEBF342CDF3F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_FB5469707BEB98AB9554FEBF342CDF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2E28DAD4551C1C76B969FEBF342BE17B" xlink:to="loc_us-gaap_InterestPaid_8C63D0527FFBB76C32DCFEBF342C1EDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2B45F7022A2999189E20FEBF360CE009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1A683BA787BD32827F2AFEBF360C570E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E83D224EA75F7544EEB4FEBF360C057C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2B855C972A3494D005F1FEBF360D0A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4859629FBE8674FF1F8BFEBF360E0FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_60917AD76CD55AE6A229FEBF360E4CAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebt_271CC672758A0073CEB5FEBF360E18D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebtCurrent_B70EA341BCE161B75DE0FEBF360EDA13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8B0D5E942CD282BD5FF6FEBF360BE58D" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_D0CA10C1197A2CD974F6FEBF360F2812" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7AE1DC76EEC59D69F6F4C51AA99F3C16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7AE1DC76EEC59D69F6F4C51AA99F3C16" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_72F22124DD0B947F77EAC51AA99F0C54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0896BE6571A1D8EF427BC51AA9D57F29" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7EF94B088BFE8932F68FC51AA9D5BFD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DCFA78018D48080F0D74F930ADBB8835" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DCFA78018D48080F0D74F930ADBB8835" xlink:to="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_418C0A4879E12B218EF9F930ADBC80BD" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_40DAC5F0F7045C62FED2F930ADBC83C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_54A1AAF1F21199FF652CF930ADBCCACD" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_40DAC5F0F7045C62FED2F930ADBC83C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3E4D0B6B454212AE605CF930ADBCFDA0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_29BC7406E62D5027FAE2F930ADBCC12B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_D2B51473BB375AA6B460F930ADBCD1EA" xlink:to="loc_us-gaap_PrivatePlacementMember_29BC7406E62D5027FAE2F930ADBCC12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7E1C14BA4AAE07BAFAB4F930ADBC9111" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B0FBC52D4F5E0726A86EF930ADBC05A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3D9A179CD515700FA3F2F930ADBCBC64" xlink:to="loc_us-gaap_SubsequentEventMember_B0FBC52D4F5E0726A86EF930ADBC05A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_83E0967AFDA6A8A1D0BFF930ADBCC9B6" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreMergerShareholdersMember" xlink:label="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FB02C855DD7D75CD6B8AF930ADBC6F2B" xlink:to="loc_xcur_PreMergerShareholdersMember_177D5CC42EBAFF38E6DAF930ADBC7A9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5A22753CAF85F2A9F9CCF930ADBC48CF" xlink:to="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_NorthwesternUniversityMember" xlink:label="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5BBD691011E4AF46B9C8F930ADBC098A" xlink:to="loc_xcur_NorthwesternUniversityMember_252A7A9DFEAE611244DAF930ADBD1B28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_234E256A316970332859F930ADBDAF08" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_7622CB08A81A7BFE91F5F930ADBDE494" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_14A4C9F8778E07E4610FF930ADBD48F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_14A4C9F8778E07E4610FF930ADBD48F8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_B9015130E6346F7F0005F930ADBD5BA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_B9015130E6346F7F0005F930ADBD5BA2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E7CAC9606283FE242E56F930ADBD57B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E7CAC9606283FE242E56F930ADBD57B2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_98D0AB19008732F5B186F930ADBD083A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_98D0AB19008732F5B186F930ADBD083A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_D81AEE23E2C19D917AEEF930ADBDD358" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_D81AEE23E2C19D917AEEF930ADBDD358" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_D52CF6C33FFE4314C1A5F930ADBD57D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_D52CF6C33FFE4314C1A5F930ADBD57D9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_D539077F8F7B81F308F4F930ADBD8D90" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4BBF62E341A08DFAE7CCF930ADBD7D52" xlink:to="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_D539077F8F7B81F308F4F930ADBD8D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_F80400291434068F6F24F930ADBD3071" xlink:to="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_312D2404866C0985DFCEF930ADBD8CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_312D2404866C0985DFCEF930ADBD8CE4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_A49877BFAB5188BD2241F930ADBDBD10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B68C4DBAFB178AE0359DF930ADBDC104" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_A49877BFAB5188BD2241F930ADBDBD10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ACCBFF32B5D2B584CBFFF930ADBD1452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60E8F283FBDACBCF17CF930ADBD1A88" xlink:to="loc_us-gaap_EquipmentMember_2354BDFE93D02D363A03F930ADBE6DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77858E15F1D1B074C5FAF930ADBEC57C" xlink:to="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:to="loc_us-gaap_InvestorMember_69905591FBF39E0298A7F930ADBE7DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_02732C9D51E8D8AEB5BEF930ADBECF7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_793983978C08F1B165A3F930ADBE5B8D" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_02732C9D51E8D8AEB5BEF930ADBECF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9FF67F50D35D2E9F00A0F930ADBE8688" xlink:to="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_6A6A969D48A3615DAA1DF930ADBE8F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_6A6A969D48A3615DAA1DF930ADBE8F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_ED923B7E73CC9FA71A39F930ADBEACBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_us-gaap_CommonStockMember_ED923B7E73CC9FA71A39F930ADBEACBD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassAUnitsMember_4E67FF4C8CDF51A929A4F930ADBECA7A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB1UnitsMember" xlink:label="loc_xcur_ClassB1UnitsMember_F31BCD75F6AD3FAF971FF930ADBE2A76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassB1UnitsMember_F31BCD75F6AD3FAF971FF930ADBE2A76" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB2UnitsMember" xlink:label="loc_xcur_ClassB2UnitsMember_A1AF0DCFFD20B0351BE1F930ADBE29D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassB2UnitsMember_A1AF0DCFFD20B0351BE1F930ADBE29D7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassCUnitsMember" xlink:label="loc_xcur_ClassCUnitsMember_61221C10007EF0B2D259F930ADBEE4F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_xcur_ClassCUnitsMember_61221C10007EF0B2D259F930ADBEE4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1353C4B6FE69DD5B2090F930ADBEFDAB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_876586DBDE855AB5BD57F930ADBE3DD6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1353C4B6FE69DD5B2090F930ADBEFDAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_21200AF7BEB0D6698138F930ADBCA389" xlink:to="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_703A13EB3C78AB78BCA2F930ADBEC177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_ConversionofStockConversionRatio_703A13EB3C78AB78BCA2F930ADBEC177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_F8C06E6D0D503A368287F930ADBE0350" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_F8C06E6D0D503A368287F930ADBE0350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_25595BB7D720FDD52764F930ADBE4E23" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_1F0A928FD3342D19DE29F930ADBFB9ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_1F0A928FD3342D19DE29F930ADBFB9ED" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_BF6D4B38BDC1B90F30CAF930ADBFA573" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_BF6D4B38BDC1B90F30CAF930ADBFA573" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" xlink:label="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_1516020404FB27322EC1F930ADBF598B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_1516020404FB27322EC1F930ADBF598B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25B3FBC0E83AC841AC0AF930ADBF774E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25B3FBC0E83AC841AC0AF930ADBF774E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_UnbilledContractsReceivable_E6A3E535E72E52314205F930ADBF4B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_EE88A3334A1B321BE280F930ADBFD0E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_9BCE463D5163337B9BAEF930ADBF869A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributions" xlink:label="loc_xcur_MembersCapitalContributions_D3627CFDDFA020688810F930ADBF5483" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_MembersCapitalContributions_D3627CFDDFA020688810F930ADBF5483" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedPercent" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_CollaborativeArrangementEquityReceivedPercent_BE7E36F8B30A2AA4B6DAF930ADBF8926" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborativeArrangementEquityReceivedNumberofShares" xlink:label="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_CollaborativeArrangementEquityReceivedNumberofShares_0A3BB9746200019176F9F930ADBFD091" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_359203391936775922E1F930ADBF3CB5" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_359203391936775922E1F930ADBF3CB5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital" xlink:label="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital_C4F43298BE8693687030F930ADBF5415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_E52B9089545DCA9D6DB1F930ADBF220D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_E52B9089545DCA9D6DB1F930ADBF220D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DB19600C72FC34273FEAF930ADBFDAA5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_DB19600C72FC34273FEAF930ADBFDAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_C8A7D8EA6105996E2418F930ADBFE80B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_C8A7D8EA6105996E2418F930ADBFE80B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_E9C7151486EA10516595F930ADBFDE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_083F1B7CFA90A9A8BD09F930ADBF9D82" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_083F1B7CFA90A9A8BD09F930ADBF9D82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_B261970F0622ECC3D86EF930ADBE7F86" xlink:to="loc_us-gaap_AdditionalPaidInCapital_F9EB6A089A33ADF1CBC8F930ADBF66BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DocumentAndEntityInformationAbstract" xlink:label="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_EntityRegistrantName_9D7B997AC76F465E9407E4377AC09FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_EntityCentralIndexKey_57FECBEB16DDCC6C3D2FE4377AC0689E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_EntityFilerCategory_2F19590EACE37A15F8A5E4377AC05A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_DocumentType_29077B5C2AAA186A623EE4377AC05C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_DocumentPeriodEndDate_F23B0D85AE87FAFCC6B3E4377AC0D841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_DocumentAndEntityInformationAbstract_386D4B5D6209902D6807E4377AC0537E" xlink:to="loc_dei_AmendmentFlag_DE20B291E1AB08E0CC6DE4377AC0C004" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1EF33FD0182926FC65B0C51AA97FD975" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1EF33FD0182926FC65B0C51AA97FD975" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_39599A04F0775A6ECD57C51AA97F6FE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C21C4F42953348CAE91C54A9252C95A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:to="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_514909F47F52470DAAF2C54A9252B17E" xlink:to="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_MinimumMember_B126687CE05249B2F3EAC54A9252A4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_MaximumMember_B8F11E1DD2C0224DA1FFC54A9253E5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_472E4D845AE886ABA45BC54A92525AB3" xlink:to="loc_us-gaap_WeightedAverageMember_23D98EECC77488123090C54A925362B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_37CD86BC05E338E112C0C54A92522A4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6EC3E5475751A26475E9C54A92539F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F1F544BBC4F3DD663449C54A925341BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_332B873E4339CEEC3E27C54A9253E4A8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_EBADB6D4CE722C98ACE6C54A9253A806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62B4713B757F31122793C54A9253DDE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D1D2FED715B7FD95FD41C54A9253A817" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DE945EADAC719DF60FB3C54A9315D2C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DE945EADAC719DF60FB3C54A9315D2C4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:to="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1A1B164041AE4F0EF3CEC54A931510FF" xlink:to="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_BC586F60D2F079247D58C54A931558AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_MinimumMember_BC586F60D2F079247D58C54A931558AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_64D23A6E839A4E74DD0FC54A9315E122" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_MaximumMember_64D23A6E839A4E74DD0FC54A9315E122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaap_WeightedAverageMember_A434A4F7CDE3DF1B0583C54A93152CD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D15CA50F00297B8AFEDAC54A93152E9E" xlink:to="loc_us-gaap_WeightedAverageMember_A434A4F7CDE3DF1B0583C54A93152CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A9B9EAE127B94206F29CC54A931530CE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:to="loc_us-gaap_SharePrice_15CC0C822CE4AD02E58FC54A93152C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10DE5C3026BE91503272C54A9315407B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_9454C9FDD9B46EB6C63AC54A9315F5DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49CDCDB3609552938D66FB33D5428511" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49CDCDB3609552938D66FB33D5428511" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_951E1214B0BDC7CF052AFB33D542BD57" xlink:to="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_720AEE360387812CFCC3FB33D54260A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_0A3E239F3E11214F28C3FB33D5422B20" xlink:to="loc_us-gaap_MinimumMember_720AEE360387812CFCC3FB33D54260A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D9A130F6F6C8BC0F3722FB33D542943D" xlink:to="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_F96D4B5015B742CE1C1BFB33D5428E69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_F96D4B5015B742CE1C1BFB33D5428E69" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_4A648BFD4CFA8E822BF9FB33D54292C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B830B6306B0179EF47EEFB33D542E549" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_4A648BFD4CFA8E822BF9FB33D54292C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_DB704CE5F15C96D82AEAFB33D542902F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8C3966C6AD5063546DE4FB33D54210D5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_InitialEmployeeStockOptionMember" xlink:label="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_xcur_InitialEmployeeStockOptionMember_E13EE7AC245B07BB6F57FB33D5423862" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SubsequentEmployeeStockOptionMember" xlink:label="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0EF32C3BFAF2223F032FB33D542782D" xlink:to="loc_xcur_SubsequentEmployeeStockOptionMember_0D5D9E68A2F29FD2CA0BFB33D542B848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_CC74EC0573E21A4493A1FB33D54286F2" xlink:to="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_AC64D2FA0FF2FE6A1AF6FB33D54282E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6A6B0E19372AB1699DFEFB33D542FC4B" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B1240E9795BAA5EAE081FB33D542DB00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BC8C01440D2860D0674CFB33D54276BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6B1D1BBB393777FDFA64FB33D5420D88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C822DFAC93F2E879502EFB33D54206B9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_BC2FB01FDE819C5A873DFB33D54235B3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_89905D772841159160DAFB33D5429934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_143913D3B241F9D8FA78FB33D54297C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3DE80A3D9319A698D7E0FB33D542721A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A1F2B8B5AFDB9DB49F26FB33D5421EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DED21CA2710D769B3CF1FB33D542536B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16D50EBF678BF7FD5511FB33D5424688" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EstimatedFairValueofCommonStockPerShare" xlink:label="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_EstimatedFairValueofCommonStockPerShare_AE6B353624885B3591DDFB33D54293F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C4C1642B04BCA3289A69FB33D54294A0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected_8A44775F1A688AF28B19FB33D5423A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_092D31101ECB665D93B1FB33D5423693" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice_E8AF4B07F32BA52EE6EBFB33D542E7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_C635B26188A915E0DE0DFB33D542C161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EB4190A6E3BDA3B3FCEFB33D5423FF3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C6273C5CE91690B01873FB33D5422132" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0F09BE35837FA00D35FFDEF104E0D90F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0F09BE35837FA00D35FFDEF104E0D90F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_020AED672BEAB6EBEF46DEF104E1638F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_199406E70575919659B3DEF104E16D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16FA1732F94A75B415C2DEF104E142D8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_282557CCC4F0CED5518ADEF104E13773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_169F1ABCC80514C5E745DEF104E169CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_956F82A0AAA30FDCE1ADDEF104E20156" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_914B78ED5BC4D2D08174DEF104E24462" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DE3D6820C5B9281C411DFEBFAE1FD779" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DE3D6820C5B9281C411DFEBFAE1FD779" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:to="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2A938CF6A9205A8AA28DFEBFAE1FB2A4" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_7D491A172009CCBBF97EFEBFAE1FD318" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_D3A408E9F70C48D91EF0FEBFAE1F8440" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_7D491A172009CCBBF97EFEBFAE1FD318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7BA2A9CEA18BAEC5AEEFFEBFAE1FE9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0C744E1E92FC190FB71DFEBFAE20757A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_D99817769E233967FD85FEBFAE205CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16E9E5C1ECE23760C7F7FEBFAE2008F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A3981D1869EA40FD8B47FEBFAE203DEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_CD0A26325E775EC1AA19FEBFAE201766" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67CA14DD206D7C4C362EFEBFAE20DA99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FDCADE20F5D5925619BEFEBFAE20B355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7FC5DEEE1BB604E726CBFEBFAE20C4ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B9D36101D70F414B5A61FEBFAE20E62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_66C96FEAD1B5C73B9B17FEBFAE20CCBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_FBF222A4A3A5BA5E58EEFEBFAE209D4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_CDF95B1F6CAC269FCE2AFEBFAE20C368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8FA3208E94D36277DC2EFEBFAE20B36A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_BB1D4A523C967D5639B2FEBFAE218D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9758CCCBEFDFED6865A2FEBFAE21C49A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19C5561B5CF424BA6901FEBFAE2114EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4DC5F9DBADECB7BC1815FEBFAE217112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B324DD5CE01F85E751ADFEBFAE218561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3FBEF566202789EFCEE2FEBFAE216F31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_E0B48EE5D7DC0BE9D45DFEBFAE212509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_C60F4DD0FC946CC4CD89FEBFAE21C762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_098F8777118151CA8484FEBFAE2116B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18CBEEA5F704788F46FBFEBFAE208296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_AD1BF9B80D4AE73AEA4BFEBFAE21476B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D484C5BFAD2F13AC2BBDFEBFAE3B7D6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D484C5BFAD2F13AC2BBDFEBFAE3B7D6E" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_57AF1C5C8F82A05094D0FEBFAE3B573B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D484C5BFAD2F13AC2BBDFEBFAE3B7D6E" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F57F5D54030136B43A43FEBFAE3B9E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D484C5BFAD2F13AC2BBDFEBFAE3B7D6E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_166DC1A00BC4FF219612FEBFAE3B3C44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C8B6E907B826249907EEC51AA94B69E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C8B6E907B826249907EEC51AA94B69E5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_916BA00C9C7BAC4E4BFAC51AA94CB60E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5479639B8575741EF5A1DEF10405641D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_DB951B0E67942657D063E0167CCB6250" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3AFD615903F95BF35EF6E0167CD1E09B" xlink:to="loc_us-gaap_SubsequentEventMember_DD362A4BCA9E2EFEC76EE016B3BF0CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_98A8B53AC3AB776DA8ABDEF10405D0B8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_04CCAA5C19EDF3C16BA9DEF104059EE3" xlink:to="loc_xcur_WarrantLiabilityMember_4A770C576944A1F63926DEF10405C2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_07D559AD954DE7F3E453DEF1040626D2" xlink:to="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_963DC7B671C4A1C328CEDEF10406A7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D46DC45756177CC969BBDEF104064354" xlink:to="loc_us-gaap_CommonStockMember_EA0FCF950FEB68668136DEF10406C5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8B538C8CAB9549256C01DEF10405DF5A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_3010E04241567E44A661DEF104068A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_BFE91D2FEB4B2639B1C2DEF104061EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_2D11A490B562DC19BB5CDEF10406644A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_90719F6C969E9BDC26AEDEF104068E17" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_116B228A6BBB59FA4A1BDEF10406D332" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_478AA6D9DA478F930352DEF104061F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3FE84D9CA723AABFB14CDEF1040696C4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6F292F35D64C398848DFE01795ECFCBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D075A34FB41C05BDCE59E06FB700975D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D075A34FB41C05BDCE59E06FB700975D" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C846045DC3FFEF5E15EBE06FB7007D19" xlink:to="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_6BAD62A69C969DB188BBE06FB70048AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:to="loc_us-gaap_PreferredStockMember_6BAD62A69C969DB188BBE06FB70048AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AAEF8B43A718CB50D7F0E06FB70039C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_104C8A47AC6E5CCC2DC8E06FB700EC9C" xlink:to="loc_us-gaap_CommonStockMember_AAEF8B43A718CB50D7F0E06FB70039C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657B8D83F895BDED57C8E06FB70090F6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_D6096C1328DF135F2066E06FB700431A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_780F1FDFC8E405DD5641E06FB7002524" xlink:to="loc_xcur_WarrantLiabilityMember_D6096C1328DF135F2066E06FB700431A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_089B57C42F0D5FD1F01EE06FB7002FB6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ADBEA9C831F83D4B7035E06FB7007353" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_137FD604B16821957AF1E06FB700E40E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_C0E1B921C28926929FCFE06FB70625FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9C58331898980F80EE58E06FB706FD2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4D6F1CF6F5E896BD89EDE06FB700D227" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_DE10B49EF2E1AFF987ACE06FB7065141" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_31C079E8BF25AC9F2507E06FB7138CAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31C079E8BF25AC9F2507E06FB7138CAA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_D02B69B5DB4BF8B01FD2E06FB71392D5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantLiabilityMember" xlink:label="loc_xcur_WarrantLiabilityMember_99E1DAA9487B66E3E62DE06FB714F45E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4B35E10BB7656ECF8530E06FB713D0FE" xlink:to="loc_xcur_WarrantLiabilityMember_99E1DAA9487B66E3E62DE06FB714F45E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_819BC2AC0CEFE5585A11E06FB714885E" xlink:to="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_000985E0D6635A2E133BE09E3E871048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:to="loc_us-gaap_CommonStockMember_000985E0D6635A2E133BE09E3E871048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_64464C15EC47A05F3D8CE06FB714474B" xlink:to="loc_us-gaap_PreferredStockMember_13376709D9F616652DD5E09CC2BA733F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1F64A6B89E09A71F5041E06FB713BE46" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_A2420C91E3E4482070C7E06FB71929F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_A2420C91E3E4482070C7E06FB71929F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_960CE116C606B7B19ECBE06FB7196E4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_960CE116C606B7B19ECBE06FB7196E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_605D36C7F1A21999F602E06FB7199BAA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_605D36C7F1A21999F602E06FB7199BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_8F788B81CEFBD6444964E06FB719940E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_086783071273EB487340E06FB7196003" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_8F788B81CEFBD6444964E06FB719940E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_B5D6F192DFF0898DBE64C51AA9493BA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_B5D6F192DFF0898DBE64C51AA9493BA2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5221398564D17EFCFB3EC51AA94976F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_B5D6F192DFF0898DBE64C51AA9493BA2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_795F6D10AAF7642DA2D8C51AA94AC1C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E968F636B99B94173190C51AA95B8A2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E968F636B99B94173190C51AA95B8A2E" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1D7F1482B23BC088E563C51AA95B9C87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3D4CE01BD5E4505CF563FB33D51A9770" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D4CE01BD5E4505CF563FB33D51A9770" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E3A63D58122A9ACC2F9DFB33D51AE05B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_A85F142F6389E884896DFB33D51ADA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6FC1C57962401D9F2C89FB33D51ACDB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_F23364925FEAD8860F13FB33D51AB181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7EE393F20293A8006EF3FB33D51ACB6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9AEDBAB94B0EEDE63DE8FB33D51A5D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_733364C0FE61768F171FFB33D51AD233" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_D27CF235BF04C56008D3FB33D51A82F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D4CE01BD5E4505CF563FB33D51A9770" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_0A69D289D886C6997776FB33D51AD8D4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8138326558159D8F1F3AFB33D51A112C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3D4CE01BD5E4505CF563FB33D51A9770" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2759066FA375FF7030BCFB33D51A464F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_26EFB2ED6DB280865A90FB33D51A083E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6617E625DD5FD819EA5EFB33D51A07B2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount_EEA5D6B24314D0904454FB33D51A6AD5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount_1E67B8A93442CC473B72FB33D51A82FD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount_E23CB0187039F36494BFFB33D51A0E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8F5DE4219C66654BAE98FB33D51AB589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_F77A03DFB3B173F01D95FB33D51A14A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_69BF7D6257D4C0FA2FD4FB33D51A2C09" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_296D7C84650FC7C7F358FB33D51A8375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FFDDD921089C4EC92232FB33D51A02D7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_327D1CA7DC76CD8CB068FB33D51A9D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6A132459D47193B85B99FB33D51A37C7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_3BCEF2BF61B4E4BC3981FB33D524E8F4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent_DEEB3406CE2FA957D30AFB33D5247293" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent" xlink:label="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent_9011B72057D6F4195FE0FB33D524C0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73E0C28F7070CB4834A8FB33D5249FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ED1FBD82315446BAAE78FB33D5245A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_FC54FA0219A168E4E93AFB33D51A20EE" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_F2BC30A9AFABA5862C63FB33D5244A78" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_65D11D54CF35CE4817B3C68CDB98B2F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_65D11D54CF35CE4817B3C68CDB98B2F3" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_25AD3AD6AD5319CD5DB1C68DE84B2871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_65D11D54CF35CE4817B3C68CDB98B2F3" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_F4C2E20E4BE6E330F857C68EA0F2E0F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46A24536986C6247FC73FDFB2D2120C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46A24536986C6247FC73FDFB2D2120C3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_82D39B81EBD75AAEF1F9FDFB2D21D552" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:to="loc_us-gaap_DomesticCountryMember_76CDE53CE15FB2D0359CFDFB2D22BA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_B28DE9FE3A5D404D4AF8FDFB2D221630" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0FC8B86192813EF4BA95FDFB2D2216E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8F657E6DD834FB6F80B8FDFB2D21C78D" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13B559E8F33758468644FDFB2D22B48C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_NetIncomeLoss_13B559E8F33758468644FDFB2D22B48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_F236F05099541123E216FDFB2D227943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_033103D08F00571869C8FDFB2D2293B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_OperatingLossCarryforwards_007D28D791A6EC7846FFFDFB2D221714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_B3FE20E68B7D03AA74F5FDFB2D22491B" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5A5A7B83253D3A703BFEFDFFAF68F120" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E478E29EC19455D09F28C51AA957AA58" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8D281631BB9CEF93B79CC51AA957E764" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75C7492078FF6AC9E51DC54A97C37C94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75C7492078FF6AC9E51DC54A97C37C94" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B53EEA47B01BBD5A4A79C54A97C41F92" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7228F9981016CC940663C54A97C4DFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_103F08D1B9DABD0A7824C54A97C496F3" xlink:to="loc_us-gaap_WarrantMember_D8C67D3EF26C59985AD1C54A97C4F482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4DD9A1BBD86F787CA8CBC54A97C4341C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6F75F761A82BC4E4EFC7C54A97C4ED86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_663569E32164CFA19B7CC54A97C49F65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6F75F761A82BC4E4EFC7C54A97C4ED86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_536D206285F0941B1A3AFB33D5109A52" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6DD699E33633A87F2D0EFB33D510F820" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_536D206285F0941B1A3AFB33D5109A52" xlink:to="loc_us-gaap_NetIncomeLoss_6DD699E33633A87F2D0EFB33D510F820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_536D206285F0941B1A3AFB33D5109A52" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A8E9A509410F5144AF91FB33D510C88B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_536D206285F0941B1A3AFB33D5109A52" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_38C863CA54E32DAC143DFB33D510DD00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_536D206285F0941B1A3AFB33D5109A52" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_F6E625CB602C65B3DE62FB9C7A70CCF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_417A5BE91E112DEE2C35C51AA9557FB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_417A5BE91E112DEE2C35C51AA9557FB3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5C893E185209DD007EBEC51AA9553ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_417A5BE91E112DEE2C35C51AA9557FB3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_761E11513C36F796AC16C51AA955574F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaboration" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_B202EB370A70F78DFC726E2D96BAE624" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_57AA018F884B037BC5EA6E2D96BAEFC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/PurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_82F4E3E4B771CD8A8313F930AD9E99D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_82F4E3E4B771CD8A8313F930AD9E99D8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_801DF69E8AF4CCB571DAF930AD9F5971" xlink:to="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4A7CA344A6FEA9D8BAAEF930AD9F05AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23262CF10A9112B5D26CF930AD9FE66A" xlink:to="loc_us-gaap_MaximumMember_4A7CA344A6FEA9D8BAAEF930AD9F05AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8DA256E9DB0FBD58DC51F930AD9FE5F4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F34A18100937967CF3E6F930AD9FBF7D" xlink:to="loc_us-gaap_CollaborativeArrangementMember_376BF0792063251885B3F930AD9F602F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9F16E8F01BA31EDB1C88F930AD9FB3C7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_E987B3B81E151AB8F35EF930AD9F1130" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_E558B755B6874BE23EF9F930AD9FDB35" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_FE089E54E865787CC843F930AD9F62AD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue_9322A0587CCF8D455A7DF930AD9F4D58" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_D43872D24538145CF213F930AD9F0E90" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue_995F65923BA504B8E677F930AD9F131C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent_04CCEE7765CC47F6AF73F930AD9F315E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting_FCC741689650925B0C04F930AD9F7C23" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_xcur_CollaborationAgreementRevenue_557A1761B2489FE100D3F930AD9FA7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_607F96039F2E87B9258DF930ADA01692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_DeferredRevenue_FB8B78FE7C04DA176703F930ADA058E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FFD423C91C0622595A20F930AD9F860D" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7C2180E008B2EB25EFC7F930ADA0C874" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2ADA1B988C44A51A58D3C51AA8E0205F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2ADA1B988C44A51A58D3C51AA8E0205F" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6F92DCBA5856575FABC3C51AA8E0C63F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_83FD4F3D81A871993798FB33D4E8458F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_83FD4F3D81A871993798FB33D4E8458F" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_032E99E2AFACDDFD05AAFB33D4E84F75" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A5767B7476ADEC42A5BDFB33D4E8C16A" xlink:to="loc_xcur_AuraSenseLLCMember_F7BE72E8F92707334F26FB33D4E8F944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34D3AB9E2ACBDD8EE1CFFB33D4E8138F" xlink:to="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4525A26A875EA773FD45FB33D4E879C9" xlink:to="loc_us-gaap_DirectorMember_5FC45F384188DC496073FB33D4E88214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E849895805872A4403E0FB33D4E8DD1F" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConsultingServicesMember" xlink:label="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_807F0E3D6184B70E5144FB33D4E868EA" xlink:to="loc_xcur_ConsultingServicesMember_E616F165C27137B1FAE2FB33D4E827B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1C05EBB40986635E23F4FB33D4E8CA34" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty" xlink:label="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty_B5C0FE08D3679E842AF8FB33D4E82B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_3806ACBA8B14AAA41CFBFB33D4E82FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_B97F4309C9B9E16D74EFFB33D4E8DB7E" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_70D0BCB51FB808CB8C3DFB33D4E8574F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_32CED2040CD468708EDBFB33D4E89B79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_32CED2040CD468708EDBFB33D4E89B79" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:to="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_A0AB52C7AE40A5B6CA5CFB33D4E83175" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AuraSenseLLCMember" xlink:label="loc_xcur_AuraSenseLLCMember_15D2BC6338B6E2F8A78CFB33D4E8500B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_DF4F518CC37A09A053F7FB33D4E83DE9" xlink:to="loc_xcur_AuraSenseLLCMember_15D2BC6338B6E2F8A78CFB33D4E8500B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_DF8F20D5CC38B9A672EDFB33D4E87ECB" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectLaborOnResearchMember" xlink:label="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_DirectLaborOnResearchMember_FDCFFC3FAF415015E7B4FB33D4E8AF04" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharedCostsMember" xlink:label="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_SharedCostsMember_85B732F191EC64C0CBA3FB33D4E8C0F5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_QuarterlyFeeForIndirectCostsMember" xlink:label="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_QuarterlyFeeForIndirectCostsMember_75CDEAAE810C18054768FB33D4E8F151" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_DirectCostsMember" xlink:label="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9B039EBD7040529EB2E1FB33D4E8241E" xlink:to="loc_xcur_DirectCostsMember_0D135CDEF3F5787607B9FB33D4E84F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_E99B03E8A8F862C92EB1FB33D4E8706E" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA97DE0C3A49D7551F22FB33D4E83E34" xlink:to="loc_us-gaap_RevenueFromRelatedParties_DA8A67D1B55784CFEF6EFB33D4E8BB9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_BE39D90F116D22ECD20EC51AA8DEC97B" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_A470F6E06815E3A39223C51AA8DE39DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_55E427C37BA360B312A8C51AA9C2C14F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55E427C37BA360B312A8C51AA9C2C14F" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_36EB6190F3865E12F76FC51AA9C2A585" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A4B0732BACAEFAD38721C54A816D57D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A4B0732BACAEFAD38721C54A816D57D8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ADDF1EC98D68ADADACA5C54A816D6DB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_EE559CBC46AF16463F2FDEF106AFBD2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1030852D4BBE04EB604ADEF106AF7ACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_UseOfEstimates_51EC1ABE563E3422AF26DEF106AF6CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C08BDEAD80531561B129DEF106AF792F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_259C23FFE0197DA35AE6DEF106AFC55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36DD63AF19A678D9E7A7DEF106AFF6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9BD2D07F7D6189BD97D6DEF106B0EB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_687377E7594109D4522DDEF106B0D9D0" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_WarrantsorRightsPolicyPolicyTextBlock" xlink:label="loc_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_xcur_WarrantsorRightsPolicyPolicyTextBlock_38CAB68FE0FC43C19FF8DEF106B0F73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_66539CF0A7BD185F3A11DEF106B52832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60C933E85891E1B05638DEF106B50000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_FD41BF56669984086604DEF106B57EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_06C4650E49B5665F2A10DEF106B59DB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1587E05E30B6C5BCA160DEF106B5AE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_166EAF41B0011B1A4E0EDEF106B5A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_FA2618B0BF9AA6C24763DEF106B5FA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3D16163D55E94757DE72DEF106AFBC6A" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_27E150C1BECE6AC4A3C1DEF106B58CAF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3CC637171ABA2195F932F930ADA92DEB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3CC637171ABA2195F932F930ADA92DEB" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:to="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_287A7D71B0CD6310CA14F930ADA987C2" xlink:to="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_FB19593F5391A9F2F266F930ADA925C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:to="loc_us-gaap_MinimumMember_FB19593F5391A9F2F266F930ADA925C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_67663FDA6E30D7CA84A5F930ADA99F0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_64F94FA731A73455F29AF930ADA9334B" xlink:to="loc_us-gaap_MaximumMember_67663FDA6E30D7CA84A5F930ADA99F0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FBE59E3A935BABB67F03F930ADA9E597" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9779BDDB64C3721D90DCF930ADA9C108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1E41B926960EA38BB9A9F930ADA9F082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1562FEEFF6B861178017F930ADA9727B" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_7A482262842A091D2B36F930ADA92E5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_040A2512841DA7E47FE6FDFB2DD6DFBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_040A2512841DA7E47FE6FDFB2DD6DFBF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:to="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_390CACB36E87AE34EFCFFDFB2DD7CAF7" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_5EB7A2734B440F5A58E8FDFB2DD796A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C071FD1636107FF8F204FDFB2DD7BA81" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_5EB7A2734B440F5A58E8FDFB2DD796A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3A7DA44B8787896D2DB1FDFB2DD7A893" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9F9D5CEE4E5D02BA1BFFFDFB2DD76F55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_453FA9C408EBAC027CEBFDFB2DD7ED7C" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9F9D5CEE4E5D02BA1BFFFDFB2DD76F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A4F2D361D923810CD01FFDFB2DD7C6FB" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_03FB90E6A4D745E45F7BFDFB2DD86F9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_03FB90E6A4D745E45F7BFDFB2DD86F9A" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementUpfrontPayment" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_AC81A7A3A5B11A604E7FFDFB2DD88899" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_AC81A7A3A5B11A604E7FFDFB2DD88899" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_BD3320ECB835952729BCFDFB2DD82424" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_BD3320ECB835952729BCFDFB2DD82424" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_11FE0F3D3C9675B29E64FDFB2DD82A79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_xcur_CollaborationAgreementRevenue_11FE0F3D3C9675B29E64FDFB2DD82A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FC0B6A3F14F5857B5E68FDFB2DD8FB92" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_us-gaap_DeferredRevenue_FC0B6A3F14F5857B5E68FDFB2DD8FB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C22CC9E967C9C5F005ADFDFB2DD83063" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8A6BAEA54E1F2ACECD80FDFB2DD7FC6C" xlink:to="loc_us-gaap_DeferredRevenueCurrent_C22CC9E967C9C5F005ADFDFB2DD83063" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_63BBC794C41AC358F46BFEBFAEB16C56" xlink:to="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_E387B4B5A2BD2CC2BB8BFEBFAEB16CFF" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_07679EA0F9003BB96A1DFEBFAEB2834E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_0019FA339A1495773E4DFEBFAEB1A994" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_07679EA0F9003BB96A1DFEBFAEB2834E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A8AD68A0BF3C046300D8FEBFAEB2CB13" xlink:to="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_PreferredStockMember_54A372F3057340777F98FEBFAEB29F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_MemberUnitsMember_EB21BFDC6851EAE36AB0FEBFAEB2C689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_45F6C7A491566A8157F9FEBFAEB25198" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_CommonStockMember_45F6C7A491566A8157F9FEBFAEB25198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_57CC2D501E3D09524A8CFEBFAEB2F7C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96F2B59D9AD0420A408DFEBFAEB2A1D4" xlink:to="loc_us-gaap_RetainedEarningsMember_BD91F37814E895319C04FEBFAEB38C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_DEA232A74827EB072825FEBFAEB3EA3D" xlink:to="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassCMember" xlink:label="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassCMember_9C58DE063E55D1ACF92FFEBFAEB38077" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIIMember" xlink:label="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassBIIMember_5973442539D0F94A47B3FEBFAEB3B1BC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredClassBIMember" xlink:label="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_PreferredClassBIMember_F796FAB0A2AA8E0BF439FEBFAEB383DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_PreferredClassAMember_028AD9E29129FE7B1CA1FEBFAEB36863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_D4F2108FFEE0104BC9CDFEBFAEB3CB55" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_D4F2108FFEE0104BC9CDFEBFAEB3CB55" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredStockMember" xlink:label="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_SeriesB2PreferredStockMember_01B47B11DB4CB16F8B52FEBFAEB362FF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredStockMember" xlink:label="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_xcur_SeriesB1PreferredStockMember_62C315A45B43295CBD3FFEBFAEB37444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_300113C05AA340CAD8FFFEBFAEB36123" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6F4C9D47D48EC4444C8CFEBFAEB3472C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A986BFD05FA85568870CFEBFAEB10AB6" xlink:to="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3D8BBB9D8959F137FA26FEBFAEB30B3F" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_SharesOutstanding_B0572E267B2465692B68FEBFAEB38FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockholdersEquity_EB1B21BC9B323A0ED222FEBFAEB40C02" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues_37F22766DFA9B5C4EB49FEBFAEB421B3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues_343F9B8808275C2FACF0FEBFAEB415E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14C0898B3DD47F8FD9E1FEBFAEB416B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_85B40FEE549B4D91706FFEBFAEB40090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6DFB64D65BFDAC5DC923FEBFAEB449E7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger_6CF4A98A1FE3DDD8A727FEBFAEB4D91D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueInConnectionWithMerger" xlink:label="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger_6CD7489FAE36A5E117BEFEBFAEB446C3" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation_7044CFA0D3D5E34CD05AFEBFAEB46959" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation" xlink:label="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation_F3B4777A053EB71B4DDEFEBFAEB4D60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2A77BA2DCF597F49D91DFEBFAEB40E90" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2A77BA2DCF597F49D91DFEBFAEB40E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59D2F0493C743AE965AAFEBFAEB4B451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_NetIncomeLoss_1705CF25F396DDE0114EFEBFAEB45F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_SharesOutstanding_BC839438641CF4F40E23FEBFAEB4A4E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C5651DC554EA9832CE96FEBFAEB34307" xlink:to="loc_us-gaap_StockholdersEquity_C6E2C82CB3187A262E52FEBFAEB427AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A74299292995B065BCF3FEBFAEA6CF67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_NetIncomeLoss_A74299292995B065BCF3FEBFAEA6CF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_205726D8646925B8E922FEBFAEA61982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_205726D8646925B8E922FEBFAEA61982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="loc_us-gaap_ShareBasedCompensation_7F8A6FB5BC11C119FEA5FEBFAEA73F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_42B1B1E1830E6502DAC0FEBFAEA722E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_221768136ADF2CD10366FEBFAEA726E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7A1956A958012098D7B3FEBFAEA6C3B5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_240951006779871ABB6CFEBFAEA7376E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_5E18E1ACF07F2CE6082EFEBFAEA73695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6AB76B25263623115B16FEBFAEA7281F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_846DCD541398503AC5FDFEBFAEA750ED" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseInAccruedLicenseAgreementFees" xlink:label="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees_C098EC7D3A726863D863FEBFAEA751CE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IncreaseDecreaseAccruedProfessionalFees" xlink:label="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_xcur_IncreaseDecreaseAccruedProfessionalFees_BE727FBBF4E009B473B2FEBFAEA7F1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_B5D87EA772AF50C104A4FEBFAEA76763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_FE2276E85162037B03A6FEBFAEA7FF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_61E0D3DC2E94EAEFDC14FEBFAEA82EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_45B201025C4CF46D5171FEBFAEA899FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_698A53832C73C19FFE34FEBFAEA71D15" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_770218C28DCB87F010A0FEBFAEA807F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_477927C73D5DC76EBA5CFEBFAEA674B3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_533523E2627D6CF118E5FEBFAEA87B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A7E3F88308253AEBD07BFEBFAEA83E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7C77AAF9832FECCA2EEEFEBFAEA8C97A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_380E53D641010C6A8CA6FEBFAEA8E370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0886129A53CF93B0B945FEBFAEA88E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_183952482893C6C470BAFEBFAEA82A98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_183952482893C6C470BAFEBFAEA82A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_71E4991CCB8E0C690154FEBFAEA81AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_A39BF474ACFF6FC8C458FEBFAEA8BDF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_98B0DB2F5CA66C034D8DFEBFAEA82499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_38D1A876BBF77E5810F4FEBFAEA8D708" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfCommonStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_800AE77C8C2F1C7AF4FFFEBFAEA8593E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsOfPreferredStockFinancingCosts" xlink:label="loc_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_xcur_PaymentsOfPreferredStockFinancingCosts_4470072E76F3E4757EDEFEBFAEA83834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBBBEB3042DC1703BBAFFEBFAEA8B2E9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CFFBFB2E8E748B55E1FFFEBFAEA9AC02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FC3CED76AD23861785EFEBFAEA91E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12D019F2605204F16C2AFEBFAEA9F4B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_731FF2B800D97C89D973FEBFAEA989A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A8F67BEFC7D3BB0C5534FEBFAEA6FADC" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_09DECF4376033F18DAE7FEBFAEA93889" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="loc_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_925DB435C604E84B0493FEBFAEA9E4C7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IssuanceOfCommonStockWarrants" xlink:label="loc_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="loc_xcur_IssuanceOfCommonStockWarrants_21D656FFB5AEFC220B11FEBFAEA9563C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_IssuanceofPreferredStockWarrants" xlink:label="loc_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="loc_xcur_IssuanceofPreferredStockWarrants_977AEDED62F3599C69A8FEBFAEA9432B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_C86CB629F25644C111C0FEBFAEA9CFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_E434C4B35BEEA73B6E87FEBFAEA93E9F" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8037122CF0669C6D2FEDFEBFAEA9561B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CollaborationAgreementRevenue" xlink:label="loc_xcur_CollaborationAgreementRevenue_D374C7520F1927E658C1FEBFAEB96638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:to="loc_xcur_CollaborationAgreementRevenue_D374C7520F1927E658C1FEBFAEB96638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:to="loc_us-gaap_RevenueFromGrants_BC5452775D86C6CDBE32FEBFAEBAA70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_A9960FC8F47DEB9283DCFEBFAEB91597" xlink:to="loc_us-gaap_Revenues_4533A32079ADDA42C0B5FEBFAEBAB0EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_621143D087359DEF0CBBFEBFAEBA4516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_74AA1032BB187E2BE620FEBFAEBAE65E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:to="loc_us-gaap_OperatingExpenses_BE9C4773FF4E39B19C13FEBFAEBA69E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_A95A526BB17F7AB540FBFEBFAEBAF260" xlink:to="loc_us-gaap_OperatingIncomeLoss_A31C40D3ED3E8A909A2FFEBFAEBAF7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:to="loc_us-gaap_InterestExpense_27A83989C3F0B66ADD09FEBFAEBA714E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_860E38FA1562EA1C7256FEBFAEBA9456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E6DB3550E9B0C8F0EB3FEBFAEBA6B43" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5E60D25610E39C60F338FEBFAEBA2287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_NetIncomeLoss_67EEA16601B0AD509DDEFEBFAEBA5FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4E6826EF212CAA0DBEEFEBFAEBA55DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BAEEEE560D643B549033FEBFAEB90364" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_872117F9083DC707826BFEBFAEBB80BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0C9C8F8A5B4B684E80A2FEBFAE5AE0C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0C9C8F8A5B4B684E80A2FEBFAE5AE0C1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FB94F2B8C441D20400C5FEBFAE5AE824" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_AB4749B08FAB90BA23DC0408CC20A0A6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_288D076E6A4DC9DFF38B0408CC24016D" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_46EA2F6C3E683A5C505B0408CC24C468" xlink:to="loc_us-gaap_ScenarioPreviouslyReportedMember_477CEB6B702B36E66D320408CC2438DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4455E40564AA64E0A6000408CC25FBB5" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_2C2A51ECF99DBE77B3E10408CC253379" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_26583C18872DC26969540408CC2588A7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember_A93C01E34FB6904370410408CC25C1D5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember_E49A697A9A0DFB3B0A760408CC257C8F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember_6E97E1734FC8BE25F0D60408CC253FA8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember_2734D23ECEB7C5DD96AA0408CC2619E5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember_EF41D5E50C1C98F57E930408CC265756" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember" xlink:label="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_DDB3210E2EF0F6FB8C1F0408CC253E82" xlink:to="loc_xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember_99373EAF2E3F194AEE110408CC26798B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_339E6788C65BDD9613D50408CC2607FF" xlink:to="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOfCommonParentMember" xlink:label="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_92A24B7F21AC3477CB1F0408CC26C409" xlink:to="loc_us-gaap_SubsidiaryOfCommonParentMember_B60D0901E9D9C106EEF60408CC261019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157064BE929E076DF6B0408CC26AA30" xlink:to="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredUnitsMember" xlink:label="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassAUnitsMember" xlink:label="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassAUnitsMember_926C22EB739730F673320408CC26ADC1" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB1UnitsMember" xlink:label="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassB1UnitsMember_FFCAF252B681F4D53BFB0408CC26E43C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassB2UnitsMember" xlink:label="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassB2UnitsMember_D80063B6BEF374382F470408CC265B0E" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ClassCUnitsMember" xlink:label="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_PreferredUnitsMember_BBBA2329099CC47B6E420408CC2687FD" xlink:to="loc_xcur_ClassCUnitsMember_3AA42A5B2E316729DDD60408CC2676C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3829EA9C6377D3F55E1A0408CC26DCB2" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB1PreferredMember" xlink:label="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_SeriesB1PreferredMember_587CC7064115F9E0B6180408CC26C767" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesB2PreferredMember" xlink:label="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_xcur_SeriesB2PreferredMember_BB49DA454DFE996BFD500408CC264BBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_35FA27A6C7D9A65A0A9E0408CC26702F" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_69324F334488DF792A530408CC2661F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_B72D92BB42B9ED07C0A70408CC2380C2" xlink:to="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_ConversionofStockConversionRatio_91961C653EB1469AB0550408CC274073" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockNumberofSharesEffectivelyNotConverted" xlink:label="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted_FAD97FEFD85C89D76DE80408CC278397" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio_0A178F8704C4037F42870408CC278902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C764D8904C18FC325FC30408CC27C1DF" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalSharePriceFairValue" xlink:label="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalSharePriceFairValue_B64AB18A4AF62E2C56B20408CC271BBA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributionsFairValue" xlink:label="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalContributionsFairValue_E49282F84D0421962E410408CC275A3B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_MembersCapitalContributions" xlink:label="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_MembersCapitalContributions_ED630578002B526A22F00408CC27E712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ADE96A63DBFF4B6536840408CC277425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_E51ADC8963DEBA1FB0690408CC27B262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_D980F3C706659D816C490408CC27CE3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_431E86BAD9CC2B43EE930408CC27F328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F789D1332FFC37036AF10408CC270EFE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccountsReceivableSaleOfStock" xlink:label="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_AccountsReceivableSaleOfStock_E5691D87859C12CAC2D70408CC271AF9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable" xlink:label="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable_D5EEAFB60F7C18693B100408CC276381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0EB7B043A29CF3DF75700408CC2730C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150830FE5A5E0C4686960408CC270B44" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions" xlink:label="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_914CF0524A6A4EFD23100408CC2756C5" xlink:to="loc_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions_35A55EBC05D18DD3704C0408CC27589D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_15D036E1888EF920B6EFFEBFAE554A40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_15D036E1888EF920B6EFFEBFAE554A40" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C1F8F7E56C86EAB56CF0FEBFAE55AA24" xlink:to="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_0D6DD2BEE2F6BC8A2D43FEBFAE55D2D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_75CB7245297F779909C0FEBFAE5515B8" xlink:to="loc_us-gaap_InvestorMember_0D6DD2BEE2F6BC8A2D43FEBFAE55D2D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_3DAD3E61596FEA7EEAB5FEBFAE5550BC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PreMergerShareholdersMember" xlink:label="loc_xcur_PreMergerShareholdersMember_21B278046534343BFB31FEBFAE55D946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56631B9A884870E9A6EBFEBFAE552755" xlink:to="loc_xcur_PreMergerShareholdersMember_21B278046534343BFB31FEBFAE55D946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_4F4036502CEBA8C95329FEBFAE56F3E8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_63CE61405E54ACCAD0D1FEBFAE56DEB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:to="loc_xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember_63CE61405E54ACCAD0D1FEBFAE56DEB7" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_04B4C3B06F06D46DF596FEBFAE56A20D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_0A19C439C7217B3579F8FEBFAE56E2D6" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_04B4C3B06F06D46DF596FEBFAE56A20D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D526475C760F45AACDE6FEBFAE5698E8" xlink:to="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_E5755C3AA01DD9D6E7D4FEBFAE56B48B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_E5755C3AA01DD9D6E7D4FEBFAE56B48B" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_9B32B4F865A05C013F7EFEBFAE56EB0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9189DBA2E273BFD617F6FEBFAE56D147" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_9B32B4F865A05C013F7EFEBFAE56EB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5DFB703F70C590AB3E47FEBFAE56B8E7" xlink:to="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_91B9F7BAF97FB66690F8FEBFAE56B507" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2FA6808FE564D945292AFEBFAE562220" xlink:to="loc_us-gaap_CommonStockMember_91B9F7BAF97FB66690F8FEBFAE56B507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_AC11364BF4453022B5ECFEBFAE55A5C1" xlink:to="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_C3988DA3D58EF51E7C14FEBFAE562C25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_ConversionofStockConversionRatio_C3988DA3D58EF51E7C14FEBFAE562C25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_FA5A2B7F5CF122EEAEE1FEBFAE566410" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_FA5A2B7F5CF122EEAEE1FEBFAE566410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_243BBA602FEA1EC972DFFEBFAE56D9AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_243BBA602FEA1EC972DFFEBFAE56D9AC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_C96854326ABE2FEB854BFEBFAE57E660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_C96854326ABE2FEB854BFEBFAE57E660" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_35C5988688D24B4D72B9FEBFAE57694D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_35C5988688D24B4D72B9FEBFAE57694D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F18FB0ADB2373068B8FFFEBFAE576359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5E04FC4614646D1DE2BEFEBFAE578524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_CommonStockSharesIssued_B915BCB3D2391DCB19E9FEBFAE572BB8" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_CommonStockVotingRightsforEachShare" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_xcur_CommonStockVotingRightsforEachShare_427138DF59424295C337FEBFAE57B166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7A573AD9CF083930F602FEBFAE574411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_F4DFFA8EFAF263480F7DFEBFAE57FD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5D844292C22F9B22E640FEBFAE574C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_632C43A7C29502D84457FEBFAE5623CA" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5AFAE61AD7C8D8C78E49FEBFAE57ABF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9F85577653C80DB5B5ABFEBFAE4E2B93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9F85577653C80DB5B5ABFEBFAE4E2B93" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5B15B469195B99832B6FFEBFAE4E8A4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D5178A3463E3753719C8FEBFAE4E6A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0867ED22B0F0E198BC0DFEBFAE4EA71C" xlink:to="loc_us-gaap_SubsequentEventMember_D5178A3463E3753719C8FEBFAE4E6A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_A3E0C8A2CCCE398830D5FEBFAE4E0C04" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_183B27B1AB317AA16950FEBFAE4E766F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1C538EBC70275FF7E231FEBFAE4E241D" xlink:to="loc_us-gaap_PrivatePlacementMember_183B27B1AB317AA16950FEBFAE4E766F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_EEEBABDE8E831AAAB08FFEBFAE4EC365" xlink:to="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E98BB19D27D4C5ABD907FEBFAE4E9732" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E98BB19D27D4C5ABD907FEBFAE4E9732" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofSharesAvailableForOffering" xlink:label="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_BA92E053E381AEB3FF15FEBFAE4EBD29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_BA92E053E381AEB3FF15FEBFAE4EBD29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_064C6AB8A8583D2000FEFEBFAE4EA575" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_064C6AB8A8583D2000FEFEBFAE4EA575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_FA537A93F14ADD116B6EFEBFAE4F165F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_FA537A93F14ADD116B6EFEBFAE4F165F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_AFD6B80BF47EA4AB8CF3FEBFAE4FECF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_AFD6B80BF47EA4AB8CF3FEBFAE4FECF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_A6A997799E315EA8067AFEBFAE4F5DA6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_A6A997799E315EA8067AFEBFAE4F5DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821FC5753C08A4BF90D7FEBFAE4F2CBC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821FC5753C08A4BF90D7FEBFAE4F2CBC" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold" xlink:label="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3B7ED344F16764EA5228FEBFAE4E9974" xlink:to="loc_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold_0A314520C360A77615A1FEBFAE4F0681" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_FF31AF586C6EAAB2E339C51AA8D3374C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_FF31AF586C6EAAB2E339C51AA8D3374C" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_FCBDED085DB92E0A5377C51AA8D37E2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3438A2848BABA67158C9FB33D4DE9414" xlink:to="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0CB2729FCD858679C2CBFB33D4DE2107" xlink:to="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCo2015EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:to="loc_xcur_ExicureOpCo2015EquityIncentivePlanMember_06DFC32783CB4A4F2F2FFB33D4DE4D4D" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A62E3F42AB504B0150D6FB33D4DE695C" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_19D1C2C7F4A34C775901FB33D4DE2D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FD40AB6A914350C35ACCFB33D4DEC03B" xlink:to="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FB606C75EF923B04CD2BFB33D4DE8246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:to="loc_us-gaap_CommonStockMember_FB606C75EF923B04CD2BFB33D4DE8246" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember" xlink:label="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_F994A1433657312C6E75FB33D4DE4C57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6363D4139AAFF7B7522EFB33D4DEF03B" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_F994A1433657312C6E75FB33D4DE4C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_83E8F10EB5D816D9CEFCFB33D4DEC40A" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:to="loc_xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember_F994A1433657312C6E75FB33D4DE4C57" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember" xlink:label="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A2A50F354BF73954EE95FB33D4DE8C18" xlink:to="loc_xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember_950148C360C4DFE1D854FB33D4DE6FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_FF002E8544A49C28A4A2FB33D4DE1421" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_EAD3E7FD3615CDB13567FB33D4DE0F02" xlink:to="loc_us-gaap_PrivatePlacementMember_79BA387E772870FC848BFB33D4DE5EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D8D94938CFE227D4AD0FB33D4DE3422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5A83E2E5AD0491AC2BBEFB33D4DEC396" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9BEE991583D639B2BF85FB33D4DE1644" xlink:to="loc_us-gaap_SubsequentEventMember_5A83E2E5AD0491AC2BBEFB33D4DEC396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_C558692428052601AB71FB33D4DE3065" xlink:to="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionofStockConversionRatio" xlink:label="loc_xcur_ConversionofStockConversionRatio_71DD789DE5359505A647FB33D4DEFF33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_ConversionofStockConversionRatio_71DD789DE5359505A647FB33D4DEFF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_068F4BD9C1AFE3AFBFDBFB33D4DEEC0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_068F4BD9C1AFE3AFBFDBFB33D4DEEC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2164B01867E76033AD10FB33D4DE6B70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2164B01867E76033AD10FB33D4DE6B70" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions" xlink:label="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions_968B93BEE6B7ED87C9F6FB33D4DE2467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FA7FDC2E80BB9A43D63BFB33D4DE4F15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_FA7FDC2E80BB9A43D63BFB33D4DE4F15" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SaleofStockNumberofSharesAvailableForOffering" xlink:label="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SaleofStockNumberofSharesAvailableForOffering_F4E6E7889631C4EE0DABFB33D4DEB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_92F0E6C3BD1483279237FB33D4DE56C4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_92F0E6C3BD1483279237FB33D4DE56C4" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement" xlink:label="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement_C39EB3CE50F82E141C8AFB33D4DECB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_DEF2EF90CD4DF7CAD796FB33D4DEB329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D9DC95B0DDC3829F9AF3FB33D4DE157D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A0A3524CF151CD8D529AFB33D4DEA81B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A0A3524CF151CD8D529AFB33D4DEA81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_1B0B6AF8A8F1CB2DEB22FB33D4DE3F9C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_1B0B6AF8A8F1CB2DEB22FB33D4DE3F9C" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod_714192F85810BFB86D6DFB33D4DE02DE" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod_C061729F6C67911C3E98FB33D4DE001F" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction" xlink:label="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_EB26D70180F964F33882FB33D4DEA7B9" xlink:to="loc_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction_486B988B0801879F0DFAFB33D4DE7BAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_AD97B8429BF73AD8EFA8C51AA9AD72A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_AD97B8429BF73AD8EFA8C51AA9AD72A9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_FE1B1FD64264945E959CC51AA9AD485E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:type="locator" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_AccruedLicenseAgreementFeesCurrent" xlink:label="loc_xcur_AccruedLicenseAgreementFeesCurrent_2957930E599CB0237667C0DBA4A0E7B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:to="loc_xcur_AccruedLicenseAgreementFeesCurrent_2957930E599CB0237667C0DBA4A0E7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_486CFF0A2DC7870ACBA9C0D6956CF0EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_486CFF0A2DC7870ACBA9C0D6956CF0EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2633C69839AB81D2D37BC0D6956CE0CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2633C69839AB81D2D37BC0D6956CE0CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E337CFCFED24E4392F9AC0D6956C5526" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_E337CFCFED24E4392F9AC0D6956C5526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_E98632A0F3E39400A1BAC0DBA6878F25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_FD368B7EA21DC6E25A73C0DF29BC2AD4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_E98632A0F3E39400A1BAC0DBA6878F25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_D48E8D96F600BCE08ADBC51AA9A82385" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_D48E8D96F600BCE08ADBC51AA9A82385" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8ACDF1DD4D31CE3E7401C51AA9A8A463" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_977954028EFAE98E3BFEC51AA9A8DF50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_EquipmentMember_977954028EFAE98E3BFEC51AA9A8DF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_AB6F53393AE79A71A022C51AA9A8B2C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_FAEEF1B27AFFE6FEF2DBC51AA9A88E81" xlink:type="arc" />
    <link:loc xlink:href="xcur-20171031.xsd#xcur_ComputersandSoftwareMember" xlink:label="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_xcur_ComputersandSoftwareMember_B7003D1DA169D9BE2B00C51AA9A920CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8B172D24287FA515DC1CC51AA9A88300" xlink:to="loc_us-gaap_ConstructionInProgressMember_9A9AC8B995B31721C63EC51AA9A9DE02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E4E0AAA5715A2F4C4F98C51AA9A84E74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_B4E7C5395765AA46901AC51AA9A906B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_B4E7C5395765AA46901AC51AA9A906B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_C6AA72F00BF61F09B457C51AA9A95642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7DE70D6CFB2E54585316C51AA9A94036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5A98BD514C688D6DAD2FC51AA9A9B1E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4AFD4D328075DD354542C51AA9A90B13" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_5A98BD514C688D6DAD2FC51AA9A9B1E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:href="xcur-20171031.xsd#xcur_SupplementalBalanceSheetInformationAbstract" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78CFA622022094A32942C51AA9AB6B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_4947043C9DD9D81A1A22C51AA9AB33CF" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9ECB80A0150C43F497ABC51AA9ABBA01" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a20171128revisedpipeline.jpg
<TEXT>
begin 644 a20171128revisedpipeline.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" -+"Y # 1$  A$! Q$!_\0
M'0 !  (# 0$! 0            <(! 4& P(!"?_$ !0! 0
M      #_V@ , P$  A #$    ;4@     %#3D
M        #Z/D                       'T?(
M                                             /H^0
M                                         #3'].@     "C1X
M                           'H>8                       /0\P
M
M    >AY@
M'&']'P     "C1X                               'H>8
M             /0\P
M                       >AY@
M                   '&']'P     "C1X
M     'H>8                       /0\P
M                                          >AY@
M                                      '&']'P     "C1X
M                        'H>8                       /0\P
M
M >AY@                                                    '&'
M]'P     "C1X                               'H>8
M          /0\P             2V2J# (>(_       +$$<D>@
M   'Z2:1B "0B<S..%*^GB2:1B                     #T/,
M                                            XP_H^      4:/
M                              ]#S                       !Z'F
M             ">SO""3KB=RG9SIGFW.;/4S35GZ;4UIEFW.;/DMN1"1,99O
MCG3P,H]#*!IS(,@]3U-,=*:$QS[.E-(81DGL>IDFB) +/%,37@%V"##C"T!!
MAH"SQ3$UYNC..</(_3I31&::L_#I#6&M              !Z'F
M                                           <8?T?      *-'@
M  #V.\ !S9G')@            'V#>'J<V       >AY@
M        ]#S             !/9U!5P%P")SCBSYSQ\E:2Y)3(WA:0K&69.>
M/DJ>6T(A.;+2&A-P51)!)J-,=05L,DG\YD[4XDV!ZE0RV9\&]*N'8$WG.G:E
M;"3"3B(2N@!;P]B+R-SE2S9)Q$)RY-AJSZ*A%GSJ32G?%)BQYO#:%=".
M          #T/,
M       XP_H^      4:/     &:6$.P/TXXY [HK&             6W*O'
M9F616       >AY@                       ]#S             !/9U!
M5P%LS@#J01.64*ODU'%&_,,W@(G+*%7R?B(23CD"!RR .5)6*ADVDAD2$YE-
MRV1'Q%Y<LJZ61*U$JF*<<2^5 +*FK(R+4%(P ;,F$D([0K4<\6H*1FU.W.Q)
MN*6%U"E9D%S"II; K"=T=250              /0\P
M                                  #C#^CX     !1H\      3X>A7
M\E,G(UIAE6B:25#G2M):8_2,3N#I35E6RTIKCK"O9JBQI^%>3;';$ EKR,"Q
M)&!P)G$;EE#+(2(K     /0\P                       >AY@
M     GLZ@JX9)<\KJ2L?I'9FD8'2D_FX*D%@#]([,TC LP1"2L1Z0D6%-D<<
M2@5))C)2(?)E*BEKB,R.BYY64L.0.99S!NR4"IY8TQ",2U!2, VI: K":@LB
M91#!:@I&68,@CDL@4O+I%*C)+F%5"U!7DR#3D6              'H>8
M                                                !QA_1\
MHT>      )\/0K^2F2\5/+KE4RVY5PG$AXL$5M.+)!/PLD4_+8E:C,)R-.<X
M8!W1%Q()6<NJ5$+@%.R638FP.9(O.P(U     /0\P
M    >AY@             GLF Y@WQSA54DLL&1J2>4Z-<7,-&5-)0+!D:DGE
M.BTA$)BEC".B12K)V)/A&QW9!IA$RE12UQ&9'1<\I06^([.^(+/<D\J@6-,0
MB,N&0208 6J.D.6._*TG+EPR"3M3],$E HZ6A-X:X[<I26L.9.C(V()
M         /0\P
M     #C#^CX     !1H\      3X>A7\E,DDK&70*REKBNQN2."TI4L_"V!
M!8<J06Q*P&06'-4<^<X8AXDC%9"[A3PN 4[)9-B;DX@BT[XC$     ]#S
M                    !Z'F             #?F\!KSE3\!U9T1Q!J0=*>!
MH0=6=$<0:DZXTYJ3HSJSC31DS$AD' X<VINCD#JS6FM.T.&-@=T:0XXW!M#D
MSHSY.>.]/ XD ]#NS8G)G-@[T\#ESOCD3<G*$KFK.:+@%'CZ.^, X8_
M         #T/,
M      XP_H^      4:/      $^'H5_)3))*QET"IQ/!O39E5"VQ4H\BWAP
MQW15DM :,W9!9K"P)X$.G$EL#B#MRH!:0T)QQL2-BS)C$6$%@    'H>8
M                    /0\P                          "7#O2LP
M               !8PDT^2*RO@                /0\P
M                                      #C#^CX     !1H\
M   #.,0^  >X/ %SRJ1J#$![GV8H,D\SR!ZGJ8H!['J8@     /0\P
M                 >AY@
M        'Z#\                 /0\P
M                         #C#^CX     !1H\               "7B,#
M               !Z'F                       "4#\
M       /T_3Y             !^GZ?(             /T_3Y
M   (V/$
MXP_H^      4:/                                ]#S
M            !<(^P                    #)/HQ              9)]&
M(             #)/HQ              "H1C@
M                              '&']'P     "C1X      'Z2R=H<L0
M\>8    !W9D&0:@XL GH@H\@ ;PUAC  $VD*'R     #T/,  'J;XYP   ]#
M>FB-\<Z    #]-@?9JP       >AY@                    '<F41X
M         #N3*(\             !W)E$>              'H>8
M        !OSX-&9QMS1FQ, SS ,0    _3\
M!QA_1\      HT>      !.)(A"Y-1'9!AMSU-&9)^&S-88YZ&Z)3,XX0U1R
M!M3'+LE(C]-R:(_2YY4LYTW!CFO/0M650      /0\P  ;TN$4@   -P6_*=
M%ERJP   !9\KL2"9I#8       /0\P                    #N3*(\
M         !W)E$>              [DRB/              #T/,
M         N49I2DGLG J:261@3H0T1T   "4#:$-@
M      XP_H^      4:/       N,5V.",TQB6"8#Z(P/HE$TAO2GQ;@U1TA
M&AG'*&H+!G)$DE,BUQR1U17HM(1,<R2D9!7HQ"3BOX     !Z'F  #>EPBD!
M9TTYTY7@]RP!IB1"G!8<K03>2,<,0(3R=X<J1J6E(@.%,PC8L$;\B CTL$?I
ML2MYJ@  #T/,                     [DRB/              =R91'@
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M2R1S8GL"&"W15HMD4O+)D6D4   'H>8                    !W)E$>
M           [DRB/              =R91'@             !Z'F
M          7*.&-.2D:0@DG AHF4AHL>5L)6..)..).>. )O-<<D345<+.D0
M$L$=FH)>.+-J1P3J1T=61J<T<4                 <8?T?      *-'@
M    61/T@8L0<R=*<0?AUASAFD!%ZREQ<$ID6'-09QRAUAIR*BY96,F<K(7/
M**EV"HA9XAH\C!)=*W&O      /0\P  ;TN$4@+SE(";S])#*_FE+;%/RX)6
MLG J6=D:\M(1(385&+>%.R638F^([(E+DE?RQQ2@LJ<(1*   >AY@  &Z-^>
M)R!Y@   '6FE/<TH!F&U.>  !F&U.>   .Y,HCP             '<F41X
M           #N3*(\              /0\P                "Y1!98HC$
MWQ!).!#1,I#9:(A4_#A#6$M$BD0&S-68AV16HL<<X2"0L>!.YSANCCS'(A)H
M.^->55                 .,/Z/@     %&CP      ,XL&=B<@5Y)&)@.7
M,0Y0RB(2V!4\FTDPY$Y(RSGSDRR1J#-*\ED#1F<5N)\,\ALGH\2O!-Y6L
M   'H>8  -Z7"*0%YRD!-Y^FO);- =F4_+@E,RWIRIUQ6(M01:2L5,+0D?FD
M-B<"6,.7,HK46\*4%E3A")0  #T/,   FP[ QC (+/<UYN#4&.;(]C3ENRNA
ML#D3\!FG9D8'0FB/(Z(U1TA*Q7<   [DRB/              =R91'@
M        .Y,HCP              ]#S                 +E%6BWI70ED@
MDG AHF4AHD\V)T17(F<\3<D5&R)2*[%DSCSKRII9(A8\"=R#"Q!S9J3F"4#0
M'T5E                 .,/Z/@     %&CP
M       /0\P  >AN#1F]-&9P, Z0U)FFG-P:0R#ICG#$-R?9CF*99FFK/HUY
MLC<'+GZ;@TALS',0   ]#S   )L.D,0]#*,HTIDF_*^%AS6D$EE"%#=G?G($
MEE:R5C,-09I'YV9(17(E8KN   =R91'@             .Y,HCP
M    '<F41X              >AY@                &Y-4;4UIGF 9QAF8
M89CG3FN-0?1TQBFA/4Z<YD^CI3G#%-L8(,XU)MS9'+GX;XRSF#Y
M        .,/Z/@     %&CP                               /0\P
M                     >AY@  $V&\([."+&$+DYFD,@Y4RB*CR+5$*&[._
M*SEJ2NQ*QW!4 Z8[$ZPD<K,2L5W   .Y,HCP             '<F41X
M        #N3*(\              /0\P
M                        #C#^CX     !1H\
M          #T/,                       'H>8  !+YKB,06 (B.E)9,8
MKZ65/TKL6 (B-N=P5Y+*$$$EF$=X<R:PZ4Z,KV2,00   =R91'@!DFR/@U!G
MF*>(      -J:H '<F41X 9)LCX-09YBGB      >YG&J !W)E$> &2;(^#4
M&>8IX@     'J; U0 !Z'F
M               <8?T?      *-'@         ";22P"-B$       #,)#(
MP          /0\P                       >AY@
M  '<F41X 2>38:,P3Q(D.3/,^SZ/(^C[/('J>0!)A/Y30 '<F41X 2>38:,P
M3Q(D.3/,^SZ/(^C[/('J>0,@MB:LBTBP [DRB/ "3R;#1F">)$AR9YGV?1Y'
MZ>IX@]3R +3GR1:18 #T/,
M               XP_H^      4:/          &P-@7,*;FK-@=Z:,CX[L^
M0<X2(<F>IQQ))]$:DSDJE7S0          ]#S
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M%9#D          >AY@                       ]#S
M     .Y,HCP D\EPCDC4G B4FPA(E8Z4B<D0Z$@8L:1*;HKF 6[*B  [DRB/
M "3R7".2-2<")2;"$B5CI2)R1#H2!BQI$INBN8)5)'*SGF =R91'@!)Y+A')
M&I.!$I-A"1*QTI$1VYVI#)/!$INBN9^FX.F)4*V  ]#S
M                                     .,/Z/@     %&CP
M  /8O,4=,4G ZL[PK(3P0:<47;*,$J$CFT/@P3T(C)B*K          'H>8
M                      /0\P                    #N3*(\ )/.G()!
M8LB,FXBPFHPC@"0#"(Y.[/TT!!H!;LJ( #N3*(\ )/.G()!8LB,FXBPFHPC@
M"0#"(Y.[/TT!!IN"YQQ1%1$8!W)E$> $GG3D$@L61&3<183481&A)!JC0'0'
MZ: @T%IP1P0^ #T/,
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M3@P#N3*(\             !W)E$>              [DRB/
M #T/,                                                     XP
M_H^      4:/                %FCJ#(*_$;             'H>8
M                  /0\P#:%G"IY/QC$F'"&K,\&K)?(E.P.*-"3B4_+=$0
MF><N=R2$58+(D/G6$L$2G8'&&@.Q(Y+ %1  =R91'@             .Y,HC
MP             '<F41X              >AY@
M                              '&']'P     "C1X
M &0>9Y@             ]#S                       !Z'F ;0M\1N=<5
MA+.'&$=FC+@E,"QIR!Y'X<^2Z<@=>142^:PBHFXJV6.(B.M.N.0/(_3G#LR.
MRQ!6XXT [DRB/              =R91'@             .Y,HCP
M      ]#S
M  .,/Z/@     %&CP                               /0\P
M               >AY@'V;L^33GF9QM3G ;<U!ZG1G-F4>9XG1G.DH&W(S.?
M-N:LV1AGL8IT9S9E'F>QC&R,4P #N3*(\             !W)E$>
M      [DRB/              #T/,
M                      XP_H^      4:/
M        ]#S                       !Z'F          #;'H:4
M   [DRB/              =R91'@             .Y,HCP
M ]#S                                                     .,/
MZ/@     %&CP                               /0\P
M          >AY@                    '<F41X             #N3*(\
M            !W)E$>              'H>8
M                            !QA_1\      HT>
M              !Z'F                       #T/,
M      [DRB/              =R91'@             .Y,HCP
M    ]#S
M.,/Z/@     %#3D                               #Z/D
M             'T?(                    !O#U.>             !O#U
M.>             !O#U.>              /H^0
M                               #3'].@     "II:\
M                  J@6O                       (O, E\
M
M                                                   %6BU
M !4XMB                               5.+8@
M    $7& 3
M
M          "K):8      J<6Q                               *G%L
M0                      "+C )@
M
M                             !5DM,      5.+8@
M               %3BV(                      !%Q@$P
M
M                                                 JR69/@
MV!4XMB 8A"Q.A\D(&L)Q(U- #O"0 1P:LELX<XXF@Y8C\WQ)@,$]#*     !
MXF(1N2@9(        *G%L01<1J6;(^(H.U/LD$WYPY@$CFK.2)!       (
M)_   !RYYG6  $7& 3
M                              #4D,GT2::X[T_0     #&.6.R
M  !P!WX -4;4                           JR18>(  !V9H35'Z7^*G%
ML0"!2G1?HY4A8D<UA*!6H[0GL[HT!1PWY9 J*2.2><(?))A-!\%#"TAVI'A(
MQJ#6'7'#&Y-N?IPQ*134E,U1/1H#GR0S((R.B.K,L     J<6Q!") 9><K><
M\28:4E0A8YTEDF ADBHG0BX[,F4%;#6G1G,EFRO1C%B"&S3&A)7.!))-41N2
MB<*;TTA^'=' DDDF BXBH]                                    #:
M%C@                                  <"103256.L)F-H=>1P?A)!P
M!\$A'&FK)&!KRHI(I84&*1<2,?1&Y)QJ#E3K#B24#F#E242K9:PC0WQ[E6RX
M1%I(AM@                         59(F   )4.T*\'X"_P"5.+8@%!BP
M9%!:4HZ9):<EHJ62<2\<R<01"=J<V<&6+(O-$:HZ@MZ>1_/,M"<T8I'AGF4=
MH<$:XEH@(FXTIPI*1$Y;@HL3X:,Q3M"OI>H[$     J<6Q!")RI(1PASID'4
MGV="91ADP'%D>' EM2I);8%1"RI!YT)ICKSNR"36EHBKYP!,!%IV!9DC\Y<B
M,G@V16(F BTNV"+B"3F@                                   #?%S@
M                              "KQV).  !P)6DD0XDWI)1"Q9HX8C(G
M0KD2N=T0B=B;DF \CFR(RPH*I$X$?$?E@R S$)W*P%B3GR'RTA#!CG:&:1N3
MV5Z-@3.006]                         !5DB8  '?ED2G!C %_RIQ;$'
M'G\_21".RWAO3=%.#^@Q4LDX[\J024< =J;$A L0<H=^2X?SP/Z)@HR6^*E'
M;D;&\++D,G4&@/4K*6 -Z<J325?+<%3"VI6,YPND4V+>G8@    %3BV((1.G
M*LEKB"S(.I-R:DV!GDP'&D5G'%JBI1<(%4RQ1"YN#%/,[HX,X<LR5R-86R(;
M.'+5%."U)4HG<_2&BV1#9.8(N().:
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M ([.%.N.^(J.](>)A.J!%Q!)S0
M !OBYP                                  .1.0)=! !/I !WI$9B$T
M$+'N3^5]!/AU@-$1P3("'SB#I3'-&=0:PL"5^)L(I(")/)(./)3(&/DM 5')
M=.+,PL8                         "K)$P !*Y:,HL:X %_RIQ;$
M           $9%4CU+?';@    K:10>!>@R     "IQ;$
M        BX@DYH                                    WQ<X
M                                             %92S0
M                    !5DB8  LT2 4F/P %_RIQ;$
M              J<6Q                       (N().:
M                       -\7.
M                                                  !5DXHM>= #
MA #Z.Y/PYPK07'*G%L01618#IS&)R.?-8<H<:"<#B2(BRQ%I88
M            J<6Q                       (N().:
M                     -\7.                                  !
MH2NY]DL&.2B?0     !JSD3<GR=6    <"=0;8Y8^3JP  <J=4 "*R5   1:
M2@?0         !RA]'4@'*G5       JR<D38:0S#F"43Q(X.K->=*0R6_*G
M%L0<X0B1J6E*/$G$LG,D3EA3HR.B7"%R9"!BU@                     !
M4XMB           :LY,D   $5DJ       $7$$G-
M                &^+G                               &.>I]@ '
MG D]%,CICOC>$F$(GR3D0R>9-9%)I2;S]-45.)!.Q(S.Z)F!SA#9+YJCO3@B
M/3'.R.O/PT)Q).ASY$!+)44N6;PY$C$XHM&0:2$=20>2<:LZLX$UA.)%YISL
MSM00H9Q+!!AU)(!&!J#?GZ=0<.9Y\GH9YQ).)2(MX<H:4F\_0    59.?+C
M^3S*Y'V6#,T J@6O*G%L0"("(RW9_/DW)VAT9$YAG9$KG>G!$B$#EI0
M                "IQ;$     &A(Z/@F0@LWI+)"AE$PD-F0=">1&Y-)JR+
M2:SC#JB&R7SJ      1<02<T
M;XN<                               50.S)\  .!*LG>G@>I.17@LF<
MV0T3:5Y)L-T0J=N9!.0.8(A.Q./,\ZHDLJF2T?)$Y:PJF=:=*1Z=&9A$).1'
MQSI:HBTC(M<?94,M&54-V6,*R&[.V,PC,D\X\\3O2+R6B,2RI#Y\@X,FLA<D
M<B$Z0Z\B0[PZ8X W)LR'R<B/C4$ZD%';F03D    "K)SY<8 'B?)D  J@6O*
MG%L0"("(RW9_/DNV?SJ+5$3EPCK#!(Z)3/(B@EP
M J<6Q     !%9R!LS3G,DC'R9YI3I"N99XCLVYTQ"QKR=3](=/PEH^25
M  1<02<T                                    ;XN<
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M&Y-Y%9-)QAS)XDT'($;%NP     1<02<T
M         ;XN<                                  #F#F2300L3.0J
M=R0N>Q,!#)^EA2OYBE@S> TYPAOB%SV+)'J161^=>9Q'AL3NB.3*.V/DY U!
M-IR)PQ*)'Q+IU1#QQ9NB1B&3?$@D1'1&<=D# -Z0Z:TSBQYA%<C))O($,XG0
MX@R#J2-36')'0$J'T1<:@FTCP[$BPQ2P9O     59.4)P    !#1<8J<6Q
M                             *G%L0     160>=:3\5Y,HL 5X/LL@0
MZ2D<*1L;<V9DG+$@FE-N1^=>3*     "+B-C:@
M             &Q)T
M         *O$\'4@          \BJY[D]'6      AX[XZ,          JR6
MF      *G%L0                              "IQ;$     $?GF2(
M              1<8!,
M
M                    *LEI@     "IQ;$
M      J<6Q                       (N, F
M
M                                       %62TP     !4XMB
M                         5.+8@                      $7& 3
M
M                                                          "K
M):8      I,=2                               142J
M           <P>!UP
M
M                 (O/Z       %3BV(
M   !4XMB                       1<8!,
M
M                                     *LEI@     "IQ;$
M                       J<6Q                       (N, F
M
M                                                        %62T
MP     !4XMB                               5.+8@
M         $7& 3
M
M               "K)/QC@    _3KRIQ;$&M/DVAS9T9KCG#LS$/$V9SQN30
M'Z;PR@:$WQJ@>YG         T!OP        "IQ;$&$>!M#Q-:>AZF4>IC'R
M98        -6;0       BXP"8
M
M                           59(G/P  'Z20<6:H_2_Q4XMB#D2CQ:TKT
M6J*9'>FD)U.*+4'\Y"ZQ24E@B<_H20004?T!*-G-$@ER04G+L'R>!D@\3V/$
M]@?!\GJ4G+L%6BTH/ ]P>)[      %3BV((1(-+P$'$5DZG&DL'3$:FM)@.7
M(Z)M,<R  >![G@>Y\GP>I^'D5:+5G@>X/(]3&,DC,^R23P/< BXA8U8
M                !V99L
M         %=#2F&3F1\3^      ?!6,L^ 04<F8I/1!9R!UY:(A@$U    $
M$_@  $.$Q@  APF,   $)G)$FG7%;3*.Z)L!$YP!OB8"NIN"Q9S!%9-16LPS
MNB=P    59(F   )O,@@@ O^5.+8@%8BL9_1<K(2J30<X1><46H/YR%UBGY8
M(K<7R(A*]G]! 4:+G&W."*!%X"NQK2Q!5@[0D0C<XHN:50,HLH4B+DE:"RI7
MPUA;@K2;\B\_HP     "IQ;$$(D+%PB #0&6=,=X0,>1,A,!#)%1UI\FC+6
MH\=F:TP"RQ7HV!-A QTYH3:FP/DUIKCJ#Z.0.G/PPS8'R6/!%Q!)S0
M               !W9;$
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MJ)8PA8W)RI)IW96D]2TI5LCLELP# +3D*G.$=D[FR*QDMF 6<!%Q!)S0
M                 !W9;$
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M5,L40N;@W9#!LR9"#3JC0'N= :TUI:HJ(2"0R66(I/$Z UI9D$7$$G-
M                 '=EL0
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M/,R3\,8R@8)G 'R8QE@\CU,$S@"+B"3F@                     #NRV(
M                                               (Z)% (_) (_/,
MX4ZXZLADE@W!"))QW8!'Y( !S!#!W1*@(Z)%(V))!&!)X(5,,G0A$SCOCBSD
M2<SDB0"/SI3$-*>!'Y.1'9S!.QQ)M"(29S1G?' $@ Y B,FLZ APYDS"83>$
M,FF,TG @@ZTDP$?D@$>D@'T     59(H-F >19 [<IP>H!KR_14XMB
M          #Q.%.C-Z     :PX\[8S0     5.+8@
M   $7$$G-                      '=EL0
M
M             59.)+/G>'Z1R?IXF>=X>)P)7@N65.+8@
M               %3BV(                      !%Q!)S0
M          !W9;$
M                                                    %63F2P)Q
M!E&G.^/PCPZ@PR0"!"VI4XMB                               5.+8@
M                      $7$$G-                      '=EL0
M                                           5=/@UY,!'Y94
M PBHY<4       'R5N+)@$*DU$.$Q@     $.$Q@K664!"!RY[$UE>3++0D?
M$7ED2K9XD[':           JR<^7& /,KN?A84R "J!:\J<6Q!'9"1LR4230
M 0^0^6?*3&,3>0^>YKBV!)Q30Z\LX                   "IQ;$
M    U!Q1)@  (<)C       (N().:                      .[+8@
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MGT@0%BBN1^EERH1)IOSDC!.]-,: D Y<W1R)TI-H     (N().:
M             .[+8@
M  %8SL";  "HAM@6$*VELRJ1+!PI'1+9PI,I78DHC,NR 53+6 BTP23BO9-1
MIB+#.-D=Z0<2P?)G'.$=D<DT'+&66K*J&.6S*EF66>*NEK05++(D)&].Z(-/
M MD54.V-(6/*RDDD4%HB#"13M2J99PJJ2,?!.X          *LG$$Z@    A
M@N>5.+8@C @(SB8B7#F2II8<WQ5DNR1N0D6U/YRDCD9']$"O!&9S1:$F<
M                J<6Q     !%9\F<1V<"=\?9+IICE2.2QI$AE&K.:.A-&
M3@0B=D<*3*2<     "+B"3F@                     #NRV(
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M0BPD &J)*(:+!D/D;EAR$#MB1R!#+.S)"*X%Q0     1<1Z;T
M           WQ+
M   .1.N .4.K.4/LXTZLWI%I))L"*203H #E#JP#A3!)((W,@[8U!]FQ-"<L
M<4202 <L91'I*QKC5'N;4C,E(TIU)RIU8.4.C-*>QG&B-F1Z=B=2".C7F228
M1<=(=:#E#JSCSE25S[          !5DM,      5.+8@U9H#T.9!W!O081RQ
MVQQYT!L".21C6G#GL2(",B30                  "IQ;$     $5G%$D$@
MD7FP) (W,@D Y0Z$U!SH-N9Y')*1I3<D6DDF[     !%Q@$P
M
M                '/'R=&                               59+3
M   %3BV(                              !4XMB     #GCY.C
M          (N, F
M
M                %62TP     !4XMB
M  5.+8@                      $7& 3
M
M                                   "K):8      IT3:
M                     5\+!@                      '!F(2.
M
M                                                      "!"Z8
M    !3HFT                               KX6#
M       .#,0D<
M
M             $"%TP     "IQ;$                               J
M<6Q                       (N, F
M
M                                %62TP     !4XMB
M                  5.+8@                      $7& 3
M
M                                                   "K):8
M  J<6Q                               *G%L0
M    "+C )@
M
M          !5DM,      5.+8@                              %3BV
M(                      !%Q@$P
M
M                              JR6F      *G%L0
M               "IQ;$                       BXP"8
M
M                                                 59+3      %
M3BV(                              !4XMB
M  1<8!,
M
M        *LEI@     "IQ;$ T15,N*:\J::PL^0X<6"9";05J-(6J(+([+6$
M;D%EB"1@<X1P0P 2X9Q,X*I'-FP+-G#$*%FCL          5.+8@
M              $7& 3
M                               # (\/L[HU9U!^@     'R: Z$   '
M+'4@T)LS+  !XGL 8YICH0  <L=2       #'-,="             59-R?(
M    /HL:5.+8@%9"OA;<UY$98DXPFDJD20369QQI4L[,[TK<3X>!#1:HKH78
M!48L(;HH67D(Z(^+8@_G*7^(!-<0^7#*NEZ@         5.+8@
M            $7$$G-                           %SS>@
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M1HB\I4LZ C0_H>         "IQ;$                       BX@DYH
M                        N>;T
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MELSBS?D$%WP         5.+8@                      $7$$G-
M                    %SS>@
M    $5&].X  .!(6)F.U*Q%I2JY.!"IR998BDXLD4CT[ [TE8',$0EA01:0V
M=Z<66M*H&46E*GG8F.<&=@=T166M.?*Z%JSBB."8B#CF2V)4PF$AL[TXT^BT
MI5<Z F<CHZHD KZ2N0.2&>YJ#\,0F(@<ATF<SSD"UI5XS34FV,XQ".2SA"QU
MY.H     *LD3'2&W.Q.9,@T)IB2#GS$.++_E3BV((E-^=V16>I&1I"P1VI$I
MTYV8!7\TA9@AHCXLZ< 0@3T2 "HY8<[$KV3V<H02"1CEBQIQQ&YT)$A9(Z$
M        %3BV(   (H(R)*): /PBT_"5 162H#E3J@           1<02<T
M                          7/-Z
M             #B3B2; 5K+(E:R02+S4$UD+F43N0 91.)WH.=(L)U!6D]#:
MF@/8U9]&S/TVI(1 AE$XD.'V2(0D6P-F5/,\ZLTQYFP->>AM33'T61*UDYE=
M3E2S1WQ'1!QSI80]S5'5$"&>=6<H99T)H2RQ#IHCDB="$#H"/"Y10TO,9@
M   *LD3'T;L$A$O$:D''3'B<^?)?\J<6Q             .9(\)I
M        !4XMB   "G)<8KJ6((G-0385;)<.[(/(Z+C@I(6?/P[$YDUYP!(!
MP!/!'QQA.AP1S1M3G"<SU   (N().:                           +GF
M]
M!34MB;D          '"D/',EKS9           $8$:%F@     "K)$Q)!Z'+
M%UCV/PIF<D=^; BPO\5.+8@                              %3BV(
M (+(S.C)<([.Z.,.4/D^BQY40NJ"IY:<J^6((5(\+7E1R=S3'(%@""3C"UI4
MLL =L=$   1<02<T                           7/-Z
M                                              #7FP
M !@&0>X           ,,RCZ      *LD3'2$H&J+,GN?)3(]3NCC3@B_Y4XM
MB                               5.+8@  &"066"*R&[.B.\(*-:?)X
M%L"J); %5"U)5,L 1$<\6L*IDRD:F26!*KGV6H(C(T)()C   (N().:
M                      +GF]
M         !J2&3Z)--<=Z?H     !C'+'9        X [\ &J.5._      .
M ._!PIVQZ C TY,QQ)QA-)^G#G;&O(:)5.B          !5DB8ZX]3Q.H)<(
MS(;.K/4''E_BIQ;$       $;'8&Y ,$^R-250                  "IQ;
M$   $!G(&]+%%;3P+"D6GX=N0P>!:($1GN1\9)VQJB;"$R0#6$;&K)S(])K*
MX&*3J=(   1<02<T                           7/-Z
M                              #@2*":2JQUA,QM#KR.#\)(. /@D(XT
MU9(P->5%)%+"@Q2+B1CZ(W).-0<J=8<22@<P<J2B5;+6$:&^/<JV3Z2:1Z9!
MV!R9HR43]-$: RC2G8''$F$7$-EJS+.<(=.F-81V34<H=.5%/Z"%62Q!6DMT
M          "K)$QZFQ)'(C-L?9IB8B.C3GB7_*G%L0",CT)).'/D]SKR+CJS
MHSD#GR0R&R3C6&E)0*'EI"O1<<V                   *G%L0
M             "+B"3F@                          "YYO0
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M70T)-9P)8LK0:(NN5A)&(++:E8S,)Z(D(J)V(A+?$.FU)U
M    !4XMB                       1<02<T
M     7/-Z                                           #D3D"700
M 3Z0 =Z1&8A-!"Q[D_E?03X=8#1$<$R A\X@Z4QS1G4&L+ E?B;"*2 B3R2#
MCR4R!CY+0%1SO2:2N()X...N-,2:1 =Z1 6!*_ E$@HYTM^9!PA6HZLF0BXU
M)8,Z4@(GDAPX\V980          %62)@ >AZGX?!Y  O^5.+8@CTK$9Q8@KX
M?!BEABM9T):DK66'(*,DE0K>?)8@C0QS3%@3MP                  5.+8
M@                      $7'%'7                           $FF6
M
M"LI9H                               JR=P?@    /TFXJ<6Q  -445
M-P3>3P      ?A3HN,                   5.+8@
M    $7& 3
M
M          "K):8      J<6Q                               *G%L
M0                      "+C )@
M
M                             !5DM,      5.+8@
M               %3BV(                      !%Q@$P
M
M                                                 JR6F      *
MG%L0                              "IQ;$
M  BXP"8
M
M        59+3      %3BV(                              !4XMB
M                     1<8!,
M
M                           *LEI@     "II:\
M             J@6O                       (O, E\
M
M                                              %6BU      !0 B
MH
M
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MPZ&/+C!.F9[U+!NJ)OTO#7^UC<75H1R-$R09(SK)X_D)T4!D9*$2"+)9"&>
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M5++32KR#/%++O.O.:5J:SX3/J?ZN1_+Q9[ZE?B01A0.K?LUF&S68;-9A.F%
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M<8:;LMO!M(S$WF32;.?RB\711YJGJ EAG\H9SG]DC3,UP5KRNZ,#H@8;E"R
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M#8$V&P)L-@38; FPV!-AL";#8$V&P)L-@38; FPV!-AL";#8$V&P)L-@38;
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M4F(&KH;/LNQDHY!C&%IRTDR?G*2R>N%&_P#C0*1.#=(.S)W0R7TZ]M@_5/\
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MB,R_A8UQ R]WQSQ,Y?T#4[4;[-P)K@2W%JBE)]E+&-TL-526VI:M$YJ$5R=
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MYK6F>2FR"0VR'MN4H*X/:_'#3*$+MF]PI>MA+55FBWLV$OOO;\G=#02/IY!
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MLWHB2>W5ME/>/7%U=4RS6=PCR1\25E6QQ" RB8HLFB;Z2 84I*0B<2-@YO\
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MA#3B_P#&-"BDGXW\T!4RS5P9@XDT,7D(#:W2$"IJM9WM296DT4'E$'NPEQ)
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MY/)[\CB]O9_VAOSA#_:*\GO$C]>CSHG/J5^2)5Q9NH2ZE1/!6)E")U)4IM0
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M#3?8H0@8\ $&0<0H%>"'TTKQ'?@#>A,M>",H[0J.X() 2Q+-#.=_UF$MD/M
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MS$VZZCZ).;O1<8FWV48W6W"D1E'W5O+PO.*O&"968<9KC=.8P6WIQU:#BFM
M85K>8=8O8Y)936 )B9>?"<,JLJIJ5EIAQCM%4K%U4^[3^4T\D$DU)W3 4DE*
MDFH(W(*53\TI)S$%Y6?4N2\V^PBM;K;A2("YAYQ]8%+SBBH^\*X_>)[M$^F&
MYB7<90A+011PFM:G@X8;FIM]"\EG2AJN,-R0-7G%!9&\D0_]H/FI@R:)=3AK
M?<N9J%6?OQ.VU,(OMARZRA?][U(7*L2P>R1HM2E4S[PA+R$4<4DEM1Q0K>AJ
M554([)SB$,-M2X)5F;:3F $/(G W)E(^46+JAW8=U@ZER65LA=P3P1-?9_1!
M^I5Z(D>T5Y8E^V7YT&0D))*F6#=42JE3N_\ F,Z/<YANH!^*8D>V/D,2GUOH
MA$^ZD&8>%0H_$3!2W)WY8&E^_LCPTB^)IC7:4WVJ*JKM8<F)]=UT9FJH) WS
M"D2DNE]E/RBE4O0I3C5 ZS?"58H-(D>V/D,2GUOH]XDOZO,,3':H\W]]DOZO
M,,3':H\W]]DOZO,,3':H\W]^5Q_,B4(GIE"$B@2EY0 A2UJ*UJ-2I1J3"4-S
MTRA"<P2EU0 @N.N*=<.*EFI,!MF=F&FQ@A#I $%QYQ3KAQ6LU)@-LSDPRV/B
MH=($91YU;SGTG%5,!MF<F&6Q\5#I C*/.K><^DXJIU+J)]ZG\QO>6*3,TZ\/
MHJ5F[VI4&A$74S[U/YC>\L77YQYQ!^+>S=[4"VU%"Q@I)H1%W7[M.//!<=6I
MQ:L5*-28#C+BVECXR#0Q=U^[2,H^ZMY?TEJJ=0-LSDPTV,$H=($%QYU;SA^,
MM53 <9<4TX,%H-"(+;T[,.MG%"W20=3_  TTZR-Y*LW>BZN?>I_*:>2*G'4N
ML3CS:/HWLW>BZJ?>I_*;ODBI-3\R,=WT>_37W?Y0_@!'%\XJX_>)[M$^F&V)
M8MW%,A>R37/4^J*!Y#?"AL0IQU:G'%8J4:DP_P#:#YJ8G_K*1FQ#JJQ,-3%D
M7WD.$+5D$&\=^$AFSYAADX!#:4I\L3:QL0XVLH![8&)%?Q2A0_&%-RC656E-
MXBH&: W,LJ96<]%1-?9_1!^I5Z(D>T5Y8E^V7YT37UJO+$CVGI,2/;'R&)3Z
MWT1+);Q,H$CCNZB9@R:\B47[PSYH7-3=2PA5U+8-+QA<O*6<EQ]HW2I*0,_;
M8P)HHR9=9*KN]$CVQ\AB4^M]'O$E_5YAB8[5'F_OLE_5YAB8[5'F_OLE_5YA
MB8[5'F_ORN/^+&.[Z/?IK[O\H?P CB^<5<?O$Z9B8:8"DIIE5A-897+O-OH#
M %YM04*WE:KR)B:8867R;KC@2:74Q/+;6'$*=)"DFH,+:F*ZU=Q(^(=^!-&8
M;OG%33H%>.-:2*FWG0FXVVC9)3PF&IMO.M!K0[N_ ;?6WOY)U5U23#A:=:;O
M8T7?6J')DBZGL4)WDQ,MHG9=;A8H$)=23!6^ZAE&24+SBKHW(DS+OM/@(57)
MK"J0PV].2[+@4K8K= .,3"DFH+BJ$<<2;;L[+MN)3G2MU((SQ)N.K2VVE1JI
M9H!F,2J9>:9?4'*D-N!6Y D)U5QL'W-W<' 8UXHRZB3>-'MB?QA<A(N!U3@N
MK<1V*4[T.2,TX&:KOH6K#BA<_,S80%&\I"7A=4?+WHNIF695O.V&W5A! PPB
M6+KK:4-K(+A5L<#NQ*IEYIE]0<J0VX%;GO$E_5YAB8[5'F^TN,M+>7C=;34Q
MH^:Y%455)3"1PM*U"IB6>?2,Q+:"J"AQ"FUC%*A0CW_+IE'U,4KE V;M./VL
ME_5YAB8[5'F^TN,M+>7C=;34QH^:Y%455)3"1PM*U"IB6>?2,Q+:"J"AQ"FU
MC%*A0CWZXTVIU?T4"IB^])OM(^DML@>UDOZO,,3':H\WVEQEI;R\;K::F-'S
M7(JBJI*82.%I6H5,2SSZ1F);0504.(4VL8I4*$>_!"$E:C@$BIB^[)OM(^DM
ML@>V5Q_Q8QW?1[]-?=_E#]UF')J7#RTNT!).%!&T4^$KUQM%/A*]<;13X2O7
M##DK+AE:G;I()PH?W!+,NV7758)3#LY-.UF 4T;1@,^Z?W9'%\XJX_FR2_J\
MPQ,=JCS?:?=*]$2^5:6[EKU+FY2GKA#!0[+J6:)4NE*PN?;0$S#/9$?'3$U]
M=Z!$\!GV?HBBDE)X=2B05'@C9H4GC&I0"IX(V:%)XQJWKBKN_3VB'9E)EI3&
MI[)?%$XTVFXVB66E*1N"[[62_J\PQ,=JCS?:?=*]$2^5:6[EKU+FY2GKA#!0
M[+J6:)4NE*PN?;0$S#/9$?'3$U]=Z!$\!GV?HBBDE)X=2B05'@C9H4GC&I0"
MIX(V:%)XQJWKBKN_35;91V;B@D=V"L(V" *D#9.*@RI84PX15-34*AI^72&V
MIBM4# *'_GVDE_5YAB8[5'F^T^Z5Z(E\JTMW+7J7-RE/7"&"AV74LT2I=*5A
M<^V@)F&>R(^.F)KZ[T")X#/L_1%%)*3PZE$@J/!&S0I/&-3-%5(4D<(U;UQ5
MW?I[37;@%_)Y1UP9R>"#*Y!3*R"4U-;T-/2Z0VW, U0, H?^?:JX_P"+&.[Z
M/?IK[O\ *'[J4L3+S*3G(;64PC_'S./^<K4= GYD"\?EE0$OS+SR1GHXLJ@B
M59O@=DLYDB,\Q+ \9]4%RXB80,2R:T[FHW-,Y+).87E\,/L)2A&05<6XH[&L
M9=U33C-:7D*C)2K1=5N[PXXKEY:]]&I]4)D%-!MY0)25'8D<<:XF,GD[UW8J
MK  %2=P0%KR<J#N.G/WA!6C)3(&XVK/^,%*@4J&8@[D2]IFYK925 9\^]#LL
MQ3***:7C3=A#4S=O+3>%TU_=4<7SBKC^;)+^KS#$QVJ/-]I]TKT1(ZS9RN3O
MWMD!2MW?XH:5-(3+LI4"HWP3W*1,A1V3ON:1OQ-?7>@0Z1+J?GGMFXI.([L!
M9;OLN5&S&R08UH^Z&D)=R:W#N4.<PWK3)NI.8(ER"3PDP^UD"+G9-N@$$0)%
MC8-OK1<_EO0%L296D$)-P9SPJ,.,S;:944K[LH%"H4;-=#C"A6ZFM$G>A%HS
M:$K=6+Z;^"$[\9 MN!DF[EB,W>WH_:,H@-4-'4)PX]5J5DD:WNMA!=/98;F]
M"B34F1Q^[]K)?U>88F.U1YOM/NE>B)'6;.5R=^]L@*5N[_%#2II"9=E*@5&^
M">Y2)D*.R=]S2-^)KZ[T"'2)=3\\]LW%)Q'=@++=]ERHV8V2#&M'W0TA+N36
MX=RASF&]:9-U)S!$N02>$F'VL@1<[)MT @B!(L;!M]:+G\MZ MB3*T@A)N#.
M>%1AQF;;3*BE?=E H5"C9KH<84*W4UHD[T(M&;0E;JQ?3?P0G?C(%MP,DW<L
M1F[V]'[1E$!JAHZA.''J!224J&<$;D9)^:>>;K6ZXLF/VFX+C200W7XQPAB4
M0:Y $KXSN?A[22_J\PQ,=JCS?:?=*]$2.LV<KD[][9 4K=W^*&E32$R[*5 J
M-\$]RD3(4=D[[FD;\37UWH$.D2ZGYY[9N*3B.[ 66[[+E1LQLD&-:/NAI"7<
MFMP[E#G,-ZTR;J3F")<@D\),/M9 BYV3;H!!$/,LBZT0%I3O5A3R)<O.H2"X
MI JM9]49"99UJE7QUJ!3W80[9CJ#?^$;;&Q!WQ"+1FT)6ZL7TW\$)WXR!;<#
M)-W+$9N]O1^T91 :H:.H3AQZI 40#B(UVMU3[]W-L:!,!LLK8;8S)2X*$\/M
M5<?\6,=WT>_37W?Y0_=D<8U'>W.HU+M301DTY[R2"3NF#D99A+-<P74GRPQ-
MW;F4&=.\:TB=;0+J;UZ@X17TQ)<2O.,(:#&6><V=Q)N]TQ*MMM*9""5+237/
MN0TR$^ZD7G3OJA;,BRVM#9NEQVIO<4$K:#<VQGIQ[H@?7)],.6DZF\4FXU7<
MWS")=AM+LRH7C?[%(C6DTTAMXBJ%-X'@A%I-IHL&X[3=WC$M9.MZ!"5'*WN[
MA#DV&\M=(%VM,3#3Q8R%Q%REZO[JCB^<5<?S9)?U>88F.U1YOM/NE>B)6XPE
M[+7NR-*4IZXV$HRD\))C*S3E\CL4C,$\437UWH$3U?I^@1]\KT1-RK/9N33@
MS[FR,)=M)U3I/TR<YX (>9LR5R 0FJEW F]"7$&ZM#:% \,)3.5E7MW-5!@E
M+<L^?I,D7OPALM+*Y=ZMV]B#O0G*[5UMLZ?1N\'!&!_WHF95F8*E*;HA.35W
M-SVA^P__ .OVLE_5YAB8[5'F^T^Z5Z(E;C"7LM>[(TI2GKC82C*3PDF,K-.7
MR.Q2,P3Q1-?7>@1/5^GZ!'WRO1$W*L]FY-.#/N;(PEVTG5.D_3)SG@ AYFS)
M7(!":J7<";T)<0;JT-H4#PPE,Y65>W<U4&"4MRSY^DR1>_"&RTLKEWJW;V(.
M]"<KM76VSI]&[P<$8'_>B9E69@J4INB$Y-7<W-43<V*28.Q3_F=4:TE+IFZ4
M &#0_O<A2UJ*EJ-2H[OM)+^KS#$QVJ/-]I]TKT1*W&$O9:]V1I2E/7&PE&4G
MA),96:<OD=BD9@GBB:^N] B>K]/T"/OE>B)N59[-R:<&?<V1A+MI.J=)^F3G
M/ !#S-F2N0"$U4NX$WH^Z3#;-H7FG4BF5 JE482LTH_1I?\ 7")J54K6ZU72
MA7Q3"<KM76VSI]&[P<$8'_>B9E69@J4INB$Y-7<W-53[DF\TTG%:T$1*A4RZ
M\AUP(6AQ956IA$S099I8 5P'<]JKC_BQCN^CWZ:^[_*'[LCC&H[VYU$/6@XI
MN]G#+>(XS%'1+Y1.(<.45WH;?E?@#4)V-,#2)S^CS!$EQ*\XQ,#Z*4#F@PQ7
M#*)\L*NXTS:CE,,@JO?$#ZY/IB3INW_.,*7:#C F:"H7,7#WJPB88?E4.H[%
M6NZ_JB<:1.R[BRD42ET$G.(:[17DB8[9'G?NR.+YQ5Q_-DE_5YAB8[5'F^T^
MZ5Z(LW[S].K-?7>@1/\ ;^B/OE>B)A][,UKEU*CO5)SPP4S%PHSH=3L@085(
MMS.7GW1>7Q#R1*3;C*7V2@50L5"J'.(2F6*&P-D"R %(/"(UZN<+I0#38W .
M//#+$LK*-,5JX,"3"+/F5I2^V+@"\'$P'<LX6*UR!'X5@RLLQ+KG%'9.-H%4
M#CW_ &A^P_\ ^OVLE_5YAB8[5'F^T^Z5Z(LW[S].K-?7>@1/]OZ(^^5Z(F'W
MLS6N74J.]4G/#!3,7"C.AU.R!!A4BW,Y>?=%Y?$/)$I-N,I?9*!5"Q4*H<XA
M*98H; V0+( 4@\(C7JYPNE --C< X\\,L2RLHTQ6K@P),(L^96E+[8N +P<3
M =RSA8K7($?A6#*RS$NN<4=DXV@50./?U):5P#BZ'BW80VVFXA HD#<$*6N7
M4I:C4DNJS_C$H91K)EPJO;(G>W_:27]7F&)CM4>;[3[I7HBS?O/TZLU]=Z!$
M_P!OZ(^^5Z(F'WLS6N74J.]4G/#!3,7"C.AU.R!!A4BW,Y>?=%Y?$/)#$Q="
MD*;!%X9B0<(4RRVTQ?&R;; 2MLPU-*G5.!I5\)"+OXUA$A+K#I"[[BTX#@A%
MGS*TI?;%P!>#B8#N6<+%:Y C\*P9668EUSBCLG&T"J!Q[^KK68*<N47'6E'L
MN$1KN^XX49TY4BB>&$24JK*,MJO+<&"CP>U5Q_Q8QW?1[]-?=_E#]V1QC4=[
M<Q*ESX,.IO5WJPZAM5Q:DD)5O&"SK)V_7LJ;'PL(EY0JO*0,Y&^36)OAN>8(
MDN)7G&)W^CS!J,S*3G(HL;RMV''9%;99<-;BS0IA:G7$N33N)3@!O"!]<GTP
MY)$^Z,JO)'\IZX3.R:<JJ[=<;W>.%+M)E3,N!F36BE&$NLONY9:J);60>.&.
M%*A^$/R\N ITT(!-*YX;1-H"%."\ #7]U1Q?.*N/VDI]<CRPN9F-BTBE2!7=
MI%TO4K])HQE9=+;;Q%6WVL#Q[\+:<%UQ!NJ'#[U/]JGTQ]TG]TF9M?\ B)DR
MJEA2L$;'<'M9+^KS#$QVJ/-]\HAU:!O)5JU22D[XBCCJUC^95=6YEG+OT;V;
MWJ2_J\PQ,=JCS??*(=6@;R5:M4DI.^(HXZM8_F575N99R[]&]F]ZDOZO,,3'
M:H\WWRB'5H&\E6K4&ABZMYQ0WBK5N99R[]&]F]K=6ZM:=Y2J^V5Q_P 6,=WT
M>_37W?Y0_=@=XQHW_?\ ^,+7A>-=1+$VSKE"<R5@T53TP=;29O[[JLP[T/ZZ
M:UXIQ=X&_=N\&$(F!+:V6$W3L[U?PAF3UCE<G79Y6E<]=Z'IS)Y'*4V%:TH
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M8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C
M1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",
M!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(
MP$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!& C 1@(P$8",!&
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MWGG$M-(%5+6: 1IB1_\ D)]<6H[)3+4RW5""ME84*WTYLW'%HG=R \Z+//\
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M>NPMV24E3:MU&HCMD_D:LE62UWKF_P#*W+MVG =^-#'_ .3_ ,8T,?\ Y/\
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M3;M@,.MN)2$NER_@<,3P1:LN_L#,%U**\*@L?@-2<LEB7<K+WJOU!0:&D/\
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M)O..JQ6J&YV5?UE:;78N[BMZOKC6;EJ,)9.Q+P4 :<83>A:4KR\T[\*\12O
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M (Z]ZHT_XZ]ZHT_XZ]ZHT_XZ]ZHT_P".O>J)Q-D3^LEMA.4.66W>QIV,:?\
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M !U[U1I_QU[U1I_QU[U1I_QU[U1I_P =>]4:?\=>]4:?\=>]4:?\=>]4:?\
M'7O5&G_'7O5&G_'7O5&G_'7O5&G_ !U[U1I_QU[U1I_QU[U1I_QU[U1I_P =
M>]4:?\=>]4:?\=>]4:?\=>]4:?\ '7O5&G_'7O5&G_'7O5&G_'7O5&G_ !U[
MU1I_QU[U1I_QU[U1I_QU[U1I_P =>]4:?\=>]4:?\=>]4:?\=>]4:?\ '7O5
M&G_'7O5&G_'7O5&G_'7O5&G_ !U[U1I_QU[U1I_QU[U1I_QU[U1I_P =>]4:
M?\=>]4:?\=>]4:?\=>]4:?\ '7O5&G_'7O5&G_'7O5&G_'7O5&G_ !U[U1I_
MQU[U1I_QU[U1I_QU[U1I_P =>]4:?\=>]4:?\=>]4:?\=>]4:?\ '7O5&G_'
M7O5&G_'7O5&G_'7O5&G_ !U[U1I_QU[U1I_QU[U1I_QU[U1I_P =>]4:?\=>
M]4:?\=>]4:?\=>]4:?\ '7O5&G_'7O5&G_'7O5&G_'7O5&G_ !U[U1I_QU[U
M1I_QU[U1I_QU[U1I_P =>]4:?\=>]4:?\=>]4:?\=>]4:?\ '7O5&G_'7O5&
MG_'7O5&G_'7O5&G_ !U[U1I_QU[U1I_QU[U1I_QU[U1I_P =>]4:?\=>]4:?
M\=>]4:?\=>]4:?\ '7O5&G_'7O5&G_'7O5&G_'7O5&G_ !U[U1I_QU[U1I_Q
MU[U1I_QU[U1I_P =>]4:?\=>]4:?\=>]4:?\=>]4:?\ '7O5&G_'7O5&G_'7
MO5$G^V+0U]E+^2]W6Y=I2O9=SWY';)_(_@"V>U;\JOG"T^)'YB8E.W<\X_ZY
MV-QO?H]^1VR?R/X MGM6_*KYPM/B1^8F)3MW/./^N=C<;WZ/?D=LG\C^ +9[
M5ORJ^<+3XD?F)B4[=SSC_KG8W&]^B%-.SS2'$YB*QI!F-(,QI!F-(,QI!F-(
M,QI!F-(,QI!F-(,QI!G41VR?R-5)FYIF5"NQ+S@17OPK6DXQ-7.RR+@73O:A
M2JU9)*DFA!F$9OQ@$&H.[&4FYEJ61ONK"8N(M:5O<+@$!234' B,K-/M2S=:
M7W5A(_&%ZTFV)JYV61<"Z=[4+*K3DPZ%72@OIK7>I6%.O.(9:3V2W%4 C2\C
M_P#)1ZXTM(__ "4>N+[#S;R?I-JO#5UJU:$JY,U*<BEY)748YM3;C'*"-N,<
MH(NM3#3BMY*P3^YAENTI1QXF@;2^DJ)XJ_NEL]JWY5:N5F7VY=K"^ZL)'XPO
M6DXQ-7.RR+@73O:BG'5I;;0*J6LT $%$I/2TRL"I2RZE1 [D-R[TVPR^Y2XT
MXX I7$(#DU,-2S9-T*>6$BO=A+C:@XVL7DJ2:@C44Z^ZAEI.*W%70.[ =EGF
MYAHX+:4%#O\ [FM,K-L3*D=D&7 J[QT_<+3XD?F)B4[=SSC_ *YV-QO?H]Y,
MQ-'6TFD5*CNPZF44I; .Q4K=]HCMD_D:KTD[F4=DVOZ"]PQ5Y"DY-61F6=].
M[ZX2Y)NA4S/)I+J3N)W5QKR9161E#4U^.O<3Z?\ S"YJ@6^HY-E!W5>J'7,K
ME5C.[,/'8HX.H0IV5FVIQQ(KD;MTGBAF0F'%&SWEY-3:_DE'=&] ^TH\ABVO
MN?UZDW_^Q7^9%J_5^D0Y)L/(96AHNWG,,0/3&:?E">&]ZH4D+,O.,'/=.Q6/
M2#$K.C8(>:2[GW*BL.2ECN"8FE9C,I[!OBWS%F$YS5?F*U,);E>J-=3RI=#=
MZZ ERJE'@A=JTNRC*5-WC\91WM60EWW[LJU:"$I8;S)S.;N_J5)H-\Q1MU"S
M_*JNJ$%:0L_%KGU,GE$W_HUSZM5$)&^8JA06-])KJ3=E!_(R3*[F3:S7^VW]
M26M%R9E%,MOY0I2I5ZG@ZI2EQ)4,0#GU3<6E=/HFOOUL]JWY5:JOKT>F)1IW
M,S:+-!W>Q_$4U$R3?P\\X&P!C=&<^@=V+297V;<NI!XPM,2%K*FU,JE+E&@B
MMZZN]C$I]L3YBXL?[&SY@B\M00G?4:1:920H7$YQVXB4[=SSCJ6E,L+R;S3"
MU(5O&D/O/NK>=7-K*EK-2<R=2X7$!?T2<_M<GE$Y3Z-<^H;CB5TQNFNI51"1
MOF*H6E8WTFNK[FM*^U-8MS^GRJU+F43?^C7/JA)6D*. )QU+JW4)5O%6I.3$
MHZIAZJ$A:<150$6:M:BI1"R5'$[-6I<RB;_T:Y_:6GQ(_,3%D&7?<8)?=J6U
ME-<YC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+
MJC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2
M,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WR
MZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHT
MC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JC2,WRZHTC-\NJ-(S?+JB4;>G9AULWZ
MH6Z2#L#_ !'(-6=,Y!+K9*ADTJJ:\(C!/B\:ZGY9+LNGLJH0H#CN807T(R+[
M9NNLUK=/JBV+-F9C*2<OELFW<2*77 !GI7#WXJ40E(SDG<BSI"QWZ26N$-O.
MW0<M50K2NY[3]F64QKZTJW3NI0=Z@Q,99<ZB4KG#94E/D$-ROLEE\O+K^5 %
MZF^",QXH<?L%8<FW$I5+J%VA%1]+-A6,$^+P]9LM,!R=9O7V\FR*730YZ4C!
M/B\)O=E3/$C*V8NY:$TYFV(5L>[ODB)MBT5WY^67G-T)JD\ X:^]6S9LS,92
M3E\MDV[B12ZX ,]*X>\3_P"WD.I";F1RC(;^E7 <7MY_]O(=2$W,CE&0W]*N
M XO>6K+LM@35J.TS$5"*X9MTP9Q:V)A*1>5+!*"?P'D,+449"<9H'6AAQC@A
MR=G%W&D;@Q4=X0O]B2XDI-)IE*#\5*W>*,NF:$\!G+:2E?X$>2-83K0D[2'Q
M?BN;]-X\&JTRRT)FT'\Z&S@D;YC7(=8EZYQ+J2V#Y/3"K%MN7$K:0S)4!2\=
MXC?A^>F57664U.^>"')JR4LV?(@T05!.?NJ!K"+%]DS*6WG" W, 4SG##,0=
M\:BIJ<<NCXC8[)9WA%KJG' 6D7"TT$BC8-[-P[D32I87ID-*+0WU4S1HX<DG
MUPY,3$FAEEL7E+4VF@_&)QV?"#*-@)0M*+NRWO>[&XWOT>\)G9Y-&<4-G=XX
M_9DH:(3F<(\GM4=LG\CVB;<9HEQNC;X^D, >/<_\1)2*5EQ9(99"U9DU/7#$
MC+]BV,ZOI*W3%FRU=BAI3G?-/TPRZ!LIAQ:U'NW?TZCDPU9\NE]:BM3N3%ZI
MX8'VE'D,6U]S^O4F_P#]BO\ ,BU?J_2(>FYM#SC:V"T R 36\D[I&]&QE)XG
MA0@?JA3LO+'*OD(;93GH!OPQ9R5 EN7#-[?-VE8,U/+U_-)22E-*-H/%NQ9G
M&O\ +5JM6?**O,(<UNQO?S+_ +W!$O)2R;K+*;HX>'4>DI12$/K4D@K-!F,(
MLY)3KE3^0!)S7JTB;:G2AYQ3N42&5%6:Z-_BC)3DN_*I42I(?2I++2>"&YXS
M3;S=\)O-52I)AY$XX7GI9RX'%8E-,U?QBT)EI7NC$^XM-<*A9B6GYO\ _(<2
MIU:G?=4I)[*&['L]PL**+SSJ#LJ;B:PW:.N&Y3*;-K*5O*X>"$25K+49J23D
MKU<ZDXC/NXXQ)3[^=#,DA5/I&Z*#OPM)>S#9F\:-,IX!#$ZS-[!:KH>8)&?>
M4(F,C<;G'6U,+%:)#G]YX?DI@I4^TJZHI-1$\J?<:6'DH"<DLJPKP1("\::[
MW^&$4-/\2CR*AZQ;-?UO+7\M,/%1&( H3W,(EG%/A:7/@WV"001Y(;>F57YA
MI996OZ5-WO$0Y9THM>LT.9%MEL_"JK2IW\\"T).=;1/-B]D65&]Q5P,2<R\:
M.O3K:E@9A6^/?;9[5ORJU5?7H],>Q>VI?,]+; J';$I_$?C$K.-]@^V'!P5B
M7E^RE+*3?5O7AG\XI'<BW>U=_-$>QX D#W#\XQ*?;$^8N)&?=SI8L]I5-\W!
M0=^';6MF==1*WREMMO\ 37,!#Z[.G7GK*?HW,,._%SYCWXE.W<\XZCL\M]UM
M<BPXM*$8*X^]#-L+F7D.R\UF:32Z;M#$O['+'66YEZF5<0:'/@FNYFSF/\3:
M,RN;.*T4NUXB*_C#=@6F^9J1>(#3BMRO8D<%<Q&K;=FV9,&77-S+R%O?Y: L
MDQ,3TK/ON3<N@O'*4HJF<TWH3(S4^N7LV33=><1V;Y. /<B6M6RI][,Y<-[L
MDGN;F:&[<?3FULEY2!]*F'?AVT[7G7&I$+NMM-_I& '#"K6L"T)D*EQ><0L[
M*[NG-CQ0B96 F90<F\D87M^)B08FE2UC2V-W BM*\),&T/8_:$TB>8%^XX1[
MIP9@(MA1Q*4'\50GV,V0\9= S/NI-*YJG/O"-C:,T)O_ #=C=KQ=</\ L8MA
MPO.MUR+JC4YA6E=T4SB+!<3\4NJIR<"UK0M7)3TU[K<R=ZZ#@*US>B+.]C]D
MIF699:4I<FP%4.Y0KX!C'ND_.+?W5@I KQ4],?\ IYR95,2;FQH<.QO)4!N0
M[;9?=#S24-!KXAV77%FV]KE[+E*_<<US=3"?8S9#QET#,^ZDTKFJ<^\(V-HS
M0F_\W8W:\77#_L8MAPO.MUR+JC4YA6E=T4SC5M/B1^8F+'^O=\I^;I+^OS%?
MPXE$PLETY\FV*F,K*N7P,R@<Q3[:ROJU>=J/JF;HEP@Y2]A=W8M52:Y#)IKQ
MUS>F/9!-*97,N+<?:::1\99=%/)!GG+&::E$[(IR=:#A%ZL+=#>0F63==:K6
MF\1P0TV&M=3SWP;(-,V^8R[=CR[;>-R@KWBNL*LJU)02=H"M+M0"1B*' PRA
M#.NIY_X)GTF-<_L:7R6.3IG[U^]#S+K&M9YC.MNN8C?$)6ZG+3+GP3"32]PG
M>$";E[&83+'.E"A0D<156%V?.2^L+4;K5HX*IC2N[P:K,LS.:TL8-#*Y^R74
M[F[FNXYH]CDG)A5WW%2E+.=:LJ<^K/3H[)EE2T\=,T3]M3'NK]_)(6K?Q4?Q
M&HJ2=5DE7@I#MVI08:D$S"YE#9-%.<.YJ6SVTS^9JEWLY.S\-ZB,.?G@/=A)
M3YJK>HO'O*SZJEK-U*14D[D/-^QJRT.R[1IEGMWOD <4,M^R.R4(8</PC./E
M(/%$W:4M==N2RGVZ]BK8U$/3<TVTTXA\M4:K2EU)W>.)R?92A;K(!"7,,0(9
MGYA#;;JU*!2WAF-(]D,UD%3+JW'V6FD_&67A3R09Z8L5@28V2D!.=([BJB"^
MRG)/-FCK)-2D^J)RSYEALR+" 04 Y12B@$#&F)A5H(L5MB1 O75(J;O#GK^$
M,ZVD5/VTXO)B314CMN+^^&$3%J62RF44:4"?PJ":=V):?EZY)Y-X [F^(M 3
M3+#6M[EW(@YZWM\\$?L:PI$3\^.S4K.E)WHUU:5D2ZY0=D4[G@J-(;GI<%(5
ML5-G%"MZ'[-]C5GIG%,YEON8>4 <9A#MMV0RJ54:7V_6"1$O.RQJR\F\FODB
MT!-,L-:WN7<B#GK>WSP0B489U[:3F#0P3O5]4:[78K)8QR81LJ=K>O0M%S6T
M\T*K8)KFWQ%F!AIE:)E2\H70<P%W"AX8<7['+(OR*303#X[/BJ0(38]NR0E)
MI:KB5I!3LMP$'?W]4V[>>5.&N92@484WMZ%OSDRVPA/TCG/$-V+7M5+9:DW*
MH2-RI57\/3%FV$VNZV"@'MUG'N"D,RLLV&V&DW4I&I(6Y)>XO+7193],9TJ_
MO>B4G$Y@^TERF]4:DM;;DTJK)327**C8X9^//J6:B2SN,N-)=*=])O*YODBS
MY0&@>=4L\-T?\HD95 H&F4I[M,\2$Z![JT_D[W 03^F+/FE=F\PA:N,C/ M'
MV4S9F7-R62JO<)W!P"+:^Z_7JRWL8L]7N:5^[J&%[=KP)'XPQ)2J;C+2:#AX
M?>[&XWOT>W$R\C_"-G=^,8449G5;%L05J-5'$GVJ.V3^1[3]G2RZR4JK9$?'
M<ZL._$A,S""QKA&6:4,1ZC@>["7%D:]9V#Z>'Z7=BS9NFP4VIJO"#7TP)8'W
M25=4E2> F\/*>]J.23C#R1E2TV\WLTKST!W\\*/T7T'RQ;#==D0TH#PO7J.W
M,^4M$T[KD6K]7Z1#\M/MEQE,LIP **<]Y(],?M"S+ZY09G6UFI;X>*!9+\NP
MP^OX*8;0$ES^57#J.]J8LSC7^6K4GYE)NNW,FWVRLW7$Y:"QFET!M';*ZA^/
MM);_ /9C\V'9AY5QII)6M6\!&L[ E@U7L-B%.4WR3F$&?MRT,HT%A.M\K7.>
M ;&+4^L1Y#$ZVK.%VDM)Y34M&]_[=.+)IB1+7P981=IO783<[(2R OCJ?12+
M/NX9&7O<6:)W_P!.D [#+5R?#3L^[&M9]M+[%Z]=O,)S]R)YFT6<A?<"T"^%
M;F?#N1:?UWH&I(?:_3"/M*/(J+55NEQ _ Q9Y_\ ['Z3$W]L5YB(LO+?]0!G
M^EN?CJ(4U\$;4JFF]E??;9[5ORJU5?7H],,2-*J=EC<[8$E/XQ/HF#GLN\NZ
M?HG./QO1/6S,9YB?>)O< /K)[T6[VKOYHCV._<?G&)3[8GS%Q)7<-;2M[BV,
M69=WE]^^J+5OX9+\:BD2G;N><=2U_LJ_)#GVI?D3#V5[*\J[7ZK-^&I8N3^&
MN_JS>G5M_@,Q^:(M3[*[YIB>^T_I$?\ <(],2=,,FS>XKT69<PHOOWU1-Y3L
M,BN]Q4BW;G\MWCHKJBV/IU:[VRU/9 $=A44XKRHMA-DS3<I/!QXJ6[O93.,#
M&FY7^_NXE+8M&<E7UMK!<4E1O$8?1$6+]]^B$I& %(195F2NO;373,<X37 4
M&)C9S,M9J#N;#T F)&7GIPS\T% K>-=U$3G;-^>(LOM5>>J+839,TW*3P<>*
MEN[V4SC QIN5_O[N)2V+1G)5];:P7%)4;Q&'T1JVGQ(_,3%C_7N^4_-TE_7Y
MBOX<F''0;CNR0O<(I$U,D%,N4W!_,:^VLNF.25Y8VZGPV_5&1M.TT)E_C)4[
MF\%(SP)5@EQ9-YQU6*U1;"G$A60=F'$UW\I3TQ0YQ%N-)S( &;B48E[:M=0:
MF6B,FI2U&M,*)W8HRS-S*MRZ@ ?B8DIXRBY$NJ'N2\?@Z5BS[;LYI3ZY2EY"
M1>*:*O TW8"+3L]QA8S%;!O#O'")BTK'#)FG*Y90J%Y\YJ#&6GVU3$G)% R2
M=VB:^<8VC.<WUQ9MKV>R[+*2IL.92FR(5P<&;VGL>^X_..K:R4XY&]WL\3"!
MV29I5?!3J%2B$I&<DZML]M,_F:D[-@T=NW&NW.8>ON1-*G%NZ\?7GN-UHD8>
M4Q*F34[KQA?QVZ52<?1$H^I5Y]L9%WMAZQ0]W4F96]=RS2FZ[U12'Y">LW*R
MRW+]>QJ<*I5NX0W*VFV6=F%!$T-C>[8>F+3:82$,(D7$H2G "X:1-?;%>8B+
M4[1/GB)7MW/.,6X\XF]K9U]Q%?I92GI.I:=GL[&77E$A P [(0&G$WD7T+H?
MY60KT00<X,6J]=V;2 A'!4]46I45V"3SA$MP..>=%M_=?KB<MN7E==2<R5$K
MI5-%9R#O9X7+6G*NRJ'4E"_E$4..&?\ " ;&2T)-PWJLFH)B>)DM=2$PKX0]
MBL5-W9;ASPJ2M5AR6;<I>2Z+R.^(919R6TR=*MY(U3GWHMO[K]<6M.S&S+!<
M6BNX;UU/>&I**EM@F:6@J2,-GL3^.>+%^^_1$M+-"ZVTV$ #BBPG4BBSDZGB
M<]I-S>O9EN;F'%.5-TH!)WJ>F%>Q:U+J@BJ&5I%+M!7O$1+K<S)6\S=KV@3Y
M=61:^.J9O#N)/KBR K'6Z3JFRK&_Q-IK-PK;%[)G>&^J%3\_[I:CXSYZY,;W
M'OF+%.Y[M^B$$8$0UPS2/-5%D5_Z9'DU+;^Z_7J3L^<66ZI!W58)_&D3MMS&
MS?F%EM"E8TQ4>Z?)[Y8W&]^CVS3*<5J"8:EFTW0D9^/=A3/R;&Q%-WVR.V3^
M1JZWEUTGYH744Q0G=5&NIA%9"4-Y5?CKW$_WZ8>DUT2[V3+GT5[D7W$*3<5D
MIEC?&[&2#@+;H#K#Z?BG<,%8"Y978Y0"\TZ/(8,H7&V$.;%6MT44K@AJUK29
M+#36R99<%%*5N*IO")JSW#=#R<ROHG$'OQ?NKDYA.8+I5#@\A$*9OL2]X4+C
M+=%>6)>U)ME3,DPK*(R@H7%;E.#ABU?J_2(FOL:O/1"V74!QI8NJ2<"(+:"H
M,DY66>W:>L0V^2-=-[!]/\V_W8=[4Q9G&O\ +5J23 ^4F+Q[B3ZX<<W79A1_
M #VC[I;NN,S6N&KXS*%ZJ3%M,/H:EW2DLMY,&F=.[W86X[*>[)26G6'=C5/'
MW!GAQQFSC+65*>ZN$&]4X=EFKCA%JRI/NFP< WQG!]$3'_[0_FZC=J2#9>?;
M3<=:3V2D[A$"RY5O+W=BVVXR5+1P"$JM95Z>F6P^NN(J2*'O1)2#NQ2](MB]
MO&Z"#WX67)>E=@I*_@W4\!B6EI)ER5NJJEN44HK4KCAM%J33DU.K-]>47?N?
MRUB;>6@AF8HXVY3,<PK^,33,VRRV&6DJ!:!SFN?=B0^U^F$?:4>146G]:GR1
M(?:/TF)K[8KS$0[:,BTMR2=7E0IH9V58]S/ LR42%K6+BIAMJBJ<*L!$G*J(
M4IF?0V2-VCE/?;9[5ORJU5?7H],65]5Z3%IV?*5#5J72$#XP4H'S@1$I)([%
MAL(KO[YBW>U=_-$>QW[C\XQ*?;$^8N)&1=S(?L]I-=XW!0P[9%M2;JI2^5-.
M-?IWQ$Q+63*/(L]D96:F'13,,!WXE.W<\XZEI2S0O.NRZTH&^:9H38LU)N7W
M9NE^M+EZ@SB)?V2V0@NOM4RJ$BIS8*INBF8Q68DII$T!G;0 4UXZPW;UH2YE
MK.8(+25;H'8I&_GSDZOL@_[C\X1:GV5WS3$]]I_2(_[A'IB3D'31+\H$WMX[
MA[\.V3;,DZN3OE3;C?Z=\0NR; D9E;DR+BUJ3GN[H 'EA,NZ09IQ65>(W][N
M0_:#$LJ9L:9QNX $X<!&Y&LK!D9IVT7Q=25I N<.8Q;;2^S0$)/?5 ]DME,E
M]A1O/(2*W3\:O =^+VLYO7%/@MC=KVU?1#OLAM O2LH:EMF\0E>:@S;P$6+]
M]^C41[(%2RIB26H*O##L+I'' 3)2<Y-3:NP9N 5/?BS)ZVT:WF)MQ+M/HA54
M@=R)]F70771=6$)Q-% G\(L[V/.2RTO56D/7LVZK#\('LELIDOL*-YY"16Z?
MC5X#OQ>UG-ZXI\%L;M>VKZ(=]D-H%Z5E#4MLWB$KS4&;> U;3XD?F)BQ_KW?
M*?FZ2_K\Q7\.77$)6G>4*Q0"@WA[:ROJU>=[3V0?]Q^<-2W?[^.83*VNN[(I
M4E "C07;E0.ZKRP76Y>5D6D"I6$)0!W8EYQCX!3P0@G= 12L24H]*IU@_0JF
M23F%:'-P0'9B6E9QI0J'2 <W J%,V,LN6>B^"0JHNW,^?>O>B)6V7$%4H_11
M-/Y;BQQ[O=A,S+N-/,*%0XC"&;'LJ49GFB0A;P.!^,1P >T]CWW'YQU76'1>
M;<24*&^#$Y9MI!6LGOE:>"OB_O<@/,3;#K7TDN B'+(LYY,S,3&Q=6T:A"=Z
MN^89:F*B8=.56@_$K@-2V>VF?S-2S+ EMDN\%*'\ZLR?[X8::_94F[<0$WUR
MZ2I7"<T.-?LF21?24WD2Z01Q9HGK"FC3*$I'UB/6*_AJ34PPSKAYILK2U6EZ
MFY#S<RAEJ:2K/+8WD;^?&%S+;#,G:)4,DEG8W\^?8\58++@4IYR2>2V#B1LK
MGX4B;LY3J4S.7RR4$]D"D#-X,/V:EU*YR9*1DTFI2D&I)[T2O;N><8M=4TL-
ML3$P^R5G!)RE03WOQA4W,OH:ETBM\GR1:MOE!3+U5<KOJ.8=Q,#^_P#\;4MO
M^CRJBU?JQYPB7^L<\Z+;^Z_7$W8UI,-2&3)0VLJ[)5?2(?F+1EI>72$DF92+
MBAW1C%KT!4Q5&3!POT-?TQ-R$^RU(S*#1#)/9[XS[L3DV]+L2<R$$M.-; J7
MN"@QA>5KDM<*R5?HT'IK%M_=?KB=$[[E)S=ZCAP"5&\D]_-&N%/-IEZ7LJ5;
M&G'"9V6!5)2I"K]/BIP[ZHL7[[]$)XHL#^G\S5=D;7F:64LG)50 $I/8JK3N
M=^#,./(0P!>RJE;&G'#EI2J3K-@WRNFX$W1WS$O;4D"7Y44=N8W:U"NY#:)A
M]N4M "BVG#="COIC73:969L8W4AN^+U=WA\HB4EV&U2\BRG/>^(GXRN/<[T(
M;0+J$"ZD;PU$V-9SER;='NKM:9,' 5W#PP'WK5L^8M-8V3NN$41P)S_C"4(M
M236M1H$IF$DD]^$S+2;RY-R^>T.8^B)4H<!F6FPV\W7.%#-7NQ9U@6>H3$QE
M:K",X"L /+$M*H[!EM+8[@IJ6W]U^O4DY0&FN'KQXDCUD19LM2A0PDJ[8YS^
M)]\L;C>_1[9V8)^ 3AQPMU>9"!4P\NM:K)]LCMD_D>\%*@%).X8O-2[3:M]"
M -6ZM(4G>,7D2K*%;Z6Q[^ ZTAT#<6FL!*$A*1N"!EF4.TPOIK "10#<'M)>
M:L^94W9[B+I]S2I(7W1O4@(M66=>FA\HP$T5W-R$KEI8A;E&6FAG('#^,2LH
M#4,-):KQ"D77$)6G>4*Q[BRAJOT$TU+CB$N)WE"HBZVA+:=Y(I[:;EE39R&4
M*F<HTD@HKFSTBO[.?UU3L;PN5X^J&IPH]S:?UT\X!F!K4#O^^VSVK?E5[W==
M0EQ.\H5$76T)0G>2*>TOW$W_ *5,^IE%2[2G/I% K[S=<2%IWE"L49:0T-Y"
M::E#G$'),H:KC<335RFMVLI].X*^T(4*@[A@EIEMJOT$@:M\(3>^E3/J936[
M64^G<%?:6GQ(_,3%C_7N^4_-TE_7YBOXCEWIMV8;4R+J<BI(\H/M)RUV79A4
MS-7[Z5J%P7E7C3-J3<U*NS"W)GLPZH$#/7-00E<R%M3"!0/M&BJ;QWX3KJ>F
MYMI.#15=3$C/,Y61<DPD-HEBD)S&N>HC6T\SE$C.E0S*2> P0FTIL-?0V,*1
M(M&^OLWG#5:H5*SS ?9.?/B#O@P<E:$VVT?B&AA6LVRIY0HI]TU6?:2=J/NS
M"9B5NW$MJ%TW57L^;V@:GY<.T[%8S*3Q&*MVA-(1O*"3"9A#:YJ93V+LP:W>
M(8:LS:[+LPJ9?*RI*U)N;(U.YJ&W5/3+TX5%=UQ2;@S4WMS53;)>FI><2I*_
M<5)":IPQ3JJF6E.R#JC4Y&EVO% >FGGY\CXCAHGNP$I 2D9@!N0N896[(K6:
MJ2U0H[VY$RS[LZZ^V6S,*(O)!^CFH(;D)9;BV4$D%T@JSFNY%I3#V6?5/%2E
MI<4*()5>JF@J(!7/3:V!@W4>6D-RLFREAA&"4Q_Z@RLQKSZ%X9/L+F]7#AU)
MIV4=F'%3%+V64#AO4 WXF)%]2TM/"BBWV4(D95;BVDDJJZ059^(1-&3=F'-<
M7;V74#A7"@&_ =F4K9F0*9=DT5W=^$Y>?FWFQ\3,(1*2;(881@D0J:5E)2:5
MV3C![+C$!<U-S4V!\0D)$-L,-I:9;%U*$C,!$T9-V8<UQ=O9=0.%<* ;\!J>
M9O%/8.)S+1Q&,]H399KV&Q\M(UO(,!I&*CBI1X3$KKQV8;UO>NY!0&-,:@[T
M4B4GIEV80[+4N!I0 .>N>HU0U/-5*>P=0:+1Q&!?M&;4R/B;&-;2+ 9;Q)Q*
MCODZBGD(7(NJSG6YV)_I]45?G9EY/T11,-S7L?F%65.M#-LS=5W<1$LBT7@_
M.A'NJP,3J3$],3,Z'GE7E!"TT\V-M6ARB.A$O,MS,\5LN)<2%+12H-?HP4J
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MX:^6NH2ZH.S:A[G+).=7'O"+:=G9EQ[X-00I1NHJ5=B-S4>LBP'M9RK!(7,
MT)IF*J^2D&TF;<<M)EK.ZAQ2E4'$JN:&IU*<FNMQU'T5C]WL;C>_1$GQGR>T
M4DX$4AY^2:RTFYN;D--O-:VDTG94S0AM."13VBN+41VR?R-6T7Y=U;#R0FZX
MVJA&S&[$VW.3TQ-(3+W@EYTJ -X;\6>B2G'95*VE%0;52N>)28FGE/OJ*ZK6
M:D[(^U=EV' Y:CB:(0GY/^8P\W-3\S,MZU4;CSRE"MY._%I.2Q4)A,LX6[F-
MZZ:4CX:T>2/JB^_.3S*<+SB*#R1/+GIAZ9ED( 2I>%Z+399M2<::0^0E"'U
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M0VVYDO=0 2: [_#^XR=D/-OJF9JY<4A(N[)5T5S^UF&)=]#SDO0.A!K=)_\
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M'<^:+9[5ORJ]Y5:%FS D9U1O*2>P4K?S8&,DBU+Z,+VN*_B16$VA[()W]H/
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MYO\ D?</]#^X?ZZ-3\SF_P"1]P_T/[A_KHU/S.;_ )'W#_0_N'^NC4_,YO\
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MN<T3[2M9H< Z@ZG\'N'^,][+\1L_N^]E^(V?W?>R_$;/[WN'^$^$VR_O0 3
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ML/VB<MH<9HQOSC7O6[0/H_*$IY"/(P^[":!DWS1["%9P30XL[U8>LMKE0ZL
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M/7Z/>R_$;/H^%SC\.?XU&Z(H0B0.@3F!V#.+2Y]"WPN9P& I3!;3' \Y1[%
M<"T\$W(_;W#!H]B74=O?FMKW99 @O$?><J$Q1D];ED%884.>&7D0NDZ'1O J
M)%[7AP&"L[&TQUC.^'ZG6]JFA;8O.ZOC$JY!'K/ 3AG#U\=!88X>L#+-1JIG
M%MO""^MO>=:\Z*Z?3[A_I U/RV_A\;OX: [?344JQAT@=7F@/:&>],ET)>Y
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M83\&\(]<'I2=57FCKG6/4/8?WSY;:$;</6=2QC8%8T>$:V]Z!BM&D=U@] V
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M=4 S7P '.BTRK!<$^[Q\@.7V?Q>]E^(V?R/&'5 ,U\#" T2<_!M/'R Y?9]
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MD2  !H1SO1ML# &AMX$$C+[0#*SB(*9'#(!X"M]H+VA;,@.!P:K;&?&5PB9
M,S@X/ Z3F+(OK3'2CJBT[&O U;N>M'"EZ;0OR)NJ:KM .0W;=:\*)D\K1.W@
M<#724@9%5NY/,/&*+Z2T6FY71DPEUI!+D.3C6Q-GVE)*4JL]!69JU&!!R6-I
M6=B.>V 3HU>:H#*OGN.R.$A,F8#9/(CCD#UH60+#-XM+RI>\SJF.DE6076!<
M%.<N@R\HW#4N?W%Y05,=WV-+^-O3TL"/RVSG0W^D?-^M,:M0'0T@11LVM%=5
M9!C-2R5E$->>9\H>P,;*JY@!=>#IQ0^6_BAYT)%J#5EGVX59!=8%P4YRZ#+R
MC<-2Y_<7E!4QW?8TOXV]/2_'IP7DGH=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*
M=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*
M=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*
M=I3M*=I3M*=I3M*=I3M*=I3M*=I3M*=I1".L$:(_?_P_Q'* ,Y >CL.,OK$U
M2[$^I#L,"YZD(@^O+P.&K<].,I<F48I3BWH%.9CP6)F6;90GO&9[D]V$5?*_
M 9;'RHZ$7)@A36D=J 7D/@=8BR@^8*><0G5J'L(I>5WXZQR<"D'/$OZ*]E*/
M(:&#CO\ 0Q(HE'-S6)*@:4?W>4;9E9U.R:CR9@]ZUU[&[R)K<E6_=>T,\]FM
MYD<\(E0@R%&5J\(-;,%/0KTA<!6LUUTGS1+0KW=U^Z!Z%>"XC+*&SK"P!LPS
M!>O"_5]TH)<J?<2>_P#"MJJC==#[I7R&T(MZAKGI#IVGVQ(8.S*AB7"R^IN2
MMC0Y]U8MQ;3ZZZO*(3K65;9-1Y/^=X9R-FZY<N<"8KP5-NOT_"[/HNCX.\:I
MU?DJ#F.QIU7D3K4P451X$OO[2)((#6A\.BQ[FYAKF]S4XQ&YKK$+GE+.O]QT
MOCX?,[^!&DERY]U=/#T<5#!9=N*AZP7A1>S]0WC1GPZ2]CY*4_H@N>(/;^8*
M'B#T0W'VZC^TQTGZ[:@5HH&;% IC!H#0Z)P"! /%V5:<FO &2):<R!6-P5[;
M!M&W&(TUJMKSCNB27QU&#QU<9A6X=6!AFW@2LA9[#J.I3ZO@X*[&&UQVWH"L
M!F+8U91;7*K?)2$D(LE <@S6.<R+KW<JVRFG$SO#\+1P()8&>1:H'(KS>L T
M81J+444M8J-O# [J0+DY5R=XQ6"+*TT#&8V<C+TN=:<Y\=M\'1^X^9P<=.-Z
M@\649"9%%-9Q+",W;!>O3[(:)ON#Y/14ZN\?UM* 6##='-P82NJNG#.7,6?!
M[/Z$ :L?&C]\C<L X&3YI?8L7@5>X/F\)/L/#D'9JN;-ZK'G !A?,JC :! S
M)%UU0\_&5\[O\*0TPTS2J9TU>;X'IM_KLO5'0>)GEL=K?1P<EZ&56]BXZH/5
MPJB@ML/YC4:9;0'H3SAXE5LKV@/>5DCJ:)8<P#Y1E%0.&<?'&#KN'6MMYL-&
M*\B%)+D;96]*!)85$69!@^M3ML\2OG"N1LZ^O-<YTQ,<B7[:9&[ W@MX(HZ:
M65[GM.4#.8@L&H>)A8$EA419D&#ZU.VSQ*^<*Y&SKZ_^CNEZ4R3Y$' JW89$
MJ=LJ;;9]OJ^(Y0W-[1FME,YQ,X'&OF+]H>H:JSK5X]3FZ8/ X/1:0%H, %ZQ
MOCPK+6^PYL+%LJ*NE!RV/. -I@,W BJ"LUK<,,2Z[8UTI#(<>DN8!&0X/5$.
M99ZJ@:=:7G3G!D-<)[R<JI.<55&I2*%>;&I0@#? TEJ;&<8@R;XK5N*;##K=
M1XS"]T1;G37@5SNS$4B.HP*XIT!H'T,:V\'HAX\'SW@')\/FK:NC&K 2\O46
MH>%[Q,LXI@5<Z\[=(U>CC#\_.X_"<E\"OOY$>JOE(1GSFJ<%PX\3T*EODT*$
M'-AZLM5/S'%ZAC-W%2E+;"/.WG,:EHK*O,#SF4R+2V N^MWQN)&O]H4%' :'
MOY4R$O0,J;6ATN,(W"D+T@#3=@O@DU0O!#)&C9C6Z'-W[Y5S+248?CSEJ]".
M;O2\-P[\ WN"2EG,XK5TB2]4&^J\=(ZUC?\ SG%^$;%_ZS.$26C8C9[(?3\+
ML\30,E\?R+?08ZS1.BWC:;XP4S4C$D B"%(X%\F($!S/0!F%AMP-%:(KCAU.
M<I>)RFL.K=UCCIF9^V"OSJ\/F=_ BDB<T6=WP%J?9)[V S ZM2O$5>YY0KE7
M\8 /N]&>L+"B(#34EAH#SH><*KNO2S?8]2>;T'& :0RA&ZNTXXZ1&\?R0O:4
MST?:#/Y"_H^R@F>A6=+IE'R!PA"%ZT')L3T@\$N".;_KF&$5/X KXN$UYZC\
M,:D''4\<DB[6X]4Q]]:$".;1SF]3(U!JXQ;J-)%JRG< +2BVDE7M/B-LRZ</
MQVWP=%\N;X/;PWB6CV\?R/I2_6-;3 G,;(N-J[$ >6/4GP>S^A &&9I8$THW
M,.E!IT6GR3S,]=0/03P)/L/#D'G\4:D7-!/.#BV92SG*4.U&\&!6W*1%P**.
M;R?&4I@MN]TUSN6-$-<Y/*6<X.QE1YO!YDI$[H\RY<X.3L*UV%%\4YGC[WQL
M(_2^6)0(>HC"KF@GG!:I4B0NZE"<B,I#?@U8;+M>7..YX$, \RSKT!"KJ\"Z
M/3>,CV] SXK.#;ANLRRH$L!>A&W1@GR\HQ7.+1Q"LB5K1Q.I-<^ETG--+^FX
M"9ZI78,X-W"*DI#5]XDOSBK#4L30T6I;KBTSTEE0)8"]"-NC!/EY1BN<6CB%
M9$K6CB=3_1W2]*&5:4B TH\><!-H> ].AR^KXCE"@@U!:=I!IKH*_:!11X']
MHGL8N@246B*LXT'JD!'9%6HLY!FCBAR 3.KH <#>5<%O#6JSF(QC>RKCLN:6
M_D% 74;0\](%'3F6"G+$<"FY7AENM^<HEN;$6K*0DE%IIH,/'ZSC$L%CQG_
M^"2^,S+CIIQ0&W11.'6SY>#E>35]J/;^"][X"Q[- &@6_%8GI;Y>#-E0)"O>
ML]_+@Q:.[9/?/I"B5/$+'U0/GA0:K7E&5R6*2VC8!QGRVT$XA#,3"B:3P9 X
MT..EYJ5_F^#4OK0M0KVMO5?+[PDJ'1>$S?O]7PNSQ9_0%'@1N#V(H!4*C:-I
M.*U\ U-"8V\4<1Z3*2B',&U3Q&I6-'%B/4('I?6(P;'K_P"F'5>IDO43JN+Y
M'.60NF65=*]'2:.$D0V,I/$;H4*Q-HTKWHL92ZX)G>:5(H8=TKR,$WAGE1Q>
M;JQQM\);VJ:$O-79PFBP&YQ%%J^1$90J"D97Y@HC$&<&I7 *49PT:<=C+-[
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M=7\&\VMZD$(:QP(OAYCB7CZOA=G^#2D$[2 BWA8O,(<F"JAHHZN5'MVW:'7
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MR^J:*Y[U+>#HML!\L.@?4<8KY_QX+A-BJ;Z30O,JF0XZV=.;%>$R13I//W/
M%.!P5F>#2\N4QGEV!RY>@L!R(A9-#;? .RSW_A?>^'M.EC:$-%X )C>X08^K
MVM:N 9USR)1+B73!]IA51N6Z5[3'5\#+FS4#:F&&W.7)>"2_12&P)"<K%YI:
M<NZY"\I+>K/82!"X":J3%4#,G%B1QFXYK;7Z$(#.@T'A:>W#X]$JYQS*WP;
M?F'!([K#+J%KS*C[Z+:+BN]%^:87XP=5\3SCLCU:*$H;*#1KFQJ*OF1(?LW^
M4L_*:99/OKMXQUI0&M4'1=!HSW7@R1IF'NBEM,Y.DK)5+H -<A7GO*SBEV];
MJA#1I;IC*XG7R=YB=":#66W52<^7BRH*[[('J5(J3J\G.[@8><RJ;STN/$&J
M>L>A6-D!TV53DF+=L3"R=57H<(5,6,+L<(9Y\B:AI(T0KZ&!!O>B  \>)PSO
M,"/3B&K?(]]YJ89\"RSH57G;*D2.@HT-RAW\#@??0<31> "8WN"]SO8;5K@#
M.N>1*?<;Z8'M,"L-RW:O:8ZO@9<V:@;4PPVYRY+P2:L;!01"<K%YIG5I"+DQ
M+OZT4!ZC+R@@&DN6L&A+;VJ+:B<<++ZIHKGO4MX.BVP'RPZ!_)Q\]N^GD*MC
MWC!*U#^SZ?B]/#X79].#X#?XN*!2W30[;R69_"W17'_'GSGS._Z*6G-(0X4S
M,68YU@\P]7POSZ\,L%\(JIJ<PJ#S2_\ '^<@;YJM\+E=EJ;Z0(KTI1"N)39T
MYLLN[,C-]5]=S)V=NS:Q-444XQSCW?NX9#<.*'.N>49X1D.3U?04R^T^ T7@
M FG&X?\ \U  WN&SIS8V!WK>.>=H-<8MCM.@XQ/*8KQ)<!9U/KX;2F.G@XMA
MP&WD1P,1%=+4>D3/[SD(^C!XY]06J'#8^1O,D*1>11S"6F846R5N.>A/<1!3
M@<%9G@TO+E,9Y=@<N7H+ <B(630VWP#LO^F.EZ4H<%'5[._G*"G;+M=U=?J^
M(Y?3>/[1/8Q?.7[T ,5YW&VPJ2-,#02VR9;0  6TXMT[D? V-@,M$.<"%:(<
M3.$XH618FH(:N1&*TXP644AHJ]57G%6)(3=ET +!Y,4!'.*.!QKH&[#6KXC8
MK-X<&_U'&*YN@?L#W$/2.?4BZZ!>48,5+6UCS ^?A:'MBUZ:N-3UEC&:&5\U
M]$B85WZCZ$ ^>M$90'HH"WP!DP)LCR">7AMY;)&(_(,/3?\ &K7U*0R!9]57
MO2%5$-R8]94K@TI(& NAES(OM<' +5E&W8(LL9CB](IW!OOWG[G@H%AI D^:
MXF'C"N6=/O7U[O@;O@8$8=:N4!=DH*>A#YP QK18DUZU:H:7-?4FNXLK<S:)
MJ1KK/I*Z5*+OP*=J4N%'IND]UXLGIK1.&-'P11YH$2H9+RUC\&DREAC5*+FJ
M'BRH*A_!VX":D>/!AA)60^$JYV#[1RCG'&K3<OT@K!SXHN4]&69]D&'DBFKP
MM2@]O%<I?+[)[/PSA"\5\"/R2"=UNSG\@TA4#IZJM\HO:);DAZRI7!I20,!=
M#+F1?:X. 6K*-NP198S'%Z3&+195+_B%GRBK$D)NRZ %@\F* CG%' XUT#=A
MK5\1L5F\.#?^3AR / 8,^,Q\9CXS'QF/C,?&8^,Q\9CXS'QF*.!SI^'PNSZ,
M>K4P5:%X;07O(@(G/-> ZD@HL-((O&_@VP5@,XV TZ5M&2IPP%,P!<=7K0X0
M]XUQ]%8E5AC'_@H&X$T7[ ]Q*P5U<D:>IY1:V]>1IYO3U)H*$?+8H<0=1E.X
MP5O SAF64>=R_@!V-<],#S(5)!AT(_49EB"7+ZHZ%O*.R%CZ)^Q\.C:+8:V)
MUG\"Q=,X .Z*^<?.L% M4)[)7ZZ>!([37AYKO'=#ICLKR@U6JRQEW3A.1NSW
M$;0]L6O35QJ>LL8S0ROFOHD3"N_4?0@'SUH_T_TO2E3,30O.A?:"KMVRYX9<
M/$+GDEI=2RR.!4)$N#5QB:<R-C(XX[!KB4HG.7!O"$<L;IDB[R1$ C%M. &=
M.,RHDL]:,C53B,D^VD#@BA]##9/9I/5#S35P@+2BXG->;WN</7@4ZS8*8YPC
M":-OG4+JQ&(ZEDK5.*OBC;&4"A=<,Q@228U;493.7(@6=H+HN$OR[@ M#N$T
M*S3F*V7B@XB@7BEK7G#;I#H10!X ".C6U&/-7D>&87-6(+S/JYE>2!-O'!R3
M=6,2K>"X1K7G71X9QF!\BP'2FSS27_B67"-G QP'K5G)&5#B+,1Q,L4H=\2S
M7*J,QFZ"NVFPP!;A4^MQ?WD[Y +-[@AP[RO+$TU-LH<P7H4(AE$:M\[&QP]Y
M30 !=)G!D1T'OBD1(L!^(=9@C=TPT#@+>OV8F99)[(<(R//6XOEK?6MR0T$/
M+PIH8,YOC)' ?JFG VZX[(X-TOC$0RW^>LUXFCQEMZ,%_GCQ./HP?G4L<"KW
MH%(?(%E)X NN  *XQ2.0PXPG%<3D;0I?<J5GT&0A9C9RAH2"ZX  0:NVJ6EU
M+#&D%"_M!=%PBB43@IZ4'0<(BTX$-KU'':4QUQWQ-@QUC#CA=;G)4>-$SY1'
MER0,15*>5N<<AC%YH?L\&/LX\3)#8P'5#>%*8H9+PGD 7%Y+,7>+U \BG_):
MR1INJH\R5$]:8&1*#D&=XFJSX,A=&F=I9&$&&5J,HVV95(>(O#A'?R$K"FK!
MKRG'% 2'09ING@<UO4D,()YL.AFHG(A1;60P+' I]8JE*8+>T+HN$SER(E'2
M@Z#A'R 6;W!#AWE>6)IJ;90Y@O0H1#*(U;YV-CA[SB@'+$Z:"O;:+%F+5%F'
M$?6</7@4ZS8*8YPC":-OG4+JQ&(ZEDK5.*O\G!"-%.3%;2W_ #_Y+?\ /_DM
M_P _^2W_ #_Y+?\ /_DM_P _^2W_ #_Y+?\ /_DM_P _^2W_ #_Y*J7#!,<<
M>'PNS_QT#<$#5[)0M+!P8S3FHA$>*)Q"BWB+8?YPR&5R*HKH2AP_6/5<'3*S
M4O0@U*<0R#J9<3'K0K0&U8K:ID"B >8&\*4Q@N:LUQ !?N6PN7#<(H"*<LDM
M;H6*Z7%"H75XMC2>*]J3J,I?!31+-V$%P6G[RB.  *N"@/5Z(]$M[1 UP6,"
M\$+N)NH&^>$;;<N44^$ZS%O6D#5O5>5XP14:^U'_ "( (Z-;48\U>1X9A<U8
M@O,^KF5Y($V\<')-U8Q_-T=CJ+-V'#_Q2BBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB[[=P :]O\ U6*S
M]PLG@5AH.$6M&Z\C3RL_KW5I5Q121AXPPQL0)QL,O#HS^42(Y".&=E%*\#AL
M<@_E=/0J9-;0:CUE@VE1K"68U_PG'PNS_P ; 4YA?()E!H,6(^[@"RDT3_XD
MZ,N/A=G_ ,Y0.C+CX79_\Y0.C+BOAG,PKQ# Z;_^ ]]]]]]]]]]]]]]]]]]]
M]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]M94Q0O -Z.N_^0]]
M]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]I_7CM#1G(<[2L6K
M)PC)&M_Z>]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
M]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
M]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]_\K[[[[[[[[[[[
M[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[
M[[[[[[[[[[[[[Z_5'[!L5=Z-OYOA=G_SE Z,N/A=G_SE Z,N/A=G_P RP.C+
MA% V\AG<G]3N3^IW)_4[D_J=R?U.Y/ZG<G]3N3^IW)_4[D_J#M'J/Z\/A=GB
MMVT"GQJQ<0+5.+NEV:T?!=W!Y1J)!E@6#1@M?T./2W,!)IH+WS8$ UHL28Z2
MS3VM3@;7'VZNS5T^GA40=6;UQ%WBH2\;$/S7!X*%:&>4'+P9]0\=PUQ I1NR
MGT\/F_YGS?\ ,XRK]N!\;K^9:\.0.EJ +7_7@9&\9)NA:J(ANG%W2[-:/IX)
M-81&U5="<.8ZJ+1.,DUT=!YHL;;<8E]/)52ZM&</I /Q#)%B)J/AFV.9P>5@
MBA214UKAC^GJL9W\QC3_ .!>C+A2M;>?\ J6C6],8,<U W^CX79XU/%MFAV'
MDLR6/S%ZJP'D<&7><GJ%AT$KFDT(29QK\P-7D1L+N9S5Y 5].,2RJ(PW05YT
M$O\ J@?+NT7K4( I#447;M3:^/AQ]UX?SF^>VR;EA!L%;'3#+; !"<@ZVXJ7
MLO@S2[<6D*+RA_V<QS'Z58ZZ1$"CJ\9&T<O :UV"^AP%9Q;Y3'3+P9IT&OEX
MHFTW^ (XL<?*O!*8]4H(X!N ?9XY,A"%O+PN]!_L\61SJM!.0O0/!F1G(0Y:
MZM-.7AD%RE6NBZ7Y^.E$Y4>7@M%LV5AII_2@#*C7OP=2ZW^=\&_75B(4^<E>
M6%=*)^TP/ @+'$Q=UXD+:X<V"/\ 30ECXLJG4J@U*G,0\P=W&7P!K6@3T?3]
MN7[)I.E+&G@^*=4H)R;F!X*!5H.+"%%,*-/2>S\,)2_+^SQT=SH/0>'*1V&#
M99DA(SH&(4\,+F.(>6TUE\!*7Y?V?3T//ZD#C4SY#^9\A_,^0_F?(?S/D/YG
MR'\SY#^9\A_,^0_F?(?S/D/YGR'\SY#^9\A_,^0_F?(?S/D/YGR'\SY#^9\A
M_,^0_F?(?S/D/YGR'\SY#^9\A_,^0_F?(?S/D/YGR'\SY#^9\A_,^0_F?(?S
M/D/YGR'\SY#^9\A_,^0_F?(?S/D/YGR'\SY#^9\A_,^0_F:7QQ<I8N__ *,X
M2&4@!K2X+W*]G6]MCFRH,3N0(\5PZ.T#*KEI6LI.K_,"]U.@&JL!000=$*&@
M665=O+Z,9D&%9T.3E\/:%&&1(-J?W9P1(/\ 05XK/,F7]_1,OW+[RX*'8'/
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M70/(/><8I2%"P-0'M,*B5493[0KUE1HE5>4G#59^ZA;)$J-(&HNCE+-48?,
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M+FU!B:%*W&_/">. @?,$" 0#B]64B55;_>*CC9_,PP\@U*'2SKF]:!JY>>)
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MH?>B 220&PKXH>!U0T=$0* U,>/_ ++[X #HZG#HGS> M5AWA]<^_@<;Q7:
MH0"RJE],?N^(S$D\*?M<(Y:)) \<P "?=ZP%IHA%7\G$]E]\ PT;Q<3I8\_
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M$B1(D2)$B1(D2)$B1(D2+RM9^M"K5I_-\+L_^<H'1EQ\+L_^<H'1EQ\+L_\
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MSQ0\#V^T--Q3D+'<A-9$+X6LC>OKYL3=*6::#ZN*9VWA1[$&:Y.N?3N#%<H
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M*4[5IX-#X/8U+Y/RB<E67!1]OY^+BZ:WE-L_G:A-&40@T$S?>^1B#J@X2?O
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MGLUO,CGA$J$&0HRM7A!K9@IZ%>D+@*UFNND^:):%>[NOW0/0KP7$990V=86
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M/&-&5R$T-7&6WF,I0L#N+''ZC;C_ &>"]UV&]8?),S'TNKA@F(YT:4%?FRT
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M)<'Y7A-*L^\[QEBME>DC;7F@CMJM<"G \?(C2F[Y$>_'@&=47U;\I="Q\#4
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MRG%O<PY>:(BEL%(U>KZ%'@#75[?JO5I'PP 8,0@<@-BF@Z=P/&%1)YJ;]HY
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M)))))))))))))))))))))))))))))))))))))))))(()!()!)! (!!!)))(
M())))))))))))))))))))))))))))))))))))))))))))(()))!)!)(() !)
M!)!() ()!(()) ()! ((() ())))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))(()!)!!((( )
M )((( ))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))()))))))))))))))))))))!)))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))()
M()))) ) )())))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))) )))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))!)))))))))))))))))))))))))))))))))))))))
M        (              (              (               ))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))
M             (              (              (               )
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))!())))))()) )) )))!))))))))) )))((!))))(())))))))))))
M)))))))))))))))))) )))))))))))))) )))))))))))))) )))))))))))
M))))))))))))))))))))))! )!!))))!))))))))))))))))))))))))))))
M)))))))))))))()!!((  )!(((!)!())))))))))!)))(())))) !)))))))
M))))))))))))))))))))))) )))))))))))))) )))))))))))))) ))))))
M))))))))))))))))))))))))))()))!!))))))))))))))))))))))))))))
M)))))))))))))))))!!!))) ! ((!(!()))))))))))))!)!))()  (!! !
M)))))))))))))))))))))))))))) )))))))))))))) )))))))))))))) )
M)))))))))))))))))))))))))))))))(!())!   )((!())!!!))))))))))
M))))))))))))))))))))))!(!(() ( )!! )( !!))))))))))!)!)(() )!
M)(((!()!))))))))))))))))))))))))) )))))))))))))) )))))))))))
M))) ))))))))))))))))))))))))))))))))(( )! )!!!) !()())()))))
M))))))))))))))))))))))))))))!!)))!) ()!( )))())))))))))!)) (
M(())!(((!( ())))))))(!))))(())!)))!))) )))))))))))))) ))))))
M)))))))) ))))))))))))))))))))))))))))))))((()! !   ()!)(( !(
M)))))))))))))))))))))))))))))))(!))  !(((!( !)( ))))))))))))
M!))! ()((!)!())(())))))))()!(!)( ))(  ))))) )))))))))))))) )
M))))))))))))) ))))))))))))))))))))))))))))))))(( )!! ))) )!)
M((! ()))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))) (()) )(!(  !))(()))))))))!! !)( !)((!!)))) )))))))))))
M))) )))))))))))))) )))))))))))))))))))))))))))))))))(!)! )()
M(()!!!(!( ))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))! )((   !) )!)))) ))))))
M)))))))) )))))))))))))) ))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))) )(!) )! )) )()))) )
M)(!!))))))))) ))(!!))))))()) ))(!!))))))!)))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))) )(!)(())))) )) )(!)(())))( )) )(!)(())))) !)))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M!(( (()( !))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))) )(!!!!! !!)))) )(!!!!! !!( )) )(!!!!!()!)()))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))()))! ()) !)))))))))))))))))))))))))))))))))))))))))))
M))))))))))))) )( )))! (()()) )( )))! (()))) )( )))  ((()!)))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))((()!  ((!)))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))) )())(!!( !)()) )())(!!( !)))) )())(!!)(!)
M(!))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))(!()  (( !!)))))))))))))))))))))))))))))))))
M)))!()))))()))))))))))) )))))))()!)))) )))))))()!)))) ))))))
M) )!)!))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))(()!) !)()!))))))))))))))))))))))))))))
M)))))))))))!! !) )  !! )) )) )))))))))))))) )))))))))))))) )
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))( )))))))))))))))))))))))))))
M))))))))))))))(( (((())!)) ! ) )) )))))))))))))) )))))))))))
M))) ))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))(!))))))))))))))))))))))
M)))))))))))))))))))!) (!))(! !) )(!))) )))))))))))))) ))))))
M)))))))) )))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))) ())()) !! )  )( ))) )))))))))))))) )
M))))))))))))) ))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))) )))))))))))
M))) )))))))))))))) )))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))) ))))))
M)))))))) )))))))))))))) ))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))) )
M))))))))))))) )))))))))))))) )))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))())))))))))))))))))))))))!))))))))))))))))))
M)))())))))))))))))())))))))))))))())))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))()))))))))))))))))))))))())))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))()))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))()))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))())
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M()))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))(!)))))))()!)  ) ) !))))))))(!!)))))))))) ) !)!!))))))))))
M)) ))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))(!!!)))))))))))))))))())))))))))))))))))))
M)))))))(!))) ())) (!!((( )(!()!! ())!()) )))))))((   !(!!())
M!!(! ((!!!(                                     ))))))))))))
M))))))))))))))))))))))))!) (!!()(())) ((((!!!!!)))))))))))))
M))))))))))))()))( )))( ! ) !!)!!)((!!!)!) ()  )))))))))( !!)
M!!))(!!(!)!) !)()))))))))))))))))))))))))))))))))))))!))))))
M))))))))))))))))))))))))) )))())) !) ) ) !! !)( ) !)))))))))
M)))))))))))))))))())) ))))!(  ) ((((!!)()!)!(( (() )))))))(
M( !!  !(()!  () !)()()))))))))))))))))))))))))))))))))))))!)
M))))))))))))))))))))))))))))))!)))!!  ! ())())))!!((!!  ))))
M))))))))))))))))))))))())( ))))!())))) () !((!!)!( ) (()))))
M)))!)())!(!)())()) !!!( !())))))))))))))))))))))))))))))))))
M)))!))))))))))))))))))))))))))))))))))())  )(())()!  !  !!(
M ))))))))))))))))))))))))))()))))))))))))))))))))))) ()))))
M!)))))))))))))))))))))))))))))()))))))))))))))))))))))))))))
M))))))))!)))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))())( )))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))())))))))))))))))))))))))
M)))))))))))))!))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))(()())!)))(!!)(! ))))))
M))))))))))))))))))))))))))))))))))))))))()))))))))))))))))))
M))))))))))))))))))!))))))))))))))))))))))))))))))))))((!))))
M))) !))))()!)))!)()))!)))))))))))!)!))))))() (!(())()   )( )
M))))))))))))))))))))))))))))))))))!))()))))))())))))))))))))
M)))))))))))))))))))))))!))))))))))))))))))))))))))))))) )))(
M!!())(()(!!()!!) ( ( (!  ()) ((( !))!)!  !!))))(! (!)))))! (
M! (()))))))))))))))))))))))))))))) (   (!()!))))))()))))))))
M))))))))))))))))))))))))))))!)))))))))))))))))))))))))))))))
M()))!!)!! !()(  ()!!)  )!!))!)(!!()()!!(( )(  )!))))(!))))))
M))! ( )!!))))))))))))))))))))))))))))))!!  ) )((!))))))())))
M)))))))))))))))))))))))))))))))))!))))))))))))))))))))))))))
M)))))())))) ) ))()( (( !!(!((()) ! )!!)!))!!) ! !!()!))))())
M)))())())!)))))))))))))))))))))))))))))))))())((!)!!  !)))))
M()))))))))))))))))))))))))))))))))))))!)))))))))))))))))))))
M))))))))))))))!()) ) () ( ()((()! ) ()( ()!!!(  )( !!(()!!))
M))(!))))()))))))))))))))))))))))))))))))))))))))) ()())) (!)
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))! ))))))()))
M)))))))()))))))))))))))))))))))))))))))))))))))))))))!))))))
M))))))))))()))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))()))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))())))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))())))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))()))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))())))))())))))))))))))))))))))))))))))
M)())))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))()))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))()))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))())))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))())))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))()))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))(!))))())(( ( )( )
M )!())))))())))))))))))())))!())))))))))))())())))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))()))( ())( ((
M()!!! !)(())())())) )))))))))()!!!())) ) )(()! )()((
M              ))))))))))))))))))))))))))))))))))))))))))))))
M)))(( )))))))!)  (( ))))))))()))!))))))!)!!)) !)))))()))(!))
M)) ))()!( )(!!!()))()!(()!)))))))(((  !(!!) ( !)((! !()())))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))!))((!()!( !)!)!!() ))(!)!)(( )! ())(! ())((()(!))))())
M) )))))) ! (!!))!)()(!( )(((()))))))))) (  !)!!)))!() )((  )
M()))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))())(((!))))))!()!() !  (()((( !! ())) !))(( )! )))
M))())(!)))) ((     )) ))) !    ((((!)))))))(!(  ! !)((()()(!
M! )(!())))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))!))()(( (  ))!( !())!!())!!  !(! )(!( ((!(( !
M!))))))())(()))))))!)))))))))(!)(( (!))))))))))))))) )()))))
M)(!()(!(()()))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))()((((! ))!)!)(())(   (!!((!  ! !(( !
M) (!)!))))))(!))))()))))))))))))))))) )))))))!))))))))))))))
M)))))))))))))))())))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))( (() ())))))))))))))))))))))))))))))))))))
M))))))))))))))))))))()))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))()  () )))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))())))))))(!)))))))())!
M!))))))!()!(((!))))))))))))(! ( ))))!!))))!))(!)))))))))))))
M))))))))))))))))))(!))()))))))()))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))(())!)( !(!(() )(
M ! ())) !)(!) ))( )!))))))))))))()))))())!()(()!())!))))))))
M))))))))))))))))))  () !!)())!)))))())))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))())(((((!( !)!)
M))! (((! )!))!)!(!(( ))! (!))))))))))(!))))())!((! )!) ) )))
M)))))))))))))))))))))))())) )! )()!)))))()))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))()((! )
M!))!) )!) )!!(  )(!(() )!)(()!(!))))))))))(!))))())!((( )!)(
M(!))))))))))))))))))))))))))) (!!!!!!(!))))))(!)))))))))))))
M)))))))))!))))))))))))))))))))))))))))))))))))))))))))))))()
M))  ) !))) ( )!()!)((!!))  )()!)())()))))))))))()))))))))!))
M(() )))))))))))))))))))))))))))))() ( ))! )!))))))()))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))()))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))())
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M()))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))())))))()))))))))))))))))))))))))))))))())))))))))))))))))
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))())))))()))))))))))))))))))))))))))))))()))))))))))))
M))))))))))()))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))()))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))())))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))())))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))()))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))()))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))())))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))()))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))()))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))())))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))())))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))()))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))())))))))((!( !)((
M! )(   ) (!!)))))))))))))))))))))))))))))))))())))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))(
M)))))))) ))))!()))())!))())))))))()))))))))))))(      ))( ))
M! (! ) )) ( ))!)))))))))))))))))))))))))))))))))))()))))))))
M)))))))))))))))))))!))))))))))))))))))))))))))))))))))))))))
M))))() (!)())()) (!  )!()!)()!))!)( !() )!() )!)))))()(! )))
M)) )()   )( ))!(())!!))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))!)))))))))))))))))))))))))))))))))))
M))))) )))))!)))!)) ))(( !!))(! )))(()!)!!!(! ())( !!)))))()!
M ()!))()))) )! !())!())(!)))))))))))))))))))))))))))))))))))
M())))))))))))))))))))))))))))!))))))))))))))))))))))))))))))
M)))))))))))))) !()!) ))()(!())((!))!()( ) ())!) )( )))) !)))
M))((( !())))( ()!)(( !)()!!)(  !))))))))))))))()) !()!))))))
M)))))())))))))))))))))))))))))))))!)))))))))))))))))))))))))
M))))))))))))))))))(!)))!)  )))    )  !) !!! !)) )!)! ()() ))
M())))))(()! )!))))))))))))))(!))))))))))))))))))))))!!()()))
M)!!) )!)))())))))))))))))))))))))))))))!))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))(!))))))))))( !))))))
M))))))))))))()()) ()))))))))))))))))))))))))))))))))))))))!(
M !))! ! ())()))())))))))))))))))))))))))))))!)))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))) ))))))))))))!))
M)))))))))))))))))()!)(!)))))))))))))))))))))))))))))))))))))
M)))((!)))) (  !)))))())))))))))))))))))))))))))))!))))))))))
M)))))))))))))))))))))))))))))))))(!!!)))))))))))))))))()))))
M)))(!((!! ))))))))))))(((!)) )))))))))!))!))))))))))))))))))
M))))))) )!! )!!!)! () )))())))))))))))))))))))))))))))!)))))
M)))))))))))))))))))))))))))))))))))))))!) (!!()(())) ((((!!!
M))))( !( ! !))))!))))))))))(()(()!))!!))  )!) ()))))))))))))
M))))))))))))))))))))))))))))))())))))))))))))))))))))))))))!
M)))))))))))))))))))))))))))))))))))))))) )))())) !) ) ) !! !
M)( )  !  ()(  !)!( !(!))))))))))((  ( )))) )  ())!()))))))))
M)))))))))))))))))))))))))))))))))))())))))))))))))))))))))))
M))))!))))))))))))))))))))))))))))))))))))))))!)))!!  ! ())()
M)))!!((!! !()!((( !!)((!!!!))))))))))()( ( )))) (  (()!!)!))
M))))))))))))))))))))))))))))))))))))))))()))))))))))))))))))
M)))))))))!)))))))))))))))))))))))))))))))))))))))))))())  )(
M())()!  !  !!( ()(() )) !) !!()!))))))))))())!!))))  ))) ()(
M()!))))))))))))))))))))))))))))))))))))))))))(
M              ))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))((    !)))) !
M))))))!)))))))))))))))))))))))))))))))))))))))))))()))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))()))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))())
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M()))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))()))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))())))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))()))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))())))))))))))))))))))))))))))))))))))))())))))))
M)))))))))))))))())))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))/_\0 %1$! 0                  P.#_V@ (
M 0,! 3\0O_\ 2:__Q  5$0$!                  # X/_:  @! @$!/Q"_
M_P!)K__$ "T0 0$  @$# @4#!0$! 0    $1 "$Q05%A$/%Q@9&A\" PP4!0
M8'"Q@-'A_]H " $!  $_$/W7+^@;T:7YNN>)AXF'B8>)AXF'B8>)AXF'B8>)
MAXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'
MB8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)
MAXF'B8>)AXF'B8>)AXF'B82)>!T['_&>)AXF'B8>)AXF'B8>)AXF'B8>)AXF
M'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>
M)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B80'JKKCCQ,/$P\3#Q,/$P\
M3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,
M/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\
M3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,
M/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\
M3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,
M/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P\3#Q,/$P@/577''B8>)AXF'B8
M>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AX
MF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8
M>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AX
MF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8
M>)AXF'B8>)AXF'B8>)AXF'B8>)AXF'B8>)@S45&ON!;_ ,?X<C]U_N-^6[O^
MA_RW=_RS[O\ PZ1^Z_W&_+=W_0_Y;N_Y9]W_ (=(_=?[C?EN[_H?\MW?\L^[
M_P .D?NO]QORW=_T/^6[O^6?=_X=(_=?[C?EN[_6H@6I*/<5ZUX]"RYQ><B+
M^<J/A-,+FYJ-6"KLZ HLX4/Z . 0HBZ0T&CIC#VHJ7H.%+-?'^L >X>HZ .K
ME&<K[H%Z+/P/Z=6R63X3K75Z%@(0'Q$\M:F?D,6/Q*?VE^^-E=X02SO=1X.<
M*V=42B. /</4= '5RC.5]T"]%GX'^V_EN[_EGW?^'2/W7^XWY;N_UT4W# L@
M$4^V&$+M']CA.^M#UFZAZ[ KOC Q:!&1'N(Y=AGGPT7J@T]UZ?\ >&-4$'QF
M3C:JJ'=+<>A!0@Y$>'#*$@D!RP6&*7"',51@ *KZ(0*F <OI76-Q^1R)L?#G
M_>&-4$'QF3C:JJ'=+<>A!0@Y$>'].LYIWUU?W@69>WFQ7Z7\,^Y;OP 3TW2W
M3U*@8843(94*0"P=>''(Q2@>S&WBX:16#$]M-O%]'BI1*$&!94WY,6/@@Y>!
M ;RQ9:Q>T8?"YLB :0O BA\7'DB!53P!C<)44'<@OIGW(-2 #Z%-4A>\ &UP
MJ<R@T/D?9@JYE2'<@IY/3<#*V$J!0J%\X,>QOHX("Z=>,1O>LWM&'XN%5>L/
MFH?-]!&?!36K3@)SSKG 8-ZJ) !RN.,$$<6 @"NOT:  ]-!?RB>5PF^'N!"E
M#P1J+</RA.-U1L#W0]DPC[+O5+>H2/4CUQ62(,5()=7X4<$9\%-:M. G/.N<
M!@WJHD '*XXP01Q8" *Z].6LYO@(KZX@."HGTK<:1L3'L@)Z) 4 JKP!A)<J
M*#N07Y&&(.B@[P&><MCWK0< ,1'A'ICD$0!5<)$FCKN:T\F6TF._Y"?(_P!?
M^6[O^6?=_P!3(GC3< (*Z-IM_3MV[=O$%Q:T&%$&G>'E<[>2A0]6_P"L!BQB
M]H VKV,<M!I5$'A$28(+2F&(LO+C&_+D@#RIR<_T'W7^XWY;N_UT7\]W^J 2
MLJ[(O5P)$$AS ?\ >:Y1%BK9TCMT$YF*(W* /'3:)W1ZKA+G,BF *"]"%X-X
MJ3(Y$:8Y>*[Y'4:\_4CI<=U?&Q)1H?\ ZL*^^$GU++?=,^><:-R4N(>XB'99
M/5+-(D^.H?'*&#T+4)TJ7H)S,41N4 >.FT3NCU7"7.9%, 4%Z$+P;Q4F1R(T
MQR\5WR.H@R@Z+1#N(GKK.<K:PXK?P3=O F]"X3X"&#;6WNB]W#XBG:?@8\Z9
MH;=6Z:%M<.M/436+OX8!U!G0(AT3LBXN.C4D)A#8D+.0FK2:/U)VMW,XCB;#
M%Q;"Q](-'J*XV)E7#D4(HKT+U-'0N.FA;900+D"RIN61V/8&YH8U9.N_7KA:
MJ3%"-.E#P]\2G/5@-.U6A!8@ZU\&$/(M!% 6<P6:<:N/(E*'*P!PC>03A#GV
M('Q4QH)6W:-J[+B$8KTC,V@+M(*4ZE)([Q@3]"CQ3A;X)V<90GEU13B^GN*U
M9GWK.S=?T"BY!14W!"+3IKC2^BI.N_URXZ,5-/\ (CL1'9F^0E@(DY QP+&H
M#'P!\J8GQGP9PFAH(JOP#(XR!I '@%_12Y%^)&=DAXVG*PP4L,C@6(G34Z9U
M%ZW/QM?IQ+).B#O1]/T,? 'RIB?&?!G":&@BJ_ ,CC(&D > 7-4]5D!5H( T
M5;A*-.J$LRPI5@4WLR[-]?!40I@ZM[&2H<P+!UEB*UN\@^D30CH%"]%[E4:-
M[OZF$E QIC QEF*>:P1T&1:EE7#@@=C$ "J8'7$U]@L10G@GDM!G-L4!'Y*:
MHI&+8C,HI29#U/JZP=D[YOPXI!M%MAJ=P1NS_6_EN[_EGW?]3(@+ \6"4A8:
MJ>E,/V\@@CXMMG3#/K:"(OP9Q?2F.5%@**%+!8O]:/G'49D(*;I 4"UWZ5[A
M#O!:V0XY-P30A32W+^@^Z_W&_+=W^NB_GN_U+.(_P"^R8=$HSL*3_KZ8#+H-
MM4^$*?-ATC(T4Q;@Y H@IU__ $R$$)"!@:52WS@U18'5CYU^><+3:J1\EHYU
M(L$UM=\H/@,XRRSK)3XA<-1U(;JJ\5?$X#+H-M4^$*?-ATC(T4Q;@Y H@IU_
M_3(00D(&!I5+?.#5%@=6/G7Y^NLX+,C/;$=[43R[X,GT<TO=P4G%KH>FSKE5
M(Z=H'8!P&$03L;A'ZOY>B[V"EB #T1 ]$,YPLBFMCO9%?APQ*7.@5]+\_1T^
M]^X' >B-GD]&9B&KT$/D0^6-+@ETX5.X)^/&],M.RWS$>A(GY-1L^2$\AD:A
M4&U*-$0WQBY$:K5^^"5$;!1%KD_#AU* G88?G]'GWK,Z@3Y5D>C%'IZ"^8UU
M,#Q2^;$0:,^&O_#]='<!":<>0ONEPB=<?6(!@^5)?@?@9,,96CVYC\%@F1Y*
M18^B)@^!%@#0]*DZ&$('K1W2(5NYTOL]HW"*1M$('R)K?G#OE6R:ZXR,6EPC
M%1$\80E3.$ _=Z49GZR0? AX,FU4J17_ !3YQZ>@)P44;5X=/GA,C2S!9HN(
M@_76D=]5<H>>"TD6A%\L'^O4Y$?1?/\ KORW=_RS[O\ KY$YBY"QCS6-%U2
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MPX3TNY#VD^YE1V]<[FZ!1$$[7:7."1K5(A& 8B=ST\;*@TE5KEE8!. X'H^
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M[Q("UU0P^;?R9R(B#G3_ "&#C'Z.MGSZK]Y]U_:JTC\CV8![=L7H<*"O)7L
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M5=!613I-A,FS!2"$T..!'H@[X4ND4F=0F7D?B'&&PULKZT/*7>%Y8'6:J_L
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M+ _!"%^ 7S/07-GP'""(^3%1Q_\ ^ [>;EI+!M)4*L#G/M4@T$'(/K2E^O\
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M)=0#U_IGW7^XWY;N_P!Q.Z>;,\<TWJMAS,G9QH]02(A*5 4F]IBF,,4@*>8
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MK](D.\P_)AD"A5K5HU"=CXZZ1H)R"B(AR<Y$%R2"R;Y3'B&"7R",1B6<*'8
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M,'*@0)L36$&8T5QK@(--QWM=,CR@9Y$^ASK&5[&B!D&LKOSTXQI5D ." KL
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M_O\ S1AW28ZJQ$/*F2TZB:7&6)T]GH0)*(O5YSK'5ZUZJIXT#5Q."-'=*_\
M3%XB+0FO+0DB.PA@$OJ+ I4 AU0':&6%4>D2D"@A H!*PL^[H:J3J0E'&@+#
M&%$PKZRH7@N\XS>H!\_ FSX9JNM/4C\E_$6;SAUBTF/.GK)G0,X_W9@]4'G.
M@X :DBJJD[JE(]O4/U.C*B-:#63&/'G%"$[IG3).\@8>7$8*K*\S L=$>RA]
MG]\$CV]LFBP-K]V,"^C]0T-7 P1.)-5HNQN0!'?H)YA-014$*M7EWANU&^ZU
M-<>B2.\>TR;%Q"Z  T-\BJM>P]H%"J 6P.,:P9*VU4 W:NFJ*KACQ?=?:/-)
MN*""B]X(H=0&JD&N_I6BWQ8;J(HGG'09GRR=,.3'=O-E!Q3""@*NQV*-%$&V
M!$':2^"K "6A(;" 4W.FY=^K#3>JQB,,T1;7>'F.DH!H@!11+T<XJX!H2,0>
M1;=X/-=9< O(-Y<;P\_J7X+0?@#QA JE=FJH+E7;5JKA)JL[.(^WIMPB88^B
MIJ :   .)F[ KCE$H*L:5JF@AVPJ- 41G N$1F2&6#T0I%+;0/F!JM! BEP,
M*A4*H1K >V?_ %TZ_3D/^3?43<A6 !6!6LK_ *IO4FN3EMU( <!,Y%%?"H "
MJ@E*Q*V4NEL#L$$UN_.;_I!-%RPE"'==XLUZS8$0;  -B"<9O&?FKD& U'S@
M&JT$"*7 PJ%0JA&L![9_]=.OTY#_ )-]1-R%8 %8%;_I0O<N<OAU,DZ(.4&=
M.9Z=--0Q;KC9Z@5J_EA=WDY2E$*!$\S)$2<1B\\='MSE3P=TW0%#U!C49%YD
MO!$*(J%0 "ZUT*,@?:R\B@3&'3A/&P09.:-[&4YPDU[' $IW%@"PO$QL%0""
M04()$]J(A@G"@#CAQA^I,[+NTV0J3D#'!R!P!-4DI(H6P<0N [.U%G 5@JRO
MIUP:_?4* 5 7:&<A82,6!:,6ZXV>LL_^BWH1AC$'DPX'!0'!(]50=QWA1W8H
M\OA:G/@MP',3QH*X")-M-Y>V;G)Q"AU6NS%M+@7=.Y.AT"!HY)NSYP3((6PK
MKTHQAWP7Z!T2;CG6D9U6@"H*H=W.%9!5=038D4<.7(V+M0@"T5(41( :-=F^
MET/5+,-U$F[FP"LB@4U  4!A^>3J %L*ZR'=X.4.B)0%!1B$U::P:F[3; KW
M.)ZD%K1A(P: X &#]#G#Y?  ^60$=[ZL,X$85< <8[!HLFRMJP$'280C]R@0
M=B3:#Y-R5*R1 ;0H4,1*:?W5^0[?JK]L&T@ ]2F+Q"A .7%@%C5I-OA/[2P%
MS.MM\UHBZV$*E7222MP&M$*.[J:)H47FA& <$H2MLFH6O=VT F%"PL_;7"\N
MW+\9V ,'@AWFH5HBI316:UDQSVHXD!@@W;47 O E-F_+ ?[P!%[ESC$"V&DB
M(BT%-?X!^0[?JL6*K@<8^O)U/99NYB,MJU_\U, 1>Y<_(=LZOMED:GE@;7*M
M/LY^$?QGXA_&*AM7B["YO:_;F;\'DHV?;+?G"G=4S\0_C'Y3R$'VPV&$-1*;
M4QMO"B@'"$X[?I8.'@6'Y(=3NNO8^?8^24J&!LO5M.'-Z3&BBY'"^;.*^.4H
M4F4X*<&%T5G4F#O1^%Z>[G#2*?)/9Q))'(+L)$?0,LO+/8^?8^9PDJJB)L7
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M]OGUL/2^&$\@M&Q&\DY!1(8(27M'!:SU=7C')O**<O ;4-YM_)1>_#\L F;
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M"8 JM H(+@ R#T\H?J-MFNR';7@("@!;U1F*"O3ZY\C0IT&>G_[?. =A6HJ
M3I $-!,/"$+CUC3%3Q'2X"8B<;QC></Y6U1E&[QE'(#?U ^FZ]]9(22/]UZ!
M";##[%1*:!5OT ZC /N7H.Q'J?M_D.WK3@$2CT<155Y1,.6_ 1#^<M.DB:L4
M)PTYXR!C&)AV2$#IU^6:"0-!0*_-K^C[5_S]HP:F<5.A3$!8Z$3D@<W-70T"
MF.=!=$ 7H(?C.W%"SZPA4G+!1)BX;8H]23:JH3'#P<J?+2A\+#G::>AQQFBA
MS4D !4E!U,.>!X0' '2)3&);V^JWVG][D$68TF=8 \JC5^&5LZS3'J(T+1&1
MPD<44S"69[1P6LQ"P00Q5'0 57$/#OR&/S<EN13!?;=PX:ZX$2Z!<1( 55@&
M,:U4@:0"^,I@FOV[&!D7 ;W15!6"X/RZT.I!! :=4%F<?#IPS!SM\@HRKND2
M[AK4WAT,)&0,+X%">ECR"8B$I.SOJ_[B!-68@,8D(QTB(HBB9U3=R5 '&T:M
MUD8JA6'<1\XOSQP1($:00.E 8CPBL!H5!9?CW9O'5XQR;RBG+P&U#>;?R47O
MP_+ )FP$14MEC!5&+&?Z7+W+AJSOMP$?'3UO@Q5D0RNEY-SO';]7Y7O@FFDE
MY@^@O/P8!0<:'LJ[\ 8SJ^+X5=,1-B;$^^QI@V1Q4CD;,&@P#.1IGX!I (M-
M5@C+PJ)A.!HUV$;@M?=,B:6P!-+RJ[8,J.$$BX*1O!P!"5T[WD(=^>#N4MS6
MPB+@W1&.,";8D  "I35H;61^.*<!I*5T7$5[W6\44!^:AQ;;.5S4Q:1;IHA"
M',O64 +W(G0?3]-=I]OG;_&%8P\PAM$<&:1/6<!W$+FHR(41!ZBEM.U75Y2^
M@3QJH>?P""\CEJ'O<W0)IG9B=, 6N.&8I(_Z!ZC_ ,%W>B(K_0A--L\1IH\X
M3XJ1#I#4#F-UT<8@%.##H:/C"N=#Y Z]T'SR4VKE+9(JC)H[D5U=FCYVHC!B
M41%':/4G7OC(:J]<1^_;&(_DX+6I;?0@$2 :.D"=,FZZK\*ZBL*JNL)+&%#H
M]$YWG$)==RZ#1OTHPRNN'/IXHNEQ;,BA2#(=1"B")A7@3@HOFKYX "%J2?T,
M&!RS63!&>\I:^FLXP&[Q20#@0%2V'P<]APN &K5!R*$; A<%!!;MU@%Q404R
MC$8+4@ $T&?@^WH1KD&@$AFUB(HC@QE F8$0&J4V<.6<_)&5#76"OEP?ALD
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MG80/8J-*FV>D$TV^@"-9$J\Q?"4-(S#L_ C(%>H3EA;R[^I$T& 55J$0G%J
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M[/@R<1VF_9C0TE;*U%)I.DHCL PJH [D6@YIE6W38A;0PO=^!- 35J0%%#U
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M[&>2+WI>KGV>9#"2X  'TP7$$^,18>$  E:A!I:$.\O/$/>8L-S02JV$.-!
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M"C>! =DE!2Y$3DP#>37D%)H:DL2*/SA#X1G9"I4=!&#':ODB*P=!HX5N!O\
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MZ0H]G]M,F3)DR9,F3)H8U DP""M>+O\ 6P'OOPO;D]]3)D I GR]!">T8S5
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MN?\ R';_ ,Y6 (N?_(=O_.5@"+G_ ,AV_P#.5@"+G_R';_SE8 BY_P#(=O\
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MJ>G(JCR$]'\T@0.2Y7@KCX()!T)L-\IZ&"TR$WNL'S<C=!<](L"\5Z.QDYP
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MSMJZ_5^5[X='4.58B\/G7G!A13P3$?6&"A]UD$? H+.T\??8@Z-WD H B4J
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M%T:(?1=&A6X6V0F0-$]F[PU(B%%DP(4#(S,#@:+C:91:<3%]8HPQH D,:!J
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MV"!% B^)'2_/_JP65TV@H$!@*P0H(*>NK[1F&/E6/Y(=WLFZ*"-0%_,^7CU
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M0Z4([K:0:. Y-AQAD*<%V#D#5SC:GF@IQ3X$DWA#3"N'_P!(^9SKT)JIJ/
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ML%0""04()$]J(A@G"@#CAQA^I,[+NTV0J3D#'!R!P!-4DI(H6P<0N [.U%G
M5@JROIUP:_?4* 5 7:&<A82,6!:,6ZXV>LL_^BWH1AC$'DPX'!0'!(]50=QW
MA1W8H\OA:G/@MP',3QH*X")-M-Y>V;G)Q"AU6NS%M+@7=.Y.AT"!HY)NSYP3
M((6PKKTHQAWP7Z!T2;CG6D9U6@"H*H=W.%9!5=038D4<.7(V+M0@"T5(41(
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3>S<]FY[-S4FTJS7_ )S[_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ast5phase1results.jpg
<TEXT>
begin 644 ast5phase1results.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9#!^P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;ITS7D'[2_P"T
MAX<_9G^']SXAUV7-PRLME;?\]Y>RUZ\S;:^1?^"B7[+OBC]J/P/H&C^%I+>*
MZLKHS.UP<+@C%2]QGY;_ +4'_!0'Q]^T<SV9GDT'09$VRZ=;/\K_ %-?,]MH
M]_>%?(L;B;=T\N)FS^0K]=_@;_P1[\+Z7H<,WQ%O9;S6E8-Y=G)^Z_G7VSX)
M_9U^'O@/1+;2[#PQI\D<(P)9K=6<_4D50C\+O!O_  3_ /C?X\\.VNMZ1X0E
MFT^Y&Z-W;:2/IBNNTG_@EW\=;Z-FNO#GV,@\*S9S^E?O/9VMOI]LEM:PI;P1
MC"1QKM51Z 5-SVI@?A#_ ,.KOC7N'_$H&/6LW5_^"7_QWT^51:>&3>HPY96Q
MC]*_?#)_"CGO2 _G7^(7["WQF^&.BC5=>\)3069;9NC)<Y^F*\3U#PWJNDW$
MD5WIUU;R1_>#PL,?I7]1>H:=::M;FVO;:.[@)R8YD#+^1KB_%'P)\!^+M)OM
M/OO#&FF.ZC*/(EL@<9[@XH _$;]FG_@H?\0_@7K%A%J.H3>(?#MO&(%T^X?(
MC3IQ]!7[4? /X^>'?VA/ ]IXAT&7>KJ/-C_N-W%?''QD_P""/O@G5/#E_-X%
MO+BSU]V+Q+=2?N>>V,U[A^P5^SIXC_9I^'4WAKQ+);S7C2M()+<Y4@GUIHEG
MU*N>>:4?6F_RH7O2D4MAS<CTIO\ #R,TO/X5XO\ M!_M7>!/V>?"=]J^LZI!
M<WD!\M=/MY TQ<]!M^N*3V&:_P"T1\?-!_9X^'.H>)-8GC\Z.)C:VK'F:0#A
M:_G?^,GQ(G^,'Q,U[Q?<P?99M5N#.T(.0F>PKTG]JO\ :\\4_M/>)I)]2E,&
MCPR'[+:+P O8D>M>!GBE'<9W7P+CW?&/P<I)_P"0E#T./XJ_IATK_D%V?_7%
M/_017\S_ ,!_^2R>#O\ L)0_^A5_2_IN?[+L\=?)3_T$5O-62(+?>BF\X'K6
M!X\\86WP_P#!.L^([Q2]KIMNUQ(J]2!6 SQ/]L+]LGPW^ROX/>:66*_\3W*'
M[%IH8$N?4\\5^-OQ._;P^+GQ&U759#XHO-.TR^W(;"!\($/5:XC]I#XN7'QL
M^+FO^)GNKB>RNKAFM8IV)$2'^$#L*\YTZQEU:_M[*V0O<7$@B11W).!313*[
M$NQ9V)9CDDG)-(N58,I(8'((/2OT*^"/_!)#QAXNT6/5_%-W#86]U$'@@5L.
M,]V%5/CU_P $F?&?@339]:\,74.HZ;:P&2>%FW2<<DCVIDGSM\(OVT?BE\(M
M2T8V/B6\N-'T^57.FR/F.11U4U^VG[)G[6GAK]J3P1'J>GRQVFMP "]T[<-T
M;'T]17\[=Y:R6-U/;3H4FA<QNI[$'!KUG]ECXY:G\ _B]HOB&TN)DM5F5;BW
M1CME4D#YAWJHZA+0_I%Z\=Z0C;T&365X1UP>)_"VE:NJ[1?6T<^/]Y0:UN0?
M:I!'Q5_P4]_:"U+X1?"6.Q\-ZO)I'B*ZE5TFB.'" \XK\G_^&V_C;_T4#5/^
M^Q_A7U=_P6BU2;_A:OA>Q#GR?L7F%<]^/\:_.$>IJ8E,]Q_X;:^-O_10-4_[
M[% _;;^-O_0_ZH?^!BO#V(/2D+5;)Z'N/_#;7QMQ_P E U3_ +['^%?4G_!.
M#]IGXG_$S]I;2M&\2>+;S5=*>"1I+:X;()&,5^=7''K7V-_P2ED5?VM-'4L
MS6TF!Z]*J&X'[P=Z!WH_BH'>LT M%%%, HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $;.WBF+QQ^M/-)D9Q0 WEACH?6E]LTI(X%*: $P,8[4W=CD"G9KC_ (K?
M%'1/@[X*OO$VOS^186JDEO5L' I-V0SL.>I--W+G[Z\^]?C7\:O^"O'C/Q-#
MKVA>&--M;'3+E6A@U '$RK_>%?'J?M,_%2.17'CO625.1FX.*8/1V/Z6,'/7
MBDW<GCCUK\7OAO\ \%@/B%X;@T;2]7TJSU"QMRD5Q<OS*R @%NG7%?K)\%/C
M5X;^.W@33_$_AN\CN+:ZC#-%N&^-NX([4Q'?>_2D;C'&:=UYHQ4@'K3-I*]<
M&G,VVDW=/2A@?"/_  5#_:?\9?L]Z#X;M_!UZVG7>I,P>X S@#/^%?C3XT\=
M:]\0M<N=7U_4IM0OKAM\C2.2,_3M7Z<?\%LI$%KX#3/SEWX_ U^?_P "_P!F
M7QU\?/%5KHWA_2+@++AVNIXV2,)GD@D8/&:42F<!X>\'ZQXJ6];2;&6\2SC\
MV=HUR$7U)K(VX!%?N;IO['?A;]F+]D[QS!:0+>ZY-I#O<WDBY;?CD ^G-?AC
MGK]:M^1&IW?P(_Y+)X._["4/_H5?TOZ:Q&F68 _Y8I_Z"*_F@^ __)9/!W_8
M2A_]"K^F'2^=+M/^N*?^@BM);("8-\W7FO'/VM$\07WP-\2Z3X9TE]7U'4K5
M[=84ZC(KV7:,Y[TH7%8,H_G4?]A3XXPJS-X!U *H+'Y1TKU+_@FG\&=,\7_M
M1/HOC#27>;2(FG%O*N/+E0GK7[LURVC?"_PEX<\07&MZ7X?L;'5[C/FWD,06
M1\]<FJ1+V.GC588U1%"HHP%'0 4RXMX[RWEMYE#Q2J4=3T((P13R/S%9OB;7
MK;PSX?U#5+N>*VAM8'E,DS!5R%)QD_2D,_ ?_@HA\/\ 2/AM^TUKVEZ+"+>T
M;$Q5>FYB<U\W:>Q34K5_25"/S%>K?M7?&*;XX?&S7_$DR*@:9H4V]"JL1FO+
MM%A>YUFPB52[-.@"KSGYA2IW25RI[G]'O[+&O3^(O@=X8GN,EX[2.,'V"\5Z
MUG@G-<'\"=%AT'X0^%+6%-@_L^%F'N5!-=M=3):VLTSMM1$+$GM@5<WJV9Q6
MB1^#7_!3+XG'XA?M 7<._>-,W6X]N?\ ZU?,OP_\.-XN\;:+HP&3?7*P_F:Z
MS]I:^-]\>_',V_S5;4Y=IZ\9JE\ ]=L?"_QD\):QJ;;=.L;])IV]$&<U,%:Q
MI-W>A^U7P]_X)N_!-?!.CC6/"$=UJ?V=3<3,V"S$9KHO^';_ , /^A(@_P"^
M_P#ZU<%KG_!6+X*Z2Q@LKFZNV3Y?ECPHJII?_!7+X.7$Q6]>\MX\<,L9/Z53
MU9$=K'I'_#N#X 9_Y$F'/^__ /6KKOAA^QK\)O@[XHB\1>%/#$6F:M$I5)U;
M) /6MWX,_M(> _CKH4&I^&-:@E68X6WF=4ES_NYKT[=\V#1L,=_%0:3-'7BI
M\@%6EI.G I"WI3 =124W=0 ^BF[N_:G4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $SCKTHW?E2?3I2XH ,\T9/-)M.<@TN
M*  4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\"_9A_8S\#?LMZ;=0Z!$VH7]Q+YAU"[4&91C[H/I7OM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* &\]1TKP/\ ;G8_\,S^*R/^>8_D:]\]:\$_;F_Y-H\5_P#7(?R- '\]6D?\
MC1;9Y_TD?^A5_1M^RH-OP'\+XY'V<?R%?SD:3_R-%M_U]#_T*OZ-_P!E0?\
M%A_"W_7LO\A0!ZTO;/6G444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%)10 M)03BCG/2D ;:*3>*6F M%%(S!>30 M%-W?G3J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #>YKP3]N;_DVCQ7_ -<A_(U[WW->"?MS?\FT>*_^N0_D: /YZ=)_
MY&BV_P"OH?\ H5?T<?LJ_P#)!_"O_7LO\A7\X^D_\C1;?]?0_P#0J_HX_95_
MY(/X5_Z]E_D* /6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPC_V$6_D* /A?_@FA_R>%X+_ -Y_Z5_0)7\_?_!-#_D\+P7_ +S_ -*_H$H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ;W->"?MS?\FT>*_^N0_D:][[FO!/VYO^3:/%?_7(?R- '\].
MD_\ (T6W_7T/_0J_HX_95_Y(/X5_Z]E_D*_G'TG_ )&BV_Z^A_Z%7]''[*O_
M "0?PK_U[+_(4 >MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*_\ 7LO\A0!ZW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?(W_  4N^$WB+XQ? >+1O#-D]]?K>++Y48R<#%?7%)R&
M]O6D,_GM7_@GS\8^,^&K@?\  #2_\.^?C%V\-W'_ 'P:_H1R:JWFL6.GL%NK
MZVMF])I50_J: /Y^!_P3Y^,FW(\-W'_?)I?^'>_QCXSX:N/^^#7[_P#_  E&
MC]?[6L<?]?*?XU/:ZS87[[+6^MKE_P"[#*K']#3$?S[2_P#!/OXR1QLP\,W#
M$#H$-?LG^PGX!UCX8_LT^&/#VO6S6FIVH821/U'2OH#FC&[KUH$.HI!P*6@8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7YQ_\%I_^20^$?^PBW\A7Z.5^<?\ P6G_ .20^$?^PBW\
MA0!\+_\ !-#_ )/"\%_[S_TK^@2OY^_^":'_ ">%X+_WG_I7] E !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !7YQ_\ !:?_ ))#X1_["+?R%?HY7YQ_\%I_^20^$?\
ML(M_(4 ?"_\ P30_Y/"\%_[S_P!*_H$K^?O_ ()H?\GA>"_]Y_Z5_0)0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 WN:\$_;F_Y-H\5_]<A_(U[WW->"?MS?\FT>*_\ KD/Y&@#^>G2?
M^1HMO^OH?^A5_1Q^RK_R0?PK_P!>R_R%?SCZ3_R-%M_U]#_T*OZ./V5?^2#^
M%?\ KV7^0H ];HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *3^*EI/XJ3 *^$O^"PD[0_LTV@5BN[44!QWZ5]VU\._P#!731+
MW6OV:X196[7!AOUD<(,[5&,FD]AK<_)#]EWP'IWQ-^/'A#PUJQ(T^^O%27'I
MUK^CGPGX9L_!?AO3M"TY-EC8PK!$/]D5_-G\ _B9%\'/B[X<\7SVQNX]*N1,
MT ZMCM7]$OP3^-7ASX\>!;'Q-X;O([F"9%,T*MEH'(Y1O>K6PGN=XJ[<C.16
M7XJT>P\0>&]1L-2M(KZRE@<203+E6&#U%:H4ALYXKA/C5\6- ^#W@/4]<U^\
MCMH$A8(C, 7.#P*CH4MS^<KXTZ9#HOQ8\5V5O&L4$6H2JD:]%7=P!7[1?\$K
M?$SZI^S?IFF$?N[,?+^-?B?\3=>C\5?$#Q#J\/\ J;R]DF3_ '2W%?N'_P $
MN_#D6E_LM:!J*_?O02>/3%7#X=2)?%H?7M+2#I2TAA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G'
M_P %I_\ DD/A'_L(M_(5^CE?G'_P6G_Y)#X1_P"PBW\A0!\+_P#!-#_D\+P7
M_O/_ $K^@2OY^_\ @FA_R>%X+_WG_I7] E !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #>YKP3]N;_DVC
MQ7_UR'\C7O?<UX)^W-_R;1XK_P"N0_D: /YZ=)_Y&BV_Z^A_Z%7]''[*O_)!
M_"O_ %[+_(5_./I/_(T6W_7T/_0J_HX_95_Y(/X5_P"O9?Y"@#UNBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#1F@!#U%<
ME\4O!-K\1/ >M:#=6Z7'VRVDCC#C(#%3@UUN[GI0WKBA[#1_,]\>_@_K'P0^
M)FL^%]8MI(9;:9MCLI"NI)Q@]Z@^'/QT\=?"=!'X6\27VDVIF6>2W@DPDC Y
MY%?O?^T]^Q[X)_:>T>)=<LU@U:U5C;7D("ON(X#$=17Y>?%3_@DS\3/ \=]?
MZ9<VVKV*%GBCA&9-O8'GK26P,V;S_@L-\1+KPO\ V6NBV<4_V<0_;%;Y\@8W
M=.M?('Q(_:!\??%9ID\2^)+W4+61RPM9),QKST J=_V;?BBLQB/@?6"P;;Q;
M'&<XKZ3^$?\ P2C^*'Q)T>UU:\N+70[9V7?!= B3;WQSUQ3$?.G[./P1U_X[
M?$[2= T6P:ZC\]'N7VG8D88;LGZ5_1/\+/AWIWPK\!Z5X9TJ)8;2RB"A5Z9P
M,UY[^S1^R?X,_9G\.QVF@V@?4I$'VF\D&79\?-@^F:]MX[]:I[60NMQPI:2E
MJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?G'_P6G_Y)#X1_["+?R%?HY7YQ_P#!:?\ Y)#X1_["
M+?R% 'PO_P $T/\ D\+P7_O/_2OZ!*_G[_X)H?\ )X7@O_>?^E?T"4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 -[FO!/VYO^3:/%?\ UR'\C7O?<UX)^W-_R;1XK_ZY#^1H _GITG_D
M:+;_ *^A_P"A5_1Q^RK_ ,D'\*_]>R_R%?SCZ3_R-%M_U]#_ -"K^CC]E7_D
M@_A7_KV7^0H ];HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 1NG3-122QQ*#(ZI_O$"I6.*_/W_@K_P"+]=\'_"GPQ=:%K%UI
M$SWQ5VM9"A<8'!(I-V&E<^^OMMKD 7,/TWC_ !J1Y4C4,\BHO]YB *_FM\*_
M'#XB7'B32T/C/6,-<Q@YNF(QN'O7ZM?\%$_%VN^'?V+_  EJ6EZQ=:=J+BV\
MRYMW*N^47.3[U<HN,5(E.\N4^]#?6I_Y>8?^^Q2_;K7&/M,)_P"!C_&OYG5^
M.WQ%[>--9_\  M_\:3_A?'Q%SC_A,]9_\"W_ ,:D9_2_]JL<\RV__?2T\7UJ
MO N(0/9Q7\SG_"^/B+C_ )'/6?\ P+;_ !H_X7Q\1/\ H=-9_P# M_\ &@#^
MF/[=:][F'_OL?XU*DD<@#HRN.S*<BOYE_P#A?'Q$Q_R.>L_^!;?XU^ZG_!.G
M6]2\1?LH^$K[5;Z;4;V0-NN)VW.W3J: /IBBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSC_X
M+3_\DA\(_P#81;^0K]'*_./_ (+3_P#)(?"/_81;^0H ^%_^":'_ ">%X+_W
MG_I7] E?S]_\$T/^3PO!?^\_]*_H$H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;W->"?MS?\FT>*_\
MKD/Y&O>^YKP3]N;_ )-H\5_]<A_(T ?STZ3_ ,C1;?\ 7T/_ $*OZ./V5?\
MD@_A7_KV7^0K^<?2?^1HMO\ KZ'_ *%7]''[*O\ R0?PK_U[+_(4 >MT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:^8_P!N
M;]DJ_P#VM/!NC:+8:Q'HSV%R9S)*NX-QTKZ<;I1CWI-7&G8_)C1_^"+GB+3=
M6L[IO'-HRPS)(0L1!."#7V=^U-^R;??M!? /0_A]:ZRFFW&G>3FZ<$A]B@=/
M?%?3&?QI<C%6Y-KE)2L[GY&?\.3_ !)_T/5E_P!^32_\.3O$?&/'5G_WY-?K
MCMR<YI&SUSSZ5(S\C_\ AR?XC_Z'JR_[\FE_X<G^(N<^.K/_ +\FOUNDD2WC
M9Y7"(HRSN< ?4UF+XKT0'_D-:><_]/2?XT ?E$/^")_B3G_BNK(?]L37Z,?L
MK_!2X_9[^"^B>"+J_74IK -FX48#9Q_A7K$<J31K)$ZR(PR&4Y!^AI=HX.:
M'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5^<?_!:?_DD/A'_ +"+?R%?HY7YQ_\ !:?_ ))#
MX1_["+?R% 'PO_P30_Y/"\%_[S_TK^@2OY^_^":'_)X7@O\ WG_I7] E !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $-(>E.HH 945U=16<$L\\BPP1*7>1C@*HZDU/7S!_P4
M0^-5S\%?V>]2O;6,O-J1-B,'&-PQ_6D]AK5GRW^VM_P5*OO"/BQ?"_PHGB:2
MPE*WNH.N^.3KPGZ5]_? +QS/X_\ @WX8\1ZA.DE]>62S73J> ^"37\U^EZ5?
M>*M;CL[&%[F^NY<1QCEF8FOVV_8S?QA\'_V3]?/Q/A;11!;R"R,IY*&-PO\
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M%6)BK2;9\2!6F; !9V/3N:_HI_89T==&_9A\$1FW6"9[-6D&,$GWK\%?V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 WN:\$_;F_Y-H\5_P#7
M(?R->]]S7@G[<W_)M'BO_KD/Y&@#^>G2?^1HMO\ KZ'_ *%7]''[*O\ R0?P
MK_U[+_(5_./I/_(T6W_7T/\ T*OZ./V5?^2#^%?^O9?Y"@#UNBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>3LI$:Q _,,],\&OZ&OASX&TSX:^#=-\.Z5"MO9V40144<9QS7._!/\ 9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^PBW\A0!\+_ /!-#_D\+P7_ +S_ -*_H$K^?O\ X)H?\GA>"_\ >?\ I7]
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ11YTN?[Q[T >G+^5+24M !1110 4444 %%%% !1110 4444 %%%% !1110
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M%I_^20^$?^PBW\A0!\+_ /!-#_D\+P7_ +S_ -*_H$K^?O\ X)H?\GA>"_\
M>?\ I7] E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #>YKP3]N;_ )-H\5_]<A_(U[WW->"?MS?\FT>*
M_P#KD/Y&@#^>G2?^1HMO^OH?^A5_1Q^RK_R0?PK_ ->R_P A7\X^D_\ (T6W
M_7T/_0J_HX_95_Y(/X5_Z]E_D* /6Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^'_ /@KA_R;8G_7W_05^.OP
M'_Y*UX<_Z^E_G7[%?\%</^3;$_Z^_P"@K\=?@/\ \E:\.?\ 7TO\Z /Z2_ 7
M_(EZ+_UZQ_RK?K \!?\ (EZ+_P!>L?\ *M^@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** $/2C^&BEH 0#%>7_M&?";3/C1\*=;T#4+?[0YMW>W7TD
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M^0K]'*_./_@M/_R2'PC_ -A%OY"@#X7_ .":'_)X7@O_ 'G_ *5_0)7\_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "4M(:,\4 &*;_%TYIP.:\X_:"^*EC\'?A9KG
MB"[NULY8[=Q;,W>3'RTOA0UJ>?\ [47[:_@7]F"UAAUBX-[K%R&$=G;$,Z''
M!<#H*_-#QG_P5X^*VM7&JVVF6]A::;<;XH3LQ(J'@'..N*^._BC\2-<^+'CC
M5/$>OWLE_?WDS,78D@#/  KUOX7_ +"_Q2^(UFNIMX?N=,T-K1KM+Z9<*R@9
MX_(T>8$7[._QD\<Z]^T)X,6\\5:I+'=:NC2QM<L4;))(QGI7[)?MR_M,7W[-
M?PIEU?15AEUV3'D1SC*D9YK\1_V<;!M+_::\&V3G<UMK:PD^I5B/Z5^DO_!7
MGX?>.O'-IX9/AK1KC4M'MH7:]D@&0A!)&:F5[IE15STG]B?_ (*-:'^T)Y'A
MKQ2T6D^,!&9"3A(9?92>]?;7WN:_EU\-ZY?>!O%ECJ=NTEO>Z?<+)A3M8,K<
MBOZ*/V2/BU<?&[X"^&_%EU'Y5S=1;77W4 9K7S,WV9[(*6D7I2U(PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OSC_ ."T_P#R2'PC_P!A%OY"OT<K\X_^"T__ "2'PC_V$6_D* /A
M?_@FA_R>%X+_ -Y_Z5_0)7\_?_!-#_D\+P7_ +S_ -*_H$H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:.U%)U^E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:]XDU/Q/?M>:K>S7URW5Y6)K[CE_X(Y_&%9G$>HZ08PQVEI>2.W>OISX8?\
M!'7P%;^$=+;QG?WD_B%5#70M9/W1;T'/2F(_.C]DO]F/Q'^T!\2-,MK73)9-
M&MYEENY70A3&#D@'O7]!O@;P;IG@#PKI^A:1:K9V-I$J)$G0' S5+X=_"_PW
M\+]!M=*\.Z7;V$-O$(A)'& [@=R>]=3C=UZU72PNMQXZ4M)2U(PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?#_\ P5P_Y-L3_K[_ *"OQU^ _P#R5KPY_P!?2_SK]BO^"N'_
M ";8G_7W_05^.OP'_P"2M>'/^OI?YT ?TE^ O^1+T7_KUC_E6_6!X"_Y$O1?
M^O6/^5;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #>YKP3]N;_DV
MCQ7_ -<A_(U[WW->"?MS?\FT>*_^N0_D: /YZ=)_Y&BV_P"OH?\ H5?T<?LJ
M_P#)!_"O_7LO\A7\X^D_\C1;?]?0_P#0J_HX_95_Y(/X5_Z]E_D* /6Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^'_\ @KA_R;8G_7W_ $%?CK\!_P#DK7AS_KZ7^=?L5_P5P_Y-L3_K[_H*
M_'7X#_\ )6O#G_7TO\Z /Z2_ 7_(EZ+_ ->L?\JWZP/ 7_(EZ+_UZQ_RK?H
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M^/:S/&,+(RCT!Q2_:)?^>K_]]&OV"_X<P^#L ?\ "3W(_P" FE_X<P^#>/\
MBI[G_ODT ?CY]HE/_+5_^^C7[_\ _!-)B?V0O!Q+%SM;D]>U>!3?\$7_  =)
M&53Q1<HV.&V&OMK]G[X-V?P#^%VE>"[&Y:[M[$$+,PP3G'^%,1Z/2T45(PHI
M&;:,TFX[<XI@*:;STI)9TMT+RR)$@ZL[ "OE']K_ /;]\(?LXZ#<VFF7,&M^
M+FP(;&-P5 /!8D'M4C.R_;&_:<T_]FOX7WNHF9/[=N8F2PB)'^L[$CTK^?GX
M@>.M4^)?C#4_$VMR";5-1E,T\BC +&NP^.W[1'B[]H'Q+-J?B/4)98=Y:&UW
M92(>@KR[^E- =U\"U#?&+P<,9']I0\'_ 'A7],6E_P#(,L_^N*?^@BOYG_@/
M_P ED\'?]A*'_P!"K^F#2_\ D&6?_7%/_016TMD3U+=-;TI?K2=:Q&>1?M)_
MM*>%_P!FGP%>:]KMRCWBIFUT\-^\G;G&!Z5^#W[0G[5/CC]H3QE<ZQJ^K7$%
MJ&9;:U@E9%2//R@@'GBO:_\ @J%^T'=?%[XUR^&I+ 6EOX6D>UCD5O\ 6YYW
M?K7Q@B-(ZHBEW8X50.2:%[VI6PUF+,6<EF/<GFEC=HV#H[(XZ,IP17Z.?LN?
M\$I[?XQ_#'2_%WB/7;C2I+T;ELA'R![UC?M@_P#!,>V_9[^&-SXQT+7+C6%@
MD"O:^620#WIRT%'4^>/V9/VPO&W[./C2VU"TU.XO]'ED47MG<2,_F1CJ%R>*
M_>#X%_';PU^T#X"L/$OARZ21+B,/+;;LO Q_A:OYHCGH>OI7Z!?\$D_VA;GP
M+\4&^'36@GM?$4H<7#-_J2H'2K2YD2C]H%;<.F*=C=2?Q=:Y#XN_$*W^%/P[
MUOQ5=+NATZ!I67UQ4-I(.I\??\%#_P!O@? ?2SX/\&RK+XLO(\M=*=RVZ]"#
M[\U^-GB?QYXA\8:E<W^K:O>7<]RYD</,Q7)/89Q6Q\:/B-=?%;XF:]XCN)GF
M6\N7DB5CG8I/ %9'@#P7??$/QEI/AZP1WN=0G6!-HSC/>E&Y6ASW'.>M6;'4
MKS2W,EE=SVCG@M!(R'\P:_6#PC_P1>T5M#@DUOQ5<#4)8P9(U3B-CVXKXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M> O^1+T7_KUC_E6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?HWN'K7YR?\%I_^20^$?^PBW\A0!\+_ /!-#_D\+P7_ +S_ -*_H$K^?O\
MX)H_\GA>"_\ >?\ I7] E !112$XZT +129I: "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A_\
MX*X?\FV)_P!??]!7XZ_ ?_DK7AS_ *^E_G7[%?\ !7#_ )-L3_K[_H*_'7X#
M_P#)6O#G_7TO\Z /Z2_ 7_(EZ+_UZQ_RK?K \!?\B7HO_7K'_*M^@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *"*_F>^!/\ R6/P=_V$H?\ T(5_3#IG_(,L_P#KBG_H(K2?074LGIBOD_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>*_.7_@M-_R2'PB>W]H-_(4 ?"__  30_P"3PO!>/[S_ -*_H$K^?S_@F?\
M\GA>"_\ >?\ I7] = !28I:* /SC_P""T_\ R2'PC_V$6_D*_+W]GGX7V/Q>
M^)5MX?U.]FL+#[-/=3S6ZAI-D2%R%!(!) .,D5^H7_!:?_DD/A'_ +"+?R%?
MG9^Q3_R6Y?\ L$7_ /Z(:@#W7_AB?X3?]#-XM_\  "W_ /CU'_#$_P )O^AF
M\6_^ %O_ /'J]?HH \@_X8G^$W_0S>+?_ "W_P#CU'_#$_PF_P"AF\6_^ %O
M_P#'J]?HH \@_P"&)_A-_P!#-XM_\ +?_P"/4?\ #$_PF_Z&;Q;_ . %O_\
M'J]?HH \@_X8G^$W_0S>+?\ P M__CU'_#$_PF_Z&;Q;_P" %O\ _'J]?HH
M\@_X8G^$W_0S>+?_   M_P#X]1_PQ/\ ";_H9O%O_@!;_P#QZO7Z* /(/^&)
M_A-_T,WBW_P M_\ X]1_PQ/\)O\ H9O%O_@!;_\ QZO7Z* /(/\ AB?X3?\
M0S>+?_ "W_\ CU'_  Q/\)O^AF\6_P#@!;__ !ZO7Z* /(/^&)_A-_T,WBW_
M , +?_X]1_PQ/\)O^AF\6_\ @!;_ /QZO7Z* /(/^&)_A-_T,WBW_P  +?\
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MBB@ HHHH **** "BBB@!O<UX)^W-_P FT>*_^N0_D:][[FO!/VYO^3:/%?\
MUR'\C0!_/3I/_(T6W_7T/_0J_HX_95_Y(/X5_P"O9?Y"OYQ])_Y&BV_Z^A_Z
M%7]''[*O_)!_"O\ U[+_ "% 'K=%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?#_P#P5P_Y-L3_ *^_Z"OQU^ _
M_)6O#G_7TO\ .OV*_P""N'_)MB?]??\ 05^.OP'_ .2M>'/^OI?YT ?TE^ O
M^1+T7_KUC_E6_6!X"_Y$O1?^O6/^5;] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[%/_ "6Y?^P1?_\ HAJ /M2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KY\_X*#?\@WX;_\ 8/?_ -&-7T'7SY_P4&_Y!OPW_P"P>_\ Z,:@#K?^
M"-W_ "<EJ?\ V"G_ *U^V'<U^)__  1N_P"3DM3_ .P4_P#6OVP[F@!:***
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M+_.OV*_X*X?\FV)_U]_T%?CK\!_^2M>'/^OI?YT ?TE^ O\ D2]%_P"O6/\
ME6_6!X"_Y$O1?^O6/^5;] !1110 4444 %%%% !1110 4444 %%%% !1110
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M^"N'_)MB?]??]!7XZ_ ?_DK7AS_KZ7^= '])?@+_ )$O1?\ KUC_ )5OU@>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]HS8([_.:_=3_@FFH7]D+P<0<Y5OZ4X[!+XCZC%+24M !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^'_^"N'_ ";8G_7W_05^.OP'_P"2M>'/^OI?YU^Q7_!7
M#_DVQ/\ K[_H*_'7X#_\E:\.?]?2_P Z /Z2_ 7_ ")>B_\ 7K'_ "K?K \!
M?\B7HO\ UZQ_RK?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;$IR!G&*8'O=+112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ'_H5?T<?LJ_\D'\*_\ 7LO\A0!ZW1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'P__ ,%</^3;$_Z^_P"@K\=?
M@/\ \E:\.?\ 7TO\Z_8K_@KA_P FV)_U]_T%?CK\!_\ DK7AS_KZ7^= '])?
M@+_D2]%_Z]8_Y5OU@> O^1+T7_KUC_E6_0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3<'/!Q3J*0"<\4M%%,!*!2TASVH ,YZ4<T8I: &\TN*6DH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OSC_X+3_\ )(?"/_81;^0K]'*_./\ X+3_ /)(
M?"/_ &$6_D* /A?_ ()H?\GA>"_]Y_Z5_0)7\_?_  30_P"3PO!?^\_]*_H$
MH **** /SC_X+3_\DA\(_P#81;^0K\[/V*?^2W+_ -@B_P#_ $0U?HG_ ,%I
M_P#DD/A'_L(M_(5^=G[%/_);E_[!%_\ ^B&H ^U**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OGS_@H-_P @WX;_ /8/?_T8U?0=?/G_  4&_P"0
M;\-_^P>__HQJ .M_X(W?\G):G_V"G_K7[8=S7XG_ /!&[_DY+4_^P4_]:_;#
MN: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ;W->"?MS?\ )M'BO_KD/Y&O>^YKP3]N;_DVCQ7_ -<A_(T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%-8X^M #J*8PW8[4O+'TH =36K-\0^(M,\)Z1/J>L7L
M-A80+NDGF;"J*@\)>,-&\=:+%J^@ZA%J>FS$A+F$Y5L=<4 ;5+110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7YQ_P#!:?\ Y)#X1_["+?R%?HY7YQ_\%I_^20^$?^PBW\A0!\+_
M /!-#_D\+P7_ +S_ -*_H$K^?O\ X)H?\GA>"_\ >?\ I7] E !1110!^<?_
M  6G_P"20^$?^PBW\A7YV?L4_P#);E_[!%__ .B&K]$_^"T__)(?"/\ V$6_
MD*_.S]BG_DMR_P#8(O\ _P!$-0!]J4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?/G_!0;_D&_#?_L'O_P"C&KZ#KY\_X*#?\@WX;_\ 8/?_ -&-
M0!UO_!&[_DY+4_\ L%/_ %K]L.YK\3_^"-W_ "<EJ?\ V"G_ *U^V'<T +11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 WN:\$_;F_Y-H\5_\ 7(?R->]]S7@G[<W_ ";1XK_ZY#^1H _GITG_
M )&BV_Z^A_Z%7]''[*O_ "0?PK_U[+_(5_./I/\ R-%M_P!?0_\ 0J_HX_95
M_P"2#^%?^O9?Y"@#UNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /A__@KA_P FV)_U]_T%?CK\!_\ DK7AS_KZ
M7^=?L5_P5P_Y-L3_ *^_Z"OQU^ __)6O#G_7TO\ .@#^DOP%_P B7HO_ %ZQ
M_P JWZP/ 7_(EZ+_ ->L?\JWZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?#_\ P5P_Y-L3_K[_ *"OQU^ _P#R5KPY_P!?2_SK]BO^"N'_
M ";8G_7W_05^.OP'_P"2M>'/^OI?YT ?TE^ O^1+T7_KUC_E6_6!X"_Y$O1?
M^O6/^5;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!%__ .B&H ^U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXYK]&?A=_P %@IOAUX%TKPZ? B7GV&(1";SMN['MFOG_ /X=_>*_^AN\+_\
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M?_P.% 'U7_P^YE_Z)TO_ ($'_P"*H_X?<R_]$Z7_ ,"#_P#%5\J?\._O%?\
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M>'/^OI?YU^Q7_!7#_DVQ/^OO^@K\=?@/_P E:\.?]?2_SH _I+\!?\B7HO\
MUZQ_RK?K \!?\B7HO_7K'_*M^@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^<?_  6G_P"20^$?^PBW\A7YV?L4_P#);E_[!%__ .B&K]$_^"T__)(?"/\
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M7[%?\%</^3;$_P"OO^@K\=?@/_R5KPY_U]+_ #H _I+\!?\ (EZ+_P!>L?\
M*M^L#P%_R)>B_P#7K'_*M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF*6BBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7K)_,T ?-7["?\ R&O'?_8*A_\ 2F.OJJOE7]A/_D->._\ L%0_^E,=?55
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_./_@M/_P DA\(_]A%OY"OT<K\X_P#@M/\ \DA\(_\ 81;^0H ^%_\ @FA_
MR>%X+_WG_I7] E?S]_\ !-#_ )/"\%_[S_TK^@2@ HHHH _./_@M/_R2'PC_
M -A%OY"OSL_8I_Y+<O\ V"+_ /\ 1#5^B?\ P6G_ .20^$?^PBW\A7YV?L4_
M\EN7_L$7_P#Z(:@#[4HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]^E '7)ZT"'44E+2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^<?_!:?_DD/A'_L(M_(5^CE?G'_
M ,%I_P#DD/A'_L(M_(4 ?"__  30_P"3PO!?^\_]*_H$K^?O_@FA_P GA>"_
M]Y_Z5_0)0 4444 ?G'_P6G_Y)#X1_P"PBW\A7YV?L4_\EN7_ +!%_P#^B&K]
M$_\ @M/_ ,DA\(_]A%OY"OSL_8I_Y+<O_8(O_P#T0U 'VI1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\^?\%!O^0;\-_P#L'O\ ^C&KZ#KY\_X*
M#?\ (-^&_P#V#W_]&-0!UO\ P1N_Y.2U/_L%/_6OVP[FOQ/_ ."-W_)R6I_]
M@I_ZU^V'<T +1110 4444 %%%% !7Y'_ /!;+_D</ ?_ %ZR?S-?KA7Y'_\
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M7_KUC_E6_6!X"_Y$O1?^O6/^5;] !1110 4444 %%%% !1110 4444 %%%%
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MUI*4+?7%;C?'/XALQ8^,M8)/4_:W_P :=R3^E^WNM.M($A@GMHHHU"JBNH
M& .M2#4K3_G[@_[^#_&OYFO^%X?$'_H<=8_\"W_QH_X7C\00/^1QUC_P+?\
MQI#/Z93J-I_S]P_]_%_QJ59$F4,CJZ?WE.17\RO_  O+X@_]#CK'_@6_^-?N
MM_P3IUK4?$7[)_A*^U6]FU&]D#[[B=MS-TZFF(^F*6D%+2&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5^<?\ P6G_ .20^$?^PBW\A7Z.5^<?_!:?_DD/A'_L(M_(4 ?"_P#P30_Y
M/"\%_P"\_P#2OZ!*_G[_ .":'_)X7@O_ 'G_ *5_0)0 4444 ?G'_P %I_\
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MS,=_8C)H _01?2EI%.[FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $/2OF;]N+]DN]_:T\&:1HEEK,>C-
M8W'GF212P;VQ7TRQ '--+#'(J6KC/R2_X<FZ_P#]#W9_]^3_ (4O_#DW7_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\/_P#!7#_DVQ/^OO\
MH*_'7X#_ /)6O#G_ %]+_.OV*_X*X?\ )MB?]??]!7XZ_ ?_ )*UX<_Z^E_G
M0!_27X"_Y$O1?^O6/^5;]8'@+_D2]%_Z]8_Y5OT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOH3%<1)-&>JN,BGK&L:*B*%51@!1@ 4 */O=*=2#BEH **** "BBB@ HHHH
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M !U-?%_[9O\ P46\+_ ?1SI'A:ZAUSQ1=1MY;V[!H[<@_P 7O7R]_P %"_\
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M /@ME_R.'@/_ *]9/YFOUPK\C_\ @ME_R.'@/_KUD_F: /FK]A/_ )#7CO\
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M!7X[? ?_ )*UX<_Z^E_G0!_27X"_Y$O1?^O6/^5;]8'@+_D2]%_Z]8_Y5OT
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M"@#X7_X)H?\ )X7@O_>?^E?T"5_/W_P30_Y/"\%_[S_TK^@2@ HHHH _./\
MX+3_ /)(?"/_ &$6_D*_.S]BG_DMR_\ 8(O_ /T0U?HG_P %I_\ DD/A'_L(
MM_(5^=G[%/\ R6Y?^P1?_P#HAJ /M2BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_0@W7_?\?XT ?IYFC-?F'_P^TT3_H0;K_O^/\:/^'VFB?\ 0@W7_?\ '^-
M'Z>9HS7YA_\ #[31/^A!NO\ O^/\:/\ A]IHG_0@W7_?\?XT ?IYFC-?F'_P
M^TT3_H0;K_O^/\:/^'VFB?\ 0@W7_?\ '^- 'Z>9HS7YA_\ #[31/^A!NO\
MO^/\:/\ A]IHG_0@W7_?\?XT ?IYFC-?F'_P^TT3_H0;K_O^/\:/^'VFB?\
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M7=S+=SL&W33,68].YI#N?3]+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YQ_\%I_^20^$?^PB
MW\A7Z.5^<?\ P6G_ .20^$?^PBW\A0!\+_\ !-#_ )/"\%_[S_TK^@2OY^_^
M":'_ ">%X+_WG_I7] E !1110!^<?_!:?_DD/A'_ +"+?R%?G9^Q3_R6Y?\
ML$7_ /Z(:OT3_P""T_\ R2'PC_V$6_D*_.S]BG_DMR_]@B__ /1#4 ?:E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7SY_P4&_Y!OPW_ .P>_P#Z
M,:OH.OGS_@H-_P @WX;_ /8/?_T8U '6_P#!&[_DY+4_^P4_]:_;#N:_$_\
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M/_09\)_^#V#_ .*H_P"'?_Q!_P"@SX3_ /![!_\ %5]:44 ?)?\ P[_^(/\
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M?_#O_P"(/_09\)_^#V#_ .*H_P"'?_Q!_P"@SX3_ /![!_\ %5]:44 ?)?\
MP[_^(/\ T&?"?_@]@_\ BJ/^'?\ \0?^@SX3_P#![!_\57UI10!\E_\ #O\
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ME"\-?]A&W_\ 1BU_3EX9_P"1;TG_ *](O_0!0!IT444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_./\
MX+3_ /)(?"/_ &$6_D*_1ROSC_X+3_\ )(?"/_81;^0H ^%_^":'_)X7@O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNU%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OSC_X+3_\ )(?"/_81;^0K]'*_./\ X+3_ /)(
M?"/_ &$6_D* /A?_ ()H?\GA>"_]Y_Z5_0)7\_?_  30_P"3PO!?^\_]*_H$
MH **** /SC_X+3_\DA\(_P#81;^0K\[/V*?^2W+_ -@B_P#_ $0U?HG_ ,%I
M_P#DD/A'_L(M_(5^=G[%/_);E_[!%_\ ^B&H ^U**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6_\ @I%_R<GJO^[_
M %KZC_X(C_\ ']\0_P#<B_FM?+G_  4B_P"3D]5_W?ZU]1_\$1_^/[XA_P"Y
M%_-: /U<HHHH **** "BBB@ HHHH _#O_@KY_P G1#_L'1?R%'_!/C_DEOQ=
M_P"N=G_Z4PT?\%?/^3HA_P!@Z+^0H_X)\?\ )+?B[_USL_\ TIAH ]IHHHH
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M_<?\5HG_ '[_ /KTO_#RS]G_ /Z'1/\ OW_]>@1]0[O_ -5*:^7?^'E?[/\
MC=_PFB?]^_\ Z]>]?#CXD:!\6/"=GXD\,7@U#1KL'RIP,;L4 =12T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5^<?_  6G_P"20^$?^PBW\A7Z.5^<?_!:?_DD/A'_ +"+?R%
M'PO_ ,$T/^3PO!?^\_\ 2OZ!*_G[_P"":'_)X7@O_>?^E?T"4 %%%% 'YQ_\
M%I_^20^$?^PBW\A7YV?L4_\ );E_[!%__P"B&K]$_P#@M/\ \DA\(_\ 81;^
M0K\[/V*?^2W+_P!@B_\ _1#4 ?:E%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7SY_P %!O\ D&_#?_L'O_Z,:OH.OGS_ (*#?\@WX;_]@]__ $8U
M '6_\$;O^3DM3_[!3_UK]L.YK\3_ /@C=_R<EJ?_ &"G_K7[8=S0 M%%% !1
M110 4444 %?D?_P6R_Y'#P'_ ->LG\S7ZX5^1_\ P6R_Y'#P'_UZR?S- 'S5
M^PG_ ,AKQW_V"H?_ $ICKZJKY5_83_Y#7CO_ +!4/_I3'7U50 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?+?\ P4B_Y.3U7_=_K7U'_P $1_\
MC^^(?^Y%_-:^7/\ @I%_R<GJO^[_ %KZC_X(C_\ ']\0_P#<B_FM 'ZN4444
M %%%% !1110 4444 ?AW_P %?/\ DZ(?]@Z+^0H_X)\?\DM^+O\ USL__2F&
MC_@KY_R=$/\ L'1?R%'_  3X_P"26_%W_KG9_P#I3#0![31110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8.B_D*/^"?'_)+?B[_USL__ $IAH_X*^?\ )T0_[!T7\A1_P3X_Y);\7?\
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M*?\ K7[8=S0 M%%% !1110 4444 %?D?_P %LO\ D</ ?_7K)_,U^N%?D?\
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M ((P_P#) _$7_84_HU?H30 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?.O_!0/_DTOQY_UZ?UKZ*KYU_X*
M!_\ )I?CS_KT_K0!^ GPV_Y*%X:_["-O_P"C%K^G+PS_ ,BWI/\ UZ1?^@"O
MYC?AM_R4+PU_V$;?_P!&+7].7AG_ )%O2?\ KTB_] % &G1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/EO_ (*1?\G)ZK_N_P!:^H_^"(__ !_?$/\ W(OYK7RY_P %(O\ DY/5?]W^
MM?4?_!$?_C^^(?\ N1?S6@#]7**** "BBB@ HHHH **** /P[_X*^?\ )T0_
M[!T7\A1_P3X_Y);\7?\ KG9_^E,-'_!7S_DZ(?\ 8.B_D*/^"?'_ "2WXN_]
M<[/_ -*8: /::*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OAW]L'
M_DMU]_UX6?\ Z(6ON*OAW]L'_DMU]_UX6?\ Z(6@#]-/^",/_) _$7_84_HU
M?H37Y[?\$8?^2!^(O^PI_1J_0F@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=?^"@?_)I?CS_ *]/ZU]%
M5\Z_\% _^32_'G_7I_6@#\!/AM_R4+PU_P!A&W_]&+7].7AG_D6])_Z](O\
MT 5_,;\-O^2A>&O^PC;_ /HQ:_IR\,_\BWI/_7I%_P"@"@#3HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *2EI.] ""E/-+12 3 HI:*8!1110 F*,"EHH **** "BBB@
M HHHH **** "D:EI#0 =:**.](!FX\TH)I.!S7"?''QA;^!?A3XEU6XO5L7C
MLI?)D9L?/M.W'OFA[#MJ?D=_P5F_: ?XA?%M? L<!BMO#4A F5LK*6!S7PEI
MM@VJ:I:6:<-<3)"I]V(']:T_&GBC4/&'BK4M7U2Z>]O;B9F>:0Y)Y.*]\_X)
M[?"'3_C%^T9HVEZO#(^G0@W)95R RD$"JIKHPD[:G[%?L-_ T_ GX#:+H]P$
MDOYT%S+,% 8A@" 3^-?0)&*CL;5+"SM[:/\ U<,:QK] ,#^53$9H;N[D)65D
M-]^]>*?MG:U=>'_V:?&]_9R^1<Q63%7SC%>V-7!_&KX3V/QN^'>J>$-4N9;3
M3]0C\N62'[V*F2NK%QT/YG+R\FU"[EN9W,D\S%G8]R:B&<X'-?IE\6O^".>K
MZ?J)_P"$%U4W]GY9(-VV&W=A7MG[%?\ P3'T?X7V(U_XE6D.K>(I"R'3Y!O@
M1>Q^O^%4A'Y?^#OV2_BQX^\/IK6A^#KZ]TUUW+,J8!'7O7EFK:3>:#J5Q8:A
M;R6UW;N8Y8I%P58=17]16C:'I_AS38K#2K*&QLHN$MX5"JH^E?.7[5G[%?@'
MXT?#C65AT:WTG6XU>\CO;.(+))(%R Q'7)%2^XT?S\[S&ZO&Q1AR"IP17ZK_
M /!+W]N+7/$FL6OPI\6RM?G9_P 2_4)7QY4:C[A_.OR^\5>&;[P7XBO]&U&!
MH;NUD:-D<8/!ZU?^&7B#4?#7CW0KW3+V73[D7L*^="V"%+KD54=26?T_4F>/
M>L;P7?#4O"&B7(E\XR64+,^<Y.P9/YUL\4@N#-MZG ]Z3S%_OK^=?EE_P5>_
M:D^(/@?Q?9^ ] >YT/1_+2[_ +5MLHTC''R!O:OSR_X:6^*?_0^:U_X$F@9_
M2UYJ?WU_.OSG_P""TH#?!WPDX=3_ ,3%A@,,]!VK\O?^&EOBG_T/FM?^!)K!
M\7?%CQC\0+6*V\1>([_68(FW)'=REPI]10![O_P31_Y/!\%^NY_Z5_0)7\_G
M_!-'_D\/P7V^9_Z5_0'0 4444 ?G'_P6G_Y)#X1_["+?R%?G9^Q3_P EN7_L
M$7__ *(:OT3_ ."T_P#R2'PC_P!A%OY"OSL_8I_Y+<O_ &"+_P#]$-0!]J44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?/G_  4&_P"0;\-_^P>_
M_HQJ^@Z^?/\ @H-_R#?AO_V#W_\ 1C4 =;_P1N_Y.2U/_L%/_6OVP[FOQ/\
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M %KZC_X(C_\ ']\0_P#<B_FM 'ZN4444 %%%% !1110 4444 ?AW_P %?/\
MDZ(?]@Z+^0H_X)\?\DM^+O\ USL__2F&C_@KY_R=$/\ L'1?R%'_  3X_P"2
M6_%W_KG9_P#I3#0![31110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P .K?@)_P! "Y_[_P#_ -:OK]3FEJ2SY _X=6_ /_H 7/\ X$?_ %J^-O\
M@IA^QS\-?V<_AOX>U;P9I\UE?7EZ89?,?<"H K]B*_./_@M/_P DA\(_]A%O
MY"@#X7_X)H\_MA>"P?[S_P!*_H$K^?O_ ()H?\GA>"_]Y_Z5_0)0 4444 ?G
M'_P6G_Y)#X1_["+?R%?G9^Q3_P EN7_L$7__ *(:OT3_ ."T_P#R2'PC_P!A
M%OY"OSL_8I_Y+<O_ &"+_P#]$-0!]J4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?/G_  4&_P"0;\-_^P>__HQJ^@Z^?/\ @H-_R#?AO_V#W_\
M1C4 =;_P1N_Y.2U/_L%/_6OVP[FOQ/\ ^"-W_)R6I_\ 8*?^M?MAW- "T444
M %%%% !1110 5^1__!;+_D</ ?\ UZR?S-?KA7Y'_P#!;+_D</ ?_7K)_,T
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M_2F&C_@KY_R=$/\ L'1?R%'_  3X_P"26_%W_KG9_P#I3#0![31110 4444
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M_2F.OJJOE7]A/_D->._^P5#_ .E,=?55 !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?#O[8/_);K[_KPL_\ T0M?<5?#O[8/_);K[_KPL_\ T0M 'Z:?\$8?
M^2!^(O\ L*?T:OT)K\]O^",/_) _$7_84_HU?H30 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?.O\ P4#_
M .32_'G_ %Z?UKZ*KYU_X*!_\FE^//\ KT_K0!^ GPV_Y*%X:_["-O\ ^C%K
M^G+PS_R+>D_]>D7_ * *_F-^&W_)0O#7_81M_P#T8M?TY>&?^1;TG_KTB_\
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M>._^P5#_ .E,=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-'_"^OAR/^9TT7_P+7_&@#D?^&,?@K_T3[2?^_9_QH_X8Q^"O;X?:3_WZ/\
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M7/\ @I%_R<GJO^[_ %KZC_X(C_\ ']\0_P#<B_FM 'ZN4444 %%%% !1110
M4444 ?AW_P %?/\ DZ(?]@Z+^0H_X)\?\DM^+O\ USL__2F&C_@KY_R=$/\
ML'1?R%'_  3X_P"26_%W_KG9_P#I3#0![31110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\._M@_\ );K[_KPL_P#T0M?<5?#O[8/_ "6Z^_Z\+/\
M]$+0!^FG_!&'_D@?B+_L*?T:OT)K\]O^",/_ "0/Q%_V%/Z-7Z$T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7SK_P4#_Y-+\>?]>G]:^BJ^=?^"@?_)I?CS_KT_K0!^ GPV_Y*%X:_P"P
MC;_^C%K^G+PS_P BWI/_ %Z1?^@"OYC?AM_R4+PU_P!A&W_]&+7].7AG_D6]
M)_Z](O\ T 4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #6K\ZO^"T$DD7P@\*M'(\>
M+\_<8C/ ZU^BU>(?M2?LI>'?VK/#FG:-XBO;JQ@L9O.C>UZD_G42Z#/YS_MU
MQC_CYES_ +YI/MUS_P _$O\ WV:_9?\ X<Q_"WC_ (J+6/?G_P"O2_\ #F+X
M6?\ 0Q:S^8_QJQ'XS_;KG_GXE_[[-'VZY_Y^)?\ OLU^S'_#F+X6_P#0Q:S^
M8_QK/UK_ ()"_!;PS9R7>K^,]0T^"-2Y>XE5!@#)ZMS^% 'X[B]N?^?B7_OL
MT[[;<@X-S,/^!FO<_P!ICPK\%O"=TMG\+M:O]7N8)FBN'NB2G!P2IKP7CJ>E
M-*X$OVZY_P"?F4_\#-?O[_P34)/[(/@XEWD8J^2YR>U?A;\-/A%XI^+6NVVE
M^&]*N+V2>01B58SY:D^K=*_H#_8O^$^N?!/]GGPWX2\1!%U>S5O.6,Y SCBF
M(]RI:2EJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?G'_P %I_\ DD/A'_L(M_(5^CE?G'_P6G_Y
M)#X1_P"PBW\A0!\+_P#!-#_D\+P7_O/_ $K^@2OY^_\ @FA_R>%X+_WG_I7]
M E !1110!^<?_!:?_DD/A'_L(M_(5^=G[%/_ "6Y?^P1?_\ HAJ_1/\ X+3_
M /)(?"/_ &$6_D*_.S]BG_DMR_\ 8(O_ /T0U 'VI1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(?"/_81;^0K\[/V*?^2W+_V"+_\ ]$-7Z)_\%I_^20^$?^PBW\A7YV?L4_\
M);E_[!%__P"B&H ^U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MGS_@H-_R#?AO_P!@]_\ T8U?0=?/G_!0;_D&_#?_ +![_P#HQJ .M_X(W?\
M)R6I_P#8*?\ K7[8=S7XG_\ !&[_ ).2U/\ [!3_ -:_;#N: %HHHH ****
M"BBB@ K\C_\ @ME_R.'@/_KUD_F:_7"OR/\ ^"V7_(X> _\ KUD_F: /FK]A
M/_D->._^P5#_ .E,=?55?*O["?\ R&O'?_8*A_\ 2F.OJJ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^6_^"D7_)R>J_[O]:^H_P#@B/\ \?WQ
M#_W(OYK7RY_P4C_Y.3U7_=_K7U'_ ,$1_P#C^^(?^Y%_-: /U<HHHH ****
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M7_81M_\ T8M?TY>&?^1;TG_KTB_] %?S&_#;_DH7AK_L(V__ *,6OZ<O#/\
MR+>D_P#7I%_Z * -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&KY?\ V]OVI+_]EOX9
M6NK:3 LVJ7TI@@WC*AL=37U#7YS?\%HE9OA!X458V<G4#RJDXX%3(:/RQ^+G
MQR\8?&WQ->ZSXFU:>YENGWM;ASY2_1>E<!CK4GV><X_<R'_@)I?LLXZPR?\
M?!J[+H"/7?V<M4^$FCZW<S_%>PO[^R7#6\=CGJ/7':OTD\&_\%7/@-\.]%MM
M)\/^$-1TZSMXUB7R( I8#N3MR?QK\??L\_>&3_O@TAMIO^>+C_@)HN)'[1?\
M/F/A)_T M:_[Y_\ L:/^'S'PD_Z 6M?]\_\ V-?B[]EF_P">+_\ ?)H^RS?\
M\9/^^32 _:+_ (?,?"3_ * >M?\ ?/\ ]C7V!\"_C)I'Q\^&^F>--#AF@TZ^
MSY<<_P!\8]:_F=^RS?\ /&3_ +Y-?O[_ ,$T01^R#X/!1HSAQM9<'M0!]344
ME+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7YQ_\%I_^20^$?^PBW\A7Z.5^<?\ P6G_ .20^$?^
MPBW\A0!\+_\ !-#_ )/"\%_[S_TK^@2OY^_^":'_ ">%X+_WG_I7] E !111
M0!^<?_!:?_DD/A'_ +"+?R%?G9^Q3_R6Y?\ L$7_ /Z(:OT3_P""T_\ R2'P
MC_V$6_D*_.S]BG_DMR_]@B__ /1#4 ?:E%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7SY_P4&_Y!OPW_ .P>_P#Z,:OH.OGS_@H-_P @WX;_ /8/
M?_T8U '6_P#!&[_DY+4_^P4_]:_;#N:_$_\ X(W?\G):G_V"G_K7[8=S0 M%
M%% !1110 4444 %?D?\ \%LO^1P\!_\ 7K)_,U^N%?D?_P %LO\ D</ ?_7K
M)_,T ?-7["?_ "&O'?\ V"H?_2F.OJJOE7]A/_D->._^P5#_ .E,=?55 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\M_\ !2+_ ).3U7_=_K7U
M'_P1'_X_OB'_ +D7\UKY<_X*1_\ )R>J_P"[_6OJ/_@B/_Q_?$/_ '(OYK0!
M^KE%%% !1110 4444 %%%% 'X=_\%?/^3HA_V#HOY"C_ ()\?\DM^+O_ %SL
M_P#TIAH_X*^?\G1#_L'1?R%'_!/C_DEOQ=_ZYV?_ *4PT >TT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?#O[8/_);K[_KPL_\ T0M?<5?#O[8/
M_);K[_KPL_\ T0M 'Z:?\$8?^2!^(O\ L*?T:OT)K\]O^",/_) _$7_84_HU
M?H30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?.O\ P4#_ .32_'G_ %Z?UKZ*KYU_X*!_\FE^//\ KT_K
M0!^ GPV_Y*%X:_["-O\ ^C%K^G+PS_R+>D_]>D7_ * *_F-^&W_)0O#7_81M
M_P#T8M?TY>&?^1;TG_KTB_\ 0!0!IT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U8/BC
MP/H/C:VCMO$&DVNL6\;;DCNXPZJ?4 UO&OD[_@H1^TUKG[,O@'1M7T,!KB\N
M3"WZ5$AH]N_X9Y^&@Y_X0C1?_ 5:/^&>_AI_T)&C?^ JU^=_[,'_  4J\:_%
M[XUZ#X6U% ME?-M>OU17M6G0SO[UCS[_ (9Y^&G3_A"-%_\  5:7_AGGX:?]
M"1HO_@*M>@XIU26>>?\ #//PT_Z$C1?_  $6C_AGGX:?]"1HO_@(M>AT4P/.
M_P#AG?X9]/\ A"-%Q_UZK79Z%X>TWPQIL6GZ390Z?8Q?ZNWMU"HOT%:-% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7YQ_\%I_^20^$?^PBW\A7Z.5^<?\ P6G_ .20^$?^
MPBW\A0!\+_\ !-#_ )/"\%_[S_TK^@2OY^_^":'_ ">%X+_WG_I7] E !111
M0!^<?_!:?_DD/A'_ +"+?R%?G9^Q3_R6Y?\ L$7_ /Z(:OT3_P""T_\ R2'P
MC_V$6_D*_.S]BG_DMR_]@B__ /1#4 ?:E%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7SY_P4&_Y!OPW_ .P>_P#Z,:OH.OGS_@H-_P @WX;_ /8/
M?_T8U '6_P#!&[_DY+4_^P4_]:_;#N:_$_\ X(W?\G):G_V"G_K7[8=S0 M%
M%% !1110 4444 %?D?\ \%LO^1P\!_\ 7K)_,U^N%?D?_P %LO\ D</ ?_7K
M)_,T ?-7["?_ "&O'?\ V"H?_2F.OJJOE7]A/_D->._^P5#_ .E,=?55 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\M_\ !2+_ ).3U7_=_K7U
M'_P1'_X_OB'_ +D7\UKY<_X*1_\ )R>J_P"[_6OJ/_@B/_Q_?$/_ '(OYK0!
M^KE%%% !1110 4444 %%%% 'X=_\%?/^3HA_V#HOY"C_ ()\?\DM^+O_ %SL
M_P#TIAH_X*^?\G1#_L'1?R%'_!/C_DEOQ=_ZYV?_ *4PT >TT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?#O[8/_);K[_KPL_\ T0M?<5?#O[8/
M_);K[_KPL_\ T0M 'Z:?\$8?^2!^(O\ L*?T:OT)K\]O^",/_) _$7_84_HU
M?H30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?.O\ P4#_ .32_'G_ %Z?UKZ*KYU_X*!_\FE^//\ KT_K
M0!^ GPV_Y*%X:_["-O\ ^C%K^G+PS_R+>D_]>D7_ * *_F-^&W_)0O#7_81M
M_P#T8M?TY>&?^1;TG_KTB_\ 0!0!IT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (W2OSG
M_P""TG_)'O"P_P"H@?Z5^C!YK\YO^"T7/P?\+'_I_P#\*SET*CU/S]_X)^X_
MX:H\(=AYA_I7]#2_=%?S9?LN_%;3/@K\:=!\7ZO;R75A8.6DBB'S'IT_*OU*
M_P"'S?PH_P"@!K7_ 'R/\*UZ&5O>;/T$I:_/K_A\Y\*/^@!K7_?(_P */^'S
MGPH_Z &M?]\C_"D6?H+17Y]?\/G/A1_T -:_(?X4?\/G/A1_T -:_(?X4 ?H
M+17Y\C_@LW\*><Z!K/\ WS_]:OL3X%_&32?CY\-=,\::'#-;Z=?Y\N.?[XQC
MK0!Z%12?6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K\X_^"T__ "2'PC_V$6_D*_1ROSC_ ."T
M_P#R2'PC_P!A%OY"@#X7_P"":'_)X7@O_>?^E?T"5_/W_P $T/\ D\+P7_O/
M_2OZ!* "BBB@#\X_^"T__)(?"/\ V$6_D*_.S]BG_DMR_P#8(O\ _P!$-7Z)
M_P#!:?\ Y)#X1_["+?R%?G9^Q3_R6Y?^P1?_ /HAJ /M2BBB@ HHHH ****
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MICKZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OAW]L'_DMU]_UX6?\
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M;  +'T%2?9IO^>,G_?)KW;]AOP]IWBC]I3PKIVJVD=[8RN?,AE&5;I7[N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M_\
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M^",/_) _$7_84_HU?H30 4444 %%%% !1110 44TMM/M1N^;% #J*3=SBC-
M"T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS
M0 M?.O\ P4#_ .32_'G_ %Z?UKZ)S7SM_P % _\ DTOQY_UZ?UH _ 3X;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  V/\&/^B@:1_P!_3_A7\YW_  C^J_\ 0-O/^_#_ .%'_"/ZK_T#;S_OP_\
MA0!_1C_PV/\ !C_HH&D?]_3_ (5X;^VS^U!\*_&7[,_C32-&\::=J&I7-KM@
MMX),L[9Z5^('_"/ZK_T#;S_OP_\ A2_\(_JG_0,O/^_#_P"% &C\/[J*Q\<>
M'KBX<100W\+R.>BJ'!)_*OZ$=!_;!^#-OH>G1-X_TE6CMHU*M+R,*!S7\[O]
M@:K_ - V\_[\/_A1_P (_JG_ $#+S_OP_P#A0!_1A_PV/\&/^B@:1_W]/^%'
M_#8_P8_Z*!I'_?T_X5_.=_PC^J_] V\_[\/_ (4?\(_JO_0-O/\ OP_^% ']
M&/\ PV/\&/\ HH&D?]_3_A1_PV/\&/\ HH&D?]_3_A7\YW_"/ZK_ - V\_[\
M/_A1_P (_JO_ $#;S_OP_P#A0!_1C_PV/\&/^B@:1_W]/^%'_#8_P8_Z*!I'
M_?T_X5_.=_PC^J_] V\_[\/_ (4?\(_JO_0-O/\ OP_^% ']&/\ PV/\&/\
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M]":_/;_@C#_R0/Q%_P!A3^C5^A- !1110 4444 %%%% "<;O>OYZ/^"AV?\
MAK?QUGK]H_QK^A;^+I]:_GJ_X*(?\G<>.O\ KY% 'N'[&.JR^&_@3:W-C%9B
MXO-2NTFDN+.&<LJ"/:/WBMC&YNGK["O</^%@:O\ W-+_ /!/:?\ QJO OV3?
M^2 :5_V%+[^45>LT =)_PL#5_P"YI?\ X)[3_P"-4?\ "P-7_N:7_P"">T_^
M-5S=% '2?\+ U?\ N:7_ .">T_\ C5'_  L#5_[FE_\ @GM/_C5<W10!TG_"
MP-7_ +FE_P#@GM/_ (U1_P + U?^YI?_ ()[3_XU7-T4 =)_PL#5_P"YI?\
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MT_\ C5+_ ,+ U?\ N:7_ .">T_\ C5<W10!TG_"P-7_N:7_X)[3_ .-4?\+
MU?\ N:7_ .">T_\ C5<W10!TG_"P-7_N:7_X)[3_ .-4?\+ U?\ N:7_ .">
MT_\ C5<W10!TG_"P-7_N:7_X)[3_ .-4?\+ U?\ N:7_ .">T_\ C5<W10!T
MG_"P-7_N:7_X)[3_ .-4?\+ U?\ N:7_ .">T_\ C5<W10!TG_"P-7_N:7_X
M)[3_ .-4?\+ U?\ N:7_ .">T_\ C5<W10!TG_"P-7_N:7_X)[3_ .-4?\+
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M^M?F?_P^O\,8S_P@]]G_ *ZBON7]G/XV6O[0GPHTGQM9V3Z?!?YQ;R')7&*
M/3*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OSC_X+3_\DA\(_P#81;^0K]'*_./_ (+3_P#)
M(?"/_81;^0H ^%_^":'_ ">%X+_WG_I7] E?S]_\$T/^3PO!?^\_]*_H$H *
M*** /SC_ ."T_P#R2'PC_P!A%OY"OSL_8I_Y+<O_ &"+_P#]$-7Z)_\ !:?_
M ))#X1_["+?R%?G9^Q3_ ,EN7_L$7_\ Z(:@#[4HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^?/^"@W_(-^&_\ V#W_ /1C5]!U\^?\%!O^0;\-
M_P#L'O\ ^C&H ZW_ ((W?\G):G_V"G_K7[8=S7XG_P#!&[_DY+4_^P4_]:_;
M#N: %HHHH **** "BBB@ K\C_P#@ME_R.'@/_KUD_F:_7"OR/_X+9?\ (X>
M_P#KUD_F: /FK]A/_D->._\ L%0_^E,=?55?*O["?_(:\=_]@J'_ -*8Z^JJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y;_X*1?\ )R>J_P"[
M_6OJ/_@B/_Q_?$/_ '(OYK7RY_P4C_Y.3U7_ '?ZU]1_\$1_^/[XA_[D7\UH
M _5RBBB@ HHHH **** "BBB@#\._^"OG_)T0_P"P=%_(4?\ !/C_ ));\7?^
MN=G_ .E,-'_!7S_DZ(?]@Z+^0H_X)\?\DM^+O_7.S_\ 2F&@#VFBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNO\ DS_PM_UTE_I7XF_M"?\ );_&W_84F_\ 0J_;+_@EU_R9_P"%O^NDO]*
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M_@FA_P GA>"_]Y_Z5_0)7\_?_!-#_D\+P7_O/_2OZ!* "BBB@#\X_P#@M/\
M\DA\(_\ 81;^0K\[/V*?^2W+_P!@B_\ _1#5^B?_  6G_P"20^$?^PBW\A7Y
MV?L4_P#);E_[!%__ .B&H ^U**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH *^'?VP?^2W7W_7A9_\ HA:^XJ^'?VP?^2W7W_7A9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*_H8K^>?_@H?_P G<>.O^OD4 >Q_LF_\D!TO_L*WW\H:]:KR7]DW_D@.E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\X_^"T__)(?"/\
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MPG_R&O'?_8*A_P#2F.OJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^6_^"D7_ "<GJO\ N_UKZC_X(C_\?WQ#_P!R+^:U\N?\%(O^3D]5_P!W
M^M?4?_!$?_C^^(?^Y%_-: /U<HHHH **** "BBB@ HHHH _#O_@KY_R=$/\
ML'1?R%'_  3X_P"26_%W_KG9_P#I3#1_P5\_Y.B'_8.B_D*/^"?'_)+?B[_U
MSL__ $IAH ]IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #&*ANKF.SAEGGD6*"-2[R,<!0.I-3U\O?\ !1+XT7?P7_9ZU*^LU+3:@39
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MP1?_ /HAJ /M2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /EO_ (*1_P#)R6J_[O\ 6OJ/_@B/_P ?WQ#_ -R+^:U\
MN?\ !2+_ ).3U7_=_K7U'_P1'_X_OB'_ +D7\UH _5RBBB@ HHHH **** "B
MBB@#\._^"OG_ "=$/^P=%_(4?\$^/^26_%W_ *YV?_I3#1_P5\_Y.B'_ &#H
MOY"C_@GQ_P DM^+O_7.S_P#2F&@#VFBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KX=_;!_Y+=??]>%G_ .B%K[BKX=_;!_Y+=??]>%G_ .B%H _3
M3_@C#_R0/Q%_V%/Z-7Z$U^>W_!&'_D@?B+_L*?T:OT)H **** "BBB@ HHHH
M *_GG_X*'_\ )W'CK_KY%?T,5_//_P %#_\ D[CQU_U\B@#V/]DW_D@.E_\
M85OOY0UZU7DO[)O_ "0'2_\ L*WW\H:]:H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /ST_:$_Y+?XV_P"PI-_Z%7[9?\$NO^3/_"W_ %TE_I7X
MF_M"?\EO\;?]A2;_ -"K]LO^"77_ "9_X6_ZZ2_TH ^M**** "BBB@ HHHH
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M53_9  K\6/V\/VCK#]I;XV7'B#3+0VMC9Q_8HF8_ZU5. WXXK]./^"437C?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?M"?\EO\;?\ 84F_]"K]LO\ @EU_R9_X6_ZZ2_TK\3?VA/\ DM_C;_L*3?\
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M]XK^H7QYX#T7XE^%K_P]K]E'?:;>1&.1)%!(![C/0U\I_P##IOX%'.-.OO\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y;_X*1?\
M)R>J_P"[_6OJ/_@B/_Q_?$/_ '(OYK7RY_P4B_Y.3U7_ '?ZU]1_\$1_^/[X
MA_[D7\UH _5RBBB@ HHHH **** "BBB@#\._^"OG_)T0_P"P=%_(4?\ !/C_
M ));\7?^N=G_ .E,-'_!7S_DZ(?]@Z+^0H_X)\?\DM^+O_7.S_\ 2F&@#VFB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX=_;!_Y+=??]>%G_P"B
M%K[BKX=_;!_Y+=??]>%G_P"B%H _33_@C#_R0/Q%_P!A3^C5^A-?GM_P1A_Y
M('XB_P"PI_1J_0F@ HHHH **** "BBB@ K^>?_@H?_R=QXZ_Z^17]#%?SS_\
M%#_^3N/'7_7R* /8_P!DW_D@.E_]A6^_E#7K5>2_LF_\D!TO_L*WW\H:]:H
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M;X/>.O\ H4M8_P# -_\ "LQGZ)_\/MM2_P"B?0?^!!_QI?\ A]MJ/_1/H/\
MP(/^-?G5_P *>\<_]"EK'_@')_A2_P#"GO'/_0I:Q_X!O_A0!^BG_#[;4?\
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M=G[%/_);E_[!%_\ ^B&K]$_^"T__ "2'PC_V$6_D*_.S]BG_ )+<O_8(O_\
MT0U 'VI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^?\%!O^0;\
M-_\ L'O_ .C&KZ#KY\_X*#?\@WX;_P#8/?\ ]&-0!UO_  1N_P"3DM3_ .P4
M_P#6OVP[FOQ/_P""-W_)R6I_]@I_ZU^V'<T +1110 4444 %%%% !7Y'_P#!
M;+_D</ ?_7K)_,U^N%?D?_P6R_Y'#P'_ ->LG\S0!\U?L)_\AKQW_P!@J'_T
MICKZJKY5_83_ .0UX[_[!4/_ *4QU]54 %%%% !1110 4444 %%%% !1110
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MKDO>QZ-1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY"OSL_8I_P"2W+_V"+__ -$-0!]J4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?/G_!0;_D&_#?_ +![_P#HQJ^@Z^?/^"@W_(-^&_\ V#W_ /1C
M4 =;_P $;O\ DY+4_P#L%/\ UK]L.YK\3_\ @C=_R<EJ?_8*?^M?MAW- "T4
M44 %%%% !1110 5^1_\ P6R_Y'#P'_UZR?S-?KA7Y'_\%LO^1P\!_P#7K)_,
MT ?-7["?_(:\=_\ 8*A_]*8Z^JJ^5?V$_P#D->._^P5#_P"E,=?55 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\M_\%(O^3D]5_P!W^M?4?_!$
M?_C^^(?^Y%_-:^7/^"D7_)R>J_[O]:^H_P#@B/\ \?WQ#_W(OYK0!^KE%%%
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MT?C41QJJ@*J@ *.@%*V?PH],=*?0GJ.%+2"EI%!1110 4444 %%%% !1110
M4444 %%)FD+?C0 ZBBB@ HI"<4F[I0 ZBDS2T %%%(6QCB@!:*0G'O2;L]*
M'44E&Z@!:*** "BBB@ K\X_^"T__ "2'PC_V$6_D*_1ROSC_ ."T_P#R2'PC
M_P!A%OY"@#X7_P"":'_)X7@O_>?^E?T"5_/W_P $T/\ D\+P7_O/_2OZ!* "
MBBB@#\X_^"T__)(?"/\ V$6_D*_.S]BG_DMR_P#8(O\ _P!$-7Z)_P#!:?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /EO_ (*1_P#)R6J_[O\
M6OJ/_@B/_P ?WQ#_ -R+^:U\N?\ !2+_ ).3U7_=_K7U'_P1'_X_OB'_ +D7
M\UH _5RBBB@ HHHH **** "BBB@#\._^"OG_ "=$/^P=%_(4?\$^/^26_%W_
M *YV?_I3#1_P5\_Y.B'_ &#HOY"C_@GQ_P DM^+O_7.S_P#2F&@#VFBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KX=_;!_Y+=??]>%G_ .B%K[BK
MX=_;!_Y+=??]>%G_ .B%H _33_@C#_R0/Q%_V%/Z-7Z$U^>W_!&'_D@?B+_L
M*?T:OT)H **** "BBB@ HHHH *_GG_X*'_\ )W'CK_KY%?T,5_//_P %#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDO[)O_) =+_["M]_*&O6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQI_X*P?#3P_X'U7_ (0VXDU3Q-Y>VUAD3";CW)]J;V&MSX(_X*?>%/"7A/\
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MY+<O_8(O_P#T0U 'VI1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0_[!T7\A1_P3X_Y);\7?^N=G_P"E,- 'M-%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8.B_D*/^"?'_)+?B[_USL__ $IAH_X*^?\ )T0_[!T7\A1_P3X_Y);\7?\
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MI/\ A@WXZX_Y$'4?^^10(]I_X?!?&G_GAI/_ 'X_^M2-_P %@?C3Q^XTD?\
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M%HK:4.0N!R<5^4'_  E&L8Q_:MY_W_;_ !JO=ZO?:@H6ZO+BY5>BRR%@/S-
M'T?_ ,$X]6L-#_:V\'WFI7D5C:1LY::9@JCIU-?N]_PN'P/_ -#7I/\ X%)_
MC7\QEO=36LPEMY'AD'1HV((_$5>_X2?6/^@K>?\ ?]O\: /Z9/\ A<7@?_H:
M])_\"D_QI?\ A</@?_H:])_\"D_QK^9G_A)M8_Z"EY_W_?\ QI?^$GUC_H*W
MG_?]O\: /U?_ ."Q/CCP[XH^$OA6+2-;L]1N(]08M%;2AR%P.3BO@?\ 8F:+
M_A>UK#)/% UQIUY;Q--(L:F1X2J*68@#)(&2<5XA>:O?:@BK=7D]PJ]!+(6
M_.H8+J6TE66"1X)5Z/&Q4C\10!^M_P#PKG6?^>FD_P#@ZL__ ([2?\*ZUC_G
MII/_ (.K/_X[7Y/_ /"3ZQ_T%;S_ +_M_C2?\)-K'_04O/\ O^_^- 'ZP_\
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M'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"NM8_YZ:3_ .#JS_\
MCM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^
M#JS_ /CM'_"NM8_YZ:3_ .#JS_\ CM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04
MO/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"NM8_YZ:3_ .#JS_\ CM?D
M]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_
M /CM+_PKG6?[^E?^#JS_ /CM?D[_ ,)-J_\ T%+S_O\ M_C3O^$HUGG_ (FM
MY_X$-_C0!^L'_"N=9_YZ:3_X.K/_ ..TG_"NM8_YZ:3_ .#JS_\ CM?D]_PD
MVKKTU6\_\"'_ ,:/^$FUC_H*7G_?]_\ &@#]8?\ A76L?\]-)_\ !U9__':/
M^%=:Q_STTG_P=6?_ ,=K\GO^$FUC_H*7G_?]_P#&C_A)M8_Z"EY_W_?_ !H
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MSK/_ #TTG_P=6?\ \=K\G?\ A)M8_P"@I>?]_P!_\:7_ (2?6/\ H*WG_?\
M;_&@#]8?^%<ZS_STTG_P=6?_ ,=KY2_X*#RQQ1^ ]/>YM9;^SM)8YXK6=)A'
M^\<K\R,5.5*G@]Z^2O\ A)M7Y_XFEY_X$/\ XU4NM0N;Y@US<2W##H97+']:
M /N'_@D3XBTKPU^T-J=UJ^HV^FVYTQU62X<(I;GC)K]C_P#A<'@?_H:M)_\
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MS2!PAR<9Q7YV_P#"3:Q_T%+S_O\ O_C5:\U*\U%E-W<S7)7H9G+8_.@#Z?\
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M ..T?\*ZUC_GII/_ (.K/_X[7Y/?\)-K'_04O/\ O^_^-'_"3:Q_T%+S_O\
MO_C0!^L/_"NM8_YZ:3_X.K/_ ..T?\*ZUC_GII/_ (.K/_X[7Y/?\)-K'_04
MO/\ O^_^-'_"3:Q_T%+S_O\ O_C0!^L/_"NM8_YZ:3_X.K/_ ..T?\*ZUC_G
MII/_ (.K/_X[7Y/?\)-K'_04O/\ O^_^-'_"3:Q_T%+S_O\ O_C0!^L/_"NM
M8_YZ:3_X.K/_ ..T?\*ZUC_GII/_ (.K/_X[7Y/?\)-K'_04O/\ O^_^-'_"
M3:Q_T%+S_O\ O_C0!^L/_"NM8_YZ:3_X.K/_ ..T?\*ZUC_GII/_ (.K/_X[
M7Y/?\)-K'_04O/\ O^_^-'_"3:Q_T%+S_O\ O_C0!^L/_"NM8_YZ:3_X.K/_
M ..T?\*ZUC_GII/_ (.K/_X[7Y/?\)-K'_04O/\ O^_^-'_"3:Q_T%+S_O\
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M^3W_  DVL?\ 04O/^_[_ .-'_"3:Q_T%+S_O^_\ C0!^L/\ PKK6/^>FD_\
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MQ",7,@3=]W.,U^9]Q=RWDADGEDFD_O2,6/ZT^SU.[T\L;6ZFMMW7RI"N?RH
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M'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"NM8_YZ:3_ .#JS_\
MCM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^
M#JS_ /CM'_"NM8_YZ:3_ .#JS_\ CM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04
MO/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"NM8_YZ:3_ .#JS_\ CM?D
M]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_
M /CM'_"NM8_YZ:3_ .#JS_\ CM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\
MO^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"NM8_YZ:3_ .#JS_\ CM?D]_PD
MVL?]!2\_[_O_ (T?\)-K'_04O/\ O^_^- 'ZP_\ "NM8_P">FD_^#JS_ /CM
M'_"N=8_YZ:3_ .#JS_\ CM?D]_PDVL?]!2\_[_O_ (T?\)-K'_04O/\ O^W^
M- 'ZP_\ "NM8_P">FD_^#JS_ /CM'_"N=9_YZ:3_ .#JS_\ CM?D^OB;6.@U
M2\_[_M_C1_PDVL;L_P!J7F1_T\/_ (T ?K#_ ,*YUG_GII/_ (.K/_X[2?\
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MKK6/^>FD_P#@ZL__ ([1_P *ZUC_ )Z:3_X.K/\ ^.U^3W_"3:Q_T%+S_O\
MO_C1_P )-K'_ $%+S_O^_P#C0!^L/_"NM8_YZ:3_ .#JS_\ CM'_  KK6/\
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M6/\ GII/_@ZL_P#X[7Y/?\)-K'_04O/^_P"_^-'_  DVL?\ 04O/^_[_ .-
M'ZP_\*ZUC_GII/\ X.K/_P".T?\ "NM8_P">FD_^#JS_ /CM?D]_PDVL?]!2
M\_[_ +_XT?\ "3:QG_D*7F?^N[?XT ?K%_PKG6?[^D_^#JS_ /CM'_"N=9_Y
MZ:3_ .#JS_\ CM?D^?%&LD'.JWG_ '_;_&D_X2;5QP-5O,?]=W_QH _6#_A7
M6L?\]-)_\'5G_P#':/\ A76L?\]-)_\ !U9__':_)[_A)M8_Z"EY_P!_W_QH
M_P"$FUC_ *"EY_W_ '_QH _6'_A76L?\]-)_\'5G_P#':/\ A76L?\]-)_\
M!U9__':_)[_A)M8_Z"EY_P!_W_QH_P"$FUC_ *"EY_W_ '_QH _6'_A76L?\
M]-)_\'5G_P#':/\ A76L?\]-)_\ !U9__':_)[_A)M8_Z"EY_P!_W_QH_P"$
MFUC_ *"EY_W_ '_QH _6'_A76L?\]-)_\'5G_P#':/\ A76L?\]-)_\ !U9_
M_':_)[_A)M8_Z"EY_P!_W_QH_P"$FUC_ *"EY_W_ '_QH _6'_A76L?\]-)_
M\'5G_P#':/\ A76L?\]-)_\ !U9__':_)[_A)M8_Z"EY_P!_W_QH_P"$FUC_
M *"EY_W_ '_QH _6'_A76L?\]-)_\'5G_P#':/\ A76L?\]-)_\ !U9__':_
M)[_A)M8_Z"EY_P!_W_QH_P"$FUC_ *"EY_W_ '_QH _6'_A76L?\]-)_\'5G
M_P#':/\ A76L?\]-)_\ !U9__':_)[_A)M8_Z"EY_P!_W_QH_P"$FUC_ *"E
MY_W_ '_QH _6'_A76L?\]-)_\'5G_P#':/\ A76L?\]-)_\ !U9__':_)[_A
M)M8_Z"EY_P!_W_QH_P"$FUC_ *"EY_W_ '_QH _6'_A76L?\]-)_\'5G_P#'
M:&^'>L*I)DTG Y/_ !.;/_X[7Y/_ /"3:Q_T%;S_ +_M_C2?\)-J_/\ Q-+S
M_O\ M_C0!UGQ]N(;SXT^,YK>59X)-3F9)$.0PW=17[*?\$T_B-X5\/\ [)?A
MBSU'Q#I]G=J\A>&>=49>G8U^%\DC2NSR,SNQR68Y)JW;:YJ-G"(H+^YAB'1(
MY64?D#0!_35_PN+P/_T->D_^!2_XT?\ "XO _P#T->D_^!2?XU_,W_PD^L?]
M!6\_[_M_C2?\)-K'_04O/^_[_P"- '],O_"XO __ $->D_\ @4G^-/A^+G@J
M>:.&/Q3I;RR-M15NERQ]!S7\R_\ PDVL?]!2\_[_ +_XU-9^,=<L+ZVNX-6O
M%GMY!+&WGL=K Y!ZT ?U'[AC/6@'-?-W_!/KXC>(/BG^S'X=U[Q->/?ZJ[/$
MTS@@E5P!^E?2(H 6BBB@ HHHH **** &MTKX3_X*S_"_Q%\2O@_H:^'[)[Y[
M*[,LT<:Y.W K[M;[M0S6\5Q'LFB293_"ZAA^M3+5#/Y>[_P/XBTAI!=Z%J%N
M8S\QDMG &/?%;WA?XZ_$'P39?8M"\6:GI5L/^6-O+M'\J_I!\4?"OPIXPTV6
MRU/0K&6*12I*P*K<^X%?*/Q(_P""4OP@\1Z)J0T"PETG69PSQ3F3**Y]L50C
MX(^$?_!5OXK_  O\*0:)<I;>)!"?ENM0.9#]3BOJSX*_\%AO#&K6+_\ "P[%
MM*N>QLTW"OG#XJ_\$C?B)\/?"-[K6GZI;>(9+<96RM4/F/\ 2OE#Q%^SK\2O
M">GO?ZQX,U6PLT&6FFAPH_6@#]^/@O\ M@?#/XZ:=+=^']>@A6,X9+UUB;]3
M7K>G:]INKL18ZC:WA'46\RO_ "-?RY66K7VFY%K>W-IGJ(963^1KU/X3_M6?
M$KX,7PNO#OB&X5UZ"Y=I!^IH _I)Y[\4GO7XX? C_@KYXN\-ZC<?\+(MCX@L
MV7$?V50C*:_4?]GWXU6'[0?POTKQKIEI)8V=]G;#-]Y<>M 'I-+110 4444
M%%%% !1110 444AY% "U'-(D*EY'6-!U9C@4NVO,OVF+JYT_X$^-;^RD:*\M
M=/DEB=3R&%2W8#M[KQ=H5A@7.M6$!/3S+E%S^9I^G^)]&U>;R;#5K*]FQGRX
M+A';'T!K^:+Q9\8O&7C2XBDU77[Z1HLA0LS*!^1KUO\ 8K_:4N_@?\;M+UG5
MM0N[K3[AEM9EFG9T4,<;B">U6M6*6Q_0M_.D7]:S_#OB#3_%>BVFK:7=1WMC
M=1B2*:(Y5@:O,PA1Y96"H@+,Q/  ')I ?E;_ ,%EM-L8X/#]VD:B]>3#MWQ7
MY8<[:^U?^"I'QJ@^(OQTN-'TC4XM1T73U #PME?,Z$?@17Q6%)8*.2>!44DX
MJQI/5G[+?\$;Y9_^%,ZK'EOL_P!J8^V<FN*_X+:H3H?@!@I($L@)].#7MG_!
M)OP7J/@_]FX_VG:-:S7EXTZ!Q@E#DC^=;7_!33X46'CS]GK5M9N5S<:)$9XC
MCD5I-\I$/>/P6]:_3#_@BWJ6[QQXJLB>5MMX%?F>M?;O_!*7XP:5\+_CE/8Z
MGPVN1K9P'./G)XJHH4C]R,5XS^UYXRB\%_ ?Q-<2-L^T6KP@_45[-7P9_P %
M<OB1;>&_@7;:+;:A&FK7=T,VP;Y_+.,G%8RV+CN?BK>2>9>7+CHTC']:^H_^
M":>@1^(OVHM#MI$$BJC/@^Q%?*QY4GN>:_0K_@D'\'=2UGXL2^.U_P"0=IR-
M;M_O&M8.SN14VL?LPJB.-47@*,"G=J1C1_#4#/'?V@OV6?!'[1VCK:^([!%N
MT8%;Z-1YH'IGTKP)?^"2_P )U/\ KKH_\!'^-?<"TM,#X?7_ (),_"=5(,UT
M<_[(_P :%_X),_"=1S-=$_[H_P :^X** /A\?\$F?A0!@377_?(_QH_X=,?"
M?_GM=?\ ?(_QK[@HH ^'_P#ATQ\)_P#GM=?]\C_&C_ATQ\)_^>UU_P!\C_&O
MN"B@#X?_ .'3/PG!SYUU_P!\C_&C_ATS\)_^>UUC_='^-?<%% 'P_P#\.F/A
M/_SVNO\ OD?XT?\ #ICX3_\ /:Z_[Y'^-?<%% 'P_P#\.F/A/_SVNO\ OD?X
MT?\ #ICX3_\ /:Z_[Y'^-?<%% 'P_P#\.F/A/_SVNO\ OD?XT?\ #ICX3_\
M/:Z_[Y'^-?<%% 'P_P#\.F/A/_SVNO\ OD?XT?\ #ICX3_\ /:Z_[Y'^-?<%
M% 'P_P#\.F/A/_SVNO\ OD?XT?\ #ICX3_\ /:Z_[Y'^-?<%% 'P_P#\.F/A
M/_SVNO\ OD?XT?\ #ICX3_\ /:Z_[Y'^-?<%% 'P_P#\.F/A/_SVNO\ OD?X
MT?\ #ICX3_\ /:Z_[Y'^-?<%% 'P_P#\.F/A/_SVNO\ OD?XT?\ #ICX3_\
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M0!\/_P##IGX3[<>==9_W1_C0/^"3/PGQ@S71/^Z/\:^X** /A_\ X=,?"?\
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M_C7W!10!\/\ _#ICX3_\]KK_ +Y'^-'_  Z8^$__ #VNO^^1_C7W!10!\/\
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MMM[J=8W;T!-?L[_P5P)_X9LC_P"OO^@K\=O@*?\ B[7AS_KZ7^= 'Z[^&?\
M@E/\*M2\.Z==2SW#230+(Q5>,D9]:TO^'3'PG_Y[77_?(_QK[!\!?\B7HO\
MUZI_*M^@#X?_ .'3'PG_ .>UU_WR/\:/^'3'PG_Y[77_ 'R/\:^X** /A_\
MX=,?"?\ Y[77_?(_QH_X=,?"?_GM=?\ ?(_QK[@HH ^'_P#ATQ\)_P#GM=?]
M\C_&C_ATQ\)_^>UU_P!\C_&ON"B@#X?_ .'3'PG_ .>UU_WR/\:/^'3'PG_Y
M[77_ 'R/\:^X** /A_\ X=,?"?\ Y[77_?(_QH_X=,?"?_GM=?\ ?(_QK[@H
MH ^'_P#ATQ\)_P#GM=?]\C_&C_ATQ\)_^>UU_P!\C_&ON"B@#X?_ .'3'PG_
M .>UU_WR/\:/^'3'PG_Y[77_ 'R/\:^X** /A_\ X=,?"?\ Y[77_?(_QH_X
M=,?"?_GM=?\ ?(_QK[@HH ^'_P#ATQ\)_P#GM=?]\C_&@_\ !)GX4-C]]=?]
M\C_&ON"B@#X?;_@DS\)VZ370_P" C_&E_P"'3/PF_P">UU_WR/\ &OM^B@#X
M?_X=,?"?_GM=?]\C_&C_ (=,?"?_ )[77_?(_P :^X** /A__ATQ\)_^>UU_
MWR/\:/\ ATQ\)_\ GM=?]\C_ !K[@HH ^'_^'3'PG_Y[77_?(_QH_P"'3'PG
M_P">UU_WR/\ &ON"B@#X?;_@DQ\)R,":Z'_ 1_C0?^"3/PGX_?77_?(_QK[@
MHH ^'S_P29^%!Q^_NL?[H_QH_P"'3'PG_P">UU_WR/\ &ON"B@#X?_X=,?"?
M_GM=?]\C_&C_ (=,?"?_ )[77_?(_P :^X** /A__ATQ\)_^>UU_WR/\:/\
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M_P#/:Z_[Y'^-'_#ICX3_ //:Z_[Y'^-?<%% 'P\?^"2_PGSQ-=?]\C_&G?\
M#IKX3]?-NO\ OD?XU]OT4 ?#Z_\ !)GX3C.)KDY_V1_C0O\ P29^$^W'G77_
M 'R/\:^WZ6@#X?;_ (),_"=C_KKH#_='^-'_  Z8^$__ #VNO^^1_C7W!10!
M\/\ _#ICX3_\]KK_ +Y'^-3V/_!*'X36.I6=WON9/L\HD\ME&'P>AYK[9HH
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M(4KZB^"__!&W68O$J2?$;5K>31P/FCT^3YS^M,1^8L<,EP^V*-I&_NHI-?T
M?\$U8I(?V0_!ZRPO!( ^4D4J1T[&J_PL_P"";7P?^%.K+J%GITNHRJ<[;X[Q
M7T_I>DV6AV4=EI]K%96L8PD,*!4'T H$7!2T44AA1110 4444 %%%% !24M)
M0 G.[VJIJ^DV>N:;=:??P+<V5PACEA<95U/4&KM-VTO4#^?+]O+]GC6/@?\
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MYWW_  2.\/:I\:9=;FO/*\)23>>;6%L-G.< >E,#[K^$/_)+?">.?^)9!_Z
M*["LW0=%M_#6AZ?I5J#]FLX5@BSUVJ,#^5:5 !1110 4444 %%%% !1110 4
M44F?6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BF_PTH- "
MT44F: %HI*3=0 ZBDI:5]; %%%%, HHHH ***2@!:*** "BBDSS0 M%-)[4=
MJ $X7G]*\%_;D61_V:?%0CC>5O*'RQC)Z&O>Q535=+M-<T^:QO[>.YM9E*/%
M(N001B@#^7G26*^)[8[3N^U#Y<<YW=*_HV_93#I\!_"_F(R/]G&5<8(X%?-5
MG_P2B\!6OQP_X2GS)3X>67[8ECN_Y;[MV,?W<U]TV-C;:;:QVMI"D$$2A4CC
M&  * )OXNM/IBBGT %%%-W&@!U%)2T %%%% !1110 4444 %%%% !1110 44
M44 %%%(: %HHHH **** "BBB@ HI#1F@!:*0FCZTK@+12?2EI@%%%% !112$
MT +13=QI0: %HI,T9H 6BFTN>*-@%HI!0: %HI*": %IK?=ZXI3F@T ?$'_!
M6Y96_9KC\J&2;_2N=BDX&!R?:OQU^ Y;_A;7AL(I=C=( JC)/-?TE>-_!.C_
M !"\-WVA:[9QWMA>1-$ZR*#@,,9'H:^.O@G_ ,$N?!/PI^,4WBZ662]LK&<3
M:5;2-D*?]H4 ?8W@//\ PA>BY!4_94R#VXK?IL<:Q(J(H5%& H' IU !1110
M 444AS0 M%%% !112$T +12=J.U "T4W<:4T +124M !1110 4444 %%%% !
M1110 4444 %%%% !129YI: "BBB@ HHI,T +1110 4444 %%%)0 M%)1VH 6
MBD!I: "BBB@ HI*6@ KYT_X*"D#]DOQX2=H^R=_K7T57'?%SX7Z1\9O .K>$
M-=W_ -EZE'Y<WE_>Q0!_-=\-5=_B%X:"1M(W]HV_RH,G_6+7].'AG(\-Z2,<
M_9(NO^X*^'OV=?\ @E[X>^#WQ2G\2ZG*FJ6=NY-C#(=V!G@GWZ5]WJBQJB*,
M(HPH'84 2T44AH 6BDYI: "BBB@ HHHH **3)HH 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE?G1_P6B8K\'?"V&8?Z
M>>AQG@5^B[5^<_\ P6D91\'O"H) 8Z@<#UX%9SZ%(_'$5](?!3]G7X:?$31Q
M=>)/BI:^%KDC/V>55)_6OG#<,4WBM23]5OA'\(/V,?A[X:2Q\5>+]-\5ZKG+
MW<S #\ !7T%\,/C3^R-\' W_  BFM:+IY88+ ;C^HK\*.,]>*0X[4@/Z((_V
M\_@+#Q'XZTV,?[/%2?\ #?/P*_Z'VP_,U_.WQ1Q0!_1)_P -\_ H<_\ ">V'
MYU[%X%\>Z%\3/#5KK_AV^34M)N>8KB/[K8K^7HX[&OZ /^"9JH/V/_!VS&W#
M]/PI@?4U+112 **** "BBB@ HHHH **** "BBB@!I)VG'6F311RJ!)&L@]&
M-/*GI0%Q[T <QXF^&?ACQCY8U71[6Y,9RI,2@_RJKX=^$/@_PKJ'V_3-#M+>
MZV[?,6,9 _*NQYHQTH 9'#%""(D2,'J%4"GKD\$4NVDP>: &^PXI3C /6G48
MH ;CC/6F2V\4V#+%'(>VY0:EHQGK2 X35O@?X(UG4I=0N_#UG)=2'+/Y8&?T
MKH]!\(:-X9LEM-,TZWM8%.0J1@?TK8"XSS2*N*8",/7I2C&WGI1M['I2XH 6
MBBB@ HHHH **** "BBB@ HHHH ***0T 'THS5+4M9L-%A\W4+V"QB)P)+B0(
MN?3)-9?_  L+PL.OB/2O_ R/_&@#H>M'2JFG:M8ZO#YMC=P7D7]^WD#K^8JT
M6'% #J::7WIDLL=O&SR.J1J-S,QP /4T@'K2&L'_ (6#X7!(_P"$BTL$=1]L
MC_QJ;3_&&@ZM="VL=:L+RX(R(H+E'8_@#3#U-D?=HI,@\4ZD 4444P"BBDH
M6BL_4]>TW155M0U"VL5/0W$JIG\S6>OC[PS*RJGB'2V9C@*MW&2?UI+L!T%%
M,AD2:,.C!T/(93D&GT -;Z9%"]..G:EYI NT'%,!!][/ZT^F[<#@5CWOC3P_
MIMT]O=ZWI]M<)]Z*:Y16'U!- &U161I_C#0M6N!;V.L6-Y.1D1P7".WY UK
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M@9)_*AC)L'L>*\)_:_\ VE-"_9Q^%>IZC=WD7]M3PLEE8[OWDI.1D#VKP?\
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M_P#!8F]N]/\ V>-'EM+J:U;^TU!,+E"?N\$BOQEC\3ZVTD:_VQJ #$#BZ?\
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MZ<5^7'_!:S4KW3X_AZUG>W%KDR[A!*4S][K@U^HYZ&ORP_X+;_ZCX>_67/\
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M 4_6OM/@YK\:O^"-NOQZ3\7/$5O(<?:K54%?L;J%XFFV%S=S,J1PQM(68X&
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M0!7\^'_!1S_D[OQM_P!=E_K7]!W\5?SX_P#!1K_D[SQM_P!=E_K4?:0':_\
M!)W_ ).PTW_KTE_E7[!?M6R&/]G7Q\RG!_LN3!'X5^/W_!)W_D[#3O\ KTE_
ME7[!?M51M-^SMX^5!EO[,DP/RJY MS^; L6R6.23G-?ME_P1\TVU7]G"YO1
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MGTHJ;,([H_G@OIOM-Y<2YSO<M^9K]5O^",^AW%O#K^HNF()4VJU?E%7[H?\
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M\4\<>'M&S]#_ (51US_@L-\3M>T6^TVX\/:.(;N!X'(!R P(/;WK[V_X=<?
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MK]\O^"DGBL^#_P!F/6;P'EW6+@XZYK\!)I#-+)(>K,6/XUG'XKFSMRGZ[?\
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MH_AHZ ?$?_!7+_DUF3_K^CK\-:_<K_@KE_R:U+_U_1_SK\-:BF-G](?['?\
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M->PY>ZE<_8JBBB@0T\5\=?\ !5#P[>^)/V7;Z&RB,KQ7*2LH'\(K[%;BN/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "4C4ZB@#P7]M;X+'X[? +7?#Z3&"2-#=JP]4!-?S
MN:I8MINJ7EFW6VF>(Y_V6(_I7]2FH62:AI]U:/\ ZN>-HF^C @_SK\$/VROV
M3O%7@GX^>(+'PSX7U+4=)D;SX[BV@+HQ8DD<4EHQGRB>:_97_@C_ /"?2]-^
M$UWXTGT\Q:Y<3M MPZX8Q<_I7Y>>&?V;_B5JWB+3[4>#-6C\R= S26S!5&1D
MDU_0W\%?!=KX#^&'AW2;2SCLC%9Q>=&BX^?:-Q/XU:=D2=N#D9I#][<3QTHR
M.<4GW>,<5&PS\@/^"O'[/=WHOCB'XFP&6XM]3*V\J(I(CVCJ?3K7P5\)_B9J
MGPB\>:7XJT9S'?6+[E(],C(K^E#XA?#O0_BAX3O_  [XALH[[3[R-HF6102N
M>ZGL:_'+]IC_ ()7>-_AG+KFO^$F36/#<<I-K9Q9:XV>A&:4=!O4^T_A/_P5
M4^$FM>"K";Q=J[:3K:H%GA$>X$XZ]:\5_;>_X*?:%KG@N+P_\)]3>YGO01<W
M^W:T/IBOSD_X9^^)'_0D:S_X"-6SX-_97^)WC/Q-I^C0>$=3M)+N01B>XMV6
M-/<GTJGJ):&IH/[57QMU*^M-+TWQSK,LT\BQ111ON))( X ]Z_=#]D/PMXR\
M(_!'1;3QWJ<NK>()!Y\MQ,3NPP! -?-W[#G_  33M/@3J;>*?'OV;6/$T;?Z
M)'& T,2D=2#GG.*^^.(U"@8 X ':GY"/S9_X+&K_ ,4GH1SS@_SK\I?AOG_A
M/O#V.OVV/_T(5^N7_!6SP7XC\7^&="CT#1;K5V7.\6J%BO/M7YD> /@1\1[/
MQOH4[^"M85$O(V8M;, !N&234T/=J/U-JC_=H_H9^%&?^%=Z%S_R[)_(5UJF
MN6^%]O+:^ =%BGC:*5;9 R-U!P.*ZE>.*NI\;L<]/X4S\#/^"GW_ "=EXA_W
M%_F:I_\ !,W_ )/!\'?5_P"E=Q_P4<^$/C?Q1^U%X@OM*\*ZGJ%BR)LN;> N
MK<GN*J_\$[/@_P".?"_[6'A#4-4\*ZG86,;/YEQ<6[(B#CDDU,-$:/<_=+^*
MOY\?^"C7_)W?C?\ Z[+_ %K^@[TK\(?V_P#X.^.O$W[57C/4-,\*:I?6,LRF
M.XM[=F1QCJ"*2W$3?\$G?^3L-._Z])?Y5^XOB;0;;Q5H-]I%ZN^UO(C%(OJ#
M7XQ_\$P?A/XU\)_M1:;?:QX8U'3; 6LH>XN8"B@XX&37[6M52&C^=3]LSX#Z
MI\"_C1KEC/9-;:/<7#/8R ?*Z5<_8Q_:LO\ ]EOXE)JX@^W:5> 6]S S<(A/
M+CW /Z5^V'[3W[*/A3]IKPRUGK<&S484(MKI1@JW;FOQZ_:&_P""<?Q.^!I%
MU#9GQ%I\TI6+^ST+NJYXW8I1?+H$O>W/U"M_^"HGP!DMXWD\4/'(RAFC\G.T
MXY&<U^:'_!0;]LP?M(^,(['P]<.OA6T&V-<\2GU-?/?_  S_ /$C&?\ A"=:
M_P# 1J]2^!?[ WQ2^-NL-:1:1-H$"'YY]2C*#'?&:+787.%_9C^#M[\:_B_H
M&A6]H]S9-=1M>%<_)'GDG%?T4>&_"%EX!\ 0Z!IR[;*PLVBC!] IKP?]CO\
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M(KD5\S?MU_LJI^TM\*[N#35B3Q/9H7LYI!Q@9)7\:;[B/SV_X(UWB1_M :U
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M=.?W"CLM?H=^UC_P3-\(_'"[U3Q)X<"Z+XKNE'"X6 L.^!Q7YC?'+]@;XJ?
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MZ9'D0IZX%/I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>I_*G4E*P$/V6!CDPQ_]\#-*MO#&V5AC4]B%%2T$9I@-/O0,YX&!ZTZEI-]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )0?>EI"
M,T &!0*** "EI*6@!&H'2EHH *3-%)MH 7-+3=M.H **** $HHHH ,T"DVTH
M&* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0T"
MB@#% "TC48S0>: #J***6@ HHHH 0TBTIYH Q0 M%%% !1110 4E%%  *#11
M2 *6BBF W)I11MHH 6BBB@ HHHH ***3OF@ IM/INV@!*<*3;2T +1110 44
M44 %)WI:2@!#]X4ZDQ2T %-_BI<48YS0 M%%% !1110 4444 %%%% !29I:3
M'- "<TM&.<TM)#&TZFXYIU !12=\TM,04444 %%%% !1110 4444 %%%%( H
MHI*8"<THHQ2T %%%(>: "EI-M+0 4444 %%%% !1110 4444 %%)CG-+0 44
M44 %%%% !1110 4444 %%%% !1110 444E !NI:3;12 &I:2EI@%%)2T@$I:
M3%+3 **** "BBB@ HHHH **** "BBBD 44F*6@!,TM)BEI@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ast008breastcancer.jpg
<TEXT>
begin 644 ast008breastcancer.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +)!:<# 2(  A$! Q$!_\0
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M* "BBB@ HKQ[XO?M;?"7X"^)K;P_X\\80^']8N+1;^*UDL[F8M SNBOF*-E
M+1N,$Y^7I7$_\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[
M_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?
M\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]
MF_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW
M_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R
M^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO
M17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17
MS1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;
M_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*
M;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[
M_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?
M\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]
MF_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW
M_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R
M^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO
M17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17
MS1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;
M_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17BGPM_;,^#'QJ
M\71>%_!OCRQU?7YHGGAL&@GMY)E09<1^;&@=@N6VJ2VU6;&%)'M= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45X1\0OVXO@=\*O&.I>%?%'CZUTS7]-94N[/[
M%=3&)F17 +1Q,I.UUZ'C.#SD5S__  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
MZ*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW
M_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\
MC%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R
M3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_
M .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X+
M+[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_
M (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\
MT?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
MZ*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW
M_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\
MC%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R
M3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_
M .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X+
M+[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_
M (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\
MT?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
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M3:K#8RR+E[:X8AXSG!!X_7N,4[,#O**R]!\2:;XFM7N=+O(KZ!'\MI(CD!L
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MP)I7BR/PM?>-O#MGXFD=8TT6XU6".\9FP540EP^3N7''.X>M '-?\)%\;_\
MHGOP_P#_  O+[_Y34?\ "1?&_P#Z)[\/_P#PO+[_ .4U>JTM 'E/_"1?&_\
MZ)[\/_\ PO+[_P"4U'_"1?&__HGOP_\ _"\OO_E-7?:CXLT/1]>TC1+_ %G3
M[+6=8\[^S=.N+I([F]\E-\ODQD[I-BD,VT':#DXK8H \I_X2+XW_ /1/?A__
M .%Y??\ RFH_X2+XW_\ 1/?A_P#^%Y??_*:O5JR->\5:+X7.G#6=8L-(.I7D
M>G6(OKE(/M5U)DQP1;B-\C!6PBY8[3@<4 <!_P )%\;_ /HGOP__ /"\OO\
MY34?\)%\;_\ HGOP_P#_  O+[_Y35Z!H?BC1O$[:BNCZM8ZL=-NY-/OA8W*3
M&UN4"EX)-I.R10RDHV"-PR.:UJ /*?\ A(OC?_T3WX?_ /A>7W_RFH_X2+XW
M_P#1/?A__P"%Y??_ "FKU:B@#RG_ (2+XW_]$]^'_P#X7E]_\IJ/^$B^-_\
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MG!'TC0!Y+\9O^2F? ;_L<;K_ -1[5Z]:KR;XS?\ )3/@-_V.%U_ZCVL5ZS0
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M HHHH ^9_CY_R>7^RQ_UV\4?^FL5],5\S_'S_D\O]EC_ *[>*/\ TUBOIB@
MHHHH **** "BBB@ HHHH **** "BBB@#RG]K'_DUCXR?]B9K/_I#-7JU>4_M
M8_\ )K'QD_[$S6?_ $AFKU:@ HI"<5Y[\*_C]\/?C?<>((/ WBNP\22Z#>-8
MZBEHS9AD!(##<!OC8AMLJ9C?:VUCM- 'H=%)2T %?FY\6M8^&6B_\%-O%$_Q
M6T"U\1^'6\ P)!:W?AV36U6Z^T0%7$"0RE2$$@\S: -Q&?FP?TCKX+\>^)/$
M'P3_ ."BWB7XB3?##X@^,O"]]X'AT6&[\'^'9M07[0;B"7!;*I@+$V<-D$KQ
M0![!\!=4_9P\5^/D/PU^'VCZ-XIT^VDNX[^+P#+H\D,9Q$Y2XDM8\$B7:55L
MD,W&,U\4?\$\+C_A5_Q<L_&#OY6D>-_%NO>![^:63;#'=1Q6UYI_L7=OM40&
M027'6OO#X9_M:)\3/'&F^&U^#WQ:\+&]\W_B;>)_";66GP;(FD_>S&0[=VS:
MO'+,H[U\D?!SX"^.6_8?^+-O_P (WJ^@>/=#\?W7C3PS!J&E3+=23V8M9XGM
MXF3=(TJQ2PH0I!+D<T 9O_!3QH?BS=_%9\P7.F?"/PQI4(5HRLL&KZMJEJS,
MK=&7[' @R!P96'/;ZS_:Z^ _PTO?@/\ &+Q5<_#OPI<>*%\*ZM>C6Y=$MFO1
M<)9RLDWGF/?O4JI#;LC KYY^)'PK\;^*O^"<_P 8=4G\(^(G^(7Q&\2?\)-/
MX9>Q>;4;9&U:V2"W$2*9,1VMO&VTC*C=D#!Q]E?M-:3?:]^S;\5],TRSN-1U
M*]\)ZM;6MG:1-+-/*]G*J1HB@LS,Q "@9)( H ^<?#?@/X>_"']@70/BOH_P
M_P#"5CXYTKX=6FKV>OIH-J;Q=0.G(R3F7R]Q<RL&+$Y))R>M>=6%C\!-&^$$
M6B>(/@5XM\>:?)IFW7/C#9>#8[I;J:5"UYJB7TKFZ9!(\D@E17  !C+J%)^H
M?!GPCN?'_P"PGX8^&VLP3:+J&I?#VRT6XCO;=EELK@Z?''\\; ,'CDY*G!!7
M%<79?M4^.?"OAVV\&ZE^SO\ $"\\?VEHMAY>C:7%)X<GN0@5&2_\W8ELV5)9
MAF,$A@2IH ^B_AFNG?\ "N?"PTC7+GQ/I0TJU%GK=Y.)YK^'R5V7$D@ #NZX
M8L%&2Q.!7A&L?&SXQ_%7QQXNTGX'Z)X(_L'P?JW]AZIK?CFZNU%Y?)&CSP6T
M-LA91%O16DDX8L-H(!->D_LM_".]^!/[/O@?P)J5^^I:EH^GK'=SM*95\YV:
M21(V(!,:,[(F0/D5>!7AGAGQ'K_[&OCCXHZ9J'PP\<^/O#_C3Q;>>,-+UKP+
MI0U((;I(A-;7$6]6A:-X_E8DAPV1C:10!YY\8/B?\1?$GQ^_9-UIOAP=,^)$
M-WXOTN3PYJ-VT%IYXM(8&N5N"F6M0C&?<JDE%*KN;!/MW@GXX?%WP7\</!_P
MY^,^C^"C+XW@U&70=2\#W-VR126<:S2Q7"7*@G,;@AT/5>G/R^?1Q_%CXF_M
M.?LT^./&'@2Y\/V%KJ/B^:.VMK621M(TV;3HH[(:E(I:.*XE97.W<!\RKC<K
M"O2/CMX3UO5_VS?V7];L=&U"]T;1_P#A*/[2U&WM9'M[+S=.C2+SI -L>]@5
M7<1N((&30!!JOC[]IOQMJFJ:AX%\'> /"OA2SU&XL[=?B#<:C'J-_#"Y7[4L
M<,86&.3&4#Y.!D\$&O+?B?\ &8_M!?!G]E#QZ^E?V)-JGQ=TA)K#SA,L4L$E
M_;R!7 &5+Q,1QT(S7F'AWP/8:E)#!\</V>?BY\7OC;%>W'VK691</X>NIC<R
M/;I%+]I2TCM K1\&((@+?+@8KI_ OPK\;Z7^RO\ LL^'KSP5K-AKGAOXO0WF
MKZ;'I\C'3[=;_4G:=MJD" ++'^]^YAU.[!&0#T+X)_%:+X+^ ?VG/%+Z5<Z_
M>0_%[5+6PT>R.)]0O)Q8P6UNA(."\LB+D X!)P<8KJ-:^-GQ\^"=O_PFGQ>\
M.?#T?#);FWAU!_"E_>OJ6BQ32+']HE$T?ESI&SJ'6+#8)*Y KRK7/V9_$WQ8
M^!O[16@OX3EN-8D^+E[XGT72M::;3X=9@C%H2J2Y4F.>)9XUD#!=Q!WKC<OF
M3_LY_"'QK-9>'O!'[&_C_3/%EU=0PRWGC>XU.PT2RBWK]HE>Z%\?,"IOVB,9
M;C )PI /J>3XZ_&SXF>,_B7X3^%_A3PA;W?@_7O[.;7?&%U=)8RPFWBD2-([
M<-))/N=RV2BJOE_>+G;/H_[76NZ+\)?'-_XQ\'0?\+'\)>(8_"9\/Z'>[K?6
M-0G, LS;22#*13?:(S\X+(H8D9&*ZW]FWP[JNA>-/CM/J6F7FG0ZEXZEN[*2
MZMWB6Z@-A9()8RP^=-R.NY<C*L.U>)^-O@?XK\7:G\9-8TSP_<3:_H7Q,T7Q
MIX8M=09K*#5Y+.SM T<<K *P=1/$&Y4/C)&,@ UOB7^T1^T1^SWX777?B'X*
M\"ZQIVI:E9Z=97'A"[O7&FO-/&I^VK,HRC(9%62,X$@C4KA\UWGCGXN_&#QM
M\1/%'A+X)^'_  B8O"DEO:ZMXB\<7-T+26\EB28VMM':J69HXI(F=F88,F,<
M9/@W[6G[27BKXQ_"%/#NA?!?XA>&+"37=&.M:GXRT==/AAA_M&W\I+?]Z3-*
M]QY"X0'"EC[C!^,G[+/@#P5\>OB'X@^(O[/_ (O^+/A[Q7J"ZQH^M>!I;V\N
M;622-?M5K=6\-S$8QYP>1'"L"LN-WR[4 /LCX"?&;5?B)=>+?"OB[2;/0?B'
MX-NX;/6[#3KEKFTD6:(36UU;R$ ^5*A)"N ZE65AD<ZO[3'_ ";A\5O^Q3U;
M_P!(Y:\=_85^$.E?#VV\=Z[H/PAN/A!H&O7EM'IFGZM?W4^K7=M!&^)KN*:>
M58#OFEVHNUL9W @*S>Q?M,?\FX?%;_L4]6_](Y: (?V7/^39OA'_ -BAI'_I
M%#7I]>8?LN?\FS?"/_L4-(_](H:]/H **** "BBB@ HHHH **** "BBB@ HH
MHH **** /#_V:_\ D;OC[_V4.;_TT:77N%>'_LU_\C=\??\ LH<W_IHTNO<*
M ."\2? [P/XPUJYUC6-!CO=1N-OFSM/*I;:H1>%<#A0!P.U>._%;]D'^V-8L
M[CP.VG:/9"#R[BTO)9L>8&)#JV'SD$#! QL'7)Q]/T4 ?)OP]_8[U33?%EG<
M^*Y](U+0XPYFM+6>??(2C!<?(F &*M][^&O:]+_9[^'VBZI9ZA9>'(X+RTF2
MXAE%S,=CHP*M@OC@@=:]'HH *0]*6B@#XT\"ZI?_ +%'Q0^).C^(O"VN:G\,
M/&&OW'B[2O%/A[2I]033YYT3[3:7D4(9X@K1KY;!"&!R3G(3MOA'\2OB5\=?
MCK>>([/2M7\$_!#1]/:TM+;7M.6VO?$=\[9^TB.5/-BMT3&W[I8D=<LL?TK1
M0!\O?MO>$==\6:E^SX^B:+J.LKI?Q3T74+]M/M9)Q:6L;2>9/+L4[(UR,NV
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M./VEM$\%_$[X@_"@ZQHWAG7;^:'X9PW+0:Q/H-S!''YDK+*%-ZLD23_9U89
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M7O$/AK7OAWXT\*>,-*T6?Q!!X?O+.&>?5K6+AA9/!*\<TNXHOE[@=S@<@$@
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M2^(/#EAXO^%_CSX<Z=XDF2VTK6?$=A"+4SR;1%!<&*:1K661G"JDJC)R.QP
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MPA%KYTA58H;GR9I&M9)'=5595&2<<8./H6@!:*** /)OC-_R4SX#?]CA=?\
MJ/:Q7K->3?&;_DIGP&_['"Z_]1[6*]9H **** "BBB@ HHHH **** "BBB@
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ML[CX?VOAM=7N$DM[C[4MVT893(1AAY>>%([!ASSSSG%\/_LT_P!A:_IFI_\
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MO@S^UA\._B+XQO&M? %YX=U#PN-2FA_T31M1DN+>=)IY?^6:SI$T08\ Q\D
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MM:/)X3T.32=;NWO]4L&TV$P7]R[*SS3Q[=LLC%$)9P22JG/ H ^?=6^(&A_
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M8K#TCP/X>\/:OJ6JZ5H.F:;JFI,'OKZSLXXI[H@8!E=5#.>!]XFMV@ HHHH
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M2I79Y;220]461Y)$9V^10BEBN.?>_CO\<?#GP'^$VM^-]<O;9;:SM7>RMWE
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M?#?49?"'CF;X<7EGX/\ '_B"-)UUQ[6.99;J)%2(SJZ.K(4C6)CL)"$E>0*
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MUWX*N-<U>2\AU  VK:A'ISG3PRM\ID\PR;,\[AQS7T3X/\)Z;X$\)Z+X:T6
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M=-ND.8+2598S&P-O_JUPK''EJG)YS7NE !1110 4444 %%%% !1110 4444
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M^2%=I/* 'UA\.?VG/A1\6M<ET7PA\0= U_6(V<?8+2]0SR;!EFC0D&10.=R
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M#N]3T3PM\&=5M_%6H:F_B&7Q:;W^T]1N6O9Q.E^D4+1L02P"'(V%>.37U/\
ML1Z#K/A7X$V^C:MK/A;6[>QU6_BTV;PAJ4U_8P6IN'9;99945OW+M)"%YVI$
M@SV ![]7FW[3'_)N'Q6_[%/5O_2.6O2:\V_:8_Y-P^*W_8IZM_Z1RT 0_LN?
M\FS?"/\ [%#2/_2*&O3Z\P_9<_Y-F^$?_8H:1_Z10UZ?0 4444 %%%% !111
M0 4444 %%%% !1110 4444 >'_LU_P#(W?'W_LH<W_IHTNO<*\/_ &:_^1N^
M/O\ V4.;_P!-&EU[A0 4444 %%%% !1110 44E&: %HHI-U "T4E+0 44E%
M"T44E "T4FZEH **** "BBB@ HHI* %HI,TM !1110 4444 %%-W"G4 %%%%
M !1110 44F:* %HHHH **** "BBB@ HHHH \F^,W_)3/@-_V.%U_ZCVL5ZS7
MDWQF_P"2F? ;_L<+K_U'M8KUF@ HHHH **** "BBB@ HHHH 1J_&F3X4Z?\
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M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JUQ'BCX1Z%XO^)?@?QU?_ &K^W/!ZWZ:9Y4H6'%Y$L4WF+CYO
ME1<8(P?6L'_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=H
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MT85HT9"IW*0"&R!5/X=_LF>!OAYXRMO%?G^(/%7B&P66'2K[Q9KESJC:3#(
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MS]H'CCQ]XI^$WP6NOA9I5V_B?P?;2?:[S6%2V"V;W,4$SPHL(,@VA-VYP2W
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M_P#0?_EI1_PO/Q5_T0?XC?\ ?_0?_EI7KU% 'D/_  O/Q5_T0?XC?]_]!_\
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M0?\ P60__$T?\*L\%_\ 0H:#_P""R'_XFNIHH Y;_A5G@O\ Z%#0?_!9#_\
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M'7Q,E\._#[P[XLT7Q-XD;7;6]O/%C:=*BM96EN8VB%G+R#;%L[_XNG'/1?\
M"Q/C]_T1;PI_X<!__E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1
M;PI_X<!__E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1;PI_X<!_
M_E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1;PI_X<!__E;7N-%
M'AW_  L/X_?]$6\*?^'!?_Y6T?\ "P_C]_T1;PI_X<%__E;7N-% 'AW_  L+
MX_#_ )HMX4_\."__ ,K:/^%B?'[_ *(MX4_\. __ ,K:]QHH \._X6)\?O\
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MZ4 >6?\ "POC]_T1?PI_X<!__E;1_P +#^/W_1%O"G_AP7_^5M>XT4 >'?\
M"POC]_T1?PI_X<%__E;2?\+"^/O_ $1;PI_X<%__ )6U[E10!X;_ ,+"^/W_
M $1;PI_X<%__ )6TO_"POC[_ -$6\*?^'!?_ .5M>D_#&[GOOAOX4N;F:2YN
MIM)M)99I7+O(S0J69F)R23DDGUKJ* /#O^%A?'[_ *(OX4_\."__ ,K:3_A8
M7Q]_Z(MX4_\ #@O_ /*VO<J* /#O^%B?'[_HBWA3_P . _\ \K:/^%B?'[_H
MBWA3_P . _\ \K:]QHH \._X6)\?O^B+>%/_  X#_P#RMH_X6)\?O^B+>%/_
M  X#_P#RMKW&B@#P[_A8GQ^_Z(MX4_\ #@/_ /*VC_A8GQ^_Z(MX4_\ #@/_
M /*VO<:* /GV.U^+WQ$^)GPXO?%'@#P_X2T+PSK%QJUQ>67BI]2FDW:9>VB1
MK$;.(<M=JQ;?P%/!S7T%110 4444 %%%% !1110 4444 %%%% !7Y-?M3:M\
M-?@A_P %0O#WQ+\4:Q9Z_HCM#_PD6B^0MS<Z1=?V<(;>5H&4;H@IM9PR%V!5
M\#<$#?K+7Y__ +47_!*;_AI/XZ^)OB/_ ,+1_P"$=_MK[-_Q+/\ A'OM7D^3
M:Q0?ZS[4F[=Y6[[HQNQSC) /=;?_ (*$?LZ/ C1_%314CP-JLDR$?\!,8(KI
M? /[8GP9^*?BRQ\+^%/B!I6N:_?^9]FL+;S-\NR-I'QE0.$1CU[&OA'_ (<8
M_P#5;/\ RU/_ +MKU3]EW_@E-_PS;\=?#/Q'_P"%H_\ "1?V+]J_XEG_  C_
M -E\[SK66#_6?:GV[?-W?=.=N.,Y !^@%?/O[:/[+-[^UU\---\&P>,V\&6E
MOJ::C<3+IQO/M.R.1%C*^=%P#)NY)Y5>,C-?05% 'Y5_\.,?^JV?^6I_]VU]
M4_L,_L,_\,7?\)M_Q6W_  F/_"2?8O\ F$_8?LWV?[1_TWEW[OM'MC9WSQ]5
MT4 ?GA^T5_P2KO/$GQ/U3XC_  7\=O\ #_Q%J$SW4NGRM-#"L\A/G20W,)\R
M%7W,3'L899@"JD*/4?V*?^">.@_LFZMJ7BG4=>?QEXXOX3;?VB]N8(;2%BK.
MD2%F)=F4;I&.2   F7W?7U% 'S7^V;^Q!X6_;$\.Z<M]?R>&_%6DDC3]>MX!
M,5C8@O#+'N7S8SC(&X%6&0<%U?Y<^&?_  2!UK4/&FEZK\9?B:_B_1=&D6"T
MT>S,\IN+./)BA::9LP1YX,4:MP6"N"=U?IO10!S/CSX=^'OB9X%U7P;XCTN#
M4?#NJ6IM+FQ=<*8R.-I'W64A65EP5*J1@@&OS3UC_@C7XOT_5KS0O"OQF:S^
M'6J3>;?6EY;S"8*C;H0\$;B*Y9>/G8Q\C(4=!^J5% 'DO[,O[./AK]EKX5V?
M@GPTTUU&LSW=[J%S@2WMTX4/*P' &$10HZ*BC).29/VL?^36?C)_V)FL_P#I
M#-7JU>4_M8_\FL_&3_L3-9_](9J /,_^"8__ "8W\,/^N5]_Z<+FOJ*OEW_@
MF/\ \F-_##_KE??^G"YKZBH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH *\I_:Q_Y-9^,G_8F:S_Z0S5ZM7E/[6/_ ":S\9/^Q,UG_P!(9J /,_\
M@F/_ ,F-_##_ *Y7W_IPN:^HJ^7?^"8__)C?PP_ZY7W_ *<+FOJ*@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -@RQ_\ 1MW0!T%%%% "$XKY-TVUB_:'_:3N[V:)+[PIX>7RQE0T,RHQ"*6
M*L))2\@#=4##M7J?[3OQ(;P!\.9H+.?R=7U=C9VY5@'1",RR#OPN%R.AD4UH
M?L\?#A?AS\.+**>#RM7U!5O+[<N'#L/EC((R-BX!'9MQ[T =MHG@W0/#,TDN
MCZ%INE2R+M>2QM(X69<YP2JC(S6U110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?(G[8'[9_C']DCQ[I%Q=?#"X\6?"V^L(3/X
M@LIVADLKTW$BRQLVUT/[KR2B.(]S,V'.#MI^ _\ @K%^SSXRMXS?^(-4\(7+
MM@6VNZ7+D<GDO )8P.,\L.H^E?7NH:?:ZM87-C?6L-Y97,;0SVUQ&)(Y8V&&
M5E/!4@X(/!S7QW\6_P#@D[\"/B9>37^F:=J7@._E=I'/ARY5;=F;)_U$JNB*
M">%CV 8 XH ]('_!07]G9H]__"UM#QZ'S<_ELS7$>-/^"JW[.GA*WG:U\67W
MB:ZB&?L>BZ5.S/QG"O*L<9_[[_K7S[)_P0]T,ZU'+'\6M0721]^U;0XS.>O2
M7S]H[?\ +,]#Z\>T_"K_ ())_ GX=WT%_JUIJ_CJ\A82*FO70^S!@0<^3"J!
MAD?=D+@Y.0: )?V:?V[O%O[6'QE@L?!WPNO-)^%%FMR-1\4ZLY:5G$0,**%(
MCC?S" 4#3$JP/R@$U]HUGZ)H>G>&=)L]*T?3[72M+LXE@MK&Q@6&""->%1$4
M!54#H ,5H4 %%%% !1110 4444 %%%% !7E/[6/_ ":S\9/^Q,UG_P!(9J]6
MKRG]K'_DUGXR?]B9K/\ Z0S4 >9_\$Q_^3&_AA_UROO_ $X7-?45?+O_  3'
M_P"3&_AA_P!<K[_TX7-?45 !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 )2UY;\;/"5M#X#\:>)+?4=
M>LM6M=(NKJ![+7[ZWBCEBMV*,L,<PC&"JD@+@G)(.377>'? NF^&+U[JTN=9
MFE>,Q%=1UR]O4VD@Y"33.H/ ^8#/49P30!TE%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%8OB2'4&LWGL=1-@T$;NP$*R!\#C.[IC';UH VJ*Y_P>-1FT>VO
M-0U$WSW4$4H7R5C$9*Y(&.N<CZ8KH* "N?L_^1^UG_L&6/\ Z-NZZ"N?L_\
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M]J;P'^RIX/M]>\;7L^^]E,&GZ5I\:RWM\Z@%_+0LHVH""SLP4949W,H;YO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5/6/^03>_]<)/_035RJ>L?\@F]_ZX2?\ H)H J^$_^15T;_KRA_\
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M8'RR2;QOQ\Q?=SNR=.;_ ((@^*AX@2&+XI:.^A;?FO7TJ9;H')X$&\KC&/\
MEKW-?<'['O["O@G]D+3;RXTNXG\1>+]1B$-]XBO8EC<QC!\F&,$^5$64,5W,
MQ.-S$*H4 ^E:*** /R'_ ."W_P#R4;X8?]@F[_\ 1R5^H/A#5K7P_P#!G1-4
MOGDBLK'0(+F>2&)Y76-+8,Q5$4LQP#A54D] ">*^2?\ @HM^PKX]_:Z\6>#M
M4\'ZMX<TVWT:RGMKA=<N9XG=GD5@4\J"3(P#U(K[2\(Z++H?@_1=(NS'+-9V
M$-K,8\E&9(PC8R.02#U% 'P;^R!^Q1^R%XU;6?$?@;4[[XN0V4BV<T7BALQV
M;E=V1!]G@W;E/#.KCY#MP5:OE+XG>#-+_9I_X*G>%=(^&<;:+8#Q!HVS3[>8
MLL2W?DK<6X+$D(ZRN-I/"R8'&*]U\>?\$U_C1\%/B1KWB/\ 9J\>KHF@ZM\Q
MTB349+2YA!8D09VM'-&A)*,[!@#C!(+-Z!^Q_P#\$V_$/P[^+C_%OXS^*(/%
M_C:*9KBRM[>>6Z19V7;]HGFE56DD4$A5"X4@-DD   ^;/VR--3P;_P %9_!V
MN7K-;V=_KOAG56FGPJ".-[>%F!Q]T?9VR?4-7T1_P6NUJU@_9W\%Z0\J"^NO
M%4=U%"6&YHXK2Y5V ] 9HQ_P(>M>G_M_?L%Q?M>:7I&LZ#JEOH7CO18VM[>>
M]4FUO;9B6\B8J"R%6)9'4-C<X*G<&3YCT;_@FC^T!\=/&N@2_'WXC)?>%]#?
MR54:G+?W<D&5+K "H5#($4&5SO&%)5MH% &3^TI\-[CPW_P2"^"UO#%<3QVF
MI66NS/C<(DO$O906(& FZ\51G'WE&2>OU;_P3B\5:=X7_P""=_A+6K^ZB@L-
M&M=9N[R5W 6%([Z[E<L>P"?-SV(-?1/Q0^"_A?XM?"#5_AMK-F8?#&H6*V(A
ML\(ULJ;3"\600&C9$9<@C*+D$9%?F)_P[-_:@\!Z?K?P\\&?$G3/^%<ZY/(U
MWLU.XLH)U*JA:XMQ&Q5G155E0N"% )(% !_P1#\)K>?$;XH>)M[!M.TNSTX(
M"-I%Q,\A)&,Y'V3UQR:]K_:L_8K^(Z>"_C#XZ/[2OCAM!73]8UL^$#+<_8C;
M^7--]AQ]KV^5M_=8V8V_PXXKZ4_8U_96TO\ 9)^$<?A6UO1JVL7EPU_JVJ"+
M8+B<JJ@(N21&BJJ@$_WFX+$5T?[6/_)K/QD_[$S6?_2&:@#S/_@F/_R8W\,/
M^N5]_P"G"YKZBKY=_P""8_\ R8W\,/\ KE??^G"YKZBH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MB?B1X5T6Z\)^)-1FTBQEOQI\[B[>U1IMRQ$*V_&<C P<\8%;^E>%=&T.X:?3
MM)L;"=DV-):VJ1L5)!P2H'&0./856^(7_(@^)?\ L&77_HIJZ"@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSQ7S%\;_ -H+0]3T77H?"U^U^^M65KIQG$,D7EHDEPTX(D3G*2(O_;4D'Y:
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M !1110 4444 %>4_M8_\FL_&3_L3-9_](9J]6KRG]K'_ )-9^,G_ &)FL_\
MI#-0!YG_ ,$Q_P#DQOX8?]<K[_TX7-?45?+O_!,?_DQOX8?]<K[_ -.%S7U%
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '/?$+_D0?$O_ &#+K_T4U=!7GWQ,^'GA6_T#Q'KEUX9T
M>YUI;":5=2FL(FN0Z0D(PD*[LJ%7!SQM&*Z#P_\ #SPMX3O7O-#\-:/HUV\9
MA:?3["*!V0D$J6102N54X]AZ4 =%1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !116)XJ\8:/X)T^.^UN]6QM))
M1"LC(S9<J2!A03T4_E0!MT5YO:_M$?#F^N)X+?Q3:S302"&6-$D)CD*JX5AM
M^5MKHV#V8'H:](H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "J>L?\ ()O?^N$G_H)JY5/6/^03>_\
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M*^_].%S7U%7R[_P3'_Y,;^&'_7*^_P#3A<U]14 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4]8_Y!-[_P!<)/\ T$U<JGK'_()O?^N$G_H)H J^$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4=>PN5&>^!ZU]D_\$U-6MM%_X)_> ]0NI4AM;*#5IYY'8!45=1NV8D]@ ,T
M?.W_  1&^(M_>:#\3/ ]U=&33[">SU:PMRO,;2B2.X.[T/E6^%Z [CW-?=O[
M6'_)K/QD_P"Q,UG_ -(9J_-7_@B-X6EO/BE\2O$@DQ#I^C6^G.F.K7$YD4YS
MV^RMV[U]$_M6?"7]J!?A[\8M8;XY:.?A[_9>L79\-_\ "/6HF.F>5,WV3SO)
MW;O)_=^9NSGG.>: /5?^"8__ "8W\,/^N5]_Z<+FOJ*OEW_@F/\ \F-_##_K
ME??^G"YKZBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /+/@[_ ,E$^.?_ &.5O_ZCVCUZG7EGP=_Y*)\<_P#L<K?_
M -1[1Z]3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "JVI?\@^[_P"N3?\ H)JS5;4O^0?=_P#7)O\
MT$T 5_#_ /R+^F?]>L7_ * *^5?A3J4WC'XF?%+XAV\JL-.LKAK%VW%E9@P@
M<!NN(X6&&_O#CT][\=>*3X*^"VH:Q'*T%Q;Z4JP2*JL5F=%2(X/! =EZ_D:X
MC]CWPVNC_"DZFT</G:M>23"54 <QQ_NE1FZD!DD(]-Y]3D =^R[X>,&EZQK4
ML:YN)%M879/F"H"7VM_=)9<X[I[5[K4,%O%;1K'#&L48Z*@  SR>*FIL HHH
MI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?E;_P4D^#GQ"^!_[1&D?M.?#.&ZD"1PG5;JWC,_V"YBA\C?,G:WEM
MPL9/W<A@Q!=<^N_MN?\ !1#Q/^R#^T-H?AF#PMIGBGPK>^'(=4GMI9I+6\$[
MW%U%\DXW*%Q$A(:)N^",UWWP8_X*?_ CXP>1:7/B%_ VKR\?8O%*K;1DXR<7
M 8PX]-SJ3QQF@#X\7_@MWXQ_X14V[?#'0SXC\DJ-0&HS"T\W'#?9MN_;G^'S
MLX_B[UN?\$Z/A=\1?VC?VFM1_::^(L,L5E")CIUU)$88[ZY>(VP6W3',$,)=
M=V?O!!EF#[?T27]GGX0ZO=C6A\-/!-[=7(\X:@-!LY'EW'=N\SRR3DG.<]\U
MZ2J"-0J@ #@ #% #Z*** /SD_P""IW[)?Q6_:.\:^ [_ .'?A7_A(;33-/N(
M+N3^T;2U\MWD4J,32H3D \C(K[\\"Z9<:/X(\/:?>Q>5=6NG6\$T>X-M=8E5
MER"0<$'H<5OT4 ?DUXV_8?\ VB?V4OCIK_C+]FORK[0M96:.**W:T\VRMY)%
MD-M)#=':RJRJ%=-QP@)VY(/J/["'[#/Q'\+_ !NU?XZ?'&:$>,[EKF2TT[SH
MYYQ<SY66YD:$^4@$;.BQID 2'[FP _HG2T ?"W_!2#]A;Q!^TC-H/CSX>3P1
M>/-!@-JUG--Y!OK<.9(A'*2%CEC=GQNP#YARR[ #\U:M^R)^U_\ MD>,O#-A
M\<KA=$\,:*[C^TKE]/4PHY3S?*BM.9965%P7&WC[PR<_K]24 >3?&+]G/PW\
M6/V=M3^$"J-&T&73(=.T]X4+"Q,&PVKA<C<(VCC.W<-P4J2,U^8>G?LN_MP_
M"7P/XA^#?A>V6_\ A]JS7$$S6=[ISVT\4Z!)O+DG(GA1USE<)R7(&6)/[+44
M ?,7[ O[(8_9'^$EQINISVM_XQUNX6\UB\M1\B[5VQ6Z.0"R1@N<D?>DD(X(
MKT?]K'_DUGXR?]B9K/\ Z0S5ZM7E/[6/_)K/QD_[$S6?_2&:@#S/_@F/_P F
M-_##_KE??^G"YKZBKY=_X)C_ /)C?PP_ZY7W_IPN:^HJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/VG_',7@'
MX'^*+QIDCNKNV;3K568*SRS I\G(RRJ7?C/"$\XKS;]A/P?=>$_ ][/=I)#)
MK,-OJ:12J598VDN(T.".C+$K@]PX(ZUR_P"WAKUWXH\2> _AIII'VO4+E;QD
MD4!&DD?[/;G=RPP3/D8[CKV^E_">AVOAGQ!-I%BGDV6GZ'IMI!'N)VQQM=(H
MR23P .22?K0!V%>9_&SXEKX'T$V5E*O]MWR%8EW$-#&<@RX'0]EZ<^NTBNX\
M2^(K3PIH=YJU\S+:VJ;WV#+'G 4#/4D@#/&37B?PK\/ZA\3O&D_CG7E?[);R
MYL8B0%+J?E51_<C_  RW<_-37F U?AL/!/[._CZ]OH5&M7_AZ_>0LI#0QFV<
MK%SW[M@#D@<[0:^@JXKXW<?!?Q]_V+^H?^DTE=M2 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKQ[XP:9XK\/Z7)K
M>D_$37-/$^JZ=:+8)9::\$,=Q>P6[A2]J9.$E8@LYYQG(X/?>$O#6J>'?M?]
MI>+-5\4>=L\O^TX+./R,;L[?L\$6=V1G=G[HQCG(!T=%%% 'EGP=_P"2B?'/
M_L<K?_U'M'KU.O+/@[_R43XY_P#8Y6__ *CVCUZG0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M2_
MY!]W_P!<F_\ 035FJNI?\@V[_P"N3?\ H)H ^</VL/$SZ=\)O"VBQ2M')JCQ
MNZ*3^\BBC!*D8Z;WB/7^$?A0\?:?=Z9KG@;P-IU\87TNUM;<-&S 1WCMAI V
M 3_ P(Z9XP<BJ?C*1/B'^T?X!\-%V^R:3:VKS0SQJ\;NL9NG &>5>,1J<^AX
M(Z^Y/\)89OBE_P )E)J+'HPLA%@;A$(P=^[I@9QMIH#T&EHHI %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M&?$GX.^"/C%H_P#9?C?PMI7B>R 81KJ5JDC0[AAFB?&Z-L?Q(0?>OA_XS_\
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MT>O4Z\L^#O\ R43XY_\ 8Y6__J/:/7J= !1110 4444 %%%% !1110 4444
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MOJ7@#0->UGQ%?ZY=ZQI=G>R1W<5M''!(\0=Q&(88S@E_XRW"CWSW]<3\$/\
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M\N_\$Q_^3&_AA_UROO\ TX7-?45 !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \\^/'_(@0?]A[0_\ T[6E>AUYY\>/^1 @_P"P]H?_ *=K2O0Z
M "BBB@#RSX._\E$^.?\ V.5O_P"H]H]>IUY9\'?^2B?'/_L<K?\ ]1[1Z]3H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,U>K5Y3^UC_R:S\9/^Q,UG_TAFH \S_X)C_\F-_##_KE??\ IPN:^HJ^7?\
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M.FQO,\@7S9C,Y)\Q@"P SA0#_"/3N22>HI %%075PMG;RSR"1DB1G811M(Y
M&3A5!9C[ $GH!7&6OQE\.7>IG3H8?$!OE6-W@;PSJ2M&LC,J.^;?Y58HX#-@
M?(W/!H [JBDI: "BBB@#B?@A_P D7\ _]B_I_P#Z31UVU<3\$/\ DB_@'_L7
M]/\ _2:.NVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_X*4?L9^#?V4?#/P\\>?"N&\\-M%J(TZ[D_M&:69KH1F:WN49V)1P892=A
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M[#P_<VVH:6DC,SQI<^:)HU!.!&'B5P !\TSGO7VQ^UC_ ,FL_&3_ +$S6?\
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M&K=-50B@*  .@ IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ?T__P!)HZ[:N)^"'_)%_ /_ &+^G_\ I-'7;4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7B/[47[)/@3]K'PE#I/BVWFMM1L
M=SZ;K5@56ZLF;&X*2"&1L#<C#!P",,%8>W5^4/\ P4(_:H^-GB+]J+_A1GPC
MN=9TF731;J(?#3,M_J=S+;)<EC(F&2*.*0?*"%&R1W) &P 9)_P0[OSJK)'\
M7[<:;U65O#[&8<]"GVC;T[[OPK[F_92_8U\"?LD>';NT\,)<:EK>HA!J6NZ@
M0;BXVY(10 %CC!)(5?4;BQ -?F2O[//_  4&D4,-5^(P!Y&?'Z@_E]MKVS]C
M+X,?MB^$_P!I7P?JOQ4U#QI/X"@^V?VE'JWC!;^V.ZSG6+? +I]_[UH\?*<$
M \8R #]1:*** "F29VG:<-VS3ZHZUH]GK^D7NEZA;I=V%[ ]M<6\@RLD;J5=
M".X()'XT ?F%X#_X(PG6O&>KZE\2OB8VK:=,[2Y\-0K#=37#L6=I&E5TC R#
M@*V=Q^[CGQ+P;I6M?\$^_P#@HQI'@?PYK]SJGAS4M3T_3[I)SM^UV-X4 $Z+
M\IDB,I*L ,E 0 &*UV7AOP7^U5_P3B\?>*="^''@JZ^)/@C6IVELY$TFYU2U
MD";=D[):LLEO/L8(P8A6VG&\(K#IOV8?V4_C'^TO^U3#\?/CCHEQX2LM/OX=
M3AT^\M7LYKFXMR!;016SGS(H8C'&Q:3EPH WEV=0#@_VK+*?2_\ @K]X4NKF
M3,%UXH\*W,.2<+&/L<9'M\T;GCUKZ8_X+57"+^S#X3ASB1_&-NX'L+*]!/\
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M/^N5]_Z<+FOJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***RM?\
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MCG*[<8W-GZCI*6D 4444 %%%% !115/4([R2$"RFA@FSR\\)E7'T#KST[]J
M+E%<GI=WXBU"^U:#[=IB?8;I;<-_9\AWYABEW?Z_CF0C'M75T +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^T)XTNOVEOBW->^"_#^J:M::;8K91?8[62:2:))9&\\HJ[D4M+@9YQMS@G
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M_P#D->*_^PFG_I';5T%<_P"&_P#D->*_^PFG_I';5T% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >>_M"?\D/\<?]@FX_] ->A5Y[^T)_R0_QQ_V";C_T UZ%
M0 4444 >5?!O_DHOQV_['.V_]1[1J]5KRKX-_P#)1?CM_P!CG;?^H]HU>JT
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M(^AJ** "BBB@ HHHH Y_XA?\B#XE_P"P9<_^BFKH*Y_XA?\ (@^)?^P9=?\
MHIJZ"@ HHHH Y_PW_P AKQ7_ -A-/_2.VKH*Y_PW_P AKQ7_ -A-/_2.VKH*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;A=0TS1=57FX; V7%Q'C"Q* JQ08"[57Y0@4']/Z2EH **** "BBB@ HHHH
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MV0<#)[DD]=X;\-Z;X1T.RT;1K*/3]+LHQ%!;Q X11[DY))R23R223DDFM6D
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M69A.EI,QW&5W)/F3 _Q#@')!8X8?4-%%( HHHH **** "BBB@ HHHH ****
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MD]S7SM_PSWXU_P"?"#_P*C_QK?L_"OQ/^%-LL^FN-0L %>2SMV-Q&O))7RR
MP.>I3L>M4[/0#Z4HKQOP;^TEHNJK'!KEN^CW7"F9<R0,< ?[RDDG@@@#^*O6
M[*^M]2M8[FTGBN;>092:%PZ,.F01P14 6:*2EI %%%% !1110 4444 %%%%
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M/0CX'D\&? [Q*;_6=3W0ZGXDM898A8V^WE+9V"_O7SCS5SL4-M(<JR0>%?\
M@DWX\^,FN6WB[]H3XM7VH:O,2)]-TQS>7*0E2ZQ+=S?)"4ED?,:0O& #M;YL
MK]>_#3]@/X"_"W1;G3M/^'&CZN;M=MQ>>((!J4\@Y& TP;RQ@](PH. 3D\T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
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MM#9VR9VPV\8C1<DDX4# R2?SKQW6/BG\8;'X-Z'XCL/@:=1\?7EZT&H>"?\
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MR.#GB@#]9Z2ORL_X;Z_;>_Z-R_\ +&US_P"/T?\ #?7[;W_1N7_EC:Y_\?H
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MQ:^.,-XZ6OA&26# *L=(E)Y X^]ZTVK ?3MU=0V-O+<W$R6]O"C222RL%5%
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MV>_#.H_&7Q-JMOI[JFGV\:SWNHN0$@=B1'&(^&9G <Y P!"V2"5#-6Z@>L?
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M9)GD*@A06D9FP 3@9P-S$#DUV=% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^TA^UUX>_9EO]"M=<\)^+_$KZO%-)$WA?38[M8A&4!$A>5-I.\8QGH:?X?\
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MK'B#5W$EY?W#=6=L9VYW$ D\NQ))8D@'LU%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M()VM*]KY1/'\+L.G- 'Z33_\$1?!#>*DN(?B5X@C\-!,-ITEE UX6R>1<@A
M,8X\GMU]/L7]F[]D_P"'?[*_AVYTOP1I<J7%X5-]J^H2":]O"O"B1P  HR<(
MBJH))QDDG\HM!_X)!_%WQ5I<6I:)XR^'.L:=-_J[NPUJXGA?']UUMB#^!KZ"
M_8S_ ."8?Q3_ &>?VD?!WQ"\2:]X0O-&TC[9Y]OI=[=27+>;9SP+M5[9%.&E
M4G+#@'KTH _4"BBB@ HHHH **** "BBB@ HHHH *\I_:Q_Y-9^,G_8F:S_Z0
MS5ZM7E/[6/\ R:S\9/\ L3-9_P#2&:@#S/\ X)C_ /)C?PP_ZY7W_IPN:^HJ
M_*;]C;XI?M=^'?V:_!FG_#3X.>&/%'@B%+H:=JVH:G##/.#=S&0LC7L9&)#(
MO*#A0>>M=A\(OVV/VP?CMH>I:QX&^"_@S7-.T[49-*NIOMZV_EW4:([Q[9;U
M&.%D0[@"O/!ZX /TIHK\U? 7[;7[8'Q.\7>,O#'AGX+^#-3USP?<I9ZY:_;U
MB^R2N9 J[Y+T+)DPR<H6'R^XI-+_ &W/VP-9^,&K_"VS^#'@N;QWI-@NJ7ND
M_;E7RK9O*P_FF]\L_P"OB^57)^;IP< 'Z5T5^;7C7]M#]L7X>>,O!WA7Q#\%
M?!FGZ_XOFFMM$M/[067[7)$$,@WI?%4QYB??*@[N.AI?BE^V=^V+\%-,T?4?
M&?P5\&:-9ZOJ<.CV4G]H+/YMW*KM'%B*^8C(C?YFPHQR>10!^DE%?G+\4?VO
M/VS_ (+^!=3\9>,_@AX,T?PWIOE?:[W^THY_+\R5(D^2*^9SEY$7A3C.3QFK
M>M?M2?ML^'_ =_XRO_@7X,@\-V.FR:Q<7W]J1-LM4B,K2;!?ESA 3M"[NV,\
M4 ?H?17YR_"[]KS]L[XT>!-,\9>#?@AX,UCPWJ7F_9;W^TD@\SRY6B?Y);Y7
M&'C=>5&<9'&*RO@K^W+^UW^T1X5NO$?P^^#7@OQ!HUK>MI\US]N%MMG5$D9-
MLUZC'"RH<@8^;KP< 'Z7T5^:'PW_ &Y?VN_BUXJ\:>'/"?P:\&:KK/@V]_L_
M7;;[<(?L<Y>6,)NDO563YH)1F,L/EZ\C-Z']LG]LBX^+$WPSC^"?@QO&\&E?
MVW)I?]HH,6?F+$)?-^W>7]]E&T/NYZ=Z /TAHK\WM>_;)_;(\+_$CPOX"U/X
M)^#+;Q;XGCN)=)T_^T4;[2L$9DF/F+?%$VHI/SL,XXR:3X@?ME?MD?"N_P#"
MUEXH^"G@O2[GQ/JL6B:1'_:*3?:;R4XCBS'?-LR2/F<A?4B@#](J*_.7XH_M
M>?MG?!?P)J?C+QE\$/!FC^&]-\K[5>_VDD_E^9*L2?)%?,YR\B+PIQG)XS2R
M?M=?MH1_"]OB(WP/\%CP<NC_ -OG4O[2C_X\1!Y_F^7]N\S_ %7S;=N[MC/%
M 'Z,T5^='PQ_:W_;1^,7@?2_&'A#X'^#-8\.ZFLC6E[_ &E'!Y@21HV^26^5
MQAT8?,HZ>E9OPB_;9_; ^.^A:CK/@;X+^#-<TW3]0DTJZF^WK;^7=1HCO'MF
MO48X61#N (YZ\' !^E-%?FKX!_;:_; ^)_B[QEX8\,?!CP9J>N>#[I+/7+7[
M>L7V25S(JKODOE63)ADY0L/EZ\C*:7^VY^U_K/QAU;X6V?P8\&2^.])L%U2]
MTG[>J^5;,8L/YIO1&?\ 7Q<*Y/S=.#@ _2NBOS:\:?MH?MB_#WQEX.\*>(/@
MKX,T_7_%\TUOHEI_:"R_:Y(@AD&]+XJF!(GWRH.>.AI?BE^V=^V-\%=-T?4/
M&?P4\&:/9ZOJD.C64G]H)/YMW*K-''B*^8KD1O\ ,V%&.2.* /TDHK\Y?BA^
MUY^V=\%_ FI^,O&7P0\&:/X;TWROM=[_ &E'/Y?F2I$GR17S.<O(@X4XSD\9
M-7-:_:D_;:\/>!+_ ,9:A\"_!EOX;L=-DU>XOO[4B;9:I$96DV"_+G" G:%W
M<8QGB@#]#J*_.7X7?M>?MG?&CP)IGC+P;\$/!FL>&]2\W[+>_P!I)!YGERM$
M_P DM\KC#QNO*C.,CC%97P5_;D_:[_:(\*W7B/X??!KP7X@T:UO6T^:Z^W"V
MVSJD;LFV:]1N%E0Y Q\W7@X /TOHK\T/AO\ MR_M=_%OQ5XT\.>$_@UX+U76
M?!M[_9^NVWVX0_8YR\L83=)>JLGS02C,98?+UY&;T'[9'[9%Q\6)_AG'\$_!
M;^-K?2O[;DTO^T4&VS\Q8O-\W[=Y?WV4;0^[GICF@#](:*_-[7OVROVR/#'Q
M(\+^ =3^"G@NV\6^)X[B72=/_M%'^TK!&TDI\Q;XQIM52?G89QQDTGQ!_;*_
M;'^%>H>%K+Q3\%/!>EW7BC58M%TB/^T$F^TWDA CBS'?,$R2/F?:H[D4 ?I%
M17YR_%']KS]L[X+^!-3\9>,O@AX,T?PWIOE?:[W^THY_+\R5(D^2*^9SEY$7
MA3USTR:=)^UQ^VC%\+V^(C_ _P &#P<NC_V^=2_M*/\ X\?(\_S?+^W>9_J_
MFV[=W;&>* /T8HK\Z/AE^UM^VC\8O ^F>,/"'P/\&:OX=U,.UI>?VE'!Y@21
MHV^26^5QAT8<J.GIBLKX,_MO?M??M!^$Y?$W@#X,>#-?T.*Z>Q>Z^W"VQ,BH
MS)MFO4;@.G.,<]>M 'Z645^:G@']MO\ ; ^*'B[QEX8\,_!CP9J>N>#[I+/7
M+7[>(?LDSM(JKODO55\F&3E"P^7W%&E_MN?M?ZU\8=8^%MG\&/!DWCS2;!=3
MO=)^WA?*MF\K#^:;WRS_ *^+A7)^;IP< 'Z5T5^:>M?MO?M?>'?B]X?^%^H?
M!GP9;^.=?M)+[3M*^W*WGPHLK,_FB],:X$$O#.#\O Y&;'Q1_;._;&^"NFZ/
MJ'C+X*>#-'M-8U2'1K*3^T%G\V[E5FCCQ%?,5R(W^9@%&.2,B@#])**_.7XI
M?M>?MG?!;P)J?C+QE\$/!FC>&]-\K[5>_P!I)/Y?F2K$GR17S.<O(B\*<9R>
M,U<UK]J3]MKP[X%O_&6H? OP9;^&['39-7N+W^U(FV6J1&5I-@ORYP@)VA2W
M;&>* /T.HK\Y?A=^UY^V=\:/ FF>,O!OP0\&:QX;U+S?LM[_ &DD'F^7*\3_
M "2WRN,/&XY49QD<8K*^"O[<G[7?[1'A6Z\1_#[X->"_$&C6MZVGS7/VX6VV
M=4CD9-LUZC<+*AR!CYNO!P ?I?17YH?#C]N7]KOXM>*O&GASPI\&O!FJZSX-
MO?[/UVV^W"'['<%Y8]FZ2]59/F@E&8RP^7KR,W[?]LC]LFY^+%Q\,X_@GX,?
MQO;Z3_;<NE_VB@VV9D6(2^;]N\L_.ZC:'W<],<T ?I!17YO:]^V5^V1X7^)'
MA?P#J?P4\&6WBWQ-'<3:3I_]H(_VE8(VDF/F+?&--JJ3\[#..,GBD^(/[9G[
M8_PKU#PK8^*/@IX+TNY\4:I%HND1_P!H)-]IO)" D68[Y@F21\SX49Y(H _2
M*BOSE^*/[7G[9_P7\"ZGXR\9?!#P9H_AO3?*^U7O]I)/Y?F2K$GR17S.<O(B
M\*<9R>,TZ3]KC]M&'X8/\0V^!_@P>#ET?^WSJ7]I1_\ 'B(//\WR_MWF?ZKY
MMNW=VQGB@#]&*^,_^"FW[+3_ !Z^"S>)?#]O(_CGP<)-0L1;H3-=VXP9[=<?
M,6PHD3 )W1A0!O)KS3X9_M;?MI?&'P/I?C#PA\#_  9JWAW4U=K2]_M*.#S
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M4/&&I? KP9;^';#3I-6N;W^U(F\NUCB,KR;%ORYP@)VA2W;&>* /T-HK\]/
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M]+\7^$?@=X,U;P[JBN]I>?VE'#Y@61HV^22^5QAD8<J.GIBLKX-_MM_M@?M
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MFN],\+VEFMA<J@+".&2_CE\QXU5BI4*!M+!!'D8^TU&%Q7YS?%#]KO\ ;/\
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M6O,[;X">'[7]H2[^,:7FI'Q/<^'QX;>U:6/[$+83+-O">7O\S<@&2^,$\=Z
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M9)^$=WX*F\1IXH:?5IM3^VI9FU"^9'$FS9O?IY6<Y_BZ<5[_ $4 ?"G[ O\
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M%% !1110 4444 %%%% !7B_[0/[7OPL_9ECMD\=^)%LM3NX6GM=(M(7N;R=
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MG8^/M>'@OP5)J]SINHZM]KB@,*Z?9& %9) R R26J@ J>9  ,D"@#]0?"?\
MP4<_9W\<>*M&\-Z)\0OMNM:Q>PZ?8VW]B:C'YL\LBQQIN>W"KEF498@#/) K
MV?XI?%CPC\%?!]UXH\;:]:^'M#MV"-=76XEF.2$1%!:1R 2%0%C@\<&O@_\
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M^ST?65B2XGTR1$N%$<R2KL9T=1\T:@Y4\$_6@#Q+_AZ/^S%_T4S_ ,H.J?\
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M,KE@,+N&2,BO2:_''_@JQI%S'^VIX!O/'ZW"?#6ZL["&*YMXY0@LTN6^W(&
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MQ!_P50_9U\/^,%T)O%]W?QK))%/J]AID\UE RDC[X7=(I(X:)74\$''-9?\
MP5J\:ZMX/_8_U*WTKSXUUS5;72KV: [3';L))7W'^ZQB6,^HDP>":\7_ &&?
MV'?@]\9OV(;36?$N@PW7B/Q']O:;76E87&GM%<RPQ&%@1L"B)'*\AMQW9!Q0
M!^CWA'Q=HOCSPWI^O^'=4M=:T6_C\VVO[*4212KDCAAZ$$$=000>17E/[0G[
M9/PI_9C>WM?''B/[/K-U US;:-8P/<WDL8. VQ1B,,00K2,H8JV"=K8^(O\
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ML3_\%(/ >K^ [;^P]$NVT_6&TVVR(H89II;6ZA0$\*Z1RG&<#S"!@  ?M)0
M4444 %%%8'CSQ(W@WP/XA\0+ +M]*TZXOA 6V"0Q1,^TM@XSMQG'>@#GOCE\
M;?"W[//PWU+QOXPNI+?1[%HXREN@>>:21PJ1QID;F).<9X"L3@ FG_ [XR:#
M^T!\+M%\>^&4O(]#U;SOLZW\0CF_=320ON4,P'SQMWZ8/M7XB_M8>/\ X\_M
M(?#RP^,7Q%M#H?P[;58M*T#2XT>WMFDE@ED,MO&V6E7; VZ=V.2X5#@%4_4S
M_@ES_P F)_#/_N)_^G2[H ]4^.G[4/PR_9ML+.Y^('BFWT62])%K9)')<74^
M 22L,2L^P8QO("@D D$C/G?P1_X**_ [X\>(;+P_HGB6?2?$5ZYCM=+URT>U
M>=LX"I)S$6;C"!]QSP*\4^-G_!-SQ1^T-^V ?B1XV\2:7>_#M[FW5] CN[D7
M2V,,05;=#LVH)'4LX1EQYTA4[N:^4_\ @K!\%?AM\"/BCX#;X<V</A?6+_3Y
M;G4-)TT^7% L<JBVN44<H[GSU.#C_1U. =Q8 _:#Q!X@TSPIHE[K&M:A;:5I
M5C"T]S>WDJQ0PQJ,EW8D  >]?*NG?\%5/V<]2\6+HJ^,+R"!]JQZQ<Z3<1V3
M,QQM+%-Z^[.@4#OUKP+_ (*X?%3Q5X>_9K^$W@C6RL&N^*"+S7Y+%BL#RV<,
M)EA"GDH9[A'&>GDK63X[_8?^&=I_P3%T[Q?I>@PQ^.8O#%CXK;Q!(6-R\DB1
MSSQ,00#'Y<DD:J1@81N6&2 ?J-8WUOJ5G;WEI<17=I<1K+#<0.'CD1AE65AP
M00001US5FOAW_@D'\2-1\<?LIOI&IW#7+^%]9GTNU9R2PMBD4Z*23R%::11Z
M*JCH*^XJ "BBB@ I*6O@C]OG]H#XXQ?%S1O@1\$='=M8U_04U6[UFR4F\MXI
M+B:!MLA(2V1?*YF;D&1=I0@$@'N6C_MR?#3Q!^TL_P #M,FU*^\8)<3VK7,$
M"-8B6&W:>5#+YF=R"-T/R\.I'O7O&K:O8^']*O-3U2]M]-TVRA>XNKR[E6*&
M")%+/([L0%50"2Q.  37X8_L!^#;WX<_\%+O#?A/4[B*[U+0=5UW2[JX@8F.
M66"QO8G=20"064D9 ..U?KM^UC\!=2_:6^#.I> -/\6MX.CU*>%[N]6Q^U^;
M#&V_R2GF1X#.J$D-T4C!S0!Y+>_\%6/V=-/\6-HS>++^>V53OUF#2+A[,,#@
MH"%\QCQ]Y8RI'1J^J_#OB72O%^AV.M:'J5KJVD7T0FM;ZRF66&9#T967@CZ5
M^5O[0_[(_P #?V4?V-?$/ASQ-J_A_6/C.RK?V%^9A!J=SON]D1AMC(7$(B5E
M;@IE9#G(R/<O^"0</B#P[^R/JE_XA6YAT-M;N[S2?M&>;411"1HP?^69E67&
M/X@Y[T >Z_M!?MR_"#]FG4O[(\7^(VD\0^6LW]B:5;M=704X(+X^2/((($CJ
M2#D9%=5\!OVGOAM^TII-Y?\ P_\ $D6L&Q95O+.2)X+FV+#*[XI%#;3R X!4
ME6 )(-?EI_P3C^%ND?MD?M,?$OQ[\4]-MO%:0P/J$EC>*Y@-Y=3?(VW=@HD:
M2JL;9 !7&-@I/"\&G_L>?\%:X_"_@^.YA\,WNLVFC-I_G<"#4[>!Q$3CF.*:
MXC90><0)DDY) /VAHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $K\;O^"3OA\_#?]N;X@^%+Z</>:?H6
MJ:1N90ADD@U"U#?+DX.(F. 3TZU^R5?E]^U%^Q/\8_A;^T]/\>/V?+>+4[F]
MN)=1N-/C,/GVES*C+<_NYB%FCEWNWRDL#(PVC:K4 >2_\%@=+D\4_MD^!M&M
M<M<WGAFPLE"+N(>2_O H SR?G'%?LW7Y<?LW_L8_&_XU?M1:=\<OVA85TE-+
MFAO[;3YFB\^ZFA4"UC2&)MMO%&RK(V[YF*8VDR,Z_J/0 4444 %%%% !1110
M 5"L$2W#S"-%F=51I HW%025!/H-S?\ ?1]:FHH _%7]FG_E,EJ__8Y^+/\
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ML LD8W')'WI)"."* /IVBBB@ HHHH **** $K\N?VWOVN/%7[2WCZ3]F_P"
M<,VJ_:Y7LM>U>T; N]IVRVZ2=$MDP?-E)P^-H.S/F_=?[5UK\0M2_9]\9Z?\
M+;*2_P#'-_:+96"1745JZ"214ED661T562)I&4[@<@8YK\?O!/\ P3]_;&^&
MNJ3:EX0\,ZQX5U&:$V\EYHGBZQLYGB+*QC9X[M25+*IVDXRH/84 ?JG^Q/\
ML@Z3^R'\,'T>.ZBUCQ5JLBW.M:Q'$8UF=<^7%&"21'&K$#/4L[87?M'Y[_\
M!.K3QX/_ ."DWC[0[J7-Q;C7; %AM+R1W2YXR><1L<9/2OH/_@GW\(?VJO 7
MQLU/4?C;?^*+GPD^A3P01ZUXMCU6'[69X"A$2W,N&V++\VW@$C/.#S/[6G[$
M?Q:\"_M,#X^_L^117VJW%PU]=Z6C0K-:W+Q-'.ZI*0LL<RL^Y0=VZ1\#&, '
MAW_!:"WEN_VK/"4,,;RSR>#K1$CC4LS,;^^   Y))[5^TJU^67P!_8Y^.WQ^
M_:@T;XT?M#0G1[719K>]MK*=XA-<O =UO!'!$Q$$22 .^\ L2PVDR,R_J=0
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M9P:?>6LR:A;:=*83/=74<:QVS&*$E84A"(PW$/NC3@Y8U^GE !1110 4444
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M&D08001E@-P7?(Q;:,M(PZ 4 ?'?_!#V\BC\8_%>T9@)Y;#3YD3/)5))PQ_
MNOYUQ'[1EM+>?\%E-*CAB>5QXO\ "TA6-23M6WT]F./0!23Z &O0OB)^QG\?
M/V1?V@M=^(_[.=A%K/A_5EG1;.W6"26S@FD61K1X)2"Z*ZH4:/)Q&N<<Y] _
M8=_8I^*B?M#:G\??CNWV;Q07GEL=/DN(YKB2XF0QM/)Y3&..)(F:-(AR,CA!
M&H8 _2*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEG(.'QG:<>G_ !0_X(I>-X_%]VWP\\:>'KKPO(2]NOB22>VO(,LV(F\J&19
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M&<<_/C 'DVA?\$4/BW<:M:Q:SXT\%V&EL^+BYL9KNZGC7U2)K>-7/3@NOUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWE% 'A7[&O[,-E^R?\%+'P='=1ZGK$\S:AJ^H1*52>[<*#L!Y"(B(B],[-Q
M+$5[K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ast008coloncancer.jpg
<TEXT>
begin 644 ast008coloncancer.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ')!8 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH \1US_D]+P5_P!B#KG_ *<-)KVZO$=<_P"3TO!7_8@ZY_Z<-)KVZ@ HHHH
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M?:#DA+>4 $E58 ^TZ6OST_:8_;6F\7_LX_&31-%UK2] \=Z!9:9J=EJWP_\
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M+8-?LY84>-)4D98XI(94::/"M'M<%BK'8P'T%0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'F?Q\\3>*/A_P#"_P 9^,=
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MZA_\<H ^SJ*^,?\ AJ#X\_\ 1,1_X(=0_P#CE'_#4'QY_P"B8#_P0ZA_\<H
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M?_;^OU3K\J_^"&?WOC;_ -P7_P!OZ_52@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DP*6B@#XT_:>T"RM_VD/A?%%%Y2
M7EW;><J$@$M=J"1Z$@]ORKZ_TW3K?2K..VM8A%#&,*HY^O/<U\H_M2?\G*_"
M'_KZM/\ TL6OKE>E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_*!MKZ1_X07PX-.T+3_[ TS[!H+Q2:3:_9(_*T]XHVCC:W7&(BD;,BE ,*Q
MX.* /BO1O&E]XJ\#_"K3==\>^*-&O_%GC:31?B'>R:X+.YL-3M;.XE.D0&-M
MMG#+<0Q(OV<H\D13YV,I8]-\#]&L=>^+O[4_PROO&FM^-? =G8:7I\5IK>M3
M:A_9T=U;WIN[=99'9N"Q4L6+X1%8DIFO</C1\$&\>:-J"^&HO"FEZGJEY!<Z
MVGB'PS#JMGK\<$3)#!>H61V"-Y3)('W)Y2@9&17G_@']CAO"_@OXCZ=-K&BZ
M)J?CY+.RU*/P;H*Z9IUCI\2>7+;6D'FNRNZ2W?[]G.'G#[/DVD ]+_9?\1:K
MXN_9O^%^M:W/-=:M?^&M/N+JYN&W23R-;H3*Q[E\[B?]JO4:I:5I5GH>F6>F
MZ=:0V.GV<26]O:VT8CBAC10J(B@ *J@   8  J[0 4444 %%%% !1110!\!_
M\%0_VV?^%(>'KKX2Z3H,>J:UXP\/7*WE]=RLL5E9W'F6P**HS)(VV?JRA=BG
MYMV!ZW^PC^VE;_MB^"=9N;G15T#Q/X?D@AU.T@E:6"02HQ2:,D957:.7Y#N*
M[/O-G->&_P#!0C]G_2/VJ?VHOA/\.='#Z9XP?2+S4=:\0)&9EL='1R("\60'
MW7'FJI#KM+\Y# K]0?LG_LC^$/V1_!5YHGAF6ZU&_P!2D2?4]7OMOG73JN%
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M7-XDM+6PUUX%-Y;V<IDBCDQR%)_EDX.0&8#<0#;HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^<_V_/BUXO^"O[,?B/Q1X*D^Q:Q%/:V[:IY2R_V?#+.
MB//L8$,1N"C@X+@]J^C*BEA2XC:.15=&&&5AD$>AH _/*Q^$?QT\7^%=+76/
MVD]<;X'0:#)XOA^(VD61TS5KD.B.EK,OF_:!$D1DG#'.0VT\A!'[+_P3D^*/
MBGXH?!37)?$.OW7C*PT7Q'>:/H7BR]M7MIM:TZ)8_*N75_F+$LP+,<\;6)=6
M)^F/^$;TB/PV- &E60T%;3["-+^SH+7[.$V>3Y6-OE[/EV8QCC&*_.B3_@H7
M\5]>UK5=&_9^^ "Z]X!\-73Z-;7MM9W$MNPB.U!&L"QQPKLV$1#<0K+ZT ?I
M917QM^RO^TI^T/\ %3XI+HGQ-^#9\"^&OL,T_P#:OV&ZA_?*5V1[I'*_-ENW
M:OLF@ HI*,T +1249H 6BDHH \9\+_\ )W_Q%_[$SP__ .EFKUZ/XV\<:+\/
M?#UUK>NWJ6-A;CYG;EF;LBKU9CV KSCPO_R=_P#$7_L3/#__ *6:O6/\4?V.
M?!7CBUUF^TJV?1?%%_/)>_VCY\DB/,S%V#HS$;69CG: 1VZ8(!U/P3_:(\-_
M&Z&]BT\2:=JUF2TFFW;+YAAW869<'#*<@''W6.#P5+>JA@W2OD'X)_L/6EO;
M7E[\28$O9W9HK;2[6Y8)$H;_ %KNA!+-CA0< 'G+'"?5^AZ+9^&]%T_2=/B\
MBPL+>.UMXMQ;9&BA5&2<G  Y)SQ0!P?CO]HCP+\.?%__  BFKZC?R^)S8QZF
MNCZ3H][J-T]J[RH)ECMH9&*!H) Q'W<+NQO7=B>'?VP/A-XLU'P[:Z5XI>ZA
M\0SQ6>F:F-,NTTZXNI(?.2T%XT0@%P5S^X9Q(&&PJ'^6K%G\/]6C_:OU[QM)
MIJ_V'<>"=/T:WU#S(RQN([Z\EEB"[MX&R6!LD;3D<D@X\(\&_L[^/M(_95^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P .V46MZ+KFNRB:\B@<0.\,TI^>5L7T(R3@>4V H(4>=^./V;_&7[+7C/\
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M_$!_#[Z%X5M]>\1>.$TBTN;W4;B65[>&!+=U\F .89YF8(W1%7;R3V?[-OQ
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MWQM_[@O_ +?U^JE?E7_P0S^]\;?^X+_[?U^JE !1110 4444 %%%% !1110
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M:%IUOIEJUPP:5HH8EC4N0 "Q"@D@#))XKHZ** "BBB@ KS#]J/\ Y-G^+?\
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M(1L<KI_[;G@75M>U;1;'P[\0KW6=(\DZCIUOX'U1[BR\U2\7G1B#='O4%EW
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MCFBD0B0 @.NT\'<.!UWX7^.]>^#.H^,M4\":I?Z7KWQ53Q[K'@ HIU*Z\/)
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MI"OF_3_^3S-4_P"N"_\ I%'7TA0 4444 %%%% !1110 4444 %%%% !1110
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MCX&_M'2WFD1OX]^(TVLBRL]UNDOV5;8V.F0/*'\OF&&.3E\*9WR0=U4O@?\
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MD1B9?,RP3:JT ?7_ .Q[_P ,7?\ "X!_PH@M_P )U_9\_P#T&O\ CVRGF?\
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M>O$/!M];WW[77Q%DMKB.XC'@WP^I>)PPS]LU;C(KV^@ HHHH **** "BBB@
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MXV_]P7_V_K]5*_*O_@AG][XV_P#<%_\ ;^OU4H **** "BBB@ HHHH ****
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MHH **\N_:"UWQ)X%^%7CCQEH&L1VDWA_P_?:G%93V:S1RS0022J&.0VTE5!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  @+L6/_  BNFC+'/ MT 'X#B@#V2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#YS_:8_;@\$?LH^,?#&B^-M.UA[77X7EAU'3(4F2WV2*CF5"ZMM
M 8-E QZ_+Z^%^)?V<?V0_P!OOQ<?%7AOQI]G\47S22WL7AK48[.]O2 H,LME
M<Q,RXVGYUC7=N)8MUK[,^*VM> -)\)SK\2KWPY9^&+IA;RCQ3+;I9S,<D1L)
MSL8G!^4^AK\EOVI-9_8?\07\D7P\T#Q1?^,;J5Q;GX?HUI:/=9"1Q,ETI0(S
M8Q]FA.>QY% 'Z5?LS_L<?#7]E/3[R/P5IUQ+JE\H2\UO59A/>SH&+*A8*JHH
M)'RHJ@[5)R0#7N=?FU_P30T7]J72_&3/\2%\56WPL>SG2*V\73(US'<(46%4
M2<_:8UV[L;56,X^E?I+0 4444 %%%% !1110!XQX7_Y._P#B+_V)GA[_ -+-
M6KV>O&/"_P#R=_\ $7_L3/#W_I9JU>ST %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%8OC#Q9IG@7PGK7B36KC[)H^CV4VH7EQL9_+@
MB0O(VT#)PJDX )..* /C7]J;P3X=_:[_ &O/AW\&K^P34="\'Z?=>)O%5U;N
MJ31),J1VUFLRY>,NPC>2,;2T;(P.5!'U9\(_@OX*^ _@^/PMX#T"W\.:&LSW
M!MX&>1I)7(W2222,SR,0%7<[$A551PH \*_X)^^%]6U?P+XH^,WBFT:V\5_%
M756UQXI"Y:WTU,QV%N">"BQ%F1@!E)4SG%?5M !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^-_\ @K3_ ,F5^(_^PEI__I0M>Q_L9_\ )IOP@_[%;3__ $0E
M>.?\%:?^3*_$?_82T_\ ]*%KV/\ 8S_Y--^$'_8K:?\ ^B$H ]EHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWD_A>S\?_M$?LQ_%7]IN_P#BIXST'QYH>J74FD:;I&K-!I5I:Q+;R-"L(7<
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M%% !1110 45R'Q"M]2M=!U;5M/UZ^TU[&PFF2W@BMGB=T1F!;S(F;D@ X8<
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M,O(R<A8XR24<C@[QA><%^,_=T,2PQHB@A5 49.3Q4E% !1110 4444 %%%%
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M)QNX!XZU93]I?X<.P4>(CEC@9L;G'Y^7BO3MH]*;-!'-&8Y(UD1N"K $'ZT
M<78?&KP+J,:/%XITU Q('GS"$\>H?!'XU>7XJ^"V.!XNT//I_:4.?_0JGOOA
MWX5U2XDGO/#.CW<\F-TD]A$[-@ #)*\X %5F^$_@IE"_\(EH@ Z!=/B7^2T
M>.?&#]I:VT^ZU_PM8:/%JEK-9^2NJ0Z@-C>= &#*H0@@!Q_%S@]*ZCX3?M&6
M_P 2M8O+"[TF+01!!YZS27PD5_F V\HN#S7E?Q6_9M\27'CK4;CPIH<#:%/Y
M<D$<%S'&(SL4.I5V!!WAF&,C##Z#6^"_[-M_#K5])XZT&+^SQ;A8(WNE8F0L
M#N'E/V (Y/\ $/P /?&^*G@M1SXNT(?]Q*#_ .*KY[^-'[1NI-JWB+PSH_\
M8^H>'[BV^RK?1[Y6=98%WE763;D%V'3M7T GPF\%Q\KX4T4]OFL(C_[+7B_Q
M&_94O/$?B^]U+0+O2M*TRX6,I8B%HEB(158!4!7!*EN,<L?K0!8^%_[3VI^(
MKJ_BUS1FO)(XU:UM?#UC++-(W.X$%R,8 ZD=Z[T?$OQ?K:AM"^'6H+ QV^?K
M=U'9%/0F,[F(^E9/P&^">I_"G4-7N-1O[2[^V11QHMJ&XP223D#U'Z]*]FH
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M_P )=H7_ $&M/_\  I/\:\L_X8W^$6/^15D_\&M[_P#'JT/^&4_A5_T)]O\
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MM[X'_ _1_@EX9^PV)^V:G<A6OM1=<-.X!P ,_*BY.%SWYR<FO2Z /%8_@_\
M$'Q0G_%7_%34[>)OG^Q>%((]/$+>@GP7=?\ > K7\-_LS?#CPVTDG_",VVKW
M<N/.NM9S>R2-_?(E)4,3W4"O4Z* (+>VBLX(X8(DABC4*D<:[54#@ #L*D>-
M9%*LH*D8((XI]% " 8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OA7_ (+'>)K_ $']DFTLK.9HX-:\2V=A
M>*IP'B6*XN I_P"VEO&?P%?=5>(_M:?LMZ-^UM\.M.\(:YK-]HEI9:M'JR7&
MGJC2,Z0S1!#O!&TB=C]0* /@7_@H3^QU\-OV5O@#X(\8?#?3[K0O&.F:]96C
M:Y'J,[3SGR)I#,<OM23S84<,BKCD  8 _5W3+U;_ $VUN>%\^)9-N>FY0<?K
M7YU?\.1_AY_T4/Q/_P!^;?\ ^)KHOAK_ ,$@/ GPT^(WA7Q?:>.O$5Y=^']5
MM=6AMYX8!'*\$R2JK87."4 ./4T ??U%%% !1110 4444 >(ZY_R>EX*_P"Q
M!US_ -.&DU[=7B.N?\GI>"O^Q!US_P!.&DU[=0 4444 %%%% !1110 4444
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M* "BBB@ HHHH \8\+_\ )W_Q%_[$SP]_Z6:M7L]>,>%_^3O_ (B_]B9X>_\
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M5!+;I8E.,$#C#+DX 4 ^QJ*\2_M#]H/_ *!G@'_O[=__ !5+]O\ V@_^@9X
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M% !1110 4444 %%%% !1110 4444 %%%% !1110!\;_\%:?^3*_$?_82T_\
M]*%KV/\ 8S_Y--^$'_8K:?\ ^B$KQS_@K3_R97XC_P"PEI__ *4+7L?[&?\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QO\
M\%:?^3*_$?\ V$M/_P#2A:]C_8S_ .33?A!_V*VG_P#HA*\<_P""M/\ R97X
MC_["6G_^E"U['^QG_P FF_"#_L5M/_\ 1"4 >RT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -**3D@$TZBB@ HHHH **** "BBB@!**^"?VUM5U+X
MV?M=?![]FYM>U3P]X/UVPN-;UXZ3/Y,E_&L=RT<#-C[H%G(,<J3*"5)1<4?V
M0_$DW[.O[7'QI^ ,WB6]O_AIX8T6+Q'IUWXBO5;^R8Q%:R2IO. L6V\R2<*/
M(W8!9B0#Z>\+_P#)W_Q%_P"Q,\/?^EFK5[/7S5\.?BYX&\4?M5_$G4M&\:>'
M]7TZ/P5HK/=V.J030JL-UJC3$NKD (LD9;GY0ZDXR*]RD^(7A:&+S9/$VCQQ
M_8%U7>U_$!]C8X6YSN_U1/ D^[[T ='17.77Q$\*V,.H2W/B;1[>+3DADO7E
MOXE6V6;'DM(2WR"3(VEL;LC&:DNO'?AJQNKBVN?$.E07-O<16D\,M[&KQ3RC
M,43 MD.XY53RW;- &_16!_PGGAK=C_A(M*S_ &C_ &1C[;%_Q^XS]F^]_KL?
M\L_O>U%KX\\-7US:V]KXATJXN+N::VMXHKV)FFFB&98T ;+,@^\HY7OB@#?H
MKF[7XC>%+RWL)[?Q/HUQ#J$<TMG)'J$++<I#GSFC(;YPF#N*Y"X.<4Z/XA>%
MI8]Z>)=(=/L#:KN6^B(^Q*<-<YW?ZD'@R?='K0!T5%<U<?$?PG;0232^*-&A
MACM([]Y'U"(*MM(0(YR=V!&Q( ?H<\&I+[X@>%]+_M/[9XDTBT_LOR1?^??1
M)]D\[_4^;EODWY&W=C=GC- '0T5@2>.O#<,[P/XATI)DO4TUXVO8@RW3C*0$
M;O\ 6L.B?>/84B>/O#,DHC7Q'I+2&_;2@@O8B3>*,M;8W?ZT#K'][VH Z"OA
M7]M+_@F_=?M4?$1O%FG^);30=0,,4'G7$;R#RU4#RV0=0""P8,O^L8$'@C[+
MM/'GAG4)-/CM?$6E7$FHM,EDD-]$QN6ASYRQ@-\Y3!W!<[<<XJ&U^)'A*^M[
M>XM_%.C7%O<6\MW#+%J$++)#$2)9%(;!1""&8< @YH ^;/V&?V&W_9";6YKG
M6;?6[[5(4CGNH0PWE6R %(&Q5&<#YB2[9/"@?7%<XWQ$\*J,GQ-HX']G_P!K
MY-_%C[$3C[5][_4Y_P"6GW?>FW/Q&\)V=K=7,_B?1H+>U@ANIYI-0B5(89B!
M%(Y+85')&UCPV>,T =+17/W7C[PQ8W%_!<^(])MYM/DABNXIKZ)6MGF_U*R
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M .WD*LCAO-570;<9;/'2NZM;?Q'?7%I!;?'32[B>[FFMK>*+3;-FFFB&98T
MD^9TYW*!D=\4 >WT5X/;KK&K1:?+#\>]+N8K])I;*2VL[/%RD/\ KFC*R_.$
MP=Q7[N#G%"V>JR1[U^/-@R?V>=5W+;6I'V('!N<^;_J0?^6GW>.M 'O%<IXN
M^).A>"9H[?4+B22^EC,L=C:0//.Z@XW;5!PN<\M@$@C->82:3YEO)<:M\=U-
MO#:1Z@);2XMK14MI" D[D2$&-\C:YX]#S7$>+ELOAMXGUFZU'Q2?$5HD5I'?
M:A-<+//ISN',27"JQ:-9 R[&*X;(% 'TGX5\::3XTL9+O2;GSTC?RY8W1HY(
MG[JZ, RGZCZ5O5\N^#])BU[5-4U2?QD_@.-KJ#1TMX[Z.WNKFZ^=E2:,D%)"
M& 2-OG(R0 ,9[&#P3H%T^V;XRZ_/<_;VTK%KXBCC!O%&3;;0#^^ ZI][VH ]
MQJO>WD.GV<]U<S);V\*-))-*VU44 DLQ/0  \UXO:>!_"]_-I\-M\8_$MQ+J
M+31V4</BF-FN6A_URQ@#+F/^+;G;WQ6+XB\ >&=>\*3_ -F_%_4M2-Y9S7=H
MNH^)8I[*YCA/[QV 'S1(1AF&0O4]* /0-/\ C[X6U#4H[8&_MK28JL.I75H\
M5K(6(V@,1D9R.6 !]:])!S7QU=>)8?%%O<:'%%';WUSIC7\DM[<116D%F6V-
M>F?=M:W4DL)$W X&.M>HS>$O"6FV=S/=_&GQ!;PVL$-S<S2^*8D2**4@12,2
M/E1R1M).#GC- 'NM%>)77@?PU8S7\-S\8?$EO+I[PQ7D<OB:-6MFEQY*R K\
MA?(VAL%L\9I&\%^&$D\MOC'XD$G]H+I.T^)X@?MI&1:XV_ZX_P#//[WM0![=
M5/5-2M=%T^YOKV9;>UMXVEEE<\*H&23^%>-?\*[\*7UU'%_PMGQ!=7,EW)IT
M:'Q'$[M<QC+P ;<F11DE!R/05C:K\,?"?B70(8=&^*5YJESJ\-Q_94=WKT,]
MM?/#RX"JI\Q$(^?:#MP<T =U;_M!>'I+J(7-GJFG:?++Y:ZI>0(EL,G"LWSE
MT5CC!91C<,X%=_?:'INJL)+S3[6[8-$X::%7.Z*02Q-R.J2*KKZ, 1SS7RS]
ML?Q79G3%FTRP%W827<NH3:M:/:QV8!66Z5DE)DC3!&X#&?O$<U]'P>//"NGV
M$*OXGTGRX]-CU+S9+^+FS.%6Z)W?ZIC_ ,M/NGUH ZBBN<NOB+X4L8M0DN?$
MVCV\6G)#)>O+?Q*MLLV/):0EOD$F1M+8W9&,U)=>.O#5A=3VUUXATJWN+>>*
MTFAEO8E>*:49BC8%LAW'*J>6[9H WZ*P!X\\-$X'B'2B?[1_LC_C]B_X_<9^
MR_>_UV/^6?WO:BU\>>&KZZM;:V\1:5<7-W/-:V\,5[$SS31#,L: -\S(/O*.
M5[XH WZ*YRV^(GA6\@L)[?Q-H\\&H)-+9R17\3+<I#_KFC(;#B/!W%<[<'.*
MDL_'7AO4)(H[3Q!I5U)+9?VDBPWL3EK0';]H&&YBSQO^[GO0!OT4E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'B.N?\GI>"O^Q!US_TX:37
MMU>(ZY_R>EX*_P"Q!US_ -.&DU[=0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?&_\ P5I_Y,K\1_\ 82T__P!*%KV/]C/_ )--^$'_ &*VG_\
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M)+"VD%QM$VZ%3YFW[N[CG';/2E;1K"5B[V5NSM()BS1+DN!@/T^\!WZU>HH
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M01'G.P<?=SVZ5=HH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Q'7/\ D]+P5_V(.N?^G#2:]NKQ'7/^3TO!7_8@ZY_Z<-)KVZ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BO#?VJ?VJ-'_9@\-Z)/-HM]XL\4>(KX:9H7AO3& N+^X('&>2
M$#-&I*JYW2Q@*=U8/[-_[8@^-7Q \3_#GQ9X'U'X9_$O0(5O;CP_?7 NTEM&
MV#S8YU102#)'E2HXD0J7^;8 =%KG_)Z7@K_L0=<_].&DU[=7B.N?\GI>"O\
ML0=<_P#3AI->W4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?F'_ ,%Q/^1/^$__ %_ZA_Z+AK]/*_,/_@N)
M_P B?\)_^O\ U#_T7#0!^G$'^IC_ -T?RJ2HX/\ 4Q_[H_E4E !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:B])+'V!KIAI7[3Q&?\ A*/A-_X3NI__ "=7O5+0!\QZ=J7[4U]XZUS0'O\
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M#I7B?2_,:'[;H]['=P>8N-R[XV*[AD9&>,BMZ@#Y;T/7?VJ=7^('BCPW+/\
M#>PL]&M[*>#6I_#.JBUU!IQ*7CA;[: 6B\I=^"<>8N<59^(.I?M3>"? VO\
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MLM CL7M]<NO#&JK::H;B-V=8&-Z QB*!7P3@NO2OJNDH ^7?B;K?[5'P_P#
M.N^(K&Y^&WBF\TVU:XBT;2O#.JR75VPQ^[C47I)8^P-=0NE?M/,H/_"4?";_
M ,)W4_\ Y.KWJL_6]>TWPSI=QJ>KZA:Z5IMN-TUY>S+##$"0 6=B% R0.3WH
M ^7/#7CW]I7Q)\6O&_@6/6?A7#<^%[/3;R6\;0-2*3B\%QM55^W9&W[.<Y/.
MX5L?$+4OVIO!/@77_$%G??#/Q%=Z98S7<6D:;X9U1[F\9$+"&-1>DEF(   /
M)KW2S3PEI8U3QU;/I5M%J5E#/>^(4>-8[BTA1FB=Y\X,:+([!B< .3TJ?P;X
M_P##'Q&TEM4\)^(M*\3Z8LK0M>Z/?17<(D !*%XV*Y 8<9SR* /)1I/[3Q_Y
MFCX3?^$[J?\ \G5RNAZ[^U3JWQ!\4>&Y)_AO86>C6]C-#K5QX8U46NH-.)BZ
M0M]MPS1>4N_!./-7.*^I:2@#Y:^*FO?M4_#OX?:WXDL)OAOXLO-.@\Z+1=)\
M,ZK)=7;;@-D:B])+<YX'0&NK&D_M/$ _\)1\)O\ PG=3_P#DZO>J6@#YATW5
MOVI]0\>:[X>>]^&EM::;96=W%K$OAK5!;7C3M<*\,;?;<%XA A;!./.3IGG(
M^./C[]I7X(_"7Q/X[O-9^%>J6VAVINGLX- U)'E&X+M#&^.#\U?6M<CK]QX+
M\?S:MX"UBYT;7;B2UWZAX<N)HII3;DI\TD!.[9EDY(Q\R^M '6KTI:XS7OC)
MX \*ZK/I>M>.?#>CZG;[?.LM0U:W@FCW*&7<CN",JRD9'0@UTVE:M9:]IMMJ
M&FWEOJ&GW*"6"ZM95EBE0\AE=20P/J#0!=HHHH **** "BBB@ HHHH ****
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MCLPF+$P<[CN,3R#)CWM]@_MK_"OXG_&KX*W/@OX7:YI?AZ_U6X6'5;O5+F6
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M9?/VB3E<!:^NZ "BBB@ KR7]I+]G'P_^T]X'M?"7BC6-=TS18;^._F@T.Z2
MWA0,%BF+1MNCRV[:,?,JG(*BO6J\'_:X^#?Q%^+G@G2#\+/B!=^ /&.BZBE]
M;RK=SPVE\F"&M[D1$Y7.UQN20?(5*X<D 'R)^QKH^A>#/V_O&D%EH<WP7L=0
M\/\ V?1O .J+<17&LQHT>;R,2)Y94""9MJOO_P!9P0LI'A'BGP;>ZA\7_CG\
M4/BI^S5XV^(OA.76Y+RUU.\N+W0GTS38WF E$>T-,/($!.0!&L1R0"37V[\+
M_P!EWXM>-/VIM&^.?QOU7PK:ZKX:TMM,T71?!0G,#[UN%9YVG!8 "XD("L2Q
M9<E0FU^8\5?LW_M7:3X-\=?"WPW\0/"OC/X?>)#=6]OX@\>7=]<:_:65Q&$>
MW:0*Z'"EU#;6SDL/+R%0 ^H_V9/$7@?Q7\ _!&I?#:*:V\$2:<D>F6MPS-+;
M1H3&T+EF8EXW5D;YF&5."1@GU&O,_P!G'X*6/[.OP5\*_#S3[Z74[?1;=D>]
MF0(T\TDKS32!<G:K22.57)V@@9.,GTR@ HHHH 0G%?E)_P %"?BYXA_:A^''
MQ'O/!6J)!\%/AM/:17>I0(63Q+K$EU# 8XI,X:"!)B^5."VUL.&C9/U8EC6:
M-XV&58%2/8\5\)?'K_@D[\*M<^%6N67PJ\+6GA_Q[+Y']FZEJNM:@]M%B>-I
M=X+RCYHA(H^0\L.G4 'DO[0VH3^)?@K^P5\+KR:4^#_&JZ'%K=G#(T9NHXX=
M.B6-G4@A=MU(< ]0IZJI';>&?!^B_LN_\%2O"W@GX=6)T+PIXY\'O<:II$,K
MM;>=&+QTD1">"#9K@\X\V7&-YKH/%'_!-V?3?V?/A9I7PYO=+\,?%7P/J-KX
MB%_=37%S876J>5;K=MEPS(KR6T4B_N\?N@NQ0Y([CX&_LU_%/5/VEKSXY?'+
M4?"UQXAM-&71=!T?PJDQMK",D[Y-TH#9^:;AFDS]H?E0JJ #Z]HHHH ****
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M^TEX=^$VO_L[Z1JW@N]^$FL:D;M?%%XUPNHVMN+B*41"-2%W,8MQ3:PR[CS
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MP9XD\ ?\%/?B]HOC#Q7/XW\3Q>$%GU#7)X_+-Q-,=+F8*F?EC3S!&BC "(H
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MJND_ WX4/(WQ4\80,9=2A<K'X<TOE9K^5P=R/C*QXYW E3N\M7^I*^3OC?\
M\$U?A+\?OB?K?C[Q-<>)(]=U;R?M"V%_'%#^Z@CA3:IB8CY(ESSUS0!\8?LP
M>/M<^#W_  2N^/.O>'+V2RUFU\526,%[$S)+#]H33;9Y$92"LBK*S*P/#!2.
ME5?BK\%?"/[)G[-'[-'[0'@&TOM*\=RWNCW6J7::A.PU 7-@]S-&R%]JH?+:
M/:@4,DK*V[.:]E_9W_X)/IX;^$GQ+T?Q_J2V_BSQ/:SZ/:76EW1N+2WL_,M;
MFWE:,HC-(ES:JQ7< 5&,\Y%C2_V/_P!HKXK6?PI^&GQ8NO!-G\*?AU>V<_VG
M1VFENM8BMHO+BBVG'/EYBW,L6 [-B0@ @'Z-K]VG4B\"EH **** $K\N?^"D
M7QD\2_'[P7\1/#_@.62W^%WPX>W/BK7-^V'5]4>XBCCT^'!_>+"9!(^>-Z#(
M&V(R?J-7YQ_&+_@CCX 'PXU@?#2\UD>-<1_V?_;NJ)]CSYJ>9YFR#=_J]^,=
M\4 1?M6S>*K_ /X):_!WPSX2T'4/$-WXCTCPS87=MIMC)=2K EE'<!@J D$S
M0P+DCG?CO6/^Q9I?P/\  7[3VC>&9?A%XW^$_P 4393S:%+XINYI5U* Q2*[
ME#A4=D29N%*9C=0^X!3ZUX<_8>\=_!?]F_P=HGP@\;S>'/B#I6K6OB75K34+
M^4Z3J]X8+=+NTD,2JWV<M I4%3D;E./,+))\,?V<_C5\5?VF_"GQG^.J^%="
M;PC8S6>E:!X8:63SI6\T":4NS@#$I8;7/*)\J_-N /MNEHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN+B.UC,DTBQ1CJ[D #
M/O4$>L6$TBI'>VTCL>%6523^&:^8O^"HW_)BOQ,_[AG_ *<[2O"/@7_P2W^"
M7Q:_9U\!>(]3B\06&O:YH-G?W5[I^IX(FDB5W*)(CH 23P5- 'Z04M?F[^P/
M\=-6^!_CGXT_ _XC>)[C6-!^&EK<ZKI^MW<;LUMIMHXCF&T,[!-CP.D2[BOS
MJ,_**V;W_@K%J$&CCQG#^S_XQD^$[70A7QC+-L5H_-\HOL$)BW;@5QY^-XV[
ML] #]":*^5OBE^WAI/PVUKX*2_\ ",37_@OXHI;/9>(WO5@^P"5H<^="4/W4
MN(W/SCHX_@YW?VB/VOHO@?\ %KX9_#K3?##>+O$GC>Y\E((K[[/]A0RQQI+)
M^[<E&+2DD#@0.: /HRBOBOXF?\%'IM+^+'B/P!\+?A#XE^+NJ^&I7M]9N-,9
MX(K>96V.B[8968*X9"S*@+(=NX88^K?LF?M@>'/VKM%UTV&D:EX7\3^';A+7
M6O#^J)^]M'?<%*O@!E)CD7D*P,;;E'RE@#WZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBFM]TT .HK\F_V3_$W[2G[7WB#XD0Z;\?[WPC!X7O88ECETB"Z$JS/<
M!0" NW:(/?.X=,5ZSX5_:"^/7[+/[3W@_P"&GQUU[3_B'X2\=RI9:)XAT^RC
MM9;:<R^4@*I''GYY(1*C[MHD1E?AE< _0NBO%/C)^V7\&O@!KT6B>._'-GHV
ML2()?L$5O<7DR*<$&1((W,>0<C?C/49JU:_M;_"2_P#@[??%.U\:6EWX$L)4
M@O-4MX9I#;2-(D:I+"$\U&+21_*R X=3T(- 'L-%<*WQM\$)\)?^%G'Q%:CP
M)_9XU3^V,-Y?V<C(;;MW[L_+Y>W?N^7;NXKDM0_;"^#VD_"?2_B5>^.;&S\&
M:J\D=A?W$,Z27;1R-'(L4!C\YRK*P.U#TSTYH ]GHKQ/X._MG?!?X^>(&T+P
M-X\LM7UD*773YH)[.>4 %F,:3QH9,!23LS@#)P*]LH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ast008lymphoma.jpg
<TEXT>
begin 644 ast008lymphoma.jpg
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M4445\*_\%,?VXO$7[+]GX;\+^!#9P^+=<CDO)[Z[A$_V*U4[%*1D[2[ONPS
M@")A@D@CYF_:)_9._:&F_9Q\3_$SXQ_&B[O#:6D5]+X1CFEF@+/+&JQ.%9(4
M8%@<(C#(XSUKW'_@B;_R;[XX_P"QH;_TDMZ^;?\ @C7"DG[7'B]F4$Q^$[UE
M)['[=9#/Y$_G7I__  7,4 _!0]_^)W_[85ZM^TM_RAMT?_L3/"?_ *.TZI?^
M"+K?\8J>(./^9ON__2.SKY9;_E,T/^QM'_I-7V+^VM-^V''\5M,'[/V\^#/[
M&A^U;4T@_P"G>=/O_P"/P>9_J_(Z?+Z<YKE_ TG[3<G[+/[37_#1H88\&7?]
MA;ETT?\ +C??:?\ CR_[=_\ 6?\  ?XJ^+_^"<'[%7@C]L#_ (6'_P )EJFO
MZ9_PCO\ 9WV7^P[B"'?Y_P!IW^9YL,F<>0F,8ZMG/&/O7P=_P2"^ GA75+6]
MNU\2^)A;OYGV76-2C,,I!R ZPQ1Y'3C.#WSS7J_[;VEVFB_L4_%#3["UALK&
MU\//!!;6Z"..*-=H5%4# 4   #I7S!_P1%/_ !:/XC_]AR'_ -)Q7U-^WA\1
M-'^'7[)?Q/N-7O([5M4T.[T:TC8C?/<7,30(B+U8YDW''10QZ FOBG_@E'X'
M\9:3^R_\>?%OA"WDB\4ZQ UEX<D94 EOK6TG: KYP\L@37*KEOER&#< U']J
M_P""F_\ =DQ_UR\-?X5^HWAK^T#X=TLZK_R%/LL7VO[O^NV#?]WY?O9Z<>E?
MCG^UE_RE\\-?]C/X6_E9U^T%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%)M%%%+112;11M%+12;11M I:****
M********************************************************^,_^
M"A_["EY^UMI&A:QX6O[+3/&FAI)!'_:&Y8;VW8AO*9U4E65LLIP1\[ ]<CPW
MPW^PW^U)\<? MOX.^-7Q2&D^"M,M6BLM%MIXI[BXE1"(!<21)\\:N$;=(\C?
M+P >1[Y_P3K_ &4?B'^R3X7\7>'O&>H>'-2L-3O8;^SDT*ZN)72384D6198(
MP 0L>"">C5YW^P#_ ,$_/B)^RK\<O$'C+Q9K/AG4=+U#0[C3(H=%NKB282R7
M-M*K,)+>-=NV%AD-G)''>NP_X*/?L5^./VP/^%>?\(;JF@:9_P ([_:/VK^W
M;B>'?Y_V;9Y?E0R9QY#YSCJO7G'IWB[]F.^\=_L06'P0U+4K2UU>'PMINCOJ
M$*M+;+=VD<!5UR%8QF6 <[0<<X!XKY*_9 _9._:V_9R\<:7X=BUS0].^%RZ[
M#J6LV\5W#*E\GR+,8F,)F4F-%&T^6#M'N:[=O^"?GQ$/[?W_  O'^V?#/_")
M_P!N?VG]C^U7/V_R_)V8V>1Y>[/_ $TQ[U^@GIQ7$_&[P7??$KX+^/O".F2V
M\&I:_P"']0TJUFNV984EGMI(D+E0Q"AG&2%)P.AZ5\P_\$X/V*_&_P"Q_P#\
M+#_X3+5- U+_ (2+^SOLO]A7$\VS[/\ :=_F>;#'C/GIC&>C9Q@9^UJ\P_:8
M^&>J?&3X"^./!.BSVEMJNN::]G;37[LD"NQ!!=E5F X[*:_,SPE_P2I_:A\
MVL]OX8^*_AWPY;W#B26'2?$>J6JR,!@,PCM0"<>M=7H?_!(?XF_$+7]/O/C)
M\8AJMI;MB1;&YNM2N?+S\R1RW2J(RPQ\VQ@#_"<5^EWPS^&_A_X1^!=&\'^%
M[!=.T+2(!;VUNI).,DEF;^)F8EF8]2Q)KJ:2OSZ^-W_!/WXB?$K]NS1_C5IF
ML^&8/"UGK.BZC):7=U<+?&.T%OYH"+ R;CY3;<O@Y&2.WZ"KFEHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI"V*\?UK]KSX+^'?'2^#=3^)7AZS\
M1^;Y+6<EXN(I 0/+DD^XCY(&UF!SVKT?Q3XPT/P/X?N]>\0ZO9:+HMHGF3W]
M].L,,:^I9B!R3QZY&*X_X2_M&_#3X[?;%\!^,M,\236?-Q;VTA6:,9QO:-@&
M"D_Q8P>QJG\2_P!J;X3?!WQ%:Z%XR\?:-H.L7.TK97$^9$5ONO(%!\M3@X9]
MHXZUZ)#XBTNZT-=:AU*TFT=H/M2Z@DZ-;F';N\P2 [=N.=V<8KS?X>_M6_"+
MXK^*[CPUX1^(.B:YKD)/^A6UQ\\H R3$2 )0!U,98"O6:6BBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL'QG
MXX\/_#OP]=:[XGUJQT#1K89EOM1G6&)<]!N8CD]@.3VKEOA-^T3\-OCI'='P
M'XRTOQ)):\SV]K*1/&,XW-$P#A2>C;<'L:J_%3]ISX5_!/5+/3?''CG2?#VH
MW>TQ6=S*6FVDX#LB@LB?[; +P>:[>S\8:%J'AE/$=MK-A/X>>W^UC58[E#:F
M$#/F>;G;M '7..*X+X;?M4?"3XO^)+KP_P"#?'VC:_K5ON)LK>?$CJOWFC#
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MG)/+<\FOOGXC?'KX<?"%GB\:>._#WAF[6U:]6RU+4HHKJ6$;OGC@+>9)DHP
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M"_V8?%VE^%;S0]<\6^([NW^W3V.@Q(YL[;=M$DA9ARV&VJ!_"<E<KGQC6O\
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MPQPQ1K%%&H1(T4!54#   Z "I=PHR*-PI-PI:,UY5^UC_P FL_&3_L3-9_\
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MI#Q#X@\)_ 'XB:UX5\P>(K#0;VYL&A0/(DR0LRNJD'++C(!!R1TK\J?V=?\
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MJQ1GC)[@#%+7S1^T]X@O?%OQ(\ ?"S0[UK?5+^X75[K[(VR]AM4<Q-<1.Z-
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M_M?Q%IVCWEYIFG^2\_VJZC@=XHO+0AGW.JKM4@G. <FOS5_X;Z_;>_Z-R_\
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M:2_X*3?#W]E_XFR^!_$GAWQ-J6IQVL-V9]+AMVAVR E0"\R-D8YXKY[^,/\
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MFZD-Q%I?AS_1;:)MHCN;R6-6DFQM+$11.L:,K 9FN0RG:A7M:6BBBBN"U?\
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ML:WGNI7N9T* X0B69_D'RKT' %=O5/4M2@TG3[F^NG,=K;1-/*X4MM1068X
MR< 'H,US_A_3-4U/4AK^O+)97&UH[/1EF5XK.,L?G<KP]PZ[=QRRQC,<9(\R
M2;JZXOXB7CZE#8>$[6?R+SQ 9()9%1G:"R1<W,H 9=IVLL2R9(22>(E7 V-U
MUK;Q6=O'!!&D,,:A$CC4*JJ!@  = !VJ>BBBBBBBBBBN+^(LLFL0V/A2T-P+
MC7&9;F2W=8S!8(4-U(6+!AN5UA#1Y</<(P "LZ=BBK&H50 JC  %/HHHHHHH
MHHHHHHKRC]JS6M7\._LT?%'5-"FDM=6M/#=_/;W$+%7A98')=2.C* 6![$"O
MCO\ X)C_  )_9_\ '_[/NFZE>^&_"_C/Q[(TW]NPZW##?W%JPGD$0$,H81*8
MPA#*HW9/)KAOVC?!?PT^$G[>_P"S\GP6ATS1O%%UKJP^(]*\/R@101-- BAH
MD.V(O"]SE0!D $CG-?JG2T444445XMKG_)YG@O\ [$'7?_3CI%>TT4444444
M444444444444444E<AK>O7>NZK<>'O#EPJ7$#>5JVJ(RL=*5H@ZJBE65[EE:
M-EC8;41Q(^08XYNETW3;72;.&TL[:*TM85V1PPH$1!Z!0 !7._$#5M0@L;71
M]%DFM]:UJ1K.VO8X5E6P'ELSW3JP*D(J_*&!#2-$IX;(V] T.R\,Z+8Z5IT'
MV>PLXEAACW%B% P,L22Q]2Q))))R:TJ****2L?Q)XC@\-V:S26]U>SROY5O9
M641EFN)3G:BCH/=G*HHR695!(R]+\+W>J:A;:SXF:"YOX5!M+" -]EL"<,Q
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MZ-/TV,V\T[W$QQ\H6)&( W+EF 4%ER1D5T/CKQ]X=^&?AF\\1^*]9L] T2S
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MT9WA@0%.#V/QC_P2G\'6OP[^-W[5'A2QGGN;+0M?M=+@GNF#321P7.I1JSD
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M;'0["*RTVRM]/LHL^7;VL2QQIDDG"J !DDGCN35VN0^)5W>-HUIHNGRFWO\
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M51@R,I ( =TM>&_#L/AZS,8EDO+R8^9=ZA.J^?=28P9)"H S@8  "JH55 4
M#8HHHI*Y&;7W\77DVG^'[T"VMYFBOM6@"R(C1R,DMM&P./.#(RL<'R\$'YN*
MZ+2=)L]$T^"QL;=+6T@&V.*,8 &<_B2<Y/4YR:NT44E>(_M!?%"70]+O=*TR
MWCU*5?*MC:),H?4-4F>/[#I ##:!<9)F9S^[@Y( F$L<WA'P?>_#;PJ/!^D7
MJS^/]:A>\O-;6V)AM0"D1N7)0H6C5E$<; -<.CL1S<2)ZA;V^D^"?#TK-+#I
MVEV43W%S=74H554 O)-+(QY)^9FD8\DL2>IK$\"V=[JTUWXHUBV-M?7[,EC:
MR*-]E8@CRXR=H(>3:)G4C*LXC)81*Q[2BBBBBBBBBBBBBBBBBBBBBBBBBBBB
MLK6O#6D^)8[5-7TJSU5+6<7-NM];I,(9@K*)$W [7 9AN'.&/J:T5 C  & .
M !4E%%%%%%%%>4_M8_\ )K/QD_[$S6?_ $AFKU:BBBBBBBBBBBBBBBBBBD)K
MA?#*IXN\::GXE<1R6NE//HFE-%,S@[747LK $*&,\0AVD,5^RL0P\UU'=T54
MU'4+72+"YOKZYAL[&VB::>YN'$<44:@LSNQX50 222, $UPVAZF-/L=1\=>*
M4.GM<MY5E;O$7FM+,NJ00JJIO::=MDAC"E_,E2(;S&A.KH>AW^KZM%X@\0Q_
M9KR'S$T_2X[@R0V43$@2/C"O<N@&YN1&&:.-BIDDFW=;U[3O#>FR7^JWT&GV
M2,D9N+F0(NYW5$3)/+,[*J@<DL ,DBO*IM'O_P!H&X;^V(KO2/AW!*IBTU)F
M1M?C**Q^U8P5A#%D,&621<[]V[9'[!;V\=K#'%#&L44:A$C10%50,  #H *G
MI#7#>%9(O%7C;7?$BRV]Y::>[Z#ILD2J^SRW4WK+)U!:X00NF<!K%>^<6_$%
MU+XHU";PWI\UY;1Q,G]JZA:.86@B92PACEVG]Z_R9V89(W+;HW,1/365G!I]
MK#:VL,=M;0H(XH84"(B@8"JHX   X%6:KWUY#IUG/=W,JP6T$;2RRN<*BJ,E
MB?0 5RUCI\_C*]MM6U6!X-*@>.XTS3+B)HY=X7B>X4G[P)RD9'R8#-^\P(NP
M Q2T444444445E^(M?L_"^C76IW\C1VUNN6VJ6=V) 5$4<N[L5557EF90 20
M*R? NDZA;Z=_:NO0Q0>)=319;^**02K;=62U20*OF)"'9 ^U=YW/M7>0.JHI
M&Z5PWPS:/Q$NI^,1/#=IKLH^P3Q(NW^SH2RVVUQ_K$?=)<*Q_P"?H@<8-=U1
M11111111111679^&])TS4[W4;32[.TU"]8-=7<-NB2SD *"[@;F(  Y/0"M-
M32T44444445XMKG_ ">9X+_[$'7?_3CI%>TT444444444444444445B^)O%F
ME^$;.*XU.[2#SY/(MH!\TUU-L9Q##&/FDD*HY"*"2%/'!K"_X1J[\<26MYXG
MB>SL(7\Z#P^DI&&RP!NVCD*7'RX(BQY2LS9\TK&Z]L.*6N<\0:Y=-=_V-HP'
M]L2Q>8;B6(O;V:;L>9+R,D_-M0'+%>RAF6YH'ANR\.P3):1_O;B1I[FYDP9K
MB0GEY&[G] ,!0  !KT444E<3J%Y/\0+JZTC3)Y;;0(6EM=4U2WED@GDD4A6M
MK61<$$999)T;,94HA\W<T'76=G#I]K#;6L$=M;0HL<4,*A4C11A551P    !
MTJS1117+>-?$L^EV\.EZ2\#^*-3#1Z=;S1F94 *K)<R1AT+0P[U9_G3=E(PP
M>1 ?)?"=]INI6]QXQT&.7Q'9Z7>7VG^$[-[N91JVJ/)*+V\D;!0!YO-A5_**
MP113.A\N;8OLWAOP]_84-Q)/.+_5+R0S7E[Y2QF1CT4 =(T&%1220JC+,V6.
M1.B_$AS 5+>%8Y$9W."FK8&X*I#?Z@,%SD8EP5YCSYG9KP*6BBBBBBBBBBBB
MBBBBBBBBBBBBBBBBD;I7YD?M&?'CQ'^S/_P4GT/Q%XN\:ZC!\)-2MHEFT?3=
M0::."/[&8B9[)'+96X(FW;,LI^7<017V5:?ML? 2\MTFC^+WA%489 FU6*-O
MQ5B"/Q%>E^!?B)X8^)V@C6_"6O:?XDT@R-"+[3+A9X2ZXW+N4XR,CCWKHZ**
M****\I_:Q_Y-9^,G_8F:S_Z0S5ZM1111111111111111117*_$+5KVRT1;#2
M)Y+;7=7E_L_3[B.!9OL\K*S-<,K?)MBC627#D!O+V#+.JG;T72+;0='L=+LH
M_)LK*".V@CR3MC10JC\ !5^DS7!>)=4A\1>(CIAN$AT+098[O6KA;AD)G 62
MWM,!>1\R3O\ .I $"E9$G;;K:/;7OB&^@UK4$FL[6,"2PTV5-DD1*,K2R\_?
M97("?P@\_-]W0\1>((/#MBDTD%Q>3S2K!;6=F@::XE;.$0$@9P"Q9B%559F*
MJI(\XMM'U'XD^)'N)=4N!I]L)K6ZGL;LQQV$WRI+:6911OE&)(Y;PMOB_>10
M['DE,/K,$*6\*11(L42*%6-%PJ@#@ =@!4U%<K\1M;N]'\+7":7))'K>H,NG
MZ:T4'GLES*=J2^63\R1Y,KYX"1.3P#501R6MK9>$O#%T(1I\4-M=WLS-.]G
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M.(88@Q81PP[BL0Y7<1\TFQ-[-L3;T5&17(:UX@O=:U:7P]X<F1+F!U35M3W
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M-<,/XM@D7:@.69T'"[G74T70;30;5X;53NFE:>>9\&2>5OO2.<<L>/8
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M>X6SOYYGRY7YW4J#&J;APO9>!_BUXQ\;6UP^C:EXPUS5;>*5YM,@T$00+L.
MJ7M_IMA%([ KA<C[QZJI>K#-^T5XB6$S#5O!]IY\IDBL5T6_OI(,*8"))"L-
MO+G<)(_+N5P<))G#USD/[+OC+6?$FEZAJ_AJWO$M[A6CU?4OB[XE.J6\)<_.
M(8E\I)51F_=QR[,Y D(.X^KW7P3\2:5HZ6GAF\\/&Y-QYLMYXW34_$TA0J!Y
M:/<7JRH 0"%$FT9;Y<L35+4?V9M4\6:Q#<^(?%NGV%G;QXAB\$^'(=(NDDW9
M+K>2R7$\1(P#Y#Q-\JX8?-N]6\$?#7PO\.K>>+PYHEII<ERL0N[J--US>M&@
M1'N)VS)/(%_Y:2,S'))))-=.!BEHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHI*^"_P!L;_@IM?\ [*WQGG\"6_P^M_$<<=C!>?;I-6:W),@)V[!"W3'7
M->'_ /#\?5?^B06?_A0/_P#(]??_ .RC\<M:_:(^$=OXRU[P?<>"+R>[EA73
M+AW<M&H4K*"Z(2&#<'&..IKV:BBBBBBO*?VL?^36?C)_V)FL_P#I#-7JU%%%
M%%%(:\M\8_M(>"O!OB:7P[)=7>J:Q;%?MT.FVKR0:<"H8&[N3BWMLAD.)I%)
M$B'&&!KA-7^)OQ(^(5Y>6/A:"3PJMF6F%Q::2VIF>'<A1S=7(M[$G875X8)Y
MV5V!\P>4Z-YQ8CX;:->:!J7BKXV^#](O(8;BWEDN_%<&HWUW$QR%>Y<PQ7 #
M;&(N[:Y"9_=>4P\PXNK?M5_LV^ [BY\)Z&T7BPR"6XF:^TN]NM-\M68.+.*.
MW:$AGVL%@2*W?>7\S<?F;\._VL/AW\1;&.^MM8OY;#3OL]E:7%MX2U>]AL6B
M9)'6'3H+0VEK+&0OD.TMS(BM&7)VF-O2H/BOX*\9V5UK4GA;QM\2A%+_ &6;
M7Q$EIIL3HA$@F33[^>SA(R1B?R?,.XKNPA5:*_MF>.)M>-O)\#?%>G:.EU-&
M]X-,U+4)S$I<1NBVUDUO)O(0YCN73:Q*N^!G%U;]HCXC^*KG[!IFL7GA"_:[
M#Q6-[X#33;LVS-+M*_VMJD(N514_>-!'N! ^4!@*PK[3_P!H[XQ:=8B'^WKG
MPR\BB.ZNKA_ .II.&*-+(D#SS&W"EOE= S,-RI@(S])I?[*/QDUS38K7Q-\0
M?!L=KLE1+>3PI#KEU;?*ZPR->W:J;J5049Y9(5,AWYQNS6Q-^PK=^-C:K\0_
MBSXDUVUL8K>.SL/#RC1K2)H45$E6W#RQP2*$3:UHMN1NE#;ED*UZGX1_9QT7
MX?W$MQX8U6?P[<2JR23:5HNC6SN&8,P9DL02"P!.>I&:Z'4OAE?ZUI]Q8ZCX
MXUV_L;A#'-;7-GI<D<BG@JRFRP0?0BN9M_@?XE\+6MVGA/XK>)K3[5>K=RV^
MN1VNI0(I)\R.W#Q!K=6&U51&,,>T;8N6S1OM6\2>$;$2^+-:\>VA\WR?M'AW
M2;37()6.YEV):Z>UP 5'+20(H8%=QRI:G8_$:#5+R&SLO%'Q;FO)F"11S^ )
MK2-F/ #33Z3'%&#_ 'I'51W(%=-]A\7_ //_ /$#_OGP]_\ $4?8?%__ #__
M ! _[Y\/?_$4?8?%_P#S_P#Q _[Y\/?_ !%2V]OXKAW;[CQY/GIY@T 8^F /
MUJ?_ (JC_J>/_*%3'7Q0RD!O'"G'WA_861].*YN+XLZGX?M];$VMV4O]G2I$
MD?CVQN/#3;RVV0-?^2;>Y ;.V2VAV8"#+;Q(>R'Q?L;-=-DU70O$&EV^I$?9
M;M=/.H6Q4X^>2:R:>."/#*?,F9%QD@X5L=1X?\5:-XLM9;G1-6L=8MX9FMY9
M;"Y2=8Y5 +1L5)PP#+E3R,BKE_J-KI=C<7M[<Q6=E;1M--<W#B..)%!+,S'@
M* "23V&:Y#4OC-X6LUL#:7%[XA^W'; ?#FFW.JH<XVEWMHW2%6R,/*R+U^;
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M"_M,?'1ENM-USX>^(?"/AZV@"Z,O@WX9ZC#<*>R7-O.L\2*HQ\L,G4'YB*]
MT?PW^U3XD\'Z?=ZA\3;O2=1N DY_L#P7IF-A3(!74+F.10<@D20QR# #*IW"
ML1_V6?V@-?N+.!O'6A^']/B4QKK$5QJ4&NO'@E5NGMKE6G.[JKW<@!)8%CP<
M'7OV:?#/B.\AL/B%^T%X9%[:720:M%I^K7]K<721;4:.59M7>-)@$.9#"6+C
M>^]RQ;6\'_#H_ '7+ZU^%7Q(\3>*--U0Q3V>@^'?#:7T=P[LT<*W>N/:W4<:
M@[OOO$L8W/MP3NN>(+K]M+4E_M#0(+#P]"TB,='U\Z=?/# $!D+7=L!OE+YV
MHEL1M_C) #1:]_PGWB3Q'9:OXH^)]Q9>#!--%::?)-;Z?J[M( H6;3]1M;"V
M"8C+(+J*Z=20\?#[T]6\0>#+'1=!\,#Q#<?%;2=,T8K!:P:#;1213.0"5N;'
M18G66-O+)(EA,(RR\>9M9OB#X$_ _P"*$-A?^*YGU.9(MT"W-R^B74"N 2DL
M=L+:3<#C]W.I,9# !"7!Z?1_A-^SWH"R+IW@SX>60D $AATJR4OMSC<=F21D
M]?6N_P!1^)GA;1]/DN!J:WB0KD6VE0R7MPW08C@@5Y'/^RBD\&N;7]HWPG_T
M"?'G_AO/$'_R#2_\-'>%/^@3X\_\-YX@_P#D&C_AH[PI_P! GQY_X;SQ!_\
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M *';7?\ OS8?_(M'_")ZK_T.VN_]^;#_ .1:/^$3U7_H=M=_[\6'_P BT?\
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MB D*,X8,\7?#KXC:Q;^+X]#^+ESX>DU)K(Z)-_PC]E<MHWE#%R"'&+@3]?G
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M:O:7=A%;Z/9XL+&-D\^S&]&,AF429E8[D+J5&%*M!-X"^(3:IY\/Q1ECL_\
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M=89RRZMA /NJ0@M?]7A1DDY-3'X=_$.2QU*)OBU=I<3>'X=-M+B/0;(&VU)
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M*UW^UW\)])\'6?B&'PU+8ZW#JQNY[5KA6"07$6S:&7!)G!SG^$U[+\-?";^
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M+.[NT "JH!)8D  5)J'[8GAC2K&YO;WP5\3K.SMHVFGN)_ .JI'%&H)9F8P
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M[G[)X$U27R)TQOB?;"=KKD94\C/(I]C^V;X3U*ZO[>T\'?$RZN-/F%O>0P^
MM4=[:4QI*$D ARC&.2-\-@[9%/1A19_MG>$M2NK^VM/!WQ,NKC3YA;7D,/@/
M5'>VE,:2A) (,HQCDC<!L';(IZ,#3+?]M/P=>:M>:5!X1^)4^J64<4UU8Q^!
M-4:>".7>(G=!#N57,<FTD '8V.AHM_VTO!]YJ]YI4/A'XE3:I91Q3W5C'X$U
M1IX(Y=_E.Z"#<JN8Y-I(PVQL=#1!^VEX/N]7O-*@\(_$J;5+..*>YL8_ FJ-
M/!'*7$3N@AW*KF.0*2,'8V,X-(/VU/!S:Z^BCPE\23K*6RWC:</ FJ?:! 7*
M+*8_)W;"RLN[&"01U%*O[:G@UM>;11X2^))UE+87C:</ FJ?:! 7*"4Q^3NV
M%E9=V,9!'44^7]LSPG#JUOIDG@[XF)J5S#+<PV;> ]5$TL431K)(J>1DJC2Q
M!F P#*@.-PHD_;,\)PZI;Z9)X-^)B:G<027,-FW@/5!-+%&T:R2*GDY*HTL0
M9@, R)G[PHD_;,\)0ZK;Z9)X.^)B:E<0RW,-FW@+51-+%$T:R2*GD9*HTL09
M@, RH#C<*9??MJ>#M+U#3;"\\)?$FTOM2D>*QMI_ FJ)+=.D;2.D2F#+LJ([
M$+G"J3T%%]^VIX.TO4-.L+SPE\2;2^U*1XK&VG\":HDMTZ1M(Z1*8<NRHCL0
MO158] :+W]M/P=IFH:;8WGA+XDVE[J4CPV5M/X$U1)+ITC:1DB4PY=@B.Y"Y
M(56/0&M72?VL/"FI>)M"T.Z\/>.= NM;O5T^QG\0>$=0TZVEN"CNL?FS1*H8
MK&YQG/RGTKVNEHHHHHHHHHHHHHHHHHHHKY@^+OQ6L?AQ^V)X-EO-"\4:P%\!
MZNNWP]H%UJ3?O=0TXC @1N%\AMQ_AWQ9QYBYWW_;0\(PZQ#I#^$/B4NK3V\E
MW%8-X#U03R0HR*\BQ^1N**TD:E@, R*#U&6W?[:G@ZPU:PTNY\)_$FWU/4!(
MUG92^!-46:Y$8!D,:&'<X0,N[;G&1GK1=_MJ>#=/U:PTNZ\)_$FWU/4!(UG9
M2^!-46:Y$8!D,:&'+A0RD[0< C/6EO/VU/!VGZMI^F77A/XDV^I:@)#9V<O@
M35%FN1& TAC0P;G"@@G . 1FGWO[9OA/3;BPM[OP=\3+6>_F-M:13> M51KB
M41O*8XP8/G81Q2/A<G;&YZ*2$O?VSO"6FW-A;WG@[XF6L]_,;:TBF\!ZJC7$
MPC>4QQ@P9=A''(^U<G;&QZ*32WO[9WA+3;BPM[OP=\3+6>_F-M9Q3^ M41KF
M81O*8XP8,NWEQR/M7)VQN>@)IFK_ +:7@_0(8)=3\(_$K3HKBXBM(9+OP)JD
M2R3RN$BB4M#R[NRJJCEB0 ,FC5OVTO!^@PP3:GX1^)6FQ3W$5I#)=^!-4B62
M>5PD42EH1EW=E55'+%@!R:-<_;4\&^&=-?4-8\)_$K2M/C>.-[N^\":I#$K.
MZHBEVA !9V50.Y8 <FDUS]M3P=X8TV34=8\)?$G2M.C9$>[OO FJ0Q(SLJ("
M[0  L[*HYY+ #DT:W^VKX.\,Z;)J.L>$_B3I6GQLB/=WW@35(8E9W5$!=H0
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MC0[BN>,9QQ1)X&T23QS;^,7LL^)(--DTB.]\V3Y;626.5X]F[9R\2'<5W#&
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M% 'R9QDDF/3_  5HVE^+]9\46MGY6N:Q;6MI?77FN?.BMC*8%V%MJ[3<2\J
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MUNNX;5"'=CRY...H('V+\$_BYHGQV^%GASQWX>=CI>LVPG6-S\\,@)62)O\
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MS\?PQP3WVDV@-E#=(SQ27,CK% KJK*Q3S)$SA@<9Y'6OE_X)_M$?MJ?$;7/
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MV4?#'[36F:&VJ:AJ?ASQ+X?N/M>B^(]%E$=Y8RDJ3M)'*ED1L<'* A@:X[X
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M ,$Y8;[XA>(/$OPX^*_BOX46WBBX:X\1:1HCEK>]+%BQCPZ>427<_-O WG:
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M0>""/2OB/4O^"8=E9:IJFF^"_B]XS\"_#76YI9M7\$Z;-FWG\P!72)]X"(5
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MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOGK_@H-_P F8_%?_L$_^U8Z_++]B_\
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MG@>L?L*_\%"/%OQ4^*U[\'_B_I-OI7C>(SI:74,'V9I)H QFMYXB>) %=@5
M!V,,9QGU7]O[]MA/V0_!>EPZ-96^J^-]>:0:=;W>3;V\<97S)Y0I!(RRJJY&
M23SA2*^+)_V\/VP?@=_8_CCXE^&!<^!M:FC\BUU'1XK6$JR[Q''+$!)&[(&*
M^:6/RDX(!K]._!OQ[\)^-/@3;?%JRO#_ ,(J^DR:O-(HWO D2,T\; =9(V1T
M('\2D5^;FE_MQ?M9_M=>*M>7X#>'K+2-#TB19&CBALGF2)BPC6>6\;RR[!6X
MC ^Z<=,U[9^PG_P4&\6_&+XK:E\(OBOHMMIWC:V%PMM>641AWS6^?/MYH]Q
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MXM;;=IFAQW.B/<)]U&\FW,2_\"$$A'^X:^L;;XN>&6_X)PKXJ76K,Z8OP_\
MLAF$PP+H61@-OU_UGG Q[>N[BOF+_@B#X3O+?1/BIXFDMF2PNKBQTZ"Y/1Y(
MEFDD0>ZB6+/^^*\@_P""=/V7XL?\%!/%&L?$RUANO$YMM2U&WM=2*R[-36XB
M4JH;(+1QM/MQ]WRP1]T8Z+_@L=HOASP-\:OAUXB\*B#1_&]S:S7>H2Z>1%-F
M&6+[)<,%QA\^: _7$8'\(K]9/A]J&J:OX"\-WVN6PL];NM-MI[ZV&,17#1*9
M$X]'+#\*Z&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBFM7Y
M??$;]EK]IS]LKXU^*8/B'KU_\*?AG$TDFF6?VF*]MC$KA84^SP7 5Y"H#L\C
M<'.., >$>&/&7Q _8)_;&\-_#S3?BE)XU\)M?V-O>VZS.UE);SNJ.K6_F.(9
MD#$C:Q((7J"5/VS_ ,%<_B%XI^&O[-_AO4_"/B;6/"VI2^+;:VDO-%OY;.9X
MC9WC&-GC8$J61#C.,JI["OG;X#? /X_?MT?LSZ/=Z_\ &W4?#WA2U6[L["UN
M//OI];D%Q*SS7LIF5BH9_)4,9 JPC"#JT7_!+?X[>/?!O[1NL_ OQAKMWJFE
MQ0WEI:V5U.]PME>VC?,L+'[L91)OEX7*KC!Z_+'[5GP9^(OPN_:.T;PEXW^(
M%UXS\77,%D\'B"XO;F>2%9)66("24F0;&!;@\9XK]&/B%X!^+O[+O_!/GXMC
MQ7\5M8\4^-%O(;ZP\1V^JWC75G \UG%Y232-YB<K*<*<?O#ZFM?_ ()$_$3Q
M7\2OV>_%.H^+O$VL>*=0A\4S6\5WK=_->3)$+2U8('D9B%RS' .,L3WK[FK\
MK/\ @N=_S1/_ +C?_MA7LGP#_P""D'[//@']G[X<>'M8\>R0:WHWAG3+"]LH
M]&OW,<\5K%'(@80;#AE89#8.,@]Z^(?B;X]'[?G_  4 \+7?P_TB]L-.:YL;
M..Z=0EQ]FMY"\U[)MSL*J6QR3A$'4XKM/^"V'_)PW@G_ +%9/_2NXK]DM/\
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M1Q]0Z3_P45_9Y_:EU3P_IOQY^%Z:7=V9DCM-4NG^WV-L9"N\E@$D16*)GY&
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M'&WF1W"!9$D!W?>#@-]17T+7R5_P4[^-"_"#]DWQ);PD_P!J>*S_ ,(]:A6
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M?]F_L;[%Y7[U)-^[SY,_<QC Z]:^R:*KW%E;WFWSX(I]OW?,0-CUQFIE 5<
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M?#_Q-?Z9J_B&;5?!=[HMB)H-1\V,)'!NR "%BAX7<0=X*_*,Y&B?L*^.9?\
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MQ(^''A;Q#X:\'>"[>4ZMXHU:Q6U%UAF_T5"&8/G)C(#9 ED. !S2^'_Q$?\
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MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ&XGCM87EE81Q1J7=V.
MJ@9)KE?A7]HF\#V-[<VDUA)J<MQJHL[I0LUNMS<27"12KDXD1955@"0&5@"1
MS78444444444445Y[^T)#H$WP(^(@\56]U=^&E\/7\FI0V!47#6ZV[M((MQ
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M%&#Y;-(Q4[B/E !7!)) ^8/^'N7_ %07P1_G_MG7Z,?L*_';_AHKX%1>+_\
MA&--\([]2N+3^S=*_P!2/+*_/]T<G//':OH>BBBBBBO*?VL?^36?C)_V)FL_
M^D,U>K44444444444444444444444444444444444444444444444444445Q
MWQ9M[K4/A_JNFV5R]E<:J(M)%W"Y62V6YE2W:9"/XT64NO3+**ZV.-8HU1%"
MHHP% QCV%2444444444445SGQ$\5:+X&\!^(?$/B,@:!I=A/>7X,7FY@1"SC
M9CYLJ"-O?-?DMXB_X*X:/_;%R-"^ ?A5=+61E@;471IG3)VLP2$!21C*@MC.
M,GK6Y\'_ /@J-_PG7Q:\$^&_^%)^#],_MC7+'3OMUM_K;?SKA(_,3]W]Y=VX
M<]0*_6]>E+1111117BVN?\GF>"_^Q!UW_P!..D5[31111111111111111111
M111111111111111111111111111111111111111111111111112-TK\P_P!J
MOXR>#?V-?^"A%O\ $[R8?%]]XB\/"SUW08EVW6F8$*0W44C#9O>.!5V$@[0^
M2 X([E/^"U?P6VC=X3\>!L<@6-D1^?VNOJ_]F[]HKP[^U!\-D\;^%['5-/TM
MKN:S$.KQ11S[X\;CB.1UP=PQ\U>JT444445Y3^UC_P FL_&3_L3-9_\ 2&:O
M5J***************************************************2N"\16]
MEXD^+'A.QFA^TR>'H+G7U9)"#:7,B-9V[.!U$D-QJ"J&X/EL<$J".^HHHHHH
MHHHHHHKA/CEX7T/QM\&_&V@^)M271O#^H:/=07VI,X46D)B;=-D\#8/FYX^7
MFOS%_9!_X*<?#[]FWX36OPW\1>&-6U6+0KFYBM-=\-Q0LNI1-.\BS/',\3(V
M&[DG &<=*^C_  '_ ,%>OA!\0O'7AWPMIWAGQM#J&N:C;Z9;2W-E9K$DLTBQ
MHSD71(4,PR0"<9X-?<U%%%%%%%>+:Y_R>9X+_P"Q!UW_ -..D5[311111111
M111111111111111111111111111111111111111111111111111111111111
M12-TK\N_VEE^$/P<_P""C5SXU^,4.E>+/"7B+08T.FW$:W[Z3>I'#$DL]GRS
M1-%"^T[6&9"<97->B+^TM_P3TQSH_@ ?7X<R_P#R#7U9^SAXP^%/CCX;IJ?P
M;@TNV\&&[EC6/1](;3(//&/,/DF*/GE<MMYXKU6BBBBBBO*?VL?^36?C)_V)
MFL_^D,U>K444444444444444444444444444444444444444444444444444
M4C=*XCP']HU?Q%XPUZXM[9(IK\:9831+B5[6T78PE/\ >%V]]@#C84. 2Q/<
M4444444444445YM^TAX5M_''P!^(F@WFK6^@VM_H-[#+JEVVV&T4PN3+(>R+
MU;V!K\V?V0/C-^QW\._@W8>&/BOX?\+-XZTRXN(M1U/4O#7]MI>MYSE)(;B.
M*8&/844<J/EZ=Z^C/ G[0G[">L>./#UAX6TKP/'XGNM1MX=*>U\ RV\HNVE5
M8"DILE\MMY7#;A@X.1C-?<=%%%%%%%>+:Y_R>9X+_P"Q!UW_ -..D5[31111
M111111111111111111111111111111111111111111111111111111111111
M111117)_$#XH^$_A3IUAJ'C+Q%I_AK3[Z\6PM[O4YA#"T[(\BQES\H)6-S\V
M!\OK7COQ8_8A^"/[37BE/'?BC29=>U"[M8H4O['5IDAEA0'85\I]I&">17&_
M\.G_ -FW_H4-0_\ !W=__'*]=\&^%/A/^Q;\+QI%MJ=CX)\))<R7"OK6IG!E
M< L%>9MS$[1\H)]J]1\/Z]8^*M"T[6=*N%O-,U&VBO+6Y0$"6&10Z. 1G!5@
M>0.M:5%%%%%>4_M8_P#)K/QD_P"Q,UG_ -(9J]6HHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHI*IQZE;2:A)8K,K74:"5XUR=JDD GTS@
M\54\7>([;P?X5UG7KTXL]+LIKZ8X)_=Q1EV/ )Z*>@)]JI_#[P[=>%/!>CZ7
M?WO]IZI# &O]0,0B-W=N=]Q/L!(3S)6=]JG W8' %=)1111111111117FNN>
M-OAQ\4KKQ9\*;WQ+I=]JUQ:3:9JWA]+X17ODS0X<;,A^8Y!\R^HYS7A/_#J'
M]FW_ *%#4/\ P=W?_P <K4\)_P#!,G]G_P $>*]&\1:1X5OK?5=(O8=0M)6U
MBZ<)-$ZR1L5+X(#*#@\5[W:_%[P5>^//^$)M?%.DW?BU8GF?1K>Z22YC1 "S
M.BDE,;E^]CKQ78T444445XMKG_)YG@O_ +$'7?\ TXZ17M-%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>??&
M[X%^#?VAO \OA+QSI(U;1VF6YC D:.6WG56598W4Y5P'89Z89@<@D'\^_%W_
M  2<^)?PWN)+CX&?&C4-,MW<G[!J5[<:=*B_]=[7*NV0.L:#BN3A_89_;BU*
M9K2Y^-%]!;@X$ESXZU)HSVR JL<8]5KV?X4_\$BO#MOK<&O_ !B\<:K\3=34
M!FL2\D%MNR20\A=I9%],%.^0>E??NDZ39Z#I=GING6L5EI]G"EM;6MN@2.&-
M %1%4<!54  #@8J[111117E/[6/_ ":S\9/^Q,UG_P!(9J]6HHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI"<5SFOZU<R7?]C:-_R%I8R[
M73Q>9!9)D#?(,C+$9VH#EB#T4$C1T/0;30+1X+9#NED:>:9SF2>5N6D<]V/'
ML  !@  <Q\4)H;Y?#?AM[>ZN9-<UBW0FWC#1Q16Y-Y*UQZ0LEL82<$%[B)#C
M?D=R*6BBBBBBBBBBBBODG]J+_@F[\.?VE/$%QXKCN[[P;XYF*-)K>F'>L[(H
M53+"Q )"JH#(R'Y1DFOD[5_^">G[7_@>XDM/!OQONKW1HVVVYMO%6HZ?(5_V
MH?NH<YX#MTZU<\._\$V_VH?B'>);_$OXZW=GH;+F5?[?U#5IR?[OE.4CZ$\[
M^..#FOLK]EO]@_X:_LIR'4]!@NM9\6S0&WN/$&J2;IF1B"R1H,)&I('0;N.6
M-?2-%%%%%%>+:Y_R>9X+_P"Q!UW_ -..D5[3111111111111111111111111
M111111111111111111111111111111111111111111111249%)Q2\5!>726-
MK+<2L5BB1I'(&<*!DG]*^ )?VYOV@_&'A'Q;\3_!/PCT%/A9X8N+D7<.OW<L
M6KSV\"K(\JH'41[8V#L"C=P-V.?2OB-_P4!TS1/V</AU\0O"?A]]?\2_$*X3
M3]!\/23;?]+WF.9)' Y6.4%. "Q*] 21!\*_VL?BIX?^/^@_"7X\>"]$\.:M
MXGLY+O0M8\-3R/9S.@9F@<.[?/M4@D-P2GRX<&L#Q!^V1\:?B1\0_B%I_P "
MOAUH/B'PKX!NFLM4U/7[F19-0GC#^9%:A'5=P*-C);C:3C>!7;:/^W]X6U+]
MC6[^/#Z9+']C!M+C05F!==0WK&MN),<JS.C;]O"-G&1BO.=._;>^-/PQU?P!
MK'QO^&^@^'?A[XYNH;2ROM'N93=Z6TJAHQ=([L"<'<5 0@*W=2M?3O[6'_)K
M'QD_[$S6?_2&:O5J********************************************
M***2N2UK7KW6M7E\/^'942X@95U74R,C3D="RK&"I62Y8%"(VX17$C@@QQS:
M_AWPUIOA738['3+;R(%P6=W:669]H!DED<EY9&VC=([,S$98D\UK5Q\37NI?
M%BX8IY6F:3HZQQR J?/GN9BTBD=5\I+6$@]&^T-W2NQHHHHHHHHHHHHHI*0X
M- Q3J\&_:Z_:-U/]G3P1H]UX=\*3>,O%>O:E'I>EZ6A9(O,?CS)' .%!*KC(
MR77D<D>2^!?VOOBQX%^/GA'X7?'SP7X=\/S^,8V.BZOX9NWDA$H.%AD1W<Y)
MPNX$<NO!!)">*_VN_C#\2/C!XY\&_L_^!/#OB;3_  +*MMK6K^(KQXUGN?G#
MV]NJO'AMT<B[B6&4). 5S>TG_@HQX>F_8_U7XS:CH4MGK.E7K:)=>&1,=PU/
M(VP[RH(0JRR%MN57<,$K@\]HG[9WQI^&?CCX?0_'3X<Z%X>\'>/+I+/3=2T&
MXE:;39I ICCN@[LI8EQD#;P'(SL(KM/C]^U=X]T_X[6?P4^"OA72/$_CT::=
M6U.\\03O'8Z?#QM#*C*S,0R'[PQYB#G)QT?[)/[4FL_'+4/''@_QOX:C\(?$
MCP5>K::MIUO(7MY4;<$FA+'.TE&[D8*$,0W'4:Y_R>9X+_[$'7?_ $XZ17M%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%87B[Q'_ ,(WI'G0
MP?;=1N'%O86.64W-PP.R/*JQ5>"S/M(1%=V^536X*6BBBBBBBBBBBBBBBBBB
MBBBD;I7YL_M8:I\4?VM/VQKS]G3P/XP/@CPUX;TJ+5=9NH9)(VF+QPN6?80T
MH NH%6/(7)9B>!MY7X ?!WQ#??\ !/\ _:-\#Z#XE^S:YH/C[4F769#)"TQL
M([&5F!5BT;/]GX.3@MSGK7U]_P $]_CAK7Q\_9=\,^(O$<QN]?MI)M,O;QAS
M</"^U93_ +31E-Q[MN-?2+=:^!_VG_C=XK_:N\::Q^SE\# DUN!]F\;>,7S]
MDT^W+%9+9&'WF;#*V.6PR#^,KQ?[7GPKTWX%^-OV&?"&D.?^$<\.^*DM7FF
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M^PCH_P '_B5_PL3Q-XZ\3?%+QO!;-9:?JOBBZ:8V,!W#;&&9FW;79<EL ,V
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M ?$LT9*,BR8Z#0]%L/#FCV&DZ59PZ?IEA!':VMI;1B.*"%%"I&BC@*J@  =
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M?LW^&O%^L*HUX&33]2:-0JR7$+;3(   -Z[7( P"Q Z5[_1111117E/[6/\
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M,U>K444444444444444444451U;6+'0=/FO]2O;?3K*'!DN;N58XDR0!N9B
M.2!SZURD2:_XZFBEF%UX6\/*SG[-\HU"_ 90A<\_9HBH<E!^^82)DP%'C;K[
M"QMM+L;>SM84M[2VC6&&&,85$4850.P  _*N%^,WC&T\.^'(=-EU)M,N]=E;
M3X;B"<QW$2&-GFE@"AI'F6-6$:QHS-,\*\!MPKW7B;5[?0Y4T?16\)>'M-AB
MVZIJEN99#;J%)6VL(B9&;8&C E\ME<J1'*!L;&L_A/X>U'2=2USXJ6MCXA-V
M2OE>+C;WL%C;F53&@#1K#"[[+=I$C4)OC09D*>;)YWXJ^(W@O]GO2_L_P_\
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MFW%D.]0C+)/I/PMT#3=5L=8NK5]=\06+226^M:U(;RZMWE3;,T#/Q;"1>&2
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M@@\$&O$/&WPUMM'U.WMOAOX@\1^%_$\$"QVVCZ'>";2((1LCC^T6=P'MK>!
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M+'_XU6UX/^!7PV^'NK_VMX5^'OA7PUJGEM#]NT?1;:TGV-C<N^- VTX&1G'
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M7E*,+PWS%L[Q9\*_BMJGBO\ M#2OC#);^&V,;3^&)M"MD\]5 $D*7T>)H%D
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M5:I_\DTZ'X4Z-!,DBWOB0LO02>*-3=?Q!N,'\:O_ /"!Z;T^TZS_ .#R]_\
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MW_+"!/WH N?[TARO0A3T+--TKXN12Z%]O\1^$;N..]O3JQM]%N83+:L#]D$
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M:KZ/I/QE31=)CU77?!\VJ+IM^FH26VG7"PR7S,?L3Q*9,B)%V^8K$ECG:17
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MK+3+:VL+Q?!6IS">W2)5B<.K[7W(%.Y1@YS70?\ #='[<W_1![S_ ,(35O\
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M0K]F#Q5^UC\&=&\(>$;_ $?3M2LO$$.JR2ZU-+%"8DMKF(J#'%(V[=.N,C&
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M@8LJQGX@6HD92P3[%=9(! ) \KH,C\Q0W[='P,698CX_M1(REE3[%=9(! )
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M[=7P*MU!E^(%K&&8(I>RN@"Q. /]5U)Z43?MU? NW ,GQ M8PS!%+V5T 6)
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M!=CX#T:YTS3I)Y+>;4M0U1C<,&;S;R\FNY0" /E$D[A1C(4*"2>2O@GP98^
M]'N=-T]YWMY]2U#5&:X8,WFWEY-=R@$ ?*)+APHQD*%!).24\%>"['P'HUQI
MNG//);SZEJ&JL;A@S>;>7DUW* 0!\HDG<*,9"A<DG)/*?!SX:ZI\/M:^)UWJ
M,]I-'XG\63:[9K:NS&.![.T@"R J,/OMWR%+#!7G)('0>!?AOI?P_P!0\6W>
MFRW4DOB?67UV]%PZL%N&@@@(C 483;;IP<G);GH >%_AOI?A'QAXT\264MT]
M_P"++NVO+])G4QH\-K%:H(P%! *0J3DGDD\#@'A?X;Z7X1\8>,_$MG+=/?\
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MI*DJ<$J#CL*V?AOX#T[X6_#_ ,.>#])EN)=+T*PATVUDNV#3-'$@12[!0"V
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M*6Z_Z*WA:U,I7IN^S:61^I:OT%J.2,2QNC=&!4_C7Y<_M5?LY_#[]G/]H?\
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M]0\6QPRZMHWQ"32=2OH5"+>NEJ7CF** JLR2N"%XRI(P#M'U7_P5>DN[6S^
M]QI*!];A\:PFP ^\9 %*@<CJP3O7WXM#5\2?M&?L:_$WXU?M9Z-\2O#'Q*TO
MP!::'HW]GV%Y!;->ZA Q642,(&"Q_-]H==WF9 "D<]&?LA_';XEZ]XP^,OP/
M\>:Y9>)/&_@I'.F>)FA\A+N-LHOGA%P-K-"<@%L.P.=N3X/:_LO_ +0'["W[
M//B#QSX=^-&EQQZ->-K5[X7L=,%Q97H9HHW9KB0!F8JB_+L &#M8$YK]%?V?
M_BHGQN^"O@SQTMJ+%]=TV*[FM5)*PRD8D121DJ'# 'N #7H5%%%%%%%%%%%%
M%%%%%?-7_!1RZU.S_8I^*4FDJ7NFL8(W _YX/=0K/W[1-(?\XKP?]HJ&T3_@
MC7HPA5 H\*>&&7;T\PW%B7/UR7S]37U]^RZ]Q)^S3\)WNP1=MX3THR@_WOLD
M6?UKT^BFLVWDG '-?FA;?L6_'[X/P_&+XF^'/C7I7A?5-2NKKQ#+INCV'VR.
M^\OSIE26:95\LCS7 4(X.1GV^N/V)?V@+[]I;]G?P[XUU:UBM-;D::RU!+<$
M1-/"Y0NH/0.NU\#H6(R<5[S17SW^TC^R_P##CXD2:_\ $CQ3X?37_$FD^&)[
M+3_MTC/;6RQK/,KK#G89-\I^9@<;5QC&:^6_V$YKNW_X)9?$^6Q&Z]2S\1M
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MK)?"EI=0MXN\2V=NJ:;IT<<_FB&,* I(E0,=OWF7:.-Y'H_[5G[%OB[XM3?
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MH89'T-7Z_/S]O_\ :(\.>(OB;H/[/6H^+X?!7AJ\\O4/&^O2N\;)9C$B6,1
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M (O?LJ_LF7WP1\1>+/'GC?Q4?'OQ1\6&,:GKGV9;>*.- ,0Q(/X?E3)PH^1
M% 6OI.BOF?\ :G_9<U[X]?&+X#>+])U?3M.LOA[KQU:^M[P2>9<QFXLY=L6U
M2-V+5Q\Q RRUH?M9?LGO^T2?"FO>'_%5QX&\?^$KHWFC:W#%Y\:G<C%)(R1N
M&Y%(/8YX8$@\=\$/V./&MG\8].^+7QQ^(D?Q(\<:/:-9:-%9V*6MG8*VX,X5
M$0.^'?\ @7&XD[B%(^N*6OS$M/\ @G7^TOHGQ6\2?$31?C+X?TSQ7KTLC7>I
M1K,TQC=@WEAFA.U0%487 PBCH!7T'IO['?C/XI?LQ^)?AC\>/'B^,==O]6.H
M:=XAL4+/IZK%$(@H9$R5=9LCNLK#(SD<SX'_ &%_B?XA^(_@G6OC;\81\0?#
MO@2Y6ZT#1K33EMA)*@3RY+A@!N*E%/S;V./O\MG[>I*_/'X^?L%?';XI?M-:
MC\6_#_Q*\/:%<PN(="699I)=.ME0JBJ#$RJQR[';_%(V#7KGP?\ V7_BMJ/P
M]^)7@SX^_$I/B%I'BBS@M+)K!F66PV^<9'4M$N&+-"PX(S$/Q\KM_P#@G;\7
MM<\-6/PM\7_'I]7^"&GR0F+2+;2TCOYH8V#I"TI!955@NW,DBC:,*, #[VT'
M1++PSHMAI&FVZVFFZ?;QVEK A)$<4:A449[!0!6@>:^7/VE?V0?$'Q(^)NB?
M%;X7^/)/AY\3-)M&L5NY;475I=PD, LD; @, [#<5;(QE> 0_P#9K_8_U;X9
M_$77_BG\3/&9^(OQ1UNT6QFU%;1+:UM;<!08XHU !)V(-VU>%P%&6SY+J'_!
M/#XG^$U\3^"OA?\ &O\ X1+X.^*+F>?4/#UQIB3W%JDRA9(H),9VE1M^5X^
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MVX^'/BN]T[Q US>W<\[6(?R)(9E53&0Z@\@$'CO7@L__  3?^*&C:#J7PO\
M"WQSETKX%ZI=//<:%-ID<E_'&[J[P+-C)#$'.'53DY0Y8'[E^'O@;2OAGX'T
M'PGH4+6^CZ+916-K&QW-Y<:A06/<G&2>Y)KHZ*^9?V5/V6=>^ ?Q=^.WBW5M
M7T[4;/X@ZZNJV,%EYGF6T8N+R4K+N4#=BZ0?*3]UO:O--<_85^+'@'QUXLO?
M@;\:1X#\)^+[Q[W5-$O].2Z^RN^=QMF96Q]X@8\M@ H+':,?17[,/[./A_\
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M$?)&<;<,1C'8>M>PZ/KEEKVCVFJV<XFL+F)9XIB"N4(R"0>G'8]*\RF_:E\
MQ2.BWMY(%. Z6K;6QW&:]'\,^)M/\7Z':ZOI<XN;"Y4M')M*G@D$$'D$$$'Z
M5X-\>?C=X5\2>"M<\-Z?=S3ZEYR1@B%A&2DREL-Z84\]ZTOAM^T/X(\-^ =
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MNO\ A%;N#RK=Y55V\QFPF%)^8\"OU0HHHI,T9%&:*^:O''_*0/X7?]B3K/\
MZ46]?2U<?X\^*GAWX:M9#7[N6V-X',/EV\DN[9MW?=!Q]X=?6N4_X:E^'?\
MT%KK_P %\_\ \17DGCK]JC7%\47@\+7EM+H7R?9VN+,A_N+NR&P?O;NM;/PM
M_:G+76H_\)U?1P0;(_LGV2R=B6RV_.P'_9QGWKT/_AJ3X=_]!:Y_\%\__P 1
M7>^#_&.E^.M#CU?1YGN+&1V17DB:,Y4X/RL >HJ'XA>-;#X;^!?$/BK5'":?
MHMA/J$Y+;<I$A<@>YQ@>Y%?.7[(OCCQYI/C35/ WQ.U.ZU#7]?T.S\=V#7KL
M6MA<_N[VQC!.%CMYE3:@^Z)N>U2:7^W)=W?AI/&%U\+]7M/ ,&NR:#J/B :E
M;-]FF%X;1)4@)$DL1<IN( *EF #;2:Y?QA\?O&>E^+OVEH?$^C:I#X.\*0Z;
M]AET?78[6Y@WB(HL3(FY6G$K3%SDJ%$9SQC[%UF1X=(OI(V*.L$C*P.""%.#
MFOS\^'&I:"O[)^D_$74OVBO%FG^/U\-G5&BN?&IN4%\(BR1M8RLPDW. OE%2
M6S@<D5Z39VOBOXZ?&_P/I'B[Q'XN\#RS_"VSU_4M&\-:S<:8L6I/=!)0ZHW5
M=S+@\C:!GBO2/AE=^(OAC^T!>?"S4/$NI>+O#-_X;;Q%H]YKTPGU"T:&YCM[
MFW>; ,R'SX75GRPRPW'%>J?$RZ\8V_A6=/ ECIM[XDN'6""35YVBM;4-PUQ(
M%!:0)U\M<%NF5ZCS?]B3Q=KWCS]E_P %Z_XGU2;6M>OA>/=W]P?FE<7LZ@XZ
M    *.   , 5[K111111111111111117SY\</^2\_#+_ *ZK_P"CEKZ#HHK%
M\;?\B;KW_7A/_P"BVKX9_P""*W_)KOBC_L;[G_TCLZ_0"BBBBBBBBBBBBBBB
MBBOGWX$?\EL^*/\ U\M_Z/DKZ"HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI*\7_:\
M^(?CCX5? 77_ !3\.=(.N^*M/DMF@L/L4EV)8S.BRYCC(8@(6.0>,9[5\K?!
MO_@LAX#UYUTSXH^'-1\!ZI'A);RT1KVTWCAMR!1+'S_#M?Z^OW/X!^*'A#XJ
M:.NJ>$/$NE^)+!@"9M-NDF"Y'1@IRI]F /M75T445X=^VE\9M?\ @#^S;XP\
M;>&;%;[6[".&.V\U-\<!EF2+SG7N$#[L'C(&>,U^?'BCXU_'[]G_ .&/PN^-
MLGQQ@^(9\:7$!N?!4EM&T862,R&) I/*@>6Y14*NRCFOH#]ISXW?%+XK?M0>
M%?V>_A9XD_X5U/=:3_:NN:VT(DN(=T32B(<94JBK]P@EI!R #6Q^Q3\=/B3I
MWQ\^(W[/OQ=UR/Q1XA\,0K?:9KGDJDMS;9C)WXZY2>!QD;AEP2<#'I7CC_E(
M%\+_ /L2M9_]*+>OI:L?7O".B>*&A.L:19:H8=WE&\MUEV9QG;N'&<#\A66W
MPF\%8_Y%/1?_  !B_P#B:\6^(7[*]]XC\77NH:'<Z3I&F3;/*LUC9 F$53\J
MKCD@GCUK=^$?[-L7@^ZU1_%$.D>((KA(Q K0>;Y14L6/SKQD%>GIS7IG_"IO
M!7_0IZ+_ . ,7_Q-;ND:)I_A^Q2STRR@T^T4EE@MHUC0$G)( ]37DW[3_P +
M-8^.'A7P_P"!;>%?^$7U36[67Q/<_:#"ZZ; WGM%'@AM\LD<4>5/RAF/85Q/
MC+]E2/P3X\^'?C[X8Q:M=Z_X?U?R]0M-<\3W]\MSI5RABNT0W<\BHZY24!<;
MC$ <\8Y^X_9S\;R?L6WOPY%A;_\ "4R^))M26W^U)L\EM?:]#;\[<^0=V,]>
M.M)\:?@5\1/$^L?M Z=H^A6E_I/C[3M*GTW4_P"T8XS'<VJPPO;R1, 1N5'<
M.#@8 ZGCWF]^!_AMO%U]XO@&MGQ#,LI ?Q'J+69=HC'_ ,>9G-N!@]/+P#SU
MYKAOV7?V:/#WPO\ @[X M-?\"^&[;QSI&FPQWFH1:?;R7"W*KAF%P%W%O]H-
M5+XE:#\1_"_[3EK\0O"'@6+QKI4GA :#-$=:@T]XIOMK3[OW@.X;<=N]6_"G
MPC\3_$KX@>(/'7Q-L(_#GV[05\-:=X;T76)FFM+5IA//+)>0^4PEDD6,?NB-
MJQ#YF)X]8^'_ ,.-%^&.CRZ9H7]I?9)IC<-_:FKW>I2;BH4XDNI9' PH^4-C
MJ<9))X;]D?X;ZY\(_P!GGPEX2\2P1VVM:<+H7$4,JRJ-]U-(N&!P?E=3^->Q
M444444444444444445\^?'#_ )+Q\,O^NJ_^CEKZ#HHK%\;?\B;KW_7A/_Z+
M:OAG_@BO_P FN^*/^QON?_2.SK] *****************AN)X[6%YI76.)!N
M9V.  .YKPCX-6K:3\6O&VH7+QQVVLSLUDV[_ %@\UV&1V)##&>:]]HHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHK!\;>-] ^'/AF^\1>)]8L]"T.Q7?<7]]*(XHP2
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M45B^-O\ D3=>_P"O"?\ ]%M7PS_P16_Y-=\4?]C?<_\ I'9U^@%%%%%%<O\
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MOSL^(O\ RFA^%_\ V+$W_I%J-?HG117,_$[_ ))OXI_[!=S_ .BFKBOV6O\
MDCNG?]?%Q_Z-:O6Z********************************************
M*******************************************************R_$GB
M+3/".@ZAK>LWL.FZ3I\#W-W>7#A8X8D!9G8]@ #7Q5\,_@S^RE^WE_PE7C+1
M?ASL&GZTUC<:A&TVFF^D")(9A'#*!L?S.K*'.#D"M;]B_P"-/[.=M\1?%OPN
M^&GA2+P!XLL;ZXM'M[F/<^KK;R.K/'<%W:0+M+;'((!) (#$?:=%%%%%%%?-
M/CC_ )2!_"[_ +$G6?\ THMZ^EJ*********************************
M*********_.SXB_\IHOA?_V+$W_I%J-?HG117,_$[_DF_BG_ +!=S_Z*:N*_
M9:_Y([IW_7Q<?^C&KUNBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOD
M[_@J-#JTW[%7CD:2)3M>S:[$.<_9Q<Q%\_[/3/L#6)_P3[\>? 7PC^S;X8B\
M*>)/#NBZI-902>(8KZ_B@O'U 1@3-*LC!L;]P4]-N,<5\M_M -\++K_@H=\#
MC\$3I,NMOK-O+XAD\-$-:M(;E6+$Q_(7\OSC(5['YN]?K>O2EHHHKS7XC?M&
M?#GX2^+O#GA?Q9XHM])\0>(9%BTS3S%++).S2"->(T;8"S!07P"<\\'$7QM_
M:2^''[.FF6=]\0/$]OH*WN_[) T<DT]R5 W;(XU+$#(&<8!(R>:N_!SX]^ ?
MV@/#\VM^ ?$EKXAL()!#/Y(>.6!R,A9(W577(Z9&#@XS7E?CC_E('\+O^Q)U
MG_THMZ^EJ******************************************_.SXB_P#*
M:+X7_P#8L3?^D6HU^B=%%<S\3O\ DG'BG_L%W/\ Z*:N*_9;_P"2.Z=_U\7'
M_HUJ];HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKR?]J+XL>#_ (+?
M _Q'XD\=Z9+K7ACRULKO2X85E:\6=Q$8MKD*00YSN(& :_/OP?\ \$P_@_\
MM2>$[3XB_"GQMXD\*^&-6FD,6F:QIBSF#:Y5XT)=20K J"6?I]YJ^M/V4/\
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M9X*UOQY^QMXZLM"BDN+NU%OJ$MO$"6D@AG227 '7"J6Q_L5^>OQ2_:R^&/Q
M_8F^"?@32&'A_P 3>$_$>E/JFD&V<+Y<%O<)->*ZKL8.[AR,[LR'(/6O1/C!
M\;/#7[9O_!0#X'6_PJM[G5;?PS?Q37FN+;&$3Q1SK/(RAP&\N-(VP7 R7( Y
M&?UH'2EHHHHHHKYI\<?\I _A=_V).L_^E%O7TM1111111111111111111111
M111111111111111111117YV?$7_E-%\+_P#L6)O_ $BU&OT3HHHHHHKY\T7_
M ).^UO\ Z\/_ &C#7T'11111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111111111117R/\
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M*\-_X)*_\F6^'/\ L):A_P"E#5]D444445Y?^TM_R1O7/]Z#_P!')6[\&?\
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MH90#@E74D'!!'X&M6BC%+1112=*X2^^.?PZTWQ<OA6[\>>&[7Q*TH@&D3:K
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ABBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ast008melanoma.jpg
<TEXT>
begin 644 ast008melanoma.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'N!:P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX:\<W&O:)<?#OQ%X$G>+Q/I&J3B1-/5?-/F>?M4,F(9<Y52I1N,;6;Q31?\
M@JI!<7^A^(-<^$FO^'/@WK>KOH]CX_NKH,A=20)'MQ%@*"K;MLK$".7;O9"M
M 'WO12*=PS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M55_9BU2ST/\ 9'^$^HZC=PV&GV?@?2;BYNKF01Q0QI81,SNQ.%50"22<  T
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MOQ# 4E\ARH$B$@-@"2$G>B']\A&X'( /HZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*(S']GCXDX4$G;_9I./I]KY-45_:V\52,%'[.GQ2!8X^:UL0.?4_:>E?2-%
M'S__ ,-.>,N_[/'Q(_/3/_DNL[_AKKQ3_P!&Y_%/_P !++_Y)KZ1HH ^?O\
MAISQEC/_  SQ\2/STS_Y+JA)^UIXKCD=&_9U^*1*G!VVMD1U]1<X(]Q7TA10
M!\]Q?M/^,9HT<?L\?$D*PR PTT'UY!N\Y]C56X_:R\5VTKQM^SK\4"R]=EO8
M,.G8BZ(/YU]&TM 'SU;_ +47C"ZA65/V=_B4%;IO73D/X@W8(_*JUQ^UCXKM
MIC$_[.OQ09EZF.WL7'KU%T0?SKZ.HH ^>;;]J3Q?=1"1/V=_B6%/ $BZ<AX.
M.0;L']*ANOVK?%EG*(Y/V=OB>S$9S%#8./3JMT1GVKZ,HH ^=[7]J;Q?>1ET
M_9W^)@4''[V/3HST'9KL'O3+O]JKQ=9,OF?L[?$YMW3RH;"3_P!!NCC\:^BJ
M6@#YUL_VJO%UZ7\O]G;XF@+U\V+3X_7INNAGIVI;O]JCQ=9J&D_9V^)C!C@>
M5'ITA_$+=G%?1%+0!\Z6O[5GBV\8K'^SM\3@0,GS8=/C'YM=#)]J?=?M3>+[
M.-7D_9W^)C G&(H].<]#V6[)[5]$44 ?.=K^U;XLNY/+C_9U^)X.,YE@L$'Y
MM=8S[5-<?M1>+[6$R/\ L[_$HJO78NG.>N. +O/Z5]"TC?=- 'S+\ _VYM)_
M:2\.ZAK7@OX?>++RTL+O['<!UM597V*X_P"6_<-^AKU#_A;FO?\ 1+_%7YVG
M_P ?KX^_X(I0QK^SIXSE"*)6\5RJSA1N(%G:D GT&3^9K]#: /,_^%N:]_T2
M_P 5?G:?_'Z/^%N:]_T2[Q5^=I_\?KTRB@#S/_A;FO?]$O\ %7YVG_Q^C_A;
MFO?]$O\ %7YVG_Q^O3** /,_^%N:]_T2_P 5?G:?_'Z/^%N:]_T2_P 5?G:?
M_'Z],HH \S_X6YKW_1+_ !5^=I_\?H_X6YKW_1+_ !5^=I_\?KTRB@#S/_A;
MFO?]$O\ %0_&T_\ C]8WP]_:2M_BAI<^H^'O!VOWUI#+Y+NHMQAMH;',OHPK
MV-ONGZ5\M_\ !/?_ ))7KG_85_\ :$5 'M?_  LC5_\ H0?$/_DM_P#':/\
MA9&K_P#0@^(?_);_ ..UW=% '"?\+(U?_H0?$/\ Y+?_ !VC_A9&K_\ 0@^(
M?_);_P".UW=% '"?\+(U?_H0?$/_ )+?_':/^%D:O_T(/B'_ ,EO_CM=W10!
MPG_"R-7_ .A!\0_^2W_QVC_A9&K_ /0@^(?_ "6_^.UW=% '"?\ "R-7_P"A
M!\0_^2W_ ,=H_P"%D:O_ -"#XA_\EO\ X[7=T4 <)_PLC5_^A!\0_P#DM_\
M':/^%D:O_P!"#XA_\EO_ ([7=T4 <)_PLC5_^A!\0_\ DM_\=H_X6/J__0@^
M(?\ R7_^.UW=% 'E]U\<H=)\1Z+HNJ^&=9TN[U:X2WMC<"$J2SJFX[9#P"P[
M5ZA7S[\?/^2S?"O_ +"$7_I1%7T%0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .#/B=X"^(6J6VD>.]#\4ZK<7>GW05+[Q(MU,TUM<VL'WKEIHV1%5 S?*N0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?.O[0'_ "<]^S+_ -AG6O\ TT3U]%5\Z_M ?\G/
M?LR_]AG6O_31/7T50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4C?=-+2-]TT ?G-_P1,NY)/@9X]MB?W,?B,2*,
M=VM80?\ T!:_1JOSP_X(HVT:_L\>-;@+B63Q5)&S>JK:6Q4?@6;\Z_0^@ HH
MHH **** "BBB@ HHHH :WW3]*^6_^">__)*]<_["Q_\ 1$5?4C?=/TKY;_X)
M[_\ )*]<_P"PK_[0BH ^IJ*** "BBB@ HHHH **** "BBB@ HHHH **** /G
MWX^?\EF^%?\ V$(O_2B*OH*OGWX^?\EF^%?_ &$(O_2B*OH*@ HHHH ****
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MS_H(VO\ W^7_ !KQC_ACKP?_ -!C7_\ O_!_\9H_X8Z\'_\ 07U__O\ P?\
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M\&_$?Q8^E'P!\1[3X?B 2_;1=>'8]6^U[MFS&Z:/R]N'Z9SO'3'/SKX@U(_
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M^P%8_P#HA*XW]L3_ )-S\6?6S_\ 2R"NR^"7_)&O G_8"L?_ $0E ':T444
M%%%% !1110 4444 %%%% !1110 4444 ?.7P+_Y+_P#$G_KO=?\ I4:^C:^<
MO@7_ ,E_^)/_ %WNO_2HU]&T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?GG_P4(^('QJ\6
M?M%_#/X$_";Q!<>#Y/$>G2:DVJV]VUEY\BM,65[A%\Q%ABMV<K&<MYH!5CM%
M?H97YF_\%0M:\;?$K]H#X/\ P=^'6@Q_\)HL3^)-,\00SBVO8I,SJ8X;@LOD
MJB6K2OAOF*Q8P4&0#GA^P-^VY_T<<?\ PM];_P#C%??_ .S%X#\:?#+X(>&O
M#7Q$\1?\)9XQL5N!?ZQ]MGO/M!>XD=#YTRK(VV-D7Y@,;<#@"O@"#X0_\%%;
M>%$7QJ"JC +ZK8LWXDIS^-?H!^S'I/Q#T/X'^&K+XK7O]H>/HEN/[3N1)'('
M)N)#'\R *<1&,<#MZT >I4;A7AG[4VO_ !EM]%T/P]\%=%L9_$&NSR6]UXAU
M1O\ 1M#MPH!N"I&&<%P5&'SL;]V_('SK_P $9[Z>^_9L\:WMY<27-U-XSNYI
MKB=RSR.UG9EF9CU))))/O0!]^[AZT;AZU^"OP\B_9O\ CQ\1?B#XQ^-?CSQ'
MX,U'Q)XHNKO2]/T6(E8+>:1I?,N)&M95VEI @VD$>4Y8 $&OL?\ :4\.V7Q*
M_:$_9R_93MM>U./X7-X<74;R>SO%+ZM;P03FW61D4*P"Z?D,HQF8L!E5P ?I
M&&#=*3</6OS-^ _Q!U7]C_QA^U5\'M.U>XUC2_ ?A^X\7>$K?4V,L=FHMQ.8
M2,Y*LUU;;@" 2KL "YKYWU#P+??"_P#9)^&_[66B^+/$#?&'4_%$C:AJ5W?&
M6.XC\ZZC\MEQN96%M'N#,0P>12"I 4 _6;]K'_DUCXR?]B9K/_I#-2?LF_\
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M/X?\%:)HGC"WU;6[I;2VEOK&V2%7.<%V6X9@..RGZ5]F4 +1110 5\F^//\
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M$J)%<,&4< LP7BO6O!+2:5_P6)\?KI]MYB:AX,B^WL& V 1V6UR/K%$O_ J
M/=OV@/\ DY[]F7_L,ZU_Z:)Z^BJ^/?B/X\U[Q5^UY^SY8:KX UOPG:6.M:X+
M?4M3N+.2&^QI5PH,:PS.X! #?.J\$#KQ7V%0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?%O\ P5V_Y,UU3_L,6/\ Z,-?:5?%O_!7;_DS75/^PQ8_^C#0![Y^R=_R
M:Q\&_P#L3-&_](8:]6KRG]D__DUGX-_]B9HW_I##7JU !1110 4444 %%%%
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M-_\ 8F:-_P"D,->K5Y3^R=_R:Q\&_P#L3-&_](8:]6H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Y7_:@_P"3@_@C_P!A6'_TK@KZHKY7_:@_
MY.#^".?^@I#_ .E<%?4] "T4F:,T +129HS0 M%)FC- 'SI\"_\ DOWQ)_Z[
MW7_I4:^C*^<O@7_R7[XD_P#7>Z_]*C7T9F@!:*3-&: %HI,T9H 6BDS1F@!:
M*0'-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'D'[5O_  M3_A2&N?\ "EL_\+$\RW^P8^R_=\]/._X^OW7^JW_>_#G%
M? __ !LX]3_Y;-?JO7P_^WY^T5\1])\=>!_@3\&&-M\0_&<3W$VH* )+2SRZ
M QL00A(BN&:0?-&L)(Y(( /"/^-G'J?_ "V:_0+]E\?$O_A1OAK_ (7!G_A8
MN+C^U<_9>OVB3RO^/;]S_JO+^Y^/.:_/+QE^SY^VE^S'X9N_B=%\;)O&<'AV
M!K_4-)GUZ^OHS;H,RL8;I1'(BH&8YVL "5^:OT1_9G^-$'[0WP+\(_$&WM#I
M[:S:EI[4\B&XCD:&=%.>5$L;[2>2NTD#I0!ZC1110 4444 %%%% 'E/[6/\
MR:Q\9/\ L3-9_P#2&:D_9-_Y-8^#?_8FZ/\ ^D,-+^UC_P FL?&3_L3-9_\
M2&:D_9-_Y-8^#?\ V)NC_P#I##0!ZO1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#_DY[]F7_L,ZU_Z:)Z^BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXM_X*[?\F:Z
MI_V&+'_T8:^TJ^+?^"NW_)FNJ?\ 88L?_1AH ][_ &3?^36?@Y_V)NC?^D,-
M>KUY3^R=_P FL_!S_L3=&_\ 2&&O5J "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \;^/W[.EI\<WT:X.MSZ'?Z8SA)HX1,K(^"05W*0P95(8-Z
MY!XQY3_PP/<_]%)N_P#P6G_X_7UU10!\B_\ # ]S_P!%)N__  7'_P"/T?\
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MX7UC6!XRN+DZ?9S7?D_9"N_RXV?;GS3C.,9QWKZFKEOBI_R3'Q?_ -@>\_\
M1+T <A^S+JUYJ_PGL'O+F2Y>&:2"-I3DJBGY5SW 'K7K%>._LI_\DDMO^ON;
M^8KV*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"C#0![Y^R;_P FL_!S_L3-&_\ 2&&O5J\I_9-_Y-9^#G_8F:-_Z0PUZM0
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MI8\*9-N2><9P,X'K(&*6@ HHHH **** "BBB@#RG]K'_ )-8^,G_ &)FL_\
MI#-2?LF_\FL?!O\ [$W1_P#TAAI?VL?^36/C)_V)FL_^D,U)^R;_ ,FL?!O_
M +$W1_\ TAAH ]7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^9
M?C-\?/BWX!^.GA+P#H/@OPGJMKXP>\70[V_UNX@<_9;83S_:%6W81_Q!=I?/
M&<9KZ1LFN&M(6NDCCN2BF5(F+*'P-P4GJ,YP<4 6:Y3XG^,/^$#\"ZOK:E//
MMX<0+(I93*QVH",Y(W$9P>@-=77#_%SX:I\5/"Z:.^HR:88[E+E9DC$@)4,-
MK+D9!#'N.<?2@"E\%_$FN>)?A=8:SK4BWFHSB9U*Q"(NH=E4$#Y<G;U  P1[
MD_E/^PG^V5\1_&G[>%]=:C:VEY_PLZY6'7+"UM500+:6TOV9X23E1 BD'<6W
M)OW!GVL/NC]OCX]1?LO?LSKH?AR:9/%VOPCP[X=A@D)N8\QA)+A<,'S'&>'4
M'$KPY&&KI_V'/V5])_9C^">A6$VCV<7CF^M5N-?U-8E-Q)/(=YMS)DYCBRL8
M"G:2A;&68D ^C:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 0]*_*/\ X;__ &+_ /HVN#_PC=%_^.5^KAZ5\2?\-Q?L2?\
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M/UXA^QQ^SO:?LQ_ 7P_X.14;6"OV[6KB,Y$]_(JF4@XY50%C4_W8ESSFO<*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1_\ TAAI?VL?^36/C)_V)FL_^D,U)^R;_P FL?!O_L3='_\ 2&&@#U>BBB@
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M]V9)4VC.\><L84?,6FC*_<:OIW]DG]G^Q_9I^ _AKP1;K&^HPP_:=6NHPO\
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M.O[0'_)SW[,O_89UK_TT3U]%5\Z_M ?\G/?LR_\ 89UK_P!-$]?15 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\6_\%=O^3-=4_[#%C_Z,-?:5?%O_!7;_DS75/\
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MKP[XJL=1U;Q]>:C8VY+26;3S2++E2-I#MCOUP3Q^- 'MM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?)'[,_\ R=)\7_\ KYO/_2TU];U\
MQ>)/V0=9F^('B#Q-X8^(VH>&#K%Q)<RQV\3K(I=M[H7CE3<N\D@$<# Y(R8O
M^&5?B5_T7/7O^^[G_P"2* /J*BOE[_AE7XE?]%RU[_ONY_\ DBD_X95^)7_1
M<M>_[[N?_DB@#ZBHKY>_X95^)7_1<M>_[[N?_DBD_P"&5?B5_P!%SU[_ +[N
M?_DB@#ZBHKY=_P"&5?B5_P!%SU[_ +[N?_DBC_AE7XE?]%RU[_ONY_\ DB@#
MZBHKY>_X95^)7_1<M>_[[N?_ )(I!^RK\2O^BY:]_P!]W/\ \D4 ?45%?+W_
M  RK\2?^BY:]_P!]W/\ \D4?\,J_$K_HN6O?]]W/_P D4 ?3?VB,3"+S%\W;
MN\O(W8SC./3-2U\F>#?V:_B;X:^.FCZ[>>-KC5M+LXE,^LW$[O--"'RUF8W=
MFPQ)YR5 )8?, *^LQQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?FG_P %)_!WBWXY?M1_!GX/W'BD^#OA]XDM)6BOK@DVLNHJ\AD5
MH]ZB:4(MLD:L?O7  (WFOTLK\U/^"FGAGX@?M ?M$_"'X$:1=6>B>%]=MI=5
M@U"_1E@FOX5N/.#.%))B@5=J+C+7(W=5*@'.C_@AQ:'_ )K'-_X3@_\ DJOO
MK]F7X(K^SG\#_#7P\36#KZZ*LZC43;BW\WS;B2;[FYL8\S;]X],^U?!<'_!)
M_P",=O"D<7[0]W%&HPJ)]L"CV \^OO;]FGX5ZS\$_@IX<\&>(/$+^*M7TL3B
M?5Y-^ZX\RXDE7.]BWRJX7D_P^G% 'J-%%% !1110 4444 >4_M8_\FL?&3_L
M3-9_](9J3]DW_DUCX-_]B;H__I##2_M8_P#)K'QD_P"Q,UG_ -(9J3]DW_DU
MCX-_]B;H_P#Z0PT >KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_DY[]F7_L,ZU_Z:)Z^BJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXM_X*[?\F:Z
MI_V&+'_T8:^TJ^+?^"NW_)FNJ?\ 88L?_1AH ]\_9._Y-8^#?_8F:-_Z0PUZ
MM7E/[)W_ ":Q\&_^Q,T;_P!(8:]6H **** "BBB@ KR'XB?%[5/"7Q<\)^%K
M6UMY++4C#]HDESYG[V9HQMP<#;MSWSGM7KU>3?$'X.W_ (P^+'A/Q5;7UO#:
M:68C<PRAMY$<AD79@8.XL5.2,8S\W2@#UBEHHH **** "BBB@ HHHH ****
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MITU.XA,4K&2YE=HY$+OAXV9HFP[#,9P2* /H.BBB@ HHHH **** /*?VL?\
MDUCXR?\ 8F:S_P"D,U)^R;_R:Q\&_P#L3='_ /2&&E_:Q_Y-8^,G_8F:S_Z0
MS4G[)O\ R:Q\&_\ L3='_P#2&&@#U>BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF+*!ZD@#D@5G_#;XN>#/C%HKZMX)\3Z9XGT^-_*EFTVY67RGP#L< Y1L$'#
M'!!KX1_;VD3Q9\0/V./ .I@WGA76M=MY=4TV0_N;L"2QB4-](YYU^DIJ[\$]
M*TKX,?\ !5KXB>#_  MIL>B>&-<\+0S_ -CZ7$MO903)';.)!$@"C[LW0=9V
MZ9H ^A_V@/\ DY[]F7_L,ZU_Z:)Z^BJ^*_&G[1GPZ^,'[8GP%\.^#_$L.LZS
MH&MZXFI6L<$T9MV&F7,9!+H ?F4CY2>E?:E !112;A0 M%%9OB"]O=-T+4;K
M3;$:IJ,%M)+;6)F$(N)0A*1ER#MW, N[!QG.#0!I45YW\ ?C+IO[0/P?\->/
M])MY;*TUBW9VM)CE[>9)&BEB)P,[9$==V!G&>]9W@_XZ0>-OCSXZ^'&F:6TD
M/@VRLI=3UAIP%%U=*9(K=(]OS#RE+%PW!^7% 'JM%-W@]Z\S\+_&F'Q-\=/'
M/PV72WMY?"]AI]\^H-.&6X%TKD*$QE2NSKDYS0!Z=16'XRUC4= \*:OJ>CZ/
M)XBU2TMI)K;289DA>[D5<K$KM\JEB ,G@9JQX=U*[U7P_IE[J.GMH]_<VL<U
MQI\DBR-:R,@+1%QPQ4DKD<'&: -2BO+?VF/CA!^SC\$?$?Q%N-)DUR'1OL^Z
MPBF$+2^;<Q0##E3C!E#=.V/>O4-W'- #J*0'-+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5\6_\%=O^3-=4_[#%C_Z,-?:5?%O_!7;
M_DS75/\ L,6/_HPT >^?LG?\FL?!O_L3-&_](8:]6KRG]D[_ )-8^#?_ &)F
MC?\ I##7JU !1110 4444 %>6^._C%+X/^*/A?PHFGK<1:H8Q-.SD,GF2&--
MH]F4DYZCIBO4J\6^)GPLUOQ1\:/!GB.P2)],L3%]JD>0*8O*F:7D9R=P;:-H
M/(YP.: /::*\J\??M&>%_AYXAET6\M]2OKZ%5,RV,"%8BRAE!+NN2593\N1S
MS6W\,_B_H?Q6AO&TE+NWEM&42V]Y&JN <[6&UF4@X(ZYXYZC(!W5%>;_ !,^
M.WA[X6:E:Z?J<-_=WD\7GB&QA5MB;BH9B[*.2K<#)^4Y[5VWA_6H?$F@Z=JU
MNDD=O?6\=U&DP =5=0P# $C(!YP3]: -*BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH BFN(K>,R2R+$@ZL[  ?G7QK^V
MEX3_ &I_$WQ T.Z^ NNKIWAA=*5;Q!=VL0>Z\V0E@)021Y9CY''%:_\ P55_
MY,B\<=C]HT[_ -+8:\Y^ '_!3'X ^ O@1\.?#.L^*;ZWUC1O#FG:=>PIH]TX
M2>*VCCD4,$P<,IY'!H \:U[]FC]OGXLZ3=^%?%/CBWM-!U*-H+PW6L01PO&1
M\T;FVC,A5AD%0"""0>#7Z&_LO?!%/V<_@1X1^'BWYU231X)//O-NT232S/-*
M5'9-\C!<\X SS7BW_#V#]FW_ *&_4/\ P27?_P ;KZ.^$_Q4\.?&SX?Z5XT\
M)7DE_P"']4$AM;B6%X6?9(T391P",.C#D=J .QHHHH **** "BBB@#RG]K'_
M )-8^,G_ &)FL_\ I#-2?LF_\FL?!O\ [$W1_P#TAAI?VL?^36/C)_V)FL_^
MD,U)^R;_ ,FL?!O_ +$W1_\ TAAH ]7HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KEOB9\1-$^$O@#7_&'B2Z6ST71K22\N9"RAF"CA$R1EV;"JN<LS*!
MR:ZBOS-_;.\<:U^VM^TOH7[,7@"_DA\,:1<_;?&&K6WSQHT1'F*VT'*P!@H5
MB UQ(BG!16H ^8-(^'$_[8WC_P 4_'#QSG3M,U[6)%L-$M)E$K10K&JJ[!%S
M$L82'S% :1HY3E2IS^VW@D72^#=#%[%%#>"Q@\Z.!55$?RUW*H7@ 'L.*^/=
M:_97\0^'=4GTOP;X36T\+61%OIL,=Y%A8$ 5!EY-Q.!R7^8G).37VAH\+VVE
M6<,B[)(X41EX."% /2@"]1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C=*_/KQQ\*_P!E7]N#]I/Q7X,L['5%
M^(.CV;WFK^)/#S_9;>=HIE@>(EMR2RJTBYD$7/'SMC _01NE?D-_P3Q_:%^$
MG['J>/O"OQ@M7\(?$JVUF:&76IM)DNI6MMD2FT$L*/( LL+R8("-O4@GL ?0
MO[%.H_LR?"OX]^,OA5X TB^TCXF:7+<:5+JWB"3SIM76!V,\=O)NVKL,>YHU
M2/<(PV'V$K]ZU^3OB7XG>"/VL_\ @HE\'-1^!VCRK<:+=C4?$?BF&P>U%_;Q
MLCN9%*A@%C5H?,D +-.J<X3/ZQ+TH 6BBB@#'\5>';;QAX7UC0;UY8[/5+.:
MRF>$@.$D1D8J2" V&.,@_2OS(_:<_P""0FF^'OAS!/\ !:/Q)XG\6?;XUDL=
M7U:S2 6Q1][@LD0W!@G\7\1X/;]3Z* /@+XR?L&>(O#/P;^",GPAW:KXQ^%&
MJMK-CI/B&[CVWS33QW,\32*$4E9HHP!N0;-XW9P3UG[*'P*^*FH?M-?$+X_?
M%W1+#P=K&MZ='HFG>&;.[CO/)@40%I6D1F4<6Z 88DEY250;0?M&B@#YU_:
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M?^36/C)_V)FL_P#I#-2?LF_\FL?!O_L3='_](8:7]K+_ )-9^,G_ &)FL_\
MI#-2?LF_\FL?!O\ [$W1_P#TAAH ]7HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI=G!86.G_%GPW:VEO;H$2"%%G58T Z* J@ >@]*U?@$N/VY/VJ<CK#X4(_\
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MKX0>%1X9DT:_M;43PVR7UJ/,.Z",ROOG90=^[8<CY0#4/P9N-0L?VZ/%MO\
M$>;3CXZNOA_H8T4Q8R]LIE_M%8CZ&[#-M'.T*>QKB?V?_ _@CXP?&K]MWPGH
M$D'_  BWB"73]/EGME#JEU+:W274J \%EN3,P(.,@$=C0!]G>/\ XI>&/A?8
MZ/=>)M4&FPZQJ=OHUAB"29KB\G)$,*+&K,2V#VP,$D@5UE?FU^R_XNUS]I/X
MH?!;P1XFLYXY/@CI5[<>*(&5WMGUF"9M.L$E)./M"1Q-<!\GYFDV]"*_2:@
MHHHH **** "OB_\ X*X02S?L9ZRT<;ND6K6#R,JDA%\W&21T&YE'/<CUK[0K
M/UK1=/\ $>E7FEZM8VVIZ9>1-!<V5Y$LT,\;##(Z,"&4@D$$8.: /A;]G_\
MX*6_L_\ @/X#_#?PUK7BZ[MM8T;PWING7L*Z1=N(YX;6..10PC((#*1D<&N_
M_P"'K'[-G_0ZWG_@EO/_ (U7LO\ PR?\$?\ HCG@#_PF+'_XU1_PR?\ !'_H
MCG@#_P )BQ_^-4 >-?\ #UC]FS_H=;S_ ,$MY_\ &J/^'K'[-G_0ZWG_ ();
MS_XU7LO_  R?\$?^B.> /_"8L?\ XU1_PR?\$?\ HCG@#_PF+'_XU0!XU_P]
M8_9L_P"AUO/_  2WG_QJC_AZQ^S9_P!#K>?^"6\_^-5[+_PR?\$?^B.> /\
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MJYA^S?;[2&Z\G=NV;T#;=V!G&<9P.E &O1244 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5\#?\% /VG/C1X5^-7@+X+_
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MI^T#\1?''B/QG^TQX@^$R:YXHNCH>BJ+V95MI93(C22(PB@C42J@W, /+<G
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M:Q_Y-8^,G_8F:S_Z0S4G[)O_ ":Q\&_^Q-T?_P!(8:7]K'_DUCXR?]B9K/\
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M][<11K)>%&PXWD D#<&&00#Z37H*6DI: "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !117*_%+QHGPY^&WBGQ5(4$>AZ7<ZD_F*64+%$SDE002,+T')[4
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M\012VJW!N;>5U"L7==A B;D!0>O\0XKY_F^.'CQU>P6;78_$+L713Y)0#<6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJQPCJO3J"!Q@T >ST444 %%%% !1110!Y3^UC_R:Q\9/^Q,UG_TAFI/V3?\
MDUCX-_\ 8FZ/_P"D,-+^UC_R:Q\9/^Q,UG_TAFI/V3?^36/@W_V)NC_^D,-
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M*22\F-4_07X&_ WPA^SO\/-/\'>"]-6QTRU&Z69\&XO)B 'N)W &^1L#)P
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M% !1110 4444 %)2T4 ?.O[0'_)SW[,O_89UK_TT3U]%5\Z_M ?\G/?LR_\
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M\9Z+XZTEM2T*^34+-9&B,BJR%7&"5*L 0<$'D="#T- &]1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=MIUQ-#*+RZ)1UB8J?];C@@=:\U_P""*O\ R:WXK_['*Z_](;&@#] ****
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M+'QC_P"Q,UG_ -(9J/V3?^36/@W_ -B;H_\ Z0PT >KT444 %%%% !1129H
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MVMWK-ND^  ?EBW[V.". "3D5X+XR_P""L'[.OA>S>6Q\3ZCXHN%8J;31](N
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MT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.X_9XNM+@:UD$E]'H>IQM;KM.9 V_P"4J,G/M7S+\"_VY/VG+CXD :!<ZO\
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MJN0J_-A6]#0!9\-?%3XN>'=#M-.;P3?ZFT"[3=7UE<O-)DDY9L\D9Q^5:?\
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MCK$A;+E45F(7. "3P* .HC\7_'N:-7'@S1\,,C,B+U]C<Y'T/-._X2OX^_\
M0F:+_P!_H_\ Y)K'_P"&W[+_ *(I\;/_  A+G_&LO0O^"@OAKQ.M^VC?"KXO
M:L+"[DL+LV/@V:;[/<QD"2"3:QVR(<;D;!&>0* ,#XF:+XTU+6(O%'Q"\'PB
MSCMQ8J+&<$;MS-'PDKL"S,5ST^8<9Q7TE\(_!+_#_P  Z5H\S%KI$,LXW%E2
M1R69%Y(VJ3CCKC/4FO#O$'[?_ASPKI<FIZW\)_C!H^G1O'&]Y?\ @N>"%&D=
M8T4NS  L[*H&>2P ZBM+_AM^R_Z(I\;/_"$N?\: /I.BO(?@?^TIH/QVUSQ3
MHVG>'O%/AG5_#:VCZA8>*M);3[A%N1*8B(V8M@B%CR!P5ZYKUZ@ HHHH ***
M* "BBB@ HHHH **** $)Q0&!KX+_ ."FVO:CXF\9_ 'X-KJ=WIOACQ_XE%OK
MQT^9HIYK=9[6)8]W*E2+F1MK*PW1QG'R\X?[*>EP?LS_ /!0;XD_ _PYJ%[%
M\.;_ $.+6=,T:ZG:<6]V$MV)5F.1\KW&2.6"Q[L[ : /H?\ : _Y.>_9E_[#
M.M?^FB>OHJOF?]H#7-/_ .&G/V:C]OMML.LZUYI\Y?DSI,X&[GCGUKZ&_P"$
MDTC_ *"EE_X$)_C0!I45F_\ "2:1_P!!2R_\"$_QH_X232/^@I9?^!"?XT :
M5%9O_"2:1_T%++_P(3_&C_A)-(_Z"EE_X$)_C0!I45F_\))I'_04LO\ P(3_
M !H_X232/^@I9?\ @0G^- &E16;_ ,))I'_04LO_  (3_&C_ (232/\ H*67
M_@0G^- &E16;_P )+I'_ $%;+_P(3_&C_A)-(_Z"EE_X$)_C0!I45F_\))I'
M_04LO_ A/\:/^$ETC_H*67_@0G^- &E16;_PDFD?]!2R_P# A/\ &C_A)-(_
MZ"EE_P"!"?XT :5%9O\ PDND?]!6R_\  A/\:/\ A)-(_P"@I9?^!"?XT :5
M%9O_  DND?\ 04LO_ A/\:/^$ETC_H*V7_@0G^- &E16;_PDFD?]!2R_\"$_
MQH_X232/^@I9?^!"?XT :5%9O_"2Z1_T%;+_ ,"$_P :/^$DTC_H*67_ ($)
M_C0!I45F_P#"2:1_T%++_P "$_QH_P"$DTC_ *"EE_X$)_C0!I45F_\ "2:1
M_P!!2R_\"$_QH_X232/^@I9?^!"?XT :5%9O_"2:1_T%++_P(3_&C_A)-(_Z
M"EE_X$)_C0!I45F_\))I'_04LO\ P(3_ !H_X232/^@I9?\ @0G^- &E16;_
M ,))I'_04LO_  (3_&C_ (232/\ H*67_@0G^- &E16;_P ))I'_ $%++_P(
M3_&C_A)-(_Z"EE_X$)_C0!I45F_\))I'_04LO_ A/\:/^$DTC_H*67_@0G^-
M &E16;_PDFD?]!2R_P# A/\ &C_A)-(_Z"EE_P"!"?XT :5%9O\ PDND?]!2
MR_\  A/\:/\ A)-(_P"@I9?^!"?XT :5%9O_  DFD?\ 04LO_ A/\:/^$DTC
M_H*67_@0G^- &E16;_PDFD?]!2R_\"$_QH_X232/^@I9?^!"?XT :5%9O_"2
M:1_T%++_ ,"$_P :/^$DTC_H*67_ ($)_C0!RGQ[FDM_@9\198G:*6/PYJ+(
MZ$AE86LA!!['.*^//^"*O_)K?BK_ +'*Z_\ 2*QK[&^*'B#29OAIXL3^TK-]
MVDW:[?/0YS"XQC-?%W_!&'5K'3_V7_%,=U>6]O(?&-TP6655./L5B,X)Z<&@
M#]"Z*S?^$DTC_H*67_@0G^-'_"2:1_T%++_P(3_&@#2HK-_X232/^@I9?^!"
M?XT?\))I'_04LO\ P(3_ !H TJ*S?^$DTC_H*67_ ($)_C1_PDFD?]!2R_\
M A/\: -*BLW_ (232/\ H*67_@0G^-'_  DFD?\ 04LO_ A/\: -*BLW_A)-
M(_Z"EE_X$)_C1_PDFD?]!2R_\"$_QH TJ*S?^$DTC_H*67_@0G^-'_"2:1_T
M%++_ ,"$_P : -*BLW_A)-(_Z"EE_P"!"?XT?\))I'_04LO_  (3_&@#2HK-
M_P"$DTC_ *"EE_X$)_C1_P )+I'_ $%;+_P(3_&@#2HK-_X232/^@I9?^!"?
MXT?\))I'_04LO_ A/\: -*BLW_A)=(_Z"ME_X$)_C1_PDFD?]!2R_P# A/\
M&@#2HK-_X272/^@K9?\ @0G^-'_"2:1_T%++_P "$_QH TJ*S?\ A)-(_P"@
MI9?^!"?XT?\ "2:1_P!!2R_\"$_QH TJ*S?^$ETC_H*V7_@0G^-'_"2Z1_T%
M++_P(3_&@#2HK-_X232/^@I9?^!"?XT1^(=+D=434K1W8X"K.A))/  S0!I4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >9?M-Z3?:]^S=\5],TRSN-1U*]\)ZM;6MG:1-+-/*]G*J1HB@EF9
MB % R20!1^S)I-]H/[-OPHTS4[*XT[4K+PGI-M=6=W$T4T$J6<2O&Z-@JRL"
M"I&000:H?M$?M0^ /V7O#%KK'CG4Y8'OG>+3],L83/>7\B %EBCR!A=RY9BJ
M@LH+ LH-C]GW]I;P'^TUX2FU[P+JK7D5K(L%[8W41ANK*4J&"21GU'1E)4X;
M#$J< '2ZW\-M-U[XD>%O&MQ<7::IX=L[^RM(8V00.EV8/-,@*EB1]F3;M8 9
M;.>,=?110!QOPI^%^E_!_P )GP]H]S>75DU_>:AYE\Z-)YES<R7$@RJJ-H>5
M@.,X R2>:I_%?X-Z-\8&\'-K%W?VO_"+>(K3Q-9?871?,N;<2!$DW(V8SYC9
M"[3P,,*[ZB@ KA_"'PFTGP9\1/'GC&RN;V74_&4UG/?PSNA@B:VMEMX_* 4,
M 40%MS-SG&!Q7<44 >"?MU^'=6\6_LE?$C1]"TN]UO5KO3UCM[#3K=[BXF;S
MHSM2- 68X!Z#L:]Z%>,?M"?M=?#7]E^;0HO'^K7&GR:TL[6B6MI)<%A%L#EM
M@.T?O%QGKSCH:O\ [/W[3W@+]IS2=6U+P%J-SJ%II<R6]RUS:26Y5V7<  X&
M>/2@#97X,Z*OQX?XM?:]0_X2%O#8\+FT\R/[)]E%T;D/MV;_ #-Y(SOQC^'/
M-=_2T4 <1\&?A/I7P-^&.@>!=#NKV\TG186@MY]1='G92[/\[(BJ3ECT4=J/
M%WPGTGQI\0O GC&]N;V+4O!T]Y<6$-NZ"&5KFV>W?S05)(".2-K+@^HXKMZ*
M $K@OA1\&]&^#[>,CH]W?W7_  E/B.[\37OVYT;R[FX6,.D>U%Q&!&N V3R<
MD]N^JM?7UOI=G/>7=Q%:VD"-+-/.X1(T499F8\   DD]* /&/VQ/#^J^)O@S
M'9:/IMYJU[_PD6A3_9[&!YI/+CU6UDD?:H)VJBLQ.,  DX KVY?NBO*?V>OV
MDO"/[3?AW7M>\&"^?2-(UF?16N;Z%8A<R1I&_G1 .Q\IEE0J7"MURHKR[7?^
M"EWP'\.?%A_ =YXENDGAN'LKK7%LG.F6MRKE##)-USN!_>*IC !)< $T >]:
M-\-=-T/XE>)O&\%Q=OJGB"QL;"ZAD93 D=H9S&4 4,"?M+[LL<X7 '.;GQ"\
M$V7Q*\ ^)?"&IRW%OINOZ9<Z5<RVC*LR13Q-$[(65@&"N<94C.,@]*Z%6#J"
M#D'H:=0!SGP\\$V7PU\ ^&?".F37%QIN@:9;:5:RW;*TSQ01+$C.5506*H"2
M !GH!TK&\6?![1_&/Q3\!^/KRZOHM8\&IJ$=A! Z"WE%Y%'%+YJE"QP(U*[6
M7!)SNZ5WE% "&N-^%'PNTOX/^#QX<T:YO+JR%]>7_F7SH\GF7-S)<2#*JHVA
MY6 XZ  DGFNSK+\1^)-,\(Z#J&M:S?0:9I6GP/<W5Y<N$BAC12S.S'H !0!X
M=^V+X9UCQ-8_!Y='TF^U4V/Q-\/ZA=BQMGF-O;1SL9)Y-H.V- <EVP .IKZ%
MKRO]G/\ :(\-_M/?#E?&GA6SU2RTEKN:S$>K0QQ3;X\;CM21QCD8^;\*\7UC
M_@JA^SSH>L7NFS^*-0>XLYWMY&ATF=T+(Q4E6"X(R#R.M 'T-X1^%&D^"_'_
M (Z\7V5S>RZEXPN+2XOXKAT,,36]LEN@B 0, 40$[F;)]!Q6C\1O MA\3OA]
MXD\'ZG/<6^FZ]IMQI=U+9LJS)%-&T;LA96 8!C@E2,]C7003+<0QRH<HZAE^
MA&:EH I:3IL>CZ79V$+.\5K"D"-(?F*JH49( &<#TKC&^#&BM\>5^+/VO4/^
M$A7PT?"PM-\?V/[*;H7._;LW^9O &=^W'\.>:] HH 0UP/P+^#.C?L_?"O0_
M /AZZO[W1]($H@GU.1'N&\R9Y6WLB(I^:1@,*. /J>_KQ;]H_P#:Z^''[+6F
MV4_C;4KD:CJ"NVGZ/IML;B[N]A4-L7A5&6',C*#R 21B@"M^T#X?U36?B=\!
M[JPTR\O[73?%LMS>S6T#R):Q'3;M!)*P&$7<RKN; RP'4U[E7CWP&_:L^&O[
M1W@[4?$G@_7E>VTD#^U;74$^S7&G94N#.K<!=JMB124.Q\,2K8\[^'/_  4F
M^!OQ1^*</@31]?O([^\F6UTW4KZQ>"QU*=C@10NWS!R< >8J;B552Q(! /;O
MAO\ "G2OA?=^,;C3+F]N7\4Z]-XBO1>.C".XEBAC9(]J+B,+ F VXY+?,<\0
M?''X.:-\?OACJW@7Q!=7]EI&I/;R2S:8\:7"F"XCG3:71U&7B4'*G@GIU'>T
MM "*-HQ7$1_";2H_C1<?$P75[_;L^@1>'6MMZ?9?L\=S)<*X79N\S?(P)WXP
M -N>:[BB@#'\6>&[;QEX5UG0+R6:&TU2SFL9I+<@2*DB%&*D@C< QQD$>QJI
M\/?!-E\-/ /AKPCILMQ<:=H&F6NE6TMVRM,\4$2Q(SE0H+%4&2% SG '2NCK
MP']I/]MOX8_LLW-EI_B^]O[WQ!>PBYM]"T:U\^[> L5\T[F6-5W*P^9P3M;:
M#@T 4?CAX7UG5?VN/V;-8L=(O[S2=)E\1'4;^WMI)+>S$NG!(C-(!MCWM\J[
MB,G@5]%UY;\,_P!I;X>?%[X3W_Q&\,ZZM[X7TZ.9[^>2%XY+-H8Q)*DB,,AE
M4@\9!!!!((->1>#_ /@IU\!/'?BW0_#6D>(=2GU;6;^#3K..329T5II9%C0%
MBN%!9@,GIUH ]\^%_P +=+^$VDZMIVDW-[<P:EK%]K<K7KHS+-=3M-(JE57"
M!F.T$$@8R34OQ(^&NF_$_3='L=4N+NWBTO6;#7(39NJLT]I<)/&K;E;*%D 8
M#!()P1UKKJ6@ KSSP7\%-$\#?%CXB_$&PN]0EUGQU_9W]I07$D;6\7V*!H(O
M)4(&7*L2VYFR<8VCBO0Z* .=^(7@NR^)7@'Q+X1U.6XM]-U_3+G2KJ6T95F2
M*>)HG9"RLH8*Y()4C.,@]*?X#\'V?P[\#^'?"NG2SSZ?H>G6^F6\MTRM,\4,
M2QHSE5 +%5&< #.< =*WZ^<_VB/V]/A-^S-XDMO#GBG4;^^\0RI'-+I>C6GV
MB6VA<G$LI+*BC"EMN[?C!"D$9 -[7- U2;]LKPAK4>FW;Z-!X(U:TEU%8'-O
M'.][8LD328VAV5'(4G)",<<5[:PRI%>=6/[0GP[U+X.O\5;?Q59-\/TM6NVU
MM@ZQB-6*,-A ??O!3R]N\M\H7<<5YK\ ?V_OA#^T=XUN?"7AC5;ZSU]1(]G9
MZQ:&V.HQ(,M+;G)# +EMC%7PK'9A20 >K_!?X1Z1\#?AWI_@W0KF^O-,L9KJ
M>.;471YBT]S+<.&*(JX#RL!\O0#.3S3OB5\)])^*%YX-N=4N;VWD\+:]#XAL
MA9NBB2XCBEB5)-R-E-L[9"[3D#YAR*[>B@ KD/!_PTTWP5XG\9ZY97-W-=^*
M]0BU*]2X92D<D=K#; 1@*"%V0(?F+');G!P.OHH \]^/7P5T3]HCX3Z[\/O$
M5UJ%CHVL>1Y]QI<B)<+Y4\<Z[&='49:)0<J>">AY'H*C:,45\T?'#_@H9\&_
MV?\ XA)X,\2ZMJ$^N1O&NH1Z98/.FF(Z*Z23MQP59?ECWMR,KS0 _P#X176_
M^'CA\3?V-J'_  C?_"J1IW]L?97^R?:O[7,GD>=C;YFSYMF=VWG&*^CKNV%W
M:RP.2%E0HQ7K@C'%>?>)?V@_ ?A7X+O\6+K7HIO BVL5XNJ6J-('CE=8TVJ!
MNW%W5=N 03@@<UYA\(_^"AOP6^.7Q$TGP1X2US4+SQ!JGF_9H9M,GA1O*A>9
M\NRX'R1L??&.] 'M?PM^'6G?"/X<^'/!>D7%U=:7H5E'86TU\ZM,\:#"ERJJ
MI;UPH'M57QE\*=)\:^.? WBJ^N;V+4/!]U<W=A%;N@BE>>V>W<2@H6(".2-K
M+R!U'%=M10 E<'\)_@_H_P 'X_%J:/=7UR/$OB*^\37?VYT?R[FZ<-(D>U%Q
M&"!@-D^K&N]HH XGXP_"G2OC7X O?"&MW-[9Z==W%I</-I[HDP:WN8KE "Z,
MN"\*@_+T)Q@\UVJC:N*6O.OCE\>_!?[.?@O_ (2GQUJO]EZ2US'9Q%(FFEFE
M<$A$1023A68^RDT <#\(?#6KZ;^UY^T'K-YI-]::3J=GX:6QU">V=+>[:*VN
MA*(I" KE"RAMI."PSC-?0=>6>-OVE?A[\.O@UIWQ2\1:\FE^$=2M;:ZL9Y8F
M\ZZ^T1B2&..(#>TC*<[0,@!F.%5B.>_9K_;,^&O[5$>HQ>#K^\M]9TY!+=Z)
MJ]O]GO(HBQ59=H9E=,@9*,VW<N[:67(![I1110 4444 %%%% !1110 4444
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M'^!O@UO$#-X T37_ .U]5FU0#6M,M9Q9"14'V:WQ$-D";,JAR06;DYIF@?L
M_ [0/''BKQ&? >CZDNO_ &7&CW^FVLFGZ;Y$9C/V2+R@8O,SNDRS;F /'2M7
M]E+XT?$7XT>'M<O?B)\,[OX9WME=)#:VEV)<W,93)<;T4X!XXKW:@#YT'[ /
MP-'Q./C'_A ]'*?V1_9/_"/?V;:_V3GSO-^U>1Y6?M'_ "S\S=]SC'>K&I?L
M&_ W4O&6B>(!\/- M5TR"X@.DVVEVJV-YYVSYYX_*R[Q[/D(88WOUS7T'7RC
M^U)^U]XM^&/Q;\,?"+X7> D\=_$?7["348DOKU+6T@A7S2 69E#-M@E8@N@
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MVGQ=^']W\,=9\%;GU*\D21],N(D$ADD@EP5/EB-MP5W&&1E8Y('@=G_P4_\
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MFMG0?V!/@=H?C3Q/XA/@'1=177/LV-)OM,M9+'3O)C*?Z+'Y0,?F9W/ECN8
M\5C_ +9G[8UY^S3H/@$^&_"S^,/$OC+4/LFG:1-YMN\B!%SA=F_S"\L"A"N?
MG(/(Q6G^R=\?OBG\:K[Q)#\1OA'>_#&+3X[=K*2[$V+QG+[P-Z+]W:O3/WJ
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M;O.=V-L7E2#&W=^].&7G=]-U@>/-!F\5^!_$.B6\B17&I:=<6<<DF=JM)$R
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ML#^-:]4-#T6R\.:+8:3IMNEIIUC!':VUO&,+%$BA40>P4 ?A5^@ HHHH *\
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M3[ U^COQ'\!Z=\4O 7B#PCK#SII6N6,VGW36KA)1'(I1BK$$ X)Z@US?PR^
M7A+X6_!:U^%=C;S:KX0AM;FR>VU9EF:>&=Y'E20A5# ^:XQCH<4 ?G=^UA<Q
M^)OV+_V-M$T2YCGUS4)M$@LHH&#.TL=BD+A0.ZRNBGT)%?JQ'GRU!ZXKY5^$
MO_!-3X-_![XEV7C73(-:U6\TR5YM)T[6K\7-EI<A8L'@38&)4DE3(SX/S??
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M(2FXKE5.QG*G:%(*_+0!]+?#73[W2?AWX7LM29GU&VTNUAN688)E6)0^1_O
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M5B][]O?PE%>A=%>;^]Y&S<%R2=@<)@E=NSY:^NP-O2@!:*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPW:I\2I/BZD$EY&?&DTC.=28:+,"0S22;@C9B!WL"(Q@XP*]N_;BU*3]CO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit51exicures1226_image1.gif
<TEXT>
begin 644 exhibit51exicures1226_image1.gif
M1TE&.#EA>0/K /<       $! 0(" @,# P0$! 4%!08&!@<'!P@(" D)"0H*
M"@L+"PP,# T-#0X.#@\/#Q 0$!$1$1(2$A,3$Q04%!45%186%A<7%Q@8&!D9
M&1H:&AL;&QP<'!T='1X>'A\?'R @("$A(2(B(B,C(R0D)"4E)28F)B<G)R@H
M*"DI*2HJ*BLK*RPL+"TM+2XN+B\O+S P,#$Q,3(R,C,S,S0T-#4U-38V-C<W
M-S@X.#DY.3HZ.CL[.SP\/#T]/3X^/C\_/T! 0$%!04)"0D-#0T1$1$5%149&
M1D='1TA(2$E)24I*2DM+2TQ,3$U-34Y.3D]/3U!04%%145)24E-34U145%55
M55965E=75UA86%E965I:6EM;6UQ<7%U=75Y>7E]?7V!@8&%A86)B8F-C8V1D
M9&5E969F9F=G9VAH:&EI:6IJ:FMK:VQL;&UM;6YN;F]O;W!P<'%Q<7)R<G-S
M<W1T='5U=79V=G=W=WAX>'EY>7IZ>GM[>WQ\?'U]?7Y^?G]_?X" @(&!@8*"
M@H.#@X2$A(6%A8:&AH>'AXB(B(F)B8J*BHN+BXR,C(V-C8Z.CH^/CY"0D)&1
MD9*2DI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=G9Z>GI^?GZ"@
MH*&AH:*BHJ.CHZ2DI*6EI::FIJ>GIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O
MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^
MOK^_O\# P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)R<K*RLO+R\S,S,W-
MS<[.SL_/S]#0T-'1T=+2TM/3T]34U-75U=;6UM?7U]C8V-G9V=K:VMO;V]S<
MW-W=W=[>WM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK
MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ
M^OO[^_S\_/W]_?[^_O___RP     >0/K $ (_P#_"1Q(L*#!@P@3*ES(L*'#
MAQ C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMQI\QL<$ """AU*M*C1HTB3%@4!YQO,7TJC*@64$9#4JUBS:@T* 8A7
M0( >_?K%DR:0K5G+LCR+MJW;MW#?DH4()ZY6"._4BH1A]RJ<C[^ ]AU,."J<
MO( +$Z6*T:KBQY#A@GB$6&]#MI MI\0<N;-GN',IOOI,%(AFBU!(!WVU\9/J
MUY\96X0:6;9%Q[!SZT8*J/).SHI/GP2^N_CGT!C?08#]5WA"W)[Q:H1N7"@(
M*( ^_7IV\-FO3X" +/]_#8&[1]J0;5>D7KU]>S!F.SLO2=R]?;O(.Z9^S?KT
M:-)0<%27:O#)],Y^4L'@FTCH/:8>1>P1EM]3CX#!UWU)F;92?8/-1Q*'?4WH
M(4Z/P.843L^H]LA'%]9VVCL/HM2@8C%*%.%@(CKWBF#&2?>A?".&!")^06KV
MS7B?@0"3<I]!<**0G=58Y$@S%B8E1#>&..5"[[1(WH(;#1G7EAZ)"1J9PIG9
M5X F>0F9AL-Y9AZ:)%5)V)4/94DDG0W9&9F2'*GI%I\:"=I6CH3RI.>='8$1
MVTMN1H9HHA7YV1>>#BUZ)J4..0I@H4!R2I&A:$TJZDXIDF8J0IK&->=,GA;_
M!\:KIRYDJ5V8-M2J6ZO6*M"N<+%I$:E;^2H1L5KU:JQ.D2KFXT'_10:#9<#:
M!\,C3TYY:URY,E3M5LH:BV"HHY*[+$/(8JAN4.'R-&!G0'SC67-%NK9N7R!\
M F9,V\+5[4+?)GON99_!.5&Z6 WL$,+WVM>N9?UB^'"1CR#9L%T0]"=CE%5U
M-O&I$8]9$<-2*4SPQ2@C]?&+/+H'PKXF<_G)N"E+]7)((;?UKT(!9[4RI[%&
M9O"QYL9L$,DUZ_:SAS1_1J_1*WWS2+/W%:A1SFCM_)S'4!OT;M$1(:U4UPB)
MG=329%OF6=J6'5@<S!!AO976K'*==HF?63TRV&2;_ZTRVZ*N#;B'/6\UM$1R
M:T7W085?A?:407?V]+!\=^WW48\/KI/@FGN(MZ2S<=R8W>=^3MKB"EUN5.?_
MJ%Y4YJS;Q'GLIR6NU46V8X5Z08U+!3NJ%JNV.[J50^TZ4;_3+M/LR_X2/ !.
M>FBOT!CE?M7P _4>5?(NO1/Y;I^8=/Q0K(\O%/?*O\0\GUWB"G=+TW\6?D;6
M2X7]KZ3/],PC4#R_[K.;*9[1S,>N]&UI?=)3%Q  \8IL,>0=OP!$_^RSHH[4
M+RKW^X?VDL9!(+Q/)03DX%N&%T(1JNI4"/10^TQXKVE12707V2 +C1,OO91P
MAEDA(0YWB+Z;I)!/W[@A"_\KJ)(+3J5C.[0/!)I")R$F\8A[>Z()>R@[ 2KL
M$TZ$S*QR8L2D9%"&)@0"& #Q"P>R+8M2-(H.T\A!*M;DAP:,HQSG2,<ZVO&.
M>,RC'O?(QS[Z\8^ #*0@!TG(0AKRD(A,I"(7R4A1?>,5$J2:6[H"AT_0JI&8
MS*0F-WE'&/F/C0  @QEQ!L/;@/(Q,(##*S[(IQ"6[Y3W^AB38#._YKWF9JWY
M)"PG^;LN\@:)NW0/!'HS'U=V#HW!5$KFFB:G1!U)-<+""#+3J*"-^/(H7TRF
M"#,($F-J;IK:- KZHD4:7,[G'2WKC,:DN1MBUNE[;=%;8EPTNG FL9HN\>;@
MP&G_SZ&X42#/5,WA<B)$ &8DG8\Q9T[@N4Z37%.-P'S,/T."175%+TZ1>27H
M$)E%;F[D:]0#"1B1,DKE/;0HV=PHGSZA2\_(LTQ6-%D()\HZTWF&I@>Q*62(
M.!*$,JJ.)UU,1!6#4YJDRD0PS>@Q\Y=)>9'FHO/L#%11,E*DO-2DI5P/4\^5
MQ5JR4ZG?W"HG_R%)PKC0(@&5UDQ:^ABO:BZH0TDI9(I:%I\JYJR4 ^L^Q3I6
M@E35J@^QZV \VLW_@:&A(,LJA/AJ,IT^AJ<'BZG"9MK7AQRU,VXMX25M",K#
MUDZQ$_DK\@;W#M) -FR2'1@_M4E7DZ!SAPI%TPKM"8+6_R($KD*1JT0U)]JB
M#/0A^@3<:I-I6Y6 5%V3,]HOF'G*\I0$MT'1+5%Y2YJ\9F:I_81-<5T"7<<!
M4FIEO=A4KP9:&S$V9J>S[F,T"AD8>.6]\(VO?.=+W_K:][[XO>]F:S7+R!BT
ML@+YQ7"%<M6)=%>ZA=FN3ARK&+<23:_"/2^ -0+'"2=DMJ0IZ4,./-0$ITVP
MA(EF%*\;5I5:^",5/C%#&"RAT-$SAA(6%8@+H^$'DWBO)E8Q1U*LXX7<U,7I
MZ7"+C=7;I!3X(L$]8XQ[+!$>B^H=R?406_V%N_)&I,@%9!\_QYO4&T<XQTS&
MB).W=%RD.)>SGA$Q13A<S[F^"/\0,\Z-@T>2Y+11-LP;&;-FGC'EN$#!ME#6
MS9$-;&4L97>&9\[GH8,\XD4;1\$IT;-.X.GH]I+RQ::L-(:@P,J6#/B):]3T
M;B"-$DEKAJ6B;DNBZU3H/*6Z8*3^ZJNIW.A9GS!PJ>73+\*[2W>^A,TPMG54
M8 "(_2;JTTD,M;"/@\)<IVU_4(@S*E79:3Q;^]K8SK:VM\WM;GO[V^ .M[C'
M3>YRF_O<Z$ZWNM?-[G:[^]WPCK>\$[D_9$,!6_/.M[[W?4XXIW&)-;XTHX,]
M:Q LL(%V=K:QD,U:B9!3-<9^<I^UQ"!>PW*8K,:T5I>-%:8@MHD*]Q7#B5L1
MYD8FRI3_8K%BU*P1#',<Y4!VD) YCA88S#E-(:_5R(.)MOX^M=H>DC;&@/Z0
M^-$<*3"/6ZLS=73(@.#CO\GYJ7:^2]@]7'ZZYD]'^-QTJ0Q:Z1I?;->=1O0-
M25U45(<E]TS^F-\*A^TAWOK8E<+E*H<]M'.'#01B?9 Z]RWO>^J(SS\3<)TX
MM4EE)YYQKE7XA[P"#!/?RLWIMW1= 7XW^'R)WRUW^4V!Y.J5IPF6B0)U]38)
MT@)NB]LY NQ,N[DDWHF@!,4CQ<R#\.R<"J%8QL+[WOO^]\ /OO"'3_SB&W\L
MB8^L:F)KD]<6[".@?\S76_*,LJXZXP-W_6YYLC^+[^:T/X*P_Y+!',BT?J;T
M+C$Z9.J>$97W)>DVB=7D7WAW\Y+?,M^@M&[@'RC<4^K.B.1^<2<30@1^&W%9
MC\%R6%5_5[9DFA$8U8%^H")^"7=_A>1$[ =[I+%Z&P%W<,&!K--Z&_=ZB>)R
MJH%77;9>V$6"C&1^H;<1^C<8&9B"-&)'(BAV+,@I)A@=R:=X7C9^.=A( H@O
M)#%XCW5[(45'-XAW%D@I,>@L/9@0FV<\#GA(WA<7/32$']@23Q@7*&A 2VA_
M0>@KSO<I8>)_QU:%B(2 D3%]@?49$:>!G_&%M!.&#=B$M=*%@]%X)_.#%3B&
M8S5Z0O%?&_8H,J&%&!.'9&.'AH:'OO^BAX%G>H7!7MNG8U?X%@:8$!X(%W0(
M$]$7'?,7,XSH:H[H*X?W8TB&AH0"@#W&AJC$$*<(&8JH>?8Q&5&H+2_(,VIX
M*I'W%K?8.JK82KNX28*89;SC&805?N+E69PRBDQ7BLNR@:E(@7\'C0!6AB<G
M$-AX5_/179[!>"/BC)9GC;[RB4-6+M3(>9WG,V3BC<Q6)%P'2]?RB\^5BUM#
MCKYRB3HCB81!B>NX/7Q29BG#?_/Q"KV(:+[V%/98-_A8*\4(@JD3C"#WC]Y%
M*-MX+\Q'*:C63Q"0B=@G<VU6B6Q3C # CQVR@A2I3*+BCJ72-:G73[9'?]DW
M@B*9-N9XDNC_Z(?5F)(J62L"F1L$:33O\ GZR$'7=QX+R3C#>"H/:9)]X8\\
M*4[+<I'E1(]= UYIY(:$QH"-"(@#9(@YJ8(E%I5_,S W21@2^$=8R4$>N94S
MB8,UZ9*W%I;!@9+3]6ZF=DC/  <'Z5+6E)0&,7I\5T6> 9$1F8Y4V)#>EI>9
MM&O5$8H.(8[>LI24TI=H(6MBB6->>6Z,V5?Q^!I:J1"2"3"4"400AYEU.99Q
MJ6Z=.6$NR)5] IC'J)C"F&$9,85?29O<UIHGIGZ9Z98@27"KN2Q.!"BW*9%H
MPHKLQILJ5I0"4RFRZ5>E&22O&1F0"1&X&3/*N6[,>6+>N#2CJ8NZ_WE.SND6
MH0E<R$DFV\F:Z=E7S02=L/F,FXDF9ZD8YXF=[3DEZYENW6EAHV>8"1&>]SB?
M0>*;<_D1V2E3TZEM_3D?GYF69?&3?3&+HAF=V;.@S2>ASZ>,OPF$PXEN#6H9
M!BH4,:D6B,@KU6.A^#.>,?$)0N<9&5E8B)F;!$IN(;H3D%@48&"5(C&BA6&5
M LJ0-0H3W^!O]Z* =):?1;*?(*JD,;&#'TBA(N$]L.%10:J4+$H1W@$(8)!V
M4G&4*)&@DX6AV':C_&*9< $!8$!%SP!YQ9&,5QJ89.E?4IJD<PH RG:G%<DI
M9LH2&JJG=5J(\3F.>AH7UXF$<YJGA=J3?/_JI(BZJ !PJ&NFHAH$J5H! WRH
M:'>JJ)8JE;@VH_.1HTTW@W\YJ)/9J4=Q&*?AI1S$J:CJ3\T&JD'B-H!7HC(9
MG-JWJ$ PF,>YJ4[YJ@# JR/1ISM!I;:VH]Q%J20)2R  ")GJ'*R:-*X*K,$:
MJSIY+B\93+M:$W$ZFQP' F#P"<^ZBGHZK< JK")!K&2REA?#%(':$A!T?/+:
M>^.*$-\PK_B:K_KJ>^_:.;&WKP ;L ([L/1J$?]*L B;L H[L#RZ$PO[>W^T
MI>$!!"\:% :W0&34K_RVL1S;L1[[L2 ;LB([LB1;LB9[LBB;LBJ[LBS;LB[[
MLC ;LS([LS1;LS;_>[,XF[,ZN[,\V[,^^[- &[1".[1$6[1&:VW>\0A<ZA5Q
M=K%PD!V_T+!'.[54.T<1-$&OL4#H6K5<V[5ZL9<5>TMPH+$?$:\/.Q;U>A#W
M>K9L"WQI2SL'^["L$[=M6[=V"[!E=[>_1[;KJK=CP;<645$X9'/):JJD66E
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5>]W[7OC&5[[SI6]][7M?_.XG(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ibddata.jpg
<TEXT>
begin 644 ibddata.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" 2P"OL# 1$  A$! Q$!_\0
M'0 !  $$ P$               @! @8' P0%"?_$ !@! 0$! 0$
M       ! @,$_]H # ,!  (0 Q    &5(
M
M
M
M
M     *%!+6RH
M
M
M   *%04.J:.-LUD.5PH
M
M
M          "A:1H(DD_=\]H\NEPT
M
M
M                   %"AKX@:>*D_.G/:/+M=8
M
M
M                              !:=0^?YN\BPD\NG/:?+JH
M
M
M                                          #CRBF:^TFJ?-4GEO&T
M>>]8U%DM-PDE2\
M
M
M   H<67SHKP*[9X![F\S^Q<FE\FL6(P$["X
M
M                '1.V7@Z9W         <1UCO H= [QUCLEP
M                                        !0I& G3KHD$4E]O&^\=>
M]F5TP\B$3K+@
M                                                6@H5+@  ?.8D
M@2$+""A.\ H><: ,B-@&7%"A<5+ <I<4--$,CZ.'I&O2 9]&S01(\](H4+RT
M %3D                                                *'2(ADE=
M8S/.KI58>1")UEP
M                                                   +#A/+/:+P
M  ?/D]\EV9&01)YFJC6QWS?I@YX9P&T#VS4)G9@YKPV4;7+RTTT1=)/FY2+1
MJ$F^:O-SF/&CCVC?IC9HX]DWZ=@Y
M               "@*E"@1<W38P\B$3K+@
M
M         >$:\*'MG;,?.(]XV"5 ( $PB,),T@R3:(NDH"-AGIWS S,#%R1Q
M!8DL:>).$4R2IG!0TT:W/.);D.CS27)#PF"0[);FF3,#1!*\UX8N29.4
M                                               &'D0B=9<
M
M                              #R#$CC.V7'3+SU#+RH! $GP1D/>-&D
MYS2QK,PPW@9&8&2*(3DJ2/IF9IHR8\$WT;V*&FC"3#R1!I\P<EL0])0$>291
M8>"?/\VJ<!R$SCE
M      !AY$(G67
M                                                   QT\<N+S,#
ME  ( D^#K$(S'"7YH,ED1Z/8,C,")-$-#SR11CYX1(8U^9,90<9IPPP]4U$2
M:(VDL2(9*\BN36,*-1&JB;QYA@QM@Y0
M                      8>1")UEP
M
M      .$J"A>7@ $,B8A<8$14)FD/SVCE-BF7F&&^S5A&4G&6D2#K%Q+T]0X
MC5YBYM0B 3:(NDC2,Q*,T@:S.,E*:I-7G7)+FQCD
M                               !AY$(G67
M
M                      %"H+#C.<H"H  *'5.T5  !0J"A4 X#D+BIUSD.
M0                                                    &'D0B=9
M<                        "A0 J5
M
M                                                         !AY
M$(G67                         QLBL<9FI)LJ
M                                                  6%I<"\ %A8
M>:>D<A<>8<YVRH!YQ>=TJ6'E'JEX!:>0>L7@
M                                    P\B$3K+@
M        >>:3(VDQS8Q4
M                             XSIG4.\=T %APD(R:AWBI#DDP9>5 (U
M&8FXBXXR,1)4[@!:0/)V',
M                      ##R(1.LN                         ,6(:$
M\@7
M           %A4\4T.>2>H;R/>.8 H1F,Q-R'E$,2;AB9I@SHVZ1H.X= VJ;
M&-4&T#P31YDYNT@23V/#-%'O&[SLE2X
M                            &'D0B=9<
M 8L0T)Y%2H
M                 !U359B)X0!ZAEAN$[ !BY%8F4:$.P;@(>$H329G1AQA
M1),B23G(0$T2&9*,U"9\1H)YD*R2QA9X9),Y"X
M                                   &'D0B=9<
M        8L0T)Y%P
M          !:<1U#SCNG?.0O         !US3ABQY(*'H&2F[3L@'$0K):D1
MB8YKPBT;&/&,I.T9L;F(/$PB&!+<B^33.,Y" Q.8^?AN4XS%2;QREP
M                                                   ,/(A$ZRX
M                        Q8AH3R+@
M                          "PPX@L=(H36-G'.         "PL/%-"GG'
M:-Z&3',5 .$TZ:X/,)?&!$>B8)CYXQI\S@W*0=)A$,"7Y$XFR8@841P)RD(R
M<YUS!38IRG(
M        ##R(1.LN                         ,6(:$\BX
M                                            L(ZD9CZ-$)SVR8AR
M%"TJ7@       H5*'0/..X>H"H .,Z)\_P F.;)*$3#HG@$H35AF9MPA>2U(
M?$SR/9B!X1*TB03A(^FNCK&]S<A4
M                          P\B$3K+@                        #%
MB&A/(N
M +##R#1LLUD3$-G%"TH=@Y          4!4  '&4* Y2IQG$7 J5+"TY04*
MXSF.,%Q0N+R\
M          &'D0B=9<                         8L0T)Y%P
M                                             !::S(3F_P T82:,
MY(]EISDPCD             !0J4!4% 4*@H5*E "A<4*%0  5   !: "X
M                                         H  "H    !AY$(G67
M                       &+$-">1<
M                          6$0C!R>!#,\TG$7'7(ADPCD
M                   !0H<1>7%P
M           +3A- &N201A!O<[8    !AY$(G67
M    &+$-">1<
M       6&IR$1O4TH2@)$',=<B$3$*@        ZAQE05.T7@ XSS2%Y,$R(
MH6E2H,)*F&GKFT2\CH:L/(/7/0-_FE"6)S&B#,C#C21V 2/-FEQQD;S$3K&W
M3;Q",F0>^<1%$EP4(XE"11>7@X36YW3.C&S1Y)@XB-!@AMTWN8>1G.<DV965
M  .,%A< 6$9R3H/"(]$H2A<4*%2I:5* %#"CQC9QR%P          !81C(S'
MH5)N(I1+;69"30    &'D0B=9<                         8L0T)Y%P
M                                                     !8<9A!J
M@V&;(.0YCKD028I4        &HCP"M#US<,7@ XS0IAI[A) Z!Y1Y)WC)B)A
MFAN0YCVSD. XB"Q.(Y34I#<E\;M(QFP3 #-#<9:#F.0P8CB2].,B 2P/GV;.
M)E'&0:)Y'7(8@F,=PY"AYA%$ER:X(T'>)J&JS61)0AX2M(D$L3R309+XN  .
M(H88=DM,L,"-5$D# SB(WDU3RC"C-3TSKF GN&4@Q,\HSLN(EDK#O'*
M     4*E#Y^$AS!ZV5&&RX_K,O8HHJ   ##R(1.LN                 !0
MZ1YP     !C1$@FX     5*'(>R7
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MR(1.LN                 !0AD:P.0     H4+#E     !4\<^CYZ!4
M                                               '7(@DQ2H
M  . U6>$<)6A<>L;=CL &&D122)'PDP4- DOB+YL8P0S,Q4R,W@"@(%$ZCMF
MFC C:)H0RDV*8":W,M.8D^=\Y#C/"-1FISSR91"PFT0J)<D/B=A"LW(<!JDF
M8<P(IFZ#8!0QLBB35(NFQ#;Y&HR,CR3V! 4GZ#Q2&A.$B\28(2$SSND#">Y#
M0F.0/)YF*D5S<9T3?IH\Z)@)SFYC99",V"=LTD3K/$-#DKR\           M
M,>(1FNBAMDFD>T "A0J5*%08>1")UEP                 *$'C)#T0
M "A4     %#1I]#ST0
M         #KD028I4       % :?/!*@]0W,<@+"TB^>F92>08 ;V-'$M2+I
ML8P0S,Q8]\WD5+ 0.)SG9-.&#DG")YK,D\8"9T;E!0H5-5G2-N%I$$WT1<)U
MFN"-IY1- AN2%!'HF49 "*!NDV*4,6(IDU".AD1N@C&;-(PDZ#KD+B<)4\,A
MN3>(N$FR%!,L[A TFL1R)9$!R>QBQ%0W =,W^:6/'-HGAD?S89J0WL=PZ9N8
MQ,T,2R+P          "PCD9<9X#(P7@H6FN331MLV>7E08>1")UEP
M          !!TR0]$            %#1I]$#T
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MTFF7 P\B$3K+@                 "#IDAZ(            *&C3Z('H
M                                                 '7(@DQ2H
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M7E2I4           M+3"37A4VX9  4!P&D2*QMDF(:L(^'G'$3L+@
M          "#IDAZ(            *&C3Z('H
M                    '&>>1F-)$A3K&[3*R\O    .N1!)BE0
M    6@M!>5   .,M.0N!0 M+"IR%A:7 J7%"PN+RA86EQ0J6EX+"XY"AQE3D
M  !Q J#D!QE#E!Q@J5+@     <9:<A<6'&<Q4     M.,O+P          "T
MJ4-<D##SBAD1/\RP%IKP]$S C.1B/IB>68H8T1^)UEP
M!!TR0]$            %#1I]$#T
M          "PBP1U,W-IFK3D)XG(7@   '7(@DQ2H        .,J4!R   XS
MSB'A+4]XJ "IAYPF*GIFSRI'XUB>0>J=\WJ:;)5EQH\RXQ,TP=@$AC8YR'$1
MT-6'8-ZFUB&1+8R,ZY%XE:4(\ D*5+@<9KP[!C9ID]@DT>B1X,%-KFZS$B-Q
MS$FC(BH !:4!:7@X2.!)(J>&:"),%Q0H5*%2A4J5!88.><;**EX
M !:06/9):G 0<-L$KP6D133))@CN9&3L+P8>1")UEP                 !
M!TR0]$            %#1I]$#T
M         "P^>QO@S,UR;)(0'TK/0+@   #KD028I4        '&><0G)F&0
M@  X31)@ID1(XX3IGBG;/<(OF:&V3F/5+RPXR"1.0[)J AH3&-T$838)@)FQ
MN4H6'(7F%$9R81QD,279\^3:Y,HX"#9/(ZY#,XR91VCD*'FD4"5I#(F::I,%
M-G&KB2Q#DEF1+)6G@FBR7I4  M.,Q<YCMGK&$&IB19BAU2,I-4Z!BIE1W3KF
M('LGOEYCAYYEA0B02P.X<X          !;'S_-[DB*$.CNDNP6GFD43##)R5
M1D94&'D0B=9<                  0=,D/1            !0T:?1 ]
M                                        L(+E3<1AQU34Y]$#L%X
M  !UR(),4J       #@(ZGG&'&@S=!L<J22.Z <)"XET0Z)MFOR'AO TP3$(
MCF:F6&1&\2I:4(&$ZCLFG#6IK@FR1[-A& F4FW >D7'(>(0=-XFV#*CK$)#/
MS8AML@\3N-2F'%AFYM0YP:9,<)" H:.,=.H;#-O$:S)R.I/8L(+$[RITC3QN
MLUF;'--&G#V#5)] R.!MTTP>:>*=8EZ0I-MFK29!%T]\UH2X,,-/F1'4)6F@
M3VC<Y>           4B,*QF3?U>4:-)KFZ@"@!0%P!AY$(G67
M       $'3)#T0            4-&GT0/0
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MZ3H-;D>#P2:9"XV\#3Y-8]T$2C>1GYJ4C^3#/3([&4FY",1LDC*3K.N0J)R
M\<AD3?(NDFB$I,X[I PFT1L):D R>QC9%(V^<!OPTB>,;F,'-!FU#31)0]$Z
M9L8Q8C^2S.0           M+36YL$QH\\STO     ,/(A$ZRX
M       @Z9(>B            "AHT^B!Z
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M    ##R(1.LN                  (.F2'H@            H:-/H@>@
M                                        6D/C0)O@]@N/:)('(5
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M(&F8$ES@(:FS260    !AY$(G67                  $'3)#T0
M    4-&GT0/0                                           .(Z8!
M0N+CME2XM+2T\L[AVBXN.N1!)BE0
M       "P H<@      +"TY06E#C*'("\J        4+2@*EX          !
M::J(1'B%#*2>YF     !AY$(G67                  $'3)#T0
M    4-&GT0/0                                           .,ZQ'
MDT,<!N<DR>B7 L.B0Z-+'L$Y3/R\ZY$$F*5
M                                                   * H4/*-=%
M#9!ZI4     P\B$3K+@                 "#IDAZ(            *&C3Z
M('H                                           '&1U(D&XCN&FS?
MA+LO*EAI<B:3[(\&?&YR\ZY$,F&7                            H6@J
M"H*@                                            H<1I\YC9I%,U
M(2!))'.     8>1")UEP                 !!TR0]$            %#1I
M]$#T                                           "P^?9MXE$5-(D
M0CZ0G?*EI%0U89(9 2?/4.8X"(I, Y                            6F
MLC&SH'?-HF0%P                                            +30
M1#$ER8L1T-B&NB:IO0     P\B$3K+@                 "#IDAZ(
M       *&C3Z('H                                           %A
M\_3:Q*@J:((G'T>.\7%I#@TF2S(T&X#;Y%8M,A)PEX
M         *%IP&K#;0+BH
M     *$#C.B59\XC9I-@A(9&2]     ,/(A$ZRX                  @Z9
M(>B            "AHT^B!Z
M      !81Y(@FSCN&K"0!+HO+RTCH:0)Z$-CR2<9<=8B*3 .4
M                 '7-6&VP
M         "A LVH;4/G\32-\D(3)27@    !AY$(G67
M $'3)#T0            4-&GT0/0
M           .,XC0AH4ZIM\DN=XN+BTQ,^?QLDUF2G)#G(=<B"3#+P
M            6E05+05*@     '7-6&VP
M                  "A%@C*>H<!]$"+Y'@FR;S     ,/(A$ZRX
M          @Z9(>B            "AHT^B!Z
M                   !8<1@!G9PFJ#;YV"I4M.$PPU29>;8.8Y#KD028I4
M                 %I87%Q0L+B\      ZYJPVV
M                          #ID9S"22IGI!,VP27.4     P\B$3K+@
M               "#IDAZ(            *&C3Z('H
M                         %AH0AX?0H\X^?Q)<E<7E2PH4+BTN*EQUR()
M,4J                  "PXS3!T2IZAN0O      .N:L-M@
M                                  H  6%Y4     &'D0B=9<
M            0=,D/1            !0T:?1 ]
M                      L/G\; )9G(: (N'T?.Z7@   '7(@DQ2H
M            +"TH:[/4,P+R\      ZYJPVV
M                                 8>1")UEP                 !!
MTR0]$            %#1I]$#T
M        #C/GZ;4)3%30Y$\^DAW2X    ZY$$F*5                  !8
M4!KH]0S$O*@    % <!JLVT7
M           H4!4J      ##R(1.LN                  (.F2'H@
M       H:-/H@>@                                           <)
MH$AV90<QB1(TEH<A<    =<B"3%*@                   M-<'K&9@
M %I:<!JLVV7%2H                                             +
M(BV9%6ZCV@"H    !AY$(G67                  $'3)#T0
M 4-&GT0/0        !0  J                              "A0L*&H3
M3)U3;)O(Y#D*@   '7(@DQ2H                   +37!ZIF8*@ % 5* H
M4.@:E,0-D&SB\N                                             !
M9+$TCLE];7) FU3NE0    8>1")UEP                 !!TR0]$
M      %#1I]$#T         8>1Z!FIOTO
M   !QG >">B>@:>-9F<&\3M N    .N1!)BE0                   <1KD
M]4S Y"X  M+2H*%#A-+F$%0;H,\.4
M              %);8\NS5M1_-,&3&^"49WBH   ,/(A$ZRX
M      @Z9(>B            "AHT^B!Z         /)(U&LB6AL$O
M                       !QFD"&1-T\\A.=@X"4!*<N*@   '7(@DQ2H
M                * P\U,<YMHR4N*EIPG">"=0\@\\\L\T\HZ !0SXW0<@
M                                            +8QK-TIN:6-<F4FV
M#0Q)PDV5*@  &'D0B=9<                  0=,D/1            !0T:
M?1 ]         %IJ(T831*@                              '&?/(R,
MF*0S,'/H>1N-'GT5.P7    '7(@DQ2H                  +#RR.YU2AZ1
MGQYIY1U#Q"A>7'H'J'I'L'H&+&!E2AL0V^<P*@
M                      LB#.;K'<W8;Z-DG,0]/7)5EIJ4P(RPW*=@N!AY
M$(G67                  $'3)#T0            4-&GT0/0         -
M0&C":)4                               \@^;9,PVF?-HW<3+-6$&#Z
M7'I%P   !UR(),4J                  #A,1-$E2A4R ]$]L[)D)V#USME
M3D*E2TXS #&SUS5YLDVN7E2A4
M        %D:]SK*]Y]0J >4<YZ!H,AN;?C6<;\TEL7 P\B$3K+@
M        "#IDAZ(            *&C3Z('H         &H#1A-$J
M                       =8^=AM<]PBT3=-P$1359]%3G+P   #KD028I4
M                  '&>"1Y*%#VR0IV@      "PQ TF9J;=.P7%P
M                                     +(AYG>K-X J<AFY,@](T:8D
M2>B+$:(T^CIR@P\B$3K+@                 "#IDAZ(            *&C
M3Z('H         &H#1A-$J                               6$<R(AQ
MFRR>1$DCX2P)+%Q<    =<B"3%*@                 H#@-%GDF2G,;+/:
M+@      "TL/ -&F1FYCL'("H   * J              "A0 J"H
M           +(CE-1WUG<9X9J4W\FBY9"V29$H\T^?1L:II@&($0B=9<
M              0=,D/1            !0T:?1 ]          U :,)HE0
M                            "PXS7QXYL\[II4H;I.8     ZY$$F*5
M                !8<1J0P WZ9 7EP        !8> :,/8-X'9+BX  %H+0
M<@              /+,'/$/7/;,P.0J                   6904TWO6\X
M$*S;:8GG77UF5XS?#J$-8\3U,F-;$<#SSC)V%P                 !!TR0
M]$            %#1I]$#T         #4!HPFB5
M          +2T J "I<     =<B"3%*@                H5.,UF:K-X&8
M@N*@        %I:>2:'.T;T/0+P5 /,-4G7.<]DVB     "@*@H"H     +"
MAK4V"=D%Q<    "A4H"H           !9E!'2M;TCRR*A*!-!S6\KF44=&6"
M%>/4\#)BIYAKDQTT:3L+@                 "#IDAZ(            *&C
M3Z('H         &H#1A-$J
M   =<B"3%*@                XRAA1I,VX;$.4J           4//-('GF
M\CV"XY "TZQK$ST]([0     .$O*@M!>5     .B8V8B92>L>V<A<    6EA
MCP*E3WCF           *&'$(3#RAN DP0^)Q&2$4R+IML]T]@E\<@,/(A$ZR
MX                  @Z9(>B            "AHT^B!Z         !J T83
M1*@                               H5        !UR(),4J
M     (4 *%3B,2-'&R3:A4Y"H          !0L.L:1/%-Y'OEX*E#C-6&PST
M3D     !Q&MCP2TN-M'HE0    #H&)&+F1GK&3%Y<    6EIC!Y)U3(#)CE
M          *%IXYB)<9V=DL.0H1,,5*@]@F$<H,/(A$ZRX
M    @Z9(>B            "AHT^B!Z         !J T831*@
M                  '&8,=0 %2IV3."\N    .N1!)BE0          =,ZX
MI'8CL1R4H"TH>$:',H-RG9+@            "TZAIDQ@W@9(#F*%IJLV">D<
M@     .(ZAXA@9M0[AS%0     #61L([8      *'@'0,O            *&
M,$$# RIMTG >J6@J5 +2A>##R(1.LN                  (.F2'H@
M       H:-/H@>@         :@-&$T2H
M  !QGSI,(+0"I4S ^BYV"X %ICA[YS ZY$$F*5          !CAC9CVF199%
M&116JT!8>>:$.^;T.<O*@            %#B+#4A@)NHS4O.B:],?/9/;,\
M    !84/%->FW2AR       UD;".V      4*'@'1,N*@           M(5F
M,$J3A(:DBB30    !AY$(G67                  $'3)#T0
M 4-&GT0/0         -0&C":)4                               XS5
MYYQ0%2I0[AM$Y2\ M-*$(3Z,&9%3KD028I4           &L:V9%T(4J@.F:
M./*) 'I%0              "AP&K#6QN<S@L.F8692=\]       'AFO#;X
M      -9&PCM@     M.(UD= L/2-EG9           +#Y^$BC?((A'(2\
M   ,/(A$ZRX                  @Z9(>B            "AHT^B!Z
M    !J T831*@                              %I:6G :U/ * \<D,<
MQ> 8T?/PQ8^CQF14ZY$$F*5          !0&LJV7%T(K2K2TTJ8F;]/7.4J
M              4.,H:V-6&UC8I>8$9@=TY       >&:[-P%"H      -9&
MPCM@     M*%#PCH&6%Q<           6D/S5I*(\DBV2D)$     &'D0B=9
M<                  0=,D/1            !0T:?1 ]          U :,)
MHE0                               "PBD1?+@7FRB?!SEQ:=4@X;"(N
M'T=,O.,ZY$<F(<@          -<UC>G0CN1ZQM".8J<!JHUN;T,O*@
M   %IX1TRH/:.Z7@  %I88&:>-FFS#!C,3N'*     #A,1,=/$,I,[.X5
M   -9&PCM@      H> = R\           0*5XA#$U0=HW83 .V     8>1"
M)UEP                 !!TR0]$            %#1I]$#T         #4!
MHPFB5                                +#YZ&S3H'2,W,=)@G*7%I&P
MU82B/GH?0\J:"+#Q";!R           U+6-Z(1WS=1R0-=&GC=9FASE0
M     "PQ@\PQXR0R@] N   *%I:82:8,N. [)M,]\     '&=(\LQ4SL[QRE
M0     #61L([14      H> = R\           MS>LEE*H>"=H]0Y3M
M&'D0B=9<                  0=,D/1            !0T:?1 ]
M  U :,)HE0                               "P^?1N SXC$2<(8'TI.
M\7EA ,P M.D92?2$O.N1!)BE0          :GK&-$5COFYX&'&DS:ILXN
M         .(P V&5     *'$:[-0'JGGGO$@@ 7E"X   'EF&FQ@      6'
M&:W,_.\7      %#P#H&7@          %N;"DU!J  5)%$K     ##R(1.LN
M                  (.F2'H@            H:-/H@>@         :@-&$T
M2H                               !QF@"))]"#Y\'EFP#Z"'*7EAQ Q
M8^<9]%3-2\ZY$$F*5          !IJL:TORZYZ1[1E,::,]-MG-%0!0
M     XC #894     H<9K@U$>L>:#)3WSVCUS)#G.4   'EF&FQ@      =<
MU@8D=LW >R      4/ .@9>           4C4E8J "I4SDV6     8>1")UE
MP                 !!TR0]$            %#1I]$#T  4.B=(J     #5
M!I<E^      <AZI4J                        #B+3##,36AJ\WF9B  6
MG0-9FR3T2\ZY$$F*5          !@IKT\\S,[IYYC5<)MZ,B&7(7%12@
M     .(P V&5     *'$8^: /0///;,A/'/%.F7'I'J&1GMGLGN',5/)-4'1
M,Y,_.4H5+BPJ6%3C*EIU#!:UX=HXC(3<L7%"\O    *'@'0,O
M!0H4,#-+'9-\&2%X    !AY$(G67                  $'3)#T0
M     4-&GT0/0 !0B*:7.T     "PL.8      \H^AQ[Y4
M          '$>$1<)4'6(?DL#-@ "TXRH+B\ZY$$F*5          !CAJHYC
M=QU301V:RXQ4R4S?+WB\J!0         '$8 ;#*@    %"PM,/,%.Z;*/4+
M= \,\(\4\8Q\L!ZQZIYAY1Z!Y)M ] Z9QG6/,.D4*'A%I8"VJ'LGF'(9N9+&
M3'KG,    4/ .@9>            6FJB"AZ!P1WB?U9:     8>1")UEP
M              !!TR0]$            %#1I]$#T  4(@' >T     4!4
M    M-1$Y#)RH                        .,AR:8)]G*09/<)Y'.7
M'7(@DQ2H         +2AK,XSR3;1I$\DWX>D>&8+6/QDQGIZ1<"A4L*EH.8N
M      .(P V&5     *%@*F F8'<+@7@  ZIY9Y)X)XI@AR'H'CG=.<]$Y2I
MVCW 5/9.<[!U3!ZZ!<#C. X3B.U'N&2F2GM'8+07%I<>"=(RLJ7@
M  %A \S<E><$0>-A:2S@    ##R(1.LN                  (.F2'H@
M         H:-/H@>@ "A$$ZQ[8            +34).<R8
M           L/GH;_)#%35I!D^E9Z1>    =<B"3%*@         XS@-*E#'
MCUCQC>ID)4H6GC5@%>"95&<QZP.,UT>4<IZYL(O      .(P V&5     *'&
M8R88= [AS&SCL'*  "PH"I8:0,1/0/--^GOG,5!:"A0Z)C1BAY!2K04.<R@\
MT\TZL<9:<)4]HR$]\]XJ:S.L6G:,\,A           +#Y_F^20Y6(:'H5+T
M    P\B$3K+@                 "#IDAZ(            *&C3Z('H  H1
M!.L>V            "TU"3G,F                         .,A"8\2C.<
MCF8B?0HYRX    ZY$$F*5         !QF)FJS&R@,_-RG(5 !0QPP \:LP,V
MCT2AAAZ!DA<7@    %AQEA@1L(%Y<4+2A4 M*E2PPNM= J5-T1WR^JQ:7%P
M +#H&LSRC/S+SD*E@*G3,7K%CPH[9E!EIXQAX!Z9LPY"TZAXIY)YIY!YIQEA
M2O6T\DJ7E(V;EF0          !:1P(HF[3H&G2=1MD     P\B$3K+@
M            "#IDAZ(            *&C3Z('H  H1!.L>V
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M(>B            "AHT^B!Z  *$03K'M@            M-0DYS)@
M                "PM!0ZQAQYYL [@+BX    ZY$$F*5         !YII8]
MHUL"IM$VH<@   !88K6!'DE:J4-M1W8     MK4%<141ZA[)USS3IG$6@[L<
MIZ)W3M5YQBH*%3*#H'0.J7G;/9CU#T3UST#F.$UJ=:NA7JQEQ:8P8T5,D,H,
MECE*@        H5+#R#314IHK9F&9@         %"I0L/'+0#N'I     &'D
M0B=9<                  0=,D/1            !0T:?1 ]  %"()UCVP
M           6FH2<YDP                       !QD4S:AK4Q0J5*'NDJ
MSF+@   #KD028I4         &!&+FT2-QEIE1L(YCE*@   '$8G6LJI505
M   !0H5*P.Q'L'?.\>B=B/2.P<Q<5!0QHP&A<<QM2.<XSJ'EUY$>:>.=,ZIS
MG=/0,<*; <I?E[YEAD,<Q4O*@         %AYYJPH*I6Q,LD           +
M"-Q$LL )*$MP    ##R(1.LN                  (.F2'H@
M H:-/H@>@ "A$$ZQ[8            +34).<R8
M  XR!IO4TR8"6@&5$\SG+P   #KD028I4        '&6FGS+CQS7I(PY05
M   .,Q,UCHH4-QY>A     %AI4XP#+#9Q>4*@   H"H* J4*@H5!0X#K'A'E
M'D&-E-@,S-AX=D             % 5!0J          "@*'S[-C&Z0#)3,@
M   ##R(1.LN                  (.F2'H@            H:-/H@>@ "A$
M$ZQ[8            +34).<R8                        L. O+#D*@%
M7EX   !UR(),4J        "T\ U.;D-!&PC:       .(\@PNJU:5-BY=L
M   L-=G7!0]\R\N           !0H6EIT#2Y;H+C949E%0
M            "TZYQD5S(R0H*G(=D     P\B$3K+@                 "
M#IDAZ(            *&C3Z('H  H1!.L>V            "TU"3G,F
M                    .(P8B^8B5*&3$W3F+P   #KD028I4        '$:
M[.F>\:6)('?*@     % 5 !0J     "A4                Z9JXX 4K/(R
MD                           %L0A-/U8=8[A0$D26     !AY$(G67
M                $'3)#T0            4-&GT0/0 !0B"=8]L
M    %IJ$G.9,                         6$#37)L@YBTR(F&<Y>    =
M<B"3%*@        ZAI<V&:K,B-NG*
M  <14J"A0Y"H                          !3+3IBU*  STV>     8>1
M")UEP                 !!TR0]$            %#1I]$#T  4(@G6/;
M          !::A)SF3                         '&0(-U$BB\N*%I>7
M   '7(@DQ2H        ,5-<FQ30Y(@]<Y
M       4*@H"H                           *94*5$ZMJFWBA&T[)(L
M    P\B$3K+@                 "#IDAZ(            *&C3Z('H  H1
M!.L>V            "TU"3G,F                         .,CN:8)+'<
M*G;-@%Y<    =<B"3%*@        U,>B8T<1NTJ<@
M                                            !0P0C0NIS*DRL&MS
M<)+T %AKPP0D 5 ,/(A$ZRX                  @Z9(>B            "
MAHT^B!Z  *$03K'M@            M-0DYS)@
M "P^?!K@M* S$^C)V"X    ZY$$F*5       !QG3-*&S31!ODQLU$8*9V;5
M-I'(5
M      !0X"&2Z9/93V@>R2K-B %I@9!<[Y]%BH!AY$(G67
M    $'3)#T0            4-&GT0/0 !0B"=8]L            %IJ$G.9,
M                         6&N#S2H!W#9)R%P   !UR(),4J       #C
M,(,3.^8@2 +BA#DF.6EY>5
M                        +2TUB9*92"AYIZX!KX@ >V=[3Z+Y ##R(1.L
MN                  (.F2'H@            H:-/H@>@ "A$$ZQ[8
M       +34).<R8                        L-;F2&/G0+@#M&PSE+B@*
M H"I<=<B"3%*@       X33QE!J@VD; *'$04)P'J J
M                                             "A::O(@G7!8;E);
M@H828V:7-5Z?1?(4!B!$(G67                  $'3)#T0
M 4-&GT0/0 !0B"=8]L            %IJ$G.9,
M  6'SI)#FBC6Q: 9B?18[)<"TX#RCNG:+SD.N1!)BE0       >&:@,N-8DC
M3L TX0;)FF_RH
M               !0H0&.:,#-QUJDF";C!0%"'QJO3Z+Y#41&XZ)WB=A<
M               0=,D/1            !0T:?1 ]  %"()UCVP
M   6FH2<YDP                       !::W,C/"/-*%0=PV$<Q<4/'(,&
M 'H$SS;AR'7(@DQ2H      +"IKH\LQ0RHVT5.$^?QKDR<GB9B5!>5
M                                                       !8?/T
MD-&M:W(>.802T  (>&J]/HOD/,/",8(TDZRX                  @Z9(>B
M            "AHT^B!Z  *$03K'M@            M-0DYS)@
M             #C->'6  !VC/B\Y2PU 1;)T$.#D)O%YUR(),4J      "PX
MS2A[YJ\D4>R#2Y!LXRX]$E"2..R<A4
M                              %"I:14-(5)^(H1Q5(8E6 "A#XU7I]%
MLA0&'D0R=9<                  0=,D/1            !0T:?1 ]  %"(
M)UCVP            6FH2<YDP                       !Q'SI,(*%  9
M@?1D[)<6@X3K$#S:1*HJ=<B*3".0      '&8X:R.H=\W4 0H-4&<E3VS59D
MY,4V"5.0J   <9:4+RXN
M              !0ZY@YF9&T\$E6>F "AH PDEJ5 ,/(A$ZRX
M       @Z9(>B            "AHT^B!Z  *$03K'M@            M-0DY
MS)@                       #A-7'0+@5 .X;/.4O .B0P,<)S&!$82P]0
MF^<H      .(U<>:8&;],A*&KR"!-XW,5. \(B(:=)"$J3U"H  !Y)I@Y#<Q
MZ)<                                                      <1H
M,Q(R$W\=TJ5     !AY$(G67                  $'3)#T0
M 4-&GT0/0 !0B"=8]L            %IJ$G.9,
M  <10PX[!E8--&=&5E2I<4.$AD>432.\<ARG7(A$PRX      '1-+G5*&_BX
M\L@&9B37.P5+"XX331$<[!+DV\ <A4 Z9$$J2\.T7@     %"PN+@
M                                      4S=$5"K4R/+':DN2RRNTJ
M    ##R(1.LN                  (.F2'H@            H:-/H@>@ "A
M$$ZQ[8            +34).<R8                        X#3A"<E$2;
M. ^>9CI.XV07%Q::<(+G>.<V\36.0ZY$$F*5      *&$&O3&3=)FX(H$>#Z
M'F1'* #C.,\LB^1Y-V$K#(3G+@#@/$+SV#D+P     "T\0]$[@
M                                   *8L.C$^DG7E%2-8:3^+BH
M ,/(A$ZRX                  @Z9(>B            "AHT^B!Z  *$03K
M'M@            M-0DYS)@                       #C/GV>B38/<*F'
MD'C)R<Y>7%#!S!@5,@-H%3KD028I4     %I0U(8R= D6<I@!\_B8IOLJ7
MH4*%#6)#@\XE.;Z+CF*E 6%Q4J      8(1T,Z)!'8+@
M                            6Y06S>WWDW>;0<1\TG^5!<     8>1")
MUEP                 !!TR0]$            %#1I]$#T  4(@G6/;
M        !::A)SF3                        'E'S8)F&ZR\N.,C(:#/H
MD<Y<    =<B"3%*@    %"T\DTP> ;2-CG1(#'NDY#N     ZYT2,Y&TVL2L
M,[+P        #JD9S)C>I<<H
M        BT@MSU@_HSMK+#,L)K=(-LF\     ##R(1.LN
M   (.F2'H@            H:-/H@>@ "A$$ZQ[8            +34).<R8
M                       X3YTF_B3(+BPA^8(3Z.8J    =<B"3%*@
M XC!#6AY1(P[I'$BP?0LRTY     6E"A@Y#\U^2I) F@3KE#TR0I4      H
M6%Q0N*@                                           "+2(6;JWI
M@ ;Z)+@    &'D0B=9<                  0=,D/1            !0T:?
M1 ]  %"()UCVP            6FH2<YDP                       !QD9
MR+Y) RXL,"(\$Q3?@.0    ZY$$F*5     !US3!BAFAN P@^?I+0D0"\
M  '&6'6-$D23*R4!KLR,W*947@
M                   H6%P !0%X    !AY$(G67                  $'
M3)#T0            4-&GT0/0 !0B"=8]L            %IJ$G.9,
M                  4. BJ1X/'+CW"29)@YP5    .N1!)BE0     8T:A,
M?) GKD&#H$]#N J     "TH5*&)$4S2AW#.R=QW2I4H"I0J5+@"TU@8T5+#:
MQD!<     "PH"I>                                    "A4  %"H
M    ,/(A$ZRX                  @Z9(>B            "AHT^B!Z  *$
M03K'M@            M-0DYS)@                        #C/*,?+#)#
MTB\O     .N1!)BE0    "AJXP ]0WN: (@'T$,[.4        '"4(<$?BID
M!DIL(S<R8V0>D<Y><A< <9JDQ$TR;O-LF1EX    !0X#"#-R\Y0
M                                     8>1")UEP
M  !!TR0]$            %#1I]$#T  4(@G6/;            !::A)SF3
M       H"H              !: "A4%P    !UR(),4J    "TZQI0Q4W:=H
M^>!(PE25+@        <1TSYVF)%#WC>I@9A!Y9U#*C)S/389EYF1ZAR%3PR'
M9-TY"XN     *&K2-YN$WX<P
M          ,/(A$ZRX                  @Z9(>B            "AHT^B
M!Z  *$03K'M@            M-0DYS)@        6&-F.FQ#D*@
M             ZY$$F*5    *%AB)JHX"0!",QDG^>B         #B,1(B N
M.R3*/1*&/F.&LS#3$S79U#C,G,E-A'GFA"?AL4O+@    "AX!I8SDV0=@
M                                           &'D0B=9<
M         0=,D/1            !0T:?1 ]  %"()UCVP            6FH
M2<YDP       !0Q@B.>63',L*@                      ZY$$F*5    !
MPFIC"3:1B1"HGH;-.0         %H*@H6EY0H 5* L,9,-,',),'-9@R(W&;
MB-HGIE2I0N+@ "AQ%0#E      !8"XH7       M!4J
M            8>1")UEP                 !!TR0]$            %#1I
M]$#T  4(@G6/;            !::A)SF3        %#@(OGH$E2\
M               ZY$$F*5    !Y1I8\PW.?/@D 2I+CF
M  !0L*$92)I87&>GBG1-@&WS;QF)VSD  !8 "\      '">"9 #D      !P
ME2\N                             ,/(A$ZRX                  @
MZ9(>B            "AHT^B!Z  *$03K'M@            M-0DYS)@
M   4+ 7E0                      #KD028I4    H8$:S,N-(FJSZ"'K@
MO                 !0%A$@U\6EQ(0W28 :<-.F'&2&US;!M$]LJ5,>(X'6
M.0RXD4      #39ILW2;;+RH    !:8P:?-F&>%0     "A0J5
M           ,/(A$ZRX                  @Z9(>B            "AHT^
MB!Z  *$03K'M@            M-0DYS)@        4*@H5
M         .N1!)BE0   "TTP8N>R0O)U&USG                   !86%2
M\M.,O.4L.N8T:N-1FJ3HFPC<AM<S4M(B&^38IW@      :Y-%D@#-#E*@
M '"8,1")!&^"X      M*%Q4                     P\B$3K+@
M          "#IDAZ(            *&C3Z('H  H1!.L>V            "T
MU"3G,F        *&"$-3A-MDKRX                      '7(@DQ2H
M+3Q33)4C*;*)F%Q>                   "TH5+BA:"\H6E"H.H:_-+&K#!
M#V#:QI@W&3+.V7EA<4!4J7  M*%A0H7G*     #C.@=$O/:+BI4     XC S
M+3T2XJ                    8>1")UEP                 !!TR0]$
M          %#1I]$#T  4(@G6/;            !::A)SF3         ZIK8
MC:30/3+@                      =<B"3%*@  %#BK6I@9J0U['T),@
M                        !0XCC,=-4D7S$2X] R\S8S0SHRTS [!:=@ '
M$4.0'&#E*@    &&D3SS3NFTR1IREP    !@9% V&2@+SE
M      ,/(A$ZRX                  @Z9(>B            "AHT^B!Z
M*$03K'M@            M-0DYS)@ "@!4    %I@)& F\"H     *%0
M          #KD028I4   '4-,5JXCZ36C=9R
M    H6@XC'SYU'EEQGQN(P,Q$Q$';,Y,H-BF<&3&9 CR:U/.,C)2GN%Q0H7
MM*%Q0\(Z9Y9KTAN;X)>'H%Q4 H7%"I4J =<UF<ILHO+@
M   ##R(1.LN                  (.F2'H@            H:-/H@>@ "A$
M$ZQ[8            +34).<R8  XP      8 1C)M@     %#D*@
M       '7(@DQ2H  !0P^M2$6C:I-..0Y0
M  4.,UJ1R!<>\2T+RT\XP\PHP(PHQ@PPM.^9X968N:\)6EIP'EGF&-%A4Q4Q
MHM*'7.(XRA:7GI&:&9&>F>F4F4G*6@O+P"TL*G(
M8>1")UEP                 !!TR0]$            %#1I]$#T  4(@G6/
M;            !::A)SF3  $:2/)S@     ZAXIDH     !SGT'.<
M     H6E2A4%2IUR(),4J (0+16IJCF:T/H09."\           %I4ZP*%YS
ME0   4 *@       H4*%X+  "A0%Q0H>08H86:V-8F  [1EI<<I[!FH!D)D9
MV3LG</5,?(8G$5-B&P#"#$#&BZO2,Z,TC-S8QDQ[X- '@GE&9F^3M
M             &'D0B=9<                  0=,D/1            !0T
M:?1 ]  %"()UCVP            6FH2<YDP !$\Q0RT            ',:2/
MH:=@            M.N=<QL]X]0'(=<B"3%*@"$"P\\CEI%<F0;Y.<
M #( *4 !8<9@)Y%<A[!GL7@  "  %                #A(5FABAW3Z%F=%
M#B+SD*@  &OCQZ\0]@Y(V@7' >682868*8$8T8P=P]<SD]4UZ>&3U,_.<
M            %"I0 J ##R(1.LN                  (.F2'H@
M    H:-/H@>@ "A$$ZQ[8            +34).<R8  B@8F9:5
M  .8TB?0T[            !:>,00,9/0)W&8%QUR(),4J "V!96"D'3+2=)S
MG(     "A0J(9"TN&B@* L. ZQ@]=\RB.^<H  *C) "F@H5*@      M!4%0
M     <9% \ %Y(0V05+2A>"H!0%#JG5K6IGIZ,=PN R10%:XM/ -?F*F!FJC
M% 2L)/G(               4*%(UK6FC9QN$O ,/(A$ZRX
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MBA[H              !0L-?90"VW+&G299O0 P\B$3K+@
M  "#IDAZ(            *&C3Z('H  H1!.L>V            "TU"3G,F
M(G&*F6E0           #F-(GT-.P            6D2C!"=A#0\PF^#KD128
M!< 4/&K3Y'0P$W;$DC(P     #C,?/4.B=0Z.GG' =<LRY3F/2.V=\] [!Q'
M3JAW@<9YE=(Z<>9'$6'(=NKSUCLQZ)V3RS("\      H#P3TSME0     5*'
M2/*.^><<!Y1P'4.$L.P7GK:=H] [L=X\J+*'HQQ'$>6=0\ZNL=8MCF.V5/9.
M C@>*>P>@2A,W  !>5*@           L(H9:1V^CD07*DZP##R(1.LN
M             (.F2'H@            H:-/H@>@ "A$$ZQ[8
M +34).<R8  B<8J9:5            .8TB?0T[            !:0X,8)UD,
MCR25)HH'DGL%H!4[IU"-IP&_#.#I      &1&:F+F'@J ><=0YCG!0H7%3/S
M$SMGN&"% 5!:<!Q'H'<!4H5,V,@,,,;*@     '?-C'0-;%X     !:;(.^8
M&>*4*@'D' =LY"I0H#T#-3 #8!Y!B10 J5.F6GK'*"I4H;,/:-.'E@  J21/
M?+P           61!N7S^O.>G/46,ZT%TS](CD@N($0B=94
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M=)>5-LF\2X          M,5/GP; -?$XC9AS   %IY!#8\4ZY[)+ SL
M'5.D1N)'G>.P7@     XR/9E)M\      H=(\TT^;G.^=@N     +#RC3YLP
M]H](     '&=,QHU@;M/1.8     %I:1+)9EQ>     4+3SC##RS8IZ1R
M            %"V(AKJK6/HCG4*Y<=WF>T>1+A%5 *       &#&FB3P
M            /!(RDMRH     *@H         :X-4$G@     "I0   J4
M  !B!H8E0       4*F7F0E0         "A88H:H-BF=%YR   %#B!4H7%AS
M@     M*%A<7 N     !86'*5      *%"AQEY4N*@     XRIQEQR@
MM!:6EY<5     !:4.,O+RH    !0H4*%"XN*@               L-&D,R5Y
M&,D74H<JE:        %#6)'PFD                #%2&I/(N
M     !0U :.)H%0               4-?$82;Y4      % 5
M
M                          !0XB-1IDSLER=N+A0        'EF%FR
M             "AYYKDVL5               !0\<P,VH5
M  /.,&-DE0                           4!0%05    !0 H7      M*
M@ H7      H "@+@     "TJ4*E0     6@N!0H7      M*E 5*E"H   !0
M J4*%P               !0H"@+BA<      4*@  M!<
M4*%2H                +2X                 H5
M           *'GFA#P3=!GA4Y0    <!0T<>D;G     !86F,&B3B-YF8EX
M   !QGG&C#'#<YGQ<<@    !0XCJD=#:YL0     '"8T1]!S$D#UBH    !P
M&"&F#)#?1SEY4    XS'B.X!<20/;                       -;$*B4AO
M8\X@(2K-R%2@*&BCQ3TSRB20!4   H5 *'&0.,Y)=%3%""1*,WL5 *&I"(1/
ML]PN*&&$&B<QF)4J"T\T^?A*TW25  !0 XR'A0F06&D"+9V"7!M4\\A>8&;7
M)?'9         !@Y$(Q<RTF89$:?(E%Q, VD>&0U,*-I$OCN@%04*@
M                  H1;-$&RC41]$SUSE    !TR/1$HD(3!*@    '&<1\
M\#*#F,./H:=X     L(K&BC91J4^BQ[!>     #A(R$429Y(      '&1X(C
MF?';)O'N      Q$^?AO(T>2I)!%Y4    L,1(6EIXIYY]#S(
M            #52P",AL^B:<V-?-6IF6;V+"P%YJ$\@[YYYO0Y <1<7%I:7%
MQ< "A:1)- 'TC/3B.2Q)N?I"9$MA0O*FE2#I]*3WB\N/-RUI&S-O1+2TJ7GE
MY?,K2:!OO*S2PN.0%"L6QX)$RW02;DZ2=?.8^U\X*DP8>:VL^C&479K0.\RZ
MS8:6RSN)"S5P.('(6ED<A6N,H786Z<E7  IE!ZL1)7U$@SYF8&=_.34W^>7)
MJ'5^C$1EC0VDMXA83&-\%!%A2N0M+3E*%A0J43D*K4
M  ^=QO\ )!'S<)E&Y3D    !&XT =,VP3$     !8=$TB;=,4('GTB/;
M +#'CH&!D-CZ-GM%X    !0U<0Y,9)?F_P      '$0R,=)/F='J',5
M(U&J25YYAE1[YRE0    "PZ9!,D0;O.0                       U4L C
MGLD DLL:^:U3-LW00N-?G7-TDN2'QY!MLCL3^. ^?Q*@V,0L,8/8)F&=%2H
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M0XR(IJPWP1<-QDP#U#F    !US'3TRT^<!,\W2     "*1JLGH0H.P37+RX
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MVSD      .,@(23-V      XC1I%,Z9(8D^=DJ     =(B :9,N)FF:%Q4
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MU*Q0C#RU%WT8V+&-RXN?2PTP1 K+HNSK$MX^DS/M9VH
M  6G$6G2/2!4O     !QE#E     !QEI>7EA8<A<     6'$6'3/1*EQ>
M   4.(N.0     '6+S@.([QQG.5     .(XSHGH%Q<7%0    "TL+RX
M                   Z!C)E9V#JF,'OG>-6F,&Y3Q3)CR2PR6*1C-<M9$5R
ML,/K4%9F;9.<  %"ACIT#+3E@<%:C,1-NF9'GF/5EN5YB->R=W+&#)].Q&!F
MJZSHVF5,2/>/1,3-.F6FW#L@%"@PQ^N/3)0><:1KV(V]F=C2U<!-7&X#,2X
MB4:0)@&3G8LRC#5FM>4FPC6Q$+6?I''J352H.$Q,H"AW#)3H&F#G-R';BL85
M6IJW&965$4(P\M::]&)&Y; 7E,L-4'A&R#7N=0^WCZ5IVLZK5"H
M
M                                    !:5 *%0  4*@H"H*%2@*@%0
M  "@*E"@*@H5 *%2@*@ J "A4H4*@J  "@ !0%04!4 %0")1I(^CQ<5+2)1'
M0V48<;/)L%P*@H 5 *% 5*%04*E"X IA&#+3G5/\N!:1)([FR3"C8Y.0O* J
M                                       4!4 H5      *%0   "A4
M                                                     %I<
M                            4+2H       /(.D9&5 .(U48J9>;+.T
M          "D>8=.O?*@'":U,*,J-H'<*@
M            XRPJ"@.0O+#C.4N    +3B*E"XY0  "AQ%Q4'&#G
M                                           *%0 "A4
M                   H1]-!%"H     !0 J "A4%"H           * J"A4
M H"I)4W2"X                                      '&:N(]&#&P20
MQL@O.D8X9>7    %I'\UZ2\.0Y 4*E 5*$;#7I0J>Z;[,^   *  %2A4
M                                      %"@*E2A0% "XJ
M                   #R#S         5!0%04             *@%   #VC
MOE0                                      #&#YSFPC;YHHQT^AYZ9
M $W:2>+@6E2I0J5+00X-*'TQ *EI0N*G*"#1J(VX#!SR"?)FA>6E2H +2XH
M<P                                          .@0,.(FN9>1^([&S
MB7!!@W&2'*E0                            4!4
M%"H         !0%0                                       :<(*$
MVC=9B!I WV:*(IFRR11QF-$F3HD73<AM$U\:(,@, -1'T*(WDB3+S6II4E">
MH<@(-&"GT?*'AGST-N$Q#7II(X#81O$CT<Y(,M(K&Q3<QRE0
M                             #S3YE'5J99(*6"III-R$ZR*)LPW*4*@
M H5  *@                     % "A0O*% 5!4% 5 * J"@*@       H
M"H    * %"I4 H 5                                       !XQ\^
M#$C.3;!OTS<B 1Y,P)#FO#71]&#Q#YLDL#=Q\]#*3/#1!Z9](3YS$A23Y#(P
M8^@AS%X(-&"GT?!:0G,')[GSE-I'6-1$\C61' ^D!B9\]"=QM<Y0
M                                 "AYI\RSUJVH3(CYR+UTV23K(*&Y
MB0YH8C(<)(TD48P0V,5-P$L3N%P                    !0%(QDT-7C&]#
M81'L]LW28 :TLD9FJCN9(;D+@6FES4Q<;6-P'9*E0    "A0H1WC!ZY#<1MH
MO * I%:J#"".8,L-W&3%2I4 H5 *%0
M      "PQLCH:@,(.8G>9T?,LE22?(6&N3Z,'B'S9)8'J$-3Z*&8D)#5Q]+R
M(!K0GZ?.,DN21*G*"#1@I]'P6$,S41]'# SU35A$ F&;3/G63I-=$>3Z,G<.
M0                                          'FGS*K>$FK+J9\0A-
MC'(DZF?FNU((WN?.XE*9 1E)K$1CTR1)$$DCI(S"Z@
M  !0XLH"FR-/5(U'T3(=&N#Z(FKXCYZL3P\F_'T^<!DI]##L%01)-1&V34AL
MHF07'1.R<@. XSME2ATSN%Q0I$%,=+/3RS3E=$DR3<YURXYBDM,YZNKW*J:C
M(0D@#P#71]"6?2:ZIRG."XH4*@J
M    :H,$)$%QAQ 0W42S/F22J)/D*S7)]$CQ3YODL#N$.SZ1&3$.32A]-37)
M  F&0\/HR9< "#1@I]'BAPD"CMDQ"$1B9EIKTF(2#(#F=FMC:)+DJ
M                                    >8?,HEHD3[K<L>,>B==)U,_-
M=J0)E!#L^FIWSB/+/FB;.,L-2F?[3IYKZ                      XLH#'
M<TWT9R9F0B-9FY#;T1_]6)X>3<>M--F)$QC:)<")1Y9,@UT0./I01&,4/")C
MF+$<3E-K$C2#AWSE)M'<*1!3'3</IY;MY6")(@Y#0)U25$>=FQDUGI5/Y?9-
M3$.CZ.G$?-PFPSIYK S%26Q'4DH6$?R;9<5
M            (_D-"6QN@U\0K)3$ASYHDBR4Q$XT,?1 UH0I);F;D#2:AM8@
M:>"?34X#YWGAF?$\3F !!HUP37!K@BH3-/#(GGT!,<(.$PR0I'HB>= GV;,
M                                          !YI\RK)FU&K&M>:S*K
M+ ITZNN4ZE^;"R C-2%M?28]8C.;F/G\2,-S&%&4FURX%0
M      4*1C1H.M0QB]?0$A]6=QH,W1)AWJS.[R;@-IM0PTYB:9<")9Y9,C+
MR 53LJ$*?1PT+-:;LV$:6-N&VX\@B?IOF(^$W#:122"G/MJCOQ[4NPR964%C
M8FG1CRM-Z^>QS]&9SY9$M34I#H^CI0^<9+PH8V:(-VEQ@1W3+R2)4J
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M&*F9'&#G/*/G(26)/'*5
M   .J1Q-P6=3-U5J2"RU<WU;C=A'=<\-H1C-:-+3=)F!T32!X)GIMTN*@
M                  %I%XCN=\RTFZ0N-IDB""AS=,[ Y:\.ID'&0*-VDBRI
M% CT>N4J8L;0(9F I=++VO%(GG9-F1+(@[7E'JDZ#T1E!>:W?Z..^>/1%*T*
M1>TY8E#7#SNN^F9@151J4@N9.>>2/)*$%C'SOFRB6I!P\LGP7
M                                      %IQD'C41(,E\7%0
M<9ILAR<!]"#*#D*@                                           M
M!4H  "I4M*@%2@  *@                     %"AYY:=PYCHG*=DZA85.0
M[90Z10[I<=,ZY0[1V@6'G'8.V4.@6'I%3KG5.Z<P$= Y].Q %#SCD.X<!8=T
M X3H O.^5.N=,[AP'@D+3?I(,J
M               6G&:K.,VB=P%0       <1X)K8V"9.4.0J
M                                  "@!4H5!0J
M             "@*E"H      *%04!4   % !%:H"H *%0  4!4H"H+31)XQ
M(([Q4                                                  H"H
M
M
M!0J    ?_\0 .Q    4# 0,+! (" 04! 0$  0,$!08  @<1$A8V$!,5%R$P
M,30U0% 4(#-@-T$B,G C)"4F@$(GD/_:  @! 0 !!0+_ /PCUK7_ .7E"BU.
M3?E]K+,97@I[1?\ R[E"9"EMUUNQYP__ /+DSDH1QJ.O5OR\0&V_'G#_ /\
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M]H>KY7C8U@28D?%*U+DPO8F*+%S I1]54?T'&D8 Y,G+2)YDH B.X<;_ /N
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MI(6M3M$2;&(_D6)P5)V,;X7-UB0EP(ZN(_M=6\?KJVCX4W0=G:E>S3K&V]Z
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MCJBA!MK\1^(/'N3_ ,$3_E+]2\:G,4%_3Q7Z\&CQ[^1$FGM.*6I:WD!R"/\
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MI*<9Z\NEB";.[<$9RU<-Z)64L(Y;J//L2E3+(JEP4BH5W4UR!:T*(9)+)*U
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M3$% K(_.A.MC%^U89C&8W_4:ZT')<&T 6]FQ6S6S6S6G(?\ @B?\I?#C5PZ
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MR!<F2VID^5%:E*Y?Y&#BZ'7HP[>[/_!$_P"4OA=>0V_FP>WR]P.;6TUR/4Q
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MOT>O+N*-,3&,;Y8X%AR+CQ3I-Y5-.:R]QHE^/)+;WHU4=WSUZ7#>U3X>P?\
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M-Q7B RP8_P F:!#I'"_G^[EW#F*^+/ALN<4-WD/=NW$J#R?L\I<*8?\ 6/T
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M.8KXL^&RYQ0W>0]V[<2H/)^SREPIA_UC]"N'2L@E7E2W$[ZE))R@FM4Q6 N
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M?:( -+&8A0*UH/2B%XV"CD%Q=)UY*KEDW^29@'_L>RK>\N\-=*-'_!C]2U[
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MYOZU&O0ODQK)KD8MDZ-N4N!A.,'<^T<5O-=53S3!C=V0.I=MUI=O='_@B?\
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M69 9T"EFD*.0%+YXT-BH,E,5=9;%766Q5UEL5)L@,ZU0 Z@'V:UK6U6O*?\
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M>T2&\+20 0!PBLG5*]S)G6Y<TK<N:5N7-*W+FE;ES2@ALSM%D3*$K<'NLIN
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M2-=(_,E<B:IG"C:"&DJ1HU!Y44T],'R$:RFQ0MPQMU#?KO=E1]!_W&R\1NB
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M![-^3JE2_']/-+.<N.%QPN.%8/N>^LIYM6!A<G5#:@]R"0965-5@^5;BMO\
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M-<XMPEJ_B47R%-D_:,>7]!44-[EC0+]X8ZB)KV\]D>YKT\I])QNL5+/W2_\
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M,G,BB=/%K#FK#-&8S[0L$,9D=S-"QS-[GB8<\>U1TT7%8/&5_NRH^J?4_P
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MYZ3CQC%AYUX2S*EF3F'7YV^G?Q(=2[NJC>!AR;SH-%+'8?TJ2%U-& \6R:L
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M%+QG.+Q^*CTW!!J,7X732W,*20ZFBZF?'F!)I-^K]T[Z*,C_ $GK);C=/_\
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MYV%HV)M-NFTPZ)M@^UR4ZCW,:7-D%B\:TZOJ&89Y!9O1OU=L_!.^B963-O&
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M+R9\9)U2I?C^GJDE286R8;[$#)I&@FV:)9I'#G"BTC9 S;?Q[E5]'^?O)<-
M/CJ_W94?5/J?X J?J#SS\QOU4/5'W9W08XW;%)9JDK:MND#,A&=16B@9HXVZ
MFC4%@>,;2I*Z*(0RQ?8'&5/./0<H7?::#XN3JE2_']/5.2YE"-7"7XK/Q[E5
M]'^?OE7^[*CZI]3_  !4_4'GGYC?JH>J/NSNB]S2UKI+B^U5%)42:-Q<,%]2
MQ,<'#^DK$XV"DH62"26;5@SLJ>#[3E"W[+0/%R=4J7X_IZK@ZZ'6\P<JO_\
MNW[Y5_NRH^J?4_P!4_4'GGYC?JH>J/NQJ4=;!<R0##@YU8W8]NQ!D-?+&T;
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M7*X_]D,3]7L08V09>Q#&\6Z$Q_./&Z6-O@WZRFH)K&[4&N;GK6H=G>Y[]Y'
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MT5%[H>9NP\9$[HQ@TD1XNRR:-R 32R\)X.H(7]82=4J7X_IXQ[O9DBYWXIK
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M?J+C4_ZBXU/^HM=/^HKBHB9T2+EK?U%P*\#\U?Q$?JK^)#]5?Q+_ )5_$?\
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MBK>LG34ML3A;-:V=B9'56LPW%E2^\'U475'?1=1-WISS(*@]VJWJ;U(#]E5
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MLWLUKUK+O'>Y8H:6&VEE=A;=<2G_ %5Q*?\ 56&JA^)F83*BGD,;QKMM"CJ
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M'63M44&YD8J&#8W8HR*70.;M57UE#5PQ7T?'*?2F2T+A>RIZ=CKOB'"3Z_\
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M<("0_]H " $!  $_(?\ ^#U_ M'BW_\ ERXWU@F7REK"9F6<(00__+5Q:@T
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M"W:>0Q_4=GLN%7DH:Q@ASYRBJ.%C. J$E_$)&LBI<X+547!C-R5"LB*PYK)
MC$Y!NI175F$@-KAA@J*P,L,K!Q$Q".^V)J(&'_L#66[\6/>YE)6["<LRX/EU
M8ZG:$@]40DPQBO\ +-3C_FF+UFT:N6_IIQ9'X6\Q0>8,AF9A]1)S"W M$+-]
MT6)1+*9F11457,%&*T2XN/[ PC$\%0IX]ZX_^A\LDP)@N66T\G@C&W'V;?[2
MH57,(?Q4-/@U_1^D& Z2S9I$O?A$0LS*+68*Z3&\,!>]1$U?3[&&!BH182.T
MTWCOMQ:]9ANY^" C!? RE5"75>Q;+.8K.DOW#2ZYC9B_&,1S.J'6#V[9%+J%
MN(?P4M"YMXNZ\RB&F'RB<:AMJ97+0N7I"[H9$*C"$=XX3#I?]9]N8VJ8XH#
M6Q+V X8N8X27YX[9W^",RD[!1&(C%+#+\PH'V",L0&_.:$S+J5G?^T]ZX_\
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MC2+13\1KK]#4J5.BM<9[?.L # WWE*JL?"Z# ]/BI$J]((\Z@&RM%/*PL0O
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MBR[K2H#VS=TM L[=(U<IJQ9R2G)M<HM6?J&>K(12H-<U/M(>IPS!P#43TO\
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M=8HZ=/ ;_KKK&+U:0M:VE6*2N!KXE_,[UQ_#\?#^S\?5LTN["=FX^D7+E_T
MM2MU,6FNL(BLE(G,W2-6K[QI"K.XH?$<?H5-:C]H:M2@XE@MX.?E=PXGH/T0
MT_B5IF0=7ZBP.J4A;XFG@N7*RJRLRA65T:LPY8&:AM>SSCX]@-:L%AH[D*O^
MNNLY2>(DI\+S15BQB8YC:0?5$0T81!:4++E_*[UQ_#\?#^S\?5LTN["=FX^C
M-! H%W"+1X3ETLVF<RG\^;T:8JF%P0Z(X"GVE966,8E5NIGRB\)U?_E%EES
M0&#<3[P40%EK(/RW<.)Z#]$-/XD"T+)?+BE^IY1> H4C3K?Q>>I@UN8=953+
M89M4,U:ZL>[ID#1W0QO9X=1IU=9=B._$I?4Q_7F%#PI.4SD@TT&%R&ZS(YZV
MXC_6 OP?0:;%\N@*!WKC^'X^']GX^K9I=V$[-Q]&5P[4_4'L\($[+PM@I7!
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M-+;(3)P Z3/S.]<?P_'P_L_'U;-+NPG9N/A8@8)0>L)/F9D[P_V=X?[.\/\
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MC.^\?R3 5P2VY+#AE>I?=/<<]QSW'/>,]X1K)4"S*[%+&&O Z94&L?Z<'0\
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MX'BOWD#9DKP[AQ/0?HAI\YTE5*++R@L*A^9-8ZT(XJ'=O'"F#HDTJ#-K_(N
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M9LFC'SM!3I*V>HNI#7EK<O6'=%Q # WC60H,'G=',C2>@2UA7G@YH(+1+8N
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MRC_?+2UMZ_.-'7$P3$WI<;6 !37S>!J^9>'06ZU&V@I:@]9;M1QN H-,D/\
ME!0!P8FCYE#EVM*BEMH%OK?E JVJV)EG2XB3,]9#=QO<5_,I+T^T5K YM5LR
MXBQ%?R7K8H,OQ%^-$LE?>:R\X\C\3%.(5H10LAEO)&:M*P+#J%O#TR\;&7G-
M,E5<+0%@EL3PHIIL?,EE3TZD648V&V3 %Q44:>%1UC>8MPN*24&<&U8@+"H8
M)R3.+SA30A\+#4T2INKF\\PK F^DRY>T*4\++-+WG)(^JW8G]<U_)+4(RAE"
M$V,_>(QL*Y\F9<L=5-.T<I]EM$,#7#UF!)7^$<.@V$*$,F=&XMI4R8XI4+X
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M/-&"7*<^%RSP/Z98TB+<P>#]N.9CR-E0RU>9<N*+25;F6W4O4BD+0]86ZO\
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M7/O&"B4%K-=]PP0?YB*I5\17,&4XT*V7CQUZ+^_$;B[+B,<;/2$#0O5F% $
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M*&ET&RW@V]0Y>3([DP\0P(:P"X4AJL2Y+U*B %.!<T>W=FG@KP]3FD7K5FU
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M2222222222222222222222222222222222222222222222222" 2222 0
M  0 ""0 0"0   "222222222222222222222222222222222222222222222
M223 'C""2222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222222200 "22"222"02  2
M2""0"  00 222222222222222222222222222222222222222222222222 0
M!-2"22222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222 22 22 " 00 "00022"
M"20"20"222222222222222222222222222222222222222222222222"!52"
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222220 22 22 220  2 0222 " "2
M0 "2222222222222222222222222222222222222222222222222222"2222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222220020222  "  20" 0"22"0  0 2"2
M222222222222222222222222222222222222222222222222222"22222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222 020"200"2"" "02"02 022""0222222
M22222222222222222222222222222222222222222222222"222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222220 "0"2"2000""" "2"20"0"0  "222222222
M2222222222222222222222222222222222222222222"2222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222  "22 "  "0  "2"  0" 02" "2222222222222
M222222222222222222222222222222222222222"22222222222222222222
M2222222"2222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222"222222222222222222222222
M2"0 22222222222222222222222222222222222222222222222222222222
M2222222222220" "20""""2"""22 2222222222222222222222222222222
M2222222222222222222222222222222"2222222222222222222222222 "
M222222222222222222222222222222222222222222222222222222222222
M222222220 0"2 2 ""202"22 "2222222222222222222222222222222222
M222222222222222222222222222"22222222222222222222222222002222
M222222222222222222222222222222222222222222222222222222222222
M2220  0 """ 20 2002"02"0"22222222222222222222222222222222222
M22222222222222222222222"222222222222222222222222220022222222
M222222222222222222222222222222222222222222222222222222222220
M0  0"2022 2 02"0 0 02222222222222222222222222222222222222222
M2222222222222222222"22222222222222222222222222 2222222222222
M2222222222222222222222222222222222222222220  02222222220"200
M"2"2  ""0" 22"  "2222222222222222222222222222222222222222222
M222222222222222"22222222222222222222222222 22222222222222222
M222222222222222222222222222222222222220 022222222220  0"22 "
M "200020""2"222222222222222222222222222222222222222222222222
M22222222222"22222222222222222222222222 222222222222222222222
M2222222222222222222222222222222222022""02222222202"0"2000" 2
M0" 020  "222222222222222222222222222222222222222222222222222
M2222222"22222222222222222222222222 2222222222222222222222222
M22222222222222222222222222222220""""2222222222222200"" "20 "
M " 222222222222222222222222222222222222222222222222222222222
M222"22222222222222222222222222 22222222222222222222222222222
M222222222222222222222222220"02222222222222 2220 2"0202""2022
M222"022222222222222222222222222222222222222222222000 "22222"
M22222222222222222222222222 222222222222222222222222222222222
M22222222222222222222222 2"2022222222222222222222222222222220
M0222222222222222222222222222222222222222222222000"22222"2222
M2222222222222222222222 2222222222222222222222222222222222222
M222222222222222222022 202222222202)9"2 "0 020222""0" 0"0 00
M2 "" 2222000 220""00 "02 "2"" 22222222220219^B22222"22222222
M222222222222222222 22222202222222222222222222222222222222222
M2222222222222200 022222222220"3#"2"00 0  2 02  "2"22"020"02"
M22"22"20"222" 2"0 0 22""222222222222  ! B$22222"222222222222
M22222220      0     " 22222222222222222222222222222222222222
M22222222220"2"22222222202";(22 2 2"2""" 2  0202 0000" "" 0 "
M022000022    ""20 0"022222222222022 " "2222"2222222222222222
M220      20      0222222222222222222222222222222222222222222
M22222222222222222220 "!("2 200" 0222"0  00222 " 0 2"     002
M02" "0 22 2"20 0"0222222222222220"02""2"22222222222222222200
M      0      2"222222222222222222222222222222222222222222222
M2222222222222222 " 8"""220"  "00002"0"0"" "2 2 2""20 22 "20"
M"20 "2"2"0 02"222222222222" "2002"2"222222222222222222
M         022222222222222222222222222222222222222222222222222
M22222222222202 22"" 0  " 2"   22"2    02 "2"2"  "020"0202  0
M2000"20" "2222222222"220 2 2 22"222222222222222222
M     0222222222222222222222222222222222222222222222222222222
M2222222220 2" ""2 022202202 "2"" " 2 " ""20 000 2222""00"002
M0 " ""2222222222  202"2 2 2"222222222222222222
M 02222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222220"0222222202000222222222
M "22222222222" 0""0"02""222222222222222222               022
M22222222222222222222222222222222222222222220 022222222222222
M222222"2"222 ""20 022 200"0 22"2"2"0"02" 2 00"""2"2222200022
M222222222"2 20 2" 02222222222222222222               0222222
M22222222222222222222222222222222222220"""2222222222222222222
M220""2220""2 00"2 2"0 0"20"22 00" 2  222222 0022222022222222
M2222"""22" 2"02"222222222222222222               02222222222
M2222222222222222222222222222222222 "2"22222222222222020"220"
M2 "22"02""0"22"22 "02  2" 2 0"0""2200 20    2 0"0"2222222222
M0 022"2"" ""222222222222222222               022222222222222
M222222222222222222222222222222" "2222222222222220" "22"00"0
M 2"20"0 22"0  2"2002 00  22 "2222222""00 " "22222222222222E@
M "2 2 2"222222222222222222               0222222222222222222
M2222222222222222222222222202""222222222222202 2"2200"02 2""0
M2"2"2 0"""2"0  2"" 0" 00 0"0 "220 0" 22"" 222222222220SR2" 2
M2"2"222222222222222222               02222222222222222222222
M222222222222222222222020" 222222222222200" "22 002"2 222"0 "
M  0  2"0 "2"22  22"0 2 02 0 "2"002"000222222222223EB""22222"
M222222222222222222               022222222222222222222222222
M222222222222222222 22 222222222222202" "222 2"2 0"20002 2020
M0"02"0"2"""" 2""0022 2" 00" "2 2"0222222222222 0""22222"2222
M22222222222222               0222222222222222222222222222222
M22222222222220"022222222222222220 202"2""  """"22"  222" 2"0
M2"""  "  0  "0  2  2 0 20"" 0 222222222220 0 "22222"22222222
M2222222222               02222222222222222222222222222222222
M2222222220"20 222222222222220"0220 00"0""""2 2" 2220 00" 202
M2 ""0" 02220 "002  "022 202222222222222  "22222"222222222222
M222222               022222222222222222222222222222222222222
M2222220 " 2222222222222222222222222222222222222222222222"202
M222220"020"2222222200"2222222222222" "22222"2222222222222222
M22               0222222222222222222222222222222222222222222
M222 " 2""0222222222222222222222222222222222222222222 " 22222
M22 00"2222222220"22222222222220"""22222"222222222222222222
M             022222222222222222222222222222222222222222222"
M"2000 222222222222222222222222222222222222222222222222222222
M222222222222222222222222"0  0"22222"222222222222222222
M         02222222222222222222222222222222222222222222220222
M 22 2222222222222222222222222222"0 2222222222222222222222222
M22222222222222222222  0  "22222"222222222222222222
M     022222222222222222222222222222222222222222220 2202  020
M2222222222222222222222222222 20"2222222222222222222222222222
M222222222222222220002"22222"222222222222222222
M 022222222222222222222222222222222222222222222000020"22 2222
M222222222222222222222222   "22222222222222222222222222222222
M222222222222  22""22222"222222222222222222               022
M22222222222222222222222222222222222222222000 "2200"222222222
M2222222222222222222220"2222222222222222222222222222222222222
M22222222 " "2222222"222222222222222222               0222222
M22222222222222222222222222222222222220 20"00 " "222222222222
M2222222 2222222220"22222222222222222222222222222222222222222
M2222  200"22222"222222222222222222               02222222222
M222222222222222222222222222222222000020 "0222222222222222222
M222"2 22222220"222222222222222222222222222222222222222222222
M0 2"""22222"222222222222222222               022222222222222
M2222222222222222222222222222200 0020  2222222222222222222220
M 0"2222220"2222222222222222222222222222222222222222222222"0
M 222222"222222222222222222               0222222222222222222
M22222222222222222222222222  "022222222222222222222222220"""2
M222220"22222222222222222222222222222222222222222222222222222
M222"222222222222222222               02222222222222222222222
M2222222222222222222220 2002222222222222222222222222202222222
M2"0"22222222222222222222222222222222222222222222200 2222222"
M222222222222222222               022222222222222222222222222
M22222222222222222202" 2222222222222222222222222222222222"" 2
M2222222222222222222222222222222222222222222223:0"222222"2222
M22222222222222               0222222222222222222222222222222
M2222222222222000  22222222222222222222222222"22220""20 22222
M2222222222222222222222222222222222222222221@ 022222"22222222
M2222222222               0222222222""22222222222222222222222
M22222222002 0"2222222222222222222222222222"22""2   222222222
M22222222222222222222222222222222222220)@  22222"222222222222
M222222               0222222222 "222222222222222222222222222
M22222 "2 022222222222222222222222222222"0 2020 0222222222222
M2222222222222222222222222222222221CR00"2222"2222222222222222
M22               02222222220 "222222222222222222222222222222
M2 20 02222222222222222222222222"   """ 2 "0 "222222222222222
M222222222222222222222222222223IR"" 2 02"222222222222222222
M             02222222222 22222222222222222222222222222220
M02222222222222222222222222202   222 0002 2222222222222222222
M22222222222222222222222223C"2 01( 2"222222222222222222
M         022222222220222222222222222222222222222222220" 0022
M2222222222222222222222200022222222"0 "2222222222222222222222
M2222222222222222222223#2 0230"2"222222222222222222
M     022222222220222222222222222222222222222222200"  "222222
M22222222222222222220" "222222202"22220"2222222222222220"  22
M222222222222222220;2"^W;0  "222222222222222222
M 02222222222022222222222222222222222222222222" 2"22222222222
M22222222222222 "022222222220 2"22"2"2222222222222202"0222222
M22222222222223:2F;C  20"222222222222222222               022
M22222222022222222222222222222222222222222" 0 222222222222222
M2222222220  022222222220" 222 0"222220"22222222 222222002 22
M2222222221("F1Y02  2222222222222222222               0222222
M222202222222222222222222222222222222222222222222222222222222
M22222200"22222222222"0 2200222222" 22222220" "222202 "222222
M2222202"2  2222"222222222222222222               02222222222
M0222222222222222222222222222222200220 22222222222222222  !"2
M0220"222222222222 0"2"0"222222"2"222222 "22222202"2222222222
M22 002 0 02"222222222222222222               022222222220222
M22222222222222222222222222220"222"2222222222222222000(*2  2"
M22222222222220"02 2"22222"0"22222222 22222222222222222222022
M0"2  02"222222222222222222               0222222222202222222
M2222222222222222222222222002"0202 2222222222220238:0"22"2222
M222222222 0"0 2222222 " 02222222 2222200 022222222222000 "22
M2"2"222222222222222222               02222222222022222222222
M222222222222222222220"00 "200"222222222222228::02"2222222222
M222222"  0 22222222 22222222 2222202 "2222222222222"0"22222"
M222222222222222222               022222222220222222222222222
M22222222222222220 022"0 ""202222222222228;*02 2222222222   "
M22"202""222220 022222222 222220 "0222222222222  ""22222"2222
M22222222222222               0222222222202222222222222222222
M222222222222222 2 2""" 022222222220*"!2 222222222222"22"2222
M  022222220022222222 22222222222222222221("0 222222"22222222
M2222222222               02222222222022222222222222222222222
M222222222002" 202" 222222222220*#820022222222222200"222 2 "0
M0""22 "2"222220""2222222222222222222#-"02"22222"222222222222
M222222               022222222220222222222222222222222222222
M2222200  22 222222222222220:1)22022222222222 " 22220002" 0 2
M2020"2222202022222222222222222223\  ""22222"2222222222222222
M22               0222222222202222222222222222222222222222222
M22 " 200022222222222222 :"00);22222222222""22222  " 200   "0
M 2 2"0"2   22222222222222222!"20 "22222"222222222222222222
M             022 222222002222220222222222222222222222222220
M2"2"" 2222222222220 2"#;8":2222222222""22222202  22"  0002
M"" +8882222222222222222202" 0"22222"222222222222222222
M         0220               "2222222222222222222222222002 22
M2 222222222222  0208:0:"  "222222""22222 2 20000"220" ""0229
M;18  " """222222222222"#)"22222"222222222222222222
M     0222      2      "2222222222222222222222222202"2022  22
M2222222222"""0+:+:2 """222222""2222222 00   000"0"" 0"2;;9)
M2 "0 0222222222222012"22222"222222222222222222
M 02200            " "222222222222222222222222220  2222222222
M2222200 02)+03000 2222220" 220" " 202"2 02  200"0 "9;1)202
M0"22222222222201#"22222"222222222222222222               022
M00            " 22222222222222222222222220022022222222222222
M202 0 2   29""22222220!"3;(0#"2!*+(0"" 22!8* "" 0 0"" !20;22
M22222222202 2"22222"222222222222222222               02200
M          " 22222222222222222222222222 02"2222222222222222""
M "222 ;:9;222222#; *3;*20+98"; 22 09 1293"  "020"2#0"#222222
M2222200" "22222"222222222222222222               02200
M      " 222222222222222222222222002"222222222222222220 "0""2
M2 "1: #;;;;;2 )"1; 00#+:#920  3!*3820     0  ""3*12222222222
M  222"22222"222222222222222222               02200
M  " 2222222222222222222222222   00222222222222222020"""22222
M*!       1!:0+(2!*03+(*02 2"!0;*22222222222"#9222222222202
M "22222"222222222222222222               02200            "
M2222222222222222222222222   ""22222222222222200 2022222 ;+22
M2222+9(00   "2"02" 22"2;1   222222222222002222222222"00 2"22
M222"222222222222222222               02200            " 2222
M22222222222222222222220 ""222222222222222" 0"222222 *2*22222
M20 "22222222222 0""0*2222222222222222222222222222""2""22222"
M222222222222222222               02200            " 22222222
M22222222222222220"20 "222222222222220   22222222  222222"  "
M222222222222 "!(8222222222222222222222222222#*""2"22222"2222
M22222222222222               02200            " 222222222222
M22222222222222022 222222222222220"0""22222222222222222222222
M222222222""0"222222222222222222222222222!) " "22222"22222222
M2222222222               02200            " 2222222222222222
M2222222222000 222222222222220 2 "222222222222222222222222222
M222220220222222222222222222222222222!)""2"2  22"222222222222
M222222               02200            " 22222222222222222222
M2222200 2 2222222222222200"2"2222222222222222222222222222222
M22222222222222222222222222222222   R""00 "2"2222222222222222
M22               02200            " 222222222222222222222222
M220"0 222222222222202"20"2"222222222222222222222222222222222
M2222222222222222222222222222  2P "2" "2"222222222222222222
M             02200            " 2222222222222222222222222202
M22222222222222200 220022222222222222222222222222222222222222
M2222222222222222222222220 620"0! "2"222222222222222222
M         02200            " 2222222222222222222222220 "2000"
M  22222222202"002"222222222222222222222222222222222222222222
M222222222222222222222"02 "2#*0 "222222222222222222
M     02200            " 22222222222222222222222220"2020  222
M2222222022 2222222222222222222222222222222222222222222222222
M222222222222222220 ;""03*2 2222222222222222222
M 02200            " 2222222222222222222222222 20000 0"222222
M2202"0 020 2222222222222222222222222222222222222222222222222
M222222222222021! "2#*02"222222222222222222               022
M00            " 2222222222222222222222222"   "02222222222200
M    2 222222222222222222222222222222222222222222222222222222
M22222222  "00"21 2""222222222222222222               02200
M          " 2222222222222222222222222""2222 00 "2222222 "200
M""" 2222"222222222222222222222222222222222222222222222222222
M22222 20""2" "2"222222222222222222               02200
M      " 2222222222222222222222222""  22"020"2222220  20 00""
M"222"0"22222222222222222222222222222222222222222222222222222
M2 2" 220 22"222222222222222222               02200
M  " 2222222222222222222222220  "2 0"02 "2222220 0 " 0000" "2
M00"222222"2222222222222222222222222222222222222222222222!0+2
M"222222"222222222222222222               02200            "
M22222222222222222222222222  022 2 22222222200"" "2  20"20""2
M22222 "222222222222222222222222222222222222222222222!K9""222
M222"222222222222222222               02200            " 2222
M222222222222222222222"2""00 0022222220002"  22 2002"00222222
M2"""22222222222222222222222222222222222222222222#]Z32"22222"
M222222222222222222               02200            " 22222222
M22222222222222222002  222222222222 000""2222 " 2222222222 ""
M22222222222222222222222222222222222222222222+KS00"22222"2222
M22222222222222               02200            " 222222222222
M22222222222202""20222222222220" "" "22222   2 "2222222""2222
M2222222222222222222222222222222222222222+FI 2"22222"22222222
M2222222222               02200            " 2222222222222222
M222222222" 22 222222222220 "2 2"2222222"0"222222222222222222
M222222222222222222222222222222222222    2"22222"222222222222
M222222               02200            " 22222222222222222222
M222202220"222222222220  "00222222" "222   22" 0222222 2"2222
M22222222222222222222222222222222 "20"222222"2222222222222222
M22               02200            " 222222222222222222222222
M20 0 22222222222220 2""222222220""22"""22"0222222"2222222222
M222222222222222222222222222222222222222"222222222222222222
M             02200            " 222222220 "2222222222222222"
M"222222222220"2202"22222222200"2 "2 02""22222" "222222222222
M22222222222222222222222222222222222"222222222222222222
M         02200            " 22222222022"22222222222222222222
M222222222020 "22222222222 "02"2" " 222222""22222222222222222
M2222222222222222222222222222222"222222222222222222
M     02200            " 222222222"02222222222222222222222222
M22220  00"222222222""2 2 02 """0"022222"2222222002222220"222
M222222222222222222222222222"222222222222222222
M 02200            " 2222222220 22222222222222222222222222222
M0202 "22222222222222222" " "  222"022222222002222220 2222222
M22222222222222222222222"222222222222222222               022
M00            " 222222220 2222222222222222222222222222220 "
M0"222222222222222220 2"  0" 0"""2222220"2222222  22222222222
M2222222222222222222"222222222222222222               02200
M          " 2222222220""222222222222222222222222222222 2"222
M2222222222222222 2""22 "2 2"2222220""222220" 222222202222222
M222222222222222"222222222222222222               02200
M      " 2222222222 "222222222222222222222222222019"022222222
M22222222222200 220 20"00 "2020"2 222222 0"222222  2222222222
M22222222222"222222222222222222               02200
M  " 222222220 ""22222222222222222222222222202822222222222222
M222222222222222 2 "0 0 02 0222222202002222220"22222222222222
M2222222"222222222222222222               02200            "
M220"222220 2222220"222222222222222222220;8 22222222222222222
M222222222220220""0" "02"2000 " 2  02"022" 222222222222222222
M222"222222222222222222               02200            " 222"
M22222"02222220"222222222222222222222!*0222222222222222222222
M22222222 02 022    "2 2"0""" 222 22022222222222222222222222"
M222222222222222222               02200            " 220 2222
M22 2222200"22222222222002022239:;; 2222222222220"("222"2"222
M2222 "  20"" 2 2 2"0 "29(0!232220 222222222222222222222"2222
M22222222222222               02200            " 222 22222222
M222202"222222222222  "22239)0 22222222;;:22 822222))*2222222
M222222222  2 2 2223 1 2  2222"2222222222222220000"2"22222222
M2222222222               02200            " 220"
M 2"22222222222222022209"0"22222" 1+90"0":1*020)+*"2222222"22
M22222"200"0001)30"!;)" "0"2222222222222222#22"2"222222222222
M222222               02200            " 222"             2"2
M22222222220"202222: "2222200202" 20 !+#;  80*0"222222"222222
M22200 "03)+9; 321 0  "2222222222222222802"2"2222222222222222
M22               02200            " 222"             2"22222
M222222222 2222!:"222222"0"#)(  0( )#00+8( 2"2222200222222002
M "0"":8(2 #;+ 2""2222 2222222222229"""2"222222222222222222
M             02200            " 222"             2"222222222
M220"""2 20 "0         """0""220 "00200"      000      "22  "
M""2 02" 02 "2"222 222222222220<BFAP 222222222222222222
M         2222             "2220              "2"22222222220"
M022220 0"       " "2 """2 " 022"  00     2        222200""2"
M 22 2 22 2222 222222222222-<X]R                   2      "0
M    "2  20     "2     " 0 ""     0      "2 "222222222200 "22
M20   222220""2"2222202222222 02222222"0"22222" 0 222220""222
M222  02222222222222222*-)W0 2222222" 22222222222222220222222
M2 222222222 0222222"222"22222"022222220"22222222220020222220
M"22222020""22222 "222222"22"22222 "222222"02 222222""222220"
M00222222222222222020#2"222222220 2222222222222222""222222222
M2222222  22222222222222202"22222222"222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222"31222222222" 2222222222222222222222222222222
M2220 2222222222222222""2222222222222222222222222222 20222220
M222222200""22222  2"22222 "2222222 "0222222"""22222  0222222
M2222222222"2 22220  020"0 2222020    "2  2   2  "220       "
M"2222222220       " 2"2222222222222222222222222"2 22220"0"22
M222"" 2222222 0222222 0222222" 0"2222220002222022 2222222222
M222222222222222 22000 0222 20 "02"0"  2"0"0"2220 "  0""22222
M2222220 0202" 22  2222222222222222222222222   22220202222222
M00"2222220"222222"0"22222    22222222022222"0"22222222222222
M2222222222,&N"" 20 000 20228-@02 02*20! ((2 9SQZ"%[GUP02)0 "
M22((9<+Z:20;20002$222222222222222222220020222200""22222""""2
M2222   "22222""222222 2 "222222"2 222220"2222222222222222222
M222220_4D02 00"" 2020" +_"0"0" 80 ;0:" 2)B3(0.I6[P20** :22+:
M31)NJ20( 0"  0,22222222222222222220"02222200 "22222" 0222222
M"  "2222002022222""2 222220 0"222222202222222222222222222222
M22_&L0 "6:32200"20;;F$P 01#=% )"(*21+\A++%S^#0*0>*";2292:D='
MA2"!SJ]A]0^22222222222222222220 20222222 222222"" 222222 20"
M222222 "22222""002222202""222222"2222222222222222222222222]"
M42"!+""" "022"2"2TP20"#I*&#"  0"351A </AQR1,282#2222;\3X  2(
MA0>U,C,22222222222222222222002222222"2222222" 222222 22"2222
M20"2"2222"200222220"2 222222 222222222222222222222222208$ 2
M63 !:" 22 !1+TB2(:95FS*" 0  "']1!-*1-R:"1L#/P22 +T5)K0":G<YR
M=(,"2222222222222222222020222222 2222222" "22222202"2222220"
M22222   2222222"  222222 2222222222222222222222222 022"" !23
M*2"2222  2 2;3";;"02002 1#1"0$0  20 ;P 2B2"2220!8 0:I 20-YN"
M2222222222222222220  2222222""2222200222222202022222220"2222
M2""0"2222222" 222220"222222222222222222222222220 00  #219222
M222!222 #!8#:0220"22#(8"0.60"22"!P"4R20 2  #(" :@8"#-"8"2222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222200 0  " 2 02 "2220
M"2 0  2 "20 0 22 0 "0"0 2022""02"2020"00"" !2"22 0"222222222
M22222222222222222222222222222" """"22220""222""0"22222222222
M22222222222222222222222222222222222222  0  " 2002 "2222 0  0
M" 2 "22" 2222222222222 22" 222222222222# 20"   "222222222222
M2222222222222222222222222 00"0"2222 "2222"2 2222222222222222
M2222222222222222222222222222222222222202"2222222222222222222
M2222222220"      "0  0"            2 0 ""2"22222222222222222
M222222222222222222222 22"2    0" 0""2""00   2200222222222222
M2222222222222222222222222222222"" 22 22222222222222222222222
M22222""2222222202 22222222222220 222222222222222222222222222
M22222222222222222"020 " 02   2""" "2"2" 00002222222222222222
M222222222222222222222222222!0T 0020"222222222222222222222222
M20"2 2222222222222220222222222222222222222222222222222222222
M2222222222222  "220"0 " "220"  """"2""2222222222222222222222
M2222222222222222222222 !"2P    0 2"222222222222222222220" ""
M02 0"2""0"22222   020"2"22 "2  "2222222222222222222222222222
M2222222222" 00"02"20 0""" " 002 ""2 222222222222222222222222
M22222222222222222228"@@"  2 02"222222222222222222222#*22"2J2
M02"""      23X2 "#2 2 2 0  "22222222222222222222222222222222
M22222 "2"2  2"22  "22     0"0 202222222222222222222222222222
M222222222222220!32R@" """;22222222222222222222220 "0"802202
M""20""""060"";8 20&R2002222222222222222222222222222222222222
M2""22 " 22 " 220"  " 2"0002"22222222222222222222222222222222
M2222222222293@2P202""3"222222222222222222222"*020:2"222 002"
M 2" ""00#I&022V@" 022222222222222222222222222222222222222"02
M 2 " 02000"22   02002" 2222222222222222222222222222222222222
M2222220/;MWA!(2 2("2222222222222222222201)(8(>:"" 2+*-02#"2
M=,+#*,4 "22"2202222222222222222222222222222222222222200" 02"
M"2"0"" "2"2  " 000 22222222222222222222222222222222222222222
M222.38%Q)( 0202222222222222222222220 13#:(X0  232,0 "2"2&I:
M)#$ 2200" 2"2222222222222222222222222222222222222220"02"020
M"  "2"" 2 2 0 "22222222222222222222222222222222222222222222+
ML^5P+  2"  2222222222222222222220 2;""@ 2" 8*3L2!;0"+$+0*2T
M2""0"0 22222222222222222222222222222222222222           0 2"
M2 "0 " "0"2222222222222222222222222222222222222222222202" 0
M0" 00"22222222222222222222222""""0"  0"0"00"02 2   2"2"0"""0
M0022222222222222222222222222222222222222222222222222"0""2222
M222 0"222222222222222222222222222222222222222222222220022"22
M22222222222222222222222222222"222222020 22200( "0"22 "0""022
M222222222222222222222222222222222222222222222222 2 222222220
M  "222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222"2223_
MQ  F$0$!  $#! (" P$!       ! !$0(3$@,$" 07!08)"@P+#0_]H " $#
M 0$_$/X)&.WJ_FY]7QRP3ZNO%SOCU>>+GZP!CU@Q'J\\35WL8]7PAEZO[H(_
MYU4YF?5XYF8_ZW6/6%]7LV9_SL#ZP/K _P 7QOM8V]7SF>/5\V9"=.;&F<^K
M9,WQ,>K9,Z,?^!\OK _];S-B?5XB>?5\9Y_U%))M)+A#4]62>-/&>)T/5K-D
MC:7.F/[=)J='+\ QQ^ -7J8U)+YOCR&&WD;/MD:G1R\]F./P!HS'2QJ7"^?)
M;AJ&TRSXH_:YJ='+L)X^= [@2Q(V)<0Y\ DVGJ89DQ+#+,-IYZLQ.T.? P:'
M:'-Q.\,/:+B-[$Q)9WQ$%MGF>?M<[J?)-'M&HW*/ )XGJ=3GHX3S'47"/ (U
M&8Y[!?'0,<ZA%\M#S]KCB7.HXEGL+Y)9[8SO8+,F6#'@$MBQTO$I<DC#%DDS
MU8BW06.C,.>V.)W@Q+,'8)XG>6+.A+FY9@@Q;H8GGTF8CN,=+Y(GCL$:CZ3,
M=UCI?)$\=DT#^R_C^,%_2,GG83[V(YU^)CG]&;A^&K,=D?N(B=/B8Y_1FX?A
M:<S,=;<I^X6(ECF0Q+'Z-RN'>8@[CSHH[!N:3C[J8C1SN$QQ^C/-Q[S$=SYG
MV8-)Q]UXLSO&TY29_1V&W?Q9[N%B,7/8S)F-OZ'/_\0 )A$  P !! (#  (#
M 0        $1$" A,8 P04!0<&"0H+# 8?_:  @! @$!/Q#^X1J#<$[U=0DP
MX=75SU@+GJXY"RAZ)#ZL\A:%N)!.]66J30UZ#TX=7FZ)1*=7[_S94)^$+' 0
MNKJ. A?JT_J_O^HEI>L*ZO0@O^7^I>L*ZP+J\^!<]7^!RZOO@7/C9>J;.7C8
MN>J;=$P]-P]BE&3JHAZEDNJR'J62_HUO5V;88Q<=7'P,8Q<=7'QAC%QU<?&&
M-"XZM+#_  &E_7%A_@:_6UA]7D\/P4I2_P VG[.T0A!?PE=#_6AHA""_A*TP
MGUCQ/UVXA"?PM>!_5,7[ B$)_"EX']4Q+]EAQ](M<^-"?&;:(/H+"$)YH0@D
M/1P;^:8F/7BFN:'\1.%*46'ST#6(0A!ID9&1D9&1D9&1D9&),A"$Q":7INN^
M5(A"$T7Y5*-A]!$(A"$(0A"$(0A"$T/-+FZN/%2^%(A"8OT)]!6V*4H^?)2L
MK*R_0IE*-CZ3IE*4?V*92C?5VE*7[FEZPKK O\"Q"2ZOH755N"W)X$+JJU3@
MO@0NJJ\2$U_@(,3AR);#P9O>K6P8/88GOB=6>"&CQP=(8MWB]67P+ ;&J)3J
MV^!!6GN-[E0_]I9"$ZNW^L-]6&4I1,I2E^?/X)"$T\X0G[6R$^/2E*+?P+-\
M-*4OVR+BCT6:!;^UPGQF/0N/ M$\#^W0GA?V"_H,'\6>0+0LP:T-4A""4^Q2
MVT/0]#5T"3ZOT>SU^?4J*AOXJ:(((&Z_ F4I11A! W="*BHJ']BF01@V4I=*
M<*BHH_J_1[/75YBY$ML6=R^K+.1PQY9?5I*"A02B@X&Q.]7F,X=7GN,6W^!2
MOHAB$/GRD;UO/L7B0EM@M'(VB&,:H@];5%H]B\2&,_\ 6+"F*U+">_BE)/UE
M?1#$(?D?.#8]"Y&//L0^/"N1<#%HY9F,;<>PN^M:+-$$C8]:PAZ#L8X@A\:G
MA:/$E$C%^L(.&)C5$IX$\-QP0U"LOF2HU!MD\B0UMEM8G2#$]QCS,73"$&FH
M=R%Q@F(:+N*)@MQ(.$KH$B9]AM]%W$<],)E#&6"BY,M+%U)184J/8HAHX;AJ
M(>5]Q<?K+D+CPL6'R(>Z(3S68E\J'QI'H8N</R>SA@N,$(9[U17D)AK?*P\>
MQS%GWAS\+<%N)OG:WIL&[K]G#0B$<\> QX\Q<?K"<&J)3Q)8?(F5%0VBE\C$
M)H93G7,6B&\*<A;8,2CPUY=VR)<EV&J01Z&MQ"'"03AN$AP&[E,N?<YBS-Q'
M/PI38AJC0:DWS2Z?9PT9!"5TV#=0T0:#5B_9GA?#8SAK]#%ACY)&]C%\!'+-
M97 SWYFE&K%H7P3U^SAX-0QYU^S/"TKS,8N-='A<F:+1B^#RPNA,8N?,G#D+
MC0O@GK]G#P8L/'<+JFHLZOH;/[IYUA?5Y8Y_@-+X?9"_-33X(UX:OVOED?/P
M.1P^P+P/YP<,'#P-T:%^U+G(^?@<A\?8%X'\X.&#AK? F)7]KYB"<(,3W$/*
M$/P5_7M4@C8;AH@\/ _$>%A<C&]+$+2^,5S&V1((B&Y(E^UN+)C%R(>&(0^?
MN5E>'H'XD(3"Y&/2Q"T\,',*4?&'!"R+]K)QW A<06Q<S[Q[BV*70F0-;WQ)
ME&[FDTM4A=/ 6J;80A!*#=+D%LG55*(7K!OV#__$ "X0 0 " @$" P<% 0$!
M 0    $ $2$Q05%A<8'P$#! D:'!T2!08+'QX7" D/_:  @! 0 !/Q#_ /!\
M-^Q:EHUJ9K5(=&%C4+FH-_\ RPC<"O8C41TZR% 1H+:1@U>NT!(O(Q""33_Y
M9N(J4+QYQSK/.3Q08HJU<I<L 8HI@*)@"J\)I_\ ++N*D\9?7$O*M2E<D% Z
MAP3MNNY',^B3I#7_ ,M#.BCH$,3?V+C%5#JRF_ )W+O&K-%Z/%/HTT?_ "UK
M5:,E1J"2 Y+)V8XTXS \'</L^D 4@J)DP'2TO]9!&YF0Z0[E?ZP*UYES;EI:
MOI#L)U:U]):<3AB*B'6HTJW-?_*EY8:?+:,<8BC685YL ^TS>Z[1^D<Z9T$>
M$N-%+5+:WS<!.@'#/2.T,ODK;*F\ P/6%U68#3[D D1ET+08>3 R?+_T._9<
MN_UOQRUQT1P8$,J>#J)AEG6(%J!WC,3;!!Z97+$W+.LN4ZDI5V5UEG6675RS
MK*=265?$LZ^RR7+.LN_9=1]L,4>:A- .ESR( !$1Y)9U(R*<J4'G&)0THT8-
MKEC(G9)A5]_1M;@@"L!$[/L6H(ZEG67+.LLZREU9<LZ_Q_982):=R[]4&U\X
MCZCZPVV#6T&'<[-3.# ^4)814X>LXTZG'$"!4P?I_>GJ?1AM\7_T)P2ZW&C&
MH!2OK-O5_6$/<0@WXP!",GSE\98"1C[H$R(4?)@P.#?6^$]<Z2R&G64$52$,
MUWR@[( 7; -;NI <G8F< "._@AB"P$0 K^XX^_)!3(!32.Q4?(2MN\ \$#8\
M)TE-53I%U$\;A;3?A*TIMW[#86,.P13 U'VS @?I#*JK-M+E7 !F7SCI04I=
M>4'J.#D5M_N<WV5W<FT<5CRM^:!FRU  ',SSXP(%EU%2Q22E:O-A1_9X@72:
M8MB%-T=+B%T ,%-PT9G7\@50;CHA['<:!2HG3=55%)SWE>%VBPP-^ST/JGJ/
M1AM\7_T&SK%*8O%J&ANI:255;WE,KQ!*EE[_ $F5"3QHDKS1EK3?B5-@%BA>
M'Y2A79C0)!0X($E0K8]H\_,E792/&DFA.NI;&18 ]8&[2@4B77UATA4+5'KY
MR[_ Y4' \FBJX':B! HTY4*7YQE1KY$L9I;K!>P9UU7=RT$K!,]+)1WA:V#K
M=2ZBRN@FP7E"IY@.GL05<"LEMP("YY(Z3*5;6"X0IX('DBT7%B$-W3*K04SQ
MDQ[N> .8GL9KRCG]@O> U?G+;G\U'!1D.\5ET7TX<$&&B0 G CJ$:,W8C#H8
MHBU:*,Y90;KAKJT8B0Z*5M0".LLN!,FQ( DPT_R 605!<L,;ECFWJL;CC?SB
M .D"O9Z'U3U'HPV^+_Z Z9G=$5>V)W5'12"#I6,S 7 2I9&KN+;L<%2*@\EE
M)K^0K'F7I;;U_1;L/DP''+Q"4#O<5OK3KIAX,^$.**2HX=,=3GC;UF [8@J9
M,(U'KLVVK-4RY*NH'BD>%-GBNJ.)NU(1S *#U?F0?)2?AIMZ&E^<8T,L+7#/
MA*V;"C%<! C &&IA&T7?!2Z4EN6%G_$ 3@$DQ'-7IF;(.&JDOR@NZR%4[^P>
MQV>RTL/+(45?6-S.S5$3Z2N@'6>A<>13EH"SYDJQ)^Q0]@-!+(VHTJV_1E&0
M7$;,#MS+_<H;UER0JA@;F-FN)=X%*T<\=X!V4RLX*^>8/SP-*J=,8EVVE?5*
M(:T098C-66?CUG.@VZ?RGT/JGJ/1AM\7_P! =,)5]PYTQ #]+3!BSE5Y4:TL
MFP=H*3?AY4QQ3;SE!(5#%SF:+R_H% [OA *V,."(IAVC:,^*12N05SVWV7F.
M4KN!JLQC:Q+ !;%=UC@FALS<0!")>QFH#6+,'JU&HZKMD@&1Z\R?0IOFNOY%
M/Q Q''!$?(8E(3_Z E1NIT%6SYP*$:-55)7^RO-KJQ*M".KTC\9C]S9$YOOE
MWVGG['9,HTAV(3K*676 . _M"(J(#L%_W X-.D+:/G"W<C >?V$V7"TEEW"C
MX&G,D(Q3:+IXPL: <I6X_P!\4D(K8XBH&.$B59P8 ]F0=1TB4HL%'R8+LC0#
M"HSGG8X_E/H?5/4>C#;XO_H-'2-!;Q#M [1%M\I0;'P@X-7TE][!^D0W4-?H
M!ZV&SB%F9C-D!A*(E"+XYW!ZHZ%'(3UI+C-*E9L.SPBM*D);15])<F/;W2VQ
MNY24BLM\X;CH&.HU#<&]%W-1M@>/$J%V%LD6%E@BJB)#%#M%"<YA7FH6 07Q
M)3Z(LR!,2R><PLIZ1^W7A[EI%)N/B?RCZ_H1;1TX@TS&8$<X,Z]C8"+M'44I
MKCF<== 3;0,S("TA9,G9&BY++6)C3_= #-HPK..H:4J=51NI.B*^B\++:L3<
MB(4ZD ZN8INR#89&IG#G,5T1$5FUC IKP5*0IOEB8@VK$^4?+%KQJH8Y2%%
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M7]:$J9KHOK4"X/E !0 >$HZ0!H"(=A*+=%RJEE:64V1L#7N^5XU<#  P 54
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ML6(7Y0(15"*)/-%[O8%0GT1**"E(2WGJCP,#,OB )JA8C&T$ZH^4"BP\S,;
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MT$6KXTI*=C#M#2!=X/T-JE"F5JN(&.='#R1A;1BIJG!37:-B1HM;\R:_K_5
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MMX(ZJ4]((%2*@]?8@:,FU)2@MQ  !1[+6@'AB]PZ'I*5:NK<$ K3K %0I=L
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MFS.8:Z>8LD14;X]UZAU?">)TP&Y!U6.GH !Z2^<?PHV3>3,,7XG0%3S6:/U
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MR^J+@,RT SFL6P%J4/S!!"N4M'0F+L9R]&L8AX:U.Q+(BV7)'AZ?$-G6R/\
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M>7YI0@OA&&.W><!&("KA7:/X)6!(*[ &43R2T0M!5P=IV5WK9ZP_B0C#HO:
MR[ #OLEM10)A<"E)H7F5!9VUF!)?8Z@)4W:)P+< X)48V+C&TU7<G=96"B14
M+SJF6]L0UJ\0KB[S<L7V Z6WQC9R=%1 (>LI#0&#AOV+1<5&]72VCX04Z'&;
M(0[2@"[AJ4!'*MLT2SG3<6 2]\LW'+I<9.%56G,0DJ%=,"T*!>3C!+ FQ;($
M1%*$!5*VM(5RO6DFUM?:<:"MJ^L(A 0WQ8ERQMK?L42*TN[,OE'W%.%P&LXY
ME $$71J%>#G1>%>,,@!@Z67*%JOET>:U+95. +FL4'$/V(KZ:P"NX%J'79 &
M[[W&);0CY(O']MG)NK);$FC"$,7L.T*6%E60Y9%=@7;@G9+/SU!IE!TG6APM
MNMS4R5AI"^K4M>E:$B@IL+H9@J,BTZ#TU*%S:;A -U=$16CZ5AC)QJ!ZK$A,
ML7I< E$Q[+,O&/ZFG$<J%J""'1@@@#G<'H -Y0XC[3M#+O08IQ!\DL"\%D"'
M,$%8*M 4VE^KE7PP4(@%@\I1S1*])&X<C%_$6.ZE\\F41:8$1DLTGA"3)+QA
M#QI(-DS=UN51@#QEC448KM]T->S:YR'$*E7<2D=::.>\0U98% >WT/JGJ/1A
MM\7]ETFWU8)Z7T_%Z/A_&ACUL<70[L=JI@5%H+BRKEKPPBZE:8%@\<7^T!^6
MP>$,= *E>4&H0T0('8E3:.;BH/?!4;8=U[KU#J^"\3IE=2P\JB,S;0144V4!
M\R(+0K*ZBC8@[,R:6]6/6,: K>A@P(ID8N_CO !/T;2S:#6'G&PKJH2G2-B3
M>#06,?.;%F9CRU7(!J"AS3 UY\*A&PXOK+P=$L@.7$)LK('B.U\0?"!2::X@
MLLE* $H =L2K5OOK2>M]'Z@B^FQU/5>J78U:G4.:*$HU@+UJ9)S=LX%T%O65
M$*N+$HIA#G.3L2MG7(Q<.XS%(0-Y<^PNI>*(,-0$9D +H\(XO#FF4%1<=0HW
M#C_EZKC D<"TD'#*N,*2T@*4&\<0(\L5LE*#&;S"WBZ[) D7[6(>KP+6$.TN
M^9 -1@K%\3.8!3IQ)XQT@4ZB8H$(5-7$&$4-.DU>)58%2J8_$DHVB^NJG+*R
M."@N#7A&A2MOO]AMD )"2.%HA6/%0(AJ4QQ.Y4>+DM&')!0'X@9"H U3 ;J(
M:M6Z\9<&R1ZMTSD@J1;U6GLC_42A7B)Q5 M=*37L17697&8#. S3>9-5%\(B
MLB%D&9K61X(_=H\ K5XP$M,'!64\68]7<6$ 8C%@N(W"LKY(A6DEJ;'S)A$%
MG */ZB2@).C02N0F#CMX1C T60LDIIL? U+AJX\BV4K B8"L1=ZI$#E)NY+Z
M%3SB.KMTJ:(*\:<IG!VY@9GTZ!CB1ZN*"C!@NRA8#R4W!*["PE6"+.(+S47U
M&5W%4LZ?G%O(V9@XE<JQJMW.6ES#.UH80<0=X5<^$1T;R?$(VQ&LK8!@N['J
MR\HGC*0$<-&(2P]L\2DU,1RPI&[+S"CG8(*AH]WZ'U3U'HPV^+^RZ3;ZL$]+
MZ?B]'P_C0QY2(R'4'?RC/>I DT8"-W#=E3%&7-S!@J$9\TL]0\/$M*3IW9]U
MF(O(TRJBY33+RK?NO4.KX+Q,K=\P_#X(,84:RW>.&XOHVR6BYSF)HH74C)X6
M.73T ,,&$R7AF:ZU[$6.ZN*."XW(.9L%*Q#8L=1VP7F4CL'J3&IJ]9^951 1
M@V-T/G+3V,!R[XA I:T%:1"%7)R0Q:] -14<:=LM2!1N*>;H@TM-P5\6Z^M(
MBJXSWCA*%^P.7"]1(@+W$L>X\:\P*YBAJ4(Y!TJ6:HZC>4SFBITP*ZPJNT Q
M$KE)/&ME0 J6JH-Z<$4.-$,5G2\@8[FYE\/L7PU94K$H@F:MU<%DC=598+=X
M<0.P;49EH[Q..%=5AB(J%J@9Q&;<CDB)[ZB+)BGE<L8!!5:\(91)MN8*V'\M
M'N$(C*1.P+K=<PKO/]!6R7T=2-"PX\849S ( = DHE"M)XI=(N-#M!JP#7RD
ML*(%E%U[-&**1UL-EWUA/1D.FX44:"Y7L@.V.\F['06(,.D(82W9!A"H?L(M
M'=KQB)\&AF%?7-"!1B $R@HPJ;@[5"IA&X7DUY:I.EP8I2+?C$=4)>A"-Q*@
MRQAZB"(<;5!,GRXLJ6XK#[%@49ZZP 0#C85TH!0*X%XC<BH%O$"I,W!O"$_"
M!!R9UB*[EHF!')'BK6NE2_<=RJ<12B,<X <>,,8\\YDQX#,A5]*$E42*XCF8
MEF0'<5 6&I<\$L*HK;*LQ*TA2U26X70R-E++B79JRT;@V;=M-L/,,,PB&&#6
M0VBQ2&S<I;P:A>;I2I&#1UXH[S+]RM.%4FL2N<T&!6+\(?1\44--K8,''YA7
M>(:4E:2OLKL303%C*!VJ#[LZJXXCI<-4MF[OK.:=V.WQ &X782S4!W>)F^'
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MHD .2<!HS4QY)*('9A7C(9%6!:+*6HY;YL9O!.)FL4I[KU#J_9_%0VU<2&6
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MU?LOB:+1_4S$MT7%MKPH3Q#'+)[7=UO?3,6,955<W7@P^'54#2]_$=BXS@U
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M>8M;G:8W4,6?]"!@"YO4!F3%GX)1B7#%PBWLPK^X[.<40B%4>:@+\R! MM9
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MF.=YAL>U1S-W9VP>U0^DM4Q@"\;@!HE$ITB60 *,?#C+ &#H5X>Q!WF!%45
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MI/3^Z!0(<RH<)6[_ )&65GPM!OW-2I)(Q?U!;7R+/TG^P_$-S+MU\HPY73R
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M87^IZ?\ M$_. 4U\HK/AS] 5F<Y#Y,5>)<@L;%[J4W6@:C,[FE1KSEAGJY1
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M=0*FQZ=)ABQ-/L 5IN4T4KBN("+"IEUE</GF+\)9G\#KYI%W6+8;5#0J"'#
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M<5C!(C>'+4 _&W*+12L:@P<;PHWA)RI I9Y1V!QR0+@=DXB5RC>95-QU^AH
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M584F,1!^4PE\)Z_U0>D:8"\IGO\ .9[_ #F>_P YGO\ .9[_ #F>_P YGO\
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MS+XLLN\[>&HHBO[USG.<YSG.<X$"BZ&H'NS)JZ8/'O#SG.<YSG.<O$4N'&
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MY%6\>$+&9NQ6HUZL5Y%/NJ]0VX4SM"$*OSBDD2F\N?Z^:IW-F'09;Q1!TA<
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MV(8+4 \X_P"#$^!%9[!'7[/=:!*RIBSNR&=9'O%0%D(/E%!$5M>[1F.L '$
M,*N% N2\>]6QUEI>+.2&R:./>*QL]=0SE&E\RNTN\=!*):*,.98 ;<.F.)@[
M&O>+6U#725@V8JNSM+R<VS-KJ@/.P@,I4KQQ&Z*Z C4.2M^^%J.PYQ^4*B$&
M;3WC,$CZA7Q%2@IP<1D:,D_O&9%<W/TBY2W%5E#[9% -/6!";<^\=TM$H=NT
MXQA=MGG"C&@:'>TBDQ*!H'2+6EY:W%[<1FQ*IKWG*L](I9 ,*6C$S;U^Y4-8
M36JAA';H[_N5;8=00+/8LD0*A7IUF54E0%AAT2[*KF!05"W=W<7=EH#Y!*W6
M&4N\56;2UC_<)R];@2UQY,M$L!A<%GG$A5K&M: <K#(A:2GSC-H.@$:&51<\
M<4I&]/25FV AWB/: M]+Y3'DAM,O5>/T@YZE >A[A0JZB!P -:$7_-E_]0A9
M1P/ AH1W'>:$(%-QF+&I5^MP J.0"_I$$-?8Q9598%N$JCB*F(V:QJ*7*TEC
MUW!)$/H#@A!!$70=D?2=W:MKF(V'#!<7*E@,L'>*A]HV_,-RM!KL$%,KA=D,
M?-%!U3 *>-U_*&MD$4&RJE-FU] Z5"[NO,)A&(+BU_W+(^-(N!*"BBBZ(@.$
M[ER1B+J2Q'RE$K S;C=E>$$?L$+]#[(WR\I3:=<H3NN.B?7V[]V'3R94NJ(G
MVN-\=:C&W=$**\8/H0 1YE%<*2K:9QM@$_TEMMPLZ/E/(2 ';!5BJXM?T>G=
M24"(26)!H:P [W>*&P93[SA9>GAZ[C;2TZ%1'\*::Z$Q,5M3[TU&=A_H(S[B
M," %>! )H)YDJMP_U (K(;]H7TQ=A21T/*2U>7,KX_/^9U3Y_P RC=71_F%*
M;!B>C'(UC$8JPK)X=(!9*#@Z7*7'0,KZ)7HDL'0EG+9BK06JAL[%71-]+FMH
M2S;6IM]J?Q6<->7LZ31GR,LEA>D81\I3Q8;9=[U&3,M*C(PW2 LO*[W!8JU'
M 17SE@=4#.!8OF0P6@.QX=P%WKP!&,'C!_P!YPB* 'DAJ'4V?_577Z#J;_JJ
MY?VY2\PB7+^R\O J.O=77M-1W,F8>UGVU9*%B7+R_N#KV&H[FT=$+L_3RG*:
MGC.'Z,I>8>PN'V _4V>$'JJP%Y)2I;KA%9[-0U'4)%2)2/,V*R.EM5+!E>)2
M,8/I4%!RX8 \"5^& X.0OY35Z+=>PW[79%K!1[77L99/9E,(ES'V, H":0X@
ML(IW<R\AF94M<^C)3,P6MYQ=7Q+C&5-8<?.=,D%C&F80 QA1@!<K 'D1)^#A
M!B:!T/ *AJ;3;^&4NKS[+(H;@UH,U$N2"/L4)BNRH L;/=@=,NXDHN>D M7G
MW"@6ZF1+,9E'GVH.8!Y_DE'25*E'L5*E2I4KV5*_17LKVU*)5>ZJ5[*]M2O9
M4KV5*]M2I7ZJ]E2CI[D8(.=K6-8ERI<M],MU^LMERWTRW7ZRY<N6RW7ZRU_V
M)1Q]8/UZNHZ%ZE?&WAZP\,00+#O,G:7*N4ET'8=R6M(P6/+6Y9(J]^8'G,"W
MBR\B7+ERW7ZRW7ZRV6Z_66Z_66Z_66Z_66^F7+?3+=?K+ELMERWTRY;+=?K+
M?3&WGZRG)<3M%E$>PS4@JR\$@(44.ERWTRW7ZQRW6:JYB=W3#N2P/X3$<-;,
M_2;QAP0-U92#VN:\I #R(:AK^'9@(47C< N+.C$#$M;J("U4QP@HX7'=UAJB
MVX(K1"]#A]@ E+S 2IRFV"E-/'3W6P"F\0R<')*C;WQ(HYZ8>4O>M5?N.TUS
MJ-'4N5X8[**-9W*1G]D<E>^W4P2NK+<?RBE_I6H+?LO]ZUA7>W35DH:XGJ_X
MGJOXGI_XGK_XGK_XGK_XGK_XGK_XGK_XGK_XGK_XGK_XGK_XGK_XEOK_ -3U
M?\3T7\0T#\/^9=JKUZ3F>OX3U_\ $5];^H7[_3M,(7 53_S/1_Q-EZ_A/3_Q
M/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q
M/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q/7_Q%_6_J>F?B*\?A_S,D^GX3T'\3U?\
M3T_\3T?\0>GR/^)57'CUJ)*<N/2HW :T,_I*?]F9I_#J[E6K=(LR-@NP4;(X
M=FEDX\Y9>&M9TU++B*"'8C#6 VJM!;0ZP#Q%=7;+*PSJ!8*PSY6P\2IRQ93>
M8BJZX@'3*=8!TW*=91YE.LI[%-FH2*?E&]>5;.'$9U[?H?W2B)!C.#, 95=R
MCS%"=I*',[Q,P69U[ B 5:9=.Y U7B,5.&RC?84G #D<T2YP5A/"!-Q,J5:B
M;3O -TZW*5=XEA+(C9#Q@CJ(&EEQ=E=9WB5J[Q*+5RO64ZRO6#9C^+4)N,1'
M4EN\>RY/$1-XS,FE-7B('?I%9UNL>PU^\T$@</ $=!3'P;%E555555555555
M5EE4"5*59]M555?&UEEE5555555555555555555555554%[FFDLLJLLLE??_
M !1R_;!?Y?Q%<3RX@U&'#$L2NA@]=DQ= R5S-]R _8C>*I8;H 4+TCUDFAC*
M]D*8$E*=54V\(#2A-A<%],15L:/H.-D $ ;%Y@'X"]CXQ1G'F@[(OII+9[LW
M*<LNAA%$+2O$ FUY%D$MJ(C,6.(W?041*!@0QPCW:8J;AVEQ-(4AR*VH3;::
ML5$:@&#>(%GQ<,$[CFN-#P()B. 0[M@$3.8FO8ZGK?5+N%6]ZO@3TM]H.M<.
MOXI3U#"E=JE5$Y>#]BU>C&L(O6"%\90B"KM6PTOP7N5)4X=$L%Y3K!# AWD1
M; :F ?%$,KT3M BMV/8C@.KAM6(RQ=FFC$>ERZAB566U,P %:_BU.<KX1)"&
M"[$" A25*8"]2]F'F(5#$0>8&0$8^4"!;77.+62V1$B(&*)B,4>$:J6%VX=U
M=>Q9C]#+[?NNC[#;7[(X^';Z_B00.J^X'&I>(Z]RXNX^E15=3/A ;<6 3J)B
M,J4.AL4+Y(#I,60=XJ9A;0N:\49UPDU#!B_LC"2UC;;-9 "(J*N:;)%Y@ENU
M1<7%Z]I;"\7!&J/ 4N,1V&19ZD-5<<A"Z\HL+Z"\4J$I\B7<^[I< *P[Q.8[
MDG"G$;+HBA:&Z [Q%M'G&K2TRRHEL$QJ #!5Y4!$T=4OB@>3HB[<-Y-<RQI;
MK,N@DH'&K:)55*+"T'^X^!<TE#SXP*PH>?8ZGK?5/4>\H@).JB;%-[7*H=9?
M527"<-?B7JG!I!"':5R+N7-DK*KI++RK<V7R1'6H);>;D>C!I>>X0R^#X YV
M0HZK B^,2Y2%+=+_ $@%N  L$+,TP5#Q>(-V6Q#VQCB:BD^()8JXD 6[AU-=
ME/0_BJU'?K<X;'G[N'T-M7B&?*@-G^(U%7FZFJDS\WU8,+$>8*9@Q[2P7JQ@
M$AE!5EYNTXX!TE$HD[E>,2Y((I=5UC<QF#9@SCQG;?.)=?"MP25F_P!KN4E;
MJ=9KQE4Y^4KGFND2-\=8@@'KNI5X0K%Y,2N<ZE*'-,OV*W690USN T]J""6X
MFY2ZE964E^\6I<:5AEBEYZ3403N0!9K]#C])Q*W68%IS$D[O-2E7!N7FH-P*
M8FG>4^QN;CB ?X8S< @4<J99-T'D\"KKB*4(2F*6]93)<;'QJX*Z&YCET1HV
M W79DM@2^S/)"Q6(!5Q7=*23*R ^,ISX@HBS<3S HM6;HQ+KWD43G?Y,]-Z)
M]6_LGH'7&)%T\D>N8TJ:"(_\LVA=D/A3S)Y0&8U>FEA;597M$I!8D#I3*(H!
M!D8A?,:NOR\8["R;2@#CCF%0F//0HV6,&%]CV)J,25>^10NWF2F_X1@'VA!P
M=?8ZGK?5/5>_L=2N9@A,K#1+VQYX0E5?/+:-IW)='NP=M'/A'B'(I[AUF6:"
M*L5HHK2*(,:T#9F*J,2Z70?*7,ZSQ05>$110-7>/O',N^+8*_5A?W7P1<";3
M)3*E;]69^&*9H!*!LEB:'\5=ST7KGC/RYAE ^NBYQ3UZ'_4HP48=8)4C3+Z5
MH?ZBVRX2K#'TF<Q'%!!Z0Q96> C$L9&G96""E@#;TC  E1T-Q1F2@M=$K6%=
MI1TPOB*@[EX7"["L\NJ,MH46(H$3XBWXJI7B*Y?YC6]@ O!!(G$;LB#K/A#7
M[766',T[0[PI5_#:4N21T]D6%D-X+RRN4RE=>QW+NE[YA'+NY1<LINUJ]_.!
M0VULB[ TM%VQ;6A'DRP)3855W+8MA'/)+CKVX=5#F*AE^PN<,K,EQA*@9]6*
M3 U90[2N;=P7NPN!X*;Z6<YB*]EQ0Y@W+)9+)3K+)=2R61RQ4(JTS!M.N+,M
M-A*Y0!;=F=S%H&EO>7$"!8'20#I]E.L4KV7(."_8N)6._@98'DR.*S!(2\@<
M@>45]]$'B&R% +[0<VQC:-DLOV*2H:AJ+B;O\,MD#*4,:)%@95;Q&N$1/T.R
M%#2/V1*6);5GU"&DZ+K(W]H39RR(6^4U04')"UQH44S>6!4;;+@H<([9P0CN
M,@TR?)B-_P#BB'+R_LA3TF<L+HOGY'5D"99DX/,43GG=DP"1Q6UL2!B6M6=6
M.P/-K>X60 ,XAXC!*O0+UHAJZN%H6@_N&S2V,C$,;*$6[M1_4:4+$+;7@C3"
MBMQEEG6O8ZGK?5/4>\N+#*HK;*9R2:Y+374&=GD<')*3-N/N[VI*_I"@\88J
M8-J*)AYW*N%+YPW,OV=EE#+C92]9^T:["&S5Q]I?MG5L,?0(QWQQ0O,CJB\!
M!R]#$$8T/T /ZBR9IQ+47O\ BWI_7%7I,HQSD( 6QU%$CW5,U%[!H?O*G.*X
MRF%JE520:A>C=&>C=4V]'!"XK\UD-2[+Y%KL/:9K(=2T%!-E%_-4IA:1,G#"
MI%(TLQ7V(=%0N#<<;G/TI%M='(86;5WSDQ!%A'VA)SQ7[:[@56UG8F7( ,&'
M'C+^^LPO5Q0I4YY()1P4L65%MD]$Z?Z@ &@(H6P9PWS<:W#IE<GSGJ_:>A=8
M:>$"@LK1DH/.I8\FUYX0Y5G,-RWUCP#A;++J&_8ZGJ?4FQN0RU/M 5Y\)_B5
M$;:3.L.YCYQE?(5["X3"PQW[Q:A-\T",<@.7<N3*]$,WW5U04@W0:@TL1/97
M'J7$;B$6$XJ:3:,^A9S_ )\2\ 0#?Z3&;Z%9:3Y1"5WUT@Y^<1; CB-(E$%U
MEERXZBX6 +439FH,2T>\!+-2[GI.Y#YG:PF"YY5HR)O:Q6D*2$%S-40]$%<*
MGYCZ,]XK*M0"X?3>;)WZG8>R\ZSF".IM_#"KO^C/")KOBS;I&X"56$93@:H_
M[1W,+09K'HYAT5Y2L S]8AZ+[H ']PI1PM(7J\ ?FPZ<"I!@!)#TP.M='R8D
M<JUF:PC&P3L=9,Q5"W-\\Y>3Z3,D%U=%9-LAWB#BE1W0F$&X+V0 $J*-T0TF
M_JH"Z\(24YH6A0\:ERD0!39OV@_%@.Q]".E)@MP7_<'F@P<@7^Y4HZ>QU/6^
MJ>H]Y45IP!*E@@M%4E1(*ME&\151> A@PMRH[B-?F0<Q\<+13.[F9'IL/CJ'
MEN.S57=>40AO*>O#,K_2X ]N1V2H)4MQH#]5G'1XF=IY$+W<M%:0>- [657S
M@ %2OXOZWUSJJ_+B+XLVK:/YJ#25>!M41,8!]IL?&87%P4. !.R/J\]&Z,]4
MZIMZ&"!N&OS3U;PE,17X,)0<3Y@4(S4;@P%[R"WYVL:ZK3>H?B&GS6^B*@C$
M5AB[Y$AK]LJ&;;_"8OOEG=79<I9^\^39"V!"=C9X2I6"MEU-P0MT=!P <0*+
MBP^B=Y4&&I=FJ?8YZ1V)0!NQJJE)>JX:>$$($!P*YH0A@N(K4^,@VCY2H=#%
M)@LE!KD/;Z-U)Z?U2HN\XY?4/E'@4N=<QCK5T %6+2TBAFD1Q,[6+_4O;<4K
M!)ACK.[@A &H 8')=RN:I@XC4M[YR !=U,<[3WQ3!$[2(V52PIH5"A@CJ_'"
M1T"<W[7K6C)#S\5J:UBX^\M7J)53<B"_HQV\Q2CS9;>1DJ?.&4T E89B. %F
M\1<[3KD!VEK!W1+H=<0XAJ5KK3I(B;"A@Z\Q-WHG"_*98>%MY&.<4)H7;XR\
M5-1^[!2.\]1W/93A[K#)!B892?2#I; PVEUK&8.U%9%^1![=JN%[[U+OG@6I
MXO9B': %\:LL?30@5VXZS>Y5L%;96W%56#3'ZA3FPV5?:!K# ]>\V_AC^$,X
M_(2SZO@P!EY+7*(PJ:RH8@L*34R$SUAK$=V\TW\_242 [7!/,FCWYW2C-!";
M,W$&YQBLFY?X&ASZ,K9DE^!,6Q'2YEL8 413+UC:F# <*LQPS8C$]58/(R?"
M7B4$"W0BH[;633*^,TB5#>HP%%F@.@QF:]>&V0GC9V0V\$J&1GJ"/]Q33]4H
M:&O.&FNXU7?]PO#D7%%W\X)H0>@,'Z'4]2ZIA%D=UW;4]<_:*DFT4(R]*NF:
M***U<L1 0U1$^9!;" XI%&2WWBO^ES#YNFN:ZICYR0.1D8YE8N=.[MS'>?/Y
M18@?MZ3) %P>@:E6TGWB:X4%MLO[BC:S$* $T/XP+]?G/7>N*%K")LJ%Y$(*
M6F:E[KGCI"FN6Z"=,QK$'RGU*>O=&#TG*;>A@@6T4KIVQRJ7' !N%SUBN@!)
M=LJ=14:OO48:>%T4N)&93;"WG%<G]TO")F#2AVQ/#@+N<TK@]RZ-Q7U'.#5F
M:>DLJ*6&0XE\0<_M1S%S&HWKK-#W'-URQ2F;9>*'-5:)76J'("G >9+U0'7I
M8X\WT0#XX-A2ACL#"QB[1!G\,T4P;=2TC34A<G%- ', JV5@:Q'5CYD7R1S3
M=(O=ZS!TMU1M@@I7!D2;(NIZ=U)\U_:]FE5YP: HD!'2*B#UQRI0VALP-0P@
M8(A!1<7N9>;R]CQ$7TM(8,7CP@-GBI>;>(.40*BN4)3AZ@$JT\HNQ$R<<S$.
M#1/(Q\)K18550QXB4)=XJ*KAB[M#<9;-P4$5V/#_ '+^)S8?1#KUPM6+O7L1
M<WOI#KE<F'=KO"$P&[PZ0VE2DB;5YAYTJW0]&72DBS'$%8^N_%B(2%&'.F*X
MVJ%J?9">0*+B1_0_N>G=9]*@KQ7]2DF@+YRSM4%XL3-1]%BZ]<6QOQ"^EBK6
MK?Q!<2T1?&GC&.9=>N&%1 7#35OSFE2V^Q.L"B '1;9<;>WW3)CRS*C.W<V_
MAAIEF]'<2C@^J+;N(=+M XN6!&M+^EPA7LC+>;EC06\ CAL19<.L8!MHNK>=
MQ:#(\"HQ[SI!0<0@;:OZ(S+)\[PKNB<[@0O1X1V\4I7;,9)F@(^0P?\ ENP4
MBVRA@B=.2P1T[0'Z01;SP4-;&G6XCO52&M^.H;.9'Z"IA>PHY+E4*!= TJ8+
M74509N)H<.@Q4H6X6(,Q$(7MGP(=*VTE=3AF2]-07? ?H"L5<&*'A4C)>B#(
M ,W_ ,)Z@^T2!)U_X2D] U?F,QZ(7D,H,-)J%$;!@.Q*CQLV-?,:CQ(1:%G<
MBG @$/(8P"M]PPRWF7<*ZEA>)C4208SPF#IUKU+ VA=:S]HJ9/GBSZ",3;3L
M8R?.5WX;T 'VE**U_&'_ &OQQ%:\'/.6T(VCGI":J;Q TK5&\D/:,IS,0?S+
MZ1!=SB"(UMGVF<NKBSRAR)0V;<$5R$F@HD9[T0L;7,:<VP7?$&=N2G4+A@P(
ML-YA3"G5U98]0A8J&%Z1@:TGD1SD486*L[Q([=EY@_-(UR^$ZQCAG-1*R2UG
M[74-=VZ$85'/(,:G6/"'U_A>[MRWG0 6($^B!E&E(VT,WA"8>8BVGL?*.:?0
M*QJ^:EW0UB#P0:=X&HL1(V$&7BQG3J?=NUC70788B_HZ*TGV2\?A"Z+REQD-
MB%<F)0(Z)Z=U(DX%7K-I7Q$( Y96%:!@Y:UN,8V3%FH(2[>-$8X,\Z!>;Z1[
M:3 %&;@6I.*KH[Q05*++P+,6V#"O(XA;:B(ZP=(9GE]3WD?&!T7$1ZRT!LCN
MU$/)2]H>FR,+120-KNX,+625U2OO!KWO!?")Q#7Y06$TNS,$C$2C?5$+AZP4
M%!0-13-7Y]&X4!2N0Y^\81OJ"#;GB'-30MS6%Z);H=426 &R/@<%BC@*+*2R
MZZS)>XM990?"!3-E*#, &V-'E'CL!JZ 1;;?+*_N&U83OD2A7GD!JZU&^S56
M!-?6<'. $;JX6BT/.F4Z4X> 9@ +Q;9N9-$^,"X(<B)6 _5 N!7\,QL@'!CF
M7#+A,)#D6J(\ZN&66]ME?2H"(F%<\TA=VR0NXH-0".>1[QV.A,JJ,MB?,A(3
MI>WEJ54#&2> N(Q0>%5P)?U7SR7'%EM0 W?"):@R,IX54+Z=<J\YA]F$UWY$
M;@HB'\ P 5X,H^T&C)U E1HK #O5QZJZ'=&1FE@KE<5%]!+ *HE2;JB+&)22
MN"X8^L"(D%N+^DQ*?.Z6_671=%5^A"%0;95; =K!:08"H;Q[,"$D=Z1./5Q?
M_0C1"MB)<LG(6L7PXD*FPF5O<7&.+ (WQ%12*[P'C1%YT?6M%LO%389\B)E;
M@=T$79MAYQ]XI=P%#>^A@U]_BS0O9@^V')W@!&@_C"LT\<6%_6*5=;?%MU&+
MI;*;\)?3"BM+W#EX;JZ;A4H@=H#I&U5&5Y-4\;G6X6.\63>R65T1]J6@P_N%
M.<<0^G(:[G6,Q;PF\&X6N!0VF4V*MWXU!ISWF<M90)=-:+'BC5MO,$AU4GL$
M$P H K$ UCV*_;#K%CA.O:*SX8=Y:CK&9282^U&9P!02_I,2?A*')3.'&= $
MQVR&-.0B[1PLWR86H.F([B.< P>6DO\ \;*,]4E:[-Q1&L$$@K+VN.8%%:AT
MG4<HI^C*:(.X7>I5Z( "(Y>Z0MQK4&/"4@I>TN3H00_KF3Y1HXW5(\:@G(#C
M9S 145]7C^81I,=4DH5A92W:!$6L+I.2X%F%P!6+F>ZY2VA8>TK>I?!Z=H%C
MRXSLA4I,=4E^-1G*7L4V$XXCH-ZL:P^47O2J3O%A=1+3T9D4FI=JDYM%IRW'
M0*)NAN9&5N*B+YM=>.H2Q:2PGY^UR6]XU'LF%10SOK%FJMRNW! R:(GN;4J*
M=KBP:*99 #81\IK3R,UW(%@Z@1#*/8 ]/D0!W3-$YU #50"S!7E#6],<^*X@
MPRJ\ \7ZD79:X&Q$?&<%DM(1+.84JT$,1RB45EUJ8,QB%#C)#9S8':%8QA64
MY9<!XFQXJ B"H P'\."#LN5$N4=)1TE*JBO"4=)3H0 *"B4="4=)2JHJ4Z$
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@*=)5P2HT2G24?!4Z2EW68A<DITE8E'C_ -?K H]S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image49.jpg
<TEXT>
begin 644 image49.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" .<#OD# 1$  A$! Q$!_\0
M'0 !  (" P$!              <(!08! P0""?_$ !H! 0 # 0$!
M       #! 4! @;_V@ , P$  A #$    ;4@
M                                                        &IR^
M(&NUXTLQ83WS(^>R)7DG&G/(M>4
M
M
M
M                      07=KUHT:W6X  )NISV=S;78Z
M
M
M
M                                       !#EN"JFG4X   !.]*Q9C.
MM
M
M
M                                                      #'^N44
MVJ&+]>0   /IV[6/>W.'V
M
M
M
M             !#5N"JNG4     G6E8LUG6@
M
M
M
M                            *O:52$;D     &\PR76Q[P
M
M
M
M                                          %4].I#EN     #;HO=
MX<:^
M
M
M                                                        !76_
M6KU?K     2A6FM_E7
M
M
M
M           -'FCI1L40    +19MN;:<X
M
M
M
M                          I_K4HPL1    ;'X]WDQ;WHYT
M
M
M
M                                           8CUYI?L4M7D\   9'
MG;DY%W=89
M
M
M
M   !B_7FLFE6B&U#\N "0X);19MK:HO8
M
M
M
M                           & ]^8ULQ83WYR7GLAUY=OB]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             #5Y/'>[EO'?7SH
M
M
M                                                   '1WF,]<\O
M>='7UQWN^[RR/GU]@
M                 JWI5(4N0<F?\>I @EERI+*-:;Z
M                /'WF']^<1[YX.\Z.NCO/OCO=]_GN6\]S<?KW<Z
M
M      //WF&]\\O>>OSW-^.]KH                    '3WF+]<\O>='7U
MQWN^WRR7GU]@                           &/]<T&>/2)H].E\:S+YUV
M3QC^\X  !].YCSW8H_6T1>]RA][Q#)O,/OT<Z
M                                  -9D\48VJ/RX -RBDM5F6MSAD
M                           '!J4OC19X]&FCU*7SJ\OC#^O/     ,KY
M];1'ZW&'WO,,F_02;5%[
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MB.U#%MF'19_'6X        /0[O\ 7DE*M++56;.>/0
M  ZW(GM109=@T">+@           '8[)E:2<J=B3*TO(            !\E.
MM:E&]B(   "18);CY%W[                *H:E2'[4    &XQ276Q[OHYT
M            5OT*T 7JP  S7GU>3%OY'ST
M#3Y?$'7:\1VHL;Z\@            9GSZEVI-,E2;=89              !5
M+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M        _/G=SO-W@  &R1^[UXM\   0S;@K9HUL3Z\@     #V<[>S$OY?S
MZ            ^"*[4,%W8(]GB^0           ?;LDUY)QI6)0K2_0
M            !\$.VX*\WZ^MR>              !MT7NQ%"S+%6;D
M      &$]^:0[-'$^O(   %BZ%FPE"R               (<MP53TZ@   'J
MYV[&/>VV+V            !$MJ&I6I3   L-0LV)H60
M       (\GBKSH5XZGBX               !(,$L]T9Y1K3?0
M !5+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5
M<          _/G=SO-W@  &R1^[UXM\  8WURJNG4BRS"       +*9]J>Z-
M@           ?)$-N&O%^MJ\G@              ;5'[L-0LR[4F^@
M          :#/'6+2JZ7+&                -ZADLYFVMYAD
M  $7V8J@ZM+@   ':[<S(N[]!(              -:D\4DV:/@[P   "T&;;
MF^G.             -'FCI3LT0.0<@V#QZO9AZ
M  &ES1UKT*T<6(@                 -OB]V2S[4G5I0           !5+3
MJ0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M      _/G=SO-W@  &R1^[UXM\ #59?%/]6GK4G@       ;G%)=C&N]CH
M        &C31UBTJNC31@               #=89+.9UK?H)
M   /-WE<="M!-V#Y<                 'V[.U*>QN?9]/.@
M5ET:L%7:X   &P^/=W<:]D?/0            !U.4PV*6B31@   2I6FMWE7
M              -?D\T5W,\#D'/1SDO%AZ&RQ>P
M!C?7*WZ%6%;D/PX                   ))KRV=S;6TQ^P          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\ :3-'3O6IXKUY       'V[=/'N[S#(
M        .CO*[7Z\"7J_6X                 /HG&E8LCGV?7SH
M      UJ3Q4G5J:7+&                   -OB]VVR[FU1>P
M!Y^\I7L4M,EC    EJK-;7+N             "N6A6K[>K    9WQZN[C7LK
MY]              8?WYHCOYP.<@Y ZMGCW91J3@
M 1C9BJWI5,%[\@                    >KG;'9]F=:5CZ          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\#2YHZ;:U/&^O(       $YTK%G,ZT
M      ->]^:E:M/1IHP                  !M4?NVV5<V^+V
M  (]GCJ+JT\9Z\@                   #W<[;#+N2C6E           &J2
M^*3[%'Q]X   !:/-MS93G            $>3Q4VUZ?PX   /MVXN3<D>O*
M            ,3[\T2^@S>0''7(.2R^5<FFA9                     ZW
M*W:-:!KM?@                      $I5IK9Y=OU<Z         !5+3J0[
M;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M   _/G=SO-W@  &R1^[UXM\:W)XI;L4L-Z\@       9SQZO)C7_ '^>@
M      :'/'4/5IXCUY                    'KYVUF9;EBK,
M (IM0U.U*GG<      'T[M4?K?()-QA][''ZS_CU[O/?7SH\O>8KUS7Y/.K2
M^-+F\:!/'AO7D      #L=LYFVIOIS@          "%;D%6M*H   !Z^=NOC
MWMMB]@          #&>N4BV:& ]^0   )_HV+(9]H              #7Y/%
M(/H<T<N <CKDL?DW)MS[0                    Q?KE1]6G'D\0
MR/.[Q!)N47O:8O>P1^LSX]9#G?1Q]'0>/US%^N8+WYUR3SJ,OC2YH]3E\_+@
M       WZ&2WV3=R?GH         JEIU(=MP   #]",+1[^=
M       &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #9(_=Z\6_P"#
MUREFO1U*7P   !DN>I(K2;M#)G?'1K<GF/YXX]L1]#EMLNY+-68
M",+,52=2GY>\      ')M,?O>X)-SA][''ZS_CU[_/?7SO)Y>\Q/KF D\ZO)
MXTN;QH$\>$]^0      /IVRV=9G>E8          $36H:G:E3J<     ')(,
M$LNU)I5K2YOQZ      X-/E\17:AA^W#JLG@     #DLIGVIZHV
M  !4O4IQ):A    W"+W=;'O>GG0          *DZE.)K4(   &\0R71Q[O<Z
M              !J,\=,M_,'/0'+@Y+%Y-V;<ZV                   !K
M_OS3S7I:G)X      &UQ^Y<J32A6EW6&3[       ,5Z\QS8CBRU%%EF'P]X
M      -WADN3D7??SH        %4M.I#MN    ?H1A:/?SH
M      T2:.E>Q1   $IUIK>95P         #\^=W.\W>   ;)'[O5BWZD:M.
M*+,(   VB/W8.A8ERK-Z.=  &,]>8WL1RW5F          BZS%4C5I]#@
M  Y-]@DEZK-*U6;.^/0      U&7Q%=J&'[4.I2^      .2Q="S8.A9
M     $;6(J@:U/H<     ['9CJ33Q1L;A%[         $?3QP3>KQ39B^7
M   .2SF=:G*E8           QWKE(]FCKOOP   !.-.Q9[-M          "%
M;D%6M*H   ![N=NUC7MGC]@              "/+<%2MW.Y!ST#G(++8U^7\
M^T                   -=D\TRUZ.O^_(     ['9<JS3G2GWR"0
M   >/O(EM0P1>@TV6,     "1();A9-ST\Z        *I:=2';<    _0C"T
M>_G0                  !HDT=*]BB   )3K36\RK@         'Y\[N=YN
M\   V2/W/%*>L>C5   [';!4+%@J-COYT              1[/%3O6I^;O
M   /MV7ZDT\4I]UAD         &A3QP3=KQ-:B^'     !9//M3Y1L
M  #4)?%+=BCX>\     DVO+97.M;;%[           &G2^*V:-6-+$0    '
MT[;'+MRY5F           T&>.F6O2ZW   !R6YRKDJUI@        !JLGBDV
MS1\?>    6JS+<RU)P               (BT*M:-J@.0'.1T+3X.E)=*P
M               !@O?FF.O2UN3P    !R2[5FL7GV=FC]@           #@
MBZS%7/0K:=+&     )BJ3VMS+8        JEIU(=MP   #]",+1[^=
M             &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #W\[U'
ME[P  9+SZMMEVY'KR@              :M)XI5LTL=WR    !(]>6RV=:W*+
MV           -2E\5NT*T7680    .2U69;F2I.       ,9ZY2?8HZW)X
M  &0YVS&;:F>I.             (HM0UATJN%]>0   !ZN=N;D7=XAD
M      KU?K5UOU@   ,IY]7=QKV>\>@       !T=Y2S7I:5-&   !+U6:V.
M7<                $"ZU*"-6ER.\Y .06]^<U=QK3
M #Q]Y3#8I:7+&    !M,?NTF9;D*"0              ?!!UVO7+0K>'O
M  +.YUJ<J5@       "J6G4AVW    /T(PM'OYT                   :)
M-'2O8H@  "4ZTUO,JX         !^?.[G>;O      !E?/JX^3=W.'V
M         !X.\I3LT=5D\    #V\[93.M3;3GY             (NLQ5?TJF
M!]^0   !WNW)R+N_P2       5(U:<3V80   !MT7NW>5<V:/V
M    ,3Z\U6U*D7V(@   !GO'J[F->ROGT          /@IMKTH\GB    D*"
M6Y61=^P       "M>C5@2[7    V+Q[N[C7LAYZ                *R;N;
M%NA5Y .>AR"[7RFUD/'H                 #@J1JTXHLP@    3;3GLQG6
MO5SH               &MR>*I:=309XP   !W.W5Q[NZ0R       "J6G4AV
MW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M  !^?.[G>;O      /0[<C(N[_!(               *HZE2'K4     VB/W
M;S*N;7%[              &,]<JSIU(ILP@   #,^?5W,:]FO'H     "%+D
M%6]*H    ),KRVURKGNYT               ?)7+0K0!>K<    $HUIK?95P
M          # ^_-(MFCB_7D   "Q-"S8:A9       $;6(J=ZU/Y<   '8[<
MW(N[]!(                !4+Z7(U.S"Z'( ,EX]76^3V\7ZC]//7KYZ
M              @J[7K+HU0   !W.VAS;4T4YP                !U.5HT
MJT&7*X    W.*2Z^-=[70      *I:=2';<    _0C"T>_G0
M      !HDT=*]BB   )3K36\RK@         'Y\[N=YN\      LWG6ITI6
M              !#MN&J6G3    $BP2VXRKF2\]               '!7F_6
MKQ?K<    $D5Y;C9-WD     UN3Q2#9H^/O    )2K36VR[??SH
M       $$7:]:-&KP    6GS;<T4YP          (JM0U&U*?    .QVY>1=
MD""0      8GUYI#LT<)[\@   6)H6;#4+(                '5WE(_K</
MI]<'(!SW@WNE8M5\WK\$'7,S>(;.]0V@               -/E\4HV:/G<
M  ]O.VYRKDDUY0                  ()NUZT:-;Y<    M7F6YDJ3@
M  52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE
M7          /SYW<[S=X     )$@EN5D7>0              # ^_-'=JAX.
M\    DJO+;O*N>KG0                (1N05@TJGR    6=SK4Y4K
M%/-:E&=B(   #>X9+E9%WU<Z                 ! -ZO6[0J@   9/SZO-
MBWLMY]           5@TJL'W*X   &P>/5W,:_D_/0    !P5#U:<6V80
M) @EN9D7?L                 U6S#47ZG&.#D Y'4R9%Z?L/2'4Y5K1P]O
MBL3Q3U/MT              ?!2W8HZ+-&   ![>=N%DW9 @D
M        A>Y!5O2J_#@  R_GU9;.M3%4F       %4M.I#MN    ?H1A:/?S
MH                   T2:.E>Q1   $IUIK>95P         #\^=W.\W>
M   =CMW<:]MT7L               5&U:<4V80   -TBDN=CW?;SH
M          $%7:]9=&J   ![^=O)BW\YX]    1;9BJ%JT@   ,QY]7=QKV:
M\>@                  *MZ52%+D    $X4[%G\VT          !YN\I1L4
M=0E\    2O6FMQE7     !!MVO6+1J@   9+SV[F-?V'QZ
M   $5:=.N?T&6.7 Z'(+'?/:LHYEP#%>HZA:/S^SQS6;H[>0Y[
M    @V[7K%HU0   .]VX&3<DBO*                    !"%R"L&E4X /H
MF>I/9/.M9/ST       "J6G4AVW    /T(PM'OYT                   :
M)-'2O8H@  "4ZTUO,JX         !^?.[G>;O     )CJ3VLS+8
M      C:Q%3G6I    9/SZN[C7L_X]                   5DT:L%W:X
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MVW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M   !^?.[G>;O    !R7@QK^W1>P              ."DVS1TJ6,   "V^7<E
MBK,                   .EREVQ2T>:,   ?;MX,:]MD7L  "'[<-4-.F
M !+U6:V.7<                    &D31TJV*7PX   )KISVDS;8
M    A"Y!5_2J    >KG;K8][;XO8   \W>4IV*.GR^    )HJ3VGS+8
M             JO]3B:7=K\CHX.09*/W<CXSZ$  5AN8<;2T\_XEM?3WLSYE
M            %=[]:O%^L   !.-.Q9[-M                      #Y*EZ
ME/<8O<_4;'?SH         JEIU(=MP   #]",+1[^=
M &B31TKV*(   E.M-;S*N          ?GSNYWF[P    2-!+<G(N@
M       "*+4-1]2F   !*E::W>5<                    &GR^*2[-'J<
M  $Q5)[6YEL  "D.S1TZ6,   >OG;TXM_-^/0                    %6M
M.I"MN    >GG;WXE_+^?0           J-JTXILP@   ;=%[NOCWO5SH  %9
M-&K!=VN   !M$?N[>->]G.@                 =?>4R^U^=\_K@'([P<DA
MYMNRGS&T  -=]0T]N_.=;FS>)[9U/H/?SV           /'WE#]NAC/7D
M;;%[NSCWO3SH                                  JEIU(=MP   #]"
M,+1[^=                   &B31TKV*(   E.M-;S*N          ?GSNY
MWF[P    6LS+<QU)P              !2K8HZ+-&   /0[>;%O[#'Z
M               K'HU8,NUP  !W.WLQ+^=\>@ ([L14TUJ0   $_P!&S9#/
ML@                    # >_-%MNAT.   "R>?:GRC8           &,]>
M:1;-' >_(   $W4Y[0YML  1?9BJ#JTN    =[MTL>[NT,@
M     U2W7JG]=A<] X.0.IV^>U9?Q=$  "M5C$BN6AP2!'<M16W?IT
M    ""KM>LNC5   'T70R+V^P2
M 52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7
M          /SYW<[S=X   !Z>=OSAZ'MYT              #1)HZ5[%$
M"=*5BS>=:                     &&]^:)[5#R]X   +$T+-AJ%D "I^I3
MB"U"   /5SM\,2_E?/H                     "JVG4AFW    -NB]WAQK
MX           $>3Q4VUZ?PX   .2VV7<EBK, ,+[\TAV:.(]>0   +)Y]J?*
M-@                  ")=G/@7Z+)'(< #BU/R._M5.P  !J7JO4&U\Z!.\
M.K.D.J          !1O:H:I)X   $R5)[5YEL
M            52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$
M   2G6FMYE7          /SYW<[S=X   !)]>:X&3<               %6=
M.I"UN    =[M[,2_G/'H                     "K^E5A"Y7   &RQ^[TX
MM_D \7>4'W,_R]X   )MISVBS;8                      TB:.D^Q1
M O#C7]NB]@           5UOUJ]7ZP   &3\^KN8U[8/'H<%/-:E&EB(   "
M2:\MQ,F[]                   %=OI<:--2B' <#CCW>/=Q?C/H_IT   5
M#L_/:AVL.QVW%?Z';_-@         #0YXZ6:]$   =SMYL6_L<?H
M                           52TZD.VX   !^A&%H]_.@
M      #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   !9K.M3K2L
M            >;O*$;F?X.\   $QU)[69EL                      :E+
MXH]LT.    77Q[V\0R 1':AJ9J4P   +NXU_<HO8
M  %(-FAI\O@   6/S[5@*-@           #K*9Z]'0)XP   ) @DN7D7>QV!
MKM>M.C5    RWGU=[&O9OQZ                   %1OKOG<'/$X XX D//
MN63^<VP   (5DS*^RY#@;CYL6ZA^AY=         %8]&K!EVN   )BJ3VMS+
M8                                   %4M.I#MN    ?H1A:/?SH
M                T2:.E>Q1   $IUIK>95P         #\^=W.\W>    78
MQ[V[PR               1;9AJ%JTP   +IY%[?()
M    *5;%'19HP  !86A9L50L@54TZD-VX   !N<4EW,:\
M        *_WJ]<-"J   )%@EN5D70           !KTGFD>Q1QOKR   !8:A
M9E6M+2S8I>=P   <EO,JY*5:8                   8N2.GOUWS@X'  <3
MWAZTN9>B   !KO8::3?- .+,Q[DJ>;X         HCMY^O>_(   NED7M]@D
M                                    JEIU(=MP   #]",+1[^=
M               &B31TKV*(   E.M-;S*N          ?GSNYWF[P   ?;O
MZ!X6AZ>=               J[I5(2N0   #:H_=Y<6^
M      ()NUZS:-4   ;W#)=3'O 4,V\_!^_(   LEGVI]HV
M          !JLOBC6S0   'IYW] ,+0[G0           !$MJ&I>I3X   !]
MNYWQW7_?D   "<J=BSN;:                    CN_3K9]!B . ' MG\S]
M!LD$X    I?+\U@47 -EY-<B/Z/Z=        &GR^*0;-    ;/'[O1BWP
M                                 !5+3J0[;@   'Z$86CW\Z
M             -$FCI7L40  !*=::WF5<          _/G=SO-W@   V6/W>
MK%O@              "BNU0UJ3P   +$T+-AJ%D
M  :])YHEM9_   !VNW_PM#U\[K<GBBFU0    O/BW]HC]@
M         43VJ&N2>   !=S'O[G#[             JWI5(4N0        #;
MXO=U\>]Z>=                    @O8RH<U,T#C@ 96*2X/S/T6-YXP_(\
M-YBPW(\/R+#<CP_(\-R+#>8\1R+/7)L%)%P 6F\;TE<N@       "#[L%8-&
MH   )]HV+)9]H                                    52TZD.VX
M!^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7          /S
MYW<[S=X   )(KRW'R;H              &$]^:&;>?P   "[V-?W&+V
M                  !1W9H:E+X   %T\B]OD$D26H:EZE,   >SG9\HV
M                     !$EJ'4I?    M1F6YGJ3@            >3O*3;
M-'5)/        ]/.W7Q[VWQ>P                   !5GZ#!TVU6<< #@>
M?-\XKYV/I<    ';-Z[['0."1>7+6<WP       !5#4J0_:@   %Q\F[)%>4
M                                    52TZD.VX   !^A&%H]_.@
M               #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   )GJ
M3VHS+8              $768J@ZM(   >AV?Z%CD
M    BFU%ILL8   L_FVYPISUUOUJ]7ZP
M     G>E8LQG6@            !ILWBE6Q1\[@      %G<ZU.5*P
M             .KO*9?2_-='>!P<X' Q6#X\69X     ^_??1:Z X^W;LOI\
MJD        H_LT-0E\   =CM_L+0]O.@
M       "J6G4AVW    /T(PM'OYT                   :)-'2O8H@  "4
MZTUO,JX         !^?.[G>;O   !8*C9L;GV0              *_7J]<="
MJ                                 )MISVBS;=3=2G$5J$
M                        2K6FMUE7              (*NUZRZ-4
M 2E6FMYE7.0                    :A8K54W, !P '&"^7BZH>     ?7>
M^BWT.!P64;<O]T0      !UN?GWO9_0X  !M4?N\N+?
M                    JEIU(=MP   #]",+1[^=                   &
MB31TKV*(   E.M-;S*N          ?GSNYWF[P   68SK4[TK
M    %5].I#%N                                  297EN'DW:6[%'0
MIHP                                !NT,EV<>\             !P5
M"U:<7680    !F_'J[V->RWGT                    !$=[.@#3R  X ZX
M>8+YF(     <GHM>N !Q*G;]H/6Z       -=D\T2VL\   2G6FMYE7
M                                *I:=2';<    _0C"T>_G0
M           !HDT=*]BB   )3K36\RK@         'Y\[N=YN\   %K<RW,5
M2<              "F^M2CBQ$                                 -M
MB]WBQK]$]JAKDG@                                 9CSZOOAZ
M           Q/KS2+9HX/WY    'T[<3)N237E                     %
M==/&BZY0X' .!QX\_F+QHP!['K,=ES'J3,=ES'9,SV3,=ES'9,QZDI_Y^=Z7
M '&9[)=R3Z@       :%/'2W7H@  "<Z5BSF=:
M               JEIU(=MP   #]",+1[^=                   &B31TK
MV*(   E.M-;S*N          ?GSNYWF[P   6^RKLHUI0              *
M.[-#4I?                                  ]_._H!A:- MS/QOKR
M                               .]W]",'1               BZS%4'
M5I    "9JD]J<RV                     !4C8^=UJ6 .!P!Q*67?W:I:S
M'9<QV3,=D]O?8   %((OE\2C <"Z\OTV>[,      !%5F&HNK3   %B*%FP]
M"R                                    !5+3J0[;@   'Z#X6CZ.=
M                  &ASQTLUZ(   E.M-;S*N          ?GSNYWF[P
M7-R+TA02               4,V\_!^_(
M     Y+YXFA1+;H=#@                                 'Z%8.CVN@
M             "K.G4A:W     ,KY]7=QKV=\>@                    /
M)WS2_9^8^7!P!P!<?(^ER_F4     "E$/S& 0N. "U\OT$D>KH      $/VX
M:H:=,   64S[4]T;                                     %4].I#E
MN    ?H'A:/LYT                   1]/'3'7H@  "4ZTUO,JX
M  !^?.[G>;O   !=S'O[G#[               H!NYV/[P
M                   "S6=;K/HU?EP
M    "_V'HY'ST             ")+4-3-2GP     2+!+<?(N_8
M           -)FJU7TOG^  .!L7B>WN7]&      *30?+X#D0 %B9-F;Y-0
M     "%[D%6-*H   +,9UJ=Z5@
M  "JVG4AFW    +_ .'HY#ST                   1U8BIKK4@  !*M::W
M65<          _/G=SO-W@   O1BW]GC]@              ?GWNYWD[P
M                              #?89='FCZG   !=W&O]P
M                   -HB]=CH             U_P!^:1;-'&^O(     %C
M*%FP="R                    (=M9D!7<@<< #@EFMHV(I;(      I-7^
M7P'(> .!-,FI9";:       A>Y!5C2J   "R&?:G^C8
M                    JUI5(5N0   "_>'H93SZ                   $
M;6(J<ZU(   2S5FMMEW          /SYW<[S=X   +XXFAGO'H
M    #\_]W.\'>   "ZN/>]W.@                            #DI1L4?
M%W@   OUAZ&5\^@                                          !\%
M-->E'T\0      [7;FY%W?8)                    *Z7<6*;&>X #C@L?
M3VI3@T      !1^M\MA>1. !*DFA::?>       AVW!5+3J   "P=&S8S/L@
M                                    5>TJD(W(   !??$T,QX]
M               ",;,5/M6D   )=JS6RR[@         'Y\[N=YN\   %^\
M/0RGGT              !0?<S\1Z\@  "^&)H9_QZ
M           H=MY^!]^0  !>K%O[+'[
M              %>;]:NU^L       -B\>[NXU[(>>@
M "IE_P">U#W6 X' %QJ'TF=\S      "A]3Y/R/+@ ;_ .[EO+/T0      $
M668:AZM,   334GM-F6P                                    *T:-
M6![M<   7RQ-#.^/0                   BVS#4+5I@  "9*D]J\RV
M     !^?.[G>;O   !^@>%H^SG0              *+[5#6)/    O!C7]OB
M]@                             4DV:.ERQ@  "Z&1>W^"0
M                                 #09XZ9:]+K<        ERK-;/+N
M                   <%)]#Y;RO( <<&6Y)<ZC].      .MR@]/Y(  ;IZ
MLW(M?2@      :!/'2_7H@  "1H);DY%T
M         "NFA6KW>K   "\V+?VF/V                   (DM0U+U*8
M G"G8L_FV@         /SYW<[S=X   /T'PM'T<Z              !2[7HZ
M#/&   +C9-V2:\H                             %0M6G%MF$   6IS+
M<S5)P                                         !C_7*1;-'7??@
M       "T^;;FBG.                  ,-V*FEWYD .. 2/'=L]6W@
M !BN1T9J?*@ .MN]6;FV?I0      ->D\T1VL\   9KSZOKAZ
M                          $ WJ];M"J   +L8][=X9
M     !"MR"K6E4   $^T;%DL^T         !^?.[G>;O   !^A6#H]KH
M          %3=2G$5J$   6@S;<WTYP
M*TZ-6!KM<   6"HV;&Y]D
M   5-U*<16H0   )*KR[A%[@6[7    ]G.W9Q[VU1>P
M-#]U*K6?G^  .!/,.O-L6H      -/\ -:FE;YH  ;3ZL72L_3       =;G
MY][V?T.   "^&)H9_P >@                                   !"-R
M"KVE4   %R<F[(U>4                   0-=KUIT:H   L70LV$H60
M      /SYW<[S=X   /T-P=+Z               *YZ%:OEZL   )XI6++YU
MH                             "%KD%6=*H   )+KRW$R;H
M                                $,VX*K:=0   #+^?5WL:]E/':7;%
M+1YHP   -TBDNICW>_G0                !$DF=7.?% < "U-??W[S<
M  'RYB^>(MCH5LAQ  !MWJS<VS]*       *0;-#3Y?    M?F7)@J3
M                               "*+4-1]2F   +=Y5R5*TP
M           KO?K5XOU@  !:'-MS=3G          _/G=SO-W@  'T?H;@Z0
M               A^W#5#3I@  "0H);FY%T
M    #3)HZ1[%$   >_G;^X6C]@
M      &L2>*2;-'Q=X   .2WN5=E&M*-8D\4EV:/A[P   "=Z5BS&=:
M            $$2Y,'291P <#BZ]?ZC))!Y^></R/#<CP_(L/R/#\BP_F/#\
MCPW(L/R/$\CZW.1Z#ET ;KZLW%L?2       "JFG4ANW    )@JSVOR[8
M                                 CZ>.F.O1   %J,RW,]2<
M            5HT:L#W:X   MQEW)7JS          ?GSNYWF[P  #M=_0K!
MT0              !JLOBC6S0   'JYV_P!AZ'?SH
M          ZW*![N?X.\   %V<>]NT,@
M            Z7*6[%+2)HP   )SI6+.9UH 0W;@JIIU    .2W^5=D^M*
M              !6V7$BCWG!P. ?7EME&UA^1X?D6/YX     'UWO/0.<CH[
MOWJW;J?Z(       0C<@J]I5   !D>>KZX=_T\Z
M              !K,GBBVU0   %C\^U8"C8                   %4=2I#
MUJ    71R+V_02          ?GSNYWF[P  #T._H/@Z(               X
M*#[F?B?7D   70R+V_P2                              5 U:<7V80
M !8>A9L10L@                                       "MNA5@*]7
M   W"+W=;'O>GG0 *HZE2'K4    &7\^KO8U[->/0                JM)
M\_'WJF.!P!U1<\=/@      'WZ[STZ Y!)_J]:B;?       &L2>*+[5
M"V.7<EZK,                                   !TN?GSO9_P .   3
MA3L6?S;0                   IMKTHYGB   %\\30SGCT         !^?.
M[G>;O   /7SOZ"86B               !4G4IQ-:A   $^T;%DL^T
M                      !!]R"L&E4   &TQ^[S8M\
M      #Y/H               C>Q%3K6I_+@   ]7.W7Q[VW1>P !X.\I)LT
M=:D\    237EN)DW?H                J'[^<U#M8<  Z*_/-7X      !
MV^SH  3'[T[*2[8       %&-JAJ\G@   2#!+<[(N@
M                  "A^WGX#WY   DRO+</)N@                  "BF
MU0UN3P  !Z>=_03"T?H          _/G=SO-W@  'NYW] <+1
M     AFW!5;3J   #8/'J]N)H?0                       /D^@    #"
M>_-#MNA\.   "YF1=D."4                      #P>N4HV*,LU9I\HV,
MCYZ             ,3Z\TBV:.#]^0   +/9UN<:4X   T::.E^Q2Z7    +(
MY]J?J-@               "F'OYC H@' 'FK<Z8N       =LKD  $\>]:?I
M-@       "N.A6K]>K    73R+V^02
M      4XUJ4;V(@  ,_X]7PQ-                   #H[S\_-W/ZG   -N
MB]WAQKX          _/G=SO-W@  'NYW] <+1                Q7KS0O<
MH=+@   N'DW9,KR@                      >/O*4[%&4*TL_4;&4\^@
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MZ                  &DS1TFV*(   E^K-;#+N          #\^=W.\W>
M >[G?T!PM$                5"U:<6V80  !)=>6XF3=
M         K3HU8&NUQD.=GFC8GBC8]W.@  "([4-3-2F   /IV[6/>W.'V
M                   !H$\=,=>E\N #,^?5@J%B;:<_?SH          $&W
M:]8M&J   !G/'J[V->ROGT    /DIUK4HWL1    ;+'[NYC7O=SH
M      %''ROC>> !P)@BTM@39CU)F.R9GLN8[)[^^P   (9\YE<?&*!ST +7
M>_H)%[=        %,]>E'D\0   %P,J[)]:4
M           0S;@JMIU   !:S,MS'4G                  $#W:]:-&J
M +(9]J?Z-@          ?GSNYWF[P  #W<[^@.%H@               "++,
M-0]6F   .2Z61>WR"0                     #2)HZ5[%+K< &6\^K 4;$
MX4I_3SH  Z7*)[=#!>_(   DFO+<;)N@                    #Q=Y239H
MZQ)X   V'QZLOG6I7JS          :A+XI1L4?-W@   ^G;BY-R2*\H
MPGOS2+9HXCUY    F&I/:[,M@              45Y\ITN. .#Z+U>OJ^UT
M     5J\X<0^<T<]Z !<SU]-LW9P       !%EF&H>K3    V/Q[O#BWO7SH
M                                  &K2>*,[5    2?7EN!DW0
M            !2[7HZ#/&   +F9%V0X)0         !^?.[G>;O   /=SOZ
MX6B                .LHOM4-<D\   "0();G9%WD
M   \O>4GV*.I2^   ,]X]63SK4O59@ ! =ZO6S0J@   6QR[DO59@
M             *K:=2&;<    %KLRY,-28         >;O*4;%'4)?    $^
MT;%DL^T      (OLQ5!U:7    !:O,MS)4G              %%O/RGGYSAP
M 9=)=OW]2      !3;S\UJ_('0 '87H]?5]KH        ^2DNS1TR6,   ";
MZ=BT&;:                       KEH5M\@DE&M*          ."A.YGX?
MUY   ^W;T8M[9(_8                 U*7Q1[9H<   'H=O]A:'IYT
M      ?GSNYWF[P  #W<[^@.%H@                0;=KUBT:H   %J,VW
M,].<                    "L&E5@^Y7    M)FVYKIS@ #Q]Y17;H8;UY
M  &5\^KOXU[-^/0                   $06X:GZ=,   #<XI+M8U[Z
M     !6+2JP;<K@   ;O#)=+'N]SH      %9M&K!-VN   ![N=NUC7MGC]@
M             4;\?*>#G@'0-L6+CR?2@     #PO%'^?+?(  -B[-<Y],
M       (PLQ4_P!6D   !R6TR[DM59@                     ((NUZSZ-
M7DF*I/9G.M9/ST         "J6G4AVW    )NISVAS;8
M JIIU(;MP   "2*\MQ\FZ          !^?.[G>;O   /=SOZ X6B
M        !Y^\HOM4,![\@  #(\[=W%O[#X]                    13:AJ
M/J4^    ;7'[O!BWNQT  "#[L%8-&H   !(4$MR,BYVN@
M   :7-'2_7I>3O   !R7+R+LAP2@        "+;,-0]6GP   #V\[=K&O;1'
M[       'G[RE>Q2TR6,   #=X9+I8]WN=             %(H_EL1R, <&]
M]M6ZD^C      $?*=47SX= <@DA=M-S?          I_K4HPL1    >SG;GY
M%W=(9                     (>MPU3TZGRX!F_/JT&9:E2M,         (
MFM0U)U*8   [7;N8U[;HO8                TN:.D^Q2^'   !9S.M3G2L
M           ?GSNYWF[P  #W<[^@.%H@                "&+<%5].H
M!O<,ES<B[W\Z                  !J,OBENQ1\'>    7"RKLFUI0  !UE
M)-FCI\L8   $V4Y[1YML                  8?WYI1L4=?]^0   )?JS6P
MR[@         PGOS2'9HXGUY    M1FVYGIS@       #5)?%)]BCX^\
MGRE8LGG6@            !36+YG5.5W X!)7J]:R7Z       0/W)@ED\]
M"<N:L]\UP         -<D\4@V:/B[P   #,^?5S<>[M,?L
M     "(+<-5-.IU.  "8*L]F\VSE//H        >3O*%[F?C^\   &]0R71Q
M[O8Z               .ERE>Q2TJ:,   =KM[\2_F_'H          #\^=W.
M\W>   >[G?T!PM$                 ?)2K8HZ/-&   !,=2>U>9;Y
M             ,7Z\TJV*6LR>    )5K36ZRK@    T.>.E^O2^'    +!4;
M-C<^R                 ,;ZY377I:9+&   !E//J\>->S'CT        !\
ME.M:E&]B(   "7*LUL\NX         (5N05:TJ@   'T[<+)N277E
M      J1%\[H'FGP "5?6A:*7>      %3_7SVA=J <] "S?C=E'E\
M    0E<@J[I5    !G?'JXF3=VZ+V                  !"%R"L>E5ZW
M !F?/JV67;D2O*        *P:56#[E<   ">*5BR^=:               %9
M-&K!=VN   !*]::W&5<           'Y\[N=YN\   ]W._H#A:(
M        &ES1TIV*74X   !/-*Q9;.M                 #P=Y3C7I:--&
M   ![^=O%BW\]X]     5JT:L"W:X    GFE8LKG6N0               #%
M>O-0-:GHDT8    MEEW)=JS         " KU>MNA5    V'Q[N[C7LCYZ
M      !4O4IQ):A    S/GU=[&O9CQZ            %8XL*)/&< =$J^[]H
MI=X     #J<I%)\MYGET  +D1_2['R<          "I6I3B6U"    ,GY]6W
MR[<BUY0                !UN5MT:T#W:_    !D.=NYC7MCC]@       #
M59/%'=JC\.   #DLQG6IVI6              ! ]VO6C1J@   "Y^1>D""0
M          ?GSNYWF[P  #W<[^@.%H@                 "NFA6KW>K
M "<*=BSN;:^@               #&^N5#U:<?3Q    "U&9;F>I.     //W
ME*MBEILL8    F6I/:/-M=_.@              :+-'4K5IZ_P"_(    F2I
M/:O,M@        #2)HZ6[%+I<   '8[<O(NR!!(          ,=ZY2/9HZ[[
M\    2;7EN#DW>0           ""8\JOL6. !*ON_:.;>      TGM6I<OSH
M#H#D]SW=J#ZGD           \/>4MV*.H2^    !VNV-S[,]T;'T
M        :_[\U3U*D>3Q    #DM=F7)@J3         "I^I4B"U    !R60S
M[4_4;              @&]7K?H5>    "2:\MQLFZ           !^?.[G>;
MO   /=SOZ X6B                  .IRE^Q2T6:,    2[5FM1F6_5SH
M            &E31U)U*FMR>    !+=6:VF7<      &L2>*3[-'']X    -
MZADMCEV]DC]@            #S=Y7F_7@6]7Z7    !N$7NZF/>]?.@
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M  #W<[^@.%H@                  :[)YI+L4<9Z\@   #=(I+8Y5O:H_8
M            Z.\K]>KU_OU^AP    ;5'[NMC7O?SH      $7V8JAZM/X<
M   'NYVQV?9G"E8^P           ?)$5N&NM^MK,G@    #+^?5U<>]L<?H
M        56TZD,VX    -_@DN9D7>QT           "O5^M76_6    [W;I8
M]W=H9           !A>14?K?+\.. )#]W+<6/HNMS%<CPWF/#\BP_(\-R/#\
MBP_(\/YCPW(L/R/SO/OT/7;,'+H =39%J3W#K@           #3)HZ:ZU/&^
MO(    'H=GJC8GNC8R7GH            $>3Q5NT:VB31@    "5:TUM\JY]
M@          KY?K5SOU@    -IC]VAS;4BUY0         !'<\57M.KJLG@
M   ">:5BRV=:            'Y\[N=YN\   ]W._H#A:(
M    C>Q%3W6I]3@    ]7.V)H69VHS]SH           X(FM0UTT*VJR>
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MQ;9AX     -OB]W7Q[WIYT            ?GSNYWF[P  #W<[^@.%H@
M              0G<@J[I5.     #:8_=B,^S+=6;[         !YN\B2U#
M]Z#3)8P    !Z^=N-DW=^@D         KIH5J]WJP     &UQ^YLI3R]5FS7
MCT      !\FASQQ!;AA^U#C?7D     #W<[<#)NR#!(         -=D\TCV:
M&.[P   "V67<EVK,             ,#[\TBV:.+]>0   )FJ3VIS+8
M     K+!AP]'F@ <<     #NF[D=+T'0'(Z%R:7TV;Y*             -,F
M\4\UJ6&]>0     .QV2*\DNU)I.KRYCQZ       'R:/-'%-J*'[<& ]^0
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M      #+^?5OLFYO4,@         ZRF6O1T&>,   "9JD]J<RV
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M)-OB][%'Z]'.@ ?)A/?G6I/.E31Z#/'']B/"^O(      &3\^K>95R0()
M        (.NUZRZ-;K<        ^G<CY[[./5SO3UY.\QWKG0X        !M
M\7NW65<V:/V         !7:_6KS?K    ;/'[NWC7O;SH              %
M8-*K!]RN   !D.=NWC7MDC]@         #HYYHW5^6QW/  V_P!6=0\U@
M ,IK>^V?H =<@DJ&]9BGN               8_URJNG4BJS"         !Z>
M=]#O9QT=YY>NMP         >KG;-9UJ:Z<X              C*S%475I^=P
M                   =SMLLNW*]68             #\^=W.\W>   >[G?T
M!PM$                     0M<@J]I5>IP       #Z=]_'M\]]?.]1X_7
M,?ZYYW         -JC]V[RKFU1>P           (WL15/U*F(]>0
M           )CJ3V?S;7MYT         "/IXZ:Z]+K<   '<[=''N[Q#(
M            /+WE*=BCJ$O@   #>X9+GX]WM=          %<(,6$X\L 6$
MEV( AR>EY'+N2[[S'9,SV7,]DS'9,SV7V>_5?]7'=#D= "?*FO,M;3
M         '!!=VO6_0K>7O                     -UADM=F6]LB]@
M          ".[$51=6GCN\                  'MYVVV5<DRO*
M      /SYW<[S=X  ![N=_0'"T0                     (]GCJ9JT\+Z\
M@                   2Y5FM)FV_?YZ            !A/?FK.G4C&Q$
M               ,OY]6<S;4N59@         !C?7*1[-#7O?D   "R&?:G^
MC8                &H2^*4[%'R]X   !8"C9L?GV0         !K?F"EE?
MYGX<Y!-LFI*?N_\ 3N8[)F.R]_>@ ".YJ58K^$'7(!R.K6YOT.Y160
M         !JTGBK^G5CF>(                   >_G;$9]F=*4_8Z
M           -4E\5)U*>HR^                 !LL?NW&5<W*+V
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MYN\   ]W._H#A:(                       B6U#6G1JX#WY
M      'V[,U2:Q^=9R_GT               !X^\@J[! ]ZOB?7D
M      ?3LK5I;%9]G;8O8           A:Y!5G2J    97SZN]C7LYX]
M              5%U:<5680   ,YX]7=QKV6\^@         -=Y#3"'YGH<'
M)=V;ZC-=E    J1J?.ZQ+7 =#D&Y16K5Y7T                   Z7(>MP
MP%?KZI)X               &1YV;*4\Z4K&>\>@                   -"
MGCK3HU=#FC              &U1^[)YUJ4JTH                _/G=SO-
MW@  'NYW] <+1                        \O>0;=@@2]7P_KR
M      /HE*M-8K/L[C%[                  \O>0W;AA.Y!I4T8
M     ]G.S%4FG:E8VN+V           !JTGBDNS1\?>   #DMUE7)4K3
M              #%^O-(MFC@??D   "4:TUO<JYR          0#XR('\9(%
MB_>S-?O4   &,]1TVV?FN!T.0.A,=+3GG/U@                  !P1Q8B
MA6Y!%MF+R=X            .QV0H))EIS2Q5F]G.@
M #@BZS% UZO'D\7            !N44D\T9Y@J3=CH                'Y
M\[N=YN\   ]W._H#A:(                        'F[R'K<,)W(-&FC
M          'KYV7ZLT[4;&WQ>P                   !J,OB)[4,8V8M(F
M\=;@        &2\^I)KR2I6FE2K+[.=             B>U#J$O@   #/^/4
MT4YP                  !HTT<8V8@   !,M2?8H_0         '0Y3R/YS
M5.5QMW;%QY/I   !&EJC6[3Q'0!T.N2RF5MR/5N@
M>+O(SLQ1?9BCJQ'KWOP         ,YX]2%!))=:64*TN6\^@
M           !JDOB'K<,568=2E\<         &P^/<IU99AJ3;U#(
M           (3N0=8  !W$U4YP                         !JDOB)[4,
M868M'F\=3@        &0YV2*TLJ5I95JS>[G0                      ,
M=ZYHTT>D31ZE+YU>7Q@)/.']<^7   /0[FX_6R1^MIC][G#[WF'WN$,GV
M                                                      :OR"GW
MGYSR/(MWZ^BWGMH  "O^ECQ)>SP'0 YZN)@?29;Q(
M   !@/?G29H].F\:M+YUR3Q@_?,5Z\^3O.  <F0YW*>/6<\>MCC];+'ZW&'W
MN<4FQ1^@                           ,#[\Q]8CT>:/3I?&LR^<#[\_#
M@   Y,QY];-%ZV^+WN\,F_P2;7%[
M                     \'>:-/'H\WC4Y?&K2^,![\X?WSX<   ]#N:\>MD
MC];1%ZW.&3>8?>Y0R?8                           /@Q_KGA]<Z'/CK
MMX]'.Y#SWV\[R
M             ",N4:M\POGJ1URUG=\  "I>Y\]K,\ #H 9N.6W_ ,_]&
M                       !TN>;TZG/IWOX]''VZ
M              !UN8KWS%>N>7O.CKY._CT\[E//<KY[Z.=
M                                             'P>#USP>N=+G7UV
M\>CG??Y[[N=Y
M                                                !#3,KFQA;=]#
MO2V !X/7BFOT?S7 ZY#KH"2J5VQ^+M
M
M
M
M                    "%V97?N/MBQ<#GT78Z -!MTZR;N('0Y'0$ZY&K,>
M9I
M
M
M                                                     13W/K9Z
MQ9TYJSKYU0!".MEPKJY@'/0 =6>^>W=YIV@
M
M
M
M                         !I7:M9/>)9?QM[SRT!6;Z##T&]4 =!T.2XW
MR7TF0\>P
M
M
M                                                           ,
M:\0-[R9M\Z>>Y,*>_6?.8J6,.N0!UFH9;>?)?1
M
M
M
M                               #2O57;_-GQ2>*>?7_ #CKD#H.A(>=
M<LE\UM@
M
M
M
M#3+M6KWU6$Z#H<]!U,F'I3?@:H
M
M
M
M                    B[6H5]^EQSHX ..!8;YK8D_*O
M
M
M
M                                       "$]W,A7=S#HXX X!:7Y/<
MW.E9
M
M
M                                                          $
M_0Y42:]  <#@<%P/C]_-P2@
M
M
M
M                "N'TF1&>G3<< .CC@78^+^A[>=
M
M
M
M                                    %;OH\F,M*F#O' '!Z?'JZ_QV
M^
M
M
M                                                       !6[Z'
M*B_2J#@ XX&5B]W.^2W0
M
M
M
M              *^;F;#VM2XX ''.C+Q>[G_ "FV
M
M
M
M                                  !#FI2KWN9PXX.@<&5C]W4^4V@
M
M
M
M                                                     -0LPU%^
MER.'1P!QP=G.WG^3V^0
M
M
M
M             <%,_IL?7IO X .!SMW/E]C*>/0
M
M
M
M                                 $0Z-6M>UGCC@Z. 6TP-*0*DX
M
M
M
M                                                   '!5;<SHTN
MU^'1QP!/^5<GC,N
M
M
M
M          #S=Y6?9H1-=@ XX&XUY;E8.D
M
M
M
M                              (YM0P;HU8\LQ=?0XXN-AZ&]5Y0
M
M
M
M                                                    /#ZYI<\6
MB6(XCN0;C!):C)N@
M
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M<O:4-C$3#0=8;E)[P,.&6#5+CI)"%"Z*D8@^MGU33$%Y13(3;IG@(3+A(ZC
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M=+[%@ _@VA\_5,%MOM.E,?(PLHGP+8U]QU+@6YA9*5REN[>]4KE+BP6H4?\
M5^MT#_$KN!H)7.'!N%UDWS X& >X%T:I>105]-4" R6=PVW=7A#K<5#<3!QZ
MS(V#_,,1K<B(;0J&N"3<%NR?D)87$1YBB=C 6^8)ND<"CS9:P,A)Y0WOPFZ7
MV+ !_!M#Y^J8+;?:=*8^1@IIG746!D6+:^Z9_P!96P-A*YRN;A=5-]0C@9![
M@'/^JV>YDKX+4IOD+;@Z4WFJ!@+CU%3 (LAPM4_VMSDEAHKJ#K65PVO&,-N6
MMQH^TOLUZ"%@;A/@43$O$^ 6?U;JM-%5J:I5TZ)W'^7-S VDWFZ[^%72^Q8
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M9+FB_P"KO32W!IWZ"& @8%<*8# KV1 H%N.CAP+=$E*!;J50+<]1J@6X:T)
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MD0 .&:!U[F=Q1N!+*X;7C6*WS4YJ:TCM<=#<3!AJS N"BBH6MFMFENINF4"
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M1+B(C)9BU#=(RM.-1M,;2.*<VDVFFH3W#FU!:6H;IY&VYU(6MJ&V6?#=4?Y
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M[1.)Q.)Q.)_5]5]PFN=(T+RP*+BKJ2?TNS=%$[2S]P4;1T:8947#)!V%L74
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M2</ZPTWB'1OM7Q,9[2/63(:9.>@8^X*+XFV?TRR_-%WK.TV;KHVKI&F&5$[
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MV;_2"".1U;+=P3.=)]RX)#.G9W/P-+.'6\,[0O/UR,73%PQAF,.,,1<$71!
MH#1-JN*!I/(OI_2K*>1%%8NJ(V=D36*-I,D:<94#EL=G5>11?1>3N%G;E[S]
M2D*Y&%V;_2""GD:-G5)4N])U%Q4MN9;Q%>I20O.%V8CI@B6>HL[<_<:2U! F
M84HJ,S49<OCS26@+$H(*3([/<G&'%P1<$71$J1H#1LKO(I/MW%3_ $FS'W2H
MVE,E3V>RIYDT;4<AIQE0.6QV=5U<N])Y%Q6W--XBO4I(5R,+LQ_""",_6.4(
M5?3.B\W?3MH!49"&T!"94%(2O.'6</F-,VC$5* )<A2><OGQ50HH,Q"5!0F*
M3[=X7ANQU=G7=5+O26B^F4$2,C^D-FZL&B^F\C9V4W447S-9TXRH'+9&U7TS
MHO(OIVT"9D(;1AIE04A*\X=8N<QZ[,O\:3[=TWAMC#=T7C2M"[RKNE GR$-H
MPTRI6AS\!79<N&1RIOMW3>'ZBTN^F=*T-S]PW!I@2FN'&"CF,M0DWD@T7$W%
M2V5I%]4J)Y03,STXRH'+9+,N1NTK0W=-X;99VY>XTK0N9N^L&1F(2J^)T5)"
MA(PM)09':F&KQO'*DZNXF>FL[<O<:3KF&F,]!9W9^PTB H2,.(+9E^H,+N*I
MOM7#,9;<PU/W*^KEG"N:84DI,CIK,J:94;0B8O#9;.BZF]1?5=1J!E0.6R R
MYPA5],Z*@%"1A:"@R.U,-7S,Y4G%W$SHV=<C=-)UO$'F,MH:;+A@"0D*3SE]
M6E8;OF9RI$A(F8<7B*GH09<Q#3F(F=)UO$$9;&,]M8<OID:1 (D8<;+9VQEF
M_P"XY>E2 L2,.,%',9:6SJDN5)Q&&J6QM(OJE2M*N=W4#*@<MEL[ETW32=;Q
M!!$N1VAMLN&4 !(D*3[E]5)I>(F=)]J][D[.E)69"$("!(4GW+HNC2H25F0A
M*0D2%)]R\;HT;:\-4X!F)BE:&I^\:T^I.>G.F0NXJ< WA,4E)"Q(PXV6S([4
MRS?YG*@XP%<TPI)29'1@R,X2;PG1=;Q$[%G#3>&F5):KRIZ@94#ELS2[Z:3[
M5_W#/9TI*C(0A 0)"D^Y<$A3:<PU4WF?R3LJ4E1D(;;#8I*4$B9A2BLS.E9;
MN#S2?<N"0STK#MTW33>;N'EEK#GZDYZ<Z>SN73=--: L2,.-EL\]H:8O>Y5)
M20L2,.M8>CLRIB[2?:G[QL+#4O<:5H5=1+OJ1E0.6S-+PU3IO,S]R=E *C(0
MTV&Q2)"1,PM5\S-2SN3]AIO,3]R=C2DJ,A#38;%-]R\;HTMG;_,TEK"!,PI1
M49G3,.7Q(YTE)"Q(PI)09'5J]2<].=0P[?$CG34D*$C#C);_ .;,TQ+FNF2$
MB9A:RLS.C;7<5.F^S+W)U[+,_<JF\N^K4C*@<MGL[GX&F\S>]R=C2DJ,A#30
M;'FG:'+QNBJ#+F(;<Q!.FZQ>YIS@B7([ VT7(0@($A3?=NBZ-*TWB*C*DZYB
M'3I44F8A"PL3%)YN^.6>K5ZDYUAL()29B&W X)U';/\ *-C0@K,A#;0;_P"U
M'W;YNC+2V==Y,J;S'Y(UK+'Y*IOKN)U0RH'+9\H:<Q!3=9O\QG!$N1V!MHN0
MA 0)"F^[<$AG7;66S. 0H3%-QH.0M!09'6@$\A#=G^5QE3<<#8G!,S,Z0 J,
MA#: V)4K0Y^ U+3F&:=H:E[QJE9>I.=6<(YT%9:I"R@S$)4%B8J.,AS_ +"V
MU(SV!NSD\U0$A(D*C[LO8-,A=Q4X!F)BFZP%<TP01R.I )Y"&F+O-51U>(J>
MJ&5 Y;0A909B$J"A,4W&@YG"VU-YZT">4-V?Y7$I4W%AL3@DJ,SH&7;AD<JA
M 5R,.6<CFC5HLZE9PAM*,JBE! F86LK,SI6&[HO&DZYAC5V=W\#2(G#K>&K4
MGU)S^LQ%X1?$8@C$C$,7S%XQ,_5H2307JVW"V82H*$Q4(GG"[-\H@I*>1UB&
M5+A#2457G;G(9ZBSN?@:BVTKSAQE2-.VRI<(;2WE4M#DO8-6,J!RVEEW#/BH
M0#R,.6?Y1&6J19U*SY0AM*,JBE!(F8<67#/1,/2]JJJVDKSA;"DY<], 3E";
M,H]4(:2C*J2$B9AUPN'2L-WS,Y4E$)$S"UE9F=8RYB#S2<0'!*""DR.I.?JF
M:@YQ*5!>>L;<+9A*@H3%4I"N1A=F_P!84A2,]0AA:L^4(90BLZ[ACS!,^9U+
M3F(FJMA*LH6RM&C0RM<(82G.JXO#3."9\SJQE0.6U,/7?:JJMM*\X79U)RYZ
M8 G*$V91SA#249520!,PZZ7#XTC#WXJK*;2O.%68_C"D*3F-"EE:OB$V8#J@
M)"<JQ(2)F'72X?&E0@K,A"0$B0I/N7C=&6M0LH,Q"5!0F*3[5X7AJ5YZ)D37
M1/,ZUMPMF$J"Q,5U,(5"K,H904*3F-$EE:OB$V7_ &,)0E&0KNO7.0S@F?,Z
MI"R@S$)4%B8K*:0O.%64_B8+2TYBJ&UJR$)LQ_(PEE",JRE!(F8<67#/6#*@
M<MK8>_%593:5YPJS?ZF%(4G,:%+*U?$)LP_*$I"<JQ( F8==+G_-,R]^*M I
ME"OB#9>Q@V=8@M+'Q$B,_6$*/Q 8</Q LI^3 LZ! 2E.0T"E! F8<=+ATS3>
M&*3[ET71KV'+AD<J;[5TWAJ%Y:*SIS- \AKT+*#,0AP.#EH2TA7Q!LR?B#9E
M?!@L.#XC#6/B)$>JZKM :6?B!9UP++W,"SH$!(3EH77[O).M:=PSX@&?,: I
M2K,0;.V8-E'P8X4]XX9<<,N.&7'#+CA3W@64?)@6=L0$)3D- 3*'G<0\LM:,
MJ!RVQE[\5:!32%?$&RCX,&S+$%I8^(E+UA"C\0&'#\0+*?DP+.@9P$)3D- I
M02)F'72Y_P U#+\O:K271VBXGM&&CM&&CM%U/:)2TCC@;'.%K+AF=-9V_P S
M2<6$)G!)49G8+.Y/VFD0%"1A:"@RU!Y>DCYJ,ID@4'>2=@2HI,Q#3P7R.>FE
M%T1=3VB0TQ,N9AU^]R3KV7</D<H!GS&TY0\]?Y#+7#*@<MM:?N^U6DNCM%Q/
M:,-':,-':+J>T2EI%N!L<X6X7#SU3;Q;_P"0E06)C:G7PGDF"2HS.F9;Q#XI
M90ZYB*V$&1F(;7B)G2=;Q!&6G6/GTCFF7IE%TQ<,7#&'&' ;!,HE0?SEL3=H
MER7 (/,;8XZEO.%N*<SV%ITM_P#("@H3&SD@"9AUXN<AEKQE0.6W-NEO_D)4
M%B8VIQ\(Y#."2HS.L2LH,Q#;P7R^=G4H)$S#CY5R&G2DJ,A"$! D*5H<_ ;&
MVO#5. 9\Q2M#?YC3D3'I1%T&+HB0H-":J+IFH[&AQ3>4-O)7M)(3S,.6B?)&
MR(<+9Y0AP.#ELJUA F8<<+F>P#*@<MO2HH,Q#;X7R.>SJ4$B9ART%7).P-V@
MIY*A*POF-D<M '),*45&9U##=P3.=)YS#'G9;.Y+VFF\WAGQIU#T#.FP.4Z&
M49[*BT*3R,(<2O+9299PNT@=,*45Y[,"09B&[0#R5L;CX3R3"E%1F=A&5 Y;
MBV^4\C"5I7ELCEH">284HKYG8@2.8A%I^%PE05EL"[0E.7.%N*7GJ6&KQO&D
MI02)F%J*S,[,PY?$CG26D+$C"DE)D=,1.NVF210>,D'9\H1:%#JA#B5Y;"5!
M/,PNT_ZPI:EY[4V\I$(>2O7K<2C.''U+Y#8QE0.6Y D<Q"+3\+A*@K+8%OI3
MESA;JEY[,"1S$(M)'5"74+RU9(&<+M('3"W%+SU3:,14H D)"D^Y?,AELZ5%
M)F(0H+$Q2>;OB8STZAZ$T4B\94;2>0&U)?6F$VA)S@$'+6*?0F%6E1R@DG/;
MD/J3G"'D+U:W4HSA=H4>G91E0.6Z D90BTJ'5"7D+U9(&<+M*1TPMU2\]K2Z
MM.1A-J_V$)>0KYTI4$YPJT(&4*M*CE!).>L;>#8E*.*\1Q7B.*\1Q7B.*\1Q
M7B.*\1Q7B.*\0NT%0D!M+;I;,<5XCBO$<5XCBO$<5XCBO$<5XCBO$<5XCBO$
M+4%&8&G(^HHV<37.C:3-<ML!*<H3:%C.$VE)S@+2K(Z4K2G,P;2@90JTJ.4%
M15GN:7%(R,)M7^PA+J%9'2J6E.9A5I'XPIY:OG9^)5VCBE=HXI7:.*5VCBE=
MHXI7:.*5VCBE=HXE7;=TNK3D83:O]A >0KYTI4!G"K0@90JTJ.4$E6>X!13E
M ?6(%J[B!:40'FS\Q?2?FC.48B!\P7VQ\P;4GX$&TJ^!!=6KY_\  ;*GVDT5
MF\HG< M2<C M"Q M7<0+2B,9L_,8B3\Q,>N\(Q$=X+[8^8-I1!M780;0LP7%
M',[TE:DY&!:5C.!:A\B ^V?F XD_-,K2,S!?;'S!M*?@0;2KXA3JU9G]L"B,
MH#ZQ M7<0+2B \V?F+Z3\T9RC$0/F"^V/F#:4_ @VE7P(+RU?.]WCWC$7WC$
M7WC%7WC$7WB^KO$S_P"#LINH H.&Z@G>;QB\KO%X]XF?TB^KO&*OO&,YWC'<
M[QCN=XQG.\8J^\7U=XG^\7CWC$7WC$7WC%7WC$7WB^KO%X_^FH%Y0$2H6LR;
ME_:]E3>=HVX\PG^TCZ;"G-5&UF;I_M,CT6-,FA$HE$HE$HE]5JO**O[3G.#R
M^K2;J *#RKC:C_:L^_T:3>6$_242B42B42B46\W6?^_VO8TWGTQ*)1*)1*)1
M+Z?Y,\DI_M?_ !J9ND^*/^25-T#Q_:_^,'6:-M,WU?VO_C>A1HOF\ZH^?[7_
M ,?]G_[1)F9_VO8/LT%&0/\ ;%@^U_\ :#O0K^V/\>?810=^VK^V+ KW$4'.
M@_VQ9EW'0:!Y_P!LM.8B J@X)+(_MBQNW57#\T+4).G^V;._B"1S]=M3DK^V
M02DS$,VD+Y*S]3Z;[9']MMVA:.6<(M+:HGZ'T7%_VX%%.4"T.#YA-I68"R8M
M(FW/^*__Q !4$  ! @(""! +!0@" @,! 0$! @, !!$P!1(A(C% 05$3(R0U
M0E!287%R@9&AL<'1%" R0V)SDJ2RX>(T4V!C=! 5,X""DZ+P@_%DPD14<-*$
ML/_:  @! 0 &/P+_ /(]4O:;D91=68*9-EN41D4;]7=!+\\^Y3DMS1S13;&F
M-(FWVN(X1 #^ASB/S!0KG$);MO!9D^:=.'@.7^=ER2L:JVF!>K?R(WAOPI:U
M%:U72I1NGQT2EDE%V5P)>PJ;[Q"5H4%(4*0H9?YUO 955$VZF^6/-I[ZI%BI
MI5+*S0RL[$[G^=5Z:=_AM)*C#\V]_$=53P;U4"#01EAI\_QDZ6[QA_.HW*@W
MTRN[Q4W>NBLFI)1N.HMT\(_[Z/YU)1K(EBVYU'NK+'JSKM><$?SJ,G/+)^)5
M98WUR?YU)"; O;K1/2.VL:<HO6$*</-1V_SJ3+2$VSJ-,0-\?*FL?G5IH5,*
MH3Q1\Z>;^=53S:*)28-LDC E65-4U*M@T$TK5N4Y3#;+2;1MM(2D9A_.JY*S
M*;9M?.#G$%F832@_PW1@6*A$O+-%UU6!(@-BA<RNZZYG.;@_G75+338=:5GR
M;XA3LEJV7S#^(.3+R00101D\5+EIX-+'SSHP\ RQH<NFEP^6\KRE?SM:JE&G
M3NJ*%<^&"6)A^7WKBA&NAH]1]4:?.ON\0!/? +$DW;C9N7ZNG_\ [?)2JR,N
ME0N$%=%$7MDI0_\ ,F-*>;<XBJ?Y7+]Q*.,:(OY^51QGDQKG*?WDQKE+?W!&
MN<K_ '1&N<G_ 'T]\7DXPOBN Q2D@C>_':+(-)H:F;B]Y?S[_P!HT&?F$49-
M$-'- $PEJ;3EI%JKH[H2AU2I)T_?>3[4!232#@(_ FFOMM\90$7UDI7^Z#%V
MR"#Q4J/4(^UJ/_$KNC^*Z?\ B,87_P"W'EO#_CB[,+3PM*BY/CE;4.R+VR4M
M_4X$]<:5,-.\18/_ .)TN.(;'I&B+ZR4H#ZY,:Y2W]P10BR,JHYM&3%*%I6,
MZ33M9?K2CC&+^?ED<9Y(C7.4_OIC7*6_N"-<Y7^Z(USD_P"^GOB\G)=?%=!B
ME)"AO;=4S,PTP/S%@10EY<RK,RCOHBB6L>>,ZYV"-++$OQ&Z>NF+ZR+PXAM.
MJ-.F7G>.X344@T'>C2IZ8;XKI$7)]:N.D*ZQ&G-2[XXI28U3(.M^J6%=T >%
MAA69\6O3@BW9<0ZC=(52/QK,RM%*RFEOC#!%!N'Q1H#ENQE87=2>Z*6CH<PG
MRV%&Z.\;?$/3[5L-B@VYZ(HEV'Y@Y[B1&IY5A@>E2L]D?;2@9FT)3&G3LP[Q
MW2:S29M]KB.$1<GE.#,Z J-42K#P]&E![8 F&'Y8YQ?B &)]DJ.Q4;4\Q_\
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MU3RFTT%:S22<:*E*"4C"3!1+TSSWY?D>UW01H_@K1\VQ>].&*3=.,A224J&
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M"QS=#^%UA.SWQOU?[OF%4S# O"=DCY8QX3+IU:P+E&S3FJDK02E232",D7Y
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MY](NI.@K/2.WGJ96DT)>I9/+@Z:,;<E'KE-U"]RK(8=E9A-JZV:#5"Q,TO\
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M,LC4SQTQ(V"NXXFEA-*64WSKFY3#;#* AIL6J4C(-JI27W*2L\O_ %42TO\
M>+ /!EC,(TR;8;XS@$7UD&#Q56W5%R94YQ6U1>,S+G](';&EV/6KC.T=D:7)
M,IXRB8O?!V^*CO,?;2GBH2.R+ZR,SR.D12M]Q?&43#,TK^.6PEW?4+E/-1XH
M94:79;2SQ<G^[V)RDJ#==<MCP)'SJ9R=4/(2&D\MT]0_!;7Z9/Q*J6^*-J;(
M<4?$*EKU:^K%G>,:F4S("U?XG:"<F<!;:4H<-%RJDV2*%E&B+X3=VRGF**$Z
M);)X#='74R)RH26SR&C]FA_?.I3V]E2RZXWHJ$+"BW31;;T:U>\?3&M7O'TQ
MK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[
MQ],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],
M:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>
M\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3
M&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7
MO'TQX8F6\&)0$J3;VU-&7 *E]@X67N@C_O'')=]%NTX+523"Y==\V;YIS=)Q
M%MEE)6ZX;5*1E,)8%"GE7SKFZ5M7-9D'0QR?.H"FUE"\Z308OUJ7QC3B#:":
M&YC2CPY.GKQ-+&1AH#E-WNJ9<T7SY+IY<'0!^"VOTR?B54M\4;4V0XH^(5+7
MJU]6+.\8U+[FX8/6-H'497G$M]O94MJ6C1$!0*D4T6PS1K5[Q],:U>\?3&M7
MO'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'T
MQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5
M[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q]
M,:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U
M>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?3&M7O'TQK5[Q],:U>\?
M3"9H2W@J@BT(M[:G?P"IFY?*T[;<X^7[+'2^\M9Z*.W\"SS&1;07S'ZL=4S<
M2^B^97F/="V74E#B#:J2<AQ 64F4:>Z-)2=BG/R[5K<5Y*128<=5Y2U%1J ,
MV(I6DT*2:08EIH>=0%'ARXE9%S\THYKG94)2D4J4:!#$NGR6D! Y!^"VOTR?
MB54M\4;4V0XH^(5+7JU]6+.\8U-DG,P;'7M!8Z7SJ6L\E'>?P+-,Y'&;;E!'
M>?V!'W3*4]9[?P*A/WC2T]O9CQLI+(TYL:<D;).?DK]'?3J)@WWIJW.UDVK*
MI.ACEN5).)/2I-UA=(XI^=.(J6KR4BDPXXKREJ*C46.;PZ<E1Y+O9^#&OTR?
MB54M\4;4V0XH^(5+7JU]6+.\8U,^YG<2.8?/:!AK(VP.<D_+\"RP^\2M/^-/
M9^R?.903S) _ MCE9W+7G%';C^CL)U$^;WT#N:UJ48%\O"K(D93#4I+BAML<
M^_M9*L?>.6W,/G4$XF62;C[93RB[WXC9%>:77U5+:ONFUK[.W\&-?ID_$JI;
MXHVILAQ1\0J6O5KZL6=XQJ75;J84>A.T$YF3:)_Q'X%L:K\Y*>>Y^RR2O_(7
M\7X%DG=P^A73C[LI,"EMP<V_#LH^+Y&!610R&K  I)R"+=U.K7[KGHC<[6MM
M9&F^D_Z*BC/XNELN.<5),7MCIGE;(C[$4\9:1VQ?>#M\9SN$:9.LIXH)C3+(
MJ5Q6J.V+]^97_4!V1=EUN<9Q79%[8]D\86W7"T;DT>+*3& -N G@RXC/G.D)
MYU"IG7=RS:\Y^7X,:_3)^)52WQ1M39#BCXA4M>K7U8L[QC4LG=.+/3M!9(_G
MJ'-<_ LN[N'$JZ?V32]TZH]/X%0K,H':!R9*DM/RJ;9*SE&YJW'WEA3LN+9M
MD_%R;73KF$:(4CDN=E0B;F'W6[8D)2BC!%\9ASC+[A'V*VXRU'MB]L=+<K8,
M:6PVWQ4 54ZC<O+'3XTD\;JE-)IX<N(+&Z=0*FR:_5CXOP8U^F3\2JEKBC:F
MR'%3\0J6O5KZL6=XQJ9#?MS_ )G:"R"]U,.'_(_@=9WS^!D*SBG'_P!W2R]2
MLF_4-FON%6U-2ZK5QLT\.]#4VQ@5A3N3E&UCSQP-H*^:"3=)J)67RH; /#EK
MK)?J7/B/C,I^Z6I'33VX@WOS">I539 ^FGJ/X,9_3)^)52QQ!U;4S_ CXQ4M
M>K7U8L[QC4V.'Y5.T$R?S%=?X&P_@>65G:2>C'O!)=6K'QA&P3GK:'"? WKC
MHS>E 4DA23=!&7:N:SKH;'*>ZHDV<(+E)X!=-?9+]2Y\1\:>8W+@7SCY8A+#
M_P D?"JIG_6)ZOP9+_ID_$JIEO5)ZMJ9[^CXTU*/5+Q9WC&IL9^G1U;0/<<]
M?X&PPH;]2A7[ME[X4^1&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:
MVR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^
MQ&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:V
MR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q
M&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR
M_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q"
M4(%JE(H &3'7)M[)<2C=*R"'9J85;.N&DUPL3-+NC[.H_#M7)L;M97S#YU#[
MYP--T<I_TU]DOU+GQ'QIQO.U;<Q^>(2Q_P#)'PJJ;)#TD=OX,E?TP^)53)^I
M1U;4S?"CXA4_\*NS%G>,:FQPS2S?PC:"8'YBNNIEW#8Z7)4VE7D;T:VR_L1K
M;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[
M$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;
M+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$
M:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+
M^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:
MVR_L1K;+^Q&MLO[$:VR_L1K;+^Q&MLO[$:W2_L0^G,LCIJ9->Z90>C\,J6LA
M*4BDDY(O"1)M7K2<_I5Z5H44K2:0H9# 4H@3;5ZZGMY=JF6LC;723_U4./'"
M\YT"YWU\^K.^L_Y'QB-VRH=1[,09WIE/PJJ;)MYPVKXN_P#!DIZC_P!C4R/J
M$?#M3,<='Q5*O4*ZQBSO&-3)C,RCJV@G4YGECIJ;'*SR[?PC;ZR*,TPX/\C4
MV,/_ (Z!_C^&38F57^H4/AQ%N:9NT7%HW2<T-34NJW:<%(.U,ZK,NTYKE1)L
M8"EL4\.6O>5NED]/C2?I6P_Q.(.'<N(/31VU,PWNI<_$/P9(*SMD=-38XYY=
MOX1M2[ZQ'74O'-+*^).+.\8U+ ] =6T%DQ_Y"STU-C3^2!M]9%/YEMSW>VID
M3E2"CF4?PP2@@S;MZTG_ -N2%+6HJ6HTDG+B7@<PO4;YPGS:L^U%,.NG9K*O
M'E6,CCB0>"FO4K,*?'D./V'$)\9@E7,H5,IF<MD'F_!EBU;S@^&IL8?_ !T#
MHVI W3Z1UU,XK,Q1_D,6=XQJ6^*-H)\9RE7.D5,J,K94CI^>WSJOO&T*Z*.R
MI?:RMOGF('S_  N[-3"K1IL4DPY-O7*;B$;E.08I^[IE>JF1I:CLT]XVGG7=
MRRJCFJ$KR,H4OL[:^<<W+*U='CV/]:,0LBWG871S5,D_@#;R5'G_  98U692
MQU5-CCZ%'2=J95.>8!_Q54V15F0@=>+.\8U*.#: +^\92KK'94S;.X>MN<?+
M;Z0?W;:D<Q^JILBQG"%CI[Q^%_ Y=>HV#A'G%9ZJW=3J)@TN>D=S'[TE&Z&E
M7'D)'DG=53<PPNT=;-LE0A$RB]<\EQO<JVFF<Z[5'343LSG4&QUGK%?9!7Y=
MKSW/'L=ZY.(*0<"A086VKRD**34R4Q325M)MN'+^"Y1S<OT<Z3W5,EO6X_S.
MU,@G.XH]%39-><MCXL6=XQJ1M!8Y_.%H/1\ZF?8W;:5\Q^K;Z7?&%IZCD(_Z
MJ6!30EY*FCUCI _"W[OEEZJ>%^1L$=YJFI27%+CAYAGAJ48%Z@73E4<IA;3B
M0MM8M5).406[IEG+YE>]FY*I+UU4NN]>1G'?"'FE!;:Q;)4,HVEEV]T]3S U
M$N<KA4L\];230-^-,G9=OC.@0[+R\VT\ZM2;UM5-RFGQ['^M&(V1;P::5^U=
M[:E4N3?2[A%&\;O?^"R=PZE79VU+8W+JQM38M/K#\-3-N;I^CF2._%G>,=J4
M.CS+P/(;G=4REVA+M+1Y<'31M]9!O*&]$']-WLJ9>83A:<2OF,!232DBD'\*
M.3+EU>!M&Z5#LP^JW=<-LHU6COIU:^+[T!N?VN2KEQ6%M>Y5#LL^FT=;-JH5
M0L5,KTEPZ2H[%6YY=I9!KCJZJB68^[;2GH_;ICJ$<95$7]D)8;VBB+L\D\5*
MCV1<+SG%;[XTN4?5QJ!&EV. XSORB\EI9'"">V+UYMOBMCMB^L@X.+0GJC3)
MZ97PNF*5**COFID.,>HXBT^!<?:'.+G=4JEB;V911_4+H[?P7/;P2K_(5,PC
M<S!^$;4R",S:CT_*I2=VZI79V8L[QC4)X=H;(,X3H14.$71U5+3R/*;4%CDA
MMU%U*TA0V]4A0I2H4$1,2ZO*:<*.8U,DNF^0C0E<*;GX36ZXH(;0+92CD$%R
MZ)9N]91O9^6J%E)E&D-G24G9*S\GB^'RR-5LB^ V:>\55(C07U:N8%]Z8W6T
MC2-PR.L^.%C"F[=C[9:#T6T]T7UD9C^E=KU1IDR\YQEDXI);UN?\3B,K,@76
M7;4\"O\ H5,O-(\II87#3S9I;<2%I.\?P59%'Y"ST5-DF\RD*Z^[:EM.XETC
MI-3(#.%*YU$XL[QC4-\8;0T&Z(FI;[IQ2.FIE#3?,C05<F#HHV^=710B82'1
MU'JJ9R04?SD#H/9^$S8F67>).GJ&4[FJ2P*4LIOG5[E,-LLI"&FQ:I2,@\;P
MZ61J1\W0/-J[JIJ;ES0XV><9H:FV#>KPC*DY1M',#<I0/\<>!W+2CV=N(STO
M12I39*>$71U51E5&ER55:_TG!V_@I;9P+24P4G"+E1.,[MFVYC\]J9S,FT3_
M (BID&MPP@=&+.\8U#/'&T1> O9AL+Y1</54S<BH^6-%1PBX>SFV^EIP"ZPN
MU5P*^8'/4RDS30@*H7Q3<.V5K2+;#1M!:-'5KUQL;GTH))I)PDU+;#*"MUPV
MJ4C+"&$T*>5?.N;I7CNRSZ;=IP4*$.2KMT84+W2<]5:.G43UQP;GTH!!I!P$
M;13Q].CF'CC%YI>9BC_(=V)3DM10E*Z4<4W14LE1H8>TISEP'G_!=D&MR^L#
MGJ)<?>)4CHI[-J;(N9"^NC@IJ&VAA6H)@ 8!BSO&-0QZQ/7M$U- 7TLY=XJK
MG714RLWD;7?<7+T0"#2#EVQM:1;8:*R:E#YU! X<G3!2H4*%PBI9MC2\QI*^
M3!T;8.S3ZK5II-L3#ED4O+8>)O;17DIR"$M65;MQ_P#8:%WE'= >E7D/MYTG
M'79N8-#;8Y]Z'9M\WR\"<B1D%4+)S*-/=&E).Q3GY:DH% FF[YE>_FY86VXD
MH6@T*2<AJA8F:7?I_@*.4;G:*?5^>OKQZR#N\A/7B4G/I'E#05]8[:IE:E4S
M#6EN\(R\OX*FCD="7!S=]1(OX AY)/!3=VH<=5Y*$E1A2SA4:346.;_-"^:[
MV8N[QC42_K$]>T4S*+P.H*>"%MK%JM!M2-^I;0HTO2VE*X-CT=6V#LP\JT:;
M3;*,+LBAU;#E-#=HJBT3D$):LHWHJ?OVA?<HC1I1]#Z/1R<-6^0*&IC3D\N'
MIJ0PLT,3=X=Y6Q[N7;#]V,*TE@Z:1LEYN3]H>E7UL.9TF$M65;M#_P#8:%SE
M'= >EW4/-' I!IQO0&%:B8-[Z:MU5>$/IU$P;[TU;FK-EI5%^G^.D91NJI#C
M:BAQ!MDJ&0P%F@33=Z\C?S\NT,V<[JNNMTMI:^*FF+RQ\R=_0C%R14.,I([8
MNAEOC.=T:9.,)XM)C3+(D\5KYQ?S$RO@('9%UEQSC.'LBY8]H\:E77$VMF3E
MVED!"2AH W343+FZ>HY@._$IJ6 I<M;9OC#!5)#BJ):8TMS>S'\%2,QNVRCF
M/U5,G,X2XTE1X<NT\^NFZI&AC^JYVU*G<C+*E<IN=IQ=WC&HE_6)Z]HUNI%#
M4T-%'#E_W?J4(6:)>9TI>\<A_P!S[8?NIA6EMFEXC*K-R?M#TJ\MAP;)!A+5
ME6__ /0T.L=T!Z6>0^T=D@TU(FD"EV5-M_2</9S5((N$0T^3IZ;QT>EM<2@Z
MK>O&A_[<D$DTDY3XNBR;ZF59:,!X1"6K)M^#N??(NH/)DA+C+B76U8%(-(.,
M&Q<LO3W1IRAL4YN6J:E&!?+PJR)&4PU*2Z:&VQS[]6012#A!BW:&HGKK9W/H
MU3<TU=3@<1NDYH:F6%6[3@I2=H'SG6>OQVGESR6M$2%T!NFBGEC3)YU7%0!%
M\J8<XRQW1]CMSZ3BN^+VQTO_ %-@]<:7+--\5 %5*,?>.VW,/G4,'=J4KIH[
M,3>M10R_IJ.7".>J#+JM5RP"5>D,A_!++X%UEZ[P$?\ 52N4)OY9?^)N]=.T
M\G)@W7%EQ7 /^^BILA,T>4I+8/!=/6,7=XQJ)?UB>O:-3R12[*G1!Q=EW\E4
MVM1IF6M+=X<_+M<IT$>$N7C*=_/R0I:B5*4:23E\7191];"_1P'A&6$M64;T
M%?W[?D\HR0EUAQ+K:L"D&D>.MIP6S:P4J&<1,2:_-JN'.,AJ0EU5$K,7CF]F
M5M:[,OJM&FQ;*,.33EQ.!M&Y346\H^IO.C"E7"($H[+J:FZ*:474'NQ93YH4
M\J]:;W2H<>>65NN&V4HY34@ 4DY!%NZ-6O77#N?1K791\7J\"LJ3D,.RDP*'
M&SSC/5> S*]2/FX3YM7=M OA\8 83"$# D45[+ P--=)_P!%1((_)2>>[B:G
MT"E^5TP<79=_)5-3;=T"XM.Z3E$-OLJMVG$VR3^")]BBDEHJ'"+HZJEMM1H;
MF1H1X<G3U[3S*@:6FM)1R?.FIE*10IVET\N#HHQ=WC&HE_6)Z]HU(4+9*A00
M8F)0^2A5X<Z<E2E3AU*]>.[V8\D4C:QQ]Y80TV+92C"YA5*6A>M-[E-1HDF^
MIK.G8JX1")-^7+4V1Y3=U![O'9LFVFZWI;O!D/\ N>J\">5JJ6%RG9HS[6?N
M^67J5DWY&S7W"J,ZZFA^:NC>1DY\/-BKC[RPAIL6RE')"GU4I93>M-[E-4++
M3*+Q)TA)RG=5^C,)U<P+WTQN:OP"97JMD7I.S3WC'W1Z1\:2;W3R!TXA/.X1
MHA2. 7.SQTI&%1HA#8P)% Q,@BD')#S &D*OVCZ-4+&3*]3NG2E'8*S<NV"6
M+%N -L*OW**0X<W!"67Z)2<W!-ZO@/9C$W+?=.J2."FY4!230H&D$1+38\I2
M:%C,K+M+,3-.FT6C?&.#OY*EMI%U:U!(AIE'D-I"!R8N[QC42_K$]>TC5D6T
MW[%XYQ#\^NJ_=SZM4RXO*=DCY;6&QDLK4[1TU0V:LW)5*LBZG3IFXC>1\^[Q
MW9=X6S3J2E0A^3=\II5%.<9#4LS;!H<;-/#O0U-L&]5A3E2<VU1DI9>K7A=(
M\VGOJFF"-(3?NGT8"4B@"X ,5-C)9>D-'3E#9*S<E4&[HEF[YY>]FY80TVD(
M;0+5*1D&(&RDLC27#IR1L59^6J:F6%6CK9MDF&YINXK XC<JQZ8'YBNOQK'C
M\T&O??.!I!7S""3=)\>0;R:,DGGIQ4NM)IF9:_3OC*/]S58E)E6KF1A/G$Y^
M':Y=C))>GJN/.)V W/#^U+$_;3<K@"MFCO@/RKR7FCE&3%D3(%[,HI_J%P]E
M2NQSJM*F+K>\OY[2IDFE4LROE;Z\O-WU,N2*42^G'DP=-&,.\8U$OZQ/7M(X
MRZFV;<24J&<0_)KV!O5;I.0U+4TPJU=;-(AN;9RW%(W*LVU7@TNO5SPN4>;3
MGJF98?P_*=5F3"4(%JA(H &05";)LITU@4.4949^2JTPDR;MQU.;TH2XVH+0
MH4I4,HVH+IH7,+N--YSW0X^^LN.N&E2C5)T1-$T_?N[V9/)BO@["M6OB]]!.
MZJFI=A-NZX;5(AN6;OEX7%[I6(K9=2%MK%JI)RB%,W52Z[YE><=]4'+IEG+U
MY&]GY(0ZVH+;6+9*AE&.SJ<SZQT^-)?U'_$U[XP*=(;'^\ -0VK[I"E]G;BQ
M=:31*3-\BC8G**IN8866W6S2E0@."A$RBXZUF.?@VL,E)JIGE"^4/-#O@DFD
MG*?$T>4>+2LHR*X1"6)BB4G-R3>KX#V8KHX%_++"^0W#V<U2E:#:K2:01D,-
MS _C"]=3F5M&X\#JA=XT/2S\D%2C2HW234S,ZH77EVB> ?,]&,.\8U$OZQ/7
MM*+(,IT^6%_1E1\N^JMC2J4<N.H[80ZTL.-K%LE0RC:@OKOG57&F]T8<F9A>
MB.N&DFJ#CJ:)J9OU^B,@J5(6 I"A00<L.,7=!5?M*SIJA8^=7J59TMP^;/=M
M.Y-3*K5"<F51S"%S3YPW$HR(&:J\->3J66-RG9+R8J[-OF]1@3E4<@AV;F%4
MN.'FWJK]X3*-5/"\2=@CO.)KEEWK@OFG-RJ')=]%HZV;5235"Q4TO2UG2%'(
M=SCMD!^:3SW?&:.Y0H]%?)2H.=P]0[:B>?S!*!_O-BSLH[<)NH7N59##LN^F
MT=;5:J%4B:EEVKB<F10S& ^S>K%QQHX4':I4G)J"YXX59&OG"EK45K4:2HX3
MXZ6)VVFY7!3LT=\!^4>2\V<V3AQ-Z7=%+;J2A7+#\LYY;2R@U*7%$^"N7KR=
M[/R0E:%!:%"D*&7:%;CB@AM ME*.00IVZ)=%ZRC,,_+4I;0+9:C0!G,2TFGS
M2*"<YR].,.\8U$OZQ/7M*012#A!A;8&IG+]D[V;DJA(SB]1+-ZH^:/=%(P;3
M.34RNT:0.?>$+F7K@P(;R(3FJO"'DTRDL:33LE9!5J0D:J:OV3OYN6"E0H4+
MA!JD6-LBY>X&7U9/1.TKDS,KT-I&$QHB[R71_":W([ZIF583;..&@;V_#,HS
MY#8P[HY3BA)- &$F+5HZB9N-C=>E5>&3"-1L' =FK-BO[QED:I9&F)&S3WBJ
M!!H(RQH;RM6L"A?I#=8Y-^E:G_$>,KU*NL5\QE2U0V.3#TTU!<^]=*NSLQ?]
MY2R=4,C34C9IS\E6F9E5VJAA2<"AF,:(R;1Y/\1DX4_+:A<E8Y07-8%O9&^#
M?@J42I1NDG+4A^4>+2\N97"(<MF%,OM46]'D'@Q-F?0+R8%JOC#Y=54FQ<VO
M25'25G8G<[0JL9)KTA)TY8V9S<%4'U"EJ4%O_5L>_DQEWC&HE_6)Z]IELW/"
M$7[*O2S<L*0M)2M)H(.0U2+'60<TG T\K8;QWMI7)F86&V4"DJ,4FEN51_":
M[3OU34LPFW=<-J!#,HU@0+Y6Z5E-9^]99.EK.GI&16ZY:M$A9)=+.!M]6PWC
MO12,&T2IB:=#38Z=X13=;E$?PVNT[]7X9,)HFY@8#L$9L5-B99=^K^.H9!N:
MIN49N4W5+W*<IAJ5ETVK38H&+>%RZ=1/G /-JS534VP;]!P9%#-#4W+FE"Q@
MRI.;&VG,CC(YP3\O&5ZA76*Y;BKB4BDPZ\KRG%%9Y:B1:P$- GA-W&/"Y=&H
MGS@'FU9JM$S*N%MU.7/O0&U4,3H%UH[+?3M*I:U!"$BDJ4: (7)V+44-8%S&
M JXM6U+,)MW7#0!#<JU=(NK7NE9\3?E?.46S9S*&""E0M5"X0:I%CK(+T_ T
M\K9[QW\?<L;(+T[R77D[#>&_5MI6FB8>TQSL&,N\8U$OZQ/7M/\ O:63<-R8
M2/BJT2%D%TRN!MX^;WCO0"#2#@(VB5,33H::3E,4)I:DFSI;6??._5_O"83J
ME\7@.P1\ZU;+J0MM8M5).40IDTJ87?-.9QWU:).>)<D\"5X5-?*$.M+#C:Q2
ME23<.T%"CHTT1>L)-WES"-'FW+8[% \E/!5B?F4:D9-ZD^<5W8J7!09ER]91
MOY^2%N.**W%FV4HY34I0@%2E&@ 98OP#..WSJLWHXN[*S";9IP4&')1Z[1=0
MO=)R&JT)Y6HGS0OT#NHI%T8U(/YBI!Z.[QE>H5UBNFC3?.#0AR_*FHEV!YQP
M(YS% P8PY+3"-$:<%"@8+"[YE5UIS=#OJTK0HH6DTA23=$(E;+&T<P)F<AXV
M;A@$&D' 1M%HTV[:;E \I7 (T/\ @28P,@X>-GK/#9I%$X\+B3YM/?BOAC:=
M(FKIWEY>_GJJ1")&RBZ',#<RK9;RN_'7)&Q:Z7,#DRG8[R>^K0I::9:7TQ>_
MF&-.\8U$OZQ/7M.MMQ(6A8M5).404"DRKE\RO>S<E6F4G*79'(=DU\H0\PXE
MUI8I2I. [0::=%F2+QA)NGAS"-&FET@>0V/)1P5?A<RG43)P'SBLU>N6=O5X
M6W-RJ'9:81:.MF@BKH0=&E2;YA1N<F:-%E7*2/*;5Y2>''5//N)::3A4LT 0
MIBQ(M$X#,J%W^D0IQQ16M5TJ4:2:L,HI2RFZZYN1WPW+L(#;38M4I&*.S#ZK
M1IL6RC#DTY<3@;1N4U0LM-(_3I/Q8R0@ 3;5\TK_ ->6%(6DI6DT%)R50L5-
M+TQ TA1RC<XTI?W3B5]G;XU&=E0ZJW3)EEOC+ B5EY68;?2"5K+:K8;W;42^
M9NEP\W?C2I9\494.#"@YX7*S*:%IP'(H9Q6!LZHD\K*C@XN:+>5=I4/*:5<6
MGDQ\DF@#*84Q8ZB:?P:+YM/?"GYIU3SJMDJL392<1I23I#9V1W6+/2CEPJ%*
M%;E60PXP\FT=;5:J&_5HE9^V?E,"5[-OO$(?EW$NM+NA2<96_,.)::1A4J%R
MLA2Q*&XIS9.=PJTH0"I:C0 ,L-L7-'5?NJSJQIWC&HE_6)Z]J')5ZY3=0O<*
MSP[*S";5ULT'?WZO23HDN3?L*P'N,6\LNAP>6RKRDXZIUY:6FTW2I1H A4O8
MD;QF5CX1WPIQU:G'%72I1I)JTR[5Z@77'-PF&I:71:--B@#$-'8 $^T+WTQN
M8*5 I4+A!R5:7Y9U3+J<"DF$L64HEWL&CCR%<.: M"@I)N@C <9*E&@#"3"F
MY/5S^=)TL<N7DBVFWK9(\EM-Q*>2L;E99-LXOF SF$2K%W*M>5:L^*_N^67J
M5DWY&S7W"J 6")1J^=5_Z\L)0A(2A(H &3&C9:51=_\ D)'Q52'6E%#B#;)4
M,A@.W$S*+UY&8Y^ XS-R^$N-D#AR>-*#=!8_Q/[*5*"1OF-,GI9'"Z(OK(-'
MBTJZHN/..<5L]L7DO,KX0!VQI=CB>,[\HTN483QJ3%Z66^*WWQ=GE#BI2.R+
M^R$R=[13&F.K7QE4U4[,;E(;'+=[!C>AJH1,(NM.YCW0Y+3+9;=1A%8EUEQ3
M3B<"D&@B$LV51;_^0V+O*(#TJ^A]O.DXXI%OX3,CS+63A.2"AQ>@RWW#>#ES
MUHF9D%,@@_W#F$)0@!*4B@ 9,7_>TNFZ+U\#H566TJ[>'RFE74*A+9/@LW]R
MLX>*<N+J;I\)F_N4'!PG)%M-.:6/):3<2FL_>LPG2F[C(.56?DQMWC&HE_6)
MZ]J;=H!,\T-+5NAN3"D+24+2:"DY*M+S#BFG4X%)-!A+%EAH:\'A"1>GA&2$
MN-K2XVJZ%)-(.,TFX!"FY75TQZ!O!R]T4S3MX/):1<0*QN5ED6[JS0.^$R[5
M\O"XYE6<279*11IXNO-)V>^-^MU.[;,Y67+J?E 1,'P&8S.&\/\ 5 (-(.7%
M2Z^ZAEL;)9H$%$DVJ<<W7DHC5+U#61ENXBM;EY=!<><- 2(M10Y-+_BN]@WL
M5\#EU:L?&$>;3GJFI673;NN&@"&Y1F[1=6O=*RG&RE0"DD4$'+&E@F3>NM'-
MZ-4B9;OD8'&]TF&IAA=NTX+9)QF=8HH"7#1P&Z/%2ZRXIIQ.!:301&F3LPOC
M.DQ222=_% YE><4KL[,<H-#<TC^&]V'>A<M,MEMU&$&M#TJ\MAP94&$HLE+Z
M(/OF</-%,I,H=.5&!0Y,7*E$)2,),%+*_#GMRSY/M0I&B^"L'S;-SG-=HCH+
M<@@WZ]UZ(A#+2 VT@4)2G)C"D+2%(4*"DY1!0D$RKM\RK>S<E:EMX^&RXV+I
MOAP*A*4/Z \?-/7I^>)J#DP'7AYEF^5\H4VP? 9<[%LWQX55J&!2EE-\ZO<I
MAMEE(0TV+5*1D&-N\8U$OZQ/7M4JR$DC5:1IC8\X.^MIE7J$96E74'D@-SFH
M7\ZO(/+DY8"D*"DG 1BI<?<0RV,*EF@042:%3KF?R4<\$/O6C/W+5Q/SK6V&
M$%QU9H2D1=H<G'!ICG8-[%'+)6/;O?*>93D](5VI9@AO[I=\CF@(LA+EA7WC
M5\GFP]<4RDTV_O)-WFQ E1H RF"#-!]P;"7O_E!3(2Z99.[<OE=T:)-/K?7G
M6::YN7EVRZ\LT!(BV50[.K%^[FWAO8JY-O7:+B$;I600[-3"K=UPTDU7ADPG
M5CXN [!.;'791_ KR5;E60P[*S";5ULT<._5?N^97J5XWBCL%=QQEF: O7VZ
M.4?*C&Y-G 4M"GARX[:.:7,)_AO#"GY0N6FD6C@YE#.*X*0HH4,!!NP$K>$X
MWN7[IY\, 3;;DFO/Y:>B[T1J6;:?WDJN\V(DJ- &4P0N;2\O<,7Y[H*9"4#?
MYCYI/,(IFYIQX;FFA(Y*\3$Q2U().'*YO#OA#+* VT@4)2G)C2Y5_+=0O*A6
M>')683:N(/(1G%<$LS)6T/-.WR?E 3/RBFCNV32.:!H,^S;'8K-J>8UIT>>9
M!&Q2JV5S""F1E%/'=O&U'-!2[,EIH^:9O17-2TNBW=<- $)EV[YPW7'-V<<=
MXQJ)?UB>O:M=DK'MWV%YE.7TA74RDRIM.5LW4GD@(LC*VA^]8NCFC4DVVZ=Q
M30KFPXA230(-O-I>6-@Q?GN@ID)9,N/O';Y7-@ZXT2;F%OJ],X*Y###9==6:
M$I3&B.4.SRQ?+W.\,679"QK=S"[+IZT]U>"DT$91 "9U3J-R]?\ 7 $W()5Z
M3*Z.@QIBWI8_F-T]5,7ED9?^M5KUQ2TZAT>@JGQJ5&@9S&FS\L@YBZ*8^V:(
M<S:%&")21<=WW5!/?!T(M2H_+12>F-533K^\M5SFQ!,M*MZ(XKF SF+FFS:Q
MICW8-[%5+6H)0D4DG)!*"1*-7K2>WEJOWA,HU*R;P'9K[AC_ (3+IU:P+E&S
M3FJ_ IE>K&!<)\XG&%.I%*Y=0<Y,!_W>Q(FHE6,(6X >#+C^@S*;H\AP>4@Q
MH;Z;9I7\-Y/DJQ"D7# #4^Z4[ER_'3&J)9A\>C2@QI\K,,GT:%"/MFAG,XA0
MB\LC*G>T9,:6ZA?%53XM)- C3)MA'&< B^LBP>(;?JB\4\_Q&^^B*):Q_P#4
MZYV"*$+:E1^4COIBF9F77_6+)Q%$W9)):EL*6<"E\.80E"$A"$B@)3@&.7M"
M)QK^&O/Z)A;#R"VZ@T*2<F(:FFWF-Y"R!%V82^,SC8[(TZ19<XBBGOC3+'.)
MXKE/9%V6FQP)3_\ U'\.:'"@=\>1-'@0.^+DM-G^E/\ _4:78YQ?&< C29!E
MOCK*NZ+U]# _+;';&J9QYX9E+-'-B"&FD%QQ9H2E.$QHCU"YYT7ZMP-R,==X
MQJ)?UB>O:Q=D+&MW^%V73EWT]U?2( ;G7%)W+M^.F )N1;<])I5KWQINC2Q]
M-%/5&EV1E^!2[4],4MN(<'HFGQJ2:!OQIL_+(WBZ*8^VZ(<S:%'L@B5DG7=]
MU01WP0UH,J/012>F-53;KXS*5<YL01+2K9==5D$6QH>G%B_=S;PWL87.V-2$
M3.%; P+X-^"E0*5"X0<F)4@T&+V:>3P.&+VR,V.!]4:YS7]TQ=LG-_WU1?3L
MPKA=5%+CBE\8TXI:,)M&4^6\KR4_.-!EDW3Y;BO*6<6-B95?ZA0^&J;E6[B<
M+B]RF&I9A-HTV+5(V@-DY9&IW3IJ1L%9^6J:F6%6CK9I!AN::N' M&X5FQ=Q
MIP4H6DI4-Z'Y9?E-+*?%L?9!L:3--W=YP7%=_/6"H#F1ELJ[.W:!<O,M!UI6
M%)A4Q+4S,CGV3?#WXM<=6.!47)EX?\AC[6__ '#%V8=/]9BE2BKAQ5++#:G7
M57 E(I)A$W9$)>FL*6L*6^\X_HS(")]L7JMV,QA;3J"VX@T*2K"-J4MMI*UJ
M- 2G"8$U- *GUC^T,PW\>=XQJ)?UB>O:U<[8](;F\*VL <^<*0XDH6DT%*A=
M&)4BX8O9IY/ X8O;(S:>!Y4:YS7]TQ=LG-_WU1?3TRKA=5&F.*<XQIQ30Y=-
M"!Y;RO)3&A2Z;9Q7EO*\I>-%U%$O/9'1@5QH5+S;1:<',=\;5(F9^VEI3"$;
M-?<(0Q+MI::1@2G%KP@SCMZTG-Z4*6HE2E&DDY:E#;:2MQ9M4I&4P&S09IR^
M>7OYN3:%QAY 6TX+523EA3"J5,JOFG-TFJ"U4F5<O7D;V?DA+C:@M"A2E0RC
M%V;((%Z\+1?&&#HZO%?L>ORVW#:'<G"#TF%M.)M7$&U4#D/B:7*/N<5LF+VQ
MSXXR;7KB[*AOC.)[XOG99O\ J)[(TRR"$\5NGMC3)YU7%2!#S[AF'0T@KOG,
MW *F;F=VL(')_P![1+F;%T,O83+FXE7!FA3+[:FG4X4J%!VLTI.A2X\I]?DC
M@SQ:RZ*73Y;RO*5M#;IH9GDB]=S[RH7+S+9:=1A!VG0Q+MEUU9H"4P'GJ'I]
M0NKR(WAC[O&-1+^L3U[7%?\  G0+UX##O*@R\VUH:\AR*&<;5(F)RVEI/"-V
MYP=\(EY9H--)P)3CF@3;0<3D.5/ 84\U3-27W@%U'&';M.&)1E3SF]@'#")B
M<HFYL71N$<&?%W9J85:M-BDPY-O;*XE&Y3D%4++3*+]7\!)R#=;1J850EY-\
MTYN50XP\@H=;-JI)R50L3-+O5?9U'(=SB[\KLR*4',H8(*5"A0N$'Q)R6/G$
M!8Y/^X7-/M*+B_*H70#%R00>,I2NLQ>6/EAOZ$(TMM*.**/'6@>4\H-]O94R
M@RK&B'EVCM)IN_'DNIN*3"G /"I3[Y P<(R;4I8EFE/.JV*1"7[*D/.8?!T^
M2.$Y82A"0A";@2D4 ;1VDPFAP>0\GRDQ:/IMFCY#R?)5M+H,JBX/+</DHX8H
M9&B/J%^^K">X;0.\8U$OZQ/7M>6)MH.HR9QP0I^7IFI+=#RD</?M.&)1E3SA
MR#)PPB8GK6:FA="=@COV@4])42<SF'\-7)DC0IMA32LAR*X#M&$I25*-P 98
M2]9(F59^Z'\0]T!B492RWO9>'&/!)=6HF#A&S5GJK9T:B9NN'=>C 2D4 7 !
MM(;)RR-/:&FI&S3GY*H*2:%"Z"(M73JUFXX-UZ6+^&-C29FZ=Y>7O\23=IH2
M5VBN W*N5EAYM%N>7_JH0VGREJ"1"&T^2@!(VE4[*:BF#N1>*Y,G)%K-L%*<
MCJ;J%<NTJ6VFU.N*P)0*282[9-SP=O[E%U9[HT*382RG+1A/"=IEL3#:76EX
M4JA4Q8NF89PE@^6G@SP0101D.T29B=MI64P@;-?="9>5:#+2<@VA=XQJ)?UB
M>O;%3TI1)36\+Q7"(T*;9+>96Q5P':,)2*2< $)>L@3)L?=^<5W1H,HREE&6
MC">$[1*9F&D/-'"E8I$*=L4Y:'_Z[IN<A[XT*;EUL+](8> X^ !23D$)<F=0
ML>F+\_T]\:F9TW*\NZLXS^[I9>J7AIBAL$=YJFI273;..&C@WX:E&!>IPJRJ
M.4[3>$RZ=1/FY1L%9JIJ;8-\C"G(H91#4W+JI;<'-O8L]*JN*(I0K,K)"VG$
MVCB#:J2<A\25FOO$ GAR]-5..84V]H. 7*B4&1!T0\FTZFW$)<0K"E0I!A3D
MBOP)W<84'N@^$RYT/[U%U'/M#H4JPM]S,@0'+)OZ$/N6;JN>+63ET-9U85'E
MVJ*UIT":^_;P\N>"M;>CRWW[5T<N;'Z)5G2\KR[B!RPEY[5DT-DL7J> ;1N\
M8U$OZQ/7MDII]M+S:L*5BD0IVQ;FA*^X<-[R&-#G)=;"LEL+AX#C] NF$K?'
M@,OG<%\>!, R[-L]E?<NJ^6TQ:?:0\V<*5BD05R#IE%_=JOD=X@EZ6+C0\ZS
M?)^6-AJ796\X=BA-,!<^Z)1'W:;Y?<(U++C1/O5W5\^-+F5WR_);;W2H<F'U
MV[KAME*-5X0^G5KXNT[!.YVG=E9A-LTX*.#?AV4?PI\E6Z&0U6@/JU$^;[T#
MNL7%E&$X;UX#H5V>),22C=:5;IX#_O34S,Q]V@J'#4S<QN4! Y?^MJ:#=$%2
M6O!'CLV+G1@@JEBB=;]&]5S&"V^TMEP;%Q-!QL)2"I1P 0"6/!6]W,7O1A@*
MG%KG5YO)1 ;EV4,-[EM- VN4MD> OG9->3[,%6A>%,#SC%WG&'&P6)<I9/GG
M;U/SY(2N=49UW<X$<V6 AM(0A-P)2* -I'>,:B7]8GKVT+3S:76SA2L4B"N1
M<,FO<&^1\H)<EBZT/.LWPQL-L-+><.Q0FDP%SS@DV]P+Y?R@&78!=^^<OE[5
MDOR:+<^<;O5=$%4A.?\ ',#M'=!*I)3J=TS?]4%*DE*AD.*6LM+NOG\M!, O
MZ')H]-5*N80%3*ESJ_2O4\PC0Y=E#"-RVFC' \Y9/0FDBAMK0*;7_*-=?=_J
MC77W?ZHUU]W^J-=?=_JC77W?ZHUU]W^J-=?=_JC77W?ZHUU]W^J&YI^;\,#=
MU+>A6HML^$[4MI4O0'VS>O!--S*(UU]W^J-=?=_JC77W?ZHUU]W^J-=?=_JC
M77W?ZHUU]W^J-=?=_JC77W?ZHUU]W^J&Y5Z:\,T.XA=I:FUS83BRVG$A;:Q:
MJ2<HA3)I+*KYI><?MEWB:&E'0W.*:G0AA>6$\@N]U2',KRRKL[-K-#F6&WT;
MEQ-,$L:))K_+52GF,$RKK4VG-Y"O]Y8/A,D\V!LK6E//BNII-YX;I*+G/ +Y
M9E!Z2K8]$ S;KLXK-Y">_IBUE99ICB)N\^V9,S*(+A\XB]5SB"JQ\W;?ES'>
M(.C2+MJ-F@6XZ,5'@LFZZD[*UH3SX("I^81+IW#=\KN@%$J'G!YQ^^/=M.I7
MADQ=-.2/MDQ_C'VR8_QC[9,?XQ]LF/\ &/MDQ_C'VR8_QC[9,?XPA8FY@E)I
MR;;DS$FV5GSB+U7.(*I"<M?0F!VCN@E4FIY.Z8O_ )P4K24*&10HQ2UEI=Q]
M7Y:28!>#<FC\Q5)YA 5-+<G5YC>)YAWQH<LPVPC,VFC;"B9EFGQ^8@&+DNJ7
M5G961%,M9!2?1=;IZ1&EN2[XWE$'I$7UCW#Q"%=4:;(S+?&:(B@B@[]1I;:W
M.*FF+RQTT=_0C1'V0-#.XXF-/FV&AZ%*SV1JB:??/HT($#0Y!M2MT[?]<!*0
M$@9!^-%,+O7!=;<W)AQAY-HZV:%#]K14:7F=*<Y,M1+RXP-HMN4_]5,JQE0V
M >'+M@?")%APG9% IYXTM+TL?RW.^F-(LCR.-=M,:6N7?XJZ#TB+L@H\125=
ML7]CII._H1B_9<3PI/CWDL\OBH)B]L;-?V2(^PE SK6D=L:8[+-#C$GJC5%D
M>1MOMIB_0],^L<[J(&@2#""-E: GGVZ/A4FTZ=T4WW/%+*GY8^BJV'3&I9YI
MW>=24]\?9 Z,[;B8TVQ\RD9]"-$4*!!S&JTF2F'>*T3%R1*!G<4E/;&J)IA@
M>C2LQ3,3#\P=ZA(@%B1:"ALUBV/.?Q9:S,NT^/S$!47)8RZL[*R/E&IK(+3O
M.MT](C2G)=\;RB#U1?6/6KB$*ZHTV0F6^,TJ*% @[]1I;:E\44Q>6.FCOZ$:
M(^R:$,[CB1&GS<NR/0I4>R-43;[Q]&A [8%I(MK5NG;_ *X"4I"4C(-N;X \
M,7\HPOC-B+MC)/\ L)[HULE?[0C6V6_MB-;)3^R(O;'2B>!E,7DNTG@0/QYX
M1+IHG6Q_<&:"%"@C"#^P-K50Q,WBMXY#_N>HG',EO:C@%RHE&<(4X*>#+MQ?
M(2KA$79=H_T"+LFQ_;$7)5D?\8BXRV/Z1%ZD#@_ U"DA7"(TR1EE\9I)B[8V
M7_I11&M[?.>^/L _N+[X^P#^ZOOC6]'M*[XN6.8Y13%Y8^53P,IB\;0CBBC\
M;WP!X8OY5A?&;$7;&2?]A/=&MDK_ &A&MLM_;$:V2G]D1>V.E$\#"8O)=I/
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M#9G35CG9$TO1 TSR;*)I^J+P<08;:3P8ZP!,E'@=R>(\?H+*9\<B$)PR5/\
M4 P80&VB,_:=\P&3(A$[V_N .[ZJ<:9N F3@$\:H&6X4Z\0B7Q<W)-YW31FD
MD\<91&"D13P^>+L1#<6#REWZ1\D\E?:G(11BT8] "K45,@H"@V$_DD ')-R'
MXA@\&63C?L\!VXPQ*N*!VRE,S')$7.YN2O)W*,D("X(F%<VYCV'&>:']-WX'
M;8:M\C8#O)3DX)USU.#;IB3&/]!Q'-0@C?'*HQVDJM\A),(Q(D3PS@D>-;*3
M.9(21E,CH:;;/&P2YFFF9T%]E$B+F&+<E L*O*I8DQVX'%XN3)DR;X!D4R9%
MQW=B6ZA-7A!')%&7$&ZANPTM7;A7-H39>K&62 $&<AP1N#!Y2[](^2>2OM#A
MDRQ<QOC@JC\F<E, * 7;%&#:)Y.K+9S^*0CR7!X$W(U01B7A3=,2(W3RH<5#
M$+F^S$.6UET5P3#H1S/-3H(R +@*##=9TAN='^C!-ZY&3&Q[28*B@,K0R**8
M.T BRC)1=B&GA#([67 H1YV6775'OB23DKS8D@',#DE,BD(NR@95QTV^JEWJ
M9,F3)DR9,B&DYGZ-V'2\9 O)5&!*&%<8SR1+ES$[O-9&4_:;_!<T6)P&WX/*
M7?I'R3R5]F<-U01P =S1/QS ,@"@&Q"Z:6H!F9!,W,[HXF>S0V/QWIZD1W])
M H-UF!L[L0C9B!A3'N>C#:,ZY0!] :G%\-RG)C;C!!( "93R)E/#5H3^)F!#
MT$.:;,>[^C1KV%"188#UBO) 8A<B$=ES[/H0YLX0Y!.?G1(3AS0.4H@$EZ=(
M$=$^G/2X*)E@%<#RD.P$6N";$KP5.2@0Z!UYSVAP?0IB.OA#(60CS: 0I3)C
MP8S&TYOPPW!B3!%Q8C!,!2?+[*;&L/F:9#&-!N"\<-9N^0&3)E([K%7BIF5
M5."(Q$0TDJ<)#GL."BVG@F\EW\X'/),&)#GI* P<6>L=4Q/PKW *?O,ZR@<-
MC&Z+D)?0N:I]2YP24FW@P93L[^A(]Z&D<Q.AND'G )[-" O!!N:"5)-35Z.
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M$6>=/Z(_?1^1RD&P2<)R +R:#%.*8C?\?5R&SSW1#,6YU9S(O<@V)7$;$,%
MD05RECW7+U/=,H:A.ZG!P8[KG++NGL.\_5LD?@0WLP(+>QM<">VS/H(&)?#O
M.@OLG(:=@*9SH,2@XQX-WWN"%% V!>CJSLB)_I\<#),EFGX@G],"-GQ.G(08
MJ9N$WL8'41^,< 4&/9"/1:9NC8/:'=>)AZN&X IO^R+CBB59"UP8;O9MF!-G
M(%RK/L0%B<8_>N<!]B?0+R?92Z%3@1!F]J\^@8SV\^NW >4QHFX_*8FZ1N_#
M'(: +.HL!/8.@QVWR5]AXBYNV@A1JQ=RGFCI>,@@H1L000@J%RT!W7+07="&
M&H7NND$'=<_!=T6<E>?JV2.>X2#C><%+(#2)V%PVIO<" T0KG,8R4IH+R;RH
MW4U@BY!\(G2]!KLPS >7[,1$0GFA8#JR.C8?<D9DV(T@0+DD@$ 1E K0&'V-
M=PFP)D %3_@7@XD?[9'(9P. <?L$ P8RX)(C9Z],Q<1:_%/H %-XX@XHRHS,
M@%B/R 28!S<%XD=<%X1;(F%BO[8DP$=<3N2LVL_6"\6]O='^DF@['H)DWS<H
M3%D<]/#<( ((<&8*,.YU1:\)9(TE6;C=@='3#:%Y@-64&>M%ZU!@-PET.34.
MN&,QR1?]-U8O&.YVMEFB?+UC=0@^,:[?Y*^P\1<W<&+=(*5&,QR1) (S+X5&
MZH\G 9@8*#%HA<O8#F;SCMA_DQFOH%%FXC)7A!#+<Y80G0WE(#-&2(4$1L!F
MQ/ ;/$TW5-P&),$75B45 4CR;V4D(8?,UR&$:C<<VXEX,9'^(T!,P(64SB<O
M,US&,*C9X/HK8KZ9$HUPTS &[X.:@%8FWG!,K^88P!G8?AH@FMYOBR%,#N#\
MSYF#LIN3-?PR9,F3)DR=D,;B/<<FW'+(VX=&HP,$892-%\CRQW3(!X^.> Q5
M$E"^4H(9H=?((%P&XX;_ (2+W&"BA^'])P.Y1=S=,5Y=IJ1:@FF.AUW!Y*^P
M\1<W>6O8D8%O*8*AUT2"%A%,'+<]"83 +RD!B4<)DA<V56)X5V\@$,8A.W.B
M11<0YAP177#B*^0=QD?.QN2N 3F^B.>^3@$+CI@8E>4R<3M$V\V0EG()#4UL
M@4D%%^4#.N&B! &8& &Y(RT+8AZNC*R) ,<&(-Z9E 1=E SKCILYX9?8E0:]
MWP=;(E])WTLWM0(/$V'+FL![OF 2P0)V!& #;D(<,8A%3A',X;'K<!3U!+<(
M.PQW*7,3'2, %>83HS!ES:*^1P'QR1.NY@P68=P5GL@=AYYHC8YB!B#N**51
M(8> ,F)X*1IJN;R:G$[A\E?8>(N;QB<D3.^1F.!3H<3#CR [C) .8!R2G4K$
M (&7?'!#VO WS"<]Q2^*JB]EHCJQEQ*ZBTKD#IMY&QS #DE&07XN\#"C@0ZV
M6-S<ID&VEU81IB:GA#,64*PJX*E@!%0\BYABW/<I#AC$*6$\B$)QRU'"EE&C
M48XMP*C2,8S.I8@[,THY:G-VR)19Q.8 @1^2) @L14()"Y9-)0X#9-26"X*Z
M.F3)DWP? .?@-<<VW./D3#@,04_D6+H[*>C@H"?*/:):L=P@QFOK8FX8E-$3
MW!J2C1\U$E0P1J3B=U.Z-0#%EEU8HPU$@,C!/5#';W6&EO["R#E53V(R\XGE
MN/R5]AXBYO* EH*30J\GWQ+FC5\PKWF.PATV\@@$D !5%'<C+7$XLH:#:(\C
MV-N:7.-S:%'WZ,4V7]%I6P5Y:.H#:Y1+"CY)]ZQ@D\,<D#F L8]V:-M3'Y8H
MY0RJ<$60?J!L0'+")4KXY$(SAFJ>%-SQ=@KRH&(,4*B.X1 \GR^R) (@?*6.
MPX9($ ""X,B-FDNL&2,NXT3)DRHV3.MP(L0R$\6,@.+(B0DN3$DIDR9-\'W$
MY9G/3QW2 P 2!!JLEV DX_R.*:H5^#Y2)4W/AG".UD)HP;DHFZ_@^I-NNOI"
M)XZ( 22 Y6[2 !!#@T*.%8AB(XR<&5_\1FC@.F.UE?YR"?L3(JBZ&>;4=$,[
MD$"X#<GDK[#Q%S>DBW[FT*./\9]WXCDM(YGO-1J!M<G.AQM GKM& 7MQ')"Q
MN<4UIHVZ[SK C7DS:NA&!W(1K*X;A%Q"@LD(V(V2C6Y#FTE$7I]Z.9". ]0N
M^<2AP>T \MLA9*K(UBQR35KKK)W=W=W>=\,P0IS77MNF-1AX@I@<.-;-W=W=
MW=ZM<+:@IC=&V8\,,@),*?\ (.'F)'^_G2O@D/H6.EBSF8\&HYCB^;)D_@F?
M 0]7'=F"0P/-,2.S+4Y$(I0:YS0P1U3>,^!ASV5@?-1]2O02.6O'--2F;W=
MAKM9B0@LYCKO.[0"^TU=-/!03'RP3LK+FE[:HABQV1U28ZQ;F5_*NO2<U_8Z
MJ8P: (!@P@-S'P$F@'U7H?HO0_1>A^B]#]%Z'Z+T/T7H?H@U1B"*2]V]ZM1
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ME1M1,5X-"C>M=!Z\#B#DFA1F#BR_,6GR*<W+Y,F4(W86 N>0/^U2ENRZY%N
MX31"1<47>DTA8,S!-\V3)]@X_P!KIPF6 /47Y.F^+)OPX0)*<R2>@_VNTAB$
MZ#N-^73ITZ=.G8$6QP .K_[7C.7HY>Z=.G3ITZ=.F'43:FZ-_M=Z^'&:.G3I
MTZ=.G4+F+G-K_P"US"FB'%[ITZ=.G3ITZ )D'@'^UX/$BCITZ=.G3KW'Q_VP
M)Q9$NG3ITZ=.A!>07+_MB#<'#41TZ=.G3IUX;1_M@XX.\FZ,KITZ=.G3H!"
M(/#_ +8/Q.1/L!&J=.G3_D=&'3#P% $$08C_ &N @(<&!!1?@AP7E'DZ?D=/
M^#IT9)QQ8/\ ;!H-H G_ &1R)_(Z=.G3IL$OI X<P_VP< ! Q!D4:;$XK5X7
M)TZ=.G3H9- *]_HX_P#;+>B%P!3IK"-4*C'C>G_!T_X=LIO?0L=/]MDOQ9'$
MX)T8HX/#4\+!U,J0T(T^ #7[YB0EJ#'-_P#;GC7"NG$N+_'.W)'U[N04^0!>
M'TC*KS)PF;CF?\5__]H # ,!  (  P   !"2222222222222222222222222
M222222222222222222222222222222222222222222222222222222223E;V
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222220S_\
M_?DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MF_\ _P#_ .DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDD?_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD7_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDW_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD_P#_ /\ _P#]))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))?_ /\ _P"#))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))U__P#\F22222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222223C?\ X$DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDUIPDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDG%DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDE)OCTDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC_L:DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDB(Z+D*DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDHB\DDDDDDDDDDDDDDDDDDDDD-,X:DDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@%XK_P#_ /$[:R2222222222222222222222
M22222222222222222222222222222222222-?_@R22222222222222222222
M22222222226H/_\ _P#_ /7FB22222222222222222222222222222222222
M222222222222222222222222222222222D)?\:*22222222222222223(L9_
M_P#^!49DDDDDDDDDDDDDDDDDDDDDDDDYN_\ _P#_ /\ _P#_ /7MDDDDDDDD
MDDDDDDD0    !DDDDDDDDDDDDDDDDD@    'DDDDDDDDDDDDDO\ _P!Z2222
M222222222222222222222220N?\ _P#_ /\ _P#_ /\ _P#WG)))))))))))
M))))(0   %))))))))))))))))))))0   ))))))))))),   !)))))]_P#_
M /\ ^])))))))))))))))%U__P#_ /\ _P#_ /XW$DDDDDDDDDDDDDDDDDDD
MDCV__P#_ /\ _P#_ /\ _P#_ /Q@22222222222221/_ /\ _P#C22222222
M222222220?\ _P#_ .&2222222222223?_\ ]$DDDDDDDDDDDDDDDDDDDDDD
MDDDDS7__ /\ _P#_ /\ _P#_ /\ _P#&,DDDDDDDDDDDDDDB_P#_ /\ ,DDD
MDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -))) ]__P#_ /\ _P#]
MR222222222221&/_ /\ _P#_ /\ _P#_ /\ _P#'"222222222222222222)
M[_\ _P#_ /\ _P#_ /\ _P#_ /\ _P"1))))))))))))()__ /\ _LDDDDDD
MDDDDDDDDDG__ /\ _P#$DDDDDDDDDDDDDO\ _P#]R2222222222222222222
M222221Q__P#_ /\ _P#_ /\ _P#_ /\ _P#_ /O)))))))))))))(O\ _P#_
M #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#222#?_P#_ /\
M_P#_ /)))))))))))) )_P#_ /\ _P#_ /\ _P#_ /\ _P#_ -BDDDDDDDDD
MDDDDDDDD@_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /ODDDDDDDDDDDDD'_\
M_P#\"222222222222222G_\ _P#^I)))))))))))))&;7WZ)))))))))))))
M)))))))))))*O_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ ^22222222222
M22+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ TDDN
M_P#_ /\ _P#_ /\ CDDDDDDDDDDDG?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ I)))))))))))))))+=__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#^J9))
M))))))))))O_ /\ _P#!))))))))))))))S_ /\ _P#\))))))))))))))(=
MMA69)))))))))))))))))))))))]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /[\DDDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]2222
M2222221__P#_ -)(5_\ _P#_ /\ _P#^<DDDDDDDDDDA2_\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ VG))))))))))))))1_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#[LDDDDDDDDDDDE'__ /\ ]B22222222222223_P#_ /\
MOR22222222222222 5]*&2222222222222222222222!_P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ )))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#22K__ /\ _P#_ /\ ^I))))))
M))))-_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ +I))))))))))))-
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ "))))))))))))*__P#_
M /ZDDDDDDDDDDDDD>_\ _P#]6222222222222220Q+T]6222222222222222
M222222,O_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ ,9)))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#2
M4_\ _P#_ /\ _P#_ /B22222222220?_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#\R22222222222$?\ _P#_ /\ _P"B6[[:C3/_ /\ _P#_ /\
MZ4DDDDDDDDDDDD__ /\ _N2222222222220__P#_ /W)))))))))))))))&(
M?W Y)))))))))))))))))))))/\ _P#_ /\ _P#_ "[,H3@,DU__ /\ _P#_
M /\ Y$DDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ - __P#_ /X^)K'LDDDDDDDDDDG_ /\ _P#_ /\ _G-UDGWO_P#_
M /\ _P#_ /\ .22222222222S_\ _P#_ /\ >5DDDDDDDUO_ /\ _P#_ /V)
M))))))))))('_P#_ /\ [9)))))))))) _\ _P#_ /O))))))))))))))) ^
M9GVY)))))))))))))))))))(C_\ _P#_ /\ _P!?TDDDDDDD^E__ /\ _P#_
M /\ :222222222+_ /\ _P R2222222222222222222/_P#_ /U)))))))))
M)'__ /\ TG__ /\ IF220^2222222222"?\ _P#_ /\ [Y4DDDDDD&O_ /\
M_P#_ /\ LR222222222,?_\ _P#_ -!2222222220:[_ /\ _P#_ +,DDDDD
MDDDDDD __P#_ /B22222222220?_ /\ _P ^2222222222222220Y8"GV222
M22222222222222222'__ /\ _P#^""2222222222=C__ /\ _P#_ (,DDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -?_
M /\ ^UDDDDDDDDDDDDDDD>__ /\ _P#Z5DDDDDDDDD@G7_\ _P#_ /\ ))))
M)))))$?_ /\ _P#^1))))))))))))K__ /\ _P#]I))))))))))()_\ _P#[
M\DDDDDDDDDG_ /\ _P#_ '))))))))))))))))"(!W;I))))))))))))))))
M)))M_P#_ /\ _P#GR2222222222221#_ /\ _P#_ /PDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ "__ /\ QDDDDDDD
MDDDDDDDDCG__ /\ _P#VDDDDDDDDDDDDF_\ _P#_ /\ W)))))))(-__ /\
M_P#>)))))))))))))(;_ /\ _P#^W)))))))))))+_\ _P#_ $I))))))))+
MO_\ _P#YDDDDDDDDDDDDDDDDDF5-BUDDDDDDDDDDDDDDDDDDDT__ /\ _P#]
M4DDDDDDDDDDDDDDB-_\ _P#_ /YDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDD
MDDDDC_\ _P#]22222222221__P#_ /\ _P#ZDDDDDDDDDDDDDDDD1_\ _P#_
M /NDDDDDDDDDDDDDDG__ /\ _P#@DDDDDDD!_P#_ /\ _?DDDDDDDDDDDDDD
MDY__ /\ _P#[DDDDDDDDDDDT_P#_ /\ ^4DDDDDDDD/_ /\ _P#@DDDDDDDD
MDDDDDDDDD5/X@4DDDDDDDDDDDDDDDDDDDO\ _P#_ /\ V9))))))))))))))
M))?_ /\ _P#_ "R2222222+_ /\ _P R2222222222222222222/_P#_ /U)
M)))))))))'__ /\ _P#_ ,"2222222222222220?_P#_ /\ R22222222222
M22220?\ _P#_ /TR222220?_ /\ _P#E2222222222222222)/\ _P#_ /H2
M2222222222)?_P#_ /S)))))))(]_P#_ /\ !))))))))))))))))),[0MI'
MI)))))))))))))))))__ /\ _P#Y9)))))))))))))))))'/_P#_ /\ XY))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /\ S))))))))))))))))/\ _P#_ /Q)))))))))))))))) W_\ _P#_ &))
M))))7_\ _P#_ ,9))))))))))))))))(W_\ _P#_ #)))))))))))"__ /\
M_P I))))))&__P#_ /[DDDDDDDDDDDDDDDDDE]Z6)4F4DDDDDDDDDDDDDDDD
M4_\ _P#_ +\DDDDDDDDDDDDDDDDDDD>__P#_ /N2222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ _P#_ "22222222222222
M237_ /\ _P#^R22222222222222221/_ /\ _P#F222227__ /\ _;))))))
M))))))))))))%_\ _P#_ ,Y))))))))))(/_ /\ _P"9))))))%__P#_ /RD
MDDDDDDDDDDDDDDDD@!I?8TF$<DDDDDDDDDDDDDDFO_\ _P#]J22222222222
M2222222225?_ /\ ()))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#_ /2DDDDDDDDDDDDDDDD'_P#_ /\ FDDDDDDDDDDD
MDDDDDDDG_P#_ /\ YDDDDD7_ /\ _P#!DDDDDDDDDDDDDDDDDDDC_P#_ /\
M\DDDDDDDDDDDA_\ _P#_ / DDDDDE_\ _P#_ +TDDDDDDDDDDDDDDDDDB&;L
M6DDN^DDDDDDDDDDDDDDE_P#_ /\ XLDDDDDDDDDDDDDDDDDDDDDS_P"R))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /TDDDDDDDDDDDDDDDG_ /\ _P#^4DDDDDDDDDDDDDDDDDDDW_\ _P#\2222
M9_\ _P#^Q)))))))))))))))))))(1__ /\ \,DDDDDDDDDDDS__ /\ _P"D
MDDDD3_\ _P#_ *DDDDDDDDDDDDDDDDDDD-+^ 4DAF,DDDDDDDDDDDDD0_P#_
M /\ ;DDDDDDDDDDDDDDDDDDDDDDD_JDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDD
MDDDDDDDDC_\ _P#]22222222221__P#_ /\ ^2222222222222220#__ /\
M^9))))))))))))))))))).O_ /\ _P!)))(/_P#_ /\ 9)))))))))))))))
M)))))'O_ /\ _P#)))))))))))(O_P#_ /[TDDDE_P#_ /\ _,DDDDDDDDDD
MDDDDDDDDCZ![2$DD,1DDDDDDDDDDDDD__P#_ /\ $DDDDDDDDDDDDDDDDDDD
MDDDDYLDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ /\ R2222222222222222_\ _P#_ .222222222222222222222:
M?_\ _P"I))!/_P#_ /XDDDDDDDDDDDDDDDDDDDDDA_\ _P#]>22222222222
M ?\ _P#_ /V222+_ /\ _P#Q2222222222222222222T;*TN221&NR222222
M22222+?_ /\ ^[))))))))))))))))))))))))))))))))))(O\ _P#_ #))
M)))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_ /DDDDDDDDDDDDDD
MDDO_ /\ _@2222222222222222222223?_\ _P"-))#_ /\ _P#U))))))))
M)))))))))))))(A__P#_ (DDDDDDDDDDDD+_ /\ _P#_ ))))_\ _P#_  9)
M)))))))))))))))))'@+7[))))WT9)))))))))))_P#_ /\ W)))))))))))
M))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#]:222222222222222?_\ _P#_ *22222222222222
M22222220O_\ _P#[))+_ /\ _P#_ "2222222222222222222222?_\ _P#Y
M))))))))))))]_\ _P#[LDEG_P#_ /\ $DDDDDDDDDDDDDDDDDDDD@))8DDD
MB]IDDDDDDDDDDD%__P#_ -222222222222222222222222222222222222+_
M /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ _DDDDDDD
MDDDDDDDDDA__ /\ \622222222222222222222223_\ _P#])(O_ /\ _P"Y
M))))))))))))))))))))))+_ /\ _P#U))))))))))))-_\ _P#_ %I!?_\
M_P#[DDDDDDDDDDDDDDDDDDDDWK+/#DDDDC8DDDDDDDDDDD'_ /\ _B222222
M222222222222222222222222222222+_ /\ _P R2222222222222222222/
M_P#_ /U))))))))))'__ /\ _<DDDDDDDDDDDDDDDM__ /\ ]22222222222
M222222222222!_\ _P#_ .2;_P#_ /\ J22222222222222222222222?_\
M_P#U)))))))))))),_\ _P#_ ._/_P#_ /\ X9)))))))))))))))))))&63
M[3))))"6F9)))))))))-_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ /W)
M))))))))))))))'_ /\ _P#Y)))))))))))))))))))))))#_P#_ /\ I(O_
M /\ _$DDDDDDDDDDDDDDDDDDDDDDDF__ /\ \2222222222222!?_P#_ /U1
M_P#_ /\ _))))))))))))))))))))V;_ &_R2220$EJ222222222 _\ _P#_
M "222222222222222222222222222222222222+_ /\ _P R222222222222
M2222222/_P#_ /U))))))))))'__ /\ ^,DDDDDDDDDDDDDDD_\ _P#_ )$D
MDDDDDDDDDDDDDDDDDDDDDD?_ /\ _P!D#_\ _P#^22222222222222222222
M2222'_\ _P#UY))))))))))))$__ /\ _P ?_P#_ /XDDDDDDDDDDDDDDDDD
MDDDD]OM]\DDDD@6R,DDDDDDDDF__ /\ _"22222222222222222222222222
M2222222222+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__
M /\ ^DDDDDDDDDDDDDDDDW__ /\ F222222222222222222222220/\ _P#^
M'+__ /\ _P#))))))))))))))))))))))))-_P#_ /\ )))))))))))))(__
M /\ _P#_ /\ _P#^9)))))))))))))))))))(&S_ .JT?."YM^T222222222
M#_\ _P#_ "222222222222222222222222222222222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ ZDDDDDDDDDDDDDDDE?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDC_ /\ _P#$W_\ _P#]MMMMMMMMMMMM
MMMMMMMMMMMMMO_\ _P#_ .2222222222222._P#_ /\ _P#_ /\ Y2222222
M222222222222228+286VVVVVYLWR222222223_\ _P#[))))))))))))))))
M))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DD
MDDDDDDDD?_\ _P#B222222222222222+_P#_ /QVVVVVVVVVVVVVVVVVVVVV
MVVVV/_\ _P#47_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /[DDDDDDDDDDDDDD$__ /\ _P#_ /\ F22222222222
M2222222220$!._2VVVVV\DO"22222222/_\ _P"M))))))))))))))))))))
M))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDD
MDDDD?_\ _P#R222222222222222;_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#\O_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))_
M_P#_ /\ _P#]2222222222222222222222[!(!&VVVVVJ!OZ22222221S_\
M_P#9))))))))))))))))))))))))))))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#N222222222222222#_P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ I))))))))))))))%_P#_ /\ _P#]R222222222222222222221;2
M:0VVVVVVLVW:22222220?_\ _P#I))))))))))))))))))))))))))))))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#V
M222222222222222+_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#<W_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))._P#_ /\ _P#.
M2222222222222222222223":6]6VM61K5:!422222222?_\ _P"I))))))))
M))))))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__
M /\ _4DDDDDDDDDD?_\ _P#R222222222222222/_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,7_\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /XDDDDD
MDDDDDDDDDD@__P#_ /\ $DDDDDDDDDDDDDDDDDDDDDD=+=FI%\DDDDP 2<DD
MDDDDD_\ _P#_ +DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDD@_\ _P#]22222222221__P#_ /I)))))))))))))
M)(__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ -L?_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#<DDDDDDDDDDDDDDA__P#_ /\ 2DDDDDDDDDDDDDDD
MDDDDDDFS=O\ ?))))))$7^Y))))))))__P#_ ,DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDB_P#_ /\ 4DDDDDDDDDDDDDDDDDDDF_\ _P#]22222222
M221__P#_ /))))))))))))))))?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /A?_P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDS_
M /\ _P#_ .-))))))))))))))))))))('_;_ "2222223[:322222220_P#_
M /\ N22222222222222222222222222222222222223_ /\ _P 222222222
M222222222227_P#_ /Y))))))))))'__ /\ _DDDDDDDDDDDDDDDG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_!__ /\ ^                              \DDDDDDDDDDDDDB7_ /\
M_P#_ /[))))))))))))))))))))(2?R:)))))))&;?\ 22222220_P#_ /\
MZ2222222222222222222222222222222222222?_ /\ _P!R222222222222
M2222222/_P#_ /\ R2222222221__P#_ /I))))))))))))))(?_ /\ _P"
M                             7__ /\ [DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDD2__ /\ _P#_ /Q))))))))))))))))))))(2V2_
M9))))))+>VQ)))))))#_ /\ _P")))))))))))))))))))))))))))))))))
M)))))_\ _P#_ #))))))))))))))))))))/_ /\ _LDDDDDDDDDD?_\ _P#N
M222222222222222#_P#_ /\ 2222222222222222222222222222221__P#_
M .Y)))))))))))))))))))))))))))))))))))))))))))'_ /\ _P#_ /\
M_P#!)))))))))))))))))))($!-L9))))))/6VQ)))))))/_ /\ _P"9))))
M))))))))))))))))))))))))))))))))(?\ _P#_ -))))))))))))))))))
M))__ /\ _4DDDDDDDDDD?_\ _P#^222222222222222;_P#_ /\ 22222222
M22222222222222222222222?_P#_ .))))))))))))))))))))))))))))))
M)))))))))))))()__P#_ /\ _P#_ /XDDDDDDDDDDDDDDDDDDDA[)?(DDDDD
MD@MDD<DDDDDDDG__ /\ R22222222222222222222222222222222222223_
M /\ _P!R2222222222222222222;_P#_ /Q))))))))))'__ /\ YDDDDDDD
MDDDDDDDDG_\ _P#_ ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDW_\ _P#^2222
M2222222222222222222222222222222222222203_P#_ /\ _P#_ /\ _F22
M22222222222222221<DOVR222222 ?\ ]DDDDDDDDG__ /\ F22222222222
M22222222222222222222222222+_ /\ _P!R22222222222222222223_P#_
M /\ R2222222221__P#_ /Y))))))))))))))(__ /\ _4DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD/_\ _P#B222222222222222222222222222222222222
M2222222__P#_ /\ W_\ _P#_ .R222222222222222223/VEO2222222#_\
M_DDDDDDDD8__ /\ ]2222222222222222222222222222222222222;_ /\
M_P"R2222222222222222222?_P#_ /[))))))))))'__ /\ \DDDDDDDDDDD
MDDDDD_\ _P#^R222222222222222222222222222220__P#_ /9)))))))))
M))))))))))))))))))))))))))))))))(_\ _P#_ ."U_P#_ /\ P9))))))
M)))))))))))%),D/)))))(1__P#_ $DDDDDDDC__ /\ \222222222222222
M2222222222222222222222'_ /\ _P#R2222222222222222222?_P#_ /\
M22222222221__P#_ '))))))))))))))))/_ /\ _4DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD/_\ _P#W2222222222222222222222222222222222222222
M21W_ /\ _P#R3G__ /\ ^Y))))))))))))))))))N2;W(UK*U[:[0EO)))))
M)))O_P#_ /$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF_P#_ /\ \DDD
MDDDDDDDDDDDDDDDDA_\ _P#^R2222222221__P#_ !))))))))))))))))?_
M /\ _=DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDY_\ _P#^R222222222222222
M2222222222222222222222222??_ /\ _P#22?\ _P#_ /\ $DDDDDDDDDDD
MDDDDDD!+?IDMMMMMMJV[(4DDDDDDDB__ /\ ^62222222222222222222222
M22222222222222?_ /\ _P!222222222222222222223_P#_ /Y)))))))))
M)'__ /\ $DDDDDDDDDDDDDDD@7__ /\ B222222222222222222222222222
M222+_P#_ /W)))))))))))))))))))))))))))))))))))))))))_P#_ /\
M_P"R22?_ /\ _P"&22222222222222221DW:6VVVVVVVKVP#R2222222?_\
M_P#_ *222222222222222222222222222222222222-?_P#_ )))))))))))
M))))))))))/_ /\ _4DDDDDDDDDD?_\ _P!R2222222222222223_P#_ /\
M^222222222222222222222222222222;_P#_ /R)))))))))))))))))))))
M)))%)))))))))))))))+O_\ _P#:DDDV_P#_ /\ [DDDDDDDDDDDDDDDDDR6
MP#MMMMMMMKM__P!))))))))!_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P"R2222222222222222222;_P#_ .I))))))))))'__ /\
M,DDDDDDDDDDDDDDDD?\ _P#_ -DDDDDDDDDDDDDDDDDDDDDDDDBDDDDD@W__
M /\ ^22222222222222222222222"@22222222222222=_\ _P#_ .2222,?
M_P#_ /\ 22222222222222220X!)*VVVVVVVUM__ ,DDDDDDDDG_ /\ _P#D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD?_\ _P!R2222222222222222
M220C_P#_ /Y))))))))))'__ /\ LDDDDDDDDDDDDDDDDX__ /\ ]2222222
M22222222222222223MN22223_P#_ /\ B22222222222222222222222#_;2
M222222222222;_\ _P#^I))))%__ /\ _#DDDDDDDDDDDDDDDD>V2DMMO>A"
M>Y)OT$DDDDDDDDC_ /\ _P#TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M/_\ _P!F2222222222222222220__P#_ .9))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDB__ /\ ^R22222222222222222222222_FZ2221?_\ _P"I))))
M))))))))))))))))))!O_P ,R22222222222_P#_ /\ ]N22222?_P#_ /\
MY2222222222222221+2;+2A"2220KX$"222222222#__ /\ ^)))))))))))
M)))))))))))))))))))))))))'__ /\ [DDDDDDDDDDDDDDDDDDD?_\ _P#J
M22222222221__P#_ +)))))))))))))))))__P#_ /<DDDDDDDDDDDDDDDDD
MDDDDDC7_ / 9))&__P#_ /8DDDDDDDDDDDDDDDDDDDDDBW__ /R9))))))))
M)(O_ /\ _P#K))))))1__P#_ /TDDDDDDDDDDDDDDD 26XDDDDDDD'X 7TDD
MDDDDDDG_ /\ _P#\LDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_P#_ /\
MYDDDDDDDDDDDDDDDDDDD_P#_ /\ _DDDDDDDDDDD?_\ _P"R222222222222
M2222;?\ _P#^I)))))))))))))))))))))+_ /\ _P"])))/_P#_ /\ I)))
M))))))))))))))))))/_ /\ _P#))))))))))#__ /\ _P#Y)))))))__P#_
M /\ Y))))))))))))))*O^O))))))) @)MQ)))))))))!_\ _P#_ )))))))
M)))))))))))))))))())))))))))))/_ /\ ^LDDDDDDDDDDDDDDDDD@_P#_
M /\ !DDDDDDDDDDD?_\ _P"R22222222222222220_\ _P#_ ,R222222222
M222222222220?_\ _P#Y)))A_P#_ /\ C)))))))))))))))))))))__ /\
M_BDDDDDDDDDD'_\ _P#_ #DDDDDDDB__ /\ _GR22222222222222_Z!2222
M222423;22222222222?_ /\ _P!V2222222222222222222222?M22222222
M222;_P#_ /\ R22222222222222222+_ /\ _P!222222222221__P#_ +))
M)))))))))))))))"_P#_ /\ SI))))))))))))))))))))7_ /\ _P#7)))!
M_P#_ /\ XY)))))))))))))))))))?\ _P#_ .W)))))))))(_\ _P#_ ._)
M)))))))9_P#_ /\ \Y)))))))))))))+V!+)))))))$A(E9)))))))))(?\
M_P#_ .S)))))))))))))))))))))!O\ GR222222222'_P#_ /Q)))))))))
M))))))))"O\ _P#_ +)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDG_ /\
M_P#],DDDDDDDDDDDDDDDDDDDA_\ _P#_ (DDDDV__P#_ /\ $DDDDDDDDDDD
MDDDDDDD-_P#_ /\ YDDDDDDDDDD*_P#_ /\ YDDDDDDDDDK_ /\ _P#YDDDD
MDDDDDDDDDD);_P#))))))(, $DI))))))))));__ /\ _#DDDDDDDDDDDDDD
MDDDDDDD'_P#_ !R22222222,_P#_ /\ ER222222222222222??_ /\ _+))
M)))))))))'__ /\ LDDDDDDDDDDDDDDDDDD__P#_ /\ TDDDDDDDDDDDDDDD
MDDDC7_\ _P#^222221?_ /\ _P "222222222222222220?_ /\ _P!&2222
M222223__ /\ _P#R2222222227__ /\ ^M)))))))))))))*[;1))))))(]L
M -I))))))))))%__ /\ _P"]))))))))))))))))))),O_\ _P#MDDDDDDDD
MD'__ /\ \R222222222222222;__ /\ _))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDD(_P#_ /\ Y$DDDDDDDDDDDDDDDDDS_P#_ /\ ]TDDDDD/_P#_
M /\ YDDDDDDDDDDDDDDDDD=__P#_ /\ 4DDDDDDDDDB__P#_ /P222222222
M2!__ /\ _P"62222222222222VT R222222923;F22222222220/_P#_ /\
M_&222222222222222221E_\ _P#_ ,V222222223[_\ _P#VY)))))))))))
M)))/_P#_ /\ _I)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDD@_P#_ /\
M_$DDDDDDDDDDDDDDDD@W_P#_ /\ _DDDDDDL_P#_ /\ _P 9))))))))))))
M))(C_P#_ /\ ^I)))))))))'/_\ _P#6DDDDDDDDDDD _P#_ /\ Y$DDDDDD
MDDDDDDG_ ,+))))))$7[>X))))))))))))G_ /\ _P#^))))))))))))))))
M))A__P#_ /[DDDDDDDDDDD__ /\ _P#TDDDDDDDDDDDDD&__ /\ _P#<DDDD
MDDDDDDDD?_\ _P"R222222222222222222,__P#_ /\ VR22222222222222
M2K__ /\ _P!B222222,__P#_ /\ FR2222222222222&#_\ _P#_ -N22222
M2222)?\ _P#_ -R22222222222"?_P#_ /W))))))))))))+LME))))) .?[
M21))))))))))))!?_P#_ /\ ^')))))))))))))))(?_ /\ _P#^9)))))))
M)))/_P#_ /\ ^')))))))))))(S_ /\ _P#_ )2222222222221__P#_ +))
M))))))))))))))))))O_ /\ _P#QY)))))))))))))"I_P#_ /\ ^=))))))
M))O_ /\ _P#S5)))))))))))(HO_ /\ _P#_ "22222222223_\ _P#^_)))
M)))))))))+__ /\ _EDDDDDDDDDDDD O_,IW<H7UEH"4DDDDDDDDDDDDDEW_
M /\ _P#_ ()))))))))))))).?\ _P#_ /\ ^*22222222222_\ _P#_ /\
M)DDDDDDDDDDDY_\ _P#_ /YDDDDDDDDDDDDD?_\ _P"R2222222222222222
M222$?_\ _P#_ .>2222222222200_P#_ /\ _P#3DDDDDDDDC_\ _P#_ /\
M_P 2222222222&__ /\ _P#_ /ODDDDDDDDDD7__ /\ \R22222222222233
M_P#_ /\ C2222222222223_]&6VVVVE9MFV22222222222221S__ /\ _P#\
MQ2222222222283__ /\ _P#_ /LDDDDDDDDDDD=__P#_ /\ [0DDDDDDDDD>
M_P#_ /\ _P#W9))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDD3__ /\
M_P#X2DDDDDDDDDDOG_\ _P#_ /\ Q)))))))))!__P#_ /\ _P \R2222221
M2;__ /\ _P#_ )4DDDDDDDDDD/\ _P#_ /4DDDDDDDDDDDDDB7__ /\ ^222
M222222222;_VVVVVVV]^WLE222222222222220?_ /\ _P#_ /Q9DDDDDDDD
M33__ /\ _P#_ /\ 6222222222222 ?_ /\ _P#_ /D,DDDDD#.__P#_ /\
M_P";)))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDE__ /\ _P#_ .DI
M))))))),M_\ _P#_ /\ _F2222222222+_\ _P#_ /\ _1'!DDBWG'__ /\
M_P#_ /PY)))))))))-__ /\ _P")))))))))))))))&__P#_ /\ ))))))))
M)))(N  +;;;;:/;V7)))))))))))))))+_\ _P#_ /\ _P#Z#Q%DDCWNW_\
M_P#_ /\ _P#AR2222222222223?_ /\ _P#_ /\ ^*I1'#;_ /\ _P#_ /\
M_CDDDDDDDDDDDDDD?_\ _P"R222222222222222222221O\ _P#_ /\ _P#Y
M3;))(M^?_P#_ /\ _P#_ .4DDDDDDDDDDD*__P#_ /\ _P#_ /Y.P3__ /\
M_P#_ /\ _P#OR2222222223_ /\ _P#_ "DDDDDDDDDDDDDDD@__ /\ _FR2
M222222222>VVBVVVVVJ3: *222222222222222 ?_P#_ /\ _P#_ /\ _P#0
M57__ /\ _P#_ /\ _P#[DDDDDDDDDDDDDDD@G_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#BR22222222222221__P#_ +)))))))))))))))))))))(
M9_\ _P#_ /\ _P#_ %75!_\ _P#_ /\ _P#_ /R9))))))))))))1_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ -I))))))))))E__ /\ \<DDDDDD
MDDDDDDDDDE?_ /\ _P#ODDDDDDDDDDDUM[UH%#Z"G9+?DDDDDDDDDDDDDDDD
MG_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \)))))))))))))))
M)"?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ :DDDDDDDDDDDDDDD?_\
M_P"R22222222222222222222237_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#\22222222222220W_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
MPI))))))))))(?\ _P#_ /I)))))))))))))))),_P#_ /\ _)))))))))))
M'*6^OI))/_3^S)))))))))))))))))&/_P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ //<DDDDDDDDDDDDDDDDE?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ ^E)))))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDDDGG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ ^K))))))))))))))()__ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#U?))))))))))('_\ _P#_  I)))))))))))))))))
MO_\ _P#ZLDDDDDDDDDDE"0DDDDD'_M_&DDDDDDDDDDDDDDDDD@6__P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _"LDDDDDDDDDDDDDDDDDDPW_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDDD?_\ _P"R2222222222222222
M22222205_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _HN2222222222222222?
M+_\ _P#_ /\ _P#_ /\ _P#_ /\ _P!9))))))))))))?_\ _P#^$DDDDDDD
MDDDDDDDDDD@G_P#_ /\ ?DDDDDDDDDDD,E<DDDDQ_M;$DDDDDDDDDDDDDDDD
MDDG]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ KTDDDDDDDDDDDDDDDDDDDD!_
M_P#_ /\ _P#_ /\ _P#_ /\ _P#[I))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDLG_ /\ _P#_ /\ _P#_ /\ _P#_ /\ M:2222222222
M22222222%;__ /\ _P#_ /\ _P#_ /\ _P#\2222222222221_\ _P#_ -N2
M222222222222222223__ /\ _P#Z22222222220F]R222.:ULV2222222222
M2222222222"U_P#_ /\ _P#_ /\ _P#_ /\ _H?222222222222222222222
M23!__P#_ /\ _P#_ /\ _P#_ /QW)))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDDH__P#_ /\ _P#_ /\ _P#_ /\ [.DDDDDDDDDDDDDD
MDDDDDDDQ*_\ _P#_ /\ _P#_ /Z\4DDDDDDDDDDDDDK;;;;,DDDDDDDDDDDD
MDDDDDDDG;;;;;DDDDDDDDDDDD 4DDDD]MV@$DDDDDDDDDDDDDDDDDDDDD1D_
M_P#_ /\ _P#_ /\ _P#7Y))))))))))))))))))))))))!&__P#_ /\ _P#_
M /\ _$Q))))))))))))))))))%MMMA)))))))))))))))))))))))))));1_
M_P#_ /\ _P#_ /\ S^I))))))))))))))))))))))),][O\ _P#\V".DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF &DDDC$
MTFP4DDDDDDDDDDDDDDDDDDDDDDD3(L;_ /\ E)7@22222222222222222222
M22222222871?_P#_ .[W:)))))))))))))))))))))))))))))))))))))))
M))))))))))))))%<KU__ /\ $%14DDDDDDDDDDDDDDDDDDDDDDDDDDDF@]>4
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD2'DDDB 0&RDDDDDDDDDDDDDDDDDDDDDDDDDDDGCC<DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD=C6Z5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDP#K6DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDE ,DD5]:"5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD_0DD:TR"2DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDEHDDO_ "W[))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))+E)'?[[7I)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))F9-_2W;))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))(0_2S[_ "2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222-EWEFR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222<@0'M22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222@;&UR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222238")\R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222220+T#>22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222"T;*Z22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222+" _^22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222228;$Y*22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222,GY*"22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222229X0/R22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222223Y2FI22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222204_"0R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222221(P;+R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222228Z'O22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222*X#&2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222UZ2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222223_Q  N$0 ! P($! 4%
M 0$!       ! !$Q(3! 05!A(%%Q\!!@D;'!@(&AT>'Q<+#_V@ ( 0,! 3\0
M_P"1RQ%09213H"@J2JJ-!^MG<*)>IXR<B@7J/K68YEIH_6K  DC&*W4?K48W
MKC1?6H.D7#8/K4CZ?7 (KAYW+ZU'\7&2+/ZU:D(-HH 0  8?6J,7(@QL$-D&
MUG]:X!9*I4.*K0$$8?6U!D7!\ 9Q4&/_ &^=] N1 @P?I<) E-R0MIX#:+;(
M&@^?*!S\1"*!FJIQIY%("2B/(B+-;_!!O+=0,@ P?^)D@2F<G@ 6"$"#&F$@
M2FY*VG@-HML@:#K9D%!9NCRA$D41(A))L@<% 6: Y" YA9@@0:CSJ_\ $@$-
MI.O2!0<!$T!$F:)I-P"@H S0%(1<AE#'_A1( <J.JB>12QX02(6:+DE%G0R$
MBLT=$<@B2*(FS1))L@4% 6: 90',+,$"#&HSY!R+-%.#!(J%FCHJ"E6/CCK:
M6TMI;2VEM+:6TMI;2&PT, .6TMI;2VEM+:6TMI;2VDP8,6\<1"<(([ZR2!4J
M.JB>12+#29!0=9HR!>-!=0+:6TMI;2VEM+:6UI0C$MI;2VEM+:6TMI;28 88
MBR6TMI;2VEM+:6TB 9-H .2R115RN;F%1L\=-D'(LT3O.#!(A9@Z*@I%I9+2
MN?%GK8H%H4]54LTQU<$&U.0IT)VR!:,T@  PQ8U'&.T0! :M-%&<BJ!8R5(X
M@HLX_P!JR(TF;'ADV/S+(Z*BBKE? DP30,5"IPJLY;%0IBJIYIH\*@5*88^.
M*H]!Q@W",\M?':"S9)M $F"$QC =W*Q.>J4:2MK&A9^X5/-,;[5D1I,V/#)L
M?F<8!=*0*# LA^*HE14XQ\\5$H.B43-2$:' 0H"<77!(M M4+JV/ X1"<VFS
MYQHN5AGU)(2J' T:&*H9H<7[5D1I,V/#)L?F<0!RB#G T#) -08B0E2$:' 0
MNJ: 2 <HYIH\XHH(!QBFRVT5@@"S&DM4KHEITY@8ZKI>#\+ITT'3P"Y(E%*G
M2:%(01\2]JR(TF;'ADV/S.$8[HIO@4J@9X<D .4]19T8]"@@'&- .AVL:25H
M@CC$D ABC-96G;H.-^>M'8(33'2]$Z=.G3\!OIVD"I1QRTP$DX0S3$?:LB-)
MFQX9-C\S@&+YHAN<$Z7X<0Z&:QI)1P@M,6(=T0WTL0G"#09Q(F"@),;39\XN
M,E3:G)./EZ<+ITZ=%6-],):I3NH):#"! .,-[5D1I,V/#)L?F>('"CF[!' "
M ###"'='-]+ DG"#1+$CH2B22YP$ $7)9#.* D )M%MA;(3^1$V2)$1R* BJ
MA& A;QQ+;.M DG"$YB0"Y%<6G] C;H%/XNG3IT^F  NE(RP(@! V2!YE#/*
MLDPC.1;:VELD2(2Y(DA$<BB&%(#!&/9 %\*]JR(TF;'ADV/S/  .49XVJ "(
MFB YE=9'>7-+('1!%#X59)PP082B23G 0P1,T0SB@! 62VB9R"VPG\B)LD2(
MCD4!%5 -(COA$O4WLI9!2=0J_)A<TI\7WL2NV0;1GD""'&(=L@6BM9(!@PT
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M]E65.3]:$)Q$DES:(3! !S.D;QME0(I@/:LB-)FQX9-V8@:"$A(A.;1#<P@
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MOCM+;YLOZ?[8V!'O?_*>_%]I?. CZV8>3$?2S%I,^/#)LP]- D;)0!UT
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M</3)**7#I?BS)L2&DM'$HAJ&V"2<(1HH((<8JC5&Z@AL0&!@MU7894<T.&)
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MOK9YL$W%1^[];( 8PCYD)DR9,F3(?K;K H5&ATQ%#X-X,#R/K<@#HER5<#H
M*(L#/Z*__\0 +A$  0(#!0<% 0$! 0       0 1(3 Q0$%046%QD:&QT>'P
M$"!@@<& \7"P_]H " $" 0$_$/\ D96&&:BAOP5/$P5%"LE*/5&?]LP]')
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MG"40"&*+!JI/$:Q03*OW>F"$ %Z$(+O1DR9,F3+;EAQZ>MY*XJ-5&!%!<O0
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MBF,RF=^:X4QY!/Y^^\!TZV[MNA+!<)_4'%D\PI\4MK;>DFHXE*^T6:A)<NF
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M!G?BDHXI%&9V<AX('$>U@ +YFTT4R9,F3)DR*!G@#B6*N4YK,PW+1"TFY:2
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M&;@9<*<V+5R96]7H-0*N'+[)P$$A!-7$:(UCT%O:[60PAN)A,*$2R)2JV^L
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M:".*NF,U]HRP<*"71U$3.$(1,(TY.SX!%>743EJ$7H98\,0X@=6 -TI1=X1
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M>&('2>?WH1QP5;A-@@!$1N)KU+ "-@2TC!9V[:=%TA'DBM *= :)4)M P\I
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M>XB#=C!M$'=/U.+8K(6DR>=^V/16TV\)2//(V2S5B1V+@70SKFTDRNBQ%?X
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MGL^EB,W4G'97C[L]OU,L+(OAW"GH+BF0K& XCW5VU/-245 *["6!W+ ,[F@
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M'6XH$(W1=2_#L#VN(8P!L!GY_''0&:8I[15\?SUV?8P):EI_S;EP_>OH)?\
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M_P#Q('CULTEW!-L?5 '>\ M2Z(+"#X)\LK=>EBD*T)>#@\;=\.@2C[)B%QM
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M<B:4>ZZLHINW<9:QTA((3UR*NKHO8M$R" HA(CA'V::H LZ<:JP?T2TD*[*
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M2\#410H5"C>$+/L$"9SA3B\[B2Z&&">J95=U]C$K*BZO32!G;PTA&JPZ&%Q
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M,?#/3_ZK8"ZH M+5,2&-3G\#(%Z:7Z,90 ,JH!6I%=81(=1 [R<KU7[G?[A
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MXL-'P"X+)U;'/)L6QCB$=J$.$!G?835>!0B;0$3VI.8C9?3M-41.RJV"IJB
M5YG,?/Q0(W&2=J2^621=8-:<(AWDU70P=T&,FMAT 'J#0-8$(!R(HG-(F"0N
M5QJR#N.P.F@(HEQ-*F%A2O&O#L0! %10;)1EJF;81X/1S=E)2)JC-VGAJ?>1
M(O;!X$7AFG((E3*O4LAD7@;@XTS=F(5$53^ ( \&<OJ_W._W*!>5RA"QF0,:
M2, 48$#".3J63K[)UD;G=Y*!\A+E]!W0 -U!DP?>PA9.3TI]2GNIH%7O8$SN
MQ;[+I14CIE'M"5.7#2.J!-YLJ_H+JM@%8"KP)#2:IVXFN42Z/2-<I"UD3*NE
MBXM,=43L9[@;EU9N:F#D2*NJ;/ J@SYD*'O"\P] X7@X&JK8*D-)8%=2:3@:
M&G*2(M( O"=].6V8$+IB/ #K'5$===5< 2J@ 58*M&R*5@W[@0ELLE@/2A_
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M[?)^UL#9$#RU+V+-H^"N;:F_HG228P?F2@^(@^3:VOZ03'O(>85?*<#N@$[
M/0S&6YAY-1=L&(0H;W&EH L $ >L0$:> RJ7FP\A9"FI<>+H[[B61$L^@@0K
M,L]RR\E:!=?+$7FAH!R(?%/=FUY+;ZA3S"H[S*_IU^(]?V*'=K1#^5=B1>:8
M!HDH[@G\U!\H&VX$O#-130+CM*'@] ]8*+: #*M'\&1; FH)A#(-!ZW]SO\
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MSW+)<Z5H1-@(RBZ*>ZN@/3,H&+V03H*2:!D]F@3"C1$BH*CZ6U7HVO8<I/\
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M>O#O1PA8 +JU8MM>4D/<H9AJ7AVKN<8+LCCU/C>\ 9& D-23:3I1V&1G7MT
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MT:8T"NTK<&JV=DPJA#A.4(.HB/VW:9IF\#R;S4-0_8(*@^EYV8-)2._XS_M
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AJ%]B3[-FBNRD!C@S_-8SSKW\"LFT_$?(B @.Q:_\5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ophthalmologyrabbiteyesdata.jpg
<TEXT>
begin 644 ophthalmologyrabbiteyesdata.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0 U8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOI[_ ()9_M,_$;]I/PO\0+OXAZ\NNW&E7EI%9NME!;>6KI(6&(40')5>N>E
M'W11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$;G>%1V,I+!<M@8QG'Z74;12T >>_M$?\F__ !-_[%C4_P#TDDKX(_X(>_\
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M-?G9_P $XK%_VB/VF_C+^T5J=LS0R7;:5HWG(,Q*X4X]G2W2!..TC>M 'Z4
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M=.\B]NX=V6,,SL[,I #;-X; !*C' !]MK3J** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-^T>_P 6/CS_ ,(+ILT;>'? YDM&:*4N)[]L?:&8= 8RHBV\D%),GYMJ]?\
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M8"PW#80?8 ^5/VP_@GJ7[07_  4N^)G@S17 UFYTZ&ZL8V8*)IH-$MYDB)/
MWE-N2<#(-???_!.C]J2X^/7PKF\-^*)6C^(O@XKIVKPW# 2W"+E4G*]<_*5?
M_:4_WA7SMI/_ "G(UG_KT7_U'XJU_P!MWX>ZY^R#^T%H?[4/PZT\2Z5<S"T\
M6:7$Q1)2^U2S<':LH4 L!A9$1B"6- $WQ8_Y3/\ PK_[ 7_MG?U])_\ !0/X
MW3_ W]F+Q1J.G9/B#65&A:6J_>$UP"AD7CEDCWN/=5'>ODO4_'VB_%+_ (*R
M?!#Q9X=NUO=&UCPPMW;3+UVM97YVL.S*?E*]B"#TK/\ ^"B?Q5UKQ]^V!X#\
M$^'?!>L?$S3?AWY6N:GX9T&.222ZN':.0K+Y<4N$5!"N2AP)7&1OH 7XO? N
MZ_8I^#W[-7Q8TF!X?$'@N\C@\4S6ZY,\5X?-GC<[>45FFA!./]:.^*_4C2-4
MM=<TNSU*QF2YLKR%+B":,Y5XW4,K ^A!!K\T/CI^U]\6OCO\(_%'@+5_V,_'
MT-GK=FUN+@K>RFWER&BF53IPR4D5' R.5ZU[=_P2M^,+>/OV;8?".J2R1^)_
M MRVC7EE<@K/%#DF#<K<@ ;X\'IY)':@#[.HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Q_%/BS0_ ^A76M^(]9T_P_HUKM^T:CJE
MTEM;1;G5%WR.0JY9E49/)8#J:X/QQX_^#OCSX37MSXH\7>#]4^'.L,VFS:A>
M:Q;?V=<.0<Q"??L\P;20%;<"N1R,TS]J/X&_\-)_ OQ-\./[;_X1W^VOLW_$
MR^R?:O)\FZBG_P!7O3=N\K;]X8W9YQ@_'OQZ_9(\$_!']A#0_AAX^^,'_".:
M'9^*!?)XI_X1F>Z\V:1;AE@^RPRLPX9COWX^3IS0!W'P1^&?[%'[/_C5_%GA
M3Q]X$.NKN%K=:EXSM+HV2L,$0AYOE."1N.6PS#."173Z2?V3],_:"UOXS2?%
M#P'?^-]22...XO/%5@\5D%B2(M GF85V5!ESEL,P! )%?)_A/_@B[I?CCPKH
M_B31/CK]NT76+*'4+&Y_X1!T\V"6-9(WVO>!ERK*<, 1G! KG_B1_P $G?!/
MPADT:/QA^T;:Z#)K-R+33TN/";%KF8LJ[$"WA)Y=<^F<F@#]BJ*:O6G4 %-:
MG4E 'X8_M4_M8#Q!^W-JVK^/?"K>,/"OP_UBZTC3/"JZH;6V=K6X=!-(QB<$
MNZ;V79R J$D+SY_^T]^V:/VCOVA/!?Q/'@[_ (1P>&[6RM1I(U/[2)_L]W+<
M;O-\E-F[S=N-AQMSSG%?OQ-X5T6XFDEET>PEED8L[O:H68DY))QR2:^$OVR/
MV$O&WQL_:H\ >//!]KX?M?"VBV6GP7T-Q-Y$C/#?3S2$1K&0P,<B#)(STH ^
M5?\ @HI\8Y?VH?@/\#?BV-#/AJ&\N-9T\Z9]J^UA&26)0WF[$SD0DXV#K[5^
MJ7[2>OV5Q^RK\3-5CGC>QNO"&H213;AM99+.0(0??</SK._:@_97\+?M.?"&
M?P1J2KH[0R_;-+OK2, V-T%8"38" RD.P93U#=B 1\12_L%?M;^(/!-M\*-8
M^,&CK\,88X[?RTD=SY"D$1X\E9'5<#"-)MX X% '@WP)\"7.I_\ !+OX^:JC
M.J2:_8N/W>05MFMY&(Y[^;C/;%?H;_P2PU&"\_8=\ 0PR*\EG+J4$R@Y*,=0
MN) #Z':ZG\17KGP\_9I\&?#[]GV'X/1V9U#PHVG3:?>B;Y)+P3!O/D=EQAF+
ML<@Y'&.@KX@T[]@7]IGX ZAKN@_ _P"+5CI_@/5KII?)O7\N>%2H&Y@8I L@
M&%WQL"VT'CH #S_]D'0_^$V_X*<?'&_M)";>%O$<RR1@,I$MWY2\Y_Z:9Z]J
MZ?\ X(H"/0_$WQRT*:4?;8VTL!&^5F$+WJ.<=L%U_,5]:_L._L9VO[)/@W5?
M[0U1/$7C77Y5GU;550A?E+%8HRWS%068EC@L3G X \3^,_\ P3Z^)'A#XYZK
M\5_V;_&MIX.U;6?.EU'3+YB$\Z5P\A0LDB-&[9;8ZX5@-O& H!XY_P %'=.7
MQE_P4<^#&B6SDSR6>CVLGEX9D9M2N&Z?[K \^M?<?[<?[/\ XR_:0^#UCX5\
M$>(+7PWK$.L0Z@]Y>7$T"-"D4R,FZ)6;):13C&/E->1_LJ_L'>,?"/QMN_C1
M\;_%]OXU\?[-EC';@O%;L8_+,K,549"$JJHH"Y)Z]/N2@#\:?'G_  2[^/O@
M_P #>(M>U/XIZ->:=I>FW%]=6T>JW[-+%%$SN@#0A22JD8)QS7KW_!#W_D2?
MBM_V$;#_ -%35][_ +1'_)O_ ,3?^Q8U/_TDDKX(_P""'O\ R)/Q6_["-A_Z
M*FH _3FBBB@ HHHH **** "BBB@ HHHH **** "BBB@#X5_;H_:$_:5^$_Q:
MTG2/@YX#O_%'AF;0X;JYO+7PS<ZDJ79N+A'C,D0V@A$B.T\C<#W%?.O_  VI
M^W?_ -$>UC_P@;__  K]=** /R+_ .&U/V[_ /HCVL?^$#?_ .%'_#:G[=__
M $1[6/\ P@;_ /PK]=** /R+_P"&U/V[_P#HCVL?^$#?_P"%'_#:G[=__1'M
M8_\ "!O_ /"OUTHH _(O_AM/]N__ *(]K'_A W_^%?J)\']:U[Q+\)?!.K^*
M;-].\37^AV-WJMG);M;M!=R0(TT9C;YD*N6&T\C&#TKKZ6@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LOQ+9:EJ'A_4K71M2CT?5I[:2.TU&6V%RMM*5(20Q%E#[20=I89Q6I10!
M^5]U_P $/9KVYEN+CXX/-<2N9))9/"Q9G8G))/VW)))ZUH^%O^"+>J>"?$VE
M>(=$^.[6&L:7=1WMG=+X25C%-&P9&VM>%3@@<,"#T((K]/Z* *UBMQ'9VZW<
MD4]VL:B:2&,Q([@#<50LQ4$YP"QQTR>M6:** "BBB@ KXC_;N_9=\<^)OB'X
M*^.?P?B6X^(WA';'+IS2[/MULC.ZJHR 6&^164D;UD([ 5]N44 ?!.G?\%2K
MNSL[;3/$7[/_ ,1['QQ)%DZ/;Z<3&[\_=+A9-IVG_EF2,$<XS4_[&WP#\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/=,E72Q)\._A5?P;=56W(@1TBBG>-I"</,;@@!5Y4*,C@D_I0*.*6@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M70<DDX/R&((?PE- 'Z/T5RG@?XF^&OB)\/\ 3?&^A:M!=>&;^U^V17['8@C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^8O^"@W[,%_P#M1? 6;1=!:(>*-'NEU/2T
MF(59W565X2V/EWJQP>!N"YXR:^G:\N_:,_:"\-?LS_"O4O&_B<RRVUNRP6]E
M;X\Z[N'X2),G&3@DD\ *Q[4 ?E#H_P#P4B_:>_9O\.V/A+Q7X6L+B3346TBN
MO&6D78NRJKA5:19H_,( ^\02<9)/6MOP'X-^/O\ P4D^-GA;6/B=H[Z1\/-
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M3_@J!\*?#'A\KK<FE1:9::DELVX0B.[FNI]Q!_@B?<?RZ\5^A7[37[,_A?\
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M^H^"?!'@O6]"DLXS!<2:7;7,V H!$K.I?S ?O;SNSG-=]_PS?\)?^B7>"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  &!3Z "BBB@ HHHH **** "BBB@ HHHH **** //?VB/^3?_B;_ -BQJ?\
MZ225\$?\$/?^1)^*W_81L/\ T5-7WO\ M$?\F_\ Q-_[%C4__222O@C_ ((>
M_P#(D_%;_L(V'_HJ:@#].:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P <H ]('6G4U:=0 4444 %%%% !1110 4444 %%%% !1110!Y[^T1_R;_\
M$W_L6-3_ /222O@C_@A[_P B3\5O^PC8?^BIJ^]_VB/^3?\ XF_]BQJ?_I))
M7P1_P0]_Y$GXK?\ 81L/_14U 'Z<T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%>.?'#]I_PK\!/&?PW\.>($N)+OQOJITVV
M>$J%M@ !YSY(ROF20J<=G)[8/L= !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2-7 <O$Z-@*[]\<T ?#WP_\ ^"U/PZ'A'3$\9>#_ !5#XCC@1+PZ+!;3VKR
M89D,EPC $\X(XSC)ZUT?_#ZKX(?]"M\0/_!=8_\ R97AGQ(U;_@G/\/=:?3(
M?!>L>+98YO)EF\.ZCJ,T$?/+>9)>1JZC'5"V<\9KVCX!_LS_ +"W[2UK<OX#
M\,KJ-Y:();G3;C6M5@NH%)VAFC:X!*YXW+D<CGF@#]"J6DI: "BBB@ HHHH
M**** "BBB@ HHHH **** //?VB/^3?\ XF_]BQJ?_I))7P1_P0]_Y$GXK?\
M81L/_14U?>_[1'_)O_Q-_P"Q8U/_ -))*^"/^"'O_(D_%;_L(V'_ **FH _3
MFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@#%+10 4444
M%%%% !1110 @I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/;!\,?\ !3KX^?LWZ-;_  _\;>"[34-6T119";Q%!<0WNU1A [!@)/E P_\
M$,')ZUM_"NV^,_\ P4L_:$\'>+?&^D?V-\-?"=VETRPVSPV7R.':*,ODS2R,
MBJQR=JCMT(!^P0IU)2T %%%% !1110 4444 %%%% !1110 4444 >>_M$?\
M)O\ \3?^Q8U/_P!))*^"/^"'O_(D_%;_ +"-A_Z*FK[W_:(_Y-_^)O\ V+&I
M_P#I))7P1_P0]_Y$GXK?]A&P_P#14U 'Z<T444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?.G_  4&^'WB+XI_LA^/_#'A329]<U^]%BUM86V/
M,E$=_;ROMR1DA$<^^..:_'W]G7QA\,/V>_&<EE\=O@AJNO:C%+S)?2R0RV8P
M, V$H1)#WR[=^*_H,KE/B!\*_!WQ4TI]-\7^&-*\263#'EZE:)-M[Y4D94Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[;4GCZ/\ 9?\ &_\
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M **** "BDS1F@!:**3- "T4F:6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BD!I: "BDSSBC- "T444 %%%% !124M !
M1110!!<W$5G;RSS.L<4:EW=C@*H&2?R!KYT_9 _;0\/?M97'CN#38X].O/#^
MJO%;6+,3+/IQ^6"Z)^Z2[+)E4)V?*#G*L_E?_!6/]I"+X1_ .3P/I6H1Q>*/
M&P>R:!<F2/30/])D.!A0X*P_-U$C[0=I*_EQ^Q-^T9<?LR_M!>'_ !2[2OX?
MN&_L[6K6-PHEM)2 S<\$QMME XR8P,@$F@#^BVBHH9DN(4EC;?&ZAE8="",@
MBI: "BBB@ HHHH **** "BBB@ HHHH **** /D#_ (*K>-[WP9^QMXEBL)IK
M>;6KRUTEY86VGRGDWR*?]EDC9#ZAR*X'_@F[\'O /P;_ &4+'XU2Z6C^*;W2
M[^]O]7D=FD2VCE?,*#.U5Q;J>!DGO7TS^US\"O\ AH[]GWQ;X$BN!::A?0I-
M8SM]U+F)UEB#<?=9D"MWPQK\=M4^*7[2OPO^%$W[,%WX4OK*SU"6:UAMETB5
M]0N8F?S)(;>0$K)$22244G#'YL4 ;_\ P3[^&Q_:Z_;+U7Q7X[MX=;L;7[7X
MCU6WN8]\%U<2/MCB*L3\@>3<%.1B+:>#7KG_  6"^"W@SX5R?#;Q5X,T&P\)
MZM>3W-O/_8L"VBMY0C>-]D8 #JS'Y@ >>O Q]'_\$W?V3_$'[,?P7\1^(?$6
MGQVWQ \1)YXL)ADVD,:,8(9,'[S,S,P![J.HKX=M9OC-_P %6/C9H3:MI[:;
MX*TJ40W$^G0,ECI<#$-*0[YWSNH  ))/R\!10!^S?PK\33>-OAEX1\17">7/
MJ^CV=_(F<[6EA20C./5JZJJ]C9PZ=9V]K;IY<$$:Q1H.BJHP!^0JQ0 4444
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M&-5NR<D#WK]<**2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKE/BA\-=#^+_ ,/]>\&^)+7[7HVLVDEI.H52\>Y2!)&6!"R(<,K8.UE![5U=
M% 'Y'-^Q?^UI^QOXLU?_ (4'XFF\1>&=0V(K0M:*S@@,3+9W9:)9$9-OF)DD
M$8*[V0+H_P"P_P#M/_MB>/K.]_:(\1WGAWP]8*H8R-:.\@1LA(+:V*Q(["20
M>:PR.<AN ?UPI,"@#$\*^#=&\$^$].\-:-IUO8Z)86RVD%E#$J1K&!C&T #G
MDGCDDU^;/QV_X)S?%+X/_%J?XI?LS:^]I<W-Y<7[Z!"T5FUB3AQ#%N/E3PLQ
MD41.JA0$4AP21^H5)0!^0>O_  +_ &[_ -J*;3O!_P 3-0N='\*-.)+JZN'T
MZV@13\CETL]K3$(S$1MD'!Z=:_1S]EO]FOP]^RQ\)].\&Z)(NH72$S:CK#6R
M0S:A.Q),CA<\#.U5+-M4 9/4^P8%+0 5^5G[=6FW5Q_P5*^ $\5K-) DOAS=
M*D9*KC6)B<G'I7ZIT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <5\8OA/H'QP^&^N^"O$UHESI6JVSP,QC1WMW((2:/<"%D0X96QP0*
M_+ZV_9%_;$_8[\0:K8?!#Q%+XC\,WC(B3VWV/$B@;MS6EV72%@S.-R$D^O.!
M^NU)0!^2WA']@G]HG]KSXC+X@_:3\27VA:/8JB+"7MI)[@*4_=006Y$,"LK/
MF7!.X?<;)(_533?"^CZ/X=@T"QTNSM-#@MQ9QZ;# JVR0[=OEB,#;MV\;<8Q
M6KBEH _*[XN?\$\_C/\ L^_%JZ^(?[,WB"1K>[GFN_[&B:"VDLLG @$<A\FX
MC_>2;0RC: !@D;CR>L_LZ_MQ?M9:MH_A+XM:K=:%X/2;S;J\N6T^&WC0LH9F
M@LRIN)%7)1'XSGYDR37Z^TE 'EO[-O[/OAW]F7X3Z3X'\.DW,=KNEN]2FB5)
M[ZX<EGEDVCKR%4$G:JHN3C->ITE+0!^1W[56F7DW_!7+X=7*6D[VZZMX=+3+
M&Q08ECR2<8XK]<:** ,_7#J2Z+?G1EM7U?[/(;-;YF6 S[3Y8D*@L$W8R5!.
M,X%?C[XJ_P""/_[0/CCQ-JOB'7/&W@/4-9U2ZDO+RZ>^O%,LLC%G; L@!R3P
MH '   XK]DJ* /QDT7_@C?\ 'OPWK%AJVE^-? ^GZG87$=U:WEMJ=^DL$R,&
M21&%ID,K $$<@C-?L)X6_MEO#>E?\)$EG'K_ -EC%^NG2/);"XVCS/*9E5BF
M[.-R@XQD5KTE "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_Q1=7EKHVO:;JUS9-MN8;&[CF>$Y(PX5B5.0>N.AH W:*** "BBB@ HHHH
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M73HV>YO9,[KFXD<R2RGGC+LV!V  [5Z=0 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG)D?I_$QH [^WA\F".,DML4+N]<"IJ** "BBB@ HHHH **** "BBB@ HHHH
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MYTVTCMI-6U(J;BZ*C&]\#J?_ -9)Y/2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %:\O(-/M)KFZGCMK:%3)+-,X5$4#)9F)P
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M"/[3WPYM/%?A6Y"MQ'?Z7*X-Q83XRT4@'Z-C##D5ZS0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 A.*P?%?CSPWX#LUN_$FOZ;H%LYVI-
MJ5W';JQ] 7(R:Y[X\_%W3/@/\(O$_CS5E,EIHMHTZP X,TI(6*(>[NRKGMNS
M7Y?_  $_8_\ &7_!2"XU#XS?%WQM?:=HUY<2VFFVEA&IE9(V(VQ;P4BA1B5
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MR[I>IZOJFK2^+?B-K_SZUXAN&9C(2V\QQEB6V[CDLQRY&3CH/IBBB@ HHI*
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MGX;?\(_I4HU36;R3[1JNM/"$DNY!G:N,G:B D*N>Y/4F@#W=>E+110 4444
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MG>@ _8]_:^\'_MP?#N_^%?Q4TZP/C,VOV>^TN[CQ%J\2CF>('[LJE0S*,%6
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M1A551P  *T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /DW]I[_@H=X._9?^+7AGP5K>BZI?"^"SZIJ,,12.QMV!"21@C]^=P^94/
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MBBB@ HHHH **** "BBB@ K\"&^!]O^T?_P %)/'?PZNM6ET.WUGQGXCW7\,
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M[/O[%&@7'C_Q99>'S<ZKJ+V]O)OEN)E609*11JSL/<#&>*\R^-WBV_\ &_\
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M\03>&XK;2[C5!=V]LL[,8YH8]FTLN ?-)SG^'WK[C_X<=^'O^BL:G_X)8_\
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M;LG'Z]>-?AKX2^)%FEIXL\,:/XFM4^[#J]C%=*N<$X#J<9P.GI5+_A3G@/\
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MK(ZD892"001@@T ?E'_P0Y_Y&;XN_P#7GIO_ *'<U]2?\%9#_P 84>*?^O\
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MS,MKIEYH.GFUFU':6\YB/^>2L% Y.6#?W:^Q*AM[>*UACAAC6**-0JQHNU5
MX  ["IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DD
M:R(4=0ZL,%6&01[U3T_1-.TG?]@L+:R\P[F^SPJFX^IP.:OT4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>psoriasisskinmask.jpg
<TEXT>
begin 644 psoriasisskinmask.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MP  +" 2F!&<! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /3;K?5'S/+HDC>I('\MZVK6?S$=_P"Y4,DGEO\ []01
MQI._R5H^1\E5;JU\MZSKJ/R_D^_1!MC3_;J>#]X_SUO6,C[_ )*Z&#;LI\G[
MRB2'YZAGK$NG\OYZR))Y?.?RMGS5!':/)_O[Z9)8RQ[_ ."HX_ONC_.CUJ:/
M8Q1_(B5U$%K_ !U:CCV5)\^_9LI_E_<H\SRWJ>HY/]BC_5U#/(FRH(T\RKL<
MGR5#))_P.A/N55>1_N5:CC^Y3J;Y?ET/]RH(ZDWU4?[]'EU)')YGWZG2G_PU
M5GJ...I(X_,2GR)]RB./R_\ KG3Y/W:?^R52NO[]9?F?[?SU.E1^?\],\SRZ
M?')\]7O,J.23?3/+I_\ JZGCDWT?ZMZ9\E1_\#H_UE,D^^GSU5GD_<UEWT_E
MI6=_KW^=]E5;J?\ @J&#[_R5J>8__ -E:$<G^AO_ +E8M].DGR5E^=Y>]*M0
M1O\ 9OOU-:Q^1>)O^>MB31_,?S=^Q*?!!%\]023^7]QZJR2)O3?\E9]U'YDS
M_/5*?_64^.^:";8E:$FRZAWUER?N_N55DWQ[_DJ?Y/)_YYO1')YU,_U=6M-C
M??\ [];4<_F0['_@K/NO[]/\_P RP\I=F^J4$;QIOK1L;JM/S/>I(XZCV4R2
M/R_GIG\/ST?ZM*JR2>8^^GQI_?\ XZNQP5/!&E/D@3R_GIFPTR2CS*CDD\QZ
MD\O^.CS$J!_OU!_ _P#Z!5*??'3_ )Y(7JU:2>9#4DDGST_^&CR_XZ@\RB..
MCRU_N42;X_N5)!)Y_P!RGO\ ?J/R_P""EDC\M*JS51DWR?<JU!!Y:?)1)&^^
MI/L[_P!ZB3]W4'F>7\_\%$F^2KM](_G55_=25>CV2(GR4^"U\RM2"#S$_P!N
MH)]-?^"F00>75J.?^"JM]]^JLR?)\]4I(_+J[INR1/GKH;%/+K423YZN^8E,
M\_S*I7TZ1U@W4GVJ;95*.!/MB([[$_OU!?3O&]4I[YY'^=Z?!'YB[ZWM'^_7
M46\E6O+\RI.:3_64?9Z/X:9YGO1/)_MU!_!4D=1R2?)3/,I\?W34FSY_N4_^
M"F>=13'JOLHI8(_,>K7EU'Y?EO4,DE31_=-22;)$JK)'LIZ24^2/Y/\ ;IG^
ML2A]]0/]SYZRY(_WW^Q3)Y_+3Y*Q+[5?(^Y]^JL&I//71:;=>8E79/X-G\5'
MF;*/,^2C_P ?I\$=2._EU4\^EDD^X]0>=YB;WID<_F?)_?K+N[I_G3_;K.NK
MI_\ @"5!YB2/4,D;S_(E3?ZA$393_/>!ZD\_S(7K+DD^>F21_/OI]C(^_96W
MIL#R;_DK>AV?9ME02?N-^RL&>-]_S_WZ@DDJE/'Y=01Q^>_SU)/^[?YZFTV3
M]]]_Y*9?0>1,]5?+\S^"B/\ >/\ [%3QQ_W*)+7^_O2M#[#Y$,$N_P"2I))U
MC?Y_N/4%U&G_  "J7^K^1'J"23S*?:[TF3Y_DKHK61)-G]RIHY/OTSS'WT3_
M +RH/,J=)/DJ#R_E_P!BF1_Z[_8J[)/]Q*DCG_@I\D_R41R/_P".4S^&G^7\
ME0>7\[U)')\E1_Q?)156ZW2?.GWZ9'LG2CR_+^_1Y?D3?[#T3Q_)_MT03I(E
M/\SS*7Y)*3_V2G_)4,\[N_V>+_@;U:@@\M/DHDIF^B3?)56??'OJHE7HY/D^
MY1Y?\='F>6_SU#3_ /8J/R/E_P!BM[4M-K(CL7WUJ06/F?/6C'8^7_P.K4$'
MET^?]VE9=Q)4$<#R/3)(_+^_56ZD^X]4H_W\U:&FQOOKI;6/RTJ?S/+J;^Y4
M_P!Q-]8.L77E_/7/27WR?[;U'YDW]^F3[Y$JC5ZQGKH;&/YTK>M8ZU(_N)1)
M)_!3(Y/OT>8_K3X_W=,G_P#'Z9''Y;T^./S$ID\=0>9Y?R?QT1_?J?RZ=4,D
M_F)4,<E1R3^6]21R5!]J\RK4<B2/3X_WCU/_  5!Y;R4R1/GI\?W31))4/E^
M93T3RZ?)/1']TTQ)*@D>L^Z_=IO2N:NKIY-^S?5+R/XWH@@^?Y*V[63R(T3?
M5F34O]NH9-2_OU-]N\SY*([KR_DW[ZT;62F3R>8Z?WZ?_%4$DG\%4O+>1'IG
MD>6Z;/OU!/!YG\%<]=;_ ..HX/N;:M6\,NS[^^I(_P!W\]03[Y*//2.SV?QO
M6?'OW[*NP0?<_C_V*TX[7_24=XMFRM6UM?N;/N/6A\D>_9]]'J&?]V_F[/OU
MEZK'LF^Y67/!_?J.2#S/,\K[B55^R^7"[_QO3/+\SY*(X/+>GSP2QIO?[CT6
ML#R)_ E0P1I),^^IH-\;_)5J2/Y$?[]3QQ_Z-4%U']RF21_)L^394'EIY+[$
M^>J4D;U:M?W#_P"Q6I!=)'_N4?:DG^X]/\Q-G_32F>8DB?._[RF>9\]31_WT
MH\SSZ9YGST_S/G_W*GMT\QZD\O\ @J:./S/]BGTQ]_WZ9Y?E_?\ XZ@_U?\
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MJK)]^I_]6E59ZFCV422/'3(/GWT1Q_/OHDD>IX(/+I_F>]59)/GJ#S*D_P"
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MLM/19;NZV>=,^]L(B+Z_*_S5]#>+/^";=@-!GE\->*[J35XH=Z0:C"GDS/\
MW-Z?<_\ 'Z^8_@;\3=5^"?Q6TO4T::"!+A+;4[-P0)8=^UT?C^'K_O**_0W]
MJU/^,??''R_\N7_LZ5\9?L"H)/CA,&Z?V1<?^APU^BMW=6]C#\\J(F_[[OLK
M%DURTDN=B7%O.[_P),E?,WQ\_9C_ .%M>/I/$!\66>C?Z,D'V6>WWO\ )O\
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MH[[T_@J""";SODW_ #UU%K&FQ$_CHDNO+JKJ5]Y<.]*YZ347C??5VUU))/\
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MJ:218TJK)3(_OOOIDB?/7S[^W,<?LR^)U_V[/_TIAKY3_P""=*>9\=]0'_4
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MS_Z[_KB_\?\ Z'7M,?\ J?\ 8J]Y?G_Z[_@%:$%N\&Q'_P!72R0)'-OV??\
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M*9Y?R4G]REDDI\;T^3]Y3)(_+IGD?/4T<?\ '1Y?F4R./S-]/_U:4SY]]/\
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MX]_@SQE_V$8?_0*X/]O;X":CH?C"X^(.E6S7&AZFB?V@8HR3:7"J$W-_L/\
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M:RU"WANK*9-DT,R;T=/]ROBWXZ_L2WNAS2>)/AF9IHXF\Y]%CE_?1?[=L_\
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M?<KM?#FE67A_1+72M/M$LM.M(4AMX4^XB)_!7F?C/]D_X5^/=5GU/5?"5O\
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M[W37\I$JK<2>8FS_ );O]_95KR(OL>^*7Y_[E01SR^3\_P!RF3^5=;-[[/\
M;K+GD\_]U_<_CI]C?/:I/$F]-]:\=TDD*2O\[[*R[B?RW=T^2I(]2>>VV/\
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MGEOO=Z/,>-_]AZ'D\QZC23]YO_@J2./]\]/_ /'*/DD_^+J"3]V^RC_6(_\
ML5)]SYZC\Q)'IDDFS_[.F1R/)1\\CT_^/YZ?'OV;/X/[CTR.1XT?>E$<GF?<
M_@HCG\RB3]Y\[_W*9YGS_)3_ /5I_?I\<GR5)Y:2?<^>H_X]]$FS9O\ O_\
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M(_F?/4GE^0F_^_1'_P!]I1_K-_S4_P"2-'1TW_W'IDG[M/DV5'Y#_P# */\
M@?R5(F_^Y\[T/OWU'Y?W/X*D_CW[*@\]]C_)_'3]E,_@^^E$<G_ Z/,3Y/D_
MCHGC3?\ )1\\GWZ(_O\ ^QLHDC3?3/\ 5O\ ['\%$DE/CG_@V?)3)H_,??L^
M>IX]]1_-)]RIX_X/G^1:C_UF_P"1]E0I5J./]W\GWZ(_[GR5'Y'D([I3(/N)
M\E/DC^>B.3RTV;/]=1))_OTSS/GHD@^3]U1)'_WW_!52K'EQ2)]^H_+3YZ(_
MN(CU)=2/.B?<=T^1-E5?+I_F)Y.QJ@DM-GST20)'3)+7Y/\ T.B/_<2H)(/,
MW[_WE59($V/\GSTS[+YG^M2B.Q79]S_<J"2QBD_@_>?QO56ZT?\ OI3/LKP)
M\B4R3399-]/@M98X?*=$W_P/4_E^6G]]Z)(_+_C^_4<D_F55NH/+D^_OH@CB
M^S.GR;ZJQQRSOO3[E3QQO']Q*@G\V-_M"/\ <JW!?>?;)_Z'2?-L?^Y6?)^\
M=_D^Y3[6#S'J[YD4'SO5ZQC\R'Y*UY(/D3Y*JSQ_)6+=0/)_!6=)#\]31VLL
MB;]GR5:@C^2K4_[B'?18QO'L2MNUC\MZU/,2--]$=PDB??J"2>+^_4GVKY/D
M1WJ/][/]_P"1/]BI/LJ1T_\ U=,OI/N?)_'6I8Q_N4J:2.JLDGEU#!)_IC_[
ME3?QUU\GW$>H(Y//=Z9/!4'D^8_^Y4_F?\ H\QY'I_\ J_GHDG23_?IDF^2F
M2?N_^!T;ZQ-5G\M'KE[Z-Y-[N_SU5M9/OH_R)1]E\]_D^>H)('@;Y*GL9$\Z
MNOL9/W-3>?\ QO\ <J2.3S-]321[_D_V*ACM?OU-!&^_8_W*O2/Y?SU!'([T
M1[]CT^.I)(_[C_<I_F?(]/3[E,D>LC5=5BM?OO4$$_GIOWT23_.B4^>?RX:R
MY[[S)D1*I23I)O1_X*(Y'W_[E6HXZ?!'\GSI]RI/,\O_ *Z??I]K)YF_[FQZ
M))/N.E/GD_>;'H_\?>ED_=__ &%1^9\^QZ?)(DB?)_ _\%2>6DG\=/\ +>--
M_P!]]],CW['_ (*/]NCFCFGQQ_)3)/N4SS'D^Y\E021O'#]]'>GR;_+_ -RH
M(Y_,WK_=>I_+3[E,CD3>^S[E/D_OT>9\B)_&G\=$?[RCS/G_ -BGR1O)\B?/
M\E"1^6GSTSSUV?\ Q%$<GR?QT?\ CE"(\>_YZ9)_N5-'(^S_ &*9)'3_ #/[
ME0^9_ G\=/>1Y*?Y_P OR4SRZ?'.D:;'IGF>6^_?3X]_^Q4GGI']RH//>/YW
M_P" 5!/^\=/EWU)\D"?/]_\ @ID\?G_.[T[RTV;-]+Y:?:7V;'3^_4?EIY/^
MY3(X/,=*/+_@I_E_WZAGWQP_(^]Z(X/+3YZ?']]/_9*/LOF?P;*9/'Y>_9LW
MU') D</SIOJKY"1_\#HDC^>B/]P\^]=Z.GW'HCM_,3Y'V5#Y'G_<38Z?^/T2
M6OEOL=/GWU5GM4^3[^RH)]-21ZJR:&_S_/\ )4']EOLWI1!!<;/*3Y$WT2;X
M*9/OV?.E9UC)Y&^+^X]:,DFR&J7F??>IH)$C_P!BF0?Z5>/_ '$^1*Z&Q_@1
M*V_+>1/]NJ4\?R?WZSKZ3RX=^RLC^^__ 'Q3X+I]GE;ZM06K^7OID%C+=7/S
M_.B5T,EJD</R??HC@>-/GWU!/&\B/]^K=C&GV9'_ -BC[4D;T^2?RX=U6H-_
MEH]3))4B??JK/^_O$B_N?.]:\'^KI\U9\Z/(E0:/^_WO_MU>GKJ/GDI\<'E[
MZ)/WC[*CCC^_1Y?R41Q_)1/)Y=58_P#75/\ P;Z@DD^3_;ID_P#?KGM<GV?/
M7.QS_-OE>I[6!)'WJE$<B0)_<>LZZDV3;?X*6'=YU==IOW*M3R>8FQ*9:R5J
M22>6E$$GSI4W]^H9_P!^F^G^9Y:)3))_+I\<E/\ ]6[[*D@W_)4TG\?]RJ5U
M)\E>,>+=2NY_$*;$=X$?[E>H:/'_ *'!O^3Y*@NIT@=W_CK%NK[S_P#EK\_]
MRGQQ^8GWZFCC^?9L^2K4\?E[T=-CI_<IGE_9=F_^.GR2>7(B;_OU:CC238B4
MR./R_P!T_P!^GQQ_P41_NW^Y1))1\\GF?QH]2?+!1)LC?Y/D=_OT>9\]$<[_
M #T>9_WV]1R;Y'^3Y)*G_C_OTR2/[_S_ / *(YWW[/DIDD'_ 'W3Y(_W/^Y3
M/+_CJ/S/+2B2#^/^.F>6GW_GH^2/_@:5'')\_P!S_P ?J3R_DI\-,GC\^CS'
MC9*G_P#'*@\SR_\ ?WT_Y(X4_@?^.B/_ &Z?')_ _P!S^_3)/WGW*)(T_P"!
MT2;]F^CR_P!SLWU!!'+&G_ Z/,^_1'_KG^>I))/+_P"!T^.U\Q/-_N4?ZRCY
MT_V*9YGF4_R/,_X!3T@\Q_D^2H?+_P"!T^.3S$V5!)&GR(E24>9Y<.S91']S
M_;I\&S_?J#8_G??J22#S/ONF_P#N41_.FRH__''H\_R_D=Z)/WGSTR?_ &/N
M4S8E'E_P4?ZSY):/+\O_ '*/+_BV5'/'YCOOID$'F??2B>U3>[_<_N5!'IOF
M/\]220/&CHD2.F^JL<?F?P?<^Y4$\"2)]RH/L/ENE5O['62Y?Y=C_P =59-*
M>-'1'WUG26LL>_>E1QR>7\]3Z;/Y</R?QO70Z;.F]/OUL?:JJS_[%8E]&\B5
MC_/YU6XZNP73Q_(GWW^_6WI4=:$D?V=ZJW4CQI562=_)>J6E7WF0HG_ *M2?
M/3[63S[G9_ E=%''\E&PU5GG\O[GWZFTJ!Y-\K_QUJ1Q^74DB>94$_[NF1P?
M94\U/^!T^3]Y72\U'Y[[W3;LV402>8_SU.],\RB/[E1U#_'5J/\ >5'/&B(]
M9EU]SY*Y/6)'W['K(D@^?[]6K63RY$3^"GS_ .N_V$^Y6=Y?F3.]:FE6*1_O
M6K8M8/,2KOE^1]_YZ9!!Y?W_ ..K4?[S>E31_NZFJ'S/OU2DNGD?YZ//?95W
M39/,2KOF?QU)1/)Y:;*RY_WF^N>DT-)-5\W9\G\=:%]/]EA_X!6#/(]UL=_X
MZJV-C%'-YOF[W>M&/]W5J"!YW^3>_P#N4^/9O?>]2>7YZ;/DHDC_ +E31_N]
MGR??I9)/G>DCDHDV3[$?[]2/_!Y2?[]/\ORTIGS[-]'D/)\[T22)3XX$_OOL
MJ#_EM4_E_?WTR.-(_P#?I_\ JZ9_!\E/C_=_]\5!Y?S_ 'ZDDC\M'2H/,>/Y
M)=FS_;I\<'G[_P"/;1Y_[E(GV(E0W4"2(FS?3X-B??\ [E,DD_N?(E$DGF.B
M.]/3[G^Q3Y)/X/\ Q^CR_,^>I/WT>]*@C@2/YW>B2/[G\;T21I'_ +;T?/\
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M%Y;_ .Q4<F_R7=/N)]^L6=_,>LO4K5Y)OW4NQ*HR1^7]QW>3_?J2QGN+1_\
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MK_D$?88?LF__ )X[/D_\<KC?BA\>O OP:C2+Q7K45E>RIOBLX4>:Y9/]Q/\
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MC[]_\'^[(:]%_;$^ ?CWX^:KHY\/ZAI5KHFGP[QIMQ+-$9+I_OR?<=/N;/\
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M=]S8B5^2G[,MG+?_ +0'@"&V#NZ:S!.0O]Q'WO\ ^.*:^N/^"F7_ "(O@O\
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M+S2I\[X5-[?0[4[5U_B+]@V_\,^!_$WBGQ1XT^VW^GZ7<W_V>RMGD29XH7=
M\[OG^#^Y7G/["?\ R<EX>_Z]KO\ ]$/7ZB2??WU/' [_ ,=,DC>-_G^>IODC
M^_4,DGF4_P#AH\OY*9_KY*CD_@^>I/,=/XZ?Y_F?[%,^>.B.1Z?Y;_\ ?=/\
MSRZ/,_V*'^Y1!&\G^Q_TTH^3YTJ&/?(]31[)-]$GW_DIGGOO^=*?')YDC_\
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M<_Z9U/'LCH>3RTK+CNO,=Y7_ (Z?Y_GNE:,/W*FCJK=3^0F_^Y1H\;QVR/\
MQM\[UJU'Y=4M2D_U<7]^BQC\^9YOX$^1*UXY*?'4^Q*/+IDD?SI3XXZ(ZG_A
MJ.1/,IB??I\D?F;Z(X/,2CR_X$J2.#RZDJ.>/Y*(?N5'/)3/,^2H))/+?_?I
MGF>6E3Q_O$2D_N4R2/?OJE/_ '/N5B7V^1_[Z)6+-)YC[/X*9IL?F:DD7W-]
M79[6*"\='?9LH@M?,N=Z5J20?<?^_67?0?.B??\ GJ>.#S-CK\Z?QT^2-X__
M (NKL$Z;/D^?Y*?'O^_3/]9_'3XX_D^_4D?[S_?J;_4/O^_3))$D??\ <^>F
M2?O'=$J/_5_)4_E^8Z;_ +B4SY9)/[E$E1_[:5)''^YWT1_P?W*?)(G\'_ -
M],@_N/5KSXH_X*JR??WU'))_VS?^Y3/X-]$<GR?/]^GQQ^9]^F1_<??1_K'V
M)\]$">7OIDG[RII)/,A^3_ONF>9YGR.E,^62:G^71)L@3>CO3(Y$_C^=*\;_
M &H/C7>_ +P)9:_IFFV^J/<:HFG^3=.Z)L>&9]__ (Y71? /XH77Q<^%6C>+
M+VPAL)M0,P>&!MZ+LG=/_9*]"DD^=/D^2BZV;_[E/\Q)YM_W_DJ>?]Y\_P!R
MH_,_=H],\SRWV4^/[^RF?)\Z/3)'\O8CT0;_ .Y3_P#5O\E,DD\SY/[E'_+;
MYTJ.3_T"CRWV?-\]%O&\<U/\O]]]_P"Y4_SR0_?^_3)(]FS^Y3XXTV.^^F1_
MW_\ EG3)_P!XCT^/91_J7_OT?/&_W*@DD3_Q_P"2IX/N?<IEQ&B-O1OGI\<G
MEI_MT>7YB;T2G^9Y?S_QU#)(\DCT_P Q)*?))]RH9/WCU''!]S^.I_+\SYWH
MC_>?[%$>^3Y'^Y3_ )-O^[3))/+IGD>?,E/DD\O9_P"@43R+'LV??IDDCT^"
M-(T?^-Z?Y?F4R./RWJ>?_?WU'_K$_@IDD_W$^Y1)O^39\]3R?NT_@J#Y]E'S
M4SY/N/1/'Y>RH_[^]/DJE)&DG^Q_<J>QG_@>M#S$DJE=3^7"_P#MUG3R>9LB
M2M&UCK1CH>2LNZD^U7*6^_Y'^_6U:?NTV5)Y]1R35ST^I?:K_P I/O\ W*ZB
MQ1((46GR2;'JU_K*D2IO,]ZA\SYZ?)^\2GU#)/Y=6O\ ?H>2GI3/]71S4T>R
M2I/+\O[]0U'_ *NH)Y/,IG\/SU'YGF55CD^?95I?^6=$G]^AY*ANOWDU9=W#
M\E<[?0/:[T>L^#?YV_\ N5=WRW3_ -^M2QC>K4DGR?<^Y61)OGN?D^3_ &ZM
M>0]O\G]^IXX_+3[]/DD^YL1$_P!BGQR>9\CI\]/@C\O_ ('4DDGS[*CC_=_<
M2I/,^1W_ +E'E^7\_P#>I\?E2(GWZ9_#3XX_DWT22/O^Y]_[E,\OYW^>HY/X
MXOOO5J>/_1MB.]0R?N_D^Y1Y:)1)^[IZ/\FW[E0?)]S9O>E\OY_X*C_U?ETR
M#]V]/_U[T_\ @_VZ9)&\'_ Z9Y?E[/\ ;I\FR/9_XYLH\O\ @>F22??2GI:_
M)YNS91Y?R5!''_P.B#]WOV)LKY:_X*2212? _0-G^L_X2*'=_P" US7:_L41
M[OV8?!S?[-Y_Z6S5[A!^\3?OWU)YG\&/X*FM8_,V.C_\ J>/9'']]]_^W4$D
M?E_/LJ&/_7?/]]Z))$_@J../S/[B25/!(DB/N^__ +:4>7Y;O_<V4S?YGW*(
M/[^SY*)/](?Y*/,\S9_?J:21/[E,CD>3Y$38E$D#_?=Z9Y[Q[TJ/RWWT?O=F
M_P#@J2.-_DV?<I_E^7_'1Y?E[W^3?1))\_\ ?_W*?_?_ /0*A>CR]B?<HD_=
M_._WZ?Y?F)\E/@V;-F^F2?O'V)_!3)(WD?\ CI\<?WZ?LH^SIOV5)Y?E_P ?
MST22?N7_ +]1^7YGW*'J2/9(^RJL_P#KJ?'&^W_<HC@\Q-_R?W*)+5(W_OT)
M]^H/WLCO_!4\<C_?>F2??394WR;]_P!__8HD_P#'Z9)&\G\6^G^6Z/L_CH\O
M[B;_ )WIDG[MZ?'!_MU)':_(^^H/+WIL^X]0?P>5_<J'RT_X'6=/)Y$R/]RM
M&.Z_<UB7UU+)<[/^6=$$G\=;<<_EI6A!/YB55GNOD^>H;'9'(\LWR;JN_:GD
M^Y5KR_+J"^G2.%W_ ($K/T/1_G^UR_([OO2NDC^Z:9)'_=J[_#3'^Y4\$E&P
MT_\ U="?<H\OY]]/CDIG^KJ=)*CG^^B?WZ/XZD\SYZ?YGR?/1_'4$\E,_P!8
ME5;J1]F^H/X-_P#'3(_O_)5J/]Y4_P#JTJKYE'EU')#\]9>I6*7S[V3YZI1Z
M/Y:/3[6Q>/\ X'6C':^6F^H+K9'6+!)YB.^_[[U=^>2%/X'2GVO[M_[]3SR)
M(GR)\]$?[OYZ/+>GP;Y/X_NU))^\_N4_RTC^7ROX*JQ^;)\GSQHE/\SR]B_^
MAT>8\;U)')YFS?*B;J?_ *O[S_[E#TS9YCT>9\_W*)/WC_.U32;(]_S[T?[_
M ,E,_P!9_N?[%,G_ 'GWZ9')_ E)'O\ XTH_UC_)1O2/[GWZ63]W_?\ GI(-
M^_>E$\?\%2>9\E03R)!]_P#OT1W'^L^2H))/]C_?J1)'\G9O_C^Y1')_Z'_'
M4<\B?P??>I/+\O[GSO7RK_P4BA\OX(:#_?\ ^$BA_P#2:YKMOV*(\_LR^!_K
M>?\ I;-7ND>^#_?I_P#Z'1:[(YD=/DJ>3]YOFW_QU5DG_@WT_P O?L_CIGEI
MO^Y_N4^/]X^^F21ILD_O[Z?_  ?/\B4SRT^?^Y1YG\#?P)4?F)_OU)_WVE$D
M#[?-_@H@D\Q-]/\ ]91)&^Q/[]$<?EQN]'E^9L=*?)OD3[__ 'Q1!YNS[G_?
M='V5]]'EI_N4>9_?_CI9X_\ @=)')^^_OI4DFR.CRWCV)O\ DJ/R_P#*5)Y;
MP/1]_P"_4?E_/4_V5MO]_P#OU!'!\_R??J?S/[_STR23S$^1*9_?I\D:>3O_
M /'$IGF+O_V*CCI_\"/_  /1LID='R2(_P#?HDV_<1_GH??_ /L4>7Y<-/CC
M2IX_X]G_ (_3(]D:/_?_ (Z@_O\ S[-]/D\J/_;>F21^9_!4[OY=$D[^3LW_
M "5!))Y?W_GJ#S$^Y3)(XO[FQ*SKZU\Q-E4K&Z^38_WZ()/,=W_OU:CL?,^2
MKL=CY=6O+\M'^>L__67+_P <"5:C@\_YZM6L;QO5KS/[]9=U&\_^Y_!6[8Q^
M6B)5N./YZG\M-M)Y?ETO-)!^[JU_JZA>B.2GT?Q4^3]Y-OJ3^&JL<CSS5-1_
M!OJ3^&CS/+2H/(>1-]'E^6E59_N5G2401_?K1@D^2II/NBJW^K>IHZ8]$D=0
M21_/3/+\RF21_P#?%9>L2>6C[*SK6/\ <I]RI_+_ -MTJ;S/,?Y/DJ>2/^#Y
M][U/Y:?QU')^[_C_ .^ZD@_N5=NK5+6\V17"72.F_>E4I_-GF_\ 9Z/,?[C_
M '_XZ/+\RGQ[XW?[GS_WZ@_Y:1U))_L?<I_R1O\ .F^F<T]*(]D'\&_8],>3
M[^S^_1)'_MT?[>ZGR1I\B?/O_OU!')LHGD3_ ('3(Y/[E'S[_DI\?[O_ 'TH
M\SYW=ZADG_?;WI_F/)L^Y\E3QR?\ JK)&\?WWJ/RTD?94GD?[OW_ ._1\D;O
M]RG_ .L?[B5\G_\ !1Z3_BR.B+_U,4/_ *37-=S^Q+L_X9E\%_=WYO/_ $MF
MKW3R_P#ONGR?P?/\],_U&Q_OT^21/X/N4R/RIYO]BIO]9L1/O[*JS;J9''+\
M]3^6F_Y*?'&[O_'LIGR1O]^CY]__  #YZCV+_<^>I/,2--FS>]'EO\GS_(G\
M%/DC\Q_DIG^KHC^__M_QT1R/\[_P4^.3Y/DI\<;P)O\ []3O4,F^G_/O^Y4<
MDGF;/X]E23_O/D^Y56/?'\F_>E6H_P!XB?)1_P"1*NVL'EPI_'5J.UMYT_>O
MLV5G22)OWI4,ETD"/\B;ZFCUA/)V55DF3[],CD^3Y*/,\O[OW*/,\Q*/,\OY
M_P#8J#[13/\ 5_\  ZM1[_N5)\]1R1_W/N4_S/N?)3/+\Q]^SY*//^?YT>B3
M9L3YZ(/N(]78]G_ *ADD_??[]1N[[_\ 8H\SY$WI4C?\M*C\AY'HDD^3_8IG
MD>?_ !TR2/R_D>HXX_E^?9]RH7_>1[*XG4M]K?NZ?Q5J:'(G[MZWHY/+ID=U
M\^RK4\_VKY(O^!O3X+5(T\I*M>1Y:?)4\<D4:?/3(X/M7SO\B?W*?)!YERB?
MW*NP05:\NIX_[M58_P!X]3O4;R>6E2>9\F^H_O\ R5)L-'F?/1OI]22;Z23]
MV]6*2/[IIDE1^9YE2))4$D?F/]^F21_]\5!'!\]$D"1T^UCJ2Z^Y\E59)/G3
M^Y4_-)YB4O-5+JH+63S$V?[=,N__ $"L6Z^>9$_N41_O/[GR5,D?\;U)'&__
M 'Q]RI_+\S8CT_R_D^_\B?QT_P CS/\ @']^H*D\OS$3Y_GHCC^Y_'1Y?F)O
MJ.2/R_N?<V5))^_^?>F^B/?)_MT>3YB?[='F)Y:(E$E'_?='F>6_]^G_ ,=$
M<GF1_+\CU'\G_ ]E0Q_YWO3/,^=WV?)3WV?Q[*(_W;HB?<=*?))YG\?ST>6_
M_P!A3'D\Q/[],\C^.G_["4^23S$VNGW?[E,D=)/D^_LIG^O^>CR_G2B=/D_@
MJ./_ &/DKY6_X*-;_P#A2.B-_!_PD4/_ *37->@?L2[%_9?\$'^/-Y_Z6S5[
M3//_ -_*(/\ ;2H9/M$DV^+[G]RK4<GS_P!RH_DD=*GD_=O3/+__ &*/M'D;
M_P#OBB/[^_\ \<H_U;O_  4?ZORWHD_>?^ST?/&GS_<3^"CY(UW_ -^IO[^R
MH4H\_P"=_GW[_O\ R4_RZ9]G3^]3XX_+_P"^ZG^T5''LD>3^.CS/,^1Z))ZD
MCV1K\^_S'J:22+R=G\=5?]9OJ2#^Y1/^Y?>CT?VXD'R;/^!U1U7Q5;^3L1]\
M_P#L5SUUXJN)/DBV0[ZR_P"W)9/D>78]/_MB[C_Y:TS^V+O_ )Z[ZNP>*I8_
MOQ(Z5L6/B.WNOD^Y6I\FS=1)LV5!_P M/N?)4_E^93XY/(=Z(WI_E^7]_P"3
M^Y3/GD_X!3_]7L_V*5Y_,?\ VZ?Y:?)OI/X8Z6./^/\ \<H\OS'WO1Y:)1!(
MD?SNE$DGF?/_ !U'/)1'O^Y3(_O_ -^G_P"O1W:JLW[M/OU53]Y]QZY?Q!:^
M1(C_ -^I]'C3R?GK1GG>"/\ OU!'J3SNGR;$K1@NHH/XZM1ZDDGW:M1SRS_<
M38E78+7Y]_\ K*T8XTJ""/S)G?\ X!5J/]W4_F?)_?H_@JKYFRG_ .LV5#/)
M\^RGQ[]B)_!3X_W<U3T>6GI1_JWHCDWO4\?\=1R2?<J?S/DH^T4<U!_%1YE&
M_P#[[IB4]/OT2?O$WT1R>71L_P"^ZJ^7\[T3T)_!1))4$GW157S/(WU5D_C?
M?61\\]P[?P4^"3R]^_\ C_@J]:R)_N5-'^[^?[_S_<I?DI(Y/X-GR4_Y]COO
MI8_WB?/_ '*(_OIL_P"^Z/,_[[J/S/+^3^"F>7\F[_ONB..+?]^GQ_\ C]3R
M2>7_ ![Z@\CS'=_X*/\ 5O\ )]RI)/WG^Y1'_N)YCI\E'^HFC\U*?) D;U!Y
M?\:422?(E'RQIO\ XZ/D_P"!U/\ )&FS;O=*@_V_OU)))Y:;W_N5!']_9]RG
MR2/O2B3]Y&GR??>F2;Y-^S[_ /'3_P"#[J;TID<GEOO=D>B3?\_R5!_&FRI)
M]\:??W_["5\J_P#!1O\ Y(1HG]__ (26'_TFN:[S]B/:/V7_  4Q_P"GS_TM
MFKV[RTD?^&G_ /H=,_X'4$F^-T_] I_W$V5)Y;IL^??4<>^.:G_[G_C],\R6
M-'=_X_[E'F?)/_'OJ3S/,^?[FRH/,\SY_GJU'&__ %TV4R23S'^Y1'O^3Y-B
M4_RW^3Y$V4^"/S/G>B23[_\ !3/,^1/DHCC?>_\ MT>8\>_^.B/_ )9T2?O/
MGI_E_?H\QY-C_P "4R>1_D^7^.G_ &5)-GWZGC@\S[[[$K+\0:K:6.Q$E\]]
MGW*XK4O$'_/67_<1*RY-2N[K_CWBV)_?>B#39?\ 6RN[SU:DTU)_D>HY--EC
M^X__ 'W6+:R+!<SQ;W?YZU(/M$B?.FRIHY'C_@K;TKQ \'R2OO2NA@G23Y]_
M\'R5/']_Y_N5/_K)GV4>7_X__'3X]D:?._ST_P S_8WT>7Y;O\^Q*/+_ (WJ
M3_?I\_[R-$^Y_MT>1\G]_P#N5!\\'WZ(Y'C^X_WZD_UG\'W:.:/X_D5*+B.H
MX]\GWT^2CYX_]51).\_\=0>9_!3)(/+^3;\]8/B.U\O8U9]K/Y";*NP0>8^Z
M7YWJ['IOF-5J?2DD^Y1:V/EUL6D'R;ZT((_+J3S/+1Z+6/\ <T^>1(Z8GW_]
MBK59?VKY*HR:DD%,_M+S]GE??K8M=\B_/5KFDDGIGS[/]^GQ_NW^>CS/OU/_
M  T)]RGR2>6E'F?)_MU5DG?SME2?^AU'Y='F?]]U/_#13X_N;*9\F^F/]^HY
M/N?)_'4/F?WZ))_+2H_,\SY*-AJ&?[E9=U/Y=9WE_P :?QT^U@\_[Z?/4_\
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MA^T;$2G^9Y?W_GH\SS/N?P5/'_!_<WT^2/S/X_N4>7_XY4D_[SYD38E0>?\
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MS_._\%22??WO3_,39_MO3/W4B;/G_P!NIK63RT?^/^Y4,B_Q[_\ <H^>1_\
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M9']Q$J>.!(T^_4'S[_O[_P#8I_F/_<V)LH_V-GR5/!L_C2G_ .LWU!]G^_\
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M@WT'R2.^_?6?)'Y")*_\=,@NGD>M.UNGWHN_95Z2?RUV/3+76+>3]TTJ0_\
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M?[E,CI\D;_)_<HDD^38GW*DCD23^/8B5!YB2?/\ WZD^>-*CDC_OT1[Y/O\
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MF?N=^^I(/]MZ?)^[W[/G394$G[R'^_4$?WDJ3S/+3Y/]8E/CVR?-_P".4O\
MXY4'^L?>SO\ )4W^K_W*/X/D^Y1')Y:??J&23STV?QU'Y#Q_QU/'^[1_EWT2
M?NWH@G\M_DHGC^^Z?)_?H\S^-/GIDDR1_P"Y4?F)_P  J3S$D=_OU')&VSY/
MD2J6I:.FJI_!O_OUQLD+V,VQZ/,3^/Y*R_/^9Z/,^3[_ ,]59+I(T??\E/@V
M20U:\RF>7\_^Q4\'[MZF?9]RMC2M->3][+\B5TD%K%&GR5:\ORZDGC_=I\_W
MZG\O[GSTD<GWZ)/WFSY:/+E^_P#P/4B2?)]S[E0?WY4I\DT6Q/[^^F22?/\
MW*M;(O\ @%0>6F_Y*/(V?['STR3?\Z?QTSR?+^Y3_,\O?\^^CS'C1/GWO_SS
MI\GR(C[?GWTR?[_W*GC2+9\GR4_R_,_CHGC?9\__ 'W4'^L^2F21_)\G\%/C
M^YL_CID<:?/O^Y1!)\B)3_(\^F>7\_R4^21_XZG^7_?>CR/+3^#?1Y?F(G\%
M$GWO_0_GJ&2#Y-_W*?\ ]]U'Y?F?<WI4\<*21_?^=*/,\OY_N.E'F?/O>G_/
M)O?YZ)/WGS[*)(_,^_\ )4D<?R?[E/CC^3Y/DHCD>1TJ-Z7]ULI_F>6^]'ID
MF]WW_P =$DGF?[]0U%_'_?2L*ZD\^_WI]RNNTJ-XX4K4CD>1*9)/\^RGQR;*
M))*(Y/,JU'1)^[ICU5DWT1_?V5=CH\OS*D\ORZPZL?P45')]^HZ6.3RTJ":3
MY*9'MD_V*(XZ?))\E,GD?96=_']RC_5O5J.K4$E21U!YB2?P5!/']]ZJSR>7
M'OK+NI/DKC;JZ>2\_@?9]RB2^EWNZ/67))\_SUU'A^#Y-^RMN.#^^E/DL8I$
M_@??5*3PS%)'O1=C_P#3.F)IKVO\=78]D?R?Q_QU/Y$4GS[*?=6J21_/LK+^
MPV\\VS91)X<_N55DT:[C^='WU5_M*[L7^=/DJU:^((I'^>+95V/Q!%)]Q]F^
MM&.^39L=T^2IX)_[CT^.=_\ <3?_  4^.3^/_OBF1R(CO_RTH_ON_P E02?O
M)M_W*D@_O_\ +.GR0?W/XZ?_ *Q-C[*6/_;J"3?)\[T2?]\4^/RM_P#?_P!N
MB.;RW_\ 9*))$G1WV[*9!)_?_=T>8FS8[_)OJ./]Y\E$D?R?["4^.-_X_GI?
M+394?S[_ "O^6=3R1^7\G\%9&I:;;ZE"F]-C_P!^N3U+2KBQF=&^=/[Z5E^6
MG\%,GDJE! \DSO+5WR_W-0>9Y=2>?_!6IINFW%\_[I*VM-T-('\V78_^Q6]'
MMD1-GW*M1P>1_OU/'Y4</W-],CD3Y-_W*FC_ +^_?LHD_>;W_OTO^L_@^2HY
M-^]_[G\%,CC>II)/^^*J^6D?_?=6HX_W?R?(_P#&E21R?(G^_4=U/]HV?NE@
M39]RBWV21[_G2F1Q^7<_?V4^/]Y_RU^2I(($N/GH\ORZ/(\OY]]1QQ[_ )_X
M*9)^[=/D_CJ?R_,?_;HDF>/8GWZC_O\ \%+_ *QT3_ONGQ_N_GV?[%1QQ^8\
MB/4D\'E_W*CH\_\ VZ9)'YB?[=3QP_NT^?[]$D?EN_ST1[Y-^_Y*?'^\=T_@
MH\SR]]'F))L?_ONF>9\_R/5J3[^]*CG@3[^_Y-GST1Q^9L_C_N5/)(OW$_CI
MDD?^_1Y?F?P42?<^1*/GC3?_ !T>7YC_ #OLHC^__<HD_=O4?F)&^QZ/,\S9
M1YGEO\E0^8G^V]07TGD0O_!6#8_O)DKM=-_Y9UL1_<JC<2)&[U#!/YDVRM".
M.I$3RZ?YGET])/[]$FRH>:@GWQR(Z?W_ )ZNQT^H9NM9_-(\E58YZD\RC^!]
MU'^L2JL\C[Z?Y=041O\ P5:V&JTD?EH])#^\^>ITC\M*9))\Z5-YGEI3+5'D
M2GR1_(]9]U'^YK!U63RX7:N0NOWC;T394$D;_P 'WZ(X/,=$_CKK]-CV0HB)
M6W''3_X(_G_X!1''Y?\ '_WQ4'R?_MT26OF?P?/4GE[$^Y1)'YB;*@^P^0^^
MK7S[=E/C_=IL:L_4K&*3YZQ)_#Z2)6=_93Q_<H>&[\[YZG@OKVU_O^75V#Q'
M\G[Y-G^Y4D?B!-_SNR)5V/5;>3_5/3_,\S?O?Y*G@DBWIO?_ 'Z?Y_F?<_U=
M'F/)\G\?]^I(]\>_?_WW3Y)/X$_X'1_OO3)/WGR?<J"!'C_^+I_]^7^-ZM01
M_N7?^#_;J&3]V^]*C_C_ .FE21[Y_P#8I\$GF;$>B#8D/W_GW_ZNF1_O$^_1
M)'+&F_\ @W_?H^>3YW^?^_4<\:2?["/4,EK_ ,#2L34M#MY]^SY/]NL2?P[+
M&KNDJ/LK/CT>[_N4^30[V-/X*?!X<>=MCO\ /6W8^'+>#[G[]ZVX($M872*W
MV/OJ[!&DGWTV4>7Y?W-]/CWR?Q['HD_=^6O\=2>7_?3>E/DD_<_W/DJ./]XG
M_H=2?ZO[M/\ +22'Y-CTR2/^!$V?/3_+^1$_CHDG23^!/D?^!Z9)(F]W^Y4_
MG^8GE;*/)?\ CV5!')Y?R/1'']]W^>IX/O\ ]S^.GR1_[=,CC23[_P CU''
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M*GC\32Q_(W[RM&Q\7)!\[Q?/_OUH0>)K21_G^3^Y4_\ PD%I']^6GQZK%/\
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MYZ9YGW*?Y?E[*9)_!_&E/DG7R:9)_P!][Z/,\N1-]3R2>?\ [[TR.U>/[_\
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MZ2;_ )-[T^/?O_N5/'^[^_\ QT^.3^.CS/D_VZADV;]GW'J../R_X_DJ2/\
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M&G\%$<'F?([[$J2/9L^_]RB3_?J#YXYOD^_1)(\C_,FRCS/+N43[]/DWR/\
M^@4>7YEL^_[]$<GW-WR/1'_KOG>I)/\ ?V41_O-]'F?\#HGG^3?]RHTV2([[
M-DE,CD>-_DJ?S_+^^GST1Q[Z/N?(]$\:;-]5?,38_P E8FN73[-F_8E3^%;7
MS/GKN+7?''\],NI/+2LO^/9_?I_E^7\]3QW=3^>\E$<]31R5/OIGF>94<?[O
M^&KT<GF477[Q*Q+K?YT#I_?J['S\U9'F;/GK+U*3S$=*Y23[[_[%5?,>1_\
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MZZM4CV;/OU/INE>8_P _W*)[66UW['?93/MUW!)\CU:@\37&S9]^KL?BI_\
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M_P#$3/\ ]\55_P""C'C8ZU\3-"\.PR^9#HVG>=+_ -=IGY_\<2&O"OC%X/\
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M[N%/GWU)/_J?E^2F1SIO_OTDDB1O\B??IGR?<^>B.-Z/GC_X'3Y/WB)_ _\
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MQ*@\O^^]3_)L^;YZJ^7YE$/[M'W_ 'THA^X[O\]/CG?Y/DJ3R_G_ /0Z>_\
M'3)(/[Z;Z@\FF20?W-]1QVOF5/ B?.CI_N4?9?/39O1/_9Z9):I']]$WU1GT
M>WG?[E4I/#\4;NGE;*JSZ!_<E=*@D\.7$?SQ2[ZI2:/>QO\ WZ9]AE_YY-1Y
M;I\C_)3Y)(HX?^FE59)XME8D\"3N^^H?L*;WV)_P"JL$<L;NF^K275W!-\F^
MM>U\07<%:EKXTEC?][6C!XN2?YY:U+77+>ZV?O4JU)=1;/W5/CG3_@=$DZ?[
M]$ETD>Q/]NK4<D4CT?ZSY]G_  .CRT\S^^]076__ ('_ 'ZXV^D\R\_OUO\
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M<.^I/W7R5')'Y;_<IG^L2GQQ_N_DH\CY7_CJ&./Y*?'!_<^Y3X['RTJK):O
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M\Z/4$D;QO\E2)(_R;'^>CRWG_P!;4=U!Y'\:?/\ .],GA^YMJ2?_ &_GJ/\
M=21_[=1^6F_?OI?+3>]026L4B/O2H)-&M)/^62;/[]9]]X1M/X*SH_"OEO\
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MNTV/_?A?^!T_VTK\ZK:7QE^PS\;GC<-?Z)<?>496'4[3^]_L3)_XX_JC?/\
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M],\ORT39L=-]$DGE[_XZ(_[F_8]/\R63[WS_ -^B.-_]RI_]7#]_YZCC^_\
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MR3/3'^_67JMUY$*?[]7;[]X\")_ E6M*CB^?=\Z5MV-JDC_*FRMN"Q\M*?'
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M<G^C5/'/Y?R?)LIEQ(DB5'YCQ[T^_4^__8^2F/)YC_<V5'/^[?Y*9'._DO\
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MOJU!'O2B2#Y_D^2HY(_,_P"FE,\M_DJ"2/S'JU!/\E3R3_N?-?Y*SI/-NO\
M82K4<?\ !LJ3_6;$2NU\,V/D6".C_?\ XZZB#?'5J.3S/G?[E$GE1_<^2B"3
M_@=22;Y/GI('_OI3)_WGW?\ OBF1_N-GW-E3>9Y'^W4_E_(CO3)I_,?;\GST
M1[(TV;ZC@C2.9-]>;^,?V<?AQXXU%-2O?#MO9:O%,DT6H:>GV:;>C_?^3[__
M  /?7HLD;QH_S[Z(Y-D/W$WT^"3R]_FI_N?/4GF>8^_^Y_?J".3S'IZ;_,^Y
MLJ2.3_OBCS/X_D^>GQ_O$?\ V/[E,GD_=HE$FV!_O[WJ"21_O[-E/CD\S?\
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M(XH]C[Z/DDV?.O\ P"C_ %GW_O\ ]^GS_O'WT1Q_Q[*/GW['^Y3/F_X!3_\
M6)]^H8]^^K4$;R?[=1^8D?\ !3)/WG]RGQ_NWV?P4R2/S-^^B-$_^P>B>1X_
MDB^Y_'3/,3[^_94T$D4GW/GHG^_LWTR>-=OW/GH@\K>_SU/')YG\='F??I\=
MTG]RF3_N]]1QR/'\^RI)/WFSY$WT>9\]$FS9]]ZJR?\ ?%4;[?';5SUQ)YES
ML_@K1M8(O.V.F^MZQA\O[E;T$E3>9\E0R34^.3^"IZ?1'4$_^W6?)-Y%S!_O
MUKP_=H>3Y*SI]TCU>TV-]B;ZT*ADCJ/S/+ID;U:C_>4M5YY/+J>"2N&D^_1\
ME,\SWI\?_?NH?DW_ /L]68_NFF7$GW-GWZ(_W:/3/,^2IXY'^Y1Y?SU/_L5'
MY;R5.DE1P?O*9/'\]9UU^[WUGP7327+ILJ;S/WWR;W2IW^_'_<ID<?\ OT^3
M?]_^#^Y1!)]^G_ZM_G=_,H\S[B;/D_OU/Y/W]GSU5\OYZGCC^=]E'F?OMGR4
M^39)_OTR.3S/]^G_ .L?9_WW5J.1_P"!_N427;['1ZSM2T=+I-\7WZY34M'\
MS[Z;'_OUS5U!-:O\Z?)_?IDD[R/\J?<K.UC4GM;.=T3>Z)OV5GZ5JKZK\[6_
MD/\ W'K3C_UU7OD^_5*>3YW3;4>F^'+NZFWP_)!7JFAZ4FE:;L1-E:$<?]_?
M\G_C]'EI]S[E21P.C_['\%$G[OYT_CI\$GW]]$>^1'_@HC_=_P"W1YB?Q_(]
M/DD22;_<HG_>?)LHCV2?(GW_ .Y4,&_>_P#'4T>[_EK]RB39&F_^_3))'D_W
MZ@^?^Y\[U/YB0.G]]*)Y'GDWT1R)L^_YE/\ ]?#L=_D3[E,\MY/+BW_)3Y-^
MQ$3Y/]RI/+^_4'R;_D^?Y*/GCI\<GD_Q_?HGD23_ &'2F01_WT^_3_\ Q_\
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MSMLJ"-_,W^55WS/,?YW^?^_1']]_N42?<_N5#_J_[]$?\&]_DHDC^_L^X_\
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M?'OWU))^_3_;J/\ >[ODV;*M3R)\C_\ +?\ CJ#S/+?_ 'ZD\C?_ 'ZC\O\
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M3R?(Z5:C^Y'4$\:;_P#;JE?1_)6=:_NX9/[E6X-FQZF^>1_[]$FS_?=Z9/\
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M]B;][TR/_8I_F?Q_?V4R29Y*@DW[_OT>1\^^E^U)'^ZE9$WU@:EXJT^QA?\
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MNK7S$K$U*U>#]ZGR.G\==?X.UG^W+!-^Q)T?8]=E)^XC1/[E$?[RG^0]J_\
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MVH]$<CQNZ4_^/>[T_P _Y)/]NJOG^?\ (W_?&RI['?'O3^#^.I[K?&FS_P!
MKS+7)/,O'?\ VZI6MUY^]/[K[*N_/'3XY_,^_1)'_&E26LCR2?/5[FHY(/GJ
M">%]Z/\ W*8\?F)4$'[MZM;Z@DD>-]E0W4_E_)562/\ <_/3_#.I/:ZPEO\
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MYWE?9_P"JL_[Q-G\?_H=/_U:)3TC2=]_FTR2-XWV5/) FQ)?N55_UC;-F_\
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M^>/^_4\>S9OV4?QNF_?1Y;[/N[Z?\D>Q/DIDG^Y1Y']__65')OC^Y\]6H_\
M4OO^2JLDCR/L3[]3VLB?.C_?IDF_R?[E5?,?^.K7^O3[]1S5)!^[^_\ /_L4
M_P"3?L?^.B?9]W94$?[O^Y4DDGGP[-_W'I\<#R?QT>71Y"0/OJ>>1-^S^.H)
M)-_^Y3//\Q$V??I\DG[M_DWO3(Y/+^_3Y-FS8E03[(T3S:D\SR_]RGR;Y'^3
M9LH3?LH\]]^QWHDD\QT?[_R5/'.F_>R?)_!1YGR;ZM6MUY#[WJ:23SON?)O^
M_7/:MH_F.[PI\]<O?::^_P"971ZY[59);6V?Y/N5CZ5?//;>:^__ '*O1QO]
M^5_^ 5:F_P"/9]E/@U+RT^_4\<CW7W_D2M'S$]*@GC\S[OWZT-*T/S/GE^_7
M10:;Y?\ MU=CC?9\GWZGD@ED3_V>H(]_]SYZG\OR]CI4TD?F?,],DC?Y$W[Z
M?)!4/EO(E/\ +2-T_OT^.3Y-E0/]^I/+??'+1/ODWNE$<;[Z?Y'SN[O1' F]
M_P"-*DDG\O[E'[V2-_[E/DM7C_?5!)YNS>B?/3+6.62%]^^F3_[E<UK$GR5R
M]U/YDU,NH_,2J,'SS3['^2K4<GD??J>/?/1/!4'SU:CC^2IXY_+JU!L\Q_GI
M_EUHZ;&\==7:_P"IJ2/_ %U6H_\ Q^GQR>74\%$_[RHXY/+^_4_F>8E9T\#R
M._\ !18VKP76_P"^CUMQR;*?''_'4FPT^B3YZ\V^2J-]/Y$+O4,$>Q$_OU-]
MHJ23]YLV?QO3_P#5I1YGE[Z9Y[R55CD_T^?_ (!6O!/^[>F23O(^^H_/\M]E
M203^9]^KL<CT/)Y:5B:D_ETR"1)/N?<K1\NG^9]Q$?93XY(I/OO\]"?ZE]__
M  "I(YTC_C39_&E1R;Y/]RB21X_DV4SY_G1/DWU/'(\:;*))$CA?Y?DJK)'Y
MFQTJ:#Y'^3>]21R?/4?VCS-B/_P-Z9'_ +GR/3_+2/?_ +=0_P -/@D\M/N4
M_P S]S\J?/\ [%,_UWR/1]G^39_!3XX_N5)/LC>H))'HC^\]3_ZM]_\ '1))
MYB)OJ../Y_\ @=3SR/\ ?E^__N4SR_+W_._S_P"Q1YB;'^?_ '*@DG>/^.JO
MVK^Y3X)WV??J2>?RT^=]]%O)]_?_ !U-!&L:/_?2F23O)\]$?[QWJ>./R]ZU
M'YGS_<^>I/(_O_/3XY$C_P!A*?YWWW3[E0R2>8Z4_P#X!1)(DFSY_P#?I\\?
MR?<^2JLD;Q_)]Q*DDD3[E$<?]RB.3_OO_<I\\_W*9'^\_P!Q*))'A1$_OT^#
MRITV?<^>AXT_@HC_ .6E3R2?(B4^..79]RB21]FS94]K)]GCCWU-YD4^^J4]
MBEU#L=-]<OJ7AE_G1$WI_<KE]2\,_/\ )O39\]4I]-NY/N.E01VM['\DL2_\
M >M'^RGWH]78[']RGSU=TVQ21_[]:ECH_P"^WO6]'&DC_(E6H)/D_@WT>7YC
M_)4_R1_]<ZI2?WTHCD\O[]303^6^_P#@H\_S/G2B23RT3^_3/]6CO_!3(X]_
MS_\ H=3?ZNH8_O\ \=3?ZNI(X/,^Y4?^HV)3)-_STQ)W@3_?_@J:.3_8?YZD
MCD\MWW_QU''=?OMGW*GD_=I\E5?,\C?_ 'ZJW4CQ['V5S7B"1)*Y>Z_UU$<?
MF55@G2#SW_OO\E7H+?\ CE^_5KRTCJ">Z_>;/OT^"Q>3YZG\ORUV)4$DB1U)
M:SO_ , K4CD^39L^>KMC)O>MN.=X]G]RKL=U_'6C!.DZ;Z))/[GW*(9JFDD^
M3Y*J^?YGR5:CIGE^9\]6HZGC>IOX:DI\CTS?7E\<GR5G:KOC1/[CS)5KR_D2
MF>7]RK4,GR4__P <IDD?W*?Y/[FL[R_^)D_^Y5[S/DHCD^2B2'S'WT^/Y*T8
MY_,>B>L36)$_\<HC_P"/9'6+[B5/)/Y^QZM1_<W[-_\ N5'YB;]TO\%3_P"K
MV?QU)']^3[F^HYXW_C_[[2F>9L_C=ZFD_=U)_K/G3[E,V?._WTJ/YXW^_P#)
M3X_[]'F>6GR(G^_4D$BQ[]^^HYY(I_\ 5)LV41_\\MG_  .F20?<_N4>9\E1
M^9Y;[-E,DC?_ /8J3S$V_P"MV4^1'C_OT21^8^_^.B3]YO?_ &*9'OD^??\
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MWP;]_P B4R21)/N;W3?3_+_V-B5#/OV;/OT^.1/N/LJ:.1/]^H?,\NF?+O\
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M*D^39LV?/2)&D"/_ ,]*9)(FRB/[IHCD^_\ WZ@CCV?\ J3^/?\ ?H\SY_\
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M_JON56\_S/O[Z?/)YZ)4$>R1]FRG_/'4_D/LW_WZ9'!\GST^/[GW*?L?^_\
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M-E$DGF/\_P B?P5/!Y7WY?\ @'EU'/(^S_II57S&D_X'_'4__+'8[_QT_?\
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M26+QN\L3^0_]RF227>Q-\6]_]BH)]]U_RR\CY/\ EI5K39/L*>5*^_\ N/\
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MG^T_],_]BGS[(Z9YB4/)\E,_] IZ?^/T^>'^-/GJK).\:;'JU!/_ 'TJ2/\
M>/L3YZM1[Y'V4:Y8O?:&Z?QP_/7E^L0?N=_\:5EP3^9]RH'WR7*1?W'WO5W9
M\_\ ?JK)LC?9_?\ N4SY(/OTRXG\M-Z5'')\];$$_D;/X*M?:DDJ">%*Q)X/
MWV_^.IX[[[Z5B1ZE]N\0I;I_J$^_7KUC)+/#&_W_ )*T/,;9]S?_ 'ZDCD?[
M^W_@%36DGF.^_P#CJ?R_+^^]'R0/]VB#]YOJ1_N5''^[3_?_ (*(]F_Y]Z4^
M-TD^Y\G_  .I))$C_P!QZ@\R+?\ [%,\_P#C1-FRII)/XWH_BID\E/\ ]?\
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M22/3_P#5I\_W*/\ ;3[E$<G_ .W4DD?\"5-:[I'\JCS/G_W/]NIXY/DV;/\
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MC^?9L^]_XY1'LDF_X!4GF/'^ZV?)1)&FS^X]/CV>3L_CJ"39'_MTSY/[]/\
M/\C?O3[]'VIXT=$V)OIDD[_QI3X_W_W/X*/+>3[E2?) B._SO1YZ1_?^Y_L4
M21IY/R40;_\ 54_R_+ID$?W]]31QI_OO1Y:>=LV?/_'4,D;Q[_O[*)/W>SYW
M^:IO,\S_ '%_OU)\DGSI1&_^P]1^6F_?3))'\ZI))/O[-]1[&JUY:1I]^CS/
M,^^[[Z@G_>/OV422?)]S?4GF??1Z3SWJ>.1([;8_WW?[],\SR_D3?55-_G5/
M':RW6]$3>Z)OJE\\=<[K$G^GHGWZM01_<W_)4%U]]_XZJS^4\*;'_?I]^L6:
M3YZ?!/YC_P!RKL<]21S_ #[ZVK']Y6I!'6I!5OFH'D^>IOM%2;ZC22I_X:95
M6>3RZFC_ +]3QT^H9_WE9UUI7G_/4^FVOD)6@]9]]_L5G6,\OG.C_?2MZ"2G
M^9[UY9/'#/\ ?^^G\=03ZS_9L/\ I'[Y/X'2I--NDN(?-W_.]/NKK[+,EP[[
M$V;'J[ILB2?O?[_SUH56NOW<+TRQV1PH_P#L55U3]Y#\_P!RJ5\B?N-B[$WU
M9\SS$JK))YCHG]UZO1W7\%5=5_X\'_O_ ,%/M9/M&R)TV>2GSU//:OYR;$I\
M>Z/Y*M?/^[H\SS*JP;-*FV?P3?<_V*NR2>95*Z@22/8WSUS=U??\(^W[WY[)
MW_[XK3L;Y(_^!_<>MB"?[^]_DJU!)#)]RGR2?/\ /LI\E"2)OW[-_P#[/1'O
MCFJ!X%C?Y*6/Y-[_ #_/4W^_4,?[O>C[ZCCC_P" )_!5J/\ =[][[ZA\S[]/
MC_=I3_\ 5T1_<2I(_P"#91'^[^1_DI_^LAHDD3[B?/4'^K?Y-^RI(Y$D1_O[
MZF\O_OBI)+KRT2H_,3^"IX+I-_\ <2I_]1]Q'V5!]H3^[4\ET\:)_<_N5!)/
M_?HCN/,3^Y1))Y:_[E59)/+V.GSU!/OG^>B#]X_[U/O_ ,=3^9Y;_(E59]\C
MNZ)L_P!RIX)WC2G^9\_W-E'^L_B_[9TR.3^]\FRHY]^[?OJ2.1_]:_WZ/,^W
M/_<J:23RWWT>9\FRI'?S*C_UCI1/^XW[$>F1R?<=WV;*NQR>8GFO56F2?O$3
M?3)(_+F1'_@I\$B2?(]2>7\^^G_PU'))_&G_ 'Q1'.GW_N41R>94DDB)LV??
M_CHCG^_%_'1'/YGR.O\ P.CFIO,^XG_H=']Q(J62-_O_ 'ZCGD\Q/N?<IGG>
M9_!1'(NS[G[RCR_GWI4WF/O3^Y4GD>9LWU'_ *OS*6/]Y'_[/4$DGEO\C_?H
M^>.IO,>-/-^__?J'[5YGS_P4_P S^Y1))\]3N[[_ /8H\OR]E/DC?Y'J">1*
M/+?Y_GV55DD\MZY'4I/,U*M"UG\Q/[E3S_O$^2L&?_652G^YO_CJC'.\;U:C
MNJO6LG]^MJQG\MWK8M9_,>M>.K7\%59*GCCIZ4>9Y=/CG\QZ9_'1Y?F5/!_<
MI\G[NA/N44R22JL<G[[9_<JU')4<\?F4R.'R_G_C_OU/_JZ>DE>'3WWES.G\
M:??K+DU+[5-YLOR00_<K0TJ1[IW=7\BMB?\ >)]GE3S]U6K6U^ROOM'V)_SQ
M>M2UU))_E^XZ??2GW<B?9G_CK+TJ1Y[.!ZT9XTGA='^='^_7.ZK=/IJ(CIO@
M1_D?^Y5Z.X2=-Z;'2GQV*?ZW^/\ N421^7\]07W[]-GWZ62-_D>+[]:$>I)Y
M+[_D=/X*?!&^SYZDDD>GP_<HNH$G38]4H+KR9O*E_P" ?[=6I/WE8/B"Q2^L
MW2N)T.270[R>TN]_V+^__<KT.UG\M$B1T\A_N.E78)/+?9N^>K7VKR_DE3Y*
M()$D_CWI4_G^6[[$HD_[[IDGR?\ V=/_ +_\#_W*@\_]]L?Y*D_O_P!^B./R
MWH\S[^]_DJ/S_P"Y4D?W/]RGQ_<^?>E,DG\M_P!U_'4T'[MZ7S$D_P#BZ?L\
MO_;3_?J.3]V],DC_ -NK4&S9_OT74?S_ "?P5!'(^_8]3Q_NXW^??_<HCG\Q
M$^_\E6O/?[_WZ9YG\?\ Z!1YGF)4<DGR;]F^B3[F_?4D>R3_ '*@\OS/_9*/
M+>/?3(YW^Y5J?^!-_P!Q*@C3S'?>_F4>7]Q-FRF21O']S[E'F;T_X!4WR1_P
M(^^JLD?_ 'Q1\]20?NW391)_&[U:CD3R:CCD_P#'Z/+\RI)/]OYZCDD63[G_
M (_1!)_!L^_2^7^^^Y4?E^1O??\ \ IG^LF^;?\ ['ST_P O[[_<>GQR)\F]
M*7R_,^3[]1^7Y>_8E'^?DIG^K^_]RIH]DDWR;Z/,\M_N??\ XZ9))YGW*?'^
M[C^?[]2?/)3XX_XTI_R1_)]^H))/+^2F22)!_!1)(GW/XZ6.'_@%64_@^>I)
M)$D^2H/]6[[Z@\R6/_<J?S//1$_N4SS/N;ZCDC_CJ?8:/DV_)_P.G^0Z0_P4
MR.?S*?YGEOO^_3/,W['1Z/X/OT>>^S^#Y*I3S^7\]<3/)Y]X[I]S?6Q'^[2K
M7S[/DK$U)/(_CK(>Z1]^RH_]94B2>6]78X_,V;WK>L8ZWK']YL_V*U$_=_[=
M6O,]Z9Y=/C3RZ2FS?=JC!/\ OME7HZFCJ38:C>2B.>I)/WE,YJ../_ONGQQT
M?ZRCYZDJ..1*^=WDEOM2G3>_D?QO_P"R420/]H1$^XE=#8SO';01?(GS_/6I
M:Q^9?O\ ["5K^7YE9=]:R[_-BE?>GW*I:EKDL>CW4KIL=$V?\#K4T.3R]*M4
M_N0I5V1ZR-8D21($_P"FU4I[5[7][;_)_L?P/5W3=5^U?(_R/_&E6KYT\G_8
MK.M?WFS?]]WWUHS[(X7JE8QRW3I<.CIM^Y6O!/YGR?QT_P SYZDCDJ;S/DK(
M_P"/Z2=-GR(_WZ?!.\#^5+]^IYXUDAWUD7UC%(K[T2L2.>XT-$_Y;V2?P)_!
M6I:ZK%O^T;W='^X\=;<=UYB(^_\ X!4T'[O_ &-U3P?O/O\ SI4^_P"=]Z?[
ME1Q[]^Q*))/,3?\ ?H\O]VF_Y'J3S_\ @%0>9_!]S=4_E_/4<D'^=E3P;][K
M]^F1R??_ +E/CCWU/)^\3?4'^L_Z:)1\_P#&E$?W_OT>8D;[/DH@_=[T=T^2
MG_P?WZGCC^=-^S93)(T\YT1_N4_S$C_X'3_DDA=_XZJQSK ^R6K7GI'3/]8]
M3^9\FQ%WU5>1XW1J?)/YC_)L3_<H_P!7_'_WW4$<GF/_ 'WJ2.?RW^3[C_P5
M-))_'1!Y4ESLEEV)3/DGWHC[*@CC^?YWJ>3]PF^F1R>8_P OWZCCWR._W*DW
M_P"Q\]/^?YW3_P <I^]]G_LE2>8D?W*C\QXWW[*9YG^_LID<B2/OV?/4W\"/
M_'1/_KME'E^9O^=/DJ'^_+O_ . 5-']S=_RS_CH^3_OBCY_D^>I)/W?R)LV/
M4$#^6]$G_ *9\F_^.G_PTR.3^_4TG^Q\],CD_CJ>.?RZCDD\O^.F3R?<V?)4
MZ?O/O_\ CE1QQ^>]6_+\OY'J/Y)'^2I)(_+=Z@GC_CHCI\DB1I\E$>R--[O4
M&_\ V/DJ2/\ >?.E'EI]_P"Y1_K(=CU!L_X&]3Q_<^3[]1R;(]GSHE6_D^Y4
M$VS_ (!6/J4;^2^RN4@D_P!)K7\_]\GR?)LJ>2ZK$U*3S*RW@\O^"B"/S*G_
M -8_SUH^6GW-F^M>UDV0UMVLGR5J03U-')4GF4S?3XWH_P!94?D)&V]/OU)Y
ME/CDJ3FHY]]59)_+>I_,^2I^:>E/ICTSFGO55(Z\#T>!]EZ[_P 'W*GL9/\
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MHXX/+_@H\S_@%3^8DBU5NH$G^2BUL?(>M!_N5GZ;']EW[W\QW?YWK1^2JO\
MO??H\S_OBJL\_F5@P2;[ET_VZ-5T.&^A?_T.N=_MB[\..D4L7VJUW_/_ 'T_
MW*Z6"^M[I/M&GR^?_L/]]*U+36'D^1_W;UHR77_C]$DC[T3[_P#MT?ZSY/\
M;J;^'?\ ?>I(_P!XGR?)3/D_C_@J/S/XZ?'(\?SI+O\ ]BI()W^>GR2?\#WT
M^/\ =M\E$F^1_D?YZ/,\OY*9')]_Y-Z4](_^ 42??^_4\G_?#TR.1_D_V?XZ
MM3R>7]]*@DC^2C[^]'?Y*((T_C_[XI\G[Q_D79_L4R3?O39]S_;I_F?P4>9Y
M?W*))WV?]-*(Y_O[/^_E3[_E^Y57YY'>GR4R3?)_L/1Y$LGS_P!RGQR)_?\
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MTFQ/[]9=KO\ G1ZJSZCY=SL?[E075]YB?)]^H8Y/,W_/\]1^6\:/L?\ ??\
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MR)Y3_?2KOSR;_P"Y6?J5KYB?[=4M*OO(_=7'\'_+:MKSTD^Y4-UJB0?[;O\
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MW_)L>I[6Z21*?!/^^?Y]F^K<<;_?I_F/L=_DJK')_MI4TDGE_P =21[)$?\
MN/1)!Y#_ -^CY_\ ]BIHY(MCO+3/X/\ V>GQR41R>7^]_CHCD^??]^EGD_CJ
M./\ W-]/CD\Q]CO\E$D#PNZ(^]-],D_>?[E$<?\ M_[E$<G[Z3Y*GCWQ_/\
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M=]CK]]*A23S'^>B.-X_G_P"^ZFCC\Q-_\=%O&_W_ +E'ST?ZO_8_WZDCG_\
MVZ@DW[__ +"G^7YB?[%0QR)'\B/\]6O,>1/*3?L_CJ#RY8W1TJ=/N?/\]/\
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MR?P4_P O8GR5!/'_ '*R)(W\YY:GCC^Y_MT3P>7#\GWZJP1MO_V*?/ DB/\
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M/]S^"I/,_?5-)'YB?^AU5@C\BI+J=XTV4S[5YGR??JS'ODJ]:_O$_P!RIO\
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M3?LJ9(_X/OT1[-]0S_["?[E'D/)4WS1_?J>3[GW*9YB1U'Y?EOOJ1_OHB?\
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M=ZWK'6$U)]\4J/!LWHF^M&"^>/Y/N?W*M6M]%OW[?OU=^U>91]N21]F]-_\
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MQ5]H]O.[NT7SUFQZ-<6+^;:7$T'^X]:MKXJUVQ3YY4O4_P!M/GK7TWXA?/\
MZ79.G_7%]]:\'C_3)/GEN]C_ ,"/"]7H_%5I=?<O;1W_ (/WNRKL&L>>B/\
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M^QXI/WLK_/\ W*WO#]\_AR:=_P#E@Z;/G2C1X/+WR^5]_P"YOKJ((/+A3?\
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MY*AT>Z^U6:.Z??2G^9YDWR?)1]J>/Y$>IX]5N(T=-_R/_!LI]CJKQILV(_\
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M?]]ZNP2>1O27[[_<>K7ETR2/[CU1FD>-_P"/95*23^/_ %E59)_+_C^_3/\
M;H\_S'V/\C_W$JK?1^0CNGS[ZJP1VEU#.C)LGW_)LK.DM?G^3Y]]6H/#][YV
MQT^?_8K7NM*6UA@V.CN_WT3^"B.!]CHZ5GZE8O&Z2H^S9]^H+[[GW*@M9/\
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MX*?)]UZI1R2QW.S9\E:$<]2;Z/,3UI_F?/0G\=,CDKB9/*D1-E9%]&DDR/\
MQT^2-Y$_] JK/:Q2(_FJE<I/ILO[^6WN/(1/N)]^M[1]<>1$BN(OG1/OI_'5
MJ37$V;$\[?,_]RIX[A)[Q)7^38GR(]6O]?#/_MUEP6OF)LEWSHE320)'\_\
M'61JOE3V<_VA$3^X]%C8O B1/_!3(+%-\^S^-_OU'H^C?Q?[;UU$>R"VW?W*
MAGD\B:"X?[E:$$_^G_[Z?)5Z>?Y/N5G27S_;/O\ \%6H+I)$VU2GM7\[?1YC
MR?WZ?'&DER_^Y3+O]Y(B5':VKQO]_P"2KVSY/D_CJU'&G^Y4<G[O_@%5;[[G
MW*YN/3?G=_G\S_8J#^S7DN)_WK[/DJE)IJ6LWE.[NDS_ ,=:$=BD?W(D2I)+
M&6-/D_\ 0ZQY[Z6!]^S94FE:P\CN]=1INN?WG_=UH1W7F?/563_17\W9L1_O
MU)Y_F(_\%0>7YE%3^9\E1^8_K4D<[P5-'/YGEO4GEI)4%U&D<+HB)61)'Y?F
M)O\ DHM9TC^3^"II)$_X ]0_Q4_^_P"51YGO3_D_X'4,CO(_R?<H@DEW_/5V
M-TG^2GU5NI'C?_8J&23[]/@_?[*?) ^^B.#[^S^"K7F)&E222>6^^H+K?)L=
M/OU2^229T^Y1)'^Y?^.L2.-Y[E$^1$IDDCQLZ?W*?'^[A^3[^^IX/W>QWJ:X
MG_@BWUHZ4_SIYK[T1*U)+KY-_P!^H([Y_G?_ -#IEW)YD/SO3(-O\?R?[=%]
M8^99NF_^"H+&=XX4?^\E:,%\G\:4R>Z^;Y*@?]\Z.[_<J[]E3R7^>J7^H=XO
MX/\ 8J;S_(?9]QZD^W1>2_S[*YV?4OO_ '?GJK/?(\/E(^]'?[E4IX_]&V0H
MZ;__ !^LO[#+&F_[CU=DM8HW@=YG^2KUU=)&R>:^_?\ <WOOJUIMQ%LW_<1*
MUX+KS$?ROGIGD;TWN^RJD<GE[T^??2R77_/6KNFS^9O\I*T8Y/D^>H/GCNO[
M]3_(B_WZJP1I)\_W*?\ )!O>IXY_,??_ -\5/)/^[V??K+OIT_</]_\ @I/M
MWD/4D^I>0B/]^H_[8^1*O:;J7E_/6U:ZE]J2B?\ W]G^W4-K.D;O_'\^RM!_
MW:?<JE)/]G=$^_O^Y4_^W_'4$\C_ ,"4R.Z??LJ;SO\ ;H\_R_GH1_,H\_R/
M]RK4=WO^2CS/G1_[GW*G\SS/GJ'SZ?'/Y>S?3]],\SR[G_8JU'_?>IZ2.2I-
M_P G]S=113_,^>G^9]^F<[MT?7^*O+[74O\ 8=*?=744B??3?3(]239\[HCU
M2GN_MSHCNB0?Q_[='E^?\D2;T_CHNM'\M/-MWV5E_P!JW=K#LO8OX]B.E;T<
MB>3L_O\ W*T+7]Q"CI4,\Z1S?[$W_H=32;)$^>N>U*1-B1)\^^;93[Z1[6'>
MGW_X$JU:Q_:(4\WY/DIFE;XT?Y_N.]6KJ1/L>S[^]ZNR;)K;RO[Z55M9/+\C
M?_ FRKWF>?#56.3_ $C_ (!5V"1-W]RIYY/,2J,DCQ_.M,^W>7-O_P!BF27W
MF/\ [E3077F;T>IX[K[FRK7F>9\F^B.=)-Z/3/,]ZJR1I)]Q*SH(/,F?Y_XZ
M9J5JDB>:FS>GW*FM9TDA3_;HN-DB/LK/GTU)/]M_X*Q_[-\Q]]6K6QE@_P!N
MMNQD^2M&UG23Y'^Y_'56>U>.;]T_[C^Y3XY_+IGGI)\Z?]\4_P SS/\ ?J#S
MWC;_ &*G@ND^X]3^9L?^Y4T<_P#?J1]GW*Q[Z#R_FKFKZ^>U=/[E26NL>9O1
MZU(YTD?[_P!^GQ[]_P G\%2>9Y?\%1R1O'OV5#)YL;[WJ.2Z\C[C[ZD@N_N;
M_P"_6A')YG\=0WT?GPOL^394$$$N_P"=_DJU'']_^_3/M3Q[/G^_4T=TDB?-
M3))_G?9\Z4SS_DV41W5$\GGS>;]S_<I\>S9\Z/O>LO48$NIOW7R;*9]E>>S^
MT/+#^Y^Y\]8\%P\C^5+L3^X]$$_EOL\W9_N/6I'!^^_V*V+7]VGS?)3[C?(G
MR?)3+&^\^V^?[Z?(]6I/N(GWZ))TV)O3YTHGU)(UV?P/6/8W4LFGNGR;X?DV
M4R#6$N[/]Z[P/OICWR1I]]*(-2\MTKH;75?(^=_G_OI56>=9[EW1'^>H))'A
MW_WZRY[YY+9_G?>E9#S[_,??\G\=,@DMY'^1_G_@K:NI/G@B3[D*??J?[*DD
M*/L??56ZDED^3RD_[XJ"QTI+I_F3R'V?WZ)[%]_R;ZO0::\$R;)7K7DV2;$>
MB2#R_P!ZFQZ9Y$4^QZFC@2UW^5\[O1)(L#H[U>\]/DV51U*^\S]TD6RF072?
M<WT7TZ;/OU!')Y<*(M21R/\ [^RGS^5(GWWK.OKI(/N?/5*>=[J9/GV)4_\
M:44:5:@NHH$W[_GJ[INL/&];?]I(Z;W>HX9$M_G3^_5Z2^^YO?S*@OIWV;_^
M!U/!=?N4=/XZF_UE59XXHYDE_O\ R4__ -#>H9)&V/3[6=)X=]222)M>+?\
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M2%5:!/\ 8-3J4M[6.95WOO\ XZP]PDUZ,6Z^0RQ.^:OPW5[?7#@S(J_[M3K
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5%_FI\C_)4$WR20?[VRM&']Y\U?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>respiratoryactivitydata.jpg
<TEXT>
begin 644 respiratoryactivitydata.jpg
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MI_:?]I?9_L7FW4=ON\KR7\S&_=C<N<8SSFH/C)^VH?A'^UC\//@H?!W]K?\
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M/X2>,],\::':IH]C]@M(S!J2P@1QD-(Z\D!5S'Y@/WAU KTG]A?4OV@?BO\
M%3QS\3_B1/K?A/X?ZF671?!NIK@!F*[&19%#HD<:@;@J^:SEN<'/S]^RS\/?
M"OQ)_P""HG[06F>+O#6C^*=-BCUFXCL]:L(KR%)1J=JHD"2JRA@KN V,X9AW
M-?I]X-^&WA+X=VK6OA3PMHOABV;K#HVGPVB'DGE8U ZDG\37SY^T;_P3K^'?
M[3GQ&/C3Q/XB\7Z;J9M(K+R-%O;:&#9&6VG;);NVX[CGYL=.!7M'P)^#.C?L
M]_"G0_ 'A^\U'4-(TCS_ "+C5I4EN7\V>2=M[(B*<-*P&%' '7K7P%^Q@?\
MC;!^T/\ ]>.K_P#IRLJ_3REHHHHHHHHHHHHHHHHHHHHHI#7Y\Z'^W]XZU/\
M:,MKEM*TW_AGV^\8R>"+;6O)*W'VT0@)(9-^/+>4[@=N-FX=17Z"Y^7K7P9\
M/_CC\>_VV]8\8:I\)/$_A_X5_#;1-3?2;/5[K34U/4+Z9%5V?9)F,*4=&Z#
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MRRHX8-C&#G&*\E\-_MQ? ;Q9XPD\+Z5\4=!N-85@BJ\S102L3@+%.ZB*4D]
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MSS6]^Q=_R:3\(/\ L5]/_P#1"U\Y^'?^3UOVTO\ L4]+_P#35'4W_!,#X >
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M14DX'&_':OO^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOE#Q9_RDJ\%_\
M8B2?^C[NOJ^BBBBBBBBBBBBBBBBBBBBBBBBBBBOA?_@D)_R07XB?]E!U'_TE
MLJ^Z*********************************************\>\8_\ )R?@
M'_KQNO\ T5-7L-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%)61XG\)Z)XVTF32O$6C:?KVER,KO9:G:QW$#,IRI*.""0>1Q7S?\9O^">OP
MZ^*GQ ^&WB/3=-T3P?9^$M1^W7FD:9X?MA!K2>; _DW 7:"N(67YE88E;CJ#
M=^/'[#.@?%CQ=HWC+PIXJUOX4>--+L$TF+5O"K^2K62\+"T:E<;5)52C+@$
MA@J@:'A_]A/X9Z'^SCJGP9FAU#4?#^K3F^U#4;BX'VZ>\)0BY\P+@.IC3 VX
MPN"&!;//? G]@31_A)\2-,\<^(?'WB?XDZYH5LUAX?/B"XW1Z5;E2@5%R<D(
MS+U"C<2%!P1]65\8_ ?_ )28?M._]@K0/_2&WK[.HHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHK&\76UU>>%]7@LDF>\EM)4A6WF$,A<H0H5R,*V<88].M?GU
MK_A/QDG[:7AJPDLM=&MOX6>6.)O$$37/E>=."5N-NU5R&^4CL?6OO/X8Z?J6
ME^"--M=7BNX=1C\SS4OKQ;N89E<KNE48;((QQP,#M75T4444444444444444
M4444444445\+_P#!(3_D@OQ$_P"R@ZC_ .DME7W111111111111111111111
M1111111111111111111111117C_C'_DY+P#_ ->-U_Z*FKV"BBBBBBBBBBBB
MBBDS1D4M%%)7SA^SG^UA>?'3XX?&7P%/X<ATB+P!J1L(KZ.[,K7@%Q/%N9-@
MV'$(. 3][VKZ0I,T49HW"BC(I:^;?BW\7OVB_"_Q"U73/ GP"L_&OA2#R?L>
MNR^*[.R:YW1(TF89&#+MD9TY'.S/0BO#O _[?WQ\^)'Q \5>"/#O[.^GZCXH
M\+2>7K%C_P )=;Q?9FWE,;W 1_F!'R,U>V^'OC#^T??> ?%VIZM^S_9:7XHT
M][(:)HB^+;.5=4$DC"Y+3!ML7E($8;B-V[ Z5]*Y%&11D49%&:,T9Q1FEHHH
MI**XKXV,T?P9\>LK%770+\A@<$$6\F"#7AW_  3#N)KS]AOX:RSRO/*W]I9D
MD8LQQJ=T.2?I7U/111117QC\!_\ E)A^T[_V"M _](;>OLZBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBOE#Q9_RDJ\%_P#8B2?^E%W7U=2T444444444444
M444E+7R=^RA\4/%?C;]J#]I_P]KFN76I:+X:U;38-(LIR"EDD@N]ZIQW\M.O
M]T5]8T4444445\+_ /!(3_D@OQ$_[*#J/_I+95]T44444444444444444444
M4444444444444444444444445X]XP_Y.2\!?]>-U_P"BIJ]AHHHHHHHHHHHI
M#7F>J_M#>"M%U6\T^[O[A+FTF>WE5;60X=&*L,XYY!YJL?VFO 7_ $$;G_P$
MD_PKP;QM^T5XBU[Q=;:II5Q+I6GV+[K6QW95^.6E'\18$\=@<#N3[/X=_:E\
M)WND6\NK//IVHE<36Z0/(H8=2K <@^_K6D?VFO 7_01N?_ 23_"O3=/O(M1L
M;>[@):&>-98V((RK $''T-6:*_/3_@GO_P GI?M?_P#8QM_Z77M?H57R!^Q7
M\5O%WQ"_: _:@T;Q%KUWJ^E^&O%"6>D6MP04LH3/>KL3CIB-!S_=%/\ VWOB
MIXM^'?Q@_9FTOPWKMWH^G^(_&L&GZM;VQ 6\MS<6JF-^/ND.X_X$:XJ]USXR
M_%[]N#XV_"[P[\0[KPAX)TNUTBXFOH8DFN;!'LH':&S4\)),[N3(V=H0X&2*
MS/C%HWQ)_8;\;?#7Q;I7QB\6?$'P3XA\46OA[6=!\;W0OW G#L9(9/EV86.3
M 4##*N=RDK7H?QN\5_$;X\?M*-\#_A[XNG^'>@>'=-@UGQ7XFT]0U_)YS#RK
M2W)_U9*'=O![\_=VOXC^V9X9^.7[&?PAN]?\#?&OQ5XK\)WEQ!:7A\53+=ZI
MI<I?<L\-UP2CD>64*X&\=<Y7]+Z6OST_8>_Y2"?M6?\ 7Z?_ $J>O=?^"BWQ
M$\2?"O\ 9)\7>)/"6L7&A:[:SV*P7UH0)$#W<2. 2#U5F'XUR7_!0;XS:]\-
MYOA5X:LO&<WPS\,>+=7FM-<\:6MOYLVGQ1+&R1H?^69D+-\^/E"$DX# X/@O
MX4^/]#\7^$_$OP/_ &C[WXP>&TU)(_$ND^,/$46K6YM&&7>*:)6,;@#Y5"YR
MRG.T,#2_:\^,&I3?M4>$OA1KOQ7O?@A\/+O0FU5_$6F,+:XU&\,K1BV^UM\L
M"JJEMS8&00<EDQVOP,^&/Q+\#_%;1=3\'_&R7XQ?!2_M9H]3/BC55U&]M9U!
MV-;W,8(D8N0""5  <$$[2)?V3/BAXK\;_M/_ +4'A_7=<NM3T;PWK&G0:19S
ML"EG&_VO>J8'0^6G7^Z*M_MK?$SQ1\/O''[.UIX<UNYTFU\0?$'3]+U2.W8
M7=J\J!XGR/ND$UY_\9_C3K7QE_:2\2?"C2?BY9_!;P3X,M[9];UI+J"WU+4[
MN9=XM[:25QL1$ZLHR&4[LY6N1\5_$#4/V/-2T7QEX8_:,E^,O@+[;;V7B#PK
MXGUVVU/4HH)9 INK:97W%D++\FWH3DD?=_12.02QJZG*L,@T^BBBOAGXQ_\
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MQA1TQW.2=S_A6?@__H5-$_\ !=#_ /$UT%O#';PQQ1(L44:A41%PJJ!@ #L
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M Y)'HY'C'_!2K]MSX>_%[X!W/@;X;ZE)XREN[JWN]6U"RM)EMM-MHY5*%W=
M-SR^6H XZY()4']2!2U^>G[#O_*03]JS_K^/_I4]>I_\%5_^3'_''_7SIO\
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MD?$7P+_:>H_V!I)\/V\^R&YDD)=D9@J$J).O/H*[+X?ZGXXO[J[7Q;H^GZ9
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M****************2O'/&GC[5/'NMS^#/ <H\U1C4]=5CLLTS@JC \N?4'U
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M?M9N?$.FI;0R+O5=J,LC9;Y@<8Z \U[-11111111111111117FWQD_: \%?
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M)O\ *C1WFC+N?,=G?RUR2..*_6V"83PQR $!U# 'KR*EHHHHHHKX7_X)"?\
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M:>$_$%EXCT^/26BA7S[576*)PT;#RL2'*KM/ PPKTQLGI7B?PY_9#\!?#O\
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M#PS9^&]/E823+;[GDG8# :21RSR$#C+,3R:[ZOA?_@D)_P D%^(G_90=1_\
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M^&SP>WIZUU>ZEHHHHHHI*\O^)?Q0O+/4T\)>$(?[0\770 )"[H[)#UDD/3<
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M=_'"/]H;]G7P?XQ:83:I+:BTU0< K>Q?),2!TW,-X'HZU\N_L%_\GU?M:_\
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MILW#'9C7I6C_  P_:AU+4RDGCKP+\-]&D?<]OX6T1;KRL1[1LCGC^8,0,[I
M1SC@!:X3XJ?\$ZO$GC#P/<M<?%WQ)XU\56BI)81^(KAVLRP!\Q,.\C(6R-K!
ML+@@[LY'SQ\(_P#@G+\4O%7C:VM?&&C?\(EX<AE)O;Z:YAF=U4KF.)(W8LS
M\/PH 8Y)&T_:O_#N'X&;?^1=O_\ P:W'_P 72?\ #OWP+IO[KPWXL\?>#K#[
MS:?H6O&.!G/60B2-SN(P#S_".*7_ (8+T3_HK/Q7_P#"DC_^,5FR?L2>*HY'
M2Q_:)^)5K9*Q$$#ZG*QCC'W5)$B@X&!D*.G0=*FL?V._B%H=Y%?Z9^TCX[%_
M =T/]ILU];YQCYX))MD@Y/##W[5OCX(_'['_ "<J?_"%T_\ ^+K.UKX3?M-:
M7#&^A?'71_$%PS;9(=:\+V]C&BXSN5HED);/&" .<UE?\(%^V%_T4KP)_P"
M+?\ R+4FJ1_M@:/X6U"TBF^&VNW45M-LOXEN8[V9BK%?+4[(1("0J[E"Y5=W
M<U^26I75W>ZC=7&H2S3W\TK27$MRS-*\A8EF<DY+%B<Y/4FOV5_8+O?$5]^R
MWX-D\1,KNB2Q6#EV:4V2R,L(?(X( VJ%R-BQ]R0/H6BBBBBBBBBBBBOG7]I2
M^ATSX@> +RZ?R[>WG\V5\$[56:,L>,YP >V:] _X:,^'G7_A(?\ R2N/_C=>
M6:1XJTSQE^U1I.J:/<_:["2%U67RW3)6TD!&& /!KZ<I:**_.G]@;4[+3/VS
M_P!KPWEW!:!_$CA3/*J;L7U[G&3[BNS_ ."K'B;P'<?LJZS!=:AH]QXPDN[(
MZ J21/>K*+J(RM#C+@>2)02..0#UKAOVN_%GB[Q)^S5\ /@-</=/\1/B3%I5
MKK+2[GGABA2%KAY03NSYI5F+=HY<]Z[31_\ @FYXRT'2[33-,_:F^*6FZ;9Q
M+!;6=IJ,T4,,:@!41%G 50      *YG]B?3KS]D7]J[QY^SIJ^N7.LZ1K=I%
MXE\/7]TFUKB7R_\ 2"1D_,RJP/.#]E)ZFH/V&=4L]-_;H_:R:\NX+17UE@IG
ME" D7EQD#)K] (_$VD7$L<46JV4DCL%5$N4+$D\  'DYK4I:************
M**********\^^//QDT?]G_X2>)/'VN1RSV&C6_F_9X1\\\K,J11*<<%I&1=Q
MX&23P*^5?A[^W=\2]-\:?#,?%WX=Z/X9\$_%&5(_#&IZ/?-//;&01F%;I23N
MWF6/Y@(\!\X^5L?==?&/P'_Y28?M._\ 8*T#_P!(;>OLZBBN:^(/ABY\9>#]
M3T:UOWTV>[BV+<)GU!*G!^ZP!4CT8UX5IOC@>#_!5Q\.[_P5Y_BGFVALTAW6
M][NSBX8YR<;03CKM&"O.SU_X,^![_P"'_@6VTK4;O[3<^8TQ122D&[!\M3GH
M#D]AEC7=T444444444444444A&:S=:\.Z7XDM1;:KIUKJ, .X1W4*R -@C<,
MC@X)Y'/->,_%+]F?2]2TF6Z\(6HT_5D8R&U\X^3<@G)4;C\A'\."%[$=QY[^
MSW\,?$MUXPCUK?<Z'8Z;,8YY'0JTY5L/ %/N"&R.,>O3ZY6G444444444444
M4444444444444444444445Y+^TE^TEX7_9A\"1>)/$D-[J$MY=II^FZ5ID7F
M7-]<N"5C09P.%)))QQCDD \9^SC^V;IGQW\9ZSX%UGP=KWPX^(.E6HOI_#WB
M"$J[VY*@2(V%)QO3(95^^",C./HVOA?_ ()"?\D%^(G_ &4'4?\ TELJ^Z**
M*^:/VU/BUXI\ Z7X1\->#K&TU37_ !?>2:=;V-S'&_G,-@ (D^4)F0;B<8^7
MYE&:\$\;?!_X_P#P&\*6WQ N/$7ASQ+::#']LNM'1"/[/4.2QMS(FUP =Y+#
M(8 JK8Y^V/@CXXN/B5\)_#'BBZ"B?5+-;AMB[1R3@XSP2 /Z8KNJ******RO
M$VI2:-X=U74(0C3VEI+.BR E2RH6&<$<9 [U\N?\-<>,/^@;HG_?B;_X]7KG
MPA^-UOXP\-W-[XEU'1M(OX[MH4@$X@W1A$(;;(Y)R6;D'M[5W?\ PL3PI_T,
MVC_^!\7_ ,51_P +$\*?]#-H_P#X'Q?_ !5'_"Q/"O\ T,VC_P#@?%_\52'X
MB>%/^AFT?_P/B_\ BJYGQI;_  H^(UO%!XI_X1'Q#'"&\G^TVMK@Q;@ Q0MD
MH2 .5P>!Z5XCJG[(GP%/B0:_X8\67?P^U9=S)<^%/$R6S1LVX.R;R^S<KE"J
M87;P .<X5MX?^-WPNMQ_PB?[0?A'X@VRH[O8^,F6.0L NT)*'D<DA2N&D5?F
M)ZG(N6G[:_CKX?\ V*W^)GPOCO8W:59=7\":K!J*-M8[2ML)&:,$&,?O)03\
MS <%1\T?M/?MM:7\0O$T-YX(TI0GDHAO-2@=)=IC!,;H)2I=7+?,HQ@#[W:]
M^RI^VQHG@'Q!>7GCBV6UWVS0_:K""25I%R&"JF_ 8LJY+<<'&WO]%:E^WEXC
M\7Z?]I^%WP5\7^*+*8-]GU:[L76VD"L%8J(@P;#!UX<8Q[$51UJ3]L;XA3JL
M&C>'O =F\BQ^5)J,;NG/,IDA9FVX8\<GY,X)P3FG]A?XN>.&^W>,_C3'9ZG+
MN,JZ78/<@$':H$SO$[C8%^\.,8YQFN[T[_@F[\*%U&.[UR\\4^+Y%/(UK5R=
MZXP$+0I&V >>&'/MQ7J7AO\ 93^$'A*. :=\.?#VZ *(YKNQ2ZE4KR&WRAFW
M9_B)S[UZLL81<* H]ABGT44444444444E>:^(/V;OA?XL\32^(-9\!Z'J>L3
M.))KFZLT<RL  "ZD;6X4?>!_6O18(4MXTBC18XT4*B(  H'  '88J:BBBBBB
MBBBBBBL7Q!X1T7Q9'"FL:7:ZB(23%]HB#%,@9P>HS@9^@K'_ .%.^"?^A8TW
M_OP*O:)\//#?AN^%[I>B65C=!2@FAA ;:>HS724445\U>+_^"<O[/'CSQ7K'
MB37?A[]NUO6+R6_OKK^VM1C\V>5R[OM2X"KEF)PH ';%:OP]_8*^ 7PMUBVU
M;P[\,]+BU&VF6XM[F_EGOVAD4@JZ?:))-K*0"",$$9&#7>7_ , _ NJ?&33O
MBM=Z']H\>Z=9FPM-6>]N#Y,!5U*+#YGE#B63G9GYR<UZ'7GOC#X!^!?'OQ&\
M+^/-:T0W'B[PP3_9.JPWEQ;RP G)5A%(JR(<M\L@889AC#$'R_QG_P $Z_V>
MOB%XLUCQ-X@^'W]H:YJ]U)>WMU_;6HQ>;-(Q9VV)<!5R23A0!4?A/_@G%^SO
MX'\5:-XCT3X>_8=:T>]AU"RN?[;U&3RIXG62-]KW!5L,JG# @XY!KZ6I:***
M*******************^3_\ @J+HM[K7[$_CL6,4LSVKV5W*D*ECY27<1<D#
MLJY8GL%)/3-?*'[0/B#2OBIX!_8:\,>$]8M=5UXS:8DEMITZS3VNR&S1VD1#
MN0(ROG<!CRV_NG'WG\:_^&BO^$HM?^%1?\*P_P"$;^Q+]H_X37^T?MGVK?)N
MV?9OD\K9Y6,_-NW]L5\Y^$_V?_VO/!OQR\=?%6RO/@I+XA\8V]I;7]M/+JYM
M(UMXDBC,2B,."0@)W.W).,5Z=_QF]_U;_P#^5RC_ (S>_P"K?_\ RN4?\9O?
M]6__ /E<I/\ C-[_ *M__P#*Y7D7B7]HC]K#PW^TGX2^#]YI?P2E\8>(M,EU
M.RU"*WU9K2*&-9RRO(9!(&(MY.%0CE>>N/7O^,WO^K?_ /RN4?\ &;W_ %;_
M /\ E<H_XS>_ZM__ /*Y1_QF]_U;_P#^5RC_ (S>_P"K?_\ RN4?\9O?]6__
M /E<H_XS>_ZM_P#_ "N4?\9O?]6__P#E<H_XS>_ZM_\ _*Y7GWQZ^-7[87[.
M_P )]=^(/B.U^"%]HNC^1Y\&EQZQ)<-YL\<"[%=T4X:52<L. >O2NXT^]_;9
MU*QMKJ(? )8YXEE4.-;SAAD9P>O-6?\ C-[_ *M__P#*Y1_QF]_U;_\ ^5RC
M_C-[_JW_ /\ *Y1_QF]_U;__ .5RC_C-[_JW_P#\KE'_ !F]_P!6_P#_ )7*
M/^,WO^K?_P#RN4?\9O?]6_\ _E<H_P",WO\ JW__ ,KE>6?L^_M#_M=?M(^'
M=?UGPS9?!6QM=$URXT&X35HM7C=KB%(W=D$<C@H1*N"2#P>!W]3_ .,WO^K?
M_P#RN4?\9O?]6_\ _E<H_P",WO\ JW__ ,KE'_&;W_5O_P#Y7*/^,WO^K?\
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MU1_T:]X#_P#"B7_Y.H_LC]JC_HU[P'_X42__ "=1_9'[5'_1KW@/_P *)?\
MY.H_LC]JC_HU[P'_ .%&O_R=1_9'[5'_ $:]X#_\*)?_ ).H_LG]JC_HU[P'
M_P"%$O\ \G5Y9\=OV2_BSJWA?5?BKKW@S2_"%Q9Z?-?:WHFGZC%-%:PVR/F6
M-O.<OF&-6*@DYSC^[5[]F?\ 9X^,'@CP[H_QC\$^#-(\8ZI?6<=SHFFZG>PQ
M0F*;!\]]TB;7"$,HSD9YYXKZ$_X7)^W-_P!$!\%_^#Z'_P"3*/\ A<G[<W_1
M O!G_@^A_P#DRC_A<G[<W_1 ?!?_ (/H?_DRC_A<G[<W_1 O!G_@^A_^3*/^
M%R?MS?\ 1 O!G_@^A_\ DRC_ (7)^W-_T0+P9_X/H?\ Y,H_X7)^W-_T0+P9
M_P"#Z'_Y,H_X7)^W-_T0+P9_X/H?_DRC_A<G[<W_ $0+P9_X/H?_ ),KCOA[
M^U]^UY\5+CQ1#X9^"G@W4)/#.LW&@:H&U98O(O82!+$"]T-P&1\RY4]B:['_
M (7)^W-_T0+P9_X/H?\ Y,H_X7)^W-_T0+P9_P"#Z'_Y,H_X7)^W-_T0+P9_
MX/H?_DRC_A<G[<W_ $0+P9_X/H?_ ),H_P"%R?MS?]$"\&?^#Z'_ .3*/^%R
M?MS?]$"\&?\ @^A_^3*/^%R?MS?]$"\&?^#Z'_Y,H_X7)^W-_P!$"\&?^#Z'
M_P"3*/\ A<G[<W_1 O!G_@^A_P#DRN#U[]M+]K/PW\6/#7PUU'X+^#H/&7B.
MWFNM,T\:H&$\<22/(WF"ZV+A8G.&8$XX[5WG_"Y/VYO^B!>#/_!]#_\ )E'_
M  N3]N;_ *(%X,_\'T/_ ,F4?\+D_;F_Z(%X,_\ !]#_ /)E>E_L^?$#]I7Q
M/X[EL_BW\+O#O@WPL+*21-1TO5([B4W 9-D95;A_E*ESG;_".:^DJ*******
M****************************************K7UC;ZI9W%G>6\=U:7$;
M136\Z!XY$8$,K*>"I!((/6O*OAK^R7\'_@_XNN_%'@_P!I&AZ]=,Q-[ C,T.
MX8980S%85(X(C"@Y/'->O444445Y)XC_ &;/#/BC]HSPK\:+N_U:/Q1X;TV7
M2[2TAFB%D\3K.K&1#&7+?Z0^"' X7CKGUNBBBBBBBBO/?CU\%=$_:(^$^N?#
MWQ'=:A9:-K'D>?/I<D:7"^3/'.NQG1U&6B4'*G@GH>:[C3[---L;:TC9FC@C
M6)2_4A1@9Q["K5%%%%%%)1FO+/V??V>?#G[-_AWQ!HWAF]U2^M-:URXU^X?5
MI8Y'6XF2-&5#'&@$8$2X!!.2>3Q7JE%%%%%%%%>5ZI^SSX<U;]HK1_C/->ZH
M/%&EZ&V@0VD<L0LF@,DKEV3R]Y?,S<AP, <>OJ8I:******3(KS;]H+X#Z!^
MTE\+M3\!>)KS4K#1[^2"66?298X[@&*59%VM(CK@E1G*G@]J])S2T4444444
M444445YQ\=?@'X-_:.\"R>$_&^G-?::9EN898)3%/;3*"%EB<<JV"P[@AB""
M#7)?L_\ ['O@7]G77-9U_1KC7/$7BG6(U@O?$/B>_P#MM])$I&(]^U0%^5>B
M\[%SG:*]SVBEHHHI*\>^%7[/O_"L?C;\7OB#_;W]I?\ "P)M-E_LW['Y7V#[
M+#)'CS/,;S=_F9^ZN,=\U[#2T444444E>$?M!?LP_P#"]OBA\'?&'_"2_P!B
M?\*\UAM6^Q_8/M'V_=);OY>_S4\K'V?&[:_W^G'/NPIU%%%%%%%<E\6/ O\
MPM#X5^,?!OVW^S/^$BT:\TC[;Y/G?9_M$#Q>9LW+NV[\[=PSC&1UJM\&/AT/
MA#\)?!_@G^T/[5_X1_2[?3/MWD^3Y_E1A-^S<VW.,XW''J:[:BBBBBBBDKR'
M]G_X!_\ "B[[XF7/]N_VW_PFGBZ^\5;?L?V?[']I(/V?/F-YFW;]_P"7.?NB
MO7Z*******3->'^./V:/^$S_ &J?AQ\9O^$C^Q_\(?I]Y8_V)]AW_:_/BGCW
M^?Y@\O;Y^<;&SMZC/'N&:6BBBBBBBBBBBBBBBBBBDKG/#WQ&\*>+M<UC1]#\
M3Z-K.KZ-)Y.IV&GW\4\]C(&9=DT:,6C;<K## <J1VKI*********X3QE\=OA
MK\.]8&D^*_B%X5\,ZKY:S?8=8UJVM)]C$A6V2.K;3@X.,<&L7_AK#X(?]%D^
M'_\ X5%C_P#':V/#OQY^&GBZTU>ZT+XB>$]:MM(MFO=1FT[6[6=+*W4$M+,R
M2$1H "2S8 P:ZS0M>TSQ1H]GJVC:C::OI=Y&);:^L9UG@G0]'1U)5@?4&M&B
MBBBBBBBBBBBBBBBBBBBBBBL#QYXJMO ?@?Q#XEO0&M-%TZXU&8%MOR0QM(W/
M;A3S7Y=Q?'3]I6S_ &=;/]K"7XG6USHTVK>7+\/_ .R56P%G]L:VPK[BW^L&
MWIOP0?,)XK]3/"GB2Q\8^%]'U_3)1/IVJV<-];2J<AXI4#HP^JL*UZ******
M*^4/^"@/[5EU^S]\,Y-"\($W7Q*\06=T^G0V^'DL+6&)Y+F_93VCC1RN>K G
MD(PKHO\ @GGX[\0?$S]C_P  ^)?%6KW.NZ]??;_M.H7C;I9=FH7,:;CWPB*O
MT KZ-HHHHHHK'\7>(!X3\)ZUKAT^^U5=,LIKTV&F0^==7/EQL_E0ID;I&V[5
M7(R2!FOS_P#"_P"TY\:/&7_!1#X4^&/%>DWGPW\'ZYH]WJ-MX.DN!)--;_9+
MWRY;S'24RVY8)@; J C.2>A^+7Q*^*_[0G[:6O? SX=_$5OA7H_A'0EU6]U.
MTT]+R>]N#]G;:V64JH^TQKM##HY.[("^G_\ !/;]HKQ)\??A1KEMXVG@O/&/
MA+6)=%O[R!%3[6%4%)RB@!6/SJ<  F,GC.!]44444445^?\ _P %(/VGOB[\
M/?"?B72_ /AG4_"F@Z/=V,-]\0)Y1%]HDF595@L%ZN 6"R2<@;73 )!/9?M)
M?M,^*?A5^S/\((O#NK6UO\0_B"-+TNVU;4@KK;&6",SW;!OE)5G3[PP#)D@X
MQ4O['&I?%"'XJ>*-*U'XW^%_CM\.H;5635;.ZM_[1M+QBIP8H7?;$?WJX=SR
MBE=OS _9-%%%%%%>'?M:2?&B;X=VFG?!"UMQXEU"^C@N]5N);=3IUI@[Y428
MA7?.T#K@;N,X(^>?V<?B+\6_A?\ MJ:I\!?%_P 09/B]H@T'^UGU>>QCM[C3
M),*PWD,S;3N52K,W,D1&T9SYC^VQ^W1XSN/CMX9\)?##5+[1_!^B^((=(UC7
MK'*QZCJ!=?-M%?'*Q(<$*>2YSQL)_42EHHHHHHHHHHHHHHHHHHHKQ7]L+X^O
M^S1^S]XF\=VMM#>ZK:)';:=;7 )B>YE<1QEP""57<78 @D(0"":^9_"7[1'Q
MX^"7QD^"^C_%_P 0Z+XQ\/?%A-L$.GZ<EI+HURWDA8E957S%5IX@2^2=S8Z#
M/Z TM%%%%%%%? 7_  4H_;LU_P" \=OX(^%]W]G\:HL5_K&K1VT=RFDVK'$<
M;)(CQ^9*Q'WONKCC,BD?:?PMUB\\1?#/PCJVHS?:=0O](L[JXFVA=\KPHSM@
M  98G@ "NJHHHHHHKS7X\?&A/@?X-M]73POKOC+4[^]73=.T3P]:F>XN;EXY
M)%!_N1A8G+.<A0.AZ5\W_P#!/#]I#XF_'SQU\=+/XCW4<;^'-5M;>RT6*& +
MI>^2\62 2QHIF"F%%WNS$[,@\G/FNJ_M0?M$?%O1?C#\6/AIKOA[0OAQ\.=0
MN;6VT*[TY;B368K9!)<223$;DQ$1( C+G>%[;C]Q? +XK0?''X->$/'<%L+,
M:YI\=U);*^X0R_=DC#=PKJPS[5Z%11111534K^/2]/NKV;=Y-M$TS[%+':H)
M.!W.!7Y^P?MT?$?X@?ML?"CP9IN@:I\/_AQKB3R_8M>L(H[[6X=DX6X=74O!
M'OA^14()P220P"^H_M6?M$>.=,^-W@[X)_#35M+\):YK6FW&LZKXNUFU6X@T
MFSC60JZHQV9)B?F0%<E!W)'HG[(OB;XL^(_ FHGXL#1-3NX+UDTCQ-X?N8);
M76K+HMP%A=E4DJ3T7AE^4$-7O%%%%%%%?*GQ^UK]H[QE\;K7P+\*9+;P!X/A
MTO[==^.M2TR.\66Y!_X]XP^Y0,,@^9,_ZP@_**3]@']J7Q#^T9\'/$&L>.8;
M&UU?PSJDVFWFJ6@\JVND2-9/-()PA 8[L'' /&<#PWX9_M[>./C9_P %!O"'
MA'0;F32_@WJD=^+&VFTZ-6UF*"UO"+T2R)Y@4W%NP&QE&(MK#=OS^CU%%%%%
M%%%%%%%5[R\@T^UEN;J:.WMXE+R2RL%5%')))Z 5\[>(/VG=5?79KWP]HIO/
M"5@Z)=7$T+[I-Q(SN!Q&&Z*&&?7KM'N?@_QAI?CC08=6TBX\^UEX((P\;#&4
M=>S#/Z@C(()W:6BBOST_X)[_ /)Z7[7_ /V,;?\ I=>U^A=>2_!W]I3PS\;O
M'7Q*\*:'8ZM::CX!U,:5J<NH0Q)#-*7F0- 4D8LN8'^\%/*\=<+\9OVD/#/P
M-\6_#GP]KUCJUW>^.M931--DTZ&-XXIFDBC#3%Y%*IF9>5#' /'KPWC_ /;O
M\"> ?B=XQ^';Z)XHUKQKX=^R+'H^CZ<MU-JKW%N+A5M$20NP2,Y=G5%7U.1G
MF_AW_P %!=,UOXA:)X-^(7PT\9?"+5/$%S]ET:X\3V+16U[)D!8]Y"E78LHP
M%(RP&[D9]'_:(_:O\+?L\SZ-I-UINK^+?&6M[O[+\*^&[7[3?W*K]Y]F?E0$
M'YCR<-@':<>,WG_!4#PKX%\-W-W\3_AGX^^'.N1J)+;1-2TP"34(S(J%K:25
MHE<IO#,K;<#.-U?:M%>6?$;]E_X4_%WQ%_;WC+P'H_B/6/)6W^V7T.Z3RU)*
MKG/09/YU\#_"W]FGX7:Q_P %2/C!\/[SP/I%SX,TKPM!>66BR0YM[>8Q:63(
MJYX),\O?^-J^U=2^!_P8_9V^&/Q%\06'P]T_3]"_X1^\DUZUTNV'F7]C'#))
M+!M9@&W(& !8#GDCK46C_M"?##X7?LI^'OB3:V5UX:^'G]FV[Z7I*VR_:0LA
M"PVR1([#S"3C 8CJ2< FO*!_P4C7PY>?;/'WP-^)7P_\&O-'$GB;5=)?R(MY
MVAIUVC8,D?=9SSP#7NGQY_:8\*? /POHNJ:A;ZEXDO\ Q!.MKH>B^';;[7>:
MI(5# 0J" 0 02V<<C&20#Y%X$_X*$V=]XTT/PW\2/A5XW^$<VOW@L=)U#Q'8
M,ME<S,0$C:0JI5F) X4@9Y8"O<X/CIH-Q^T!/\'UL]1'B:'PY_PD[71BC^Q_
M9C<+;[ ^_?YF]@<;,8_BSQ4WQ[^->B?L[_"?7/B#XCM=0O=%T@P>?!I<:27#
M>;/' NQ7=%.&E4G+#@'KT./\>?VEO!_[//AG2M4\1_VA>WVLS?9M(T/2+4W-
M_J,V ?+BC!Z@$99B "RC.64'Q70?^"BMEI^L6T7Q,^$?C[X3:'>W2VMKXA\0
MZ6XL=S'"><^U?*)YZ!@,9)QR/L".1)HU=&#HPR&4Y!'M4E%%%%%%%%%%%%%%
M%<A\7O![_$+X3^-/"L9 ?7-$O=,4EL &:!XQD]OO5^2@^*$U]^P78?LJ1>&-
M>/QG_MPZ;)H#:;*&BB_M-KS[0SXV[,GR^N<@G&WYJ_7/X9^#8?AS\.?"OA.W
M<R6^@Z5:Z7&Y).Y8(4B!Y]D%=/11111117YK_M!_L[?M!>%M8_:,^*DE]\-]
M=T77?#^K68FU:XU*34M-T!893]GM$5%ACE,(4G.Y3("<X9B?4O\ @DQ_PF__
M  R?H']N_P#"/_\ "&?O_P#A&_[.\_\ M'_C_O/M?VS?^[_UNWR_+_ASNYK[
M6HHHHHHHK\__ (R?\ID/@5_V)ES_ .B=9KG_ !AXJL/V/?\ @I+XX^)GQ MM
M0L/ WC3PR+?3]8M+.6YC:X46>82(U.'+6I4 _P#/1"<!LCT3_@E?\-=9\,_"
MKQIXSUS2KG19?&_B&;5+*TO$9)?L@&(W9#TW,TF/50IZ$5]N4444445\6?\
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M4.\"V_@(>!W\0VOP],^C+X_:Z-H)&N9!<-;"W^;[08AZ8\L2YZ"NL^,_@_\
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M(5:*8KIQ+&4+O;_CYFX+$?-[##OV,?V@O'/Q>_: _:4\,>*=6CU#1O!GB/\
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M?[8T_P "OC'=^'_$<^K::^K:=J7AVV:!+4A&E$7S!2R;8Y!\P+9"_,036=\
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%***__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>smafibroblastdata.jpg
<TEXT>
begin 644 smafibroblastdata.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /F O4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIEM<>)H(YXK=$=##+PP4 C[E 'K]%06-]!J5G!=VT@EMYD$D;@$;E(R#S4]
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MK/V*?^31_A#_ -BQ8_\ HE:Y/_@I'_R9)\4O^O.V_P#2R"NL_8I_Y-'^$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5\>/VF/AAX.\!6LG@_P'>>+])M;J6;:VH:E"U[$K)(1E8HV4X*(22,@N02M
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MP444 %?/7[0/[!GP<_:2U5M9\5>'9+3Q$ZA'UK1IS:W,@ P/,P"DA   +JQ
M  ..*^A:* /AOPM_P1U^ ?AW5H[R]E\5^)(4;=]AU35(UA;V/D0Q/C_@5?9_
MA?PMH_@GP_8:%H&F6NCZ-81"&UL;*(1Q0H.RJ.!Z^Y)-:M% 'C_P4_9?\*_
M?Q]\3O%V@7^L7FI?$'4QJNJ1:E-$\,,HEN)=L 2)"J[KJ3ABYP%YX)/L%%%
M'SOI_P"PO\-]&_:B3X\:;)J^G>+1)-/)I]M/"NFRS36\D$LK1F(ON99&8XD
M+\XY.>C^&?[*WA/X8_&[QW\5K74-9UCQ=XO^2[FU:>&2.UBWAO)MPD2%4PD2
MX8L<1)SP2?9:* "N,^,GPFT'XZ?#+Q!X$\3),VBZU;^1.UJRK-&0P=)(RRL
MZNJL"01E1D'I79T4 <9\'?A?8_!7X9>'_ ^EZGJ>KZ;H=O\ 9+6ZUB6.2Y,0
M8E$9HT12%!"+A1\JKUZUV=%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UJ*&HH _
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M=-(^-4>FS1>'9M)U*SW)]H:Y60/&>=I&T=#DCZFO&Z^P_P#A@FP_Z'*X_P#
M!?\ XY7SC\3?A;J/PY\?7'AA]][)YBBUE6,@W"M]P@<\G/0$X/% %?X5^+M,
M\">-+'7=4TM]8CLR9(K59!&#)_"Q)4].O3KBOI;_ (;VL/\ H3;C_P #U_\
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M(JA(N.H'KTZG.*_=C1_#MC'X)L]#:VC_ +.^P+:-;J!M,9C"E<>F,T ?$_\
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M^(VI^'I!/I.AZ<A6PBF!#+(V4C7 95;8L2[BJ[B0-I^Z** /E_\ X*%_LO\
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M[/OB[0+_ $>STWX?>(#JNJ1:E-*DTT1N;*7; $B<,VVUDX8H,E>>21]0444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?$W_!13Q)NNO"6@*^-D<MZZYZ[B$7/_?!_.OMFOS3_ &W/$G]O
M?';4K=6W0Z=!%:I[$*&8?]]$T >Z_P#!/+PW]D\%>(];==K7EXMNA]410?\
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M?X0_]BQ8_P#HE: /:J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO9U90,[>'4#^)17F/ACQ)IOC+_@I1I/B#1KI;[1]6^+<-_972J5$T$NLAXW
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M96P^IW4-IM[E<ES_ .@#\Z^;?V!_#?\ :WQ?N]3=-T6FV#D'T=V 4_D&KO\
M_@HIXD(7PEH*-C_6WDB^H.%7_P!!;\ZU/^"=_AO[/X5\4:ZRX:ZNDM5/JJ+N
M_FYH ^OJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_AQX5^&6KW5C+'=6]]H6G6,L]I*C!D<%%WQ.K $'@@@=#0![Y1110 4444
M%%%% !1110 4444 %%%% 'S3_P %(_\ DR3XI?\ 7G;?^ED%=9^Q3_R:/\(?
M^Q8L?_1*UR?_  4C_P"3)/BE_P!>=M_Z605UG[%/_)H_PA_[%BQ_]$K0![51
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!^;7[<GB0ZY\=+NT5]\6F6L-LOL2N]A_WTQKZ[_8]\-_\(Y\
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M_P#HE:Y/_@I'_P F2?%+_KSMO_2R"NL_8I_Y-'^$/_8L6/\ Z)6@#VJBBB@
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MN4 ?-/\ P4C_ .3)/BE_UYVW_I9!76?L4_\ )H_PA_[%BQ_]$K7)_P#!2/\
MY,D^*7_7G;?^ED%=9^Q3_P FC_"'_L6+'_T2M 'M5%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#@I'_R9)\4O^O.V_\ 2R"NL_8I_P"31_A#_P!BQ8_^B5H ]JHHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** &M10U% 'RO_P]&_9B_P"BF?\
ME U3_P"1J\6^/W[0G[!?[2XBF\<>)8[K584\N'6++1=5MKV->R^8EL-ZC)PK
MA@,G KS[_AQC_P!5L_\ +4_^[:/^'&/_ %6S_P M3_[MH \ZL?A=_P $ZK/4
M%N)?C!XTO80<FTGM+P1'VRFG*^/^!5]F?L[?M9?L?> #HGPZ^%'B"STJ;6+^
M&RM;.WT/4EDO+J5UCC\V>6#+,695WR/P.X KYX_X<8_]5L_\M3_[MKJOA/\
M\$:_^%7_ !4\&^,O^%O_ -I_\([K5GJ_V+_A&?*^T?9YTE\O?]L;;NV8W;3C
M.<'I0!^E5%%% !1110 5\)_MA_\ !+'PS^T-XIN_&?A#68_!/BR\.^^B>V\V
MQOI.\K*I#1R'^)ER#C)7))/W910!^.O@W_@B5\1KK6HU\6>//"^FZ0&!>71A
M<WEPRYY 22*)0<=]QQGH:_3W]GG]G?P=^S+\.[7PAX-LVBM5;S;J\N"&N;V8
M@!I9F &6. .       !7IM% '@G[7/['?A']KKP;!IFN2RZ1KFG[GTS6[5 T
MENS#E74X\R,X&5R#QP1SG\YI_P#@B7\5%U_R8?'7@^31/,Q]LD:Z6YV>OD"$
MKGV\W\:_92B@#YX_8[_8M\*?L@^$KFTTRY;7/$NH[3J>NSQ"-I]OW41,G9&,
MG"Y)Y))-?0]%% 'S3_P4C_Y,D^*7_7G;?^ED%=9^Q3_R:/\ "'_L6+'_ -$K
M7)_\%(_^3)/BE_UYVW_I9!76?L4_\FC_  A_[%BQ_P#1*T >U4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y-_M">(
MCXL^-'BR_0^9&U_)%$1SE%.U?T K]3?%VM+X;\*ZSJS$*+&SFN,G_80L/Y5^
M4'PWTI_&WQ9T"S(,IOM4C:3=SE?,W-_XZ#0!^I7PH\.CPG\-?#6D;=IM+"&)
MOJ%&3764R&,0Q)&OW54*/PI] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 UJ*&HH KZIJ=KHNFW>H7TZ6ME
M:0O<3SR'"QQHI9F/L "?PK\3_P!HS_@J3\6_C)XXN=&^%E[>>$/"[3F#3[?2
MH VIWPSA7>3!=6;J$CQC(!+$9K]COBWX.F^(GPI\9^%+:<6MQKNBWNEQSMG$
M;30/&&./0MG\*_*#_@E+=^%/@7^T1\0O"WQ0BM?"OQ"6"*PTMM:*PF)E=_M,
M*.W >0& K@_.JG!(/(!X1)\1/VS?!MNVOWFI?&6RL8AYK7>IQZDUJJ@9R?-4
MQXQZC%?:O_!/+_@ICKWQ=\;6/PQ^*K6]UKFH*RZ1XA@A6 W,JJ6,,Z* @9@#
MM=0H)&TC)!K]%]<\7:'X7TF35=8UG3])TR-/,>]OKI(857KN+L0,?C7XH>"M
M-T+XZ?\ !5:PU+X3V87PG%XJM]:66TA,<(@M1')=3XP-J2R1R$9QGSE'4@4
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M_8L6/_HE: /:J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQSCDGDU]N?\ !-/_ (*)>)_BSXTB^%7Q/O4U;5[J&231=>:-8YIFC4N]O,%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7Y4_M/>)/^$H^.GBV[#^9'%=FU1NQ6,;!C\!7ZD:[JB:'H>H:C)_J[
M.WDN&SZ(I8_RK\D?#-C+X\^*.FVLA,S:IJJ+(3W5Y1N/Y9H _4/X'^&_^$1^
M$OA72RFR2"PB\SC^,J"Q_,UW-16L(MK>*$=(T"#\!BI: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% 'S3_ ,%(_P#DR3XI?]>=M_Z605UG[%/_ ":/\(?^Q8L?_1*UR?\
MP4C_ .3)/BE_UYVW_I9!76?L4_\ )H_PA_[%BQ_]$K0![51110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y5^U%XD_X1CX$^*[E
M7VRS6XM8^<9,C!2/^^2U?#7[&OAO_A(OCYH;%=\>GQRWKCMA5VC]7%?27_!0
M;Q)_9_PUT31U?:^H7YE('4K&O\LN/RK@/^"=WAOSO$'BG773B"".UB;W8EF'
MY!: /N>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^B5H ]JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5\0)/'&N?#'Q\?%DC+(^JZ;X,GT^5G7I(?LUO&"_^WC<>,F@#]R%_9,^!ZJ
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M +%BQ_\ 1*UR?_!2/_DR3XI?]>=M_P"ED%=9^Q3_ ,FC_"'_ +%BQ_\ 1*T
M>U4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPWXX@U+7]3MM*M9;NPLUA26>58D9RMVQ"AG&2 3C. >E<_\ \.5/@A_T-/Q
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M^S7X9_:H^'<7@SQ9?:MI^EQW\6H";1IHHI_,C5U S)'(NW$AS\N>!S0!\_\
M[?W[17PH\9?L?_$C1O#_ ,3O!NNZQ=VENMOI^FZ_:7%Q,1=0L0D:2%F( )X'
M0&O;OV*?^31_A#_V+%C_ .B5KX,_:V_X)9?"CX"_L[>,_'OA_P 0>,KS6-%M
MXI;>#4KVT>W8M/'&=ZI:HQ&'/1ASBOO/]BG_ )-'^$/_ &+%C_Z)6@#VJBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEW_@H#XD_L
MWX5Z5I*OMDU'4 WU6-22/S=:^HJ^"O\ @H9XD^V>.O#VBHVY+*R,SCT=V/\
M[*JT 6/^"=_AO[3XL\3ZXZ_\>MK';1M[NQ+#_P =6ONVOF7]@7PW_9?P@N]3
M9,/J=_(ZMC^% $Q^:G\Z^FJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M10U% #J**^#OVL
M/^"KW@_X#^*M0\'^#M$_X3OQ-8.T%]<&Z\BPM)1P8]X5FE=3D,J@ 'C=D$
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M_L%^.;3XJ6WQG^*VG7FCFR:6YTO3M6W?;KR[D# W,Z-\R!=SL-^'9R&Q@?,
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K44-10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[7/"7B30/#NCZ19Z!/JT+Z5%<"X\Q+FVB56=Y64KMF;.%!R!R.0>_P#V3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7YB?MD>)/\ A(OCWKP5LQ6/EV:C/0HH#?\ CV:_3>XG2U@DFE8)'&I=F/0
M#)-?D-XAN9_B%\3[V49-QK&JE1W.Z27 _G0!^E/[+WAS_A%_@3X3M2FQY;47
M3KZ-(2YS_P!]5ZI5'0]/32=%L;*--B6\"1A?3"@5>H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** &M10U% %?5-/M-8TN\L+^%+BQNH7@N(9/NO&RE64^Q!(K\*OB9^S
M3\6/V2?B+<>/_@AK-_XE\$N\G]F>+O!\PO@ENQ!\B[$6X<?*"6!C?"D<_*O[
M8?&#P_JWBSX2>-]$T&46^N:EH=]96$Q;:$N)+=TB;/;#LIS7XQ?\$P_B!I?[
M._[7&K:7\1[UO!INM*NM%==68VT=O?":%U6?=@)Q%(H+8&6 SS0!\^^ ?C?\
M7O"OQ2\3>*_".K:I:^._%"W,6J7EA8H]S<?:)EGFVH(SY;-(BMF,*1C P.*^
M\_\ @FO^P7XYM/BI;?&?XK:=>:.;)I;G2].U;=]NO+N0,#<SHWS(%W.PWX=G
M(;&!\WZG:;K>G:U;I/I]_:W\+#*R6TRR*1Z@J35V@ HHHH **** "BBB@ HH
MHH **** "BBB@#YI_P""D?\ R9)\4O\ KSMO_2R"NL_8I_Y-'^$/_8L6/_HE
M:Y/_ (*1_P#)DGQ2_P"O.V_]+(*ZS]BG_DT?X0_]BQ8_^B5H ]JHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6SE\ZRL=MC$P(()08<@CJ"VXBON;]E/PW_PC/P&\*P%-CW%O]L8=\RDOS^=
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M%% !1110 445C>,/&6A_#_PY?:_XDU6UT71K*,R7%[>2B..-?<GN>@ Y)X%
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M$Q?V3? /[4'CGQBGC^6XN;7P_:V\L&BV]RUNUV97D5G9EP^R/8H(4CF5>>Q
M/?O^'YW_ %1/_P NO_[BKJOA/_P64_X6A\5/!O@W_A4']F?\)%K5GI'VW_A)
MO-^S_:)TB\S9]C7=MWYV[AG&,CK7OZ_\$M_V8U4 _#0L?4Z]J?\ \DUK>$_^
M"</[.W@?Q5HWB31/AY]BUK1[V'4+&Y_MO49/)GBD62-]KW!5L,H.&!!QR"*
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M[%/_ ":/\(?^Q8L?_1*T >U4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45X)^UE^T%'\(/"9TS2IU_X2G5(RMN%/-M&>#,??J%]^>U 'C?[;?[1'VV:;
MX>^'KK]Q$W_$VN(F^^PZ0@^@_B]^.U<K^QG^SO\ \)_KB>,->MMWA[3I?]&A
MD'%W.IZ^Z*?S/'8UY7\#?A#JGQU^($>G*\@LU;[1J5\>?+CSSS_>;D#\3VK]
M2O#?AW3_  EH5EH^E6R6EA9Q+%#$@X"@8_.@#250J@ 8 X %+110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #6HH:B@!U?S7ZU^TMXLE^,UY\3_"D5C\-?$]V
MS23_ /"'^?;6[NQS(QCDEDX<\LF=A(SMK]IO^'HW[,7_ $4S_P H&J?_ "-1
M_P /1OV8O^BF?^4#5/\ Y&H _*>'_@J!^TW;QA%^)K$#CY]#TUC^9MB:]#_9
M[_X*/?M$^./C[\-/#>M_$/[;HNL>)M,T^^MO[$TZ/SH);J..1-R6X9<JQ&5(
M(SP0:_17_AZ-^S%_T4S_ ,H&J?\ R-6KX3_X*/?L[>./%6C>&]$^(?VW6M8O
M8=/L;;^Q-1C\Z>618XTW/;A5RS 98@#/) H ^E:*** "BBB@ HHHH _GO_;6
M_P"3ZO''_8QK_P"C%K^@'0?^0'IW_7M'_P"@BODCXH?\$M/A3\6OBQJOQ!U?
MQ!XRMM:U*]%_+!8WMHMNLF0<*K6S,%X[L3[U]@6ELMG:PVZ$E(D6-2W7 &!F
M@#\4?^"O'P;U3P'^T;'X]MK>6/1?$UO%+%>1#"QW42A)$R.0W"O_ ,"KZMT?
M_@KC\*+;]GJ&_N+N^3XCPZ6(/^$<CL9B3=A-H83E?*\O=SDL&Q_#GBOM[XE?
M"_PK\8/"-WX9\9:':Z_HET/GM;I,[6P<.C#YD<9.&4@C/!KX^G_X(V_ 6;7_
M .T%O/&$-IYF_P#LF/5(3;8_N;C 9<?]M,^] 'Q1_P $I?@[J'Q4_:B_X3J>
MT<:+X9$M]+<$'8;J4,L<8/0G#.WM@>HK]P:X[X4_"'PA\$?!]KX7\$Z';Z#H
MMORL$&69V/5W=B6=CW9B378T ?-/_!2/_DR3XI?]>=M_Z605UG[%/_)H_P (
M?^Q8L?\ T2M<G_P4C_Y,D^*7_7G;?^ED%=9^Q3_R:/\ "'_L6+'_ -$K0![5
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%5M2U&VTC3[B^O9TMK2WC:66:0X5
M% R23]* .7^+'Q/TKX1^"[WQ!JKY6(;8+<'#7$I'RHOU[GL 37Y>ZSJWB;X]
M?$QIW5]0UW6+@)%"N=J#LH]%5?R KK/VE_CM=?&SQL[V[/'X>L&:+3[<]QGF
M1A_>;]!@5]5_L:_L\?\ "O=!7Q;KUMM\1:E'^XBD7FT@/('LS<$^G H ]6^!
M/P;T[X*^![;2+55EU"0"6^O,?--*1S_P$= /05Z-110 4444 %%%% !1110
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M[51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;'_ J^M?@_\  SP)\ _#/]@^ O#=GX=TYF#R^0"TL[@8#2RL2\C8[L3CH.*
M.[HHHH **** "BBB@ HHHH **** "BBB@#YI_P""D?\ R9)\4O\ KSMO_2R"
MNL_8I_Y-'^$/_8L6/_HE:Y/_ (*1_P#)DGQ2_P"O.V_]+(*ZS]BG_DT?X0_]
MBQ8_^B5H ]JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J*2ZABFBA>:-)I03'&S ,^,9P.^,C
M\ZEK\Y/VHOV@-3USXT--X:U.2TM= 62RM+BW;JS K*XY(YR0#UP!Z4 =9^VQ
M^T1_PD.H2^ O#]SG3+5_^)E<1-Q/*/\ ED#W53U]3]!5+]BW]G?_ (3#58_'
M'B"VW:+8R?Z!!(.+F93]\^JJ?S/TY\E_9^^"VH?'+QY'9'S$TFW83ZE>?W4S
M]T'^\W('XGM7ZCZ'H=EX;T>STO3;=+2QM(EAAAC& J@8 H O#C@<"EHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K44-10!^ ?_  ZX
M_:=_Z)G_ .5_2_\ Y)H_X=<?M._]$S_\K^E__)-?O]7PO^U]_P %3_"?[/7B
M:]\&^$=(7QQXOLF,5\YN/)L;"0=8V< F20?Q(N IX+;@5 !^=/\ PZX_:=_Z
M)G_Y7]+_ /DFN_\ V>_^"</[1/@?X^_#3Q)K?P\^Q:+H_B;3-0OKG^V].D\F
M"*ZCDD?:EP6;"J3A02<< FNKTG_@MI\5(=4634_ O@^[T[=\UO:+=03$>@D:
M9P#[[/PK]#OV1OVVO W[7FAW3:&)=$\3Z>@DU#P[?.&FB4G DC<8$L>>-P (
M)&Y5RN0#Z&HHHH **** "BBB@ HHHH **** "BBB@#YI_P""D?\ R9)\4O\
MKSMO_2R"NL_8I_Y-'^$/_8L6/_HE:^*?^"H/[<_]B?\ "P?V>_\ A"?.^V6=
ME_Q4?]K;=F_R;G_CW\@YQC;_ *SW]J^UOV*?^31_A#_V+%C_ .B5H ]JHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGDU*UOM6#>=K.H/G;*N[ED0L9#)T+*H&?FV@'[%T444 %%%% !1110 4444
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M,D^*7_7G;?\ I9!76?L4_P#)H_PA_P"Q8L?_ $2M<G_P4C_Y,D^*7_7G;?\
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M*M&\2:)\//L6M:/>PZA8W/\ ;>HR>3/%(LD;[7N"K890<,"#CD$4 ?2M%%%
M!1110 4444 %%%% !1110 4444 ?-/\ P4C_ .3)/BE_UYVW_I9!76?L4_\
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M/H7;<S#Z!37OO@KX _#[X?;'T7PK80W"=+J=//G!]1))N8?@17H-% "4M%%
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M\,?\\]0E3_T%A67<?$+Q5> B?Q-K$X8Y(DOY6R?7EJ]9MOVE-=L@HM_#GA6
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M*** "BBB@ HHHH **** "BBB@!K44-10 ZBBB@ HHHH **** "BBB@ HHHH
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M,$5W(B1H,!5#'  KNO\ A]7\$/\ H5OB!_X+K'_Y,KD;K_@J?^RW?7,MQ/\
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M[Z(?W5O'Q^N37S/_ ,/J_@A_T*WQ _\ !=8__)E'_#ZOX(?]"M\0/_!=8_\
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MHHH **** "BBB@ HHHH **** &M10U% #J*** "BBB@ HHHH **** "BBB@
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MZKJEYX=LY[F^O?#MG-//(T2EG=VC+,Q/4DY->N_\,G?!#_HC?P__ /"7L?\
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MTS0-9^V>(;;^S$LO[1M?,A;RML%NPE^5)1MDPOS]>37T!_PR=\$/^B-_#_\
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M_P!$%MY!S*0_+>_7BOO^B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M **** "O&/VP?A+XD^.7[/GB?P3X3N[:QUO55BBBGO)WAA51*K/O9%9L;0>
M#GTKV>B@#\COBW_P3#\+?LT_LA_$/QIXAUF3Q;XZM;& V\L2F"RL6:ZA5C$F
M=SMM9EW.<8/"K6'_ ,$3_P#DLGCO_L$1?^C#7WO_ ,%(_P#DR3XI?]>=M_Z6
M05\$?\$3_P#DLGCO_L$1?^C#0!U/_!;WQ%<2:]\,]!RPM8K6YO<9X+NX3I](
MQ7U]_P $RO#D/AO]C/P(D2KNO$FO79>I:25GY/MG'X5\9?\ !;NQF7QY\-[P
MI_H[Z;/"K^K"4DC\F'YU]N_\$X[Z'4/V-?AR\+;ECLVA;_>5V5A^8H _+3_@
MJUHL?AK]M#Q!>6+_ &=[RULKS]R"A23R4RP(/4L-V>.37W#_ ,%%/B1=S_\
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M!ZXH^&/P>\%?!G2;K2_ _AJP\,Z?=3_:9[?3X]B22[0N\CUPH'X4 ><_MM?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT+XA>&[74++1=8\_R(-4C2.X7RIY(&WJCNHRT3$88\$=#P #T"BBB@ HHHH
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M_#K]DWQ]I_A'Q=HOBC4=2O=,CU6.71+6VEA$3RRQ!29+B,[MT+\8Q@CGJ!\
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MZ[/:>#_AYJGBK3HG*#4+[45TX2X/WD3RI6VGMNVGU JW_P %K/B5J'AWX/\
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M\[R?,\K_ %\K[<>;)]W&=W.<#'XK?\Y3?^ZS?^YR@#]P_C5\;/"7[/WP^O\
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MR>0_;XOOV?M9^(&A>(?V?M1A%I>P2#5],L=.NK&WM)T9?+DC2:) N]68;8^
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M^Q?8;73[>![R/[5:O=1^:KS*@PD9#;7;#$8R.:_);_@E_P# 7P)^T3\?=?\
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M[\$?!GQK\/M;\%>'K'PQ#XBM;V*[L-+A6"V,ELT&)%B4!4)6?!V@ [0<9R2
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M ."KEM%_SS\1>)%_*UOQ7W]_P5IT.+5OV*_$EU(N7TO4=/O(^.C&X6'^4QH
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M/F'.6/W5QCG/BW_#J7_C*;_A<O\ PM'_ )G/_A+O[%_X1[_I^^U?9_.^U?\
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MM,2>-Q;NNB^$M/G9[HK\AN;B-H(X@?4H\S>P3W%7O^"U?_)TWA;_ +$RU_\
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MQ;-\$$7E[/-DSCR,[MP^]C'&2 ?FM_P6K_Y.F\+?]B9:_P#I=?5^@,4;3?\
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M'',,_P# J])_9W_X(T+X6\8Z=KWQ5\5:?KME83+.- T2*0P73*<A99I IV9
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67I=I%96ENO2.&- B*/HJ@4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>snatlrgraphica06.jpg
<TEXT>
begin 644 snatlrgraphica06.jpg
M_]C_X  02D9)1@ ! 0$!*P$K  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" , !E$# 1$  A$! Q$!_\0
M'@ !  $% 0$! 0            @$!08'"0," 0K_Q  4 0$
M        _]H # ,!  (0 Q    'OX
M ?@/@^CZ!\ ^C]
M                                                  /P\C&B%Q+X
MS<]RB(ZDC2I/T
M                                                _#Q,;.=AL(QT
ME ;J*L@09F3'/0^@
M                                                 ?A\EJ(7DAB#
MQ($\#7AEI-0A20C.MYE1D)]@
M                                                        'P1L
M(D$EB.Q2&@3I(::)<G&<W<3Z-J$#CH<5I]@
M
M     'R?)XGR>1RZ.FQS6-W$1C!# #I@:8-AD]3%CD$2&.@IE
M
M                    !^&@CFT3<):'&LDB0Q).F'&3$:3J$8V<R2?)I4MY
M/XW274\BI/T
M                                        'X6TY\FI#JZ<M29)"@P\
MMAK8UT90"31%PW.9^3C-E$7#8!*H]P
M                                                           ?
M)Y$<#E:;8(QF^S2Q((B86@V&8F;U):$'2^G4P_#G*8V;-.P)6
M
M                   ^#5)L8@83?.>Q;CF4:/)$E*9D:_+:9^2O+>?ACYG9
MOPGL7<]@
M                              860<)<E<68V":N-\D323!>@ 8.<8CL
M@<;B4AJL@*:./@W48Z8,2D/4U.;%)<E 6LG 2S--&_BK/H
M
M        _EH.BA XZ/'!\_I^.6AW9/XHS^AHZV  \3G*1<*\CL?!]D2#S,2-
MA@K#;QEY;B19CYL,OYG!EQMHF,>X
M                                                 !S7.'!*DG@<
MCC<IM\D*:S.=1_6^ #Y,*(GD9C+2(QKHQ N9HT]3(RWF_#7!L@D<5AX$UBE-
M!G4TNA[
M                             '\RAU=/YZ#N 59QM)TD+B6Q T_IL)2
MUZ4)L<@8:G-JG)8^3""M--'H9F:]+ 2H/,V ;6*@D$9<;9)I'J?H
M
M             !I@YODQ39@/LUJ:\.@!H(LQ)8&)G'(GJ<^S+S5QJ4U>:E,-
M)'&D#)389<#"#;!FI)0PDVD=%C01)TV2>@
M
M  +(<YS4)D!T--%&B3E*8.8(;[-;FNS?IL\OYDYC1NDDB1D)-F=&E#K65@
M
M                          /D^"/9AQ?CAP;1,4(SF5F8&OCY*4D.::)@
MF*EM.T)"8RXPHV.=#RI
M                                                /DB.:>-3$O22
M1P:/(_#5Y'LS J20)A1T+,Y,R(G&P"0I+\%Q/4
M
M       ^3S-8FK"&AL@A09D:8,N->$B#6AJTS@S(M1+0E09&:C)T
M
M                       'X>)%4YADJ2RF4DB" A' Z.&GRTEP.IQ H^CH
M<59\%P
M                                     !J4@0:>.QIJ0@6:Q/(ZM'"X
MDP9 7<ZDG+,TF945IUT,S
M                                                    !3'.XQ\Z
M,D*B&ATO(_FKS##I.<B"5!AAFQ.0YWDRR0Q=0
M
M        ?!3@]BQ$>C7)-,_G^.SQNTU,0())FXC<1KLV&>Y]@
M
M                      ICGP36,X(S',,ZPF\B'YMPW"?9Z
M
M                          &$')@Z]&1GD?AZGT
M
M                   "F+"9">Q\GX?8
M
M
M
M
M                                         .>1JLZAE^
M                          /DP<PDPTM!1'L59D!FIG1DP
M                                             !H<_FM.K9M<P<W0
M5Q&(F89H:T,D(0'4 AR:1.D!%$P\D61 );F*&E#IN58
M      !CYH4TZ8.>A<BY'N>Q\GB4I;2U%Q,]-UF\2N
M                           /P_0?A^@       \CB*<Y"0!)8WB:W.?!
MT@(MFGBVDHC'"'!V-(R$3SH,<I239'0E,3W.HP
M -2$837YDQ>P     #X,>+(;5)1&P
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M(:FIS-ST          !X&$FY"8)<                   :W(DF#&3%X/T
M% 6$MAG)M0W>9X             #5Y&0QDT ;?/8VV1/.A1I(F:78
M       $<S7!,X]0                      #6I"$OA=             6
MHLI-<V@                 ?A$DT"9P>H    !:S&"YFV3>QM$
M  Q4CV2:("%W,[(?$?SK405.J1RQ)%$\       :L+4;#,E     /P_0
M                    :((@&=GV             #X,$)2DD0
M      0J-<&2        HS%BK-UDAS,          8B<T":1# ]S7IBII WN
M7LTJ;,.I)3FOB70     /Y+2>9SM/ZF#%R0)KXQHVF:*)$&L###<1_.@?T:F
M)%H,_-?&5FJC:QF@                   !&@C,9P 1@,J-Z@ UT7@T42B
M        !AQN$F.?H              !'(C.9:         "W&(F<DD#=9]@
M       %.1+- $>3617FLBZ%O)-F#DRS39D1N0GP     #^2DDR:K/@WD2I.
M8Y*<C824)!G&8Z)E^.;1_2@<)#+26) 4Z0'.HZ#G:@
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MTIC7II@V88F;',N)'&?DICV)YGH?H !0'-4S,Q(Z3%:     <TSI8
M                 0)+<5X !I W>4AJ,]#8QBI9RH*DYL%(6DZUFC23)J S
M\L9L        P@EV;T             .?16@              _##S,R9IE(
M   !!LUV:4,F(ED)"Q&VS'C*S,RL)4E"3;*\EX9F?H !@Y PS,PXG49^
M                         "-)'0RD       &!FDB2Y<@          8&
M=$3(P            <^BM               !2F%DKR0X   ,3(L%^(HFA2'
M)AQG)JTW294;>,;.F!'HV$;\);'Z"T$/3$"TER+H8:3O,[
M               ,,.?AGP  !A1A!FAG       /@I#$3/       "B,C)Q
M            @B4A^@               &)F<DVRX   &E"/QJ<V<<R"G(]%
MP+V9T3=,[+65YT0+^7, CD1X+X ##">9G     !8C"C&"VG@>Y5&1&5F5%4
M                 >9SS+B>X  !R*-3F@#N09*7XQ(S\OI'TWT?9I$D&:T,
M/-Q'"D[ D629)CQL\_#6I?#9P    -?G0XRH            B\:1+N
M          "VEJ)WF8   \R@.4Q]&JSU+*;M(D&;$KS6YU*-/DE@ #'CGD9J
M?H!:#>Q)D   L)HLU"8(4!<BN/4]#X/,I"@*,R8V ;U-OGH
M   1+--F0    Y%&AS2QUL.3IT'(H&'DJC3!.H@.;)-S'.HF878@"=F"%AH$
MF8:L-9$O2&9_0:    "UFXR5(           !BYSN-@@
M'@863H-E@  T8<[#J@0?-.&;$5"2Q@QU).,)*<D42U  !JTA&9,7  QLZ-'T
M ?AI4C>8"9*7L_0     >!C!\DAR2Y5               U20A,\    .11(
MHFH:,.?9(0A"7TG<16-%&O29)N4Y^G8,@01I.RYS7--'=HXM&O#K4<H3^A,
M    K2=8            ('EO*@                 ^# "<9M<  P,YM&WR
MQ&QS6)Y&\R(Y?3H@1R).&:   %C(2%*5(,9)8&[@:*(KE,96?8        +$
M6DEH;W             !9CG69F?0   !%PVD;1,#-'DG#F4;N-Z'/@FL5Y"$
MZ/D7"5)I(P<R(]C$R9Y$8TN8Z1?._8    !^$^0            8*0#,^
M              !\F DY#:@ -/$-B\E"5Y8C59UF-%&?FS#U    !BQSX,X!
M^%,2^(:EH,L/T          &'F9$UR_@           'F0!/(KP
M      "+I#4GN;U    !1F>DQP            ")YI4R(
M  'R8$3X,_ (?FOBI*8\SX+N3G/<^3U     !!HLQ[ PPM)L0]0
M  "B,2)F&Y@           0L->%^                       ,!)[&P
M          #X(#%"7(                 'F8B=#"_ B":_/8 &/G1@
M   UT08,T!YFNC9(            !^&#F["7Q[@         $1#3)E(
M-%G%\MQV3)) P Y3& G=8            &/FT"9              !;3GZ5I
M7@                 HRF.@A4D=R.Q>0 ?!/L       QXYPFQC]!@9E9<0
M             6,^"<1FH        /DAR:D,K      .*1T;-OE.<62W'5<Y
MH&N3^A             Q<SLG">@              +20"/8NH
M      +,9V36-=D&S, "R&^B3(     !^$<"+95%490"F,$-B
M   '@802C))'Z       6<@X6 R(      '&\F4948:<7B;1*P@\:Y/Z$
M        "D,.),DFC]               !1$&#%S)                  8
M<2E-XG-HV #\,<.BI[@     UJ0[+:90?A0E> 416@              &+EU
M)B&QP     ?)H,B:925X      !@IQI* [-G,\UX=2R&!AYUK          *
M Q VH2W,K                 /DBL1V,Z/H                 P$G401-
MA Q,F";C     ,8(AFKS-CU                   !XF%&>$E#;QZ@  %G-
M"D=#Q,K                     !\&.%H-SDFS,P                  #
M5Q"TN)>@                >9@95&; QLZ.     Q0BJ:=,R*T
M            'F8H4IGIFYD17%D,1,#,8,C+Z?H                    /
M(QXLIGYOPWB5@                    *4B6:&,U*H                Q
M0K2_'R9"39   !@I%PU*9D5H                        *,ICQ*DK3U
M                   +:8V?!LHW6;K+B                       8<0_
M-?&:GJ               :^,[/8LI(HD0  6\T81],/,R*L
M                                  %$8\6TS@VH;C-CGT
M               #6)%(P@S0]@             #6YL@&&&2F[3(2A,*-=&#
M%^,A/H                                              '@8^6,RT
MV:;C-J%4                            #6Q%LUJ9<7$
MLY> :Y-A%K*4]"XE:
M   #\+,8T7HV6;@-O%T                               !C!&0TF5AD
MY]@            %D+V
M      #Y,?+"9T;G-UF6                                   \32A'
MHUX9&7T_0
M       "VF(F;F^#>Y<@                                     64T
M4:.,&,@+\?8           /DQ\L1Y%R,D*X
M                %D+&;X))F2
M       LII,TR:X*LR4JP         8X7$DF;5+@86:%-&&;'J
M                             "C,1)'$F2K
M                      /(U::/-0 RP^@       8F;L);E(1C)"&#FVS!
MR!AF)]@                                      QHR4FR7\
M                                      'R:6(GGL7T      %&9 3C
M,0(FFJC+#)S91)HUX01,Y                                      ,
M7-M$Q3]                                               /(A*88
M7H      P(Z)%F(5&@S%2C,S-]FYB5Q" L1Z@      'D>9YGP?)^'X?1]'T
M>AZGH?H                      !0%X)W@
M                        ICFL9T      6LZ&$>2.)S.-+F5FVC=1.8F,
M:=(L&1@'X49;RWE$4Q<BYES+D5Q7%P*PK"I/4] >)X'B>)0%L*$HRB+06HMA
M[%<5Y7E>?8                 ->G18R0
M                      %K.;QGH     !5$ZS4IS-(,FI#W-HDSB1IT,,'
M(!E:7$R8R0R\R\RXRDR(YKD?BZG9H  YZD["_       ^"R&+&(&'F)&-F*E
MD+H7<NIZ               MIT*
M               !;B")2%R      /$GX0$-<G,PU>5YO8E&;D)IFS# #8)>
M0   ?R:'>8OYD)#$JCI\<9CFR?U,'+\V ='CC(2X)TG&\EX;+(;&2FE#K@0H
M-2'84^P  6\P0UX:U,),5+F9 5H            *PG8
M            6LP4Q8QDL9:BTGP?I\GV#[*@N9<B^%S+V7TR8R0]       "
ME(^D82_ES      !@ITB,<(4$?B/I6FYR1A)\W8?0    !_)H;S-ZFZC#3F
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M         U^=("\                          $>2*1>B_GT
M   "F+<6TMY1'Z>AY%07(NQ=SZ       *4P\S$WN;X+D#"3X-)&YS/C]
M   -'F'@W"5I@9NXB^9L;?-%F0FWB+ILTVJ1?-QGF74UZ;!+66LPPD0
M    >9ITCT:U,G+L        6HV&3*                         !JP@\
M9X                          "W&,FX23!FP
M             +01L(_%S,@       !A1)4DP
M  1H-#%X                         !2&'F\R4A?
M                    4Y'DC$7PNX      !B)F1+4S\
M         Q0YX&P@   4A9BU%&7LO1<2N/TH"B,?+09"9 ?0
M ,0,\)AF4               $0",AGYMLF :J.?1L(Z+'T
M    "A(KFA#-3T      !3&'F0FTS99GQF)]@    _"UEK*(LY2GD>1Z'H7\
MRDN0          !H4A^7\KSP* M)5F9&=&R38!F9Z@   LII<T*8*9L5
M        /(PLER;X                -8'\Z!_02<,C^D(@H<^C1!UU(;'0
M\E8                  #!2$!7ER       !1%E+441<"XE05 / ISS/ MQ
M3GN>I[GN?1]GV?AYE,4)=C+S8YMLVB>H        !8S3QCI<#*C8!DH
M  !@A#\Q0RX          %.8T3N,W                 /YNC^D4_F]/Z0B
M"AR,-6G] YQ?.D)TH                   *(@N6,O(
M    !;C'2D-D&\S=Q6@                   $=B*9G9]         'P8B=
M #*0                 <E#K6<0C&"6IM@U<?9& FH3P
M    !XD#BW%P                      /,QLM)MPDL;$
M     !JH@Z9\?H        ,')R&S  1A/Y^P
M            #N438   +<<[#*S]                       *8PXRXE2;
M;                   -)$/3-P       "E,O)I@ $#R IW&
M                         .1QLXZC@   T813,G
M      /@PXRTF49J                  "$!C!7        PPG,;%  ('D&
M#NN"D/LJ ?A1E2>@   /@IBJ/H'B>95    %,?I4 _"D*@]    ?)2%6?0/$
M\BK    *8_2H!^%&5)Z Y &<'4<   'F<V3,@
M #P,))'DI3]                 !BASS,_       !KTZ;GV  03(-G;XAD
M1%*PF4;^("&G#8)/LW.  #5Q!@UV;0)RFHR(!;"39,4NH !0$.R')4$RR1)
M0TD9\3^-T@  UX1<,2,O)0&"$>RB-P$F2[@ %"19(QGT27-]D.#5!E1,8W2<
MGC,SI>    0%/H                          QDS(G*>X
M     .?!7@       UZ=.#Z   (RG%P^ 5Q)TBH 2).SY>  4!R7(W $DC0)
M:P#K"2G  (\G#X\@59+ B( 2$.UQ>@ 49 (U( ;1->%" 34)(  &CSE(>0/4
MD 1Z -IG5XOX    ! 8_0                          60S,G
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MF;@      ^3"SH$98     6LTT:9-8'H9.58          /(R0FR
M         <_BI        !CQ>291FP ,5.1Y%D$T";AQ],5*TZTDR3]  (O'
M*LMA?#JP1=(6@W^=6C+P #'#DF1"!- GL<;C"BK.N),\_0 "/Q"DHBM)H&HR
M/P-B$[3,P #'CF\1Q!(@F0<VC%#U.@A,4^@  "RD3S3AFH      !@Y-$V^
M      ?)JPT6:F+>907(         P,G(;0                !:SFX9^
M       >!AYL$D&;A*HBT<9 #T-T&DP#?9VJ+V "W'(XCR ;=-5%. =4R6H
M!&\XA@'T;T-$@&]CMT7P %$<_#58!FAB)X@$RB30 !H@Y3  VH:K -E'60R(
M  UL1Z--&5%Q       *(OA.D         &!FBC4)BAD)?3T      /@P0E(
M22                 (NFCB]@         'P8V6DV(9"0N(TE,  9N=&2=1
M[  ^"'ISP,+  *HWX=0C8  !B1R7(IE(  9N='B>)[  ^2-1%(Q\  ]38A-L
MV   8J<XB/Y3  &2$S":YZF$FKS5IKHIC*"J        ,!.B)DH
M !8#39IXUP4Q?2\'N   4QB9>R8ILT                 LISG,Z
M     /PMI5G@<V"V@$T"<1LPR$OAZ@ \S"3E^1Q ,A.MYN O   !:R+)R%+.
M 3D.G!E9Z@  ^##2%1J4 N!.8VJ7D   M9'0YQ%K )#&SBI+&8R5!?"[GT
M       6HV:3              !AAJXUP8@8^6@H3]+F9"; -\FT0
M          ""I8"X@             K2))& 'Z=73 BB*8\2I*PK"M*DJ2Y'
M.  E*2$/L]3U/8^S]/T'Z?!#(B2 =@SV/P_#Y/P_#Y/P_#Y*TBZ ;:,K/$\B
MF*8IBG*<H2W'V6DCL 3R+">@           !@)T=+R
M                   "+Q'XRH              \3GB86#])6DM2R    O)
MH$BH 9:3E/D_ ?@/P _#T.=!@0!*\E\6$ 'Z ?I=RRFF0"[F^C&S\   !=2(
M!B(!O0D$6$           %"9X3*
M    !'<BN9P              >I&<B4  =42F   !D9S,  )&DCBD   /TCN
M0R  .JY\    S$C$  ;+,P*    &OR,X !.,I            8"= S,P
M                                "-)&0SD               ^B"I0F
MS#3A(8E"64   %X-*$=S:9A!\DRBF    *D@86DVJ:5)"DKBP@   NQ;#5YE
MQ8CR-U&+GX   "\D7"U&P#61M<WF6$           %L.A8
M                      /(AH:H,O               !^E\/TH"Z%J*$
M  %:7DM17'T6 ^0   #]+\?1;B[EH+>    "L+V6HK#T,?/D    _2]'H6XN
MI;"W@           M1N8E.                                    8:
M0?/@OH
M       !A9.0V0                                   >1&HC&9N>X
M
M -<G34J0                       #_\0 .1   00" 0$%!@4"!P # 0
M!0(#! 8!!P ($!4@,$ 1$A,4&% 6%S=@<"$Q(B0R-#4V.",S09#_V@ ( 0$
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M<!%DUW_78U0BH";!<9>V*V."50$-)%Z[\@MN6='Q4$"<C)@6RXJ&2#,RH@_
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MZRVQ9^H9BTUSI=_[SL<1(UWMNT;FU9'!Z=*R;!7-7_KYOO\ 2;I7_P" \XA
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M+LE?;XJY5A',WBK8Y^.ZIS-]JN.?CRJ<Q>:JKC5GKSV(\R)+QZ>WTU!W'S)
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M 0,! 3\!&$'_Q  4$0$                   #@_]H " $" 0$_ 1A!_\0
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M*8,N!$"?5TRL"".6S\74UN[5,SLE@U4VL/@0&DU4!Z.1DAK,X %9\.-,P,Q
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M&OVR*HZL:)+3&4;899I$YV'85P>"LGM1'%8<++B5PC+49-B8GF>B YQG,;)
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MPK*57,K%GQVV*%1[0,YU9D6679,>C;$]S+M=3["+=>(QP0X;<1PU[8&HIZR
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M8J-BSA>)@^6K%5NK-BD^\D!X<Z7:9L5US)! M'K%EJVZ)6<;V.X)NL3E!L(
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MQ/I.&%STA-[V/><+0PLEP.+5DK;,BN0+4(SC. 8LP%[T'C."X)=Q&H,5O9;
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M!\"WPS%$@C2N#59'0[PC:EO(I".$(^!UPPO""8@85]T<0U%7?TI>[E[.VT;
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MUN?804(YZO<])GTS7B?!OVFQ?,S-DR9#)21F13G).9,R4D7;//5SYEGG&T"
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M0B[HG*?G!8WDQ_",#4W.$SBE^M3E\CEJBNMS!98(<XU"D3F(YS&6W1-WM[<
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M>%XS3 XD9G#_ &>W6PU#=,\XA[,/>Y991Q$&E@Y@0%.^C.\L>H!/J7A^J/\
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MRY_:"3KY*/W/[T7Q>1]SU?>]^P4\3!EZB.0P+"^F4!'+Z6?.<- 8[%,DAZL
MMB(SVZ1A]@71&7$7XKT%/DN5/6">4Q$\P/*969CS^I8+<KAB]3&,.98M89C.
M&UDV$5H6/AJUP3M(/AF?#F= .GAZM"RS9D!XG /NTG -L!5$W;+/!<"JA,1
MO==!=O+@JGASH ^&V"C;$PQ=#NG7DUL6WG16Z6+.+:0N:6%R*6]96!X(%:U<
MH> Z1>.:SC(:803K6"\:WNN^F^U=PM-O05*#"S#M-5A0V4$HEVX(?#)XBE6P
M=P)G;?/>_&S]D+M'=M][$G54RT(Q'%G&M*JR7 L>%63T:MQ%DGH2J[;<:^(*
MY6BQ8-M>L($*@S34'FW(,XT&P)&QQ>">O2R9.!RVJ0J:^BXMPN4HBB3:N>>D
MM(:AZH<;-8F:Q9,1(1!;8=8Z C#BIK:%AL50KM>/2:_15N0N$P5>&*@J_%,I
M#4TRF) 9?79B[K-G#U(6@Q2:*MF;K(B#BR]43(KT 5JP8:C*4C&099[,NJAS
MZBBA.'I:RNPU87$JKKOA6""Z88U6H<U[7S8T OAZP)(#N]AN$UIBN]= G.Q&
M\1,,)KV+1<-,DJMF/6"8Z3'AHR=2@$2<VN.U@MX5"L07JP<!V)7I$[<8;?X2
MP *M=<VS8$7"XJ4BZ.+Q8%"JB*Y8RUOL:I2B*TZRUZ50)]#O)BKAMBA!'HQ7
MPNE:Y:5;3(/(\,BS:QVS,R&-7L*M6PW=PM-Y9D-.HXV-KNU/92@C&I<87$MV
M'/>Z>!"[]_*G*PL5,7J6<5M#2UX8P56(?4MV! :Q0*K/1F1PIU1X/1X.!+ M
MVZW]SE4QKHM7[=RC8OUURVOQ,/HU\/>%2MQ4N&L_$&)\$ECB2E02P4XA1G4E
MNH9B2B26U92#5%(:AF5F,Q)!)+.,C43%D)3]%C4__@RX'\X@UQ^4MFS_ (;+
MY #_ '_.7/F>/Y09M@TS_P!00'\V/#C\@_;WV&IL^F[B_ILQGG7J%RX?+L;:
MYQYQ1JG3'%4>W$./#-CGGY =L!ZY[3].4>3S^P!K;P8/0Q92\Y5TRN#&(DLM
M4UW<G5Y+*(*4L"2B,ISC:'!NC3DHG/)MS%;"OC0^^Q)1[V5S'HV33H5:]*I7
M#AHJU$KKUTA'D*2H16L?0(Q'V/7Q.C.G0S6$>1S]MKG$9>":$D.493HF8'*0
MU;5\0JSX-X9R,^,ID<F)/WZSS&>XN1CF!#,_95O+EJ;0_/HU8GY9S^T.AH08
M^GN],3VQ/IC8;V%O:!+YP:_;!CO%@>*Y4^6)"0%'M@:=ET\4X='$)ZHLSTU+
M1=VDBGP#2[.$R9$BRX;)(X5'U %DR4FJPFRET"+"6U#.($Z61(2,SJ!@$,BQ
M92!<MO9W<Z&,,26O$,(4M+2:B'$P;%.&!G-JN)2J(]M8F.1\3,IQ#&\4ILIX
MKBV(V9TV!8EXT1,00#%9Z(UF!,U:(/1PP*<@RVO4I70N;JX1BR:=FK46)6;-
M:SA55DKM6#AD@2CMR/@8&0L# ,68D('O+3W.P%>$5MYU-KXB5FT6(DQMI1 B
MO2"&D*!FOTB'I#6T!L<?P2U<A#I>'8JUV'34Q10+F)K<4,T\=AKAX/@VC*?!
M+DIB EA+GBJAV)C8!]4F.P\8&55I(C !FQ"F0?%:.8J7Q.N/6*='4E]0EUV,
M3#RX68+<I+LATK9EGK(4K88L6R.)PA,53I9M)DR 0;G-R9H >+"FDM8M@1&%
M$D37PSR-4LCF6<CLB:S"JK('KK/@4QE1R!!%.4L(A%X\2I9 :\P:5$Q+*X$+
M585PZ.*6DX7>%UJQ<;-C# 9T6;#3>;9$[!D<DMELT9J&:^>BUD5.WC=A==!X
M/89AH-K<.TMY+ J\B(M;J>C(EQ"@*8:8Y990)J*GAC]?5K7-XA72#$["1?&M
MU6NVQPPNG6^EAFP]T-0 (#A@$CM:K[LU26^*3'5CM:@Q<L5I%QS5B@LB2F]Q
M0*NR"'4L3E2\EE$[>R]F]PMWL7F,:Q/"U21W;]T*1LOU)<7#E%2T=/I3K&<<
M)C(1$"8Z]E8/NCARJV&5&64GC]E6J%.08@88/77,U;,N4SHG2GA9 V6H0*8L
ME$;6;,L=].XE8:59BU@M#U^ >5(UQ'%K68 &1_!LUCJ+F<_/==N,A5= ZC.<
MY[9R$1&.9&93 B,<Y*8C8UX+6&JF)G2PU19M$/<1ZM5=6?;HT'E/+BEMGT]_
MWE$/R<,?T;%7N7K!(9&3%DY0*.,\\C!&6J,XSYC.PJSU3S(I\Y3YO1'*/B^<
MO^7C^@S;!8__  =5+[Y<%_7]O'7W=8A\'73GE+[)Q/#5'HY2;)YR*@,HB9C*
M7XI>*6F;981%^^.GGE$=D+5&4"$9",0 #&D9CZA7G'<:PO!XM2R*TXG>KTHL
M2G1Q83TA@<3A\5>O3GIUCGXT;?\ WWW5_'V&_P#,[2O!MX,%Q9@C)DO#<4HW
MF",=I$%9["&([YF/J\D10(QVD4Q$1ZYGEM8N6WJK5*J6V;-EYBI%>ND)8YSF
MG, M2EB1L,I@1&)F9RC9RL"Q[",897 6/7AN(5;II YD0-HUV'("11,1)91,
M\OL U%V%'*?<EY)1ZI^7LV;@EHM*+QY*SGJJOAU1RYQ&5H(X6>4R;!K1'*9^
MRT7(SF+%6J_T<1##3(Q]PI4S\/[1RQ.2W=OO#]<>27OH^ZB<\X##L8XMF@.0
M"1=:U3CR9 I]OKQ'+AS,R(9< ](<$UVJC@?7<.I;5SF)1_443F)#.1 42)1!
M1,?4*E_=6\I&)X98)_L?:T] Q>N8P#:EDN&9I9 Q]+N"<@+QHZVH'5,1PCV!
MQ=.N222G6&RNN)M^EPGB=,1:-8H%U>&F4MTJ#B9$,[R[]WYP;$L8WG7O#4PU
MPGTUN'8>"$8<%VDL&-0MURL&)-8Q8E"U)0]PC)J'>^=W+>!#BF(X/?&'5.&-
MMMAL#"O P$6(XKP%6I:A""9$SGGGMTJWAZ\8J4\:7&, R+2@?T@-5$+)U'+L
MX=#"6V!O2<YN1I8Q0<-%F6X3X&L\5M6++4VGU>$]DAIU+)?)W$@&FOB&,>,.
MGETU!2\0;,P1H@K-$EO2[AQ'$A#PC7)(@X&3ZR6,#*-" P@+ABX-5B+"T"T;
M;&G+K()3,K),\29CB# K9SKRZ!,1:#UFOAV$NKS'4C7PA,VZVE/6F'-C(HT'
M*B&,Y62IJ6*Z4J<O+C<%4Q#*R[DW-%E4.ECX<12)%&G+3G @"QC8<%WBKIP?
M$<#PB[AM'%@L2TL/J8E4,K#^CLF5MN%PTGPO",,YG@\#+D/S/<)L8G:Q"^=D
M!W@?A#UU&8J?AP(K! (@LF'T<$K7HT:U-/QF[7L+PS!+N\%]N+VSKBC4C#*X
M#IK23\2(7S &X0/@J0;N&7$X@Q&C9F#XS0L814Q.VVT08)B\OPZ+5L]3</9.
M(X/2Q2HFXUI>"0YX0UD 70SF5J1AE.NFO1JIA%>LO5H6$#ERDM1ZNW(I*9@I
MXDZSV572 @E"P6H(SZ@K& $8SSY:8CMSGTS]!5D/:QQ)7&B/37LP$S[V"Y?"
M(?-LGAQ$9CUO2?8<S]U$_%E]"J?,Z/R@?^[;!9'LC#*8<O.M(++Y"&8GT_5-
M-O$*54O<V+2$E]ZPQG\FV18NF?Y)5E\?*E#(_+MD!7;$>Z35RC_XAB"_-V_<
MN+3_ /D]3^N]&W*EBN7GX52)^3ID_P!+;]RXM'_Y/4_JO3MS'$0^%67_ &+!
M;1_?+AS/DMJ7!F/64()?R'.T2O&<-Y]D%<0L_P";88'^;MK0Y3@]TI@L'Y0F
M8^TQ&9"  ,D9E,"(B,9D1%/*!B.<S/*(V@$3,8?5U+J1SRX><<6V<3EUWS$:
M8F!R"$KF->J2%81D(1E'_KSSVS/?/U#<?^6WA_H8-MA&\Q[SV,.;B8W)FJ.%
MKLK3T7$;=&,F3>01ZXK0SQ1RDI'GEGM@]BOC,V0M\6U@^,5 /#[:K- T\<#3
M#G2AR.D5R$PL,!H,[IABQP7?#&K->D)X<9XK;:8)K+?0L.P^Y9.>J"5ML5C;
MI\5<,@(Y1GM;Q9>].!GAM%BDV[@8A7)*7/@I0DB@^;G0!RI0YL9H+0,Y3LVS
MN[C%+%E5R +'16YLKDR"E</0<"]/$@#X?%6,,T'HST%D5#&-Z,*J70G2VKQI
ML6$%[FPJJ+SKEWZ7PN<N?9SVZ;@6*T,6K1.DFT;*[$+.8SX;A I-#,N?#<(,
MR\G9MR_:KTJE<=;[5MRZ]=(>[:YI M8^DBB-I1_=CA.N.6<$^4_%8A,UY]<,
MRV7>PR[4Q&FZ,U6J5A5JNSX+DD83EWQGG'9.S;V)7*N'TD#J=;N/56KJ'LS8
MYQ L<YY1F7.>4<]HI5M\,&FP1: AKRK+,YY0(6+()KG)3R"!;.N>0YSMG'.)
MYQ,=DQM. )WBPAN-Q8=4G"PNI*]%FMKFPCH\%Q.*GA,X@99CH+/LV+#KN]V#
MJN ?":L;$O%+(G22WNKBU"# N3!:P)7,3!P.6WLJJ[5=AG1RMQ?2];:<U0&3
M.P-A9$HDB D4G!2,1$\^6U6FG>0+.Y6&8[N^ZF-.PL<)):_8ZS:M6#3D%PDV
M)L>%LDWH^@A7PXB=MZ P_>/#2PE^$8QA=_&JSE6ZN%P[##Z0]^EJPGHE>P-I
MBR<K->69A$ZML==N_O\ 8;OBVU2JJL5Z-9*"I+6\R!QRK$[^J&%,A$2*^<>-
M/9M& W-XL(K8U+JU>,+==2%V7W14517 DM?$L"],J'+,X8&7C1L6'XQO1A5.
M\$Z6U>-+WH+W-E=8'36++GI?PYTS!993$[*Q#";]3$J+L^%:I/79067C#Q%$
M0ZPGD83D8%U2B)Y;,Q#%[]3#:*LN):O6%UD#,^*/$:0C)GV $9F<\AB9V]C\
M%WFPN[>G/14ATIL.TQ,ET=5D4G9TQ$E/ AF0Q)3U8SVG"L*WBPC$,2&&R5*I
M=2ZS$(Y.S4!27@O+Y=7O^IINJF0."&),>4BP.LHXGMU<NWNT#M1Q$<L["8EL
M1V \,UV COTBX#@<^T<I[_LK#KXQG%2PU#,HYP%L!D2F?<B=> Y^4V,NW9)=
M\! %\(.K/RY:O5/VCTLCG'BG'C!ZI\WGB>4^O+;-4\:DTLVUCF>CV([)(>W@
M6('L..<91KARHTS%JBSLRAZ#RA]<Y\AHYSVY3H.,P9$3IGD41]%S]>TY=_C=
MD\IF,XYQ)1RS[.67KVWA!]9UNU.])X37HBRK6UUDTJDU"7:L+9%=@IJZP3<
MZ%B;+28/,#6J+'S-MY,!<4LA.*5Y;?"IF9Q/"94"1M552(6-+5^$B257*%\,
M]L41@02JN]6%%>'%CCIIX@F,2M%T2G9!$,RJ6%3PY@YT:H2IQGE [T3:8[H;
MQFR"E6EV 25AI/N5ZXU?WICVDRLY'64)&#&"0P-?'^F5]X'6>ANQ(*[ +"+X
MY,<"0&I25I&O-2A;\#(V&/19 !<##@,5OXPK#\6.YP+*@KN:-6GQAG6JN*6!
M(* +&B%F[7/"C-8'!3MC5#$:-O *C\9Z*BNS#+.)U:]%5D.C0VS6S:]K0B+'
M&JM#A*78/FN=.V&83@F\6[6.1B2[+>/@JWOLH6LH &VCOB,*M91P4(;D4Z"X
M];K"W;I#XQ2QC1*Z;898OZ)FQ,$1B (A<++K:C63#C6/#AJ@F2VH8>^R3</W
M6JNLI=<<EI\9P>"5TNJ?!8%9DQX=T"TC$E/8XH$S7AV&51JU5$Z5)$R+K.:3
MW3J8<F1<0CGF?+NZL;)Q2A8&G97>1:R-)L#JMEUF0D791+2(B#,)D#Y>)H@/
MH;6'V/:[*Y#5EG*SCK*:,>Z4R!.//IRGEM8PO$(TZ&9:O(Y^(\)[U.#*<^[E
MG$3!1]"Q<>-EJ#X0\\ONO%^/9^$L+PN'G+41WE5><D41Y^%8DM4]T.6/=]0U
MW[M>K&4E$.:(F<1V\-7MC9]"Q*?1M(T*MG$)B?'+*F@H\XDP6/\ B*L&TC14
MBF.<\ZU?I#<O,9V.,OE[H4KVD;F(VS N>A]ULJ_F0(@'[R-O"6(]0!G^<4Q_
M1VYFZ?N@B/Z']>WM4EZ98S^HHC\FWM$??,_XMOW.'Y?]^WM _?''Z"V]H_\
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MU1D^-)_:)E:RH'H<.ABF1J Q],?EB>T9B"B8F(G:<2PN6.PW/.?*=2S\A_\
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MK8C"1EC%X??3(<:RM(FXZSZU9DK R1QX6S1>QW'\0KX7A.'*XUR[9+2I0:H
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M,ILL!/%E%H<X;MB:W0NW4?I;6Q%S6/Q$RDIUHM-L$VPS+(69DXE\34Q<#Q9
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MGEQ[!QWG/<$<]"AZ@>DI(B^T>[?_ &?<[_:KOG)_RPW=_P!AX9\[?;X.[_\
M\U8'MB6\%C',7PG'$XWB&$T^#%.QA,#6H8;90RS4.L-MA2VXR&\+$51*X#0(
ME$R1[L_-:W3HVG5<3517BMYUHJ^!7,_I3$BI$R,,Q+"+FNN\;-JM)5D&O$%'
MI E%=P!^)HPAH/KXGAF)69'H:,0J"V$]*SF/I9Z7/KM)<ZUB[C +)7PC%.#<
M?>+=!"F2E>&3AV^> /H%J-G1JA _%:N'L$B87!KT0TD9<LV;8G@]O L-P'&<
M!56L,7@R^!A-ZI8(U<>M4*3938AH"MZ"<\9XJF+;UB4K[3LK65 ]#AD&*9&H
M2&?/'Y8F.8SE,3$Q$[3B6&D;<,DN?E,J:I]KL?PB)GJ@[SY S(]!LSCDP?;
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M%&1"0SRD9CE,3RF-AQ'#H*<-<?*.9=%87/HS9[22<>TG//R"G6(FR&!ZB'O
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M[6,X=0;Q5 U)'X"TS3DP<CTESRRGVG=+\36_VKM[3NE^)K?[5V]IW2_$UO\
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MYY_0R,\X*)&?5/*=H-67251,+F>0V49S,#J[C&9G+/E$R0ERF"@E. EL"<B
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M"DS*>V2*<YGZ"EKSG]T)B9[TAKT_$$C Q\"/HK9U\^(G#++53'DGI9F8^^"
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M'XC;S&N$=!X0E*G\-FI8SDC5R;+!+"7*4=$%3!&SG^L"]2<VH<DVZ@K==O\
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M7>J$+AKMG;8'P<W!F:/#X:UP,FS*E-C_ )J4@R8O2IQP1IBC8O3'E8,;+E
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M]=G($ Z- F26ZAY^Q,\@ F:,].HJ\NX#XP^<3-^SQ.SH1BGZP:+&:T5M@TP
M*!]9=\-2J9;,*WTVTH_2 1?"Y\.TJREJ>(9&]C5YLM>Z/[#K-WA'FGI!4F_V
M4S,=1N8J,L9V09.07I.N$RC48;($1B*( 5RW+69@%-8$FZ=@E:CF77JOU[2Q
MCK*!J#\AAB5SPLT#5#;.$36&FB\J,Q4D(  /W!!20L2A 8'$P, RCP+RTVHH
M&<C/C>..^K]A$\QI?5:T0DIX![O-=J2 IFN<S4($@ <%3./X1M9HV<H= ?[)
M5 J@ JK #E7H'5PVT(,ILA"74D7)-V!5Z&P"B)-'AXLF(?H >O?]2RJ:J-5Z
MI]_'C+RQ- 1[?<)\&#B] U4SH'N"W!20(>HP4X - $Q( #7!;!B2LG33/IR7
MYSHFA>% +:0,4NS/0(B0O"0N=,X$#K;I=Y;9;,G)M_A,2Y9,B(P;Y%X+;2B3
M;@UV#PZ2V6IPP&NSRPVX2D;E=%J-,*H"I\+:4:@'2.SC W*P)[#YJ<C<9A/#
M1=0_PE%NTZS$GB_BOZ4_IB' \':["_URPMB@WO@5! CJH7(90T)#V IQVEQL
MN(L;V/U$$*"H+*C'<Z Z)X']S0:5I [*VB(&AWRWJ>/< C4$025F'1,' < 0
M Z!]:?$4<IR)1'LF0'6#/>K8(*RD<=F)(<<4Z+'B;]C .G-P[U;:TQ)%' G
M.X";IXUJX>A]"-PV X>*>S90VL_8THNZ?C)!_F>2:Y&D-P<X[:)-FZ!"S;Y*
MR)!4BLL1;>S8:W2?2SE)@8">M0RA0U@>,\]PT0+ 7=\;ED-5SO$PN47_  Z-
M,\W*+)@+%@>5VGU0>-R^7&A1NIA6PXV2%)_<)IA%DTQ!<%&KJC*?V1A55OAH
M6;#S< X:0RO9$V^=6[8E=B#X V91P^)QIT2E>RC3F/>+,SMHJ>D!KQS]!FXJ
MR@FDBHT#<MU$3/I"Y+^K^9%YJ/U4L%-WV3]J/L^F(A"4;WB5"8L N*";JDKL
MXBHLNG&3Q3@)VDD,?_\ S:X:A)]!MAO?Y)Z6]VL,0$R!QKC^SY$?I<#$EUY0
MX:+M%_!3S?"HWC0+?2S<ZP-G@5,%J34^%3-6-"JSVX\*P[=%;HG9S/>Y49.>
M]HQ# $&4YJ]DH(;)A,@$ECNHMJ;=@@Y:REP%:C..EZ!S(J* 'V QJ8P8F3(A
M#!$6I]ZGX1M"/'!SLF$YK+>XF?M4P\5<(MMM&S9;6V.ZY2[5MK3+=BVD_(31
MLBF4E*LF"'!:TJW=J, 4_P#ED@C4(6(2-Y<"E1HUKK3P2!F^#[OYJBK-2 K:
M/I4>[6BGE>@OHZP<&6@C(7TQ'=8=@ $ "% [$32)L3G]@'JL'Z<M&Q@;Y'R\
M!OB3T/;=$F/I2UX!.(AT@[EW#AYP#?& 1 #>#MTN-:D=#BK1V';6AFKBS%U>
MRR* #8'\ !\7E (*(B,^BIR=(X^>G#2!=FO4QPV6#$9ML4,N"QVNAK?U 8K7
M3<,'$B.$):D8+'4N>=DO,T9]+FNJ;I.79N&[KYJ2HA@UNI!([8Q<[S.9ZTX$
MOMG2"DVK. <2<=2&!0F@?%.&,]\Z+JJ:W1&#6*5/U3&H"*F$7^+<I*/,]=2P
MC!GPU@,W7)GT?OV800*EJ_JI0X DA_BS-1(4.:HF>#!0>BGIAUS/X!YJB4R]
M\RWP 31 K,'YUTGP.M:H1#.D9%<T$T.RGL9J#>A$+PNY[/Z',Q/_ /<O0#9.
M=5S(6^O8045B@QS]JZE,K SD;;D)WXL?',!H,U!%XTV<0_('\%Y [#BXM<NM
MO2^J/+D_>Y[ L*1^PD@PL9'\I)^X5,"X",[4GEBQ >W9E=9CV"N;,W8RQ4"L
M* ,M17DAA\R:/;L^*Q#ES0FM PX*#[UG5" 5\3?SJ=\A!^:>89Q_]IP* 2H7
M?@*U=J1P"*F07N_2+"E.Y'RY*U8+PXM2% M+4_[C1X.5M(?"U$]' L!8G9:\
M=Z_ 4V*>Z#"@9H]$14!,CUJ8"Z$5]7O"[_(ZVD& H$M.0' W!]J,*/.(,1FO
M9ZWK\3 6P?"9 V3#EZ]:TG&#82!WO,@ $X"Y3PZV0(<(L<#4&"D '5M)C:F=
MZEX]@?0_/F3PY:-."35]@BN+9"I D3$'!<>9C0"V?DY(?JYU+^C- )Q+I_\
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MYF<S:<#0G4/23Z TZ+N^KYI]9#=MPV+4A<1C*QPV@D5Q#5:WN+)AI)PVUT:
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MM+&1 ;$-W-!Y<(/N%6-GLR!V?V/K[FL,_<7=:J0C7Q(C&(;F -0\0V".NAE
MP+%J#OSRWT.XZ(V].V6)VHKMEN6->1*; MPO6)>C@/E!SU()(E(SN;S-5O56
M-JDHN4F,3<%BT))EE%DKW^LQO7W@@4EREM>C1"66\2[8:2S2$,K:(<LM[B,I
M.IT9+D>0=LZ[-ABGS@0W^=/%'56>RDBYJQMD:"5/!E0$CI7$-HC.T?,=/49"
MX8:0^H+D'+N\1O0M!TS"-+XB"-'8G"=SY$&V7F61Y XD;6(Z,#G:S0X_04&_
M>08DF?1G>M^$8MUQP)033Q[NEK=:CHJN]/9<Z0EQ#$[(]49,:7^NP]BS[L)B
MSRGVS@7^]O[>:9_M??;%>?:_I/P63V\:#^?_ #B'2]!/[_TC$@;;9X\TNVOK
MB>CYC"0.6:%@:1@<PD*<B9E 6ZHW4)F!M!:<3JL=%, 1\Q$7E<(($1G[$2^[
M<.80-)&Z'C%K&CF>>-2FBT5=/Z*M#0NNN2=60D%YMM$ .=E82DZ%1"L:H*0(
M)F2$/"PR]Z[F/JT3HAUKZFN#2R&X-2AP:$!OM7@"<'GLS3T3:5@J!!D$H4@'
ML&2WB+2*@2,;=3S;*/,_0C(<I2&(U%E?RZ#5)?&EY8@+*5HAXP(AZ!D4I#;H
M?!7\YGB<;@]=A$5&(5R(!#%V POZ-NS>S+3$P9'*H7.JYD:#CR,282!B#7/Z
MW\.,_P"KANGP! P^#5XJQ"!+"-K8W"E)B=#DER:TP_-"NDLN%X*<RL* _E/5
M39SQ>Z5-??ZH#N_IA#X,YEJ]"IT1UQ:X<M!-GG*$*N_JNPLDI(1-S!U&=<*2
MINC7+>A?(->G]D'<DX7J)$.4";0[RM5E"9)K M[9*<D8(.V1\X@$^=+X;E 0
M8F9)=V&62IZ"->_$R(\#\?\ [@086U8*T;K%#K1PGF?\\@DZ/"D$R3+A2>AF
M_!0W0!"X+E;M@KG2VX<MQBM5OK7:4",-HD:ZA#4T"6LSNQT5=L4.](K) O (
MMTR#H;"O:DU2UA#WWS(C8;+RM>81+:OYYE\*;G3+]>$!MPDW.V@TE;10(V;E
MV"H!8;^R(NHM<+Y $[9G!JY1T/ PPSG@!0-(-$TFSY% 50 JN@#E7H&*G:-8
MA16+P@5B8/\ <\(Z0S)JM$%,Z^? Z-W5SSNZX<=W[+S"WG*   " $ . #0?J
M\X_@@O6#7DCYRJ]#T^2I_$';IDH(F]B(!8'+0Z<!)I"[^4'.50]<WI8=ZPR0
MI38G(_7ED@\!#;A.Q3@P]I*,%;.B6I;=?TE;XN7\3LU\T,#$BN\T;J!$HRLY
MS\'WRKH@_BEP$4X)5#LA\DCP#,V?QR-#96*A:=#4JYNE("L+%DXK1U,3O,AN
M3B7E=5 M+,DR2>:MKZ5!V9IO7VXUWBO8J2"V.D0W2^ 0 ,:FDR^IP+T Y(!I
M=WNH]D'X7_R7?(1ULPKX(4H%6&>K,7442*$JK@P@RAIW$T]SXG<<7M:$E2%G
MT?L8$.EXEH^D:&,'!J#51>ZLOZA:YL;4YKJB':OU?5>5AW1J!:ML7%2O"%*;
MA8M#H$Z?LB'P#B'(CR8/J"M301(1&UWC;K(^2-^?AGYJE2YIG'L"E!1C3ME;
M7\!JU;=D*82V/#^(FF$8*7$8*(4\9$5#"'6.ZG*85R<C@5%"EE[2^4PHBJ,E
MPU0$; /N$,> X:?8A!/71I)#PTP62Y3W412NUP/UOLZ9W0O69/MXD!4N6"([
MI**]C!"=\P+Z8*'LPTHN93]!L736K!H,$>P!K&%MMH4OAZN7Y_@=3Y/+ZKS'
MQV;*]]C^OZDF<\>=36N6DM:_S\9"WPG;(650.HAWY?N"A1L-I(&LGLZFJC3H
M.AI4+ELT,X$-V !['T>_3ND1[]_Y1H0#$*S3"FHI9Q@&(W*MYV$DXP3O?6XP
M<8_T7T.$%K8RT@B4%/,S9O. L03#  ! &@#0&@_2);-4HW<FS[#8K*G\5+.[
M_4V?AL]@",=BYB52&]_!=P0@^8A,Y<)C1$P6[ CVA=T026&T06@B52"GBZ-D
MFV)->!"4+]?O75[?&@.CK> 8" 963E: [_%\D0-,@,; SE0]R@@B46SB=RCF
M#)M<"2!!<;I,)&BC)?AL+!=W%SP"LNJ\3JL>40/5\3@R!5M[U16RI*S@KYY
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M_P!%$+Y5U^ML# A?9I'C4[FHCO=C'J) M,KEYO>';*X HVD*+_1M.@IX=4(
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M:-GBK[8KQAB>@35V 3CK-W!7H!0D6WP%H[2]=7DF[!Y*1_PV+T%BR(SCIQ!
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M0U2CHXA7G07.#B-1@/"%$>Y]",H[0W;K_P#E'0G.T8  3QE2UJR6    $ T
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M.%4(16XN?G<^WL(9!H *LT?<&[LV:<P_5%"\"#_@@AZ#&CCO2U>@=XG&NP#
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MBN"O(#A)/87V4%%C+!U]X1E#+4 N-UKRQ/@)02^)0I@.B\>#?(YO@AC<<?0
M'8T?JE-2M^@:(@AFKQDM\+OXJ)'4M?@D;06@0X.Y1XY)!^#%/;CS $X?/Q1I
MXUMJC&58K_L:('SB(.K!IH*CYX>=0DU1S;+.:#HB;ET48"22: AV+T=J!UBC
M-RPG/ JW&3$K<;55@>A3\36["#^^1K3Q-'M9@;%.Y74K3@T]6T,B([,@+X!!
M#,XXM?C[H3Y##=?FFHL)(6.AMO'FPIKYU-: R BIK8_6H),0BRD1EFZD24P
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M"=-0.LB1VH* :.<&*M#\L"PM%UW=Q4$DH,G)&DMEFJQC3R43?EB'KP'S(,P
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M/C'.A)^'1[YTT/S%.<&_XVWG(/K.-_H"$H8 D0OR'7G\+4I[%)OICP-I:8@
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M.;#F?]G8D9S)%4*?O!14<[3J-8)4:4<6"7;II6@8*JJU6J\J\K^B6X9&0!*
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M^Y?_V@ , P$  @ #    $                                !! !)
M
M                                  !))(((
M
M                 ))!
M                                                        ( )
M (
M                                     !)! (!!()
M
M                 !)(!))!( !
M                                                           !
M() )) () !(
M                                           ))!   ()(
M
M                      ( ( !)(!  )(
M
M   !!(!)!! )  )
M                                      )(     ) !(!)!)((!(
M
M                   !!!)   ! ))((! ((!((
M
M ((((!  )  ! (() !)(
M                                           !!) !  )!(!()! ))
M (
M                        )) (!  )) !(  ()!!
M
M            ! ! )!))! ()
M                                                     !)(( (!
M)()!)!
M                                   ! (  )! ())((
M
M                 ()(( ()!
M                                                           )
M)!(  ) )!
M                                         !(!! (( )
M
M                       )!))!!!((
M
M    )  ))!) )
M                                                !!! !
M
M                                 (
M
M             )!(
M
M
M
M
M
M     !!(
M       ))!! !() !!(                         ! (!!)()
M                                                 ! ( !(!) ()
M                         !      ! (
M                    !!        ))!  !) ()!(
M    !)          !(                    ! )))(               !
M(!)!        (  )!((!)((                                    )
M                    )   ) (             ! ()()
M )                        !(            !!
M!(     !((           !( (!((      !(
M       ((             !                  (        (((
M   ) (  )(      ( ()(! !) )(                    (    !)
M     )                !          !!(        ( (((()(     !!
M!      ))                    !   !)(()! (      !(
M   (           !(!         !!!)))(      !!  !()(! (
M          !   )))!  (                        (             )
M(      )!!!)!! (    ! !( !() )                         (!) (
M !(!       (              !               (      ) ! )!))  !
M!                                   (! ))( ( (       (
M                        )    !(((!))((   (!(
M                      !(           )
M      )    ))! )  )) (! (                             !    )
M                !             !(                !(    ) )(()
M)  ( !      ) ((                        !!! !)!() ( !(
M                              !   !(!)(()   (( !      ()! )!
M(                !    ))!!(!)  !))                   !(
M            )   !!)( !    !     !(       )(               )
M   ! (! () ()( ((     (             (                 !    !
M(!((    (  ( (          !              )        !)!  )  (!
M   !             (                  (( !( )(!     ( ((
M      )              (                (      (             )
M                   ( ) )(       ) (             !
M !                                      !)
M!(   !          (             ))                 !((!(
M       )               (                  ((!  (       (  (
M            !(          (        !!             !
M     (                  ! ( !        ) )              !(
M    !(       ( )(           !((               !(
M      !) ((     !)!(                        !!        ()(!
M         (                  !                   )        (!
M                   ()(   )!                      )(
M           ((                   (    !!(
M  )!()!!                       !                      !
M            (!    ((                         (((
M         (!!                       !)                (!    (
M                                                !) )
M                  (               ! ((()!
M                            ) (
M!((              ! ((
M       !! (                                )!
M                                               ! !
M                            (
M                             !
M        ! )(            !((
M         !(                                         )(
M       ((
M                                  !!!        !(   (
M                              (
M                 !!(       (()(!
M           !(
M!        !! ) (       )(()  (                       (
M                                          (      !  (()) ! (
M (  )( !()!)!()(                 !(
M                                )( ) )()) )(          ( ( ))
M               (
M    !!        )!())        !!)! !))    !) )             !
M                          !  )! ! (!!        )        ))! !
M     ! (!)((!(!( (     !))!           (
M       ! (!    !!    )(  !          ) ()(      ))()(!) !!)
M        !          !(                          (!
M  ( !) !        )! (!       ))!  (  (!()          ()(
M )                          (                            (
M                                 !)        (
M         !(                         !!(
M                !        )(                        )    ! )
M)!                                 ( ))                   !)
M       (!)(    !!(!()            (!)(!)     ((            !
M                ))!                      )        ) ) ( ()()
M)!))!          (!)        !!           )(                  (
M) !                    )
M         !(         )(                   )))
M    !(                      ! (                    !(
M     )))))))))))))))))))))))))))))))))))))(   !)
M            (                    !         (  (
M                                                      (!
M               )        (  !(!( !    ((      !  (    ) )
M   ( (    (                                             !
M     !(  ! (()!   !()!!   ! !(    ( )(    )(!)((    (
M                   ((                 !        (   !(!( !  (
M !(!   ! ) !( !  )     (!( (     !
M !                  (            ) (()( !( ) !  ! !)!(  ! )(
M      ! !     !        !!(!!
M !            !( )!   )  (!(  ! ! (( !  !    ! !(!!     !
M    )!  !( !            !                  )        ((    (
M!  !( (    !(!( (  )       )   !     (       )(     !!(
M      )                           )     ) )  !  (!(  ) !(!
M (!)     (! !(    )       !(       !!
M      (         ()(  !  (  ( ) !  !(!(       ( (  ! (
M       !          !!((      !                  )          !!
M)    !  ((       (     !)      !(   !!)
M !)!     !                  (            !((   (  ((  (   )
M )(   (      !! !( (          )                )) )
M          (             !( ((! )! !)!! )!  )!((!  !()( (( !
M           !                                      !(
M      ) )(   !(  )!!() !( ) () !!    ! !
M                                (              (       (  )
M  !(       (      (  !            !
M            !(               ((!(    !(!(   !)(     !!)
M!!!
M          !!)              (       !!     )             !
M                                  ((
M                                      !
M               (
M                   !                         /_$ !01 0
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M*:Y#VX:R<>&M36OAM[9SEFLJ0)Z=%(*NVG''%XI)G@+1S@()M"++K;(N!='
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M2D@A9$II$*I1>TE#)6=ZX1%F0&30-4@X ,T+>7'E?*"2.C7D#EW^WJ0+6$2
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MHL-@29[*BH(H%72X\+7=@]4W]:%-W$Y3SC<\4N(51^EF_8, \$Q[#2FQZS:
M,\#:99R=1AD\JJFSF@A*W6Z%KK?"%CUD263;8,MP92XS<!!)^3X7(*+)5!SQ
M\)%W*5A[Z%;D; ?O1JM?@)Q8)KD#'7Q8JO!]]3* "?9V6W@IZ8JE6*)$^BE]
M\:A:W P05Z_3-E&3KDW5'0HEE]_#CA:D88.,#$S%D<VC45AL I]O#83+;/KM
MX)&Q!\HY'TU!;O"X'F?%"7$J!; <[ &6SC!P .7!CZ3E029B%F/PR(@#7417
M%O/ (5&"0)AB .*_W%$B;]<41(EXM6$K3H3C1+XC );OS\EY6ZB)39J80!=H
MP0DH!71O.?F<$#VMD'K$F#T7Z+CW!GM$/;)/VMZSK1+WF_6Y_P!"QV<[4\Z4
M\FK3VRLJO+0^:YL6^_\ E%C=/HU&M?VIE>7>*(387^VZ#W;[Y4N>!IVN:=:^
MQFRZOT[-_8#$ $P-@T\MCT0J*- # ).@5.4$P$ [3(Q[@BIC!A::%/TW3O[_
M ([YO:0%A J"EH* R*)R/@H;4#NZY8?RZ^<UKJ"K$!**V FZZF_0IP(9W@6P
M&Y0=7L#;46H3,II8FWI/ZCPT 9$\^7Y^D=#+\IHUA(W2[+R& GAB[6L";9>!
M2G,_N!U56\'4;7&J ZP9I0=8C"5'1H[)MS:.G.M[;6DU 7R472JR]$BKRG$?
M!;R5 2>"TPX^)9\X*:\RY/2'U&VRMF<LU09IN.\DZ($;Q,LK,D35L$ @D,AY
MJ[&=9@>M%7O+FH^%+:2K8$F7?LTRT<AO_4A3Q+:/"FLT9O9?@N5L.4CL 7[F
M!OW.F,-W>S&<]CVJ#?1"/+%88)A43E='>73"69FTLIL6P5:V@RNL>2IQ*(!)
M& [#W5XX^K1YH'.15NP3VR])0[(@4QMOB1I M,%TKM=#"JP4QNZ%V 8$,2@&
M.:)O=U?1D+Q^EPQQ]U#.,M08S;)8^I\@RJU%RP'1,R1X0*\<7VP[%9- "8&G
M"0-L@<E2D@TJ\ T[0<+A0GXKPN"O#-:*_1<'VP=NJ  ] ?"LGM!_6?PU1 MW
MFH!#?31N%%.D60I[N>8F6F/6:N[/19Z2"IU@;_AAFQW/][VW6-OM<LY2-(PQ
M4TK+)Y@/X>V: N&\=F+>R.*%I0L,5!3 U=DGP4#A1H5^$#K<X0(.!90M"1D5
M F&#-K$YMGX7>J_BAOZKT2N-XH'Q)YO!5Y5&BBP,*)<(\')?(HA>?@T0"!90
M36L498=^/U#;MG<,IEW49#GVZP4G7HY+.204(_\ PQ,_$*<":&@-!]OBG%0U
MP R]H+E:0AX1E5*.R7&?\!6@M\@(IU"4PO9)65K"5=J%6K7T:#AT"!!XXU*=
M!@6.;>\99F%HXO@V\9VZ,DIMXFQCVW,8@2VI^"W[6RT5BJ2/QI#NA#2]&%1(
M$ZL&8+5Q&6)H989'@B(H6LONHBNM%DZ(&G;>!4+PUW>P;V XAB1*T@$.ZGCG
M=ZJX3SB%R \[YR:&Q/GNPZDU<HUO;3;@H.ZB:"@F*;#'1AT274G'"4OV&."I
M5S%) #$3$+D/MZ<*H')"<LAPA>ZF,P\P94PU]P6\K4.>#V9"2S>Y.<'6S28C
MOD142,HR(B,,34(4I0F()\G!P"L%J,88 RN*=.B( DV>@-R"8VB@EWX>V8SH
MS) S $E5,H["ZZLG8XW<9V1RT9!C@3T-"JP<=+%.0@&,+-_@NN0/)?).&'UG
M\/%??GE1X#8/H6;BNOA7X"W$\Z.G% @$P43*T5NY&]1G5J5N0QC79CA@:.U2
MA1+5@0ITW&J"YQK,5>"^/ZN"O+@R!<E^?KW09K)41 <&<"BW."Y"GE4_39M<
M9M0C<5!X,OVX]!B*V54^-G?XY-1TL/KG/6)>P+2C">B'X2Y/D?N=U!2R*BW]
MN;+3@&]]H&)='?XNB;&H,7-93HEUH0*^  % SI<4;(Y&AD; 7',3!4%"I0*B
ME57TW%%T"A"NG5#/),,$..##V:"0E#%.!4E[&>@:<'8#NTIVO^SJ?"PJ3Y-+
M.Z:1JP//3#*)K1!QQ,?-,WZ-ZEYH-DJN#FA!>L-R52KR@ UAT1!QF@  -  '
MEY3-9R\HV/<'WR]U.TQIPN].+J!,TS 3($?.%!21(IA$GV'I05FT]H,5(+BI
M6@VDET>@;28^WK)7;0H#UO3?T(SW%'GO%F!H*H(LA-/QGESDK^:=6)8.WZF!
M(D-B?,?@YL8>M@"<)O\ @G*I60(F 8WBGB@3K!O!L/*Y<S2!?/VBY^EW$2#Y
MZQ%RR$7SVNHOO;C^6P]=;,P2X!1H 1 >N@O+]Y-,BKA Y_6]0CA8G8O5!P(9
MWPVP&Y1]O=(!?1@0Q!8$%F(SFA(X"(P,MF@"M*,D H22";ZN[_THK5$B,E ]
M!F'" B\P;G2$QWAFCN(3>X_9%DJ8XSG@RH( %1 !5F6O@P4 )%TS'.:36_E
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M(/*Q[ZGD6&$4NJ;PF#!!C<=<VC1TS[ZF<1B+-UUC:.);J4K^-0A%,N,TXG<
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MFXH"K VKP'=R06*.AH'-4==F$4%HF+*VG H,BGK0@]&C!5F.DP4*[;!81U6
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M#6&WN3U35<J?8<\W />=(I8 B@%0!1BD4?&-Y(J:6R*<6+J:BIELXT<
M ( : #0!P?84\B_C%/8MO!41N;&%;HQ:^.06G@SI2-QJ=MVP?91\#Q0PBR&K
MO4#9\=(%N]E[H[3K!OMV>O0#K=)UN;WT1?#^/_;XHF8@ *A  *J@!765S!@L
M[0F?07-!L]8G?H)-"FCZL%%&KQTU)R)E\AZ<A)5+1H]4#3G06^>1H:HR8@
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M5/8:_P#[F"1R@3)IJ(\J@;&Z9-F(&\08)JMBH!$J+T5)3"FD55K@#5U]((U
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MF)<<%FR,*,!=%*7] <[)8\NQ%]=&$;7>%R"SBF((O6NPW^!P!,'AHN0A:0C
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MB,"86?#'_(F!X"J$=(OR*,UB*Y_Y>)^K40<-(,)1:P2#F$G"1K$.2]S.0\D
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M^9OMG73M\SL?^N')ORA_$_&LN!+R5=[UTZ0>]QX\^?\ .>'^+O!'BN_F$_\
MR]_>#M":01[I6>U+W,'%IM%'L.OLCYP;A'!-Z%7.[L=W&!!+S[U$_FA]L$K4
ML7ON#7BWW(;QT@@)!>PON,Y4,:,0*D\ M?;;VP* ^S; ONAZ S+"?1M\ '4
MU#-)V1:E:-_F=F8.61%%6ADIDS1LQ%27T1 M2]WZXR7I&['B@:;JE%,;SSK
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MPB=UK15(%15)3>@]A*!Z%&'*.3>&PJ)==Z@*.\:6%@B1Z!:=(!7ZZ@*L#:O
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M*GDYLCNFF#UDY#]WUK!=B#T9A-!$X*%>&Y9"["!$@H<M3U-NR%;U #QU0<*
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MNB(]'UJ!#H2\$BXHU!J6"!.I6?)&"=0N7$E2N%:WDC-G\'[#.*?3BF4/A4/
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MRV_'Q#XUV)!SH!N.>;!"$L8@317$<6\J]HK2S-#A=X-@D3$[LH-ALNLP$)J
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M]+;ZDY%L0G%PSJ1#<XS[<(",C8'1 RG)>80(V.@,C(GFW<O?=.\E!H=9#5@
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M,;#_ /:N#,B,5T- &E!=WUEFC@3,9(I0+N[ B8@ULN@0$)V@#Q&6<Y0 !51
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MT+A5:W.K3WVF&PDXD%J5)8 '*J/*"!S&&P!%S440E'T"CI0@Y+3B4\!YYBF
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>twosnasa04.jpg
<TEXT>
begin 644 twosnasa04.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" -5!_(# 1$  A$! Q$!_\0
M'0 !  (# 0$! 0            8'! 4( P(!"?_$ !0! 0
M      #_V@ , P$  A #$    >J0
M
M
M
M
M
M
M
M
M
M                               5@2(EH       !\$-((:8Z)
M                                !4!$BP"PC*
M                                                        *L*:
M+4+D       /$I<JDDI[&R.AP
M  #\.<2H#]-L7F7&?H
M                              *H(@8)T*9X      -(<BGN2@L@^RS#
M/                                      !3A418I7Q(C,.C#Z
M
M      -444:TE!>!Z       QCF<DQ,2.GT6:;TP2*FC/$E1,
M                        #\*U*\)02$I,NPILDYT$
M                                                      "/%"D(
M+//0N WX      *K!IS4FR)X9YRZ0\L@C1/2Z27
M              &$<TDY)$5>9ID%=E=G]"P
M                                            #3E;'.98)8)L"RS8
M    %>D0+))0"A36$H)\1XRBO"-$U,LF)[$O
M            !""FBY#>%9G@<U'] 3[
M                                        !I"BB&%W'B;,F1M@   0
MXJ0AA<);P*0(B2PP2W"1E/$/-L6$?I.
M        "M3*-J<]E@%*F =T
M                                  \CG(@1+"R2/%@DZ   *Y*'-&;D
MZ/)D 0<JX^"TR:'J8)S4:LN\L@
M    AI5Q=1S(00O O\                                $%)R?I$"6G
MT   1 EX (@2\   @9.3[ !IP;@$0)>                  #F4P#/)P:(M
MPRC<@  % D8,@DA;1OP#Y*1- 2$M4W((R488QTP90
M                  (L;@@11)@'7!NP                  "-F0;P^3Q,
M@          '!)=IT2<<'8![@  ''!V. "J2U@  81P"=5%P@ B@)6#CD[&
M                 (8<H%WF000L@T)NRVSV  !XE2E;&A-F7P3P Q"@2*$[
M+R/<'-)!B4G4I^@$.*U(Z:@^#JDS@
M "-E&%4E_EW                    H(RC9GN:8B!T\?8         .,3].
MHSF(Z_.4#K<Y'.E#E<]2^RA"_2@P=*G/!TL<JGL7N6>"@B1%%':!1) 31%VF
M05F>93!_1,ITB1AF&>0!Y%GEPGZ          ?)0)N2YP0LJ<UQKCZ/<]#:F
M])Z3(   TI2!IS3%QEK@$=*$(*7R6\"!E5E8E\%S&B.>3[,DP3/)"7>>P
M                             !'SFLRCJ(R                   ",
M&<1TC)$B:'-1W>          <8G6AQZ;0[ .03L8XX)R6@3@P#DTQB3& ;DC
M!/BQB?&N-L#@HN,H<[C.6CLPU!5Q]E-'91QV=B&B!F&8>H *C*>+(+Q/0
M      JXIPLXN8'B08A! #[, R3#,<D1+25DN)$?0 *F(B2HJTO\F !H#G8J
M\N(Z/-&5Z8)49T^467H:8KHG9K"T#;
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MQI"7DI              !KSEHI@\2PR+DS/H]":$#)$:0^37F 3,N0MD
M                                TAST81T&2H  ^2.DD!R22<WI)"S@
M    14J,UYH#*(T=@&P!K" F.0\U)FD?+/.<B5$^/PFA(2MRO".GV6R8AN#3
MES&J)^ :LY:-8=&DJ-J                             #0'"1<A(#?$H
M+"              !2A #>& 8)9!7!J37&:>1BDR*/)N=)%D
M                          &N.?2/%]DY!YE*DO)F?1Q27<99L"R3.
M!\E=&2<WFX/TN\L8 Y/, 'T:TQ#*(T602LBY 3),@W1O2UBPRD36$I,\GAM
M "H2@SJ\E8                             !'CD\O KTM<@9^$B+G
M          !2A"2=E9%_E6DW/TYG.V3"*'(X7X3D
M                    QBA"$EWF><V%H&268<O%HGV;<N     &L.=2GRP"
M='08 (@0XA17IBF4;4FQ8Q7)6Q(2>'H6>2,^@5F5H>QMR^@ ##.?"$DZ.BP
M                            #".>#"++( 3HWY]$L,D]0
M 5J5F8AO29DL*#.>33'41KSH,E8
M        !\%'G,A.22',A?A@DS->3HMTD@   !7!S"; O\DA,@#'*?*M->3T
MV1 B5&^-,:<SC?FP+=/< &L.>#4DO.@#] !XE!FF("=L@
M               J KP^P>)C&&81@GR9A*RPRU#)          / Y](H2\E)
M.3^?Q#P=2'6                                            ,<YL(
M05010R2\"=GV2\I8ZG)@   5J4 5T=9D5)P6: 444(6<"YR)E7F:3,L@U11!
MORU"R   4F5.?9TB3  Q"(FL->4.=J
M &M(N5F91Z%:&K,PTYAF,?9,3K V@         !2Q79%SJ@X-(49IOR1'7I9
M(                                           (:5T<5&.#,+U+$-H
M:0CIU*;,  T1Q"6R:TNHQR=&X (.4281\%R&O*[,HE1MBY#F4CI>I8X /DUA
MH3G(PSI G@!B%:$:,,B1UH   :\K\K UI*2=E@&:
M      "FC&,\@I*S1&*>QA'3@         !0!!34%G%H$@-D
M                                  5H1DT)H2"&F.D"$&S-$=#DC/4^
MS\*;*G/DWIFFX)(2@F( (T5Z4N:HVI+37&46V6<>9RT1$ZC/ UI5)5Y\EC&$
M1DWIT\2<TA4)B&X)004OX  $$*'-V1@V)'33%OE_&8
M         4J;XV9S^3 R3GL[H-X #S-*9A\D8-*6J    #5E/E.E_%L
M                                            &N.?B($P,@K<L$VY
M%";%9D!)J3@@I[DV,H%]GV #\.;3$*^-&6 2@LXL4\SF,C)&#X,PGI*C>$+/
M$T9 SQ.A#**Y(T6"1 M4NX_0 :PYY/HRS7'X;8VA%3>'00
M  !&CE Z$+./H        U)0Y:Q5Q8)S$=5$[ ! S\(D:HW159UR    8!2Y
M-#G(]#LD^P                                         5"998IG
M    TY1I#S)(@;\C1B& ;$W)*C$,<\33GT3<G9)RP@ :XY>-6:\TQ+R.E\&*
M2<@1I#3$Q-0>Y(S7D)-J"/FF,@T9DF 2<LXZ%/0 %6E4$W(68YD%AF.;\SB?
M                 %=G%1T^2PLX        _#&(L5P0$KD[O,\ %:$?(\3,
MW94ITP    >91!A%=D9.J"R@
M    #!*9*A+8+Z    !J2M35FF-60HL D!FF@*Z-26T?)]$:+5*A(H:\\#Q+
M5.I"L"KSZ(H:XWY9AN"CC,+8+/*<-&:0]C,/TO0VARJ?A:A:AZF8?9SH0X\3
MH\G8 !19#RQ2 $:)V99)RTS[                 !49S"=T%)EGGF00M,W8
M      -,5Z8I0!8YTZ:0AAJ3W(^?AJC**^+F+D    !$C2&P.32PCJ@
M                                    C!3I69=1=8   !7I2!C$Y).1
MP@@.DR2G.I6I+22D?!KB9F4"G##-&8YYGZ9Y(#8&A)V;HL(P3G$DY8!B&8>Q
ML2O"RR0%DG-)5AT^64 0@@YIB'G7   .?C[-<2 TI=!(#]
M    !2)5ITP5F9!NB?%0EXGZ      "%%.D3.FS/.="V2L26%:FI+=-.4N=O
MFQ    !2Q S((<: [L/T
MPRJ#.*&-V=9'Z   :(YC)">9Y&Z-,1$ML@!U6<&$K)^;LC1J2]"-'Z1TVA61
M/S2E<& >99I'#((P:<Z<( ? - ;PW9\&";PNLK0N B1Q^=!EU Q"#$!)L5H=
M+@ 'R<U'P2XJ\SSJT                   %'D;+T*U,DWY&#4%E$V
M /DY[*J+]+>*"(6:DV)H3?&>:0B)TJ6V    "*F<:(JLWYS<=Y&:
M                               "O",GT:PB9YG4I6Q5!JR3DG+K!K2A
M2VR7&L-<<:%G&N-$2\JTE)OB2$^-86^1H@IB&B*X),9!'S!(L>99A+#.-2>Q
M S+-\:T]#9'B?!OC--B7"<_%0'N=L@B)"CU/@C9;)OS- -4<VFJ+N*S(N=A
M                   J$I0GQCEJD2-H3XJ O4^P     1@YL,DO4GA41S>3
M8\C[/8C9I"7'7)E@   'P14KHKPL<^BB3N$_0
M                4>08F9(BF21GB0(F!LB4%%G2Y9H  (><KF^,0\C'(Z3\
MWYMR/&T.C 5@:,PR0GR5"14^CW)230UQYF8:TK$R#+/$FA&S#):2TRRTR)',
MQMR$';)$S0F05Z0$T)C&V+=+[)$#GDB18!79X'7P                   (
M,5(3@K8\BZ#4'H4V6J6L9P !7I3!EEHEFF.<KGL6&7(?8*>*6-";8QR3$K)6
M:DO0TA S4F8;8WYMC+*?/@RR.DP*L)R7>           #1'.1U4"G2?$D
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M)F5Z4^?!%3MXBQ2Q-S5D,)"7B1DQS.(J:8]2J#=%\EQ
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M!6Y"#9$>-&2DBI^&N-X91^EC&>2LL,]P  1,K(RBQR&E:D0+.)L2$HPZ(-R
M  #5%3E<F_-87,;<BQ!2M"/%JDK,XSC.,XSC-,XSC* !I#B<FAM27EG'$!<)
MN"^3E,V!;)59AGD=3G.1U0<L'112!HSH,J$W!7!C'7!]G(9UT?14)K2%'4IR
MN=$'+A]'1)1YU0<KG19RL9Y;Y7)TH90   /,H<KPA1T41TF!KC9D9*[(D6^8
MYI"*'4A)BEREB9'5!]FO*H*<,PFY&"2D-)(1XUAA&(30R2)%LGR0,WYZD /8
MDI]D5) 9!\&N(L8)KB;&\(>3 P#K4@Q49*C0%5':)(P  #",T
M           TISB;@OLVI5!"3:FW*^-:1PWY@&O(^>QUN5@2<JTM WA #H0^
MP "I#S*H+E*9,TT1TH4X=%&G-V9(  !#BF39%VE#&<6\24A!S<;,FI7I>Q9@
M        ..#L<  ')QTV;8                      'B4 5B6H;<TA"34D
M:+7)>6B4P5B6B5&899A$R2'4H-0<^D!/ W9K20&V->08Q#8'H;4VIO#T-::P
MBA8Q%#<&010Q3]/<Q37&E-@2,UQOB?E<G:94!1I=9&RC#MHD8 !7QS$=4DU
M            /DC!O#-       !$2A3 ):0<FAFE[E&$,*W+ (6:\RSHXN,@
MQS\725T3\D1HC'-6:\V9N2MC+) 5R2,\B'F].ES:    $'*?*P.LR6G,Q8A)
MBL"E2T#HXV)"#G,MPN<        CQ(0  :$W1Z
M  CIS"0 F)-RP#F O\L4A!"B&F<1HO,A!DE.G?![D+(@04C9YF(>YCGR1TBY
M<YCGV2<SS",,RB#F(28^SP!XF@(\>AI#-/<\B?F_/@DQT.5B4"6*:<I0[:)@
M  1 Y'+..F0  #FP@!TX38        A)S43PZ/        (^461@QP20^R+F
MJ-48A\$S+?,,O8^"AB+&":LT9L3#)0:,S37&>2TM(YA.U2BBO2R2XS> ^# !
ML#Z!&RF30$R,4MTJ(QB#DS,\FA71<9X%;E-G0A;H
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MC9S 6Z=,E%F4>)L#1GD;8TIG$ ,XZZ/L
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M/'N52>Q=YM3U)"        <_&R*U)V34LD  _"I"H#V,@^#,+H.6C='7YD
M K@YY.M2+D0/<B);Q-3[ *V.126FJ,HN,VY+"I3%*3.MBPBKBEC'+#+D*2+!
M/PQS%-,8A&2"D1.D##+K)&5H6F>H/$JHQC0&](^:TAA,#IL
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ML<WE/F23DUY8YT.    #"*1-80PUIVF
M #X*5( ?)91@FD)&4V=&DZ.9#S+;/$C!' 0 EY&S:E4GP2HV1) 91$3<$L/T
MQ"ER^2N#2%A$9*M+D( :LV)BE@&G/H^CS,0\3!/HQ#)-B>)!RQC)(^>AIC=F
MT)&9YY$.+5-^4T2(KDW!:1J3;E('50-08I&B*F07P1@LDE         !I#E\
MVY/"=FS-D?I595ACDE*W.G"BSH JLVY1A*#KD   I<CAL3+*[/D\#1$Y)48A
M$#'(H;4T9AFT)V0<V9/R'D/-V=.$;,8T!ZETG/Y(CT(@4V28W1NB G0Y;P
M  -.<_&X*H/$[>                              !5A2Y9A%S8D@/(EA
M3YI#JDYF+++ .:B3F(;T^2C23DI/<SRICV.B#GD@1T60LU1BEMGX8IZ%5'J:
M(^0:8DQNS5'J1<R"Q",$>,DCY-C2E>E@$@/ TYZD@(V>YL"=D),@LLAQ<I#B
MM#&-.2DF1#SJ(IXJ(O,PC1$C(,6V>QYEKGJ         #G\KPMLT!=QS23TK
MPUY81-2ISI(@9/RGR7'-YX'0);(  /(Y9)H4R?IE&>;@U1LC-(T?IHCX-$30
MUQ(2+DZ,,T!GFM-R8I*#,)>:@GI(3F0L@B) B?$2(L62=7     \2D#U(^:T
MZB                              /PI$_38&8?)L2P35$'.:SJ4U1/#F
MDP"1&^-^1$@Q""=ET$K-Z0PYU*5-$6.="'X;@I$WY89ED1-^1,V!6Y^FX,$_
M#.(X?!,B*GP5Z:LL$A9*B9D'/4FAK#P/0U18!BGZ;<E!'3Z-8?1HS,+I-F:L
MYZ.L2/%*DN(B?9(C<DT/LM(          AAQZ7:?)("+$?,$_#H4V)5Y?@,<
MHTM<I4K\F)TD90  -:<HFK)L1PUY*3%/ _24$7(D: WA99'S)(P2LTY@FS-R
M:<W1N3H\$<*=(R6\; IPCY*2*F&:@[C/T    $<*]*\.@R2@
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M<^%I%:$P+?)D>ARF1DVI]&J.L3?D8((5:4H?9@FJ)V8!@%J&:6@10@!8!K"
MDI*S+?($2 \BLBWB*FK-29!*#Y-81@L@W)FGL0LA)>AX&<0(BY:1XF^/T^BD
MCHHD9KCP(H81[F,1\O CA;P/(W)[@          ILYP.BB)$8-N=3     '*
MYIC[.FR!%M&D,0YV->;H^#?$)-<?AG&C,$_#W)^;TPB4'F3@FQ1Q5)A&^(N;
M4WIU6<W&:=!G+A"RVC1D(-@>Q-"-&E.U    #3'*YJR,'6)98
M                    !\'/!#S:G0A(01PY9-\>YT\>P,(X_,0LLT!#2Z3<
MD6+&*L*W-T>1\D^*(-8;TO(BIE$W/T]#DLEYL#(/4QB1$(-N?)[$!)N:<UIF
M$F/L^SZ,LQ30EI&65>2,R#X,XTAK2*%J$E)H9Q@E>GD:DU1-B[3?
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MTJ8KDZ9+()2   #Y.="MS#)B:@KDZP+=
M    *P(\0@^B:$N)\5N3(W9'3W*W*N(H1\O@Q2&FJ-R6*3D@!SR=!E?D7,8V
MYE&@-V91HS9%>FV(X6,?1XF:8AO31&>;DB!G$0-X:@V9)#/-J1HUIBD^)"5X
M2<_31&^-L3 U10IM3Z.KB5 $?.=B%';A]                       YO*0
M.EC",LK<T)L2R3"+!(V0$NDIDAI'C>DE(X6F:\TAYG3I6Q'RIS#,$IT^09I8
M)N#V/PWY8I=13!8ISX5X=2%O@  'B1,V)R^1PS2XR/%9&[.QP
M                    #4F,<^FN)8;(WY\FY/0IXM$I,@A>!3!<9JSX-*8Y
ML25E5D;+A(X?1!27F40HL(C!%36FG)0?!)")DA-H8I*"&'P995QJ3\+R-.>!
M-CT/DUY##<FU)H>A@&R(T1 &K.@RHP?I<I>P!YG,A69TZ6<
M         #2G'1Z$H!H3T.FSY*)).89:I21)RG2:$%+F(^20B@/ L$C!J"/&
MC*A,\DI>QY%8FZ/8\2]RX "*%;%;&"=3&_/8 &A-64":DTAL"[B'%ME"E8':
MA+@  ?)]                             &B.(SJ,UAN35GX9Y#"R#G,S
M3J8Y*+%!XF*>)H3?$9,HCYF&:0TLDU)EF&>!@$9(N2<&.5L6Z?I^DM-09)H"
M&'N1@Z1*P-T99EFR/4A!XDL-N8YM#**R,4VQH"?%UG*!=9?IO@"GB@B:E1G:
M)-     >![@               $1.?BQCU*I-^?)6Q:9BDJ->?9,3W*L*O,X
MR#4'3IG$"(H99XFM,HT1KB1$Y,XW1SP=#%2FL+\*N.F@".FH**(42PZ0(Z60
M0(F!0YK3 (J;LWIT ;@P"C"D2]BY38D1)40PWI5Y-R<
M            %='-9T"08FYIC(!7!#3M '&!9Q]&(?1[&B,X_"*DD-(:XR"2
M&L)<5"99D$+(H;8MTP#0D;)V5B3,W1DF0:0]R!$L(434W9O#P-(:0QSX+*,$
MDAAD%-6:@EYC%GET%?E\ _"*'(AOB7E?F^.O    "HBCCJ EP
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M0U!\$Y*=(67"7D  "+'&I,"\#Y/(RC6'V:4E1/39@
M         &$5>:HUAH#?D2)>8)"33%BFS.ABE2('X:HUY,B&D2,HDQ/B+$/-
M4>)&RR@5&1DO<T!NS7GB99MC!,PU1H"Y23GR5<00VYAF8;4QR-FC+!-8?!CG
M0) BGRQ3S.@C>D8*J, UAOSX-B7"<YEZES&(98!I2)% &N.CBR0
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MO23 %$E+F"8I[':QN@<X&W!!"VR'E3EA%^G/)>9 2%&M-"6<1LBQ]&&7B7>
M8YRL:@WIT24T5,66=''N   #%.7"/EFDV(X1@W)OSGXZ$+9
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MJ>I'2VSKDY4-499J#H,GYE %+DK*R-,5^=K',IHRVS!*7)(9ABEIDJ)V
M               #6%!FG+K)X "!%)&Y-T547Z6>  :4YU-J:H]2%%O%9G7!
MS$>9&CV-H:LV!?1$RT#>
MPCF,RS(-J2LV1LB&%%%V&>>10IT(4T9A:Y7!'C6EU&F*P,P\RX2B")&87438
MP#4&K*0+4):91KCS(B:PVQ%"&&U,(]#4DB-&;(G!'B=&K-6:@K LDVYJSQ-L
M9ICFJ-@:,[(+&*H*0,,M0OX  ^#[($00JDN@L8AI'C#(2;@SR>FL+4-@
M                   #!.:#2EIEJ'P;L  AAS06V1TDI3)9A:!3QLB>E+'Z
M9Q!BZC\- =(@                                       %;E)$H!,S
M;EA@^3G$C)(C,*R.H#EPFA;A.C0')1*C++;*S)P5P5L6(10L8L<T9%S=D5(^
M;@J$WA:AI3%/LCQJ#7&(;TB)(#7$M) ;,UIBFK(21TE))#U-464?!5A+S1$<
M.TRQ31G'Q+CJL]",$E/H 'B4R1,\2U#,-(5:;0L D! RV#=@
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M3,Z0  !$#2$!(\?9.2-%<E\ENF 4P0\DY^$8)>7B9(
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M:ITR  8)4!;)5!ORE31&>>!KS%/4RBT2XR1
M                 'B<K&06(38K R2IRXB(D_-,;\U)0QT*6X 14Y_,,RSR
M(\5P;<V!41."Z2:$=,(DA1Y'B\S:FO(X>I&#<%>$P-P1DWA@'J89FF:: ]3>
MF:>IA$2-T1\R3]/4^"RCP*_(N3\WAIC<E>@F1(""G8)O0 "M32EE&Z
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M,>Q"32E7&H+E-:?!BFO/<M@KHCAU4<A'0!9 /DJ @YH"3E=F^.MP
M                                  1TPB7@ A)S.8Y;9E%''4)8(!$3
MF,JTWQ<ATP8QSR0@]CJ I\L,G9SX:,HHDYXEYD</(U1'#]-*>YN3?D4/(VYI
M25D0/<U9NSY)P>AL2($9/HDI[FQ-H:(T9K3H8N,QC'-B#D,FA,#G8NXLD^"6
M@ &C*4+6)B                     " %:E;'N;HF!LR/EE$&-8;H^RG"3F
M28!Y'V>IZ&J,@^C4DL.HP >1'R+E5D=->=I@
M                     '@00U0)L2$ JTYR(L6";PZ$).#4'*AF'4YG@BI#
MBG"KB>&23,RC6FN-81TU1)37'L;4TYO#1$/-X;,UIK2QB6&0#5&&>ITL<SD)
M+Q(B5>?!U"6D  0@K$Z$..25EHFC++-J1@]#2%'&D.NS;
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M817A&BV32FS,PV)!C2DL(\7R7& #$*W*=*Q+I.F@
M                          #S.8#,*^,,L0Q2/%CD),8ZV!S230R2T2/'
MD0PAAC ]C'(:3$V1\ B!MB,&"2PQ"*FV,,RC (T9YOB6DE- ;X^CY/$UYX$=
M/@D9,""FN/D[3    -><5EUF_(<2,CI59(3J0W(
M*>*K+#*N.J3]*J+N  , TQEF](V<IE<FK-L2PLTRC&)<5:1LZW)6 0XYQ,4W
MYU2?H                !RT=2@B)%2V            <S'3(-<<KGX>IU@>
MH          /PYV*H/LMPDIO",$9(>9)KCL,H<IP\C")V:@LL@9J3<$L-<;
M^36F 99X&$1XRC5$M-B14^C8&J!!S<FP+,(@20\3]-@:PD!5QOR.%WDM.?3$
M-N6T6*: C1"R(FE)87B6 14YH+6(H;$B);9;                       *
M#).1TWA5!(R^S:     &A(V?AZ%?&\-"9)81S62HZA!ISGL@A-SIX^@
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ME:F0;PFY"RZC\,@@161MS./ FI-B8%>D\*M-Z;$A)?YLP
M          4B58;TVAE'0P       !%BKB?$1*])L5$="&_.1"1EM%U'H
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M\E<G0!("6        UY31=A2)8Y4IT408Y!)27.1HE):QF@
M       KXL$                                T1[%+%-%CF_+@-^ #
MQ,(CI3)"SH\HXUQ R?&M)$=$$H!^%1%?D:*M+4)22$R"1G-!:I?ALC%*0/LG
MI%3<%;GL1D_3<$H)(:<D!2I#2X"#EB%[                          P#
MF<UQ)SHH]P       ?) BI":GR1XU99)RX6:6224UI'BZCT
M                                        (6:HT1SX;,W1T$3H  %>
M%6%>& 6,;HG!!#:F@+<)R?A69&"E2+$A,0NLLL@Q2I,R:%IDD *_(N>1\$!.
MJS[  *S,0IDRSU(\=#%D                          QSG@BYJ#H\GX
M     /PJ$D!#RSRDC5FV,0%M%'&<38Q 7D?0
M                          ,4@QOS7D,-*5$;(D);9:   -<4N5R0TZ-)
MZ2 YH)":0D9;I695!%#")":<Z>(\8!$R&$L)&?)AG30(21LQ";% G3AL0  5
M,4$=,F.<^'59M3(                         (.0\ILT9U<3H       T
MA]E"END9,8N,KDH0ZX.?BT2L"4F":XVQ=(
M                     !7YS(34RBYC7F]*P):5N20RCGDGAJ#JHW@ !C&L
M*#,0A);I;YO2OSG8Q#P,PBQM3=GZ2LZ"-T?A3!7I!39&"8QNSLX%0&:: \2M
M3L _0  4>0@Z4.:CQ+9/DL@PS=@                   &.:X^3='B?AHS7
M'X08AA69=IT"      #!*2-*9AH37G0)-CG,F);9#"D#7&W-86(>!DEN&:
M                                             <Y&A/,T)D&H)Z?I
M,R/$U(01(F16Q:!T$  5T:<BY@$4/4ZX*R.;"?$4-4;8UI]&.= %S  &J.4S
M1F\,DFQ/BQ#R*C/,P2O3K4   H CQT*<XGF7X:,UAKS4%]F8
M     #\*&*[*U-@;$W!NR4'F;TT9K23E*&].R     ?)J#<@J@KLS#Q,HT1:
M!J2L#KH^P1 J(T9]$8)80\LHEYE%E'H
M                8)SH?I)C'-\8I696I[&6;0FY,SP*N,LZZ  -$08B96IO
MC<%K'.Y<ACDN-T5*5X8IA'2)8X !3Y5!Y&Z-6?1JB;DX*\)85P6Z6V   <G$
MS+7.8"7&4#0'X;LO,D                  -"<H&^)28!%##,8V9JCQ-@;0
M]S4GB=G    %.'F0D]SHHY\-0?1(BPSP*%(N=C$B !\$.((0LT)A& 81YDT)
M\78;                                             ^#GTUI+BQ2/
MFD.9":&6;<^",GD9Y@F@.[S]!%B/D()0;DYS-:2TT1?1&25EG HL@Q*S6%=D
M_+W)& <C%C'Z>)I"OS#->2,\R5%<'<AD@  '$!?9E%'D@/ SR;DO)X
M            #\/$J(^#6%FG@5@6Z1<A97A'C,).=$DJ    .;C'/LUQOC7D
M:-F6^24YB(\=:DP   !^&F(.4@:\TA@GV=&%U@
M                      I$K4O,Q2P#D8LTUA:)HBU#$-408UI8Y*@8I###
M(P8!-S7'.Y8)B%E@]BV3]*B/DK<W!JB,FK.J"; XV.@2%$F+7/@UI11Y&H(Z
M7:6V   #B(Z$,TCAA&83LFH                     *\*[)N6@  ?!@&R
M    *$*"+@!"R7GD89&"&ENG29MP     10C1$R'E6'39<@
M                               (D1LC);1J#%(@2D@)9A-@#X(R1D\S
M<E3$Y*Q)(:DD1J"2E,$M)D?1N2UP1DYV,XLTC)*BNRL3LTVIRJ6:?1^DH)D"
MOBJS!/(L0PB9&<2 V( .5"6GH20A!DG@666                      #Y-
M:;0        &B.."+&Y-L:8UQDEKEY$V      !7Y59&B*$B.NC(
M                                     !^'X5\4^2 \B<EDGL :HY^(
M*;@_#[/$R34D=+8.BSP.=RNC-+C-J6@>X*L*@(T3$^R?D'-D=%%.'T:XE!.3
M8GF4Z0D]CZ/,\3S-63DOT &N*&-P>A%2/G@>!UV98
M            /$KTAQCFW)@3(R        8!ST5D30ZC,H
M                                 @A31*3V+-)( #R*>(81,DAYGH;4
MEI8IN2,&D*.,0@!=1T490 (>4N:H^2>&U( =.GP4V>I9QM 1<YR)06$?)"S:
MFM-<7,2D  &B(68!G$E).>P
M     !6A3)YDB.CST
M    !%2A"S3Y+,,X  \2GBO#[+%+B!YE,%5F(;\Q3:FO+G+)  !YE9E4&"?1
M,3H(&.5B6L 4 0<NTLH @IH2;$B
M                !SL5P?9TN38
M               \2/DF    -&4:2<LXW)@G()*#8%FFT)F#X/L   %8E8&C
M(P20ZX/0  PSA0Z0/8M\^@
M             544Z2XNHWX
M                 / C)X$T.8#2%K$A-Z28     KDTIHRO"(DA.O#8  $)
M.;RW28D0+;,P
M  &I.5C2%[&A+Q-B
M            <?EK&O,$L(L8     BQ31J"G3<$[.M   1TY1+K(>2XSBV0
M                                                 <XE;%JFQ+1)
M                                                         "H@
M:,W981O     5R5F1$K<D1+SI\W   !RZ3XPS0&838LT
M                                  Y4)D3DL
M                                       %#FI)&1LO\V    ,(K,K0
MT1K20EQEG@   &"4B3 @9@$Y+>
M                / _#(
M                   *S( 8Q.2R39   &E.;2"FX,DDIT@;      \BJRK2
M/F0=4&[
M                                                        ,0Y^
M)V6B    5\<SD@/<DA;!*#.      !I#0$Q,D
M
M                          &A-X?0   !Y%%&@-*;4DY;1O0
M
M                                                      #5'.QL
M3!-87"6:
M
M            "EC3&2:DG9:!Z
M
M                             $3*.,D^2RBR3[
M
M                                              ! "GRSRT
M
M
M"-DA/L
M
M
M
M
M
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M71YG8E,>9VI+'F=P18YG=D&.9WS7\<SU#UW',]2=;QS/4_6<<%)K-&^NR?\
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M%T_VMU,"*CAI!$F^OMUA\/6M4Z+E6U?OQ-;7;1LY6U,_IT=V02G]LD0S8/6
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ME\/UCYMFY!ZA4M.@S7\ZRO/$2Z[T@#8I/\$U/-NUZ73S8@#ZVBWHC_S/+/\
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M5ZP!;I[D>Z:P3*,L^DM;E[]?^W?+B*=75GDTU:FZRY6_W<I8A@O9EP? C*6
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MNU:M>4T*4#EU*U52JN:,6PFFBL>O^VZ@(/D!TQ-VM.=K*[YS)G:PNNLQ'"A
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MM_0+J*R(.A24TQW5B5+1ODB%Q 5@PNLMCDY^R66Q.0:/ADM:I"DA'I?35J&
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MB5$%+C53NAKR]P$-?N22)@O\XMZPOSUW-YVF(N3O;BK5413RX<:H2K]%1?\
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M66P[#U-U.W9D^N=5K=?"V;>3-_IT_6\:[KAREMTNV"WK>+XVJZJTW#8^J/\
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M%T"84Y ES3MA(F?_ &#DN88@A1;N=:8]=-:1!0Q;5P]WQ"]YP@(<JO<!X82
MM?B:-<L$[8:<A6A4$4Z\D.W"/<\(@PH(?Q!/TG:O_<%X=!68QQ#'/]^5KQ:9
M_2\,<OE(]0\?I!<+79]\HXG&E>*-/[LXQ+&%(.)_7*X65OVR6!SL_N\Y],;V
MNA"@F7IE1<:!DS5S0H:\V+#+^S=5\R00V-FU&;(%34POK_CIKJAFK^A;88.Y
MP?)T3L+4(><BZ6O&;61\T2*;ES]+K<45%/;S:'"FRZ;@,Y401>-X</Y:-45
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M54TB?D&%1#H.WH?,&_=./)R->94JR26NUV+F2'0PU<OR3 ZCQ_'+TAB2Y6;
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MBC5%M5H<15SU?M8\3J[(VU__ 'G85GGC5###D7;#V"@1S"&OX:(+:1CB$?\
M[T^U_)&2\9'EH898J[_[ZTU\-OR$,5P__LR__\0 %!$!
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MH/+^Y<T14GNX+=!7'U12,%TA5.KF*]*UM+<E-.3L!XX%/*,:^2Y\:O1+PO2
M=2S'VB#S_CSKAO)ZI8L$@[$YK1"=2[4H\!_[C5[N6;EX5<%Y@\R#=?JBHKF\
M5F0$NOAJ\34LUI*A5&.4?8Y\*6>5(WF3&E(]]-1^D21EP/9/3XTL,?Q8^)_H
M3$[ @>\&'.@J^C0\0]]R,M]O_*I(D9[F0G,8C&YJ6_G<Q\9-/H_[_IN/CJ^V
MKB.4I;W)?7%,^<$=5-+;\=Q.._(T6.^*E$5F\FD9$D*<Q4<EPI5_VA@X^AI!
M^JE)(/@:D0!9-8Y.,_/XT;61=$3=]M(]ZEDL62UW.62+G\:>UNE+11+CB:<
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MXW'XU<7;7JRKG*(-AC]] QN891U'6MUBBN(X@N3&.+J_.K>XC6,M=+WIM6-
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MVSH!\%7K\Z;M/LOM5Y5A[TG#!C8#QQDY%<28 7D!T38Z^#?/Z8[!&Q+>/O\
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M=1\ZWGC'^^*WNX!_\05O?VH_^,M;]IV8_P#VA?WUOVO8#_\ :4_?7_MBQ_\
MYA:_]KVG_P T5_[6MO\ Q5_[5A^_]U?^U$_\#_NK_P!IC_Y,G_[M0W$+:X94
M#HWB#R_0@_VJU_!/H]+MDS?VHR,<Y$ZK5E%<'7Z)'PD;KISM4?\ A%75I<-P
MGDC:)=7UPPV_&GFGD6*)!EG<X J*]C_5RW1*9^K@XI;B-=1M)0[?X3L?RJWM
M@X]*M!PWCZX]T_95U>2.%94/#!]Y^@J[N.T61X48)$RIIR?>_*NTO]GD_P#N
M)79_:B Z-'!+>!!R/Q/V5#>0."2/6)U1NHJ6[D*M-RAB)]MJFNI[-;5$?0C*
MV=?C^51_[1!_P+7&C&IK242M_AY'\14%IK'I5IZMTZXSL:N;V9PNA3H!]YN@
MJ\G[19'@C(2-@FG+=?R^WZ+V]SB1$Q'_ (SL*O\ M*[A2=/U,?%74,\V._RK
M_P!G6G_R%J]BMK*"*Y":XFCC .H;X^?*KOLB1N?KXOP8?A]]6_:I4\"1XY]N
MN,!A_'C4=Q;R++#(-2NO(U:6G9LR>F$ZY1I#87H/G^5*]]@7;<)I0!C#9Y5;
M?]Y)_P 57-I>'A6[ZH-;<@I.4;\/MK.=O&HA;.)8+91%K7DS9R<?QT_I&>6W
M]'N3_P#K$'=;Y^---V/<M?V?,QH,_;'^ZA!VO">SY^1D7>//XBEFMY4GB;D\
M;9!_T%M#:9&&S?5\ZDN]'"[NE93ML:F80B6YG?0)V;V5/0"I#Q.*\G,XP/T=
M,B+(O@PS2N8U+K[+$;BL1$:U!Q4JP7/HZ,WLN-+-YU#!I07;Z1(=1WVW-!!:
M87B!&6USR^^GX':B3Q+XI@C\J$<J89MU\ZTLO>\,[_91EX$O#'-]!Q]"/'*W
M!U#7%T8=:CGB;5'(NI3^@5F5'CZAQM3O-%WL'2-(*9^%21]F6FB%7[XT[%NN
M_P *FX5H%M)(M+'GHQ[N>O.C9Y_FMSLGSY??M^@^D3B) >48T_Q\*EN;B"1\
M-F+5LV>AQ5EQ8]5U(0FMV&?@2*DBD'L-I)HQ9U6S\T\#XBI \DVDG*LJXV_Q
M5 L\J2CV3B,[C',]:CCN$DFA(!5HP!I^.W*K:^XP/%EQCP3^ ?MJT[*C.D2>
MTWU4%065J#%V;P@&TIL=^6?D*CBM95BB<C6%8MHWW.:EG$A ]K3X4MO96,EQ
MPSEI$&26/C4DCQG4V!(IV*D?\ZB]'[V_,[4D4CZV'A69G[Q]F,<S06&UCT_]
MIDFL7-BZGQC;-+-QC;HVV9UTC[>5((Y%N-76)P:$D3:E/]O>@6[[^^14<D,8
M:?<NYY\S2W=]J%U<=T'3M$/\Z66UETVW^'.JKD.>(L9V?&/E_8Z!V C8X,9_
M+SH12>I#>R['8T\>8[A/>7.:4V0CMFY$'.#Y_&H.RX[E'UE8S*1C&:XABCXL
M:81J:[QHM)%"JK_UC>(%3W7N0)C/F?X/TM'QO3+H?U-OOCXGD**6$1[.[/.V
MM3H7YOS/RH<3MH!NN+?/_JK?MD__ ,M_^5;]K2?_ "!^^M^U)O\ Y8K?M&Y_
M\*UO?7G_ )?W5O=WW_B3_P#=K_K%\?\ XB__ +M>W>'_ .*/W5RN3_\ %K]3
M,?\ XQK_ *I(?_C-^^O_ &>3_P#'D_?4-O"NB&%!&BYS@#8?H1]NB]5%66*3
M@\/?N8ZY\OIGN[.]6SBE.HPF+.&ZXWI5\!BI+ZQN/0[F0ZG1AE&/CY4B]K]M
M-+:H?U<;,_\ Q<JM>U+6=(+6WTZ;8)X+CGFF1U#HPP5/(BC==A]HM8-S$;9[
MOP8;TC]M]M-<(O16:1C\VY5%:6D8B@B&%45<]H->K<":-DT"/&,L#X^52VEW
M$)H)!AE--+V)VRUN#]<LC#_>7G2S=M]L-<XYA"78_P"\U16MK&(8(AA4%+V_
MZ:JH)(Y.!P]^ZH'//E3(X#*PP0>M&[[#[0;L]\Y$;9[OP8;TC]M]MM<(OU6:
M1OM;E45I:1B*",8"CZ+>VCO5M(HWUL"FK4>G7XU;]GHW$X?M/C&ICS/TCM>R
M[06&,3F40<+W3S7.?B*-K>ID<T=?:0^(IX^R^WN%;MTUO%]RTM_VE<_RC=J=
M2C'<#>/G4E@LPMR[*VLKGD:BL&F%P49FUA<<S2F4FWNT&$N$&^/ ^(H6G\OX
ML.6@.^,?X.562V=YP>"/6/)'J:5L\_Z8^F6HXW2>/NR#Y_OIKK_H]>O<1<S$
M-F^:\FKT7MZS:SF79I8U.WQ7F*$]G<1W,1]Z-L_TS.QTJHR37:;.[B&-0@4'
MQS^[[ZLI)4/"AQW' )('(_&IKU(U-FK'2Q^MY#^A[KF-^>0.E+H:?M'M%.])
MI'=6C<7GJ+JX4/(GA7:2RVF.(,QON /V<4);@FW@1L<3/>;X5==GWBI++WDC
MN7&=.G/Y5HME?7*ACTQC.L5Z/<6K1]H@MJD"=? _=19(Q;C '#7?E0XH.F.0
MI&WB/T&$668>Z!FK:W_DA86E3A27+#42#S8^'P-.)^TW3B/J09TJ#\*-K86G
MI-I'G5(A//J2:[)NFMUMR)BBMKR7PP_?^@\F,Z1G%1>BVVG)\0<T!<QG;#!$
MY"I!O_.!ITMRIE7?O8%007O#D>)1W2NJO2#-"=2X+@9./ TKVPDELV)75&G)
M>I^5006S%K>!< MS)ZU<\?5Q2HC1P.Z@ZY^ZC#:/%/,&5^'K'>Q3:YY(9>&2
MB(,YVY&@EZ Y9-B!S/G3<_1'YLHV#[4LT8XZGOO$=@327'![VS8Z?1#/GN2+
MI^8_YTIE#=SJIY?&FCEC@S,F8W0;^7P->A]I1_S6,9"^%+-!)I1AL4&,>56T
M,Q:)Y,KKSS%/K;B*CZ4;R_MQY-6)F&$%2/=XE[A8*^^34UQ%GT0%ET!0$5JC
M@M8M3*PXFKW-^9I%-S)I'/8;UHAB2)?!!C_3^-<R"-*(BMF<>+MBM[,8_P ?
M^5=^V=?\+9KO/+%_B2N[?+\U;]U%X[F.8_51MZQ*3 V<=X;?;4C&"/7(,,X7
M<_.M$':*-H!/";VJ4PPRVND:3+[OPSRKB2'C6V2H";,WG\*T]H3BR$![_%!)
MP*DX%RUUCV78'\Z$URY8+R7W5\@.E#C;2S'C/Y>7V4T<#?RC<CW(#W1\6_=F
MN[_^CNS&^,:$?BWX4LER/Y2N1UF'<'P7]^:  P!T']Q=%_:I,>DG)U^!HWG_
M $;[0<D?U1;2_P /!OG7H?\ TCL'CD7G*B:6^:_NKC6-U'<IUTG<?$=/Z1U5
ML/*"*M> $@BFCR[>]RY_'G45O'Q&51I+ $\AS/V5<6:Y95.O5^7W?T($\*2@
M='&:E]$@2)I-SCK4]IH#LBZM4K8 WY;5_/Y ;S#<29=RY).!4UQ)?/P"NJ*'
M)( %36<L6)II1H<[CGC>M42L.&-''5O9-/I9RW/B$G6?*K:*5GR\G?QN57_E
M45M FB&,:5'Z.(@6+;'1S^%2+%%<SR(Q#:Y!@>"CK1[(C0/*^9"Q;=-A5G"K
M:XXYA'& =MWW^_Z"[L$0<V8X%"&!S=3DX"IL/MJ6"3AVX4>RIR6KB7<BRC7R
M0'8>%*2NJV./CCXTT=KV?).RC(<8'#SRY\J6^[1N(EX+9]&5LX/[1K6MVT,K
MKG",,$>.*2S%U-$K>[[08^&>E'LPH..H(4:MF!WS2G&,^%=H/<@O)&^53.Q'
MG1.]RD2Z@J;'?.QKTRV1H9&Y GV3X5=V_:D:B.4*?X(J?LN#/H[RKA#OX;@U
MEXUN),YUR*#CZ6,TG",?>1O.M7UJN^SYTMXI]/JI60:L^.:*78$EVI]'!4[8
M-:[*TB;Z\*KC/GBD>>4VZ,#W=/?%0V<1U+'[QYG^W'56]3'LM37 FX*Q=1S)
MJ"SB7@C1^JD/K >IJ=9>T%DNINZ%TZ0!^^EM@'U-LK8V/^GM-+R'3QH.QW8X
M Z"B5AD8>2U'#H97<A>\,4G'N]*D=%I+0R9B+XU#PJ'T7$).QR=J6.+_ *P@
MU&85'!,'#>RY'A2R6]T_>[P8GI44@F*3J#B5*N/2+V21%[O#8YH@33N!UUG%
M)9?KY, ,>E%SZM.>YY4)S";YX]TAY(3XL?RH->2?R=V:WNL-"X\EYM\Z61HO
M3KH?UMP,X^"\A_<K@WUK'<ITUC<? ]*],_Z.W[PRKN(G?2WR<?G0L_\ I)8.
M_P#VH72_[FK58W22MUCY.OR_2))P!UJ.U4ZF?D1]/HZMD*?X_.K6:XF=I9,R
M1QGDJ]*N(9O5_P"I)7?/6IK9OZSOKD;D]?Z-HR6XQV7 ZUKEDE7LU<F2;.,8
M%&#LR_E>+ZDC;^>U6]WJ>6YT:SQ/96O8,CJ^/9YFDFEC/"8Z",]X^.*A2!=$
M6D:1](>4\^0',UF.W0#]HYH!K5"2>C5=M)PY=>,(Y((\>1IXK:'AR3^J5%)P
MN6J;LY[X2R,FH\/<QY]W5_'.O2I%]3:#7D\M73\S\J,5IBXF^M[M%IIF(^J.
M56M_(>)MJX*\]^5/?7EHB:R AUAC4'9L_$E@9<M\<<OA18D^CCV(UZ5.1=#+
MXUZV!.WD*8PWC3!!D+POS-80'2VP2A$4)TG.*;T2W+?E\30MY,<2/N''+:KH
MV:_SF.X;<-I."!_G5MZ3)+-/*NJ76_=)VV\:M[KL^0PV<FD\-)2=#]=N=)<+
M,VAAS3K0DXN84)*[]X_'] PR%E'BG,5Z*HQI&.77S\Z33OJ.G ZTDT,$:W_=
M.H[?*HHII.)(.9_MVZ;]G'V[4YD4NNHD@'%=F]G\"2SLYEU,&&C6N.AJVL1$
MXF3O#+%=..N:''_F]JG.16!+?#_.A</=O.(_U2$8Q\3U_P!/=?<B[BC\:?8G
MB1M%MYBI;M<1HHTF%#J<CQI[<8>-N?%&],(R&T;*ZJ=#?.H@]LBW:H.)PW*G
M/4T\4(E]&)_KCKWJ96C>V;3JP1IJSFDN;5A<XX4"NW$?;. ,5%I66*$'3H9=
MOA6JSM&F4=TLN*)6RG4GGN*E>XBC@M\;O<3J OWTW!D2\E)YP@Z?O%))?-_)
M]K_VH[WR3]]*\,''N1_^L3]YOEX?W.,%W!'<1'W)%S7I785VUE.NZQ2,<#X-
MS%+;?](+)KJ'D)6V;Y/R:@+2Y F_U$O=?[.OR^DLQ"J.IID@FSJ[H3.WV5#V
MB3F9D[SDYP>HQ7$A?6N<5+)RTJ326YR4:0!S^R/:_.I_2&TVZPX")S8YIEXA
M]&MWWU>VWA48L-9N#GN1MEA_&]1>D?KM/>_H2 <'QI;F[F22.,Y6%1D9\34L
M" ZO8;2-@*>3=5!SJ;VC3N)\3H=*QEL=WQ/C37<;2N=?<5=]ZFFO1#<NV-&V
MK'VC]"6V"8TD(-M\4+65&;F.(I/WT?7=T>\W0T.3:\ZB=B,>-2IGU,N Z==N
M526MLJLTVY>9O9'4DTO8W9;,MHARSGG(WB:,$46AA[3S'2H_CRH>EPMVE./=
MY)G]WQJZ8V[)N!$X39<<Q7 CEGNI6)9E.R+GPHI9Z+4-[3(O>;YU;S7<\C6T
MAR7>3I1LH[<W%JDF=.G4U$S(T*9UQ1$8Z]14-UZ5%:P,H9<99QU_C>C)--/<
M3'FQ; ^RECB18XUY*HP*GSU.H5/';VWI(F37IZY7_*F/:!&, CN=?"C+;31+
M93=Y2!N/E26ZL7T^\>OZ4$".F5;27YA2<?1#-_6+ZN3_ !#^WKI3]7\Z@MF!
MX+DM(?V1O_'QKL_+QI;PZ@<-AE.V*CN89CIM9!ZXDY.W+--PM,<J^T&;.!2)
M'@..>V0U#7'+9;94;C53I<PW*VVCVI5.,_/_ $V4^Z_>%'QJ2.SMY/27[JZ3
MDU%;K(MM(=M;\OA4?9B2E3&.[+CWO'%<65N)<VY*/OC5YXJ2\BL@LRR9=68\
M_AG%'M&_+J_LA(VPTW[-=EW-T0%#&.*(>S&NDX HPW$8EC/0UF1XK.U3JYP*
M]%["M6O9VV65U./DO,_=2W/;]ZUK!S$3>U\DY+0-I; S?Z^7O2?;T^7]TFBG
MB2:)N:2#(-&?LJ4]G3\PAWCS^(H1=K6YO[$;"1SG[)/WTJ1S^C7)_J)^Z?ET
M-",#5<3MHB7/6G:]?,B;K'&03(:FO$862*C.$DR&&!X4L1_F=WJ];$23D_6&
M>E3>+;5?7ID"%1IY][<]*N99?76W#QRW0T%[+FR2VE0F<GY5 K$Y"L?CMU_H
MVCC?0Q\>M1P+*L@!9FD1ML4D2G2FK2N:[0F51<&&,>LY:<^%6IA8P123@2J_
M(]#^B'NHCQE&%FC;#"I(XNT1%&_,&+43YYS20I-'<#EJ3W3\*E>,A79=ZA@:
M46\>KORXSIJ;@,QQW1JYU/VKVG*/1(<DP ]X_'RJ27THK'Q2O# [R*/.H9(K
M^)1(!W,]X_?7H2Q:;=6XA5EY^8-3]I/ +"R&6Q='27\@.>]1I?6T5HDC!FWR
MX7\MJL^R[&WE%K)I!;O,.>^]11VEK,84/)!J5OC7'N+).-( 7SXT !@#I],%
MP%_88_A^=0W:)K:!LZ?$<C]U"^N OH]TVIDA/>3.XYU!8H>+:ZM@PW )\?TI
MN&,OI.!5S&9DM;XRX6.;*/C&V/OJ%(8FC=$ ERVH,_4U-8G]7*NL?XA_;TT7
MUT(I75FBF3V77F*M[NXE:[BC;45(!-30VY:W=1JCCC30=7X4D=Q8"\GE&9Y&
M]O?H#TJVFCCB5DW77(?OR:C2XCCE*'NS,@8+2P<D8X$I-;7$1_WQ7==6^!_T
MNW?&.8S]$#W!(A!R/(]*;MFP;TBW>0NXCYKUS]M/!/-ZW5ZL-U'A3F2(<?3A
M95V8>%$Z3#)GUD3+CB&FNKIL#E'$/9C7P%6MVN[02K)CX&O1/^CU@\\S;"21
M,GY(/SI;S_I)?O&/]4#J?]RUIL;5(VZRG=V^?]UBCJ&4[$'D:>:T_P#T9/S]
M6,Q_^'I\JC2:X-[':MW-3%ACR\*-QK=+YMD$F $/^*KJ>XNM?JB,8\O&EEC;
M2ZG(-2EV/I03O*QS4US#;-)$'.J3H*N>)IA&G2"&!SSYU%WT[[X&C<U'>2V%
MPZZ-+LZD?^:M5I,&8#+1GVE^7]%);02A&]F23/L4MK$<J@P6\:BNS;L]RQ*J
M')TL1X5+,;Z,)/C;W3BK<NHGE7O\3)Q^@TLSK%&O-F. *T6B&^?Q!TK]M03W
M"8M)>5O$<!J(CL!)Q<\.,G&/$YHRW3A(T8C3;GO9\#5[&(FEX:@*8T"@'?=L
M?"DGO+5I[*$<29%_\(S]U7#P 2=ES1E986/*G'HJ_P E1GB(=>SKG.,<Z]+M
M-5J\;9%N%S&<>\#32W"E=0V!&,K4_P#^D%?T>34+>?EIQ[6?XY5<R74RO*(Q
M'!O[('7'V4S[744W)4!(!J-V3ALR@E#T\OT98=LL-L^--&XTL-B*6-M$\2#:
M.4^T/"N)/_,1%C93L_V_I.RKJ*J2%\:,EM#KN8I._I]T8JXMHX^).V9M]NZ/
MXQ\ZLY<X"R@'X'8_V^]Q;(98F[S*.:_T'.O5W$J?X7(K(O[C_>D)H"7AW(_;
M7!^ZM-W$UJWUAWEI987$D;<F7_1FCD&I&&"*DA<;J:U)S%26%YDI,<%@>6:$
MXNM5NC:U&.\?C3WEX^E%]E1[3GP%-=7/=4;1Q#E&OA],G9,T<<-RYU138 ,G
M[)/]V95',J132\!-?BPR<UG:UF;K$.?RI^S9;GB1;'0KZA_E]"RQ-I=>M<)&
M)D$O$>VUD+(-JDNY87MD<Z5B1B= \?.HN+Q()H6++,QSJ\-JMA*/1.,HP ?:
MSXBO3;)^$FKG%MH)Z?#:DN=EF'=E0=#_ $'#B(-Y(.Z/JCQI;J;4)3+J<N3W
MA2B0G#OWB.>*LK6RBX<42:8B1L/'--"9YAVB#WQJRIZ_#%/.S8L0O#C35G<>
M7Z%M;<1ECTZL#QS0D;UT0W[O/[#5O$_:8AS%C+IR?ZO/PZU(T$,,\D;^T)%S
M_P J7T9O19'&9AJ8@M]M7D2=GEKE5];+G4'QU-7*+&)/2K8P][IOSI(3P;:.
MW56"*N'=LX;[MZA@DMN-8@=]@NI@G4G'A7"CTS",9TX*[4LULN)+==/#4<T\
M/E3<.5HM0TDH<9'A4G:UDZHMNY!MLY('7Y4;>48G U @<Q^F+N,8CE]KR:L<
MCXTA,Y &VC.U"-%9&@ 4@G/W_H-+(< 5*TL94HV.YOFI.U+&:0R3+E4'=U \
MP:M[VYF6%0'!M]62? >'G5S#RP^1\.8_N >-;QOYE=ZRAFA\D?\ ?FEM;:,M
MJ/MN.Z!XYI4Q R$[R!MA7=>U;_?8?E122,#SU;&M6WVT$M[61RPSJY+]M-&\
M9U*<'&^#6F.&21O!5S6'4J? CZ!)"^4]Z,\FJ.YA]E^G@?#_ $:$(S<8Y3EW
M?H5\MQ,\N8-?RC<SJT04?J^;MX"C<7!T1+M%"#M&/XZ_1ZJ"67_ A-=SLF]/
MGP& I6C[-D0C<%I%3'VFA;]N6\>4'=N%E!8_XA^?]V6F<RX8Y,0;"_OHKP4]
M-?\ 5PP^T?,^ II)#J=OI2>%M$B'(-3"X;ARR%0?JIYTL:LUPRIB'Q?;PI./
M%$ETR+A5Z4T5I;F2/&IHXT.?,U=>AO)!D L">[Y5;S'&IT!..6?TI;J3W1L/
M$U*_MRMEMSR%07=TT?%G!.F+D!C:DN3 ))[W'"+KG;5I[OGG\JNAVQE8#C1J
M&=NN:FMX8Q&A.K.,\2F-MLB-H*XQC]!9$EX4Z#2,^R:_G<1B7.D,>1K)WI)H
M9Y%74"RYYBHUL+HV\[.%Q)W<9Y4;E>T)Y+G2?8D&&\<XI+BV8&6(Y5AR/C2W
M#37#73+WU.RZL?"I[E7;TU93&K%O:4 ;5%/ZF.#F^AM_A]#S2A. [;%3UKC6
M[Z6Q@@[@B@>%%#VD5]9H3&?G^CDG \ZPUW #X<05)%Z4,'JG>Q3J763P=#D$
M5Q^#%<C&#',N17\UCCADYO&@_0:*4:D-$6V'L0"1#,^I3Y8IRR368QIC73J5
M]]_ABGGFNOYQ;3:$CT89A[N,59F[C"74T2Y ^)']!JGD"> ZFNY&SM^UM1X=
MO"H\=!_?0U"+'G'7K;>%AX+E?WT.)K@;S&1]U<2WE69/%3_:X]%''3/L$Z<?
M.O6W91_",9&*2TM(%:VMUTY<Y:G=[E)IILN\*+@)O5[<A?6J="GP%&UCFC:2
M9M2:FV"TB=K)PH)5(5D?"ZOC1G[)N./'C/"D._R/6FL9P4XQT%6VTN/]&AFB
M=9%!+\-]OOI9!MGG\:U4]WVG:<6$;0HY('QQ0T=D6?\ O0AOQKU5K!%_@C _
MN\\T]DS3.<M)QWR?OKN^E0_X)?WBO5=H72?XPK?NKU7; /D]O_\ E49]*MY4
M?8'<?E6JS6%YXCG09 /QYU;R^B#LWM, K*.()"OP.3C-%_UD2RZ]#CNRD=*<
M.T4<0BP>&=R,U8:RLEDTXCT9YYVHV:G28AC2B[#RI98FU(W6AD@9\?HR=A7
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MV&#'-8IK-_UEMR\U_C\O[R/"_7D? ^-:7)CFB.4D7;YBN(9S+EBVPPV]6]C
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MO'\*FM;A4LS<JKVID]X9\:T L3H:/2/9,GC^>:;1$/3QSQ[(Z5!VK;7'%CE
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MMA8L\2,^UBK;AW,MO;'N.PZ>?WBDM[B6U[3M)7V<[Z3U'WUHCOY;TZLA<:4
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M,,SL=(R?8HW'978Q2S]T\$N3\^ORI.S>V;9;>9VX:RH"N&\&!J\N4 +PPO(
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MU0Q1$@7DH!_PXS^ZK:<(/2+L<61^I\!]E203QB6&0:61N1%7'9:L3"[20'S
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M*CN4&G5S'@?Z'5,VYY*.9HZ&]%B'U3O]M".!&GE;D%&2:!NY(NSHCR,KC)^
M%"*.]FN+D;R )LHQ4,T5JLRNH8.[,<_;6_9\'R7%9@:>S;_LY,C[ZU6,Z7R?
M4?N-^ZM-VCV]TO)5/>KT9[B1.SP=P3S^)]ZAH[2O'D [Z#2I'RQ6\MZWQD7_
M /=K>.X;XRUO9.WQG?\ ?6W9:_.5S^=;=E0?/)K;LBS^<(-=WLFQ7X6Z?NKN
MV-LOPB6N[$B_!?T;^.-2[O;R*JCJ=)J9^S^S;J)I0 V;?5R^-?\ 5+C_ /DQ
M^ZK-+JUG%JTR"4FT [N=^GA5BEE:RW3+,2PB7.-J[,AF1HI4MU5D8;@XJ^'9
MDG"OK<O/'OC)#\L_.O17["+7?+B>C/\ ;CE7\N]OG-WJUI$VYU?6/Y"KBQN1
MF&9<'',>!J7T* ]HV#G/<0NC>>!NI_C>C96G9$EDD@TO(L;+\M3;"GEG99>T
M)AAV7D@^J*['_P ,O_II(HK/^5.S) )(R$+!<[]/9^=0QW5J>S>ST;/?0HH\
M\'=C5O8VPQ%"N/CXFC?&RG%GQV/'T=W&@]?HLI+*RGND6#!:),X.HUVA'&I>
M1[>154<R=)KM7TVTEM>(8M/%7&?:JPN+6RGN(5AC#21ID#OM7:L,2&262UE5
M47F3I-=I+>VLMJ7="HE7&=C4=W9E4[1A&G#;"1?"A:7G8TEU(G=65XGR?F-C
M4=_V]&UG9)[C#0=/U57G\S2H@TJHP .GT*9;&XC[-6181*R$+PUYG/GO]M
M8 Z?1_-XC+=VSB2-5&[#D1_'A4W9_:-G/;<!LPF5",J>GVY^VKY[VRGM4:'
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M(, "N$I+O]2.A$-"RM[HW-.DCR #E4B<;N@[9I5?OJ>M+'+'P)6&>[6NY/$
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MXK7*LOLY*3 [_"H0_J;A_P"K/C]#*>1&*FDD1LMR;1A?D:;UGH]JG.73G4?
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M!<70YR3>MQ]O6H_4&=<ZC%&G3Y=*FU!4 ^J*DT -H]EFSFI;C@R21(Q!D49
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MP)%[G=TX\?X\Z6*(?J^Z *C:6X6XD1N]$YSMX9JRNKF-$XDRHREL#34$]LL
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M.HY9%94Z@>1'6E<QD*-LFI.S[IQ%H.J-CUSS%<5M7#P=PAI9EW#<J*'FA-
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M2117.*]H-7*B-1K7G)-#K3'Y5@[BE[*BMC,9-4:R<3V2QVV^=+%)JC](C!S
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M"][/SJ2.1DBXK@0L^U-WUETG&M*W%+$Q)7EMSJ;CXXDSZ^>HXZ9-2QKCB%2
M34D:KPY(S]E6E];6LK>DQXU1#/>!(_*I8KV+$I//?%74;V(FDE( FYZ15P>T
M459[MS&O$^K^SX?&K@SO*$.YFDDW3X4\79PE2TS_ %K9+'QKTF==-W,.7U%\
M*Q+<KJ^JN]8];\=(_?6(;A=7U&V/Z!4[@[5%=VYXEN-CD>P:MI.$NJ/8K4T\
MFAY3$.'&PSMU-0^BP1*S=U8X@ =6?"H9.T8H[F2)-31'V=QRJ/T&(6P'K#A0
MO3E2P6DKM/<DS2R$8TYVTC[/H$\ZD6,9W_[0^%  8 Z#^@C[6A0&-SID7]KQ
MKBIMC!QT.U<6)'6]SI0)^56S7.)+Z,(C2*=U;K3VCIZV<:Q+G?;I0@P"7WWZ
M4+[A(C:=,L2]?A4^AUE)CSH!R?LJ40OU-6R6]O'!IC ?2N-35KM9&4GW.8;Y
M5$\B<*1E!9#[I\/[6R3@5W'5O@?Z$C5ZJ/91^=7O:,T?%UH8X(_Q:O0KSL=S
M<'7B=ETY\#XU%V@MTT<J]ZU4;@8^MD4MKVG#+>7C*>%Q]E4@9QIJ;TJVF@F8
M>JCQCE2-''E-DFC/OC]],]H1;W)&IH)N[G_.C9W$/I$* A$DV9/GU%9F[1"7
M1_J4&&C/SYT8$D9QGB.[^/\  J\TI+;74*AS*NZM\? U'/"RS2</H-6/VJ-S
MP=-Q(2,D;D>-1VET@$@[O=.^D<J\%'):6U@3&KFQJRM8_P#K&.^QY9ZTD.0C
MEL+*#HIHWEET,>N'S\ZCMIKAB$/=&!^-<>.XAE"]W'%U,N/A0FEG:[)77GDM
M2QHJH\9PZJ,?"HE?U4#-DGJ0-]JX?#?B'NX&^:B6/ 91AUZYIYR-Y#M\*X2#
MO'KX5Z8LA:2)L8Z-XBOY25&RY.@/[OT-%*@=&IH,DH=XSY5AAFI6M7"1DX.K
M>@DDBX)QW=J: *MQ$3G&<$5B2#1#[WPJ/@_JM(TX\*$6>_"Q4_B/QIE\:&@G
M@2'EX&HT7E'MFMJD6.4B(-L,"AQG+>%'3EVK'5CDT3MSZ4P;D1L*B[N7'AX5
M:-XY[M1RJO>Z^=312@#5C!IM6<#<5V;V)8F$71D5WC7V!W#N6J.VMTFG[24@
M-I/=8XWTBFN-*J&.,#GGSJ%R4]+L1W-1^I_^-%<=WGBO1+EI+N_677$JJ2R)
MCF3UJV[/NHBCN#$\,?=*Z>OX&KA(G&)0$+#GI_SK4U8'+I3W4)6%F8K,Q?3K
M7 QC/SVHV=M%IF9 I4IC?JV:66X80+K.J0^^?'^/"OY=[-TF!^],%\_>'YTO
M95[IDC)S 9-])^K5OJ<@*!I/1:2ZU+I7N_X@>=7,<DP;(/\ O'-1S/NK#,87
M]G?>A+.0F -7QITB)U)S!I8;>7 09;;PYYJTXL9@MDU%9.G+GGKN*FC$VM9'
MU'%2M%&S)&-4CCW11UQ<"'3J"1<ML;?V-QENFMHM^] =+[]*F>>3CZT"8Y?.
MEA@3AQKR%7*MRD&H5$+M-8MPT1'F.7Y5+Z.G#C'CXTD(DXG>]C&:92< ;"K!
MVW/"'Z#(>4:@#[,_G4,:C46/*IN(I%Q'I6-6V^=)((P9AG26W /C2VT"ZF.Y
M/11XFH+.+=8AS\3U^FWDMH#//%-Q%M].<[UQ+B)E;;^;$XTU.WI8].E D[P(
M"^0\:AMY8PH/)M6 3^5.ES+;271;*Q*ZNR"O5Q"$,Q!); )\?*LCO(>3"EMK
MJ)KFV7V2GMH/SI?1;N.1COP\X<?[O.I8F(#N=>HGF*L<';0=_F:BEA"W*2E4
M33WE9_"HB=!3D C9/V5:S-=2S7Q7OQXV7P&:1)&+*#B.%!M0[4[9PKC>*W//
M/GYTT<3<"W^H*6<%I)G)'/9:XDMD\,/5G(VIO7(^/"DM+M]1;]7(Q_\ +^@\
M,R"2-QAE/6FFA4RVAW#@>SY&K4Q(\,L+ ['%6$C-HD%RADDDZ;TLE_PPO0NV
M,_OI88(5T(?UAV)^'E] GO%:"T^J=FD_RI(HD$<:# 4=/Z%X9!J1Q@BN'+"K
MJ!W68;/5E<VB\*5#G8\L5;,_ZHARP)(+[<OS^5+=6\.B56'?#-E1Y>&]27<\
MITY[AE]HIT-++=S+PHUU<-O?-=GQ\=44.6&>;XZ5):6[#PE<?A05%+NQP%49
M)I;N] >[YJG2/_/^U2S$*HYDT;7LU#<7'+6!G[!UKB3V7:+_ !@?'X4D<9:%
ML[2<A7H]\XOHDV.>?R;]]<2UD[_O1'VE_2DPV)).XOYU^V^U)_),<T,5L@"6
MR=X!0-]56\LCHE[[7# Y8VY]*=;BY,7'73@^R6\S4?:5L^DKA=07=*C8(!>F
M(.A<;ANM2S@B40X+>6>M17#R\:7V21MFNRV/"N7>(R,^WEU_=0O;68-"RAPK
MCQY8-3&":Y>U5C$Q_6 >6^:N9(YVEXBXEPN13^C\0.PT:%CZ>%,ZQ2>;O_G4
MT4LA0QC4<<S4<UNND#9LG-;[<1"G\?90N&V [K#'7QJ0POQ& RR+N12RPCU;
M(& \/*FVQ1:*1HVY94XIY+:240M[6H94_;4-Q<*@FN2TAT]1G:HYHRN8^7F*
MCOVC*%AD1MS6FDCD*?M*:BAD87!*Z^?+.]7\<Q6.>0+PAX\\@?=4T7O*=501
MNA1DR,'XT9$4,?.M:]Q_>3/*K+Q[_P"5'FQ.WPK0_=;.=^M#QS4>KEJ%% /B
M:7T2.X:!SI&.51+Z2D3R+JU9RI\C30:T6ZTY55Y?.C;SR1\=N4:>Y\:*:L:>
M@K7(<*O,FG(Y$T-JU ;U$\;8A8:6QR)H+E%'E4NKNQKRS49/M4\S)I,7)?(=
M*]G QL/"H<;]W&H=:AAF;2LLV&?P'C45QWY;A-]1.V?'%2W,EDLC?JU!V8#Z
MWV5=7O"DB>60LL2^[5N;<F5-8DE!^]:@[1L8F6SNXP_"Y\,]1\*U3CBF==&5
M]I?\JN;N/.ER, ]-L5GF:B3B:M7U>E2<2,RP1#5'+[NO->CG$21,29I.60#M
M4U]=((UE7U8;VAXGRJ>X75.@FP'U97R^ZK981)%K&Z/N'<G?2*GM68Y1LJ_B
M.AI)+B-&EP8I-AL<;_#-75G(^OT;?4W4=*LI'D26,>K=AOI!ZU:SH1)$4.&&
MZM4?I"&0\,'<XTGI]E1)%;G,L?K6/[/O9^/XU?.J:'*$.2/$;U"UTLD64]0#
MMW*CM[==<DAP!1[.W*R#UKCFS>-:(AECS<\_[)CN4&>%L_P_C\:[<MY8^+G$
MT:$[')"G\OLHWG#*KEAY&DTPF%)8>)C'CUK,IWTD@^-6'_=_H7'^[_PBNSC-
MM'Q@I/QVJZN)L]JLW33W4\O\Z:3LVW2UE#^\.1J*Y,@CN<95X]U/EN*D/:&9
M;,@Y"H 4^%&6V8]W9E889?I;B(&&#S&:MDE5^#H;:(Z=6W(U*5@ =5[L9?7@
M>-<=6T\%BRQ'JM37$BZ1Q-EZ8\:@CMK1YTY:U7GYT5:O2HKK%TAP;<IU\=50
MS7DDCJ1W':372622E+7'=5HQR._.N&96X>K7H&PU>.*#R<>X?D&;+4[OZI$V
M):M5E;/)VMIR9W&='B1X4S371Q$N O4FA_*DO 35A(.LO[JA]$$$5NN_!.PP
M*M9(AHXZ=]%;V3X5<=H7@61)B83'+[(&?O/*H^ [-9S]^%_J^56]R-N(@./
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MLLAA25^&S#I42V^_H^Q)YG/7[?QJ7LZ631+&-:E^]MUQ]U1".TBU1C <KO\
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MJI%_JWYFFN%[V/:^=1RQQA(BND_&@%AQ'+K]:WO;?Q]M6$J2M)Z."Z,/>/O
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M!P7. 2=LT+3M-M:QP>^=.ILC[:4VH")%DLJ; -X"H[93@.=3MX+UI40:548
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M=$LZ,!L!X5V=;P8>X.IYYL=[.?9J1;XK9SO$OHVD#=>OY5#:]E-,5M@$:9L
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MYY),:M(SBG>Y3DV,Q>%)( .\VG+<A5U%-I7W1H/M*13E"Q#;1R [U;ZKF4L
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MI(T?+.I0A#[%1VL$GK$]XTEUVC<MB+G'PSF0_NJ5( PC.PV%.EXDKY/=$0!
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M<TR+:0@2<F08T41W93KSU!QX5QH@_%*:3J;/Z9::W4N??&QKU5U+'Y. U?\
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M* -XBH985#O$<ZD R>7[J>22X?0AU$ZM(7[*[MS&LBG.#SQXT^AF=W]IF_\
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M%5Y9K+<L_FSW_0L4".5X?9CT_2*E5>!!*)UGQ(+[9\: ^V?$L'[$DALSDKT
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M ++UB?7 "9@Z(_"I^P,)ME2IX,ELKU+4#U\F)$^V#2M1;B7KFZIU%+A4N=8
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M-E:RFK3TAA.<4P.X&2AF.\=\039,$V>1NG%_#MGC-S<T$_."UTN]?,HR(_\
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MM*Y"9OGU^,G[=W5V>G?&*8MS&'0!J43K_N7/'!*@2W(+QD0"C4%-28_C$M^
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MXG.DM)I1+YPSIPH.54K/G#UQ_D=O. $B$5!>" +-,9$#6-%?TMN$ ;,8-;W
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M58C)OQW,-JX9JNN[J9>!G.DVG$?<QQ!D<!3E ='$'@($INWJOZ?VL;X!1/\
MH+],1:$AQ/\ $Z>WC)>P\V-)-!'F>V'KJT-HZD>V.0)"T*2Q9I]L%BV;K&'K
MKCC)HK7?DLO73"1TM05%\"/G&UYEQ:UDE>IQ/=9I(B5X-G7"1&SI S$>V:%]
M74"JCG6+%2T0'M62[J)- ]9/IBQQ.A*P#GIOC%!CHMCU.M1B5![%1QK*BL[
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M#"$EE,WA%8>]]0DJR=TI]]/=R! A-L3*I//R1AD1#H :/T.'$<-5ZD\,-L*
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M13(I=X\08ZAQ);&B40]-X+/BF.6.N6A,",)##CGG(YVSP<3%Q+WQ> 8IG9"
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MRN-W!I;=JX.W?$:G0DRL=0#*Z3&(T7YPX-UW8,OM&A;#;WQ)NP(R=G3OD<0
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MX8H]9Q6U3>@.ZC>4<P,YZ+YY[SDB+:VQ20L((W[M>N!%:XQA<*9.;QR-STT
MUZY(V\5C>T3A1*L>)DU*"/&":D"T#FDG)&((T.G& -)1+3;[7@$N"+RO+@EF
MX/J],(GJ#?6:#WR>T;43A/5*39A%P9I6,VC1"-FO-ZS0$BTX6KT!^QEYD[##
MKD,H4G9KT\9#$B8DN/\ >'"(@\P*5TJWOB100U18Z*]=B(PP.>P\L%$3W[8J
M)J:L&B<0#2,I'2\T$]<7BUX0SV!F!D5Q7DBRZ+Y&+B2PP>%)8]/:W?0SD)LZ
M"MWAXC$WODA ;#IPF<*KCY#QTRZBQA[?B_?-C.AU<%WG5,@F#I,6QXR>N8J#
MF9=F,K>B2UL[\,8/E7;!R:KYR.'B77E[/NX!01:DPP-'_F$>6#J8XUER]?XC
M"<:3H):6[1UQ"J%ZG .M96 910Y*1!YZ8C+7!BI>V1KE,2*TAXF//I_2%$8'
MI9&(FE14I&7S.5LG>1_98M-5:!55P7$9&-(ZZW^W2#(T>F7@/:]#QDHD1SA5
M0;/T=<+8*7Z$?81PRE7,P2S&L42B2@@)Z_SQO?6DO)71.!S(2$T$N"D"QR#7
MYTP$P("9= \P^F0YB1AJU!1\XV1*X9"D7;'1A<PSWYP.5@0X[X1C*%N6Q%GC
M$5@3I553"P=DQ.%(6-=AHR]Q.3AS)FUR4D!I@(.E!\93!*-$D61*OOA&93L8
M<*"8$.JKW?IO]SX"X=VL@:45*?6=@KQO :4,3R.GV+[N.Y,&KN1^F'=Q'+03
M!Y1%P7OAPB1+@=&_YQ.<X8 *X-2UIS/NY+BS61$EG_DT8TT*UBZ8#[?TI7\<
MV/5Z&-YRX0)$]?AR*#M@_67Z8,*\;+JO+_@;_J:2NDB1@$8=2+A9T]LDS:--
M*DYF?V24(.&(=/SA'Q(%@NX8_P".1A.$L6K#QA1!P*R^D'=,?F<FD1$#5N^<
MZ,+C!,5+=[P$#"$6'G]'ZJ7Y OIGE5,0A=:]AQ(^B04_8L]O. I.XZ^]SB4-
MJL%-S'%Y-/(PTRR/,8L$M&$/.0:8('#*VPL?))QVQ@]<0^@MSUPV;X+Z)P$[
M=8_$?.-#G?Q>9QE$C=3[8(H=\AW]IP^F/KE=T=^^41A#:4/9<"EK!RZ1UR5Z
M0Y)QZ+34^>F1!U,+QQB  0S4;UG3!!RZ3QD2\PZ?=@@$XG!HA> /C'DP6'KE
M.KX-N-HD4LAO 8<ZL2Z/?#@;:GPB,GXF2!3<?RQ=W)*4Y GD;+T9G&G#/6DQ
M!DN4J!\^V//E4A]S&&F= [!P33UQ0(Z$?SENQ]"3.(<IZ<9PY<&+XZ%6EO;*
M96IX'!P8Y-B</N><7H0DFL3Z+6!; "YTC7SC:QEJ2O!6+F L2))1HE'G%1"\
M\ =OGZ9;!]'+D'D]:@Z1C99\@@WK('8(DA!'3('_ )4'EX[8$5:0*-K"?PS4
M4ZL3I\7E>NPKI$U3O&B)W1-M8O %5)QFFG;*9A)DD@@] ^3 ]:TC93U8]7-K
M-DNY>I@+XQ^ST :W7!BCUTM-DQN ]L0/S(3D9OG>$!M[$:/;$2"P *EZ]G!#
M7*]'9Y2<7*:P/ 31D^O;->NI?<>N.^:DR?(E$6>I&$B?1P?^<@,T=G\![9'0
MI39T/664JX8"$SW(<F>&@*!T#)BN3+,*D2)76N/ZD29P+['NF'@3))S]NHZX
M<= (MP<N>,!S-B"6@OQEC7?$ D72X,*I$AB?I2'F7.;,(0PWOEBM8E:E<5EV
MZY1=$)CMIRF^AFV@9@U1X<96K<,0Q3DM;YC N3%+D=\>FPHZ*-/4'KB$Q2>C
MI$X5!]#)2:.F5ZA)*\G M!A*E!,4V7^<XK<0^@[UTQ>8$B,= Q<84JY'?,\!
M??!@4RON+B<.D+A@^?L:!T(ZLOKBF8UO"OF&?!RWFK4FCD)>[AS02&$U[Y0_
ML]3JO/KDY#C@/H9,F4/63:/^'.<_97\R?8KNXN680(T<&1Q87X=W7 D<!OUO
MJ)1%M1T^@1*Z!5#2:CQB8:S'>IUM7$YL,25)&7"/M_WC)]<PD/<ZV9:C+1"@
M-O3$/2K''V!+_2Z9 -OHQ$"RF=-%^!+AF^3:8=:$2"/2?7S_ (%+*B27?!XS
MA9+\YPQ2EPF>>,:#:Z(@&DZ 48W=>KZEX?J-R N]'TR%\Q Z5)R(]L"4S0#V
M*,(K%(%J%%N>89)?!D98"#]8BHX08$M>F)M7?5G"TFA+0FEQ'C0A1Q9/5F?3
M'+4"=L3$XM3L+D3(3+--2#T=KP*%[^ @\G?O'&"=@G?>#9B.EU>.]/<B#KJ_
M[F_B.P.REK[\9*4[ >A[N"ED R3!)X6\G>,=$4D]=5@8#>@0D<'2: I8KU0X
M*R.^*PH@<J[.G?(%#(@LOL'VG(A<2;<W>1*RW:02.[IEJ7# G=Z.)%;:]9S7
M";!\# )6)K&N)T?$L5*CCG(_XVP4M^D?.+:BG\G.7W29:'<Q,D[U0I,ZS00^
MV2HM)'8;^F.$&%#NNCD:9RF"]",8$SU#$_I5'1XG(G"O*B".B8O&Q(CIPR!0
M,#)*:],#!$-U^@.ASB2&XKL:OO@(#27 6GIBS$T1(:3Y?;$SH7)J)[RF; /0
M232FL,9'I0'$(S2<)CKVR1^05@N9>V! AE7<*.^!'[[!W(\'YQE/)" BX<?)
M3B.5UAGGE].*;MQ?B8A%60%7C([4\"B0*(O\<-9A6^>H<C3[X Q>">AY)KMD
MDPDO;-[]N_&%R-%!M;4GF]87F)(BD1 WOG UQ2HE"3[)+IGMC(]=;%4OO'IA
MP9J-A2/&,S!$I+)(C8_C%F*G1;K_ -@YC1I.,68NWS'U'MG01K6/9BQ+@<IX
MRB)C;3<]7Q._]6W S?AL^<8)1<+]G[8!X,VI"(=_M@$*\04$_$9=0-!"B+Z%
MGI@5 &S<B#)KXSH>CJ3\88-.6E6T^'OA!0T#0=,;^5P3D,L9:;)AS3??B,^_
M+ T.^*00DPHB3*\3\D$;$%H!-<]LBX"6O/PUBJR @5.6[OUP<WP^4+C;?&\
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MC>)A@98C"/EB""F+:,@36L5CH^\9L TR7D!BGD'$N##D$\];QO#)&=0;9)C
M8X02$NSO@ HV,1+P8IZU-FZ^^,DRL/GS3ZYQ-B)$C_QZ8JC"(B%9X<X&#,..
MK?MA!@B  TG3.0*O1\#]7]DAY090XGC)CR-R)X9*D^F/9*(+10)=]L52F,HL
M7;7J>_\ []C1#3^K$%9$"!W=O]8MQ". Q3Z,.,#52X3"Z+$396&3M],9!4Z
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MSD2[D%):M1#TS9(-0G[T],ZJ.EM2C(W%8O+TH:K)/OTCD.Y]GKB74I@-)=Y
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M#X/]."BN6YN 1]O\2)3(0SV;-8%8H. "5VV_&&#G2B\/T(P\)H0D<4%4;N$
M<RUXP7$;R]5"/WQ*2&K UT0XP;U15:OVQDE@:&*6.F0GULL.=H?-QP''B$0
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MPF"Z; ::7[86."EDO.D<MF&@'8UBBIT)<L\B@82XQFGSFF!] QT0"U3V.G?
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MYY%!02=8^ZH>SUQ%!U<OH9H"]. C.:(WL","251L4GP2CYPC*!;RMP';._\
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M^_.(]&.X#I16(JKW4$2;)1OICV#VUQ0?V&TOJ8[9TEOT';09Q@7+ML]<7A_
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MR6$9A[AG,2^XXQ@%7?C:!HK67+R>Y5GT,AE7/8YUT_<X.*82>Q.N\E@?=/G
M'SC)U7X?WG:%.F8"[56-UK+  _QG'3D(93V&S7/3/B3&B=?4O)\LLS%M(#%
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M.!(/!)^9R44=$>PL]!ED=001U,OB2]9R:#WP"=98>1"7UP]K*6Y,%W5R,O%
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M PGMQ/[83ZX!Q7.8?]$5G;#M_P CWQ7HPA<S@-B6?$?&Q#U8W C5Y=!HOPF
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M7Q#=.J>V5Y[.0/"E0_8RY9L7W@&-WAV@BE.V%6@QT[80QD:V_$##2Y*P4S?
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MQE%$5<"%?L]\2EDE5Z)]<*#9):>_^/3&],D%8<0?R<'%*V/J;CWQ%QDF</7
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MQ/.:HM'RB]5^']"/!5;%\ >F0#&P3+I/)?2&"$8**I].^$W$@Q$Z*?G $5J
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MC(%V=<.O_O2VL!#S8!=E6'5SORL)\#UT,F[;9Q<K)2'+$SYR<B:5>" &'X*
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MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$D$DDDDDDD@
M@ D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DD$$DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$$ DD
MDD@ DDD  @ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD D@DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD  $DDDDDDDD$D $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@D DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDD@$DDD  DD@ D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDD@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDD@DD$DDD$DDDD$DD
MDDDDDDDDDDDDDDDD@D@ DDDDD DD $D@DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDD $$DDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDD$D$DDD$D@DDD$
MDD@DDDDDDDDDDDDDDDDDDDD@ DD@DDDDD@D@D DD@D @DDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDDDDD $DDDDDDDDDDDDD@$ @
M@@ $@$D@@@$DDDDD@DDDDDDDDDDD@ D$D$ DDDDD DDD$D@@$$ @DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDDDDD$ @DDDDDDDD
MDDD@$@D  @@D D@ D@ @DDDD  $DDDDDDDDD$DD$$@ $D$DD@$D@DD@D @ @
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDDD  DD
MD$     $DDD@DD$@D  @$D$$$@ DDDDDDD@DDDDDDDD$DDDD $DD $D@D$D$
M@ @D$ $@ $$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDD
MDDD@D $@$      $D$@@$DD@ $  D$D@$D$DDDDDDDD$DDDDDD@@DDDDD$@
MDD@@$DDDD@ D @$@D DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@ DDDDDDDDD
MDDDDDD@D$D@$@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDD$D
MDDD@@ $@DD@D$$DD$@$  $@@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DDD
MDDDDDDDDDDDDDD$D@D$  D$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$
MDDDDDDDDDDDD@ D$D $ $D$@ DDD$DDD$DDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@D@$DDDDDDDDDDDDDDD@ D@@@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@ D@D@$$DDDD$ @$D @@DD$$@@$@$DDD$DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD$$ DDDDDDDDDDDDDDD$D$ @$DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD $$D DDDDD@@$D@D@D@ $ D@@DDD DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD@DDD$DDDDDDDDDDDDD@$D@$$DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD  @ D@DDDDD$@DDD@$$DD$DD@@DD@$DDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@@@   $DDDDDDDDDD@D$$DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DD  $DDD@D@DD$$ D@$@DDD @D@
M$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ $$D  $DDDDDDDDDDD@$D$DDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$D@$ DDDD@D D@@@ @@@
M$DDDD$D @$DDD $DDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ $@DDDDDDDDDDD$
M@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ @   D D @$
MD@  $DD$@$ @@D $$DDDD  DDDDDDDDDDDDDDDDDDDDDDDDDDDDD @ @DD D
M@DDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD D
M$D  @ DDDD D@$ @D$@  $@D@DD D D$DDDDDDDDDDDDDDDDD@@$DDDDDDDD
MDD DD@@$$DDDD @ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ D
MDDDDD@  $@@$@@ DDD @ @  @@@DD@  $D@$ DD$DDDDDDDDDDDDDDDDD $D
MDDDDDDDD $DDD$$ DDDDD@ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDD@DDDDD $ @D@ @$@@   D@D@ D@$@$$$ DDD$@@DDDDDDDDDDDDDDD
MDDDDD @@DDDDDDD@$$@@@D@$DDDDD @DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@ DDDDD$$  D@@  DD@ @@D@  @$ @DDD$$DD@D DDDDDDDD
MDDDDDDDDDDDDD@$DDDDDDDDD$   D$DDDDDD@$ DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD@@ $DDD@$ D$@@@ @D D $$@D D$@$ $@$$DD@$$D
MDDDDDDDDDDDDDDDDDDDDD   DDDDDDDDD@$$@DDDDDDDD $DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD@D DD$@$  DD  @D $$ $$$D @@D@@DDD
M$ $DDD$DDDDDDDDDDDDDDDDDDDDDD @DDDDDDDDDD @@$DDDDDD  DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD   @$$DDDDDD$  @@$DDD@@@$$
M @D @$@ D@D@ DDDDDDDDDDDDDDDDDDDDD@@ DD DDDD@ DDD $@@@$@D @
M@DDDDDDDDDDDD$DDDDDDD@D@$$DD@$DDDD$DDDDDDD$ @D@ DDD@$@$D$@$D
M$@ $$ D$@$D@D$D$DDDD@@DDDDDDDDDDDDDDDDDDDDD@D$$$D   D$@DD $D
M$@$ @ @D$DDDDDDDDDDDD$@D @@@$DD@@$DD D$$DD  $@DDDD$@$D$$DDD@
M@@D@$@  @D@D$$ D$@@$DD$ @D$@@$DDDDDDDDDDDDDDDDDDDD D$  D@ @
M$$DDD D$$ $ @D DDDDDDDDDDDDD@D@D$@ $@ D$ DDD$@D@DD$ $$DDD@@D
M$ D $DDDDDD$ @D$ @@@$@DD$$ DD@ DD@@D$DDDDDDDDDDDDDDDDDDDD@$
M$D$$  D @@DD@@@@$DD DDDD@ @$$  DD@$D$D$D$$ D$ @@$$@ D$ $ @D@
M@D   DDD @@@$$@  @ D  D@@D@ $  D$ @ $$ DD@DDDDDDDDDDDDDDDDDD
MDDDDD $$$@D@ $DD@DDDDD$$$DDDDDD@@D@$$D $D$DD$@$$D@D@@D D $$@
M@@@D$$@D$DDD@@$$$D$@@ DD$@$  DD@ D D@  $@D@$@ $DD@$DDDDDDDDD
MDDDDDDDDDDDDDD@@@DD$@$$ @$DD$@ @D$DDDDD@$D $DDDDDDDDD@DDD$DD
MDDDDDDDDDDDDDDDDDDDDDD@@@D@@ @@D @$$ @D@$ $@DDDD$D $$$DDD DD
MDDDDDDDDDDD@@DDDDDDDD@$$D DDDD@ @$@   $ DDDDDD @DDD @DDDDDDD
MD$DDDDDDDDDDDDDDDDDDDDDDDDDDD@D@$ @ @D$$$@@@$@@ $@$D  D$  D$
M$DDD@$DDD $DDDDDDDD$$DDDDDDDDD@D  @$DDD@@$ @D@@$D$$@D@@$$@ D
M$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$@$ D @ $@ $ @$  $$D
M@@D $D@ $DDD@@DD $DDDDDDDDD@$DDDDDDDD@  @@D@D @$@DDD$D $$D$$
M@@ D$@D $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@D@@D@@@$@D$@
M$DD$ D$@$D$$D@D DDD$@DD@D DDDDDDDD$ DDDDD$ DDDD $@ DDD@DD@
MDDD$D@@$@$$ @  $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD @DD@D
M$$D@@@$D DDD $@@D$$@D  DD$$  D D$$DDDDDDD@$@DDD@ D@ DDDD$D@D
MDD@@@DDD@@@@$@ $@ D@$@$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DD
MD@ D $$$@D$ DD@@$$@  $$ @D$@ @   DDDD@@ $DDDDDDDD@$@DDD@@ DD
MDDD$D$DDD@D@@DDD$$DD @ $ @D D $$DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD $$$DDD$$DD$@ @D$ D@D $$  $@ $D@@D@@D$D   DD@DDDDDDDDD$$D
MDD@D D@$DD@$$@$D@$$@$@@$$$$ @@ DDDDD@@$DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD$$$ @  DD    $@D D $@D@$D$D$$  @D$ DD@@DD    DDDDD
MDDDDD @$ D @DDDDDDD$$$DD  @@ $$@@@$@$D$DDDDD  DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD@$ $ $ DD$      D$@D@@   D@$  $ $$@ D@@@$D$
M@$$DDDDDDDDDD@D@ @$D$@$DDD@$@ $DD @ D  @$$ $$$DDDDD@ DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@@$ $D$$D@@$DD @$$DD$  @ $$$@D$$ @$$
M@ $  $$DD@DDDDDDDDDDDD@@$D$@@D DDD@D$$D@$D$$$@ $@$DD@@$DDDD$
M@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD $@@D@D$DDD@D@DDD$ D@DD $D
MD$$ D$ D@  @D D$ $DDDDDDDDDDD @ DDDDD@ DD$ D @   @@$$  @$@@
M@$DDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDD $D   @$$ $D$
MD@D@ $D  $ DD DD $DD@D$@ DDDDDDDDDDD$@ DDDDDDD$ $$$ @D@@$$DD
M@ $ @DD@ DDDDD$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DD@D@ $@$
M@D@$ D$ $D D$ $ D@ $D $@@@ $  DDDDDDDDDDDDDD$@DDDDDDD$ @@DD$
MD @$D@   D$$$$ D$DDD@$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ D@
M@$D  $ $$DD$$@D@D$  @D DD$D@$  $@D@@$DDDDDDDDDDDDDDDDDDDDDD@
M$D   $$$$@$@D @$@@D@ D$$DDD@@D$$DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDD@@$@$ DD@ $$D$@$$  DD $@@$$@D@@$@$@D@@$DDDDDDDDDDDDDDD
MDDDDDDDD $ $  $@$$@@$D$D@D@$D@DDDD $ D@DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@ @ D@D$D$$$@D @$ $DD@ D$ $$@@DDDDDD@D DDDDDDDDD
MDDDDDDDDDDDDDDDDD@@$ $$@ @   @ @D$$D D$DD$D@D $DDD$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDD D @$ @$$@$@D$ $ $D@@$$@$   D$@D@$DD$D
MDDDDD$DDDDDDDDDDDDDDDDDD  @  D  D D$$D$ DDD@D@@D DD $ D @$$D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDD D@@  @$D$$D@$D$$$@@@D$$$@@D D@$
M D@D$ $DDDDDDDDDDDDDDDDDDDDDDD@$@@@$D  @DD D @$ D@DD@$@@@$$D
M@D@DD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@@@ @ D$D$$D @D$  D@$@$
M@@@DD   @$D@D@$$DDDDDDDDDDDDDDDDDDDDD@D @D$$DD@@ $DD$$DD@DDD
M@$$@ DDDD@@$ @$DDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDD$$    @ $D
M@$@ $D $@DD$$@@DD$ $ $@DDD@ DDDDDDDDDDDDDDDDD@@$@@DD $@$$ $
M $@DD$D@$D$$DDDD@D@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@@D$@
M @$D DD$  @ $ D@$$@ @ @ DD $$ @$ D DDDDDDDDDDDDDDDDDD@$ D$DD
MD$$DD$@ D$DD @D@$D$ DDDDD@  $DDDDDDDDDDDDDDDDDDDDDDDDDDD$ $D
MD@DDD  @@$D @$@@ @@$@@$@@$DD$@$ @$$$ D @$ DDDDDDDDDDDDDDDDDD
MDDD$DDD $D$ $$@ $D$@@@DD$$$DDDDD$D@ DDDDDDDDDDDDDDDDDDDDDDDD
MDD@@ $DDD$ @   @@D$D$  $@ D$D $  D$ @$D$D$@$    DD@DDDDDDDDD
MDDDDDDDDDDD@$D@D$DDD$D D@D @ $DDDDDDDDDD DD$DDDDDDDDDDDDDDDD
MDDDDDDDDDD  D @D$$D $@ @$ DD$@@@$@D@$@$@$   D@ $$D DD @@ DDD
MDDDDDDDDDDDDDDDDDD@$DD@D DD@@$ D$ D$$DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD$@DD@ @$$@  $@ $D@@ $$D    @$ @D  D@ DD@@$
MD@@D $DDDDDDDDDDDDDDDDDDDDDDD@D $DD$$@$$DD@$DDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@@$$D DD@D$$$ D $ $@D$D@ @  @D @@ D
M@DD$DD@$@ $@DDDDDDDDDDDDDDDDDDDDDDDDDD DDDD@ @ D D$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD  $$@$DD$DDD$$D  D$DDD DD$@
M$D$@ $ @DD @DD@@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDD$DD@$D D$$D $D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DD$@ DD$@D$DD   $
M@ $ @$D @D $DDD@$ $ DD@@ DDDDDDDDDDDDDDDDDDDDDDDDDDDD $DD@@@
M$$ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@DD@@ @DDDD$
M@DD $  $@$@  D D $ @ $$ @@$$D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDD@
M$$DD@$$ @$$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$@$
M@DDD@D @$ $D D$DDDD@ DD$D $DD DD$$DDD@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD $$D@ D  DD$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@$$$@$$$DDD$DDD@ $$ D@@D  $ D@D $$ @@$@@$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDD@D@  D$ D @ DD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD DDDDDD D$$D$@$D$@@D@DD $@ D@D @ D@$DDD@DDDDDD
MDDDDDDDDDDDDDDDDD$ @@ D @D@@$@DD$  DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDD@  D @DDD$D@$$$D$@ $@$ @ $D @@ $DD$ $ @
M@@$DDDDDDDDDDDDDDDDDDDDD @ @D@$D$D  $DD@ D$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ $@@DD@ DD$$D$D@DD$  $D$$  @D
MDDDD @$$DDDDDDDDDDDDDDDDDDDDDDD@D$DD @ $@  @$DD$  DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$ $@@ D@D@ @@$ @  D@$D
M  $ D@$DDDDD $  $DDDDDDDDDDDDDDDDDDDDD@@D@DDDD@$D$@@DDDD DDD
MDDDDDDDDDDDDDD@DDDDDDDDDDDDDD$@@$DDDDDDDDDDD @ $DD@@D@  D$DD
M$ $@@D$D@@$@@    D@@$$@$DDDDDDDDDDDDDDDDDDDDDD DDDDDDDD@@DD@
MDD@ DDDDDDDDDDDDDDDDDD$@D$@$@ @$D$$@@DD@$D @$DDDDD@ D$@@@$D
M@$@$D@ $@  $@ $D$$D @@@$D$ D$$DDDDDDDDDDDDDDDDDDDDDDDD@$DDDD
MDDDD$ @$D@@DDDDDDDDDDDDDDDDDD@D$  $$@@$@D@ D$@D@$ $D @    DD
M$DDD@@ D$  $$@@@D$$D@  $   $$ D $DDDDDDDDDDDDDDDDDDDDDDDDDDD
MD $DDDDDDDDD $$ @@$DDDDDDDDDDDDDDDDDD$@@@@@@@D D  $ D$D@@D $
MDDDDDD@$@DDDD@@ $  $$D$$$D  D$ $ D@$$@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD@$@DDDDDDDDD@$DD@D$DDDDDDDDDDDDDDDDDD $D $$DDD@@ $$$
MDDD  $@@DDDDDD$ DDDDD$D DD $D D@D   @$@DD$ $@@DD@@DDDDDDDDDD
MDDDDDDDDDDDDDDDD@D$DDDDDDD@ $@D$D$DDDDDDDDDDDDDDDDDDDD@@DD@D
M DDD@DDDD D DD DDDDDDDDDDDDD@@@DD$$$@$$$@D$$D@$$DD DD@D D$DD
MDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDD$ D $DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DD@D$  $DD  $ @ DD@@$$
M @$D$DDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDD@D$ $$  DDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DDDD  $$D$ D@ $
MD$D@@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDD$  @@@DD$DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@   D$DDD@$@
M @$@$$@@@$D  DDDD@ D$DDDDDDDDDDDDDDDDDDDDDDDDD D$DDDDDDD@D D
M $@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD $D$@
M DD@$ @D   DD@@@@$@$$DDDD@$$ DDDDDDDDDDDDDDDDDDDD@ D @$@DDDD
MDDD$$$DD@$DD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M @@@ @ D$DD$D@ @$DDDDDD$$$$$$DDD@D@ D$DDDDDDDDDDDDDDDDD@D@$$
M@ DDDDDD$$@$D@D$@ DDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD$$D D@D$DDD$D$ D@D$DDD$D$ @$DDD@@ D @DDDDDDDDDDDDDDD
MDDD$@D@@D$$DDDDD D$D@ $DDD$@ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDD $$D $  DD@$ @  D D@$D$@ D$ $DDD$$@$DDDDDDDDD
MDDDDDDDDDDD$  $D$@DDDDD$ $DD$DDDDD@DD@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD$$@$@@$D$D$$$ @D@@ $DD@@D@DDDDD$ DDD
MDDDDDDDDDDDDDDDDDDDD $DD $DDDD@@$@DD$DDDDDD @DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DDDDD@$@$$DD@@@$$ DD$ $@D
MDD@$@$DDDDDDDDDDDDDDDDDDDDDD DDDDDDDDD@@  DDDDDDDDD$@DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@DD@@@@@@ $DDDDDD$D
M@ @@D$@DD@ $  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ DDDDDDDDD$D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@  DDDDD$D@@D
MDDDDDD$D@DD$D$$DDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD@$@$D$@DDD $ D$DD D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@$DDDD@DDD $DDDDD$@ DDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD$$D$DDDDDD$D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD@$$DDDDDD D$DD@$D$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$$DDDDDD $DDD$$ $DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDD $@ DDDD@@ DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@D$DDDD@ DDD
MDDD$@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDD
MD@  $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD@$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD$D DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD  DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDG_Q  4$0$
M      #@_]H " $# 0$_$%4K_\0 %!$!                    X/_:  @!
M @$!/Q!5*__$ "X0 0$  P " @$# P4  P$! 0$1 "$Q05%A<8$0D:$@,+%
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MUS<C_OE=&$5]!2)"()I31%W3J6XZ1(:_@"6-#6DO4?8C1-;NXF-^&]L;& I
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M5YDD$,_ ?7^G25[N40-JJ '<^I&&0W>ZCY6F[]2?_C>G]TH7$.TJ\< K]O\
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MK2@5=E';<T9$2A"(^A0MVW1X@/%M)+T!2-!TRKL,G6":8@4W UCE J+@$*$
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M5'6Q@TXC[1]@_D05W\?TI4Q$UIQ@F""%! 2(Q:%YFKI!M3-#I/WX2J@ E"4
MFHTLU2W;(3;!8;;Z F>;4(* PMW.'QK%5@.JE(I0<)=:WDRBB5,ZE -ZIS'M
M[)7D2#9OH9SI1.>C2-AV\1P#U\59$D@AQ0!&"!B7N*01G0J?3O9X=?T0B&;!
MM4T[GB@CSC53U%1'J4'YZA 4K8#EI4H)0=:1(4!$7;0T-8!C>U)R%?X 5Y3^
MAL<!3U@#0MB$S;.RO1@++)$(FI-PE2UEQ=4@,#T"\@%YC<1)DGA?#,<4:E Q
MCQ*/ $2Q$M4WAA$H&D'SX(9/.QA+741)0"(HN#N RBUM  /R>F&=Q''U*NAK
MZC-G)-Y*GUUNVHZH><8;Q5%%1E: HMAF&,_M(&TL5VB?#'%@6PM=!;*L$QU1
M]9!1\$2!O73#R!E% ;X#1*;TF0& 8;2W2DZFGYAC#K0+=-D%"]0^C"0+/8OG
M@:ZA\W651\(AHZ$\^\@4)OGWJ$_=P57EKX@M]T^8^L*CZ@68U073KXRHVC3L
M&(=$?_3_ 'Y@I3PFOKR/W?AD?_!V@ M0-"[ =N;>M8(L%X!H!!F&(_JH-*PN
MZD2?.:G_ .Y*.H/%/S\?[/LXSF4-8H4TNXWFFX/%?0]M\;3Q>4KC1W'2@M4H
MZ=:Q\!-_+1J5V&QI"QNAFQ@\=D:ZII4746V'!H&#'A8P^,XCN'1!#4TI"M.4
MP-I6Y ^-5_\ W]:9M=&/BFAZ5/MBUK+[<0E#@8CO(7H/FD @+Y0OHS^$F_R>
M?^38]O/_ #7'MY_XOCVL_P#%,>UG_@WO:S_SM?@Y_P"5)\'/_"%]'/\ QE_B
M9_YV_P #/_*F^#G"_ICZ5@!4K-J_T/E;E1;6.^^/:?KW$K@PX#41I0:@(]72
M)8!<2NI6[T*%MH NX*J=M!,9\HHND_6;?P'2B]*FDJEJW#2U;**32(HCT<'=
ML=2V>@(ACM5TH32"X;\',W<>JPM0[0J*JJ]Q!&%5!3I!1/;QFW*P"QH&T @1
M$$R])3Q0W_(_%D>7@,V^>=OW>.X6T!K%MJ[154JJJJN,&C) QI'DO'M,!C14
MU$-(BB/;B.:  -GQ32?366*,L=+&+AOP<SI]WB[JFU*C:J_H^@_#Z?$>MJ>3
M?D\-U"AA8!6 \?JVB85K@)1CP)IF1PY)(E8@S2(HZ.HG'8BK[CI"TOHRS@-L
M5JT^A@.U((*V,B2F:63N(5C(LIN$L[FRM;:%M0LH*(K"AA22N."$.?$F4&64
M@$D1 !$#RJK_ '>=) U(:M3P!>L ZHTKPUB:IMX.0 N4>;W_ +[KP9H*R*3X
M&AY@GD_O*^..#*GP N5%HX1(4P<ARUMS?\?!B Q\'6FG97"V(Z#O)- /337]
MAK:'0"27PJXO&PQQ6W(C):Z8AT.0#$J5A#R;1056[,T $MNBU0/8OPY#'UXJ
M3D5(K!4@ \ S<R_K"B7 C5 7A5M-R/9Q)5OBO,6:^_>+ 2BDZW&N <>TM+II
M2?=H\9Z@JUU![*K\>/Z$1T"TI7LI22NW6\MKHMM4!KWL4/!.YMNJ6GH51(/N
M AMZD 4K3)KQHTPP!0\/:0%78>/Z';@>L%GQ]^,!(AQH15CHIK9+=@:1;6ZM
MIHE UY=,,!Q!("'+I2(G&AR--$$Z"$Z.0C$3#>B:I0Z87F/1F[AVJ@:\/.9"
M+]+!:[ (@=$8CO(O"6@=/ *,F#5JH 50"8V2[#$^<2PJ#4+K;#E=X ;UW$RM
M40C70F/U2'I YT"J(:?(,)1-D ($^X@IXAB%4@[.XH;H4,-;8/[9V0(>PU^W
MF'Z12VT549?2"'OV9I50=+80Y2"MVZB<[\F5(9(&B*-JW!9!0$)/%M78*,RT
MC @(E#P'[#LUD+>71C#PV&[=G&55\-\-BH*0G%'_ 'Q[%+:!4'XRZ?:=!Q$"
MZ2< E$(CZPAF*' )TRN$*L7+[><;4TB;0-IH+K(HZN$I@<H>4]N;1F;RNH!5
M]]_U_P!/$(*!5_&O.+V2!DYYI]PK_/%Q[U#_ "R)"/N@U[_Q,\* 1?W PNT[
M[?!O0]J:R]#REN@4/=D\^\@()"K8!7CSX/6&C,.B*"5$JB-GIUCE>:_'5/&A
M5$Y37A<>\X.+6JV#Y8URJNMH25 (^"4P>Q0XQHL#.D\E]X\QVFA3F"I#T\N\
M?ZT>"S>B373A3&G0KXD_M(>ABV>!2E][7/5HSI7:+]@*_+V)@=[& B !H \?
M\%K;TW[(RN]J\CG1ACL[./Q@_& *N' .$\'MQ#;@X8!@J\)F^"?[@$K (B<3
MV!]D;W.V?%@Q )!2RIISS=D.;'("$JJ]P_ CY%D<X$_/K^R\[OD B.D^'6N9
M&_\ 1UC*JH58(&@*X4/>8QD$!U(NS)"BRX$(9 P2+BN-6 .- R54 'JU8=$_
MJ %'1A]&CF%S !(08@+^* SSM,4UD&"3@=F:-ZR'5X"@LE#V>>&;3RQ0=5\I
M55VJOG^FIN*U9D'0/4U4XXIUIP2IP!!%"/-0H*X7;A4"(/3N+</O"PHVC*#[
M$\!^DJ2 !]JT&,^(TA=QA-+1@;DZM<=RPB4@L?%,5J"H;C*BSP$+MLQ11RHV
MU%?"SQ].=[6.MM"AVU\L'DD@TJ0]%J+T%,9UBSHV44)O;VEW@X*$6I&%-: /
MFL()5)-L%"FX$9I!F"28I*==V%O;/..HDAB,.CV)O?8E\,]&3J<$BK5/&7;V
MM&FRGT"@ZF\(="/=(A=!"FW>L%>706Y?>;30^SCJ,$].BX\+\N_4_11:!UBX
MG $&EGG$_ER#L\_6/J6[4X4!4;A"C0T\>D3K=R^!./1='GKHN+,0U$""2P,9
M"_,54( @@.XSPVY=MB:#J\JOX_WLRPJI />$=6M(.F>YM^5C"Q+#;7":.OR0
M[&2&14GA*EU@/ 9FPW>G!O*:&I]2Y]>B3"\'B*.^/]>I$0GV\)Z]?@%X9+NL
MB>-^XM\N\%"4%Q]*#BU%E0L%@AY^LB4^19D4P;54.&MT''[6WZ.Z"">=OG'7
M5M=+.SQXZ76&.4':804*G5$D^\8D14T,77K;9W*P%I@!X>D:^]8.S!>HI2)1
M#]X:.._Y.YX;GS?6(WW8T^C'XPD41J*7H6&*G;3QB.\?K2KQA@@CB>F*J!5$
M 3"A,.TH1>6T5X.<-;$;Y]AL4'  0T?\)4P=C:/1SYA.)E6^1"P*/)!.N<K]
M.9TD)XU?FG#6N&R\ZY+J!7A?ZDX0% .JO,?^JD:$_*:2^_C?ZK1C'H=/K=^<
M' 1$4%HAY=4U U<3L?:T1D4Z;X*$#$\@-@7L@T^F3=_M,@$1/N#80WO6L7:2
M]P(<! (FUWCPC""A7K#H85WO9PV$H :X("U&RZ"*4@D*D!,"33N7SF]?YW62
M5-")4[&#SG#@(?>U=55_4\"PPL*P4T:JH%/9AU X8'MX?6\(,4][9T/[TF/]
M W2HKVDVX?#:%L:7^HA"1OHYE0M#DT#U"J%\TJ**8'0L^14./LP[WT%7^(C]
M]'$VRL<@?A@P\\#K[QJ)",H J>=8&SAM'"(29E,I%HH#ZQB!8%M)W4#M;&EU
MKD"]_P ]H.3;I76X[\)VZ@(!9CD,6:M0>*G@%4<>;/.T7@*^A[\XUC*L)I'K
MKSMC/C&S(H^J G237GP5PGDV:K94@TT4-.$98+@+:$$<OGSJ1/X9".OBM6TB
M/HV3>(C++18QI&J&(>#;HAK8#536DN5.P(((U  Q1:'"Z_5?]]J00> V/<+1
M;IV/1AXB;%@NUP;R4<!NJ#\XP;_HYF]GR<%T8B2Z:A%#M*@OKQP_WQWAWZP
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M/'E>#!XV+!O)6!M*?G#79XVO4$R/*B>_U'.D<#Y7-J,7,@!>*H4I=^L.H/\
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MJQOTQ^$W.^,C7B:F[*$40KMT8 U:]16H7P=9K'@$BW'5!88PZ&<7X8Y$&7"
M";>4?!]#9_&7DVJ$FI/(_OIXG^F-B<8"T!^6WR3T8<FGDGG"' PZ5 FD(-TP
M^<G7D76"4K7:0+ D6=0HJ\.:0L5!P!B(\:W'[F7'(FS\4_G"#O$(T"@1WK>"
M#@<LXND/D:M5?\86:6 8WQ"JI[O#6)>Q<^AA!5HJ'9T9]09#1 #P  'H_4A*
M]UL>)Q'B.G'D/#@A*LU6BZG8IMX(?7MMT82@WME(Z2"/QT$(*<CDEWH@X!5!
M5)W 4U44T#RT5V=+W A>2BB2?$,_J98F1*?]^WX' [/-=U@KH* ?)G3GUAX
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M.ERI0$PCP"J?3L?.;+ +>W0F\T)K-1L:0)/$TT$ :T.ED!$=F1@E+R4#L0L
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MUK;>*12C-J<C@0*Z0H*'0!61T00;0;"\T"RA"<!$^F(:T])H+'[_ &']J<2
M1^D>XM7LXP[,QC6H)SSC]Z/U'& 0-"-7XQ.T[DX:G6CC0G$7 1KIBMV=N87^
M/\WS_P 4MWIE+S^V$\@881WFX@H)WKT?Z91I$M .3N/=!S"Z#? G\W^V\*C
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M4PC%I)1QV14A=A$YL;.GNJ07)P0/D-PVN,%HF_'^T^U&X.>17_O)%T]^&/\
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MC0[L$VBF0?*#)B8@]$:AAD;>>15^]!_S_M+UI7'G_"3]V)QI9-4(6 U.T\S
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MXB"E,0+SU"A/,TN'%1.F24<1$/@OF!W^, ' #]29:3.T5 NEL:VE7$)5E]8
MVG4(7W@UB?C@ ?0KR"_(UFLP'">=(&@PNJT4"M99Z+M[S8?]!Q)*4(WQL*XO
M^ 8U,92D 996K_NJ@N?08._([-+1<*U+WYP$'3S^D>9C0;V4C3L37<L!X'^!
M#_&-JCPF3R"ZCOR7_&0/(LG[2O[8$(;[O\&.^50%!5G0Z<VJYWN@+:LV8IK
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MU4L0T"-*>\JOF2!*H3(RH(8S'>%+J "N@._/HQ"BA3CZS>99&.L.5NP.OO\
ML'+6M/B)J?F8,LZ-H]\'\GXPL=L'TNR?QF@_%*/WP"MWA_*#DR\X,_9_RX^
M(E'%!\513]O0?,QW/PP15+H W<JZ/O\ VN*F@_\ *F4M%_XTRIH/_"N4]/Z%
MP5?P)O[L5_PZN"G\)_T&%'X;_HL5?A/^BP5(YXO^,9[4\U_A,]B>?_3<2Z\J
M//& D=DW_64Z*$5#[6W _P"C=)E%JDR^E]!D_DWBV0^*"^Q[PX #=N6'A3Z
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M#YQ@4!CSQB]7TP3;LY_""*'H8A!!9V=M0 >W (G*P$ 4%/WQT2XE4.%P;6Q
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M/(\%_P#:S31]3H4@!0#3!^,6WZD@1 @:*)K4W5:&=5#X-K:V5T2").)QMO\
M%R<Q&7S-?S@(=S"$])*&[$PPR_>54C:((]$^\5Z:GXL#=';35V;P6%V)#8Z/
ML$S0G,\Y&7I I%TW6W;@HXHQT$#"*M'X0P,7E5$ -$U1J!Y<JGZEP8DWH"WK
M2_K=!=R'1HQB6PA1QEX/&U;"!J:;!I-O;%T#HSD&/ I&3.5)*0 K=8+X,Y@!
MP$3H)6NG0OGH<ZZ7[* :.M&+$$-G$J3US0SK@;J"FI03@H[*:PD@0M9$_@_
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MB9*$5&AZ27!M>_E@-B"!0[.XEJD]EHU5FAOV%"#K50  N"=C*7Y0J1W=U;@
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MZ"&#)/3U#9CL-9N$-(-%= U8$JEGIYQ]4F: %6T JN+=8W 1&'GPXQXQJH4
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MJ& 6B,5U ]$1K8\OZ!Z6Q;8M/+*'0CI,(EJSXC?!4"_*Y3L6T2-F.DO/>'?
MFT-^"-/@P*&E31(^,"SJ&PA[;K7[>\-*I0#50>2ZGP>,V_A'#[%X8;)?*H"T
MAV"/%(K3!"KI96O .O"ZP=\3R^YX"3Y-JKDM)J&ZG3U79DFG3 @ @$X364^:
MW4(_P'SB7-CQ%EMY:T?/<4K/#DE1<4[7/1@,'!U!38"Z=N3*,*F>C[ADF #
M+ K Q\R2+<H&_1_&)\/3U5]%3OX,*GK.\]O[8'3V+B&K9WS?>;[E-91 O[N"
MP %.D\F$:-/!$W;O64[(/$?28UP 0?0F(O" #%M.P5[UG*;A ^?*>KM7N>BC
M. 87Q>RLWXQ[F;\J+;T:\M.!ZA N)W0_YS31&18"*^]Y? X5=</?[_C)"3NQ
M)&&H!=DIRX_D8^?3>^-"<WZPK/01!X P2ER8!]I ^?&;TT\DE4+L(Z9NL&5P
MM[_Y<L)66V!L,Z>!&&-)#+4$:!HVC#6$E+5!3T":5V6]7OZ$W2P@J 4_>ACM
MG ].X&H!U(*0 $-A%3>RCHVZL62L("D,JK50W>N=>VG?A:1E>%T;.$KX!HK=
MJ%%T@HL:U(BD,1%2/D%'(0@$S('9NK5Y'V.44 8O,%>QX:VWZ;E.NZV@#Y<:
M24.40);;T KQ(-M\@:&UDNWB_8I0]/G--6C'/:ZQ#ZH@05::4>?;%'MK(%Z+
MOPN%R*Q'JWEO"EED_P!,,M9?(1/V<IRX6ZBCPTT/O&O1:YMJ=D=#*T+@OU;$
M6JC-FO>@LR:L,5!LY;-^?RR02W987F*WS@Z_$QZG"H ^&U0V/,?VFX[?8]OW
MR%X("65EX?Y,?\G(@)*]D_98H $6D0%X1T0)#%-+%X@#\I?Z:>WT.Z:&F"$>
M'@'E.E_=/@ID VK(O2 P^^VFLHFTS0Q1@>-!HF0C%4I(:4+KZ<*B<MQ,!H@4
M8<;7-_++1\6@X!AK<H&/&&(2X(Z=#W"_.#)8@2&A/!K"1+- 9YK2C \MF0L2
MR$0)D*WM(<Q4#U<5??O'DW5#8>5RQ), A*^8?5-=<%:AFGV)P#:Y#!0OEF+B
M3XU5!7WK<-P?6$D1T_+BAE\/@C1#MZT;XVH8VTU^'>T^/G;P+2O<$5B_,9L+
M@//.O&#W61TE7376RLA1NYQ0$55%4H+5J5@B118]U^<=\:%K:'R%IZ&>OT='
M>:/5=Y6[S1E=8NC<+@=D@OJ"A3(8MEJ)H<38;5!680D0UP'<CNIP:ZEP2D_.
M#';I ".P(HA2 L'X2C&0'?R_MS:H/%DGJ;P=AIZMJ"JC>E-NU(+J I#.R1<'
M?080"RVUV#)H-&OF:'O+?;.]A'^ULG)Y >Z%25VW0QE,0KYDT@2W65;R<&&A
ML)^(A,V860X)5MIU5_X&@4GBRJD$O!'5KR^#V%70Y#X5P0H4!Z$)!T"VT(3?
MZP^CN\A8\\7$9H/;H' W4WY/1C9'-/"#H%KKPAXPY[]UM/HO1T'G#;: 8!-%
M'9%"MHML$%'6R*;;7@U[/DHP"X/2?'Z:XC_]45X+Q5*,?3=A@BP63+V(7G!F
M_ #MH(C>'V."P5$:%3]O-Q),JPB+ 0TFJ>3.@=LC#EH;8[+YZ@R %5=!B'AP
M'N0Z(_E+'*V=C%J)L:2\(AS'?1H(>P,-OTQC-=Q!\"5UX,7]"K/O1X,L.!!^
M'^+ M33 >V6<RI0$HFE1Q;NQ397YS-(?-;5ZX?/A[O$X&O?%9+JSUDIIAR]+
M[*U)@Q00P AZD0U8(EATQ+2(?#6>>X9M\%!$()5[XR)D2X"P+2=/%!-&%C$B
MZ^ZH_$^,FH(-3]A=H*J"/L:^P NH7\*_C#>X4UB=#XQ!E> "M7CFI_[6&FC
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M"EE2255IV\L^,52ZA@O77GY_TYR%5#9+3X1OZ]LN06S>B'M#^<4+[>$T&B.
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MIA 8*"@II/DOAB&Y1)C'CB94?2/J ?O?!7%'*3<P-PM:-MBHG]Q#$$&PM7X
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MR:1919=5X.2R85AM;_$^\+@!\%@"NBJ;7+Z#;'\T8_"Y-HO7A^N/W'! J\
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M$QPG83X,G"YXHK=I1 ^W+ 8JU6D1U=\8O\2R@USZ>/G$(*,-B:L16:95E"1
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MWD*!*1(;K5:PUDZ<= DA-@!YHV#A8J8F]@"A/#;29 NC9225T;=P/&"_85L
MFMVCV0'$_B^2>?"*_*YV#4C$%@'JV8*^-:*^73BN8/2W<*?&74CB)_G * G%
MV7V++/G-F]/(J-V"W=>^A,0D"<JFUL2J:_[Q2]-PI$H2N'Y?&4<*0KI]FW0/
MGSAB+3^&4PO Q$=/#G[Y%Y:46E@_XN*@;75&;1]<,Z,2T_RQ*S=[W4IY-;/.
M%&\2: [%?V_C#3KP$#36M81'5?)K6::.2"$ VNP>C*A@%HR'2QTVOS-2D&*Q
M7A4NSU[Q.-YNV0NP@[1X>7"^HSZ6- -ODNM3(@M=*!&J^-&!6;%=2%(-G:"\
MSN9$O+K!19(*I!$38.$0Q]'5*R%*+5/#E5OE!W48UV_NX E6D*L*058A=7Y&
M"QI#49_]X H)$0 QT=0Z><P93XS;A-(3/2'K$AT4&E,$8@>?DP$NZ<2:VA8,
M.@ @RU@T@RG%&O(G#MQ$K93:%2Z61//=8$LI@Y'0(0C&X"HU&FFY^K*^S0 E
M'WO!FJ6#V$J%M=@5XS7H-D?/<-3#@),7JC$#ZO\ M\S? RMFH*)SR4\Y0[6D
M(XG8= @QQ,<Z"QD>!0$!%ZKDR/\ %A0:;0^2$' 80"<!"HKKY]&"0#<%ZX9S
M#4/2"[,S6Z'G"PM/%>Q#V0+%=&F!9I=6.@CN+ IXV9/M8CM= (!MUI7!^ N6
MN<4++$HM$$")2VA(AJBF@N@[D?P$UL%:D:.B8@:C"&40 U8;K(2_.H(^.%1]
MC;?.7#EH#35!(G\8#9FJH#2SR&]KJX>N'O:805O>EK5<EFH<P X .AL'@T\)
M K=&_10\!4V4@K>CPR505N/IIA'>])/_ */O!95-+N[THK\$YYPL2 ".1 X%
MVX=&Q ."^4"O^  '-9UO!\%UA$I=\'6N<XE'9NVD?7WFE7HMCA?+_@?6:NB'
M4'A>C"2[840K#?E0QN=M1= ](1"-BC<NT];H[#0FT%%#HY/&76-1?"%@3PM!
MK?!0/ (:5("&C%6>&91"0*!M/5R6MU&Q$!79L9XF=7@ 0\DMB!CZ8)0Y-:@O
M HH''P_HEP(H6.#JNA?.#4Y;$R*:\@33'N J_#B1LCLHL)7,+X)1*2@V>#W.
M='B,"GP5=])[CO/ERMX"?P_TA=R)IJ#0].BOQLQLE(*L,6=!NTTYM48MPQBU
MY$-JWBF6@U( 6ALJI\ B*F_+B6D7X_*W):WJZ-Z6KRQH57:::J[Y$20+1QL/
M((#"%PH2"B@!A  5I\W&/UF^4!H>MW;SBQC0# =AJ=?/K$4.$22:NJJ<V3^L
MY *(*?1?]\:C8J;P5/*Q/3[!'MK>Q:VGC_A/8XUN!I2S63I$@SX::#G9J;B8
M.O"H%F$?;&!XK&>(+H$\WM:NK41J@T=.VB&&R.YBK<%H608;V%#76@0].B"=
M/;@GOQ&**J"W2ZF6*0+I;!5%2KPQH#,.KVT>H95\>,6JZI )3L)#AJ1;ZDFJ
M04]B?G*%@%"1%$H="5/;-5E#?"7N0V=Z767&4J5%- M8EJ<28P;@<V=_^V%(
ML2.G)53HWO\ . (?P:!=$0$T->5_Y.@5D(U!#\OB"_$"!V,&I HNP><*8)[1
M)'818GOF8JP-H#$GK232:Y<7= .-H-F?/D\R8'"RYI@!4% S2Y>XTEDU.B ^
MQZUP:G)("@A+!\8+11Q8+0BVO$O.90#A55?>Z)HY^<-"R@4%9H1R$(&C)=H6
M0WS["@&Z]HGHF14'5 &P4T:\9I90^0 @U&D*:8]R"D!&FGD@?>&$F+MC5/6K
MG>ELJ!"?)3X3F4L$""QI6&IW(7&*D@)8:N(Y)U%\YI\"1IJ>0 9R/9B16T5#
MZ<]H,.L%T0[>2/=$IDHZ8YKT=POXPQI+1L&E(6]^'*$E,=05VH_QKQE7AD(:
M-#Z/KU@C52 Z\W( ?O >#I/V<K:4W05"6>1Q@C!+!G O^,2[<0K$ /,N_C!_
M*-]4,0613@(W @_/3 HR1U/">=/7'>*7?)@3=-J\.Q>L?U76T2CPFO#WO.\U
M6/>C_O+#,* (C5[WQ?&+6*0[83[U?ON5,$.;$-AP^ @Q$(/@!&P;-LS8<4*Z
MKQ=.0>YK81H1*/?_ %<0Z,&&NIN%>/OPXP0)E]X.ZF:X"3;0"]#HK;OP0 !0
MB*);+4'+%F D@!T"@,[3KDD)/".D.E4A-&VS$_\ P.Q+L!2LT7!D2&%A2#3,
M#9:["ZU"()"!8*6>8ZW]2E]E0'X*$@CNG6LTNK#3[S:BX;.W*A*T(34;:PDH
MK D"/*SX;ZQU5USC++PI$.LT?VSNS P2UNFOC_8GS6J4B* ^#T68Q>$ECI(V
M3735%,DG,D+:*(BT8/CI@WA6TA% P:U%]8BH@$W< $Z2;$41R7K&Z+E 8ALX
M"XY89MI0 1A(-L<'$)PFVQO6Y^WQ@" 1]0&-=1'P\,CJ7Y;0NX\Z%YS6'FD8
M];:J)U-C2G#E$G) WW4Z&U%MQ1AGT,J.@-PUKMPB@$(M8JEPT>MFWG5)$XM0
M@2"AE:%/Q,*H_2OAHQI 8BE<Q'8F_&%F7'T5OQ%ACAQZU'>W!H5WX%;AS:!9
MS05Y:W#%$0R(,4T#U$$.-6Q[)>0 3V!H8-<3.),V$^63-SB)'F&3W(%!4>H2
MFMWUFZ\E5T;5Q>+FQ(>]D?&($4Z\_6O>)B!B>3P_QC=4P!@ !V%;TF*[<(N8
M C0WU+E-/E$6V0 :[&'O+1O70Q -;\G9A.S/QHU [ IP34+O&Q25L,:^S\^V
MS\@(4=;0#-"7N0>]LG*9W+"V=\9L71N!C% 5!+TC,(9J,^^UWL);?F& TRPV
MHN+IE'CX?Z#*"6"K9!G::Z&==HQ$ T"U%353LN5&C9$LR-)4F\Z*G:$WOS]/
M^V.5>:#.EIP#;BZYGR;CH9&%';GL\7)-CTW%T!*)P[9AMC42B>S%0XK)84>0
M9MQ0*LZ)[(666%R10"E6U;4D6^ #PP!'(AT&^1221Y%TG2UV$%#]S2LR +B+
MPP?;SZC5G6P:-V&-<EK82R7%6IO;BD[NUK8,5T5@&WN*%R$3L/5R U'9J :,
M*FX_6 TDHCJCP/>D&K@Z8%@4:TZ+/O% IIII/>M7Y!UQ[M:9W+#A1+\8?5O/
M'YQ:A8"5W B,C6]Y[Y7AY# _)<08\E57P@4Y/SEF,]H0#"DGGLQ$_89U/0#(
MH5^>,T+&)#@3;NO/G_?%CNH40 W2$,?/'Q*>A<!3JHV*,#$HOW.! %1)9;/"
M6CC&'WO$H7E *.R(X3+7,C2&TVI%NURY9H Q:AT#Q5680DDJ"4*JIO%)BP'<
M!+Z@51LU(=0F;6P0Q5="+(1+B7IP3@M2P=4*@=Q@8CQYS3J%/MSI=U=I^$#^
M,8]&RKT7X0_+'0]5VT5TMHA-S2(-PG//3:&XIXE(K6C8KZ1LQ0Z;S( :THK/
MM$@7(A4=!ALJ!8$+?"NXX-F1'PG5&P(:*6X3QX4C%</8[3#\4&4]**B7P#^,
M$@F)HB^"@2AX^HW K,0:$Z*[E5GC;V#&&F*6T5W?._,Y&+98M-2Z#X^<)YTX
MBT:-M!/GXQ03<@D/+8V:@%3//K:NNW2(:6X,4#IC4(FNHN^LCHE8B$'0">!/
M&]X'?J8L-A"6$T[Q,D%(3P>G_9E2=BGF?'^3\N-')T^64_PX>!(()A1-LE+J
M4\C$NU1832>S=N1&\BX'Q]Z/S?&.?&^;\W+;1I^D"&D*AO>.GG637-._C.O+
MH3;9V;[DL/O@!4>&B]$>&,B!632<_EA$?,]AO:>%]885H6SV3QM'XQW2:#=<
MUB6U$V!LQAX*8V=$]&]_.$^P3?QA3Q"T6P^K$_C'X W4Q$-@+=23SA:"W9;_
M )K#&9RE ,-1[! -#[P=9;PH&Q[UYA/B<W!'4A&).Q]I"CK#"BH^Z!SGS@X/
MLSMBM0KO2,W,U?W$[ -\"_\ ]POTWU\X8/2AJ0A+!ISW<0LFO?LCB'FO&+B+
M#=D4-T H!SWFL6K#X77@#OY\QF[(:PH.A=7:[3Q[,6EC!'82_3$S=@AK("Q$
M4A8[-X(P9ZA@\P/ 2R&-_,+LU"I"&!X;(@Y;RC>C\N>'$UG@>!,H2*  ;I#&
M_J?D5. .J^#-B1GEXCHLZ\CXRW]+UP-KZ #T!@FEP5;05W$@M+S)X2J0!:)8
M 045J%BX$^FEM&@5&>6(X5@+Q?MA]O\ :D?$!Z]WK.>#QU4+,$VF-G=G<3AS
M7I/8 O665\?[ X70IRXP)3P^,()<(B3OHML["KN\P* *ZL)H7M!KTQW*,D2B
MZM(0ZET/[<"%&8NS0NV8WJD"4VFBK3EVUT$LV-%25 FC2HO$4*$%S@2$2$M$
MZ01?ZSN8 4H0E0*IS%Q$M':[1IAJ<]X'431.DTJ@3H"EQH8BPH"B"F:H.RY1
M4\A1A0(;'P]O?UKD.?PC]6/R89SWU?C04D-#!CU@W@/AY5V^;B?A0U04M\&?
M!X,%7:&'LJ/:Z^-8,P76A)SP><Y?QG5]7B/")I/DUB!1K#GKWE\A]"_SC&@'
M&G]\%JTE6@^+<$/HC._Y_P#S'X@U3$:VP;K2I^R9>@3-1/3C(^&7P!/!J7UD
M FCW>1@!L-Q:83/B/$GY)QU:>$.^:2AH"=!H(3F*?$KJ%K'R39T=[@0R$\]
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M 9B!WLB- W,&Z0O'HZP!@#1/*Y,T W>E)X2'T#RR"++5]\=S\AB J&=K_/\
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M?$)]H><TUI('BD-!#XZ;!%C @@D2@:8%Z&I7 -5PDS5[HE71^3"%-L&SY0/
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MD& BJ^C "\3+COK:Z:\+W_=4&N(G=5=!\N--=%0NP17W:35B1Q[V- /=,F^
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M$4&@+7!P4GX\QP>01C\#."'X\^6RX@ML!$MV[UC)!.?D%PFM'.&,B(@&'80
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MC7QW(8TN2<NV#K&#M5?&+@5L -7QK";F1\JNA*ESA#@E' GV1VX%=NWV_P!
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M=<%@EKJ5.H/SER)E7I(B^589!EZR'AJ(D&.X$<,1VY<@511"76^A/-A=MD+
M;B2@DQ3UJ&H-BQ!!1>SA')0<MS0*;#H(=$?(A[+0>]O[3V&2Y-J?8, L-*@C
M,*I:6-)5Q7CON8VMO-$#10WV4T1K8\\PG@40%6 V,V49X("Q;40_B5Q@1W@D
M _+FA1+4^8 !1;#R0AE&X$X'P$F6T5 CVD$XM_LQ()53A*;O 0!M:N.G!ZP"
M) !&J$<@5$VY6 Z 4HHJ3SDVQ/T=#X.(W@6J"G@ZBM 5,$2(?#8O7-"B6EJ!
M.T7"T4[XA"W[>TF1 !S-OJV'31U'LPXL"'WQ@M39HQ17 5SW#QR'M31ZNT "
MBKH@=T T/:J(W(/;]FC0]^<54-=$;J/H\)%NHJ8AJ 97H:;T4#SA8 \'D@F]
M0GI6-1:AI( I2E-6J.#FD?C2 J,  V717$) )87:RIL5;O<V3\S14MPT>R^$
MR0C4+0E[#:#>W6,(V'P0""2'$F;G$RCR%]V_G#T(_>;< A\# ;E(A]R@BIT:
M(.1FI9T]E)&'\IANU];&&'DQ9]@&2N6'&#+!DJL&<<=8W35!U6C&]VE$PM<#
M 0LGK6"0 ">6L$?[$P$^Y4^'UE=&6W#V"F.IO :])!J>D<<\*V.F(3?K!JS)
M1#Q$ZGCOSAL7L%B0@,AVT$0=BMR4 K7ACS\%DP#CT(ND2&GA>7S=)0P#('9#
M1JJ/+XQX\@H(98/0>%TV87/10(A#P/+\)W#F5?(#WCB.4 F WR"&B5]BOP,U
MI0E..'>!"5^"310?6.; J-.ANNL/S\ JP@TQ0BP0:;>2;P QO2ZON@T8FQB4
MAHW4"'7@]Y2D7%0*GE/P^\!)'HL8@3C[-N$%H-KQ"NY#'R^?T-?,^? "I[1X
M>FK A(:L5!(B@IC'*6Y$8%BP-!5=>5>N4P.#I 0XN('G;77]+2G:/Y1>/S^C
MH=S!H0A;-:CR;6-;I& H&Q\EMU-&;.TL0&VC8^','WV3 CX3J>KQJ!QQ@-1W
M@4BG,&0VL )J[A]$\&/AS*R[ "]\8NN"1Q2W%*7B]NC7JB^5:OVJN+B(L8NX
M)0<(OGF$)U</!4CW76YXS8'6Q+)V/@/+K2*F#*: Z(2%+O6G+X"F(PK . T&
M@_W&(5%H$K?JGXQY_P )$1B/TX[#S=]&3[J^(R9<XZ1+4&0>/&;^,93B34V(
M5%+:'P9<&*2RPKP"P-%?*_U#CSH)H<KM@OQ@HL^TM6)H#A0BEJ-FN1LJY4X=
M [@JYUXRS!Z!I7T7#<&/&0"=6"$&P29,ND+!DAJ[72:\VZ-23 &,Z*M<)SY<
MV?57K N5J$=QW[M=N@%5<(0KQ%])"K4B0@%!#H,Z'L(2&_2# "(X$FR; 2PX
MH!%L-\">=F/9-*8B"$!+#JQ,0.X41#:0LVCK9J)B@5]<J*#Q6SYG2M'S7."0
M"6&)NK%BGE,H)HJ@ @+ 3 6->$40C !"2^W_ !$]FL#( /\ -?X,A01FN:KY
M%! :/)R! <(I79=:/-S?%/B !;$6$I#>\<S4UZA-EB*Q09)L&6J.A0V-?L&O
MU-FIS@D1Q[@EF[$(DUI=KEN2 K4*$'82;V-W*/@AV% !=PGIL,CM\-.Y&R:S
MX]8S$6N,A-@%7EF)<)WLNDG:=4A"$@=I(V*&K#(5$B>0=#QY;'1 $P*6$'1+
M6P.3,>?87_SCI, H=(3IXFVSR(-K>(!'&]H['_%%["EE.SKLD#2=)@,MI-0@
M!$.]FRCU;?VDNA#LA \)I\"B2JJ3ROI$<"0:7>@X #0LU"W&T)F'0'00#"-6
M R8>"#P9;DL95 B>#\S6!0-K:-4>Y_UD&^Y0KH7(?S=><I\:D@HR^21KRF*H
M1([Z*&]JGTGK&ASB@@1\#S&CY<&Y1\PA/+*WQ?S@+R0FUCHPKWQH&BE4--!T
M7$4:^PP!O1N#>&*!!0 KT]8T'6).LHK2DE>T-'<)BCR8MPV7H^K\X<*20(KI
M!\%8*#04,L'II-82$A#J9".P2%&X#5LM#%N-,8H:<M2;"[@"Z,2D+!)W*T1;
M^SN6>@U^IWQE0TALI#9Q5)>^,Z(P#L^/28605*0FT!WC]+%<(2>EW^V,EH @
M!.><!2(:2X;7_KK@#)XZ"I*7R[U]86"\B(A!YKSC =<!3<$]=PGF<MQX1N3P
MY %H@Z1[W*JBTY!NH]WER*-#/!.GSDZQ;1]IQQ;63DH2H"^ZX?7R5J_X#UCR
MH*6S2T\\1?6&M B^4\?&(Q9/^2'\#G10Q[2,.=7YKA%!430@EG=P>;YPD[ZF
MH(XPZJK%ID$=.IHT(GV^/C*;8<P%0EH@$"#.8FNDX8MO @%\#E@LWK&J@0^1
MOO*[I*ET 56K$#>H0_B$%0!H  #]*1'M+T$M\,PR$#"!1$Z)Y_IWCU'$M-FQ
M$$38F6SOBZ1!*$MV:3>;:W<PE %51.J5,WQ2K$A6PCLU/O;# +TI2#2 G:?#
M!0B!!") JX@%UZ8AUS79)4Z(L330->#.QSIBB^@#\9UYTA$^P)Y"DVT1-VN^
M,O(%R;4=UZQH"NWI V8%*6X:+5FALM=E4"#?$,(4ZPH_<KSQS_<VLQ107JG*
M4_0Q59S&W /I#'O9!B!@(B/.3'TPK)4L 'EZ[?ZC?(4"-2(57YUB,M;/);P
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M2S?Z?[?SK*PG=W6&NEX$J&0PO@1TQ4S3#Y:&%"#2$KX4*N:JH)870^#%X^4
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M:OP!!Y$"[@.S8N6%2("AL72ZT731=#%18-L 0$$7627&+JKS^-_.0,IR*00
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M-S[CBW"0.*B_QBPTG!DES5T^4;H18:2,SJ=AQL\:3B,C3VX\?4TKPAUW%M:
MH%HB=OV<^T!9 ?%L TQII<$&4D#X_+??G'TLTGA)]B%^+AEBBRU4J)VJI$2F
M)L&P>H$K?A;VR9HAB<)T)NC\+7Q8JB4,">JM^0U>M#1X_DD@5":/-8.,(/OB
MW5W'_)1Q/?S2]3!&0'[WS#SM(&G1]UW/!?#D:'0$ZA!JS_\ ,,B%=(*'2%*:
M-_$,5F0$!&B[^!^,BI.@,&]/V(-UVTMOB_M$_P /C6)P5H&P*A:_(&)6M.T'
M;#Z[ZN'2">"Q61[6WP_)EMBU-Y"K)&]9(WX5@"VWED?(N)D+<KSX%2DTDVX:
M8IAN,1DVE#^$Q%5"T0T 1@(0(!CW,B H*:ZT# 1-5(@!FM2X@AH):@[IE3YO
M?T&((AC6!U:)DZ=5-;?#SQEEP 8H=4^=SY?61%#8P3"WVG,:/!($0+DCO&+.
MS",E@.J#^Z%FLLQ6'4#VM20UYR6"=ZZT=2P"D;"(Q:>L2:M480T<E78.A*?!
M@:*K%$)5NKB%03MY>L;BPJ)&G>P?E\^\[8<N;::^SL+I5H CWMV:#I4$2A#!
MRP V$^[*5F@(X1B@N,MP\A8(5BM2"&D4XKVO.\\V7; 'P7V^NX,7730$:$%H
MOCJ)FVUN%5V'X"% .3%K2@[;9+86G_U@$@+U(+8I*$%2[G]5D6D>@%%L:JMK
M(:RA9=G[V?\ A@)&BV63W7X(+H#7^\Q,- GA0!"U1-;PIPHP7*@HP\/.(=:B
M'#S12HMTS;$11BT-$\/UE96-XJ'K_%,*1= ![5Q&@(KQ/"@#]IF@(]F/X'!:
M_P 5/XX$U?O<\'FD+Y3*=/A H#6Q@CVZQ<A0B J6(BWP)3>#\^$+KBD>+M7F
ML!;) G"6PZA#4)S#M'!@" '@#%*1.ICL%#L.([!<Z3-9ZX)7/@GH.(B2M*GJ
MB!?1QN?(2^4\QQYF"S -_P M%W\#Z4[W(*C$403L[<>N0 @%HB@FL?L4&A]3
M(8!'ZH9H$V(F+Q*JQ&0<$A)Q\H?\5/J"C" @=$ 3SBTR0.AFAV.A=H^X):)A
MOP)!$$1>C<)GM91@%[:)N",YB]-&K$C#=>3X/6%2J*#0#Z##,Z\B0:0\AO#=
M1TIT(-D!726#3QDG.$CD4PL-1L"$,K+*T!Z@%TV4@P72/S0HT%R])Q8NJ$6Z
M$.Z!FRT!DQ'E(L(&SR&CG,.&9;SKS=S0\@8;P?GP0( /  'ZA)50@!U7'L$'
M$Z1\M<(5WVL(*50$3=$\UU5900CH!3*4NKBW*A$J:24+YQ+JHUL20"25(V:4
M;@C&(K-)TD;N)(-XR62?::'6SK4<0;8J'DJE@%%>,/.-/ E4@*0T%"+ *C;6
M-# %;:UF2D9@"O5=H'[T_EP\P)!CR(5R\*-RB5%*G@;#PFYJ0N*&**B:2+)0
MSKKR8Z]Q+P2"C2K*+1C!C7B"]GS*>RFKC[H0<H2/'M]8WT@G>ZJR-V&SQ</6
MFQ;<%$]!,83R @*:P4*:-0TX$>Q!]2(4^((([A"^\W;1S:3I&,\!,)-Z(N [
M(%9%2$,$=!@(-U;T3H^\ =] #7@@.L)^^0?89X-ZXEIKF!140]2$3XS9)?V!
M-/7B>C#8.V@_(/(4?3]EA#T>)5L%L?\ >% \^R/ L_ X/!Y[2 ?*7QBTWY*B
M/'=/XWB'A3FE]'[Q_&:@D""78>B\>\;L9VPJO)"KB B*5"_!UPZ\Y@T&R*G:
M)HTR8RLNP(45)HZ!3[3-KW'!*@)9[O'CBK]87@" %(%K26XJ2 A%-2!HDKWW
M6P-:.M(!STT=/Q0*Q(CFE]5T?/HQ6[4&)8E>@,7:O-7"$!(?BOAUK_\ *P70
M\!FB$>==:P4(P=.V7@&Z+':9IVP8G0,#EL?C)_9CLD:T048(AL,+$6Y(Q)?6
MDP1$.E%1M!\@74:QM(C84IC46RGM88TSHY%$= CYR\_UF@;RB")\OMS>+*F;
MVF ^5GSAW(DZ=BQ%T6_L1DKEM_M]#["X>.V>PJ6&%;I-++AKM)KVV15BNWV)
M:"RE$&0*QJ'C> VE96%5D 4K1X!K/]ZF/J8TY3Q_0SZT<Q:^V_L.64R+6 VZ
MI1(H6(3@S.O03M?9%YA>,W8=JDT H.H5M^.2!Z2 +X+TAFDWAA0'SIE]CATM
MEXPQ&>;V17QGD! O\0=?EK\X, AX(X#0'U)O%,1@Y.8GB-:[L.GITY</D>FV
MBWM0+422&&%[HDL, 9J#OB7+?<7%FP;K;>D7&$/:Y;IX*-TAPM*+F(&C>"O5
M8!U4#;C'"8ZP>8N*L(&&2.:JM6N(.T-GP_5:\! 'HCTP.^SS#1.BRL:&Z8,4
M% S>1;ZB+2+<8RKJ#1MX(^VLVQ10[U2BR(>8UA(G>D&))*N( XR0^H0N'7H_
MS_XOS[RHT*EXZ1Y[PL<WIR\!:,%GOP?T1CLL2/ .Z\-\Z$RJ9UP#SR$WK9=@
MZP)2W#Q&(*R!-1=BL05V*L7 SK<DU@H"90(3DM32AU].XEVKE52JP4^ 7ACP
M07:$+[M*4E'@C]2J[HBHB/T_B&;W*"(DT=I\R8:>6J>$4SP;5\DUDM#/S;,B
MDEZ(DQ^GSFAT$H1H7L\#]/ @! /@,#WFJ ;^311TPIE04(%2-WPJSYJ<8H3Y
M N"? U>+\X<S*"D(L6D]I?G ZPY-&)%%HB)"9QFDH![ ]AHYPP'I +:@(3O:
MKW( OQTBRB7^<VSF=I/JT:'D=X[LFIQO6-4MV4DTU"Z VJXE?:2U=8 )Y J/
MK#P8#N*H>M_A<J$2>S15R@PM%U<. $HU&1%H/(H^<&K940$0\=7H>,&7&:1!
MO<Y9"1'9C[>AE15T\,T53>.3@"=B*:W!R" 7I^GGU@P%H-UE#UHY'TXMJPIH
M)NH179=/.]-*O6]^,0L+9?$C0[\[<\;L%A:-VB-I8(U3V@,H3":%8H!GT,UB
MZ,QQBHKR[_8/..04!1/@4\[U?*X35.&DR)=,5/AERV\<#\H<R$2FI#?B&LXD
MG95_,7UOPXVZ:V=Z #1LHG-8BX0M<G.%&FO2L$#"ML;*2+BD#G-Y>U@%XL0;
M1-Z'@^<0FQ %.*"VLDC)D,/)D&A /AV9XP(%D1@=6=?&+ :I$C1UP1>='9A\
MCX=EFNB;2)9AT<C&[22-*7$;=/G4]1#B=D7P(&&#.)7PAP! 0;W<@4B+0DEV
MM@Q"36(ZBA:*H@2H9"B%)ZE_D?T%\ !GX#B=0MNX_!@  $#P?HV!0Y$?D'3#
MQD(G])(*100THW=\LBX5$-#42M\=:QXPZ"#TL/#9)GA,^)9,\@=#,&CP[/A"
M'!O0-:)NUT\2O- @$=$VZ<O]2XIR%($OJ]\ZQJ!*)V@!CD)342L@AFIJD9Y3
MM*?2+_MAPF+61!C:=^*_!PB( -I=0WXI.\%KKJ3JZ8#'$PN!?-4<KZ._6'4;
M$*/ T]-C"^YFW*^!1$^F8^U5[?#?2F#S\IO^7BX%Z=B==FR.)8'';0-)7:2@
MI;O927F8\A 8FT&@IC@^B,JMN*M-09\H(XB#P0(PEUH'/):(.-:#\K8Y<OM(
M4200V**4J<#%WA<(%C]$/QCYV-1.ED?QDSWN2*2-"P'6OBB],3-91MJK!CH[
M=2$JYW!7("*S5;S-D4Z@^$#! -(CC.B D#S'R=Q&1.#_ /7O&XR: M#&D$>]
M'F)9]UT7@+:!"T87<8<>! -Q2DM!6J>9#-0UN[;>B/V9_19F*YA#=/3SAE2(
M<14&I8H#=,UFPWJZ$* UPL5> Q67(H&;C0(-(_#$1EI"Q!.QB-O:MH8Z$;E^
ME8=^/^/<3F\WICY/#TQ>NM07^%'X!\8B\#"/TK_QAD$U;OB5KZ3':=+?G!5A
M=H0YK1^J@50#:N0/OK] H2>C#VPO,R26$Z(AI!7N(;ROG+_@.%7M[#(5Y@$:
MI&+@_;3%2.$.CY$Q6,4 D,*L":\[^OU.X!&:B/MC[%'2YHM-"0M79(K>P4BU
M]^I+:( L-=/@.!W/T"C#B[/W^M]01C(;[&Z,&.\@*TU(4<HL6\0=X@M]$ EQ
MHN"TM.16B^[:FXT<=$"HGHWK\^<8)R>Z)RQXT\F)3O81PQ45"!NGSEV=502-
M> H5&C?&4N8=N"JAJ>SK#T7$S8"CO1@3R=EE]^9&^@+HH'PU@:B)AL:07##:
M,'1*?MB(! #=>/LA@,Z1,4\A]F,&36-U2_(85P+)728J@"T#Y_\ W!\A# A-
M_.6&<<+-EI*>33AI= ,Z3_8#'63(%>T22^\"L/A%^SF "'-: ==]Q#W=@&:>
MD\^/.+P-6X#1;;/C"O=6O3))2FUCQQ5RAK3K8B?=N!A8T(!]& M(+3#*EAN=
MH9_?!""TA\:AB!*&[1@-#!/ #;7P"N\?;4HD221(#UZ_$2[MTQ(M!(!HFDNS
MHV<E!V(%=]2.C9*?7V/0L0'B]@G6GZ@B!'PJ+][N($ZFDR@.K17?3SK(QE$>
M3?[O]OZIC-T*M=G.A\4\8&1(<P :M*4'):X!\0. . >#/+;L_P!'H!'Y8\UF
MHS& -(#Q6:8VD,W$(4>([:[$P#?[DD$3>AWXR1Q@J@E+>5(WQ]GLQ_LB>%6!
MB?(340:-)B")I=HZ5CM%B#'#L/A\>N8M&PZ0U(\-ZW.N:737C-(A+HB22NAD
M/EZR4^B\ZL#;B7J77P^XCQHT&C_;%A0/A 2<.4.Y.6W-J@>&ZDUV"O?3AAX!
M;!["&@.;?.!9Q5AS'P6AXWBM#)B:"%&/P>,0"D8T*X[(:\AWG!   =#MV\YF
MM%K4-5(0M#Y9O;HFX;<XL,9D(QYG0#^WK-_@IQB@Z4Z7\9&VF0AZZHHI2(ZQ
M4"&0';JGEENMXS3"X^1(CSC:TA^GP*PH2KW: N27J+ HHX/-<1JW"B!D8-*2
M+A)P3 :VO!L$H,*5OPP8 Q:Q0XS4?,N[BEU0VPV(423SYPJVJ6*EE!? ^V.P
M8J-$"K9>&T X3%F87ZE(FHV!.B.TF4IYXEE#](GXPGQ(8@?">LF6=-(%A$V5
M CU@Z&^D.JORJJKM56J_T@51!C*V]/\ D,EV#0G):%4=0F.B;3@!-C3;G;3_
M )T@50%L0]@\"7#2;I 3EWWQB-FDJUMTI 2>OP/^/U>YS1\ ;3X 5\&-?1"D
MU1UWT7R.>=/)J:4L).6PF\5?(<QI%]P:4H[PV5N[,^S^!]Y(Q#\X*0O5?8PV
M6#OD!I/FD^,B)*!00!H#0&:?U%^,=&9A0D.R&@(G@@X^[%%[2.$\GG6K_0<D
M4*B/1,)PL"^@&*>*D=@K%@0]X@?I;!2= Z7PRF6?D/-:5>RFY#[X3;TW\XIM
M?O"F6GDP36[09@"PJ5#3X-\D<8]4K):^45)XMG<#<B(>\0I>217CK#<3J H1
MZ5B7@_;(1F8S2 M#/6FHEQNYU 0BJ*%&> 8MHZ\&1X$<'L4XN+[@J1RUI;9A
M%=[2U:M-V[?*LW\XGHDIQ8_GSKYP*J$"[1H#]_-RSHPBA](<T;'%1>MM6Q"M
M??(Y:S>R?E?]#A#AQ^%)?>Q^<)((<(!H \&<M/!$]1^\H_02"A13_P!S&6IA
M @SUYQ!=(]A\0]^<9^2$ZH$. I,U'E!9Q^7J;IE/7  >W+[M 8B8U71"^,C#
M"Y 0*F_!W US[FT=M0L+/. %P8!J0(!Y:\,67[&6FHB'ZTX1TK%P-!0X$5'P
M*BF*?0$:1DK U,$CJH2PM2&$K::<F3#[ F3 V'K2S9$G&))H110T 3R!7P#U
M;:T!2B0O7 19.(4E\:&GT+J[^YI0=%CS<_\ N&$OD1)5KVU^?[,,$(!W9#1A
MG\&'H[ %U*A5Y2X-<DT^457(H!X6B#@YC+H8%7@ Z!:# 1?([U!TO4,$=<"0
M*4ZK5DB3<VMPPG8IV1I(H%%D=@F-J$FJ,$U2U50"W0FQOR#R@]JL.3X799HX
M5R""E6@2!M@;VKR_VP+NZ#5%&>08^%^F2"MJ,(WD0C51NH)_!?$<#A"2((X3
MEVP/8&NR.MO<(L(FQ&B:H:(&@WF^T'(;<\0VN+O6)01-R)>*J:$^M&#+6Y7D
M1(@.Q/";7JD$XD(*.M.GD,%"T&M]HD>8-ISI] XW7\7%B=;"^T@/V.*2J);5
M6N"@[N)<(T(I5OB>SYPA@<,O0PTJ641"H@854U4U7V17R.,E4FN5['?+L8X_
MWJKPE)HXN+OF:EJHU%+O2W!,FWX2H-$/? Z/,+1L&([TAC^,L%#HVDU6Q[\9
MWV @([(]W=X3V"%A6KY =_AYBG#Y/"!0UOIC12.]MGK\Y4J$*6MWI=>8=*_T
M6+8/7[09*JC:>FZH"@BS<N).%IP-[6V *G9K.C&-QL!K\X]$-8+TSB.J5\#0
M( " &@_X_P 2;R&57\&'&:*X20W*'A"EJ>E PH1UY34->F;V"W,),=0#WL4'
M>#H+6!:1825@%/: .\G)&\)I03JJ^XO4=]@ &-&V5%@**8=UU5"7B[M/VADN
M<MMB_O"!.6H>/S^#BRDQ2:= *@..^"0-!W22J555V^</CI;4V >4H!\YM*=P
M$ 2]04]O<[PAZ0Z$&G;JCA6K;UDPRZLI[#FPD8QJ#JHH79JX3@A4%*/2GQ7L
M&L(- [R*FF$S7/XU;5?3VB"&L%FK,Z[P,+0]1A[?+!7)>H51=$*TLWMS>TM^
MN4TM!77O'BHG!;1+523_ !W!BH!*] F_QED@&KAI\Z0;<.*ML8RE 2>6I-85
M8]TQ=VD($_QO$$! %)(O8!3OGXS2[2)UX6D/*?#*+" (40ZETGL<-.Q=L O=
M.OK[#+^-LBABNDE?#EW!( C7D\"]\8.F!6K.(MTV#X\X/(;N@/HC-\WAKM@;
M6(#0:P>&E#Z4M;%?)PGG/-C11=," -B7?)B%FF$J:((3>K+BL4=T!$I:D5$&
MW[PQ:%4N7VUXUX]9V3VVKBT[^,,RI1-TZU0'8^L2QM"0::A*M+Z-=PMRV(;P
M'SC9M=M H*,4=E6,#%[8#.([15%LPV!3)<6-/(5^*YWHPD.RT[@1KKY,I#D(
M>@,\.GU\8FS!)R((MNRQ?O)M/1>YK8%.(DU,30Z40W$0\@GP76$@@+2H"TW:
MGVF^Y2>4#$8H;-&A5VCD^L*6@\(!!&8$R(&.3K)V4:'H,)@9<N*(4JA_ .#(
M27T#<4 -1[S6_P"S$BK39QD8D#X0RZ&RQ"*#VHKHJ\X1,7_&%1IZ5$E+EQ4"
M0DB>RTI2PH[I@#)$0G1070S&)!M>PHUM #H7F%0!FQ#OF7IT.%BZT'4BDT6"
M^]U;D>+\TNY"S)=5J]P9#TT1'SAKZ+  #_;3,C/QK8^T/QEV!JV+,:> [%O2
M8R0^VLG62&A12J)4J3K'?ZS5$]:A\QR3%0;143IEBV4=&4J",.CS4PL8$^@I
M2AX"5Z?U/:I.VU/)CU._ _9!C2IM\>P%/PYS+;8D"E!\[;6F'D$:X5*CQII]
MC6A9>$*617_WBUW$UM<KD?2!2#TI/SCI[_V5%T06T<S9-*;,24X=!::WEAR"
M1"!ULU)\9I:A2L#2H8P!@# G&'"$% HH-@XMI&\#5-^?K-;T&T #[$'%:P"R
M!O8P-/M/#_0%%RL119#K:<#"D9AOMM%!:YI^<,60%%%HCJ(GGC*;):RR7#R:
M&H0U7#OB#@#@'@_V1(J)$>C&[;L]+O\ 680,C26]%:5C3."4T@T\*=TNM?ZA
MG90!U9CL(LW^K0<6IP #:* "J@"N7RQO138(_A>M8,Z?D'LL_B,P'G@BOAIX
MT$::1,$"$B":4(B='_3G)%2@#JN#JPLM=(M]*"IPTXJ>C38IO(0*J\L?G6@4
M"(:U5C#YN/=X@#5D:@I7"[1TC@NCD>X;J(->1AK4IV;Z5T-+L0,44(,*"K""
M#%2JXE'2 5P<-VZZ;YCJ0S@++ FF2J1O6(5>'(%<--#X<2;5*-$6:.QZ?&\/
MXHB-XB:3 DIGBKY J0]'VY6PQDRI0$1.RX9;XEFS HDU@'B;&1=P 8MH&$T)
M?I,8&N"Z4D^#HVCFV=R4H(E+AISF/#D]"(DDQU L>14^*A18Z#*<VICP3A*,
M^4I%X 3#3_HM?$+-S9\?."_H$A.KLFPLH<\8-4U&$U6A4V4U=F/+V$XFGH1:
MK?)O 4QA2J6 \.WGO)DPE*"C0L%A5$WHPIE&.P=#'2[XEM=006J :0W'2XQ9
M91J@U>40M*]N=_U\#:NY0H%9HPB*5&3M+>U5]L"W4T JITQ8PT\+G4=C4A^)
M/"L4G4QIZ"RRBJR/T3\8HD,1?V?;V4^CF6OJL:'L4#YR]6!-VNU$_C"=FNCY
MH4HJGD>/'$)AV;"&W9'WV8CXF"!8)VNP22>LA)S?BO5/(_XP*%B=X>4G&W2^
M<B%)5B(98 S]O<R  $"$)H_&!.2BL2^#L(?0^](>MF"?&L$"$H&&KDZIV0-H
M(&MWXPV>;-2T"3C8>\=(MH+9[+S*Y%9*7)5W95="U?>$&0Z@48ZBZCKQM!UB
MO0)#*0 %PJ>'(SAQ.LNPZ  T<"L++2FQ575JAU ,=CE3%1"P).;Y+P402V1A
M(.WBZI[F =671HX34\@:QK_(0/21"<U+M;<SA"W2-TDU\7DLB_Y*H78NV&];
MN"-Q)P VG<'+'::Z@G<!W91(A3/+;1F\345C"R:;JCE\XOR< /QMOS/J8J![
M-_ H/P8L4U+-]F*26*YH>-C;F'E(TVKI;]@>@Q?TLX!%5$C[6+IPB.\34;!"
MD&E&5V"]RGJ!%CK22[T4]L!6R."82*)&'91-OCY@GXPGU?NP4,/M6"<W:NV8
MX<270C2@,>]7TP"  @!H/]N9831)LA^P9$Q&:T4STC/RQN"I0?( %;%=>.Y1
MZJ7ARP$>6VS<QL9W))A7\AZTXLF]4AI1)--*"6-F""U"($'R-(1K9O\ N=/M
MB?VOYXZD%\@?QD8-AY?^C,N*$B@J+0:*;V8)-]91#I&@P3X.8OR ^*P%VPH.
M;''16*A:@\SVA]X_/A)=;(H6;+6FLUC;+;8FDN*BQ8X\<!D96?(]$TB/'!4-
M.AM+OS#Y]D/U3X-B,%HW-OW,B]60PO;6GFN^MP8T54':>%]:N/O2Z](!1Z2-
M2="X!7(0(@ X!J?[15-:DZ-D$(>7/&3NBS4<$("3$OWN>D^IT^&+\TG8O+BQ
M15[',] 4 V@VO%)@*H?H,>P H'@)&@((H$<#;POY[!7XI]X'@HRGB"BNAGPH
MT-L'JL* #:  *J!W&DWJ;^],8Q?Q.8 PX"FPT7OL#RA7#\B)4#Q'R9(+@>(J
M2*;#8(Z-S92>;+X83XU]X6=I6C$@I1"S*0D,UC?].\0A$\>,"DVBJ9A(C%>%
M%%&,)K9T$P34H@*G1("V\ B!P#FRO_ Y1\Y6 4XB^$(H]FJ1P:-@\A:T 4K
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MQKV@H3A0#X!6S3PRO-C.R%,0-TM@;-.RFFC)'$:" UWB4[#'RZ8>TV-PITG
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M9/R;S.6C3+@'Y!PBX3FAK;XH_'Z!31L(P04TZFM/ETH>0!2RE=M"E[7$+34
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M[(WZN36X;9M)YA==JL$^*<.H%)OSA1@TN3\@2M7\8"C098 Z)G!$.94DT%
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M6\4D*"Q:'%,$XC-(E1AD8*%V@(MT8Y!I-8ACX$CY/K-^.H$AT+04YX\/,I8
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M"*+78@G\?K76[,%0UV=H,E]?H*\1/W^<N[>.YX DC #5&U'H 9C-/6B0& H
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M5"6Z81>@J*70+KA"V$2,5V+C6(&-?J@#= %E.3')<;.VLFH>#Y$8 ;X2Y@<
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M6M='M_W2[8$G5<J$".T]8J*&%B@% ""'\S#D&@Z"R^2)!V1D[CZQ0W%Y 0*
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M1$X1VAP:3#_$[N#/JF7UEU'C1AX$3"#+:H@<82UT&I$8\"[!%XSAYL\AB;_
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MKP"PJ=H1,4.A#>ZW>@^@ @3^Z'6)W,MFK*; 8FJP6B4"5 '36T[#+RYEH0H
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M?1A& <2^3W_9&CB!EP/&V("[$/>(Z%'U5BKH.VIO)J0$^H6(1/#=\9K<4P,
ML*32Z9J;?BJIM@4.^(U::YJ?(A/V3^IEFH\2[3ZQW[[M]26&;2,R&E ##2/0
MX?DNP<0O0I0H**AZ0>8DP,8KAN7Q?^4ZWJ$,0ENM4UHKI1QG=+!>1+J!2=VR
MX#!^(&G@70S5/>3,Y&%*J3CP'_+VU/#)]@'-N?B!!%A NKKHN[G'4$ 1" 0
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18"DC6 %<) (!]!__ *9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>xcur17preclinicalresults.jpg
<TEXT>
begin 644 xcur17preclinicalresults.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" F1"[(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY]/YTV33?B3M.=3P1ZDCG .#S_D _C^/B_M_?%U0H_MPX7IR>/U^OYFI+?\
MX*!?%J&X1WUDNJD9525R!V]AU[=S0!^N4J?%..0JKSNO9AGFHUC^*C$;FN 3
MC)R0./:LK]B?]M32?CWX?T_1)B&U^"("<ACR>.V/?OBOKEFVX]2< 4 ?+^WX
MJ<8:8_F.V>_^>*/+^*OK-V_B]:^H&8+USTSP":=0!\N;?BKC/[_IGK[XI?+^
M*OK-W_B]*^HJ* /EWR_BKZS=OXO6DV_%7&?W_3/7WQ7U'10!\N^7\5?6;O\
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MKZS=OXO6DV_%7&?W_3/7WQ7U'10!\N^7\5?6;O\ Q>E'E_%7UF[?Q>M?45%
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M0 !<;01QV/0?KUJ1E+9!"]01GFO+?CE\?O#OP1\'WFKWUY;^=#DB MR>^?\
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MWXNERK+_ +O\(!Q],?XU]2_\%/F*_LZW+<\,YXZ_='N/YT ?@O1110 4444
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M&\[NAV].G?./\_2@!]%-=BN,#/L!UX_2J&H^(-.T>(/?WT%LN,[I&V@\9XH
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M_P J /Z4?A+_ ,DU\.<D_P"AIU&.U==7(_"7_DFOASDG_0TZC':NNH ****
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M /YZZ="=LJ$@,-P^5C@&EG_UTG&/F/7/K[TR@#]T?^"=?QZTWQ9\.-.\-1R
MW5J%4COT  ^G/UR#7VF[?,5/0J3\O7CK[]^U?BK_ ,$C[Z\_X7-) )6:#Y?E
MR3CIG\.?U)K]K=PW$9YZXH :P*G(&YNV<#''\N*1L/N&U68#&&QR#_3_  HY
M9,;=VX'J,#V!HV^6>",MG"GC)Y/^/:@!RC!;@#)[=^.].HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSZ=N^: %V[_F9=O0]B3]?H:X3XP_%_0OA'X4OM6U2\BAG@C+11.0&8]ASV/
MK9^(7B?_ (0GP7J>LA0&M(=X4'Y1CZ\>OZ5^#/[8G[6WB#X_>.+F.*>:VL+>
M1XEBA8@-ACVR?T]* /H#]H+_ (*I7WCWP[J6AZ' UA(SM&MQ&".A."#^7?\
MH:^.M+\4_%WQ%;_:M/N]9N;>3.'B'R\GG''2O?/V/_V [OX^6,>J:EYMO:9W
M_,=@/&0.1@@X-?K?\%OV8/"'PE\'V^C)I5K=.@ :22,$G''7\OR% 'X/G4/C
M6,'?X@R?F^[^'I5+5O&/Q;\-QB[U*_UFTB4XWS_=ZCCZ=*_HL_X5GX5_Z 5G
M_P!^Z\T^/G[*OA/XQ^"I='&EV]K.3E)$7'8^_4=O>@#\[/V??^"J5[X+T33M
M"UNW-VV]4:9TSW'MZ9[C^M?JA\+/BEHWQ0\+V.J:9>1SM/'O9%ZKU_I7X,_M
M7?LDZC^SKJ3!]SV1<A&))R,XQSSG_/T][_X)>_M%0^#?%\VE>)-6*V<C>7 L
MKYY(X&/KGGV&* /V>"H&P NX<^_)_KBO@/\ X*<>+M>\,Z&#I%XUNS)\NUL#
M.!QU[\?^/9XXK[TTW4(-6LX;RUD\RWE7<C=F!Z&OS_\ ^"I!8>'UR>RG';L.
MGT- 'YT_LU_&3QMJ'QN\,PRZ]=SQR70#H[_+MW XZ<#(%?T'Z/\ /H>GEE7S
M&MHQB3OE02/T_P#K5_.-^RPV/CWX:8_,/M:GUS\X^O\ 6OZ.]#^30]/'7_1X
MQ]W'\([=J +<<?EMV/7YN_;^?7M2[0Y#<]..Q'?Z^GY4J_O%5OQ^4\=/UIJ[
M57^\PPI(Y/\ GG]: '+AL'Y68<;@/S_E7YV?\%7_ !SKOA3PG;MH]_)9,S+G
M:VW<N0#C!YYSZX..F*_1-6W*#QGO@Y&>]?FW_P %>%V^"8R"P+$9&[_ GT].
MGH.: /._^"1_C[Q+XJ\=:M#JNI3WUHG \PYPVU>.GM^GMQ^M(4#) QGDU^/'
M_!&U0WC_ %L[>1GD9S]U?;&!]>]?L/N^8#^E 'SS^V3J>HZ3\,-4FT^9H)UB
M;:^[!VX'?/3)]\?@!7X37WQC\?:AKMS;P:]?23R3L%CB8_,P)Z#UX'Y"OW1_
M;:'_ !:G5#T'DOVZG;_^OGGIU[5^)/[/-K;7W[1FD0W:+-!)J+!D?!#?/[Y^
MO?I0 U=2^-4BEE?Q RG#$A"1VP>GTIPU#XV+D[_$ S\WW2,]O3G_ .M7]".B
M?#7PHVBV##0[-@;>,AC'U^4<U=_X5GX5_P"@%9_]^Z /YX!J'QK;/S^(/[QR
MOI^'M67K'CSXJ>'-LNIZIK%F.F9B1Z<>V>*_HS_X5GX5_P"@%9_]^Z\3_:'_
M &*?"/QITEH8K"WLIB#]U._'O[?S]> #\N_V6_\ @H7X@^$6I6\.MRS:C;LZ
M(S2<C:6 /3VSQ_\ 7S^RWP@^,6A_%SPAI^J:?>1R37,89X5/S*2,]O;^7XU^
M%_[6/['U_P#LZ7TC'S9+/=A68'';/)_SS7OG_!)CXES:3X\O-/U34G-FX"PP
MO)P.@QC^A/\ 2@#]CU39)_#DYXSR!DDG]1_B:<5#8\P+\PVXZ_4>_P#]:DCF
MCN8!+'^]C/*X[X^M1S2QQ0O-*W[L9).?E9<?7'\N?K0!,&+KE<#@]><'TX_Q
MJGK.M67A^RDO;^X6W@4?,SM@5YI\7/VC/"/PO\-:G?W.J0_;;>-MD.X!F89P
M.>OTYZU^37[0_P#P4D\3?&+3[S0-%BDMED<Q0O$<;EY'KSW[<\4 6O\ @H;^
MU5JVO?$<:;X8UF6*PCW9:)R1P<<\\YZ\BOT#_P"";NN:KXB^ ME>ZQ<O=7C
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MQ7V-OPQ!]N!R>?\ )_*OFO\ :S^%^H?$[P[<:9;([1R @LH) R6&>/KVZ>E
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M^5 ']*/PE_Y)KX<Y)_T-.HQVKKJY'X2_\DU\.<D_Z&G48[5UC_=;DCCJHR:
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M* "BBB@#] ?^"0?_ "6"\X].V>PZ\<?IU/6OVE89;^(<'Y@>E?BU_P $@_\
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M'K7XG?LYDM^TAHX'S%M1;O\ [>??/3UK]L?VV3CX5ZH,]87X! _@[C//Y?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y->.OF_P""A5K\
MQ8_:U)Q\Y'W?8Y/?I^76OJ7_ (*@'_C'.[!) 9G& <9X'!.>/\\5\M>.N?\
M@H5:C# K=KGY<D?=/W<''TQ^76OJ7_@I\VW]G2ZQNY9AM7^+@<?YS]#0!^"]
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^@/_!(/_DL%YQZ=L]AUXX_3J>M?M*<[AUQT[8^O^?6OQ:_
MX)!_\E@O./3MGL.O''Z=3UK]I6^^OKSSCM]>W;\J !!M51@+@=%Z"HY%.X'(
M]AT)Z''Z'O\ G4BJ1&  J'& !R!2#()"\C/\6?J>?QH 7=\I*_-CT_E4<?S\
MJ2%_O<98\9R,>V/S]J?_ *Q>,$9!!/(/0Y%?/_[6W[0EG\%OAYJ36]PBZJJ8
MB3< <D$@#!'3CU_2@#R?_@HQ^T)X.T/X7ZMX.N9XIM8F7(4D9CQ^.>:_#*O3
M/&'BSQ/^TC\27NIVDN]1NF8QQG+$ MT'YJ,=J_170_\ @FGIVM?LTQSQP8\4
MR6^1\OS;MO3_ .OU_E0!YY_P3?\ VQ[K0?%D/A#5T2/3&4!'R/8<9YSU_$CI
MDU^ONFZE#K%K#=VS^9 ^<,I_(_\ UO4^U?S/:UI.N_ _X@2V-R'M[RSE&['&
M]0WY=C[5^V?["O[67A_XN^"]/\/?:5&LV<0$F]N6^4'.,?\ UO?I0!];K(=V
M""I)Z-CT[8Z]* W[P@C!Z8SGUYQV^M#1\Y3"GOV]\^_/\S0H#L&[CJI(.#_C
MS^M 'Y(_\%E<_P#"2:%CA>,C(].O%9?_  2NOK>.ZV2["YEVKE1S\Q)&2/0C
MTY^E;'_!92.9O$&BMY;>6NW+<XZ<?S_PZ\_-7[!OQ,?PI\4M.TT2%!<2X'/N
M#_=)Z\\?W: /Z (2&B0@[@5&#SS^=/JOITGG:?:OC&Z)6Q]0*L4 %%%% $:J
M6;#%OE'TSSUXX[?YS2*X&3M8]RVWG')'^&.M17$T5K')+-(L:QY<DE1VZ\CT
M!'TKYEU[_@H9\,O#_BV7P_-?*UVDHAW*_!8]L>O3C_&@#ZB5=N><^IQR3ZG]
M*_/7_@J2S?\ "/C(YP/Z8[]_Z]J^]O#?B"W\4:3;:G:C,$R_*?3UY].E?#__
M  4T\*WFL>%VN;=6,4:!BQ)QQU&/K_,>E 'Y5_LMY_X7[X:7:SYNU''!^^/7
MG^=?T=:'_P @+3MIW#[/%RH R-H[=J_G'_99A,?Q]\-PL""+L)CN#O ]/Z5_
M1SH^YM&TX\[O(C)/_ 1G/3_/:@"TK91<G<=H8;6Y;'Y>WYTX,H#;!G&3A>YR
M?US2E-RA2=PZ'('S<=Z9Q)&H/)/'S#/.#G..* 'KC<S YSQGCMV_G7YL?\%>
M"?\ A#8^?FX(^;:"/E!XSR?SZ$=Z_28-MW,PVKURQ_S@<5^8O_!6KQ?97WAE
M+"-T-RH&]%.".@]>>IY_V>GH >:?\$;S_P 5YK(W?Q'Y2O\ L+R#C\QGTK]A
M\?,3_6OQX_X(XX7Q]K!X&3Z9)^4=\<#VSWS7[#<[NY&/; _S_2@#YS_;9D5?
MA3J@<LH,3#/;[OIGGDC\>/>OP*M_#M]XM\=3:7IT9>^GNG6.,9)W;CP,=3[]
MZ_?3]MIEC^%6J$N%_<OW[E<8_7OGK[BOQ/\ V<3Y/[2>CGRP^W47^5L#'SX]
M"/TH ["'_@G[\8IH4D32EV.H(_>'H0/Z8_*FW?[ ?QALX)+B73 $0;F(=B>W
MM[#\A7] >AG.B:>=NS_1X_E]/E'%6I4CN%>&10ZL,%6'4?Y- '\N_BGP[K/@
MG6)M)U5);6[@.UH]QXQQC\.F*W?A;\+/$?QD\0+HVA SW1[.QQSP?Y_CFOV8
M_;'_ &"?#_Q4\*ZAJFA6B0^(&!_>*G3CC ] ?RS7Y%Z+X@\7?LI_$RX6.+[-
MJEK)M.\<<9!QD=>?T% 'Z"_LN_\ !+JV@AAO/&\:O<1,LG3N&SC/ID8X_I7Z
M5^$?">F^"]#M=(TR%(;>V0(H50#MZ#./I^E?)_[#?[:UE\>M-32M1ECAU:)5
MW+D9)(QCH/3K]:^QU5."JY!^8,.1GV^N?YT *WRK@;@-OWAR1_B::PPQ9FVG
M#<\84<=\?C_^JEW[6 <X+<]1@=!@?B:0Y;YLL%'/W3T],>O'IWH 5F9E("L#
MMS[@^GI3EQC@8&3VQWIK;8P. 7ZAF&,GIR<=:<O3J3R>HQWH _"'_@J3_P G
M$2$-O7RWVG=N^7*^_KG\^]?I+_P3-Y_9YTT]?D7GKZ]^?Y_G7YM?\%2B#^T1
M-C(.QR5/8_+[_P"?>OTE_P""9O/[/.FGK\B\]?7OS_/\Z /KHJ&X(SWJ+[N/
M^6>[/MMSCZ@G/\ZD9BN,#\<9[BFCY"..N%&?O'&>^>>.?SH DJ/:$PQ; 7NV
M.!CIG]:23#+D-E2-W"[NG<>_3\JP?B%J4NC^!]9OHV\N:"V:16'.&'IF@#\U
M?^"LWQJO=!U"RT32[H*LOR2"-O0=#SP.&Z?X9^<O^">O[.^H_$KQY9>*A&'M
M;*<,QZCALG/8?=_GTKQWX_?$;Q!\:OBU>6%Q-YC"[:&)<Y ()ST)X']*_6?_
M ()D_!G5_A'\,9DU:/9)>@R#=P1RN1C\_I0!]FZ?;K:V-O$J[0D:KC&#PH']
M*>,;?FW%@!G&>W/8>_XTYF"MD+SP"<'ISC]:CVE1\V1TQR#@G ZGN/Z]Z )B
M<=LU5U!<:7<@+C]RPVJ-W\)X [U8R6!X.-W&#@]:KZAC^S+H@9!B<X;CL?7I
M^- 'PC^S[S^U)JA'(\T\@;AV_BZ_X_A7WS7P-^SZ#_PU)JG4CS3SL^G<\CZ?
MX5]\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5&XSN^7<,<@\ANO YJ2D*@X)&<<B@!H&TC) 9NN!C<<?_6I5;=V(.,X
M-*3TXS_2D5MQ(Z$=N_UH _/7_@H)^Q3XN_:*\96.IZ!A8XL!OD)!'(]<=_Q)
MKY&7_@DW\4#CYEYQT3Z>_O\ R]:_<6D+ 8!.,\"@#\/5_P""3GQ.]0WIA0,]
M,#\<CZ9[T'_@DW\3S]UA@#).SMP<]?0_R]>/W"7.T9&#WQ2!@<<\D9 /!_*@
M#\/A_P $F_B?NVEQGG_EGSUP._\ DT?\.FOB@Q&U@03@'R_8'U],U^X3'"DX
MS["EH _#M?\ @DW\4&4'>G;C9ZX]_?\ 4>O"_P##IGXHDC#*PSC*IUX!XY],
MG\OP_<.D+!>2<=J /P\7_@DW\4&4'>G;C9ZX]_?]1Z\)_P .F_BAMR&4_+D_
M)[9]>G(_.OW#60-T#?BI'I_C1NZX!.#B@#\??@3_ ,$R?B%X%^*&CZWJ(+VM
MG+O8*N.A[_E^?TK]=]'M6L=*L[<CF.)4/M@=^!5M6W*&49STY[>M-YY5@6R,
M$8&#ZG]>_I0 #+L#G!QG.W!P3TY^G/\ 2I*C23<J<J2>>O4>H_3\ZDH ****
M &28YR&QM.2I/].]*KY8KZ>G/IU].M.HH 8JLO/RDG&<#'/<_E_*C;A54J",
M\8& ,=/Z4^FE5)R5!/';TZ4 *%"\ 8[TW/S=6^]Z<=/ITI]% %?43C3[HYQ^
MZ;OCL?<?SK^=/]M;+?M#>)&QQOQNZYY/N?6OZ*]0;_B7W1^[^[?O['GK_6OY
MT_VU<']HCQ*0<DOS^;>YH \,KJ?A;S\1/#XQG_3$[9[_ $/\JY:NI^%O/Q$\
M/C&?],3MGO\ 0_RH _I1^$HV_#7PYP%_T-.GTKKJY'X2C;\-?#G 7_0TZ?2N
MM8;E(/?T.* &;EC/&  -N >F!D #Z5X5^VAXWU7X>_!#5M5T>4Q7D:L5(;GI
MG(R:]WSMR6( SQV_SS7SC^WXVW]G77<G"[2>F><>F>>,\>U 'X#>./'&J_$+
M7IM7UBX-Q>2]6;D_GU/XU@4Z3'F-@;1DX .<?CWHWG9M!8>O/';M^'\J /M/
M]A']I/P5^S]JW]H:S!&TS8SC P>=O4GGO^%?=G_#V;X8.QV'C.!\V?I_^KV]
M^/P^HH _< ?\%9/AD<?PEC@ G/\ ^OJ/\GCY_P#VM_\ @H-X.^+WA)M-T=D6
M1H]HRQSR<@]>G/<=NE?E_10!/?3"XOKB53E9)&8'&.I)Z5!0#UXS_2B@#],_
MV&_V]_!GP'^$\?AW6POVK<IRN!SC '')QS@?K7T8/^"LWPQ9MN<$XP-V<YZ8
M_/\ 3WX_$"A5+, !DG@ 4 ?TY_";XFZ?\7/"=MXCTL?Z%./W;$<D'!_S_P#6
MKXW_ ."O"8^#,#CZ>W4_XG_ZW?V+_@GG MO^SGHJJK*NT8R/KWP,_P">>:\G
M_P""MMG)=_!6$1C)&6Q],]OQ_KVH _$JBBB@#]7_ /@C.O\ Q+]:.UL989SQ
MG+?_ %Z_4C'S$_UK\L?^"-=]%'::Q"6P[,PP1D\D_EV_7WK]2Y#_  [=P/48
MSNX/'_ZZ )*^=_V[KC[/^S_K+;]@VGD<$<=>HX_QKZ$V$JP(4D]?1^,<_P">
MU?.O[?2[OV=M>RK,-A''/X8SS0!_/3<,)+B5E.59B1^=1G'&!]:=,Q:5R>I8
MD\@_RII&W_\ 70!]>?\ !-WP;%XP^,"Q2IY@B(;&,D=!GI[_ *&OW?TG35TG
M2X+2)501)M&T<?6OQ8_X)'A&^-<JNH(X^\,CG ]/\^U?MI0!&ORK\J;?E&%)
MP/IQTIRJ0QYXYXSG-.HH ^;?VNOV3=+_ &A/#DI>$/JJHRQ, >,\^O7_ #Q7
MYH7'_!)KXGB:3RBOE98J2F.!^-?N JA5  P!P *6@#\.O^'3?Q1SP5/)'^K(
M]A^OIT_2AO\ @DW\41GYDP,]4Y[_ .'\_2OW%HH _#FX_P""3WQ/MX99&=?D
M!;[G!QUYSZ\?ETKY$^)'@&^^&?BZ]\/ZB0;NU8J^.Q!(Q^E?T^74C1VTSKRR
MH2,>N*_G5_;>N#<?M%>)6R2OF$ ;L@?,V,<GC&* .F_8/C63XEP!@Q F#=/3
M!XR"![_ABOWQ\(X'AVQP<_NEST]!_3!Y]:_ []@WYOB=!SC$H!+=!E3^O'Z=
M\U^^7A+/_".V&?\ GDH'X#'\\T :]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSGISCVQ0!^>?_!3+]E_2]:\(7?BO1['.KL&+^6A9NGMV_GGVK\JOA#\4-?\
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MY8 >4RG)(ZKQWQG..,=_QK\2_P!G&3'[1VAG=DMJ+ %ARWST ?T9Z"N[0--
MVX^SQ8[\!1CTJ_\ >'((Y]?>J6@8_L'3=O*_9H\?]\BK9;9G:% ]^/F/X=\T
M  8JQ!Y]@<D<X';ZU^?O_!2S]EO1O$7@FY\5:5IZ_P!LG=N:-.>"#G/X_P#U
MO3]!,'/7C/8>W>LOQ)X9L/%6FR6=_"LL;J1\PSV(S^&: /YIOAW\0_$/P5\:
MQWVFSM8WMM,HE SV/-?O7^R/^T-9?&CX>Z6KR+)J4<(6X7ECG:"<\?7/U[5^
M57[>W['FH?!GQ5J7B2W39HUT^Z),C"YZ_P B?RJM_P $_OVMK?\ 9_\ %[0Z
MS(7L[QQ#N<9"@@ >_7C\10!^[PW,H7+*<<DCGI^6:),KT))Y;H<#CT'7Z5C>
M$/%EEXT\.V6JV,@DBN8EE"HWZ?Y_&MI@6[=&'7&#_G^E "-M&YA\FTY)/ Z?
MKQ_GBG+TZD\GJ,=Z!A3MSR<G!//^>:53E0<8]C0!^$'_  5*;_C(B8'&X(^<
M9Y^[SC/^<=Z_27_@F;S^SSIIZ_(O/7U[\_S_ #K\V?\ @J0^[]H>4!RZJC[?
MFSQ\OO\ Y]Z_2;_@F:PD_9\L&5_,&U?F('O[?C_G@ ^NB-W_ .NF$%CT9??/
M'!^O?_\ 7Z4K,-QR0 HW?>^O7VI5XP-K >I.>E "C/?FOGK]LKXO6WPV^&FI
M12S>3)<P,@^;!/&>.>?\]:^@E38RC@_+CA< =.!Z#V_PK\P?^"QFM7>FZ?H\
M5O(T:2.NXCZ#_ ?YS0!^>/PO<>)/VB-,G W1S:F9".V"2,9P>Y K^C#P3;K;
M^"]*CCC$9^RK\JC;SM_#FOPH_8!^$3?$#XD6=^L2R_9)<X(SZ?UQ^1YK]YM&
MM!I^AV=NH_U42J "?;'0=/PH M-M+%3@G=@'JPZ'(Z]R/TIV\;B&/\0 P>_I
MQSTY_'TIS-VQ@[@!DXSWX_7\J%4QJ3RQ QC/Y=3U]Z %"[%X&X\9/&3VR:KW
MWS:;<=6S"WWAR?E/;']/PJP6^7.=O./F'OBJ]]\VFW(!W_NF&>N>#[?TH ^$
M/V>\G]J34SR1YIYVY';^+)_^O^%??-? W[/9)_:DU,[21YI^?J.W&>>OU[=Z
M^^: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** &LIW;@%) (&?\:55"J !@#@ 4M-R_P#=7MW_ #[4 #/M]\<D=\<]
MJ;Y9W9/KUS@XZCMV/&*<J84+T Z;>/H*HZMK6GZ1:M/?7,<,*YR7/'I@_P#U
MZ +%Q=16,1FN)5CC ^9V.!^7YUS]]\3/"UC#(\VN6BK'RW[T#'/_ -;\:_/C
M]MS_ (*-6OAF:\\)>%IA<LP.;J+!X(..AQ_D5^8>K_'+QOJ]Q-))XBO=LA(*
M^8?NGMSGT% '[%_&C_@IKX5^%^L264"I?E6QE"""..G/7K[<=>]>7-_P60T+
M_H%*/HK^_P#L^W^<BOR3U/5[W6;@SWUS)=3'K)(<G\ZJ4 ?LCX9_X*Y^'-=O
M!!-8BV)&?IT]3]>E?5'P>_:F\)?%2R>5=3M[5EQCS) @Z_KV_#\:_G'5VC8,
MK%6]0<&NBTGXB^)=#R+#6;JUSS^[;% '].>E^(-.UY"VG7L5V%P28FS@9[\5
MH*-BJN..GRC  [5^$O[)?_!0;7O@;)+;ZY/+JEK)PID&[;[GCW/Y5^M'[//[
M47AWXXZ&D\=U'%>D!C ^ 0>,<#OG/Y4 >X21[B2%#<'.X]>.G3I_A0J]5+9/
M!^]S]?;I3I&*J<#\<9QQZ=Z9(-R.6X'(Y. %[D]0?6@!1)N;"C/3U&/7/''!
M%24W:,8(R,YYY[YIU !1110 4444 %%%% !1110!5OOETZZ/*_NWZGV/O_7\
MJ_G5_;6S_P -#>).007SG()ZGW/IZU_15??+IUT>5_=OU/L??^OY5_.I^VH0
M?VA_$O<^9USGN?\ /4T >&5U/PMY^(GA\8S_ *8G;/?Z'^5<M74_"WGXB>'Q
MC/\ IB=L]_H?Y4 ?TH_"4;?AKX<X"_Z&G3Z5UI..V:Y+X2C;\-?#G 7_ $-.
MGTKK6.%)QGV% "(Q903Z#G!'Z=J^=/V^+&\U#]GG7(;&!KF9D;]TH))XSQS[
M8_&OHK;E@67GL<Y _P#KX-4]1TBRUJU>VOK=;F%AEH9><9S_ )_#B@#^8B3X
M=^*%D.[0M09NI(@8_K1_PKKQ/C/]@ZATS_J&]<>E?TH'X*^!]Q8>&[%6/4B/
MG.<YI/\ A2?@4DD^&-/;ZQ].,8H _FN_X5[XG_Z &H?^ [?X4?\ "O?$_P#T
M -0_\!V_PK^E3_A3'@@YSX:L3_P ^_O[G\Z/^%,>"#G/AJQ/_ #[^_N?SH _
MFK_X5[XG_P"@!J'_ (#M_A5:\\'ZYIR[KK2KNV7KF6(K^/-?TN_\*8\$'.?#
M5B?^ 'W]_<_G7R-_P4 ^&G@_1? <\UCHT%M=B(L#'&.&[$9.3G)X]: /Q%QM
M+!@0W3TP:2K6JJ%U*Z"C"B5MN/3/'Z55H U]-\(ZUK-OYUCIES=1?WHHRP_S
M_B/6K?\ PKGQ1_T ;_L/]0W>OV+_ ."87PW\*>(?@2ESJ&CV][>%EW/*A!Z9
MZ8&.V.37V'_PI7P%Q_Q3&F\G _=]_3K0!Y)^P#87FG_L\Z+'?6[6UQL4,CK@
M].G\_P#$UM_M=_!AOC-\-KJP _U,;,.Y!]0,_P#U_I7M-CI=GH-F+>QMDM8!
MGY8Q@#@GOQ^?%/U*,3:;>QD+EXG!48.<@@4 ?S%?$SPF? _C;4]&)YMI-N/3
MVKF*^I?V[O@CJ/P]^*6K:Q=!DM[Z8LK,N >2/S_P[5\MJNXXYZ$\#/:@#ZK_
M &$?V@I/A+X^L=/WNL5[,$;C(&6'.,?_ *_Y_O7H-X-4T*QN2H"S0*VWJ.17
M\P'@_7/^$9\3Z=JF,_991)CUP#7ZN?LX_P#!4JR\1:CH_AC5[<6:X$9F8#GC
MG!QVZT ?IBJC<2&R>AZ?4#\,_K7P[_P4@^/&F^'OAQJ7A*1E:[N-PV[AG&,<
M^G/3U]^_IOQX_;:\'_";PG#JECJ-OJ$TJ>8(5E!.#SW].?\ #M7XQ_M7?M+7
MW[1GCI]9=GBM>52$Y&!GK@^HH \->0F5G#'=NSNZ'ZTB*9&55&68X%)6GX;T
M.^\0ZS:V>G6TEU<O(N$C&3UH _3C_@E;\ =3\/\ B4>+IXG$$H4K(R<$=\<=
M.*_5O^(<'H><\=J\+_8Q\,#PY\"= @FL_LUVL864,H'. ?0=#_D\FO<UX;I@
MG).!P>G)..N* 'T444 %%%% !1110!7U!MEC<L.,1L>?H:_G5_;:(_X:)\3
M'<!*0/FSQN;C\\U_17?9%E<;>6\ML?D:_G4_;88']HCQ*%;*B4XY)[GG_/I0
M!U/[!N?^%FP]QYF>G3@>W'7U]/Q_?+PG_P B_9G@YC7E1@'@>P_S^5?@;^P;
M_P E-BXZR=>>P^F._MU/K7[Y>$_^1?LSP<QKRHP#P/8?Y_*@#7HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R:\=<_\%"K4
M88%;M<_+DC[I^[@X^F/RZU]2_P#!3YMO[.EUC=RS#:O\7 X_SGZ&OEKQSD_\
M%"+/CY1=+MV+GC(Y P?U'Y=:^I?^"GW_ ";I=#.-S,,<X/ X."#0!^"]%%%
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MV1]W!'/KW]:;M^7=C)ZA6/0\]_QH7.#MQR2.,$ Y//;\:!+W(P,@ GCJ/?\
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M)_S_ $'I3SC=P?FW<]3CCI[<4 *0-V-W7G&3GC'Z?XT+]Y@N %/(]S@_UIJ
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M7X1_&+X/Z[\'O%E[I.KV4END4[112/R' Y'/^>E?TU,H92",@\$&OF_]J_\
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M_=%:GB3PSJ/A'5IM-U2V:UO(3M>-NQK+H ***7:VW=M.WUQQ_GD?G0 E%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444J*9
M&55&68X% 'Z ?\$@_P#DL%YQZ=L]AUXX_3J>M?M*<[AUQT[8^O\ GUK\B/\
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MR%)XQD_YXH,9;[QSD8;C@_@?QJ2B@!K)NSWSP0W(Q]*#EE'&#P<$XQ^5.HH
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MQ0 Y5"J !@#@ 4M%% !1110 4444 %1RP1SKB2-9!TPR@U)2%@O)..U %/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/KVH_P"'=/Q>;&-)'/3@]\8_F,_48S0!\O45]0_\.Z?BZ<8TG(_W3GM^O(_
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M.01^O3T[T >RJIR23D_I3JB7+."?4GD$]..O;M^O6I: "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX[COVK]7=6!'A3P'GOX?@QQC_EK-^= &-12MG<<XSGMC'Z4E !1110 4444
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MT )O(?:<#GCGKQ].O'2EW<X((YP/RIJD=>02<G"$9SP,_I^5*R%H]N[/&#N
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MY[9X&.>/3WI5)QW8=.F#UP322*>N6P#GCL,=,8Y_^O0NZ-><L!U/X=NI/XT
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M$^0V/-(!/3[QX'Y_K0!U/[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D
M$QKT ],>GM7X&_L'#_BYT!X)W_B.![?U_P#K_OEX3P/#]D !CRUP0#R,<=O3
M^7X4 :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!^3?CI6D_P""A-HK#S?]*7&X9W<CD_>_/_\ 77U)_P %0#_QCG=@D@,S
MC .,\#@G/'^>*^6O'*;O^"A%FOE@_P"E+\I.Y3R.G7C_ /7[U]2_\%/FV_LZ
M76-W+,-J_P 7 X_SGZ&@#\(-+S_:=IC.?.3&W&?O#UK]7-6Q_P (KX$QU_X1
M^#/_ ']EK\H]-_Y"5KD9'FIU&>X[=Z_5W5O^14\!_+C_ (I^#\?WLU &2&QD
MC &<@,,_ATIK8R<<CMFE9GRP8MG.6!]?>D9BQ))R3R2: $HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $\<G;^SW\0F\PI\]
MF,*?^NW/4?YS^/Y9U^I?CIE7]GWX@\LK[K/YAZ?ON.H_S^OY:4 ?H%_P2"_Y
M+!?<?W>WM]/\*_:1N6V[MN0?K]:_%O\ X)!?\E@ON/[O;V^G^%?M'(1R&P5V
MG*XR3_G^M "_>49!7OC//Z4WR^H)8C^]N().,=J=DJHW<GH<"J&L:I%H^ERW
M\S*B1J&9P1C YZ]QU_\ K=: /DC]N[]L:#X#^&[W0H,KJ]U%MBD3AAD8R.>F
M3^E?C5HMKXD_:0^)]O:7-S)=:C?2G#MEBH+=,_CU/I7T+_P4T^+%C\3?BE$;
M)LBW8JP5L@$9!]^X]*]E_P""7?[,\/BBWB\<./WMN<HW&!SUZ8)Z ?0]Q0!]
M5?LM?L ^%/AW\/8;7Q3IB:CJ<J@LTH!(R 3VZ?7-?1FB_ WP9X?M_)L=&AAC
M[  <?3CBNY7]VB*5Z #Y>@Z#_/%'EG=G/&<@YY'Y_4T <1KWP3\'^)K7[/J.
MDQ3P_P!T@?X?YQ7R[^UY_P $^O#7Q&\"L/"&FPZ7J%NK./*098X)S^@K[89B
MQ(SA<CD@COT]\\_IUIX7*E6&0<Y!.: /YD-6T'6/@Q\1C;7T<MO<Z=<@,V"
MP!SC_/I]*_;']@/]JZR^.OA*+14 -[IR>7(V#GA<C([<?X5C_M??\$]=-^/M
M\E_I#1Z=?,X9I<<]1QG/IGD_X5+^Q/\ L-W?[,&L7=_<70NI+ALLQ.2 0 !Q
M^/?% 'V<\9Z+\H.1P#QG.3U'?'^33P^Y>!SP"N1D?6C?\IX^;&=N1FN1^)7Q
M.T7X:^';W4=4O8H&@C+K$S ,W&1C- '7+GG/K6;=>(-)LY D]];POZ,X!Y/]
M3^=?F_XP_P""P&E:?>7ME9:>SF-BB3(AY/KT/MTXZ_A\)_&#]KSX@?%/QE=:
MKIFH7MM9G**D(<Y!ZYY.,X'% ']!MKXBTN[<K;WL$K$X/EMGGIS^7Z5H#).X
M#@@=21^G:OYY_@Q^VAXV^&?B1+K4M2N+Z -N9)B6QDC/R_F:_37]E_\ X*4:
M%\;/%4>@ZC&-/<J")),@DG/M[9_R,@'W%O+CY6'(_A()P3P:%7R\L=JJ!^0'
M3GTZ_G3;:ZBO(4E@<2PN,K(IX/.*H^(K_P#L7P_?W@Z6\1D '&,#VH O--#\
MRED.3AAQZ=_P'?THP=Q9 ?F&>1W.!TR.F._-?EUXB_X*72VGQ:E\/#(ACNA;
M>8O3&?7)'7;T[#WX]N^*O_!1CP[\(_#5C<C9J$]PN[RUYVD@'!'7N>U 'V?>
MZS8:7D75W%;XY/F/CKD]_H:K0^*M%G?RX=2MF9/X$D'& >,?GQ7X4_M+?MY^
M+_C=X@$OAZXN;"TR<I"&W8Z 8^F?UKRWP)^U5X^\'>+++4KO6[NZB@?<\,C'
MG)#'C/<@9H _H[D4EN-V#P=K8_SU[<\4K/M8#MT/'KTY_P ]17YZ_LZ_\%1-
M'^(7B+3/#.JPBU>154W3*1STR?Q_GUZ5^@6FZG9ZM;BXLIDN(6P?,CY4\>OT
MQ0 E\P;3;P.5P(G#'!_N\\=:_GA_;?MXH?C]KLD9R9'9CEMQ^\3UR1W]>U?L
M!^V1^U"OP!\*W+KR\B$1JIR.GWA[<<#G]:_#?XP?$-_B=XXO=<<$><Q(SGG)
M)[G@<]* /T,_X(\R#^U-05B.IQD@D_0X^G'_ .L?K$TBN JL&+<?*>WKD>Q_
M45_//^RS^U3-^SO.\L*EB^=RJI]?RS^%?JG^PS^V!_PTIJ.I0NOEO;C/ED=.
M#^O]"* /L/<G)9E5@V[.,'OZ^P/-/CV;?D(*_P"R>!P/Z8KXN_;N_:\E_9SO
M[&SA7+W!5AMY*Y&<[0?4=?K3/V>?V[]!\6?"74_$VLWL-O<VRG,4CX8E>,\_
MX]3CK0!]C7FM:9IK!+J[@A;@?O7&3@\=?<_G4MIJ%KJ48EL[B&Y7[P*ON'3L
M>W4?K7X+?M/?MN>,/C1\0)[[PU=WECID+N(UMP?F&[@X'0< _C7N_P#P3[_;
MBUR/Q+9^#/$%S->3W#!%DE));G&.A/?- 'Z\K_K#ST8CN>HSZ_S^E2*-J@#M
MZG-4WU*WM;&&XNY5B4JK;Y..2/TZ_K7QY^T%_P %'O"WP;UB2QMS'?LO&8R&
MQSWP3SUZ9Z=.] 'V+?:I9Z6F^[N8K=>N9& _&J0\6Z([<:G:L5Y_U@..H_QK
M\2_VG/\ @HSXA^,D45OX<FFTP9Y,:%6_SQ^8KYSM_P!H?XCZ7=0S-KUZ!#(&
MV2$@$@8Q^0Q]* /Z5(I%FB#Q,)$8\-G(//.#2\LPR!\O/3/T.?IG\Z_*3X#_
M /!5V/2+#2-!UVW-Q(S+$]PPQU/WLX R>!7Z9?#SXB:1\2/#EIJ6F72SK<1[
MRJ]0".O'3J.: .J4!<J.@Z#' 'H/RK\:_P#@KHI/Q$B8AAAQC)'&<GU/<>G:
MOV45=I.,!?0#OWK\:_\ @KH?^+BH > XRHZ=ST!Z\GK^'>@#R+_@F_&9/CC9
M#:6&X9P,_P!#_*OWO7[D>%Q[+P!Q^%?@?_P3?8?\+TLAMW-O7:&'!)Z#I_GV
MK]\%7]V@!PHQVP?Z8H %)& O(Z#<#V.#S4E-VC&",C.>>>^:=0 4444 %%%%
M !1110 UNG0GD=#CO5>^7_B6W*A<#RF 7'L?K_*K#8QR<#([X[U7OOFTVXZM
MF%OO#D_*>V/Z?A0!\(?L]DG]J34SM)'FGY^H[<9YZ_7MWK[YKX&_9[.?VI-3
MZ']Z><C/;ZG]?SXK[YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &[AQ@YYQQS1YB[02=O&[YN.*:2K-D]1@< [AS_+C]*=M*A0
M#P/7DT -5F8DCGMUXZG/XT[<=Q VGH>O/6D7;A"3EB, L,$]_P"E(I+J%8;@
M5YW#KZ=OS]* #R_XL*6Y(XP">WZ<4*V1A6&-OR9YS[]>1R*15R^=N><Y(QZC
M([YQ@4_<Q_AQT/S'\Z &JH8AL8YW#CD\8YR.*IZKHMCXAL&MK^VCN8)5PRMR
M#^-7>6.#T!Y(R/<?6D955LEB.,Y/89R>3_GB@#\VOVPO^":]MXNO+_Q3X< @
MD 8^2F 7;D@D9XZ$$^X/K7YC^)?V?/'/AW5KFS?P_>RB%MN\1XX[9S7]+LBI
M*C)(F]#\I5ER#6'-X$\-W#$RZ-9L6R/FB'/7/^/X ]J /YC=:\)ZQX;(&IZ=
M/99.!YJX!K)K^@']H3]@_P )?&R%D6"*P8G.]5!.=N,^_(_EC%?/!_X(W^'F
M&#JS#/7;(>^,X_4CTR/3D _(VRT^YU*0QVL#SN!DJ@R:Z+3_ (6^+M1;_1-!
MOIF4_P "="*_9+X0_P#!+GPM\-]4EO9KA+R1AC$G(QCTQV.?T^M?3W@G]G[P
MCX-\TQ:3;2.V,$QC'M[\?D/K0!^.7[)O_!/#Q!\>(+VXUN&?188"=HFRA."!
M@_\ Z^]?J7^R_P#L:^&_V?\ 1#"]K!?7_&R=@"5Z$G./8=_6O?\ 3M#T_1$9
M-.L[>S+#[L2!00#[?7]:O*V&(+=\#(P<]?QX_E0 K2!<\Y([9&>>E-QEP2<-
MV QTS]._&:"I5@1NP/1NN3SG-(N67[S;L9&X''?D]/Q% #MQW<<^Q!'0\\T^
MFECN )4<X'OQ_G\J=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR?SISE5R#N.[).#SC'4?IT]:_%'P7_P5&^).K>+]+LY\&"XF6-U4^N<_S^F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#\FO'*;O^"A%FOE@_Z4ORD[E/(Z=>/_ -?O
M7U+_ ,%/FV_LZ76-W+,-J_Q<#C_.?H:^6O'*;O\ @H19KY8/^E+\I.Y3R.G7
MC_\ 7[U]2_\ !3[_ )-TNAG&YF&.<'@<'!!H _"#3?\ D)6N1D>:G49[CMWK
M]7=6_P"14\!_+C_BGX/Q_>S5^46F_P#(2M<\#S4ZG'<=^U?J[JP(\*> \]_#
M\&.,?\M9OSH R/E8X^[D\$GH/?BD8Y).,>PH;)8Y;<<_>]?>DH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!OCIE7]GWX@
M\LK[K/YAZ?ON.H_S^OY:5^IOCIV7]GKX@\[$WV?S#@Y_?<=1_P#6S[U^65 '
MZ!?\$@O^2P7W']WM[?3_  K]I&YP#RK<$8S_ )[U^+?_  2"_P"2P7W']WM[
M?3_"OVD;.5QGKSC'IWH %RT8(/S$=2I'Z5R7Q6T)O$7P_P!6TV)1F:$H%R5[
M>HZ?I76?>C'WFR,>A^O;%)&Q;J>P[$#Z^WT^E '\W?[3?PEN_A7\1+^UN$91
M-.Y&>_.0>I_STK]5/^"1TIE^"4Q+!CD#IR>G?'^>.M>!?\%8/@GK6H>++77]
M,LF.FQ ER <+G/..?7K[>XKPO]A?]K[5?@GXRTSP]<MMT:>3RI0I[Y [?TZX
M_( _>/D;L#J?4^U-48"YW;CZGOCOCC^E8_A'Q;IOC?0[?4].G2XMY%5LJ01G
MK_/^5:SJS,W!9<'@@$'IQU^O7_\ 6 /QYF<Y"^Q(/<&A5()QQ\V22!SQ[?A^
M5(R@J4V84GG@8/<_GTJCKVK6^@Z/=7]TZ(L$+.6)V]!SCGZ4 ><?'+XW:9\%
M;.UNM3N!%!-A1N;GG(^O;W.3[53\&_M8?#[QJL"6.KQO<RCB(')SQ^77GT]Z
M_(;_ (* _M5:C\7O%TV@QW!-C8R[0T;\''N#]>W.37=?\$K?A&GQ)\67U_?7
M<P2R<M&K E<[>H)]_P"= 'ZL?M 7"77P7\12H2T;6K=\<$$'/(XP3WK\#_@#
M_P G.:;AMP_M63D9(/[P^_\ .OWQ^.ED;3X*Z[:Q;I/+M"JG^(X'7J/Y_CWK
M^>/P_P")'\"_&)M5*D/;WTDG/)&6)SS_ )YZGN ?TK>'X]N@:<C*O%O'QC_9
M'/2KB@<!74,<YV_J0/J:\/\ V1?C$OQF^&=IJR2;A&BH5+9/08^G_P!<?A[E
MMW84Y(7!R<<_YZT .#;O_P!5?$W_  56D"_ >12V,AP5X((P?O<CCC/X5]L1
M@*NT=%XZ8_ 5^?'_  59^*6A2?"F;P_!=))J8W\*V2N1@'@_YSTZ4 ?ES^S3
M)>K\2K'['N9A(AVC)!^;/3UX_2OZ!O#ZS+\$3Y^XR?8'SN'/0]>!FOQG_P""
M9_@&#QU\7S%<('6$JPW $=0..#@Y(Y_GV_;GQ+IL6D_#[4[2%?W<-FX4*-I.
M!Q0!_./\>-LGQHU[@;#>=,#!&?H./P'T%?KC_P $O/\ D0W^7'R_>QUX'M_4
MU^1_QV4)\9]<4'<!=X!XYY]C7ZX_\$O\?\(*>.3'D\ =L=A[=Z /NJ1BH+8/
MR]\C&.I[_A1'D;@>@X&23_3Z?F:=@*Q;J3@=/T_SZT+@DD9].<]J /PD_P""
MICEOVA) 0V5611Z?>!]3V(]*_1?_ ()CJ?\ A15H6Y/EH#P>O)]/?OSZU^=/
M_!4['_#0S@%<[)"0.O5>3S[>@Z?C7Z+_ /!,<#_A1%F1M_U:\J,>IQQQW]3]
M: /KS4O^0;=8X_=/T..Q[]J_GB_;EQ_PO[6\?WVS@8YW'/<]Z_H>U'/]GW6.
MOE-CKZ'TY_*OYW_VX65OCUK)7IN/Y[CGN>_O0!]B_P#!'[/]I7I]1C.W/<]^
MW3U[8]A^L6/F!_K7Y-_\$?DVZE>G&W//"G'?V_KC/Z?K)SN''% 'Y(_\%EFS
MX@T,?3O[?7_/MTJU_P $F5A^SR.RAB9-I;/(Y/?GZX^GTJM_P66_Y#^A'=DD
M@8SZ#Z_T_+I5K_@DNJM#(3R^\[05Z'=CO^' SD=O0 _6).%4!=HQ]WT]J%ZM
MR3SW'MVHVC;M(RN,?-S0J[2Q_O'/Z8H _ '_ (*/L6_:,U3)W'D<G)ZCWX^G
M'TK],/\ @F_:Z>GPHL7A1/-V*=P R>V3D=3S^N#VK\]?^"E?P[UJS^-FHZU)
M;M]@8-B1F+8 Q]?\GWKV;_@E3\:[S4O%D?A6XD^6,+CC@#)'7'I@\GJ* /UR
MD^[SQGCKCKQUIU-;.01^7:FJNT@<KS@!1QC!Q]/TZ4 8'Q"81^!]8:1L!;<D
MD#^E?SJ?M.3VEQ\4]4-HH11*P(0J5SP3T/O7]"/QN\267AWX;ZZ]Y,(O,M75
M,L!S^8_R#7\YWB:WD\:?&"^MXV,KWFH,BG&>_7'IWH _7#_@DF9?^%7W7F#D
MQCYL=<;>G ]>E?,__!79O^+C1+G'S X+'GW SC]!7WE^P7\)[OX7_#B..YA\
MK[3"K?RQCCI^)]J^#?\ @KHW_%QE7=_&/EW>WIN_I0!Y!_P3?;_B^=D %9@P
M.UNG3O[?YXZU^^*J/*0 9 QC<,?IBOP0_P"";X+?'.Q SG>/N]>GT/\ *OWQ
M.64952>"1GB@ 4;1T"\GI]:=35&T= O)Z?6G4 %%%% !1110 4444 -;IT)Y
M'0X[U7OL-IMS@$@Q,<$'/(/8@_RJPQVCJ%Y'7ZU7OOFTVY ._P#=,,]<\'V_
MI0!\(_L]Y/[4.J'+$>=ZG']?Y^O6OOBO@;]GM0W[4FIOR2)2,YXYQ]?3U_.O
MOF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;M(
M^ZV.O7D9-1W6?LDV1CY&_D:?]YBIPP!_+H>??O45P1]DN-HP-K=,<\<_K0!^
M&/\ P4;^;XBW60=P?CY?8Y[\C 7GMFOBVOL__@HXMT_Q(N5%K*8VE'S $KP#
M@C'KC_.*^-?LD_\ SQD_[X- '2_"L!OB)X?!_P"?M.V:_I3^%/\ R3GP^,8_
MT5>.??U _E7\UWPQM;E?B%X?VVTDA^V1_*%Z\_2OZ3_A/G_A6_AW*;&^R+E<
M8Y^F* /RA_X+%_-\1-*Y4E5&<#D<'CVX/7_&OSBK]&_^"P_VB3XD:6@B9DX.
M[&>S>G\^OZY_.G[)/_SQD_[X- $5%2_9)_\ GC)_WP:/LD__ #QD_P"^#0!%
M14OV2?\ YXR?]\&C[)/_ ,\9/^^#0!%14OV2?_GC)_WP:/LD_P#SQD_[X- $
M5%2_9)_^>,G_ 'P:/LD__/&3_O@T >O_ +(B^9\>O#:D9!DQQ]1['_/Y5_1G
MX=_Y .GX.1Y"8_(>P_E7\YG[)MO<Q_'7PWMM)I,RX.U#\H)')XK^C'PVNW0;
M '@^4N1Z>U &CN&<<]<=#Z9IU1JP8@AF()XP..GKCI4E !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U!MEC<L.,1L>?H:_
MG5_;:(_X:)\3 '<!*0/FSQN;C\\U_17?9%E<;>6\ML?D:_G4_;88']HCQ*%;
M*B4XY)[GG_/I0!U7[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D $QKT
M],>GM7X&_L'#_BYT!X)W_B.![?U_^O\ OEX3P/#]D !CRUP0#R,<=O3^7X4
M:]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3?N*269L#T_7BD92S'MT[GL?2D5=RG(9<Y_B.>: #)?H<?>&5
M(('/\_\ Z].^\& )!Z9Q32P$@XZ_*>,'ID?UI NX  ;5'*G;C'&./0_A0!(.
M_.?Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^"7/B6X\?3S^!X%_LYP?E5,J".@ZCMCGVKRG_AUC\7=W$<./>-O;_']#[9
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MGD\=N>OXT "MMR,*/4+S\QZ]O?\ 6I*8JJV&!W#J._KR/SI] !1110 4444
M%%%% "'/;BJ^H9;3;G(Y\IL@<]C[?TJ=NG0GD=#CO5>^7_B6W*A<#RF 7'L?
MK_*@#X0_9[7=^U)J;X!_>D;N2><=^1V]?ZU]\U\#?L]@M^U)J;<%?-.>,GMW
MY]^_/OBOOF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U$XT^Z.<?NF[X['W
M'\Z_G6_;<R?VBO$^0V/-(!/3[QX'Y_K7]%.H?\>-SEMH\MOF/;@\U_.K^VUD
M_M$^)F*X)E.>,<[FXZGL10!U/[!O_)3(AC_EH#D9[+CGC_:]OY5^^7A/_D7[
M,\',:\J, \#V'^?RK\#OV#%W?$Z$X  E W8SC*]2>PX_4U^^/A//_"/V1( )
MC7H!Z8]/:@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HIH=2<!@3SW].M*6 P"<9X% ",I9@?EXP1D=/7]*#G9R
M.>N%/?TI&!W< G./XL#@U\W?M4_MF:+^R_<V4.JQ?:'N2"JY&<>F!SW_ "'Y
M@'TAMVXRS$<9ZY)XQTIBIM)#,">AVCG![C'(Y_E7A/[+/[5FE_M-:3-J&F0&
M".+<"I]00.OK[?7VKWIE8GJ/4'GCCN._>@!]%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_VNV?Z\YQ2G]NCX6!N/"2;1_=N9AZ=/FXZ?^@^^ #MO'7_)O7Q#PVT[K/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?BK_ * 5Y_W[K^BT6?PQ.,:5:^V(&]L?S'_COH*!9_#$XQI5K[8@;VQ_,?\
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M?BK_ * 5Y_W[K^BT6?PQ.,:5:^V(&]L?S'_COH*!9_#$XQI5K[8@;VQ_,?\
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M@#MZG-<6WQ,TU<YN,X)!*CV)QTZ]_P L]Z&^)FFKG-QG!()4>Q..G7O^6>]
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M_BYT!X)W_B.![?U_^O\ OEX3P/#]D !CRUP0#R,<=O3^7X4 :]%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSSTX_(>G.7_PHT%N;V7!Z_/CTS_-OR'M7KG\0.?PIDK,JDCC ))/3I]1_D4
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M_B?\*+C_ (;QEP/EW$#'H.!TX ([\_CZW10!Y)_PHN/^&\9<#Y=Q QZ#@=.
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M'&#GG''-&X<=>3CH::9(W_C'(QPV.N/\1^='F1D@AP><_>]@/ZC\Z '9^5F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5^:/_!9#/_"'Z3RW&!@>[#)ZY[ ?CS7Z75^:/_!9+GP=HXZ]
M\=?XD^O\OQ] #\A:_7+_ ((UJ3X8UHGIN;# 9!YY&[&?[O&>U?D;7ZX_\$:U
M_P"*9UIB WS%0V"2,<]<8[GOQT[B@#]-Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-\>/VVO!GP,N/)OKF&Z?.#L<''7/?_/YU^3O[4'[>GBWXH^.KV?P_JCV>AR
MJL2$@$;O0-[?K0!]@?MT?\%"],L_#=WX9\(W6=2;*N\;CIG'!SGL.W?/;C\E
M_$&OWOB;59M1OYFGNIN7=J@U34[G6+Z6\NY6FN)3N=V).356@ KJ/A?_ ,E"
M\/X7=_I:?*._/2N7KJ?A;S\1/#XQG_3$[9[_ $/\J /Z4OA.,?#?P[_UZ*>
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MC'';T_E^%?@;^P;_ ,E,B&/^6@.1GLN.>/\ :]OY5^^7A/\ Y%^S/!S&O*C
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MZI,I5B",$<$&@#Z1_P"'@'Q?Y_XGK#\6]_?W_2E'_!0#XO;N==;'LS>_O_G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?:MK[S;E.>Q[],_UH C52Q ;HP.5()X/4'G'I^1J:F Y;[QSDG:>.G'Y4^@
MHHHH :S%>BEN,\8_*D<[3G.T 9+'H!QGO2LH;KGIC@D4)SDXP#R,Y]/0]* $
M_P"6F2#G&!QQ[\_YZ5\G?M[^--;\&_#J]NM'N&M;@(<,K!<\<#KZ#O[<5]9*
MQ89Q@=O7_P"M7QY_P42.WX7ZAA<9C;C@=NO7\?Z4 ?A_XT^(&O\ CO4)+G6[
M^:[E+$XE8G'MSSQP/PKG*EN_^/J;_?;^===\/OA+XD^)&I6]OI6FW$T,KA3.
MJ$J 3CCUZ4 <I:Z?<7\S1VL+W+CM&I/XTVZLY[&4QW$30R#@JPQ7[!?L6_\
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M1110 4444 %%%% !1110 4444 (1N_\ UTS=M( P6S\^T>P_+M^%/9@JDDX
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M(XP /TK8VYQNP2#D<=/\BA2>0>H/IBG4 %%%% !1110 4444 %%%% !1110
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M&?4E?Z5?L_\ @DKXNFO(HVO9MC$9.T'_ -ES7Z\_",D_#3PYG_GS3_/2NNH
M^?/V/?V;A^SEX)_L@C,DB@,203GC/OV_(#ZU]!U&DA;C\>>#@]#C].?0U)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ/YMQ.& STSU[?ET-24 %%%% !4>?,V\KR"58')] 1QZ&I*;MSG/S#.<'M0
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M ,;O0GMWK\T_^".)_P"*0U3YE/#<#D_>/?'Z=L&OTM(W?_KH 6BBB@ HHHH
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M\1M;\;>)K_6;S4+H3W<A=AYS<=L=?<_F:Y]M1NV8,;J8L#D$R'.?7K["J]%
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M1/#XQG_3$[9[_0_RKEJZGX6\_$3P^,9_TQ.V>_T/\J /Z4?A*-OPU\.<!?\
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M?A;^P1X,?QA\58HDB\UHW4X(X/?.<8X..OK7[W>$=.?1O#]M:RA@T2X((.>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXRT[2?@;JVGRSQI=RC*(S 9^@[\_R- 'X SDF:0GKN.<_7Z4RAL;C@8';-%
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M[XY_,_A7Z6U^:7_!')<>$-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5^:/_  62Y\':..O?'7^)/K_+\?3]+J_-'_@LESX.
MT<=>^.O\2?7^7X^@!^0M?KC_ ,$:P?\ A%]9)7=RP\SMUSC..HRHQ7Y'5^N/
M_!&J,CPSK3$-G+#<5.#\V<9/L5_SS0!^F]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5S'Q+D9/ ^K;#AC"P&.3TSTQS^E=*ZEL8"Y[%NW'
M6LSQ!IZZQH%W:  "2,H!NP%[<X/;^E '\ZO[54D\OQ*U%IBQ_?OU)(^\>_?O
MZ?CV\712[*HZDXKZQ_X*%?#^3P3\37+IY9GE+%<GN#SR3W#?YZ_)M '[R?\
M!,F"*W^!D"PA0& )X /4XR,>A]3T]J^H?'7C*S\#:#/J=[*L4,:$Y8@=,?X_
MYZ'XW_X)>>,M'L_@/$E_JMO;W0VY260#C&2>1[^I^]UKI_\ @HA\5M(T_P"
M]_#I^K0RWL@)$<,@)(QZ9^GYCUH _(O]L?QE:^.OC=K.J69)A=V .#C[Q/J?
M6O#ZFO+R6^N))YFWR.22:B*D*#U!_P X_P ^M '8?"7PK?\ BKQUI,%C"\I2
MX1V**3C##L.OTK^CSX)Z?+I?PKT"UF5@\=JJX'!X&/PZ>WX5^0?_  2I^'NG
M>-?B5=-?0K+Y#;@'7/0#D<<=^_45^V%O9QV=I';0C9%&H51SP* "6XBAM3)*
MP\O:<EB/F&/RY%?B+_P5,UBTU3XE0"UF6;9)AMA!&<-D\>N?05^P'QL\8Z;X
M9^'>ORW.HPVDR6K,@9QNR.>.?8U_.A\8O&FH^,O'6K7%_<M<!;EQ'GL,_P">
ME '#U^Y__!*F$0_ -!U.5R<YYVCV'/?\:_#."&2YF2*)&DD<[551DDU^\'_!
M,G0[K0O@;!%>1-#*RJ2C+M/UZ#C_ #TQ0!]A+ECN!'7!P<CC/Y&GTP<MG&UN
M^!U'..<4^@ HHHH **** "BBB@ HHHH JWQ_XEUT<G_5OR>.Q^G^>]?SJ_MJ
MY/[0WB4]5\SAO7D]_P#Z]?T57Q_XEUT<G_5OR>.Q^G^>]?SJ?MJ<_M#^)3G.
M9/ZGG_)H \,KJ?A;S\1/#XQG_3$[9[_0_P JY:NI^%O/Q$\/C&?],3MGO]#_
M "H _I1^$HV_#7PYP%_T-.GTKK6&Y2#W]#BN2^$HV_#7PYP%_P!#3I]*ZUAN
M4@]_0XH 1E^5CACWP#2*I*D,6Z8YP#]>/6CE26.#QSA>?;^M()%56<@* ,LR
M\C(Z_EB@#XP_X*'_ +1W_"OOA?>Z9I%VL6JR9RJMAL;?P/7O[]J_#K7M>O/$
MFI27]_)YUS)]Y_6OJ[_@I-XPU#4_COJ%G]H8V0!(CW[AZ>IXQ_GN?D&@ HHH
MH ]"^'OQX\8?"^)D\.ZC]BR-N0#_ (]<UUDG[97Q5DD9O^$DFYSU9N^?]KWK
MQ-E^56'0_P ^_P#GWIM 'MO_  V5\5AC_BHY/_'O;_:]O\YH_P"&R?BJ5Q_P
MDDOYM[?[7M7B5% 'MO\ PV5\5MV?^$DE'T+8/.>1NKZ4_8'_ &F/B!XZ^-]C
MI>LZQ+>V<A4,K$D=\=<^GL./S_/ZOK?_ ()ID?\ #0-B.^5_DWM0!^]_W0H"
M\=..@K*\4:7!JV@WT5S&'4P/A7 .T[36L3TXS_2HFA^4AONGY2.I(Z 9Z^_X
M]: /YNOVJM"N=$^-OB1);-[6!KEC$2N%9<G&#_G\L5Y%7[9_\%%/V1].^(7@
MTZIH%ALU>$;WD1<L<'/)]/P_G7XO^(/#]YX7U:>POH3'-$Q7#=_?@T :_P +
MO%W_  @_CO2=9)PEM,&;Z9[\5^_'[*O[5GAGX]>"8IK:[AMI[*%%D1VV'@ 9
M_2OYW2<]L5UG@OXI^)OAZKC0=4FT\.<MY;$9Y'^% '])?C;XG>'_  )X8OM8
MN=1MC!:KN*I*&Z#H #TP.U?A[^W+^UW=_'+X@7*:/<-%I$+,@5'X.#QT.,^O
MT[UX?K7[0GCWQ%I[V.H>(;FXM7^]&S$ \ ?TKSIF+,23DGDDT  8C(!QG@U/
M8VTUW=Q101M+(S#"H,GK4#'+$@8]A7V?_P $Y?@'_P +"^)D%[K.FF72@5*O
M(I(R#Z8Z\_ITH _3[]A#X<:?X<^">B7QLO(OY5#MN4AE)&<<C/?]/>OINL_0
MM"L_#FFQ6%A%Y-M'PJ#''&/Z5H4 %%%% !1110 4444 5]0R;&Y Z^6V,?0^
MXK^=7]MI@W[1/B8CD&4GM_>8=1]/UK^BK4,FQN0.OEMC'T/N*_G5_;98-^T1
MXF8=#*?3^\?3MC% '4_L&Y_X6;%Z>9GIZ#Z>_KZ^O/[Y>$_^1?LSP<QKRHP#
MP/8?Y_*OP-_8-'_%S(O7S!U!QC;SC]/3MZU^^7A/_D7[,\',:\J, \#V'^?R
MH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .8^)G_(@Z[_UZM7\U7Q9.?B5XDXQ_ILG\Z_I5^)G_(@Z[_UZ
MM7\U?Q:S_P +*\1Y.3]L?OGO0!^IW_!')<>$-6.W&2><=>G?'/YG\*_2VOS2
M_P"".2X\(:L=N,D\XZ].^.?S/X5^EM !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 54U?_D$WO\ UP?_ -!-6ZJ:O_R";W_K@_\
MZ": /YTOVR3_ ,7VU_[W^M;ACG'/KD\_C^5>9_#<X\>Z#SC_ $M.^.]>E_MD
M'/QTU[#[QYIYZCKU!R?Y_E7FGPW_ .1]T'G'^EIV/K[4 ?TI_"3Y?AAX>W-M
M_P!#4[L8QUYKL:X[X0_\DQ\.[0I/V1?7&>:[&@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *_-'_@LESX.T<=>^.O\ $GU_E^/I^EU?FC_P62Y\':..O?'7^)/K_+\?
M0 _(6OUP_P""-2_\4SK7RKD,23M /).#TST_F3WK\CZ_7'_@C6#_ ,(OK)*[
MN6'F=NN<9QU&5&* /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YH
M_P#!9+GP=HXZ]\=?XD^O\OQ]/TNK\T?^"R7/@[1QU[XZ_P 2?7^7X^@!^0M?
MKC_P1JC(\,ZTQ#9RPW%3@_-G&3[%?\\U^1U?KA_P1J7_ (IG6OE7(8DG: >2
M<'IGI_,GO0!^G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBNHS$Q /<9_R: /YLM:\"ZU\1OB=XAM_#NG37Q^V2 "-2<<].,^E?;W[!?\
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M3DB4CO\ WF/?ZU_15J!"V-R3T\MLX..Q[U_.M^VT"/VB/$H.6_>GYCG&=S'
MYZ<_K0!U'[!O_)3(AC_EH#D9[+CGC_:]OY5^^7A/_D7[,\',:\J, \#V'^?R
MK\#?V#?^2FQ<=9.O/8?3'?VZGUK]\O"?_(OV9X.8UY48!X'L/\_E0!KT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <Q\3/^1!UW_KU:OYJ_BUG_A97B/)R?MC]\]Z_I4^)G_(@Z[_ ->K5_-5
M\6<?\+*\28Y_TV3^= 'ZG_\ !')<>$-6.W&2><=>G?'/YG\*_2VOS2_X(Y+C
MPAJQVXR3SCKT[XY_,_A7Z6T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !535_\ D$WO_7!__035NJFK_P#()O?^N#_^@F@#^=+]
MLEMWQVU\[]_[UN1]WKU')_G^5>9_#?\ Y'W0><?Z6G8^OM7IG[9)_P"+[:_]
M[_6MPQSCGUR>?Q_*O,_AN,^/=!XS_I:=L]Z /Z4_A#S\,?#H!Q_HB\K^/K78
MUQWPDPWPP\/<>8/L:C'7/7CFNQH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS1_X+
M)<^#M''7OCK_ !)]?Y?CZ?I=7YH_\%DN?!VCCKWQU_B3Z_R_'T /R%K]<?\
M@C6#_P (OK)*[N6'F=NN<9QU&5&*_(ZOUQ_X(U1D>&=:8ALY8;BIP?FSC)]B
MO^>: /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIWI]1JK;CGO_ !#&>#T_(^GKS4E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RAE((R#P0:3RP6R>
M1UP>1GCG]*=10 W:=JC.?4YP?TINTM&P*XW=F^;KZ_X5)10 T9VG'RGG&[G^
MM"]6Y)Y[CV[4ZB@!C*Q(P1[=>.#^?;BD"="!M[[2!P>_X\FI** &_=8#+=SC
MJ.OK3J** "BBB@ HHHH **** *^H-LL;EAQB-CS]#7\ZO[;0 _:*\3@=I<=2
M3]YN3G_/%?T5:ADV-R!U\ML8^A]Q7\ZO[;3!OVB?$Q'(,I/;^\PZCZ?K0!U7
M[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D $QKT ],>GM7X&_L'#_BYT
M!X)W_B.![?U_^O\ OEX3P/#]D !CRUP0#R,<=O3^7X4 :]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',?$S_
M )$'7?\ KU:OYJOBR<_$KQ)QC_39/YU_2K\3/^1!UW_KU:OYJ_BUG_A97B/)
MR?MC]\]Z /U._P"".2X\(:L=N,D\XZ].^.?S/X5^EM?FE_P1R7'A#5CMQDGG
M'7IWQS^9_"OTMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "JFK_P#()O?^N#_^@FK=5-7_ .03>_\ 7!__ $$T ?SH_MD'/QTU
M[#[QYIYZCKU!R?Y_E7F?PWQ_PGF@YZ?;(_3U]Z]-_;)8M\=M?W$[O-;(QP.?
MJ?YUYG\-_P#D?=!YQ_I:=CZ^U ']*GPC4_\ "L?#H)P?L:\@8]?:NPKC?A'C
M_A5_A[!Q_H:\J"?7]:[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-'_ (+)<^#M
M''7OCK_$GU_E^/I^EU?FC_P62Y\':..O?'7^)/K_ "_'T /R%K]</^"-2_\
M%,ZU\JY#$D[0#R3@],]/YD]Z_(^OUQ_X(U@_\(OK)*[N6'F=NN<9QU&5&* /
MTWHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY:KEFW= !C./8?SY[ 'N*J<DG@]\  ,<#FGT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %?4,FQN0.OEMC'T/N*_G5_;9
M8-^T1XF8=#*?3^\?3MC%?T5:A_QXW.6VCRV^8]N#S7\ZW[;3%OVBO$V<@^9T
M)!P-S<>W.: .H_8-_P"2F1#'_+0'(SV7'/'^U[?RK]\O"?\ R+]F>#F->5&
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M110 4444 %%%% !1110 4444 %5-7_Y!-[_UP?\ ]!-6ZJ:O_P @F]_ZX/\
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MV@'DG!Z9Z?S)[T ?IQ1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?FE_P1R7'A#5CMQDGG'7IWQS^9_"OTMH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JFK_\@F]_ZX/_ .@FK=5-7_Y!-[_UP?\
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MZ'IW[5QW_"YO!(S_ ,5'8X'4^9T'/)].011'\9O!4F?^*BLP1U&__#WR/PH
M[ L<\?=Z?=/KBG9.[ ''<Y_S_DUQ?_"Z/!74^(;,=S\_3&,_EG]*=_PN/P5&
M /\ A(+-5SM'S8'MV_"@#L@ZDX# GGOZ=: Q;IM(SC.?\]ZYW0OB+X;\2W7V
M;3-7M[R?&?+C;)ZXQ^%="W'S.5PN3DCI[_E0 ^FJQ;!^4J><@Y^E&[)P,'!P
M>>G'_P"JC:6V$A01R>_;M0 ZBFH-JJ,!<#HO04Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_-'_@LESX.T<=>^.O\2?7^7X^GZ75^:/_  62Y\':..O?'7^)/K_+
M\?0 _(6OUQ_X(U@_\(OK)*[N6'F=NN<9QU&5&*_(ZOUQ_P""-49'AG6F(;.6
M&XJ<'YLXR?8K_GF@#]-Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5BH9CDG!(Y/K[>W;I7]+EPS+:S'[K!6Q@^W%?SL_MPL6_:(\1%B6.\C)] S
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MP;@#R<;N_((Q^7Z=*D^;=V*_K_GK0 JYVC(P>^*6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_-'_@LESX.T<=>^.O\2?7^7X^GZ75^:/\ P62Y\':..O?'7^)/
MK_+\?0 _(6OUP_X(U+_Q3.M?*N0Q).T \DX/3/3^9/>OR/K]<?\ @C6#_P (
MOK)*[N6'F=NN<9QU&5&* /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'//S''.WD\ ]OT8>ARZS_P""KNMG6+2)\+;MM#[@>P_'HW/X&OS,HH _I%^
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M([=?;/T_+G%?FS_P4&^*$GQ&^)SF1MQM963&[IR>V3QUQ7RA0!_1;\(?VR?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCDG'&2,&@!U%%% !1110 4444 %%%% !1110!S'Q,_Y$'7?^O5J_FK^+6?\
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M:#^/L<9_.C.0IR<AN1U(SVX^H_SS0 [YAC!W?7ZTWE\%2I'56&?3CZ]Z% 4
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M%?T1VG_'K#_N+_*@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% ',?$S_D0==_Z]6K^:KXLG/Q*\2<8_TV3^=?TJ_$S_ )$'7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-'_@LESX.T<=>^.O\2?7^
M7X^GZ75^:/\ P62Y\':..O?'7^)/K_+\?0 _(6OUP_X(U+_Q3.M?*N0Q).T
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M =@GQ@\:1QB-?$5Z$& %WCMT[4O_  N+QI_T,5Y_WT/\*XZB@#L?^%Q>-/\
MH8KS_OH?X4?\+B\:?]#%>?\ ?0_PKCJ* .Q_X7%XT_Z&*\_[Z'^%'_"XO&G_
M $,5Y_WT/\*XZB@#Z+_98^*GC#4/C=X=@FURYGB:4!A(00!D9/3TK^@SP[*T
MV@V#N,,85R/3BOYS/V1/^2]>&SC.).^/4>H(_P _A7]&/AH!?#^G =H$'(P>
MGI_G\: +X4;@ .%XQC 7CJ./?%24@SWYI: "BBB@ HII8 XSSQP.3S0SJO5@
M.,\GMZT .HHI"P7DG':@!:*0,&Y!SVHW?,!_2@!:*0,#D YQP:Q/%'C31_!M
MH;G6+R.SAQG=(0 >"3U^GZB@#<HKR_\ X:6^'/;Q+:G_ (&/\?I^?L<2VO[1
MOP]O+A(8?$=J\CG"@..?U^GY^QP >ET5#:74=];1SPMNBD7<I]JE+!>2<=J
M%HINX;2Q. .I/%*&!R <XX- "T44W<,XSDYQQVXSS0 ZBD5MR@COZC%-FE6&
M%Y&X5%+'Z"@!]%>;ZA^T1X TN]EM+GQ%:QW,1P\;.,J??G_.?K3M-_:%\ ZQ
M>+:6GB&UFN&^[&K#)_7_ #^= 'HU%-CD6:-9$.Y& 96'<&G4 %%%% !135D5
ML8Y!Z$#CIFAF"D GD]N_^>: '44@;=_^JDW MM!R>_M_G- #J**Y'Q=\5O"_
M@6=(=<U:&PD?[HD8#/KCGM0!UU%><Z;^T'X"U>[2UM/$%M+._1%<9/Z_Y_$9
M]"AF2XB62-MZ-R&'>@"2BD+!>2<=J16W*"/_ -7M0 ZBD# Y .<<&EH ****
M "BBB@ HHHH KZ@VRQN6'&(V//T-?SJ_MM #]HKQ.!VEQU)/WFY.?\\5_15J
M&38W('7RVQCZ'W%?SJ_MM,&_:)\3$<@RD]O[S#J/I^M '4_L&_\ )3(AC_EH
M#D9[+CGC_:]OY5^^7A/_ )%^S/!S&O*C / ]A_G\J_ W]@W_ )*;%QUDZ\]A
M],=_;J?6OWR\)_\ (OV9X.8UY48!X'L/\_E0!KT444 %%%% !1110 4444 ,
M;[R]">H'?TS^OZUP'Q^Q_P *C\29.T?97^;TX//T%>@,V&7)P/7C'IC]:\_^
M/S!?A'XD)&0+5R><<8/?L??M0!_-KXX.?&.LD#'^E2<#_>-?L3_P2#7_ (M#
M>G:.@^;OU^G^<?E^.WCK/_"9:UN.6^UR9.<_Q'O7[$_\$@U_XM#>G:.@^;OU
M^G^<?D ?H'1110 4444 %%%% !1110 4444 %%%% !1110!S'Q,_Y$'7?^O5
MJ_FJ^+./^%E>),<_Z;)_.OZ5?B9_R(.N_P#7JU?S5?%DY^)7B3C'^FR?SH _
M4_\ X(Y+CPAJQVXR3SCKT[XY_,_A7Z6U^:7_  1R7'A#5CMQDGG'7IWQS^9_
M"OTMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJFK_ /()O?\ K@__ *":MU4U?_D$WO\ UP?_ -!- '\Z7[9)_P"+[:_][_6M
MPQSCGUR>?Q_*O,_AN,^/=!XS_I:=L]Z]+_;(.?CIKV'WCS3SU'7J#D_S_*O,
M_AOC_A/-!ST^V1^GK[T ?TJ?"1A_PK#P\=^!]C7YL].OKZ5V-<?\(]R_#'P[
MP"WV-2.,#OCM784 %%%% !1110 4444 %%%% !1110 4444 0W?_ !ZS?[C?
MRK^=C]M[_DX;Q'_UU8?^/-_G^G<_T3W?_'K-_N-_*OYV/VWO^3AO$?\ UU8?
M^/-_G^G<@'C7A,X\4:3RH_TJ/[_W?O#KSTK^DK]G5=OP:\,+M9,6JC:W4<=#
M7\VOA,X\4:3RH_TJ/[_W?O#KSTK^DK]G5=OP:\,+M9,6JC:W4<=#0!Z11110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+/_!1
MPX_9RU;D#ANOX?\ Z^_ /%?S^U_0%_P4<./V<M6Y X;K^'_Z^_ /%?S^T ?J
M)_P2B4C6P<<94$Y/8C QCZ_X"OUDK\F_^"4:_P#$\1MB\$+N[CE>.G]>PX%?
MK)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >:?M'-L^#'B9M[)
MBV/S+U'TY'\Z_FU\3'/B+4N<_P"D/_Z$?>OZ2OVCFV?!CQ,V]DQ;'YEZCZ<C
M^=?S:^)CGQ%J7.?](?\ ]"/O0![;^PRN[]H?P_C&[>"/EST93TP>./IZU_1%
M:?\ 'K#_ +B_RK^=W]AE2W[0WAX["X616P!GHZ\]#VS^M?T16G_'K#_N+_*@
M":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5.N=HSR>^* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$@3+,!QZ9[\ <\5\,4NWY<D_2@#]P/V6_P#@HMH/Q(TN)/%-Y':7T@"_,_\
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M$<EQX0U8[<9)YQUZ=\<_F?PK]+: "BBB@ HHHH **** "BBB@ HHHH ****
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M.6K<@<-U_#_]??@'BOY_: /U$_X)1K_Q/$;8O!"[NXY7CI_7L.!7ZR5^3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% "!0O &.]'.X\<4M-XW'GYL#(S]>U
M'XF?\%<6!^-T//\ >]NY[=_K_C7P97WI_P %<L_\+OA!)SAOO'!ZGMZ>_P!/
M6O@N@#]^O^";*[?V=-.^7:3M.=N,C'T'O7U:,]^:^4O^";*[?V=-.^7:3M.=
MN,C'T'O7U8O3A=O)X_'K0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD^\S?T]* .E^)WQ6U[XL:_+JVMW+RSR'<5+EAD_6N/\ EVCGYNO'\J:JEF
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M<?L3_!74OB5\3],OK:-GM[2=68*N>,\_7IC\:_H&\.V[V6@:? RC?% D9"C
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M_;)/_%]M?^]_K6X8YQSZY//X_E7F?PW)'CW0<=?M:?S^E ']*GPCW+\,?#O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/'?]?Y4 ?EY_P5E^&<_B.:'5XU/^CKNR#TX]">X'\O2OR>=2C,IZ@XK^@?\
M;M\&1ZQ\*=2O2OS)&V,8'(!/J/3.>/TK\ =64+JEX , 3. !_O&@"K7[9_\
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MZG^=>9?#?'_">:#GI]LC]/7WH _I4^$F5^&'A[)Q_H:G*KSW[8KL:X[X0_\
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M+PD<8\06)S_TU'M_B/S% ^*7A(XQX@L3G_IJ/;_$?F*_FN_X6YXR_P"ACO\
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M&2J-WZ@@C\,>N:_(.@#]1/\ @E#&6UQ2$!(P-V.1R..G3CUXQT%?K)7XC_\
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M #]Q_F/P[?\ ZN^* /KNBOD3_AX'X2_Y^X\?A_A_GZ4?\/ _"7>[C'Y'^0H
M]Q_:.)7X,^)B&9,6Q.Y.H]QR/YU_-IXHR/$FI@]1<R Y_P!X^_\ GVK]J?C5
M^W%X9\0?"W7+&VNXVN+F!D" @$J1Z8'^3^?XI:_<?:M<U&8'<)+B1@?7+'F@
M#W+]A9&D_:(\/!5W$N <+DXW#GH>G7UX]J_HBM5*VT0(P0@!!^E?S=?LJ^,;
M7P+\9-'U:[*K#"P)+8QC<.,D']/S&*_9)/V^O"26]N/MD>YD''')SC@ ?3CZ
MT ?7%%?(G_#P/PEVNXSZ=!G]./QH_P"'@?A+M=QGTZ#/Z<?C0!]=T5\B?\/
M_"7:[C/IT&?TX_&C_AX)X1_Y_(\>N/\ ZU 'UW17R)_P\"\)_P#/W'CUR/\
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M*^1/^'@7A/\ Y^X_S'X=O_U=\4A_X*">$\$BY1NOH,XQZ_7]* /KRBOD4?\
M!0+PESF\B&.?\\4K?\% ?"2@XNXW(SPO)X_"@#ZYHKY(LOV_O"5SJ,5N]Y%'
M&YVF0D8!SCKCI_GGI7TCX-^(FA>/K%+K1;^*Z5NJJ<E?4''XT =-13=Q&01N
M/L,<$TU9/EYYPH)P#G\J )**8Q;.!@GJ!@^G3/UI] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !13#(&7Y3G(&&P2.>E9OB#Q-IOA6Q>
M\U6[CL[9>?,DX Z?GR1^= &K17ROXK_;O\(:'K;VL-[#-"#]Y2&P.W^.:S?^
M'@7A/:";J,#H>G'Z<]NE 'UU17R)_P / O"?_/W'^8_'M_\ K[9H_P"'@7A/
M_G[C_,?AV_\ U=\4 ?7=%?(G_#P/PE_S]QX_#_#_ #]*/^'@7A/_ )^X_P Q
M^/;_ /7VS0!]=UYA^T0GF?#F_P",XC8\\#IWY'^?:O$3_P %!O":];A.N.Q^
MO^?RS7&?&3]N3PYKW@>]M+:\C,KJPV],'ISTQ_\ KH _(?X[9_X61J6?[V?U
M(_D!7V)_P2!4GXO7S;>!CD_A_G\37Q3\5M8CUSQM?W<3;D=C@_B3^'7I7TC_
M ,$Y?C%I_P 'OB+=ZA?R^3')A=QZ=/I_AU[T ?O317R1<?M_>$89"HO(_ID$
MCU[=O\BH_P#AX%X3_P"?I ?0X'TZCO0!]=T5\B?\/ _"7_/T@'J1U'J./7BC
M_AX)X3Z?:H\].HZ\_P"'7IR* /KNBOD3_AX%X3R1]J3/O@9XX/(_S].:/^'@
MGA+_ )^H_7MZCV]\T ?7=%?(G_#P3PGMR;E%[\XSV[8]_P!#74_#7]M?P;XT
MU865QJ4-L[84;B!DDD#^GYT ?25%5--U2UU>U6XLYEN(&Y62,Y!_'_/459<[
M58Y"X'5N@H =14>_;DG@#D[N !_D?K4E !1110 4444 %%%% !1110 4444
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MR;_OH^N:HU]T? ?]ESX;:Q\+='\2^,%U&235"ZP+IZ)(1LV[BV]EQ]\8Q_\
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MP1R7'A#5CMQDGG'7IWQS^9_"OTMK\TO^".2X\(:L=N,D\XZ].^.?S/X5^EM
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MS\O( QGXEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]#?\
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M_P!-O7'Y?C0!^<_]N:@,?Z9-_P!]GV_P_P YIRZ_J*J!]LEX]3FOT6_X9;^
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M+W/F=<Y[G_/4U_17?973KK/'[MS][V/?(K^=;]M96'[0WB7/_/4CISG)[_\
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M\'GC+$=:S?#ZC_A&]-#' -M%U.<Y4<<^M:E $8(9AN*[NFW(.&QV_ U)110
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M_P D?T3_ *XK_(?Y]/UH ]93[J\D\=6&#3J** "BBB@ HHHH **** "BBB@
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M.XY.?K7ZH>&_^/B^X4_Z!=##-@']RW!.1_.ORO\ $QSXBU+G/^D/_P"A'WH
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M_E5O!^Z0#SD Y/?KG\N*J:+AM'M.V8U/R\<]>Q_S^E72JJF-ORKV ]/:@!C
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MI7$=SXATM;Z1<%?, X]^1D&N.'[%?PIY_P"*<AR?8=>N?SR?QH _G1^R3_\
M/&3_ +X-'V2?_GC)_P!\&OZ+O^&*OA-SM\-1#CCIP?R]A^5'_#%7PFYV^&HA
MQQTX/Y>P_*@#^='[)/\ \\9/^^#1]DG_ .>,G_?!K^B[_ABKX3<[?#40XXZ<
M'\O8?E1_PQ5\)N=OAJ(<<=.#^7L/RH _G1^R3_\ /&3_ +X-'V2?_GC)_P!\
M&OZ+O^&*OA-SM\-1#CCIP?R]A^5'_#%7PFYV^&HAQQTX/Y>P_*@#^='[)/\
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M!X'CC0<'C[?#@GC_ ):#W_S[UAIW.,XY]ASWK<\!_+XXT'G/^GPC([_O!]*
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ML3XZTD?,<  ]<=#CO_O<8[]>E?L)7X]?\%CN?'>D#>3T;;V'!!.,^Z\_AZT
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MD?ZT ?TB>'-O_".Z9Q@?9X_N>N!Z?K^-:E9GAS=_PCNF<9/V:/[WIM'I6G0
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MV<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6WAI5/RKHUL N?N\,<8W';USC"=<X.=[ '/4444 %%%% !7>?"MML/BP]/\
MB4288=CYB8Y[?_7QWK@Z[SX5MMA\6'I_Q*),,.Q\Q,<]O_KX[T ?EM\=,_\
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M4 %,;&6.X@@ D#DX^GYT^F28X8G '4[B,#K_ $H 0$J-J@<9 7:0/4<^F/\
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M_"=Z2"6/(P/X1\I_4X_3KVK]AJ_'O_@L:Q/CK21\QP #UQT.._\ O<8[]>E
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MOS2_X(Y+CPAJQVXR3SCKT[XY_,_A7Z6T %%%% !1110 4444 %%%% !1110
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M9%:L,]O7_P"O_3_ZWE'P&4_\+!L" N=Z_,>O7I7J_P#P4./_ !D5JPSV]?\
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M1/\ BQ9;;_= ;!'89YQ@]NYZ4 ?=M%%% !1110 4444 %%%% !1110 4444
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M/<>Q_E0!_1I^QR,? 'PWC@>4.  /X5.?UKVI/NKR3QU88->+?L<_\D!\-_\
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M ."?*EOVC-$X8@'^[D?7H?\ .>17]"$?^K7C' ZY_K0 ZBBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]_I0 H/7C']:6H>!G:N,   *5Z$X&?3_ #WIZ9#$'/KCJ.I[_P"<4 /HHHH
M**** &1MNP=V[Y0>!Q]13Z9&V[!W;OE!X''U%/H ^8/V]F_XLWJ@S_!TS[#W
M_I_]?^?W4/\ C^N>,?O&Z8]3Z<5_0%^WLW_%F]4&?X.F?8>_]/\ Z_\ /[J!
M!OKDCIYC8Q]3["@#],OA&!_PS7\/\<CS+KG_ (##[?Y]ZU^B]-N1_$.O/;C_
M #@UD_"7_DVOX?G;M_>77;_9A]O\^]:W1>FW(_B'7GMQ_G!H 91110 4444
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M[.?@6VUO3]YD=\$#G/7CKZ _B!ZUU7P*_9;T'X'6]N-+?,JJOF?*,%NY_/\
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M\-ZE=-(H)!5W+#''3VZ__6JM\.O"'B3XG:Y!H&BS2O/(?]7YA P<_GW_ %H
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M)FW*.<G)) Z#\/P_E7R__P %'%$?QGM$V;"MDB[=NW;A5&-NU<?3:N,8VKT
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MZ?KU_'KC\+;OQ]K]]JRZQ+,S7*X(E"D#C'O[5]+_  ;_ &!?&_[0.DVWB?\
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M=?>TDGDFN--EV*W7!&>3CKU_SS0!^S7P?_:&^'7[,OPPT6QUBZAAN)H$&U7
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M3?[[?SKXM_894M^T-X>.PN%D5L 9Z.O/0]L_K7VE=?\ 'U-_OM_.@"*BBB@
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MF\(IIEZF;:: 1R(O';!S7C6C_L1_#KP[XG37=/TZ.*]60R?-&",D[O?OWZT
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M$T,/(XQP,?\ UNU '4KG<>./4GZ=*^,?V\/VSM-^"WAN^\.VT'VC69T<*IY
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MW^<?UKH_B/IL6E^.-2AC*B&0I<*L:[%C$L:R!0/1=^. .!T'0<RQR2<8]A0
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M1#[+P.0W\7.:%^^I;;^F/3D4#G:%&2>-N,GH/:@!74QR!3P.FYEQ[$_GGWI
MVT9'&>,+UZ8Z_C2[2N2#M^7(QW['K^-"/F3>>-N",'IR/?)_.@!%(+%CP<YZ
M#'Y=Z:3GMBE(YVD;"N0<YI&.23C'L* $HHHH Z;PG_R+WCP%MH/AV<9_[:PU
M^3.MDMK5^3U^T29P<_Q'O7ZS>$6V^'_'?(7_ (IZ?K_UVAK\E]8Q_:]]@8'G
MOC/^\: /HO\ X)\C=^T9HG&><_\ U\8/Y\8]>:_H0C.8U.=W Y!SFOY[O^"?
M*AOVCM#X!.<]"3_(_P!/K7]",9S&ISNX'(.<T .HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D8X4G&?84M1R+N;(7)Z]L''0'\3F@ CQN W X! ^8^O/'MQS3E
MP>0V[J.OOTIJDL"G)'0L<@X]>G7/I]:$5@Q)&3T+=/R]NO6@#\=?^"Q<:?\
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M9)P?0'((YIU1E26R5!/'8 'GCWR/Z_E)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5]0R;&Y Z^6V,?0^XK^=7]ME@W[1'
MB9AT,I]/[Q].V,5_15J'_'C<Y;:/+;YCVX/-?SK?MM,6_:*\39R#YG0D' W-
MQ[<YH ZC]@T?\7.A/!)?GN1@?3CKZ_\ U_WR\)X'A^RP!CRUY //'T_#\*_
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M8@]"#\O'7X3_ +-O.?\ 19_3_5GUQZ>M?K+I_B[;8PZ9J^FVNO:/'P+2[7E
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MI45TC>4P8(B!\D#!R.V.IX]J]G_;L_9-LO@[\+=#O?#.G,=7M?+=I(URQ^8
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M:9XEN(_,BM2&*]>=P(P#Q^E?7R_M>_!WRQNLM9\S:<XN5QGM_P L^G3\O?@
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MO.,KI%XP]HB: /V+'_!7OP!NYM%(X[D'^9Z<_G2_\/??A_C_ (\>V?OG\O\
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M]4&?X.F?8>_]/_K_ ,_VHY&H76<D^:WWNO4T ?IC\(P/^&:_A_CD>9=<_P#
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MOD _\%AO&:@XTT$\@8Q[8/)Z?X?7/9?\%F%#:KHOJ-K=?15'3/O_ )XK\NJ
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M(Y+CPAJQVXR3SCKT[XY_,_A7Z6T %%%% !1110 4444 %%%% !1110 4444
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M$!7;M7'TVICIM7H #Y\^%V3XVTX ')D'W1D]1Q]/P-?T1?LN?\D=T7_KFO\
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MW[.8+?&?PN 2I-VOS#J.:_1_QQL_X3'6_+^Y]LEQ@D_Q'UH Q**** "BBB@
MKS7]L3G]G'31U_XFDYQU[0?7^7X^GI5>:_MB<_LXZ:.O_$TG..O:#Z_R_'T
M/S\K[^_8S$;?L[ZP9))%8:G%Y2JNY6/S\'@;1]_D9R1C'\5? -??O[&<TD/[
M/.M)$[)'-J<*RJ"5W##G! ZC*AOP!ZT >H4444 %%%% "J<!N2,CMWYK>\"_
M+XZT'HO^GP]#Q_K![_Y]ZP5. W)&1V[\UO>!?E\=:#T7_3X>AX_U@]_\^] '
MYO\ [27_ "6KQ3SN_P!*;_\ 57OO_!.?YOB#"""1YN"%3)Q^(/3GMSGVKP']
MI#'_  NKQ3CI]K;^=>_?\$YR?^%A0>OG# Q^7ZY]/Z@ _=+1?^019\8_=+Z^
MGO5M\;6W'"XY.<?K5/0^-(M!C_EF.W7WZ=ZN.=JL<A<#JW04 *._.?Z4FTG!
M+8/MZ9H48+< 9/;OQWIU " ;?_UT'/&/QH+ 8!.,\"DW*VP[NOW<'KQ^M 'Y
M\_\ !8 G_A4VG@<GGC/N?\]/_K?C7HW_ "%K+@']\O4X[BOV4_X+ -M^$VG_
M (\=>Y_ST_\ K?C7HV/[6LLX_P!<O7/J* /W>_X)\9_X5[;<8&S\SSST^GKT
MKZ^KY!_X)\K_ ,6^MB>\?'';YO;Z^M?7U #3&#G/(/53R#3J** "BBB@ HHH
MH **** "BBB@ HHHH *_(#_@J%S=S*>-I)"Y Z]^O3@<;1WK]?FSM..#VS7Y
M ?\ !4)A]MG1=N5SA?[H[CD]?P!Z4 ?G1X<&[Q!IG_7S'W_VA7ZN^+I/,M_#
M8#9VZ-;#:6^[D,<8W';USC"=<X.=[?E%X<Q_PD&F9X_TF/\ ]"%?J[XND+6_
MAL%LE=&M@5#[MO#''WCCKGHG7.#G>P!SU%%% !1110 4444 %%%% !1110 4
M44H5CR%)'/;TZT )1110!E?M];?^%4^'  %_XE-MN4 X_P!2F!CN>?3H/PK\
MS].YU"U&,_O5[9[CV/\ *OTR_;\)_P"%5^&PW+?V3;C[V<DPK^F,\8Y)_"OS
M-T[G4+48S^]7MGN/8_RH _HU_8Y_Y(#X;_ZY+_Z M>U+PH&<^YKQ7]CG_D@/
MAO\ ZY+_ .@+7M2\*!G/N: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\%_;<_Y-\\0\ _NR/F. ?E/&>/Y_XCWJO!?VW&Q^SU
MXC!)"F)@?^^2?SX_SU !_.M=_P#'U-_OM_.OJ;_@G+-%;_',RS[_ "4MRS^7
M*(FP%8G#DC:?]K(Q@_,*^6;O_CZF_P!]OYU]7?\ !-5VC_:!@=(9+AEBW"*,
MC<Y 8[1D@9XZD@=>10!]-4444 %%%% !1110 4444 %%%% !1110 4444 =-
MX1;;X?\ '?(7_BGI^O\ UVAK\E]8Q_:]]@8'GOC/^\:_6CPFVWP]X\(_Z%V?
M\?WL/%?DSK?_ "&K_G=_I$GS'O\ ,>: /HC_ ()\J&_:.T/@$YST)/\ (_T^
MM?T(Q@+&H'3 QD8_2OY[_P#@GRI;]HS1.&(!_NY'UZ'_ #GD5_0A'_JUQQP.
M@Q^G:@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A7Z6U^:7_!')<>$-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@ HHHH
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M4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?H=_P1[7=\4-2(&XCM@GC"Y/3MQWK\\:_0[_ ((^_P#)4-2/
M'!Z8S_<'I[^W:@#]FJ*** "BBB@ I >O&/ZTM(,\Y_"@#^?3_@H<?^,BM6&>
MWK_]?^G_ -;RCX#*?^%@V! 7.]?F/7KTKU?_ (*''_C(K5AGMZ__ %_Z?_6\
MH^ RG_A8-@0%SO7YCUZ]* /TX^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*
M.3P3EFX^NP^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^@ HHHH
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M1@\>G?CBE5@Q!&<D?4#';TS2A=RG<,ANJMCCCI31E<X'S'. 22.OKVZ_YQ0
M[ 9MPX/0\=<9XKXR_P""CQ;_ (59?;6P-I^923CU[Y_ ?2OLU01D=L\<YKXS
M_P""CS-_PJ^\RVT[#\O<CCG&><<?CCZ4 ?A/)_K&XQR>F/Z5_0'_ ,$Z?^3=
M-([<#C&,=>,=J_G\D):1B>N3G!S^M?T"_P#!.L@_L[:25&%PN ,>_I0!]/;1
M'EB0JC)] .YS2#<"0H.%&!D\'@=3U_G0ZG;A!@\GKCG!YZ>M*L8SDJ-V>O4]
M^_XG\Z !P2>,],]<#/&,]_\ )IPX[YIC;B5(4CH<>GKGGT/Z4Z-=B@9_ # '
M':@!U%%% !1110 4444 %%%% #(VW8.[=\H/ X^HI],C;=@[MWR@\#CZBGT
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MLG;C[O.WKP.^/;U/7VK\1*_;O_@DH/\ BQ9.W^[DX'H,=L]CW/2@#[MHHHH
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MF$ CN,J&Y[@'T-? -?H#^Q>N[]G37CY,+%=1B.Z1PK)DL,H.-Q/I\W!)QP6
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M1[4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1N_\
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M.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?H?_P1[!;XH:EC(.<AA]%R.G<9]*_/"OT._P""/J[OBAJ7'.>"3Q_
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MI]K;^=>_?\$Y^?B##@EMLN=JC)]_<' &.GK[UX%^TD2?C5XIS_S]-WS7OO\
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M[LYP >QZ\'^5=M7%_&#'_"O]4W*2-AY7J.#SZ_EZT ?ST?M/'=\3[X\'+O\
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MCAGTH1)(<;C'@#]#C]?KVK[C^"'[3GA3XP:'#<P:E!'>2#=]GW<]NV/>@#V
MO][^+G.5W>IXX],?B?K4B].%V\GC\>M-\L<@C([$L2>F/PX_G3@0J[B-F[&<
MXZ]* '44UG5>K <9Y/;UI0P.0#G'!H 6FLQ';'3G&>]*&#<@Y[5A>+/&6C>"
M-.DOM7O8K2-%+ RM@MWP": -E(RIX^4=.,< '@=/0_YZTYD.<C&>HW#.#C&>
MM?GA\8_^"K6D_#_Q!)I^F6ZWZ(Q7>JAPV.XQ]?TKS\?\%F%.?^)+CCC,/>@#
M]4-HSGGKGJ?3%#*6&,X'?U_^M7Y7M_P66"G TE6]Q ?2M#P]_P %A[?5-5@M
MKG31;Q2,%+M'C&?3@_E[]: /T]W.O'5CWV\=!R,>_J?6E;E03^[&,DYP5X_+
MUKS/X/\ Q^\,?%C0K6ZLM3MS=S#/D;_F.1G_ .M7IC+MW,.._ /7'?'7MQ[4
M .7NO?KC.>I-.IFTY'' ;/WCZ?X]J?0 4444 %%%% !1110!7U A;&Y)Z>6V
M<''8]Z_G5_;:S_PT3XF!.2)2._\ >8]_K7]%6H$+8W)/3RVS@X['O7\ZW[;0
M(_:(\2@Y;]Z?F.<9W,<#GIS^M '4?L&_\E-BXZR=>>P^F._MU/K7[Y>$_P#D
M7[(]C&,9.?KVYYSSWZU^!O[!JY^)L1V_=DX;'7(]?;C\^O8_OEX4&/#]GD8/
MEC(VX[?3_/3M0!KU^/?_  6-8GQUI(^8X !ZXZ''?_>XQWZ]*_82OQZ_X+'<
M^.](&\GHVWL.""<9]UY_#UH _-ROTP^#(Q^SGX,XQF6?MU^6/V_Q_H/S/K],
M/@R,?LY^#.,9EG[=?EC]O\?Z  W:*** "BBB@ HHHH **** "BBB@ HHHH *
M>YW<_>RQ^8]3]>:93W.[G[V6/S'J?KS0!Y!^WDO_ !9?X>DX/-P1QG_EXD_+
M_/K7POIVI7.DWD5W:2M!<1G<DB]0:^Y_V\?^2,?#[GO<=C_S\2?YYKX/H ]+
MC_:.^(<42QIXDNT11@*LA &!@8YXIQ_:2^(G/_%2W@_[:M[^_O\ H*\RHH ]
M-_X:2^(O'_%2WF/3S&]?K^% _:2^(G'_ !4MX?\ MJWM[^WZFO,J* /31^TE
M\1./^*EO#_VU;V]_;]30/VDOB)Q_Q4MX?^VK>WO[?J:\RHH ](N?VBOB#>6[
MP3^([J6%UVM&SD@\=_SKSR[NYKZYDN)W,LTC;G=NK$]ZBHH ZOPC\4_$_@6(
MQZ+JDMDIS]PUT0_:2^(G'_%2WA_[:M[>_M^IKS*B@#TW_AI+XBELGQ+>?3S&
M'IQU]OUH'[27Q$X_XJ6\/_;5O;W]OU->944 >FC]I+XB<?\ %2WA_P"VK>WO
M[?J:!^TE\1./^*EO#_VU;V]_;]37F5% 'IH_:2^(G'_%2WA_[:M[>_M^IH'[
M27Q%"X_X26\/3_EHW^/U_/Z8\RHH ^P?V3_VRO&'A[XA:;8:QJT][;7,ZH-[
M,Q/7CN3S@\>IK]U/#-Y_:6@V%W@AIH%8[AST^E?S0?!.(3?%3PT" P%XIPPR
M#]?2OZ4OA^H7P3HH P/LR8RN.WI@?RH Z"BBB@ HHHH *_/?_@KRV/A5:\L/
ME/4^NX9'/?H:_0BOSW_X*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/\ 8+R?V??B
M)SP'MQC _P"?F*OS\K] _P!@WG]GWXA'KAH!D]O]*BX'M0!Z51110 4444 %
M=!\._P#DH'AG_L)VO_HU:Y^N@^'?_)0/#/\ V$[7_P!&K0!\!?MDMN^.VOG?
MO_>MR/N]>HY/\_RKS/X;G'CW0><?Z6G?'>O3/VR3_P 7VU_[W^M;ACG'/KD\
M_C^5>9_#?_D?=!XS_I:>OK[4 ?JE\1MP\7/CY6^RV>#C;_RZQ?YS7+5T_P 1
ML?\ "629^8?9;/.WC_EVB]JYB@ HHHH **** .6_:0CQ^RSKLFS&=0QYFSDX
MB'&=G/7IN;&2=JYRWYMU^DG[2$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6
M_-N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OT._X(]X_P"%
MH:D#T^G(X7!S@]^.W45^>-?H=_P1]'_%SM2)&5R,D+G'W<<]OS[]Z /V:HHH
MH **** "D&><_A2TU<9;!R<\\].* /Y]?^"AQ_XR*U89[>O_ -?^G_UO*/@,
MI_X6#8$!<[U^8]>O2O5_^"AQ_P",BM6&>WK_ /7_ *?_ %O*/@,I_P"%@V!
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M_P :_HB_9=_Y([HO_7)3_P".C_/]>P /6Z*** "BBB@!N/F)P.@Y[]Z^,_\
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MMQ_G!K(^$8'_  S7\/\ '(\RZY_X##[?Y]ZU^B]-N1_$.O/;C_.#0 RBBB@
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MEYV[?XCV[5^;W[.8+?&?PN 2I-VOS#J.:_1_QQL_X3'6_+^Y]LEQ@D_Q'UH
MQ**** "BBB@ KS7]L3G]G'31U_XFDYQU[0?7^7X^GI5>:_MB<_LXZ:.O_$TG
M..O:#Z_R_'T /S\K] ?V+9/*_9UU]?.DA,FHPJ5B08FY9@KG@[0!N[_,!QSD
M?G]7W[^QFL3?L\ZT9';>NIP^7M4-DD/D$Y&!C/KR /< 'J%%%% !1110 JG
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MT+DM\H7YMP.T=<^M1W&19S@]=C<^O';F@#\-/^"C>?\ A8MX >-_(&<CY?\
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MBM%2(LI=@I8@' Y]P:_$O]MS]N+6_C9XAFTG2KJ2STRSF,:M$Q7*CIWY/O\
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M<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_0[_@CW_R5#4FVY X)QD#(7V/^0:_/&OT._P""/:[OBAJ1 W$=L$\8
M7)Z=N.] '[-4444 %%%% !2!@<@'..#2T@/7C']: /Y]/^"AQ_XR*U89[>O_
M -?^G_UO*/@,I_X6#8$!<[U^8]>O2O5_^"AQ_P",BM6&>WK_ /7_ *?_ %O*
M/@,I_P"%@V! 7.]?F/7KTH _3CXH7BW.M:?&I8_9].MX2K9PORDX7YB,88=
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M_KU]?U\@_P#!/C/_  KVVXP-GYGGGI]/7I7U]0 4444 %%%% !1110 4444
M%%%% !1110 C,%4DG '))K\@O^"H3LMY+']TX)*[\8ZCUQ^@ST!]/U^K\?\
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M<ZA:C&?WJ]L]Q['^5 ']&O['/_) ?#?_ %R7_P! 6O:E;<H([^HQ7BO['/\
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M9S&ISNX'(.<U_/?_ ,$^1N_:,T3C/.?_ *^,'\^,>O-?T(1G,:G.[@<@YS0
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "FLVT9. O<DXP*=2'/&/QH 8JG;LX48Z*",#'0'Z
MTVZ;=:3?[C=O8T[R_ESA0W4#&0&YR?UI9(P\;K_>&#G)'3% 'X3?\%'KY?\
MA95U$.2TH'8@$#Z__7Z?A\9U_0_\4_V(? ?Q;U22_P!;A::9\YR,^AS^?^>*
MX#_AUS\)%;(LO<?+_0D\9^O^(!^#XQSD?2BOW?\ ^'7?PFV@?8>>G3MUZXIQ
M_P""7_PG'W;$8.,_*![XZ=,_R% 'X/45^\7_  Z]^$NT@V0/N(P,Y!S].?\
M/%!_X)>_"7G_ $'U_@'OC^?X<4 ?@[2_+CH<X]>^?\*_>'_AU[\)O^?)1T)_
M=@_Q9_E_ATIJ_P#!+OX3#&;($]?NCMG _EF@#\'RV[_]5%?O"/\ @EY\)E _
MT($X_N <Y''Y#K_C2+_P2Z^$RG/V0$_]<QV'U]0/S/X@'X/T!L9]_:OWA/\
MP2]^$_\ SXJ><_< QT/X\Y_"E'_!+WX2AO\ CQXR,?(.GK^@_6@#\':*_>!?
M^"7?PG_Y\E'I^[!QTY]^G^<FG#_@EW\)0W_'EQD ?NQT]?T''UYYH _'W]DR
M;R?CQX:.W<3-@<9 Y'L:_HT\,D+X=TW/RCR$QGCJ!CL/_KU\S>"?^"=?PU\!
M^([36M-M0EW;G*':/7./?D#GM^%?4]M;BUMX88\!(U"].N!0!(N.0!CGTQ[T
MZFQ@JH!_F3V]>].H **** "BBB@ HHHH **** "BBB@ HHHH *:V=IQG/7C&
M3[<TZD8;E(/?T.* &*-P//RY[$GG)[_TI-GWD/(/+''7H.>,'.#^E.:3K@@!
M?O,>@Z=?PH!P H.T]@W)(!^O^<T ?'/_  4WUCR/@;<VJ@$N&(R1^..<GICN
M?8U^$%?O+_P4STN-_@)?WA/S888YYX'4 \]>G3]*_!J@":SA^T7D$7_/215Y
M]SBOVO\ ^";G[,VE^!/#*^*9+2.>:^CW!G0$ GN/T'4_SK\4]+<1ZG:,QPJS
M(2?^!"OZ#?V&_&5CK7P=TBT@8&6.)0RCDC''.!R.@S[4 ?1VWR\(@50!E5'&
M?TZ<BGLH92",@\$&D=]G.,_B.O8?C2_Q Y_"@#\E?^"N7P[N=0\1V&J:;9>7
M!%CS3&." ,9('X]L<#N#G\PW4QLRL,,IP:_9/_@J+\1=)\/Z/_95R%>YN =@
M<Y(;:.V>G'Y8Z5^-]PPDN)64Y5F)'YT ,YC8$'!'((-?O=_P3+:5OV=; RS&
M8X3YB0<\'OC/:OP0K][_ /@F8LB?L[V0D# _)C(//#<C(Y&<\\T ?6KKYGRL
M.?3D@C(Z_P"?6N>\=>)K+PIX;OIKR01KY#X8XY)![5T(16?>-I^GKT)_I7QO
M_P %-/'%QX+^$/F02O$)00=C8)'.>_/ [?7M0!^./[26L_VY\9/$MVER;B&6
MY9D^;(')XZD?D:\QJSJ.H3:I>2W5PV^60Y8Y)_G58MN__50!ZK^SG\.=4\=?
M$S05L[8S6ZW0\P[<C QG/'3G^?I7]%/P]\,V.B^#](MX[&.)TMU)W1C=DCGG
M%?EQ_P $A_ MAXBN-0OKJ"*1X6;!9?FQD]#CV_3\OUM$06'RU"XQCE1C\J "
M2&*?"R1K)MY&Y<C_ #Q7Y2_\%1?V;9K[6)O&-C:>3;QG#>4N. /_ *_YD5^K
MB[MQXXYZ]J^<?V^_*_X9WUPR(K84X9CC''(XYZ9]: /YYZ=#)Y4J/C.U@<?2
MB3_6-WY/3']*:6+<DY[4 ?M]_P $X?VA+'Q=X'LO"*,OVFR 4KC'' SQZYZ>
MIR:^Z<?,3_6OQ._X)%N__"ZYD#MLX)3&5[<]#S_AVK]LJ "BF+)N.,$'OWP<
M9P<?YYH:0+GOCT(Z\8'U.: 'T444 %%,:0*<'CW)'3'7Z4I;!Y!QQS0!#J&3
M8W('7RVQCZ'W%?SJ_MLL&_:(\3,.AE/I_>/IVQBOZ*M0_P"/&YRVT>6WS'MP
M>:_G6_;:8M^T3XF)R#YI&"0<?,3C'XF@#J/V#5S\38CM^[)PV.N1Z^W'Y]>Q
M_?+PH,>'[/(P?+&1MQV^G^>G:OP,_8-Q_P +/B]3(!T]N.W'?OV_/]\?";*O
MANR/RJ/*4GGIQW^@_0"@#9K\>O\ @L=SX[T@;R>C;>PX()QGW7G\/6OV%K\>
M?^"QS#_A.])!+'D8'\(^4_J<?IU[4 ?F[7Z8?!D8_9S\&<8S+/VZ_+'[?X_T
M'YGU^F'P9&/V<_!G&,RS]NORQ^W^/]  ;M%%% !1110 4444 %%%% !1110
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MK67)7]\O3ZBOV4_X+ -M^$VG_CQU[G_/3_ZWXUZ,=NK67)7]\O3ZB@#]WO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3B(<9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-E<8R&'H?\ /Z5_+[X#\97G@3Q-9ZQ9.4F@<,,$CH0?Z5^_/[$OQBMOB?\
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M<?@3I<WABT79J=]'A)%'('.#^@S7Y!W7[27Q%NKEYCXFO5+.7"B0X7.>GYT
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MX_#H#^5?K@W*D9Q[B@!BL6893G&,^G7/4=.*DI-HW$XYZ9I: "BBB@ HHHH
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MF#_@HTHC^-%LF-I2S1?+";=N%7@C:N,>FQ<?W5QB@#Y1HHHH **** "BBB@
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MV2XP2?XCZT 8PPW&.<>O^>U)N.W'0=_?WI** 'KNCVR#@@@@_P"?I7)_M-?
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M,\?_ *ZS_AS\-="^%?A]-)T2UCM+2/GY5"] !S^5=264A0PY.#M/)ZC^1Q0
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M_)38N.LG7GL/ICO[=3ZU^^7A/_D7[,\',:\J, \#V'^?RK\#OV#%W?$Z$X
ME W8SC*]2>PX_4U^^/A//_"/V1( )C7H!Z8]/:@#7K\>?^"QS#_A.])!+'D8
M'\(^4_J<?IU[5^PU?CW_ ,%C6)\=:2/F.  >N.AQW_WN,=^O2@#\VZ_3#X,C
M'[.?@SC&99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH *
M*** "BBB@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- '
MD'[>&?\ A2_P_P 9ZW&<8_Y^).M?!U?>/[>2_P#%E_AZ3@\W!'&?^7B3\O\
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MVZ_+'[?X_P!!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &[1110 4444 %%%%
M!1110 4444 %%%% !3W.[G[V6/S'J?KS3*>YW<_>RQ^8]3]>: /'_P!O'_DC
M'P^Y[W'8_P#/Q)_GFO@^OO#]O'_DC'P^^MQWQ_R\2?G7P?0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '<?!'_ )*QX8X!_P!,3J?Y5_2AX 7;
MX)T0;0O^B1\#Z?0?RK^:[X(X_P"%L>%\_P#/ZF*_I1\ +M\$Z(-H7_1(^!]/
MH/Y4 =!1110 4444 %?GO_P5Y;'PJM>6'RGJ?7<,CGOT-?H17Y[_ /!7EL?"
MJUY8?*>I]=PR.>_0T ?B_7Z!?L%@?\,_?$,A>C0 L3S_ ,?473_/:OS]K] _
MV#?^3??B%V^:#ISG_2HN3Z&@#TJBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#EOVD(\?LLZ[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;=?I)^TA'C]EG79-
MF,ZACS-G)Q$.,[.>O3<V,D[5SEOS;H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K]#O\ @CW_ ,E0U)MN0."<9 R%]C_D&OSQK]#O^"/:[OBA
MJ1 W$=L$\87)Z=N.] '[-4444 %%%% !35QEL')SSSTXIU(&!R <XX- '\^G
M_!0X_P#&16K#/;U_^O\ T_\ K>4? 93_ ,+!L" N=Z_,>O7I7J__  4./_&1
M6K#/;U_^O_3_ .MY1\!E/_"P; @+G>OS'KUZ4 ?IQ\4+Q;G6M/C4L?L^G6\)
M5LX7Y2<+\Q&,,.@4<G@G+-Q]=A\4+Q;G6M/C4L?L^G6\)5LX7Y2<+\Q&,,.@
M4<G@G+-Q] !1110 4444 %%%% !1110 4444 %%%% !7S!_P4;0Q_&BT0KLV
MV2J$V;=N%48QM7&/3:N.FU>@^GZ^8?\ @HVGE_&BU0KL*V:*%V[-H"J,;=JX
M^FU,=-J]  ?*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]0_\
M$ZP3^T9H_<9'&,^O^>AKY>KZ@_X)UX/[1NCC^+(POKU[=_RH _H&;JORYYZ^
MG'7_ #ZTZFMU7@GGL?;O3J "BBB@!D;;L'=N^4'@<?44^F1MNP=V[Y0>!Q]1
M3Z /F#]O9O\ BS>J#/\ !TS[#W_I_P#7_G]U#_C^N>,?O&Z8]3Z<5_0%^WLW
M_%F]4&?X.F?8>_\ 3_Z_\_NH$&^N2.GF-C'U/L* /TR^$8'_  S7\/\ '(\R
MZY_X##[?Y]ZU^B]-N1_$.O/;C_.#63\)?^3:_A^=NW]Y==O]F'V_S[UK=%Z;
M<C^(=>>W'^<&@!E%%% !1110 4444 %%%% !1110 4444 %>)_M\;/\ A7/P
M^VC:WE2Y&,?\MI.<?7//?'M7ME>*?M\LQ^&_P]# 8$4N"&S_ ,MGX]C_ (B@
M#X=K]N_^"2B_\6+)Q_=S\H]!CG&>Q[G\*_$2OV[_ ."2N!\"^F"<=NO [[?Z
MT ?=M%%% !39(UFC:-QN1@593W!IU% 'S+\4OV&? OCJ_FU.+38(KZ9MTC!<
M9ZD].?ZUY#X__P"">OA#0_AWJEY#9QB>TB,@;:01[@<<\C]:^]F8J1QQ^M<A
M\8&*_#'Q$0<?Z*P_44 ?S/\ B[3UTOQ-J5HGW8IV4=/Z5UGP!\*P>-/BIHFC
MW*EHKF4(0HR>H%<[\0SN\<:X?6Z<\#W_ ,_XGK7H7[(I9?C]X6*_>\\?S'L?
MY4 ?K19_\$Y_!ESI5E(MC&KF(,<H>XSVQW'IW^E;G@W_ ()Z>"=%UI+JXT^)
MTC8,JLO"XQV[]!T/?KBOK;2/^039?]<$_P#015N@#'\-^&M.\(Z?'IVF1+!;
MKT0MSC!Q_*MBBB@ HHHH **** "BBB@ HHHH **** .>^(3;?!&MG./]%?G.
M.WU'\Z_FL^,_'Q3\2C&/],;MCL/85_2G\0FV^"-;.<?Z*_.<=OJ/YU_-9\9^
M/BGXE&,?Z8W;'8>PH U?V<P6^,_A< E2;M?F'4<U^C_CC9_PF.M^7]S[9+C!
M)_B/K7YO_LZ[?^%R^&-Z[D^U+E<9R,],=Z_2+QX6;QIKA<%6^V2Y!()^\?2@
M#"HHHH **** "BBB@ HHHH **** "BBB@!5. W)&1V[\UO>!?E\=:#T7_3X>
MAX_U@]_\^]8*G ;DC([=^:WO OR^.M!Z+_I\/0\?ZP>_^?>@#\WOVD,?\+J\
M4XZ?:V_G7OW_  3GRWQ B&>3)QMZ\?@>1D=N_P"->!?M)$GXU>*<_P#/TW?-
M>^_\$Y\?\+"A^8\3+G:1\N,]>.,=>?4_@ ?NEHHQI-IQMS$IP!CJ*MN=JL<A
M<#JW053T/C1[/C'[I>WM]*NL<*3C/L* $4Y+<@X/;MQWIU(#UXQ_6EH *:V,
MKDX.>.>O%.I">G&?Z4 ?GQ_P6 /_ !:?3QGU_P#9O>OQKT8[=6LN2O[Y>GU%
M?LI_P6 PWPFT\'D<G'XGW_I_];\:]&.W5K+DK^^7I]10!^[W_!/E?^+?6Q/>
M/CCM\WM]?6OKZOD#_@GP /A_;X7DIRV,9^][<_\ UZ^OZ "BBB@ HHHH ***
M* "BBB@ HHHH **** $;.TXX/;-?D#_P5"RM[,!A0 <*'P5'IR?Z#TK]?FSM
M..#VS7Y ?\%0F7[5)MVA,''.<9SC )_7';\* /SG\._\C!IG_7U%_P"ABOU>
M\7-FW\-KOW[-&MEY;..&/3<<=<XPG7.#G>WY1>'#CQ!IG&?])C_]"%?J[XN;
M-OX;7?OV:-;+RV<<,>FXXZYQA.N<'.]@#GJ*** "BBB@ HHHH **** "BBB@
M HHHH **** ,S]OPG_A5?AL-RW]DVX^]G),*_IC/&.2?PK\S=.YU"U&,_O5[
M9[CV/\J_3+]OH$?"GPTH)V_V1;X! ''DIDX]^!G'?&.U?F;IW.H6HQG]ZO;/
M<>Q_E0!_1K^QS_R0'PW_ -<E_P#0%KVI<[1D8/?%>*_L<_\ ) ?#?_7)?_0%
MKVI6W*"._J,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5X-^VV2/V>_$6.#Y1PV<$':>_^>Q[5[S7@O[;F!^SUXC)_P">3=>A
M^4\?Y]#0!_.M=_\ 'U-_OM_.OJ[_ ()JNT?[0,#I#)<,L6X11D;G(#':,D#/
M'4D#KR*^4;O_ (^IO]]OYU]5?\$W;>2\^/201/Y<DD.Q9/F^4D-S\K*W'7((
M/!P10!]/4444 %%%% !1110 4444 %%%% !1110 4444 =-X1;;X?\=\A?\
MBGI^O_7:&OR8UK(UB_!7:?/D^7T^8\5^L_A%MOA_QWR%_P"*>GZ_]=H:_)?6
M,?VO?8Y'GOC/^\: /HK_ ()\KN_:.T/Y0<'KU(_0_G^HK^A&/_5KQC@=<_UK
M^>[_ ()\\_M':&,9.<_=S^N#C]/K7]",9S&ISNX'(.<T .HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAYZ"OSLK]$?^"2N/^$PO<G^(_>'';]?_ *U '[+T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5]0;98W+
M#C$;'GZ&OYU?VV@!^T5XG [2XZDG[S<G/^>*_HJU#)L;D#KY;8Q]#[BOYU?V
MVF#?M$^)B.092>W]YAU'T_6@#J?V#?\ DIL7'63KSV'TQW]NI]:_?+PG_P B
M_9G@YC7E1@'@>P_S^5?@=^P8N[XG0G  $H&[&<97J3V''ZFOWQ\)Y_X1^R)
M!,:] /3'I[4 :]?CW_P6-8GQUI(^8X !ZXZ''?\ WN,=^O2OV$K\>O\ @L=S
MX[T@;R>C;>PX()QGW7G\/6@#\W*_3#X,C'[.?@SC&99^W7Y8_;_'^@_,^OTP
M^#(Q^SGX,XQF6?MU^6/V_P ?Z  W:*** "BBB@ HHHH **** "BBB@ HHHH
M*>YW<_>RQ^8]3]>:93W.[G[V6/S'J?KS0!Y!^WDW_%E_AZ.G-P.._P#I$AYS
M_3T^M?!U?>/[>&?^%+_#_&>MQG&/^?B3K7P=0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '<?!'/\ PMCPQ@X'VQ,\]:_I0\ +M\$Z(-H7_1(^
M!]/H/Y5_-=\$3_Q=CPOQG_34_"OZ4? "[?!.B#:%_P!$CX'T^@_E0!T%%%%
M!1110 5^>_\ P5Y;'PJM>6'RGJ?7<,CGOT-?H17Y[_\ !7EL?"JUY8?*>I]=
MPR.>_0T ?B_7Z!_L&\?L^_$+AAEH#TX/^E1<]/\ /-?GY7Z!?L%_\F_?$/YL
MY:#@#C_CZBZ\?YS0!Z71110 4444 %%%% !1110 4444 %%%% !1110!RW[2
M$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-NOTD_:0CQ^RSKLFS&=0QYFS
MDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_D7O'@+;0?#LXS_ -M8:_)G6R6UJ_)Z_:),X.?XCWK]9O"+;?#_ ([Y"_\
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M:8M^T5XFSD'S.A(.!N;CVYS0!U'[!P_XN= >"=_XC@>W]?\ Z_[Y>$\#P_9
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M>)/R_P ^M?!U?>'[>/\ R1CX?<][CL?^?B3_ #S7P?0 4444 %%%% !1110
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MVKC^ZO0?3U?,'_!1M?+^-%HFSR]EDJ[=NW&%7C&U<8Z8VKC'W5Z  ^4:***
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M)G=@;3W"Y(/'^11D[>=S\\8&"<>OY>PIP^4X))/)Z4UH]W!Y'.2<9QGITZ4
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M.;@<=_\ 2)#SG^GI]:^#J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM2)&5R,D+G'W<<]OS[]Z_/&OT._X(]_\E0U)MN0."<9 R%]C_D&@#]FJ***
M"BBB@ IJXRV#DYYYZ<4ZD!Z\8_K0!_/I_P %#C_QD5JPSV]?_K_T_P#K>4?
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MZ_>QCOTSCKU[U5TO']DV6<_ZF/IGT%7: "BBB@ HHHH **** "BBB@ HHHH
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M-_\ 7)?_ $!:]J7A0,Y]S0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M-1C& !@X_I7\]_\ P3Y&[]HS1.,\Y_\ KXP?SXQZ\U_0A&NV-1C& !@X_I0
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M]EQSQ_M>W\J_?+PG_P B_9G@YC7E1@'@>P_S^5 &O7X]_P#!8UB?'6DCYC@
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M\J_3+]OPG_A5?AL-RW]DVX^]G),*_IC/&.2?PK\S=.YU"U&,_O5[9[CV/\J
M/Z-?V.?^2 ^&_P#KDO\ Z M>U*H50 , < "O%?V.?^2 ^&_^N2_^@+7M2\*!
MG/N: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\%_;<_Y-\\0\ _NR/F. ?E/&>/Y_XCWJO!?VW&Q^SUXC!)"F)@?^^2?SX_SU
M !_.M=_\?4W^^W\Z^IO^"<LT5O\ ',RS[_)2W+/Y<HB; 5B<.2-I_P!K(Q@_
M,*^6;O\ X^IO]]OYU]7?\$U7:/\ :!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>10
M!]-4444 %%%% !1110 4444 %%%% !1110 4444 =-X1;;X?\=\A?^*>GZ_]
M=H:_)?6,?VO?8&!Y[XS_ +QK]:/";;?#WCPC_H79_P ?WL/%?DSK?_(:O^=W
M^D2?,>_S'F@#Z(_X)\J&_:.T/@$YST)/\C_3ZU_0C& L:@=,#&1C]*_GO_X)
M\J6_:,T3AB ?[N1]>A_SGD5_0A'_ *M<<<#H,?IVH =1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !368J.!DGIZ?\ UJ=368JI(&<4 ,VDL/E8<Y!.#CD\_P"?6E?[PP>3CY<]
M@?K[T-E4 "@ = I/KQT'2A9 J$\#^([F/ )ZG/2@!5^>,9.=PSE3Z^A%*&+'
M@<<]>#6!J'CKPYH\@2]U>VMG4=)I,$=N_?FJ?_"UO!^X'_A(+$GH/GY^GX_K
M0!UM%<G_ ,+8\']O$5B?3$N<^P]3[4?\+8\']O$5B?3$N<^P]3[4 =917)_\
M+8\']O$5B?3$N<^P]3[4?\+8\']O$5B?3$N<^P]3[4 =917)_P#"V/!_;Q%8
MGTQ+G/L/4^U'_"V/!_;Q%8GTQ+G/L/4^U '64Q5*G&X[1TYSVQC^M<M_PMCP
M?V\16)],2YS[#U/M3?\ A:G@OI_PD.F]A_K1VZ4 =5M#2 @8P<DX[XQZ>G?V
MI58[0""S# /^/:N6_P"%K^$/^AAL?^_GY_EW].](WQ6\',I!\0V!![>9G(_J
M/_KT =2LN>HPO8GCT]?K7-^,?AUX=\>JL>MV,5Z%^4!@/K47_"UO!V[/_"1:
M>">YE S_ (]_UI#\5O!I.?\ A(]/SQR)P#Q0!R]C^S'\/M)OHKW3]#AM+J,Y
M615''3V]OYUZ/IUL;*$1@A44A>H]\#]5]_?&*Q['XD>%+ZX2"UUNRFF;A4C?
M)('I[?\ UZZ..3S5#+TZ]#R,<?TH =M^;.2/Y4ZFQXV@@[L\[N.>.M.H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *^H9-C
M<@=?+;&/H?<5_.K^VTP;]HGQ,1R#*3V_O,.H^GZU_15J&38W('7RVQCZ'W%?
MSJ_MLL&_:(\3,.AE/I_>/IVQB@#J?V#?^2FQ<=9.O/8?3'?VZGUK]\O"?_(O
MV9X.8UY48!X'L/\ /Y5^!W[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D
M $QKT ],>GM0!KU^//\ P6.8?\)WI()8\C _A'RG]3C].O:OV&K\>_\ @L:Q
M/CK21\QP #UQT.._^]QCOUZ4 ?FW7Z8?!D8_9S\&<8S+/VZ_+'[?X_T'YGU^
MF'P9&/V<_!G&,RS]NORQ^W^/]  ;M%%% !1110 4444 %%%% !1110 4444
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MS[#W_I_]?^?W4/\ C^N>,?O&Z8]3Z<5_0%^WLW_%F]4&?X.F?8>_]/\ Z_\
M/[J!!OKDCIYC8Q]3["@#],_A+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSV
MX_S@UD_"52/V:_A_D?\ +2Z[8_AA]O\ /O6MT7IMR/XAUY[<?YP: &4444 %
M%%% !1110 4444 %%%% !1110 5XI^WRS'X;_#T,!@12X(;/_+9^/8_XBO:Z
M\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M 'P[7[=_\ !)0?\6+)V_W<G ]!CMGL
M>YZ5^(E?MW_P25P/@7TP3CMUX'?;_6@#[MHHHH **** &L3QV'J.O4>U<?\
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M?'2E?&>M@G.+R7G;M_B/;M0!A4444 %%%% !1110 4444 %%%% !1110 JG
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M /0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH ****
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M64*,]2!UZ>O<4ETQ6VE(."$)!'TI_P V.P.?KQG_  J.X51:S#[J[6S@>W-
M'XC?\%"?'7BG1?B1.EAJT]K;JY 6-L$#';GWR3[]J^0/^%J>+OF_XJ"^.[KF
M7_/J?S-?5/\ P4=(_P"%C78W Y<':3Z 8/7W/Y"OBR@#JF^*OB]NOB&^/&#^
M]ZY]?7_ZU#?%7Q>W7Q#?'C!_>]<^OK_]:N5HH ZIOBKXO;KXAOCQ@_O>N?7U
M_P#K4-\5?%[=?$-\>,'][USZ^O\ ]:N5HH ZIOBKXO;KXAOCQ@_O>N?7U_\
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M>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@ HHHH
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M\#>!/!UU'X6>WO\ 6$S'M5 1'TQC'OCZ<5^8GQ^_;.\3?'[1AIVKVL=O$/\
MGB<9^OK0!\\ ;O\ ]=#8W''([9HI5;;GJ#C P<?YXH &SGD8.!VQVHXV]B<^
M^1_G^E(&*\@X[5[E\ OV4?&'QLU&TEL=/D&EF3]Y,ZD+MR._XT 4/V1WV_'G
MPTH&2TP ^7=SD>QK^C+PZOD^'[ -\H6!>HQ@8^@KY ^ _P#P3A\&_#F[TCQ!
M+$HU:!58KC.#D$] .01D?7-?9<"B&-(5*J$"J!]!T^N!Z=Z )2RE@-W(.,9[
MXZ?E3JCC8X&XGYNA;'/\N>,_C4E !1110 4444 %%%% !1110 4444 %%%%
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M_@,/M_GWK7Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ HHHH
M*\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M>UUXG^WQL_P"%<_#[:-K>5+D8Q_RV
MDYQ]<\]\>U 'P]7[=_\ !)1?^+%D[<?=YV]>!WQ[>IZ^U?B)7[@?\$E;?;\
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MO>+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH **** "BBB@
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MAEBW"*,C<Y 8[1D@9XZD@=>10!]-4444 %%%% !1110 4444 %%%% !1110
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MS/!S&O*C / ]A_G\J ->OQY_X+',/^$[TD$L>1@?PCY3^IQ^G7M7[#5^/?\
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M^#IGV'O_ $_^O_/[J!!OKDCIYC8Q]3["OZ OV]F_XLWJ@S_!TS[#W_I_]?\
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M-10!]60_\%)/BW#&D8U!=J!5&&(X'X4\?\%*/BZ,?\3!<@8^^?\ /0U\H44
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M?->^_P#!.?'_  L*'YCQ,N=I'RXSUXXQUY]3^'@7[27_ "6KQ3SN_P!*;_\
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M2OKZ@ HHHH **** "BBB@ HHHH **** "BBB@!&Y4C./<5^0/_!4-E^VW !
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M?\$Y9HK?XYF6??Y*6Y9_+E$38"L3AR1M/^UD8P?F% 'U%1110 4444 %%%%
M!1110 4444 %%%% !1110!TWA%MOA_QWR%_XIZ?K_P!=H:_)?6,?VO?8Y'GO
MC/\ O&OUH\)_\B]X\!;:#X=G&?\ MK#7Y,ZV2VM7Y/7[1)G!S_$>] 'T1_P3
MYY_:.T,8R<Y^[G]<''Z?6OZ$8SF-3G=P.0<YK^>__@GR-W[1FB<9YS_]?&#^
M?&/7FOZ$(SF-3G=P.0<YH =1110 4444 %%%% !1110 4444 %%%% !1110
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MVOE_&BT39Y>RR5=NW;C"KQC:N,=,;5QC[J]  ?*-%%% !1110 4444 %%%%
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M+TVY'\0Z\]N/\X-9/PE_Y-K^'YV[?WEUV_V8?;_/O6MT7IMR/XAUY[<?YP:
M&4444 %%%% !1110 4444 %%%% !1110 5XG^WQL_P"%<_#[:-K>5+D8Q_RV
MDYQ]<\]\>U>V5XI^WRS'X;_#T,!@12X(;/\ RV?CV/\ B* /AVBBB@ HHHH
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MN=0M1C/[U>V>X]C_ "H _HU_8Y_Y(#X;_P"N2_\ H"U[4O"@9S[FO%?V.?\
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M_P")H_X?*VO_ $"/_(9_^)K\H** /U?_ .'RMK_T"/\ R&?_ (FC_A\K:_\
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MB@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'C_[>/\
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M110 4444 %%%% !1110 4444 *IP&Y(R.W?FM[P+\OCK0>B_Z?#T/'^L'O\
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MV2C9MV[<*HQMVKMQCIM7']U>@ /E&BBB@ HHHH **** "BBB@ HHHH ****
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M^&'V_P ^]:W1>FW(_B'7GMQ_G!H 91110 4444 %%%% !1110 4444 %%%%
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M$\@!X/SFB&SGN6410R2%NFU2<UI2^#]9AMQ.^G3A",_<.>^?Y?J* ,S[7/\
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M444 %/<[N?O98_,>I^O-,I[G=S][+'YCU/UYH \@_;R7_BR_P])P>;@CC/\
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MA\W' QT_E0 ^BBB@!D;;L'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O\
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MX2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./O''7/1.N<'.]ORA\._\
M(P:9_P!?47_H8K]7O%S9M_#:[]^S1K9>6SCACTW''7.,)US@YWL <]1110 4
M444 %%%% !1110 4444 %%%/7[HX4]>I]OK0 RBBB@#,_;\)_P"%5^&PW+?V
M3;C[V<DPK^F,\8Y)_"OS-T[G4+48S^]7MGN/8_RK],OV^@1\*?#2@G;_ &1;
MX! ''DIDX]^!G'?&.U?F;IW.H6HQG]ZO;/<>Q_E0!_1K^QS_ ,D!\-_]<E_]
M 6O:ESM&>3WQ7BO['/\ R0'PW_UR7_T!:]J7A0,Y]S0 M%%% !1110 4444
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M_G^HK^A&/_5KCC@=!C].U #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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MP^]R!_%QGI['/TK\AOC-^TQXO^+6O:E->:K*=/FFWQ1 GY5SGO0!]B_MD?\
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MQ)^=?!]?>/[>3?\ %E_AZ.G-P.._^D2'G/\ 3T^M?!U !1110 4444 %%%%
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MXQM7&.F-JXQ]U>@^GZ^8?^"C:>7\:+5-OE[+-%V;=N/E7C&U<8Z8VIC^ZO0
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M\3_;XV?\*Y^'VT;6\J7(QC_EM)SCZYY[X]J /AZBBB@ HHHH **** "BBB@
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MY5^F7[?A/_"J_#8;EO[)MQ][.285_3&>,<D_A7YFZ=SJ%J,9_>KVSW'L?Y4
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MKR* /IJBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"+;?#_ ([Y"_\
M%/3]?^NT-?DOK&/[7OL<CSWQG_>-?K1X3_Y%[QX"VT'P[.,_]M8:_)G6R6UJ
M_)Z_:),X.?XCWH ^B/\ @GSS^T=H8QDYS]W/ZX./T^M?T(Q_ZM<<<#H,?IVK
M^>__ ()\C=^T9HG&><__ %\8/Y\8]>:_H0C_ -6N%V\#Y1VH =1110 4444
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MSD_X9I^'';PU:CT^4'^?O_G'%>F-(5/( '<Y. /KCT!_R:4L<_+Z'@@CD>]
M'EUQ^S3\-Q;RD^&;7&TY^7/;_/U[U^"_[8OA_3O#?QY\066E1"&RCDVJJ]."
M?<^W^>!_1I?#%A<Y;'[MOF/&.#Z8K^=7]MC)_:&\2,><RG/ ^]N8$<$T =7^
MP8P_X69 &7($N1P>F!GG'!Z?K[5^]WA'_D7;'I_JEZ?[HZU^!W[""[OB9 <E
M3YO4 >@..AZX/IWQWK]\?">?^$;L<'GR5QD' ^4?YXH UT;<JGCD9^4Y%?CW
M_P %CF'_  G>D@ECR,#^$?*?U./TZ]J_8:OQ[_X+&L3XZTD?,<  ]<=#CO\
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M\P_\%&T\OXT6J%=A6S10NW9M 51C;M7'TVICIM7H #Y0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OJ#_@G7@_M&Z./XLC"^O7MW_*OE^OJ'_@
MG7S^T9HXVYR1_7C_ "#0!_0*PR5X!P>_;CM3J:PR5X!P>_;CM30N6SM4_-GI
M@CC&??\ PH DHHHH 9&V[!W;OE!X''U%/ID;;L'=N^4'@<?44^@#Y@_;V;_B
MS>J#/\'3/L/?^G_U_P"?W4%VWUR,8Q(PP,^I]>:_H"_;V;_BS>J#/\'3/L/?
M^G_U_P"?W4/^/ZYR,?O&ZC'<]NU 'Z9_"7_DVOX?G;M_>77;_9A]O\^]:W1>
MFW(_B'7GMQ_G!K)^$JD?LU_#_(_Y:77;'\,/M_GWK6Z+TVY'\0Z\]N/\X- #
M**** "BBB@ HHHH **** "BBB@ HHHH *\4_;Y9C\-_AZ& P(I<$-G_EL_'L
M?\17M=>*?M\@CX;_  ]^<L/*EX..#YS_ *=/U]: /AVBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /V8_X(\KM^%NH\;<Y/3KRO/0<_X"OT
M-;AB<8Z#<HR3STZ=/\37YY?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49
M)YZ=.G^)H ?1110 4444 <]\0FV^"-;.<?Z*_.<=OJ/YU_-9\9^/BGXE&,?Z
M8W;'8>PK^E/XA-M\$:V<X_T5^<X[?4?SK^:SXS\?%/Q*,8_TQNV.P]A0!J?L
MZ[?^%R^&-Z[D^U+E<9R,],=Z_2+QX6;QIKA<%6^V2Y!()^\?2OS>_9SS_P +
MG\+[0"WVM< G ZU^D/CI2OC/6P3G%Y+SMV_Q'MVH PJ*** "BBB@ HHHH **
M** "BBB@ HHHH 53@-R1D=N_-;W@7Y?'6@]%_P!/AZ'C_6#W_P ^]8*G ;DC
M([=^:WO OR^.M!Z+_I\/0\?ZP>_^?>@#\W_VDB3\:O%.?^?IN^:]]_X)S_-\
M08002/-P0J9./Q!Z<]N<^U>!?M)?\EJ\4\[O]*;_ /57OO\ P3G)_P"%A0>O
MG# Q^7ZY]/Z@ _=+1?\ D$6?&/W2^OI[U;?[K<$\=%.#5/0^-(M!C_EF.W7W
MZ=ZN/]UN">.BG!H %ZMP1SW/MVIU-7JW!'/<^W:G4 %(3TXS_2D?MGD9&>,_
M3]<4*I&,!5Y)(% 'Y\_\%@"?^%3:>!R>>,^Y_P ]/_K?C7HQVZM9<E?WR]/J
M*_93_@L VWX3:?\ CQU[G_/3_P"M^->C';JUER5_?+T^HH _=W_@GP /A_;X
M7DIRV,9^][<__7KZ_KY!_P""?&?^%>VW&!L_,\\]/IZ]*^OJ "BBB@ HHHH
M**** "BBB@ HHHH **** $8X4G&?85^0/_!4+/VV91GY0>1P?^^<\ ]^.W>O
MU^8X4G&?85^0'_!4/ OIE)Y4$#<, ^^ >/R'Z4 ?G1X<&[Q!IG_7S'W_ -H5
M^KOBZ3S+?PV V=NC6PVEONY#'&-QV]<XPG7.#G>WY1>',?\ "0:9GC_28_\
MT(5^KOBZ0M;^&P6R5T:V!4/NV\,<?>..N>B=<X.=[ '/4444 %%%% !1110
M4444 %%%% !113U;"@;F'7@?3^M #**** ,S]OH$?"GPTH)V_P!D6^ 0!QY*
M9./?@9QWQCM7YFZ=SJ%J,9_>KVSW'L?Y5^F'[?6W_A5/AP !?^)3;;E ./\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36.T=0O(Z_6G44
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MB4L>PK[;_8__ ."<^K_$V^CU+Q5:2V%O;NLOE297=T.,$8XK[G_8Y_8+\/\
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MW&1WR/;U'?UK][_"F4\.V>_Y<1 G=QVR>WKFOP-_8-&[XGQ8ZK(,\#IC\_\
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MI]=PR.>_0T ?B_7Z!_L%_P#)OOQ$QR-]OGZ_:8J_/ROT#_8-R?V??B$>&PT
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MW'UV'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$8PPZ!1R>"<LW'T %%%% !1110
M4444 %%%% !1110 4444 %?,'_!1N/ROC1:)MV;;)1LV[=N%48V[5VXQTVKC
M^ZO0?3]?,'_!1I1'\:+:,+LVV: IMV[2%48QM7;]-J_[J]  ?*-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5]0_P#!.L$_M&:/W&1QC/K_ )Z&
MOEZOJ#_@G7@_M&Z./XLC"^O7MW_*@#^@9L97.>O&,^G>G4UNJ\D<]A[=Z=0
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MMNCD (QR/7T]_P"5:A8+R3CM0 M%1JYZE@1G:3D 9]OQXQ3E8MGE2/4?4\4
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M."* /IZBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"+;?#_ ([Y"_\
M%/3]?^NT-?DQK61K%^"NT^?)\OI\QXK]9_"+;?#_ ([Y"_\ %/3]?^NT-?DO
MK&/[7OL<CSWQG_>- 'T5_P $^5W?M':'\H.#UZD?H?S_ %%?T(Q_ZM>,<#KG
M^M?SW?\ !/GG]H[0QC)SG[N?UP<?I]:_H1C.8U.=W Y!SF@!U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #,Y;KNPW\/;COS_ )R*;='%M*2,_(>#]*=G+==V&_A[<=^?
M\Y%-NCBVE)&?D/!^E 'X7_\ !1UA_P +$O%)Z.#V] .F>>W;CFOBROM3_@HX
MW_%Q;L DG?\ =!YY Y_#![=#7Q70!ZA^S>LC?%72?+7<_F#'R@_A^/ICFOZ,
M_AX%7P+HWWMJVZGI@\'T'\J_G/\ V:R#\5]&0IOW3+QC/?TP?7T-?T9_#PY\
M$:*<8S;*?S[T ;8W+DL-S ;AD$\X'0C\>WX5*K;LXZ XS2,A9=I;(*X.0,GW
M]/TH52K=.N<_,3WX_G0!^=/_  4Z8-X?G)(VL<%E) 8$#=W]"?R]J_'"OV/_
M ."GS%=!G)^]@Y8^P)R.>!D'L>_7M^.% %O2=-FU:_@M849FD<+P/6OWH_8-
M_9YT/P'\+=&UMK6-]2N(PQ+*"0<9Z^Q/&?2OR _8]\(6_C#XK6=K<1K(FY3M
M;O@YQT/7 K^@OX:Z*OA_P?86<:[8UC7:,<]!_A^E '22-Y2@)M'& O\ +'XX
M'XTH5B1G('&23R<9].!VH?<V0 W<=<#IUSU]J4?-Y@897.,$<8P/:@!-V_&
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M (LO\/1TYN!QW_TB0\Y_IZ?6O@ZOO']O#/\ PI?X?XSUN,XQ_P _$G6O@Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .X^".?^%L>&,' ^V)G
MGK7]*'@!=O@G1!M"_P"B1\#Z?0?RK^:[X(G_ (NQX7XS_IJ?A7]*/@!=O@G1
M!M"_Z)'P/I]!_*@#H**** "BBB@ K\]_^"O+8^%5KRP^4]3Z[AD<]^AK]"*_
M/?\ X*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/]@U3_ ,,^_$(E1C=!AL8/_'U%
M^?\ ]:OS\K] OV"U _9^^(9(^8M!@^WVJ+\J /2Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** .6_:0CQ^RSKLFS&=0QYFSDXB'&=G/7IN;&2=JYRWYMU^
MDG[2$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OT._X(^KN^*&I<<YX)/'\!QTZ\>W2OSQK
M]#O^"/>/^%H:D#T^G(X7!S@]^.W44 ?LU1110 4444 %-7&6P<G///3BG4@/
M7C']: /Y]/\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTKU?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &9RW7=AOX>W'?G_ #D4VZQ]FESP-ASCZ4[:58')
M;J,?4C^5,N_^/6;_ '&_E0!^&'_!1YO^+B7:Y7._(&1Z#L3^OM[U\65]J?\
M!1QC_P +$O4^8Y=3@=\#^G&>/2OBN@#N_@KXHM?!_C_3]2O-OD0N&(;H<'I[
M^F,=^U?LKX9_X*:?"NQ\-V$,MX$DA@56Y&..WL>G^2*_"^B@#]Y&_P""GWPG
M4G_2R,%OXAV!_EC^7K3O^'GGPG+%?MF#DKRX.#D\?R^N#CV_!FB@#])/VY/V
MQO!OQDT66WT24,0/UQCIV.?8\U^;=%% 'MW[)GQ*TWX7_$B'5M3VBW0@G/'3
M/.<=OZX[U^MFD_\ !3KX5+I\$;72K*JA2%8  \8'UZ_7MTK\):* /WD_X>??
M"?C_ $MCG'1AW&1^>#^8_%O_  ] ^$_RXNV89YVG.>@[>_\ ,?C^#M% '[QC
M_@J#\)=N3=MP Q^8#C_.?S'XN_X>>_"C;_Q],3[,/?\ ^M^8]17X-44 ?T >
M!_\ @H=\-O'GB"UTC3KDR75P0%&>N3U'\OK7T_9RI>VJ3X5ED7.>>X&1@].G
M2OYP?V2;<7/QY\,J<X$X)QG/##V-?T9^&?E\.Z8-O6W3_P!!_#_/YT :((5@
M#@R$ ' ^OY#K3Z8'_P"!#)&5''7&/\^E/H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH CD;@Y(48.0QP<9ZY^G\QTIVTMU.T\@;3^M*!M
M_P#UTM # 'W<GC)/7\AT_&E52O\ %P. /RZG_/6G4A4-P1GO0 U) WU_'CZ^
MAP1Q3<LS X8=#QVR1QZ'H:D''?-+0 PX5N,@Y!.%ZYX_S]*20-Y8Z%QWQWQC
MCKCK[U)10!%&=FU>F>BD8P,' 'KTH5 K=,X/I[#DD]?3/O3U55Z*!QC@=O2G
M4 -^[@MR>G&>Y]*1=^TY.&QCD<9]?\FE90W4<XQGO^=.H BC^3@C:#C:O3UX
MZ^@'2G%SMW<!< Y8X^N>/2G,-RD'OZ'%&T;B<<],T (K;NHP>>Q[&FR,2I"<
MMT.W!(XSW_SS3P-O_P"NEH CW&-&+ X&XYR/7W/^?:AEPS-E@.O!)^HQ^'ZF
MGX^8'^M(J[1ZGN>Y]Z $56SR<#.<=?7N?PI](%"\ 8[TM !1110 4444 %%%
M% %?43C3[HYQ^Z;OCL?<?SK^=7]MK'_#1?B@CG]Z>00?XF&/T-?T5:@VRQN6
M'&(V//T-?SJ_MM$?\-$^)@#N E('S9XW-Q^>: .J_8,7=\3H3@ "4#=C.,KU
M)[#C]37[X^$\_P#"/V1( )C7H!Z8]/:OP-_8.'_%SH#P3O\ Q' ]OZ__ %_W
MR\)X'A^R  QY:X(!Y&..WI_+\* ->OQY_P""QS#_ (3O202QY&!_"/E/ZG'Z
M=>U?L-7X]_\ !8UB?'6DCYC@ 'KCH<=_][C'?KTH _-NOTP^#(Q^SGX,XQF6
M?MU^6/V_Q_H/S/K],/@R,?LY^#.,9EG[=?EC]O\ '^@ -VBBB@ HHHH ****
M "BBB@ HHHH **** "GN=W/WLL?F/4_7FF4]SNY^]EC\QZGZ\T >0?MY+_Q9
M?X>DX/-P1QG_ )>)/R_SZU\'5]X?MX_\D8^'W/>X['_GXD_SS7P?0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '<?!$X^+'ACDC-XG3O\ 6OZ4
M/ "[?!.B#:%_T2/@?3Z#^5?S7_!'_DK'AC@'_3$ZG^5?TH> %V^"=$&T+_HD
M? ^GT'\J .@HHHH **** "OSW_X*\MCX56O+#Y3U/KN&1SWZ&OT(K\]_^"O+
M8^%5KRP^4]3Z[AD<]^AH _%^OT#_ &#<_P##/OQ"X*_-!VX/^E1<U^?E?H%^
MP61_PS]\0\;A\T&?0_Z5%[?YYH ]+HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Y;]I"/'[+.NR;,9U#'F;.3B(<9V<]>FYL9)VKG+?FW7Z2?M(1X_99U
MV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_0[_@CZ/^+G:D2,KD9(7./NXY[?GW[U^>-?H=_P1[_Y
M*AJ3;<@<$XR!D+['_(- '[-4444 %%%% !2#/.?PI:0-G/M[4 ?SZ?\ !0X_
M\9%:L,]O7_Z_]/\ ZWE'P&4_\+!L" N=Z_,>O7I7J_\ P4./_&16K#/;U_\
MK_T_^MY1\!E/_"P; @+G>OS'KUZ4 ?IQ\4+Q;G6M/C4L?L^G6\)5LX7Y2<+\
MQ&,,.@4<G@G+-Q]=A\4+Q;G6M/C4L?L^G6\)5LX7Y2<+\Q&,,.@4<G@G+-Q]
M !1110 4444 %%%% !1110 4444 %%%% !7S#_P4;3R_C1:IM\O99HNS;MQ\
MJ\8VKC'3&U,?W5Z#Z>KY@_X*-H8_C1:(5V;;)5";-NW"J,8VKC'IM7'3:O0
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M **** "BBB@ HHHH **** "BBB@ KQ3]OEF/PW^'H8# BEP0V?\ EL_'L?\
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M6RV @G/^K7&>A/./R^M>2_LA_L#W?P/^,FJ:WJ">9IS.[6P(R!@G!R<],]*
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M^"@_[;TG@70+KPWX?@Q=3+Y<COCN1D>H_GWK]#)H%GBDB<9C<8////6OBO\
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M*MW_ ,?4W^^W\Z^IO^"<LT5O\<S+/O\ )2W+/Y<HB; 5B<.2-I_VLC&#\PH
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M]3Z[AD<]^AH _%^OT#_8+R?V??B)SP'MQC _Y^8J_/ROT#_8-Y_9]^(1ZX:
M9/;_ $J+@>U 'I5%%% !1110 4444 %%%% !1110 4444 %%%% '+?M(1X_9
M9UV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ_23]I"/'[+.NR;,9U#'F;.3B(<
M9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7Z'?\ !'M=WQ0U(@;B.V">,+D].W'>OSQK]#O^"/O_ "5#4CQP>F,_W!Z>
M_MVH _9JBBB@ HHHH *0'KQC^M+2#/.?PH _GT_X*''_ (R*U89[>O\ ]?\
MI_\ 6\H^ RG_ (6#8$!<[U^8]>O2O5_^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_
MX6#8$!<[U^8]>O2@#]./BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9
MN/KL/BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/H **** "BBB@
MHHHH **** "BBB@ HHHH *^8?^"C:>7\:+5"NPK9HH7;LV@*HQMVKCZ;4QTV
MKT'T]7S!_P %&X_*^-%HFW9MLE&S;MVX51C;M7;C'3:N/[J]  ?*-%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5]0_\$ZP3^T9H_<9'&,^O^>AK
MY>KZ@_X)UX/[1NCC^+(POKU[=_RH _H&89*\ X/?MQVH#'/W2.OI0V,KG/7C
M&?3O1L^8=P,GGDY_SF@!U%%% #(VW8.[=\H/ X^HI],C;=@[MWR@\#CZBGT
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M_9UV_P#"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I0!A4444
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M#G>P!SU%%% !1110 4444 %%%% !1110 4H4?W@.OK24H8CCCOV'>@!****
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M(^\,=/NY//Y4@S&H 4$!>B\?@!_]>C<200IVX],'G_"D+LI&<#IGC@?CW]*
M'*V[..@.,TZD4Y4'&/8TM !1110 4444 %%%% !7@O[;F!^SUXC)_P">3=>A
M^4\?Y]#7O5>#?MM\?L]^(F!VXB))7J/E//\ GV^H /YU;O\ X^IO]]OYU]7?
M\$U7:/\ :!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>17RC=_\?4W^^W\Z^JO^";M
MO)>?'I((G\N22'8LGS?*2&Y^5E;CKD$'@X(H ^GJ*** "BBB@ HHHH ****
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M'<]NU 'Z9_"52/V:_A_D?\M+KMC^&'V_S[UK=%Z;<C^(=>>W'^<&LCX1@?\
M#-?P_P <CS+KG_@,/M_GWK7Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH ***
M* "BBB@ HHHH *\4_;Y!'PW^'OSEAY4O!QP?.?\ 3I^OK7M=>)_M\;/^%<_#
M[:-K>5+D8Q_RVDYQ]<\]\>U 'P]1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '[,?\ !'E=OPMU'C;G)Z=>5YZ#G_ 5^AK<,3C'0;E&2>>G
M3I_B:_/+_@CRNWX6ZCQMSD].O*\]!S_@*_0UN&)QCH-RC)//3IT_Q- #Z***
M "BBB@#GOB$VWP1K9SC_ $5^<X[?4?SK^:SXS\?%/Q*,8_TQNV.P]A7]*?Q"
M;;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["@#5_9SS_PN?POM +?:
MUP"<#K7Z0^.E*^,];!.<7DO.W;_$>W:OS>_9S!;XS^%P"5)NU^8=1S7Z/^.-
MG_"8ZWY?W/MDN,$G^(^M &)1110 4444 %%%% !1110 4444 %%%% "J<!N2
M,CMWYK>\"_+XZT'HO^GP]#Q_K![_ .?>L%3@-R1D=N_-;W@7Y?'6@]%_T^'H
M>/\ 6#W_ ,^] 'YO_M)?\EJ\4\[O]*;_ /57F=>E_M(8_P"%U>*<=/M;?SKS
M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH */X0<_A110!]/_L([6^)
M-N&4-^^[@'!VY!]NA].W7%?OAX34KX;L2 ,F%2/^^1[?XU^!O["BEOB5;DY(
M\T#E=PXP>WN<^F<'M7[Z>% 5\,Z?@ DPAN@ R>>PH UMHW XYZ9I:** "BBB
M@!&8*I). .237Y ?\%0B/MDRG8"N05+<J?3 /]!VK]?V&Y2#W]#BOR!_X*A3
M;KR=MQ_ C)SGGKG'_ 1G\L 'YS^'!N\0:9_U\Q]_]H5^KOBZ3S+?PV V=NC6
MPVEONY#'&-QV]<XPG7.#G>WY1>',?\)!IF>/])C_ /0A7ZN^+I"UOX;!;)71
MK8%0^[;PQQ]XXZYZ)US@YWL <]1110 4444 %%%% !1110 4444 %%%% !11
M10!E?M];?^%4^'  %_XE-MN4 X_U*8&.YY].@_"OS/TXXU"U.<?O5[X[CW'\
MZ_3+]OPG_A5?AL-RW]DVX^]G),*_IC/&.2?PK\SM-R=2M0.OFIC'U'N* /Z-
M/V.?^2 ^&_\ KDO_ * M>T)D_-T!YP<_AUZ<=J\7_8Y'_&/OAD^L0Z@C^$?Y
MXKVI3E0<8]C0 SF-3C:.IR ?Y=Z=N;D[>G09Y-.HH \U^-'P/\._&3PCJ6DZ
ME8PRW%PA59V&61L''?\ VJ_/JZ_X(TQS7,LB:WL1G9E0/C .<#V[?Y'/ZGT4
M ?C#^T)_P2[;X,_#B^\3)JK7 MN2-V0!@=3GKU_*OSUK^@__ (*$2F/]G76@
M'VAE/&.3T']?UZ>G\^% 'N7[)?[.K?M(>/O^$>64P\ E]VT#\?4_TK[B?_@C
M*!G;KC$<8'F#U/OZ8_7KW\+_ ."3\K0_'P.%R JG[N>F3C/;@&OW(H ^*?V4
M?^"<V@_ 37+G4M5\O6)FY3S,-CV]?3TK[/MK.&SMXH((UCAC^ZN,XZ]/SJ>B
M@"&./RP#L!("\@\^GMQ]/4\4\LVX@#L<9Z'IW[4^B@ HHHH **** "BBB@ H
MHHH *\%_;<_Y-\\0\ _NR/F. ?E/&>/Y_P"(]ZKP7]MQL?L]>(P20IB8'_OD
MG\^/\]0 ?SK7?_'U-_OM_.OJ;_@G+-%;_',RS[_)2W+/Y<HB; 5B<.2-I_VL
MC&#\PKY9N_\ CZF_WV_G7U=_P35=H_V@8'2&2X98MPBC(W.0&.T9(&>.I('7
MD4 ?35%%% !1110 4444 %%%% !1110 4444 %%%% '3>$6V^'_'?(7_ (IZ
M?K_UVAK\E]8Q_:]]@8'GOC/^\:_6CPFVWP]X\(_Z%V?\?WL/%?DSK?\ R&K_
M )W?Z1)\Q[_,>: /HC_@GRH;]H[0^ 3G/0D_R/\ 3ZU_0C& L:@=,#&1C]*_
MGO\ ^"?*EOVC-$X8@'^[D?7H?\YY%?T(1_ZM<<<#H,?IVH =1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %-8AOD(W9ZCCISUIU-<!OD/?VR,>E #3(?]WC=CJ??
M@?YYI74?>.<#DCKT]O\ #TIG/1SCUY*^HXY[\<?UIX^9LC *D@YY/_UNQH 1
M54X4\E>V[/&>#^E><?%/]H#P=\)E>'7=3BMKLH2D+.%+<=OQ]*X_]I[]J30/
M@-X5OFN;D+J^S]S#G#9YYX['&,^]?A;\?_VCO$OQZ\82:UJ=W-& 2(XTD( &
M>.![?SH ^ZOC3_P5BUGP[XQGLO#40N[),_..![=\?_6K@O\ A[_XZY_T#]??
M_>]*_/F1G9LN6+'G+=:;0!^@W_#X#Q[S_P 2X=./G[_G0W_!8#QYSC3\^F6]
M_KZ5^?-% 'Z#?\/@/'G_ $#_ %_B_+O1_P /@/'G_0/]/XOS[U^?-% 'Z#?\
M/@/'N/\ D'#./[_?/U]*</\ @K]XZVG-CENW8'C_ 'N/UK\]Z* /U!^"/_!4
MCQ?\0OB7I.A7]LT=K=2!#\V.I '0GZ]^I'I7ZMZ/=&]TJSN&&#+$KG.>XK^<
MC]D-%D^/7AL,N[]Z"!MSSN7V-?T8>&HQ'X?TY1R/(3^7^?\ Z] %]6)VYX/0
MC:>N,U)3-S%L8 [D\GO_ (?E3Z "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"OJ!"V-R3T\MLX..Q[U_.M^VUG_AHGQ-GG]Z
M<G;@9W'/]/SK^BG43C3[HYQ^Z;OCL?<?SK^=7]MK'_#1?B@CG]Z>00?XF&/T
M- '4_L&_\E,B&/\ EH#D9[+CGC_:]OY5^^7A/_D7[,\',:\J, \#V'^?RK\#
M?V#?^2FQ<=9.O/8?3'?VZGUK]\O"?_(OV9X.8UY48!X'L/\ /Y4 :]?CS_P6
M.8?\)WI()8\C _A'RG]3C].O:OV&K\>_^"QK$^.M)'S'  /7'0X[_P"]QCOU
MZ4 ?FW7Z8?!D8_9S\&<8S+/VZ_+'[?X_T'YGU^F'P9&/V<_!G&,RS]NORQ^W
M^/\ 0 &[1110 4444 %%%% !1110 4444 %%%% !3W.[G[V6/S'J?KS3*>YW
M<_>RQ^8]3]>: /'_ -O'_DC'P^Y[W'8_\_$G^>:^#Z^\/V\?^2,?#[ZW'?'_
M "\2?G7P?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<?!'_D
MK'AC@'_3$ZG^5?TH> %V^"=$&T+_ *)'P/I]!_*OYKO@CC_A;'A?/_/ZF*_I
M1\ +M\$Z(-H7_1(^!]/H/Y4 =!1110 4444 %?GO_P %>6Q\*K7EA\IZGUW#
M(Y[]#7Z$5^>__!7EL?"JUY8?*>I]=PR.>_0T ?B_7Z!_L&_\F^_$+M\T'3G/
M^E1<GT-?GY7Z!_L&\?L^_$+AAEH#TX/^E1<]/\\T >E4444 %%%% !1110 4
M444 %%%% !1110 4444 <M^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5SEO
MS;K])/VD(\?LLZ[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?H=_P1[Q_PM#4@>GTY'"X.<'OQVZB
MOSQK]#O^"/H_XN=J1(RN1DA<X^[CGM^??O0!^S5%%% !1110 4@/7C']:6D&
M><_A0!_/I_P4./\ QD5JPSV]?_K_ -/_ *WE'P&4_P#"P; @+G>OS'KUZ5ZO
M_P %#C_QD5JPSV]?_K_T_P#K>4? 93_PL&P("YWK\QZ]>E 'Z<?%"\6YUK3X
MU+'[/IUO"5;.%^4G"_,1C##H%')X)RS<?78?%"\6YUK3XU+'[/IUO"5;.%^4
MG"_,1C##H%')X)RS<?0 4444 %%%% !1110 4444 %%%% !1110 5\P?\%&U
M\OXT6B;/+V62KMV[<85>,;5QCIC:N,?=7H/I^OF'_@HVGE_&BU3;Y>RS1=FW
M;CY5XQM7&.F-J8_NKT !\H4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7U!_P $Z\']HW1Q_%D87UZ]N_Y5\OU]0_\ !.OG]HS1QMSDC^O'^0:
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M5+P<<'SG_3I^OK0!\.T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110 4444 %%%% !1110!].?L)J&^)5OE0?WPZQEO[O\
MGMCK[5^^?A4!O#-B H),"Y## /%?@9^PF WQ*MP0"/.!Z%B/NX.,''/?Z^E?
MOIX5RWA?3P54GR -I/!XH V**** "BBB@!&&Y2#W]#BOR!_X*A,TE[,=V[()
M!4\X/MGH>YVC^E?K\PW*0>_H<5^0'_!4)@]Y,<ARV3\S'VY'..?H.5H _.?P
M[_R,&F?]?47_ *&*_5[Q<V;?PVN_?LT:V7ELXX8]-QQUSC"=<X.=[?E%X<./
M$&F<9_TF/_T(5^KOBYLV_AM=^_9HULO+9QPQZ;CCKG&$ZYP<[V .>HHHH **
M** "BBB@ HHHH **** "GJN5!VL>O(^G]*910 4444 9G[?0(^%/AI03M_LB
MWP" ./)3)Q[\#..^,=J_,W3N=0M1C/[U>V>X]C_*OTP_;ZV_\*I\.  +_P 2
MFVW* <?ZE,#'<\^G0?A7YGZ=SJ%J,9_>KVSW'L?Y4 ?T:?L<C'P!\-XX'E#@
M #^%3G]:]J3[J\D\=6&#7BW['/\ R0'PW_UR7_T!:]J7.T9&#WQ0 M%%% !1
M110!\R?\%"F/_#.^K@''!/7'H/4>I_SFOY\J_H-_X*%,?^&=]7 ..">N/0>H
M]3_G-?SY4 ?;W_!*+_DO7N$4CZY&/I]>U?N57X:_\$HO^2]'_<'\^A]J_<J@
M HHHH **** "BBB@ HHHH **** "BBB@ KP;]MLD?L]^(L<'RCALX(.T]_\
M/8]J]YKP7]MS _9Z\1D_\\FZ]#\IX_SZ&@#^=:[_ ./J;_?;^=?57_!-VWDO
M/CTD$3^7))#L63YOE)#<_*RMQUR"#P<$5\JW?_'U-_OM_.OJ;_@G+-%;_',R
MS[_)2W+/Y<HB; 5B<.2-I_VLC&#\PH ^HJ*** "BBB@ HHHH **** "BBB@
MHHHH **** .F\(MM\/\ COD+_P 4]/U_Z[0U^3&M9&L7X*[3Y\GR^GS'BOUG
M\(MM\/\ COD+_P 4]/U_Z[0U^2^L8_M>^QR//?&?]XT ?17_  3Y7=^T=H?R
M@X/7J1^A_/\ 45_0C'_JUQQP.@Q^G:OY[O\ @GSS^T=H8QDYS]W/ZX./T^M?
MT(Q_ZM<<<#H,?IVH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_A']. &W$"#!ZCCIT%>$^$OV%?ACX+UR'5=.TQ8[N+E&V \YSWS_DU]!6L
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MD9Z8[U^D7CPLWC37"X*M]LER"03]X^E &%1110 4444 %%%% !1110 4444
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M\H/(X/\ WSG@'OQV[T ?G/X<8KX@TP@X_P!)C'_CPK]7?%KAK;PTJGY5T:V
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MU_0C'_JUXQP.N?ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)Z<9_I2TC9
MVG'![9H 8J[E (8#;C[QS_GWJMK.GKJVF7%HXRLJ[2#TY]:L;51B"<;@%"J,
M$ <=N>_X4X94GY0<GJO!_P XQ0!^%O\ P4N^%\'PY^(R>5&$-S)OZ\\@GOSW
MS^/M7Q97[,_\%,/V2]:^+UJWB[3-[#3HPY1,MD8.?EZ@^W]>OXVWUC/IMY+;
M7,;131L596'<'% '[F?\$JW)_9_C#*%.4/S+ACP1UP/Z^QK[1:09.&&T<E@1
MQUSGVXQ7Y+?\$R_VOM&\&QV7@'49%A%QCYY!@[N!Z<^Y_2OUBL]3M-2C$MI<
M)<KC<#$^0>W^?PH M;AN SSUQ0K;E!'?U&*3:2,$]\\<=Z%7:H'&!TP,#':@
M!U%%% !3?,&TG#=,_=-.INT<<9P<C/- #=Y+$?*.<<9/OSZ<?S_,:,MN'?!
M;N,]N/PI6RP8;01@C:W1O_K4X=^<_P!* $"GKG'.<9SGM3JCV[G)].^.1TX'
M'0_Y]I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG&,RS]NORQ^W^/\ 0?F?7Z8?!D8_9S\&<8S+/VZ_+'[?X_T !NT444 %%%%
M!1110 4444 %%%% !1110 4]SNY^]EC\QZGZ\TRGN=W/WLL?F/4_7F@#R#]O
M)?\ BR_P])P>;@CC/_+Q)^7^?6O@ZOO#]O'_ )(Q\/N>]QV/_/Q)_GFO@^@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .X^")Q\6/#')&;Q.G?
MZU_2AX 7;X)T0;0O^B1\#Z?0?RK^:_X(_P#)6/#' /\ IB=3_*OZ4/ "[?!.
MB#:%_P!$CX'T^@_E0!T%%%% !1110 5^>_\ P5Y;'PJM>6'RGJ?7<,CGOT-?
MH17Y[_\ !7EL?"JUY8?*>I]=PR.>_0T ?B_7Z!_L&Y/[/OQ"/#8: 9[K_I47
M']:_/ROT#_8-4_\ #/OQ")48W08;&#_Q]1?G_P#6H ]*HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y;]I"/'[+.NR;,9U#'F;.3B(<9V<]>FYL9)VKG+
M?FW7Z2?M(1X_99UV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_0[_ ((^_P#)4-2/'!Z8S_<'I[^W
M:OSQK]#_ /@CV"WQ0U+&0<Y##Z+D=.XSZ4 ?LS1110 4444 %-7&6P<G///3
MBG4@/7C']: /Y]/^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_X6#8$!<[U^8]>O2O
M5_\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTH _3CXH7BW.M:
M?&I8_9].MX2K9PORDX7YB,88= HY/!.6;CZ[#XH7BW.M:?&I8_9].MX2K9PO
MRDX7YB,88= HY/!.6;CZ "BBB@ HHHH **** "BBB@ HHHH **** "OF#_@H
MW'Y7QHM$V[-MDHV;=NW"J,;=J[<8Z;5Q_=7H/I^OF#_@HTHC^-%M&%V;;- 4
MV[=I"J,8VKM^FU?]U>@ /E&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_K![_P"?>@#\W_VDO^2U>*>=W^E-_P#JKS.O2_VD,?\ "ZO%..GVMOYUYI0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TY^PF/^+E6YVY/G#H
M"#_#W /]/<X-?OGX5POABP RN(!]U?;.1ZU^!G["?_)2K<X+?OAP-W'W><@'
M^GN<&OWT\*D_\(S89X_<+@KR>GIB@#8HHHH **** $8X4G&?85^0'_!4+_C\
MFCPS;<D  #/3G&>!P.,#H:_7]F"J23@#DDU^0'_!4(@7LZ9^89+1EN ?SX/T
M S[]* /SH\.8_P"$@TS/'^DQ_P#H0K]7?%TA:W\-@MDKHUL"H?=MX8X^\<=<
M]$ZYP<[V_*'P[_R,&F?]?47_ *&*_5[Q<V;?PVN_?LT:V7ELXX8]-QQUSC"=
M<X.=[ '/4444 %%%% !1110 4444 %%%% !3U/RCE1UZCV^E,HH **** ,K]
MOK;_ ,*I\.  +_Q*;;<H!Q_J4P,=SSZ=!^%?F?IW.H6HQG]ZO;/<>Q_E7Z9?
MM^$_\*K\-AN6_LFW'WLY)A7],9XQR3^%?F;IW.H6HQG]ZO;/<>Q_E0!_1K^Q
MS_R0'PW_ -<E_P#0%KVI>% SGW->*_L<_P#) ?#?_7)?_0%KVE,;5VC"XX&,
M?I0 ZBBB@ HHHH ^9/\ @H4Q_P"&=]7 ..">N/0>H]3_ )S7\^5?T&_\%"F/
M_#.^K@''!/7'H/4>I_SFOY\J /M[_@E%_P EZ/\ N#^?0^U?N57X:_\ !*+_
M )+T?]P?SZ'VK]RJ "BBB@ HHHH **** "BBB@ HHHH **** "O!?VW&Q^SU
MXC!)"F)@?^^2?SX_SU'O5>#?MMDC]GOQ%C@^4<-G!!VGO_GL>U '\ZMW_P ?
M4W^^W\Z^IO\ @G+-%;_',RS[_)2W+/Y<HB; 5B<.2-I_VLC&#\PKY9N_^/J;
M_?;^=?5W_!-5VC_:!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>10!]-4444 %%%%
M!1110 4444 %%%% !1110 4444 =-X3;;X>\>$?]"[/^/[V'BOR9UO\ Y#5_
MSN_TB3YCW^8\U^LWA%MOA_QWR%_XIZ?K_P!=H:_)C6LC6+\%=I\^3Y?3YCQ0
M!]%?\$^5+?M&:)PQ /\ =R/KT/\ G/(K^A"/_5KQC@=<_P!:_GN_X)\KN_:.
MT/Y0<'KU(_0_G^HK^A&/_5KQC@=<_P!: '4444 %%%% !1110 4444 %%%%
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M/@!=O@G1!M"_Z)'P/I]!_*OYK_@CG_A;'AC!P/MB9YZU_2AX 7;X)T0;0O\
MHD? ^GT'\J .@HHHH **** "OSW_ ."O+8^%5KRP^4]3Z[AD<]^AK]"*_/?_
M (*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0+]@M0/V?OB&2/F+08/M]JB_*OS]K]
M _V#<_\ #/OQ"X*_-!VX/^E1<T >E4444 %%%% !1110 4444 %%%% !1110
M 4444 <M^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5SEOS;K])/VD(\?LLZ
M[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444
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MJ@S_  =,^P]_Z?\ U_Y_=0(-]<D=/,;&/J?85_0%^WLW_%F]4&?X.F?8>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO?M(8_X75XIQT^UM_.O-*],_:2)/QJ\4Y_Y^F[YKS.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /IW]A-=WQ,MAM5\2Y(/..!S[>Q[GBOWS\*
MY;PS8 JI_<* ">#QWK\#/V$UW_$NW&U7Q,&VGMQU[_TYQSZ?OEX47_BE]/&Q
M>8!\O8_7CO0!LT444 %%%% "-G:<<'MFOR _X*@L/MDH7;C&5'8+^)_H/TK]
M?V&Y2#W]#BOR!_X*A,6O[@$ODY8J?F!]\9X_[Y'<T ?G/X<&[Q!IG_7S'W_V
MA7ZN^+I/,M_#8#9VZ-;#:6^[D,<8W';USC"=<X.=[?E%X<Q_PD&F9X_TF/\
M]"%?J[XND+6_AL%LE=&M@5#[MO#''WCCKGHG7.#G>P!SU%%% !1110 4444
M%%%% !1110 4]6PH&YAUX'T_K3** "BBB@#,_;\)_P"%5^&PW+?V3;C[V<DP
MK^F,\8Y)_"OS%K].OV^@1\*?#2@G;_9%O@$ <>2F3CWX&<=\8[5^8M !110.
M>^* "BE9MW8 9S@4E !1110 4JJ6!(QQZD"DH'?G']: "BBB@ HHHH ****
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MNY;'- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (4 =3^P;_R4R(8_Y: Y&>RXYX_VO;^5?OEX3_Y%^S/!S&O*C / ]A_G\J_
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M@YR&'T7(Z=QGTK\\*_0[_@CZN[XH:EQSG@D\?P''3KQ[=* /V:HHHH ****
M"D&><_A2TU<9;!R<\\].* /Y]?\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V
M! 7.]?F/7KTKU?\ X*''_C(K5AGMZ_\ U_Z?_6\H^ RG_A8-@0%SO7YCUZ]*
M /TX^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^NP^*%XMSK6GQJ
M6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^@ HHHH **** "BBB@ HHHH ****
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M])G[+WC";QQ\'-$U2YD$EQ-&&;UY4'G\<UZOM+,"0O&??Z'\OYU^:W_!+_\
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M7!S@]^.W45^>-?H=_P $?1_Q<[4B1E<C)"YQ]W'/;\^_>@#]FJ*** "BBB@
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MA+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSVX_S@T ,HHHH **** "BBB@
MHHHH **** "BBB@ KQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^6
M8_#?X>A@,"*7!#9_Y;/Q['_$4 ?#M%%% !1110 4444 %%%% !1110 4444
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MG_G]3%?TH^ %V^"=$&T+_HD? ^GT'\J_FO\ @CG_ (6QX8P<#[8F>>M?TH>
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MU_;.TXX/;-?D#_P5"_X_9D!P "1'S@ >O.<_@/?I0!^<_APX\0:9QG_28_\
MT(5^KOBYLV_AM=^_9HULO+9QPQZ;CCKG&$ZYP<[V_*+PXQ7Q!IA!Q_I,8_\
M'A7ZN^+7#6WAI5/RKHUL N?N\,<8W';USC"=<X.=[ '/4444 %%%% !1110
M4444 %%%% !2AF' ) Y[^O6DHH **** ,K]OK;_PJGPX  O_ !*;;<H!Q_J4
MP,=SSZ=!^%?F/7Z=?M^$_P#"J_#8;EO[)MQ][.285_3&>,<D_A7YBT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!U"_
MLZZ%@8XYXQ_0?RK^>:$XE0YQ\P]OZBOZ&?V!UV_LZZ%].F,8]N@H ^C:***
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M8]?\:^1_VW_VRM+^"/@>[M-+NE?7I 8Q""-X/';.>F[GU'M7O?QN^)=K\)/
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M$JD?LU_#_(_Y:77;'\,/M_GWK6Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH
M**** "BBB@ HHHH *\4_;Y9C\-_AZ& P(I<$-G_EL_'L?\17M=>*?M\@CX;_
M  ]^<L/*EX..#YS_ *=/U]: /AVBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /V8_X(\KM^%NH\;<Y/3KRO/0<_X"OT-;AB<8Z#<HR3STZ=
M/\37YY?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49)YZ=.G^)H ?1110
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M:S%>BEN,\8_*E!Z\8_K0 M%-W'.-IZXSQZ=:=0 4444 %%%% !1110 4444
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M*=\RXP=W8[NI]_YT ?E__P %5OVC/%?P\UB#PII$KV]CJ$6)9 Q&>IP"/P_
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M@SC&99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH ****
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MGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^68_#?X>A@,"*7!#9_Y;/Q['_$4
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MOV:-;+RV<<,>FXXZYQA.N<'.]@#GJ*** "BBB@ HHHH **** "BBB@ HHHH
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M_A9L7IYF>GH/I[^OKZ\_OEX3_P"1?LSP<QKRHP#P/8?Y_*OP._8,7=\3H3@
M"4#=C.,KU)[#C]37[X^$\_\ "/V1( )C7H!Z8]/:@#7K\>_^"QK$^.M)'S'
M /7'0X[_ .]QCOUZ5^PE?CU_P6.Y\=Z0-Y/1MO8<$$XS[KS^'K0!^;E?IA\&
M1C]G/P9QC,L_;K\L?M_C_0?F?7Z8?!D8_9S\&<8S+/VZ_+'[?X_T !NT444
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MCQ^RSKLFS&=0QYFSDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%%
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M_0C&<QJ<[N!R#G- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^#J^\/V\?^2,?#[GO<=C_P _$G^>:^#Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH [CX(G'Q8\,<D9O$Z=_K7]*'@!=O@G1!M"_Z)'P/I]!_*
MOYK_ ((_\E8\,< _Z8G4_P J_I0\ +M\$Z(-H7_1(^!]/H/Y4 =!1110 444
M4 %?GO\ \%>6Q\*K7EA\IZGUW#(Y[]#7Z$5^>_\ P5Y;'PJM>6'RGJ?7<,CG
MOT- 'XOU^@?[!O\ R;[\0CA3AH!G'(_TJ+CI_GBOS\K] OV"P/\ AG[XAD+T
M: %B>?\ CZBZ?Y[4 >ET444 %%%% !1110 4444 %%%% !1110 4444 <M^T
MA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5SEOS;K])/VD(\?LLZ[)LQG4,>9L
MY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?H=_P1[7=\4-2(&XCM@GC"Y/3MQWK\\:_0[_@C[_R5#4CQP>F,_W!
MZ>_MVH _9JBBB@ HHHH *0'KQC^M+2#/.?PH _GT_P""AQ_XR*U89[>O_P!?
M^G_UO*/@,I_X6#8$!<[U^8]>O2O5_P#@H<?^,BM6&>WK_P#7_I_];RCX#*?^
M%@V! 7.]?F/7KTH _3CXH7BW.M:?&I8_9].MX2K9PORDX7YB,88= HY/!.6;
MCZ[#XH7BW.M:?&I8_9].MX2K9PORDX7YB,88= HY/!.6;CZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "OF'_@HVGE_&BU0KL*V:*%V[-H"J,;=JX^FU,=-J
M]!]/5\P?\%&X_*^-%HFW9MLE&S;MVX51C;M7;C'3:N/[J]  ?*-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5]0?\$Z\']HW1Q_%D87UZ]N_P"5
M?+]?4/\ P3KY_:,T<;<Y(_KQ_D&@#^@8YXP/K2TUADKP#@]^W':G4 %%%% #
M(VW8.[=\H/ X^HI],C;=@[MWR@\#CZBGT ?,'[>S?\6;U09_@Z9]A[_T_P#K
M_P _NH?\?USD8_>-U&.Y[=J_H"_;V;_BS>J#/\'3/L/?^G_U_P"?W4/^/ZYX
MQ^\;ICU/IQ0!^F?PE_Y-K^'YV[?WEUV_V8?;_/O6MT7IMR/XAUY[<?YP:R?A
M*I'[-?P_R/\ EI==L?PP^W^?>M;HO3;D?Q#KSVX_S@T ,HHHH **** "BBB@
M HHHH **** "BBB@ KQ3]OEF/PW^'H8# BEP0V?^6S\>Q_Q%>UUXI^WR"/AO
M\/?G+#RI>#C@^<_Z=/U]: /AVBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /V8_X(\KM^%NH\;<Y/3KRO/0<_X"OT-;AB<8Z#<HR3STZ=/\
M37YY?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49)YZ=.G^)H ?1110 44
M44 <]\0FV^"-;.<?Z*_.<=OJ/YU_-9\9^/BGXE&,?Z8W;'8>PK^E/XA-M\$:
MV<X_T5^<X[?4?SK^:SXS\?%/Q*,8_P!,;MCL/84 :G[.NW_A<OAC>NY/M2Y7
M&<C/3'>OTB\>%F\::X7!5OMDN02"?O'TK\WOV<\_\+G\+[0"WVM< G ZU^D/
MCI2OC/6P3G%Y+SMV_P 1[=J ,*BBB@ HHHH **** "BBB@ HHHH **** %4X
M#<D9';OS6]X%^7QUH/1?]/AZ'C_6#W_S[U@J<!N2,CMWYK>\"_+XZT'HO^GP
M]#Q_K![_ .?>@#\W_P!I(D_&KQ3G_GZ;OFO,Z],_:2_Y+5XIYW?Z4W_ZJ\SH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z=_837?\2[<;5?$P
M;:>W'7O_ $YQSZ?OEX4^7POI_&S]P#\@S^/3K7X&_L)KO^)=N-JOB8-M/;CK
MW_ISCGT_?/PG\WAC3AN;_4CG'(_2@#8HHHH **** $9@JDDX Y)-?D#_ ,%0
MV9;J53\N"P()RH/'&!QGGK@=17Z_U^0'_!4)0M[,.!P3R>GT!(QT_NC^E 'Y
MS^',?\)!IF>/])C_ /0A7ZN^+I"UOX;!;)71K8%0^[;PQQ]XXZYZ)US@YWM^
M4/AW_D8-,_Z^HO\ T,5^KWBYLV_AM=^_9HULO+9QPQZ;CCKG&$ZYP<[V .>H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH S/V^@1\*?#2@G;_9%O@$ <>2
MF3CWX&<=\8[5^8M?IQ^WUM_X53X<  7_ (E-MN4 X_U*8&.YY].@_"OS'H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T)Q*ASCYA[?U%?T,_L
M#_\ )NNA#&,#'3']!7\\T)Q*ASCYA[?U%?T-?L#\?LZZ",8X],?T'\J /HRB
MBB@ HHHH *\%_;<;'[/7B,$D*8F!_P"^2?SX_P ]1[U7@W[;9(_9[\18X/E'
M#9P0=I[_ .>Q[4 ?SJW?_'U-_OM_.OJK_@F[;R7GQZ2")_+DDAV+)\WRDAN?
ME96XZY!!X."*^5;O_CZF_P!]OYU]3?\ !.6:*W^.9EGW^2EN6?RY1$V K$X<
MD;3_ +61C!^84 ?45%%% !1110 4444 %%%% !1110 4444 %%%% '3>$VV^
M'O'A'_0NS_C^]AXK\F=;_P"0U?\ .[_2)/F/?YCS7ZS>$6V^'_'?(7_BGI^O
M_7:&OR8UK(UB_!7:?/D^7T^8\4 ?17_!/E2W[1FB<,0#_=R/KT/^<\BOZ$$S
MM7=RV.:_GN_X)\KN_:.T/Y0<'KU(_0_G^HK^A&-=L:C&, #!Q_2@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %1R-M_BV\'TR.G//I4E-8D#CU';/>@!H).XD,<$D#./48[?
MKZTBGY@%+,G!!SGC![_AZYYI<&10&R&VY/ QGU[\C%'&U2"PYSSGO[?C^'X4
M )_K<'"] <\D=<_TZT\*I7;C(7'WN?Y]:X[XA?%;PU\++%;OQ#J$=G%CAG8<
M ],Y/T_SQ7B7Q"_;V^'&A>&[FXTK6H+NZ"_(%?)SUZ ^Q]!0!]/\[AZ5Q/C/
MXS>$OA_,(M=U:&P;G_6.N!CUYXK\E?%7_!6SQRNM7L6FQ;K$2%4RQ^Z#CN?3
MZ9_6OE;XY?M,>*OCAK O=3O)X0"3M65N2<Y/7CMTH _8+]HW_@H+X3^&^CR2
M^'M12_N% _U>#SS_ +6/7\O3%?"7Q)_X*J>+_'/A6^T5+=K9;A=HFCX89SWS
MQQCISR?7-?"=QJ%U=\3W,TW?]XY;^=04 ;]YX^\17UQ+-+J]T6E8LP$A .>O
M%8<T\MU*TLTC2R-RSNQ)/U)IE% !0!N__75W2='N]:N#!:1-+(!G !-,U#3;
MC2[IK>Z3RI5ZA@?<?S!% %>.0QMD''XD?Y_^M6[X5\"ZWXUN/(T>QDO)<X"H
M"2?IZU@5^A/_  2?T.QU;QI<->VT=TJ/PLH&!T]>F<XS0!\LZ7^R7\3-0OK>
MW;PW=Q"5@"QC8[?TK[N^$/\ P28L/$_AN"[\03O:3MC@Y![<$=_?'ZU^I":'
MIENORV%JBJ.ODK_/'M5M8E@C"0QK&.P50 ./2@#P/]FO]D7PO^SKHIMK2VBO
M;C'$S+N;)X/;TQWQR:]\^5HP,#R^@"C(((QZ=* QR-_RXP1VZY&/3]?Z42;5
M^; !!W=.,X/4XXX[T "Y)#*!AN<@C!Z<_7%24U0!G&[CCDFG4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D_QV^ MA\;-'>QO
M9-J,FT@GKU].GZ\]J]8IK;NP!X[G'- 'YU3?\$>_!\TTLAU!@6;/4\\D\<]^
MG^%1_P##G;P?M_Y"+\_[1XZ_GV_3WK]&78JI(7/!/_UJ/FPV, ]CUH \C_9Q
M^ &G?L[^#5T#3I%>WR,$8R/3)X[_ ,Z]<CW;1N'Y]>G>C/S9&X@\=,8QGFA,
M;5VG*XX.<_K0 ZBBB@!#GC'XUS?B[P#HGC31[W3K^QMY1<Q%&+(,@$8KI:AD
M4KDY"KR?0#OD\\\C]?K0!^=7CW_@D?X;U*XU35+&\'VB9WF$8)P.AP!Q[_CZ
MU\$_&']AWQYX'\236VDZ-<7]F#A6C4D8R1D'OZ>O!-?T'JQ.<]/7!'<]JK/I
MME=,7DLX9&)!+20C)/7/(H _G$T_]DGXG7U[';MX:NH V27=#P/7WR.:^K?@
MK_P2^U#Q9)"->62W1N2.0W4=S@=!G\>V:_8I=(TM3N6RM 3SD1+SGOT[XJRD
M,-ODI$J'!/R)^?04 ?-GP _89\'_  /^9(8+]QR&*GK_ ) -?2,,$,-NL5LJ
MQPKT2/@ 'GC'3KGBI/O-MW9QR?S!QD?R[T*A4#(WXQSG)ST)YZ<>_K0 HW;L
M9SZ\8 '/YFGTU0#\PXSR1C&>G)IU !1110 4444 %%%% %?4"%L;DGIY;9P<
M=CWK^=7]MK/_  T3XF!.2)2._P#>8]_K7]%6H$+8W)/3RVS@X['O7\ZW[;0(
M_:(\2@Y;]Z?F.<9W,<#GIS^M '4_L&+N^)T)P !*!NQG&5ZD]AQ^IK]\?">?
M^$?LB0 3&O0#TQZ>U?@;^P</^+G0'@G?^(X'M_7_ .O^^7A/ \/V0 &/+7!
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M^DQ_^A"OU=\7-FW\-KOW[-&MEY;..&/3<<=<XPG7.#G>WY1>'&*^(-,(./\
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MG()'.3^5 ""/YLD+U)^[SGH#^7%*OW0<DYYY&#2D;O\ ]= &W_\ 70 M%%%
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M?S9RT' ''_'U%UX_SFOS]K] _P!@O_DWWXB8Y&^WS]?M,5 'I5%%% !1110
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M%JFWR]EFB[-NW'RKQC:N,=,;4Q_=7H #Y0HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH _9C_@CRNWX6ZCQMSD].O*\]!S_ ("OT-;AB<8Z#<HR3STZ=/\
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M<X.=[ '/4444 %%%% !1110 4444 %%%% !1110 4444 97[?6W_ (53X<
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MIBN!+$QPF!Z^GU%?(M% '[D:'_P52^'.H&UAD/[YP [!NO'7'^1^5?5OP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3_F;_4#D#)Z4 ;%%%% !1110 C'"DXS["OR!_P""H6?MLRC/R@\C@_\ ?.>
M>_';O7Z_,<*3C/L*_(#_ (*AX%],I/*@@;A@'WP#Q^0_2@#\Y_#O_(P:9_U]
M1?\ H8K]7O%S9M_#:[]^S1K9>6SCACTW''7.,)US@YWM^47APX\0:9QG_28_
M_0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH **** "
MBBB@ HHHH *4*/[P'7UI*4,1QQW[#O0 E%%% &9^WT"/A3X:4$[?[(M\ @#C
MR4R<>_ SCOC':OS%K]./V^MO_"J?#@ "_P#$IMMR@''^I3 QW//IT'X5^8]
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M/T[5_/=_P3YY_:.T,8R<Y^[G]<''Z?6OZ$8_]6N..!T&/T[4 .HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% '<?!'/_"V/#&#@?;$SSUK^E#P NWP3H@VA?\
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M1QC/K_GH:^7J^H/^"=>#^T;HX_BR,+Z]>W?\J /Z!F&2O .#W[<=J=36&2O
M.#W[<=J=0 4444 ,C;=@[MWR@\#CZBGTR-MV#NW?*#P./J*?0!\P?M[-_P 6
M;U09_@Z9]A[_ -/_ *_\_P!J.1J%UG)/FM][KU-?T _M[-_Q9O5!G^#IGV'O
M_3_Z_P#/[J"[;ZY&,8D88&?4^O- 'Z9?",#_ (9K^'^.1YEUS_P&'V_S[UK]
M%Z;<C^(=>>W'^<&LGX2_\FU_#\[=O[RZ[?[,/M_GWK6Z+TVY'\0Z\]N/\X-
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M_A<OAC>NY/M2Y7&<C/3'>OTB\>%F\::X7!5OMDN02"?O'TH PJ*** "BBB@
MHHHH **** "BBB@ HHHH 53@-R1D=N_-;W@7Y?'6@]%_T^'H>/\ 6#W_ ,^]
M8*G ;DC([=^:WO OR^.M!Z+_ *?#T/'^L'O_ )]Z /S>_:0Q_P +J\4XZ?:V
M_G7FE>F?M)$GXU>*<_\ /TW?->9T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!]._L)KO^)=N-JOB8-M/;CKW_ *<XY]/WR\*_+X8L#C:3 "2H
MR>G7IUQ7X&_L)KO^)=N-JOB8-M/;CKW_ *<XY]/WS\)\>&=/"+R(5XZ#.,T
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MM] CX4^&E!.W^R+? ( X\E,G'OP,X[XQVK\Q: "BBB@ HHHH **** "BBB@
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M^1_I]:_H1C_U:\8X'7/]: '4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %1F0KW4CDELX P?\_E^4E,9FSP/89[G&>O84 *K9X. V,D YQ6'?> _#
M^I3>;=:3;3R?WG3)ZYK:;$9'K_M$XY(_R*;G<GSE1\AQO/4=R1Q[?G0!\U?M
M'?L/^%/CCIOD0VT.G2GDN@(P>O08]OS/MCX?^-'_  2;/@;PL^H:)>RWLRYS
ME^GIU/\ 0_I7Z\M\V0K8QP<<D<?_ *J9);I<(4F19%)SM;D?Y_QH _FEU;]G
M7X@Z/)<+/X<N]L RSA#C&"0?8''>O.KB&2UF>"5=CQL0RD8.:_J$U#P+H&H6
MDUK+I=KB92"?+&[IC(/7T_2OB/QE_P $E_!/BCQ)?:L+OR_M4OF&-688]?\
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MOT"_8+(_X9^^(>-P^:#/H?\ 2HO;_/-?G[7Z!_L%Y/[/OQ$YX#VXQ@?\_,5
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M7R_C1:)L\O99*NW;MQA5XQM7&.F-JXQ]U>@ /E&BBB@ HHHH **** "BBB@
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MO/;C_.#61\(P/^&:_A_CD>9=<_\  8?;_/O6OT7IMR/XAUY[<?YP: &4444
M%%%% !1110 4444 %%%% !1110 5XI^WR"/AO\/?G+#RI>#C@^<_Z=/U]:]K
MKQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVH ^'J*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-;.TXSGIQC(]^: #S
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MS/!S&O*C / ]A_G\J ->OQY_X+',/^$[TD$L>1@?PCY3^IQ^G7M7[#5^/?\
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MDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 5XI^WRS'X;_#T,!@12X(;/\ RV?CV/\
MB*]KKQ3]OD$?#?X>_.6'E2\''!\Y_P!.GZ^M 'P[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '[,?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MP
MQ.,=!N49)YZ=.G^)K\\O^"/*[?A;J/&W.3TZ\KST'/\ @*_0UN&)QCH-RC)/
M/3IT_P 30 ^BBB@ HHHH Y[XA-M\$:V<X_T5^<X[?4?SK^:SXS\?%/Q*,8_T
MQNV.P]A7]*?Q";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["@#4_9
MUV_\+E\,;UW)]J7*XSD9Z8[U^D7CPLWC37"X*M]LER"03]X^E?F]^SGG_A<_
MA?: 6^UK@$X'6OTA\=*5\9ZV"<XO)>=NW^(]NU &%1110 4444 %%%% !111
M0 4444 %%%% "J<!N2,CMWYK>\"_+XZT'HO^GP]#Q_K![_Y]ZP5. W)&1V[\
MUO>!?E\=:#T7_3X>AX_U@]_\^] 'YO\ [21)^-7BG/\ S]-WS7F=>F?M)?\
M):O%/.[_ $IO_P!5>9T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!]._L)KO\ B7;C:KXF#;3VXZ]_Z<XY]/WS\)_-X9T_EL&%1Z8XQQ7X&?L)
MKO\ B7;C:KXF#;3VXZ]_Z<XY]/WS\*L5\,V!)5<0+ACTZ=30!L4444 %%%%
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MYK^BG43C3[HYQ^Z;OCL?<?SK^=;]MK_DXKQ1R/\ 7'C'/4T =3^P8N[XG0G
M $H&[&<97J3V''ZFOWQ\)Y_X1^R) !,:] /3'I[5^!O[!P_XN= >"=_XC@>W
M]?\ Z_[Y>$\#P_9  8\M<$ \C'';T_E^% &O7X]?\%CN?'>D#>3T;;V'!!.,
M^Z\_AZU^PM?CS_P6.8?\)WI()8\C _A'RG]3C].O:@#\W:_3#X,C'[.?@SC&
M99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH **** "BBB
M@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'D'[>&?\
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M7C']: /Y]/\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTKU?\
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M ?SZ?\%#C_QD5JPSV]?_ *_]/_K>4? 93_PL&P("YWK\QZ]>E>K_ /!0X_\
M&16K#/;U_P#K_P!/_K>4? 93_P +!L" N=Z_,>O7I0!^G'Q0O%N=:T^-2Q^S
MZ=;PE6SA?E)POS$8PPZ!1R>"<LW'UV'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$
M8PPZ!1R>"<LW'T %%%% !1110 4444 %%%% !1110 4444 %?,'_  4:41_&
MBVC"[-MF@*;=NTA5&,;5V_3:O^ZO0?3]?,/_  4;39\:+50NP1V:(5V[=AVK
M\N-JX^FU<?W5Z  ^4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP<<'SG_3I^OK7M=>)_M\;/\ A7/P^VC:WE2Y&,?\MI.<?7//?'M0!\/4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'HZ<W X[_Z1(><_T]/K7P=7WC^WAG_A2_P_QGK<9QC_ )^).M?!U !1110
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M4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%%
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M'\,/M_GWK6Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ HHHH
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M?T%W%G#J-JL5U$LT9P2KC@GW''\J /DC_@GO^S_:_#7X8Q7MS8BVU*X3#?*
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MX/7D8)Y&?3T _P :D9-WN#PP/((YH9=V0QROICJ,=#0 ZBBB@ HHHH ****
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M@9[_ .>C5Q(=O4 MZGGV/;K_ )Q5#Q%XDL/"NGR7^HW*P6\>-Q9@,=>?\^E
M&H&#<@Y[4M?*/Q6_;^^'OA;0+TZ9JJSZC$#M 8  \'/49^E?GYXG_P""KWQ!
M_MR[73ROV0.57(SQG..O/?ZX]Z /VO52O5BW&.<?G3J_#Z/_ (*R?$OS 9%W
M*>HW^Y_/@^W4U]%?L\?\%08?$.L0IXMG\J L S.0".N?YDY]/QH _3,E]QVY
M//T'3ITZ=.F:<=V>",<=OSKS7X=_M#>#/BA.L6A:G'<LWO[?Y_7TKT<JRX/R
MX')V@]>_ ZYY_P#KT /#'@,N"?3D9IU0QQ\9Q@_WNIZ\CD=.!SWJ:@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% '<?!$X^+'ACDC-XG3O]:_I0\
M+M\$Z(-H7_1(^!]/H/Y5_-?\$?\ DK'AC@'_ $Q.I_E7]*'@!=O@G1!M"_Z)
M'P/I]!_*@#H**** "BBB@ K\]_\ @KRV/A5:\L/E/4^NX9'/?H:_0BOSW_X*
M\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/]@U3_PS[\0B5&-T&&Q@_P#'U%^?_P!:
MOS\K] OV"U _9^^(9(^8M!@^WVJ+\J /2Z*** "BBB@ HHHH **** "BBB@
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MT7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+XZT'HO\ I\/0\?ZP>_\ GWH
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MIG_7U%_Z&*_5[Q<V;?PVN_?LT:V7ELXX8]-QQUSC"=<X.=[ '/4444 %%%%
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M5BK @X(Y!%=-X#^(FL_#OQ!;ZOI-TT=S"X< G@D'.?SK-\2^&K_PGJ\^G:C
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M;1D].Y[#WIU% $,BEU')ZGYB.0>GITYZ\476?LDV1CY&_D:?YAW8V_49&>N
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M0 _:*\3@=I<=23]YN3G_ #Q0!U/[!P_XN= >"=_XC@>W]?\ Z_[Y>$\#P_9
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MZ9]A[_T_^O\ S^Z@NV^N1C&)&&!GU/KS7] 7[>S?\6;U09_@Z9]A[_T_^O\
MS^ZA_P ?USD8_>-U&.Y[=J /TS^$O_)M?P_.W;^\NNW^S#[?Y]ZUNB]-N1_$
M.O/;C_.#63\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP: &4444
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M]A7]*?Q";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["@#4_9UV_\
M"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I7YO?LYY_P"%S^%]
MH!;[6N 3@=:_2'QTI7QGK8)SB\EYV[?XCV[4 85%%% !1110 4444 %%%% !
M1110 4444 *IP&Y(R.W?FM[P+\OCK0>B_P"GP]#Q_K![_P"?>L%3@-R1D=N_
M-;W@7Y?'6@]%_P!/AZ'C_6#W_P ^] 'YO_M)$GXU>*<_\_3=\UYG7IG[27_)
M:O%/.[_2F_\ U5YG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% '3>$?^1?\ '?!/_%/3]#C_ );0U^3&M?\ (8O^0?W\G*C
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M-?J/)CJ1TZ;C@$YX_4"OR\_X(TM_Q+=8&5ZMQCGJW?\ #_/-?J,QPI.,^PH
M212RX!^O..*^=OV]EW_L[ZV,X/&#D_TKZ(9BJDG"]?F[#W/2O!_VV(/M'P'U
MM!_SS<\_[ISW';TH _G6N!MN)1@+ACPO0<TQE*@'J#W[?2KFN0&UUF^B.!MG
M<?*,#[QJE0!]S?\ !*/6(M)^-$CS$;?E[=.G)].@_IDU^WX(D =#]#S@C/\
MGFOYV/V-?%S^%?B?;2(^S<Z@';G&>O8]AZ5_0/\ #[4FUCPG8W;G+RH"3C'.
M!G- '1,<*3C/L*8I&\^I[G@G!/MT&?UI8UVX^15^4#Y?Y=.E+@JIV\GJ,F@!
M(UVX^15^4#Y?Y=.E/IJMNY&"I&00>M#.J]6 XSR>WK0 ZBD# Y .<<&C<-P&
M>>N* (-0R;&Y Z^6V,?0^XK^=7]MI@W[1/B8CD&4GM_>8=1]/UK^BK4,FQN0
M.OEMC'T/N*_G5_;98-^T1XF8=#*?3^\?3MC% '5?L&+N^)T)P !*!NQG&5ZD
M]AQ^IK]\?">?^$?LB0 3&O0#TQZ>U?@;^P:N?B;"V,XDP3CIP/;COW]?Q_?+
MPG@>'[( #'EK@@'D8X[>G\OPH UZ_'K_ (+'<^.](&\GHVWL.""<9]UY_#UK
M]A:_'G_@L<P_X3O202QY&!_"/E/ZG'Z=>U 'YNU^F'P9&/V<_!G&,RS]NORQ
M^W^/]!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &[1110 4444 %%%% !1110
M4444 %%%% !3W.[G[V6/S'J?KS3*>YW<_>RQ^8]3]>: /'_V\?\ DC'P^Y[W
M'8_\_$G^>:^#Z^\/V\?^2,?#[ZW'?'_+Q)^=?!] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 =Q\$?^2L>&. ?],3J?Y5_2AX 7;X)T0;0O^B1
M\#Z?0?RK^:[X(X_X6QX7S_S^IBOZ4? "[?!.B#:%_P!$CX'T^@_E0!T%%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** /IW]A-=_Q+MQM5\3!MI[<=>_\
M3G'/I^^7A4#_ (1BP)&,P#.W.3Q[=\5^!O[":[_B7;C:KXF#;3VXZ]_Z<XY]
M/WR\*8'A?3]N5'D#[J\_7% &S1110 4444 (V=IQP>V:_('_ (*A96]F PH
M.%#X*CTY/]!Z5^OS9VG'![9K\@/^"H+#[9*%VXQE1V"_B?Z#]* /SG\._P#(
MP:9_U]1?^ABOU>\7-FW\-KOW[-&MEY;..&/3<<=<XPG7.#G>WY1>'#CQ!IG&
M?])C_P#0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH
M**** "BBB@ HHHH *4,1QQW[#O244 %%%% &9^WX3_PJOPV&Y;^R;<?>SDF%
M?TQGC')/X5^8M?IU^WT"/A3X:4$[?[(M\ @#CR4R<>_ SCOC':OS%H ****
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M@B@#Z>HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z;PCG_A'_ !WMZ_\
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MP!GCG_(_*F%BW).>U?1?[)G[+_B/XQ>.M,E.FM_8H<-++("!C/T/O0!]5?\
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MASZ\#GI_D8H [0*H.0H!Y[>O6FB3@?O$/"]O4_7OV_K3FW9&,8[@_P"?K3J
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MW[\=J=2'/&/QIJL<CY@PR1\HH ?1110 R-MV#NW?*#P./J*?3(VW8.[=\H/
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MS[#W_I_]?^?W4/\ C^N>,?O&Z8]3Z<4 ?IG\)?\ DVOX?G;M_>77;_9A]O\
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M?4W_  3EFBM_CF99]_DI;EG\N41-@*Q.')&T_P"UD8P?F% 'U%1110 4444
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M?\B_IWR[?W"#;Z<=/\_K0!?&2=PY&X\*V?;_ "*DIFTY'S'IRV>>/;ISS3Z
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MS(O)/4GU.>./RKY'7&"#^?>@#ZU_8"^/"_"KX@65C(P1+RXV;F;C!QV[#/\
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MMV#NW?*#P./J*?3(VW8.[=\H/ X^HI] 'S!^WLW_ !9O5!G^#IGV'O\ T_\
MK_S^Z@0;ZY(Z>8V,?4^PK^@+]O9O^+-ZH,_P=,^P]_Z?_7_G^U'(U"ZSDGS6
M^]UZF@#],?A&!_PS7\/\<CS+KG_@,/M_GWK7Z+TVY'\0Z\]N/\X-9/PE_P"3
M:_A^=NW]Y==O]F'V_P ^]:W1>FW(_B'7GMQ_G!H 91110 4444 %%%% !111
M0 4444 %%%% !7B?[?&S_A7/P^VC:WE2Y&,?\MI.<?7//?'M7ME>*?M\LQ^&
M_P /0P&!%+@AL_\ +9^/8_XB@#X=HHHH **** "BBB@ HHHH **** "BBB@
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MNY5^=<;LJIR!@#C /N<G X-?K]7X_?\ !4+'VZ<8Y&?E8\?7J,=/[HSCOTH
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M6J_:;_@KR?\ BS]N"<<<<XSSP.O./F^F:_%F@#IOAG_R/VA?]?2U_23\%?\
MDE^A;5V'[,O'8<#MQ7\VWPS_ .1^T+_KZ6OZ2O@HNWX8Z#@$+]G7&1CC [4
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M^I]*_2O2;/\ L[3+6USGRHU3\A0!.K/T(YX[8[\GO^524W:O/RCDY/'?UIU
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M?A4G_A&;#/'[A<%>3T],5^!G[":[_B7;C:KXF#;3VXZ]_P"G..?3]\_":_\
M%,:</N9A'W?YT ;%%%% !1110 C9VG'![9K\@?\ @J$=MW,,E4R0$ R![')Z
M\CL#S7Z^N=JL<A<#JW05^0?_  5$4K?3*,IMW#Y6X [#D^QYP,^^* /SF\.#
M=X@TS_KYC[_[0K]7?%TGF6_AL!L[=&MAM+?=R&.,;CMZYQA.N<'.]ORB\.8_
MX2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./O''7/1.N<'.]@#GJ***
M"BBB@ HHHH **** "BBB@ HHHH **** ,K]OK;_PJGPX  O_ !*;;<H!Q_J4
MP,=SSZ=!^%?F/7Z=?M^$_P#"J_#8;EO[)MQ][.285_3&>,<D_A7YBT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!\C]
MG70@1C X_P X%?SS0G$J'./F'M_45_0S^P/_ ,FZZ$,8P,=,?T% 'T;1110
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M<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3TZ\KST'/^ K]#6X8G&.@W*,D\].G3_$U^>7_!'E=OPMU'C;G)Z=>5YZ#G_
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MZ;OFO,Z],_:2_P"2U>*>=W^E-_\ JKS.@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /IW]A-=_Q+MQM5\3!MI[<=>_].<<^G[Y>%?F\,6'&[,
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MB$<*<- ,XY'^E1<=/\\4 >E4444 %%%% !1110 4444 %%%% !1110 4444
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M^SKM_P"%R^&-Z[D^U+E<9R,],=Z_2+QX6;QIKA<%6^V2Y!()^\?2@#"HHHH
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MG]/7+?D?7ZX_\$E?F\,;NN%^\!N(.3G'7I\O'OTYH _3>BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5]0(6QN2>GEMG!QV/>OYU?VVL_P##1/B8$Y(E([_WF/?ZU_15
MJ!"V-R3T\MLX..Q[U_.M^VT"/VB/$H.6_>GYCG&=S' YZ<_K0!U'[!O_ "4R
M(8_Y: Y&>RXYX_VO;^5?OEX3_P"1?LSP<QKRHP#P/8?Y_*OP-_8-_P"2FQ<=
M9.O/8?3'?VZGUK]\O"?_ "+]F>#F->5& >![#_/Y4 :]?CW_ ,%C6)\=:2/F
M.  >N.AQW_WN,=^O2OV$K\>O^"QW/CO2!O)Z-M[#@@G&?=>?P]: /S<K],/@
MR,?LY^#.,9EG[=?EC]O\?Z#\SZ_3#X,C'[.?@SC&99^W7Y8_;_'^@ -VBBB@
M HHHH **** "BBB@ HHHH **** "GN=W/WLL?F/4_7FF4]SNY^]EC\QZGZ\T
M >0?MY+_ ,67^'I.#S<$<9_Y>)/R_P ^M?!U?>'[>/\ R1CX?<][CL?^?B3_
M #S7P?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<?!$X^+'A
MCDC-XG3O]:_I0\ +M\$Z(-H7_1(^!]/H/Y5_-?\ !'_DK'AC@'_3$ZG^5?TH
M> %V^"=$&T+_ *)'P/I]!_*@#H**** "BBB@ K\]_P#@KRV/A5:\L/E/4^NX
M9'/?H:_0BOSW_P""O+8^%5KRP^4]3Z[AD<]^AH _%^OT"_8+ _X9^^(9"]&@
M!8GG_CZBZ?Y[5^?M?H'^P;_R;[\0NWS0=.<_Z5%R?0T >E4444 %%%% !111
M0 4444 %%%% !1110 4444 <M^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5
MSEOS;K])/VD(\?LLZ[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?H=_P1]'_%SM2)&5R,D+G'W<<]
MOS[]Z_/&OT._X(]_\E0U)MN0."<9 R%]C_D&@#]FJ*** "BBB@ I >O&/ZTM
M(,\Y_"@#^?3_ (*''_C(K5AGMZ__ %_Z?_6\H^ RG_A8-@0%SO7YCUZ]*]7_
M ."AQ_XR*U89[>O_ -?^G_UO*/@,I_X6#8$!<[U^8]>O2@#]./BA>+<ZUI\:
MEC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/KL/BA>+<ZUI\:EC]GTZWA*MG"_*3
MA?F(QAAT"CD\$Y9N/H **** "BBB@ HHHH **** "BBB@ HHHH *^8?^"C:>
M7\:+5-OE[+-%V;=N/E7C&U<8Z8VIC^ZO0?3U?,'_  4;0Q_&BT0KLVV2J$V;
M=N%48QM7&/3:N.FU>@ /E&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^H?^"=?/[1FCC;G)']>/\@U\O5]0_\ !.L$_M&:/W&1QC/K_GH: /Z!
M6ZKR1SV'MWHW#..>N.A],T-U7YL<]/7CI_GTH"GKG'.<9SGM0 ZBBB@!D;;L
M'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O^+-ZH,_P=,^P]_Z?_7_ )_=
M0_X_KG(Q^\;J,=SV[5_0%^WLW_%F]4&?X.F?8>_]/_K_ ,_NH?\ ']<\8_>-
MTQZGTXH _3/X2J1^S7\/\C_EI==L?PP^W^?>M;HO3;D?Q#KSVX_S@UD?",#_
M (9K^'^.1YEUS_P&'V_S[UK]%Z;<C^(=>>W'^<&@!E%%% !1110 4444 %%%
M% !1110 4444 %>*?M\@CX;_  ]^<L/*EX..#YS_ *=/U]:]KKQ/]OC9_P *
MY^'VT;6\J7(QC_EM)SCZYY[X]J /AZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /V8_P""/*[?A;J/&W.3TZ\KST'/^ K]#6X8G&.@W*,D
M\].G3_$U^>7_  1Y7;\+=1XVYR>G7E>>@Y_P%?H:W#$XQT&Y1DGGITZ?XF@!
M]%%% !1110!SWQ";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["OZ4
M_B$VWP1K9SC_ $5^<X[?4?SK^:SXS\?%/Q*,8_TQNV.P]A0!J_LYY_X7/X7V
M@%OM:X!.!UK](?'2E?&>M@G.+R7G;M_B/;M7YO?LY@M\9_"X!*DW:_,.HYK]
M'_'&S_A,=;\O[GVR7&"3_$?6@#$HHHH **** "BBB@ HHHH **** "BBB@!5
M. W)&1V[\UO>!?E\=:#T7_3X>AX_U@]_\^]8*G ;DC([=^:WO OR^.M!Z+_I
M\/0\?ZP>_P#GWH _-_\ :2_Y+5XIYW?Z4W_ZJ\SKTO\ :0Q_PNKQ3CI]K;^=
M>:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]._L)KO\ B7;C
M:KXF#;3VXZ]_Z<XY]/WR\*_+X8L&^5#Y );MTZG\*_ W]A-=_P 2[<;5?$P;
M:>W'7O\ TYQSZ?OEX4POA>PP54"'[V#COSSCZT ;-%%% !1110 C9VG'![9K
M\@/^"H3?Z9,@&T#.(RW'UZYX]P,^_2OU_;.TXX/;-?D#_P %0CMNYADJF2 @
M&0/8Y/7D=@>: /SG\.8_X2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./
MO''7/1.N<'.]ORA\._\ (P:9_P!?47_H8K]7O%S9M_#:[]^S1K9>6SCACTW'
M'7.,)US@YWL <]1110 4444 %%%% !1110 4444 %*%)YX[]QVI*4,/[H/7U
MH 2BBB@#*_;ZV_\ "J?#@ "_\2FVW* <?ZE,#'<\^G0?A7YCU^G7[?A/_"J_
M#8;EO[)MQ][.285_3&>,<D_A7YBT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!_^3=="&,8&.F/Z"OYYH3B5#G'S#V_
MJ*_H:_8'X_9UT$8QQZ8_H/Y4 ?1E%%% !1110 5X+^VXV/V>O$8)(4Q,#_WR
M3^?'^>H]ZKP;]MLD?L]^(L<'RCALX(.T]_\ /8]J /YU;O\ X^IO]]OYU]3?
M\$Y9HK?XYF6??Y*6Y9_+E$38"L3AR1M/^UD8P?F%?+-W_P ?4W^^W\Z^KO\
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M6B;=FVR4;-NW;A5&-NU=N,=-JX_NKT !\HT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7U!_P $Z\']HW1Q_%D87UZ]N_Y5\OU]0_\ !.OG]HS1
MQMSDC^O'^0: /Z!CGC ^M+36&2O .#W[<=J=0 4444 ,C;=@[MWR@\#CZBGT
MR-MV#NW?*#P./J*?0!\P?M[-_P 6;U09_@Z9]A[_ -/_ *_\_NH$&^N2.GF-
MC'U/L*_H"_;V;_BS>J#/\'3/L/?^G_U_Y_M1R-0NLY)\UOO=>IH _3+X2_\
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M>B_Z?#T/'^L'O_GWK!4X#<D9';OS6]X%^7QUH/1?]/AZ'C_6#W_S[T ?F_\
MM)$GXU>*<_\ /TW?->9UZ9^TE_R6KQ3SN_TIO_U5YG0 4444 %%%% !1110
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M)C'_ (\*_5WQ:X:V\-*I^5=&M@%S]WACC&X[>N<83KG!SO8 YZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#,_;Z!'PI\-*"=O]D6^ 0!QY*9./?@9QWQ
MCM7YBU^G'[?6W_A5/AP !?\ B4VVY0#C_4I@8[GGTZ#\*_,>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** '0G$J'./F'M_45_0S^P.H7]G70L#
M''/&/Z#^5?SS0G$J'./F'M_45_0S^P.NW]G70OITQC'MT% 'T;1110 4444
M%>"_MN8'[/7B,G_GDW7H?E/'^?0U[U7@W[;?'[/?B)@=N(B25ZCY3S_GV^H
M/YU;O_CZF_WV_G7U5_P3=MY+SX])!$_ER20[%D^;Y20W/RLK<=<@@\'!%?*M
MW_Q]3?[[?SKZF_X)RS16_P <S+/O\E+<L_ERB)L!6)PY(VG_ &LC&#\PH ^H
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** .F\(_\ (O\ CO@G_BGI^AQ_
MRVAK\F-:R=8OR6W'SY/F]?F/-?K/X1_Y%_QWP3_Q3T_0X_Y;0U^2^L'.KWQ
MQ^_?@?[QH J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZX?\
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MWUN!5&(U$C+GEL?Y_,5_-S7W]_P3?_:ZN?ASKFG^!&BS;WS[0>N#D#/3OZ4
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MH *^H?\ @G6"?VC-'[C(XQGU_P ]#7R]7U!_P3KP?VC=''\61A?7KV[_ )4
M?T#,,E> <'OVX[4!B6(&TX.#S[4-U7Y<\]?3CK_GUHV],_,0<@GM0 ZBBB@!
MD;;L'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O^+-ZH,_P=,^P]_Z?_7_
M )_=07;?7(QC$C# SZGUYK^@+]O9O^+-ZH,_P=,^P]_Z?_7_ )_=0_X_KG(Q
M^\;J,=SV[4 ?IE\(P/\ AFOX?XY'F77/_ 8?;_/O6OT7IMR/XAUY[<?YP:R?
MA+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSVX_S@T ,HHHH **** "BBB@
MHHHH **** "BBB@ KQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^6
M8_#?X>A@,"*7!#9_Y;/Q['_$4 ?#M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?LQ_P1Y7;\+=1XVYR>G7E>>@Y_P%?H:W#$XQT&Y1DGGI
MTZ?XFOSR_P""/*[?A;J/&W.3TZ\KST'/^ K]#6X8G&.@W*,D\].G3_$T /HH
MHH **** .>^(3;?!&MG./]%?G..WU'\Z_FL^,_'Q3\2C&/\ 3&[8[#V%?TI_
M$)MO@C6SG'^BOSG';ZC^=?S6?&?CXI^)1C'^F-VQV'L* -7]G,%OC/X7 )4F
M[7YAU'-?H_XXV?\ "8ZWY?W/MDN,$G^(^M?F_P#LZ[?^%R^&-Z[D^U+E<9R,
M],=Z_2+QX6;QIKA<%6^V2Y!()^\?2@#"HHHH **** "BBB@ HHHH **** "B
MBB@!5. W)&1V[\UO>!?E\=:#T7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+
MXZT'HO\ I\/0\?ZP>_\ GWH _-[]I#'_  NKQ3CI]K;^=>:5Z9^TD2?C5XIS
M_P _3=\UYG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'T[^PF
MN_XEVXVJ^)@VT]N.O?\ ISCGT_?+PHN/"^GC;C]P.$.,_P N:_ W]A-=_P 2
M[<;5?$P;:>W'7O\ TYQSZ?OEX4P?"]A@$YASA1M/?ITH V:*** "BBB@!&8*
MI). .237Y _\%0B?MLRCAE!!52"5]L ]/4X_PK]?Z_'_ /X*@D&\EY0KC*\G
MC\ ?UVCM0!^='AP;O$&F?]?,??\ VA7ZN^+I/,M_#8#9VZ-;#:6^[D,<8W';
MUSC"=<X.=[?E%X<Q_P )!IF>/])C_P#0A7ZN^+I"UOX;!;)71K8%0^[;PQQ]
MXXZYZ)US@YWL <]1110 4444 %%%% !1110 4444 %*-O<G//;\J2E#,. 2!
MSW]>M "4444 9G[?A/\ PJOPV&Y;^R;<?>SDF%?TQGC')/X5^8M?IU^WT"/A
M3X:4$[?[(M\ @#CR4R<>_ SCOC':OS%H **** "BBB@ HHHH **** "BBB@
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MT3XF!.2)2._]YCW^M '5?L&+N^)T)P !*!NQG&5ZD]AQ^IK]\?">?^$?LB0
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MT7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+XZT'HO\ I\/0\?ZP>_\ GWH
M_-_]I+_DM7BGG=_I3?\ ZJ\SKTO]I#'_  NKQ3CI]K;^=>:4 %%%% !1110
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M !GU30]%NC!9V[L!EB >>@]P/3'7ZUXB/^"D/Q<50!J?U_>,![=.G?IQ[<4
M?OXR[A@].X['VIGRJ^2<X/)X^\<8_'!Q7X,>'?\ @HY\5[KQ!I\,^H-)#+<Q
MHRAR2P+8QC'OVP/;IC]M_@[KEUXF^'.B:G>,?M%Q &<>^!Z@'^76@#LE;')5
MAG!YYZ\8I]1K'\HP%3Y<':.GICZ<]JDH **** "BBB@ HHHH **** "BBB@
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M0[_@CW_R5#4FVY X)QD#(7V/^0:_/&OT._X(]KN^*&I$#<1VP3QA<GIVX[T
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MVY'\0Z\]N/\ .#63\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP:
M&4444 %%%% !1110 4444 %%%% !1110 5XI^WRS'X;_  ]# 8$4N"&S_P M
MGX]C_B*]KKQ3]OD$?#?X>_.6'E2\''!\Y_TZ?KZT ?#M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?LQ_P1Y7;\+=1XVYR>G7E>>@Y_P !
M7Z&MPQ.,=!N49)YZ=.G^)K\\O^"/*[?A;J/&W.3TZ\KST'/^ K]#6X8G&.@W
M*,D\].G3_$T /HHHH **** .>^(3;?!&MG./]%?G..WU'\Z_FL^,_'Q3\2C&
M/],;MCL/85_2G\0FV^"-;.<?Z*_.<=OJ/YU_-9\9^/BGXE&,?Z8W;'8>PH U
M/V==O_"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I7YO?LYY_X
M7/X7V@%OM:X!.!UK](?'2E?&>M@G.+R7G;M_B/;M0!A4444 %%%% !1110 4
M444 %%%% !1110 JG ;DC([=^:WO OR^.M!Z+_I\/0\?ZP>_^?>L%3@-R1D=
MN_-;W@7Y?'6@]%_T^'H>/]8/?_/O0!^;_P"TD2?C5XIS_P _3=\UYG7IG[27
M_):O%/.[_2F__57F= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?3O[":[_B7;C:KXF#;3VXZ]_P"G..?3]\O"C >%[!@0O[G.2N .O;CBOP-_
M837?\2[<;5?$P;:>W'7O_3G'/I^^?A5BOAFP)*KB!<,>G3J: -BBBB@ HHHH
M *_'_P#X*@LOVR4!^"-VTD[?8XSQ[?*/\/U_8;E(/?T.*_('_@J%(6O9OF+D
M[F 7K@CDDYZ<>@[T ?G/X<8KX@TP@X_TF,?^/"OU=\6N&MO#2J?E71K8!<_=
MX8XQN.WKG&$ZYP<[V_*+PX-WB#3/^OF/O_M"OU=\72>9;^&P&SMT:V&TM]W(
M8XQN.WKG&$ZYP<[V .>HHHH **** "BBB@ HHHH **** "GK]T<*>O4^WUIE
M% !1110!F?M] CX4^&E!.W^R+? ( X\E,G'OP,X[XQVK\Q:_3C]OK;_PJGPX
M  O_ !*;;<H!Q_J4P,=SSZ=!^%?F/0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #H3B5#G'S#V_J*_H9_8'7;^SKH7TZ8QCVZ"OYYH3B5#G'S#
MV_J*_H9_8'R/V=="!&,#C_.!0!]&T444 %%%% !7@W[;?'[/?B)@=N(B25ZC
MY3S_ )]OJ/>:\%_;<_Y-\\0\ _NR/F. ?E/&>/Y_X@ _G6N_^/J;_?;^=?57
M_!-VWDO/CTD$3^7))#L63YOE)#<_*RMQUR"#P<$5\JW?_'U-_OM_.OJ;_@G+
M-%;_ !S,L^_R4MRS^7*(FP%8G#DC:?\ :R,8/S"@#ZBHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Z;PC_P B_P".^"?^*>GZ''_+:&OR8UK)UB_);<?/
MD^;U^8\U^L_A'_D7_'?!/_%/3]#C_EM#7Y+ZP<ZO?$#'[]^!_O&@"I1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?KC_P $E\_\(R"<X PK;,D=
M.G'J3Z]>G(S^1U?KC_P254_\(P0 >1@<8SR#@G'')]?0]\D _3>BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "F2=_E8_*?NG']>M/HH 8R
M?*0O'!^4' )/O_GK2>6%8D+D9R!Z'N?\^_K4E% #%C&T;ADX'!)(X^O\Z<5#
M<$9[TM% #&4[2% '7(Z9_$=.>])(O[J3@$L#G Z_S[5)3)N8G&,_*>V?Z&@#
M^?/_ (*#L6_:&UGG(#MWSZ<=3_GL*^9J^F?^"A'/[0VL'.[#,N>,]0<=?>OF
M:@#:\$C/B[1P#C_2H^1VYK^DWX!!1\(_#>U=@^S+A=NW [<8&.,5_-CX,7?X
MLTE1SFY0<_6OZ3_@'S\(_#9VD VP(R,9R3_GGTH [U0=S')Z\C'';^GI[T^B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@#N/@B<?%CPQR1F\3IW^M?TH>
M%V^"=$&T+_HD? ^GT'\J_FO^"/\ R5CPQP#_ *8G4_RK^E#P NWP3H@VA?\
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M.W^R+? ( X\E,G'OP,X[XQVK\Q: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ="<2H<X^8>W]17]#/[ __ ";KH0QC QTQ_05_/-"<2H<X^8>W
M]17]#7[ _'[.N@C&./3']!_*@#Z,HHHH **** "O!?VW&Q^SUXC!)"F)@?\
MODG\^/\ /4>]5X-^VV2/V>_$6.#Y1PV<$':>_P#GL>U '\ZMW_Q]3?[[?SKZ
MN_X)JNT?[0,#I#)<,L6X11D;G(#':,D#/'4D#KR*^4;O_CZF_P!]OYU]5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1\#Z?0?RH Z"BBB@ HHHH *_/?\ X*\MCX56O+#Y3U/KN&1SWZ&OT(K\]_\
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M/7C']: /Y]/^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_X6#8$!<[U^8]>O2O5_\
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M]<D=/,;&/J?85_0%^WLW_%F]4&?X.F?8>_\ 3_Z_\_VHY&H76<D^:WWNO4T
M?IE\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP:R/A&!_PS7\/\<C
MS+KG_@,/M_GWK7Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ H
MHHH *\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M>UUXG^WQL_P"%<_#[:-K>5+D8
MQ_RVDYQ]<\]\>U 'P]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '[,?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49)YZ=.G^)K\\O\
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M0!^;_P"TE_R6KQ3SN_TIO_U5YG7I?[2&/^%U>*<=/M;?SKS2@ HHHH ****
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M!QV]?J/TKH8I#(N2,=\;2,?G^- "[OFQO7[V,=^F<=>O>GTW)STXSW/MVIU
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M#/;U_P#K_P!/_K>4? 93_P +!L" N=Z_,>O7I7J__!0X_P#&16K#/;U_^O\
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MX*A';=S#)5,D! ,@>QR>O([ \T ?G/X<&[Q!IG_7S'W_ -H5^KOBZ3S+?PV
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M/V_Q_H/S/K],/@R,?LY^#.,9EG[=?EC]O\?Z  W:*** "BBB@ HHHH ****
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M3B(<9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444
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M&-NU<?3:F.FU>@^GJ^8/^"C<?E?&BT3;LVV2C9MV[<*HQMVKMQCIM7']U>@
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MD%"\ 8[TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3)%+8QSR/EP".HYI]-W'.-IZXSQZ=: &JQC"A@H)/)'
M Z_S)(X]Z\'_ &P/BTWPF^'=Q>H^QIHG3ZC!SW&?P_'M7O&S#CC'4@@#OU!^
MIY_"O@[_ (*W7TEG\%XO+;:S>_N1TSSUH _'+XD>*'\9>--3U>0LSW$I9BQY
M)SD_KFN9HHH ^V?^"<7P#M?BMXPBU.XC5VL)MZ\9Y&<'\.?T_#]Q-*LETW3;
M6U1=JPQ*F!["OR\_X(TQ(UGK+,BDAF()7I][VK]2F4[PP'''<^_;\?\ /% #
ME! Y]3WSWKX\_P""BGPBT;7O@_JVO2P(U_"&*DKU8XQW'O\ YYK[!R<*?FZ#
MYF'7)]/7\.,U\Z_M]?-^SKKJX)!7GC/;@=0>OIVS0!_/,^-S;>5SQ2*Q5@0<
M$<@BGS[O.DW<MN.<^N:9N^4C^E 'Z3_\$GOBOK&I>/G\.3S.]F@#;0Q/ V]L
M9_Q_6OU_.=PZXZ]L?3_/I7XE_P#!)&14^-<V]T &WY6X/4?_ *_P-?MH^3@
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M6)\=:2/F.  >N.AQW_WN,=^O2OV$K\>O^"QW/CO2!O)Z-M[#@@G&?=>?P]:
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MC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/H **** "BBB@ HHHH **** "BBB@
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MK\\O^"/*[?A;J/&W.3TZ\KST'/\ @*_0UN&)QCH-RC)//3IT_P 30 ^BBB@
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M#GJ*** "BBB@ HHHH **** "BBB@ HHI0H_O =?6@!**** ,K]OK;_PJGPX
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MCY2I12N,*HQCI\J_[J]  ?*=%%% !1110 4444 %%%% !1110 4444 %%%%
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MP+\OCK0>B_Z?#T/'^L'O_GWK!4X#<D9';OS6[X#.?'.@8&"VH0 *N>\B\=:
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MHK^AG]@?_DW70AC&!CIC^@K^>:'/FIC).X?=ZU_0[^P9!)!^SKH ="F5XR,
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MSZ9X]CW]/45^>W_!7>/_ (MC$V[ XXS]1Z\=_P!*_0U5VDGJ3W[_ $K\_O\
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M+7Q&U/Q,R[/M;9"\_*,DXY[<US*^$=9;IIT_7'*XIO\ PBFK_P#0/F'U&/\
M/]: .\^ GQB;X.>)DU9$WLKAA\N<<8_EUQCM7WUIO_!8]K.RA@?1V8Q*%#>5
MG.!WZ?I[5^9?_"(ZQN*_V?-D9R,?Y_\ KT?\(CK'/_$OFR!G&.?R_P ]_0T
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M_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\
MAO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A
M?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ
M^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&
MW'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8
M_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X
M_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_
MWP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G
M_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^H/C[
M^U_X=^(_P]N_#/AKP\=$AO'5[A?-E?>R@A3\[-T#-^=?)57;[1+_ $U0UU:R
M0+QRP]:I4 %%6K'2[O4Y-EK TS>BU</A/65_YAUQZ_<H R:*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'
M_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'
M_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ^BOV.?VJ'_9?\4W>JK;M<"88*@9SP!Z>F
M:\*_X1/6/^@;<?\ ?!H_X1/6/^@;<?\ ?!H _3__ (?,?]0;&/\ IC_G^G]"
M?\/E_P#J#^_^J_\ K?X?4]_S _X1/6/^@;<?]\&C_A$]8_Z!MQ_WP: /T_\
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MJ.Q_PWA\+_\ H0/?_CZNO_CG^/U';X7_ .$4U?\ Z!\WY?I]?;V-'_"*:O\
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M^GR]:;_PB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T
M95%:O_")ZQ_T#;C_ +X-'_")ZQ_T#;C_ +X- &516K_PB>L?] VX_P"^#1_P
MB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T 95%:O_")
MZQ_T#;C_ +X-'_")ZQ_T#;C_ +X- &516K_PB>L?] VX_P"^#2MX3UE6(.G7
M'''"9H [GX#_ !A;X/>)H]46,NRN'^Z#TQ^/K_2OOS3?^"QS6=C!;OI.XQKL
MWF+\N?\ ZWX5^97_  B>L[2?[.N/3[E!\)ZP,'^SYB#R, '/T]?\F@#]/O\
MA\P/^@,1WYA_E_G\1V/^'R__ %!_?_5?_6_Q^H[?F$WA'65ZZ=/UQPN:;_PB
M>L?] VX_[X- 'Z?_ /#Y?_J#^_\ JO\ ZW^/U'8_X?+_ /4']_\ 5?\ UO\
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MF_+]/K[>XH ^Z/\ AO#X7\_\4!T;_GZNCZ\?ZP9'OQTZ4C?MX?"_YL?#_/7
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M[H_X;R^%Y_YI_C'_ $]77_QW_#^A/^&\/A?_ -"![_\ 'U=?_'/\/J>_PO\
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M@T?\(GK'_0-N/^^#0!]T?\-X?"__ *$#W_X^KK_XY_A]3W/^&\/A?_T('O\
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M_P"^#1_PB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T
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MW_+(QD$TG_#!?@EB0;6WV\\;6(&<\XSZ'GZG\?I]B5&>PY/&30Q(P>V>>,T
M?,,G[!O@I\'[-;]"""&/7''7D=?3H*<W["/@O&1:P9QTY/IW(X[CCM]>/IMF
M96]N.V>_^?I2JI7JQ;C'./SH ^8E_8.\%J/^/> OMP6PWK]>WZ^U(/V"_!"M
M@6MN%!!&T,#Z?RX_#WX^GUSM&>3WQ2;3G.X]<XX].E 'S$O[!O@G:N;:WSU.
M%;@XZCGUS^?YB_L&^"/E_P!&M\YSPK<=<XYYZ_S/M7T_3=IX^8]<]OR_SZ4
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M?O#KZ\^_ZT?\,'^"E!(M;<L>O#<GUYSV_$8Z]Q]/TASQC\: /F+_ (8.\$@
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M,&^"-V?LEOU)Z-Z8'.?U_"@?L%^!Q@?9;?'RC[K=!SZ^O0=NOM7T_10!\O\
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MM+^S_P#L4^$M>^&FF7][;QB::,!P4YR!DCU')^O!_'\8_A;G_A.-+P"2)5/
MS_$.<5_1)^RZS?\ "G-#!SM$2X]/NCV_J: /.!^P;X)Y/V6V#9R,(1S@#/&/
M?H!QCI2_\,&>!QTM+?'88;H/NCKZ\^WZU]/+G:,C![XI: /F#_A@OP/T-K;D
M=#\K=#RW?N>WX\]*/^&#?!/7[+;ANN<-UZ9Z]A^?M7T_10!\P?\ #!G@<=+2
MWQV&&Z#[HZ^O/M^M'_#!?@?H;6W(Z'Y6Z'EN_<]OQYZ5]/T4 ?,'_#!O@GK]
MEMPW7.&Z],]>P_/VH_X8,\#CI:6^.PPW0?='7UY]OUKZ?HH ^8/^&"_ _0VM
MN1T/RMT/+=^Y[?CSTH_X8-\$]?LMN&ZYPW7IGKV'Y^U?3]% 'S!_PP9X''2T
MM\=AAN@^Z.OKS[?K1_PP7X'Z&UMR.A^5NAY;OW/;\>>E?3]% 'S!_P ,&^">
MOV6W#=<X;KTSU[#\_:C_ (8,\#CI:6^.PPW0?='7UY]OUKZ?HH ^7V_8,\$;
M2/LEL>W*L,YY/?N?\>>E*?V#?!.XD6MOU)!PV2>,=_3(_+Z5]/TASVXH ^86
M_8.\%LH!MX"<YZ-CVXS^/X >](/V#/!(55^S0[5X!PV1T ([=,]O:OISYN!E
M@V"/F&0?<X_SS4E 'R^O[!O@K:,VUN#U^4-PQZD<_7ZY_-/^&"_!/E[?LUNH
M/!VHV.F!W]NGH>O'/TZY*KRV#MY/0=LGO0N_=\W&><=1C XS@=_\^@!\QG]@
MOP1M!^RVV[KC8W'.3W^A_#WX1?V"O!"\"W@V^ZGMT/4<]/R ]Z^G^=Q&6'0Y
MX_+_ #ZTUMW.TMZCICT_^O0!\R-^P?X+W9%M <'(W;N/I^'\SZ<@_8/\%JQQ
M;6^">3A@3T]_K^E?3NTXQN/7.>/7I2$D$XRW?&/;H#0!\Q0_L'>"XCG[-;[O
M[P!SUSDYX/4]OY\)_P ,%^"MHQ;PKMQM&"0/\C(^GUX^G]K%1EL'&#M'?UH^
M;/48SZ=L?XT ?,/_  P7X(PRBSM]IX"[3_4'T X[$CZK_P ,'>"VQ^XA7C!9
M5/Y^OX$X&3^/T[R&QU[DGTY]J=0!\P?\,'>"VQ^XA7CDJIX_J<>YQR3CU/\
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M&[/V:WZ@YVMZ<GK^'^<5]/T4 ?, _8-\$JHVVUNK8 QM; '/'7MG^?3/"?\
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M=*_(C_@C6)O^$JUPF!Q%VDP2&X/MCCGKZ#UR/UTD/7EA\I^Z,_TZT .50J@
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M$WEK\K C^$>W_P!?UQB@#UI!M51@+@=%Z"G444 %%%% !1110 4444 %%%%
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M3M(?L&FP6PQF.(*<<8^4^G3IZCZU;4!F9N#S@'.?3/TY'Z4N"P4G@CG@\?\
MUZ1E+,.VWD9 (_\ UX_G0 ;@&)V^Q.#GV_#FGTW"I\Q. ,DDGCUI2P& 3C/
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M0.GI2-)A<@KW /7D=L=^_P"5 $E%(#GMBEH **:K%NJE>,\X_*AB>PR<>O%
M#J*:74'!8 \=_7I3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *:S;<=,DX&3C_/%.I&4,I!&0>"#
M0 W:&!P6!Y&>?7WJ*\MTNK2>W*_+(I##'!!SD=1UY[]ZDV$9/RD]1C(R??\
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MSSZ8/49_.GKG:,\GOBFK^[4 E0H  P,#/^<4^@ HHHH **** "BBB@ HHHH
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M8?G4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT= O)Z?6HU&WY O8+][! YYP.GX?IBI0,9]_>@!:*** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR/SZU?K*\+X_L&S & L:C;Z<#CU_/FM6@ HHHH **** "BBB@ HHHH ****
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MAOHM7NKCRR&VR2%N1G')^M>=T4 ?H7X,_P""M/BCPQHL5C-:M=&-=H9@.,#
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M&<TJ#;@)M*=.O/?/UY_K3U8,H(.0>010 M%%% !1110 4444 %%%% !1110
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M=>,4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /4Z*0<=\TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-CCE?8?[/<YK\VZ_2/\ X(Y@?\)YJAV_,0V&Y]!Q_P#J]Z /V%HHHH ****
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MX?\ @KX!OM,N)HYKW4(C"J!L[2>_![<?E7X(^*M236/$FIWT?"7%P\H_%B:
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M,\C@]..OI3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P %4O&WB3P_X\2+3=4FM+8-D^3)COU')/.5_/\ /X"'Q9\8C/\ Q4FH<_\
M38U]S?\ !6J4-X_'<;L'D\\G;SGG@9Y'J<\U^=M '6M\6O&3=?$>H=<\2D4@
M^+/C$9_XJ34.?^FQKDZ* .L_X6QXPP0?$>H$$8(,Q(YK?\!_%7QE/XVT9!X@
MO7,EW&"I?@_,.3_CVQ7FE='\.&"^/-")Z?:T[D=_;^7>@#^E'X.32W7PS\.S
M3[FE:U4EG^]SU_7Z=*[%E)8$<?B?Y?B?TKCO@W_R3'P]\N&^RKNQZ\_G7:4
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M^8>QK^C?]DAO,^!'AQMNW,0XQ_LK["OYQ-)S_:EG@X/G)C(_VA7]&G['>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/0DX.1@YSGO]/\* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[W/3OUKS;]FSCX*>%N,?Z*O;_P"M7I:'<JG(;(ZKT- #J*** "BBB@ HHHH
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M(.0>012;2!@'OGGGO2KG:,C![XH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,WS<N !CCZY
M'^?I1M^;.Q?O9SWZ8STZ]J&;#$;U'3@^Y^O>C W],G.><\<8X_SWH ^1O^"F
MS#_AGB^!8=&XX]!GJ<'@&OP3K][?^"FS%?V=[WG;][G(']WO[8S]/6OP2H *
M_23_ ((Y _\ "=:KA>,/DX]DYZ?Y_2OS;K](_P#@CFO_ !7>J'I]\].O">W^
M<?A0!^PM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 57NK@6MG/<,P811LQ]/E!)
M_P YJ8L-N[.U5SG/'\Z^'_\ @I!^U1?_  5\()8:#.IO+P&)S&P) .!R,^I_
M3Z&@#Y/_ ."CG[6LGBK5Y/#NB7CHD!\J1HY#D\ 8)4_7\01[U^=3L9&9F.68
MY-:'B+7;KQ+K5WJ=[*TMS<2%V9JSJ "O<_V7_P!F'7_C[XPL88+)VT;?^_FY
M P"../J3[[:\[^$MGH^H>/-+@UYECTMI!YSL<!1D<DX./R/T-?M)\#_CY\ _
M@#X/MM&T6^M;<A%\R2+&[..<^@Q_(^F* /;_ -GG]F3PW\ ?#<6G:;;12R*O
M,C*"<\>V.W^>_K[2 J%3Y=O;'( &>@.?3BOG5?V_/A)CG7(PW7:&&<8SG_/;
MFE;]OOX2*I/]N+ZYR,>W/Y?F* /HM8P6;<,GG/ P03ZX] *7YE8]^,\9YZ\>
M@/(^M?.3?M^?"1<YUR,<D?,P'3_Z_P#GM2+^W[\)9&*IK<;MG  ;D^_\OU_$
M ^CV.67J,-Z'TIJMY>U2%7/OC//) ^N/SKA?AO\ &SPS\5(]^@70NA[$9Z9Z
M?Y[]^#W3\G:3SWVYX!/H#^OL: ')M7;A-A*],= .WZT^FJ!P5X'7;C'7G/\
MGUIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,HVG'! )Q]?SQ7Z.4 ,C/3EC\H^\,?TZT^FJQ;JI7C/./RIU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U
MU+*P!P2,9K\K?VHO^":OC3XO_%S4_$NDS;(;H#.Y< <G&,]?7K^5?JDQVCJ%
MY'7ZT;B1D#OCGCO0!^*7_#H?XCY/^D+QQT]O7'X=,>_%>Q_LQ_\ !-OQE\)_
M&D>KZG.75",[00.G8'MS]?UK]2@XVEB5V=0V>,8ZT%CG[I/3TH I:+:MI^FV
MUNX^9$"G&>H_#@<?2K]-7!)8#GIG&#Q3J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
MK*6Q]W'7D9[BFR1I<0M'*FZ.12K(W.01R#3RP7DG':H9(2S8SD'/!&?;OD=S
M^@Z"@#P?XE?L9_#WQOINK2?V.B:G=*2)E4$[OQ]L#_.*_-_Q)_P2-\=R:]?-
MI\W^AM,WE#'\.1[=.?TK]F]_E@ \'J>2?4\<<].E.5MV,C![\''% 'XH_P##
MHKXC;<FX4>V#[_[/M^HH/_!(GXDC'[U>?<?X5^U[9VG R>V:3=\V .>V3U'&
M3^M 'Y$_!O\ X)/^)]#\?:=?>)V$VE0OF6,#/H<].>,C\Z_2;X?_ +-O@3X:
MW\5]HVCPP7D:*@EV#/''^?QKU#<54EAT].:15Y!"[>3D9Q^/^?6@!Q&[_P#7
M3"I4YW-[\9[\4ICW$Y"D'@_+U&.GYTH;Y3_&R]0OKB@!K1E0NP#Y> NT8'49
M'3U_(4Y57:I48&, =./I35'S!0,*O3 P!_CU_2F[MRY<#;M^8MD#!'H?IT[4
M 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -9BO12W&>,?E3J:RANN>F."13J "F]&)(Z\#&3_\ J[T;F/\
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M3:VS!MT,2C XS@>N!Z?XU<5=I/7W/'S<#FD;+,,=B.Q_'OS_ (TY%*]6SV%
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX'^<5)&NQ0,_@!@#CM40_=MACMR-QP1@<DG\/?'?\IZ "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH 0C./;WI%55Z*!QC@=O2G44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !12*P900<@\@BEH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD+!>2<=J6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI P.0#G'!H 6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BDW#<1GGKBEH ***0,#D Y
MQP: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***3<-Q&>>N* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***1F"J23@#DDT +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIUX]:<JA1@#_ !- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D9@JDDX Y)-+2'GOB@!#NSP!CCO\ G1N/(^7>.=N?RINQ54EA
MNQWQDX'(^M#*2V/?.#R.,?D?_P!= #OFST&,^O;'^--D<KC!QGCD=\@#O[].
M]*RA?N@!N0#MSC/-)N#8^;8WW<9&0<9^F:  JK-R!DYRK<DCH<>W2DRKML;Y
MAZ'\>HQT^M+LW,=OR@'I@COD]^?_ -=(JE552,*,?=]<\ 8[#Z?UH 5E+9(&
M/]DDC.#QTH(+*R]1R"6'Z8[CFG+E8QQD@= <_J:8S%6(Q\QYQDG/;\.V>.]
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MA[XX_*G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !32N6!XP/;G/\
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M+344JHR>P&,Y_6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI]ZS-5\0Z7X=MO/U*[ALHP,%GXVCL#C/K6%_PMSP5][_ (2&QS][[W/IZ=:
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MHS7,.0-S/DXR!@]?7T[=.#7YY5]]_P#!,#YO'MO\JR<CG&<<@>GTY]@,'!H
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MZ@ HI"P& 3C/ I-ZYQN&<XQGOC./RH =13?,7:#G.1N&.<CVH9@O4\XSCO\
ME0 ZBBB@ HIID49'7'7 S_GK2LP522< <DF@!:*;N''.,G SQ1N&T,3@'UXZ
MT .HI P;D'/:D\Q=H(Y&,@J,\4 .HI"P& 3C/ I/,3:#N7&-V<]O6@!U%-+
M'&>>.!R>:7<-P&>>N* %HII=0<%@#QW]>E.H **;N&<<]<=#Z9HWKG&X9SC&
M>^,X_*@!U%-#J3@,">>_IUI2P& 3C/ H 6BFJZMT8'C/![>M"NK=&!XSP>WK
M0 ZBFJZMT8'C/![>M.H ***0L%Y)QVH 6BF[AM+ Y ].>E&X<\YP<''- #J*
M0-N__52T %%%-9U7JP'&>3V]: '44C-M4D]O09I-P 8DX"]2>!0 ZBD+;?\
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MH *:QP5Y R>_?CM3J* &H=RJ<ALCJO0TGR2?W7^7Z\'^AQ2N2.=RKV^8=^U
M)W$'ZCB@ 9@O4\XSCO\ E4-_?0:99S75S(L5O"N]W8X %%]?1:;:RW5PX2"-
M=S,>,>]?F1^W]_P4%313>>#O!US]H2<-%/-$Y^4@$9![<X/MGOV />?VEO\
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M]:YBB@#IS\3O%9P#KUZ0.!^\KZ\_X)^_M1ZYX;^(%KH&IZC/>07<FT"1B>I
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M@,=!C].WXTJ*1STW<D$#.?P].E #Z*** "BBB@ HHHH **** "BBB@ HHHH
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M3G^,U_1S^U4?^+&^(3\Q_P!';KQGY#U&1SWZ=C7\XNO?\AS4<'=_I,GS#O\
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MMZ+S0!:9RI  )/ICKP>_3M_G-+G:/F(Z_3OQ4:P@A21AAUX'.".><^@I_*<
M#EN !CZY_6@!-WRX7.,[=V<GTSW[^OO3MQ.1T;MP2/:FJR[2V=Q Y./FZ9Y'
MX]/>AD^9=HQC)Z#&<_SZ_F: #S"&)P2#PHX&<?7OU_*ALJV<,0.?T/  Z_\
MUZH>(->LO#&EW&H7TRPP1*78LV.@[9KYZOO^"@GPHL+R6W?5,O&VT_,/Z9%
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MW!<@@D ]#C^5 'P5<?\ !(SX;M;R".3$FT;>.^/\0/\ ZU?#/[1G_!/?Q9X
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M_P %"_A.PS_:J@^A?'?'I0!]-,A,>,EB!ZXSQ[4F"&; ZD'*@?Y[?E7S(O\
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MS^M(6&U2Q (&[<RD >OTX-?,S_\ !0KX41LP;554KUW2 8YQZ4U?^"A_PE+
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M['.,8'7CJ/;_ .MTKD?A7X\L/'_A&PN[&594\A0S(3_='L/Z5V7*L,<@]?\
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MY^\?6JU 'Z1?\$_?VI_&GQ(^-EOHVM7;7%FP7N6(&,8P!Z*/3_']A&7<5/\
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M<=^!_P#6K\+?'GC;4?'WB*YU34IWGED8E2[%B!]30![Y\2/V_/B3XV75-/\
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M)),QN.20./KD8H N^7A9 1A<%>$'3' 'TYZU(H 9\=SSQCL/SIL:GC*CJ3T
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MWW%=WR9)Z@GV&,9Y'UK]R-NUA@;1D],\YY_#G_/-.5@W3/3/((H _/GX6_\
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M_P!5.H **** "BBD)Z<9_I0 M%-W';G:<XSMXS]*19-S8^4XSG#9[X'\C^5
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MGX+^)6B_892BS7 1NYY],_RQS0!_2E'()D$RC<"ORC S[C/Y?E4BJ%4 # '
M KGOA_=-J7@G1KB7YGEMU<[ASZUT*J%4 # '  H 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1#R ,9QU]>:_??X=^,H/B%X3T_7[5=D-TFX+CMUX^O'Y5_,1I*AM4LP1D&9
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M'8* !ZG%15]-_L#_  IM?BM\8+?3[M$DAC978-Z Y]^^.W'\@#ZZ_P""?_\
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M^PY_R1'32!C**>1C^]VP/\^O6@#Z&HHHH **** "BBB@ KY;_P""BG_)O>J
MMM^1^2<8^[SU_P ^HKZDKY<_X*)MM_9]U+Y@HVL3GIC*Y[_Y_F ?S]5]K_\
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M:IK:V3]Y)I2A%QCN"../RX_"OYYOBUX3OO"7CK5[:\MWA#7,C)N!R?F/7WH
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M^O45^$\.?-3'7<,=?Z<_E7[J_P#!,-0OP?Z8)52/DP#TR>GT]<]CU% 'V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_X*(W\EQ^T%JD#$;8R3M&./3N3TK]WOB1XXM/AYX5N]:O95A@@&2S8Q^O\
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MH)_;B/\ Q:C43QPA&2<8X[<_IG\#7\^VK_\ (6O?^N[_ /H1H J5]^?\$P_
M*S>.K;6&7:ZG<)"N>N.GO@]/K^'P'7ZH?\$NM/7R[>8#<S !2O))R><XYY_F
M: /U6;&.1D9';/>FJVUCD!<XSZ;N._?M^5244 ,P6*;A@CGC!&<8Q^M?F3_P
M64^;PYHG\6&'X>W?GOT[CZU^FX7:>.!SP.G/?_/K7YD?\%EN?#NB#J<@_AGT
MY]^<?RS0!^2%!X[YHHH _:#_ ((__P#))]0./3M_N^U?H.5#<$9[U^?/_!('
M_DDM]E?HW_?.1_+_ ":_0/=\W7(!_A'3IP?SS0!Y?^TC_P DTO\ _=/&<9_Q
M]?PK^>;XUMGQ]?C.[YBV03_>(]?;_P"N:_H8_:28K\-;['!VD=0.U?SS_&IB
M?'VH9X^=CR3GJ>V?3'XYSSF@#A*^W?\ @ES<QP?%202=3(NWISTXZ?YYKXBK
MZ]_X)S22Q_%!3'@'>?F_X#],#MU]^E '[RVS*+5&PJ+C/H/KT'\J=RW/RY7&
M5!/![_7@^E5-%W+I%N H!"  =/P/'6KN]=N[<-N,[L\8]: $]%SN(P3S@_7C
MW%>,?MB?\F_^)N ?W)ZG_9;I7LW&T*%W8Z;L]O>O&?VQ,?\ #/\ XFSU\DX_
M[Y:@#^<K5/\ D)W?)/[Y^6&#]XU6JSJG_(3N^2?WS\L,'[QJM0!]D?\ !+M=
MW[0EL"3@A5(QGKGV^O7^E?N\<[ACD=Z_"+_@ERQ7]H2U(&3\N/QS]<?YZXX_
M=UEW#''4'D9[T <-\:-8&D^ -4??L)A/(//H/\Y'2OYROC7<&Z^)VNR$[BUP
MQSVZ]O:OZ)/V@K-KKX<ZF01Q$>.XXZCD?3\1UK^=/XO0_9_B-KB#D+<, 3_G
M_/Z  X\C&/?WKV_]C_1$U3XS:+*XR(IEP",Y^8'C@]L]N_O7B%>\?L9ZDEI\
M:-&B=]N^92/7J,D<=O\ /N ?T/Z"ODZ'8*"J[8D'3 Z#_/\ C5[:&R.2O(*M
MT.>>]4=!8OH-@V-I>!&^7'&0#Z>__P"NKN=T9W_*!]X,,#&.A_/]* &M(6;:
M 1STZ'@C)Z\C!'^>*D'R+RS-T[?AVIO&TJP!&W++DL>?;N.OY4YFSE<L#TR!
M[4  W9Y QSW_ "H&[/. .>/Y4;<*0N%/TXS494J2<X^; +,<<CTSSR?;]!0
MY5);)X; /'./4 GMQ1L#9*N?3J2,Y_Q_PI[<J1G'N*8OWL]"<$[AV],_7ZT
M>6_M0-L^"?B0YQ_H[<_\!;W'\Z_F_P#$W_(Q:H,8Q<R#C!Z,?2OZ0?VGFV_!
M/Q(?F.+=ONG'\)SSD8XS7\WWB;_D8M3^7;_I,G_H1H S:^X?^"8R[OB9 /\
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M_B?L/LK@_D?ZXK^;;Q1@^)-5Q@#[5)C'IN.*_I)_:0./@QXFY7_CV8[6S\V
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MC]#C\>U/8A/F(QZMQP!GK_GO35RJ L<;><+D]NGJ: '?-GH,9]>V/\:^ /\
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M0U/B_4%M+LKDL[Y.=H.<?GP.?8<"@#[I7+YR& /([?AZ]N_K36RF1T^7.5!
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M6<'L1@'N>.WY4 ?2\F%^<\#N>AX/KGH.:/X09..V#C!.>#_A]:>% R0,9Y-
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MFRNC^'OB"7PWXNTN\C=D"W";MO7K_P#7H _II\$WRZEX8L+E%4"2,'*]_?\
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M2XY_:$M^2,;!D#)&=W^'_P"OM^[K-M8$G Z=L9R,4 <W\1K%=2\$ZO%(611
M[''7@'N#Q7\WGQZMUM/BUXDA48"73KT /!(YP3SQZU_2MX@M3>:#J%JN-\T$
MBA5XSD'/?WY^M?@#^V]\"];^&?Q+U+5[Z%DL]0G9D9AC.3G^H]/\0#YHKU/]
MF&4P_&[PRRMM/VA<'MU'M^/'IZ9KRRM?PGXDG\)>(+/5;8?OK=PX]: /Z?O#
ML?\ Q3>G*,'-K']X<<J.U:# ,V,<XP3R" ?0_A7Q-^P/^VA9_&#PG!I&NW4<
M6KP*D:AGYSD#&,>YZ>G:OMK[ZY5N".&7^= #?O=/F4X;=GC\,?3]:Q?%7BC3
M?!>DW&H:C,L-O%&6RP7 VY(';\/I6Z!C/O[U\(_\%*?VBO#^@_#6]\,V>I :
MWEOEB<$XP.N#T_/MUP10!QX_X*?VUO\ %ZYT.:15T>*3:)2<C XX&<]<_G7T
M?X0_;B^'FLMY=YJ\-K@*-TD@ 'Y_U/:OY[9+R>:Z:Y:5C<,Q<R X.3WIZ:E>
M1\)=3J.GRR$?U]Z /Z6_"/Q\\%^.KK[/HNK1WDV0"JD''..<$^_Y5Z"LFZ,.
MV%&,]<C'UK\>/^"1N@7GB+QGJMS=7DSVT?W5E8L.G(&?IV-?L,I$>$_+@>O3
M ].* /+OVGLGX)>)5!QN@(SDCL?<9K^;[Q,NWQ%JG&,W,AP,\98GO7]('[3T
MAB^"?B)B>1;MSCC.UO<?SK^;_P 3?\C%J?R[?])D_P#0C0!FU]Q?\$Q>?B;!
MWPY/KC@_7'Z?4]*^':^XO^"8O/Q-@[X<GUQP?KC]/J>E '[B-TZD<CH,]Z^%
MO^"LUG/>_!%$MXS(_P W"GGH??TW=O\ ZWW2S;5)XP.N3@8[UY?^T-\*[3XJ
M> +^PNUWJD3,%)..!Z?XT ?S4LI5B",$<$&@\=\UV_QJ\+Q^#?B5K>D1+M6V
MF9, 87J>G/2N(/;G/]* /U,_X(Z6^D7EOKD.H6D,\[-B(R+NY^;U'U[_ (=Z
M_4/_ (0W0AC_ (E%GD=&\E<CIWQ["OYY/V5OVBM1^!7C;3YH)/+L9+@&<@X^
M4]<_B!_GK^]WP9^,GAWXT^%+?4-%NHYRL2B5%YV-C!QD=L_K0!UW_"'Z%Q_Q
M*++'IY"XZYQTZ9[4U?!^@]4TFR&.,K"HZ8]!ZBMEE#*01D'@@UE>)/$6G^#]
M'N=5U.806<(W/(>PY/4GZ_G0!R\FL> 8]:72'M],_M!F""%K="V1C Z?3CZ^
M]=+_ ,(;H(&!H]B!C!_<+S^GM7XG_M<?M77%G^T1-KW@W4FGLXGRNV0E., ]
M_P!.G.?2I(?^"KWQ-@M4A'\"; =PP1CT^N/K0!^UO_"(:&,8TFS !R (% SZ
MXQUJS:Z3IVF86WLX;<8V_)& .<\9Q^'Y>U?BC;?\%8_B6+J+<-ZEP&.<'&>2
M ._)_P G%?KC^S]XRG^)7PKT/Q'=KMGO(M[8R#]T =O0]?\ Z] '6^.+-M2\
M&ZM;KRTMNP7C!]ASTK^=C]J'X9ZGX!^*.M->1,L4]PS*2,8Z #^5?TA!A)E2
M,@CE2,X]0>W<5^4/_!7SP&MM=:?J5C9Y#%=[1J?3/KZ9_*@#\NN"O8$<]\GV
MKN?@CXN_X0?XE:/K)8*+:4,=WL0?Z?I7"TK*5 )'![]O\\T ?TI?LZ_%BW^+
MOP_L=5MI-RB-4)XSP![?@?I^7J38W$G=E1GC.._Y_P#ZO:OQ_P#^"</[7UC\
M-=-B\+ZU<^7;2$;6<\'''U]!^'OD?K?X=\0V'BG38M1T^59[>3.R12#Q_D?I
M0!>R5 5CTV@$Y&>1SG)]>AIR,JJN /F/!!SGC@Y[\"G,I;&#@@YJAK&M6OAW
M39;N]F6.&-2<L<<#W/MWH \U_:1^+6F_";X>ZA=W\RPB6(A"S<Y)[<CT/_U@
M*_G?^+&M)XA^(&L7\9RDTQ(K[G_X*6_M2V?Q-4>'M)O#Y-K(5;RW/)STZ^AS
MV_'BOSKH "V<>WM7N_['OPWU/QG\7M#N[2%WM[6X5W9/8CK[5X9!"]W.D48R
M[<  5^N7_!)_X'SZ;H-[K.MV(5B28F903U.""1QR>QYQTXH _1_PW&UKX?L$
M?JL"YV\]JT@V<^WM3?+"QJB_*@&.^<8]:(\[<L"&[Y^@Z<G% 'X-_P#!3XEO
MVAK@XR-K9;.>XXSD^GK7Q]7V!_P4]82?M#71!W85@6!R!R.#R?YU\?T 6](_
MY"UE_P!=T_\ 0A7]'/[(ZE?@#X85>"(  3T^Z.W'].<U_.-HXW:O8CUG3J<?
MQ"OZ//V2H3#\!?"^=N6MU;"@#'RC'0#]10!Z[$O5B,$_7\LGKSFG*ZMT8'C/
M![>M+M&XG'/3--+'<0"%.#C(SGISUZ4 >;?M(D?\*7\3@_Q6KXYQV)_I7\VW
MBC'_  DFK8Z?:Y?3^^?3BOZ2?VD/^2+^)P=VTVS9*]0.YZBOYMO%'_(R:F<8
M_P!)D..>/F/K0!F5]0_\$ZBJ_M%:26^[D?U]C_*OEZOJ'_@G6N[]HG25/.2H
MX_&@#^@5B1@]L\\9KRC]I+P#%X\^'M];RH66.,DX],'_  'XD?AZN[%<8VDG
M@;CCM5+6(!<:+>Q2#<&A<')QG@X.>* /YG/C-H'_  C'Q&U?3@ !#*1QCU/I
MZ=/PKB:]U_;'\'ZEX=^-WB*6Z@*P2SL4?UYST_&O"J /=OV0OB%<>#_BII%O
M&[*L]PNTCU) P,#(S[5_0SX5N&F\*Z;.>"UNLA_$9/I7\P_A'6CX=\3:;J:]
M;6=9/\\BOW<_8K_:NTGXK>$+'2[FYC6^MX5C'SY+8P,@8[D]J /K)2,X3& <
MG X[_KFF,S;]O0M\N>GJ01]!GM^E2(%^\IR&YSG(]?ZTI&[_ /70!7N[R'3H
M'FGD55ZG)Q[=S]*_G[_X*%ZI;ZM^T1J\UM()(\L =V[H0.3D\\&OU4_;H_:J
MT'X5_#_5-%MM0C7Q!(I"1AUR..O7H,C\17X7>-O&%]XXUZ?5+^5I9Y3DLW6@
M#!K4\*Y_X272]OWOM,>/?YAQ[_3O676GX7 ;Q)I@/3[3'VSCYAS0!_23^SA\
MWP3\+@ECFT4>AZ5UWCC36UKP?JEB!\]Q 4"YX)/;-<?^S<#_ ,*3\,8^4FU7
M'' X_#Z_C7IG.[N1CVP/\_TH _G:_;&^#<_PK^)5_P"8A6.XF9E.",C/!_SZ
M'Z5\_;OE(_I7Z8_\%@/"LG_"4:;>VD)*<M((^0/P_7\OQ_,Z@#UG]E[Q3IW@
M_P",&CZCJD2RV<;_ #JPX(R,\]A^!K^@[X:WWA'XB>$[#5=*TZSEMVB7K"OI
MC'TQV/K]:_F95VC8,K%6]0<&OVA_X)C_ +0V@77P[M_"=[?AM7 5AG&6X YX
MZY/<^I[T ?=P\'Z&,$:39Y'3]RO;IV[9IO\ PAN@2+C^R+$@<#]RO&.W3ZUK
M^4O/  /48'/7@_G3AWYS_2@#%D\*:!;1F1]+LD1/F+-"O&!CT[=O2L30-0\$
M^++J6VTR#3[B:$998X5&,8]!]/R'I7S#_P %$_VIIO@OX'^Q:'/G4[H%&VN,
MKU&0,^F?TK\MOA;^V_XZ^&/B.[U>TN9))K@DE2^<9S_+C\J /Z!?^$.T+C_B
M3V..N/LZXZYZ8IT/A/1;=U>+2;*-UX#+ H/\J_%=O^"LWQ,93A%Y!XW'ONR.
MOKM^N*^D/V._VQOB7^T%XD*3P226<,F9)-A(4;CCD#K^7).>G(!^DRHJY"#@
M;@ H X[@$=.<?E^-2\JV PYY /)Z\]_?\*AL#_HL&=VXQC/7''X>_P"-3JOR
M@,/<C.>>M #J*** "FMNW# Z8/L:=2%0W!&>] #1\JAF)&%YW'^?:O*OVC/A
MO9>/OAKK"W,*O.ELVU<9R>GMZGZX%>IJ^,$E</SG)P. .#]?IUJ.\LUO[&6W
M?Y5E4AMW.,_C0!_,/\2?#EWX8\9:K9W<#0%;F15R<YP>WTS7,5^F'_!2[]D'
M4[/6QXD\+V(EL8QYEQL&.N!D^G4?E7YHR1M#(T;C:ZDJRGL10!UOPI^(=Q\+
MO&EEXAM8_-GM3N5<#U'K7[H_L:_MC:'\?O!ME%?7<<>O_*K6[-N).,?AC!K^
M?^NW^$?Q:UOX/^+K77='N)$EA/,88A6_SD_F: /Z;VSM.,YZ\8R?;FFJNX=5
M=<GWYS]>W^<5^;W[,'_!3JT\62A/&UPMJ<X=F8DYZ=/I]>GTKZC_ .&Y_A/W
M\01?GG_/0_E[C(![Y(VYE SSD'J.,@'_ /7_ "S1/<)8VLDT[X2-2[MTX'-?
M/MY^W9\*K>TGE378G>-&8)N') )Q^A_R1G\\/C]_P5#\3ZAK6L:-H$K_ -F2
M!H0ZG:0I[=>#Z_2@"S_P5/\ CY:^.-<@TO0M2S':,(Y5AD/;KT;KR.W?MW_.
M5F+,23DGDDUH^(M?O/$VL76HWT[SSSR-(6<],GH/2LZ@ KZP_8 ^#?B#Q1\7
M=(\1P6,DFEVK_--_#Z\G&.W3Z^E?+V@Z'>>)-7M=-L(6GNKAPB(HYYK]W_\
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M![]N.U.IK#)7@'![]N.U 'P[_P %8F ^ K@DJ,,?8^H^\.Q/UX%?AW7[C?\
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M<X_'_/:@!IX[YHHJ:SC\Z\@C W%I%7:>^30!^@__  2)T*XC^*%QJ$D1\AB
MK%>.V#G'K]/Z5^S//F ]L?Y[_P">:^0?^">_P1T[P?\ "_3->CC47-R@;>$P
MQXSU(XZ_KZ5]?##-D!3C@-WZ\C]* /RU_P""S'_'CHG'\2]O]WVK\HZ_5W_@
MLR!]AT/')RN>.G3_ #V_Q_**@!T.?-3&2=P^[UK]U_\ @F&I'P=SLV_*I^X
M#G'.?P]_?'0?A1#S*@QGYAVS_0U^ZO\ P3#3'P=R%S\J_,.@SCV&3Q[XQUH
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M%WX4Z/\ &#P7>Z%JMM'+%<(<,Z\@D8_S]*[AAN4@]_0XI: /Y^/VOOV.-=^
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M<]_J?YUX?7MO[8!GF^.GB F%PBR,0Q!.>>N<GC&._>O%/)D&<HP_#Z_X'\J
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M+%0J= I[8]OY4 ?$K=<9! X! ZUZ+\&?CMXE^!^M/J.@7+1NV,KN.![X]?\
MZU<)=:7>6,\EO-;2)(C$$&,]02/2H&M9E4DPR #DDJ: /L#_ (>@_%DYS=+G
M[PY[\'^8_2O"_C3^T/XJ^..H)<:]=NX3^$.3NXQS^9XKS/[/+G'E/G.,;3UQ
MG'Y5[O\ LZ_LB^+OCSJ5O)8VDD>G+(#(S(>5Y/7'&<'M0!YIX3^%6O\ C+2;
MG4M/M7DLX!EI I(ZX/\ GWKDIX6MYI(G^_&Q5L>H.*_=X?LP^'_@G^R]J]H+
M2-=1%F_F%E )8J1ST.>_7U]37X8>)FW>(M4(Z?:9/P^8\4 9M?5'_!."/?\
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M\MM.Y2>>,Y/Y#K_.O)?CQ_P4(\;?%#2[K0H[IH]-ERC[<KP>" >OK^=?(M%
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M_!/Q*0H9C;-E.3G@G'4<?TK^;SQ+'-)XCU,M#(':YDRK+SG<?\#0!E5]0_\
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M< 8QUJ&UMX].M8X(QB&,8&2/E%3JH50 , < "@!:*** "BBB@ HHHH ****
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M/_AA?X3?] %0?PQ^H]A^OJ:^"OV;_P#@J%+X5TBQTWQ-(UQ,[+&2Q+8ZCO\
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M3V!'_P!:G,@QT)/3.>>3SS_GI29,C#;T4]<_X?CU[BB-2O&>0><#&>!USUH
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MG_/]: /G_P#X87^$W;05&.G3]>.>@_7U-;G@G]DOX>> -9CU/2-)6"Z08#@
M'IZ_@#]17L3?N]VWC@D#;D?7CZT2_=]3_"IQR>H_E0 ;O,VE>!U#9X_0]Q3D
M7;VV]@ >,#I2+A 06. 0/F_#OWIG).-C<CG+$8SU_EV_2@ S_$!SNR54<_=Z
M'G&?K[4EU:QWEL]M,#)'(I5O<5(6X5@<#@8;CJ1^M(T>Y5&<]MQ_GC&,Y H
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M#/XTZ@#\0IO^"2_Q*69E23*]!NCP?\\C\Q3%_P""3/Q,91^]7)_V/\^PQ_M
MY[5^WL<A<<J5. >G%#2JJ[L@C;N'(Y% 'X^_!7_@E1XJTGXAZ7=^*"L^D1/F
M:/:5)'?^H_ _6OT.T+]BWX8>'[B">UT.(30X()1<9  !QCV_7MUKW,3+SGY0
M,G)(['!_S[TFT[E/S#..#DXZDYYQW_SQ0!6TO3K;1;.*QLXEB@C "(.P)/7B
MK4F%!"_*Y!P![GKCZ]\4?*R[4XZD$=,@]\>_]:;'G<VTJ1G[H(]>>WL?Q)H
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MI'@O1;D^/K'[=>-POF+@'Z#J._Y\8ZU^A!;;_P#JI@D#<-A>G\1!SG^61^-
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M /GW_AA?X3]] C)/7@8_SR?S&,8&#_AACX3]_#\7Y8_SU/Y^PQ]!44 ?/O\
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MCP/7.,_U]:\F7_@DQ\33G]X,]/\ 5_7W]1CMUK]OE8-TSTSR"*4L!@$XSP*
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M_LE?\$R;7P7<SW'CRV6^;# ;D_Q]QT]!^7Z1!CG[I'7TH8C:V[Y57G.<>^:
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M^S?4;ZWM8O\ 632+&OU)P*_;;_@FG^S??_"'PL-:N-VS4$+98\D$9]/<=/\
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MDJ!T/S8.#T_6FW%G%>0F*=?-C.<JW0^WZT ?R^>-O!][X'\176EZA$T,L3,
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MX 1PP[<94G\^0#^M244 1,1'V484E>@  QQ3U!48[#@<Y-.HH :P.01R>G7
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M #&PO\.XK\W.3UST_7BF[/+)/"!0.<87 SQU]/7BI2H."1G'(I: (]GIN&W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4(_X(X:!\I.K'ALD!C@\\C_/3GVQ^EH;.?;VI&8\X7GH,]#Q^E 'YH_\.;M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^;^?7I0 W[KXSSPNYEY..?QXST]Z<P$BY Y*\9RIY_44K*64@'![4BL!\P7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *CDC#*V!RW!_''/OQ4E% #$);G(*MR"#GZ8XI&W[
MB!['/3C/3ISW_3ZU)10 G\0.?PIC,P4$_+W8YX'3/]?_ *U244 0M&?+ ;!(
M&T'&[.1CGVS[]NM2@Y[8I:* $;.TXX/;-1A?,8DG!'3D94D>G3^?4U+10!&R
M_+M"X4<  #VP1]/Z4OECDJ &ZC(X!YYQ^)I]% #=QW'C(Z=.GO\ RH90W7/3
M'!(IU% $;95&P?<=<CU]<]_Y4HC()^8\GU_'O^-/HH 1<[1D8/?%+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'(
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M.'W3MX//WL]:=10!'@R'G*G&1P.,CU]>OYTJY)+=%//.<]!^7TI]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781860768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXICURE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001698530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784530496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,936<span></span>
</td>
<td class="nump">$ 19,623<span></span>
</td>
<td class="nump">$ 18,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled revenue receivable</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party (Note 12)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">24,280<span></span>
</td>
<td class="nump">20,041<span></span>
</td>
<td class="nump">19,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net (Note 4)</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposit on leased facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,371<span></span>
</td>
<td class="nump">20,576<span></span>
</td>
<td class="nump">19,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt (Note 5)</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedLicenseAgreementFeesCurrent', window );">Accrued Northwestern University License Agreements fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities (Note 4)</a></td>
<td class="nump">2,496<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue (Note 3)</a></td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">8,276<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,529<span></span>
</td>
<td class="nump">12,158<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net (Note 4)</a></td>
<td class="nump">2,670<span></span>
</td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PreferredStockWarrantLiability', window );">Preferred stock warrant liability (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiability', window );">Common stock warrant liability (Note 10)</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,689<span></span>
</td>
<td class="nump">18,128<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (Note 6):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 35,513,987 issued and outstanding, September 30, 2017; 30,782,380 shares authorized, 131,644 issued and outstanding, December 31, 2016</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">43,219<span></span>
</td>
<td class="num">(17,578)<span></span>
</td>
<td class="num">(18,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(31,541)<span></span>
</td>
<td class="num">(22,604)<span></span>
</td>
<td class="num">(5,663)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">11,682<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">18,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">25,371<span></span>
</td>
<td class="nump">20,576<span></span>
</td>
<td class="nump">19,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (Note 6):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Non-redeemable preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,483<span></span>
</td>
<td class="nump">33,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember', window );">Series B-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (Note 6):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Non-redeemable preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (Note 6):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Non-redeemable preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (Note 6):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Non-redeemable preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedLicenseAgreementFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Agreement Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedLicenseAgreementFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785217088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">30,782,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">35,513,987<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">35,513,987<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,239,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,239,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember', window );">Series B-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,403,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,403,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,403,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,451,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,451,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,451,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,381,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,381,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,381,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,158<span></span>
</td>
<td class="nump">166,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,158<span></span>
</td>
<td class="nump">166,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,660,096<span></span>
</td>
<td class="nump">14,464,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,660,096<span></span>
</td>
<td class="nump">14,464,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series B-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781855680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,624<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">11,279<span></span>
</td>
<td class="nump">8,329<span></span>
</td>
<td class="nump">13,659<span></span>
</td>
<td class="nump">10,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">4,806<span></span>
</td>
<td class="nump">2,736<span></span>
</td>
<td class="nump">3,539<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,772<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">16,085<span></span>
</td>
<td class="nump">11,065<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
<td class="nump">15,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(2,275)<span></span>
</td>
<td class="num">(3,262)<span></span>
</td>
<td class="num">(8,461)<span></span>
</td>
<td class="num">(10,719)<span></span>
</td>
<td class="num">(16,162)<span></span>
</td>
<td class="num">(13,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (loss), net</a></td>
<td class="nump">163<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
<td class="num">(779)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (3,526)<span></span>
</td>
<td class="num">$ (8,937)<span></span>
</td>
<td class="num">$ (11,299)<span></span>
</td>
<td class="num">$ (16,941)<span></span>
</td>
<td class="num">$ (13,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (36.09)<span></span>
</td>
<td class="num">$ (48.73)<span></span>
</td>
<td class="num">$ (103.15)<span></span>
</td>
<td class="num">$ (74.16)<span></span>
</td>
<td class="num">$ (121.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average common shares outstanding</a></td>
<td class="nump">1,725,906<span></span>
</td>
<td class="nump">97,691<span></span>
</td>
<td class="nump">183,395<span></span>
</td>
<td class="nump">109,539<span></span>
</td>
<td class="nump">228,447<span></span>
</td>
<td class="nump">108,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783295728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Class C</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Class B (Series B-II)</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Class B (Series B-I)</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Class A</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Series C</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Series B-2</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Series B-1</div>
</th>
<th class="th">
<div>Non-Redeemable Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th"><div>Common Units</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,911,450<span></span>
</td>
<td class="nump">2,827,848<span></span>
</td>
<td class="nump">4,937,818<span></span>
</td>
<td class="nump">22,924,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2014</a></td>
<td class="nump">$ 11,397<span></span>
</td>
<td class="nump">$ 13,479<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="num">$ (11,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares) | Scenario, Previously Reported</a></td>
<td class="nump">166,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,464,445<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2015</a></td>
<td class="nump">$ 18,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,039<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(18,293)<span></span>
</td>
<td class="num">(5,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares) | Scenario, Previously Reported</a></td>
<td class="nump">98,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net</a></td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) (Scenario, Previously Reported) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,660,096<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,239,359<span></span>
</td>
<td class="nump">1,403,984<span></span>
</td>
<td class="nump">2,451,560<span></span>
</td>
<td class="nump">11,381,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="nump">$ 2,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,483<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(17,578)<span></span>
</td>
<td class="num">(22,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">58,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger', window );">Share conversion in connection with the Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,239,359)<span></span>
</td>
<td class="num">(1,403,984)<span></span>
</td>
<td class="num">(2,451,560)<span></span>
</td>
<td class="num">(11,381,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,556,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger', window );">Share conversion in connection with the Merger</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,483)<span></span>
</td>
<td class="num">$ (3,641)<span></span>
</td>
<td class="num">$ (5,371)<span></span>
</td>
<td class="num">$ (135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">42,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net</a></td>
<td class="nump">17,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,937)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,513,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2017</a></td>
<td class="nump">$ 11,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 43,219<span></span>
</td>
<td class="num">$ (31,541)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Conversion During Period, Shares, In Connection With Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareConversionDuringPeriodSharesInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareConversionDuringPeriodValueInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Conversion During Period, Value, In Connection With Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareConversionDuringPeriodValueInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784438912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,937)<span></span>
</td>
<td class="num">$ (11,299)<span></span>
</td>
<td class="num">$ (16,941)<span></span>
</td>
<td class="num">$ (13,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Unbilled revenue receivable and accounts receivable</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees', window );">Accrued Northwestern University License Agreements fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_IncreaseDecreaseAccruedProfessionalFees', window );">Accrued legal expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(948)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(6,207)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,447)<span></span>
</td>
<td class="num">(10,677)<span></span>
</td>
<td class="num">(5,050)<span></span>
</td>
<td class="num">(12,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">20,302<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">19,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(595)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of long-term debt fees and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsOfCommonStockFinancingCosts', window );">Payment of common stock financing costs</a></td>
<td class="num">(1,264)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsOfPreferredStockFinancingCosts', window );">Payment of preferred stock financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,486<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
<td class="nump">6,336<span></span>
</td>
<td class="nump">19,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="num">(4,663)<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">19,623<span></span>
</td>
<td class="nump">18,731<span></span>
</td>
<td class="nump">18,731<span></span>
</td>
<td class="nump">11,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">22,936<span></span>
</td>
<td class="nump">14,068<span></span>
</td>
<td class="nump">19,623<span></span>
</td>
<td class="nump">18,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction', window );">Common stock issuance costs (accounts payable and accrued expenses)</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_IssuanceOfCommonStockWarrants', window );">Issuance of common stock warrants</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_IssuanceofPreferredStockWarrants', window );">Issuance of preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt issuance costs (accounts payable)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash investing activities (capital expenditure) included in other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (107)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_IncreaseDecreaseAccruedProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Accrued Professional Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_IncreaseDecreaseAccruedProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_IncreaseDecreaseInAccruedLicenseAgreementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued License Agreement Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_IncreaseDecreaseInAccruedLicenseAgreementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_IssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_IssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_IssuanceofPreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Preferred Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_IssuanceofPreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsOfCommonStockFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Common Stock Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsOfCommonStockFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsOfPreferredStockFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Preferred Stock Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsOfPreferredStockFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767456576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure, Inc. (&#8220;Parent&#8221;) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. We believe the design of the Company&#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Throughout these unaudited consolidated financial statements, the terms &#8220;the Company&#8221; and &#8220;Exicure&#8221; refer to Parent and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the merger agreement,&#160;Max-1&#160;Acquisition Sub, Inc., a wholly-owned subsidiary of&#160;Max-1&#160;Acquisition Corporation&#160;(&#8220;Max-1&#8221;),&#160;merged with and into Exicure, Inc. (formerly AuraSense Therapeutics, LLC), a privately-held Delaware corporation referred to herein as Exicure OpCo., with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of&#160;Max-1&#160;Acquisition Corporation (the &#8220;Merger&#8221;). The Merger was effective as of September 26, 2017 (the &#8220;Effective Time&#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of&#160;Max-1&#160;Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement, options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of&#160;Max-1&#160;common stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware,&#160;Max-1 changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger,&#8221; whereby Exicure OpCo is considered the accounting acquirer in the Merger. Exicure OpCo was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i)&#160;legacy Exicure OpCo shareholders own approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">94%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii)&#160;legacy Exicure OpCo directors will hold all six board seats of the combined company, and (iii)&#160;legacy Exicure OpCo management will hold all positions in management of the combined company. The transaction is accounted for as an asset acquisition rather than a business combination because as of the acquisition date,&#160;Max-1&#160;does not meet the definition of a business as defined by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).  Consequently, the assets, liabilities and operations that are reflected in Exicure&#8217;s historical financial statements prior to the Merger will be those of&#160;Exicure OpCo, and the consolidated financial statements after completion of the Merger will include the assets, liabilities and results of operations of Exicure OpCo up to the day prior to the closing of the Merger and the assets, liabilities and results of operations of the combined company from and after the closing date of the Merger.  The assets and liabilities of Max-1 included in the accompanying consolidated financial statements are recorded at the historical cost basis of&#160;Max-1.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In these unaudited consolidated financial statements, unless otherwise indicated, all share and per share figures are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capitalization Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date.  On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement.  Pursuant to this agreement AuraSense, LLC received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class A Units of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$143</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, scientific equipment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$309</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$317</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for accrued legal expenses related to patent protection. The net book value of Parent&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License Agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company.  Under the terms of the License Agreement and the Partial Assignment of License Agreement, Northwestern University received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">113,816</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> units. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Unaudited Consolidated Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively. No preferred stock was provided in consideration for fractional membership units.  Each outstanding option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> common unit of AuraSense Therapeutics, LLC was converted into an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> share of common stock of Exicure OpCo. In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,837</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> was reclassified to Additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Refer to Note 6, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">for more information on capital stock transactions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been presented in conformity with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liquidity risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017, the Company has generated an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50,378</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, it believes that existing working capital at September 30, 2017 when combined with the aggregate cash raised on October 27, 2017 and November 2, 2017 of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11,211</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the sale of common stock (see Note 13, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">), but excluding any potential proceeds from option exercises, is sufficient to fund its current operating plans into 2019.  Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unaudited interim financial information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying interim consolidated balance sheet as of September 30, 2017, the interim consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, the interim consolidated statement of changes in stockholders&#8217; equity for the nine months ended September 30, 2017, and the interim consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016, are unaudited. The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of September 30, 2017, the results of its operations for the three and nine months ended September 30, 2017 and 2016, and the results of its cash flows for the nine months ended September 30, 2017 and 2016. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2017 and 2016 are unaudited. The results for the three and nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, or any other interim periods, or any future year or period.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Description of Business</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Exicure, Inc. (formerly AuraSense Therapeutics, LLC) (the Company) is a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on the Company&#8217;s proprietary Spherical Nucleic Acid, or SNA, technology. The Company believes the design of the Company&#8217;s SNAs gives rise to chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. No preferred stock was provided in consideration for fractional membership units. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date. On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement. Pursuant to this agreement AuraSense, LLC received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class A Units of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$143</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, scientific equipment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$309</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$317</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for accrued legal expenses related to patent protection. The net book value of Parent&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company. Under the terms of the License Agreement and the Partial Assignment of License, Northwestern University received </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">229,242</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> units. Also on December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B (Series B-1) units with net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B (Series B-2) units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In June 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,911,450</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,010,219</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,542,783</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In January 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">195,651</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These transactions are described in more detail below in Note 5, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements as of, and for the years ended, December 31, 2016 and 2015, have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Going concern</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2016, the Company has generated an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$41,441</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans, existing working capital at December 31, 2016 is not sufficient to sustain operations beyond September 30, 2017. As discussed in Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, on September 26, 2017 the Company completed the Merger with Max-1 Acquisition Corporation and the Private Placement for the sale of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,302</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of Exicure shares of Common Stock, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares, at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share (see Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). The combined company is expected to have approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$17,394</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in additional capital after the Private Placement. Management believes cash as of December 31, 2016, when combined with the cash raised in connection with the Private Placement, is sufficient to fund the Company through September 30, 2018. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, the Company completed the Merger with Max-1 Acquisition Corporation (see Note 12, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). Pursuant to the terms of the Merger, each outstanding share of Exicure capital stock (other than shares of Series C Preferred Stock of Exicure) was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Acquisition Corporation&#8217;s Common Stock and each outstanding share of Series C Preferred Stock of Exicure was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Acquisition Corporation&#8217;s Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767279168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts receivable and unbilled revenue receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&#8220;Purdue&#8221;) and, in 2016, grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.  Management believes that the Company&#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of credit risk and other risks and uncertainties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22,936</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Liquidity Risk</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">seven</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> impairment losses were recorded from inception in December 2011 through September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common stock warrant liability</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet.  Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has entered into certain grant contracts containing milestone payments.  The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured.  If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract.  For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, the Company was not participating in any grant research activities involving milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments and geographic information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred rent</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease and is presented in &#8220;Other noncurrent assets&#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company established a full valuation allowance against its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts receivable and unbilled revenue receivable</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments. Management believes that the Company&#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of credit risk and other risks and uncertainties</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,731</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> at two institutions, respectively. These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation-Going Concern</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three to seven&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets. Depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$180</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$133</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the years ended December 31, 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> impairment losses were recorded from inception in December 2011 through December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred stock warrant liability</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of preferred stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The preferred stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. The Company classifies the liability as noncurrent as settlement is not expected within the next 12&#160;months. There were no preferred stock warrants outstanding as of December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purdue Collaboration </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue Pharma L.P., or Purdue, and referred to as the Purdue Collaboration. Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In addition, the Company is eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$770,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> upon successful completion of certain research, regulatory and commercial sales milestones. There can be no assurance these milestones will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of the Company&#8217;s control. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive single to low double digit royalties on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&#160;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverable (2)&#8212;obligation to participate in a joint research committee, deliverable (4)&#8212;a non-voting board of director observer role, deliverable (5)&#8212;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, and deliverable (6)&#8212;the option to obtain an exclusive development and commercialization license for AST-005 or a new TNF-&#945; development candidate other than AST-005 do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverable (1)&#8212;the exclusive rights to the TNF-&#945; target and deliverable (3)&#8212;the provision of research and development activities, as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverable (7)&#8212;the option to select and develop three additional collaboration targets and deliverable (8)&#8212;the option to obtain an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> is allocated to these deliverables. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of 14.5 months. During the year ended December 31, 2016, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$690</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As of December 31, 2016, deferred revenue relating to the Purdue Collaboration was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$9,310</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8,276</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> is classified as current portion of deferred revenue in the accompanying balance sheet.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has entered into certain grant contracts containing milestone payments. The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract. For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of December 31, 2016 and 2015, and for the years then ended, the Company was not participating in any grant research activities involving milestone payments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segments and geographic information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All material long-lived assets of the Company are located in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred rent</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes. Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company established a full valuation allowance against its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The Company adopted this guidance in the first quarter of 2016 and adoption did not have a material impact on the accompanying financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160;Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160;The guidance will be effective for the Company in the first quarter of 2017 and early adoption is permitted.&#160;The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767245280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purdue Collaboration<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Purdue Collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue and referred to herein as the &#8220;Purdue Collaboration.&#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s lead therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> additional collaboration targets. Additionally, Purdue has rights of first offer to some potential collaboration targets. These rights of first offer are subject to limitations in time and scope. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In addition, the Company is eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$776,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> on future net sales of such commercialized therapeutic candidates. Additionally, Purdue had an obligation to invest in a qualified equity financing of the Company if such financing was completed before June 2, 2017. The Company did not complete such qualified equity financing before June 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In accordance with ASC 605-25, the Company identified the following deliverables at the inception of the Purdue Collaboration agreement: (1) exclusive rights to the TNF-&#945; target, (2) the obligation to participate in a joint research committee, (3) the provision of research and development activities based on a prescribed full-time employee rate per year, (4) a non-voting board of director observer role, (5)&#160;Purdue&#8217;s right to participate in a future&#160;qualified equity&#160;financing of the&#160;Company&#160;if such financing occurs prior to&#160;June 2, 2017&#160;or the pricing of&#160;the&#160;initial public offering&#160;of shares&#160;of the Company&#8217;s common stock, (6) the option for an exclusive development and commercialization license to AST-005 or a TNF-&#945; development candidate other than AST-005, (7) the option to select and develop three additional collaboration targets, and (8) the option for an exclusive development and commercialization license to any developed therapeutic candidate targeting the three additional collaboration targets.  The Company determined that deliverables (2), (4), (5), and (6) do not have stand-alone value to Purdue, and accordingly, deliverables (2), (4), (5) and (6) were combined with deliverables (1) and (3) as a single unit of accounting. The Company concluded that, at the inception of the agreement, deliverables (7) and (8) are substantive options and do not contain a significant or incremental discount; as a result, no portion of the upfront </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> is allocated to deliverables (7) and (8). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The upfront payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> was allocated to the single unit of accounting consisting of deliverables (1), (2), (3), (4), (5), and (6) above and was recorded as deferred revenue and is being recognized on a ratable basis over the estimated performance period of the relevant research and development activities of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">14.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> months.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Purdue Collaboration agreement includes contingent payments related to specified research, development and regulatory milestones and sales-based milestones. Each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties. The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved. Any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively, when such payments become due and collectible, over the remaining expected performance period under the arrangement, which is generally the remaining period over which the research and development services are expected to be provided. To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration as revenue.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the three months ended September 30, 2017, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,497</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which included </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$428</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the nine months ended September 30, 2017, the Company recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$7,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which included </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,417</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  As of September 30, 2017 and December 31, 2016, deferred revenue relating to the Purdue Collaboration was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,103</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$9,310</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,103</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8,276</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively, is classified as current portion of deferred revenue in the accompanying balance sheet.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767300672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,835</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$70</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$46</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the three months ended September 30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$159</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$132</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the nine months ended September 30, 2017 and 2016, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Northwestern University License Agreements fee (Note 11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Components of property and equipment were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Construction in process at December 31, 2015 represents the purchase of scientific equipment in December 2015 that was placed in service during the second quarter of 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767310560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2016, the Company closed a </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> loan facility, with an initial advance against this loan facility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, with Hercules Technology Growth Capital (&#8220;Hercules&#8221;). The loan bears a floating interest rate equal to the greater of either (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> or (ii) the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> plus the United States prime rate minus </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3.50%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. &#160; Total proceeds net of fees and issuance costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,839</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Fees and issuance costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$161</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, as well as fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$231</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on our balance sheet and will be amortized to interest expense through the maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> using the effective interest method.&#160; Interest amounts were payable monthly beginning on March 1, 2016 through the maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date.  In 2016, the Company met certain terms in the loan agreement so that principal amounts became payable monthly beginning on July 1, 2017.  The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&#160; Additionally, HTGC shall have the right to participate in a future financing of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> under the same terms and conditions and pricing afforded to other participants in that future financing.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the February 2016 HTGC loan, HTGC also had the right to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">80,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Series C preferred stock at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and recorded as a reduction in the carrying amount of long-term debt on our balance sheet.  This discount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> will be amortized to interest expense through the loan maturity date of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> using the effective interest method.&#160; The Company estimated the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and recorded any changes in fair value to other income (expense), net on our statement of operations. See Note 10, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information on the fair value of the preferred stock warrant liability.  The warrant agreement to purchase shares of preferred stock was terminated on September 26, 2017 in connection with the Merger. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At September 30, 2017 and December 31, 2016, the carrying value of long-term debt is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,221</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,667</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At September 30, 2017, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$158</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$153</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> during the three months ended September 30, 2017 and 2016, respectively, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$470</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$327</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> during the nine months ended September 30, 2017 and 2016, respectively.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2016, the Company closed a </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> loan facility with Hercules Technology Growth Capital (HTGC) at a floating interest rate equal to the greater of either (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> or (ii) the sum of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> plus the United States prime rate minus </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3.50%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, with an initial advance against this loan facility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160; Total proceeds net of fees and issuance costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,839</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.&#160;Fees and issuance costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$161</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, as well as fees of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$231</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of September 1, 2019 using the effective interest method.&#160;Interest amounts are payable monthly beginning on March 1, 2016 through the maturity date of September 1, 2019.&#160;Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date. In 2016, the Company met certain terms in the loan agreement so that principal amounts are payable monthly beginning on July 1, 2017. The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.&#160;Additionally, HTGC shall have the right to participate in a future financing of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> under the same terms and conditions and pricing afforded to other participants in that future financing.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the February 2016 HTGC loan, HTGC also has the right to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">104,348</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Series C preferred stock at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and recorded as a reduction in the carrying amount of long-term debt on the Company&#8217;s balance sheet. This discount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$134</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> will be amortized to interest expense through the loan maturity date of September 1, 2019 using the effective interest method.&#160;The Company will estimate the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and will record any changes in fair value to other income (expense), net on the Company&#8217;s statement of operations.&#160;At December 31, 2016 the carrying value of long-term debt is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,667</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and the fair value of the preferred stock warrant liability is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$201</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. See Note 9, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information on the fair value of the preferred stock warrant liability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2016, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$478</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> during the year ended December 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6611760512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, in connection with the Merger, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;Max-1&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of&#160;Max-1&#160;common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">200,000,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of common stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> authorized and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">35,513,987</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The holders of shares of the Company&#8217;s common stock are entitled to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&#160;non-assessable.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of September, 30, 2017, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of preferred stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> authorized and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Private Placement Offering</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, following the Effective Time of the Merger,&#160;the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering (the &#8220;Offering&#8221;) for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share (the &#8220;Offering Price&#8221;).  The aggregate net proceeds from the initial closing of the Offering (after deducting placement agent fees and expenses of the initial offering of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,037</font><font style="font-family:inherit;font-size:10pt;color:#000000;">) were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$17,235</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Warrants to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">163,174</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of common stock were issued to the placement agents.  The warrants expire on March 27, 2021 and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share.  The warrants to purchase common stock are classified as a liability and presented as a dividend that offsets the gross proceeds of the Offering within the accompanying consolidated statement of equity.  The common stock warrant liability will be remeasured each period at fair value.  See Note 10, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for more information on the common stock warrant liability.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As discussed in Note 13, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">the Company held subsequent closings on October 27, 2017 and November 2, 2017 (the &#8220;Subsequent Closings&#8221;) and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. common stock in the private placement offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to certain customary exceptions, investors in the Offering have anti-dilution protection with respect to the shares of common stock sold in the Offering such that if within eighteen (18)&#160;months after the initial closing of the Offering the Company issues certain additional shares of common stock or common stock equivalents for a consideration per share less than the Offering Price (the &#8220;Lower Price&#8221;), each such investor will be entitled to receive from the Company additional shares of common stock in an amount such that, when added to the number of shares of common stock initially purchased by such investor in the Offering and still held of record and beneficially owned by such investor at the time of the dilutive issuance (the &#8220;Held Shares&#8221;), will equal the number of shares of common stock that such investor&#8217;s aggregate purchase price for the Held Shares would have purchased at the Lower Price. Either (i)&#160;holders of a majority of the then Held Shares or (ii)&#160;a representative of the holders of the then Held Shares, which representative shall be appointed by the three investors who then hold the largest number of Held Shares, may waive the anti-dilution rights of all Offering investors with respect to a particular issuance by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This price-based anti-dilution protection will automatically terminate upon our receipt of gross proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$40,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> or more in one or more related closings in a bona fide transaction in which we issue shares of common stock or certain common stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Offering was exempt from registration under Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Offering was sold to &#8220;accredited investors,&#8221; as defined in Regulation D, and was conducted on a &#8220;reasonable best efforts&#8221; basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Registration Rights</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the Merger and the Offering, the Company entered into a Registration Rights Agreement, pursuant to which the Company has agreed that promptly, but no later than 60 calendar days from the final closing of the Offering, the Company will file a registration statement with the SEC, or the Registration Statement.  Each Investor in the Subsequent Closing also entered into the same registration rights agreement signed by investors in the initial closing of the Offering, which requires that the Company file a &#8220;resale&#8221; registration statement with the SEC covering the shares of common stock and warrants issued in the Offering, certain other shares of common stock issued in connection with the Company&#8217;s recently closed reverse merger, and shares held by the Company&#8217;s&#160;pre-merger stockholders, within 60 calendar days from the final closing of the Offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Capitalization Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All share and per share figures herein are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July 9, 2015, Exicure OpCo converted from a limited liability company into a C corporation.  In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively.  Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure OpCo, resulting in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">46</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> less aggregate shares of outstanding preferred stock of Exicure OpCo as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">one</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> share of common stock of Exicure OpCo.   </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class A Units/Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement.  In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class A units.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per unit or an aggregate value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,217</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&#8217;s net book value. The net book value of AuraSense, LLC&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class A units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">11,381,640</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure OpCo Series A preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class A units/Series A preferred stock were senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class B Units/Series B Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Class B units/Series B preferred stock were divided into two tranches and have been issued in two series: Class B-1/Series B-1 and Class B-2/Series B-2.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-1/Series B-1</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,571</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B-1 units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.22</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,432</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> including a receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$500</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for </font><font style="font-family:inherit;font-size:10pt;color:#000000;">225,677</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$61</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-2/Series B-2</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On June 27, 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,995</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B-2 units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.62</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,676</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and proceeds net of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$35</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in financing costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,571</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class B-1 units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,995</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class B-2 units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,451,560</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,403,984</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure OpCo Series B-1 and Series B-2 preferred stock, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class B units/Series B preferred stock were senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class C Units/Series C Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 13, 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,532,112</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,596</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$117</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 6, 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1,541,168</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per unit.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,073,280</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class C units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,073,226</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure OpCo Series C preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,016,134</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15,048</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$69</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">149,999</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share.  Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class C units/Series C preferred stock were senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Exicure OpCo Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders were entitled to receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> times the aggregate cash contribution of all holders of Class C preferred units/stock.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As discussed in Note 1, the Company converted from a limited liability company into a C corporation on July 9, 2015. In connection with the corporate conversion, each common unit, Class A unit, Class B-I unit, Class B-II unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into one share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure, Inc., respectively. Fractional units of AuraSense Therapeutics, LLC that were outstanding prior to the corporate conversion were not converted to shares of stock in Exicure, Inc., resulting in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">17</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> less aggregate shares of outstanding preferred stock of Exicure, Inc. as compared to aggregate outstanding preferred units of AuraSense Therapeutics, LLC in connection with the corporate conversion. Each outstanding option to purchase one common unit of AuraSense Therapeutics, LLC was converted into an option to purchase one share of common stock of Exicure, Inc. The Company completed a reverse-merger with Max-1 Acquisition Corporation on September 26, 2017; see Notes 1 and 12 for additional information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class A Units/Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, the Company entered into agreements with AuraSense, LLC: the Bill of Sale, Assignment and Assumption Agreement and the Partial Assignment of License Agreement. In exchange for the contribution of certain assets and agreeing to certain undertakings, the Company provided to AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class A units.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For purposes of determining the value of its initial capital contribution, the members of AuraSense Therapeutics, LLC agreed that the Class A units provided to AuraSense, LLC were to be valued at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.10</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per unit or an aggregate value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,217</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. For accounting purposes, however, as the Company and AuraSense, LLC were under common control, the assets and liabilities transferred and the Class A equity contributions were valued at AuraSense, LLC&#8217;s net book value. The net book value of AuraSense, LLC&#8217;s contribution at inception was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$135</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,210</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class A units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">22,924,209</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. Series A preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class A units/Series A preferred stock are senior in right of payment only to the common units until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class B Units/Series B Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Class B units/Series B preferred stock are divided into two tranches and have been issued in two series: Class B-I/Series B-1 and Class B-II/Series B-2.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-I/Series B-1</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On December 12, 2011, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B-I units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.10</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,432</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> including a receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$500</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for </font><font style="font-family:inherit;font-size:10pt;color:#000000;">454,545</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the sold units. The receivable was collected in 2012. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$61</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$5,371</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Class B-II/Series B-2</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. On June 27, 2013, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class B-II units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,676</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and proceeds net of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$35</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in financing costs were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,641</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,818</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class B-I units and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,848</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class B-II units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,937,813</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,827,844</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. Series B-1 and Series B-2 preferred stock, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class B units/Series B preferred stock are senior to the Class A units/Series A preferred stock and common units/stock in their right to payment until such time as they have received aggregate distributions equal to their unreturned cash contribution.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class C Units/Series C Preferred Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 13, 2014, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,911,450</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units at a price per unit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,596</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$117</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,479</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 6, 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,010,219</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of its Class C units at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per unit. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,624</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$43</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$4,581</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As further discussed above, in connection with the corporate conversion, </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,921,669</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> Class C units were converted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,921,662</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. Series C preferred stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In October 2015, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,542,783</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15,048</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$69</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$14,979</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On January 11, 2016, the Company sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">195,651</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of its Series C preferred stock at a price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.30</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share. Total gross proceeds raised thereby were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$450</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Net proceeds after associated costs and expenses of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$6</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$444</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The Class C units/Series C preferred stock are senior to the Class A and Class B units/preferred stock and common units/stock in rights and privileges as established in the Operating Agreement. Principal among the rights of Class C units/preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred unit/stock holders are entitled to receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.5</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> times the aggregate cash contribution of all holders of Class C preferred units/stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769527440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September&#160;22, 2017, the Board adopted and Exicure&#8217;s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which is expected to become effective on or about November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5,842,525</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure common stock, which includes </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,158,708</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,683,817</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) and were assumed in the Merger. Awards that may be awarded under the 2017 Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards.  The 2017 Plan also provides that the number of shares reserved for issuance thereunder will be increased annually on the first day of each year beginning in 2020 by the least of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4,600,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares, five percent (</font><font style="font-family:inherit;font-size:10pt;color:#000000;">5%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">)&#160;of the shares of Exicure common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares as determined by the Company&#8217;s compensation committee. No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan.  The aggregate number of common stock options available for grant under the 2017 Plan was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2,158,708</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> as of September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 6, 2015, the Exicure OpCo board of directors adopted the 2015 Plan, subject to approval by the Company&#8217;s stockholders.  Such stockholders approval was received on October 13, 2015.  The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.  Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the &#8220;2014 Plan&#8221;).  In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure OpCo common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The common stock options are contingent on the participants&#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason.  The initial stock option grant to an employee, director or consultant vests </font><font style="font-family:inherit;font-size:10pt;color:#000000;">25%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48 months</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  Subsequent stock option grants vest 1/48th monthly until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48 months</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  The term of common stock option grants is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">ten</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> years unless terminated earlier as described above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at September 30, 2017 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,352</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.5 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 6.9 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 1.41%; weighted avg. 1.26%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.9% to 82.4%; weighted avg. 80.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2017 and 2016 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of Exicure OpCo&#8217;s common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid). At September 30, 2017, for financial reporting purposes and principally to aid Exicure in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is the per share price paid by outside investors in the Offering on September 26, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.92</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1.53</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2017 and 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$202</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prior to October 6, 2015, the Company had granted common unit options to employees, directors, and consultants under the terms of the Equity Incentive Plan which was adopted on September 1, 2011 and subsequently amended and restated on June 13, 2014 (the 2014 Plan). In connection with the corporate conversion (see Note 1), each outstanding common unit option became an option to purchase one share of Exicure, Inc. common stock. On October 6, 2015, the Board of Directors adopted the Exicure, Inc. 2015 Equity Incentive Plan (the 2015 Plan), subject to approval by the Company&#8217;s stockholders. Such stockholders approval was received on October 13, 2015. The 2015 Plan replaced the 2014 Plan and all outstanding options as of October 13, 2015 became subject to the terms of the 2015 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate number of shares of common stock available for awards granted under the 2015 Plan is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">9,806,006</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. As of the first day of each calendar year beginning on or after January 1, 2017, the number of shares available for all awards under the 2015 Plan, other than incentive stock options, will automatically increase by </font><font style="font-family:inherit;font-size:10pt;color:#000000;">4%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the number of shares that are issued and outstanding as of that date, unless the compensation committee approves an increase of a lesser percentage. The aggregate number of common stock options available for grant under the 2015 Plan was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,318,400</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> as of December 31, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The common stock options are contingent on the participants&#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial stock option grant to an employee, director or consultant vests </font><font style="font-family:inherit;font-size:10pt;color:#000000;">25%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> months. Subsequent stock option grants vest 1/48th monthly until fully vested at the end of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">48</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> months. The term of common stock option grants is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">ten</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> years unless terminated earlier as described above.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at December 31, 2016 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,630</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.6 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions. In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 2.24%; weighted avg. 1.58%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59% to 2.08%; weighted avg. 1.73%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.2% to 83.6%; weighted avg. 79.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.9% to 85.4%; weighted avg. 82.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2016 and 2015 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br clear="none"/>weighted avg. $0.69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br clear="none"/>weighted avg. $0.69</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s common stock has not yet been publicly traded, therefore the Company estimates the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&#8217;s common stock has been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company has periodically estimated the per share fair value of its common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the years ended December 31, 2016 and 2015 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.90</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.53</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 3, 2014, the Board took action by way of unanimous written consent to modify the strike price on all outstanding common unit options to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.32</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> (the Modification). The Board determined that for all periods wherein common unit option had been granted, the fair value of the Company&#8217;s common units was equal to or less than </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.32</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per common unit. No other terms of the repriced common unit options were modified and these repriced common unit options continued to vest according to their original vesting schedules and retained their original expiration dates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All outstanding common unit options were revalued as of October 3, 2014 (the Modification Date) based on valuation assumptions reflecting current facts and circumstances then existing. The Modification affected grants to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">twenty</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> participants comprising all current employees and board members and to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">seven</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> non-employee advisors. For all common unit options, the Company calculated the incremental fair value attributable to the Modification by calculating the fair value of all outstanding awards immediately before and immediately after the Modification under the valuation assumptions existing as of the Modification Date. For all vested options, the incremental fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> calculated thereby was recognized as expense immediately. For all unvested options, the incremental fair value of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$90</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> as calculated thereby will be recognized as expense over the remaining service period of each awardee.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,954,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,941,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(166,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200,625</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382,321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,956,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,025,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the years ended December 31, 2016 and 2015 was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$63</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$36</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767219936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company incurred a pretax loss in each of the three and nine months ended September 30, 2017 and 2016, which consists entirely of loss in the U.S. and resulted in </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> provision for income tax expense during the periods then ended. The effective tax rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in each of the three and nine months ended September 30, 2017 and 2016 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pretax loss before income taxes was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$16,941</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13,151</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the years ended December 31, 2016 and 2015, respectively, which consists entirely of losses in the U.S. and resulted in no provision for income tax expense during the years then ended.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax expense at statutory rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss prior to C corporation conversion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity classification change</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s effective income tax rate for the years ended December 31, 2016 and 2015 is </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of the Company&#8217;s net deferred tax assets are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Net Operating Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Fixed Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Accrued Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Equity-Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Deferred Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Taxes, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has recorded a full valuation allowance against its deferred tax assets at December 31, 2016 and 2015.  This determination is based on significant negative evidence, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Cumulative losses:</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> The Company has been in a significant cumulative loss position since its inception in 2011. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Projected realization of net operating loss carry forward amounts:</font><font style="font-family:inherit;font-size:10pt;color:#000000;">  Projections of future pre-tax book loss and taxable losses based on the Company&#8217;s recent actual performance and current industry data indicate it is more likely than not that the benefits will not be recognized.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2016, the Company had a federal net operating loss carryforward of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,727</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which will begin to expire in 2035.  The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,727</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of state net operating loss carryforwards which will begin to expire in 2027. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December&#160;31, 2016 and 2015, the Company had </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> unrecognized tax benefits. The Company&#8217;s estimate of the potential outcome of any uncertain tax position is subject to management&#8217;s assessment of relevant risks, facts and circumstances existing at that time. The Company evaluates uncertain tax positions to determine if it is more-likely-than-not that they would be sustained upon examination. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to taxation in the U.S. and various state jurisdictions. The Company remains subject to examination by U.S. federal and state tax authorities for the years 2013 through 2016. There are no pending examinations in any jurisdiction.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769496880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,906</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6937127248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s preferred stock warrant liability and common stock warrant liability are classified within Level 3 of the fair value hierarchy.  The fair value of the preferred stock warrant liability and common stock warrant liability was determined using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the preferred stock warrant was based significantly on the fair value of the Series C preferred stock, which was developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.26%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">62.99%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> expected dividends.  In connection with the Merger, the warrants to purchase preferred stock were terminated and therefore the related liability was reduced to zero.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the common stock warrant is based significantly on the fair value of the Company&#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">2.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.44%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">78.71%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> expected dividends.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> change in the estimate of expected volatility at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.  A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> change in the estimate of fair value of the common stock at September 30, 2017 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$34</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the nine months ended September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs&#8212;unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs&#8212;other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs&#8212;unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the preferred stock warrant liability was determined using the Black-Scholes option-pricing model. The fair value of the preferred stock warrant is based significantly on the fair value of the Series C preferred stock, which is developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">5.0 years</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">1.26%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">62.99%</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">no</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> expected dividends.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the preferred stock warrant liability at December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> change in the estimate of expected volatility at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$12</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. A </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> change in the estimate of fair value of the Series C preferred stock at December 31, 2016 would increase or decrease the fair value of the preferred stock warrant liability in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$26</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the year ended December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the reverse merger (see Note 12), the warrants were terminated under the terms of the warrant agreement immediately prior to the completion of the reverse merger and the preferred stock warrant liability will be reduced to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">zero</font><font style="font-family:inherit;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6937163424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six years</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> through February 2021, and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$52</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> as of September 30, 2017 and December 31, 2016, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of September 30, 2017 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, we obtained exclusive license as to NU&#8217;s rights in certain SNA technology we jointly own with NU (the &#8220;February 2016 license agreement&#8221;). Our license to NU&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of September 30, 2017, the Company has paid to NU an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,247</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in consideration of each of the obligations described above.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015. During the first quarter of 2014, the lease was extended for an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six years</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> through February 2021, and includes a renewal option and an early termination option at the end of February 2018. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016. Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$52</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$50</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$48</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> as of December 31, 2016 and 2015, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense allocated to AuraSense, LLC (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Note 11, Related-Party Transactions, for more information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of December 31, 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Northwestern University license agreements</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (NU) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product. In August 2015, the Company entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology the Company jointly owns with NU (the &#8220;February 2016 license agreement&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;June 2016 license agreement&#8221;). The Company&#8217;s rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;). As of December 31, 2016, the Company has paid to NU an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,534</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in consideration of each of the obligations described above. At December 31, 2016, the accrued Northwestern License Agreements fee was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,500</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, which was paid in January 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6937127248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per quarter.  This decrease is to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$13</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> at September 30, 2017 and December 31, 2016, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company or (of the Company paid by AuraSense, LLC), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$75</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in each of the nine months ended September 30, 2016 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited consolidated statement of operations.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC. When scientists employed by the Company perform work on research grants awarded to AuraSense, LLC, the hours worked are accumulated on timesheets and the associated salary cost is billed to AuraSense, LLC on a quarterly basis. The Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC. Through December 31, 2015, these shared expenses were allocated between the Company and AuraSense, LLC on a percentage basis under the terms of an agreement between the companies. The value of these shared expenses was also included in the quarterly billing between the Company and AuraSense, LLC. Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement. Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$8</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC. The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$15</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$57</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> at December 31, 2016 and 2015, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following presents amounts billed to AuraSense, LLC and recognized in the accompanying statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shared costs with AuraSense, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of the Company paid by AuraSense, LLC, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board of Directors of the Company. The Company paid </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$100</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in each of the years ended December 31, 2016 and 2015 in connection with these consulting services and these amounts are recognized as an expense in the accompanying statement of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767152736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Private placement - subsequent closings</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On October 27, 2017 and November 2, 2017, Exicure entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with several accredited investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to issue and sell a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of the Company&#8217;s common stock, par value </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share (the &#8220;Shares&#8221;) resulting in approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$11,211</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in gross proceeds to the Company. These shares were issued in Subsequent Closings of the Offering for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of common stock (the &#8220;Maximum Amount&#8221;) at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share (the &#8220;Sale Price&#8221;). The Company and Katalyst Securities LLC, a U.S. registered broker-dealer (together with its sub-agents, the &#8220;Placement Agents&#8221;) may agree to extend the period for additional closings up to November 30, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As of November 14, 2017, the Company has sold a total of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of common stock for a total of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$31,513</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in connection with all closings of the Offering (before deducting placement agent fees and expenses which are estimated at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). Placement Agents have received an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$1,968</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> in cash placement fees and will receive warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">413,320</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure common stock (the &#8220;Warrants&#8221;) in connection with all closings of the Offering as of November 14, 2017. The Warrants have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share and have been issued on the same terms in all prior closings of the Offering. The Placement Agents will also receive </font><font style="font-family:inherit;font-size:10pt;color:#000000;">50,000</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure common stock in connection with all closings of the Offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reverse merger</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the Merger Agreement, Max-1 Acquisition Sub, Inc., a wholly-owned subsidiary of Max-1 Acquisition Corporation (&#8220;Max-1&#8221;), merged with and into Exicure, with Exicure remaining as the surviving entity and a wholly-owned operating subsidiary of Max-1 Acquisition Corporation (the &#8220;Merger&#8221;). The Merger was effective as of September 26, 2017 (the &#8220;Effective Time&#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of Max-1 Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure&#8217;s common and preferred stock (other than shares of Exicure&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Common Stock, and each share of Exicure&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:inherit;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Common Stock. As a result, an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Common Stock were issued to the holders of Exicure&#8217;s capital stock. In addition, pursuant to the Merger Agreement options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">7,419,740</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure&#8217;s common stock issued and outstanding immediately prior to the closing of the Merger were assumed and converted into options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Max-1 Common Stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, Max-1 Corporation changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger&#8221;, whereby Exicure is considered the accounting acquirer in the Merger. Exicure was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i) legacy Exicure shareholders own approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;">94%</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii) legacy Exicure directors will hold all </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> board seats of the combined company, and (iii) legacy Exicure management will hold all key positions in management of the combined company. The transaction will be accounted for as an asset acquisition rather than a business combination because as of the acquisition date, Max-1 does not meet the definition of a business as defined by U.S. GAAP. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Private placement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following the Effective Time of the Merger, Max-1 (now renamed Exicure, Inc.) sold </font><font style="font-family:inherit;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering for up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of Exicure, Inc. common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share (the &#8220;Offering Price&#8221;). The Company may hold one or more subsequent closings at any time prior to October 31, 2017, unless otherwise extended, to sell the remaining shares in the private placement offering. The Company may also sell an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;">3,333,333</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> shares of common stock at the Offering Price to cover over-subscriptions in the event the private placement offering is oversubscribed. The private placement offering is referred to herein as the Offering. The Company granted to the investors in the Offering registration rights requiring the Company to register those shares of common stock for public resale. The then existing stockholders of Exicure who agreed to become parties to the registration rights agreement also became entitled to such registration rights. The initial closing of the Offering was on September 26, 2017. The aggregate gross proceeds from the initial closing of the Offering were </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$20,302</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> (before deducting placement agent fees and expenses of the initial closing of the Offering, which are estimated at </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$2,900</font><font style="font-family:inherit;font-size:10pt;color:#000000;">). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the initial closing of the Offering, the Company issued warrants to the placement agents to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">163,174</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;shares of common stock. The warrants expire on March 27, 2021 and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> per share. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the financial statements through the date the financial statements were issued.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784119760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements as of September 30, 2017 and December 31, 2016, and for the three and nine months ended September 30, 2017 and 2016, have been presented in conformity with GAAP.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying financial statements as of, and for the years ended, December 31, 2016 and 2015, have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The accompanying consolidated financial statements include the accounts of Parent and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts receivable and unbilled revenue receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&#8220;Purdue&#8221;) and, in 2016, grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of grant proceeds for services under government grant agreements. The Company&#8217;s management believes these receivables are fully collectible.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and other risks and uncertainties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$22,936</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Liquidity Risk</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$18,731</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> at two institutions, respectively. These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation-Going Concern</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from </font><font style="font-family:inherit;font-size:10pt;color:#000000;">three</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> to </font><font style="font-family:inherit;font-size:10pt;color:#000000;">seven</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> impairment losses were recorded from inception in December 2011 through September 30, 2017.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three to seven&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets. Depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$180</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$133</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> for the years ended December 31, 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">No</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> impairment losses were recorded from inception in December 2011 through December 31, 2016.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_WarrantsorRightsPolicyPolicyTextBlock', window );">Stock warrant liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of preferred stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The preferred stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. The Company classifies the liability as noncurrent as settlement is not expected within the next 12&#160;months. There were no preferred stock warrants outstanding as of December&#160;31, 2015.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet.  Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company&#8217;s grant contracts have typically been cost or cost-plus-fee contracts. Revenues on these contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost and cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company has determined that it is the principal for each of its grants with governmental agencies since it maintains primary responsibility for research efforts in connection with these grants. Therefore, it recognizes revenue related to these grants with governmental agencies on a gross basis.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has entered into certain grant contracts containing milestone payments.  The Company recognizes revenue from milestone payments when earned, provided that the milestone event was substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collectability is reasonably assured.  If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of its performance obligations under the grant contract.  For a milestone to be considered substantive, the payment associated with its achievement must have all of the following characteristics: (1) relate solely to past performance; (2) be reasonable, relative to all of the deliverables and payment terms within the arrangement; and (3) be commensurate with either the Company&#8217;s efforts required to achieve the milestone or the enhanced value of the delivered items(s) as a result of the milestone achievement.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered and risk of loss has passed; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. When payments are received in advance of recognizing revenue, the Company includes the amount in deferred revenue on the balance sheet. Amounts deferred that are not anticipated to be recognized as revenue within a year of the balance sheet date are classified as noncurrent liabilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has generated all of its revenue to date through its research collaboration, license, and option agreement with Purdue Pharma L.P. or as a primary contractor or as a subcontractor on government grants. The Company has not generated any commercial product revenue. Historically, the Company&#8217;s research collaborations and grants have been either as a direct contractor or as a sub-awardee on contracts funded by various governmental agencies.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In arrangements involving the delivery of more than one element, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. The determination is based on whether the deliverable has &#8220;standalone value&#8221; to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The arrangement&#8217;s consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (&#8220;VSOE&#8221;) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Payments or reimbursements for the Company&#8217;s research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis. When upfront payments are received and if there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, the Company recognizes revenue ratably over the associated period of performance.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period. For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments and geographic information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company has determined it has one operating segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All material long-lived assets of the Company are located in the United States.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred rent</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease and is presented in &#8220;Other noncurrent assets&#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease. Rent escalation represents the difference between actual operating lease payments due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company established a full valuation allowance against its deferred tax assets.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC. Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes. Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company established a full valuation allowance against its deferred tax assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160; ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160; Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160; The guidance was effective for the Company in the first quarter of 2017.  Adoption of this guidance did not have a significant impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), Revenue from Contracts with Customers. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017. The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The Company adopted this guidance in the first quarter of 2016 and adoption did not have a material impact on the accompanying financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting.  ASU 2016-09 changes several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;ASU 2016-09 requires all excess tax benefits and tax deficiencies to be recognized as income tax expense or benefit in the income statement and treated as discrete items in the reporting period.&#160;Further, excess tax benefits are required to be classified along with other income tax cash flows as an operating activity.&#160;The guidance will be effective for the Company in the first quarter of 2017 and early adoption is permitted.&#160;The Company is currently evaluating the impact of this guidance on its financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of this guidance on its statement of cash flows.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. </font></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_WarrantsorRightsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants or Rights Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_WarrantsorRightsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784964160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,835</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Components of property and equipment were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued Northwestern University License Agreements fee (Note 11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">979</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767284976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Principal Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At September 30, 2017, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">At December 31, 2016, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769854304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Equity-Based Compensation Expense Classification in Statement of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Fair Value of Common Stock Option Grants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2017 and 2016 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.91 to $2,12; weighted avg. $1.98</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 6.9 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 1.41%; weighted avg. 1.26%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.9% to 82.4%; weighted avg. 80.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2016 and 2015 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.95 to $1.20; weighted avg. $1.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br clear="none"/>weighted avg. $0.69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.51 to $0.98;<br clear="none"/>weighted avg. $0.69</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2 to 7.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.01% to 2.24%; weighted avg. 1.58%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59% to 2.08%; weighted avg. 1.73%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79.2% to 83.6%; weighted avg. 79.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.9% to 85.4%; weighted avg. 82.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Common Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,954,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,941,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(166,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200,625</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(98,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382,321</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable - December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,956,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,683</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and Expected to Vest - December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,025,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767264912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax expense at statutory rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(860</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss prior to C corporation conversion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity classification change</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The significant components of the Company&#8217;s net deferred tax assets are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Net Operating Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,107</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Fixed Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Accrued Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Equity-Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Deferred Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Taxes, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6667254048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,725,906</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(103.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,222,448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,528,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,678,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,038,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771076992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions used to Estimate Fair Value of Warrant Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the common stock warrant liability at September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following assumptions were used to estimate the fair value of the preferred stock warrant liability at December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the nine months ended September 30, 2017:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the year ended December 31, 2016:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6648631936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of Rent Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense allocated to AuraSense, LLC (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">See Note 11, Related-Party Transactions, for more information.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of September 30, 2017 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future minimum lease payments as of December 31, 2016 are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767302880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Revenue from Related Party</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying unaudited statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company or (of the Company paid by AuraSense, LLC), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following presents amounts billed to AuraSense, LLC and recognized in the accompanying statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct labor on research activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shared costs with AuraSense, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct costs of the Company paid by AuraSense, LLC, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862152880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 09, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 13, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2011 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 14, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 26, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,513,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">19,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate', window );">Accumulated deficit generated, since inception | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,578)<span></span>
</td>
<td class="num">(18,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction', window );">Percent ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,666,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember', window );">Class A Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,381,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember', window );">Class B-1 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember', window );">Class B-2 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember', window );">Class C Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,581<span></span>
</td>
<td class="nump">$ 13,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,168<span></span>
</td>
<td class="nump">4,532,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,624<span></span>
</td>
<td class="nump">$ 13,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,073,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,016,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember', window );">Subsidiary of Common Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled revenue receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued legal expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembersCapitalContributions', window );">Capital contribution at net book value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital', window );">Reclassification to additional paid in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment | Subsidiary of Common Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod', window );">Number of options converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,414,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod', window );">Conversion grants in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember', window );">Conversion of Common Unit of AuraSense Therapeutics, LLC Into One Share of Common Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember', window );">Conversion of Class A Unit of AuraSense Therapeutics, LLC Into One Share of Series A Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember', window );">Conversion of Class B-1 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-1 Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember', window );">Conversion of Class B-2 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-2 Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember', window );">Conversion of Class C Unit of AuraSense Therapeutics, LLC Into One Share of Series C Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember', window );">Conversion of Options to Purchase Common Units of AuraSense Therapeutics, LLC Into Options to Purchase Common Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio', window );">Option conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=xcur_NorthwesternUniversityMember', window );">Northwestern University | Class A Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborativeArrangementEquityReceivedPercent', window );">Percent of units received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborativeArrangementEquityReceivedNumberofShares', window );">Number of units received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=xcur_NorthwesternUniversityMember', window );">Northwestern University | Subsidiary of Common Parent | Class A Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborativeArrangementEquityReceivedNumberofShares', window );">Number of units received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_PreMergerShareholdersMember', window );">Pre-Merger Shareholders | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Exicure OpCo Common and Preferred, Excluding Series C Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction', window );">Percent ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,666,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Exicure OpCo 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod', window );">Number of options converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,419,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod', window );">Conversion grants in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,836<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,504,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,211<span></span>
</td>
<td class="nump">$ 20,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,158<span></span>
</td>
<td class="nump">166,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class A Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class B-1 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class B-2 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class C Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,219<span></span>
</td>
<td class="nump">5,911,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,921,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,542,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital, Conversion Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AdjustmentToAdditionalPaidInCapitalConversionOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborativeArrangementEquityReceivedNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Equity Received, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborativeArrangementEquityReceivedNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborativeArrangementEquityReceivedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Equity Received, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborativeArrangementEquityReceivedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Percentage Of Ownership By Legacy Shareholders After Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionofStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionofStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembersCapitalContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Capital, Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembersCapitalContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained Earnings (Accumulated Deficit), Inception to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion Grants in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Converted, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Converted in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xcur_NorthwesternUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xcur_NorthwesternUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_PreMergerShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_PreMergerShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6666719920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Concentrations of Credit Risk and Other Risks and Uncertainties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,936<span></span>
</td>
<td class="nump">$ 19,623<span></span>
</td>
<td class="nump">$ 14,068<span></span>
</td>
<td class="nump">$ 18,731<span></span>
</td>
<td class="nump">$ 11,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770160656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785106688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Purdue Collaboration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2016 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,276<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets', window );">Number of additional collaboration targets | target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue', window );">Potential milestone revenue</a></td>
<td class="nump">776,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue', window );">Potential milestone revenue</a></td>
<td class="nump">$ 770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Number of Additional Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771684688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Purdue Collaboration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2016 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Reimbursable research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,276<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets', window );">Number of additional collaboration targets | target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue', window );">Potential milestone revenue</a></td>
<td class="nump">776,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue', window );">Aggregate research milestone revenue</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue', window );">Aggregate regulatory milestone revenue</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue', window );">Aggregate commercial milestone revenue</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting', window );">Performance period for unit of accounting</a></td>
<td class="text">14 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Purdue Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent', window );">Commercial sales royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Number of Additional Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Commercial Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateCommercialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Research Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateResearchMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Commercial Sales Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsCommercialSalesRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Performance Period for Unit of Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsPerformancePeriodforUnitofAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787067040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767277824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedLicenseAgreementFeesCurrent', window );">Accrued Northwestern University License Agreements fee (Note 11)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,496<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedLicenseAgreementFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Agreement Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedLicenseAgreementFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787030320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PreferredStockWarrantLiability', window );">Preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="nump">$ 327,000<span></span>
</td>
<td class="nump">478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember', window );">Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan facility</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Initial draw amount</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds net of issuance costs</a></td>
<td class="nump">$ 5,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember', window );">Hercules Technology Growth Capital | Secured Debt | Loans Payable | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating interest rate (as a percent)</a></td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease', window );">Reduction of prime rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares issuable on debt instrument</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PreferredStockWarrantLiability', window );">Preferred stock warrant liability</a></td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount', window );">Right to participate in future financing, amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FeeTypeAxis=xcur_FeesatIssuanceMember', window );">Fees at Issuance | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FeeTypeAxis=xcur_FeesatMaturityMember', window );">Fees at Maturity | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Non-Redeemable Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series C | Hercules Technology Growth Capital | Secured Debt | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares issuable on debt instrument</a></td>
<td class="nump">104,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentBasisSpreadonVariableRateDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread on Variable Rate, Decrease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentBasisSpreadonVariableRateDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Right To Participate In Future Financing, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LineOfCreditFacilityRightToParticipateInFutureFinancingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FeeTypeAxis=xcur_FeesatIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FeeTypeAxis=xcur_FeesatIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FeeTypeAxis=xcur_FeesatMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FeeTypeAxis=xcur_FeesatMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795503760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Principal Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2017</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance outstanding</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">less: unamortized discount</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">less: unamortized debt issuance costs</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">5,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion</a></td>
<td class="nump">$ 2,670<span></span>
</td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781855312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Current Capitalization (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 26, 2017 </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>vote_per_share </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,513,987<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">30,782,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,513,987<span></span>
</td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockVotingRightsforEachShare', window );">Common stock, voting rights for each share | vote_per_share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-redeemable preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-redeemable preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-redeemable preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-redeemable preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="nump">26,666,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod', window );">Number of options converted (in shares)</a></td>
<td class="nump">7,414,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod', window );">Conversion grants in the period (in shares)</a></td>
<td class="nump">3,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Common and Preferred Stock, Excluding Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Pre-Merger Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockVotingRightsforEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights for Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockVotingRightsforEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionofStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionofStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion Grants in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Converted in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_CommonandPreferredStockExcludingSeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_PreMergerShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_PreMergerShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6859545296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Private Placement Post-Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2017</div></th>
<th class="th"><div>Sep. 26, 2017</div></th>
<th class="th"><div>Nov. 14, 2017</div></th>
<th class="th"><div>Oct. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold', window );">Price-based anti-dilution protection gross proceeds threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleofStockNumberofSharesAvailableForOffering', window );">Shares available for sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="nump">3,736,836<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="nump">10,504,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleofStockNumberofSharesAvailableForOffering', window );">Shares available for sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross</a></td>
<td class="nump">$ 11,211<span></span>
</td>
<td class="nump">$ 20,302<span></span>
</td>
<td class="nump">$ 31,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price-Based Anit-Dilution Protection, Gross Proceeds Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PriceBasedAnitDilutionProtectionGrossProceedsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SaleofStockNumberofSharesAvailableForOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Available For Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SaleofStockNumberofSharesAvailableForOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792746208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Capitalization Prior to the Merger (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2017</div></th>
<th class="th">
<div>Jan. 11, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 09, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 13, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2011 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 19,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions', window );">Liquidation preference, percent of aggregate cash contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredUnitsMember', window );">Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted', window );">Number of shares not converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember', window );">Class A Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,381,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembersCapitalSharePriceFairValue', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,381,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember', window );">Class B-1 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccountsReceivableSaleOfStock', window );">Accounts receivable as result of sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable', window );">Number of shares related to sale of stock accounts receivable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember', window );">Class B-2 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember', window );">Class C Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,073,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,168<span></span>
</td>
<td class="nump">4,532,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,624<span></span>
</td>
<td class="nump">$ 13,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,581<span></span>
</td>
<td class="nump">$ 13,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,381,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredMember', window );">Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,451,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredMember', window );">Series B-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,073,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,016,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from preferred stock offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember', window );">Subsidiary of Common Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembersCapitalContributions', window );">Capital contribution at net book value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember', window );">Subsidiary of Common Parent | Class A Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembersCapitalContributionsFairValue', window );">Issuance of common stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Series C Preferred Stock Converted into Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember', window );">Conversion of Common Unit of AuraSense Therapeutics, LLC Into One Share of Common Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember', window );">Conversion of Class A Unit of AuraSense Therapeutics, LLC Into One Share of Series A Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember', window );">Conversion of Class B-1 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-1 Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember', window );">Conversion of Class B-2 Unit of AuraSense Therapeutics, LLC Into One Share of Series B-2 Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember', window );">Conversion of Class C Unit of AuraSense Therapeutics, LLC Into One Share of Series C Preferred Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember', window );">Conversion of Options to Purchase Common Units of AuraSense Therapeutics, LLC Into Options to Purchase Common Stock of Exicure OpCo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio', window );">Option conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted', window );">Number of shares not converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class A Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembersCapitalSharePriceFairValue', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class B-1 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable', window );">Number of shares related to sale of stock accounts receivable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class B-2 Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Class C Preferred Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,921,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,219<span></span>
</td>
<td class="nump">5,911,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,924,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,937,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series B-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,827,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,921,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,542,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccountsReceivableSaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Sale Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccountsReceivableSaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionofStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionofStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionofStockNumberofSharesEffectivelyNotConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Number of Shares Effectively Not Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionofStockNumberofSharesEffectivelyNotConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembersCapitalContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Capital, Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembersCapitalContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembersCapitalContributionsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Capital, Contributions, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembersCapitalContributionsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembersCapitalSharePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members' Capital, Share Price, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembersCapitalSharePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Percent Of Aggregate Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PreferredStockLiquidationPreferencePercentOfAggregateCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Related To Account Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SaleOfStockNumberOfSharesRelatedToAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Converted, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassAUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassB1UnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassB2UnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ClassCUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_SubsidiaryOfCommonParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfCommonUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfCommonStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassAUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesAPreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB1UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB1PreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassB2UnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesB2PreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfClassCUnitOfAuraSenseTherapeuticsLLCIntoOneShareOfSeriesCPreferredStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ConversionOfOptionsToPurchaseCommonUnitsOfAuraSenseTherapeuticsLLCIntoOptionsToPurchaseCommonStockOfExicureOpCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787023312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 22, 2017 </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 06, 2015</div></th>
<th class="th">
<div>Oct. 03, 2014 </div>
<div>USD ($) </div>
<div>individual </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 13, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 2,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EstimatedFairValueofCommonStockPerShare', window );">Estimated fair value of common stock, per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of current employees and board members affected from modification | individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected', window );">Number of non-employees affected from modification | individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice', window );">Modified strike price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental fair value of compensation cost from modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xcur_InitialEmployeeStockOptionMember', window );">Initial Employee Stock Option | Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights as a percentage, by month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xcur_SubsequentEmployeeStockOptionMember', window );">Subsequent Employee Stock Option | Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights as a percentage, by month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">5,842,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">2,158,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding', window );">Number of additional shares authorized as a percentage of common stock outstanding (in shares)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,806,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,318,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding', window );">Number of additional shares authorized as a percentage of common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">3,683,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan | Initial Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan | Initial Employee Stock Option | First 12-month anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights as a percentage, by month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan | Subsequent Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of employees affected by the modification of an equity-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EstimatedFairValueofCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value of Common Stock, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EstimatedFairValueofCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Modified Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationModifiedStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Non-Employees Affected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationNumberofNonEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xcur_InitialEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xcur_InitialEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xcur_SubsequentEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xcur_SubsequentEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772185104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 682<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770117760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.97%<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">80.80%<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
<td class="nump">79.20%<span></span>
</td>
<td class="nump">78.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.17%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">83.10%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">85.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.07%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">80.90%<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
<td class="nump">82.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772927088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="nump">1.91<span></span>
</td>
<td class="nump">0.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">2.12<span></span>
</td>
<td class="nump">0.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">2.12<span></span>
</td>
<td class="nump">0.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
<td class="nump">0.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790126640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, beginning period</a></td>
<td class="nump">3,089,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">657,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares</a></td>
<td class="num">(58,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(10,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, ending period</a></td>
<td class="nump">3,678,359<span></span>
</td>
<td class="nump">3,089,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning period (dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted (dollars per share)</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised (dollars per share)</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeitures (dollars per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending period (dollars per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="nump">$ 5,257<span></span>
</td>
<td class="nump">$ 9,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares</a></td>
<td class="nump">2,131,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 3,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest, shares</a></td>
<td class="nump">3,595,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Expected to Vest, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Expected to Vest, Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and Expected to Vest, Aggregate Intrinsic Value (dollars per share)</a></td>
<td class="nump">$ 5,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, beginning period</a></td>
<td class="nump">6,222,448<span></span>
</td>
<td class="nump">6,528,052<span></span>
</td>
<td class="nump">2,954,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">3,941,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,283)<span></span>
</td>
<td class="num">(166,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(382,321)<span></span>
</td>
<td class="num">(200,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding, ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222,448<span></span>
</td>
<td class="nump">6,528,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning period (dollars per share)</a></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">0.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">0.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeitures (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending period (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,143<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,956,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,025,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Expected to Vest, Weighted-Average Exercise Price (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Expected to Vest, Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and Expected to Vest, Aggregate Intrinsic Value (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772389952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 08, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (3,526)<span></span>
</td>
<td class="num">$ (5,663)<span></span>
</td>
<td class="num">$ (7,488)<span></span>
</td>
<td class="num">$ (8,937)<span></span>
</td>
<td class="num">$ (11,299)<span></span>
</td>
<td class="num">$ (16,941)<span></span>
</td>
<td class="num">$ (13,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860744256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,760)<span></span>
</td>
<td class="num">$ (4,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount', window );">Loss prior to C corporation conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount', window );">Entity classification change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent', window );">Loss prior to C corporation conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent', window );">Entity classification change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.80%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Entity Classification Change, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Entity Classification Change, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationEntityClassificationChangePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Loss Prior To C Corporation Conversion, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationLossPriorToCCorporationConversionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767226512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">$ 8,107<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity-Based Compensation</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation Allowance</a></td>
<td class="num">(9,088)<span></span>
</td>
<td class="num">(2,519)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Deferred Rent</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Taxes, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767235728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 08, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="num">$ (3,526)<span></span>
</td>
<td class="num">$ (5,663)<span></span>
</td>
<td class="num">$ (7,488)<span></span>
</td>
<td class="num">$ (8,937)<span></span>
</td>
<td class="num">$ (11,299)<span></span>
</td>
<td class="num">$ (16,941)<span></span>
</td>
<td class="num">$ (13,151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">1,725,906<span></span>
</td>
<td class="nump">97,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,395<span></span>
</td>
<td class="nump">109,539<span></span>
</td>
<td class="nump">228,447<span></span>
</td>
<td class="nump">108,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (36.09)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48.73)<span></span>
</td>
<td class="num">$ (103.15)<span></span>
</td>
<td class="num">$ (74.16)<span></span>
</td>
<td class="num">$ (121.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222,448<span></span>
</td>
<td class="nump">6,528,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6668687312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222,448<span></span>
</td>
<td class="nump">6,528,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">3,678,359<span></span>
</td>
<td class="nump">3,038,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">163,174<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784917616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2017</div></th>
<th class="th"><div>Feb. 17, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate', window );">Impact of 10% change in expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock', window );">Impact of 10% change in the estimate of fair value of the common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">78.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772688576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details) - Warrant Liability<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">78.71%<span></span>
</td>
<td class="nump">78.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793799024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - Warrant Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss included in other income (expense), net</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss included in other income (expense), net</a></td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss included in other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769473120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommitmentsandContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Extended lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Deferred rent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsforLicenseAgreements', window );">Aggregate consideration paid to NU for agreement obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedLicenseAgreementFeesCurrent', window );">Accrued Northwestern University License Agreements fee (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedLicenseAgreementFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Agreement Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedLicenseAgreementFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommitmentsandContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommitmentsandContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsforLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsforLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767130352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Rent Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Straight-line rent expense</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseContingentRentals', window );">Contingent rent expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty', window );">Rent expense allocated to AuraSense, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseContingentRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increases or decreases in lease payments that result from changes occurring after the inception of the lease in the factors (other than the passage of time) on which lease payments are based, except that any escalation of minimum lease payments relating to increases in construction or acquisition cost of the leased property or for increases in some measure of cost or value during the construction or preconstruction period, are excluded from contingent rentals. Contingent rentals also may include amounts for which the triggering events have not yet occurred or the specified targets for which have not yet been achieved (such as sales based percentage rent), but which events are considered probable of occurring or which specified targets are considered probable of being achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77895616&amp;loc=d3e36728-112689<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=77910666&amp;loc=d3e35050-112683<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseContingentRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Rent Expense, Minimum Rentals, Allocation to Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_OperatingLeasesRentExpenseMinimumRentalsAllocationtoRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773654944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2017</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792872096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Board of Directors | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">AuraSense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty', window );">Quarterly revenue from related party for indirect costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Quarterly Revenue From Transactions With Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RelatedPartyTransactionQuarterlyRevenueFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792882336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Schedule of Revenue from Related Party (Details) - AuraSense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Direct labor on research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Shared costs with AuraSense, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Quarterly fee for indirect costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember', window );">Direct costs of the Company paid by AuraSense, LLC, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=xcur_AuraSenseLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_DirectLaborOnResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_DirectLaborOnResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_SharedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_SharedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_QuarterlyFeeForIndirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_QuarterlyFeeForIndirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_DirectCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_DirectCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773183216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th">
<div>Nov. 14, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 26, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleofStockNumberofSharesAvailableForOffering', window );">Shares available for sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,836<span></span>
</td>
<td class="nump">6,767,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,504,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions', window );">Number of additional shares available for over-subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received from sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,211<span></span>
</td>
<td class="nump">$ 20,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SaleofStockNumberofSharesAvailableForOffering', window );">Shares available for sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement', window );">Payments to private placement agents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">413,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Series C Preferred Stock Converted into Max-1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember', window );">Series C Preferred Stock Converted into Max-1 Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7666652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionofStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,666,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,666,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction', window );">Percent ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember', window );">Exicure OpCo Common and Preferred, Excluding Series C Preferred | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction', window );">Percent ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod', window );">Number of options converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,414,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember', window );">Exicure OpCo 2015 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod', window );">Number of options converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,419,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod', window );">Conversion grants in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod', window );">Conversion grants in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock, Percentage Of Ownership By Legacy Shareholders After Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionOfStockPercentageOfOwnershipByLegacyShareholdersAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ConversionofStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ConversionofStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Private Placement Agents For Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsToPrivatePlacementAgentsForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Additional Shares Available For Over-Subscriptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SaleofStockNumberofAdditionalSharesAvailableForOverSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SaleofStockNumberofSharesAvailableForOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Available For Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SaleofStockNumberofSharesAvailableForOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion Grants in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversionGrantsinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Converted in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConvertedinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=xcur_SeriesCPreferredStockConvertedintoMax1CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_ExicureOpCoCommonAndPreferredExcludingSeriesCPreferredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureOpCo2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781887216">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">$ 14,979,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">(8,677,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">8,677,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues', window );">Membership Units Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues</td>
<td class="nump">4,581,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">233,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">(246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">(18,530,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">233,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">18,837,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_NetIncomeLoss</td>
<td class="num">(7,488,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_NetIncomeLoss</td>
<td class="num">(5,663,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember', window );">Member Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">$ (61,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
<td class="nump">153,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="num">(153,750)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
<td class="nump">13,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="nump">153,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="nump">22,924,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">$ (135,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="num">(22,924,210)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">$ 14,979,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">$ 18,060,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="nump">7,921,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
<td class="nump">6,542,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIMember', window );">Preferred Class B-I [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">$ (5,371,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="num">(4,937,818)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassCMember', window );">Preferred Class C [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues', window );">Membership Units Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues</td>
<td class="nump">2,010,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">$ (18,060,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues', window );">Membership Units Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues</td>
<td class="nump">$ 4,581,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="num">(7,921,669)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">$ 5,371,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="nump">4,937,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember', window );">Series B-2 Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="nump">$ 3,641,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="nump">2,827,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIIMember', window );">Preferred Class B-II [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Value, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
<td class="num">$ (3,641,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation', window );">Share Conversion During Period, Shares, Limited Liability Company to Corporation</a></td>
<td class="th" style="border-bottom: 0px;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
<td class="num">(2,827,848)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Membership Units Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembershipUnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Membership Units Issued During Period, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_MembershipUnitsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Conversion During Period, Shares, Limited Liability Company to Corporation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareConversionDuringPeriodSharesLimitedLiabilityCompanytoCorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Conversion During Period, Value, Limited Liability Company to Corporation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareConversionDuringPeriodValueLimitedLiabilityCompanytoCorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xcur_PreferredClassBIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_PNPM9KLS/_V/@LV'?PZR[Z+U!+ P04    "  ZC'Q+F5R<(Q &  "<)P
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M>7IDT2'B&A&WR(HB*$G,))$7)*A+O-0IN#H7@L2C&I:4L J5^6F2]>=)8HJ
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MUD4]@" O-C>4@;<F(*G@&@LN&<%#P'JSE,-R,Y3!AFO-41I3,4=9O QM&&K
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MNIVX[J+*3_TN8W#9ZIS_#U!+ P04    "  ZC'Q+X1U(X6L%  !Q'   &
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M7O*L;'[V7M[+*E^UJSA75LFO[>_ENOG]N?U+9%HSW@!: ]@9B/"H@6P-Y,Y
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M92PUU@:.5$Y"+(D(!4$Y]TV((\+M+:TP*L0184CI.%_:>GJ\B)F(D+R-27V
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M8OLEV/9-E6_:+_B"W;>,P]]02P,$%     @ .HQ\2\@M##KG!0  !2$  !@
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M#J5QTXV=JZ$#AL#(=FQN,OUALO]02P,$%     @ .HQ\2S<9SC/- 0  ;00
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M;\C?="6E 5M*<&-?=V-[?PXX5,9--W:NQ@X8 R.[J;G)_(?)_P-02P,$%
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MSLSE>,W&0(MN>D'(_(QE_P!02P,$%     @ .HQ\2Z[/EJ'2 0  ;00  !D
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MQ-.6ECB?OZE_<K6;6BY4P4FP7TVAZQ3O,2J@I#W3SV+X#+Z>>XQ\\5_A"LS
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M+J:>, 6*]W.[PTO/S?\ 4$L#!!0    ( #J,?$L?$TBJQP$  #D$   9
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M/T)+0*%29GK0<S%=Q2E0O)]?&;P\==D?4$L#!!0    ( #J,?$OL-Q5:Y $
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MS0&#4MOISLSE>!7'0(MN>F7(_-1E?P%02P,$%     @ .HQ\2UD&!];2 0
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M(L[&HJ"$. A''(13PT^+(WQV*$O('\E<259Q,=OJ2X!**>/]%0#1)-81YCO
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M3ZD@,B?_3C;I4<YBW:8D>Z&6J5RS=B!I-X(V9MCRNHEO_A]02P,$%     @
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M41]<.\8$E9KAC4S?05[@ADE%=T(-L1QW_2VFGPC6FAM:,%P3%W\ 4$L#!!0
M   ( #J,?$MP;RS?[ (  &0,   9    >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;(U7ZV[:,!1^E2@/T,3.Q4D%2"NL,&F34*=MOUTP$#6)L\1 ]_:S'3<#
M^\#"#Q*;[W+.L7UD)F?>OG4'QH3W7I5U-_4/0C2/0=!M#JRBW0-O6"U_V?&V
MHD(.VWW0-2VC6TVJR@"'81I4M*C]V43/K=O9A!]%6=1LW7K=L:IH^^>)E?P\
M]9'_,?%2[ ]"302S24/W[#L3/YIU*T?!H+(M*E9W!:^]ENVF_B?TN$*9(FC$
MSX*=NXMW3Z7RROF;&GS93OU01<1*MA%*@LK'B<U962HE&<=O(^H/GHIX^?ZA
M_JR3E\F\TH[->?FKV(K#U,]\;\MV]%B*%WY>,9-0XGLF^Z_LQ$H)5Y%(CPTO
M._WM;8Z=X)51D:%4]+U_%K5^GHW^!PTF8$/  P&3NX3($*)_!'27$!M"/):0
M&$(REI :0CJ60 R!C"5DAI!9A*!?#KV^"RKH;-+RL]?V6[2AZB2@QTSNH(V:
MU!M&_R:7N).SIUF4)Y/@I(0,YJG'X$M,9F'F$":]QBP #(JN,9]'Z#R/T%E"
M.N0:LX(PV8 )9-V&XF&P>%@+1%<".2P0@0*1%H@O!(B5[+R'$ VI-03'N97)
MP@6%5EU=!$EQ;!7VOS)+%Y'F%F9U3^6J)C%8D]BI293;1>DQR85%C#,K8Q>#
M8D3@2!(PDL2)!$56R>:)XQ*AT-[48T!+%Y1+%!QO"L:; I6S%F>>.HL#Q#L&
MM'1!&;9W[\H%W<B(@!D1=P72!!;(0(%L_ G-08$<J"FR^F/N+B]L@4*X!X>
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MTT0$:055F[1)4:=UOYWD)J :3&TG=&\_VQ"4V%ZU/\$VYYQ[CKFQBY&R-]X
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M&$K<P!CJ8+&>,0(M+'%PRV&@YY"OQT$@9HF#.P0#+8*XQ046&(MG5!5+C"T
M"]*S71AS-K;/6(ZER($429<B-Z5HZ1@<:Y ##>JK]IT"C01/PIZ094^$)*A/
M%&Y*\,-06($<*) "BPNL0#Y#@1PKD -QD=YS$,BF0(X5R)&X;%2QN'@T(ULL
M+@Z6+]+[C0*!I<,2"ZN0(Q5:BD987N3/V*)C[1#2CIXQF>L7"YDU8<+:(: =
M87-A^:*@&0EC31#:XAL)FQMO3A\DC+5#0!;"LF 0E@6%,Q+&LB"PY@A]6TKF
MWH\SL)^>B-LB'/K (7-K:JLQ5BP!Q0K+\D%8B#1CRRFP$ 58YXP:"W.=,SX<
M/X5L 42K[)@PEKT LA?"X@++6<PX'Q!8S@(M<?I&1(%&S<=O=Q&Q)93EPQ[(
MWMB)*!!CU\6]T6>3=W7JU)U]_I-4+VE1.\]ETY1Y?\QT*,M&MA[]FY;V42;[
MRT,F#TUW&[7WU7#F.#PTY4F=IWJ70]WU_U!+ P04    "  ZC'Q+&4\^KGL"
M  #-"   &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R-EF^OFR 4QK^*
M\?VN@/BG3=MD;;-LR98T=]GVFK:T-5?% :UWWWZ UE@\7?9& 9_S\#MX!!>M
MD&_JPKD.WJNR5LOPHG4SCR)UN/"*J1?1\-H\.0E9,6VZ\ARI1G)V=$%5&1&$
MTJAB11VN%FYL)U<+<=5E4?.=#-2UJIC\L^:E:)<A#N\#K\7YHNU M%HT[,R_
M<_VCV4G3BP:78U'Q6A6B#B0_+<./>+[%+L I?A:\5:-V8%/9"_%F.U^.RQ!9
M(E[R@[86S-QN?,/+TCH9CM^]:3C,:0/'[;O[)Y>\26;/%-^(\E=QU)=EF(?!
MD9_8M=2OHOW,^X22,.BS_\IOO#1R2V+F.(A2N6MPN"HMJM[%H%3LO;L7M;NW
MO?\]# X@?0 9 C#]9T#<!\3_&T#[ .H%1%TJ;FVV3+/50HHVD-WK;9BM(CRG
M9O4/=M MMGMFED>9T=N*TF01W:Q1KUEW&C+2D$?%9JK Z:-D"TBR01(9Q@&4
M@*#$Q<</\3%L$(,&L3-(G$'=98%&"%VJG2@;B5+L)SO58(*?H% 0A4(HN8<"
MB%*"/!90](0E 5D2B&7FL0 BG/GK HE2"K.D($OJ'.A#,7IUM$XGLR0440]E
M*DH10C!*!J)D (I?+-EDE@_CA#L40$1F.8R2@R@Y@.(72PZ@>"]Q VCB! :9
M@2"S*0C!'LAL^GJ(+]H HC1]LAM@!.];"%@5OVQ[T4-))HE/ Z@>/NA^_T*3
MS_Y)0>$G.RV>$B?()\:364B:^5\]H#*[-O6)IRJ?.!H=$_:@_\;DN:A5L!?:
MG#CN7#@)H;FQ0R]F@2[FWV+HE/RD;3,S;=D=L%U'BZ;_>8B&/YC57U!+ P04
M    "  ZC'Q+I3J)*%L#  #'#@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6R55^UNFS 4?17$ Q1\;0Q42:2E:;5)FU1UVO:;)DZ""C@#M^G>?C90
M%NQ+EO C8.?<CV/[7-NSHZQ?FKT0RGLOBZJ9^WNE#K=!T*SWHLR:&WD0E?YG
M*^LR4[I9[X+F4(MLTQJ510!AR(,RRRM_,6O['NO%3+ZJ(J_$8^TUKV69U7^6
MHI#'N4_\CXZG?+=7IB-8S [93GP7ZL?AL=:M8/"RR4M1-;FLO%ILY_XG<OM
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MJ;;)'K%0VSPX&>!E%#(W=N?:@GI:#NIDD Y!Z?UDY.',NOJ?/!<IV/,@1+4
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M8HL++**,KI=AAI6- 4GBFFP]0)!%MQ@6+@:4B]MF#4L."VZH%BL* Y)B5HM
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M?[+OA)!<Q6X_J'P_J'-B.\CX3NK;4-V7U\/2=2#%L3D(6NUI=/D74$L#!!0
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M UY*GX1V;]4RY.PD)J$$1TAJP$L)G)U]: +'2!EXO02 20UX"46!\I48<!(
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M&V4O/"=$.*]56?.5FPO1+#V/'W)28?Y$&U++-R?**BSDEIT]WC""C]JH*KW
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M3[S$:)6 FIKK@IE$+J$A%)%!41J&_'M88AS*)3B$(O=W.(GNI[7K.3^8AA*
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MXV$,BVM9W1QVSENYST&RPG62B%7EGZ*K(BV!!&;IIFI;(M-6&+UE^&6Z KV
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M51? +-5YMA^$CG/P^TXN -]TU39N$.IU,#P24T6WJ.<B[5LW,;Q)/.F/:0M
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MD5-[DH;,5P2]RIB55?#J ,)D?%-8V8A;@Y%:PY<( KWO;0+'!T3?<))/XY!
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M"_E"$+&>03=#9F?":J^3)K+K6.P#Y(@C1>/V?3G)DE:N(N._]+/3TS@,1"M
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MO67+RA;GI)@37(FIN,KQ-JCI<CW 6EI8R[87^3\P^YGO.P@,5;'8:@K>?<Z
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M(58/Z$WB+KG(@=].HVDG@3][<3_IFG4DXR&EV9%P[*QB.HE[DSY/U7<7T9_
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MLJ%WV ]**U%LUSALTH_[??I?6R%D=R\_I)\H-.6<KH?9$Q8#<4N 24/V9WV
M2QM4T,U)G32#[AXZIW]/X8 >JHW;DYHH7<HM&,KL!J.-B)&6Q<]9>3;/8%C0
MQ3?%349V,T(NDGZV5V<I!@N)_5R6\=[<C_,;#RO1,4^XP_T?,/R)'>?<BY1#
M_$PPH+E/#%1S>]2BH9X=\P/&488C5BN,G7.0,^G&P^X@3J:CM@.BM=@7:C@%
M)'&8]$-TD#KOMF'(B72=F[-%#EF[ 17!D;F#&O%8]#7:DNVA#JCQK!]/1Z,(
M#K@.;8[N-BPIX,F:CB:T=*Q!8A=@IJ9,87D_7(^N/N8 $;[7=6"IA*T5Z;5:
MNIN']"A8IN&S9X0WM=@)%L1=I,]LZSWBGF%:AUYN?N%$AK!.DW/K<<[2;EL<
M+Z)Q, 184F,4NL,N]73= [='@J;9/$A[V<Q==I4Q4[,A,RIB<V4E56*P/()-
MXS816EK-Q;!F&X^,#\Q-$8W0DPYQW<_#HP]^RCMP5VO@ZHWTRKL<"R?FHHJ6
M-\81T-FS)#J?P2ZENQ#,Q66LD?J!X+58/)QQ> #"*9_G8BENOGGAM/8[L73\
M+%%\CGFY$ATDP7.%+9Y-7^MIV^[,J50?WX+P=.=6GT)#@;]$:YUZU&)=QD,@
M\EF%@(V"T(V&7,_?5*A[HUF%^F.^S"P<J+T1H\)"*NFGT456;KC!(5U&G56U
MCDOT=&QD0]S"44M]Z ?M:VL"JOWY-9#ZAGK-(T>3**P=6!#-T+LR;QV1)&43
MZRV'5Q=D2-"O56,X<<J!->ZZ&:"MBLFI4B,*SW *CK>7C6#*H#!SSM2VSB5T
M['8&T]%@ZBR*P>.6QV/=9??>6PNP?,&5CT?P?\/>SK63B)"*>!@W^!;@,8P1
MCWKCG:-XPJ LM%D0WR("A]YKJ5// +B/2MDN# Z['<>#9!J/!P%&$12C/Q?4
MR32HH:0<@>H>06BI_7@TZ<;3Z6Z PK%0Q+-/%4AH^VQT(3;S.DU8J:806^Y6
MQ-.+6CL#AP3FE8GUP?W;,#Z7&PF9PT@<KDNG)-U_6S7:[8J30V;$:4MEISQC
MQ[Q<*ZS%%JRV,;Q.BEZAF1]LC1@F0-@.#W4_IPDEAM4BE9S9I=/)&?R^KRM4
MT\$W.@$@W16M<*8NNY4TWGPP_1+8-.RBGC5LM>*>1.#6%C8WQ@V2I"@AAB)'
M<VPVB1:0*DNM::>^.@UT#8QL&PO6AOXY>W Z_F&]2OMDRS2,1!OKJC*E=^3T
M,M%TR.S!50=3AQT!KAIFD4976-(IJRJ9QN^:8AO5N .@[*78/R\RMB4MLTR*
MO64@DIG,%V<"PKEKVHFVX_OK^?G[3L#L\<H[09]-U@^2UW&R*NXQ]R-%6N)=
MN5-6SD;Q>#2.^Z, C5/F[%(XEXY2.%=.324=9,(<K?JZBP-5]1T3/T$K-RK+
M#LT<Y6]".K(*2AY+R+:4<A@[.KXL#5=K4]]$P&Q7F$/&U_X>]1Y--HHY*!^+
M@-ZZ@J=LWK2); -=<]FDT+#UQTM4W&L#D9@:'SP4+4LI8/B?,]<69E9G@])W
M'#'F62&EY@&NM!7Z[C?<P%,DZ/E*)?*P<D7N22L46.N:K-3LC:TJPH8DVI;U
M+;U%CKM"33 1Y]GML%"L*=8=Y9MT(:5)-]3[7?N;MC3O(2NSM>(!/<&R:91?
MDQG#6&C-UK]%QXZ$:)FQDB(>"8K)#KS*JPM<5 ].E%H;4O#$3V.DMYHMS_2<
MVCL!^65ZW;C?[3W)'B,#[IDG;K7;].(I4(K3UF8 >P=VD44$/==(0]?"W\5N
MXXUVI0NC&</=3" -A N3$TWV[5YBS2>'&%M^YQ8*I_CAN17(WA=P%?'ZG.A?
MI_4WGVOZIWCTZ'[4'_I8]WYX@3/!U3ZVZ!5^_0O;;L:.L<PV@F-+%0:Y<,E!
MP&F2(?;NL7U;_FH=!U6\TY]ZX.H<@1J0%5:PQL*_G%&$4BP6!E^;WG(9IAS@
M)](V.(P-] ! A>@$]WG:V.A[.RA=+#W)SW/NFM#NJ 8TS_O4!(.BJI-TN]]$
M=;N6=3[9#%;C"CD';D[)GBK8;]S(*S)&Z71$X3 'AVM>2H:$V64#(C]R/J<2
MQ8:+CIET!KS(JY#:LO\@NBF=J%QI'<N0IS];:BS;<"H!<_UU:;9XJR7@,]/O
MGJ1*+A^/K]83*QT:Q$>MB=1M[_C%EULWJ;%<H>5("ER-13F]&FT9>^VQ^8,%
MR17E*R.&6* 4-F',JY+,Q:<QAF>19W>9.G'3"F0]+C/+RI#39IV=";?Y@H*:
MMI3\C788U&6P N\\1YZFK!LE';.,V#TYH\/(W')06.G#J1%<5)FW8EG0"C/C
MJ9* TVHV=:MQ:VO)PHL9,H85>R:J!\9F'WX$!3H$T*5RC2GC<(?\/<-Z)!Y;
M^V?NA4+][D2?EHOOJ$3&O_R%J%IYE_WE7UU6JB8'KGUR"X+7 I,<X3:HZ]<I
M!J\E3 #6&_4$$B(B0Q ^0,4G*@T.;U:MK]_><R4+[.$@U$ TV*XD9D63-NWO
MGV$(K9' 5T)2=MFI!1NPL29X2[EX.@M'-O:D)?K%O(KI:1B[DC("2$8;\Z:B
MYJGGU]]O2XPF>@_RSC*-WG1 D59' ?]D';U8?)\C5X&MDDKA"+;8WD!#*3C
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MXKS41\-!^XK#2L//P73D':#%UV*Y7Y%S#K3H+2H*[XU&&B@+2X_H]"B3,15
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MF7I<7^='J_A<4VZE84]=%QD)TYVZLXZSA)*Z!3.:3FJ *3'/;F9-&A]438L
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MW[,#Y1Z_3T_%2?+OA2O,N?J(\4#$TP-#"OIF,O:9C(,-GFM(U<:KX$LS]$Q
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M_+7GYAU02P$"% ,4    "  ZC'Q+'R// \     3 @  "P
M@ $     7W)E;',O+G)E;'-02P$"% ,4    "  ZC'Q+9O,+8((   "Q
M$               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #J,?$O:% #4[@   "L"   1              "  9D!  !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #J,?$N97)PC$ 8  )PG   3
M  "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .HQ\2PSL
MTB\# @  N@4  !@              ( !]P@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #J,?$O9!78C.04  /(<   8
M  "  3 +  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  Z
MC'Q+P8[UP,H$  !4'   &               @ &?$   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ .HQ\2]G= ]=L!   ]A0  !@
M         ( !GQ4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( #J,?$OA'4CA:P4  '$<   8              "  4$:  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  ZC'Q+R"T,.N<%   %(0
M&               @ 'B'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ .HQ\2W?C*$+. 0  ;00  !@              ( !_R4  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #J,?$NM4)QUS@$
M &T$   8              "  0,H  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  ZC'Q+U(*,W[0!  #2 P  &               @ $'
M*@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ .HQ\2Q&(
M#<_- 0  ;00  !D              ( !\2L  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  ZC'Q+-QG.,\T!  !M!   &0
M    @ 'U+0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M #J,?$M4RC]JS@$  &T$   9              "  ?DO  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ .HQ\2W%TQKO, 0  ;00  !D
M             ( !_C$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  ZC'Q+L!46L,T!  !M!   &0              @ $!-   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #J,?$LJ322=S@$
M &T$   9              "  04V  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ .HQ\2_!LJ6S- 0  ;00  !D              ( !
M"C@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  ZC'Q+
MNZ;P_\X!  !M!   &0              @ $..@  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( #J,?$NA]1.VS0$  &T$   9
M      "  1,\  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ .HQ\2RTCY #/ 0  ;00  !D              ( !%SX  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  ZC'Q+./PJ(^P"  #@#
M&0              @ $=0   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( #J,?$N%\$I1W $  -($   9              "  4!#  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ .HQ\2Z[/EJ'2
M 0  ;00  !D              ( !4T4  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  ZC'Q+BIGT]/8!  !_!0  &0
M@ %<1P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #J,
M?$L?$TBJQP$  #D$   9              "  8E)  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ .HQ\2\.&VOW@ 0  T@0  !D
M         ( !ATL  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  ZC'Q+#G5%,^0!  #V!   &0              @ &>30  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #J,?$OL-Q5:Y $  /8$
M   9              "  ;E/  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ .HQ\2UD&!];2 0  ;00  !D              ( !U%$
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  ZC'Q+BX>F
M-:<)   7/@  &0              @ '=4P  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( #J,?$OMIYES\0$  $(%   9
M  "  ;M=  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M.HQ\2_R27[NF @  _0D  !D              ( !XU\  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  ZC'Q+ LL#YYT"   R"@  &0
M            @ ' 8@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( #J,?$MP;RS?[ (  &0,   9              "  91E  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ .HQ\2PF(,;]P P
M\@\  !D              ( !MV@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  ZC'Q+#&EW3RP"  #4!@  &0              @ %>
M;   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #J,?$O0
MCLC&%P0  . 5   9              "  <%N  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ .HQ\2QE//JY[ @  S0@  !D
M     ( !#W,  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #J,?$N#J-1\LP(  /()   9              "
M 2*)  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ .HQ\
M2_[9^,,G P  F0X  !D              ( !#(P  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  ZC'Q++DL3EYH"  "J"@  &0
M        @ %JCP  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( #J,?$L _EQU!@4  "<9   9              "  3N2  !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ .HQ\2^98]E@- P  H P
M !D              ( !>)<  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  ZC'Q+4E[8/F,#  "W#P  &0              @ &\F@
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #J,?$O\?3HO
M9@(  %\(   9              "  5:>  !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ .HQ\2S)5]I($ P  Y H  !D
M ( !\Z   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  Z
MC'Q+".F03%H"  !Q!P  &0              @ $NI   >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #J,?$NI</]:[0(  -0,   9
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M970U-2YX;6Q02P$"% ,4    "  ZC'Q+/,6!#"H"   %!P  &0
M    @ &=M   >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M #J,?$M<6IA9/P(  -0'   9              "  ?ZV  !X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ .HQ\2]KV+9KO @  B P  !D
M             ( !=+D  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    "  ZC'Q+XS:EML $  ">&0  &0              @ &:O   >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #J,?$OPS+)0' 4
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M:V)O;VLN>&UL4$L! A0#%     @ .HQ\2Y08Y'(4 @  620  !H
M     ( !Q&\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ .HQ\2V3'G-'E 0  XB,  !,              ( !$'(! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     $4 10#5$@  )G0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>314</ContextCount>
  <ElementCount>305</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Purdue Collaboration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/PurdueCollaboration</Role>
      <ShortName>Purdue Collaboration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Debt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/EquityBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Income Taxes Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesIncomeTaxesTables</Role>
      <ShortName>Income Taxes Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/LossPerCommonShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Significant Accounting Policies - Concentrations of Credit Risk and Other Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesConcentrationsOfCreditRiskAndOtherRisksAndUncertaintiesDetails</Role>
      <ShortName>Significant Accounting Policies - Concentrations of Credit Risk and Other Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Significant Accounting Policies - Purdue Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPurdueCollaborationDetails</Role>
      <ShortName>Significant Accounting Policies - Purdue Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Purdue Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/PurdueCollaborationDetails</Role>
      <ShortName>Purdue Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/PurdueCollaboration</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtPrincipalMaturitiesOfLongTermDebtDetails</Role>
      <ShortName>Debt - Principal Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Current Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Stockholders' Equity - Private Placement Post-Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityPrivatePlacementPostMergerDetails</Role>
      <ShortName>Stockholders' Equity - Private Placement Post-Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Stockholders' Equity - Capitalization Prior to the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCapitalizationPriorToMergerDetails</Role>
      <ShortName>Stockholders' Equity - Capitalization Prior to the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Equity-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedForFairValueMeasurementDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationFairValueOfUnderlyingCommonStockAndExercisePriceOfStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleOfStockOptionsRollforwardDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareComputationOfEarningsPerShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedToEstimateFairValueOfWarrantLiabilityDetails</Role>
      <ShortName>Fair Value Measurements  - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsReconciliationOfLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Commitments and Contingencies - Schedule of Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfRentExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Related-Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Related-Party Transactions - Schedule of Revenue from Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsScheduleOfRevenueFromRelatedPartyDetails</Role>
      <ShortName>Related-Party Transactions - Schedule of Revenue from Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="xcur-20171031.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - xcur-20171031.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - xcur-20171031.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>xcur-20171031.xml</File>
    <File>xcur-20171031.xsd</File>
    <File>xcur-20171031_cal.xml</File>
    <File>xcur-20171031_def.xml</File>
    <File>xcur-20171031_lab.xml</File>
    <File>xcur-20171031_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001628280-17-011891-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-17-011891-xbrl.zip
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MB8L&,DL%ABC29.V$!Q]+"S:"EBOWJY/A_,J6H:G;.4"=2(())*)@G4V],YI
MZ>7*/$<=$MRA\4J1H*5V5D+^22$#)Q2J0IRFSJ<Y&*CJ?H?E']Z.J*H.)&5=
MU-A _/88@*A$('Y&%);:%CH-:B.JLJ$(:PX%)]3-EIF(H-2D:69E%#X&(8NG
M[-@J;9;0!: :CO*VZ3E]3U\&%"YN"#W-ZLSG&B*]P2+0]/[X]*KY T@<K;-_
M##A%  GKC??>1A[2]"Q"J2+IE*$OBWN8*BSP0FF]AJGC2V#O,=1$:[61/!K-
M583@B!T5WG+PJUA80LK< -&$0>0]>4%:O )+\W[0ZR ED]H@)B#-%9"C.P@N
M4$<:3J'R+1,  SG)TP?2 O][0-*\& 6R,4J+?.",@)V!^S$Q6HHAJD13OE$"
M-8;"ZO3%2#9R25)X%"U84L!0WVH.[DD@*)H@&S&0OI56M@Q1K?EY26#/0'*4
M6<$ANC*6)M!S@V0.I)0G"^;*=F2(2OVFIP\DMQ&.$ 'G8[W"W@?IP-5(0;E.
MT[$(6NJ6?UY]0Y(2=?H.V1TRL@G-O9?8L,"\B>E@&?P1M1 2NTA-68H@-8&:
M7M<KQ^GBQVN%N+A+9K;;Y?31F31#'PME.*<Z&"$AVM-(&7':EZYMY-D26X^I
M&7NG)(B]0\L& OF_AY2)6>73;8@(I*LQ(]82@<H67*=)$UJ/K>/*<\OM<ZRU
M#^"6A1/<>&NPQ09\%24.0RU2NER8^ZITW??YR6'_*\7:8B;2X(Y -56>!&&2
MRU+(*!?):I=%3DZ<N=.?RM+B9V&NS:$PBQ#XB(42CGOPX%%[KG$$:6!M2I<S
M\V1<G)Z?JA+ WH&DM<;!,<@:I%'11/A'ZF>@P6/OO"Z3XS0;IR<M1[(QD+QU
MSJ(@F;?20_A+W"<@,0W9I#=H53*NV%D)8.] HLY3PI%F3JAT$MJP&$&4#(%M
M:LGQRFS\$'(LZ;Y<Z][G%KG6.B.&E6 &ZA$=M4ICY[3E*EC+-8(BMWS?+OT?
MD>?"_.NZ+BMR;P(Y-_%<<D9-ZO>0:3,MD-3"0T)IT\=K1)>:T6[[H_$POZ[<
MMD;=T<>'8=;JO.W_'7"?VM$^@&R*0GSJK\-SR_7GVF$WS^ERQ^M]_FI1:VR^
MSUA1EA8 /<<:Q:!=4* S%8*F3AL_W_+2S[M7\UZEA>6+3?6P6G=/!U?+AI>L
MO4E7RTB<(X$RQ(-("2AU8*LT.F(0+AS4%,N]'U6D[$YRU8(]9MYC"21;CITS
M@E'$.#4R@I=!ON3Z<K8TBV(WDF_3AE0V&B=E3/O)W@%$X8W675;8T;J<'M0/
MK?[=XL._=OO=^\E]M6$D,%&D,0E<IIL&K30Z&08D%5!68[ZU852)?[72_NBW
MIJ/N0+[=47L'^Y!<6 (%1;J&*PA%8KJ16*-TPM]04[R&2ZL*K)60\TK:*R>1
MD#3[54.Y;:S25!@K(QB*%10[@8HWA*2EBP/1?EDV4MM"P>)D .0@D>1!"D*)
M)E1S$V/PC*=V6,:+$T#H:]4'24*KW\[R,9!/,T_\9 C.,=TMW!I]>3M,.^?=
M5F_V[[G-]:T''TB*O/*,TG0KBX;R(C#E(U)>4R8(+PQR6.;L-<3NF?-U-SA8
M(KS41AA$5&1"6:,XHI!+>"7%<KMVNDH.%Q5[TNQ73[R@-"#**7A1H0W$"";T
M5/'$8[=\K/#\V%\S;B$21"W&8,1IRT8X""AXIGV'>7$DSOXXG[JBZ?37Z??]
MEFT9'B.X*$NM4S(:ZR)F4<H\/&)DA*6%6Q$I7U)E*0T[D5DY3LTQ \@"_VF4
M09ZE^XXY:"&?E$UQR9#??9!Y&4$O_XF89<_//KTP:CV#<]VT?L$-X>#ITF!N
M VF)MPR2PYC&C2E3O(4:BV4/T.AC(WW\VAJGDY*/ZP;(*ZQ,U$JG2WNY\)3F
M=]1''B7WD16G#18\\L;Z^)!]S?K;]HU)H91UD/*$2 F$38,IX3;UX?ET'KI0
M\>F<OA("9[^^%6%5?D5'*R0#6A@#P4$%'=/T'*5Q)*F[MGCA$$9T1\)VFMM(
M,!7:4D_2N6<$H2;$-,X2*Y\N34"%<9:K*2N91K@I@94SR2)4B998XC!X99+N
M[0Y3 I5RE!<$J,C2N,WZR*S2LPD2(1F,9#B)TG$OT]"Q&)B7$M%"_%BGY_5D
MIMB]B\:M"H9C'H))IW33F3F;:SPJ2*\E*03DU32^4+ CF96C.VEJ-(B:@9$@
M;VRR[BF9D1.D"\D_R'.YN*F7V"KM4X(<"]XA*$T0 Q^IH)H.4$9'1C&D%G7)
M]/?6M^GHS[\-!IT_N[UT'\AM?]SJWW7!W>\R5C=*Q5Q(\\(%DE%J+C7U(&%+
M#+9:%AQ[?F=U"?F;4%8?1Y4)IU)!4H8M#U;BJ.'??LJ1MC:(HL=%Y?[BU1R5
MYJ!5NH R#W,"V8TW)H#/,RHBH!S@'H)URX.XEON,RWY_>_JJ)&L-I,4\W<QM
M+"0"SB(WHR\20'FA#YJ\CKZW#UFZXZ9_]V8P&N5KL)\'PS];P\ZVDZ.I4^"7
MA29&2D,C4*N ;&R\]"KJ8BXI67EROP%EM3%4V23O-$3GJ$0(+HJ(0]1RRA!X
M2FR+,P:7A_'6Q="[X0 ^.'Y\UVOUQV >:;9??OG.=@HR)BJ2SL=!QJ]UZO4Q
M24%$4($$M84<1*P!UDJRZF*F<CD8)=\C$$/:(LR<33.[<F8X&(\L7KZY1C6[
M,0-_>7IM=@?1_+5$\#4VZV>?N^/1=-K\\KU%*3_?3H><0V:++?'!$R>MM5I%
M8)M!]BTEEL4K]-0:OFO@X/ 2J@(&)%L*<A@)^19.UU)0$O!,0@SLN5"B,+HF
M+AU>0NFFK>'7;)1N(6NWAQ-@,O]OUGG3;7U*-6TWV]8Y@P/FF@-<N*72:1%$
M\F4,0]XGF"NF>;I\?>BU5!]&$E7X,-HXCL%^&,((($*M<#-)6!>+^,!J3?S?
MAR32":8IO'J]P9^IE-_2U2,#I9N5'C,2"!60WX?$I*4H;=D65W;YBH6V"HI>
MS4!E61(U),8<ZGGM03&(.3%E@$3/3/%><8W4\G;?K@SL;&-!4<*9\2A5T2KU
M*2L&- MO/5!?K$W+J5T/D=VA[QF3B!D6&:$JN<C45IT3: 3XQST0^"9KC=*6
M?AHK=)?OS&U;.#$>H!@UX+,0BHH3')+C$E">IHM&"W%^I;%6$U43)Y4WFD#-
MFHYO2R@%#?=! KQGG#APS85=Q)79US:</ R!F"GLYVZ:FSFF+/V]4)YLL&-H
M"2&"1X-D4(H&;M+YT1!IH)*8R(H^E"XOPFQ$5RVLB.JK?*VD,C"%J7$,,BI@
MB6B.":;(485BP2;8<K9P4$XJE0*YGB4*J[08$M,EA%C#GXIQC:T*)9<^+B/L
MD*Q4;TQJH;2&K#YR%2+P(8F?XDMHB6G!^V.UO%IR.%;67!6-,>-1$P5%O5>:
MX33J9H8OIFGQPAYY5$XJK[KT&!)K#8ETVHXP3(%NIO@R6!%:O/B7+Z<4V[,R
MR=*U5W.S E+OQBZKL=I +B1L-()%$@*Q/+IT0Y&26IK@UY:+%82\BN -YBR8
MR;#U,:65;]ZX=1>L@P>#.E@$C0!DD.H3"Q60MYQY8Q@JK!P=A,O*8LU33KUT
MUGHI3401NYE:E(Z8EU^?>@""ZU6+QM'&B$@4.@!_(1IBDUHHZ(7SDDN=#L%E
MU3J[8#) 5 \8!\HH5$F<<^V%$(J;I0;H62@Y#,'UJL6GF\PM@Z(XK<$CG>YT
M2E>[>20H9)V%]; =N2S<.0@I6SM=HIVN^EL><56>?,W/ @]I5(=)(ZV$,"$9
MC08P05GD'5'*KIR5>0-!YP<Q=T)F#5VO8J&8=,VSH#A*]YP1DW:VTP2#",F7
M9$0S+D ->"4+5/PP?P9QSQQ4*(%Z*/0,D5!.@6E+R'J9GW& !'BTU4I ] ?,
M#\5"%8X\HY8A@HQ%,E*D?!KF-L61EV .*UF0[ <L#L-!,;>:YT!&;320RZ#L
ML $Q&A29*8%*O=R\,J^$'R@[& ,5*C H2*BD B.,R]3V[X*>,:"""RMOA+EA
MZ@>YHR5__IRUTP6CM_WVX#Z#:C*U<3N@N]N?P'?,=B@&_9*KT(M^:>%F2FVH
M8D(+$G4:?QND0CY2XFE* Q=FVLSUF<\[U,UIVQ]'\^I!D4K,A#?.!A*)BSAP
M)W0Z\>"U7U@SG>?HF Q5^UU.HS51>Q9 6<@A9A&#6B1&HY.:Z&DR5*$AIH,(
M*)_YB!&464%RFC/DI&5T82?W=!BJ,B)%TK!7<%[&1B$%E0R[J1$I1:Q=<5CC
MU#A:P)QV4" ZDV9Z(P5_1DB!A49<BWQ*T0FJJ#KJ" S!GS. '"B%4L9,2)A3
MTF 9HR6GR5"5AKP4H!P<+%/6:4I8P+D164MDX(<UH@\94)_:-J=+ ^.8=>##
MO72N8S(>#!\7'MXV1%E0F+ 06*,B!FID+5#PD<0 X1=>+>>4LK6L;D7TWF50
M[6$(%]C;"!XE>$$=2S/-9S*PA(K3E('[DI:W;_M;;S.MQX1/LTP9E(+@EK R
MR :3TA::DAF.%H[:/\GC!OV ]98"V8*#@PIG33B*,DHL!!3%VBI, DX3/7+A
M2(U56<( PH%8=3+">3O^D@U-Y_],1N.2+9OU\&#2$L?3)&G"G6(R'2Y.$DCM
M%UAKMVM KJ:R?BZK]<P#%%(!2M@0>73I5DK+IEQBGVZZ/PTN\\-]4-:\&;1;
MO>?GEC=!-P@#P2C/<6JPI\X1B A2I"0KC3.'(F:%3K'>CMM5U.Z/ZVH=2V'!
MQ5E@T!".$4Z7(\RX-E OK^":XSUP??_0&SQFV6SE;&X[<[>E?1>PM=@:18G!
M'AQZ2!.IK50N2ND+O0YLZ=KFM>2\DO:J]6\&Z;&C'@?JI9?<N^DU*U;*_ 17
M84^%+=T#OF_:*X]RI2;\M+. O W8.21)6OWR0G'%2]IH.:Z!]H_9\&NWG96W
M6OTVR&='9QV3]U3^/ABW>LNM6+\-QO_,Q@FT=_V-;E99[$;@)%TY#UZ2> 31
M43+G'==,$1$)"<4V*K'4Q[TW/HXDK,HS.=YH"S'$$F:)(B @BM)E=(R!G6I6
MV/9(M]I>JK"2K-A[]K8]1JL%%@2/EEF5[@'@04-)AI6/2@>K(=L@A0T)?4G8
MFMY2'@?#V4OI.;PZR+U$<Q:<]-Z)2(70G@G/73))XZ45A*OO?WY'_BE_%?X
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M=VUN*[G51O]+OGNJT1>@^WQ(55_S.C49>R[)KOWI+8Y$>WB.+'E3DC/>O_X
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MMB2O%^LGCB!TKRN_53W/-?KZ-PZM#R6QRW4M.6+ET)&4C(6RRAF.\EIO(@F
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MWS49W0&>;6I^7<T&N.^(7S\^)?(0Z 9:@Y$+L8S>).^S<6RK2Y.7:"FO,R%
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MZ++Q]KL7[D$ZEJC#$0,U6+!1'L5"G^7BE_A[?QL"\H(9'L8@#E!#@=_XXX:
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MQSV\#JY1B]3O<:V85G<Y/%\RJ^QK,J&7U"JY<1-IF8QFVL:"AY<C"ZRA@K$
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M](]-YP(U*XL;V+?;3BVSJ$IO2,.A@ _9QM3F@VI)UDA?X#?#DHS6DM"H"]@
MGQH+!3Z^Y0D+DJEI'\P#[K'1&WR7:-@RR?=;ZE1HL^X HV.4,TFNEA9C 6HG
M B*:X'N$<^2I9A1+HWP&X*S8PI7UCH.U,Z*95"-9JUS'W4^O'D[=O-I9M>V[
M)'XM,!)*"^.*0MF0MB[C:LLHS!O#S#BVS\E.IEGQQ^W5&A^K0^:F>]4D-=G4
M(V@Y<-#!3%'45JR1VG/[*3T?+21L$PZ+_<1VPC2J">;!4MBV7E2Q =T([C\K
M^YR:X(/ \LO>@[O@>6'IJ>5A@BTR9)/,X<X5M</6P5)=SBXR+)N><F&W3<P3
MS@>47E8#[.N.9Q)X63,?%2OGF.N[;)U*TQ*P- M?A%<"V?UOJ3( #R2[C\U]
MHXD"9/[P./L2%09J;(<J&8O.E[27@E# 601[:2D#F2;J=(@^F'P8V>5HWM^?
M5(K+_.FLF<'#";751[5V%M2>MVWYOL,E1#G@\/&*J;1-?]S"X[GD9>Y0W/B]
M8AAH4/,2 \Y7N0S'DA12=,*\55# 20A$'DX$IP!M@C,A/!J^T9:3%>5D;*8N
M?R>K)FF!I?)G;?E1O-:+Z^6C*9,&-,^.*:2,S. 32R_"[^JK47BPYR[! JY7
M4B9JD9;07DMG':CU]Z^%I2]5/()X"V,C8)C4C?9YD0_IW]7[K^$^'.3 >0YJ
M67@]U:%4G 5D/(A_9$55854/BRFJYJ2-FIE&2_6Z^KS]S))#X=MJX.UD4&C>
M@&;)7&#-0J_KH!H9 %B04#9:MWH9]9DFL)@VU:&.7<5.O017 ?QRN,^\SLMC
MJOJ3@U?S/KI<=OQP#'&':E8S4:TA^E5OC44=I)G0GU1YJ&:5^R@#Q*C*\KLT
M"-?76,]#K74;,?PP:_2E(&7E!EA0QE65L&2QC9*FUB#89EF=T$"Q_4;[G@*&
M&1-='J(*]"@8)DW48=JYGRR.V3O&"=.+>LID.XKZ=BE:KX 8JJ.\,I'$0?K?
MX>Z'6+ U4089_-&>*#3!,V7D,D(=%FQ.9$,_ M11H^:EDTP-+1N9-!Q '0+J
MH]?6\/KG9HT_(W.RG7");GU2_C!1LU0)?>!++\NY=#$_W!;UF2:)KFSJLF3.
M](7I2 M1-6UG-N9<=G(N&V? 1JLU3^&=EDS1DWX.L'SE8HR'+5<V)B6P#.Y&
M]0F+07D^*^EFMJ47-]H/1 BSJF)]#5CCLR85OY": 20I5[ZV,O4;;,_,OPV6
M1<1,QB"F.UK]E*=-Q9/EN/T+?L1N&\"_ZB[@_/T>=AO)F5+*@R2-J,4 7#<+
M_V#MXH80066WC 9$9(EY,"MG$OKVX^ >LVLV;.A. V!9@ >Z!;&MY&%OS<!5
M0[%V6;%V6ZSJOP9CMO'\@-OX-)ITDX9K+X7-,9@OUV$<9CGC^=BA@_>?K.8G
M,KQ@O5]![2-Z:QK[_(UPWG_@T[F?B%6GH22[#P [O2<=:1Y-.&72CG).RKK8
M&FV9+PT'&I%66E6Z305[1Q"'0%3B7);!?C=>R)"-?L(<'B%<H^^#E]E1+@^^
M; AM8IB*6D;'Z*"A3A:\8)N[:!J^<#@2@"ZYPDOO%$,A]!J6'26Z9YA-^"$S
M/,6RM!T>GA(YMQ&3ZRF[\)LB833^L5P6%>HUCY#&$Y(^Q,\<=[7MVT<D1L9^
MA4R>FS0LE(8KYXO@-_7H5/#PP4=^#3,S8RCE=Y@I"MXS[<:VHNQ[D<][)G*O
M\W79-I4".:4\V<+!R_$N_MJDDM:<P5;FT(]'B[7Z5/"RMS;<>/.3&G5S::Q7
M3FLA$EY3/9@%_GR01OR:O_X@_D"?4426GY]O4( P!06)+=(K\J3\@M*#V#?W
MX3*_A:L!>-<8N$ROR+&VR8(?RS\Z.%2O.ZW^(H<<K#;^ZP^2_H.0)O?\0W7Q
M7_)E_6?:^PB^0[8FU?KSI]:#&F_H>^CV_=(K;Q??]O7CYL?-O__-/\$)L)L,
MEAIP[L/8>EN&R5LLOOF9BX'F5XSUX3=/+K/![E']PX8)/]Z&2V#QAY*1[+XJ
M4_%QEU@+YM5RC1\.#ZM>]MV 1E>"UOLR7P8.<Z?WZ#O%(7]A4:(%*E#[:@='
M769+:7S&08Z(/B(Z>\YG- W?)YZ/7/Z5R*\\@?Q<=2_-GLT?./PH7 JE^748
M6/*WD/W2><5)T1)5%YP4$]X?=B.27@Z2=N.WHZ8PXN'(+$=F.2+IRYGEB]3-
M:\___29-BGAYQ5W7OA\$J]4;L-9M?^LAL?9;*Q+5C%N])0O8"?R#<8(A8?JG
M0X'N21Q\#(0#0(K0]Z"@ZAGL>VA8G07*X'W7J>!'@9?^]8<XB8,?_E(!X1B8
M=,&*XLB]1NXU<J^1>XW<:^1>E\2]9+4[>V1D7R/[&MG7R+[.@7T=SEM^WCCS
M6O9U)M'8(4%8E2#E+W6!56N7W\"1^PS/[.'IT#A8L. IT)P*M@RM+XQJP063
MTP%]"B,YC>1TZ>0D*]U"MI&>1GH:Z>EEX)(L::2G(]A7^_F,I+.WO!KDU_/7
M=QI7</)9":<"S)/P'IV,@P@0:'!XG,K)#RWS1Q?VR&=&/K.+SPSOB#Z5DQ_Y
MS,AG1C[S-GQ&-0]G>IWZR8]\9N0S(Y]Y(SXC'BZB=^HG?T#?SE^H:T_?]4=;
MV'MJ#N6R"838\@\'*$;M7GZ[.W/!/? C:QZ5_7@L<(V=HX;H'*4=I'&489YU
M Y[CMKUZF;/Z*,6)AY$9!Z]$_!_LTHH]9F&UK:: ;ZERO3.5],3*9$^J$O9+
MU71VC_[28U7L?ED#!RR!/R&0G1Q=C]G?IV>'GD?VM]D=OS,F?X_)WR]D]MU>
MUZ.N]FI=[:G<J+/+?5+4@SG@3P7WWX1]G)!&-#!?&;[ <F0XSTC&/"00WY@3
MC2[Z4<-Y!B>2#Y8*-S*<]ZSA: >K/CH5W!\UG$'YRO I*2/#N40-1QM>=3X5
M*AH5G%>#\#O\%'BK/$A'-><-N,Y[*W)CX#)E27X.O%X%HU.AI%%=>M-:MU&;
M>D]!QU-!O).(*YY,Z%":2$>('I[*V1^0H;_##-<C3X#_G*3Y[7V0@:(:"[_%
M(>!4AC-\X0(:@EH-@;V<*?%?XCII3I(IBU>:"!^DCX)=I-XW!,M$^/EG1_"R
M#!;,)G"WYHSC1/F5$.:9<)^DT?(^7 8"<8V,3S0': /(,SY>OOW82M4S/F7P
M;M'JG@6;&KWKZ#Z43Y#%3Y]_JSY(GSZ6<YQ781!54VV+C":%QUZ<;#QD*%&0
M3>AC'OBW,<#GYF$BK$,_;7PA)"E=LO;@[2&PH&L/QZ/CR-P\+7R6#PU/3[U-
M4, S,[S!\WT&H9 -;:]_]'"Z^SKPXHS-E8YP,_!6G%P=_+$!8&71 _Q53M)>
MAMY-G&1T[P?<1&/+U:G0+IO;_R1\D#_6 AJ @2M*EU[L!_4@;IR?S<X))VZ'
M;* [P2K,^)'C&6R-EL^R8HTSP^'HRT'88< >DUP#7GO5<SI()&1!CE/5X?VP
M),2:[H'S@VOOC0VO_J"T]T1J/:)D%OB8K[ZU;KH'G[6!H\/N<@PO5VFR%C[_
MMK4K?#^\(?R(S]MX#W %W __&Q=>5"US%<!>V"#U-5QS'0A^&@#D$!XW7@@H
M(>#3TN3!BP@JRR+ !\+#RNGFWCH0'H#M IV%[&UI$*ZOBQ0>#Y?AS/ER8#WN
M)?%#FF)='=HF37"[-)D<-[CVD,AB.MER%CI?;6O?]+[6]NI5,I2F!SX(<8"-
M^.Z"&)9^$\28X @_7C\TX=6BW,R+ D3Z/ 6L7K&1[?@@OHPE+GD)E#)AAQC>
M-18Q*>&"+\Q;1W(#CT/J$K+BNMP1XR*-/2ZW-XF_P5EZ?'2\)VR"%/- O1L"
M#V)M_;R@ 0.DVNV+'X-&<UW!B^ Q%82?8B"2FP+0!EBO!J@%@""62:PS@9<@
M]Z17[F*-OW78PNY;FBQBBB]W@^NT\-('/D,=7I]<YX!0<#.QH RX4_V8C*%R
M:[.<J. 4?=#1X%;AVV=;:+!/>.8_$]@,<+7D/MZYZ-9*GEKYER*M+MF]).0N
M:Z)-+K7:/&4BW";W<+(I+O'6@XW&P$D*(&VZS6,41GM.X'VX^'JSQ&H:^\*7
M5'LFT/Z]B(,:K.U3C7N@6P(&7T=GT)6H\%,)9)#QX768)RDQVINH\)/L(8)?
M006 &[*'.+^ER?:,!88I"3]Z*-"0<!N !@+2!;X  7,=Y$%7NE0;V.<T&C*_
M*008<6?\.0T-JV+C6#,$A 08&^<@7:.'FDMZY?V/$0%Q\P8-"1^PX"7P<X M
M/"P-@ !3A@+PO,;V\+F[](J?^6OLK067.Q;L'250;:$")P#L*5QR"8#BY :>
M", A]M)1,U^OT/U)F<@]Z0FO?S 1.)PH(%?** ,V$'A +%SF-$]]&61^&EZC
M4+Q.[H+IX^8.__O?_U)D5S>>M_D1P ?T1V"WXV75'M8'+CT/,S]*,A#VWT%+
MGD6)__M__-__\^\ONQ,WA,KVK\'JKS^X<T31?ZC_\WW^@Q NX0O/SZ\D417G
MBKG0;=L09Z+BS'33T45%,^:V+9K:#_^Q91(TH?M$65>?,3J\1?%89=Q+[*Q.
M243C#(@=M$[A/=N7>U2 O"?;\7N#T:'YP$PAM <WG$40^_:$E>>CC?# E3?@
M@DE5-<,J2YE"#1838(U/0E+XQ4OA*R!)F9#H'FM.0<:$,8F(S+\-ED7$V'I
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M<&B;T@J9 #Y'?L'81,+.D!TMQX]*^&QAW>.:\WO2)GYMT@49&AD!B\&'=92
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MJ$,H,EX?( 2K%4^VJ$"P#O+;9-FDH)_*GQBT.3\H3Q*,]OPVPJ3T&["R\<$
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M<V_M#GX$9*)=>JL5X]R8$$ZJ:P69N$Q&!]S;AL[E>*=_(D='S'V,57U-N]J
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M15Y"7[$6(UYV>W5-8H<!=2IL<23JBU&Q)=HS=;W<1C[4_U+2,(%S55P+5:J
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MBY84MNI:/G!J -,_\OQZA2H7&V@= R&U:+_$=,*&[2>CYHS]KQI;:S7Y:4$
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M-<0FOQ)1F6E1:[H'D YP,B1] \ ,%OE5J60)@))WH4_XNJ27-<39BG58*9!
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MR=!<Z")DWR1%'A%\^,;M=8"A@ECX*8;%Y06+3SG(X"B ])6PHHR846^MKRF
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M_'KW4R F/!$]$10'-\D>VQ$\]]\;/3/=+=F.>?4$1!9%[(  C4-J^=,_F54
M"5X2)0)D <A=[[I%$D A*^_*_&7_!%7 ]RMDG-VY8P*;O*.K]N5/&0$E?]J4
M2*Q=LJU:%O"B/=3U^&115\0]2K%=4S><)DM<VE3XU%AHX?*-%<*]]3R'U['
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M@]P^LO 1G<(-RCIS<&0P,CACS?&^^VE%V/,QS''TO1\Q4M](9.8\P@I1+C'
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M3&MQXY1*DK)P(B4",P/2.W>FKL<M6DN9@H/CP 51[,SGRI(C((ERXNP;]('
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M7.4I"/\45V571 +0!F\:\/+._X.GY%C_J'#!WMR]M"N;7>06SP4G(<*[H$J
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M6*5EHH1^];K(1;''? 4=V!T^#L1KF1_QBX=!%$\"<=D \3M3L,5^#A.Q+U!
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M!^PK,V*M=&"JMS1#:W4,RD53+O'J%ED6WKDD*KLTFD!K&X6I1%DVDI1 ]92
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M5A5060:L*8IA0M=>$/*:;IUUG.":O*ANZYQI&#IAC"<>7*,32<Q]9>X$0<@
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M*@D?M.LZ!S/Y7FG@I3_'AQ#=1)7.B0<WP(R\("1#R4N^^UQ31[?5>#USA#2
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M->N8WRIKW/(0>; VS/:#^[0WA/O1XL&H/%S'X;74510;!@JV*[G\T&=GA8B
MB2B(>(#",\ T_6NJ1F:VHZKI4'RPTI$Y_\YA(U94O$9'YV\\RBC(0>"2C%#)
MF$R.BEW+BK,YYMOB,<M!C7G3-)!PC40DTEZ]$-= RI&1DB0URD4.A MD?>1\
M7"&A&8,M8Y^O <_[]LY9N[C(@-RY<PH%JEPKUKM$KS$<&XF3WD3EAO[Z('TO
M.3()!4-4BKSQU-?C&K-D292!Q,JDRBLJ^RIV=6\H_9N]AQ83DEF?3%4<-JS1
M$=AC+VL0L08 +\ 6"M 4:J;RP!,AI=%LJ!LU>X[8PX\2F+)CM".;E'#K@:L
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M0*+22A>42$+1:SGG_%BW>NZ)T3E49(T:]5X8?F:Y9_7*H&-2^T:2-C*<5"(
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MY&TR1TKI&MFS3S1I&JQ81/D# [PLZ8"U8CR:12_C7EPPA6K&-CCPWF/W!L'
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M@(!9!IR]?@V"+4[*HWZ4WUCC;/(DS;V(<C!NKH+%E5WL+:K\8ZYVHL6F/K!
M#SY#!;T9!;7OCOLC][C?,$JZL=)"];<)"+7QD@9+^SM'\.]&K$5E3)7IBW;
M(@,+Q\G;@)'R(U@SZE8S06BWUVUDU3#]@M$H=4D^:-)(4X7Y1$:+KN0SN/M,
M,#=)*)]7(.!Q@[ "!M2H9KSGW;[;[]-_FR5]"[&I2!^_>7#X^=J9KA$6PJ(3
M]BU($*BWC:)<OA>H!7_!-9EKM@&LD /^/P]8WVV:.1<^,'E&L_CT:88Z^!]'
M%T=PF2Z#E/G^/(F_^\GATH>A$WAA?.E3&(K8-WIQ0"8<>I?(WEG?-J;S14G=
MZ66)_Z\]P9V1$$$"^@)! U87Q,LB_I64U()PE;SJ=UA@[84Q+$.!0*]J S 7
MC"6V*?: N-D_V*R8ZW;<86?@=AO).*J[[$09>EG-\_I^UQTVDRI=$;I%\VQ1
MQ[D/YCZLWG>6_C)?,-R-NF)T!YV5[Q<\<*P3D8&;9K1-C0$6]=W)J E*  Y6
M9"7%=%H3QJBIO#-872,U $@%:*GKLU2G>(-@;=(9<>,EB8=K-V$,GV'E Y3I
MO49$6;GASU:Y_D^Q Y8@>>@E\JH9*$M)^0:F+P^![/QD$;Q]5:$2^B%F[USJ
MK4$*^\DZ)>49-H_Q5NNVD+>J="6)6+TP;=1]-NRXG6;VZ@Y:?""9[8]"\JV@
M=_AH:Y*8,3PMY.F5P@A5OP01TI NE__*TXS("&&-.;^)O872>2QJ$4'<IQF,
MRRZ'["J)\TLV]I?(^VI_:5A(#_9GUKDF'^F_+.&O=_NCT5EO=CX^Z_:/9R>S
ML^FT-QMUAN/II-?O'Y^T_LO]]E]^981AAQ&&]X:E?*Z"278M5Q]>]]\8=UDY
M&-T*]&4@%PGU[0'[B</P]C"^B01W"I8!)E@ []Z.VWQ@.Q<.NZ8&XO+Q+(50
MB(2S5"7XT<=2IB3^VF-H4Q%9 TYW'5SC!Q2 8@.],-58A?4>-.FB5X2)J.09
M$-N(H3Z%22^TI/(IE$8]4X\@/[+W)=_$DH6'!.^- <"9GV3!*E@(A?4W SP;
M?WKA+Q(_$PN\R,2OZ!OYQZD?>C>89+$W%V+*&+7V7K/)'X+J'X*:B@Z;B#74
M+;? 6?A@-2R/G)H1J6F"@D471%OE6^9PM!TL/HC)-91=@=Y<TJ:L0>I"Z.\?
MW$5!Z%^21@Q:+J# -Z R=HX&D]&@801)/LP9[_H%>_3)P+_SI&KS%-[6'H]'
M\)]AP]G8Y5V&*Y(2SA7&%=SGL+.!Q<)*W5&OD?JV;6NUH@CBT(T<@4HV(/"W
M.4\ (=^EM_9N.2W:,=B.C ;6/'8'W8D['CR/N5@;@7NJ^X9GY"% OQBKV!+F
M>3:U[XZ..^YD\NQ$"A>2$@YM?8*\WD^F4;CJO5J-XD8&2PIV1.0IB>WBC;W1
M0@QE,2#>#ZHH!8D\4R%,;)M%*X2N3 M3RK ]"B4O:21W;T$>@D2Z ?C-1^IA
ME#^R50"SK;E?.\8<M1[I[V)7EWV[Z'*2^K("PQS3#Q3:X0?G('A/>M9"3YTH
M5?'(FV>(.4\&_]7$E5.-I]9SVD?9D0MU/&>5@Q'B+(,P1S8#FP@G9K*M%1@I
M\8ULU%#)MUS8O?+V+>%4>)O):WA%L2KX1P,K3(,?3>S;//82S"7QLK1N#UE1
M@^67U[_V(N^2A:&] =]]$ 8QJ^WDCC5^6?,:MN*H&X$GO9,PTES=!%^$4U/2
M8K"9 5\,81P GU-JN^?,<SA#;"_%KV$>./<77IY*JY OF1X _6^2<RYCX-_8
MAVOM^VQB+/T5->T0Z8?Z!71_5[02X D4>/[;=/KEF<LZ7SHC;6^DQ[G%*VS#
ML\@RF)8.HO@&%' 4NDM;Y+YOL")P/!J[_='SZ(S2*#>U15-[AANI&MYHYDK%
M,86\QGBGLGNV;,].)_"H(.4=23P802&1@5WLX,#7F!50D=A*NP6_)R0J96/(
M%-!^5WI6\X@Z"I("=(/13D[(\9<N=5'$A$FJ&E#.2W%40C6K)\?RM"E R"F8
MD9GATXBI\ORI:**;E'V0U-$L!K78P?\Y---H4[M$8OMNHL*,(X@!YNC(^W;G
M$\K[ [- !9RZKE4$=.4I76($7#L"=$*N+#*18W.:F#"31$4)Q_4DEY=#4DD%
MYY3!YW'J;TONV>1S$)?H>?%"T?L(QHK8QTG$9Y09F/':FZO82/@%G25&JL>N
M=;[*HJR:LZ=;W2%QHK*SMNM!",ZMXE&>706+MO8)+97*SH_\N/8K%1(_J6MN
M=I\7-%6YUNNX_4XCKK?'I#*)9=^Q&^YSICSUW$DC,N+]'H&;U'1UOO.8308C
M7&QFBA2Q4INFGCUUJCOJN]UQ$]6?K!MT1YU?JSDILQ:U'W"',-L"OOW-@^6+
MZH]>5^<%[4ZNTQY=G3;W9K,)Z5U>>.*%, '_XLKW,UUR^*!RPM/Q<# \&PRG
M_=/AZ<EH/!N<34=G@_/^N-,?3 >=-AVG(AU'GX CCL"A,P#;3?6LWH<+6;T_
M7Q),WA!I'7CO-IRI$OG/Z_FY!S7>24CF1"(\VM!Z;1=_HP;.J#/- @P]\9N_
MO.N\H[_3C;>0?S_\'MT$R^P*_@G[,(\3, $.X1A";Y/Z'^0_2HO7DTK4O]!]
MBE.)_O+N^)V3Q#?\[Z[Z[2_94O\SJ1Q!S)ZG-)K\UZ_60/H%E8,6G^_^Y./]
MEWW]/BW^#GK J&RP\$)!@GQ-;;;4*UQ9\V]QK<V/R-JD3^Z<IG&AT56P"N.;
M#U?!$B[Q4[&]@OZY7:Y;>ZZFVW^W?:_$S98,;O,#_;W!TI&\MH&]K-@_@XTL
MJ [:V(GCQVW@<;T@5=X!K&G#4>>8@>][R5_>17'DO_N%<D0Z%>C']1O>$F1+
MD(\E2-5R$MW$6^BQ7/%5L]^/XIIS;_']$LR-:'DHU*W%PO=7JQ>@WONJ5(^A
MWHM%@/[&5;#02N)+WO/:;1<7@?2]TBUX+;OYIZ?:NCNI;]L6-K!31+A/NE5=
M=WA\[QO\Z.UZ$U13Q^.>C9CV6!"W#*QE8(_;JLFD'-YMV=<CV-<;,6J;W,)/
M6!Q#>17!>I-@A?B=!88U]D3O#GOB,?OV .N@ 3UA4@X#/_*:O9;3;EK>MV)]
MA^_#\,G<,+MR'5KSOGYOS_,D"K)<X'"L@A_X[T8$RY-NZ(O>L'X97N^I];K7
M0AZMY?D&1-3NW*R* M/V9K5&4<T68GY1GA%*.H+GQJL,*R5;)1 OTI-Y3E_+
M8;<VT>L1..UU>//7H;6)MLF5*,V2G+.^@XC+'M)FC*([HO>[H]HI$(K>TQD/
MC]V\UT)HK77U!H3=_ES1ITO@VON;V5IGM?GE5$KX6K32^\=/G_TRNL?]<C^N
MG[N/NQTF?GW7Z^T*O5V[2]T*E/CV+K7FX6/V]A/8@A\0P2A?YR&5-"[]3>)C
MJ]F["LI:%?2.O3T8CY\NY_-G=TV3WD.W[06I\WUK/+XB.;I'-W?T"LS'_;BY
MK7'YZ.+EALV%U[(]3Y:EW=R:F]#R.\,RY/F>QWE>'UMX=<*\Y0*[Q 6&G2>K
MNG@MY_B$QOPO!'Y1]?MGF]B.@*K0**>&X<_M<=8Q4-+_\0<"'HY0]DI;\O,O
M_].X$;0J7$83LQTTTHH581D).?T*&_:NX8&KU"& 4,?&+5 =Y;$PW$4,QPW#
M_(8"#;N)-7<K%))7?$3=?B.(BO*,(KCNCSRBO6AE0%^6T ZFBT6""((*;%(W
M!%CD28(8:6'@S8.0NF4_USX)E(?[(GJ].3"GM9=<!A%/TLNS6'[ .B]]TN(]
MU3S>XCVU>$^OW.9KX75:O*>6(-\(0;9X3\_H;)#JYN]@R%[=^ B,'SE_1 &"
M^V,3V$_!@HQ:U3,O13QTY^#W./.=;O?)PH^/RD!YTS 9+;3*BR:3OVG:^5D7
MX1MB?J].=+=LK&5CCXU8#BLZ#K0,K$VX_QG-3?9=9W?A8VR0G:O_[+J=3KG7
MR9Z'!5_?[7AUHGV';T2O#9.W7H$'RY:-=YO$87B8^)SYWJ24V9W<V&&W>230
MUT(IK27Z!L35[ERMP=/)L9V_6JV-].MGRIOP"BD5C5RQ!N(T+WK3)N,G2ZZ^
M:V]>"[6T%M8K$EF[=I^ZW2?S2.S+?6HMM'O=OGO^ZPD3"]N 2!L0>8JMZKF#
M2=OSI[6CVXCN:R+%EH$]@($!J;4,[(F5O?JJM;LZM=^_"?O3-6\?_6-@-V\_
MZ8U'P_[Q\4G_O'\V&DS/)MW!;'@^&9\/9Y/IJ-<V;]_>G/SL7GTG=Z0(B$9!
M9'.X,)A<&:\0?[8"[,"Y\;%K1^JLXA"$9_KAN7:GE/#;EOJTI3YOLE;G32W^
MC7CO7YTRKZ8[?MT>QN>MHVC4Y=92W?WK>7:P7N<AI3@M*3T=*>UA:1B0VKU!
MDMOH03UA7BP".*M@%2RT@=$ZS%J'6?-9!6V3[-;?_](2MF5?+?MZW%:-GJ%C
MY9N@F9]E7V_$SFP65]Y+_2M0;9U@O4F 25)U_6,,A9VK5FE[FK=V<UN\U5Z'
MUK9_Q-Z>YTD49#D&"Z.ELPI^X+_;BJVV$7EK>+X9$;4[-^L)NX3L^LUJ;2)*
MA,DS/^'D]#1>93=>XK=*X&7;T[RUB5J;R)0K+;Y+:Q,]0*Y$:9;D"^K3$$28
M8KGPFVE+O#\MX%Y! [C70E^M4?4&9-P>W<Q.>S5;J^S)MK"N^R*<>S,R]%$Q
M^+8=^:LAF-:R>SU2;[?NTG&OW+*JO4FM4?B8O?T$%N '!(?*USG#&RZ-_GZM
M!OHS>]NV!__9'7RRSAJOZ#:_72FZ1S=WT&]O[O/<W-:TK#4M(_]%ZU%>R_:T
M+;U_;MFOY1Q;@[AQ4=[R@%WB ?WC>]=Y[@L/N!= TK--;+?@=RJCPXZ7.58O
M2JP^=A+T$:2$U8--SC=YLKCR4A^!>]**JEH<3PU" V17,.Z-ESJ;T%OX2_Q!
MZB?7P<)WEGD">T#CIOXB!I7HW[F79/ DC(YE]MO[HC\=(M8?J?]Y=99FP=K+
M_/0>F%>#P>EX-.B=];NST^GIX/AX<#HY/9_,!N>]<;<SGKT]S*N&:>X;T@[0
MDI>0MPD/&(]]%41P2($7PNBP]=QP$R@$3F 5)VOLR'D39%?.WZ;3+T"*0&5P
MA YLFG=)/W:R&/[Z[CN^.CS4K+TTS=<;?%'*].>M5OXBHU?").($O5_>&BPQ
MAJ""W_L9/VI@PM+?2T4Z^$.D#-A"?'/=,_R6)<QEZR+QN;KI)/ZU'^5B @J_
MUK@M_!#^!=9$$"^/G-_TELP]_'4 0^E-@1U?@+3P8&O-O;FY"A97\%-G[H<!
MO!3>F.#H7AI'!$<%O\?W+8)DD:]A]G"A:%+P('P+-R&'5<&1Y&&&UR8/<<-@
MKQ-GE<1K>#9.C;-QS9-;QO"Z*%;O%@<5W3K 8&"+^=WXO#EC,:$(>+<#C&+M
MW-!+KSP8P'-2H'7D1QZ,[_.1Q_P 9EK"V*JSYOC7U#B739P&.+ZKU@*G@)::
MQV^-05QXZ96#&F!ZY$SM=<.<5CE5(/!IW&,G'LK8; :%K.O'(D\^_--+$EAK
M&B=?D36D7^(P6-SR_VZ!\!O_HV^SLV%O>MH?C$Z/Q\#7NM-I_[3?'9T-.N?=
MX60ZZ9ZU[*S SLX3W\?K@!, X<:GX,BV0<"4TBL/.173--VII>^O\4ZY!A,)
M;ZTO@,R ZRD9FS+'6:^!AM,,3U(-A_<&5_J#WU9'X?&-?!(?6H1PD^!Z(+.!
MFZ[8UNVV2S)G,0H+ CEZY" ?MZ:D%L^K7* +;(E<<.4%B7/MA3DL3-+]TLE3
MR<-.0!WX?GBQN(I#7"G=[\--$B#4G;..EW[H$JM9>\EW7B7]*\.Q?0_8EC4S
M9K@D*YA]*%:AYR'YL5ZWFB_\EJ'!@PA6YSL'@NN^)]>,',I@WQ9_.'+N>9WO
M?VE_]HJ7-);CT7#2GPR[H^/>J'M^TC\_ZYR=GD][X^/C?G_0Z;17_,6N..A%
M("?@5Z_JEA=GU5YTO.C?] ;JG4X+;_-0L8EDEP'X"S3%C.T2)V"E!U^[P'W"
ME2BEYD?F='O:'01<-KOBE\*>$R!J%-<?3)QGBF ]FKFTQ/20TJZ[KP+R,(X%
ME_[[AU4<9[!$_Q/\X?R@CY(8[^%5EFT^_/++S<W-T8]Y$A[%R>4OO4ZG_PM^
M_0O^\)WX?7:[@=_#R#Y0__(=#OU+:>R__B=,#\8)/N#__O7_ U!+ P04
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MD4G_9#6+KV[\:AFZ_3:=3^]7]Q]"V]'L>O2X[E2?PBJOZ93Z;"3NVT,\7S3
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M58<\:0>,[@SK%UN&?@PC_W,5[X3LGC2VRSTB0I@X1)G", OUQQ@)FL?)!"A
M=7%H^=*PQ@WP5O#J36)*65%'>D5$:\^0PP0J(*Q7CA?K8]!%*1KF/MT>.T_)
M2VWHWJZH#$H7N @):4AW,,G]?3(?S2?/$Y+=M_%LE54NV'LUZF;<RS@T6":_
MC;[!S5..WT7:YNLBSA R&@@EH.+:.PD]S=%R1 XP#+$1WB>#@[:R(#8L:%6I
MA401([W@7#C '6$0Y!XT2X0?8!7.Q@6I&^AJK%A/]&X&$1;EY=6-6J6CCV%E
MCS_=Q>GH(5XMI^/%^_?F71CPU3Q>.[KR'NMA7]VX3<;;U8-)3BU;[;TSTA)
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M27;5P*(S-\:^=(33WJS#O2*(*39$,^^"-F:I1D 6)H"WJKHKJ[T,D>:4EN:
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MT"V.X2?SENJ0EQ:9UNJ0GP?V:,AUR(,RDMS''Y?!I,S>^3[9Z"@G,JZ/](I
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ME*!Q1@@C!E)G"%> >FR%R:DBG S]]HSZW#H=/5X-HK<B (-430;!]TN,) <
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M0EDF%- >&T 8!B"8J%M:C8;#C0EI6%5H )RN!.'%4$]N#GO;1Y)YI*FT4EE
M$% $B$+(@[Q?BJI0CV])>TB]+6D8MIHP "'HA_EA"]LXE=8>FI/JP;[F$24*
M<^0QH!P3P#GWLL!)>CG N(F:''J5D5D;E,X2]M>#^QR0/AU?]:IM%(8.PQYI
MF*#0*8>9TJ"8$$P,\)"Z64;71:2[ *G[^V1>;D:_:AL1ZIGABDA(&5,"TB"Z
M.4T4RNJI^:V=#C?+Y;J(=!9)643&7(^FDW=S,WJ8+D>STW&3Q_I%E ?#V%(
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M5$AQKA6RQE/)/9'-Q-\ME]R I2=\&\GVU A.(:$QP'R>Y NIM,@#(K'A!*N
M*U6=@]:$#F@[]&JS\SD!+&4\'^IU@&GQO7Z_6)TRDM^NJR 'U'A$/98L^%
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MF1Y7,6Q"L$< =90H8Y0%MIVIF74Z_NCQ*$T5>^M^,3EH!Q*,C-YO$1!-#-:
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MYRUA$$YOTR:F6=PV&5.8A F<;Y#]TO65I9 +A0G##G.*.92FFW^9 A/LH)Q
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MX^'4=O'^W9H_FC*2__FO_P=02P,$%     @ .HQ\2VO]=-7HR   A!T+ !4
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M=)M2T-GJ%C$N5454/"BO2$4EG).145D.>764+JO=/Y:;^_)@\K#E+8DSD$8
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MY2EOS\TM*C'CP-2?&OY:5QL16:*=3N&.1@ K(L.0H"P"6>33-(NFEV)26.!
MX#)2\2\7:>52UXR.1^KEE52",9[E0*-4"2[5'5T[(*6@$A2)+&@9I4IRL4F,
M,LYEGZ>.GEV2D6;$ <U4 %]K:16B:MD?=QNM4(HA#9,0I7E XR*)$!U?"&3R
M'&'^W2;BWVUZ*\ATF%51+049XY5+<V3)Z.5XZ%=>,05I$I5,<W2I:*8 ;0*J
M^<C7B[(IQXHKNBF)_IEPJK @H)SAL94B]_TT0BDB-,KB* ]I/+X8GR;(YWKD
M5/:[+2EGJ*R<8HQQ*Z<QLN24,U153C&:A)73&%UJRLE-FXARAMS**<6*,\HI
MA_ZY<BJPP*^<^-A(!&$<P@2%) K2+ 1%,=V+D&8I%KA;0/BKK>@F5E5-,;9X
M1=,843*:B1454XPB4<$T1I6*7G)3)J"6F%<LI1AQ12OEP#^32@4.N!>Q3UT1
M.%K,0T @P&F4945$DX0$TSGD J.0;V)3AR7CLYSGKOX47+]6(?.RJMIF44QB
MS]Z<.M.R]7F2+JU9:Z#6D05K'9X\7:W6QH[ RW!'EUX-II(\PSCSTS@($@J(
MC](@G[;R9&G&7<K)&C"]E^;L?7;"[X-)D,=1V=G@34I\'E,F_:J:!&O"KZ:9
M94_I531!%D7>.WOF];GZ3Y4D!ZI 91>>OT>FRH>([(9/32$4@P+&25Q0 D"*
M:)'XHZD8(?ZI1UD#MF3WV?U3X@(B3AZ_[!KE35)V0RVR*\Z:N.P:94]1=H58
M%)+=IUZ_(+O2)+DCN_(NG)!=13[$!N+X9'V=@BB,:13%<9X7- ,A3*:;)M*
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M?UO\Z=%YK3P:D7=SDBZAY-QTN2W@_&YPZK8@+]SG$HX>$>NFD_K)HVE&/5C
M@H 4IE&!*(U1FD1I'H]VLS@4.Z.@;,WVQC&%36,:*>:;P+;+KIBDG]QJ-&PP
M$MY0I.EPPTMT79BMUD>U&Q/5&OUY>@!",U.*PM;/E@<+D@2PP#E@9@F" 45^
M"D:C*$RYJE%-I@Q+VM#)JG[9J'JTH6=<I],N;MPT*RF;"8;UR5J/S@E-&X@2
M%S11AIU6,V%G^*1,CB/NS0;+3?GA> _FA^MCLV^W1R\6+@J0^S1J[^%($U#D
M08KC"0(F$=>BFQ'#MC6N8> UJ)M>\CFW(<S%N^!FA('A<[O&WTZQ.,)K>4^"
M ).7=B:8"(@;0FG&M:>[%,SQ)R&BW>+8QW+705C$44#R%,$", ,HC@@!T]8(
M&H6YI&"*&;&\/^&D/,IN6%!G6%@5S9&KI( ]S0Q7KX"S2=TC>OAD38Y1YR1,
MTHWS<J7"BX0TL?JRJ1A=W>3NIW)55M_+]8='\DBS'!1!%(64XBCSHQ32:<W&
M)Y3K[C,SEHV+6+TJRW7C[09T7ML4'@O9E7>SJQO.Y0%#_ NKF67JE23N$59O
M!.O5;M1X+S/)IX8:(^*<1.KT[;QN:F>0:_$9KE;U_7;?] :77S?E$20V.D]!
M4.19G@ <A!CBL)B. @20<CV!K<&,89D<P0TRV:+SENW?FOO-OA/*8\$46$A5
M))=C*=H>KV(:.%%Z ';E=<+XX5KX6DY%&@56I.W1*;<FK4 KW[+T10+.+4SK
M8<V!I6E-CM3:6Y3(T>]S$P>?RLUR7ZZ_U .D Z)%D1 "*4I]FN$@3T&$#C=K
MI5$>\)_J-F#<]N+UKH?J[>LG(_[EB30A=RF*D1AQ9(NYPR-11W]X.EGZ89HL
M'4![7VIO@'TDBW-'0^0H]<Q1D3PE;20ZG(>?Q1D[E[M,DN] 1C/J7FVI$8O-
M#0U'G<?[(\<S!KAN]LW")RA#?AS!$& :%31+LLEDY&.A'0Q*ADRO[749JQK/
M5ZQ:3&)3/&HT\LWH6&-0+/&,L Z7R4X'5?!%(HU,UEPBZ<+<C!9NW9B*T>-*
M;:#M"2K3,!U+F8>CO0_7C^_3AMMU_X.2_;(?) 2)GT<^)0E,B(_CE"EE.LWZ
MH#@6TBPS$&S-8W?3UW?3Q?)]75Y?L[]6VQM!?3,4#$[EFS\.@IKX* 3'!_>>
MOABWW*Z] ^XY+O^7(_>2EIJ-EB,J:]C)I_IK@U.N&9/'-M]5_[JOUMU8Z&#[
M8\EZQ7;_X1K>W.S*&U;0XF7S[?%1@XA!2@C"?E($>5%$[?TYT\FP'!3<DRB6
M\!C6["/<@V*WP*_:O1(M]%8YEB-X;\70/SK_)7)<R5;\."98' R=J,P_$O,K
M[SB,'X_".+C1#O@G1[S6$^E39[;"*# SXV XY29KK(65;_Y&#Z_GIG0L1\V!
M61[;'M?S]1&Q$=>'NVX]?7OSKEPV[5S4=D]^M'?EE;]4V^KV_K;]R7+3+'!,
M?13$09'G/HE@% $_*@AES1:$"$*A>2%M1HW/$>V6U<TWUK3:EW)V;;<O>YQB
M(RE])/.-G6;A5RR-3A"]'N.5UV+R!IA7W@#4&Y#:'1[Q\G=A0*0]!&X,@?2[
M51MNNKKDL!5C]O.RG9\?$! (@R)M%3CU,0;0+X(109( KHN(3-@U+(H'0$84
M48)G55$T2[%>73QBWS%I?,:BE#K*Q\)U@53PC%LC5=GCF@WBE6BXZ8+!BM=]
M/:QQ?ESN]@^+/&G/9L.0)B&,LAA'44X+&N1YAJ+0S^ABVY7 ZR^<TT'& 7%U
M=]!W]V?8N;O^IR,U]98]UGZ7#;S?+3_W_?_=.RPP8V ^5!Q3/FZ$QT:5>N4=
M?&CC-N[PZ-QP*FP"4SQ.A4]N<L=*&/DF=E39/#>E8RU*#DSFV/.UGJ,?Z!JQ
MO"_WB\+/4>03"O/81S1D14"<#>D_@@2R,4K-,*N.47@L"8U*)E#<7?Q+^T^,
M#$BX:%0=@NAF4&^:>W_AKEG+HPP&16I<(4*PZR,)(5^XQP[B#/%*U+MZ>\/J
MX=NB_+K_9;F_WU7[JC5]-VTP^KBKMJOJ;KGY5-XNJ^VZW1Q)JV:UW/P_Y7*W
M"%&<T,P/0Q@" ((<D-"G!-&(#6D(J[Q%9EJ,@S$\_=+V&#%I,T\_G_HYQ;R8
M0+;0W[!@W7HM>%8P3O!;J;P[V@TYN=#^8G"B_7GOAM?Z85=*55F_H+;6 NJ&
M(-MSMYZIXQB3];?;%L>7/^I% -,\0C!C16\1A7F8T1".4)+,%[IIP @ \_*=
M&Y-O 9JU2[89AHW+='MM30O<8\B=%>:)6SUB+!ZJ5R? $B[*BZXLG^:$EK73
M<D'RJ C#F,",B7\2QX2@> 3C)QDV*[5<$,R++3 MMGQ4FY);[2Q;%-P6N^N2
MVV+4*KI" 7NMLBOFI++P2G#**[TMB+?;9K_K5AWP<K=[J+8W\+8]I\G*ZCQ)
M,,A"&,4@+GP_H<%@LO!ADHI,KBH9,CRW>NB[7Y>;_E#+_;[9+[=KX3-%:GSR
MJ:@U*M6T\N\7+Q4SHG^7F+F@<EH(=4/+]+A2&VAP*KKTZW9Y6^_VU?];K@LV
MZN_LQGD"TA!01/(TBRDSFJ/!+O$IP@*;+/09M;.18E,VS;][]P=\WGH J")6
M4B3+*)8Q8J5DJ\7F'<!=>4?PO.(E7BW(V FZN+5,A6H7!4W)GXNJILX4O[3U
MIR5HM9V.F[=K4ZD/@@P668J+)(&D?:D(C-9B#*&4H,F9FDW&VKZH<F6%-+>\
M.F:03P7U>G0WQ0S+V6=XN2A3:DRZ(DZ*7CR3)!VLR$R[+<(LP#C-VJ-6T/>S
M"!.4C":"O,A%QGI"7VQX;'<8E;3B(C]9]C)!XE-@6KE1&:S--TO%.??$S90;
MNB '_<(\D:#_,@J [W?M[K(%RGS"AG(!PB1( Y0E!1G74DD!@VCQO=Q]K67F
MU7DMB+3Z8S#<C7\ XMVU=<>%F[?U<2:N#2;(4IO/&5D[S%G.)QL#%D[U$.72
M/1$1]N""ELBQ(2,I[YFC@['"QS#P<1" #(:X &PXE0[&:)@'H;RJ"!@Q+BP'
M+.K:(D*>N+P88DU-8<B/U>:^G7-W2FL.5''*C02W[BF.C!,71$>:$ZX3>\5P
M:@9NUV2[K_8/;[?7]>ZV.Z0 OS;[W7*U7T1Y6L0H*=+0!\ /BS3W,Q)'60:Q
MGT392UN&]!DR.!LPP/,8/J\'Z!TA]'X;,?XO@<-:>L@5.)!EG62Y0U<:R.8[
M4L7#QPEITL^E T>C]/I3FVIU?-JU+JM%;^M3>5.U)K;[]\O;<@&*# $FCSA+
M:9PF!,0',X 67&_'2W^YX3U+0T\Y@/):5'QZ)$_896VWPI68E O2=*$*:LK5
MWV[J[S\S)]L"*&[_T*I,?%3WG"/@A*PH<S6OBJC#KS6U&5&-P$R<=NV>H'7Y
MXW^4#XLDHP0C@H*T*#!.<52$=+23YH!KI[G\M]M1B0&5U\'R&"Y1G1 FC5<H
M3/(EI13\5&G3BB<<7!0+6;Y<40MI_,_D0HT)?KV@U:;<X>6^O*EW#XN0!B !
M/H&81!D,$IK#9*I<8)R)J878=]O1B@Z3-X(2%0I!MGAEPAQ14B+!R9$VA7CD
M_D5]D"/*%7601/],&U18X%&&<9#SA?V+10C\+$,)#B&$09["-(S(]/484%Y)
M$/I2PUHP#<I;,/P:(,;+RYW?&"62\T$7V=#0VX_]/=/-I2B9OW_+P:X5FX)X
MC_Y8[JIZ3;;K@JG'@H81\HL\@23/**2LK$#1:*?(8Z[G_.2_W58?[U%Y#);7
MXA+O[H*D\?=[<WQ)"@ O51JUX!$'+XB"'%_NJ(,D_A,RH<($CUY 9F3=&J*;
MY<VB(*&/0A"0 "(_)SXS4(S?CWV?ZV$A\6\UK \3&*]%PZ\*@M2\K ;F6!%3
M 4Y"-/3]1QZ?Z?-RK,S?UR5QUZKM06S_Q>?5MW)]W[[$>%@[_W!]O!3[I7UY
M\4OY8X\V[7,Z64C#, CCHO 1B#.:96R\D000 D!]G B]+:;=N&&E.!S\.^!M
M#_-R[HZT%(#+0N,$]V)Z-$)MJ;Y$O/=;!]EK,7L=:.ZE5#W;0$0YO;!!Q%AX
MW-@Z8LZ]VE(S%Y39^Z]-^:][IN7D._N?YK!"'$<Y#/,X1Q#!- N2G WK4!05
M<4% ''#W9MGO-]AK)TA>CTEBAX.F;GF&G$O=3Y5/1[J9LAM/NY,>7B2[3==5
M%SA)\A2$<9C[29CZK!S*@M%4Y*=<NQV4#!BN,IYVG"&M<>[!4J-.2FWTLZ:F
M-"\29D-EOIQY0UX+ATZJBZ +EY5%A@_N5Y59ZVFW7L ?5;/P,0JS$%!<Y,Q6
M!G"(T6@B#'RNA4ZI+S8]5F%_Z_8 L;3+X BJAQA%?*IAC!TQM> FQLQ+PT<D
M7% '*:[<4 4YZ$_?^I7W7U0%BKJ](G0!TY!$- XA2OP8^4'B%^EH) 6)T.UP
M@E]M3PEZ0)):P$N4F!H8X$A:#UZBQZ@B],8Y-$&0,;=4013\&5V0XH#K; CY
M4;'_E!_N<,T"EI!_W7=[N]OG2*OO96O_E_+V:[E;^&E!<11F>811#&,:LO\;
M;<?L?[A?[]9FT?2^J1ZGUP+U6J1>#]6;L'HM6(&C(OJXOJPY\]$L)D6<#'N_
M]4A%3N7HHUK@9,XLE,N=SM%&/=\9'5YF3J0#,\PZ<%9'OT^UR;8HGE.8M;^U
M3>&\[0 4 :MN,QK#*,99E@!_&N^&1<+UA*I>BW9RRE7;S?[6]KM,5U+10#9_
M4K'+LU12>9%BA:RB@6OQK&*7<Z6LHH%[H;3R(C4OI!5]U+J35C3Z="*MZ&:,
M*ZU\+G=5V>"/N^$:L,_[>O4[KK??R]V^7%?;??W+\D> Z]O;>MO];H "$C^(
M<]S>!!T7E 1%GL33J(D2KJD.HP!,+[!TL#WL3<"]#ITW0?=:[!X#_R;P>OC]
M)Q2[IR1?YWJK:?H=Z+S&7:PM-F?QM<]J72UW#Y^7[?Z%SF(W'TJI[X>$&6'E
M*<!A#F,8CO:"..3:K:UNQ70G7?8;?OJ>*;.&H4 @_S*H>>X$UT)%:#.V#GJ2
ME1<60]68=&.64X,?)Y9%=3##K3H'*^T\ZX?K+[OEMEFNVK)WF'0EL(A(1HLH
M#1)<H"!*TFPT[%,_%)(?=7-V=4AJ!44'J9R29)=/)6V:9;7E98(NR90^=AW1
M*XT./14NW5QQK^ONJN_+?3OT6I7MB'THTC* 8)1G),O"//,I;K>JC<820H54
M2]*$Z77>'I4WP1)<YI7DC7.YUSQE@LN^3]D2GH/1M/Q[DIA+R\!J3+HA/*I.
M/%T6UL&)Y*;4=]6V?+LO;YL%06%:9'Z0^Q2D,8VB/)\J,I@AH6>YI8V8+H>>
M[;5LH7D=-K4=J@(\\@_/C%,H6 %)L6=CN^K$S@NC-"5"W= >=3<N;UV5Y85O
MSI>55?505MVW(E=?P_6Z:JNJY>;SMR5K?/#[LMJTVV=IO?OPO=RU\%:[ZJ[]
M3+, :8Y A A)44:*/,. 3EMFPCCEVN]J!XEA)>M!M^.1Y03;:SK<WG($[EW7
M[",,^IOF&+O $IGY@'$L4SH5*X5!XY5WB-K! :_WP)M<\)@/7NO$F\_.1DU@
MP=.IZ,DMA-J((N<:C"*99Q=C; 7)A549:[[6<W0#M71\ LGU=;FKMC<+&I.4
M9'D.TBC ,2%^ :?Q"$H#KANT#)@U/60XE5.;01":;B[PIVH[I-Z_JHFT"OER
M>=02[YJ2YFF-'0#/1[U:,K04 LV93RX4TDGN/$D"&4T#TVZF+QV.O9"KM'''
ME9@^#J_#?ZF?SHW!F_;GS/S37RQP! B*,$E\FH<DB .<PQ$&1G[*G9Y,&#<]
M>3Y ]O:U=S=,#=]-4\/+#K: /AJAGR-!S<V\X!S\2/J7VGL^']\C[F11<FG#
M7"@$$M;<(9%+6P9"PY>Z).@ZE\!,,N] &C/J7FVI!8LMO>#-LFD^7/]SN6N?
M3_BP^U3=?-OW"?;#]>=R-5SP@Y>;3;E&#\/GFN&#S:(@-"04^)C!H!F&10:F
M$2"*0J$5&M-8K$U_#G.>JPZH]_7!^V. *CXLLQ8GOA4@ET(DEAD[Y&UP!DQ,
M2KP.U*,1Q.2!AZ?@C4Y,_\+R4WB*G%]8?K(533=6J:QY6\_39S0(/_E1[E95
M4[+DLRJG7TY0@D4!"@P2Y!<%CO(04 !I-&V13#*N(]IF$1@6^1%?.Z19E9V>
MK^O-9KEKO#NF(9VVZY!V]4@H"+K5(&B3\2DT'>RCS[BEW"^1*ZK7VH+EL$KK
M\Y%'FS4SRK?LT0K'UV53KG%]>U=NF_[9P];R35?_?WTX?&08/D!65JX_]$LQ
M1X=J^@O,%QD;(H"0YDD>^(BB/"W28MH+&A9<KY/-!,U:H5[W"+W5=$Q-<MW$
M?O1XUE:<#IS@^DL+]$V'U#OVQCMRIRW6CS\WN.1U/EUY@U=7CPXE#N\RN!UK
MD<4<IV,NN> S4^PY5X9T,WYV]6BVT#HP-3>C\[43W<MZ+=&P/_Z]*WPFK-A/
M@_;:P!2G&0@"'!&03UA]D=T6<R$T7%D<<'DW_<B#J<S^6]F.#=O7?^:L+F3B
M::W(,!S*N6N-KD7\?6H1,]4<,BW >NEAN"6X4H&(M0B;E<CS )@M2!0"_J>I
M2U0XT%^>*$>$JTHYV!H.M3)3[24_RYORP_6'/[;L=]^J._3PKKQ9KGK8W^H-
MBV4#KUEJ/CK\NHCS%($\1W[N!WD&J%_0:6DT0Y!_JL,B)M.[;WK@7CV"]I8M
M0F]_@"B0?VS&BJ/F<#1,@C/9ASSP8=K,>'"D_>'DBH<>O-X9[]@;KW/'^^)\
M3 6J"$=C*U<WV(TQ7Y6@C^!S=<$,(72@$IC#ZWK>CB.VXEQ4S6I3-^V5L=?'
MY<FG<K/<MQ5+LV^>52>']Y!"' 8XIG$(DBB*<PP)"' 20Q F(08)Y%SP-(S"
M7+XX &]7+AZ-0@;L7@?^ZM0H9+ZGPM3XOK 8:BF0;JR*VG*VGJ6SR#ZPVIE&
M%X8[#7HX?.9XO-,_AA1EN&!2A_V$1%%.@B#$_H@OA+'0"R7V4)D^7';T-BC/
MO$=S<>)#\JDU>R'FRQIN1E=P6M-N8 V_!ZL8APN)Q7ZLW<@Q,_A]]FE9N\SS
M9IY/K?7NJL@DB($/:)S1)(PSOX"0AN/WHR#CFG$2_U;#RM\!D;H85H 8/KTU
MPXF87G+1843E)N\OJ)0X0VZHC 3N6K5M2/3RX;ZS. M)7.1Q DF>IQ#!.$&C
MA02B2+B?<WZOG9XN=?6J$#T"O=T ,U+]?99+5(\8>*G/"_+D4*\717ZJWTMY
MS]OS?ZFVU>W][6 #!6&:YADF/E,7@$(:M>_6]S9@3(7..HA]L^'>/X 1Z_:"
MW/!U?'.TB'7] <=,%Y8^8N%"]Y=CRPT!D,1>ZV@O@B*P_'%L(Z=!0(*B8 .(
M,(P+&% ZV(A(@KFVO,E]LVD1Z,$(BH 8-YPB8(P601'H<<PE L<L7!(!*;8<
M$0$Y[$]%0($!7A'X9]D>]2G7\'NY6TY51Q@5("<$XRR+\SP((Q^,LPI1&B)?
M1 SD+!@6A1&4-Z 24P=)TOA4PCQ?8FKQE*J99.,D+1?D0XU&-V1$T8=:9\,2
M7+IZ:5KSW*SFN^D&9&8\SH((94E&HR (PPQ$(["B($(:9 &.Z<4JU8VY*K>M
M6P@FY^J46W$47):R$T(SRU'*Q%]:A[(753=TW:;#3U>>;',ME#$N[>A&9W9T
MTV6U^\=R<U_"IKF_[;=WDQ]WY8JENB_E[C98I 2S"CEF>), ABG[ P$C8$##
M1#B3S /3<(89P7CLWPJ.EN>,G4#B<#]LEA/*E=>ZYW7^>4<.ME>,#(WARZ7&
M8"[5& G52REHWO;A4&J:F8A3*<N%V!@?_)P"_*EJ?J>[LGR[9;I<-OM/RWVY
MH %-XA@A'%.6<M,TBN,)=QP@9&5LI VMZ35@ANG--0/5/LW=H?)V#):E,9"^
MF!H>(LT23F<27NNIU[KJC;YZGRXU$K=&6;RQ,S$(T]YN'$J$;O"A:PAG*%*S
MI,4QC_^CWK"OV53[APYY%(4HSR(21Q' I,WN838MDL0PGRTQ2N*U->;[/L&:
M.S?*!G:&[&@AIL[DQZFE')Q][0GR=/ALI4C%QO,G3)*JC)A,DUJB9?9.JU.P
M:;V[+JO]_:[LX!($"Y06,299&&*00TS2$2[,!5YIF1.DX91X0".0"6<GQ>@%
M5I:#YDS..VH*%U.=8TW!QDU6EIO$;)=9J38-P_=9O1R&$^6,,Y%WX"X+)VC0
M<K&5]KC,.JPOJN_5NMRN.]Q%4(24%%F0H(P6(*%%'!QP!USOCKN#UM:0?CV
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M*CGSLS)/1A:,FK8TW CM6KCH049Q4A!" H12/R99F&(T>H!C4F@=-UO$/>^
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MJSU_WKO#@Z8_GP>]%D/=F<9?3(_=&W@YU;[$[YT=\.B3T29/1_LUJ>\\F?G
MN0GR)V:!>0?7C;EB9I^?GP]?@'&Q:L#3P\.NO2AJO<-=QNS3MX+G[N^JPWT+
M!WVICX?UYK@*LS !84"R/,_R%"*(?)]$$*$,-9,?$;MDVZ ]B_O?%RB]'J;7
MXO0N@'I_#%"E+G<UR;A,Q=="S"L6=AD; <'2+7%VKE9H62#8A4(L&VY5EA],
MN<C[]E UR^/CXVUC_-C$^3P!_< !?2Y^'''#Q#]724H8BGT?-/]D(0K\+!P-
MQS@0*G@V:,YR;F% >..U&-N5[HA2+JHUP:U8R#HSK7(SRB2CWA^?VZ(&#M1K
MD<Y\T=S;U$U$DP9Y=R-4-.E09>T9E=P-WGPKMJ==\>$.;3:'T[E\M0E#VX?O
M#""C!*<  1@!$@8LS!*$!P"X^;94^:@YLY8E;T#*UX$]5N\"K&0QJ4&VQ<1O
M(:(EP^IICA>707$2IW;US8^$&[)HP['G50"VN).7R8^-*-,?O$U;\<QR@) ?
M,D*3.,$T@5&4IH2&8>@'>1RR@*CIH[J]&861@_1ZE*J*J$&LK!3.PZFZ!E[2
MZ9#X7:5-2/7T27=-[@QX=%7G3+$E+W#L=#P=BM_*?7E_NO_8KKYOUX]M"TM6
M'3XT86JS]-Y_?<\O.GXAOC@+6>:S&* D#4"8QRD:L054KM'\+(AF%,G.#:_W
MP^L<\09/5&73ZG#)"JLK(Z4NO=.#Y-U5!V]TP^O\<$BA-?@7TO YQM<UE9_%
MYZOSP'R,B\X4>5EO=E7=H/IP][1A\6Y]Y#V,ZV,]5$<4VP'LQ?R515F&0,A
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M^<R0\9%T0ZQG\U8LKV2)9:&T4U=RU@A;=> M;>NB^5O?AL+4G#!& H98"",
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MN[91E!^QJQ4O?'M%^)3==^#B0B78E>:PR^M:7MTW*\X5"'R6(8""+,:09%$
M(CP88#D1NEE!X6-GT[8.C\+;+,J/N+Y9H$95X:RS(J]R%MA1T[F!'.^N.GA6
M1*\S\(;L2?+ACO#) G]%^I1\%Q6_>GT<MF5_*^Z_%(=5@J(F2$2,7Z5 ((2
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MD/1?;;'V;M\\&D5]Y&O$3\?F/]O;HGF.]L?UUV)%\BB+(I A@ %$%&8PR0<
M"1'K]VO!K'4QZ;!YAP;7C5>W\+R'$9_.LDZ/;I65WFQ,:RW^;KR1]8\MZQU4
M[_9MUF=8$4YQ*+Q(-#(0;DB=#<<FEY(&N5.3R?::AT\/AV*]_;"_3+G#5<!
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M!F31MJQ&NW8<FI_^<'?^P>>?4N-6?-O4X>?BQQ$W?^F?JRA!#)*(I"QMG(E
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M&AF@U0TQ,N%(9?R1D^OK]W#BKV_S*'VJ[H[-2KWHK>&D(22'.8)QEF>8^AB
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M\\4Z NA;L1P7C,#&IG&2JP@-_L0T81[JY$3BS-H :K$5QE5Z)J1$GU(WM,6
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M!IT'L)#(*Q*3IM[!R$T#-(E$M+5MS=%H5>]V,+D=C$?OIIO+2 YM:NYND<@
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M10*5QTAH@YU3Q F57U-4(( !Z]G)R<:H51O"%SA"<(8=7J%UXCG25EI,D,;
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M'5O_?]/9<#E)YY_2X9=I-LGNG_XQR_Y:?#&#Q_%B,#D<;*_4.#$:0@6PD@Y
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MNW@,I:8Y(Q;'.$VODZ&KJ/K%DXG'4!O+J6?*XCP\P&$1!G=(\;X5UZI3US%
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M*R,(5 :40Y-SXGH67*O?XFP$Y[98]L?T\W@RR>?[Z>JJ\/F'=)B.OQZY;_U
MJ\0QA1W%U''D*,*0H+(6G2<:Q>3+7\,QL7@^U0?NQ8^(_6.6S<\Z=KAJF#@G
MA,+!\E508P2U0Z((47L+7$SP]AJ.7L13J59\VV*3&@YG82X-?;]+YSD<@XE/
MT[E9SG(4@Q2_9]/A^C\.4.N$MR12&T<8ML$."&AP+;4JX W@RJ@[,ZXA 3:>
M:,VA?;8OL-[FFIO!XW@QF*PFT_'GY<I-V6?<'VB26,P0-]Y:KX*MR(00L!PK
ME(@8Q_(J-I(BS?7ZH(UP#B=!X=ELD)_GW_)IUR?]UXMLH/#:C=CO_YWPDB0
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MD'$39DY$>W;)T05X\=IHK44/%^39\0NU]K5)L/*602H!SH\^>TR=9VL9+71
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MIZ"(C$.L'?F><B4K$Z^!F@8UZ>>Z$PHL0)I)3:TFV@L-8&[G;&25R/XH;M
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MX:ZQ+RTW)C2/<T@I3GP];B)A2J[+$=*J*V4H/])],>Q+L=[.M;+G![CTZKD
ML:94.N$QYE00)A@A]>)+1#_9WT; FA;27>3#]?RN\7B$F0<42$D)A B[N+96
MX^.2I,1XG=5JD\Z;/ A?ZEDGP!@";('P % .!9.FUA(DUBD\&V$FCRYYUAGH
MPZM0K32G  "W40?E$BKFHDY F/>UHLAA2L#U"#-L=$FM;"#W1:4_RF*\B[OY
M]+^;@Y$J@_X!'NUI$:BBBFN!$<46*PZP]BZ.SRM?YKQ&*1Z!$2:YZ))$>1#N
MYTAJ$TM=+,WB_GXQW]1=&.PDRDV6\RB0LCN;CC2Y ;NG27"$"X>D,U 22BV0
M'NWJ[U*N%&T46-3/*)N</N]M$T1<DB##4&MIG(\[&I>F&J?C[,)*H*>+^ZTF
MD0G8H>:JBBK/S73V6"I#OY>5JD=1!S;G1.;4<"(1X,)[IHQT%%I#B9+<8&YD
M(X)W'63RL13<W]>SQPBXCS2.(GMXW,K\ZO8=Z8Z</>?]4"#62A5Y;07S7'"C
MA-$[1 DF\,+\).G$VAN/,H T^M(J$X>FGSY^P9&S\0Z_&C3%SBG"-2C!IHJH
MN*#O<(9>7M@!^U D78Q5H,-.G"^3^^+HX?ZQI@$"[(&P4$NKM 6*"T2J$4N6
M5*9IA!0>!7<:\;FUB'KS=-X_S!9/1?'[.FJV5P^-CG[WM@D<(>&E%!! 9N)&
M"1C#U1BM5[WJ#S^+Y9^+08C81NAOC8],$/=%HW^7(:OS]5'JO'HN6&$8M]AY
MQ R-8Z+*PFHLGHA>8P3.FBXIL)Z)WOBY00!!KD^$.*<HDPXCR(CQ"DK-32T'
MSU+2]XWPW.\R-,*VTCL3_N]-99WU_2&*C'K.RAS>VA!'7)DU<8>=BQ+]-7;P
M+DF7E_6MQ#:42_+@2"[),TDQLP@P)*@'DD -57T+%TC5+&1_3/%3S%HF([DQ
MPU@)[I$%5945X$72^=\(S<MTL1X,FCH-S-XT^&)Z]V-=W*BXZD[NBB^/I2IY
M=;L!X.IQO5I/YC<1%#U93:_5_,:62U9Q<TC5;_7"H(2+4);P D\A(<I+6*%C
MA+BP ,_L5.L%]=Z<$V\=-XW)=Z1EP,*(:#<K2N*.;96!9).,?#->:T'*@C;"
M@*OL+,L+[S\:^$M5SK.RGIG1#"##J,8V_M%K:;CBP)BD#)DG!VSUH8%G)^<0
M8AA*HQXXPTE.G9E KJAV$CH(D74.&4QW4164^V8QL%V?YA]9]]JD-3GEC8$:
M(;&#@B(@RW64.^TJC+"R_>0R'W[;:DR5_>E,.H2]_TPFJ6Z[DQB;ZV.!LU)^
M%&*#F>>2136!5:A2_K;$^\5J^NED'D@B_>QY7Q^7-X^%6<PB*7?)? ?;[K[%
M4<11_R@7BN)G,5L\E%DL&VQZAQL&C0!R&G,0=0O/A?6&(^:0E4RKJ'8,&,CV
M O>?A2H/F>Z*^TV>\"JY1Y/%XX2WA#(H$T#AA2 :8*X-=:K&PIN4HY<1;G&Y
MB+'H"_#!)OW0[N&NYKY /AK)CFC.H;%""0RQEQ@H*YV4=L!H].<-9A^=RBQ;
M7Q;SZST__AY_MYI<[[)6-@UDS?6Q(#UD3G@ M<+0E<GGA-@A&[?5I-(HY[>2
M-*;97BUC(+GTI4U_VQ2(/1R$6C\3!(#6,^F$\L0833FTJAH#E9>66G)($BSR
MB*!7&AT-@WKQ5$ 8,60\!$I& T!3BYBIQN$8NS";OH7\/F) *^SZXL!OD[^G
M]X_W1UGPZKE %#<*$Z*8=RJNR&7>[VHL@*J4@Z^Q\N!4*2[RX=<7%[['KT4+
M_7DI/++%?/A\$%8ARIRT&GAMJ;#1*J\1HDEG B-TE8QHN\DACMZ.M][A,_D8
MDJ,+TXEO"AX3!04$0&(N&3<>.U:CZ_F%93A-Y,3;TZI.L>Z+>_LFZE&J'6X8
M,&?: RX18!A1* 35E=GB&4 I/N(1,JLS+C1T#[4"?6B*G; 7?&X00Y[S,V7-
M:(*PD=  AA"55"%0(2D82%D81QAF,J)]>T I'I\/>TH%OG)WJKMEL>G2]O+/
M-HYK<:MN;J;EGR>S5T]_GRSOB@\SNV1Z<W!2<(W+#+J00J6%Q[36KB&\M"S"
MP]!G,:3(,M/VCX>(ZGS]=?)4_NDT8KYN&QRE0G-*-1.<:(=P'$4U#JOQA5W&
M&2OUDH32FES?BI_%_'%39^9NOB'[;X^S]?1A5MP4LVD9XQIWB9<H?5VLXR_3
MR>RWZ:Q8K1?S8O>*?13,]X7@'1#24>($H^7%)R/(L]Z$U(7M]L,3=3#1]4=G
M=1?GW]VFTM+V>*<S6A_]4I 8(05HB8X7EE"JN*TP(K99WJSSR21XAO3.+<)!
M:'[W."MY\]0'T?=]*UB"!4>V+%8C(*'&H_JTU ,G+RS?X7E3/9,0!R![&<==
M+*^[5%8:?"M(23VC$N&R# 71PC'.:SL!)R7]:EXM^Q^R]RG$_LC^W.7?)['+
MWQ9/D]GZ:5?"/AO-#WXE &*,<YPS:@SAGBG/ZX4 0^H2"-Z\*/8_!.]'?#V:
MFL7R=K&\+TMVQ]].%S?Q3W_$EHM;=7U=WB&:SN_R69T-/A:\,9Q )B2C0"*J
M@0&D0HH;E)(%[/22V?\0O1<I9O;;'5% #C8*E'(%.8,:$2&]@P#8>J8J[E,T
M"?D/_YIZZMI)H[< N8_C5)_Q*6LUE"&KWQ>[V>(7RZOUCRA.LUBMR_+NCR4)
M_K4\G, BZW<" U&;8@!+CYS@.DY+L3.<%8 L+44H^(?:'Y[A#2G!OF9#5;=Z
M_[*[Y\G@M=!<>,?C[F#+><X!KL9#A4N*;O_G1.YC1J;)8"!.F7(2',Q;\'&#
M$'4-*( #0&CD-*)E3JEJ=$;PI/H!HTS/.$:.M1-&/[>TOA6SR;JX^3I9KI]>
M@C#@':V/.]3HEM;AI@%%I*&60AA"%(4J;A]X<S=6.(  ;12)UN^H3[NC><);
M O,26:,C!I113KW2IL;",'QA47GYJ/%.P>D*\F'G_Y<R:K%<)(>_L]G=>B!P
M7. ]M@(JP:$L(S#%)CL-<8)0,>!Z\!R&MV\0^NG53QI?S3SA?2'N>]1I38 4
M96I,A[ G%3[E/8U?;(UH3)>]]R^[ [^_"-['>13%0]G/,NGUD:LP'ST> $9.
M2H>45\9:;P%5JL;1\PM+#]"Q]-\%S28#WI\7Z>%Q>?UCLBIJM]?;WA\MJM'X
M'4'1:-II3CA3UAF"%-6V!A1>VA7--!J\TW&Z ;FUVUL]+B>_EQ6(/W\V>V^G
M['DR>*X=1TY$98P#CC'QB%5]]))<W*:677:+G/CVM]@T67N/Y0YH_)* B<5*
MEY/-:&N%<]#X"@6(FZF6YQ/PW.\>UYD8AB!C@RWN[<.!4$058E$+I4YQ7JJE
MM!H5ET9>VA*67]P'&-4*X][\PM-E<1V%>?1.YNL' _4F=A\+ H6P91V:N#)7
MHQ$HJ8+XR!ESJCC?NG)3<!QX<VNWFVTF4E0(I9!4E''&2!$"L /5.*V%*=O7
M"*]!C&+[:H'[P/PZ:>MZURX(P#UPV#(HB.; E3GKJ[$RX2[,(LLB]69,:H5O
M0@S2?%5&3,WO?B^6/Z?7Q?[<% >?#XY!YB&C!G&(N89>.53U%\4__Q)\.%5V
MB_S(#KRJ?&YPP?]8TZ E]P2#N+%';1 RRXFK%4&K>4JX\ CO.8UB_VH+?D*P
M[X?]^'\?XU\4R]G3[O2]S)W\$HI_3]<_7C;=']Z;Y?5!4P/*JXD6,R[C2H^4
MKT\-D.875H\]'SD6@\NB-Z-NV_,7/9T6JP8A/P>:!2P BT:P$AH2I12)AK"N
M1^IMR@(XRKB?[+SK .6!-U;W]T/IJ5VU6! SO3EP8($VFD*O!1!&"X-K'W-B
MN8 1FI6=<;)?,0P;B/)2MZD7^5<.G@L.4,'(.(L  <82)C@0SM;KB]2\D:/W
MD@-4G)0Z&LM""2\8,A(Y#6NO'F IN]SYZ%8MZ)(E0.4T\,\I0$4!I2DR7#D"
M%-7,*&JJD6'X3X#*2=)O$J!R&N"7&:!BH_5-H3 &<P6D A1[7F-@W84=ZJ71
MH'6 RFD@#Q.@ JE%VC",A68.>:&XJ%&@ %Q:$O'\LCL2H'(:ON=[AF>]\ A8
M&@$36BK&D:NU?.[,A55A[G<7RX?[>9_AE>A)IRV/2B=%\7?(U?@A G\-!?PT
MJ9]TAG<:OJWWJVV4P^?R9MS5O,X\=G#C.M D>&N\-]@K3R %D#JNZY,%Y<$%
M1YLD2'#1";BM*;$I*WFSN81]F CO'@R":HZ1AQ(ZPX@!1JLZ2,8 ?V')7CL0
M?RJDK85>'ZCXHO"+Y:?YS8:(#5APO&7@U%BGE!,0&"@ )9S5AR\>TI3S_?-Q
M_J;0(CO&B?M% UJ\>S  "W'928]]F:65 :[E\R4$=&$92#O;&]I#>A'A'4IR
MZX#!BDC+*84>U0$MV"5=3!SA4C(*TZ8M^/W1[:/3H6EQF&=[V@2K1%3A+=0T
MSBABO//,56/46EZ<#R:7R-]Q*0_ PQY!;N;391XP:H>EE<!#R"Q"SE@$W#8E
M@75&\D8\'^J <2.6)FDQ3GU54(2#R$? 1#2OL,(2(5RA$O'Z-4*V6I#DY&/%
M)-S[611^G][-I[?3Z\E\_9S?\>MB-KV>#K@FO.]*@]5@?Z- J2.(&\RC7<F
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M'^-7:ZA;7S%R6^/XZL$LMA?^Z\(040[N[^O98^F1^[U83HN5J7^P=_]+?F=
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M9=O=J\?U:CV9EX<=S128=\T"(EAKQ0#R3D%G)$?6UV:F5"D!92,\;\]-HFS
MMC]%RI7L<SK?YF3<>[Z4^T/!2"8HP8@I[2)*.OZABI[ACK$+*ZJ9<1\<6A0#
MD[5<M?\5FZQ7_7#V_?<"IM$P%H)%;0,132Q'NHJ=X$R2E$/3$;J61D?=9(D,
MMF.KQ_6/Q7+ZWP^SN3=H%3P47@-E-<(< R:T\+X>)Z8IR45&:%1VO%^WQG4
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M,.QPP^ PYL8;[RPBCF")O%35:"E%*4$/(_+7]$:OK&CWO#F>1*L#8Y2"8:2
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M?_ZO_Q]02P$"% ,4    "  ZC'Q+4?^+-$W% 0!RT1@ $0
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M+3(P,3<Q,#,Q7VQA8BYX;6Q02P$"% ,4    "  ZC'Q+OB-,,[V6  !!OP<
M%0              @ $G-0, >&-U<BTR,#$W,3 S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  !?, P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
